[
  {
    "id": "recj7SuVIShfr36Sx",
    "Question": "Is there any relationship between eating sugar in foods and COVID-19? ",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On COVID-19 & sugar",
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Sugar is a natural part of all foods that have carbohydrates, including fruits, vegetables, grains, beans and legumes, and dairy products. These foods are all part of a well-balanced diet. When looking at diet, consuming sugars as part of unprocessed, whole foods is not usually a concern because of the other health benefits that come from those foods. Added sugar, however, is a significant concern.\n\nThe World Health Organization (WHO) guidelines advise that adults and children limit their daily intake of added sugar to less than 10% of total calories (about 50 grams or about 12 teaspoons) to prevent excess weight gain, type 2 diabetes, heart disease, and dental cavities. Other leading health organizations including the American Heart Association recommend further reducing added sugar (no more than 9 teaspoons or 36 grams of sugar per day for men; no more than 6 teaspoons or 25 grams per day for women).  One 12-ounce soda, for example, has 8 teaspoons (about 32 grams) of added sugar.\n\nThere are many different kinds of sugar used in food preparation and processing, including white or brown sugar, honey, syrups (i.e. maple, rice, golden, corn, agave), molasses, coconut sugar, fruit juice concentrate, malt sugar, and others. Other common sources of dietary sugar are often called “hidden” sugar because they are included in processed foods yet can be difficult to find on food labels, if the food is labeled at all. Examples of “hidden” sugars include sugar sweetened beverages (i.e. cola, soda, flavored milk products, some juices) and processed or packaged foods (including products cookies, cereal products, sweetened dried fruits, sauces and condiments like ketchup or salad dressing, snack foods, and candies).\n\nIf possible, the WHO has said that there may be added health benefits if people are able to decrease their intake to less than 5% (about 25 grams or about 6 teaspoons) per day.\n",
    "What our experts say": "While a varied and balanced diet including fruits and vegetables does help to support the immune system in general, there is no evidence to suggest that special diets, consumption of particular foods, or taking vitamin, mineral, or herbal supplements will prevent, treat or cure COVID-19. For patients with type 2 diabetes, using medications, diet controls (intentionally eating for your condition, like controlling carbohydrate intake and limiting sugar), and exercise to keep blood sugar levels within a normal range has been associated with better outcomes in patients with COVID-19.\n\nWhile diets high in sugar have been shown to impact health, it is not well understood how much added sugar is needed to cause health problems. Studies show that people who consume diets that are high in sugar are more likely to be overweight or obese and have other health problems like insulin resistance (where their bodies are not able to use sugar correctly), type 2 diabetes, high cholesterol, kidney disease, or fatty liver disease than people who consume little added sugar. In addition, sugar has been linked with inflammation and poor immune function in the body, especially when a person has insulin resistance or excess body fat. Researchers do not know how much, what type, or under which conditions sugar may cause problems in the short or long term.  \n",
    "Glossary Terms": [
      "recdZ6UWmASzGmRHV",
      "recLK0olU5qv4lqZ9",
      "rectZMnCI5KMhjzkJ",
      "recD4a9f8HElQ0U8G"
    ],
    "Variation of the answer depending on country of residence": "No\t\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "immune system",
      "inflammation",
      "nutrition",
      "diet",
      "prevention"
    ],
    "Other resources": "1. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type-2 diabetes, 2020 ([Cell Metab](https://pubmed.ncbi.nlm.nih.gov/32369736/))\n2. The impact of nutrition on COVID-19 susceptibility and long-term consequences, 2020 ([Brain Behav Immun](https://pubmed.ncbi.nlm.nih.gov/32311498/))\n3. Opposing Effects of Fasting Metabolism on Tissue Tolerance in bacterial and Viral Inflammation, 2016 ([Cell](https://www.cell.com/cell/fulltext/S0092-8674(16)30972-2))\n4. Fructose-induced inflammation and increased cortisol: A new mechanism for how sugar induces visceral adiposity, 2017 ([Progress in Cardiovascular Diseases](https://www-sciencedirect-com.ezp-prod1.hul.harvard.edu/science/article/pii/S0033062017301627))\n5. WHO calls on countries to reduce sugars intake among adults and children, 2015 ([WHO](https://www.who.int/mediacentre/news/releases/2015/sugar-guideline/en/))\n6. The sweet danger of sugar, 2019 ([Harvard](https://www.health.harvard.edu/heart-health/the-sweet-danger-of-sugar))\n7. How much sugar is too much? ([US AHA](https://www.heart.org/en/healthy-living/healthy-eating/eat-smart/sugar/how-much-sugar-is-too-much))\n",
    "Last modified manual": "2020-08-22",
    "Last edited (simplified)": "2020-08-21T13:50:45.000Z",
    "Last edited (experts say)": "2020-08-22T04:05:35.000Z",
    "Last modified": "2020-08-22",
    "What our experts say wordcount": 214,
    "Background and context wordcount": 304,
    "Other resources wordcount": 96,
    "Wordcount": 614
  },
  {
    "id": "recqw7drq7lMSYbhV",
    "Question": "Why do self-isolation or quarantine timelines sometimes change? ",
    "Status": "Do not publish",
    "Category": "Quarantine, Testing",
    "Subcategory": "On: COVID-19 & quarantine",
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "According to the U.S. Centers for Disease Control and Prevention (U.S. CDC), the incubation period for COVID-19 (the time between exposure to a virus and the first appearance of symptoms) is anywhere between 4 to 14 days. While one study reported that approximately 97% of people with COVID-19 who develop symptoms do so within 11.5 days of infection, the body of evidence is still evolving. An earlier study from China estimated that the mean incubation period was about 5.2 days, with approximately 95% of patients experiencing symptoms by 12.5 days.\n\nAt present, there is no evidence that suggests people with COVID-19 can be re-infected after recovering. Once symptoms start to go away, the levels of virus in the body decrease significantly, but tests can sometimes still pick up detectable levels of virus in the body after recovering. There is no evidence to indicate that this poses a transmission risk to other people. These factors play an important role in determining how people quarantine or self-isolate, and for how long. For example, a high proportion of asymptomatic cases may make it difficult to rely on symptoms alone in the absence of adequate testing. Previously, the U.S. CDC  recommended that people who test positive should quarantine until they had two negative tests, but lack of testing availability made this approach impractical. At present, U.S. CDC guidelines recommend that people who have tested positive for COVID-19 or been exposed to the virus should self-isolate and quarantine for 10 days after experiencing symptoms. \n",
    "What our experts say": "The U.S. Centers for Disease Control and Prevention (U.S. CDC) recently changed quarantine guidelines. They now recommend that most people who test positive for COVID-19 isolate themselves for 10 days after their symptoms begin.\n\nThe CDC previously recommended isolation for 14 days for the general population. They changed it because the latest data shows that people with mild to moderate COVID-19 (the majority of patients) are not likely to be infectious for longer than 10 days after first experiencing symptoms.\n\nIn some cases, people who are experiencing more severe or critical symptoms from COVID-19 may need to quarantine for a longer period of time (up to 20 days after symptoms have started). Asymptomatic patients (individuals who never experience any symptoms, but still test positive for COVID-19) can discontinue quarantine or self-isolation precautions 10 days after their first positive test for COVID-19. \n\nSometimes detectable levels of the virus can still be found in recovered patients, but there is no evidence to indicate that those patients are actually able to transmit the virus to other people. As a result, the U.S. CDC recommends ending quarantine or isolation measures after symptoms have ended.\n\nIn general, given the limited testing availability in the United States and many other countries, the U.S. CDC does not recommend re-testing patients repeatedly if they have completed a 10-day quarantine if they have no symptoms or if symptoms have gone away, as long as the patient does not have other health conditions that leave them immunocompromised. It is important to note that isolation should only end at 10 days if the person hasn’t had a fever for at least 24 hours or any other symptoms have not improved. Patients with severe immune deficiencies may require additional tests in consultation with public health and infection control experts before to ending their quarantine.\n\nThe World Health Organization (WHO) still recommends a 13-day period of self-isolation for any person who has tested positive for COVID-19. For asymptomatic patients who test positive for COVID-10, WHO recommends isolating for 10 days after testing positive. If countries decide to implement testing as part of their isolation strategy, the WHO recommends allowing people to stop isolating after two negative rapid tests at least 24 hours apart. Overall, most public health experts recommend a 10-day quarantine after a positive COVID-19 test, or after the start of symptoms.\n",
    "Glossary Terms": [
      "recE7xmnXgtg8ZanX",
      "recx2PeCcs1Awb9rG"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "Yes. In some cases, severely immunocompromised patients may require a longer duration of self-isolation or quarantine.\n",
    "Topics": [
      "quarantine",
      "testing",
      "virus",
      "asymptomatic"
    ],
    "Other resources": "1. Duration of Isolation and Precautions for Adults with COVID-19 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html))\n2. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19) ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html#:~:text=The%20incubation%20period%20for%20COVID,from%20exposure%20to%20symptoms%20onset.&text=One%20study%20reported%20that%2097.5,SARS%2DCoV%2D2%20infection.))\n3. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application ([Ann Intern Med.](https://pubmed.ncbi.nlm.nih.gov/32150748/))\n4. How long should you isolate if you test positive for the coronavirus? At least 10 days after symptom onset ([Washington Post](https://www.washingtonpost.com/health/2020/07/21/how-long-should-you-isolate-if-you-test-positive-coronavirus-new-cdc-guidance-says-10-days-not-14/))\n5. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2001316))\n6. Q&A on coronaviruses (COVID-19) ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-coronaviruses))\n7. Criteria for releasing COVID-19 patients from isolation ([WHO](https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-19-patients-from-isolation)) \n",
    "Last modified manual": "2020-08-22",
    "Last edited (simplified)": "2020-08-20T20:46:39.000Z",
    "Last edited (experts say)": "2020-08-22T04:05:35.000Z",
    "Last modified": "2020-08-22",
    "What our experts say wordcount": 386,
    "Background and context wordcount": 250,
    "Other resources wordcount": 91,
    "Wordcount": 727
  },
  {
    "id": "reckgFENw9gVgnWtC",
    "Question": "How long is a person infected with COVID-19 contagious?",
    "Status": "Published",
    "Category": "Spread",
    "Subcategory": "On: COVID-19 & contagiousness",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Some viruses are capable of replicating themselves, shedding and spreading even after symptoms have stopped. Scientists are still studying the new coronavirus. Evidence we have so far has given us a solid idea of this length of time for the vast majority of patients. There are still some outliers, but most patients fall within the time frames of contagiousness. Severe cases of illness from COVID-19 and immunocompromised persons would need individual advise from infectious disease experts because they are capable of being contagious longer than others.\n",
    "What our experts say": "Recent research has shown that a person infected with COVID-19 may be able to spread the virus up to 72 hours before they begin to have any symptoms and up to 10 days after symptoms disappear. New studies have suggested that people are the most infectious in the 48 hours before they start to experience any symptoms.\n\nPeople who test positive for COVID-19 but do not develop symptoms in the 10 days following the test result are considered to be likely no longer contagious after those 10 days.\n\nThere may be exceptions to these timings, so experts recommend 10 days of isolation after either testing positive for the virus, being exposed to a person who has been infected with COVID-19, or developing any symptoms. The best way to ensure you are no long contagious is by having two negative COVID-19 tests more than 24 hours apart.\n\nHowever, as per the U.S. CDC, individuals who were severely ill from COVID-19 or are severely immunocompromised might need to remain isolated for longer than 10 days and up to 20 days because they may still be producing viral particles.\n",
    "Glossary Terms": [
      "recOcmLKbzV6NUkAH"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "contagious",
      "symptoms"
    ],
    "Other resources": "1. When you can be around others ([U.S. CDC)](https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/end-home-isolation.html)\n2. Harvard Medical School questions about COVID-19 exposure ([Harvard Health](https://www.health.harvard.edu/diseases-and-conditions/if-youve-been-exposed-to-the-coronavirus))\n3. Duration of Isolation & Precautions for Adults ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html))\n4. Clinical Questions about COVID-19: Questions and Answers ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html))\n",
    "How often revision needed": "Bi-monthly",
    "DB (French)": [
      "recUyWCYQ1yfy9JL3"
    ],
    "DB (Hindi)": [
      "rec7shgDZuifvN3Lk"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recU5ImzlcIGvrQol"
    ],
    "DB (Spanish)": [
      "recdrbgnS7Z7jCniX"
    ],
    "DB (Bengali)": [
      "recV4yPjvAaCmtJpY"
    ],
    "DB (Portuguese)": [
      "recw59Hxtujyubnpy"
    ],
    "Rollup test 2": [
      "recotKMvpWi8KUY3f"
    ],
    "Last modified manual": "2020-12-01",
    "Last edited (simplified)": "2020-12-01T19:25:12.000Z",
    "Last edited (experts say)": "2020-12-01T19:31:21.000Z",
    "Last modified": "2020-12-01",
    "What our experts say wordcount": 183,
    "Background and context wordcount": 86,
    "Other resources wordcount": 36,
    "Wordcount": 305,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Des recherches récentes ont démontré qu’une personne qui a contracté la COVID-19 peut transmettre le virus jusqu’à 72 heures avant qu’elle ne présente des symptômes et jusqu’à 10 jours après disparition complète des symptômes. De nouvelles études ont suggéré que les personnes sont plus particulièrement contagieuses pendant les 48 h avant qu’elles ne présentent des symptômes.\n\nLes personnes qui ont obtenu un résultat positif aux analyses de dépistage de la COVID-19, mais qui ne développent aucun symptôme dans les 10 jours qui suivent le dépistage sont considérées comme n’étant probablement plus contagieuses après ces dix jours.\n\nIl pourrait y avoir des exceptions à ces durées et les experts recommandent donc encore une quarantaine de 10 jours soit après avoir obtenu un résultat positif aux analyses de dépistage du virus, soit après avoir été exposé à une personne qui a contracté la COVID-19, soit après avoir ressenti des symptômes. La meilleure façon de vous assurer que vous ne présentez plus de risque de contagion est de recevoir un résultat négatif à deux analyses de dépistage de la COVID-19 à 24 h d’intervalle.\n\nCette entrée a été mise à jour avec de nouveaux renseignements le 20 août 2020."
    ],
    "French - Background and context": [
      "Dans la mesure où le virus de la COVID-19 est un nouveau virus que les chercheurs n’étudient que depuis moins de six mois, nous apprenons encore tous les jours de nouveaux renseignements sur lui. C’est le cas pour la durée de contagion possible d’une personne porteuse du virus. Les données probantes que nous avons jusqu’à présent nous donnent une bonne idée de cette durée pour la grande majorité des patients. Il y a bien des observations aberrantes, mais la plupart des cas correspondent à ces périodes de contagion.\n\nCette entrée a été mise à jour avec de nouveaux renseignements le 20 août 2020."
    ],
    "Hindi - What our experts say": [
      "हाल के शोध से पता चला है कि कोविड​​-19 से संक्रमित एक व्यक्ति लक्षण दिखाने के 72 घंटे पहले से वायरस को फैलाने में सक्षम हो सकता है, और, किसी संक्रमित व्यक्ति के लक्षण पूरी तरह से चले जाने के 10 दिनों बाद तक वह वाइरस फैला सकता है। \nकुछ और नए अध्ययनों के हिसाब से लोग किसी भी तरह के लक्षण का अनुभव करने से पहले 48 घंटों के दौरान सबसे अधिक वाइरस फैला सकते हैं। जिन लोगों में कोविड-19 पॉज़िटिव टेस्ट के बाद 10 दिनों में कोई भी लक्षण विकसित नहीं होते हैं, वे संभवतः अब संक्रामक नहीं होते हैं। इन दिशानिर्देशों में हमेशा अपवाद होते हैं, इसलिए विशेषज्ञ अभी भी वायरस के लिए सकारात्मक परीक्षण के बाद 14 दिनों के अलगाव को पूरा करने की सलाह देते हैं अगर आप एक ऐसे व्यक्ति के संपर्क में है जो कोविड -19 से संक्रमित हो गया है, या कोई लक्षण विकसित कर रहा हो। यदि 2 नेगेटिव कोविड-19 टेस्ट 24 घंटों के अंतर में देखे जाते हैं, तो यह सुनिश्चित किया जा सकता हैं कि  आप कोविड-19 नहीं फैला रहे हैं।"
    ],
    "Hindi - Background and context": [
      "कोविड-19 एक बहुत ही नई बीमारी है, जो कि छह महीनों से भी कम समय से अध्यन की जा रही है। इसलिए इसके बारे में रोज़ नई जानकारी मिल रही है। जैसे कि कितने समय तक संक्रमण हो सकता है। पर कुछ सबूत ये स्पष्ट कर पाते हैं कि कितने समय तक रोगी इससे ग्रसित रहते हैं। कुछ ऐसे रोगी भी हैं, जो इस समय सीमा के बाहर थे, परंतु ज़्यादातर लोग इसी समय सीमा के अंदर होते हैं।"
    ],
    "Telugu - What our experts say": [
      "కోవిడ్-19 బారిన పడిన వ్యక్తి లక్షణాలు పూర్తిగా అదృశ్యమైన 10 రోజుల వరకు ఏవైనా లక్షణాలను కలిగి ఉండటానికి ముందు 72 గంటల వరకు వైరస్ వ్యాప్తి చెందవచ్చని ఇటీవలి పరిశోధనలో తేలింది. ఏదైనా అధ్యయనాలు అనుభవించడానికి ముందు 48 గంటలలో ప్రజలు ఎక్కువగా అంటువ్యాధులు అని కొత్త అధ్యయనాలు సూచించాయి. కోవిడ్-19 కు పాజిటివ్ పరీక్షించిన వ్యక్తులు కాని వారు పరీక్ష తీసుకున్నప్పటి నుండి తరువాతి 10 రోజులలో ఎటువంటి లక్షణాలను అభివృద్ధి చేయలేరు. ఈ మార్గదర్శకాలకు ఎల్లప్పుడూ మినహాయింపులు ఉన్నాయి, కాబట్టి నిపుణులు వైరస్ కోసం పాజిటివ్ పరీక్షించిన తర్వాత 14 రోజుల ఒంటరిగా పూర్తి చేయాలని, కోవిడ్-19 బారిన పడిన వ్యక్తికి గురికావడం లేదా ఏదైనా లక్షణాలను అభివృద్ధి చేయాలని సిఫార్సు చేస్తున్నారు."
    ],
    "Telugu - Context and background": [
      "కోవిడ్-19 ఒక కొత్త వైరస్ కాబట్టి, పరిశోధకులు కేవలం ఆరునెలల లోపు అధ్యయనం చేస్తున్నారు, మేము ఇంకా ప్రతిరోజూ దాని గురించి కొత్త సమాచారాన్ని నేర్చుకుంటున్నాము. వైరస్‌తో ప్రజలు ఎంతకాలం అంటుకొనుతారనేది ఇందులో ఉంది, అయినప్పటికీ ఇప్పటివరకు మనకు లభించిన సాక్ష్యాలు చాలా మంది రోగులకు ఈ సమయం గురించి దృమైన ఆలోచన ఆలోచనను ఇచ్చాయి. ఇంకా కొంతమంది అవుట్‌లెర్స్ ఉన్నారు, కాని చాలా మంది రోగులు అంటువ్యాధి యొక్క ఈ సమయ వ్యవధిలో వస్తారు."
    ],
    "Spanish - What our experts say": [
      "La investigación reciente ha mostrado que una persona infectada con COVID-19 puede ser capaz de diseminar el virus por hasta 72 horas antes de que empiece a tener algún síntoma, y luego de 10 días después de que los síntomas hayan desaparecido por completo. Nuevos estudios han sugerido que las personas son más infecciosas durante las 48 horas previas a que empiecen a experimentar algún síntoma. Quienes han testeado positivo para el COVID-19 pero nunca desarrollaron síntomas sobre los 10 días siguientes a partir del momento en que tomaron el ensayo, probablemente ya no son contagiosos. Siempre hay excepciones a estos lineamientos, por lo que los expertos aún recomiendan completar 14 días en aislación luego de testear positivo para el virus, haber estado expuesto a una persona que ha sido infectada con el COVID-19, o desarrollar cualquier síntoma. La mejor manera de asegurar que ya no eres contagioso es tener dos ensayos negativos para COVID-19 separados por 24 horas."
    ],
    "Spanish - Background and context": [
      "Como el COVID-19 es un virus nuevo al que los investigadores han estado estudiando por solo poco menos de seis meses, aún estamos aprendiendo nuevas informaciones acerca de él cada día. Esto incluye cuánto tiempo pueden ser contagiosas las personas con el virus, aunque la evidencia que tenemos hasta ahora nos ha dado una sólida idea de este lapso de tiempo para la vasta mayoría de los pacientes. Aún hay algunos fuera de rango, pero la mayoría de los pacientes entran dentro de estos marcos temporales de contagio."
    ],
    "Bengali - What our experts say": [
      "সাম্প্রতিক গবেষণায় দেখা গেছে যে, কোভিড-১৯ এ আক্রান্ত ব্যক্তি লক্ষণ দেখা দেওয়ার ৭২ ঘন্টা পূর্ব থেকে লক্ষণগুলি সম্পূর্ণরূপে অদৃশ্য হওয়ার ১০ দিন পর অবধি ভাইরাসটি ছড়িয়ে দিতে সক্ষম। নতুন গবেষণায় পরামর্শ দেওয়া হয়েছে যে, কেউ একজন কোনও লক্ষণ অনুভব করতে শুরু করার ৪৮ ঘন্টা আগে সবচেয়ে বেশি সংক্রামক। যেসব ব্যক্তি কোভিড-১৯ এর জন্য পরীক্ষা করে পজেটিভ হয়েছেন তারা পরীক্ষার সময় থেকে পরবর্তী ১০ দিনের মধ্যে কোন লক্ষণ দেখা না দিলে তারা সম্ভবত আর সংক্রামক নয়। এই নির্দেশিকাগুলিতে সর্বদা ব্যতিক্রম রয়েছে, তাই বিশেষজ্ঞরা এখনও ভাইরাসটির পরীক্ষা করার পরে পজেটিভ হলে, কোভিড-১৯ সংক্রামিত ব্যক্তির সংস্পর্শে আসার পরে বা কোনও লক্ষণ দেখা দেবার পরে ১৪ দিন কারো সংস্পর্শ থেকে বিচ্ছিন্ন (আইসলেশন) থাকার পরামর্শ দেন। আপনি আর সংক্রামক নন তা নিশ্চিত করার সর্বোত্তম উপায় হ'ল ২৪ ঘন্টার ব্যবধানে দুটি কোভিড-১৯ পরীক্ষা করা, যার দুটি ফলাফল নেগেটিভ।"
    ],
    "Bengali - Background and context": [
      "যেহেতু কোভিড-১৯ একটি নতুন ভাইরাস যা গবেষকরা মাত্র ছয় মাসের জন্য অধ্যয়ন করছেন, আমরা এখনও প্রতিদিন এটি সম্পর্কে নতুন তথ্য শিখছি। এর মধ্যে লোকেরা ভাইরাসের সংক্রমণে কতক্ষণ সংক্রামক হতে পারে তা অন্তর্ভুক্ত রয়েছে, যদিও এখন পর্যন্ত আমাদের কাছে যা প্রমাণ রয়েছে তা দ্বারা আমাদের বেশিরভাগ রোগীর পক্ষে এই দৈর্ঘ্যের একটি শক্ত ধারণা এসেছে। এখনও কিছু ব্যাতিক্রম রয়েছেন, তবে বেশিরভাগ রোগী এই সময়ের মধ্যে সংক্রামকতার মধ্যে পড়ে।"
    ]
  },
  {
    "id": "recuRBvIUfjcJfEOX",
    "Question": "What do we know about the new strain of this virus that is more infectious than the first strains?",
    "Status": "Published",
    "Category": "On: COVID-19 & viral mutations",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Research about the virus that causes COVID-19, the novel coronavirus SARS-CoV-2, is ongoing, and scientists and researchers are continuing to learn and understand how the virus spreads, how long it can live outside of host cells, and how it affects different people around the world. Another major area of interest is understanding how the virus mutates (or changes). Some viruses mutate as part of their life cycle, and sometimes these changes can impact humans by making the virus easier to spread or more likely to cause serious infection. \n\nRNA viruses, such as influenza and measles, are more prone to mutations than DNA viruses, such as herpes and human papillomavirus. Coronaviruses are RNA viruses that generally mutate slower than influenza. Some forms of SARS-CoV-2 have mutated and now look different than the original version of it found in China. More research is needed to understand the implications of any mutations in SARS-CoV-2, the virus that causes COVID-19.\n",
    "What our experts say": "Though previous studies have claimed that newer strains of the COVID-19 virus spread more rapidly and are more infectious than the original strain of the virus, current research published on November 25th, 2020 has suggested that the current viral mutations (or versions of the virus) do not spread more easily than the original strain of the virus. \n\nViruses constantly change as they reproduce in order to keep spreading into more cells. These changes are called \"viral mutations,\" and though most mutations are not helpful to the virus, the mutations that help the virus reproduce contribute to the virus spreading. Mutations create a new, updated version of the virus, which we call a \"strain.\" \n\nThere are many mutations of the COVID-19 virus that have been explored, and researchers believe that the most common mutations have occurred as a result of interaction with the human immune system (via RNA editing). Scientists are continuing to monitor the virus as it changes and spreads around the world.\n\nTo prevent the spread of COVID-19, international health agencies and the public health community continue to encourage the everyone to wear face masks, practice social distancing (maintaining 6 feet/2 meters physical distance), avoid crowds especially in indoor areas, and practice frequent hand washing with soap and warm water. \n",
    "Glossary Terms": [
      "reco4mXMlx86yOkid",
      "recMOA1iUEl0oP2Vi",
      "recmIgJvajdxBf3eI",
      "recS7r4IRJ4w3tzwS",
      "rec7N5hddau1BMOkc",
      "recjclD4IZEmv7SlP",
      "recr3NlaEcaDxSbvI",
      "recohdNoEKptcRCtT",
      "reccH9Nhjj0fi18nJ"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No \n",
    "Topics": [
      "mutation",
      "strain",
      "infectious",
      "contagious",
      "D614G",
      "G614"
    ],
    "Other resources": "1. No evidence for increased transmissibility from recurrent mutations in SARS-CoV-2 ([Nature Communications](https://www.nature.com/articles/s41467-020-19818-2))\n2. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus ([Cell](https://www.cell.com/cell/fulltext/S0092-8674(20)30820-5)) \n3. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity ([bioRxiv](https://www.biorxiv.org/content/10.1101/2020.06.12.148726v1.full.pdf)) \n4. This coronavirus mutation has taken over the world. Scientists are trying to understand why. ([Washington Post](https://www.washingtonpost.com/science/2020/06/29/coronavirus-mutation-science/?arc404=true)) \n5. Viral Mutation Rates ([Journal of Virology](https://jvi.asm.org/content/jvi/84/19/9733.full.pdf))\n6. SARS-CoV-2 genomic variations associated with mortality rate of COVID-19 [(Nature - Journal of Human Genetics)](https://www.nature.com/articles/s10038-020-0808-9)\n\n",
    "DB (French)": [
      "recQc3te6Xja0OheW"
    ],
    "DB (Hindi)": [
      "rectBcCsddJwBt55Y"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recZSiPbUOzYU3zRV"
    ],
    "DB (Portuguese)": [
      "recATTHpSIIU2LdRv"
    ],
    "Rollup test 2": [
      "recTPQuI9KP0ALSVg"
    ],
    "Last modified manual": "2020-12-07",
    "Last edited (simplified)": "2020-12-03T19:38:36.000Z",
    "Last edited (experts say)": "2020-12-07T14:38:03.000Z",
    "Last modified": "2020-12-07",
    "What our experts say wordcount": 210,
    "Background and context wordcount": 156,
    "Other resources wordcount": 83,
    "Wordcount": 449,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "French - What our experts say": [
      "Des études affirment que les nouvelles souches du virus de la COVID-19 en Europe et aux États-Unis se propagent plus rapidement et sont plus infectieuses que la souche originale du virus, qui a d’abord été découverte en Asie au début 2020.\n\nUne nouvelle souche connue sous le nom de « variante G614 » ou la « mutation à spicules D614G » a été découverte dans de nombreux pays. Jusqu’à présent, les recherches démontrent que la nouvelle souche du coronavirus ne change pas la gravité des symptômes. Le public devrait continuer à prendre les mêmes mesures préventives recommandées : porter un couvre-visage, garder une distance physique de six pieds (deux mètres), se laver les mains avec du savon et de l’eau tiède.\n\nLes virus changent constamment alors qu’ils se reproduisent afin de continuer à se propager dans plus de cellules. Ces changements sont appelés des « mutations » et bien que la plupart des mutations ne soient pas utiles aux virus, les mutations qui aident le virus à se reproduire contribuent à la propagation du virus. Les mutations créent une nouvelle version transformée du virus que nous appelons une « souche ».\n\nDans le cas de la COVID-19, la « mutation à spicules D614G » est actuellement la plus courante. Elles concernent les « spicules » du virus, en forme de pique, que l’on trouve sur le pourtour de tous les coronavirus et qui les aident à s’introduire dans le corps d’une personne et à infecter plus de cellules. La souche a plus de spicules, ce qui signifie que le virus a plus de chance d’adhérer quand il tente d’envahir le corps humain, ce qui augmente la probabilité que la personne exposée soit infectée. Grâce à ce changement, certains chercheurs pensent que la souche actuelle du virus est approximativement dix fois plus infectieuse que les versions précédentes étudiées en laboratoire.\n\nIl est important de noter que ces études récentes démontrent que malgré la facilité accrue de la nouvelle souche du virus à infecter les personnes, cela ne rend pas les infections pires ou meilleures que pour les autres souches du virus de la COVID-19. Même si la mutation G614 augmente vos chances de tomber malade à cause du virus, vos chances de développer des symptômes graves sont les mêmes qu’avant.\n\nCette entrée a été mise à jour avec de nouveaux renseignements le 25 août 2020.\n"
    ],
    "French - Background and context": [
      "Des études et des articles de presse circulent sur une nouvelle souche possible du SARS-CoV-2. Les virus mutent (ou changent) pendant leur cycle biologique. Certains de ces changements ont plus d’impact que d’autres sur les êtres humains.\n\nLes virus à ARN tels que les virus de la grippe et de la rougeole sont généralement plus susceptibles de muter, comparés aux virus à ADN tels que le virus de l’herpès ou le virus du papillome humain. Les coronavirus sont des virus à ARN qui d’une manière générale mutent plus lentement que le virus de la grippe. Certaines formes du SARS-CoV-2 ont muté et ont maintenant une apparence différente de celle de sa version originale découverte en Chine. Des recherches plus approfondies sont nécessaires afin de comprendre les implications des mutations du SARS-CoV-2.\n\nCette entrée a été mise à jour avec de nouveaux renseignements le 25 août 2020."
    ],
    "Hindi - What our experts say": [
      "हाल के कुछ अध्ययनों ने दावा किया है कि यूरोप और संयुक्त राज्य अमेरिका में कोविड-19 वायरस के नए उपभेद अधिक तेज़ी से फैलते हैं और वायरस के मूल तनाव से अधिक संक्रामक होते हैं जो पहली बार 2020 की शुरुआत में एशिया में खोजा गया था। हालांकि, कम से कम इनमें से एक अध्ययन अभी तक सहकर्मी-समीक्षा या प्रकाशित किया जाना है। अब तक, इन निष्कर्षों पर कोई वैज्ञानिक सहमति नहीं है और न ही यह निर्धारित करने के लिए पर्याप्त सबूत हैं कि क्या वे सटीक हैं।\n\nवायरस लगातार बदलते रहते हैं क्योंकि वे अधिक कोशिकाओं में फैलते रहने के लिए प्रजनन करते हैं। इन परिवर्तनों को \"म्यूटेशन\" कहा जाता है और यद्यपि अधिकांश उत्परिवर्तन वायरस के लिए सहायक नहीं होते हैं, लेकिन वे परिवर्तन जो वायरस को पुन: उत्पन्न करने में मदद करते हैं, वायरस को फैलने में मदद करते हैं। ये परिवर्तन वायरस का एक नया रूप बनाते हैं, और प्रत्येक अद्यतन संस्करण को हम \"तनाव\" कहते हैं। \nकोविड-19 के मामले में, इस नए तनाव को 'G614' कहा जाता है और यह वायरस के \"स्पाइक प्रोटीन\" नामक किसी चीज को प्रभावित करता है; सभी कोरोनावायरस के बाहर स्पाइकी भागों जो उन्हें एक व्यक्ति के शरीर में जाने और अधिक कोशिकाओं को संलग्न करने और संक्रमित करने में मदद करता है। G614 तनाव में अधिक स्पाइक प्रोटीन होते हैं और जब वे मानव शरीर पर आक्रमण करने की कोशिश कर रहे होते हैं, तो वायरस से टूटने की संभावना कम होती है, इसलिए यह उस व्यक्ति को संक्रमित करने की अधिक संभावना है जो इसके संपर्क में आया है। वायरस वैज्ञानिकों के शुरुआती तनावों को खोजने में सक्षम थे, उन्होंने सहमति व्यक्त की कि ये प्रोटीन पहले से ही बहुत कुशल थे और वायरस ने इसके उपयोग के माध्यम से लाखों लोगों को संक्रमित किया। इन स्पाइक्स की संख्या और ताकत में इस नए बदलाव के साथ, शोधकर्ताओं का मानना ​​है कि वायरस का G614 तनाव प्रयोगशालाओं में अध्ययन किए गए शुरुआती संस्करणों की तुलना में लगभग 10 गुना अधिक संक्रामक है।\n\nहालांकि, इन हालिया अध्ययनों से पता चला है कि हालांकि यह वायरस के नए तनाव के लिए लोगों को संक्रमित करना आसान है, यह इन संक्रमणों को कोविड-19 के अन्य उपभेदों की तुलना में किसी भी बदतर या बेहतर नहीं बनाता है। इसलिए यदि आप वायरस से बीमार होने की अधिक संभावना रखते हैं, तब भी आपके गंभीर लक्षण होने की संभावना वैसी ही होती है जैसी कि वे हमेशा से रहे हैं, और आपको सबसे अधिक हल्के से मध्यम मामले की संभावना होगी।"
    ],
    "Hindi - Background and context": [
      "उपन्यास कोरोनोवायरस SARS-CoV-2 के एक संभावित नए तनाव के बारे में अध्ययन और समाचार लेख प्रसारित हुए हैं। प्रजनन के लिए आनुवांशिक कोड की नकल करते समय वायरस अपने जीवन चक्र के हिस्से के रूप में परिवर्तन (या परिवर्तन) करते हैं। सभी उत्परिवर्तन एक अलग वायरस तनाव पैदा नहीं करेंगे, क्योंकि कुछ उत्परिवर्तन मौन (अवलोकनीय प्रभाव के बिना), कॉस्मेटिक (केवल उपस्थिति परिवर्तन) हैं, या समय के साथ गायब हो सकते हैं। आरएनए वायरस, जैसे इन्फ्लूएंजा और खसरा, में एक स्वयं-सही तंत्र की कमी होती है और डीएनए वायरस, जैसे दाद और मानव पेपिलोमावायरस की तुलना में उत्परिवर्तन के लिए अधिक प्रवण होते हैं। कोरोनोवायरस आरएनए वायरस हैं जो आमतौर पर इन्फ्लूएंजा की तुलना में धीमी गति से उत्परिवर्तित करने के लिए पाए गए हैं। उपन्यास कोरोनोवायरस SARS-CoV-2 के साथ, चीन में पाए जाने वाले मूल आइसोलेट्स से आनुवांशिक अनुक्रम में थोड़ा अलग होने की सूचना आइसोलेट्स (या संक्रमित मरीजों से अलग किए गए वायरस के नमूने) थे। SARS-CoV-2 में किसी भी उत्परिवर्तन के निहितार्थ को समझने के लिए अधिक शोध की आवश्यकता है।"
    ]
  },
  {
    "id": "reco2uYADZHn5mpCd",
    "Question": "What do people mean when they refer to COVID-19 as being a blood vessel disease?",
    "Status": "Published",
    "Category": "Symptoms",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "There have been reports of COVID-19 patients experiencing disease symptoms that impact the blood vessels and vascular system, such as blood clots and damage to the endothelial lining of blood vessels. The existence of vascular COVID-19 symptoms is particularly relevant to patients with certain pre-existing conditions (like hypertension or cardiovascular disease), where infection can mean increased risks of severe illness, serious complications, or death. It is important to note that COVID-19 symptoms can vary widely from person to person, with many experiencing primarily respiratory symptoms, other types of symptoms, multiple types of symptoms at once, or no symptoms at all.\n",
    "What our experts say": "Patients who have been infected with COVID-19 can sometimes develop severe symptoms. Some of these symptoms include things like blood clots, heart problems, and \"COVID toes.\" One thing all of these issues have in common is their link to blood vessels, which are the tubes that deliver blood and oxygen throughout the body. When these tubes, and the cells that line the insides of the tubes (endothelial cells), have challenges carrying and spreading blood to organs and tissues, issues like blood clots, kidney damage, inflammation of the heart and swelling of the brain (encephalitis) can occur in patients. This is why some doctors are calling the virus a \"vasculotropic\" virus (virus that affects blood vessels). More research is needed to present such findings conclusively.\n\nThough COVID-19 was originally thought to be a respiratory illness, some researchers believe that the virus may be able to move from the lungs into the blood vessels (pulmonary system), often causing additional symptoms such as the ones mentioned above. While some patients have been impacted by blood vessel-related symptoms, more research is still needed to determine its exact impacts on the body and its organs. At this point in time, blood clots due appear to be a major cause of negative health outcomes in patients with severe cases of COVID-19, bringing heightened awareness to the potential involvement of blood vessels and blood flow as an effect of the virus.\n\n \n\n",
    "Glossary Terms": [
      "recqf9kWDH9WkLibg"
    ],
    "Variation of the answer depending on country of residence": "No\t\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "blood vessel",
      "respiratory system",
      "blood clot",
      "COVID toes"
    ],
    "Other resources": "1. Endothelial cell infection and endotheliitis in COVID-19 ([Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30937-5/fulltext)) \n2. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2015432)) \n3. Doctors race to understand inflammatory condition in kids ([Science](https://science.sciencemag.org/content/368/6494/923)) \n4. COVID-19: the vasculature unleashed ([Nature](https://www.nature.com/articles/s41577-020-0343-0)) \n5. COVID-19 and the Heart ([American Heart Association](https://www.ahajournals.org/doi/pdf/10.1161/CIRCRESAHA.120.317055))\n",
    "How often revision needed": "Bi-weekly ",
    "DB (Hindi)": [
      "recGTHUEZHVc2Ddb1"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "reczawDROyc15MBGz"
    ],
    "DB (Portuguese)": [
      "recab7v5MslXdufG9"
    ],
    "Rollup test 2": [
      "recJoUNmmqlm8uW6t"
    ],
    "Last modified manual": "2020-08-21",
    "Last edited (simplified)": "2020-07-07T22:49:46.000Z",
    "Last edited (experts say)": "2020-09-24T20:03:32.000Z",
    "Last modified": "2020-09-24",
    "What our experts say wordcount": 234,
    "Background and context wordcount": 100,
    "Other resources wordcount": 43,
    "Wordcount": 377,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "कोविड-19 से संक्रमित रोगी कभी-कभी गंभीर लक्षण विकसित कर सकते हैं। इन लक्षणों में से कुछ में रक्त के गांठ, हृदय की समस्याएं और \"कोविड से पैर की अंगुली पर असर\" जैसी चीजें शामिल हैं। इन सभी मुद्दों में एक चीज है रक्त वाहिकाओं की लिंक, पूरे शरीर में रक्त और ऑक्सीजन पहुंचाने वाली नलिकाएं। जब ये नलिकाएं और कोशिकाएं जो नलिकाओं के अंदरूनी हिस्सों को लाइन करती हैं, तो रक्त को अंगों और ऊतकों तक ले जाने और फैलाने की चुनौती होती है, कई रोगियों में रक्त के गांठ जैसे मुद्दे हो सकते हैं।\n\nहालांकि कोविड-19 मुख्य रूप से एक श्वसन बीमारी है, कुछ शोधकर्ताओं का मानना है कि वायरस फेफड़ों से रक्त वाहिकाओं में स्थानांतरित करने में सक्षम हो सकता है, अक्सर अतिरिक्त लक्षण जैसे कि ऊपर उल्लेखित हैं। जबकि कुछ रोगियों को रक्त वाहिका संबंधी लक्षणों से प्रभावित किया गया है, कोविड-19 को अभी भी मुख्य रूप से अधिकांश रोगियों के लिए एक श्वसन बीमारी माना जाता है।"
    ],
    "Hindi - Background and context": [
      "कोविड-19 रोगियों में रोग के लक्षणों का अनुभव करने वाली रिपोर्टें मिली हैं जो रक्त वाहिकाओं और संवहनी प्रणाली को प्रभावित करती हैं, जैसे रक्त की गांठ और रक्त वाहिकाओं के एंडोथेलियल अस्तर को नुकसान। संवहनी कोविड-19 लक्षणों का अस्तित्व विशेष रूप से कुछ पूर्व-मौजूदा स्थितियों (जैसे उच्च रक्तचाप या हृदय रोग) के रोगियों के लिए प्रासंगिक है, जहां संक्रमण का मतलब गंभीर बीमारी, गंभीर जटिलताओं या मृत्यु के जोखिम बढ़ सकता है। यह ध्यान रखना महत्वपूर्ण है कि कोविड-19 लक्षण एक व्यक्ति से दूसरे व्यक्ति में व्यापक रूप से भिन्न हो सकते हैं, जिनमें मुख्य रूप से श्वसन संबंधी लक्षण, अन्य प्रकार के लक्षण, कई प्रकार के लक्षण एक साथ दिखाई देते हैं, या कोई लक्षण बिल्कुल भी नहीं होते हैं।"
    ]
  },
  {
    "id": "recoVpGV8P1VgMvtc",
    "Question": "What are the symptoms of COVID-19?",
    "Status": "Published",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "There have been many reports of people experiencing a variety of different symptoms as a result of COVID-19 infection. While some symptoms occur in just a few people, other symptoms are more common or “typical” for many people with COVID-19. Typical symptoms for most people with COVID-19 include fever, dry cough, and tiredness; and less common symptoms include headache, loss of taste or smell, rashes or discoloration on fingers or toes, diarrhea, and others according to the World Health Organization. The medical and scientific communities are continually learning about COVID-19 and its symptoms in people based on age, ethnicity, body composition, pre-existing medical conditions, and other factors. The World Health Organization, U.S. Centers for Disease Control and Prevention, and other leading health organizations are continually updating their public information to share what is currently known about the COVID-19 and its impacts.\n\n",
    "What our experts say": "COVID-19 can impact people in different ways, but most people who are infected with the virus will only have mild to moderate symptoms and won't need to be hospitalized. Most cases of the virus are not dangerous, but should be taken seriously. The World Health Organization says the most common symptoms are:\n- fever\n- dry cough\n- tiredness\n\nSymptoms fewer people have include: \n- aches and pains\n- sore throat\n- diarrhea\n- conjunctivitis\n- headache\n- loss of taste or smell\n- a rash on skin, or discoloration of fingers or toes\n\nSymptoms that are serious and which mean people should contact a medical professional as soon as possible include:\n- difficulty breathing or shortness of breath\n- chest pain or pressure\n- loss of speech or movement\n\nA person may have mild symptoms for a week or so, and then their condition might worsen rapidly. There maybe others who show no symptom at all. Children, generally speaking, have similar symptoms to adults but with milder illness. People who are older have been shown to have more severe forms of illness.\n\nSome people with COVID-19 have also been experiencing neurological symptoms, gastrointestinal (GI) symptoms (relating to the stomach and intestines), or both.\n\nBecause we are learning more about this virus every day, including new symptoms, it is important to pay attention to what your body is feeling and contact a medical professional if you begin to experience any of the above symptoms or notice any other changes in how you normally feel.\n\nAdditionally, the United States Centers for Disease Control People with COVID-19 have had a wide range of symptoms reported – ranging from mild symptoms to severe illness. This list does not include all possible symptoms, but these may appear **2-14 days after exposure** **to the virus**:\n- Fever or chills\n- Cough\n- Shortness of breath or difficulty breathing\n- Fatigue\n- Muscle or body aches\n- Headache\n- New loss of taste or smell\n- Sore throat\n- Congestion or runny nose\n- Nausea or vomiting\n- Diarrhea\n\nAdditionally, the United States Centers for Disease Control urges people to seek emergency medical care if they are experiencing any of these symptoms:\n\n- Trouble breathing\n- Persistent pain or pressure in the chest\n- New confusion\n- Inability to wake or stay awake\n- Bluish lips or face\n\n",
    "Other resources": "1. WHO overview of COVID-19 ([WHO](https://www.who.int/health-topics/coronavirus#tab=tab_3))\n2. Symptoms of Coronavirus ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html)) \n3. Clinical Characteristics of Coronavirus Disease 2019 in China ([NEJM)](https://www.nejm.org/doi/full/10.1056/NEJMoa2002032)\n4. Harvard Medical School - [COVID-19 basics](https://www.health.harvard.edu/diseases-and-conditions/covid-19-basics)\n5. Mayo Clinic - [Coronavirus disease 2019](https://www.mayoclinic.org/diseases-conditions/coronavirus/symptoms-causes/syc-20479963)\n",
    "DB (Hindi)": [
      "recojD7yFZ5jkWu1m"
    ],
    "Translation notes": "a note with remvoals or other stuff\n\nAdded/changed sentences: \n- [Roughly half of people with COVID-19 will have a fever and 2/3 will have a cough.]\n- \n",
    "In translated DBs?": "Yes",
    "DB (Arabic)": [
      "recKS3JWIBfUWDk5H"
    ],
    "DB (Bengali)": [
      "rec8bZn6SmuDLJv3T"
    ],
    "DB (Portuguese)": [
      "recJcAfkQgDzTr93t"
    ],
    "Rollup test 2": [
      "recgiWE748uNAUVah"
    ],
    "Last modified manual": "2020-08-21",
    "Last edited (simplified)": "2020-07-09T22:37:00.000Z",
    "Last edited (experts say)": "2020-08-21T15:24:46.000Z",
    "Last modified": "2020-08-21",
    "What our experts say wordcount": 355,
    "Background and context wordcount": 141,
    "Other resources wordcount": 33,
    "Wordcount": 529,
    "Hindi Q Status": [
      "Published"
    ],
    "Arabic Q status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "कोविड-19 लोगों को विभिन्न तरीकों से प्रभावित कर सकता है, लेकिन ज्यादातर लोग जो वायरस से संक्रमित होते हैं, उनमें केवल हल्के से मध्यम लक्षण होंगे और उन्हें अस्पताल में भर्ती होने की आवश्यकता नहीं होगी। वायरस के अधिकांश मामले खतरनाक नहीं हैं, लेकिन इसे गंभीरता से लिया जाना चाहिए। विश्व स्वास्थ्य संगठन का कहना है कि सबसे आम लक्षण हैं:\n- बुखार\n- सूखी खाँसी\n- थकान\n\nकम लोगों के लक्षणों में शामिल हैं:\n- दर्द एवं पीड़ा\n- गले में खराश\n- दस्त\n- आँख आना\n- सरदर्द\n- स्वाद या गंध का नुकसान\n- त्वचा पर एक दाने, या उंगलियों या पैर की उंगलियों के मलिनकिरण\n\nलक्षण जो गंभीर हैं और जिनका मतलब है कि लोगों को जल्द से जल्द एक चिकित्सा पेशेवर से संपर्क करना चाहिए:\n- सांस लेने में कठिनाई या सांस की तकलीफ\n- सीने में दर्द या दबाव\n- भाषण या आंदोलन का नुकसान\n\nएक व्यक्ति में एक या एक सप्ताह के लिए हल्के लक्षण हो सकते हैं, और फिर उनकी स्थिति तेजी से बिगड़ सकती है। वहाँ शायद दूसरों को जो कोई लक्षण नहीं दिखाते हैं। आमतौर पर बोलने वाले बच्चों में वयस्कों के समान लक्षण होते हैं, लेकिन हल्की बीमारी के साथ। जो लोग अधिक उम्र के हैं उन्हें बीमारी के अधिक गंभीर रूप दिखाए गए हैं।\n\nकोविड-19 वाले कुछ लोग न्यूरोलॉजिकल लक्षणों, गैस्ट्रोइंटेस्टाइनल (जीआई) लक्षणों (पेट और आंतों से संबंधित), या दोनों का अनुभव कर रहे हैं।\n\nक्योंकि हम हर दिन इस वायरस के बारे में अधिक जान रहे हैं, जिसमें नए लक्षण भी शामिल हैं, इस बात पर ध्यान देना महत्वपूर्ण है कि आपका शरीर क्या महसूस कर रहा है और यदि आप उपरोक्त लक्षणों में से किसी का अनुभव करना शुरू करते हैं या आप में कोई अन्य परिवर्तन देखते हैं, तो किसी मेडिकल प्रोफेशनल से संपर्क करें। सामान्य रूप से महसूस करते हैं।\n\nइसके अतिरिक्त, संयुक्त राज्य अमेरिका के रोग नियंत्रण के लिए कोविड-19 वाले लोगों में लक्षणों की एक विस्तृत श्रृंखला है - हल्के लक्षणों से लेकर गंभीर बीमारी तक। इस सूची में सभी संभावित लक्षण शामिल नहीं हैं, लेकिन ये वायरस के संपर्क में आने के 2-14 दिन बाद दिखाई दे सकते हैं:\n- बुखार या ठंड लगना\n- खांसी\n- सांस की तकलीफ या सांस लेने में कठिनाई\n- थकान\n- मांसपेशियों या शरीर में दर्द\n- सरदर्द\n- स्वाद या गंध का नया नुकसान\n- गले में खरास\n- कंजेशन या बहती नाक\n- उलटी अथवा मितली\n- दस्त\n\nइसके अतिरिक्त, संयुक्त राज्य अमेरिका के रोग नियंत्रण केंद्र ने लोगों से आपातकालीन चिकित्सा देखभाल लेने का आग्रह किया है यदि वे इनमें से किसी भी लक्षण का अनुभव कर रहे हैं:\n- साँस लेने में कठिनाई\n- छाती में लगातार दर्द या दबाव\n- नई उलझन\n- जागने या रहने में असमर्थता\n- नीले होंठ या चेहरा"
    ],
    "Hindi - Background and context": [
      "कोविड-19 संक्रमण के परिणामस्वरूप विभिन्न प्रकार के लक्षणों का अनुभव करने वाले लोगों की कई रिपोर्टें मिली हैं। जबकि कुछ लक्षण बस कुछ लोगों में होते हैं, अन्य लक्षण कोविड-19 वाले कई लोगों के लिए अधिक सामान्य या \"विशिष्ट\" होते हैं। कोविड-19 वाले अधिकांश लोगों के लिए विशिष्ट लक्षणों में बुखार, सूखी खांसी और थकान शामिल हैं; और कम आम लक्षणों में विश्व स्वास्थ्य संगठन के अनुसार सिरदर्द, स्वाद या गंध की हानि, उंगलियों या पैर की उंगलियों पर चकत्ते या दस्त, और अन्य शामिल हैं। चिकित्सा और वैज्ञानिक समुदाय लगातार कोविड-19 और इसके लक्षणों के बारे में लोगों को उम्र, जातीयता, शरीर रचना, पहले से मौजूद चिकित्सा स्थितियों और अन्य कारकों के आधार पर सीख रहे हैं। विश्व स्वास्थ्य संगठन, अमेरिका के रोग नियंत्रण और रोकथाम केंद्र, और अन्य प्रमुख स्वास्थ्य संगठन लगातार सार्वजनिक सूचनाओं को अपडेट कर रहे हैं ताकि वर्तमान में कोविड-19 और इसके प्रभावों के बारे में पता चल सके।"
    ],
    "Arabic - What our experts say": [
      "يمكن أن يؤثر كوفيد-19 على الأشخاص بطرق مختلفة، لكن معظم الأشخاص المصابين بالفيروس سيكون لديهم أعراض خفيفة إلى متوسطة فقط ولن يحتاجوا إلى دخول المستشفى. معظم حالات الإصابة بالفيروس ليست خطيرة، لكن يجب أخذها على محمل الجد. تقول منظمة الصحة العالمية إن الأعراض الأكثر شيوعا هي :\n- الحمى\n- السعال جاف\n- التعب\n\nتشمل الأعراض التي يعاني منها عدد أقل من الأشخاص ما يلي:\n- الأوجاع والآلام\n- إلتهاب الحلق\n- الإسهال\n- التهاب الملتحمة\n- صداع الراس\n- فقدان حاسة التذوق أو الشم\n- طفح جلدي على الجلد أو تغير لون أصابع اليدين أو القدمين\n\nتشمل الأعراض الخطيرة والتي تعني أن على الأشخاص الاتصال بأخصائي طبي في أقرب وقت ممكن ما يلي :\n- صعوبة في التنفس أو ضيق في التنفس\n- ألم أو ضغط في الصدر\n- فقدان الكلام أو الحركة\n\nنظرا لأننا نتعلم المزيد عن هذا الفيروس كل يوم، بما في ذلك الأعراض الجديدة، فمن المهم الانتباه إلى ما يشعر به جسمك والاتصال بأخصائي طبي إذا بدأت بالإحساس بأي من الأعراض المذكورة أعلاه أو لاحظت أي تغييرات أخرى عن شعورك المعتاد.\n\nبالإضافة إلى ذلك، ظهرت مجموعة واسعة من أعراض كوفيد-19 التي تم الإبلاغ عنها في المراكز الأمريكية للسيطرة على الأمراض - إذ تتراوح ما بين أعراض خفيفة و مرض شديد. لا تشمل هذه القائمة جميع الأعراض المحتملة، ولكن قد تظهر بعد يومين إلى 14 يوما من التعرض للفيروس :\n- الحمى أو القشعريرة\n- السعال\n- ضيق التنفس أو صعوبة التنفس\n- العياء\n- آلام في العضلات أو الجسم\n- صداع الراس\n- فقدان جديد في حاسة التذوق أو الشم\n- إلتهاب الحلق\n- احتقان أو سيلان الأنف\n- الغثيان أو القيء\n- الإسهال\n\nبالإضافة إلى ذلك، تحث مراكز السيطرة على الأمراض في الولايات المتحدة الأشخاص على طلب الرعاية الطبية الطارئة إذا كانوا يعانون من أي من الأعراض التالية :\n- صعوبة في التنفس\n- ألم أو ضغط مستمر في الصدر\n- اختلاط عقلي\n- عدم القدرة على الاستيقاظ أو البقاء مستيقظا\n- زرقة الشفاه أو الوجه"
    ],
    "Arabic - Background and context": [
      "ظهرت العديد من التقارير عن أشخاص يعانون من مجموعة متنوعة من الأعراض المختلفة نتيجة لعدوى كوفيد-19. بينما تحدث بعض الأعراض لدى عدد قليل من الأشخاص، تكون الأعراض الأخرى أكثر شيوعا أو \"نمطية\" للعديد من الأشخاص المصابين بـ كوفيد-19. تشمل الأعراض النمطية لمعظم الأشخاص المصابين بـ كوفيد-19 الحمى والسعال الجاف والتعب. وتشمل الأعراض الأقل شيوعا صداع الرأس و فقدان حاسة الذوق أو الشم و الطفح الجلدي أو تغير لون الأصابع أو أصابع القدم والإسهال وغيرها وفقا لمنظمة الصحة العالمية. تتعرف المجتمعات الطبية والعلمية باستمرار على كوفيد-19 وأعراضه لدى الأشخاص بناءً على العمر والعرق وتكوين الجسم والحالات الصحية السابقة وكذا عوامل أخرى. تعمل منظمة الصحة العالمية والمراكز الأمريكية لمكافحة الأمراض والوقاية منها وغيرها من المنظمات الصحية الرائدة باستمرار في تحديث معلوماتها العمومية لمشاركة ما هو معروف حاليا عن كوفيد-19 وتأثيراته."
    ]
  },
  {
    "id": "recq1zzyVh3GSLrhz",
    "Question": "What short and long-term effects does COVID-19 have on other body parts, including lungs, brain, heart and kidneys?",
    "Status": "Update ready for review",
    "Category": "Symptoms",
    "Subcategory": "On: COVID-19 & short- and long-term effects",
    "Source of the question": [
      "Fact-checking organization"
    ],
    "Country question was sourced from": [
      "Philippines"
    ],
    "Background and context": "COVID-19 has been linked to a series of health problems beyond respiratory failure (breathing problems), including heart, brain, and kidney problems. Health professionals, scientists, and journalists have reported major differences in COVID-19 symptoms from patient to patient. These differences often occur as a result of patient age, illness severity, duration of symptoms, and organs affected. \n\nCommon short-term symptoms for people with mild or moderate COVID-19 illness include shortness of breath, fever, cough, fatigue (tiredness), and body aches. Even with mild or moderate illness, some patients report lingering impacts of COVID-19 lasting for months, and the long-term effects of the disease are not fully known. For patients with severe illness from COVID-19, long-term organ problems appear to be similar to those that occur as a result of other major illnesses the require intensive (ICU) care, including infection, trauma, organ failure (like heart failure), or major surgery. Since this is a new illness, however, the real long-term impacts of COVID-19 are largely unknown.  \n",
    "What our experts say": "COVID-19 is still a new illness, and researchers and healthcare providers are continuing to learn about its short and long-term impacts. Many people infected with COVID-19 have mild or no symptoms. Some of the short-term impacts reported by people with mild symptoms include shortness of breath, fever, cough, fatigue (tiredness), and body aches. For more severe cases, short-term impacts may include respiratory (breathing) failure, confusion or other neurological problems, and kidney or heart damage due to a lack of oxygen or blood clots that can sometimes cause long-term problems. The worse the symptoms of COVID-19 are, the more likely major organs are to be negatively impacted.\n\nCOVID-19 may impact organ systems directly (in the case of the virus causing inflammation in the lungs and airways) or indirectly (where organ damage is caused by illness that is a result of COVID-19 infection, but the organ damage is not caused by the virus infecting the organ directly). Recent studies document long-term impacts of COVID-19 on different organs in the body, including lung scarring, limited lung capacity, neurocognitive impacts, heart damage, renal failure, and more. \n\nLungs: Though it can impact other organs, COVID-19 is primarily thought of as a lung (or respiratory) illness. Patients with lung problems like asthma, chronic obstructive pulmonary disease (COPD), and other chronic (long-term) lung diseases may be at higher risk of having complications from COVID-19. In any infected patient, COVID-19 may cause pneumonia (where the lungs fill with fluid), acute respiratory distress syndrome (ARDS), and sepsis (a bloodstream infection). Lung problems may be short or long term, and experts have suggested that it can take months, possibly even more than a year, for lung function to return to normal after a COVID-19 infection. Early rehabilitation has been shown to improve respiratory (breathing) problems in patients who have had severe COVID-19.\n\nHeart: Studies have shown that heart problems are also common. One German study reported that 78 out of 100 patients recovering from a COVID-19 infection had heart-related problems, such as inflammation and scarring, that could have serious consequences. In addition, heart problems have been reported in 40% of COVID-19 deaths. In September, US CDC reported that heart conditions like myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the covering of the heart), are associated with COVID-19. Such heart damage might also explain long-term symptoms like shortness of breath, chest pain, and heart palpitations. Although rare, severe heart damage has also been seen in young, healthy people.\n\nKidneys: The American Society of Nephrology reported that approximately 50% of patients with severe cases of COVID-19 in intensive care experience kidney failure. During July 2020, the impacts of COVID-19 on the kidneys made the news, following updated recommendations from the American Society of Nephrology. On this topic, Mount Sinai Health System Associate Professor of Nephrology and RenalytixAI Co-Founder, Dr. Steven Coca warns about the rise in “chronic kidney disease in the U.S. among those who recovered from the coronavirus...Since the start of the coronavirus pandemic we have seen the highest rate of kidney failure in our lifetimes. It’s a long-term health burden for patients, the medical community — and the U.S. economy.” New research and media reports are continuing to be released.\n\nBrain: Emerging evidence has revealed that some COVID-19 patients experience neurological symptoms in the brain, spinal cord, nerves, and ganglia (cell bodies that relay nerve signals). Researchers believe that these effects are an indirect impact of COVID-19 (meaning these effects occur because of illness related to COVID-19, but not as a direct result of the virus entering the tissue). Studies from around the world have reported neurological symptoms in COVID-19 patients ranging from brain inflammation and delirium to nerve damage, stroke, and impaired consciousness in as much as 30% of patients. Researchers have long been concerned about the risks of post-traumatic stress, dementia, and delirium in patients who require intensive care (even without COVID-19). The long-term implications of COVID-19 on the brain and nervous system are still unclear, since COVID-19 is a new disease and there has not been enough time to observe patients over long periods of time. Neurological complications have, however, been reported during previous epidemics, such as the Severe Acute Respiratory  Syndrome (SARS) epidemic in 2003 and the Middle East Respiratory Syndrome (MERS) outbreak more recently in 2012.\n\nSince this is a new illness, the real long-term impacts remain unknown. The longer-term effects of COVID-19 are still being studied. Exhaustion, anxiety, dizziness, headaches, muscle aches, loss of taste and smell, and difficulty breathing are often reported in patients who experience symptoms for weeks following their infection with COVID-19. For some people infected with the virus,  symptoms have lasted longer than 100 days.\n",
    "Glossary Terms": [
      "reccJtjL0z55J1CPG",
      "reciKuzcOIBjSFsU4",
      "reclXuRND3ea8LAA1",
      "recU4JuZ6HJpfe2ZK",
      "recOcmLKbzV6NUkAH"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "stroke",
      "brain",
      "lungs",
      "kidney",
      "renal failure",
      "impact",
      "short-term",
      "long-term",
      "blood clot",
      "headache",
      "dizziness ",
      "neurocognitive"
    ],
    "Other resources": "1. Coronavirus ([WHO](https://www.who.int/health-topics/coronavirus#tab=tab_1)) \n2. The Long-Term Health Effects of COVID-19 ([GAVI](https://www.gavi.org/vaccineswork/long-term-health-effects-covid-19)) \n3. What are the potential long-term effects of having COVID-19? ([AP](https://apnews.com/113bef255eb0c33570f77e33515a6ca6))` `\n4. What Long-Term Effects Could COVID-19 Have on Your Lungs? ([Banner Health](https://www.bannerhealth.com/healthcareblog/teach-me/what-long-term-effects-could-covid19-have-on-your-lungs)) \n5. Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels ([Radiology](https://pubs.rsna.org/doi/10.1148/radiol.2020201561)) \n6. Extrapulmonary manifestations of COVID-19, see [Figure 2](https://pbs.twimg.com/media/Ec6A_F3UwAAf76_.png) ([Nature](https://www.nature.com/articles/s41591-020-0968-3.pdf))\n7. What Coronavirus Does to the Lungs ([JHU](https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/what-coronavirus-does-to-the-lungs))\n8. COVID-19: Interim Guidance on Rehabilitation in the Hospital and Post-Hospital Phase from a European Respiratory Society and American Thoracic Society-coordinated International Task Force ([European Respiratory Journal](https://erj.ersjournals.com/content/erj/early/2020/07/30/13993003.02197-2020.full.pdf))\n9. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China ([JAMA](https://jamanetwork.com/journals/jamacardiology/fullarticle/2763524?resultClick=1)) \n10. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) ([JAMA Cardiology](https://jamanetwork.com/journals/jamacardiology/fullarticle/2768916))\n11. New data shows COVID-19 can cause kidney failure — and launch a different kind of epidemic ([Poynter](https://www.poynter.org/reporting-editing/2020/new-data-shows-covid-19-can-cause-kidney-failure-and-launch-a-different-kind-of-epidemic/))\n12. The American Society of Nephrology's Resources and Recommendations ([ASN](https://www.asn-online.org/covid-19/ASN#Kidney_Week))\n13. COVID-19 and Kidney Failure in the Acute Care Setting: Our Experience From Seattle ([AJKD](https://www.ajkd.org/article/S0272-6386(20)30618-1/fulltext)) \n14. Coronavirus: Kidney Damage Caused by COVID-19 ([Hopkins Medicine](https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-kidney-damage-caused-by-covid19))\n15. How Covid-19 can damage the brain ([BBC](https://www.bbc.com/future/article/20200622-the-long-term-effects-of-covid-19-infection)) \n16. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China ([JAMA](https://jamanetwork.com/journals/jamaneurology/fullarticle/2764549)) \n17. Neurologic Features in Severe SARS-CoV-2 Infection ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMc2008597)) \n18. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings ([Brain](https://academic.oup.com/brain/article/doi/10.1093/brain/awaa240/5868408))\n19. Long after the fire of a Covid-19 infection, mental and neurological effects can still smolder ([STAT News](https://www.statnews.com/2020/08/12/after-covid19-mental-neurological-effects-smolder/))\n20. Delirium, PTSD, brain fog: The aftermath of surviving COVID-19 ([American Psychological Association](https://www.apa.org/monitor/2020/09/aftermath-covid-19))\n21. Study to explore how COVID affects cognition over time ([Vanderbilt University Medical Center](https://news.vumc.org/2020/07/22/study-to-explore-how-covid-affects-cognition-over-time/))\n22. Coronavirus Disease: Long-Term Effects ([US CDC](https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html))\n23. COVID‐19 and the heart: An update for clinicians ([Clinical Cardiol](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323229/))\n",
    "DB (French)": [
      "rec8sg7onKcFdH8Y6"
    ],
    "DB (Hindi)": [
      "recvtv5hqPycd51X9"
    ],
    "Media": [
      {
        "id": "att6FPXV1lEe51o5i",
        "url": "https://dl.airtable.com/.attachments/96b233be341cdeff0b73ff3309755d35/ff0dd52c/Slide_1",
        "filename": "Slide_1",
        "size": 372129,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/bb4850ee2432e5801d5640c215cf9f64/6ff27450",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/302f5b733e4724fc710d0c27f5ea2e94/2eeb907e",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/1b29bea8598742ceadecfae42dcd9d4e/2b673509",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attCVdVBSWd509qg9",
        "url": "https://dl.airtable.com/.attachments/1fbabe58265c5f03745752fafb48a661/83fe89fa/Slide_2",
        "filename": "Slide_2",
        "size": 243344,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/cb6bb321fe40651df2bee9743425b170/98342a85",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/fd9cc348e0051d1ade29e96496e9168c/7bfb71da",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/685b0cfba397c3d2cedf3519152c89aa/422d504a",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attZLw9m3jGYBx0JE",
        "url": "https://dl.airtable.com/.attachments/bf258d3c6bf844525ef06eded04b0706/454d81e2/Slide_3",
        "filename": "Slide_3",
        "size": 257145,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/289413005c34863773a8d4f521a55005/56f90dac",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/f4b67d55329b0ffd12141ea6566923d1/dd49de16",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/605efbb80b3fdad375fff863c1ce8490/0478591d",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attGw7ZamdUlcfxZt",
        "url": "https://dl.airtable.com/.attachments/8e8058f5baee9a41c25a1b23a6b7d69e/ba6e0d9b/Slide_4",
        "filename": "Slide_4",
        "size": 328957,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/8f97eed698b39e9a0f9c6c79046fe3e0/43751ed4",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/941e44d4ef4a3fff651cfda0d719e1be/217f6989",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c46b08882d3bc496cc12e2f08f95e59d/3ebfdb81",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Arabic)": [
      "recKuCJKLPYXqrorF"
    ],
    "DB (Bengali)": [
      "rec8NynUVAdGfxzpR"
    ],
    "DB (Portuguese)": [
      "recJO9f8TumCnfdpr"
    ],
    "Rollup test 2": [
      "reci7CUIYlLntgLrZ"
    ],
    "Media Package": [
      {
        "id": "attjgE1L3X9yjNCLh",
        "url": "https://dl.airtable.com/.attachments/af68660cc315dd056104b9f9b98e4602/29baa2c3/Effectsonthebody.zip",
        "filename": "Effects on the body.zip",
        "size": 1202872,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-12-08",
    "Last edited (simplified)": "2020-12-08T19:16:24.000Z",
    "Last edited (experts say)": "2020-12-08T19:42:28.000Z",
    "Last modified": "2020-12-08",
    "What our experts say wordcount": 774,
    "Background and context wordcount": 163,
    "Other resources wordcount": 274,
    "Wordcount": 1211,
    "French Q status": [
      "Ready for expert review"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Arabic Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Dans la mesure où la COVID-19 est une nouvelle maladie, nous ne connaissons pas encore toutes ses conséquences à court et à long terme. La plupart des personnes atteintes de la COVID-19 présentent des symptômes légers ou aucun symptôme. Pour les personnes qui présentent des symptômes légers, les conséquences à court terme comprennent des essoufflements (dyspnée ressentie dans les poumons et les voies respiratoires), de la fièvre, de la toux et des courbatures. Pour les cas plus graves, certaines conséquences à court terme peuvent affecter plusieurs organes. On relèvera ainsi des embolies pulmonaires (poumons), des accidents vasculaires cérébraux (cerveau), des lésions rénales provoquées par le manque d’oxygène ou des caillots sanguins. La Société états-unienne de néphrologie a rapporté qu’approximativement 50 % des patients souffrant de cas graves de COVID-19 en soins intensifs ont subi des insuffisances rénales. Une étude allemande publiée en juin 2020 a trouvé que 70 patients sur 100 atteints de COVID-19 en convalescence présentaient des problèmes cardiaques qui pourraient avoir des conséquences graves, telles que des inflammations ou des cicatrisations, mais les conséquences à long terme de ces résultats de recherche sont en cours d’évaluation. Plus le cas de COVID-19 et ses symptômes sont graves, plus grands seront les risques que les organes de la personne subissent des effets néfastes.\n\nLes effets à long terme de la COVID-19 sont à l’étude actuellement. Épuisement, anxiété, étourdissement, maux de tête, courbatures, perte du goût et de l’odorat et difficultés respiratoires sont souvent signalés par les patients qui présentent des symptômes plusieurs semaines après avoir contracté la COVID-19. Pour certaines personnes infectées par le virus, leurs symptômes ont duré plus de 100 jours.\n\nDes études récentes présentent plusieurs conséquences à long terme de la COVID-19 sur divers organes du corps, dont une cicatrisation des poumons, une capacité pulmonaire réduite, des conséquences neurocognitives, des lésions cardiaques, des insuffisances rénales et plus encore. Le Centre médical de l’Université Vanderbilt a lancé en juillet 2020 une étude sur les états confusionnels aigus, les troubles de stress post-traumatique (TSPT) et les dépressions chez les patients atteints de COVID-19 qui ont été hospitalisés. Ces conséquences invalidantes sont aussi appelées trouble post-soins intensifs (TPSI), et des études précédentes de patients des soins intensifs semblables à ceux atteints de COVID-19 suggèrent que 33 à 50 % souffrent de démence, 10 à 20 % d’un TSPT et 33 % d’un trouble dépressif caractérisé. Les chercheurs tentent aussi de découvrir si les patients atteints de COVID-19 et qui souffrent d’une inflammation cérébrale courent ou non un plus grand risque de troubles auto-immuns tels que la démyélinisation, qui est une attaque par le système immunitaire de la gaine protectrice des cellules nerveuses, et qui peut provoquer des faiblesses, des engourdissements et des difficultés dans les activités quotidiennes.\n\nNous avons affaire à une nouvelle maladie et les conséquences réelles à long terme sont inconnues.\n\nCette entrée a été mise à jour avec de nouveaux renseignements le 20 août 2020."
    ],
    "French - Background and context": [
      "Les professionnels de la santé, les scientifiques et les journalistes ont rapporté de très grandes différences de symptômes d’un patient atteint de la COVID-19 à l’autre. Il y a entre autres des différences de gravité et de durée des symptômes, et d’organes affectés. Par exemple, certains patients signalent des conséquences persistantes de la COVID-19 pendant des mois, et les effets à long terme de la maladie ne sont pas encore connus.\n\nRécemment, des nouvelles circulent sur les conséquences potentielles à long terme de la COVID-19 sur d’autres parties du corps en plus des poumons. Par exemple, les médias ont couvert les conséquences de la COVID-19 sur le cœur, à la suite de la publication en juillet 2020 d’une étude allemande sur les problèmes cardiaques chez des patients atteints de COVID-19 en convalescence.\n\nDe plus, des lésions cérébrales associées à la COVID-19 ont été rapportées dans les médias à la suite de la publication de deux études sur des patients britanniques et français qui avaient présenté des symptômes allant d’inflammation cérébrale et d’états confusionnels aigus à des lésions nerveuses et des accidents vasculaires cérébraux. Avant la pandémie de COVID-19, les chercheurs se sont déjà inquiétés des risques de TSPT et d’états confusionnels aigus chez les patients qui demandent des soins intensifs. D’après l’analyse d’une recherche antérieure sur les états confusionnels aigus publiée dans le journal « Intensive Care Medicine » (médecine des soins intensifs), de manière générale, un état confusionnel aigu a été constaté chez 20 à 40 % des patients en phase critique. Un respirateur était nécessaire chez jusqu’à 80 % de ces patients.\n\nEn juillet 2020, les conséquences de la COVID-19 sur les reins ont aussi fait les manchettes à la suite d’une mise à jour des recommandations de la Société états-unienne de néphrologie. À ce sujet, le professeur agrégé en néphrologie du Système de santé Mont Sinaï et cofondateur de RenalytixAI, le Dr Steven Coca, tire la sonnette d’alarme sur l’augmentation des « maladies rénales chroniques aux États-Unis chez les personnes guéries de la COVID-19. Depuis le début de la pandémie de coronavirus, nous avons constaté le plus haut taux d’insuffisance rénale de nos vies. C’est un fardeau de santé à long terme pour les patients, la communauté médicale et l’économie états-unienne. ». De nouvelles recherches et de nouveaux reportages des médias continuent de paraître.\n\nCette entrée a été mise à jour avec de nouveaux renseignements le 20 août 2020."
    ],
    "Hindi - What our experts say": [
      "जैसा कि कोविड-19 एक नई बीमारी है, हम इसके छोटे और दीर्घकालिक प्रभावों के बारे में अभी तक नहीं जानते हैं। कोविड-19 से संक्रमित अधिकांश लोगों में हल्के या कोई लक्षण नहीं होते हैं। हल्के लक्षणों वाले लोगों के लिए कुछ अल्पकालिक प्रभावों में फेफड़े और वायुमार्ग में सांस की तकलीफ, बुखार, खांसी और शरीर में दर्द शामिल हैं। अधिक गंभीर मामलों के लिए, कुछ अल्पकालिक प्रभाव कई अंगों को प्रभावित कर सकते हैं। इनमें ऑक्सीजन या रक्त के थक्के की कमी के कारण फुफ्फुसीय एम्बोलिम्स (फेफड़े), स्ट्रोक (मस्तिष्क), और गुर्दे की क्षति शामिल हैं। अमेरिकन सोसाइटी ऑफ नेफ्रोलॉजी ने बताया कि लगभग 50% मरीजों में गहन देखभाल के दौरान कोविड-19 के गंभीर मामले गुर्दे की विफलता का अनुभव करते हैं। जुलाई 2020 में प्रकाशित जर्मनी के एक अध्ययन में पाया गया कि एक कोविड-19 संक्रमण से उबरने वाले 100 में से 78 रोगियों में दिल से संबंधित समस्याएं थीं जो गंभीर परिणाम हो सकते हैं, जैसे कि सूजन और निशान, लेकिन इन निष्कर्षों के दीर्घकालिक परिणाम अभी भी हैं अनुसंधान के तहत। किसी व्यक्ति में कोविड-19 के मामले और लक्षण जितने गंभीर होते हैं, उतने ही प्रमुख अंग नकारात्मक रूप से प्रभावित होते हैं।\n \nकोविड-19 के दीर्घकालिक प्रभावों का अब अध्ययन किया जा रहा है। थकावट, चिंता, चक्कर आना, सिरदर्द, मांसपेशियों में दर्द, स्वाद और गंध की कमी और सांस लेने में कठिनाई अक्सर उन रोगियों में रिपोर्ट की जाती है जो कोविड-19 के साथ अपने संक्रमण के बाद हफ्तों तक लक्षणों का अनुभव करते हैं। वायरस से संक्रमित कुछ लोगों के लिए, उनके लक्षण 100 दिनों से अधिक समय तक रहे हैं।\n \nहाल के अध्ययनों में शरीर के विभिन्न अंगों पर कोविड-19 के कई दीर्घकालिक प्रभावों का उल्लेख किया गया है, जिसमें फेफड़े में जख्म, सीमित फेफड़ों की क्षमता, तंत्रिका संबंधी प्रभाव, हृदय की क्षति, गुर्दे की विफलता और बहुत कुछ शामिल हैं। वेंडरबिल्ट यूनिवर्सिटी मेडिकल सेंटर ने जुलाई 2020 में एक अध्ययन शुरू किया, जो कोविड-19 के साथ अस्पताल में भर्ती होने वाले रोगियों में प्रलाप, पोस्ट-ट्रॉमैटिक स्ट्रेस डिसऑर्डर (पीटीएसडी) और अवसाद का अध्ययन करेगा। इन अक्षम प्रभावों को पोस्ट-गहन देखभाल सिंड्रोम (पीआइसीएस) के रूप में भी जाना जाता है, और कोविड-19 रोगियों के समान गहन देखभाल रोगियों के पिछले अध्ययनों से पता चलता है कि 33-50% अनुभव मनोभ्रंश, 10-20% अनुभव पीटीएसडी, और 33% प्रमुख अनुभव डिप्रेशन। शोधकर्ता यह भी अध्ययन कर रहे हैं कि क्या मस्तिष्क की सूजन वाले कोविड-19 रोगियों में स्व-प्रतिरक्षित विकारों का अधिक खतरा होता है, जैसे कि प्रतिरक्षा प्रणाली द्वारा तंत्रिका कोशिकाओं के सुरक्षात्मक कोटिंग पर हमला किया जाता है और दैनिक गतिविधियों के साथ कमजोरी, सुन्नता और कठिनाई हो सकती है।\n \nक्योंकि यह एक नई बीमारी है, इसलिए वास्तविक दीर्घकालिक प्रभाव अज्ञात रहते हैं।\n\nइस प्रविष्टि को 20 अगस्त 2020 को नई जानकारी के साथ अद्यतन किया गया था।"
    ],
    "Hindi - Background and context": [
      "स्वास्थ्य पेशेवरों, वैज्ञानिकों, और पत्रकारों ने रोगी से रोगी तक कोविड-19 लक्षणों में बड़े अंतर की सूचना दी है। इसमें लक्षणों की अवधि में, लक्षणों की अवधि में और प्रभावित अंगों में अंतर शामिल हैं। उदाहरण के लिए, कुछ मरीज़ कोविड-19 के स्थायी महीनों के प्रभाव की रिपोर्ट करते हैं, और बीमारी के दीर्घकालिक प्रभाव अभी तक पूरी तरह से ज्ञात नहीं हैं।\n\nहाल ही में, अधिक समाचार फेफड़ों से परे शरीर के अन्य हिस्सों में कोविड-19 के संभावित दीर्घकालिक प्रभावों पर प्रसारित हो रहा है। उदाहरण के लिए, मीडिया कोविड-19 से उबरने वाले रोगियों में दिल से संबंधित मुद्दों पर जर्मनी से जुलाई 2020 के शोध प्रकाशन के बाद, दिल पर कोविड-19 प्रभावों की रिपोर्ट कर रहा है।\n\nइसके अतिरिक्त, ब्रिटिश और फ्रांसीसी रोगियों पर दो अध्ययनों के प्रकाशन के बाद मस्तिष्क में कोविड​​-19 की क्षति को मीडिया में बताया गया, जो मस्तिष्क की सूजन और प्रलाप से लेकर तंत्रिका क्षति और स्ट्रोक तक के लक्षणों का अनुभव करते थे। कोविड-19 महामारी से पहले, शोधकर्ताओं ने पहले से ही रोगियों में PTSD और प्रलाप के जोखिमों के बारे में चिंतित हैं जिन्हें गहन देखभाल की आवश्यकता होती है। गहन देखभाल चिकित्सा में प्रकाशित पिछले प्रलाप अनुसंधान की समीक्षा के अनुसार, प्रलाप ने गंभीर रूप से बीमार रोगियों के 20-40% को प्रभावित किया है और 80% उन लोगों के रूप में जिन्हें मैकेनिकल वेंटिलेटर की आवश्यकता है।\n\nजुलाई 2020 के दौरान, अमेरिकन सोसाइटी ऑफ नेफ्रोलॉजी की अद्यतन सिफारिशों के बाद, कोविड-19 का प्रभाव गुर्दे पर पड़ा। इस विषय पर, माउंट सिनाई हेल्थ सिस्टम एसोसिएट प्रोफेसर ऑफ नेफ्रोलॉजी और रिनेलिटिक्स एआइ के सह-संस्थापक, डॉ. स्टीवन कोका ने कोरोनोवायरस की शुरुआत के बाद से अमेरिका में \"क्रोनिक किडनी रोग\" में वृद्धि के बारे में चेतावनी दी है जो कोरोनोवायरस की शुरुआत के बाद से है। महामारी हमने अपने जीवनकाल में गुर्दे की विफलता की उच्चतम दर देखी है। यह मरीजों, चिकित्सा समुदाय और अमेरिकी अर्थव्यवस्था के लिए दीर्घकालिक स्वास्थ्य बोझ है। \" नए शोध और मीडिया रिपोर्ट जारी होने का सिलसिला जारी है।\n\nइस प्रविष्टि को 20 अगस्त 2020 को नई जानकारी के साथ अद्यतन किया गया था।"
    ],
    "Arabic - What our experts say": [
      "نظرا لكون كوفيد-19 مرضا جديدا، فنحن لا نعرف جميع آثاره قصيرة وطويلة المدى حتى الآن. يعاني معظم الأشخاص المصابين بـ كوفيد-19 من أعراض خفيفة أو لا تظهر عليهم أعراض. بعض الآثار قصيرة المدى للأشخاص الذين يعانون من أعراض خفيفة تشمل ضيق التنفس في الرئتين والممرات الهوائية والحمى والسعال وآلام الجسم. بالنسبة للحالات الأكثر شدة، يمكن أن تؤثر بعض التأثيرات قصيرة المدى على عدة أعضاء. وتشمل هذه الانسداد الرئوي (الرئتين) والسكتات الدماغية (الدماغ) وتلف الكلى بسبب نقص الأكسجين أو جلطات الدم. أفادت الجمعية الأمريكية لأمراض الكلى أن ما يقرب من 50 ٪ من المرضى الذين يعانون من حالات حادة من كوفيد-19 في العناية المركزة يعانون من الفشل الكلوي. كلما زادت خطورة حالة وأعراض كوفيد-19 في الشخص، زاد احتمال التأثر السلبي للأعضاء الرئيسة.\n\nتجري حاليا دراسة الآثار طويلة المدى لـ كوفيد-19. يتم الإبلاغ عن حالات الإرهاق والقلق والصداع وآلام العضلات في أغلب الأحيان في المرضى الذين يعانون من الأعراض بعد أسابيع من بدء الإصابة بـ كوفيد-19. بما أن هذا مرض جديد، فإن التأثيرات الحقيقية طويلة المدى تظل مجهولة. بالنسبة لبعض الأشخاص المصابين بالفيروس، استمرت أعراضهم لأكثر من 100 يوم."
    ],
    "Arabic - Background and context": [
      "أبلغ المتخصصون في مجال الصحة والعلماء والصحفيون عن اختلافات كبيرة في أعراض كوفيد-19 من مريض لآخر. وهذا يشمل الاختلافات في شدة الأعراض، ومدتها، وفي الأعضاء المصابة. على سبيل المثال، أبلغ بعض المرضى عن آثار طويلة الأمد لـ كوفيد-19 التي استمرت لأشهر، والآثار طويلة المدى للمرض ليست معروفة بالكامل حتى الآن.\n\nفي الآونة الأخيرة، يتم تداول المزيد من الأخبار حول التأثيرات طويلة المدى المحتملة لـ كوفيد-19 في أماكن أخرى من الجسم، خارج الرئتين. على سبيل المثال، ذكرت وسائل الإعلام أن كوفيد-19 يسبب تلفا في الدماغ، وذلك بعد نشر دراستين على مرضى البريطانيين والفرنسيين عانوا من أعراض من بينها التهاب الدماغ والهذيان وتلف الأعصاب والسكتة الدماغية.\n\nبالإضافة إلى ذلك، جاءت التقارير الإعلامية حول تأثيرات كوفيد-19 على القلب في أعقاب ورقة بحثية صدرت في يوليو 2020 من ألمانيا حول مشاكل متعلقة بالقلب لدى المرضى الذين يتعافون من كوفيد-19.\n\nكذلك، خلال شهر يوليو 2020، ظهرت تأثيرات كوفيد-19 على الكلى، بعد توصيات مُحدَّثة من الجمعية الأمريكية لأمراض الكلى. حول هذا الموضوع، يحذر الدكتور ستيفن كوكا، أستاذ أمراض الكلى المشارك في شبكة مستشفيات Mount Sinai Health System ومؤسس شركة RenalytixAI، من ارتفاع \"أمراض الكلى المزمنة في الولايات المتحدة بين أولئك الذين تعافوا من فيروس كورونا... منذ بداية جائحة فيروس كورونا شهدنا أعلى معدل للفشل الكلوي في حياتنا. إنه عبء صحي طويل الأجل على المرضى والمجتمع الطبي والاقتصاد الأمريكي \". يستمر إصدار تقارير بحثية وإعلامية جديدة.\n\nتم تحديث هذا الإدخال بمعلومات جديدة في 4 أغسطس 2020."
    ]
  },
  {
    "id": "recV4VyzVzjxUii3m",
    "Question": "What do we know about calprotectin and COVID-19?",
    "Status": "Published",
    "Category": "Testing",
    "Subcategory": "On: COVID-19 & calprotectin",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "France"
    ],
    "Background and context": "Due to recent pre-print studies about calprotectin in COVID-19 patients, many people in the medical and scientific fields are questioning if neutrophils (the white blood cells that release calprotectin) can help doctors predict which patients with COVID-19 might get more sick or develop more difficulty breathing than others. There is no consensus and not enough information to show whether or not calprotectin can help doctors in this way, but researchers are studying the protein in COVID-19 patients now. \n\nSome scientists have put forward the idea that calprotectin is linked to inflammation in the body, though usually in the intestines, and are trying to create medications that focus on the protein to decrease inflammation in COVID-19 patients.\n\nOne such pharmaceutical company is named Blade Therapeutics and they have begun phase 2 of clinical trials for a medication designed for COVID-19 patients. This medication, called BLD-2660, tries to stop the immune system from overreacting to the virus and causing organ damage, and it also works to lower the amount of calprotectin in the body. The company hopes that by decreasing the levels of calprotectin, they can help the immune system fight off inflammation and help patients have less severe cases of the virus. It is still too early to tell whether this medication will be successful, but the focus on calprotectin as a marker of inflammation is linked to earlier findings in gastro-enterology studies.\n",
    "What our experts say": "Calprotectin is a type of protein that is released into the body by neutrophils (a type of white blood cell). Neutrophils help heal damaged tissues and stop infections from spreading. When there is any type of swelling in a person, the amount of neutrophils produced by the immune system increases naturally, in order to help protect and defend the body.\n\nWhen there is inflammation in the gastrointestinal (GI) tract (the digestive system in humans and animals that help them digest, absorb, and discard food and liquids), neutrophils move to that area and release the calprotectin protein to help protect and defend the body. Because of this, studies have shown that increased levels of calprotectin in the body are linked to higher levels of inflammation in the GI tract, so calprotectin levels are often tested in people with gastrointestinal issues to determine whether or not they have illnesses like inflammatory bowel disease or other infections.\n\nDespite calprotectin normally being used as a marker for inflammation in the intestines, new research claims that measuring levels of this protein might help determine whether or not people who have tested positive for the coronavirus may develop more severe symptoms. Recent research in a pre-print study and a Letter to the Editor (in the Journal of Infection) shows a potential link between the levels of calprotectin in people infected with COVID-19 and more severe cases of the virus. \n\nIn another pre-print study (which should not be used to guide medical treatments or practices) researchers found a potential link between higher levels of calprotectin in the body of COVID-19 patients with a higher number of patients who require breathing support with a ventilator (a machine that makes sure your body gets enough oxygen by moving air in and out a patient's lungs). \n\nBoth of the studies suggest that testing levels of calprotectin in people with the virus might help doctors predict how severe each patient's symptoms and outcomes might be. \n\nStudies are ongoing, but there is not enough evidence at this time to support this finding and no scientific consensus whether or not calprotectin can serve as a prediction of how serious the virus will be in some patients. Researchers will continue studying calprotectin in COVID-19 patients, but for now, calprotectin is still used primarily as a way for doctors to see if patients have inflammation in their intestines.\n",
    "Glossary Terms": [
      "reck7IhKrrEgx4fLm",
      "recIlhWzXY8Lee18X",
      "rec1d5TIlnBd7ZyOt",
      "reci6AkPuYYC5pFzD",
      "recnFUXyIZy81Rj1I",
      "recD4a9f8HElQ0U8G",
      "recb7T7hH9zHd3k1R",
      "recucR551Bn0MfzmY"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "immune system",
      "calprotectin",
      "neutrophil",
      "white blood cell",
      "inflammation",
      "GI tract"
    ],
    "Other resources": "1. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19 ([Cell Pre-Proof](https://www.cell.com/cell/pdf/S0092-8674(20)30993-4.pdf?_returnURL=https%253A%252F%252Flinkinghub.elsevier.com%252Fretrieve%252Fpii%252FS0092867420309934%253Fshowall%253Dtrue)) \n2. Faecal calprotectin indicates intestinal inflammation in COVID-19 ([BMJ](https://gut.bmj.com/content/69/8/1543)) \n3. Neutrophil calprotectin identifies severe pulmonary disease in COVID-19 ([PAHO](https://covid19-evidence.paho.org/handle/20.500.12663/1443)) \n4. Neutrophil calprotectin identifies severe pulmonary disease in COVID-19 ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.05.06.20093070v3)) \n5. Blade Therapeutics updates enrolment progress for Covid-19 pneumonia study of BLD-2660 ([PBR](https://www.pharmaceutical-business-review.com/news/blade-therapeutics-updates-enrolment-progress-for-covid-19-pneumonia-study-of-bld-2660/)) \n6. Calprotectin ([Circa](https://www.cicra.org/what-is-ibd/what-do-doctors-mean-glossary/)) \n7. Neutrophil extracellular traps and thrombosis in COVID-19 ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.04.30.20086736v3))\n8. Outcome prediction by serum calprotectin in patients with COVID-19 in the emergency department ([Journal of Infection](https://www.journalofinfection.com/action/showPdf?pii=S0163-4453%2820%2930711-8))\n",
    "Last modified manual": "2020-12-01",
    "Last edited (simplified)": "2020-12-07T14:46:24.000Z",
    "Last edited (experts say)": "2020-12-07T14:46:24.000Z",
    "Last modified": "2020-12-07",
    "What our experts say wordcount": 388,
    "Background and context wordcount": 230,
    "Other resources wordcount": 85,
    "Wordcount": 703
  },
  {
    "id": "recufj0t4myAoM7yM",
    "Question": "How many days after exposure should one be tested to yield the most accurate results, and with which test?",
    "Status": "Published",
    "Category": "Testing",
    "Subcategory": "On: COVID-19 & testing accuracy",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "USA",
      "India"
    ],
    "Background and context": "There have been stories circulating in the media about how some people initially tested negative for COVID-19, only to test positive a couple days later. This has raised questions about what types of testing are most accurate, and when (during the course of an infection) is the most accurate time to test someone.\n\nThere are currently two main types: 1) diagnostic tests (including molecular tests and antigen tests), also known as viral tests, which indicate whether someone has an active infection; and 2) antibody tests, also known as serology tests, which indicate whether someone was likely to have had a COVID-19 infection in the past. An antibody test is not used to detect whether someone has an active COVID-19 infection, in part because it can take 1–3 weeks after infection for the immune system to produce antibodies.\n\nMolecular tests are considered more accurate, in general, than the newer antigen tests for diagnosing the virus. Antigen tests detect specific proteins on the surface of the virus that causes COVID-19, and are more likely to miss an active infection compared to molecular tests. Antigen tests require repeat testing to confirm negative test results.\n\nWhile molecular tests are currently considered the most reliable way to detect if someone has an active infection, there can be differences among the different types of molecular tests. For example, newer rapid diagnostic tests can provide results in less than an hour, compared to how most RT-PCR molecular tests provide results in a few hours to a few days. These rapid diagnostic tests are currently not as accurate, however, and researchers are investigating potential issues with the accuracy of rapid diagnostic tests.\n",
    "What our experts say": "Research suggests that diagnostic testing is more accurate a few days after symptoms start, or around a week after exposure to a person who is infected with COVID-19. Testing more than once can confirm negative results, when appropriate, and when tests are available. \n\nDuring the wait for test results, it is essential for people who suspect they have COVID-19 or have been exposed to COVID-19, to take precautions and self-isolate when possible. It is also important to consider what type of test is being used to check for a COVID-19 infection, as this will likely impact how accurate the test is and how long it will take to get results.\n\nMolecular tests are among the most accurate diagnostic tests currently available for detecting whether someone has an active COVID-19 infection. Molecular tests use methods such as RT-PCR (reverse transcription polymerase chain reaction) to detect genetic material from SARS-CoV-2, the virus that causes COVID-19, in respiratory samples such as nose and throat swabs. \n\nMolecular tests have a higher risk of false negatives in the earliest days after exposure and symptom onset, according to an August 2020 publication in the Annals of Internal Medicine by researchers at John Hopkins University who reviewed 7 published studies on the performance of RT-PCR molecular tests. The researchers found that on average, the false negative rate was lowest around day 8 of an infection or 3 days after symptom onset (symptom onset is typically several days after an infection starts), with the false negative rate rising again as the infection continues. False negative test results in the early stages of infection are concerning, because other research (including studies published in Nature and the American Journal of Pathology) have found that COVID-19 patients can be most infectious to others in the early days of infection, when test results may be more likely to come back as false negatives.\n\nSome testing policies recommend that people get tested twice to confirm a negative result. Repeat testing to confirm negative results can be particularly important for people who may interact with high-risk populations (ex. healthcare workers, caretakers), people who may interact with many others outside of their household (ex. an employee going back to the office, a student returning to in-person classes), and people who may need medical care for COVID-19 (e.g. elderly patients with underlying conditions).\n\nMolecular tests are a relatively accurate type of diagnostic testing, and they have a lower chance of false negatives when conducted a few days after symptoms start, or approximately a week after exposure. A lower chance of false negatives does not mean there is no chance of inaccurate test results, so repeat testing may be recommended to confirm test results in certain situations. With all the ongoing research and development work on COVID-19 tests, pandemic testing guidelines may continue to evolve.\n",
    "Glossary Terms": [
      "recPNexvQiug4RFJu",
      "recmajcAORyuqhZPc",
      "rectkO1d0FhUHQ0Of"
    ],
    "Variation of the answer depending on country of residence": "No (although testing policies may vary)\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "testing",
      "infection",
      "COVID-19"
    ],
    "Other resources": "1. Coronavirus Testing Basics ([U.S. FDA](https://www.fda.gov/consumers/consumer-updates/coronavirus-testing-basics))\n2. Testing for COVID-19 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html))\n3. The Latest in Coronavirus (COVID-19) Testing Methods and Availability ([GoodRx](https://www.goodrx.com/blog/coronavirus-covid-19-testing-updates-methods-cost-availability/))\n4. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure ([Annals of Internal Medicine](https://www.acpjournals.org/doi/10.7326/M20-1495))\n5. Association of Initial Viral Load in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients with Outcome and Symptoms ([American Journal of Pathology](https://ajp.amjpathol.org/article/S0002-9440(20)30328-X/fulltext))\n6. Temporal dynamics in viral shedding and transmissibility of COVID-19 ([Nature](https://www.nature.com/articles/s41591-020-0869-5))\n7. Study Raises Questions About False Negatives From Quick COVID-19 Test ([NPR](https://www.npr.org/sections/health-shots/2020/04/21/838794281/study-raises-questions-about-false-negatives-from-quick-covid-19-test))\n8. Performance of the rapid Nucleic Acid Amplification by Abbott ID NOW COVID-19 in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution ([bioRxiv](https://www.biorxiv.org/content/10.1101/2020.05.11.089896v1.article-info))\n",
    "Media": [
      {
        "id": "attrn9FcXShRm4AgY",
        "url": "https://dl.airtable.com/.attachments/2b7bee01a09cad8afeccfc37c225cbaa/bd938f40/Slide_1",
        "filename": "Slide_1",
        "size": 166254,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/1b0485caccc591eae0e483cb09950290/5b5951f4",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c319ce9472b30e3b8969b5212bdb06e2/cfeb5ad1",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/7142f5cbc2854d973b61537c2967fc55/60bf1829",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att4pznttEysOQrZS",
        "url": "https://dl.airtable.com/.attachments/2df47ccdaeb78d99146fa74b3778fdeb/1cee3fd5/Slide_2",
        "filename": "Slide_2",
        "size": 192777,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ce4e8586e27ee877361686c483bd7dfd/64b9dc60",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/8b86de93fbda0969c847c0e33a34803c/290dd9f2",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/2cb5ec571e3fd08018d1e290cb37b013/1c0fe7a3",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attWhb45H5SdGLjpB",
        "url": "https://dl.airtable.com/.attachments/449b2c3810c673dd5cc3915c0081f8fa/43aee508/Slide_3",
        "filename": "Slide_3",
        "size": 184610,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/04efdb734641dd4eb4c79873df564da1/e0597750",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/95b37d8f81b3d16cd1a8631e7f17188a/ec24b8c0",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/7d3796b7ec674c361cd2d59e57635ce6/47e4b26d",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attAKD4Mv7OwbWkpq",
        "url": "https://dl.airtable.com/.attachments/a639a2110a4adc5c1accaf2d5d64e9e4/be1b9ba6/Slide_4",
        "filename": "Slide_4",
        "size": 243670,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/912095ee5f31bed73ed12bfe97005427/ab9212f2",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/a06cd57264955fb416f5625670c6735e/9760d4f7",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e19b8cdb2066c4baf248c135835986ba/aca55430",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "Last modified manual": "2020-08-28",
    "Last edited (simplified)": "2020-08-21T14:28:19.000Z",
    "Last edited (experts say)": "2020-10-13T20:22:35.000Z",
    "Last modified": "2020-10-13",
    "What our experts say wordcount": 465,
    "Background and context wordcount": 266,
    "Other resources wordcount": 115,
    "Wordcount": 846
  },
  {
    "id": "recIWpxnU5BOReqN2",
    "Question": "What are virus shut-out masks?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & shut-out masks",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "Uganda"
    ],
    "Background and context": "There are many new products being marketed to the public to help prevent, treat, and cure COVID-19. Unfortunately, many of these products are not backed by scientific evidence. \n\nTo prevent the spread of COVID-19, the World Health Organization (WHO), U.S Centers for Disease Control and Prevention (U.S. CDC), and other leading health organizations advise people to practice social distancing measures (maintaining at least 6 feet/2 meters from people), avoid large crowds especially indoors, practice frequent handwashing, and wear masks to prevent the spread of COVID-19. \n\nScientists have said that cloth face masks may provide some protection for the mask wearers, and surgical or N95 masks provide even more protection. Masks should not be worn by infants and children under the age of two; people who are incapacitated, unconscious, or have trouble breathing; or people who would not be able to remove the mask without help. Masks with exhalation valves or vents should not be worn to prevent the spread of COVID-19.\n",
    "What our experts say": "There is no scientific evidence that products marketed as “virus shut-out” (i.e. masks, cards, tags) prevent, treat or cure COVID-19 infection. In a search of medical and scientific literature, there were no search results or studies that mentioned “virus shut-out” masks. \n\nBased on the Virus Shut-Out Tag Facebook page and a search of \"virus shut-out\" website information, the primary product being promoted is the “virus shut-out” tag for wearing around one's neck. that will reportedly “reduce the 90% risk of being infected by continuously sending out the lowest concentration of chlorine dioxide.” \n\nThe Virus Shut-Out Tag Facebook page states that the cards “are not specifically made for COVID-19 and there’s no approved therapeutic claims.” The U.S. Environmental Protection Agency (EPA) states that the product is not registered with the EPA and “its safety and efficacy against viruses have not been evaluated.” The U.S. Centers for Disease Control and Prevention (US CDC) website states that the alleged active property, chlorine dioxide, is toxic and can be dangerous with long term or frequent exposure.\n\nOn the Virus Shut-Out Tag Facebook page, the “virus shut-out” tag is promoted to be used “with masks for better and stronger protection.” It is not clear if the masks on the company website are medical grade or provide protection above and beyond what cloth face masks provide.\n",
    "Glossary Terms": [
      "reclKahoPRbBLqUKg",
      "recCEG85awzcotyRi",
      "recnFUXyIZy81Rj1I",
      "rec1XtRl9QPx5zxBQ"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\t\n",
    "Topics": [
      "prevention",
      "disinfectant",
      "face masks"
    ],
    "Other resources": "1. U.S. EPA Acts to Protect the Public from Unregistered \"Virus Shut Out\" Product Imported into Honolulu and Guam ([EPA](https://www.epa.gov/newsreleases/us-epa-acts-protect-public-unregistered-virus-shut-out-product-imported-honolulu-and))\n2. Virus Shut-Out Tag ([Facebook](https://www.facebook.com/pg/virusshutouttagofficial/posts/?ref=page_internal))\n3. TOAMITSHOP ([TOAMIT](https://toamit.shop))\n4. Chlorine Dioxide ([US CDC NIOSH](https://www.cdc.gov/niosh/idlh/10049044.html))\n5. Chlorine Dioxide ([PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Chlorine-dioxide#section=Literature))\n6. Considerations for Wearing Masks ([US CDC](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html))\n7. Coronavirus disease (COVID-19) advice for the public: When and how to use masks ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks))\n8. Still Confused about Masks? Here's the Science Behind How Face Masks Prevent Coronavirus ([UCSF](https://www.ucsf.edu/news/2020/06/417906/still-confused-about-masks-heres-science-behind-how-face-masks-prevent))\n",
    "Last modified manual": "2020-08-21",
    "Last edited (simplified)": "2020-08-21T13:57:53.000Z",
    "Last edited (experts say)": "2020-08-21T13:57:53.000Z",
    "Last modified": "2020-08-21",
    "What our experts say wordcount": 218,
    "Background and context wordcount": 160,
    "Other resources wordcount": 68,
    "Wordcount": 446
  },
  {
    "id": "recxfVwuGguIhiJlV",
    "Question": "Are teachers more likely to be infected in the general community, or in schools? ",
    "Status": "Published",
    "Category": "Infections, Prevention, Community Transmission, Schools",
    "Subcategory": "On: COVID-19 & Schools",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "Africa "
    ],
    "Background and context": "Many school districts are deciding whether or not to reopen schools, switch to online or distance learning, postpone opening until later in the year, or use strategies that involve some combination of these options. One of the biggest considerations these school systems face is how to protect teachers and students from getting infected with or spreading COVID-19 to others. The most effective strategy to prevent widespread infections in schools is distance learning, but this poses many challenges to school districts, teachers, families, and students. The U.S. CDC states that in-person learning \"is in the best interest of students, when compared to virtual learning,\" so this is not the optimal way to teach or learn. \n\nTeachers, families, and school districts must compare the benefits of in-person schooling against the risks posed by the COVID-19 spread. Many teachers and families are concerned about the risks involved with putting their lives and family members at risk of becoming infected should they return to schools. Ultimately, the decision of how to teach students is up to each school system and family, but teachers may want to consider their individual risks and the policies their schools are taking to prevent becoming infected with the virus.\n\nThe fact that children with COVID-19 are less likely to have severe symptoms or have asymptomatic infections than adults may help make their families more comfortable with sending them back to school in-person. But regardless of their roles, all people returning to schools soon should use as many prevention tools as possible from wearing masks in public spaces to rigorously washing hands with soap and water to distancing between people as much as possible. \n",
    "What our experts say": "This question can only truly be evaluated on a case-by-case basis, as there are many different points that have to be considered. Variables include: \n\n- Where schools are located (major cities, rural areas, small towns, etc.)\n- How many children are in each classroom\n- How many students and teachers are wearing masks all day\n- How much distance is between desks\n- How many other people live with teachers in their homes\n- If the school is located in a place with a virus outbreak\n- Individual behaviors like taking public transportation, social distancing and mask wearing\n\nIn addition to the individual risks each teacher faces, schools pose additional risks due to the high number of students who are in close contact with one another in closed, tight rooms. This can make prevention tools like social distancing and frequent hand washing difficult. It is also why it is important for school systems that are reopening, or have already reopened, to create safe, healthy spaces for students and teachers with policies like mandatory mask wearing, allowing for six feet/two meters of distance between desks, routine testing (if possible), using proper ventilation, consistent and frequent cleaning and decontamination of surfaces, installing physical barriers, and avoiding group transportation. \n\nKeeping both students and teachers safe in schools and communities depends on the behaviors, environments, underlying risk factors, and choices made by school systems and individuals. This is why it is not possible to accurately estimate where teachers are more likely to get infected with COVID-19, but shows why it is so critical to prevent the spread of the virus in all environments.\n\n",
    "Glossary Terms": [
      "rec8po7cJXvqkaQYB"
    ],
    "Variation of the answer depending on country of residence": "Yes\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "Yes\n",
    "Topics": [
      "schools",
      "community transmission",
      "teachers",
      "prevention"
    ],
    "Other resources": "1. How Many Teachers Are at Risk of Serious Illness If Infected with Coronavirus? ([KFF](https://www.kff.org/coronavirus-covid-19/issue-brief/how-many-teachers-are-at-risk-of-serious-illness-if-infected-with-coronavirus/)) \n2. Operating schools during COVID-19: CDC's Considerations ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/schools.html)) \n",
    "Last modified manual": "2020-08-21",
    "Last edited (simplified)": "2020-08-21T13:46:00.000Z",
    "Last edited (experts say)": "2020-08-21T13:46:00.000Z",
    "Last modified": "2020-08-21",
    "What our experts say wordcount": 262,
    "Background and context wordcount": 274,
    "Other resources wordcount": 25,
    "Wordcount": 561
  },
  {
    "id": "recHgpMkShciBa9VJ",
    "Question": "Is there any evidence for a relationship between staph infections and using masks to prevent the spread of COVID-19? ",
    "Status": "Published",
    "Category": "Infections, Masks",
    "Subcategory": "On: COVID-19 & staph infections",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Due to requirements and recommendations that people wear face masks in order to prevent the spread of COVID-19, many news outlets have been reporting the potential for negative health outcomes related to wearing masks. There are very few health risks when it comes to this prevention measure, and masks are recommended for the majority of the population. However, one of the issues being widely discussed in international media is the potential for staph infections to occur due to face masks irritating and chafing the skin, causing a cut or wound. Staph infections can only occur through a skin opening, so while this concern is a valid one, it is highly unlikely to occur.\n\nMany of the health concerns related to face masks are very low risk, including staph infections, breathing difficulties, and allergies. In order to prevent any illness from occurring related to wearing a mask, it is important to speak to your doctor about any medical concerns you might have. It is also important to practice cleaning your face and mask, washing your hands rigorously with soap and water, and maintaining distance between yourself and others.\n",
    "What our experts say": "It is very rare for a person wearing a mask to develop a staph infection as a result of the mask. Staphylococcus aureus, also known as a 'staph infection,' is a germ that can be found on people's skin, and can potentially cause serious infections if it enters the bloodstream. \n\nUsually staph infections are minor and can be treated with antibiotics, but more severe infections can be worrisome. In order to develop a staph infection, the person wearing the mask would have to have an open lesion or untreated wound on their face, but even then, it very rarely happens. \n\nSome of the same prevention tips health organizations recommend for preventing COVID-19 infections can help prevent staph infections, like washing your hands rigorously, cleaning and bandaging wounds on your skin, and regularly cleaning your mask. Wearing moisturizers like lotion can also help protect your skin from irritation which could lead to an open wound, if the skin becomes raw. Though cases of staph infections related to mask wearing are very rare, it is important to take prevention measures seriously to avoid a potential infection.\n",
    "Glossary Terms": [
      "recDcsncLISZFuB6t",
      "reclKahoPRbBLqUKg"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "face masks",
      "staph infection"
    ],
    "Other resources": "1. Staph infections can kill ([U.S. CDC](https://www.cdc.gov/vitalsigns/staph/index.html)) \n2. What Causes Staph Infections, and How Can You Avoid Them? ([CC](https://health.clevelandclinic.org/staph-infections-what-are-they-and-when-should-you-worry/)) \n3. VERIFY: Getting a staph infection from a mask is pretty rare ([K5](https://www.king5.com/article/news/verify/verify-staph-infection-risk-masks-should-be-low-wounds-treated/507-3fc1834e-b0f3-4b9f-bb01-4acecdbc8733)) \n",
    "Last modified manual": "2020-08-20",
    "Last edited (simplified)": "2020-08-20T20:32:12.000Z",
    "Last edited (experts say)": "2020-08-20T20:52:35.000Z",
    "Last modified": "2020-08-20",
    "What our experts say wordcount": 183,
    "Background and context wordcount": 186,
    "Other resources wordcount": 33,
    "Wordcount": 402
  },
  {
    "id": "rec5d5bDYQKs3umW2",
    "Question": "What do we know about pregnancy and COVID-19?",
    "Status": "Published",
    "Category": "Yes, pregnant women of color may be disproportionately affected",
    "Subcategory": "On: COVID-19 & Pregnancy",
    "Background and context": "A pregnant individual might be at increased risk for severe COVID-19 disease, and there is also emerging data to show potential complications related to birth and infant outcomes. Since it is possible for someone who is pregnant to transmit the virus to their newborn, it is common to test pregnant individuals pre-labor for COVID-19. It is unknown if the virus is spread before, during, or after birth. \n\nThere have been documented cases of mistreatment, abuse, and obstetric violence of pregnant individuals globally in the context of COVID-19. Examples include limited prenatal care, lack of choice around who is in the delivery room, separation from newborns, and verbal abuse. The World Health Organization has issued guidance on pregnancy and COVID-19 aiming to address these concerns by discouraging negative actions such as newborn separation and forced cesarean sections.\n",
    "What our experts say": "If a pregnant person becomes infected with COVID-19 there is a higher chance they will require hospitalization and suffer more serious symptoms of the disease. \n\nIn early November 2020, the U.S. Centers for Disease Control and Prevention (U.S. CDC) released a report on 400,000 women between the ages of 15 and 44 with symptomatic COVID-19 which found that admission to the intensive care unit (ICU), invasive ventilation, extracorporeal membrane oxygenation, and death were more likely in pregnant women than in non-pregnant women. \n\nThe report includes that increased risk for admission to the ICU was \"particularly notable\" among Asian and Native Hawaiian/Pacific Islander pregnant women, and that both disproportionate risk for SARS-CoV-2 infection and higher risk for death was observed for pregnant Hispanic women. \n\nHighlighting the racial/ethic disparities, the report states that \"regardless of pregnancy status, non-Hispanic Black women experienced a disproportionate number of deaths.\" This report adds to the current knowledge around increased risks related to COVID-19 for pregnant women, particularly pregnant women of color, and suggests that pregnant women should be counseled about increased risks of severe illness or death related to COVID-19 as well as measures to prevent infection in their families.\n\nPreterm birth has also been associated with COVID-19, according to another report released by the U.S. CDC in early November 2020. The U.S. CDC encourages people to take preventive measures while pregnant and to seek prenatal care throughout pregnancy. If a person is infectious during labor, it is possible for them to spread the virus to the baby.\n\nOutside of the U.S., the World Health Organization (WHO) has reported that emerging international research suggests pregnant women with COVID-19 are more likely to need intensive care if severely ill, and more likely to give birth prematurely. The latest findings also suggest that pregnant women with COVID-19 who have pre-existing medical conditions, who are older, or who are overweight are more likely to suffer severe health complications due to COVID-19.\n",
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "pregnancy",
      "infection",
      "transmission",
      "symptoms",
      "children",
      "infant"
    ],
    "Other resources": "1. COVID-19 and Pregnancy ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/pregnancy-breastfeeding.html))\n2. Q&A: Pregnancy, childbirth and COVID-19 ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-on-covid-19-pregnancy-and-childbirth))\n3. How has COVID-19 affected women's rights during childbirth? Help us track this globally ([Open Democracy](https://www.opendemocracy.net/en/5050/womens-rights-during-childbirth-help-us-track-globally/))\n4. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–October 3, 2020 ([U.S. CDC](https://www.cdc.gov/mmwr/volumes/69/wr/mm6944e3.htm?s_cid=mm6944e3_w))\n5. Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19- COVID-NET, 13 States, March 1-August 22, 2020 ([US CDC](https://www.cdc.gov/mmwr/volumes/69/wr/mm6938e1.htm?s_cid=mm6938e1_w))\n6. New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies ([WHO](https://www.who.int/news/item/01-09-2020-new-research-helps-to-increase-understanding-of-the-impact-of-covid-19-for-pregnant-women-and-their-babies#:~:text=The%20research%20findings%20show%20that,likely%20to%20give%20birth%20prematurely.))\n7. Impact of COVID-19 mitigation measures on the incidence of preterm birth: a national quasi-experimental study ([The Lancet](https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(20)30223-1/fulltext))\n",
    "DB (Hindi)": [
      "rec6JSRxYEBnuLp68"
    ],
    "Media": [
      {
        "id": "attQikJmSRwatkDEo",
        "url": "https://dl.airtable.com/.attachments/369c5c74ae8aa7a7c9eb181935fb048d/cdc2db38/Slide_1",
        "filename": "Slide_1",
        "size": 202607,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/8a5c427ecbbef4b7514c9efc6a864905/4ceda84d",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/70c1e99de0a081588087d277e54f4e9d/7f678f3f",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/f0ba3c5fb18d9726b9cc2760f48d134b/fbf8ad23",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attNa995h84UwzKxZ",
        "url": "https://dl.airtable.com/.attachments/393cb257c4d4bb7a25bc85b244abb441/1834a40c/Slide_2",
        "filename": "Slide_2",
        "size": 145539,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/0ba5c83e19c094922f69d9a6f1d9cbb3/51c55084",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b7b124c36b36df4ec489186b62a342c5/74604fd6",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/1878ff08c41279025b27e97c0d45d15f/42807018",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attglLTI8x5mJBPOu",
        "url": "https://dl.airtable.com/.attachments/bb65a7dc82e843ed1d732bace13f2cde/d6ba1b69/Slide_3",
        "filename": "Slide_3",
        "size": 167704,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/417bea1fb3b1860dd7565b9c2d0e1d19/40a48be9",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/8b747b707266ced25a77963bf25ffd5f/074fe0c6",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/95f056139c369e8b65565fd0bef17219/c99f6781",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attXI19nzALMjr9ky",
        "url": "https://dl.airtable.com/.attachments/6ee26664647d025034060f0bdc610162/39162f4e/Slide_4",
        "filename": "Slide_4",
        "size": 210106,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/772113c315f525be1d56a19269980477/f1760f86",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/7c6322070142c472c5672500a208f297/36d169b8",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e004e7cec27e24aeacfb59036b7edb2d/3bc120cf",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attpVLhckBQeMOZEG",
        "url": "https://dl.airtable.com/.attachments/88204d382ae7db22d2f8a1edceac7a26/f6d79cf4/Slide_5",
        "filename": "Slide_5",
        "size": 180218,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/7fec78c1e63a154265e95767d31f76e2/28051621",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ca7e52951e95b422709fae17b36e7be5/eb40ba2b",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/1956b3b6c3bcaf0017a41106125dc385/5d32fe03",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recPlwgQhdyeRdVmj"
    ],
    "DB (Portuguese)": [
      "recqm784f7HaZVzmT"
    ],
    "Rollup test 2": [
      "recvrpgPkeLqlFbhv"
    ],
    "Media Package": [
      {
        "id": "attKqIpjnt4b4e06U",
        "url": "https://dl.airtable.com/.attachments/a24b500c95f62a08cc79da5522c1a97a/5b486009/Pregnancyandcovid-19.zip",
        "filename": "Pregnancy and covid-19.zip",
        "size": 907741,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-12-07",
    "Last edited (simplified)": "2020-11-25T19:24:50.000Z",
    "Last edited (experts say)": "2020-12-07T14:36:44.000Z",
    "Last modified": "2020-12-07",
    "What our experts say wordcount": 319,
    "Background and context wordcount": 136,
    "Other resources wordcount": 107,
    "Wordcount": 562,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "गर्भावस्था गंभीर कोविड-19 रोग के लिए जोखिम बढ़ाती है, जिसका अर्थ है कि एक गर्भवती व्यक्ति जो कोरोनोवायरस से संक्रमित हो जाता है, को अस्पताल में भर्ती होने और बीमारी के अधिक गंभीर लक्षणों से पीड़ित होने की संभावना है। इस समय पूरा और उपलब्ध अध्ययनों के अनुसार, प्रसव के बाद और जन्म संबंधी अन्य जटिलताएं कोविड-19 से जुड़ी नहीं हैं। यू.एस. सेंटर्स फॉर डिसीज़ कंट्रोल एंड प्रिवेंशन (यू॰एस सीडीसी) गर्भवती होने के दौरान लोगों को निवारक उपाय करने और गर्भावस्था के दौरान प्रसव पूर्व देखभाल के लिए प्रोत्साहित करता है। यदि कोई व्यक्ति श्रम के दौरान संक्रामक है, तो उनके लिए वायरस को बच्चे में फैलाना संभव है।\n \nइस प्रविष्टि को 20 अगस्त 2020 को नई जानकारी के साथ अद्यतन किया गया था।"
    ],
    "Hindi - Background and context": [
      "जबकि गर्भवती महिलाओं को गंभीर कोविड-19 बीमारी का खतरा बढ़ सकता है, लेकिन पूर्व-अवधि की जटिलताओं को दिखाने के लिए अभी तक कोई डेटा नहीं है। क्योंकि गर्भवती महिलाओं के लिए वायरस को नवजात शिशु तक पहुंचाना संभव होता है, इसलिए उपन्यास कोरोनरी वायरस के लिए गर्भवती महिलाओं का प्रसव पूर्व परीक्षण करना आम है। यह अज्ञात है कि क्या वायरस जन्म से पहले, दौरान या बाद में फैलता है।\n \nकोविड-19 के संदर्भ में विश्व स्तर पर गर्भवती महिलाओं के साथ दुर्व्यवहार, दुर्व्यवहार और प्रसूति संबंधी हिंसा के मामलों का दस्तावेजीकरण किया गया है। उदाहरणों में सीमित प्रसवपूर्व देखभाल, प्रसव कक्ष में आस-पास की पसंद का अभाव, नवजात शिशुओं से अलगाव और मौखिक दुर्व्यवहार शामिल हैं। विश्व स्वास्थ्य संगठन ने गर्भावस्था और कोविड-19 पर मार्गदर्शन जारी किया है, जिसका उद्देश्य नवजात जुदाई और मजबूर सिजेरियन सेक्शन जैसे नकारात्मक कार्यों को हतोत्साहित करके इन चिंताओं को दूर करना है।\n\nइस प्रविष्टि को 11 अगस्त 2020 को नई जानकारी के साथ अद्यतन किया गया था।"
    ]
  },
  {
    "id": "recgZZwuf8TlI84F8",
    "Question": "What is assurance testing and how can it help with COVID-19 testing?",
    "Status": "Published",
    "Category": "Testing",
    "Subcategory": "On: COVID-19 & assurance testing",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Many nations have reached a point of being able to loosen some pandemic restrictions, like sheltering in place and avoiding gatherings. Governments have considered ways to prevent another rise in COVID-19 cases and one of the most talked about tools is widespread testing for infected individuals. While testing is usually done on patients who have symptoms of the virus, have been exposed to people infected with the virus, or who are at high risk of catching the virus, monitoring entire populations for any potential outbreaks is a strategy that many nations are considering. \n\nAssurance testing is a form of surveillance testing, but instead of tracking at-risk groups, they track an entire region to make sure new cases aren't happening. Since it is currently presumed that many cases of COVID-19 are spread by individuals who do not experience any symptoms, this type of testing could help find cases that would not be detected by prioritizing only those with symptoms. \n\nThis type of testing would also give public health groups the data to more accurately target areas with small outbreaks quickly, in order to isolate patients and complete contact tracing to inform others about their exposure to infected people.\n\nIt is not known what testing strategy many nations and regions will use to monitor COVID-19 cases, but assurance testing has strong potential for its ability to keep large populations safer as  economies and societies reopen.\n",
    "What our experts say": "Assurance testing, also called 'universal testing,' is a process in which an entire population gets tested for a virus several times over a specific period. So far during the pandemic, testing has mostly been saved for people who are experiencing symptoms, people who were in contact with individuals who tested positive for COVID-19, or people who are at high-risk of infection. Assurance testing would remove those limitations and allow everyone to get tested. \n\nAssurance testing tests large regions so that if an outbreak happens, it can be caught early and controlled through isolation measures. This type of testing could help different regions as they begin to reopen economies, schools, and other large gatherings after the lifting of lockdown and shelter in place orders. \n\nAssurance testing can help people interact with one another safely without leading to an increase in cases and uncontrollable outbreaks. Social distancing and mask wearing are still recommended in most regions for the near future, but assurance testing could help to maintain lower levels of the virus in populations that have been able to reopen.\n\n\n",
    "Glossary Terms": [
      "recjKaIisozM0oUHu",
      "rec0Z0wt4ie5D2pH7"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "testing",
      "assurance testing"
    ],
    "Other resources": "1. Why We Must Test Millions a Day ([Harvard](https://ethics.harvard.edu/test-millions)) \n2. A Better Way to Scale Covid-19 Testing ([HBR](https://hbr.org/2020/07/a-better-way-to-scale-covid-19-testing?utm_source=linkedin&utm_campaign=hbr&utm_medium=social)) \n\n",
    "Rollup test 2": [
      "recV4FafwNfu8pk9e"
    ],
    "Last modified manual": "2020-08-14",
    "Last edited (simplified)": "2020-08-11T23:31:15.000Z",
    "Last edited (experts say)": "2020-08-14T17:40:31.000Z",
    "Last modified": "2020-08-14",
    "What our experts say wordcount": 178,
    "Background and context wordcount": 233,
    "Other resources wordcount": 19,
    "Wordcount": 430
  },
  {
    "id": "reczdKiAkOFyEuS5P",
    "Question": "What do we know about monoclonal antibodies as part of a treatment or vaccine for COVID-19?",
    "Status": "Published",
    "Category": "Prevention, Treatment",
    "Subcategory": "On: COVID-19 & monoclonal antibodies",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Monoclonal antibodies have been trending in the news during the COVID-19 pandemic, and also previously for cancer drugs and other applications. Monoclonal antibodies are typically produced in a lab through cloning, to act as antibodies which are proteins made by the body to fight infections. \n\nMonoclonal antibodies have the potential to be produced with consistent quality and purity at a large scale. Additionally, monoclonal antibodies have the potential to provide therapeutic benefits to the immune system because they are highly selective in how they bond to specific foreign invaders that cause disease.\n\nMonoclonal antibodies were first developed in the 1970s, and later Georges Köhler and César Milstein received the 1984 Nobel Prize in Physiology/Medicine for developing a key way to produce monoclonal antibodies. Earlier, Paul Ehrlich and Élie Metchnikoff received the 1908 Nobel Prize for Physiology/Medicine for work that set the foundation for making compounds to selectively target a disease-causing organism. \n\n_This entry was updated with new information on August 11, 2020._\n",
    "What our experts say": "Antibodies are tiny proteins created by the immune system to attach to any foreign invaders in the immune system (antigens) and also tell the immune system to begin defending itself from this threat. Monoclonal antibodies (which means 'one type of antibody') are antibodies created in a lab that can act as a replacement for the antibodies the body normally creates. The difference between these lab-made antibodies and those created by the immune system is that the monoclonal types are uniquely designed to target a specific antigen, in this case the virus that causes COVID-19, so it can send it messages, try to destroy it, and even make it easier for the immune system to find the antigen and attack it. Once the antigen is mapped out in the lab and scientists are able to produce monoclonal antibodies to attach to them, the lab then makes a large amount of these antibodies so they can help the immune system in its fight against a threat.\n\nCOVID-19 is unique because it is characterized by its spikes, which you can see under a microscope. Monoclonal antibodies created in the lab work by targeting and breaking these spikes on the virus, which are critical for the virus to enter our cells and infect us. There is growing interest in their potential for use in both vaccine development, but also treatment for infection. The hope is that these antibodies can work as both a vaccine to prevent infection, and/or as a therapeutic treatment to help reduce severity of illness in patients with COVID-19. It is likely that after rigorous testing for safety and effectiveness, these antibodies would be produced in labs, manufactured in large quantities, and they would be injected into people to prevent infection from the virus. As of now, no monoclonal antibody treatments have been approved for this use and are still being heavily researched.\n\n_This entry was updated with new information on August 11, 2020._\n",
    "Glossary Terms": [
      "recmajcAORyuqhZPc",
      "recFg30lvATvVhmBG",
      "recJhCnFxAX2jAH0h",
      "rectkO1d0FhUHQ0Of"
    ],
    "Variation of the answer depending on country of residence": "No \n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No \n",
    "Topics": [
      "monoclonal antibodies",
      "antibody",
      "immune system",
      "protein spikes"
    ],
    "Other resources": "1. The history of monoclonal antibody development – Progress, remaining challenges and future innovations ([Annals of Medicine and Surgery](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284445/))\n2. The birth of monoclonal antibodies ([Nature Immunology](https://www.nature.com/articles/ni.3608))\n3. Monoclonal antibodies — a proven and rapidly expanding therapeutic modality for human diseases ([Protein and Cell](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875100/))\n4. Monoclonal Antibodies for Prevention and Treatment of COVID-19. ([JAMA](https://jamanetwork.com/journals/jama/fullarticle/2767383))\n5. Designer antibodies could battle COVID-19 before vaccines arrive ([Science](https://www.sciencemag.org/news/2020/08/designer-antibodies-could-battle-covid-19-vaccines-arrive)) \n\n",
    "Rollup test 2": [
      "recR8Xa8PNvTsbyZg"
    ],
    "Last modified manual": "2020-08-11",
    "Last edited (simplified)": "2020-08-12T00:18:21.000Z",
    "Last edited (experts say)": "2020-08-31T19:09:10.000Z",
    "Last modified": "2020-08-31",
    "What our experts say wordcount": 321,
    "Background and context wordcount": 160,
    "Other resources wordcount": 61,
    "Wordcount": 542
  },
  {
    "id": "recVRsQKdIEEtButM",
    "Question": "How does the immune system work to fight COVID-19?",
    "Status": "Published",
    "Category": "Immune Response",
    "Subcategory": "On: COVID-19 & immune system response",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "One of the reasons it can be difficult to understand how the immune system responds to the virus that causes COVID-19 (and all viruses) is because everyone's immune system is unique. After being infected, each of us produces different levels of antibodies -- these are proteins that attach to the antigens (any substance, usually a protein, that triggers your immune system to produce antibodies against it) and attack them. These differences can impact how long patients remain sick with COVID-19 and how severe their cases can be. A further complicating factor is that non-active parts of the virus can still cause your immune system to overreact, as if the virus is still reproducing in your body, when it isn't really doing that. \n\nInducing an immune response in our body is also a crucial component of vaccine development. A successful vaccine must produce antibodies to prepare our bodies to defend against the virus if we are exposed to it again in the future. The better a vaccine can mimic a natural infection, the better it will be able to trigger an immune reaction that mimics a natural immune response.\n",
    "What our experts say": "When our bodies are exposed to pathogens - tiny, foreign organisms such as viruses, bacteria, fungi, worms and other invaders - our natural defense called the 'immune system' tries to protect us and keep us healthy. When the body senses that the pathogen, in this case, COVID-19, is trying to get into the body through the nose, mouth, or eyes, it launches into the first part of this defense called the 'innate immune system.'\n\nA. Innate Immune System\n\nThis part of the immune system tries to prevent the virus from spreading and reproducing in our bodies, and from moving around in our bodies. The innate immune system is made up of several types of defenses, including the skin and body openings (like the mouth and nose); different white blood cells to defend our bodies from pathogens; and different substances in bodily fluids and the blood to try and stop the virus from reproducing. This system tries to prevent the virus from entering the body through the mouth, nose, and eyes, but if the virus does get inside a person, then white blood cells will move toward the virus' location and cause an increase in blood circulation there so it becomes hot and swollen while the body might also produce a fever (as high temperatures can sometimes kill pathogens).  At this point, other cells in the blood and tissue try to enclose the virus and eat the viral particles.\n\nBut if after four to seven days, the innate immune system is not able to kill all of the virus and the virus causes an infection, the adaptive immune system will begin to defend the body.\n\nB. Adaptive Immune System\n\nThe adaptive immune response, also called the acquired immune system, is a much more focused effort to target and destroy the foreign threat: the virus. Two important parts of the adaptive immune system are white blood cells called B cells and T cells. B cells create antibodies - small proteins that attach** **to unique parts of each pathogen called 'antigens'. When your body senses a particular antigen attached to the virus in the body, B cells then creates antibodies that can connect to those antigens using a specific shape that was created to match it. \n\nMeanwhile, T cells try to kill the antigen like an army fighting off an invader. Some T cells also help B cells make antibodies while others are busy working to stop the virus from reproducing in your body and spreading to different parts of your body. This part of the adaptive immune response also creates longer term memory of the virus that will help it fight off the virus if it is exposed to it again in the future, and to launch its defenses more quickly. Researchers are now studying how long-term this memory-based immunity lasts and how strong it is in defending against COVID-19 infection in the future.\n\nC. Conclusion\nHopefully at this point, the innate and adaptive immune systems are able to kill the virus and create some immunity to it. If not, the immune system continues working to fight off the virus, but symptoms might worsen as the body weakens after spending so much energy to fight off the virus. In some cases, COVID-19 might impact organs so severely that it can result in death.\n\n\n\n\n",
    "Glossary Terms": [
      "recEwiYdLnp5pCbQD",
      "recicqEslROBkl8gG",
      "recmajcAORyuqhZPc",
      "rectkO1d0FhUHQ0Of"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "t cells",
      "b cells",
      "cytokines",
      "immune system",
      "antibody"
    ],
    "Other resources": "1. How the Body Battles COVID-19 ([Tufts](https://now.tufts.edu/articles/how-body-battles-covid-19)) \n2. How The Body Reacts To Viruses ([HMS](https://onlinelearning.hms.harvard.edu/hmx/immunity/)) \n",
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "reczBw4HjVLgRWCor"
    ],
    "DB (Portuguese)": [
      "recaC7WVhPUcZEgo1"
    ],
    "Rollup test 2": [
      "recgPJULcid09Rr4g"
    ],
    "Last modified manual": "2020-08-02",
    "Last edited (simplified)": "2020-08-02T20:36:17.000Z",
    "Last edited (experts say)": "2020-08-02T20:36:17.000Z",
    "Last modified": "2020-08-14",
    "What our experts say wordcount": 544,
    "Background and context wordcount": 188,
    "Other resources wordcount": 16,
    "Wordcount": 748
  },
  {
    "id": "recp0leXTiAvzw4cH",
    "Question": "Can we trust antibody tests to tell who has been infected and who hasn't?",
    "Status": "Published",
    "Category": "Testing",
    "Subcategory": "On: COVID-19 & antibody tests",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "While COVID-19 diagnostic tests determine whether or not a person is currently infected with the virus, antibody tests are used to determine whether or not a person was infected with COVID-19 in the past. This occurs through a process in the immune system whereby the body develops a type of protein called  'antibodies' in response to the presence of a foreign object threatening the body, also called an \"antigen\", which in this case is the virus. The antibodies latch onto antigens and then work to remove them from the body. Antibodies are detected in the blood of people who are tested after infection; they show the body’s efforts to fight off a specific infection. This is why antibody tests can determine whether or not a person has had a specific virus.\n \nIn comparison, tests for active cases of the virus (such as a polymerase chain reaction (PCR) test) looks for the actual genes of the virus itself in a person. This means that COVID-19 has to be active and have a large enough amount infecting in a person in order for the test to be accurate. One difference between these tests is the fact that antibody tests look for prior infection from a virus using blood, whereas PCR-based tests are run on saliva or mucus samples to look for the virus's genetic material and diagnose people who are currently infected with the novel coronavirus. \n\nEach tests have different levels of of specificity (how well a test identifies patients who do not have a disease) and sensitivity (how well a test identifies patients who do have a disease), and each have different ideal standards. \n\nFor instance, while with antibody tests the key metric is specificity, with diagnostic tests, the key metric is sensitivity. This is because an individual with a false negative test result may be mistakenly reassured that they are safe (just as one would with a false positive antibody test), and in turn pay less attention to basic prevention (e.g., social distancing).\n",
    "What our experts say": "Antibody tests are now available in many parts of the world, and they can play an important role in understanding COVID-19 trends and identifying groups at higher risk for infection. \nDiagnostic tests are never 100% accurate. Sometimes, a test will produce false positives (when you test positive for the virus, but don't have it) and false negatives (when you test negative for the virus, but you really have been infected). The antibody tests for COVID-19 are similar. To be able to trust the results of an antibody test, we must look at its ability to detect the presence of COVID-19 antibodies when they are present, and its ability to confirm the absence COVID-19 antibodies when they are truly absent. \nIn the context of the current pandemic, it is important for us to reduce the amount of false positive test results that can occur by choosing a test that is highly specific. This means we must choose a test whose ability to correctly identify those without the disease is as accurate as possible, so that a negative test result truly means that person has not been infected with COVID-19. This is because an individual with a false positive test result may be mistakenly reassured that they are safe, and may pay less attention to basic prevention (e.g., social distancing). In this context, the U.S. CDC recommends choosing a test with very high specificity, perhaps 99.5% or greater. Irrespective of where people reside, they should choose the test available on the market with the highest specificity. However, it is important to note that at this stage of the pandemic, we don't know yet exactly what a positive antibody test means in practice. We are not sure yet if a positive antibody test means that the antibodies will give the person immunity (i.e. prevent them from getting sick again with COVID-19); and if they do, how long this protection can last (weeks? months?). Several studies are currently underway. \n",
    "Glossary Terms": [
      "rec06X4QusZL1zCzd",
      "recc8ZAXzbbMiYc51",
      "recmajcAORyuqhZPc",
      "recPNexvQiug4RFJu",
      "rectkO1d0FhUHQ0Of"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "testing",
      "antibody",
      "immunity"
    ],
    "Other resources": "1. Interim Guidelines for COVID-19 Antibody Testing ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html))\n2. Waiting for Certainty on Covid-19 Antibody Tests - At What Cost? ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMp2017739?query=RP))\n\n",
    "DB (Hindi)": [
      "recmCB2gfbWWiSPYm"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recRUiE5cFAC5eDPU"
    ],
    "DB (Portuguese)": [
      "recsVTwjazJydWhPu"
    ],
    "Rollup test 2": [
      "recwyLXULjdLUSLOy"
    ],
    "Last modified manual": "2020-08-14",
    "Last edited (simplified)": "2020-07-15T21:22:09.000Z",
    "Last edited (experts say)": "2020-07-15T21:22:09.000Z",
    "Last modified": "2020-08-14",
    "What our experts say wordcount": 323,
    "Background and context wordcount": 333,
    "Other resources wordcount": 21,
    "Wordcount": 677,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "एंटीबॉडी परीक्षण अब दुनिया के कई हिस्सों में उपलब्ध हैं, और वे कोविड-19 रुझानों को समझने और संक्रमण के लिए उच्च जोखिम वाले समूहों की पहचान करने में महत्वपूर्ण भूमिका निभा सकते हैं।\nनैदानिक ​​परीक्षण कभी भी 100% सटीक नहीं होते हैं। कभी-कभी, एक परीक्षण गलत सकारात्मक उत्पन्न करेगा (जब आप वायरस के लिए सकारात्मक परीक्षण करते हैं, लेकिन आपके पास नहीं है) और गलत नकारात्मक (जब आप वायरस के लिए नकारात्मक परीक्षण करते हैं, लेकिन आप वास्तव में संक्रमित हो चुके हैं)। कोविड-19 के लिए एंटीबॉडी परीक्षण समान हैं। एक एंटीबॉडी परीक्षण के परिणामों पर भरोसा करने में सक्षम होने के लिए, हमें कोविड-19 एंटीबॉडी की मौजूदगी का पता लगाने की इसकी क्षमता को देखना चाहिए, और अनुपस्थित कोविड-19 एंटीबॉडी की पुष्टि करने की इसकी क्षमता जब वे वास्तव में अनुपस्थित हैं।\nवर्तमान महामारी के संदर्भ में, हमारे लिए ग़लत सकारात्मक परीक्षण परिणामों की मात्रा को कम करना महत्वपूर्ण है जो एक परीक्षण का चयन करके हो सकता है जो अत्यधिक विशिष्ट है। इसका मतलब है कि हमें एक परीक्षण का चयन करना चाहिए जिसकी बीमारी के बिना उन लोगों की सही पहचान करने की क्षमता उतनी ही सटीक हो, जितना कि एक नकारात्मक परीक्षा परिणाम का सही अर्थ है कि वह व्यक्ति कोविड-19 से संक्रमित नहीं हुआ है। ऐसा इसलिए है क्योंकि एक ग़लत सकारात्मक परीक्षा परिणाम वाला व्यक्ति गलती से भरोसा दिलाया जा सकता है कि वे सुरक्षित हैं, और बुनियादी प्रतिबंध पर कम ध्यान दे सकते हैं (जैसे, सामाजिक दूरी)। इस संदर्भ में, यू.एस सीडीसी बहुत उच्च विशिष्टता के साथ एक परीक्षण चुनने की सलाह देता है, शायद 99.5% या इससे अधिक। भले ही लोग निवास करते हों, उन्हें उच्चतम विशिष्टता के साथ बाजार में उपलब्ध परीक्षण का चयन करना चाहिए। हालांकि, यह ध्यान रखना महत्वपूर्ण है कि महामारी के इस स्तर पर, हम अभी तक वास्तव में नहीं जानते हैं कि व्यवहार में सकारात्मक एंटीबॉडी परीक्षण का क्या मतलब है। हमें अभी तक यकीन नहीं है कि अगर एक सकारात्मक एंटीबॉडी परीक्षण का मतलब है कि एंटीबॉडी व्यक्ति को रोग प्रतिरोधक शक्ति प्रदान करेंगे (यानी उन्हें कोविड-19 के साथ फिर से बीमार होने से रोकेंगे); और यदि वे करते हैं, तो यह सुरक्षा कितने दिनों तक (सप्ताह? महीने) रह सकती है। वर्तमान में कई अध्ययन चल रहे हैं।"
    ],
    "Hindi - Background and context": [
      "जबकि कोविड-19 नैदानिक ​​परीक्षण यह निर्धारित करते हैं कि कोई व्यक्ति वर्तमान में वायरस से संक्रमित है या नहीं, एंटीबॉडी परीक्षण का उपयोग यह निर्धारित करने के लिए किया जाता है कि कोई व्यक्ति पहले से ही कोविड-19 से संक्रमित था या नहीं। यह प्रतिरक्षा प्रणाली में एक प्रक्रिया के माध्यम से होता है, जिससे शरीर में एक विदेशी वस्तु की उपस्थिति के जवाब में शरीर में एक प्रकार का प्रोटीन विकसित होता है, जिसे शरीर को खतरा होता है, जिसे \"एंटीजन\" भी कहा जाता है, जो इस मामले में वायरस है। एंटीबॉडी एंटीजन पर चिपकते हैं और फिर उन्हें शरीर से निकालने का काम करते हैं। इनफ़ेक्शन के बाद परीक्षण किए जाने वाले लोगों के रक्त में एंटीबॉडी का पता लगाया जाता है; वे एक विशिष्ट इनफ़ेक्शन से लड़ने के लिए शरीर के प्रयासों को दिखाते हैं। यही कारण है कि एंटीबॉडी परीक्षण यह निर्धारित कर सकते हैं कि किसी व्यक्ति में एक विशिष्ट वायरस है या नहीं।\n\nइसकी तुलना में, वायरस के सक्रिय मामलों के लिए परीक्षण (जैसे कि पोलीमरेज़ चेन रिएक्शन (पीसीआर) टेस्ट) किसी व्यक्ति में वायरस के वास्तविक जीन के लिए ही खोजता है। इसका मतलब है कि कोविड-19 को सक्रिय होना चाहिए और परीक्षण के लिए सटीक होने के लिए एक व्यक्ति में एक बड़ी मात्रा में इनफ़ेक्शन होना चाहिए। इन परीक्षणों के बीच एक अंतर का यह तथ्य है कि एंटीबॉडी परीक्षण रक्त का उपयोग कर वायरस से पूर्व इनफ़ेक्शन के लिए देखते हैं, जबकि पीसीआर-आधारित परीक्षण लार या बलगम के नमूने पर वायरस के आनुवंशिक सामग्री को देखने के लिए चलाए जाते हैं और उन लोगों का निदान करते हैं जो वर्तमान में कोरोनावाइरस से संक्रमित हैं।\n\nप्रत्येक परीक्षणों में विशिष्टता के विभिन्न स्तर होते हैं (कितनी अच्छी तरह एक परीक्षण उन रोगियों की पहचान करता है जिनके पास बीमारी नहीं है) और संवेदनशीलता (कितनी अच्छी तरह एक परीक्षण उन रोगियों की पहचान करता है जिनके पास बीमारी है), और प्रत्येक के अलग-अलग आदर्श मानक हैं।\n\nउदाहरण के लिए, एंटीबॉडी परीक्षणों के दौरान प्रमुख मापीय विशिष्टता है, नैदानिक ​​परीक्षणों के साथ, प्रमुख मापीय संवेदनशीलता है। ऐसा इसलिए है क्योंकि एक गलत नकारात्मक परीक्षा परिणाम के साथ एक व्यक्ति को गलती से आश्वस्त किया जा सकता है कि वे सुरक्षित हैं (जैसे एक झूठी सकारात्मक एंटीबॉडी परीक्षण के साथ होगा), और बदले में बुनियादी प्रतिबंध (जैसे, सामाजिक दूरी) पर कम ध्यान दें।"
    ]
  },
  {
    "id": "rec97kmL37it92c2r",
    "Question": "What do we know so far about face masks and their ability to prevent COVID-19?",
    "Status": "Published",
    "Subcategory": "On: COVID-19 & masks",
    "Source of the question": [
      "Partner Organization"
    ],
    "Background and context": "There has been a lot of debate about how effective wearing face masks are in preventing the transmission of COVID-19. Part of the reason for this is the confusion that occurred in February and March of 2020 when the World Health Organization (WHO) and the United States Centers for Disease Control and Prevention (U.S. CDC) advised the public not to wear masks. This guidance was based on several important points: \n\n1) These agencies did not think there was enough proof that the general public should be wearing masks unless they were infected with COVID-19 or they were around people infected with  COVID-19. This is because it wasn't known yet that people could still spread COVID-19 even if they had no symptoms;\n2) There was a shortage of masks for doctors and healthcare professionals ; \n3) The difference in the types of masks and materials that were available; and\n4) The research that is still in progress about how COVID-19 spreads (like through droplets, surfaces, etc.). \n\nHowever, the research has evolved since the beginning of the pandemic, and we now have evidence that masks are effective at preventing the spread of COVID-19. This is why once the international scientific community had reached that consensus, the WHO, the U.S. CDC, and other health organizations changed their recommendations and now advise people to wear masks while in public settings. \n\nIt is common to change policies as new information becomes available. Because COVID-19 is a new virus, we are still learning more every day and changing and improving our recommendations.\n",
    "What our experts say": "As per the World Health Organization (WHO), wearing masks is part of an overall strategy to suppress the transmission of COVID-19, along with maintaining at least 2 meters (6 feet) distance and frequently washing your hands. \n\nThere are generally two kinds of face masks that are available - medical (or surgical) masks and non-medical (or fabric) masks. Medical masks can protect people from getting infected as well as prevent people who are infected from spreading disease to others. Therefore, WHO recommends medical masks to be worn by health workers, care givers of patients infected with COVID-19, anyone who has mild symptoms of COVID-19, people with other health conditions which make them more susceptible to COVID-19, as well as people who are 60 years or older because they have a higher risk of getting infected with COVID-19.\n\nWHO advises that non-medical masks should be worn in areas where there is high transmission of COVID-19, crowded places where at least 2 meters (6 feet) physical distancing is not possible, on public transport, in shops and other closed areas. COVID-19 can be spread by people without symptoms, as they may not know that they are infected but are equally capable of spreading the virus. Hence, masks should be worn in public settings.\n \nThe U.S. Centers for Disease Control and Preventions (U.S. CDC) warns that masks with exhalation valves or vents may not help prevent the spread of COVID-19 from the person wearing such a mask to others, therefore these masks should not be used for that purpose. The U.S. CDC also does not recommend face shields as substitutes for masks because of the large gaps below and alongside the face. Ideally, face shields should be used in combination with face masks. \n\nWearing a face mask protects others from you when you cough, sneeze, talk, or just breathe, particularly indoors or when standing close to someone. Face masks also protect the wearer by preventing people from touching their mouth and nose, as well as reducing the amount of virus inhaled from other people nearby and reducing the risks of severe illness. \n\nIn addition to social distancing measures (maintaining 6 feet or 2 meters between people), face masks are recommended to prevent the spread of COVID-19, even in hot climates. There is no evidence that surgical masks or cloth masks lower oxygen levels at all. It is important to use a mask that allows you to breathe comfortably while talking and walking and that fits well on your face. For safety, there are exceptions to wearing masks for children under the age of 2, for people with certain medical conditions or who have trouble breathing, and for anyone who is unconscious or unable to remove the mask without assistance. \n\nMask wearing is a fundamental element of pandemic response for respiratory illnesses because masks act as a physical barrier from the release of infectious respiratory droplets that may come from your mouth or nose when you speak, sing, sneeze or cough.\n",
    "Glossary Terms": [
      "recPFoN1pnhj4RUOc"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "face masks",
      "carbon dioxide",
      "symptoms",
      "asthma",
      "COPD"
    ],
    "Other resources": "1. Facial Skin Temperature and Discomfort When Wearing Protective Face Masks: Thermal Infrared Imaging Evaluation and Hands Moving the Mask ([IJERPH](https://www.mdpi.com/1660-4601/17/13/4624)) \n2. Effects of wearing N95 and surgical facemasks on heart rate, thermal stress and subjective sensations ([IAOEH](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087880/)) \n3. Does Wearing a Face Mask Reduce Oxygen—and Can It Increase CO2 Levels? Here's What Experts Say ([Health](https://www.health.com/condition/infectious-diseases/coronavirus/does-wearing-face-mask-increase-co2-levels)) \n4. Face masks for the public during the covid-19 crisis ([BMJ](https://www.bmj.com/content/369/bmj.m1435/rr-40)) \n5. From the Frontlines: The Truth About Masks and COVID-19 ([ALA](https://www.lung.org/blog/covid-masks)) \n6. Does prolonged wearing of a facemask cause harm? ([Vanderbilt](https://www.vumc.org/coronavirus/latest-news-you-asked-we-answered/does-prolonged-wearing-facemask-cause-harm)) \n7. Partly false claim: Continually wearing a mask causes hypercapnia ([Reuters](https://www.reuters.com/article/uk-factcheck-coronavirus-mask-hypercapni/partly-false-claim-continually-wearing-a-mask-causes-hypercapnia-idUSKBN22H2H1)) \n8. Killer COVID-19 Masks? The Truth About Trapped Carbon Dioxide ([Hartford Healthcare](https://hartfordhealthcare.org/about-us/news-press/news-detail?articleid=26712&publicId=395)) \n9. What People With Asthma Need to Know About Face Masks and Coverings During the COVID-19 Pandemic ([AAFA](https://community.aafa.org/blog/what-people-with-asthma-need-to-know-about-face-masks-and-coverings-during-the-covid-19-pandemic)) \n10. Severe Acute Respiratory Infections Treatment Centre ([WHO](https://apps.who.int/iris/bitstream/handle/10665/331603/WHO-2019-nCoV-SARI_treatment_center-2020.1-eng.pdf?sequence=1&isAllowed=y)) \n11. Will an air cleaner or air purifier help protect me and my family from COVID-19 in my home? ([U.S. EPA](https://www.epa.gov/coronavirus/will-air-cleaner-or-air-purifier-help-protect-me-and-my-family-covid-19-my-home#:~:text=When%20used%20properly%2C%20air%20purifiers,protect%20people%20from%20COVID-19.&text=Return%20to%20Frequent%20Questions%20about,Disease%20(COVID-19).)) \n12. Air purifiers: A supplementary measure to remove airborne SARS-CoV-2 ([BE](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180358/)) \n13. Scientific Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science-sars-cov2.html))\n14. Considerations for Wearing Masks: Help Slow the Spread of COVID-19 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html))\n15. Masks Do More Than Protect Others During COVID-19: Reducing the Inoculum of SARS-CoV-2 to Protect the Wearer ([Journal of General Internal Medicine](https://link.springer.com/article/10.1007/s11606-020-06067-8))\n",
    "Rollup test 2": [
      "rec8HIQKii7l6nJaU"
    ],
    "Last modified manual": "2020-12-01",
    "Last edited (simplified)": "2020-12-02T20:00:39.000Z",
    "Last edited (experts say)": "2020-12-02T20:01:54.000Z",
    "Last modified": "2020-12-02",
    "What our experts say wordcount": 494,
    "Background and context wordcount": 255,
    "Other resources wordcount": 217,
    "Wordcount": 966
  },
  {
    "id": "recgfRiqVgG4lMH4w",
    "Question": "What do we know so far about the ability of asymptomatic people to transmit the virus?",
    "Status": "Published",
    "Category": "On: COVID-19 & asymptomatic carriers",
    "Source of the question": [
      "Newsroom"
    ],
    "Background and context": "There is concern about transmission by people without symptoms because this makes disease prevention more challenging. For example, while it is a helpful public health measure to recommend that people self-isolate when ill, it is insufficient to stop the spread of the novel coronavirus. This is because if someone never develops symptoms, or who has not yet developed symptoms, they can still infect others.\n",
    "What our experts say": "Asymptomatic people are those that do not show any symptoms but have been infected with COVID-19. As per a recent study published in the medical journal, JAMA, asymptomatic people have similar amounts of virus as symptomatic people and are capable of spreading the virus as much. Because asymptomatic people may not know that they are infected, they may not isolate themselves and that way can spread the virus even more.\n\nThe U.S. Centers for Disease Control and Prevention (U.S. CDC) has revised its current best estimate and now advises that it estimates 40% of people infected with COVID-19 are asymptomatic. The World Health Organization has yet to provide an official estimate and noted that it will vary across populations.\nSome studies have noted that asymptomatic carriers might be the biggest spreaders of COVID-19 in certain populations. There is also evidence to suggest that pre-symptomatic people infected with COVID-19  - people who eventually develop symptoms but haven't had any yet - spread the most amount of virus in the time before they have symptoms.\nThis is why it is very important that everyone wear masks, wash their hands vigorously for 20 seconds, and maintain a distance of six feet (2 meters) between themselves and others. \n\n_This entry was updated with new information on August 13, 2020_\n",
    "Glossary Terms": [
      "recx2PeCcs1Awb9rG",
      "recbZcFUtsYMA9Vsh",
      "reclKahoPRbBLqUKg"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "asymptomatic",
      "pre-symptomatic",
      "transmission"
    ],
    "Other resources": "1. Follow-up of asymptomatic patients with SARS-CoV-2 infection ([Clinical Microbiology and Infection](https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30169-5/fulltext)) \n2. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. ([Eurosurveillance](https://www.ncbi.nlm.nih.gov/research/coronavirus/publication/32183930))\n3. COVID-19: in the footsteps of Ernest Shackleton ([BMJ](https://thorax.bmj.com/content/early/2020/06/09/thoraxjnl-2020-215091)) \n4. SARS-CoV-2 Community Transmission During Shelter-in-Place in San Francisco ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.06.15.20132233v1)) \n5. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.05.10.20097543v2)) \n6. Prevalence of Asymptomatic SARS-CoV-2 Infection ([Annals of Internal Medicine](https://www.acpjournals.org/doi/10.7326/M20-3012)) \n7. In the W.H.O.’s Coronavirus Stumbles, Some Scientists See a Pattern ([NYT](https://www.nytimes.com/2020/06/09/health/coronavirus-asymptomatic-world-health-organization.html)) \n8. White House Adviser Warned of Risks of Pandemic; Trump Misleads on Testing ([New York Times](https://www.nytimes.com/2020/04/06/world/coronavirus-live-news-updates.html)) \n9. COVID-19 Pandemic Planning Scenarios ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html)) \n10. Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of Korea ([JAMA](https://jamanetwork-com.ezp-prod1.hul.harvard.edu/journals/jamainternalmedicine/fullarticle/2769235))\n11. Can asymptomatic patients spread coronavirus? Here's what a new study reveals ([Advisory.com](https://www.advisory.com/daily-briefing/2020/08/10/asymptomatic))\n",
    "DB (Hindi)": [
      "recZtbTsR4v0zcLyf"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recBtL5f1dTl6oFWM"
    ],
    "DB (Portuguese)": [
      "reccumXtZ72he6jWm"
    ],
    "Rollup test 2": [
      "reclMl0epvo02J40E"
    ],
    "Last modified manual": "2020-08-13",
    "Last edited (simplified)": "2020-08-13T20:56:52.000Z",
    "Last edited (experts say)": "2020-10-20T21:47:48.000Z",
    "Last modified": "2020-08-13",
    "What our experts say wordcount": 213,
    "Background and context wordcount": 64,
    "Other resources wordcount": 153,
    "Wordcount": 430,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "स्पर्शोन्मुख लोग वे हैं जो कोई लक्षण नहीं दिखाते हैं लेकिन कोविड-19 से संक्रमित हैं। मेडिकल जर्नल, जेएएमए में प्रकाशित एक हालिया अध्ययन के अनुसार, स्पर्शोन्मुख लोगों में वायरस के लक्षण समान रूप से होते हैं और वायरस को फैलाने में सक्षम होते हैं। क्योंकि स्पर्शोन्मुख लोगों को पता नहीं हो सकता है कि वे संक्रमित हैं, वे खुद को अलग नहीं कर सकते हैं और यह तरीका वायरस को और भी अधिक फैला सकता है।\n\nयू.एस. सेंटर्स फॉर डिसीज़ कंट्रोल एंड प्रिवेंशन (यू॰एस सीडीसी) ने अपने वर्तमान सर्वोत्तम अनुमान को संशोधित किया है और अब यह सलाह देता है कि यह अनुमान लगाता है कि कोविड-19 से संक्रमित 40% लोग स्पर्शोन्मुख हैं। विश्व स्वास्थ्य संगठन ने अभी तक एक आधिकारिक अनुमान प्रदान नहीं किया है और नोट किया है कि यह आबादी में भिन्न होगा।\nकुछ अध्ययनों में कहा गया है कि कुछ आबादी में स्पर्शोन्मुख वाहक कोविड-19 के सबसे बड़े प्रसारक हो सकते हैं। यह सुझाव देने के भी सबूत हैं कि कोविड-19 से संक्रमित पूर्व-लक्षणवादी लोग - जो लोग अंततः लक्षण विकसित करते हैं, लेकिन उनमें अभी तक कोई लक्षण नहीं है - लक्षणों के होने से पहले समय में वायरस की सबसे अधिक मात्रा का प्रसार करते हैं।\nयही कारण है कि यह बहुत महत्वपूर्ण है कि हर कोई मास्क पहनता है, अपने हाथों को 20 सेकंड तक जोर से धोता है, और अपने और दूसरों के बीच छह फीट (2 मीटर) की दूरी बनाए रखता है।\n\nइस प्रविष्टि को नई जानकारी के साथ 13 अगस्त, 2020 को अपडेट किया गया था।"
    ],
    "Hindi - Background and context": [
      "लक्षणों के बिना लोगों द्वारा संचरण के बारे में चिंता है क्योंकि यह रोग की रोकथाम को अधिक चुनौतीपूर्ण बनाता है। उदाहरण के लिए, जबकि यह एक उपयोगी सार्वजनिक स्वास्थ्य उपाय है कि लोगों को बीमार होने पर आत्म-पृथक करने की सिफारिश की जाती है, यह उपन्यास कोरोनावायरस के प्रसार को रोकने के लिए अपर्याप्त है। ऐसा इसलिए है क्योंकि यदि कोई कभी लक्षण विकसित नहीं करता है, या जिसने अभी तक लक्षण विकसित नहीं किए हैं, तो वे अभी भी दूसरों को संक्रमित कर सकते हैं।"
    ]
  },
  {
    "id": "recbykOUrOWpaKYKn",
    "Question": "Does exhaled carbon dioxide in a mask cause any side effects?",
    "Status": "Published",
    "Background and context": "The claim that the prolonged use of face masks can cause carbon dioxide intoxication, dizziness, or other health challenges is not grounded in science. In fact, healthcare workers often wear masks for long hours in the hospital. There is no evidence that surgical masks or cloth masks cause significant build-up of carbon dioxide. This information has been primarily circulating on social media among individuals or communities resistant to mask-wearing in general. While masks are restrictive and can feel like they impede air flow, properly designed masks do allow air flow by design, and the feeling of inconvenience or minor discomfort does not equate to health risks such as a build-up of carbon dioxide. Inhaling high amounts of carbon dioxide can be dangerous and lead to hypercapnia (carbon dioxide toxicity), but is extremely unlikely to happen as a result of wearing a mask.\n\nThere is some evidence that prolonged use of N95 masks in wearers with particularly severe health conditions, such as lung disease, could cause some build-up of carbon dioxide in the body. However, these cases are rare, and the use of N95 masks is not recommended for the general public in order to reserve them for frontline workers who are at higher risk of exposure to the virus. \n",
    "What our experts say": "Exhaled carbon dioxide caused by the use of face masks, including the N95 mask, has not been shown to cause carbon dioxide toxicity or lack of adequate oxygen in healthy people. Because the masks we make and purchase, and even the airtight medical masks listed above, are designed for constant breathing, the risks of any side effects are low. Again, for people diagnosed with illnesses such as COPD, emphysema, and obesity, and in heavy smokers, the consistent use of N95-like masks over long periods of time could cause some build-up of carbon dioxide levels in the body. If people in this group are experiencing these side effects, they should speak to their doctor. \n",
    "Other resources": "1. Partly false claim: Continually wearing a mask causes hypercapnia ([Reuters](https://www.reuters.com/article/uk-factcheck-coronavirus-mask-hypercapni/partly-false-claim-continually-wearing-a-mask-causes-hypercapnia-idUSKBN22H2H1))\n2. Fact check: Wearing a face mask will not cause hypoxia, hypoxemia or hypercapnia ([USA Today](https://www.usatoday.com/story/news/factcheck/2020/05/30/fact-check-wearing-face-mask-not-cause-hypoxia-hypercapnia/5260106002/))\n3. This Myth About Carbon Dioxide And Masks Is Similar To A Debunked Claim About Climate Change ([Forbes](https://www.forbes.com/sites/marshallshepherd/2020/07/01/debunking-2-myths-toxic-coronavirus-masks-and-breathing-warms-the-climate/#4f94baee30f4))\n",
    "Last modified manual": "2020-08-26",
    "Last edited (simplified)": "2020-08-26T01:31:46.000Z",
    "Last edited (experts say)": "2020-09-08T20:52:29.000Z",
    "Last modified": "2020-09-08",
    "What our experts say wordcount": 114,
    "Background and context wordcount": 209,
    "Other resources wordcount": 43,
    "Wordcount": 366
  },
  {
    "id": "recisKOQNAShlHmql",
    "Question": "What are the many benefits of testing?",
    "Status": "Published",
    "Category": "Testing",
    "Subcategory": "On: COVID-19 & testing",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "COVID-19 access to viral testing (diagnostic tests that tell you if you are currently infected with the virus) has varied significantly during the course of the pandemic. In the US, testing was largely unavailable except for those with acute symptoms until recent months. According to the U.S. Centers for Disease Control and Prevention (CDC), specimens tested by both the CDC and public health labs multiplied by more than 12 times from the beginning of March to the beginning of May. Limited testing early in the pandemic has left gaps in the data, particularly with regards to asymptomatic cases; however, because testing was initially (and in some regions still is) limited, there has been confusion about the benefits. While viral testing is not perfect in terms of accuracy and will not alone slow the pandemic, it is a crucial piece of the response effort. If one can get regularly tested, one should. In the initial months of the pandemic, countries that rapidly scaled up viral testing capacity, such as South Korea, were able to better contain the spread of COVID-19 in comparison to countries that were slow to increase testing, such as the United States. \n\nSerology (antibody) testing has also varied in availability and recommended uptake since the onset of the pandemic. There has been less of an urgent push for serology testing because it does not tell you if you are currently infected and there is lacking evidence on how protective the antibodies are and their length of protection. Additionally, there is a chance that a positive result could be due to antibodies from an infection with a virus from the same coronavirus family (eg. the one that causes the common cold). The U.S. CDC has also issued warnings about the risk of high false positive rates in antibody tests. While antibody tests are an integral part of routine surveillance and particularly understanding disease prevalence and the frequency of asymptomatic infection, they should not be seen as a silver bullet to virus control. \n\n\n",
    "What our experts say": "Testing provides several benefits during a pandemic, including early diagnosis, contact tracing, prevention, and surveillance. Viral testing identifies if an individual is currently infected with the virus that causes COVID-19. At the individual level, it allows infected individuals who were potentially experiencing symptoms to be diagnosed and access the care they need. At the community level, viral testing prevents further infections since an infected individual can take all necessary precautions to not infect other people. It also allows public health experts to identify new cases and track the spread of the virus through contact tracing by following the chain of transmission. Viral testing is commonly used to test people who have symptoms of COVID-19 as well as caregivers, essential workers, travelers, and others who may not show active symptoms. \n\nSerology tests - also called antibody tests - are useful to find out if an individual has been previously infected with the virus that causes COVID-19. These kinds of tests look for antibodies in the blood, which determine if there was a previous infection. It allows public health experts to find out how many COVID-19 infections have occurred in the past, and to track what percentage of the population has been infected over time, which has important implications for surveillance. At a policy level, serology testing can guide social distancing or quarantine guidelines. The U.S. Centers for Disease Control use a serology surveillance strategy to better understand the spread of the virus by testing in different locations, at different points of time, and within different populations (ex. across age, ethnic and socioeconomic groups) in the United States. \n\nHowever, it's important to note that the evidence surrounding serology testing and its link to immunity (protection) is still evolving. We do not understand fully if prior infection is evidence of immunity, know how long antibodies can protect the body, or whether patients can get infected again after a previous infection. \n",
    "Glossary Terms": [
      "recmajcAORyuqhZPc",
      "recPNexvQiug4RFJu"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "testing",
      "transmission"
    ],
    "Other resources": "1. Testing for COVID-19 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html))\n2. The important role of serology for COVID-19 control ([Lancet](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30322-4/fulltext?tk=eo_8486e9ce-cebe-4df1-95f1-85f8d09ebd05_9xtbTcXSkB4rVgEFWKrNTSEWIJMnkj3G2byL))\n3. Disease Control, Civil Liberties, and Mass Testing — Calibrating Restrictions during the Covid-19 Pandemic ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMp2007637))\n4. Testing data in the US ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/testing-in-us.html))\n5. Coronavirus Disease 2019 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html))\n\n",
    "DB (Hindi)": [
      "rec8B6FXmTmTrWtdv"
    ],
    "Media": [
      {
        "id": "atteY7qe9JC2KUk9V",
        "url": "https://dl.airtable.com/.attachments/c6b3ddb163d95977b7037ca9e1c1c748/c9a9b45e/Slide_1",
        "filename": "Slide_1",
        "size": 120624,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/8b821d024257b97d2dd222295806f896/4781ecc3",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b7763d7f5ac2d4501e769f2c531ab808/e64e13e5",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c0d067b9b7649f0c9421ae3f48eddc37/3b3efaab",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attFBrrQd54E5O9sm",
        "url": "https://dl.airtable.com/.attachments/0b86a523141fdcc54e103376bbc29665/f187a355/slide_2",
        "filename": "slide_2",
        "size": 161194,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b4e2188852cf997450598da38fa7ac74/6cfcf644",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/41e1d03182dd9eedf1745240a80ca619/6aaa363b",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/4cbb8a42ebd8db1df7b9fe20a8af6cd5/0387d9c4",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attytUd7HWtMBLQks",
        "url": "https://dl.airtable.com/.attachments/3e4768ac1e04eead5772f4301f272b8c/d5719513/slide_3",
        "filename": "slide_3",
        "size": 204428,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/4a043428a05ae65535fb595e5e3d30d6/e35e0370",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/531eb80c3d0d0137eca9242860088291/e01c1f3b",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/40694fd38cded4f568a0ab9010f038d0/49fa74d1",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attvETa6oohf31ZBy",
        "url": "https://dl.airtable.com/.attachments/720f87320e98b2933f7bdaa93a1a5785/69114367/Slide_4",
        "filename": "Slide_4",
        "size": 180874,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/54ea1a15af56487582d31142727351cd/e7857487",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/714153fd399cbe04ddc1fc9631864032/0c05f652",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/de0f6a517f7eaac9830789ccc8530897/388ca250",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "atthaAe0sBtrBq2fo",
        "url": "https://dl.airtable.com/.attachments/b2dd0fe23b778024abb90af3e44e074e/5a6c9f90/slide_5",
        "filename": "slide_5",
        "size": 201844,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/468b01eaa0e5419593afc6a2c5af99c4/c7a6a7b2",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/8eca1f2a759e0e30fd993c2a7568f024/f1d55eb6",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/4bd080393c1ffd6e15411c0a9935979e/fcfbdfed",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attQCQLz2noG1Y69c",
        "url": "https://dl.airtable.com/.attachments/858fa617bcd2addda810691714d6d50f/37df9a98/slide_6",
        "filename": "slide_6",
        "size": 222641,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/13fa1fb63be73e237f6bb791237f806b/eb69b784",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/07b73154e8f2754b49bc1aac65943f59/c827a3be",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/4867a038bb010a34f444308fd894226c/4f52062b",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recCSJt2QDc1R9Iyt"
    ],
    "DB (Portuguese)": [
      "recdTklgOxlXZRmy3"
    ],
    "Rollup test 2": [
      "reczBjt6f2z5cy3bD"
    ],
    "Media Package": [
      {
        "id": "attqWqQx7SUflvRH7",
        "url": "https://dl.airtable.com/.attachments/c90dfde07608217db3761b67bd2ef54f/9375488e/Testing.zip",
        "filename": "Testing.zip",
        "size": 1093139,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-08-13",
    "Last edited (simplified)": "2020-07-07T23:24:41.000Z",
    "Last edited (experts say)": "2020-08-13T15:09:27.000Z",
    "Last modified": "2020-08-13",
    "What our experts say wordcount": 318,
    "Background and context wordcount": 334,
    "Other resources wordcount": 42,
    "Wordcount": 694,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "परीक्षण एक महामारी के दौरान कई लाभ प्रदान करता है, जिसमें प्रारंभिक निदान, संपर्क अनुरेखण, रोकथाम और निगरानी शामिल है। वायरल परीक्षण यह पहचानता है कि क्या कोई व्यक्ति वर्तमान में कोविड-19 का कारण बनने वाले वायरस से संक्रमित है। व्यक्तिगत स्तर पर, यह संक्रमित व्यक्तियों को अनुमति देता है जो संभावित रूप से निदान किए जाने वाले लक्षणों का निदान कर रहे थे और उन्हें आवश्यक देखभाल का उपयोग कर रहे थे। सामुदायिक स्तर पर, वायरल परीक्षण आगे के संक्रमण को रोकता है क्योंकि एक संक्रमित व्यक्ति अन्य लोगों को संक्रमित न करने के लिए सभी आवश्यक सावधानी बरत सकता है। यह सार्वजनिक स्वास्थ्य विशेषज्ञों को नए मामलों की पहचान करने और ट्रांसमिशन की श्रृंखला का पालन करके संपर्क ट्रेसिंग के माध्यम से वायरस के प्रसार को ट्रैक करने की अनुमति देता है। वायरल परीक्षण आमतौर पर उन लोगों का परीक्षण करने के लिए उपयोग किया जाता है जिनके पास कोविड-19 के लक्षण और साथ ही देखभाल करने वाले, आवश्यक कर्मचारी, यात्री और अन्य लोग हैं जो सक्रिय लक्षण नहीं दिखा सकते हैं।\n\nसीरोलॉजी परीक्षण - जिसे एंटीबॉडी परीक्षण भी कहा जाता है - यह पता लगाने के लिए उपयोगी है कि क्या कोई व्यक्ति पहले वायरस से संक्रमित है जो कोविड-19 का कारण बनता है। इस तरह के परीक्षण रक्त में एंटीबॉडी की तलाश करते हैं, जो यह निर्धारित करते हैं कि क्या पिछले संक्रमण था। यह सार्वजनिक स्वास्थ्य विशेषज्ञों को यह पता लगाने की अनुमति देता है कि अतीत में कितने कोविड-19 संक्रमण हुए हैं, और यह ट्रैक करने के लिए कि समय के साथ कितने प्रतिशत आबादी संक्रमित हो गई है, जो निगरानी के लिए महत्वपूर्ण प्रभाव है। नीति स्तर पर, सीरोलॉजी परीक्षण सामाजिक भेद या संगरोध दिशानिर्देशों का मार्गदर्शन कर सकता है। संयुक्त राज्य अमेरिका में रोग नियंत्रण के लिए अमेरिका के सेंटर अलग-अलग स्थानों पर और अलग-अलग आबादी में (उदाहरण के लिए, उम्र, जातीय और सामाजिक आर्थिक समूहों में) अलग-अलग स्थानों में परीक्षण करके वायरस के प्रसार को बेहतर ढंग से समझने के लिए एक सेरोलॉजी निगरानी रणनीति का उपयोग करते हैं। ।\n\nहालांकि, यह ध्यान रखना महत्वपूर्ण है कि सीरोलॉजी परीक्षण और प्रतिरक्षा (सुरक्षा) के लिए इसके लिंक अभी भी विकसित हो रहे हैं। हम पूरी तरह से समझ नहीं पाते हैं यदि पूर्व संक्रमण प्रतिरक्षा का सबूत है, तो जानें कि शरीर को लंबे समय तक एंटीबॉडी कैसे सुरक्षित कर सकते हैं, या क्या रोगी पिछले संक्रमण के बाद फिर से संक्रमित हो सकते हैं।"
    ],
    "Hindi - Background and context": [
      "वायरल परीक्षण (नैदानिक ​​परीक्षण जो आपको बताते हैं कि क्या आप वर्तमान में वायरस से संक्रमित हैं) तक पहुँच के दौरान कोविड-19 की महामारी के दौरान काफी भिन्नता है। अमेरिका में, हाल के महीनों तक तीव्र लक्षणों वाले लोगों को छोड़कर परीक्षण काफी हद तक अनुपलब्ध था। यू.एस. सेंटर्स फॉर डिजीज कंट्रोल एंड प्रिवेंशन (सीडीसी) के अनुसार, मार्च की शुरुआत से लेकर मई की शुरुआत तक सीडीसी और पब्लिक हेल्थ लैब दोनों द्वारा जांच किए गए नमूनों को 12 गुना से अधिक गुणा किया जाता है। महामारी में सीमित परीक्षण ने डेटा में अंतराल छोड़ दिया है, विशेष रूप से स्पर्शोन्मुख मामलों के संबंध में; हालाँकि, क्योंकि परीक्षण शुरू में था (और कुछ क्षेत्रों में अभी भी सीमित है), लाभों के बारे में भ्रम की स्थिति रही है। जबकि वायरल परीक्षण सटीकता के मामले में सही नहीं है और यह अकेले महामारी को धीमा नहीं करेगा, यह प्रतिक्रिया प्रयास का एक महत्वपूर्ण टुकड़ा है। यदि कोई नियमित रूप से जांच करवा सकता है, तो उसे चाहिए महामारी के शुरुआती महीनों में, देशों ने तेजी से वायरल परीक्षण क्षमता को बढ़ाया, जैसे कि दक्षिण कोरिया, उन देशों की तुलना में COVID-19 के प्रसार को बेहतर ढंग से सक्षम करने में सक्षम थे, जो परीक्षण बढ़ाने के लिए धीमा थे, जैसे कि संयुक्त राज्य अमेरिका।\n\nसीरोलॉजी (एंटीबॉडी) परीक्षण की उपलब्धता में भी विविधता है और महामारी की शुरुआत के बाद से इसकी सिफारिश की जाती है। सीरोलॉजी परीक्षण के लिए एक तत्काल दबाव कम रहा है क्योंकि यह आपको यह नहीं बताता है कि क्या आप वर्तमान में संक्रमित हैं और इस बात का सबूत नहीं है कि एंटीबॉडी कितने सुरक्षात्मक हैं और उनकी सुरक्षा कितनी है। इसके अतिरिक्त, एक मौका है कि एक सकारात्मक परिणाम एक ही कोरोनव परिवार से वायरस के साथ एक संक्रमण से एंटीबॉडी के कारण हो सकता है (जैसे कि सामान्य सर्दी का कारण बनता है)। \nयू॰एस सीडीसी ने एंटीबॉडी परीक्षणों में उच्च झूठी सकारात्मक दरों के जोखिम के बारे में चेतावनी भी जारी की है। जबकि एंटीबॉडी परीक्षण नियमित निगरानी का एक अभिन्न अंग हैं और विशेष रूप से बीमारी की व्यापकता और स्पर्शोन्मुख संक्रमण की आवृत्ति को समझते हैं, उन्हें वायरस नियंत्रण के लिए चांदी की गोली के रूप में नहीं देखा जाना चाहिए।"
    ]
  },
  {
    "id": "recYvTpiS4HB4XVtT",
    "Question": "What do we know about the association between blood type and severe reaction to COVID-19",
    "Status": "Published",
    "Background and context": "The media is now reporting on how more recent studies found that blood type is not linked to risks of intubation or death from COVID-19, after adjusting for other factors like age and gender identity. Furthermore, it is important to note that Type O blood does not mean immunity to COVID-19.\n",
    "What our experts say": "As of now, there is not enough evidence to indicate whether or not there may be some connection between blood type and COVID-19 risk, though the link is likely to be minimal if it does exist. Studies previously cited in the news suggested that Type A blood could be associated with higher risks of severe cases of COVID-19, and reporting included studies that had not yet been assessed by scientific experts (referred to in science as the peer-review process). One of these recent studies had been peer-reviewed and published in the New England Journal of Medicine (NEJM); however it used genes to determine the blood type, which is a method that is not very accurate. The gene testing company, 23andMe, recently released the preprint of a study (awaiting peer-review and using a similar gene association method) that identifies a strong association between blood type and COVID-19 diagnosis. The study suggests that people with blood group O tested positive less often compared to people with other blood groups, under similar circumstances.  \n   \nTwo more recent studies from Columbia University and Massachusetts General Hospital in the U.S. found that blood type is not associated with risks of intubation or death from COVID-19, after adjusting for other factors. While scientists continue to learn more, age and underlying health conditions remain more significant risk factors for severe COVID-19 symptoms, and Type A blood is not thought to be a major risk factor at this time. \n\nWhile some studies have suggested a potential risk reduction for people with Type O blood, not all the studies have been peer-reviewed and the use of blood donors as study participants can give the appearance of Type O being more protective than it is (Type O blood is over-represented in blood donors, compared to the general population). Type O blood does not mean immunity to COVID-19.\n",
    "Glossary Terms": [
      "rechQcO5gs3FZMcPs",
      "recvEcanaG84OrPm4",
      "rectkO1d0FhUHQ0Of",
      "recmajcAORyuqhZPc"
    ],
    "Other resources": "1. Genes, Blood Type Tied to Risk of Severe COVID-19 ([NIH](https://directorsblog.nih.gov/2020/06/18/genes-blood-type-tied-to-covid-19-risk-of-severe-disease/))\n2. The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association and analysis ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.05.31.20114991v1))\n3. Genes May Leave Some People More Vulnerable to Severe Covid-19 ([NYT](https://www.nytimes.com/2020/06/03/health/coronavirus-blood-type-genetics.html?searchResultPosition=2))\n4. Is there a relationship between blood type and covid-19 infection? ([MIT Technology Review](https://www.technologyreview.com/2020/07/14/1005173/blood-type-covid-19-coronavirus-infection/))\n5. Genomewide Association Study of Severe Covid-19 with Respiratory Failure ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2020283))\n6. Testing the association between blood type and COVID-19 infection, intubation, and death ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.04.08.20058073v1.full.pdf))\n7. Relationship between the ABO Blood Group and the COVID-19 Susceptibility  ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.03.11.20031096v2.full.pdf))\n8. Blood type and outcomes in patients with COVID-19  ([Annals of Hematology](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354354/))\n9. COVID and Blood Type ([Harvard Medical School](https://hms.harvard.edu/news/covid-blood-type?utm_source=twitter&utm_medium=social&utm_campaign=hms-twitter-general))\n10. Trans-ethnic analysis reveals genetic and non-genetic associations with COVID-19 susceptibility and severity ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.09.04.20188318v1.full.pdf))\n11. Early research from 23andMe strengthens link between blood types and Covid-19 ([Statnews](https://www.statnews.com/2020/09/14/23andme-study-covid-19-genetic-link/))\n",
    "DB (French)": [
      "rec1Y0HsS4cS3Iqfl"
    ],
    "In translated DBs?": "Yes",
    "DB (Arabic)": [
      "reckMAWuSzRcPgce3"
    ],
    "DB (Bengali)": [
      "reci4OWYt0YN1ockY"
    ],
    "DB (Portuguese)": [
      "rec7QTdBAZsJxcYzT"
    ],
    "Rollup test 2": [
      "reccOnjDknlhiEoeQ"
    ],
    "Last modified manual": "2020-08-12",
    "Last edited (simplified)": "2020-09-29T00:26:55.000Z",
    "Last edited (experts say)": "2020-09-29T00:26:55.000Z",
    "Last modified": "2020-09-29",
    "What our experts say wordcount": 310,
    "Background and context wordcount": 51,
    "Other resources wordcount": 137,
    "Wordcount": 498,
    "French Q status": [
      "Ready for expert review"
    ],
    "Arabic Q status": [
      "Published"
    ],
    "Arabic - What our experts say": [
      "‫حتى الآن، لا يوجد دليل كافٍ للإشارة إلى وجود علاقة بين فصيلة الدم ومخاطر الإصابة بــ كوفيد-19 أم لا، على الرغم من أن احتمال ذلك قد يكون ضئيلا إذا كان موجودا. أشارت الدراسات التي تم الاستشهاد بها سابقا في الأخبار إلى أن الدم من النوع ‏A‏ يمكن أن يكون مرتبطا بمخاطر أعلى للحالات الشديدة من كوفيد-19، بما في ذلك الدراسات التي لم يتم تقييمها بعد من قبل الخبراء العلميين (‏يشار إليها في العلوم باسم عملية مراجعة الأقران).‏ تمت مراجعة إحدى هذه الدراسات الحديثة ونشرها في مجلة ‪New England Journal of Medicine (NEJM)‬ ؛ لكنها استخدمت الجينات لتحديد فصيلة الدم، وهي طريقة غير دقيقة للغاية.‬\n\n‫وجدت دراستان حديثتان من جامعة كولومبيا ومستشفى ماساتشوسِتس العام في الولايات المتحدة أن فصيلة الدم لا ترتبط بمخاطر التنبيب أو الوفاة من كوفيد-19، بعد التعديل، حسب عوامل أخرى. بينما يواصل العلماء معرفة المزيد، يظل العمر والحالات الصحية الأساسية عوامل خطر أكثر أهمية لأعراض كوفيد-19 الشديدة، ولا يُعتقَد أن الدم من النوع ‏A‏ هو عامل خطر رئيس في هذا الوقت.‬\n\nمع أن بعض الدراسات اقترحت مخاطر المحتملة أقل للأشخاص ذوي فصلية الدم O، لم تتم مراجعة جميع الدراسات من قبل الأقران، كما أن استخدام المتبرعين بالدم كمشاركين في الدراسة يمكن أن يظهر أن الفصيلة O أكثر مقاومة للمرض مما هو عليه (تغلب فصيلة الدم O في المتبرعين بالدم، مقارنة مع عامة السكان). فصيلة الدم O لا تعني المناعة ضد كوفيد-19.\nتم تحديث هذا الإدخال بمعلومات جديدة في 27 يوليو 2020"
    ],
    "Arabic - Background and context": [
      "تذكر وسائل الإعلام حاليا اكتشاف الدراسات الحديثة أن فصيلة الدم ليست مرتبطة بمخاطر التنبيب أو الوفاة من كوفيد-19، بعد الأخذ بعين الاعتبار عوامل أخرى مثل العمر و الجنس. علاوة على ذلك، من المهم التأكيد على أن فصيلة الدم O لا تعني المناعة ضد كوفيد-19.\n\nتم التحديث بتاريخ 27 يوليو 2020 : يُرجى الانتباه إلى أن كوفيد-19 مرض جديد، حيث يواصل العلماء اكتشاف المزيد وإصدار منشورات جديدة. يمكن العثور على أحدث إجابة وأكثرها دقة أعلاه."
    ],
    "Bengali - What our experts say": [
      " \"এখনও পর্যন্ত যথেষ্ট পরিমাণে প্রমাণ নেই এটি নির্দেশ করার জন্য যে রক্তের ধরণ এবং কোভিড-১৯ এর ঝুঁকির মধ্যে কোন যোগাযোগ আছে, যদিও যোগাযোগ আদৌ বিদ্যমান হলে সেই যোগাযোগের সম্ভাবনা ন্যূনতম হওয়া উচিৎ। খবরে ইতিমধ্যে বলা অধ্যয়নগুলি প্রস্তাব করেছে যে টাইপ A রক্ত কোভিড-১৯ এর গুরুতর কেসের অনেক উচ্চ ঝুঁকির সঙ্গে সংযুক্ত, এর অন্তর্গত সেই সমস্ত অধ্যয়নগুলি যা এখনও অবধি বৈজ্ঞানিক বিশেষজ্ঞ দ্বারা মূল্যায়িত হয় নি (যা বিজ্ঞানে পিয়ার-রিভিউ প্রক্রিয়া হিসাবে উল্লিখিত)। এই সাম্প্রতিক অধ্যয়নগুলির মধ্যে একটিকে পিয়ার-রিভিউ করা হয়েছে এবং সেটি নিউ ইংল্যান্ড জার্নাল অফ মেডিসিন (NEJM) এ প্রকাশিত হয়েছে; যদিও এটিতে রক্তের ধরণ নির্ধারণ করতে জিন ব্যবহার করা হয়েছে, যা পদ্ধতি হিসাবে খুব একটা নির্ভুল নয়।\n \n মার্কিন যুক্তরাষ্ট্রে কলাম্বিয়া ইউনিভার্সিটি এবং ম্যাসাচুসেটস জেনারেল হসপিটাল এ হওয়া আরও দুটি সাম্প্রতিক অধ্যয়নে অন্যান্য কারণগুলিকে সামঞ্জস্য করার পরে দেখা গেছে যে, রক্তের ধরণ ইনটিউবেশনের সঙ্গে জড়িত ঝুঁকি অথবা কোভিড-১৯ থেকে হওয়া মৃত্যু এর সঙ্গে সম্পর্কিত নয়। যেখানে বিজ্ঞানীরা ক্রমাগত আরও তথ্য জানছেন, এখনও পর্যন্ত বয়স এবং অন্তর্নিহিত অসুখগুলি গুরুতর কোভিড-১৯ এর উপসর্গের ক্ষেত্রে অনেক বেশী গুরুত্বপূর্ণ ঝুঁকির কারণ হিসাবে রয়ে গেছে, এবং এই সময়ে টাইপ A রক্ত খুব বেশী ঝুঁকির কারণ বলে মনে করা হচ্ছে না। \n \n যেখানে কিছু অধ্যয়নে প্রস্তাবিত হয়েছে যে O টাইপ রক্তে সম্ভাব্য ঝুঁকির হ্রাস দেখা যায়, সমস্ত অধ্যয়ন পিয়ার-রিভিউ করা হয়নি এবং অধ্যয়নের অংশগ্রহণকারী হিসাবে রক্তদাতাদের ব্যবহার টাইপ O রক্ত যতখানি প্রতিরক্ষামূলক তার থেকে বেশী করে দেখাতে পারে (রক্তদাতাদের মধ্যে টাইপ O রক্ত অনেক বেশী উপস্থাপিত হয়, সাধারণ জনসংখ্যার অনুপাতে)। টাইপ O রক্ত থাকা মানে কোভিড-১৯ থেকে অনাক্রম্যতা নয়। \n \n এই এন্ট্রি নতুন তথ্য দ্বারা জুলাই ২৭, ২০২০ তে আপডেট করা হয়েছিল।\"\n "
    ],
    "Bengali - Background and context": [
      " মিডিয়া এখন প্রতিবেদন জানাচ্ছে কিভাবে সাম্প্রতিক অধ্যয়ন থেকে জানা গেছে যে রক্তের ধরণ ইন্টিউবেশন অথবা কোভিড-১৯ থেকে মৃত্যুর ঝুঁকির সঙ্গে জড়িত নয়, বিশেষত বয়স এবং লিঙ্গ পরিচয়ের মতো অন্যান্য কারণগুলি বিবেচনা করার পরে। এছাড়াও, এটি মনে রাখা গুরুত্বপূর্ণ যে টাইপ O রক্ত মানে কোভিড-১৯ থেকে অনাক্রম্যতা নয়।\n \n আপডেট করা: জুলাই ২৭, ২০২০: দয়া করে মনে রাখবেন যে কোভিড-১৯ একটি নতুন অসুখ, যেখানে বিজ্ঞানীরা এটির সম্বন্ধে আরও জানবেন এবং নতুন তথ্য প্রকাশ করবেন। সাম্প্রতিকতম এবং সবচেয়ে নির্ভুল উত্তর উপরে পাবেন।\n "
    ]
  },
  {
    "id": "recxWz9YItyyFuO5s",
    "Question": "In hot countries can wearing masks suffocate people? Is there an alternative?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & masks",
    "Country question was sourced from": [
      "Senegal"
    ],
    "Background and context": "New policies around the world require people to wear masks. The point of these rules is to prevent the spread of COVID-19 between people when they speak, laugh, cough or sneeze. However, the more rules requiring mask wearing are established, the more false claims about the dangers of masks wearing circulate on social media. There is now substantial scientific evidence supporting mask wearing. The evidence shows that face masks are safe, do not cause suffocation or difficulty breathing if worn correctly, and should be worn by most people. For special groups like children under the age of two or people who struggle to breathe in general, they should speak to their doctors about how to protect themselves from the virus if they are unable to wear masks. The World Health Organization suggests all non-healthcare professionals wear cloth masks, maintain your distance from others, and wash your hands frequently to prevent spreading or becoming infected with COVID-19.\n\n_This entry was updated with new information on August 11, 2020._\n",
    "What our experts say": "Masks may cause an increase in your body temperature, but there is no evidence to suggest that cloth masks will cause suffocation (a struggle to breathe or get enough oxygen). In addition to social distancing measures, cloth masks are recommended for the general public to prevent the spread of COVID-19, even in hot climates. It is important to use a fabric mask that allows you to breathe comfortably while talking and walking. For safety, masks should not be worn by children under the age of two, by people who have trouble breathing, or anyone who is unconscious or otherwise unable to remove the mask without assistance. It is not known if face shields alone provide protection against COVID-19, and they are not recommended as an alternative to face masks.\n\n_This entry was updated with new information on August 11, 2020._\n",
    "Glossary Terms": [
      "reclKahoPRbBLqUKg",
      "recl0hjDTA7B27y2q",
      "recCHVGM1yzhwlN3G",
      "recqnngV0Ej32WU8H"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\t\n",
    "Topics": [
      "face masks",
      "airborne",
      "spread",
      "transmission",
      "COVID-19",
      "temperature",
      "heat"
    ],
    "Other resources": "1. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis, 2020 ([Lancet](https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931142-9))\n2. Q&A: Masks and COVID-19 ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-on-covid-19-and-masks))\n3. Considerations for Wearing Cloth Face Coverings ([US CDC](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html))\n4. Coronavirus disease (COVID-19) advice for the public: When and how to use masks ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks)) \n\n\n",
    "Questions answered by entry": "What do we know so far about airborne transmission? How does it differ from respiratory droplet transmission?\n",
    "Rollup test 2": [
      "recT8djGXIjfkk1YL"
    ],
    "Last modified manual": "2020-08-12",
    "Last edited (simplified)": "2020-08-12T00:18:09.000Z",
    "Last edited (experts say)": "2020-08-12T00:18:09.000Z",
    "Last modified": "2020-08-12",
    "What our experts say wordcount": 139,
    "Background and context wordcount": 166,
    "Other resources wordcount": 51,
    "Wordcount": 356
  },
  {
    "id": "recWWXBObp8mm4ii4",
    "Question": "What do we know about Bro-Zedex as a treatment for COVID-19? ",
    "Status": "Published",
    "Category": "Treatment",
    "Subcategory": "On: COVID-19 & Bro-Zedex",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "India"
    ],
    "Background and context": "Bro-Zedex is a liquid medication that may be used to treat cough symptoms by thinning mucous and decreasing swelling so that people can breathe easier. Both formulas are made of a combination of bromhexine, guaifenesin, menthol, and terbutaline. There is little research available about this medication, but similar medicines are being tested to see if they may help people manage symptoms of COVID-19.  \n\nThe first listed ingredient, bromhexine, is not available in the U.S. and is labeled only for animal use in some other countries. In places where it is approved, bromhexine is used to treat chest congestion by breaking down mucous and making it easier to cough the mucous out. The other ingredients are commonly used either alone or in combination with other medications. Guaifenesin is used to help cough up mucous and clear it from the chest and is found in many non-prescription cold and cough medicines. Menthol is used to help decrease coughing and is commonly an ingredient in non-prescription lozenges. Terbutaline is commonly used to help open airways to help people breathe more easily; it is usually only available with a prescription.\n \nSide effects common to Bro-Zedex include nausea, vomiting, diarrhea, stomach pain, sweating, increased heart rate, tiredness, headache, and tremors. While side effects usually go away once the medication is stopped, contact your doctor if you experience these or other concerning side effects. Taking this medication for a long time or in large doses may be harmful. In addition, there are many interactions between common prescription and non-prescription medications and the medications in Bro-Zedex. If you are taking other medications, you should talk to your brother before taking Bro-Zedex.\n\n_This entry was updated with new information on August 11, 2020._\n",
    "What our experts say": "Bro-Zedex is a cough syrup that is used to treat symptoms of a cough. There are Bro-Zedex formulas for both wet and dry coughs, and the ingredients in each type are different. For wet coughs, the key ingredient in the orange-colored Bro-Zedex is bromhexine, which is a medication that treats respiratory issues that cause excessive mucus and phlegm in the throat and mouth. Bromhexine does this by making the mucus in the throat thinner and easier to remove through coughing. This formula's other ingredients - menthol, guaifenesin, and terbutaline - can make the phlegm in your chest and throat thinner so it's easier to cough up, cool and soothe sore throats, and relax the muscles in your airways. For dry coughs, Bro-Zedex comes in a green liquid and its main ingredients are ambroxol, levosalbutamol, and guaifenesin. This formula loosens congestion in your chest and throat by breaking up phlegm and also relaxing the muscles in your airway so you can breathe easier. Though these formulas work in similar ways, their ingredients are meant to relieve specific symptoms that come with wet and dry coughs.\n\nBro-Zedex is not used as a treatment for COVID-19 on its own, but may help relieve some of the uncomfortable symptoms that occur in mild to moderate cases of the infection, like coughing and phlegm build-up. Current research is looking at whether bromhexine can be taken for prevention - before a COVID-19 infection to prevent someone from getting sick, or as part of a treatment plan in more severe cases to help improve some symptoms. Bro-Zedex is also part of clinical trials where researchers are looking to see if it can shorten the amount of time a person has COVID-19 symptoms or help prevent hospitalized patients infected with COVID-19 from becoming infected with other respiratory illnesses while they are still in the hospital.\n\n_This entry was updated with new information on August 11, 2020._\n",
    "Glossary Terms": [
      "recYMG7uKJJEWbf0s",
      "recOXgLYM6oNNR5WX",
      "recUOHoAQtR97mxFC",
      "recM4p8QOERmuESKr",
      "recOLVaA8YtoF3ofN"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "cough syrup",
      "bromhexine",
      "Bro-Zedex",
      "clinical trial"
    ],
    "Other resources": "1. Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy? ([IEM](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249615/)) \n2. Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2 ([PR](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192109/)) \n3. Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia ([Clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/NCT04355026)) \n4. Changes to the use of bromhexine or codeine-containing cough and cold medicines in children ([Medsafe](https://www.medsafe.govt.nz/safety/ews/2015/BromhexineOrCodeine.asp)) \n5. Bro-Zedex ([1mg](https://www.1mg.com/drugs/bro-zedex-syrup-180516))\n6. Bromhexine ([RxWiki](https://www.rxwiki.com/bromhexine)) ([drugs.com)](https://www.drugs.com/international/bromhexine.html)([Practo](https://www.practo.com/medicine-info/bromhexine-8-mg-tablet-45693)) \n7. Terbutaline ([Merck Manual](https://www.merckmanuals.com/professional/resources/brand-names-of-some-commonly-used-drugs))\n8. Guaifenesin (Oral Route) ([MayoClinic](https://www.mayoclinic.org/drugs-supplements/guaifenesin-oral-route/description/drg-20068720))\n9. Bro-Zedex LS ([1mg](https://www.1mg.com/drugs/bro-zedex-ls-kid-expectorant-raspberry-308389)) \n",
    "Rollup test 2": [
      "recfau8Rzh3wGIrKw"
    ],
    "Last modified manual": "2020-08-12",
    "Last edited (simplified)": "2020-08-12T00:17:53.000Z",
    "Last edited (experts say)": "2020-08-12T00:17:53.000Z",
    "Last modified": "2020-08-12",
    "What our experts say wordcount": 314,
    "Background and context wordcount": 282,
    "Other resources wordcount": 90,
    "Wordcount": 686
  },
  {
    "id": "recDcWzSA3u9hSsLZ",
    "Question": "Should people with asthma wear face masks? ",
    "Status": "Published",
    "Background and context": "Public health organizations around the world recommend the use of masks and face coverings. There are some exceptions, such as for children under 2 years of age and people with medical conditions that can make it difficult to breathe through a mask. However, people with asthma have generally not been included as one of these exceptions.\n\nIn fact, the U.S. Centers for Disease Control and Prevention (CDC) warn that having moderate-to-severe asthma may increase the risk of severe illness from COVID-19 and recommend that people with asthma avoid potential triggers for their condition, keep a 30-day supply of necessary medications (ex. inhalers), and consult their doctor regarding any concerns about their condition. For cleaning of indoor spaces with disinfectants, people with asthma can request assistance and make sure they are not in the room during cleaning. People with asthma should continue following guidelines when possible for using masks in public, in combination with social distancing and hand washing.\n\nThe American College of Allergy, Asthma, and Immunology provides additional information about the use of masks for people with asthma: \"There is no evidence that wearing a face mask makes asthma worse. However, it is possible that some people with asthma may feel it is more difficult to get an adequate breath while wearing a face mask. While we support and advocate that people follow U.S. CDC recommendations, some people with asthma do not feel they can breathe adequately while wearing a mask...If you feel you can only wear a mask for a short time, plan for any necessary outings to public places to be as short as possible and to wear your mask as long as possible. It may be helpful to try different face coverings at home to find one that is most comfortable, and practice wearing the mask at home for a period before your next outing. Always use a clean mask for each outing.\"\n\n_This entry was updated with new information on August 11, 2020._\n",
    "What our experts say": "People with asthma should wear face masks. The U.S. Centers for Disease Control and Prevention (U.S. CDC) note that people with moderate to severe asthma might have an increased risk of severe case of COVID-19. Therefore, wearing a mask is an important way to prevent the spread of the virus.\n\nStudies also show that wearing a mask does not reduce oxygen levels and should not make breathing more difficult. The World Health Organization (WHO) recommends the use of face masks in public and when social distancing is not possible, and it is safe for people with asthma to wear a mask for as long as needed. People who feel it is difficult to breathe adequately with a mask ca, for example, try to limit the length of their outings requiring mask use. However, every patient is different and if you have been diagnosed with asthma, have a severe case, have difficulty breathing normally, or have difficulty breathing with a mask, you should speak with your doctor about options for protecting yourself and others from COVID-19. \n\n_This entry was updated with new information on August 11, 2020._\n",
    "Glossary Terms": [
      "recqnngV0Ej32WU8H",
      "reclKahoPRbBLqUKg",
      "recVIQ6pNiGYNEgqk"
    ],
    "Other resources": "1. People with certain medical conditions ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#:~:text=Having%20moderate%2Dto%2Dsevere%20asthma,severe%20illness%20from%20COVID%2D19.&text=Follow%20your%20Asthma%20Action%20Plan,is%20another%20word%20for%20corticosteroids).))\n2. Recommendations on the use of face masks to reduce COVID-19 transmission ([American College of Allergy, Asthma and Immunology](https://acaai.org/news/recommendations-use-face-masks-reduce-covid-19-transmission))\n",
    "Rollup test 2": [
      "recYIHmcOnGqmTyr4"
    ],
    "Last modified manual": "2020-08-12",
    "Last edited (simplified)": "2020-08-12T00:17:36.000Z",
    "Last edited (experts say)": "2020-08-12T00:17:36.000Z",
    "Last modified": "2020-08-12",
    "What our experts say wordcount": 185,
    "Background and context wordcount": 323,
    "Other resources wordcount": 26,
    "Wordcount": 534
  },
  {
    "id": "rec7sYlAOUsRLHy0O",
    "Question": "Should disinfection tunnels be used?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & disinfection tunnels",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "Nigeria"
    ],
    "Background and context": "Disinfection tunnels (also known as sanitizing tunnels) are being installed in several locations around the world, with widespread media coverage and claims that they can safely prevent the transmission of COVID-19. However, there is no scientific evidence showing that the use of disinfection tunnels is safe or effective for preventing COVID-19 transmission. \n\nOne of the earliest installations of a disinfection tunnel during the COVID-19 pandemic was in an industrial complex in China. There are now installations around the world attempting to disinfect people while crossing borders or entering healthcare facilities, office buildings, sports stadiums, banks, supermarkets, and even schools. There have been public outcries about the dangers of these disinfection tunnels, particularly following their use on migrants and school children. \n\nAdditionally, the WHO warns that the use of chemical disinfectants (such as chlorine) in disinfection tunnels can take away from the supply needed for other important interventions, such as treating drinking water and cleaning healthcare facilities. Researchers have also raised concerns about the financial costs of disinfection tunnels, which can channel economic resources away from other pandemic response and recovery initiatives.\n",
    "What our experts say": "The World Health Organization (WHO) and other international health agencies do not recommend using disinfection tunnels to prevent transmission of COVID-19. This is due to concerns about their safety and effectiveness. \n\nDisinfection tunnels are spaces (such as a tunnel, room, cubicle, or cabinet) in which people are sprayed with chemical disinfectants or exposed to other disinfection methods, such as ultraviolet (UV) light. \n\nThese disinfection methods are often applied to the surfaces of objects. Their use directly on people can be dangerous to human health and may not stop the transmission of COVID-19. \n\nIf a person is infected with COVID-19 and passes through a disinfection tunnel, any disinfection would only be external and the infected person could still exhale droplets (by breathing, speaking, coughing, sneezing, etc.) that could transmit COVID-19 to others.\n\nPeople passing through disinfection tunnels can experience physical as well as psychological harm. Chemical disinfectants sometimes used in these tunnels can be toxic to the human body, leading to irritation or damage of the eyes, skin, lungs, and gastrointestinal system (for example nausea or vomiting). Some chemical disinfectants are flammable and explosive, generate toxic gases, and are harmful to the environment. UV light exposure, which is also sometimes used in disinfection tunnels, can lead to skin burns, skin cancer, and eye damage. The International Ultraviolet Association (IUVA) states: \"there are no protocols to advise or to permit the safe use of UV light directly on the human body at the wavelengths and exposures proven to efficiently kill viruses such as SARS-CoV-2.\" Psychologically, the pain and stress of passing through a disinfection tunnel can be traumatic.\n\nPreventative measures (such as physical distancing, hand washing, wearing masks, and ensuring good ventilation) are recommended to help reduce the transmission of COVID-19, but disinfection tunnels are not recommended as a COVID-19 preventative measure. \n",
    "Glossary Terms": [
      "rec4crPh6OQvCngsk",
      "recjGuHkvGujLMjV7",
      "recjOgLIjiAbiBH5F"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "disinfectants"
    ],
    "Other resources": "1. Considerations for the cleaning and disinfection of environmental surfaces in the context of COVID-19 in non-health care settings ([WHO](https://www.who.int/news-room/q-a-detail/q-a-considerations-for-the-cleaning-and-disinfection-of-environmental-surfaces-in-the-context-of-covid-19-in-non-health-care-settings))\n2. COVID-19: Cleaning and Disinfecting Your Facility ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/community/disinfecting-building-facility.html))\n3. Disinfection tunnels: potentially counterproductive in the context of a prolonged pandemic of COVID-19 ([Elsevier Public Health](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200329/))\n4. UV Industry Associations Discourage the Use of UV Light on the Human Body to Disinfect Against the Coronavirus ([PR Newswire](https://www.prnewswire.com/news-releases/uv-industry-associations-discourage-the-use-of-uv-light-on-the-human-body-to-disinfect-against-the-coronavirus-301047108.html))\n5. “Disinfection Tunnels” Are Popping Up Around the World, Fueled By Misinformation and Fear ([Leapsmag](https://leapsmag.com/disinfection-tunnels-are-popping-up-around-the-world-fueled-by-misinformation-and-fear/))\n6. Disinfection tunnels: a problematic COVID-19 invention? | Analysis ([Africa News](https://www.africanews.com/2020/06/25/disinfection-tunnels-a-problematic-covid-19-invention-analysis//))\n",
    "Media": [
      {
        "id": "att89djJcxqVfYGXL",
        "url": "https://dl.airtable.com/.attachments/490b160dfb49b7553b615ecc680d94d8/7a75a8ab/Slide_1",
        "filename": "Slide_1",
        "size": 137607,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/f100ea9789ae46ab44d7646673ece260/b644fc39",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/1f609bbac202ddad2ea1cf0d57ba36cb/72318cf7",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/89240cab4f7d446c05d59b18fb10aa00/552c8acd",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attNLpkWlWu9AqLMi",
        "url": "https://dl.airtable.com/.attachments/c94419c0812166b1c8a9d338af044f4a/98863d43/Slide_2",
        "filename": "Slide_2",
        "size": 233305,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/4b966e327bf3e7c3802e7e000ffeaed2/737f6135",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/bd42a8c73e5b060e717ccadbaf458004/3c8909aa",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/a4e0b31bda5e9c8d7fe6c9b594ba5e50/f118cb9d",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attCs4DZ5zBwA61ZZ",
        "url": "https://dl.airtable.com/.attachments/c00533caaabb2ec5322dbb3ee8c40c16/96438ac0/Slide_3",
        "filename": "Slide_3",
        "size": 175029,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ec3c71ed9d9467285d259446e8d0a78f/2d0387ad",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c3ccd6a5bc6d5eaabbd6639dbdb49ad7/4b5de961",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/12618361a32e1aa3c5577af2cd313995/be17080d",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attEvyj8Qri4B3Sxp",
        "url": "https://dl.airtable.com/.attachments/e8c75389d5873c60dc4b51042ead2c07/e9710aa6/Slide_4",
        "filename": "Slide_4",
        "size": 294092,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b8fd18d9b340e16d83861de64c513302/398f9134",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/97fe20351869cfff12fc4fe3dceff983/2b5f73c3",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/654b565a916bec67169bccd1a081a609/6c955c54",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "Rollup test 2": [
      "recqD5CWejCR7ZMVp"
    ],
    "Last modified manual": "2020-08-12",
    "Last edited (simplified)": "2020-08-11T23:34:30.000Z",
    "Last edited (experts say)": "2020-10-13T20:17:15.000Z",
    "Last modified": "2020-10-13",
    "What our experts say wordcount": 299,
    "Background and context wordcount": 181,
    "Other resources wordcount": 88,
    "Wordcount": 568
  },
  {
    "id": "rec7DJ38UBOLWSnqC",
    "Question": "Why don't we know what animal COVID-19 came from?",
    "Status": "Published",
    "Subcategory": "On: COVID-19 & animal origins",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Most disease-causing agents, such as viruses and bacteria, stay within one host species, with many barriers preventing a jump from animals to humans. When a disease does break down the barriers between animals and people, it’s called a zoonotic disease. It's rare to have that jump result in a global outbreak, but even more rare to result in a global pandemic, as we're experiencing now. These jumps are becoming more commonplace, likely due to climate change. According to Margaret Wild, an expert in wildlife diseases and a professor at Washington State University in the U.S., “These diseases don’t transmit to humans often, and when they do, it’s typically when we push natural systems by destroying animal habitat or crowding different species together with people in a marketplace.” \n",
    "What our experts say": "While scientists have hypothesized that COVID-19 came from snakes, pangolins, bats, and other creatures, we still don't know exactly which animal passed the virus to humans, or how many species it might have impacted along the way. Scientists have determined that the virus did come from animals, not humans, and was first traced to a wet market in Wuhan, China. Many countries are hoping an independent investigation will take place to determine when and how COVID-19 first entered the human population, and at exactly what location. Many experts believe that the virus is a \"wild\" one, meaning that one animal species transmitted the virus to another species before it was spread to humans. The only way to determine exactly which animal the virus came from is to find the original animal species in the wild.\n",
    "Glossary Terms": [
      "reclGZpfnO5BRIJdt"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "animal",
      "source"
    ],
    "Other resources": "1. First Reported Cases of SARS-CoV-2 Infection in Companion Animals ([U.S. CDC](https://www.cdc.gov/mmwr/volumes/69/wr/mm6923e3.htm?s_cid=mm6923e3_x)) \n2. Coronavirus: A hunt for the 'missing link' host species ([BBC](https://www.bbc.com/news/science-environment-52529830)) \n3. Virus Mutations Reveal How COVID-19 Really Spread ([Scientific American](https://www.scientificamerican.com/article/virus-mutations-reveal-how-covid-19-really-spread1/)) \n4. Animal source of the coronavirus continues to elude scientists ([Nature](https://www.nature.com/articles/d41586-020-01449-8)) \n5. Infection of bat and human intestinal organoids by SARS-CoV-2 ([Nature](https://www.nature.com/articles/s41591-020-0912-6)) \n6. Explainer: What we know about the origins of the coronavirus pandemic ([Reuters](https://www.reuters.com/article/us-health-coronavirus-china-origins-expl/explainer-what-we-know-about-the-origins-of-the-coronavirus-pandemic-idUSKBN23H1HQ)) \n7. SARS-CoV-2 in animals ([AVMA](https://www.avma.org/resources-tools/animal-health-and-welfare/covid-19/sars-cov-2-animals-including-pets)) \n8. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China ([The Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext#%20)) \n9. Genomic variations of COVID-19 suggest multiple outbreak sources of transmission ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.02.25.20027953v1.full.pdf)) \n",
    "DB (Hindi)": [
      "recwnWJGFipJOsK7H"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "rec3m61JgaMh3T8qJ"
    ],
    "DB (Portuguese)": [
      "recEnHTXe4VdbBMqj"
    ],
    "Rollup test 2": [
      "recySWRCYqEtY7GJP"
    ],
    "Last modified manual": "2020-08-11",
    "Last edited (simplified)": "2020-06-24T20:46:46.000Z",
    "Last edited (experts say)": "2020-06-24T20:46:46.000Z",
    "Last modified": "2020-08-11",
    "What our experts say wordcount": 135,
    "Background and context wordcount": 128,
    "Other resources wordcount": 101,
    "Wordcount": 364,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "जबकि वैज्ञानिकों ने अनुमान लगाया है कि कोविड​​-19 सांप, पैंगोलिन, चमगादड़, और अन्य प्राणियों से आया है, हम अभी भी यह नहीं जानते हैं कि किस जानवर ने मनुष्यों को वायरस पारित किया है, या रास्ते में यह कितनी प्रजातियों को प्रभावित कर सकता है। वैज्ञानिकों ने निर्धारित किया है कि वायरस जानवरों से आया था, मनुष्यों से नहीं, और पहली बार चीन के वुहान में एक गीले बाजार में खोजा गया था। कई देश उम्मीद कर रहे हैं कि कोविड​​-19 ने पहली बार मानव आबादी में कब और कैसे प्रवेश किया, यह निर्धारित करने के लिए एक स्वतंत्र जांच होगी। कई विशेषज्ञों का मानना है कि वायरस एक \"जंगली\" है, जिसका अर्थ है कि एक पशु प्रजाति वायरस को अन्य प्रजातियों में स्थानांतरित करती है, इससे पहले कि वह मनुष्यों में फैल गई थी। यह निर्धारित करने का एकमात्र तरीका है कि वायरस किस जानवर से आया है, वन्य में मूल पशु प्रजातियों को खोजना है।"
    ],
    "Hindi - Background and context": [
      "अधिक रोग पैदा करने वाले एजेंट, जैसे कि वायरस और बैक्टीरिया, एक मेजबान प्रजाति के भीतर रहते हैं, कई अवरोधों के साथ जानवरों से मनुष्यों को स्थानांतरण से रोकते हैं। जब कोई बीमारी जानवरों और लोगों के बीच बाधाओं को तोड़ती है, तो इसे एक जूनोटिक बीमारी कहा जाता है। यह दुर्लभ है कि स्थानांतरण का परिणाम एक वैश्विक प्रकोप है, लेकिन एक वैश्विक महामारी में परिणाम के लिए और भी दुर्लभ है, जैसा कि हम अभी अनुभव कर रहे हैं। जलवायु परिवर्तन के कारण ये स्थानांतरण की संभावना आम होती जा रही है। वन्यजीव रोगों के विशेषज्ञ और यू॰एस में वाशिंगटन स्टेट यूनिवर्सिटी के एक प्रोफेसर मार्गरेट वाइल्ड के अनुसार, “ये बीमारियाँ अक्सर मनुष्यों तक नहीं पहुँचती हैं, और जब वे करते हैं, तो यह आमतौर पर होता है जब हम प्राकृतिक व्यवस्था को पशु आवास को नष्ट करके या विभिन्न प्रजातियों को एक साथ बाज़ार में लोगों की भीड़ में धकेल देते हैं। \""
    ],
    "Bengali - What our experts say": [
      "যদিও বিজ্ঞানীরা অনুমান করেছেন যে কোভিড-১৯ সাপ, পাঙ্গোলিন (বনরুই), বাদুড় এবং অন্যান্য প্রাণী থেকে এসেছে, আমরা এখনও ঠিক জানি না কোন প্রাণীটি মানুষের মধ্যে ভাইরাস সংক্রমণ ঘটিয়েছিল, বা এটি পথে কত প্রজাতির মধ্যে প্রভাব ফেলেছিল। বিজ্ঞানীরা স্থির করেছেন যে, ভাইরাসটি মানুষ থেকে নয়, প্রাণী থেকে এসেছে এবং প্রথমে চীনের উহানের একটি মাছের বাজারে ধরা পড়েছিল। অনেক দেশ আশা করছে যে, কোভিড-১৯ প্রথম কখন মানুষ সমাজে প্রবেশ করেছিল এবং ঠিক কোন স্থানে ছিল তা নির্ধারণ করার জন্য একটি স্বাধীন তদন্ত হবে। অনেক বিশেষজ্ঞ বিশ্বাস করেন যে, ভাইরাসটি একটি \"বন্য\", যার অর্থ একটি প্রজাতির প্রাণী ভাইরাসটি মানুষের মধ্যে ছড়িয়ে দেওয়ার আগে অন্য প্রজাতির মধ্যে সংক্রমিত করেছিল। ভাইরাসটি ঠিক কোন প্রাণী থেকে এসেছে তা নির্ধারণের একমাত্র উপায় হ'ল বনাঞ্চলে মূল প্রাণী প্রজাতিটি খুঁজে পাওয়া।"
    ],
    "Bengali - Background and context": [
      "ভাইরাস এবং ব্যাকটিরিয়ার মতো রোগ সৃষ্টিকারী বেশিরভাগ প্রতিনিধি একটি অতিথি প্রজাতির মধ্যেই থাকে, প্রাণী থেকে মানুষের মধ্যে ছড়িয়ে পড়ার অনেক বাঁধা রয়েছে । যখন কোনও রোগ প্রাণী এবং মানুষের মধ্যে বাধাগুলি ভেঙে ফেলে, তখন একে জুনোটিক রোগ বলা হয়। এই সংক্রমণের ফলস্বরূপ বিশ্বব্যাপী প্রকোপ দেখা পাওয়া বিরল, তবে ফলস্বরূপ বৈশ্বিক মহামারী এর চেয়ে বেশি বিরল, আমরা এখন যেগুলো দেখছি। জলবায়ু পরিবর্তনের কারণে এই সংক্রমণ আরও সাধারণ হয়ে উঠছে। বন্যজীবনের রোগ বিশেষজ্ঞ এবং মার্কিন যুক্তরাষ্ট্রের ওয়াশিংটন স্টেট ইউনিভার্সিটির প্রফেসর মার্গারেট ওয়াইল্ডের মতে, \"এই রোগগুলি প্রায়শই মানুষের মধ্যে সংক্রামিত হয় না এবং যখন হয় তখন সাধারণত যখন আমরা প্রাকৃতিক ব্যবস্থাকে ঠেলে দিয়ে প্রাণীর আবাস ধ্বংস করে বা বিভিন্ন প্রজাতি একসাথে বাজারে মানুষের সংস্পর্শে নিয়ে আসি। \""
    ]
  },
  {
    "id": "recN7xZOc6jUGgDCA",
    "Question": "Are there any side effects of using hand sanitizer?",
    "Status": "Published",
    "Background and context": "The virus causing COVID-19 can spread from touching an infected surface, from exposure to respiratory droplets, and from airborne transmission. Person-to-person spread (i.e. not from touching surfaces) is the most well understood form of transmission, as well as the main transmission route for COVID-19. Hand sanitizer is one way to clean your hands after touching surfaces and/or interacting with people, particularly when hand-washing is not an option. The U.S. Centers for Disease Control and Prevention (U.S. CDC) recommends soap and water for hand hygiene whenever possible and especially during cooking, after using the restroom, before eating, and when hands are visibly soiled. When using hand sanitizer, it is important to rub it over the entire surface of hands until dry.\n",
    "What our experts say": "Side-effects of hand sanitizer are short-term and often mild. The side effects are usually related to skin irritation, like cracking and bleeding, due to either irritation from the product or overuse and drying of the skin. It is important to always check the label to ensure safe use. Ingestion or use around the eyes and nose can cause irritation. \n\nAlcohol-based hand sanitizer should contain at least 60% alcohol to be effective. Hand sanitizer is a good way to clean hands when soap and water isn't available and is effective against the virus that causes COVID-19.\n\nThe U.S. Food and Drug Administration (FDA) has recently issued a warning on the increase in hand sanitizer products containing methanol, instead of ethanol. Methanol, or wood alcohol, is a toxic substance when absorbed through the skin or when ingested that can lead to blindness, hospitalizations, or death. On August 5, 2020, the U.S. Centers for Disease Control and Prevention (CDC) reported 4 deaths and 3 patients with visual impairments from drinking hand sanitizer. The FDA has recalled over 135 hand sanitizer products for safety reasons, and also warns against false labels claiming a hand sanitizer product is \"FDA-approved\" (because the FDA has not and does not approve any hand sanitizer products). Hand sanitizer products should be stored out of the reach of children to help prevent accidental ingestion. If you become exposed to hand sanitizer containing methanol and are experiencing symptoms, seek immediate treatment for potential reversal of methanol poisoning. \n\n_This entry was updated with new information on August 10, 2020._\n",
    "Glossary Terms": [
      "rech6tPR0hLDA3JH3",
      "rec5yviiSvJkufYvu"
    ],
    "Other resources": "1. Safely Using Hand Sanitizer ([U.S. FDA](https://www.fda.gov/consumers/consumer-updates/safely-using-hand-sanitizer))\n2. Hand Sanitizer Use Out and About ([U.S. CDC](https://www.cdc.gov/handwashing/hand-sanitizer-use.html))\n3. FDA Updates on Hand Sanitizers with Methanol ([U.S. FDA](https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-hand-sanitizers-methanol))\n4. FDA expands hand sanitizer recall to at least 75 brands across the U.S. ([NBC News](https://www.nbcnews.com/health/health-news/fda-expands-hand-sanitizer-recall-least-75-brands-across-u-n1234246))\n5. C.D.C. Warns Against Drinking Hand Sanitizer ([NYT](https://www.nytimes.com/2020/08/05/us/drinking-hand-sanitizer.html?referringSource=articleShare))\n6. FDA updates on hand sanitizers consumers should not use ([U.S. FDA](https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-hand-sanitizers-consumers-should-not-use))\n",
    "Media": [
      {
        "id": "attFC6KKp33B8bjSP",
        "url": "https://dl.airtable.com/.attachments/e7921c3d47f3930cbff36369c5ce1a6b/575e768f/Slide_1",
        "filename": "Slide_1",
        "size": 143570,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/200873bef9c31efc0d10e5979718f14a/86c54190",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/fae8659facc913511c9d43d7e469b7e4/f4eedaa6",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/9e8e6fcfdcc9dafb37b2c98e3fa14bf1/11bae963",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attyrNiDETOdswIyw",
        "url": "https://dl.airtable.com/.attachments/2534980928a9054fd76a61fb572f4fcc/d8e9c0ac/Slide_2",
        "filename": "Slide_2",
        "size": 187500,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e82724d0b6e4d1605bedf6d50aee90fd/24a58686",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ff07eaeb954a976efcca74a3bf2dd8bf/ac52132f",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/2229b1c610d0ecf912b105dd6e24b3d8/519e491f",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "atttkb2mqheE7CpYf",
        "url": "https://dl.airtable.com/.attachments/62057632982b77c79086376905ce1972/23be326f/Slide_3",
        "filename": "Slide_3",
        "size": 226955,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e09585380f999dad3c760e9f7fa7725c/873c1b54",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/f3ebc3d227761ddaa2c529b09c9ae81b/e730e012",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/9f4989b2debdf179cc68732eb03e4bbd/d5a75d15",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recLxnl7CuJ8g61Qo"
    ],
    "DB (Portuguese)": [
      "recmyYdlAoS4oOFQY"
    ],
    "Rollup test 2": [
      "recFJ5gudFZic6R9L"
    ],
    "Media Package": [
      {
        "id": "attCu1Vf210L3pXSJ",
        "url": "https://dl.airtable.com/.attachments/630f665a763ab5b3906bc6f8a544329c/d3f0a1ac/Handsanitizer.zip",
        "filename": "Hand sanitizer.zip",
        "size": 558899,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-08-11",
    "Last edited (simplified)": "2020-07-22T21:24:14.000Z",
    "Last edited (experts say)": "2020-08-11T21:57:04.000Z",
    "Last modified": "2020-08-11",
    "What our experts say wordcount": 255,
    "Background and context wordcount": 120,
    "Other resources wordcount": 57,
    "Wordcount": 432
  },
  {
    "id": "recE68fRyDEYYEuIr",
    "Question": "Can the virus be transmitted through the air?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & aerosol transmission",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Respiratory droplets are little beads of liquids that fly out when a person sneezes, coughs, or uses their mouth. The World Health Organization (WHO) has stated that COVID-19 mainly spreads from person to person through these droplets when people come in close contact with one another. Airborne particles tend to be lighter than respiratory droplets and can stay in the air for longer periods of time, which makes airborne viruses even easier to spread. Some studies have shown that COVID-19 could potentially be spread through the air in enclosed spaces with poor ventilation. The evidence on this mode of transmission is still evolving.\n\nAirborne transmission of COVID-19 is trending in the news, in part because 239 scientists signed an open letter on July 6, 2020 urging the WHO to update its COVID-19 guidance in response to growing evidence that airborne transmission is possible, ranging from case reports to epidemiological studies. The WHO has since acknowledged the emerging evidence for airborne transmission in \"crowded, closed, poorly ventilated settings,\" while cautioning that the evidence is preliminary and should be assessed further. If airborne transmission of COVID-19 is significant, this has major implications for containment efforts (ex. masks may be needed indoors and in socially-distant settings, ventilation systems may need to minimize recirculating air and find ways to filter or disinfect contaminated air, etc.).\n",
    "What our experts say": "According to the World Health Organization (WHO), the virus that causes COVID-19 is primarily spread through respiratory droplets (little spit droplets that fly out when a person sneezes, coughs or talks). Respiratory droplets can infect other people who are nearby, or indirectly infect others when they touch a surface contaminated with infected droplets. After an open letter by scientists in July 2020, the WHO now acknowledges the possibility of airborne transmission, which is caused by smaller and lighter 'droplet nuclei' (residuals of respiratory droplets from infected people) that can remain in the air for longer periods of time and remain infectious over long distances.\n\nExperts are looking at previous data from China to see whether the virus may spread through the air or through vents via airborne transmission. While a few lab-based studies have found that the virus can be present in the air for up to three hours, these studies did not assess if the virus is viable to infect anyone else. Recently, a research study published in Nature found viral contamination in air samples from patients isolated at a medical center, which supports the use of airborne isolation precautions in caring for COVID-19 cases. A few studies have also looked into how airborne transmission may have played a role in certain outbreaks, such as the one in the Diamond Princess cruise ship. One of these studies in pre-print found that it was likely that a combination of both close-range (respiratory droplet) transmission and long-range (airborne) transmission contributed similarly to disease progression aboard the ship.\n\nThus far, the WHO still claims that evidence points to close person-to-person respiratory droplet transmission as the primary mode of COVID-19 transmission. However, experts warn that there is significant reason to believe airborne transmission is happening. The U.S. Centers for Disease Control and Prevention (CDC) now provides infection control recommendations for airborne transmission as well as respiratory droplet transmission. Definitive studies may take a long time to alter the body of evidence in the coming weeks and months, but proactive prevention measures such as universal use of masks could save lives in the meantime.  \n\n_This entry was updated with new information on August 10, 2020._\n",
    "Glossary Terms": [
      "rec5yviiSvJkufYvu",
      "rech6tPR0hLDA3JH3",
      "recSf7dMrMv3l3Tcl",
      "recMOA1iUEl0oP2Vi",
      "recRXYuU3tstg6EO0",
      "recfxNeRDVhNKMgNe"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "virus",
      "contagion",
      "spread",
      "airborne",
      "transmission"
    ],
    "Other resources": "1. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMc2004973)) \n2. Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19 ([JAMA](https://jamanetwork.com/journals/jama/fullarticle/2763852?utm_source=twitter&utm_campaign=content-shareicons&utm_content=article_engagement&utm_medium=social&utm_term=032620#.Xn048zPgZVA.twitter)) \n3. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals (unedited but accepted for publication) ([Nature](https://www.nature.com/articles/s41586-020-2271-3))\n4. High SARS-CoV-2 Attack Rate Following Exposure at a Choir Practice — Skagit County, Washington, March 2020 ([U.S. CDC](https://www.cdc.gov/mmwr/volumes/69/wr/mm6919e6.htm?s_cid=mm6919e6_e&deliveryName=USCDC_921-DM28169))\n5. Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients ([Nature](https://www.nature.com/articles/s41467-020-16670-2))\n6. Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care ([Nature](https://www.nature.com/articles/s41598-020-69286-3))\n7. Mechanistic Transmission Modeling of COVID-19 on the Diamond Princess Cruise Ship Demonstrates the Importance of Aerosol Transmission ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.07.13.20153049v1))\n8. Airborne Transmission of SARS-CoV-2: Theoretical Considerations and Available Evidence ([JAMA](https://jamanetwork.com/journals/jama/fullarticle/2768396))\n9. Open Letter: It is Time to Address Airborne Transmission of COVID-19 ([Clinical Infectious Diseases](https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa939/5867798))\n10. Coronavirus: WHO rethinking how Covid-19 spreads in air ([BBC](https://www.bbc.com/news/world-53329946))\n11. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations ([WHO](https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations))\n12. Transmission of SARS-CoV-2: implications for infection prevention precautions  ([WHO](https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions))\n13. Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html))\n",
    "DB (French)": [
      "recBVqNYCcZL2zeqx"
    ],
    "DB (Hindi)": [
      "rechStEyPqYtEuAfa"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "reckynr9JweNlQBnP"
    ],
    "DB (Spanish)": [
      "recDUQlXgrve918hr"
    ],
    "DB (Bengali)": [
      "reclxdUTTUGJcSuos"
    ],
    "DB (Portuguese)": [
      "recWyOM7ROPFkA8o2"
    ],
    "Rollup test 2": [
      "recd7CRY4ryc6RPMI"
    ],
    "Last modified manual": "2020-08-11",
    "Last edited (simplified)": "2020-08-11T21:32:09.000Z",
    "Last edited (experts say)": "2020-08-11T21:32:09.000Z",
    "Last modified": "2020-08-11",
    "What our experts say wordcount": 359,
    "Background and context wordcount": 220,
    "Other resources wordcount": 181,
    "Wordcount": 760,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "D’après l’Organisation mondiale de la santé (OMS), le virus responsable de la COVID-19 est transmis principalement par des gouttelettes respiratoires (des gouttelettes de salive qui s’échappent quand une personne éternue, tousse ou parle). Les gouttelettes respiratoires peuvent infecter d’autres personnes à proximité ou indirectement celles qui toucheraient une surface contaminée par des gouttelettes infectées. Après publication d’une lettre ouverte par des scientifiques en juillet 2020, l’OMS reconnaît maintenant la possibilité de transmission par voie aérienne, transmission provoquée par des noyaux de condensation plus petits et plus légers (des résidus évaporés de gouttelettes respiratoires, expulsé par une personne infectée) qui peuvent se maintenir dans l’air plus longtemps et rester infectieux sur de plus longues distances.\n\nLes experts examinent d’anciennes données provenant de Chine afin de déterminer si le virus peut se propager dans l’air ou par les systèmes de ventilation, par voie aérienne. Bien que quelques études menées en laboratoire aient démontré que le virus peut être présent dans l’air jusqu’à trois heures, ces études n’ont pas pu établir que le virus reste viable pour infecter quelqu’un d’autre. Récemment, une étude de recherche publiée dans la revue « Nature » a trouvé une contamination virale dans des échantillons d’air provenant de patients isolés dans un centre médical, ce qui renforce le besoin d’appliquer des mesures d’isolation pour soigner les cas de COVID-19 et éviter la transmission aérogène. Quelques études ont aussi examiné le rôle joué par la transmission aérogène lors de certaines éclosions, telles que celle qui a eu lieu sur le navire de croisière « Diamond Princess ». Une de ces études, prépubliée, a trouvé qu’il était probable que la transmission rapprochée (gouttelettes provenant du système respiratoire) et celle à longue portée (aérogène) avaient ensemble contribué à la progression de la maladie à bord du navire.\n\nJusqu’à présent, l’OMS déclare toujours que les données probantes indiquent que la transmission rapprochée, de personne à personne, par des gouttelettes provenant du système respiratoire est le mode principal de transmission de la COVID-19. Cependant, des experts avertissent qu’il y a d’importantes raisons de croire qu’il y a transmission aérogène. Les Centres de contrôle et de prévention des maladies des États-Unis donnent maintenant des recommandations pour le contrôle des infections à la fois pour la transmission aérogène et par gouttelettes provenant du système respiratoire. Des études définitives pourraient prendre longtemps pour modifier les éléments de preuve dans les semaines et les mois à venir, mais des mesures proactives de prévention telles que l’utilisation universelle de masques pourraient sauver des vies entre-temps.\n\nCette entrée a été mise à jour avec de nouveaux renseignements le 4 août 2020."
    ],
    "French - Background and context": [
      "Les gouttelettes respiratoires sont des petites perles de liquide qui s’échappent d’une personne qui éternue, tousse ou utilise sa bouche. L’Organisation mondiale de la santé (OMS) a déclaré que la COVID-19 ne se propage principalement que de personne à personne grâce à ces gouttelettes, quand les gens se trouvent en contact rapproché. Les particules en suspension dans l’air sont généralement plus légères que les gouttelettes respiratoires et peuvent rester dans l’air plus longtemps, ce qui facilite encore plus la propagation des virus qui circulent dans l’air. Certaines études ont démontré que le virus de la COVID-19 pourrait se propager par l’air dans les espaces fermés dont la ventilation est mauvaise. La preuve de ce mode de transmission évolue encore.\n\nLes nouvelles couvrent souvent la transmission aérogène (par voie aérienne) de la COVID-19, en partie à la suite d’une lettre ouverte signée le 6 juillet 2020 par 239 scientifiques qui exhortent l’OMS de mettre à jour ses directives concernant la COVID-19 afin de refléter la preuve croissante de la possibilité de transmission aérogène, preuve émanant d’observations et d’études épidémiologiques. L’OMS a depuis reconnu les données probantes émergentes qui démontrent la transmission aérogène dans les milieux « fréquentés par un grand nombre de personnes, fermés et mal ventilés », tout en soulignant que ces données probantes sont préliminaires et doivent être examinées plus avant. Si la transmission aérogène de la COVID-19 est considérable, cela a des répercussions majeures sur les efforts pour endiguer la maladie (p. ex. les masques pourraient être nécessaires à l’intérieur et dans les situations de distanciation sociale, les systèmes de ventilation devront peut-être réduire la recirculation de l’air et trouver des moyens de filtrer ou de désinfecter l’air contaminé, etc.)."
    ],
    "Hindi - What our experts say": [
      "विश्व स्वास्थ्य संगठन (डब्ल्यू॰एच॰ओ॰ -WHO) के अनुसार, कोविड-19 बीमारी का वायरस मुख्य रूप से साँस की बूंदों (खाँसने या छींकने से निकलने वाली छोटी थूक की बूंदों) के माध्यम से फैलता है। साँस की बूंदें आस-पास के लोगों में बीमारी फैला सकती हैं, या फिर अन्य लोगों में जब वे उन साँस की बूंदों से दूषित सतह को छूते हैं। हालांकि, कुछ विशेषज्ञ चीन के पिछले प्रयोगों को समझ रहे हैं कि क्या यह वायरस हल्के कणों के माध्यम से फैल सकता है जो हवा में लंबे समय तक रहते हैं (एरोसोल ट्रांसमिशन)। हालाँकि, कुछ लैब-आधारित प्रयोगों में पाया गया है कि वायरस हवा में तीन घंटे तक मौजूद रह सकता है, ये प्रयोग यह निर्धारित नहीं कर पाए हैं कि वे वायरस किसी और को संक्रमित करने के काबिल है। अभी तक डब्ल्यू॰एच॰ओ॰ (WHO) और यू॰एस॰-सी॰डी॰सी॰ (US CDC) का मानना है कि अधिकतर गवाह यही साबित करते हैं कि वाइरस व्यक्ति से व्यक्ति तक साँस की बूँदों से ही फैल रहा है। फिर भी, विशेषज्ञों ने चेतावनी दी है कि एयरबोर्न ट्रांसमिशन को पूरी तरह ख़ारिज नहीं किया जा सकता है।  सुनिश्चित प्रमाण आने में समय लग सकता है, लेकिन इस बीच सक्रिय रोकथाम के उपाय, जैसे मास्क का सार्वजनिक उपयोग करने से कई जीवन बच सकते हैं।"
    ],
    "Hindi - Background and context": [
      "साँस की बूंदें छोटी तरल बूंदें होती हैं जो किसी व्यक्ति के छींकने, खांसने या अपने मुंह का उपयोग करने पर बाहर निकलती हैं। डब्ल्यू॰एच॰ओ॰ बताता है कि कोविड-19 वायरस इन बूंदों के माध्यम से एक व्यक्ति से दूसरे व्यक्ति में फैलता है जब लोग एक दूसरे के पास संपर्क में आते हैं। हवा में पाए जाने वाले कण हल्के होते हैं और अधिक समय तक हवा में रह सकते हैं, जिससे वातानीत (ऐरबॉर्न) वायरस फैलने में आसानी होती हैं। कुछ प्रयोगों से पता चला है कि  खराब वेंटिलेशन वाले बंद जगहों में हवा के माध्यम से कोविड-19 वाइरस फैलने की संभावना है। इस तरह से वाइरस के फैलने पर अभी भी सबूत पक्के किए जा रहे हैं।"
    ],
    "Telugu - What our experts say": [
      "ప్రపంచ ఆరోగ్య సంస్థ (డబ్ల్యూహెచ్‌ఓ) ప్రకారం, కోవిడ్-19 కి కారణమయ్యే వైరస్ ప్రధానంగా శ్వాసకోశ బిందువుల ద్వారా వ్యాపిస్తుంది (ఒక వ్యక్తి తుమ్ము, దగ్గు లేదా మాట్లాడేటప్పుడు బయటకు వెళ్లే చిన్న ఉమ్మి బిందువులు). శ్వాస బిందువులు సమీపంలో ఉన్న ఇతర వ్యక్తులకు సోకుతాయి లేదా సోకిన బిందువులతో కలుషితమైన ఉపరితలాన్ని తాకినప్పుడు పరోక్షంగా ఇతరులకు సోకుతాయి. జూలై 2020 లో శాస్త్రవేత్తల బహిరంగ లేఖ తరువాత, డబ్ల్యూహెచ్‌ఓ ఇప్పుడు గాలిలో ప్రసరించే అవకాశాన్ని గుర్తించింది, ఇది చిన్న మరియు తేలికైన 'బిందు బిందువుల కేంద్రకాలు' (సోకిన వ్యక్తుల నుండి శ్వాసకోశ బిందువుల అవశేషాలు) వల్ల ఎక్కువ కాలం గాలిలో ఉండగలదు. సమయం మరియు ఎక్కువ దూరం అంటువ్యాధులు.\n\nవైరస్ గాలి ద్వారా లేదా గాలి ద్వారా ప్రసారం ద్వారా గుంటల ద్వారా వ్యాప్తి చెందుతుందా అని నిపుణులు చైనా నుండి మునుపటి డేటాను చూస్తున్నారు. కొన్ని ల్యాబ్-ఆధారిత అధ్యయనాలు వైరస్ మూడు గంటల వరకు గాలిలో ఉంటుందని కనుగొన్నప్పటికీ, ఈ అధ్యయనాలు వైరస్ మరెవరినైనా సంక్రమించగలదా అని అంచనా వేయలేదు. ఇటీవల, నేచర్లో ప్రచురించబడిన ఒక పరిశోధన అధ్యయనం ఒక వైద్య కేంద్రంలో వేరుచేయబడిన రోగుల నుండి గాలి నమూనాలలో వైరల్ కలుషితాన్ని కనుగొంది, ఇది కోవిడ్-19 కేసుల సంరక్షణలో వాయుమార్గాన ఐసోలేషన్ జాగ్రత్తలను ఉపయోగించటానికి మద్దతు ఇస్తుంది. డైమండ్ ప్రిన్సెస్ క్రూయిజ్ షిప్‌లోని కొన్ని వ్యాప్తికి వాయుమార్గాన ప్రసారం ఎలా పాత్ర పోషించిందో కూడా కొన్ని అధ్యయనాలు పరిశీలించాయి. ప్రీ-ప్రింట్‌లోని ఈ అధ్యయనాలలో ఒకటి, దగ్గరి-శ్రేణి (శ్వాసకోశ బిందువు) ప్రసారం మరియు దీర్ఘ-శ్రేణి (వాయుమార్గాన) ప్రసారం రెండింటి కలయిక ఓడలో వ్యాధి పురోగతికి సమానంగా దోహదపడిందని కనుగొన్నారు.\n\nఇప్పటివరకు, WHO ఇప్పటికీ కోవిడ్-19 ప్రసారం యొక్క ప్రాధమిక రీతిగా వ్యక్తి నుండి వ్యక్తికి శ్వాసకోశ బిందు ప్రసారాన్ని మూసివేస్తుందని ఆధారాలు సూచిస్తున్నాయి. అయితే, గాలిలో ప్రసారం జరుగుతోందని నమ్మడానికి గణనీయమైన కారణం ఉందని నిపుణులు హెచ్చరిస్తున్నారు. యు.ఎస్. సెంటర్స్ ఫర్ డిసీజ్ కంట్రోల్ అండ్ ప్రివెన్షన్ (సిడిసి) ఇప్పుడు గాలిలో ప్రసారం మరియు శ్వాసకోశ బిందు ప్రసారానికి సంక్రమణ నియంత్రణ సిఫార్సులను అందిస్తుంది. రాబోయే వారాలు మరియు నెలల్లో సాక్ష్యాధారాలను మార్చడానికి ఖచ్చితమైన అధ్యయనాలు చాలా సమయం పడుతుంది, అయితే ముసుగులను సార్వత్రికంగా ఉపయోగించడం వంటి క్రియాశీల నివారణ చర్యలు ఈ సమయంలో ప్రాణాలను కాపాడతాయి.\n\nఈ ఎంట్రీ 2020 ఆగస్టు 10 న కొత్త సమాచారంతో నవీకరించబడింది."
    ],
    "Telugu - Context and background": [
      "శ్వాస బిందువులు ఒక వ్యక్తి తుమ్ము, దగ్గు లేదా నోరు ఉపయోగించినప్పుడు బయటకు వెళ్లిపోయే చిన్న ద్రవ పూసలు. ప్రజలు ఒకరితో ఒకరు సన్నిహితంగా ఉన్నప్పుడు కోవిడ్-19 ప్రధానంగా ఈ బిందువుల ద్వారా వ్యక్తి నుండి వ్యక్తికి వ్యాపిస్తుందని ప్రపంచ ఆరోగ్య సంస్థ (WHO) పేర్కొంది. వాయు కణాలు శ్వాసకోశ బిందువుల కన్నా తేలికగా ఉంటాయి మరియు ఎక్కువసేపు గాలిలో ఉండగలవు, ఇది గాలిలో వైరస్లను వ్యాప్తి చేయడానికి మరింత సులభం చేస్తుంది. కొన్ని అధ్యయనాలు కోవిడ్-19 పేలవమైన వెంటిలేషన్తో పరివేష్టిత ప్రదేశాలలో గాలి ద్వారా వ్యాపించవచ్చని తేలింది. ఈ ప్రసార రీతిలో ఆధారాలు ఇప్పటికీ అభివృద్ధి చెందుతున్నాయి. పరివేష్టిత ప్రదేశాలలో కోవిడ్-19 గాలి ద్వారా వ్యాప్తి చెందడానికి ఒక ప్రత్యేకమైన అవకాశం ఉంది, ప్రత్యేకించి పేలవమైన వెంటిలేషన్ ఉంటే, కానీ సాక్ష్యం ఇంకా అభివృద్ధి చెందుతోంది.\n\nకోవిడ్-19 యొక్క వైమానిక ప్రసారం వార్తల్లో ట్రెండింగ్‌లో ఉంది, ఎందుకంటే 239 శాస్త్రవేత్తలు జూలై 6, 2020 న బహిరంగ లేఖపై సంతకం చేశారు, WHO తన కోవిడ్-19 మార్గదర్శకాన్ని నవీకరించమని విజ్ఞప్తి చేస్తూ, గాలి నుండి ప్రసారం సాధ్యమేనని పెరుగుతున్న సాక్ష్యాలకు ప్రతిస్పందనగా, కేసు నుండి ఎపిడెమియోలాజికల్ అధ్యయనాలకు నివేదికలు. అప్పటి నుండి WHO రద్దీగా, మూసివేయబడిన, పేలవంగా వెంటిలేషన్ చేయబడిన అమరికలలో వాయుమార్గాన ప్రసారం కోసం అభివృద్ధి చెందుతున్న సాక్ష్యాలను గుర్తించింది, అయితే సాక్ష్యం ప్రాథమికమైనదని మరియు మరింత అంచనా వేయాలని హెచ్చరించారు. కోవిడ్-19 యొక్క గాలి ద్వారా ప్రసారం ముఖ్యమైనది అయితే, ఇది నియంత్రణ ప్రయత్నాలకు ప్రధాన చిక్కులను కలిగి ఉంటుంది (ఉదా. ఇంటి లోపల మరియు సామాజికంగా సుదూర అమరికలలో, వెంటిలేషన్ వ్యవస్థలు పునర్వినియోగ గాలిని తగ్గించాల్సిన అవసరం ఉంది మరియు కలుషితమైన గాలిని ఫిల్టర్ చేయడానికి లేదా క్రిమిసంహారక మార్గాలను కనుగొనవచ్చు, మొదలైనవి)."
    ],
    "Spanish - What our experts say": [
      "De acuerdo a la Organización Mundial de la Salud (OMS), el virus que causa el COVID-19 es diseminado primariamente a través de gotitas respiratorias (pequeñas gotitas de saliva que vuelan cuando una persona estornuda, tose o habla). Las gotitas respiratorias pueden infectar a otras personas que están en las cercanías, o infectar indirectamente a otras cuando tocan una superficie contaminada con gotitas infectadas. Sin embargo, algunos expertos están mirando datos previos de China para ver si el virus puede diseminarse a través del aire o a través de conductos vía gotitas más livianas que pueden permanecer en el aire por periodos de tiempo más largos (transmisión aérea/por aerosol). Mientras que algunos pocos estudios basados en laboratorio han encontrado que el virus puede estar presente en el aire por hasta tres horas, estos estudios no evaluaron si el virus es viable para infectar a alguien más. Hasta ahora, la OMS y los U.S. CDC aún mantienen que la mayoría de la evidencia apunta a transmisión por gotitas de persona a persona, estando estas en cercanía. Sin embargo, los expertos advierten que hay razones significativas para creer que la transmisión aérea está ocurriendo. Estudios definitivos pueden tomar un largo tiempo para alterar el cuerpo de evidencia en las semanas y meses venideros, pero las medidas de protección proactiva, tales como el uso universal de máscaras, pueden salvar vidas entretanto."
    ],
    "Spanish - Background and context": [
      "Las gotitas respiratorias son pequeñas gotas de líquido que vuelan cuando una persona estornuda, tose o usa su boca. La Organización Mundial de la Salud (OMS) ha afirmado que el COVID-19 se disemina principalmente de persona a persona a través de estas gotitas cuando las personas entran en contacto cercano entre una y otra. Las partículas transportadas por el aire tienden a ser más livianas que las gotitas respiratorias, y pueden estar en el aire por periodos de tiempo más largos, lo que hace que los virus aerotransportados sean aún más fáciles de diseminar. Algunos estudios han mostrado que el COVID-19 podría ser diseminado potencialmente a través del aire en espacios confinados con pobre ventilación. La evidencia sobre este modo de transmisión aún está evolucionando.\n\nLa transmisión aérea del COVID-19 está marcando tendencia en las noticias, en parte debido a que 239 científicos firmaron una carta abierta el 6 de julio de 2020, urgiendo a la OMS para que actualice su guía acerca del COVID-19 en respuesta a la evidencia creciente que la transmisión aérea es posible, abarcando desde reportes de casos hasta estudios epidemiológicos. La OMS ha reconocido desde entonces la evidencia emergente para la transmisión aérea en \"establecimientos atestados, cerrados y pobremente ventilados\", mientras que advierte que la evidencia es preliminaria y debiera ser adicionalmente evaluada. Si la transmisión aérea del COVID-19 es significativa, esto tiene implicaciones mayores para los esfuerzos de contención (ej.: las máscaras pueden ser necesitadas en interiores y en establecimientos con distanciamiento social, los sistemas de ventilación pueden necesitar minimizar el aire recirculante y encontrar maneras de filtrar o desinfectar el aire contaminado, etc.)"
    ],
    "Bengali - What our experts say": [
      "বিশ্ব স্বাস্থ্য সংস্থা (ডাব্লুএইচও) এর মতে, যে ভাইরাসটির কারণে কোভিড -১৯ প্রাথমিকভাবে শ্বাসকষ্টের মাধ্যমে ছড়িয়ে পড়ে ( কোন ব্যক্তি যখন কথা বলে বা হাঁচি দেয়, সামান্য থুতু ফোঁটা বা কাশি উড়ে বের হয় )। শ্বাসযন্ত্রের জলীয় কণাগুলি আশেপাশের অন্যান্য মানুষকে সংক্রামিত করতে পারে বা সংক্রামিত জলীয় কণা দ্বারা দূষিত কোন পৃষ্ঠকে স্পর্শ করলে অপ্রত্যক্ষভাবে অন্যকে সংক্রামিত করতে পারে। তবে কিছু বিশেষজ্ঞ চীন থেকে পূর্ববর্তী তথ্যের দিকে নজর দিচ্ছেন যে ভাইরাসটি বাতাসের মাধ্যমে বা বায়ু চলাচলের পথের মাধ্যমে ক্ষুদ্র জলীয় কণার মাধ্যমে ছড়িয়ে যেতে পারে যা দীর্ঘ সময়ের জন্য বাতাসে থাকতে পারে (অ্যারোসোল / বায়ুবাহিত সংক্রমণ)। কয়েকটি ল্যাব-ভিত্তিক গবেষণায় দেখা গেছে যে ভাইরাসটি তিন ঘন্টা পর্যন্ত বাতাসে উপস্থিত থাকতে পারে, তবে এই গবেষণাগুলি ভাইরাসটি অন্য কাউকে সংক্রামিত করতে সক্ষম কিনা তা মূল্যায়ন করেনি। এখনও অবধি, বিশ্ব স্বাস্থ্য সংস্থা এবং মার্কিন যুক্তরাষ্ট্রের রোগ নিয়ন্ত্রণ কেন্দ্র ব্যক্তি-ব্যক্তি থেকে জলীয় কণা সংক্রমণ সবচেয়ে যুক্তিযুক্ত হিসেবে দাবি করছে। তবে বিশেষজ্ঞরা সতর্ক করেছেন যে, বায়ুবাহিত সংক্রমণ ঘটছে বলে বিশ্বাস করার উল্লেখযোগ্য কারণ রয়েছে। আগামি সপ্তাহ এবং মাসগুলিতে শরীরে প্রমাণ উপযুক্ত পরিবর্তন আনতে সংজ্ঞাগত অধ্যয়ন অনেক সময় নিতে পারে, তবে মুখোশের সার্বজনীন ব্যবহারের মতো সক্রিয় প্রতিরোধ ব্যবস্থা এর মধ্যে জীবন বাঁচাতে পারে।"
    ],
    "Bengali - Background and context": [
      "শ্বাসযন্ত্রের ক্ষুদ্র জলীয় কণা একধরনের তরলের সামান্য বিন্দু যা কোনও ব্যক্তি হাঁচি, কাশি বা মুখ ব্যবহার করার সময় উড়ে যায়। বিশ্ব স্বাস্থ্য সংস্থা (ডাব্লুএইচও) জানিয়েছে যে, কোভিড-১৯ মূলত এই ফোঁটাগুলির মাধ্যমে এক ব্যক্তি থেকে অন্যজনে ছড়িয়ে পড়ে যখন লোকেরা একে অপরের সাথে ঘনিষ্ঠ সংস্পর্শে আসে। বায়ুবাহিত কণাগুলি শ্বাস প্রশ্বাসের ফোঁটাগুলির চেয়ে হালকা এবং দীর্ঘ সময় ধরে বাতাসে থাকতে পারে, যা বায়ুবাহিত ভাইরাসগুলি ছড়িয়ে দেওয়া আরও সহজ করে তোলে। কিছু গবেষণায় দেখা গেছে যে কোভিড-১৯ দুর্বল বায়ুচলাচল বদ্ধ স্থানে বাতাসের মাধ্যমে ছড়িয়ে যেতে পারে। এই সংক্রমণ পদ্ধতির প্রমাণগুলি এখনও উন্মোচিত হচ্ছে। বদ্ধ স্থানে বাতাসের মাধ্যমে কোভিড-১৯ ছড়িয়ে যাওয়ার আলাদা সম্ভাবনা রয়েছে, বিশেষত যদি খুব কম বায়ুচলাচল থাকে তবে প্রমাণ এখনও বিকাশমান।\nসংবাদে কোভিড-১৯ এর বায়ুবাহিত সংক্রমণ প্রবণতা রয়েছে, কারণ ৬ জুলাই ২০২০ ২৩৯ জন বিজ্ঞানী একটি খোলা চিঠি স্বাক্ষর করেছেন, বর্ধিত প্রমাণের জবাবে যে, বায়ুবাহিত সংক্রমণ সম্ভব, তার প্রতিক্রিয়ায় WHO তার কোভিড-১৯ নির্দেশিকা থেকে শুরু করে মহামারীবিজ্ঞানের গবেষণার প্রতিবেদন হালনাগাদ করার আহ্বান জানিয়েছে।\nবিশ্ব স্বাস্থ্য সংস্থা তখন থেকেই \"জনাকীর্ণ, বন্ধ, দুর্বলভাবে বায়ুচলাচল বিশিষ্টে\" বায়ুবাহিত সংক্রমণের জন্য উদীয়মান প্রমাণগুলি স্বীকার করে সতর্ক করে দিয়েছিল যে, প্রমাণগুলি প্রাথমিক এবং আরও মূল্যায়ন করা উচিত। যদি কোভিড-১৯ এর বায়ুবাহিত চলাচল তাৎপর্যপূর্ণ হয় তবে এটি নিয়ন্ত্রণের প্রচেষ্টার জন্য বড় প্রভাব ফেলে (উদাঃ অভ্যন্তরীণ মুখোশের প্রয়োজন হতে পারে এবং সামাজিকভাবে-দূরবর্তী বৈশিষ্ট্য, বায়ুচলাচল সিস্টেমগুলিকে বাতাসের পুনর্নির্মাণ কমিয়ে আনা এবং দূষিত বায়ু ছেঁকে ফেলা বা জীবাণুমুক্ত করা, ইত্যাদি)।"
    ]
  },
  {
    "id": "receKnYroVO0B9I3X",
    "Question": "What do we know so far about inhaled steroids as a treatment or cure for COVID-19?",
    "Status": "Published",
    "Subcategory": "Steroid",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Recent studies have shown that the steroid dexamethasone may be effective in treating severe cases of COVID-19 when given orally or through an IV (intravenous). However, this same impact has not been demonstrated in patients with mild or moderate cases or when dexamethasone is administered through a nebulizer. It should be noted that giving steroids to patients who are not severely ill with COVID-19 might cause more harm than benefit as steroids are known to suppress the immune system rather than help it fight infections more strongly. Doctors have warned against off-label use and hoarding of drugs.\n",
    "What our experts say": "In early September of 2020, the World Health Organization (WHO) issued guidance that a class of steroids called corticosteroids - specifically dexamethasone, hydrocortisone, and methylprednisolone - should be considered treatments for severe cases of COVID-19, but should not be used in milder cases. These steroids are given systemically, meaning through the veins or in an oral pill form. Inhaled steroids have not be recommended or approved for use in COVID-19 cases by the WHO or U.S. FDA.\n\nInhaled corticosteroids (ICSs) are used to treat asthma and other lung diseases, such as chronic obstructive lung disease (COPD). Due to lack of sufficient scientific evidence, whether ICSs protect or contribute to worse outcomes in COVID-19 patients is still debated. According to NIH Clinical Trials website, a randomized clinical study by Oxford University is underway to understand if ICSs can prevent or treat COVID-19.\n\nThe Lancet Respiratory Medicine Journal published more information in September 2020 on the relation of COVID-19 mortality and inhaled corticosteroids. The publication states that using ICS might reduce immunity to fight viruses and increase pneumonia in patients with COPD.  ICS use has also shown protection against COVID-19 by reducing the frequency of exacerbations and replication of SARS-CoV-2. However, there were significant differences in age and underlying illnesses about the groups studied.\n\nCommon devices used as inhalers include a metered-dose inhaler (MDI), nebulizer and dry-powder or rotary inhaler. There have been rumors circulating about using \"nebulizers\" to inhale steroids, such as the anti-inflammatory drug budesonide (brand name Pulmicort), to potentially treat COVID-19. \"Nebulizers\" are a type of inhaler that change liquid medications, like budesonide, into a mist that can be more easily inhaled into the lungs. Nebulizers can be more expensive than the most common type of inhaler used by people with asthma, and patients usually use nebulizers for specific reasons, such as if a child or someone with severe asthma is having difficulties inhaling medicine.\n\nInhaled steroids like budesonide can have side effects, and are also crucial for patients with health conditions who do not have COVID-19, so these should only be used when recommended by your doctor. Budesonide can be inhaled or taken orally, and when inhaled is part of a family of anti-inflammatory medications called inhaled steroids that are primarily used to help manage symptoms for conditions like asthma and chronic obstructive pulmonary disease (COPD). Budesonide is a prescription-only drug that is not approved by the U.S. Food and Drug Administration (FDA) for treatment of COVID-19.\n",
    "Glossary Terms": [
      "recXoBYjLFsoNt5pc",
      "recNOYE5yvxCxa7Tn",
      "recReyhOIWxm2lHoe"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\t\n",
    "Topics": [
      "inhaler",
      "nebulizer",
      "steroid"
    ],
    "Other resources": "1. Inhaled corticosteroids: A rapid review of the evidence for treatment or prevention of COVID-19 ([Oxford Centre for Evidence-Based Medicine](https://www.cebm.net/covid-19/inhaled-corticosteroids-a-rapid-review-of-the-evidence-for-treatment-or-prevention-of-covid-19/))\n2. STerOids in COVID-19 Study (STOIC)([NIH](https://clinicaltrials.gov/ct2/show/NCT04416399))\n3. Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying? ([The Lancet](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30447-1/fulltext))\n4. Inhaled corticosteroids may not increase COVID-19 mortality ([News Medical](https://www.news-medical.net/news/20200928/Inhaled-corticosteroids-may-not-increase-COVID-19-mortality.aspx))\n5. Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection ([Journal of Allergy and Clinical Immunology](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165083/))\n6. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15 ([bioRxiv](https://www.biorxiv.org/content/10.1101/2020.03.11.987016v1))\n7. Budesonide (Inhalation Route) ([Mayo Clinic](https://www.mayoclinic.org/drugs-supplements/budesonide-inhalation-route/description/drg-20071233))\n8. Inhalers and Nebulizers ([John Hopkins University](https://www.hopkinsmedicine.org/health/conditions-and-diseases/inhalers-and-nebulizers))\n9. Asthma Medicine Not Proven as COVID-19 ‘Cure’ ([FactCheck.Org](https://www.factcheck.org/2020/08/asthma-medicine-not-proven-as-covid-19-cure/))\n10. Corticosteroids for COVID-19 ([WHO](https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1)) \n11. Steroids Can Be Lifesaving for Covid-19 Patients, Scientists Report ([NYT](https://www.nytimes.com/2020/09/02/health/coronavirus-steroids.html)) \n",
    "DB (Hindi)": [
      "recQwFO94hnJzL3iV"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "reclcdK1XWCeoPGDa"
    ],
    "DB (Portuguese)": [
      "recWdOCfVQLawxkDK"
    ],
    "Rollup test 2": [
      "recfJZBuWfirHezIA"
    ],
    "Last modified manual": "2020-12-03",
    "Last edited (simplified)": "2020-12-03T17:13:36.000Z",
    "Last edited (experts say)": "2020-12-03T17:13:36.000Z",
    "Last modified": "2020-12-03",
    "What our experts say wordcount": 405,
    "Background and context wordcount": 97,
    "Other resources wordcount": 109,
    "Wordcount": 611,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "वर्तमान में कोविड-19 रोगियों में साँस के स्टेरॉयड के उपयोग पर कोई नैदानिक ​​परीक्षण या अवलोकन संबंधी अध्ययन नहीं हैं। कोविड-19 उपचार के रूप में इन दवाओं को फिर से तैयार करने से पहले अधिक शोध की आवश्यकता है।\n\nकोविड-19 के संभावित उपचार के लिए \"नेब्युलाइज़र\" का उपयोग करने के बारे में अफवाहें फैल रही हैं, जैसे कि एंटी-इंफ्लेमेटरी ड्रग बुडेसोनाइड (ब्रांड नाम पल्मिकॉर्ट)।\n\nनवजात स्टेरॉयड जैसे इनसाइड के साइड इफेक्ट्स हो सकते हैं, और स्वास्थ्य की स्थिति वाले रोगियों के लिए भी महत्वपूर्ण है जिनके पास कोविड-19 नहीं है, इसलिए इनका उपयोग केवल तब किया जाना चाहिए जब आपके डॉक्टर द्वारा सिफारिश की जाए। बुडेसोनाइड को साँस या मौखिक रूप से लिया जा सकता है, और जब साँस लेना विरोधी भड़काऊ दवाओं के एक परिवार का हिस्सा होता है जिसे साँस स्टेरॉयड कहा जाता है जो मुख्य रूप से अस्थमा और पुरानी प्रतिरोधी फुफ्फुसीय रोग (सीओपीडी) जैसी स्थितियों के लक्षणों का प्रबंधन करने में मदद करने के लिए उपयोग किया जाता है। बुडेसोनाइड एक प्रिस्क्रिप्शन-ओनली ड्रग है जो कोविड-19 के उपचार के लिए अमेरिकी खाद्य एवं औषधि प्रशासन (एफडीए) द्वारा अनुमोदित नहीं है।\n\n\"नेब्युलाइज़र\" एक प्रकार का इनहेलर है जो लिक्विड दवाओं को बदल देता है, जैसे कि ब्रेसोनाइड, एक धुंध में जिसे फेफड़ों में आसानी से साँस लिया जा सकता है। अस्थमा वाले लोगों द्वारा उपयोग किए जाने वाले सबसे सामान्य प्रकार के इनहेलर की तुलना में नेब्युलाइज़र अधिक महंगा हो सकता है, और मरीज आमतौर पर नेब्युलाइज़र का उपयोग विशिष्ट कारणों के लिए करते हैं, जैसे कि अगर किसी बच्चे या गंभीर अस्थमा वाले व्यक्ति को दवा लेने में कठिनाई हो रही है।"
    ],
    "Hindi - Background and context": [
      "अमेरिका में, टेक्सास के एक डॉक्टर हाल ही मे कोविड-19 का इलाज करने के लिए ब्यूसाइडाइड जैसे साँस के स्टेरॉयड के उपयोग को बढ़ावा दे रहे हैं, जिसने सोशल मीडिया पर ध्यान आकर्षित किया है। हालांकि, यह दिखाने के लिए कोई अध्ययन नहीं किया गया है कि साँस लेने वाले स्टेरॉयड कोविड-19 के इलाज में फायदेमंद हैं। इन दावों को करने वाले डॉक्टर ने यह भी सुझाव दिया है कि साँस के स्टेरॉयड हैं, क्यों कि ताइवान जैसे देशों में कोविड-19 की मौत कम होती है, लेकिन विश्व स्वास्थ्य संगठन (डबल्युएचओ) ने FactCheck.org को दिए एक बयान में कहा कि “वहाँ कोई सबूत नहीं है जो आपको बताए गए कॉर्टिकोस्टेरॉइड हैं। ताइवान, जापान, सिंगापुर और आइसलैंड में मामले की मृत्यु दर में कमी आई है। ”\n\nसामान्य तौर पर स्टेरॉयड के बारे में, हाल के अध्ययनों से पता चला है कि स्टेरॉयड डीएक्समेटासोन कोविड-19 के गंभीर मामलों के उपचार में प्रभावी हो सकता है जब मौखिक रूप से या एक IV (अंतःशिरा) के माध्यम से दिया जाता है। हालांकि, हल्के या मध्यम मामलों के रोगियों में या डेक्सामेथासोन को नेबुलाइज़र के माध्यम से प्रशासित किए जाने पर इस प्रभाव का प्रदर्शन नहीं किया गया है। यह ध्यान दिया जाना चाहिए कि कोविड-19 से गंभीर रूप से बीमार नहीं होने वाले रोगियों को स्टेरॉयड देने से लाभ की तुलना में अधिक नुकसान हो सकता है क्योंकि स्टेरॉयड को प्रतिरक्षा प्रणाली को दबाने के लिए जाना जाता है, बजाय इसके कि यह संक्रमणों से और अधिक मजबूती से लड़ने में मदद करे। डॉक्टरों ने ऑफ-लेबल उपयोग और ड्रग्स की जमाखोरी के खिलाफ चेतावनी दी है।\n\nइस प्रविष्टि को 10 अगस्त 2020 को नई जानकारी के साथ अद्यतन किया गया था।"
    ]
  },
  {
    "id": "recsT1TN71sp4UzkN",
    "Question": "Are air purifiers especially the mini, portable ones worn as necklaces effective in preventing transmission of COVID-19 or other coronaviruses?",
    "Status": "Published",
    "Background and context": "Miniature, portable air purifiers are currently being advertised around the world, particularly in online marketplaces. Unfortunately, many claims made by these products around COVID-19 prevention are unverified. Some products have claimed to use high efficiency particulate air (HEPA) filters, which are physical filters that meet a standard of catching at least 99.7% of particulates that are 0.3 micrometers or larger in size (although the SARS-CoV-2 virus particles causing COVID-19 are smaller on average than this 0.3 micrometer standard for HEPA filters). According to Pediatric Pulmonologist Dr. Nidhy Varghese, “even if these microbes make it into the purifier, they may elude filtration...the data so far suggests that it is unlikely that air purifiers will help with coronaviruses.\" The U.S. Environmental Protection Agency (EPA) also emphases that \"by itself, a portable air cleaner is not enough to protect people from COVID-19.\"\n",
    "What our experts say": "Mini, portable air purifier necklaces (such as the type available for purchase on consumer websites) have not been shown to prevent COVID-19 infection and there have been no studies about their effectiveness to date. Indoor air purifier units can help reduce tiny parts of virus in the air (airborne contaminants) in a home or confined space if they are used correctly, but they are not enough to protect people from COVID-19.\n",
    "Glossary Terms": [
      "recPFoN1pnhj4RUOc",
      "recy3qWpegJbN2rbV"
    ],
    "Other resources": "1. Will an air cleaner or air purifier help protect me and my family from COVID-19 in my home? ([U.S. EPA](https://www.epa.gov/coronavirus/will-air-cleaner-or-air-purifier-help-protect-me-and-my-family-covid-19-my-home))\n2. Air purifiers of 2020, according to experts ([NBC News](https://www.nbcnews.com/shopping/wellness/shoppingairpurifiers-n1183336))\n",
    "Last modified manual": "2020-08-23",
    "Last edited (simplified)": "2020-08-27T18:46:17.000Z",
    "Last edited (experts say)": "2020-09-08T20:53:56.000Z",
    "Last modified": "2020-09-08",
    "What our experts say wordcount": 71,
    "Background and context wordcount": 137,
    "Other resources wordcount": 30,
    "Wordcount": 238
  },
  {
    "id": "recLb3N3jf8NIqfhK",
    "Question": "How effective is it to use only a face shield to protect from COVID-19?",
    "Status": "Published",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "Nigeria"
    ],
    "Background and context": "Face shields are a type of personal protective equipment (PPE), along with masks, protective eye goggles, gloves, gowns, and other equipment. Proper use of PPE can help reduce the spread of COVID-19, yet some people are asking experts about minimum PPE recommendations. This may be due to access barriers (ex. cost, limited supply), use barriers (ex. heat, difficulty breathing, physical discomfort, aesthetics), cleaning and maintenance barriers, or other reasons. It is important to remember that PPE is a risk reduction measure that lowers the chances of infection, which is different from risk avoidance measures (completely eliminating risks is not always possible, particularly when exposed to other people who could transmit COVID-19).\n\n_This entry was updated with new information on August 07, 2020._\n",
    "What our experts say": "Wearing only a face shield to protect from COVID-19 is not as effective as wearing a mask, or wearing a face shield in combination with a mask. \nCloth face masks primarily protect people in close proximity to the mask wearer. This is because face masks cover a person's nose and mouth from all sides and are meant to trap droplets that are released when the mask wearer speaks, sneezes, coughs or sings. This is particularly relevant in the case of COVID-19 where many infected patients are asymptomatic or pre-symptomatic and therefore can spread the virus to others without feeling any symptoms. Face masks also offer some protection to the wearer by filtering out virus particles trying to enter and reducing exposure to the virus coming from other people.\nFace shields primarily protect the person wearing it. This is because face shields have the advantage of protecting the entire face, including the eyes, and often prevent people from touching their faces. However, due to insufficient research to date, we do not know how effective face shields are at protecting people in close proximity to the person wearing the face shield, in case that person is infected with COVID-19. \n",
    "Glossary Terms": [
      "recuQuM83b2X3K9Bx"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "transmission",
      "spread"
    ],
    "Other resources": "1. You're getting used to masks. Will you wear a face shield? ([NYT](https://www.nytimes.com/2020/05/24/health/coronavirus-face-shields.html))\n2. The growing scientific evidence for masks to fight Covid-19** **([Vox](https://www.vox.com/future-perfect/21299527/masks-coronavirus-covid-19-studies-research-evidence))\n3. CDC calls on Americans to wear masks to prevent COVID-19 spread ([U.S. CDC](https://www.cdc.gov/media/releases/2020/p0714-americans-to-wear-masks.html?utm_source=Global+Health+NOW+Main+List&utm_campaign=ba35be8398-EMAIL_CAMPAIGN_2020_07_14_03_18&utm_medium=email&utm_term=0_8d0d062dbd-ba35be8398-860399))\n\n\n",
    "DB (Hindi)": [
      "recOSiq7r71gpwfWY"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recWVdHU7dvRsViUV"
    ],
    "DB (Portuguese)": [
      "recxWOz857ENADWUv"
    ],
    "Rollup test 2": [
      "recwhVuJbSp06j058"
    ],
    "Last modified manual": "2020-08-07",
    "Last edited (simplified)": "2020-08-31T19:04:34.000Z",
    "Last edited (experts say)": "2020-08-31T19:04:34.000Z",
    "Last modified": "2020-08-31",
    "What our experts say wordcount": 197,
    "Background and context wordcount": 121,
    "Other resources wordcount": 36,
    "Wordcount": 354,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "कोविड-19 से बचाव के लिए केवल एक फेस शील्ड पहनना उतना प्रभावी नहीं है जितना कि मास्क पहनना, या मास्क के साथ संयोजन में फेस शील्ड पहनना।\nक्लॉथ फेस मास्क मुख्य रूप से मास्क पहनने वाले के नजदीकी लोगों की रक्षा करते हैं। ऐसा इसलिए होता है क्योंकि फेस मास्क हर तरफ से किसी व्यक्ति की नाक और मुंह को ढँक देते हैं और इसका मतलब है कि मास्क पहनने वाले, छींकने, खांसने या गाते समय निकलने वाली बूंदों को फँसाने के लिए। यह कोविड-19 के मामले में विशेष रूप से प्रासंगिक है जहां कई संक्रमित रोगी स्पर्शोन्मुख या पूर्व-लक्षण हैं और इसलिए किसी भी लक्षण को महसूस किए बिना वायरस दूसरों में फैल सकता है। फेस मास्क पहनने वाले वायरस को कुछ सुरक्षा प्रदान करते हैं जो वायरस के कणों को छानकर अन्य लोगों से आने वाले वायरस के संपर्क में आने और कम करने की कोशिश करते हैं।\nफेस शील्ड मुख्य रूप से इसे पहनने वाले व्यक्ति की रक्षा करते हैं। ऐसा इसलिए है क्योंकि फेस शील्ड में पूरे चेहरे की रक्षा करने का लाभ होता है, जिसमें आँखें भी शामिल हैं, और अक्सर लोगों को अपने चेहरे को छूने से रोकते हैं। हालांकि, आज तक के अपर्याप्त शोध के कारण, हम यह नहीं जानते हैं कि फेस शील्ड पहनने वाले व्यक्ति के करीबी लोगों की रक्षा करने में फेस शील्ड कितनी प्रभावी होती है, अगर वह व्यक्ति कोविड-19 से संक्रमित है।"
    ],
    "Hindi - Background and context": [
      "फेस शील्ड एक प्रकार के व्यक्तिगत सुरक्षात्मक उपकरण (पीपीई) हैं, साथ ही मास्क, सुरक्षात्मक आंख के चश्मे, दस्ताने, गाउन और अन्य उपकरण। पीपीई का उचित उपयोग कोविड-19 के प्रसार को कम करने में मदद कर सकता है, फिर भी कुछ लोग विशेषज्ञों से न्यूनतम पीपीई सिफारिशों के बारे में पूछ रहे हैं। यह प्रवेश बाधाओं (मूल्य, सीमित आपूर्ति) के कारण हो सकता है, अवरोधों (पूर्व ताप, साँस लेने में कठिनाई, शारीरिक परेशानी, सौंदर्यशास्त्र), सफाई और रखरखाव बाधाओं, या अन्य कारणों से उपयोग किया जा सकता है। यह याद रखना महत्वपूर्ण है कि पीपीई एक जोखिम कम करने वाला उपाय है जो संक्रमण की संभावना को कम करता है, जो जोखिम से बचाव के उपायों से अलग है (पूरी तरह से जोखिमों को समाप्त करना हमेशा संभव नहीं होता है, खासकर जब अन्य लोगों के संपर्क में जो कोविड-19 संचारित कर सकते हैं)।\n\nइस प्रविष्टि को 07 अगस्त, 2020 को नई जानकारी के साथ अद्यतन किया गया था।"
    ]
  },
  {
    "id": "rec2shxecDOlAie8Q",
    "Question": "What do we know about the Moderna vaccine so far?",
    "Status": "Published",
    "Background and context": "Over 165 vaccines against the coronavirus are in development around the world, and approximately 54 are in human trials. Moderna was the first American company to test a vaccine in humans, and is the second U.S. drugmaker to report successful preliminary results from a phase 3 trial. Moderna’s vaccine trials are part of the U.S. government’s Operation Warp Speed program, and received approximately $1 billion from the U.S. government in funding to support the research and development of the vaccine. \n",
    "What our experts say": "The Moderna vaccine is being developed and produced by Moderna, Inc. and is a genetic mRNA vaccine (mRNA-1273) currently in Phase 3 clinical trials across the U.S. Here's a breakdown of everything you need to know so far about this vaccine's development.\n\n**Collaborators:** Moderna is collaborating with Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases (NIAID) on vaccine development and testing for mRNA-1273.\n\n**Latest information on how well the vaccine works:** On November 30, 2020 with primary efficacy analysis data from its Phase 3 (COVE) trial, the experimental COVID-19 vaccine was reported to have 94.1% efficacy; protection against severe COVID-19 was reported at 100%. The study recorded a total of 196 infections among the 30,000 trial participants who received either the vaccine or a placebo (injections of saltwater). Of the 196 infections, 11 occurred among those who received the experimental (mRNA-1273) vaccine, and 185 infections occurred among those who did not receive the experimental vaccine (participants in the placebo group). Of the 30 severe cases of COVID-19 reported in the study, all were in the placebo group. There has been one COVID-19-related death in the study, which occurred in the placebo group. These new results are consistent with the first interim analysis conducted during the study (announced on November 16th, 2020) that reported efficacy of 94.5%. In a \"Letter to the Editor\" published in the New England Journal of Medicine on December 3, 2020, Moderna shared interim analysis findings from their Phase 1 trial that suggested that at day 119 (119 days following the first vaccine dose; 90 days after the second vaccine dose), binding and neutralizing antibody titers remained high in Phase 1 patients across age groups. These titers suggest ongoing immunity, though precise levels for protection against COVID-19 have not yet been established.\n\n**Distribution timeline:** The Phase 3 trial has exceeded the required post-vaccine follow-up (2 months) required by the US Food and Drug Administration (FDA). The company plans to pursue US FDA Emergency Use Authorization (EUA) and an application for Conditional Marketing Authorization (CMA) with the European Medicines Agency (EMA) on Monday, November 30th, 2020. Safety and efficacy data is expected to be reviewed by the US FDA on Thursday, December 17, 2020.\n\n**Approvals:** This vaccine is not yet approved for public use by any regulatory agency. In addition to the US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) and Conditional Marketing Authorization (CMA) with the European Medicines Agency (EMA) submitted on Monday, November 30th, 2020 (as highlighted above), Moderna has already begun the rolling review process with the EMA, Health Canada, SwissMedic, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA), Ministry of Health in Israel, and Health Sciences Authority in Singapore. The company plans to request Pre-qualification (PQ) and/or Emergency Use Listing (EUL) with the World Health Organization (WHO). \n\n**Distribution plan:** Together with the US Centers for Disease Control and Prevention (CDC), the U.S. government’s Operation Warp Speed program, and McKesson (a COVID-19 vaccine distributor contracted by the US government), distribution of the vaccine could start before the end of 2020, but the exact timing has yet to be determined and will depend on the timing of the progression through the FDA review process. The company expects to have approximately 20 million vaccine doses for the U.S. this year, millions of which the company has already made and is ready to ship if they receive an EUA approval. Moderna is on track to manufacture 500 million to 1 billion doses globally in 2021.\n\n**How the vaccine is being studied:** Vaccines are tested and studied in multiple phases (phased testing) to determine if they are safe and work to prevent illness. Before a vaccine is tested on humans, in the preclinical phase it is tested on laboratory cells or animals. Once it is approved for human research, there are three phases that take place before the vaccine can be considered for approval for public use. During the first stage (Phase I), the new vaccine is provided to small groups of people—the first time the vaccine is tested in humans. The second stage (Phase II) involves testing the vaccine on people who have similar characteristics (such as age and physical health) to the target population, or the group for which the vaccine is intended. The goal of this stage is to identify the most effective dosages and schedule for Phase III trials. The final stage (Phase III) provides the vaccine to thousands of people from the target population to see how safe and effective it is. Once the vaccine has undergone Phase 3 testing, the manufacturer can apply for a license from regulatory authorities (like the FDA in the US) to make the vaccine available for public use. Once approved, the drugmaker will work with national governments and international health organizations to monitor vaccine recipients for potential side effects from the vaccine that were not seen in clinical trials (this is called surveillance). This phase also helps researchers understand how well a vaccine works over a longer time frame and how safe it is for the population.\n\n**Type of vaccine:** The mRNA-1273 vaccine is what scientists are calling a genetic mRNA vaccine. This type of vaccine works by using genetic information from the coronavirus, which is injected into the body. The genetic information enters into human cells, instructs the body to make special spike proteins like the coronavirus, and causes the immune system to respond. \n\n**Dosage:** In the current Phase 3 clinical trial, participants receive two injections of 100 micrograms each into their upper arm muscle. The injections are given 28 days apart. If approved, researchers expect that the same dosage and schedule will be prescribed to the public.\n\n**Vaccine storage conditions:** Storage requirements are important to consider for new vaccines. In order for vaccines to be safe and effective, they must be held at the correct temperature during distribution and storage in health centers, pharmacies, and clinics. Maintaining the correct storage temperature can be difficult, especially if the vaccine's temperature requirement is very cold. The Moderna vaccine can be stored in a standard refrigerator temperature range (2 to 8 degrees Celsius or 36 to 46 degrees Fahrenheit) for up to 30 days. The vaccine can also be kept in long-term storage at a standard freezer temperature (-20 degrees Celsius or -4 degrees Fahrenheit) for up to six months. Maintaining these storage temperatures is already possible across vaccine distribution channels.\n\n**Preclinical testing:** Before testing could begin on humans, the trial vaccine was tested on primates. Vaccine doses of 10 micrograms or 100 micrograms of the experimental vaccine were tested. On July 28, 2020, results were published and showed that the vaccine was protective against COVID-19. The vaccine was then permitted to advance to clinical trials in humans.\n\n**Phase 1 trial:** The first patient dose of mRNA-1273 was given on March 16, 2020 and results from the Phase 1 trial were published on July 14, 2020. The Phase 1 trial included 45 participants, between age 18 and 55, who received two vaccine doses each, 28 days apart. Participants were divided into 3 groups (of 15 each) to test vaccine doses: 25 micrograms (two doses of 25 micrograms each given 28 days apart), 100 micrograms (two doses of 100 micrograms each given 28 days apart), and 250 micrograms (one dose). By day 43 of the trial, researchers observed immune responses in all participants that could reduce the ability of COVID-19 to infect people by 80% or more. By day 57, participants who received 100 microgram doses of the vaccine had average levels of neutralizing antibodies (special proteins that disable viruses in the body) that were about twice the average levels found in patients who have recovered from COVID-19. On day 119 (119 days following the first vaccine dose; 90 days after the second vaccine dose), binding and neutralizing antibody titers remained high in Phase 1 patients across age groups. These titers suggest ongoing immunity, though precise levels for protection against COVID-19 have not yet been established yet.\n\n**Phase 2 trial:** Phase 2 approval was given on May 6th, 2020, and the Phase 2 trials started on May 29th, 2020. Phase 2 evaluated the two doses of 50 micrograms (given as two injections of 50 micrograms each) and 100 micrograms (given as two injections of 100 micrograms each). On June 11th, 2020, recruitment of participants was completed with a total of 300 participants between 18 and 55 years of age (50 total participants were over 55 years of age). On September 29th, 2020, Phase 2 findings were published and examined the immune responses for the vaccine in 40 older adults at different doses. The study examined two different vaccine doses (25 micrograms and 100 micrograms given in two doses each, 28 days apart) and found that the higher dose (100 micrograms) produced a greater antibody titer (immune) response in the older adult population.\n\n**Phase 3 trial:** This clinical study was registered as a randomized, placebo controlled trial (participants are selected for participation and randomly assigned to either receive the experimental vaccine or a placebo injection) on July 14th, 2020, and the study began on July 27, 2020 in study centers across the US. The total Phase 3 study enrollment is more than 30,000 participants age 18 and older. On October 22, 2020 the company announced that recruitment was complete, and that 25,650 participants had already received two shots. 37% of study participants were from Communities of Color (>11,000 total with >6,000 who identify as Hispanic or LatinX, >3,000 who identify as Black or African American), and 42% were from populations considered high risk (7,000 Americans over the age of 65, and 5,000 who are under the age of 65 but have high-risk chronic diseases including diabetes, severe obesity, and cardiac disease that put them at higher risk of COVID-19). Data collection from the Phase 3 trial is ongoing; efficacy results are noted in the findings section above with current a efficacy (as of November 30th, 2020) of 94.1%. Efficacy results as reported were consistent across age, race and ethnicity, and gender.\n\n**Reported side effects and safety concerns:** No safety concerns have been reported in the Phase 3 study, and most side effects have been mild to moderate in severity. Severe concerns that have occurred in >2% of cases include injection site pain, fatigue, muscle aches, joint pain, headache, and pain. In the Phase 1 trial, side effects including fatigue, chills, headache, muscle aches, and pain at the injection site were commonly reported, particularly after the second vaccine dose. In the early phases of research, participants who received the highest vaccine dose (250 micrograms) had more severe side effects than those in the other experimental groups. The most commonly reported severe symptoms included fatigue (39-40 degrees C) and chills (significant, prevents daily activities).\n\n**Special populations:** On December 2, 2020, Moderna registered a new Phase 2/3 (combined phases) randomized, placebo controlled study with plans to enroll 3,000 healthy adolescents between 12 and <18 years of age from across the US. Using the same dosing schedule as adults (two injections of 100 micrograms each given 28 days apart), the study aims to evaluate the safety and efficacy of the vaccine (including the type of side effects participants experience and the frequency of those events). The estimated study completion date is June 30, 2022.  The mRNA-1273 vaccine has not yet been tested on infants, children, or pregnant or lactating women.\n\n**Other relevant notes:** N/A\n",
    "Glossary Terms": [
      "rec9qqItwSTjq3Eae",
      "recMJMGqkERKGcbL5",
      "recM4p8QOERmuESKr",
      "recJK5tI9LgCGFRAU",
      "recJhCnFxAX2jAH0h",
      "recr3NlaEcaDxSbvI",
      "reccH9Nhjj0fi18nJ",
      "recmajcAORyuqhZPc",
      "recyXylBebc7GlxTi",
      "rec10nAxiKgWhYJLd",
      "recR5R4QhqxWEg2nF",
      "recdTCKk9cPKJzUAf",
      "recTwPtyLhmTc3TBa",
      "recaXXF6coF4J2EUz",
      "rec5Cya6SiM7o3VRq",
      "recKI7Pa78bZM8n78",
      "recQYfy6k4QB8HKXM",
      "rec71GRZ4tY3XHahI",
      "recAz0hbQJmTotphI",
      "recDjpljNhPHIGIdl",
      "recjO3BV7pxq9azVL",
      "recpDS35Y5vAuQ7Oa",
      "recrEr81iMQyugyYC",
      "recOUL3lqEfAuhDdH"
    ],
    "Topics": [
      "vaccine",
      "vaccine effectiveness",
      "clinical trial",
      "prevention"
    ],
    "Other resources": "1. A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 (TeenCove)([Clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/NCT04649151?term=Moderna&cond=Covid19&draw=2&rank=1))\n2. A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/NCT04470427))\n3. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2022483)) (Supplementary Appendix- [NEJM](https://www.nejm.org/doi/suppl/10.1056/NEJMoa2022483/suppl_file/nejmoa2022483_appendix.pdf))\n4. Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study ([Moderna](https://investors.modernatx.com/node/10316/pdf))\n5. Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures ([Moderna](https://investors.modernatx.com/node/10311/pdf))\n6. Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus ([Moderna](https://investors.modernatx.com/node/9116/pdf))\n7. Moderna Completes Enrollment of Phase 2 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273) ([Moderna](https://investors.modernatx.com/node/9406/pdf))\n8. Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) ([Moderna](https://investors.modernatx.com/news-releases/news-release-details/moderna-completes-enrollment-phase-3-cove-study-mrna-vaccine))\n9. Vaccine experts say Moderna didn’t produce data critical to assessing Covid-19 vaccine ([STAT News](https://www.statnews.com/2020/05/19/vaccine-experts-say-moderna-didnt-produce-data-critical-to-assessing-covid-19-vaccine/))\n10. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2024671))\n11. Moderna’s Work on a COVID-19 Vaccine Candidate ([Moderna](https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19))\n12. First data for Moderna Covid-19 vaccine show it spurs an immune response ([STAT News](https://www.statnews.com/2020/07/14/moderna-covid19-vaccine-first-data-show-spurs-immune-response/))\n13. Will Moderna Match Competitors’ Covid-19 Vaccine Prices? ([Forbes](https://www.forbes.com/sites/johnlamattina/2020/07/22/will-moderna-match-competitors-covid-19-vaccine-prices/#2ee3c6e5e014))\n14. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2028436))\n15. We can stop COVID-19: Moderna vaccine success gives world more hope ([Reuters](https://in.reuters.com/article/health-coronavirus-vaccines-moderna/we-can-stop-covid-19-moderna-vaccine-success-gives-world-more-hope-idUSKBN27W1EG)) \n16. Moderna: Covid vaccine shows nearly 95% protection ([BBC](https://www.bbc.com/news/health-54902908))\n17. Early Data Show Moderna’s Coronavirus Vaccine Is 94.5% Effective ([NYT](https://www.nytimes.com/2020/11/16/health/Covid-moderna-vaccine.html))\n18. Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 VaccineCandidate and Filing Today with U.S. FDA for Emergency Use Authorization ([Moderna](https://investors.modernatx.com/node/10421/pdf))\n19. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMc2032195))\n",
    "Media": [
      {
        "id": "attejjFsTwMqr6VJQ",
        "url": "https://dl.airtable.com/.attachments/7fed8871ca16910d825f968bdafa72b9/a95c309c/Slide_1",
        "filename": "Slide_1",
        "size": 146817,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/2056b40f3ff6d79bc33ad755d6630e24/5cdf85f7",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/72fb0af63ea7e8ed5b341e197ba867e3/01f67867",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/5eac57a24193e24075d642baff64054c/f8298da0",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attfXzi5SM0wkXmde",
        "url": "https://dl.airtable.com/.attachments/d35f974d0eb894db405f9b95d3b35f3e/90e3aa46/Slide_2",
        "filename": "Slide_2",
        "size": 186205,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/68574e4e479fe0bbb92231e338a4dbbc/e367f6a6",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/5e91f2781ece482db773cd83ad5a0907/81a3906b",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/def67e898a9778c6793179094dc30a7c/4a135c87",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attBmtG17ngXf4Zla",
        "url": "https://dl.airtable.com/.attachments/033942d4692d04541c9e80f6adc363d0/ccf0c49f/Slide_3",
        "filename": "Slide_3",
        "size": 181909,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/718b2893d840bf238e3c3cc09e4a5c17/8ddafbe7",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/9cd4b6b9cafdaf2d91c303393054bb0f/d48daa85",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/098d83df00917d767f05a06d463e1abb/09d68f53",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attNxJTv5Y0Pfqp3Q",
        "url": "https://dl.airtable.com/.attachments/d3c4de353d7f62439f121901f328f368/24867690/Slide_4",
        "filename": "Slide_4",
        "size": 193640,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/f6770cf43e9d0357ec0f898b518e6970/ca5fdb90",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c1f66f5abdf0b91abc0345d56b1481e8/fdb7d80c",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/cc3e3e50f7791b3586cf8e21cbec59ed/426b81a7",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attAsuW7THYi6wjjW",
        "url": "https://dl.airtable.com/.attachments/6643d75861ef9e4238b497a2e1b74f02/e32be8a4/Slide_5",
        "filename": "Slide_5",
        "size": 194289,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/f10cda19320ecb83cd2c0fba3c6b11ba/c994fb5d",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/006e9486a72a6b5b077cddc837cb2ee9/a98741de",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/07e6571780fe9a6bbc25584413f25658/fd8c7b8d",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recO0xAuKbGhseNw5"
    ],
    "DB (Portuguese)": [
      "recp18sII5PdAWrwF"
    ],
    "Rollup test 2": [
      "recQIO8jvG2ESSGK0"
    ],
    "Media Package": [
      {
        "id": "attvD36elmKSgwq9T",
        "url": "https://dl.airtable.com/.attachments/ee9fe3bef47ca73dbb6c1ab90112a3c3/bc6155b5/Modernavaccine.zip",
        "filename": "Moderna vaccine.zip",
        "size": 904297,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-12-07",
    "Last edited (simplified)": "2020-11-25T15:45:30.000Z",
    "Last edited (experts say)": "2020-12-07T15:26:28.000Z",
    "Last modified": "2020-12-07",
    "What our experts say wordcount": 1884,
    "Background and context wordcount": 80,
    "Other resources wordcount": 272,
    "Wordcount": 2236
  },
  {
    "id": "recUakBDhgsxJwFic",
    "Question": "Can cannabis prevent, treat or cure COVID-19?",
    "Status": "Published",
    "Category": "Treatment, Cure, Prevention",
    "Subcategory": "On: COVID-19 & cannabis",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "Canada"
    ],
    "Background and context": "In recent years, there has been a significant interest in the development of therapies and other consumer products derived from cannabis and its components, including cannabidiol (CBD). The U.S. FDA has approved only one CBD product, a prescription drug product to treat two rare, severe forms of epilepsy. In the context of COVID-19, media reported the results of a preprint study indicating the possibility that cannabis could prevent COVID-19 by blocking the virus' entry into the lungs. This study has not gone through the peer review process, has not been assessed by peers, and has not published in any scientific journal. \n",
    "What our experts say": "There is no reliable evidence so far to suggest that cannabis can prevent, treat or cure COVID-19. One pre-print (a type of study that is yet to be peer-reviewed) from Canada suggests possible anti-inflammatory properties in cannabis may be effective in future treatments of the disease. The study also suggests that cannabis could be used to prevent infection from the SARS-CoV-2 virus that causes COVID-19. SARS-CoV-2 gains entry into cells in the human body by interacting with the ACE2 receptor protein, which is found on the surface of many cells. This study suggests that cannabidiol (CBD), one of the active ingredients in cannabis, may affect the virus' ability to bind to the ACE2 receptor protein and enter cells. However, none of the claims in the pre-print study have been validated in large-scale studies, and pre-print data should always be treated with caution. \n\nAnother lab, in Israel, is studying the effects of cannabis on the immune system's response to COVID-19 and analyzing the potential for molecules in cannabis to prevent the virus from entering cells and spreading. This research, however, has been undertaken by a cannabis research and development company based in Israel, and not independently verified by other scientific studies that are not linked to the cannabis industry. At this point, there is insufficient independent research to make any claims about the use of cannabis in preventing, treating, or curing COVID-19.\n",
    "Glossary Terms": [
      "rec8sQHhdcKiEVR9f",
      "recwkZVfZQxlVPfdW"
    ],
    "Variation of the answer depending on country of residence": "No\n\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n\n",
    "Topics": [
      "cannabis",
      "treatment",
      "prevention",
      "marijuana"
    ],
    "Other resources": "1. Could cannabis terpene formulation treat COVID-19? ([Health Europa](https://www.healtheuropa.eu/cannabis-terpene-formulation-treat-covid-19/99586/))\n2. Cannabidiol (CBD): what we know and what we don't ([Harvard](https://www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476))\n3. NIH Research on Marijuana and Cannabinoids ([National Institute on Drug Abuse](https://www.drugabuse.gov/drugs-abuse/marijuana/nih-research-marijuana-cannabinoids))\n4. In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues ([Preprints](https://www.preprints.org/manuscript/202004.0315/v1))\n\n",
    "DB (French)": [
      "recqi3pOFpURsQnNr"
    ],
    "DB (Hindi)": [
      "rec3F7UpkqC6pvtSM"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "rec8Ax1rNk6fkZPEU"
    ],
    "DB (Spanish)": [
      "recrW0VfkfnG8amyw"
    ],
    "DB (Arabic)": [
      "recLgrQ1NXjsmVxHl"
    ],
    "DB (Bengali)": [
      "rec9znubXIybb1IFx"
    ],
    "DB (Portuguese)": [
      "recKAYmpVCH7jJmF7"
    ],
    "Rollup test 2": [
      "rec9ODXAvy1BZ3S8S"
    ],
    "Last modified manual": "2020-08-07",
    "Last edited (simplified)": "2020-06-03T20:21:33.000Z",
    "Last edited (experts say)": "2020-06-24T19:47:44.000Z",
    "Last modified": "2020-08-06",
    "What our experts say wordcount": 231,
    "Background and context wordcount": 101,
    "Other resources wordcount": 49,
    "Wordcount": 381,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Arabic Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Il n’existe actuellement aucune donnée probante fiable pour suggérer que le cannabis peut prévenir, traiter ou guérir la COVID-19. Une prépublication (une étude qui n’a pas encore été contrôlée par des pairs) provenant du Canada suggère que les propriétés anti-inflammatoires du cannabis pourraient s’avérer efficaces dans les traitements futurs de la maladie. L’étude suggère aussi que le cannabis pourrait être utilisé pour prévenir les infections par le virus SARS-CoV-2 responsable de la COVID-19. Le SARS-CoV-2 s’introduit dans les cellules du corps humain en interagissant avec la protéine réceptrice ACE2 qui se trouve à la surface de nombreuses cellules. Cette étude suggère que le cannabidiol (CBD), un des ingrédients actifs du cannabis, pourrait affecter la capacité du virus à se lier à la protéine réceptrice ACE2 et à s’introduire dans les cellules. Cependant, aucune des affirmations de l’étude prépubliée n’a été validée dans des études à grande échelle, et les données prépubliées devraient toujours être traitées avec discernement."
    ],
    "French - Background and context": [
      "Au cours des dernières années, il y a eu un engouement important pour le développement de thérapies et d’autres biens de consommation dérivés du cannabis et de ses composants, dont le cannabidiol (CBD). L’Agence américaine des produits alimentaires et médicamenteux des États-Unis (FDA) n’a approuvé qu’un produit à base de CBD, un médicament sur ordonnance pour traiter deux formes rares et graves d’épilepsie. Dans le cadre de la COVID-19, la presse a rapporté les résultats d’une étude prépubliée qui indique la possibilité que le cannabis puisse prévenir la COVID-19 en bloquant l’introduction du virus dans les poumons. Cette étude n’a pas été contrôlée par des pairs et n’a été publiée dans aucun journal scientifique."
    ],
    "Hindi - What our experts say": [
      "यह सुझाव देने के लिए अब तक कोई विश्वसनीय सबूत नहीं है कि कैनबिस कोविड-19 को रोक, उपचार या इलाज कर सकता है। कॅनेडा से एक प्री-प्रिंट (एक प्रकार का अध्ययन जो अभी तक सहकर्मी की समीक्षा करना है) बताता है कि भांग में संभावित विरोधी भड़काऊ गुण रोग के भविष्य के उपचार में प्रभावी हो सकते हैं। अध्ययन से यह भी पता चलता है कि भांग को कोविड-19 का कारण बनने वाले SARS-CoV-2 वायरस से संक्रमण को रोकने के लिए इस्तेमाल किया जा सकता है। SARS-CoV-2 ACE2 रिसेप्टर प्रोटीन के साथ मानव शरीर में कोशिकाओं में प्रवेश करता है, जो कई कोशिकाओं की सतह पर पाया जाता है। यह अध्ययन बताता है कि कैनबिडिस में सक्रिय अवयवों में से एक कैनाबिडिओल (सीबीडी), एसीई 2 रिसेप्टर प्रोटीन को बाँधने और कोशिकाओं में प्रवेश करने की वायरस की क्षमता को प्रभावित कर सकता है। हालांकि, प्री-प्रिंट अध्ययन में कोई भी दावा बड़े पैमाने पर अध्ययनों में मान्य नहीं किया गया है, और प्री-प्रिंट डेटा को हमेशा सावधानी के साथ व्यवहार किया जाना चाहिए।\n\nएक अन्य लैब, इज़राइल में, कोविड-19 के लिए प्रतिरक्षा प्रणाली की प्रतिक्रिया पर कैनबिस के प्रभावों का अध्ययन कर रही है और कैनबिस में अणुओं की क्षमता का विश्लेषण कर रही है ताकि वायरस को कोशिकाओं में प्रवेश करने और फैलने से रोका जा सके। यह शोध, हालाँकि, इज़राइल में स्थित एक भांग अनुसंधान और विकास कंपनी द्वारा किया गया है, और अन्य वैज्ञानिक अध्ययनों द्वारा स्वतंत्र रूप से सत्यापित नहीं किया गया है जो कि भांग उद्योग से जुड़ा नहीं है। इस बिंदु पर, कोविड-19 को रोकने, उपचार या इलाज करने में भांग के उपयोग के बारे में कोई भी दावा करने के लिए अपर्याप्त स्वतंत्र अनुसंधान है।"
    ],
    "Hindi - Background and context": [
      "हाल के वर्षों में, कैनबिस और इसके घटकों से प्राप्त चिकित्सा और अन्य उपभोक्ता उत्पादों के विकास में एक महत्वपूर्ण रुचि रही है, जिसमें कैनबिडिआल (सीबीडी) शामिल है। अमेरिकी एफडीए ने मिर्गी के दो दुर्लभ, गंभीर रूपों के इलाज के लिए केवल एक सीबीडी उत्पाद, एक प्रिस्क्रिप्शन ड्रग उत्पाद को मंजूरी दी है। कोविड-19 के संदर्भ में, मीडिया ने एक पूर्व अध्ययन के परिणामों की रिपोर्ट की, जिसमें यह संभावना व्यक्त की गई कि भांग वायरस में प्रवेश को रोककर कोविड-19 को फेफड़ों में रोक सकती है। यह अध्ययन सहकर्मी समीक्षा प्रक्रिया के माध्यम से नहीं गया है, साथियों द्वारा मूल्यांकन नहीं किया गया है, और किसी भी वैज्ञानिक पत्रिका में प्रकाशित नहीं हुआ है।"
    ],
    "Telugu - What our experts say": [
      "కోవిడ్-19 ను గంజాయి నిరోధించగలదు, చికిత్స చేయగలదు లేదా నయం చేయగలదని సూచించడానికి ఇప్పటివరకు నమ్మదగిన ఆధారాలు లేవు. కెనడా నుండి ఒక ప్రీ-ప్రింట్ (ఒక రకమైన అధ్యయనం ఇంకా సమీక్షించబడలేదు) గంజాయిలో శోథ నిరోధక లక్షణాలు వ్యాధి యొక్క భవిష్యత్తు చికిత్సలలో ప్రభావవంతంగా ఉండవచ్చని సూచిస్తున్నాయి. కోవిడ్-19 కు కారణమయ్యే SARS-CoV-2 వైరస్ నుండి సంక్రమణను నివారించడానికి గంజాయిని ఉపయోగించవచ్చని అధ్యయనం సూచిస్తుంది. SARS-CoV-2 అనేక కణాల ఉపరితలంపై కనిపించే ACE2 గ్రాహక ప్రోటీన్‌తో సంకర్షణ చెందడం ద్వారా మానవ శరీరంలోని కణాలలోకి ప్రవేశిస్తుంది. ఈ అధ్యయనం గంజాయిలోని క్రియాశీల పదార్ధాలలో ఒకటైన గంజాయి (సిబిడి) ACE2 గ్రాహక ప్రోటీన్‌తో బంధించి కణాలలోకి ప్రవేశించే వైరస్ సామర్థ్యాన్ని ప్రభావితం చేస్తుందని సూచిస్తుంది. ఏదేమైనా, ప్రీ-ప్రింట్ అధ్యయనంలో ఉన్న వాదనలు ఏవీ పెద్ద ఎత్తున అధ్యయనాలలో ధృవీకరించబడలేదు మరియు ప్రీ-ప్రింట్ డేటాను ఎల్లప్పుడూ జాగ్రత్తగా చూసుకోవాలి.\n\nఇజ్రాయెల్‌లోని మరో ప్రయోగశాల, కోవిడ్-19 కు రోగనిరోధక వ్యవస్థ యొక్క ప్రతిస్పందనపై గంజాయి యొక్క ప్రభావాలను అధ్యయనం చేస్తోంది మరియు వైరస్ కణాలలోకి ప్రవేశించకుండా మరియు వ్యాప్తి చెందకుండా నిరోధించడానికి గంజాయిలోని అణువుల సామర్థ్యాన్ని విశ్లేషిస్తుంది. అయితే, ఈ పరిశోధన ఇజ్రాయెల్ కేంద్రంగా ఉన్న గంజాయి పరిశోధన మరియు అభివృద్ధి సంస్థ చేత చేయబడినది మరియు గంజాయి పరిశ్రమతో సంబంధం లేని ఇతర శాస్త్రీయ అధ్యయనాల ద్వారా స్వతంత్రంగా ధృవీకరించబడలేదు. ఈ సమయంలో, కోవిడ్-19 ను నివారించడం, చికిత్స చేయడం లేదా నయం చేయడంలో గంజాయి వాడకం గురించి ఏవైనా వాదనలు చేయడానికి తగినంత స్వతంత్ర పరిశోధనలు లేవు."
    ],
    "Telugu - Context and background": [
      "ఇటీవలి సంవత్సరాలలో, గంజాయి మరియు దాని భాగాల నుండి పొందిన చికిత్సలు మరియు ఇతర వినియోగదారు ఉత్పత్తుల అభివృద్ధిపై గన్నబిడియోల్ (సిబిడి) తో సహా గణనీయమైన ఆసక్తి ఉంది. రెండు అరుదైన, తీవ్రమైన మూర్ఛ చికిత్సకు చికిత్స చేయడానికి సూచించిన ఒక CBD ఉత్పత్తిని మాత్రమే US FDA ఆమోదించింది. కోవిడ్-19 సందర్భంలో, మీడియా ప్రింట్ ప్రింట్ అధ్యయనం ఫలితాలను నివేదించింది, గంజాయి COV పిరితిత్తులలోకి వైరస్ ప్రవేశించడాన్ని నిరోధించడం ద్వారా కోవిడ్-19 ని నిరోధించగలదని సూచిస్తుంది. ఈ అధ్యయనం పీర్ సమీక్ష ప్రక్రియ ద్వారా వెళ్ళలేదు, తోటివారిచే అంచనా వేయబడలేదు మరియు ఏ శాస్త్రీయ పత్రికలోనూ ప్రచురించబడలేదు."
    ],
    "Spanish - What our experts say": [
      "No hay evidencia confiable hasta ahora para sugerir que el cannabis pueda prevenir, tratar o curar al COVID-19. Una pre-impresión (un tipo de estudio que aún no ha sido revisado por pares) proveniente de Canadá sugiere posibles propiedades antiinflamatorias en el cannabis que podrían ser efectivas en futuros tratamientos de la enfermedad. El estudio también sugiere que el cannabis podría ser usado para prevenir la infección por el virus SARS-CoV-2 que causa el COVID-19. El SARS-CoV-2 gana entrada dentro de las células en el cuerpo humano por interacción con la proteína receptora ACE2, la cual es encontrada en la superficie de muchas células. Este estudio sugiere que el cannabidiol (CBD), uno de los ingredientes activos en el cannabis, puede afectar la habilidad del virus para enlazarse con la proteína receptora ACE2 e ingresar a las células. Sin embargo, ninguna de las afirmaciones en el estudio en pre-impresión han sido validadas en estudios a gran escala, y los datos en pre-impresiones siempre debieran ser tratados con precacución.\n\nOtro laboratorio en Israel está estudiando los efectos del cannabis en la respuesta del sistema inmunológico al COVID-19, y analizando el potencial de las moléculas en el cannabis para prevenir que el virus entre en las células y se disemine. Esta investigación, sin embargo, ha sido emprendida por una compañía de investigación y desarrollo del cannabis basada en Israel, y no verificada independientemente por otros estudios científicos que no estén vinculados con la industria del cannabis. En este momento, no hay investigación independiente suficiente para efectuar cualquier afirmación acerca del uso del cannabis en la prevención, tratamiento o cura del COVID-19."
    ],
    "Spanish - Background and context": [
      "En años recientes, ha habido un significativo interés en el desarrollo de terapias y otros productos de consumo derivados del cannabis y sus componentes, incluyendo al cannabidiol (CBD). La U.S FDA ha aprobado solamente un producto CBD, una droga de prescripción para tratar dos formas de epilepsia raras y severas. En el contexto del COVID-19, los medios informaron los resultados de un estudio pre-impresión indicando la posibilidad que el cannabis puede prevenir el COVID-19 al bloquear la entrada del virus a los pulmones. Este estudio no ha pasado a través del proceso de revisión por pares, no ha sido evaluado por pares y no ha sido publicado en ninguna revista científica."
    ],
    "Arabic - What our experts say": [
      "لا توجد أدلة موثوقة حتى الآن تشير إلى أن القنب الهندي يمكن أن يقي أو يعالج أو يشفي من كوفيد-19. تشير إحدى الأوراق البحثية الأولية (نوع من الدراسة التي لم تتم مراجعتها بعد من قبل الأقران) من كندا إلى أن الخصائص المضادة للالتهابات المحتملة في القنب الهندي قد تكون فعالة في العلاجات المستقبلية للمرض. تشير الدراسة أيضا إلى أنه يمكن استخدام القنب الهندي لمنع العدوى من فيروس SARS-CoV-2 الذي يسبب كوفيد-19. يكتسب SARS-CoV-2 الدخول إلى الخلايا في جسم الإنسان من خلال التفاعل مع بروتين مستقبلات ACE2، الموجود على سطح العديد من الخلايا. تشير هذه الدراسة إلى أن الكانابيديول (CBD)، أحد المكونات النشطة في الحشيش، قد يؤثر على قدرة الفيروس على الارتباط ببروتين مستقبلات ACE2 ودخول الخلايا. ومع ذلك، لم يتم التحقق من صحة أي من الادعاءات الواردة في تلك دراسة في دراسات أخرى واسعة النطاق، ويجب دائما التعامل مع بيانات الأوراق البحثية الأولية بحذر.\n\nيدرس مختبر آخر في إسرائيل تأثيرات القنب الهندي على استجابة الجهاز المناعي لـ كوفيد-19 ويحلل إمكانية الجزيئات الموجودة في القنب الهندي لمنع الفيروس من دخول الخلايا والانتشار. ومع ذلك، فقد تم إجراء هذا البحث من قبل شركة بحث وتطوير عن القنب مقرها في إسرائيل، ولم يتم التحقق منها بشكل مستقل من خلال دراسات علمية أخرى غير مرتبطة بصناعة القنب الهندي. في هذه المرحلة، لا يوجد بحث مستقل كافٍ لتقديم أي ادعاءات حول استخدام القنب الهندي في الوقاية أو العلاج أو الشفاء من كوفيد-19."
    ],
    "Arabic - Background and context": [
      "في السنوات الأخيرة، كان هناك اهتمام كبير بتطوير علاجات ومنتجات استهلاكية أخرى مشتقة من القنب الهندي ومكوناته، بما في ذلك الكانابيديول (CBD). وافقت إدارة الغذاء والدواء الأمريكية (FDA) على منتج واحد فقط من منتجات CBD، وهو منتج دوائي موصوف بوصفة طبية لعلاج شكلين نادرين وشديدين من الصرع. في سياق كوفيد-19، أبلغت وسائل الإعلام عن نتائج دراسة أولية تشير إلى احتمال أن القنب الهندي يمكن أن يقي كوفيد-19 عن طريق منع دخول الفيروس إلى الرئتين. لم تخضع هذه الدراسة لعملية مراجعة الأقران ولم يتم تقييمها من قبل الزملاء ولم تُنشَر في أي مجلة علمية."
    ],
    "Bengali - What our experts say": [
      "এখনও অবধি কোনও নির্ভরযোগ্য প্রমাণ নেই যে গাঁজা কোভিড -১৯ প্রতিরোধ, চিকিৎসা বা নিরাময় করতে পারে| কানাডা থেকে একটি প্রাক-মুদ্রণ (এক ধরণের সমীক্ষা যা এখনও পাক্ষিক পর্যালোচনা করা হয়নি) পরামর্শ দেয় যে গাঁজার সম্ভাব্য প্রদাহ-বিরোধী বৈশিষ্ট্যগুলি এই রোগের ভবিষ্যতের চিকিৎসায় কার্যকর হতে পারে। গবেষণায় আরও বলা হয়েছে যে SARS-CoV-2 ভাইরাস সংক্রমণ রোধে গাঁজা ব্যবহার করা যেতে পারে যার কারণে কোভিড-১৯ হয়। SARS-CoV-2 রিসেপ্টর প্রোটিনের সাথে মিলিত হয়ে মানব দেহের কোষগুলিতে প্রবেশ করে, যা বহু কোষের পৃষ্ঠে পাওয়া যায়। এই সমীক্ষায় পরামর্শ দেওয়া হয়েছে যে গাঁজার অন্যতম সক্রিয় উপাদান ক্যানাবিডিওল (সিবিডি) ভাইরাসটির এসি২ রিসেপ্টর প্রোটিনের সাথে বন্ধন তৈরি করতে এবং কোষগুলিতে প্রবেশের ক্ষমতাকে প্রভাবিত করতে পারে। তবে প্রাক-মুদ্রণ অধ্যয়নের কোনও দাবিই বড় আকারের গবেষণায় বৈধ হয়নি এবং প্রাক-মুদ্রণ উপাত্ত সর্বদা সতর্কতার সাথে অনুসরণ করা উচিত।\nইসরায়েলের আরেকটি গবেষণাগার কোভিড -১৯ প্রতিরোধ ব্যবস্থাটির প্রতিক্রিয়াতে গাঁজার প্রভাব সম্পর্কে অধ্যয়ন করছে এবং ভাইরাসকে কোষে প্রবেশ করতে এবং ছড়িয়ে পড়ার জন্য গাঁজার অণুগুলির সম্ভাবনা বিশ্লেষণ করছে। এই গবেষণাটি অবশ্য ইস্রায়েলে অবস্থিত একটি গাঁজা গবেষণা ও উন্নয়ন সংস্থা হাতে নিয়েছে, এবং অন্যান্য বৈজ্ঞানিক গবেষণার দ্বারা স্বতন্ত্রভাবে যাচাই করা হয়নি যা গাঁজার শিল্পের সাথে সম্পর্কিত নয়। এই মুহুর্তে, কোভিড-১৯ প্রতিরোধ, চিকিৎসা বা নিরাময়ে গাঁজার ব্যবহার সম্পর্কে কোনও দাবি করার জন্য পর্যাপ্ত স্বাধীন গবেষণা নেই।"
    ],
    "Bengali - Background and context": [
      "সাম্প্রতিক বছরগুলিতে, গাঁজা ও এর থেকে প্রাপ্ত ক্যানাবিডিওল (সিবিডি) সহ অন্যান্য উপাদানগুলি দিয়ে বিভিন্ন ভোক্তা পণ্যসমূহ উন্নয়নে উল্লেখযোগ্য আগ্রহ দেখা গেছে। মার্কিন যুক্তরাষ্ট্রের এফডিএ দুটি বিরল, মারাত্মক আকারের মৃগীরোগের জন্য একটি প্রেসক্রিপশন ড্রাগ হিসেবে সিবিডি পণ্য অনুমোদিত করেছে| কোভিড -১৯ এর প্রসঙ্গে মিডিয়া একটি প্রাক- মুদ্রণ স্টাডির ফলাফল জানিয়েছিল যে, ফুসফুসে ভাইরাসের প্রবেশ আটকে দিয়ে গাঁজা কোভিড -১৯ প্রতিরোধ করতে পারে। এই অধ্যয়নটি পাক্ষিক পর্যালোচনা প্রক্রিয়াটির মধ্য দিয়ে যায়নি, সমকক্ষদের দ্বারা মূল্যায়ন করা হয়নি, এবং কোনও বৈজ্ঞানিক জার্নালে প্রকাশিত হয়নি।"
    ],
    "Portuguese - What our experts say": [
      "Até o momento, não há evidências confiáveis que sugiram que a maconha possa prevenir, tratar ou curar o COVID-19. Um estudo em fase de pré-impressão (um tipo de estudo que ainda está para ser revisado por pares) do Canadá sugere que possíveis propriedades anti-inflamatórias presentes na cannabis podem ser eficazes em futuros tratamentos do COVID-19. O estudo também sugere que a cannabis pode ser usada para prevenir a infecção pelo vírus SARS-CoV-2 que causa o COVID-19. O SARS-CoV-2 consegue penetrar nas células do corpo humano ao interagir com a proteína receptora ACE2, encontrada na superfície de muitas células. Este estudo sugere que o canabidiol (CBD), um dos ingredientes ativos da Cannabis, pode afetar a capacidade do vírus de se ligar à proteína do receptor ACE2 e, assim, penetrar nas células. No entanto, nenhuma das hipóteses do estudo mencionado foi validada em estudos de escala mais ampla, e os dados de estudos em fase de pré-impressão devem sempre ser tratados com cautela. \nOutro laboratório, em Israel, está estudando os efeitos da cannabis na reação do sistema imunológico ao COVID-19 e analisando a capacidade de certas moléculas da cannabis de impedir que o vírus penetre nas células e se propague. Esta pesquisa, no entanto, foi realizada por uma empresa de pesquisas e desenvolvimento de cannabis com sede em Israel e não foi verificada de maneira independente por outros estudos científicos que não estivessem vinculados à indústria da cannabis."
    ],
    "Portuguese - Background and context": [
      "Nos últimos anos, houve um interesse significativo no desenvolvimento de terapias e outros produtos de consumo derivados da cannabis e de seus componentes, incluindo o canabidiol (CBD).O FDA (Administração para Drogas e Alimentos - Food and Drugs Administration) dos EUA aprovou apenas um produto de tipo CBD, um medicamento comercializado sob prescrição para tratar duas formas raras e graves de epilepsia. No contexto do COVID-19, a mídia relatou os resultados de um estudo em fase de pré-publicação indicando a possibilidade de que a cannabis pudesse prevenir contra o COVID-19, bloqueando a entrada do vírus nos pulmões. No entanto, este estudo não passou pelo processo de revisão por pares, não foi avaliado por pares e não foi publicado em nenhuma revista científica."
    ]
  },
  {
    "id": "rec5CB2EhWwQ6bTAh",
    "Question": "What is COVID-19 delirium?",
    "Status": "Published",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Recent studies have shown a concerning trend of delirium in COVID-19 patients, without predisposition for age or gender. Often, this manifests in the central nervous system. Unfortunately, documentation is often missed in 75% of delirium cases, which has been challenging for the identification of COVID-19 related incidents. As more research is pointing to COVID-19 delirium being a trend in hospitalized patients, there is a need to ensure documentation occurs. \n",
    "What our experts say": "COVID-19 delirium occurs in patients who have a sudden onset of mental disturbances that results in confusion and a lack of accurate perceptions regarding their environment and current state. Delirium itself is a change in mental abilities that results in the inability to think clearly, reduced awareness, and often emotional shifts. Delirium often occurs rapidly in patients and is frequently attributed to severe or chronic illness, changes in metabolism (the reactions and processes in your body that convert food into energy), infections, and other factors. Researchers and doctors have been drawing attention to the fact that regardless of age, potentially 1/3 of COVID-19 patients can develop symptoms of delirium. More recent studies have seen delirium in 20-30% of hospitalized patients with higher rates occurring in critically ill patients (upwards of 60-70%). For example, Vanderbilt University Medical Center launched a study in July 2020 that will study delirium, among other impacts on the brain, in patients who have been hospitalized with COVID-19. The researchers share that in previous studies of intensive care patients similar to COVID-19 patients, 33-50% experience dementia. Delirium can lead to longer hospital stays, which increases the risk for complications. \n\n_This entry was updated with new information on August 20, 2020._\n",
    "Glossary Terms": [
      "recBBELvoZKXpdyST",
      "recU4JuZ6HJpfe2ZK"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "symptoms"
    ],
    "Other resources": "1. COVID-19 Delirium research paper, ([Critical Care](https://link.springer.com/content/pdf/10.1186/s13054-020-02882-x.pdf)) \n2. Delirium: a missing piece in the COVID-10 pandemic puzzle ([Age Aging](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239228/))\n3. Delirium, PTSD, brain fog: The aftermath of surviving COVID-19 ([American Psychological Association](https://www.apa.org/monitor/2020/09/aftermath-covid-19))\n",
    "DB (French)": [
      "reccLqkEvDwZa9jyJ"
    ],
    "DB (Hindi)": [
      "rec15gZ2TyiR3EZLv"
    ],
    "Media": [
      {
        "id": "atte4AFr2Bz2FYPrs",
        "url": "https://dl.airtable.com/.attachments/2a2f60db24fd332cdb24185610c886a6/357fac57/Slide1.png",
        "filename": "Slide 1.png",
        "size": 146906,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/eba136ce5826341ca99b8ef43d11b89f/42d0d0ab",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/9d508c3be461b5b8ebab69106c1fe6ac/0b045287",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/60adb4aabcf6382cca32c2ed811a07db/d39de6d9",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attQd4nSfE2DNZjGr",
        "url": "https://dl.airtable.com/.attachments/db1a342fd6c1d31d00123d3dd2f980b5/dbe86ecf/Slide2.png",
        "filename": "Slide 2.png",
        "size": 143357,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/76b3418abe72681f7b0e63bf6274e64c/a222d41d",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c8d245ee2dd01280e151b630513c79e2/4f195547",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/01d2e99d5f48ae198db6ff0315ab3b66/4501802c",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attMa2gWdjf8ImVow",
        "url": "https://dl.airtable.com/.attachments/8f8df8807eedd112d1794651e859441d/39fedbca/Slide3.png",
        "filename": "Slide 3.png",
        "size": 136469,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b3f689ad1dc7b72c19e5965ce3161f3d/bd627898",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/89a1349c979899256333c49367253496/7b559457",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/0087709732ff5649e94af9b78b43b3a2/25c18269",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attmK30idOuAqzCBn",
        "url": "https://dl.airtable.com/.attachments/9e4d541e8c7ff343a93cbb53e2f1f7a1/e8a1e747/Slide4.png",
        "filename": "Slide 4.png",
        "size": 158379,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/852b6a807021491f5a658e1e970f2a49/b75f50dd",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/24d0b6b6280caf20374a4435562f940c/bb27666b",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/79bd14e33c7683123ec68d66f4383739/fefd9386",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attsfYhI6Frw6fDl0",
        "url": "https://dl.airtable.com/.attachments/f9e73421540bc5e1f6f0ea40671b989e/2f164b89/Slide5.png",
        "filename": "Slide 5.png",
        "size": 179371,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e68d058fff5d645d0f44acd877fa9a7b/376ee981",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d46fec0cbbc1d882fb8cd6fcb723bc19/e50df18b",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/bf35fea483355fa9032f659c077b9669/4f32b3ff",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recxHype7A5IeDWpA"
    ],
    "DB (Spanish)": [
      "recQ31j2Evm92Otjc"
    ],
    "DB (Bengali)": [
      "recyGoSYhYxE5FPqd"
    ],
    "DB (Portuguese)": [
      "rec9HZKcfSGAdntqN"
    ],
    "Rollup test 2": [
      "recfc5LVC9Kl6kuKf"
    ],
    "Media Package": [
      {
        "id": "attUyFDa2kpL4muOX",
        "url": "https://dl.airtable.com/.attachments/fa8bb3ff0a6f9789b7cbd92bdd81da90/3060b80d/WhatisCOVID-19delirium.zip",
        "filename": "What is COVID-19 delirium.zip",
        "size": 1352969,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-08-20",
    "Last edited (simplified)": "2020-08-06T20:54:08.000Z",
    "Last edited (experts say)": "2020-08-31T19:06:57.000Z",
    "Last modified": "2020-08-31",
    "What our experts say wordcount": 203,
    "Background and context wordcount": 70,
    "Other resources wordcount": 31,
    "Wordcount": 304,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "L’état confusionnel aigu provoqué par la COVID-19 se traduit chez les patients par l’apparition soudaine d’aliénation mentale et l’absence de perception juste quant à leur état et à leur environnement actuels. Un état confusionnel aigu est un changement des aptitudes mentales qui entraîne l’incapacité de penser clairement, une réduction de la conscience générale et souvent des changements émotionnels. Un état confusionnel aigu apparaît souvent rapidement chez certains patients et est fréquemment attribué à une maladie grave ou chronique, à des changements du métabolisme (les réactions et processus de votre corps qui convertissent la nourriture en énergie), aux infections et à d’autres facteurs. Des chercheurs et docteurs ont récemment attiré l’attention sur le fait que, quel que soit leur âge, un tiers des patients atteints de COVID-19 pourrait développer des symptômes d’état confusionnel aigu. Des études plus récentes ont observé un état confusionnel aigu chez 20 à 30 % des patients hospitalisés, avec des taux plus élevés chez les patients en phase critique (plus de 60 à 70 %). Par exemple, le Centre médical de l’Université Vanderbilt a lancé une étude en juillet 2020, qui étudiera l’état confusionnel aigu, parmi d’autres impacts sur le cerveau, chez les patients qui ont été hospitalisés avec la COVID-19. Les chercheurs ont exprimé que dans des études précédentes sur des patients en soins intensifs semblables aux patients atteints de COVID-19, de 33 à 50 % étaient atteint de démence. Un état confusionnel aigu peut entraîner des séjours d’hôpitaux plus longs, ce qui augmente le risque de complications.\n\nCette entrée a été mise à jour avec de nouveaux renseignements le 20 août 2020."
    ],
    "French - Background and context": [
      "Des études récentes ont démontré une évolution inquiétante de cas d’état confusionnel aigu chez les patients atteints de COVID-19, sans prédisposition quant à l’âge ni au sexe. Il se manifeste souvent dans le système nerveux central. Malheureusement, l’on manque souvent de documentation dans 75 % des cas d’état confusionnel aigu, ce qui a représenté un défi d’identification des incidents associés à la COVID-19. Alors que de nouvelles recherches soulignent l’évolution de cas d’état confusionnel aigu chez les patients hospitalisés, il est nécessaire d’assurer une documentation adéquate."
    ],
    "Hindi - What our experts say": [
      "कोविड-19 प्रलाप उन रोगियों में होता है जिनके पास अचानक मानसिक गड़बड़ी की शुरुआत होती है जिसके परिणामस्वरूप भ्रम होता है और उनके वातावरण और वर्तमान स्थिति के बारे में सटीक धारणाओं की कमी होती है। प्रलाप स्वयं में मानसिक क्षमताओं में बदलाव है जिसके परिणामस्वरूप स्पष्ट रूप से सोचने में असमर्थता, जागरूकता में कमी और अक्सर भावनात्मक बदलाव आते हैं। प्रलाप अक्सर रोगियों में तेजी से होता है और अक्सर गंभीर या पुरानी बीमारी के लिए जिम्मेदार होता है, चयापचय में परिवर्तन (आपके शरीर में प्रतिक्रियाएं और प्रक्रियाएं जो भोजन को ऊर्जा में परिवर्तित करती हैं), संक्रमण और अन्य कारक हैं। शोधकर्ताओं और डॉक्टरों ने हाल ही में इस तथ्य पर ध्यान आकर्षित किया है कि उम्र की परवाह किए बिना, कोविड-19 रोगियों के संभावित 1/3 प्रलाप के लक्षण विकसित कर सकते हैं। हाल के अध्ययनों में, हालांकि, गंभीर रूप से बीमार रोगियों (60-70% से ऊपर) में उच्च दर वाले 20-30% अस्पताल में भर्ती रोगियों में प्रलाप को देखा गया है। प्रलाप आपको लंबे समय तक अस्पताल में रख सकता है, जिससे जटिलताओं का खतरा बढ़ जाता है।"
    ],
    "Hindi - Background and context": [
      "हाल के अध्ययनों में कोविड-19 रोगियों में उम्र या लिंग के लिए पूर्वसूचना के बिना प्रलाप का एक संक्षिप्त प्रवृत्ति दिखाया गया है। अक्सर, यह केंद्रीय तंत्रिका तंत्र में होता है। दुर्भाग्य से, 75% प्रलाप मामलों में प्रलेखन अक्सर छूट जाता है, जो कोविड-19 संबंधित घटनाओं की पहचान के लिए चुनौतीपूर्ण रहा है। जैसा कि अधिक शोध कोविड-19 प्रलाप को अस्पताल में भर्ती मरीजों में एक प्रवृत्ति होने की ओर इशारा कर रहा है, वहाँ प्रलेखन सुनिश्चित करने की आवश्यकता है।"
    ],
    "Telugu - What our experts say": [
      "కోవిడ్-19 మతిమరుపు ఆకస్మికంగా మానసిక అవాంతరాలను కలిగి ఉన్న రోగులలో సంభవిస్తుంది, ఇది గందరగోళానికి దారితీస్తుంది మరియు వారి పర్యావరణం మరియు ప్రస్తుత స్థితికి సంబంధించి ఖచ్చితమైన అవగాహన లేకపోవడం. డెలిరియం అనేది మానసిక సామర్ధ్యాలలో మార్పు, దీనివల్ల స్పష్టంగా ఆలోచించలేకపోవడం, అవగాహన తగ్గడం మరియు తరచుగా భావోద్వేగ మార్పులు. డెలిరియం తరచుగా రోగులలో వేగంగా సంభవిస్తుంది మరియు తరచూ తీవ్రమైన లేదా దీర్ఘకాలిక అనారోగ్యం, జీవక్రియలో మార్పులు (ఆహారాన్ని శక్తిగా మార్చే మీ శరీరంలో ప్రతిచర్యలు మరియు ప్రక్రియలు), అంటువ్యాధులు మరియు ఇతర కారకాలకు కారణమవుతాయి. వయస్సుతో సంబంధం లేకుండా, కోవిడ్-19 రోగులలో 1/3 మంది మతిమరుపు యొక్క లక్షణాలను అభివృద్ధి చేయగలరని పరిశోధకులు మరియు వైద్యులు ఇటీవల దృష్టిని ఆకర్షించారు. ఇటీవలి అధ్యయనాలు, అయితే, ఆసుపత్రిలో చేరిన రోగులలో 20-30% మందిలో అనారోగ్య రోగులలో (60-70% పైకి) అధిక రేట్లు ఉన్నాయి. మతిమరుపు ఎక్కువ కాలం ఆసుపత్రిలో ఉండటానికి దారితీస్తుంది, ఇది సమస్యలకు ప్రమాదాన్ని పెంచుతుంది."
    ],
    "Telugu - Context and background": [
      "ఇటీవలి అధ్యయనాలు కోవిడ్-19 రోగులలో మతిమరుపు యొక్క ధోరణిని చూపించాయి, వయస్సు లేదా లింగం కోసం ముందడుగు లేకుండా. తరచుగా, ఇది కేంద్ర నాడీ వ్యవస్థలో కనిపిస్తుంది. దురదృష్టవశాత్తు, 75% మతిమరుపు కేసులలో డాక్యుమెంటేషన్ తరచుగా తప్పిపోతుంది, ఇది కోవిడ్-19 సంబంధిత సంఘటనల గుర్తింపు కోసం సవాలుగా ఉంది. ఆసుపత్రిలో చేరిన రోగులలో కోవిడ్-19 మతిమరుపు ఒక ధోరణి అని మరింత పరిశోధనలు సూచిస్తున్నందున, డాక్యుమెంటేషన్ సంభవిస్తుందని నిర్ధారించాల్సిన అవసరం ఉంది."
    ],
    "Spanish - What our experts say": [
      "El delirio de COVID-19 ocurre en pacientes que tienen una repentina aparición de perturbaciones mentales que resultan en confusión y falta de percepciones precisas concernientes a su entorno y estado actual. El delirio en sí mismo es un cambio en las habilidades mentales que resulta en incapacidad de pensar claramente, conciencia reducida y, a menudo, cambios emocionales.Con frecuencia, el delirio ocurre rápidamente en pacientes, y a menudo es atribuido a enfermedad crónica o severa, cambios en el metabolismo (las reacciones y procesos en tu cuerpo que convierten la comida en energía), infecciones, y otros factores. Los investigadores y doctores recientemente han llamado la atención al hecho que, independientemente de la edad, potencialmente 1/3 de los pacientes con COVID-19 pueden desarrollar síntomas de delirio. Estudios más recientes, sin embargo, han visto delirio en un 20 a 30% de los pacientes hospitalizados, con tasas más altas ocurriendo en pacientes críticamente enfermos (más de 60 a 70%). El delirio puede llevar a estadías prolongadas en hospitales, lo cual incrementa el riesgo de complicaciones."
    ],
    "Spanish - Background and context": [
      "Estudios recientes han mostrado una tendencia concordante de delirio en pacientes con COVID-19, sin predisposición por edad o género. A menudo, esto se manifiesta en el sistema nervioso central. Desafortunadamente, con frecuencia falta la documentación en el 75% de los casos de delirio, lo cual ha sido un desafío para la identificación de incidentes relacionados con el COVID-19. Como más investigaciones están apuntando a que el delirio de COVID-19 sea una tendencia en pacientes hospitalizados, existe la necesidad de asegurar que ocurra su documentación."
    ],
    "Bengali - What our experts say": [
      "কোভিড-১৯-এ প্রলাপ এমন রোগীদের মধ্যে ঘটে যাঁর হঠাৎ মানসিক অস্থিরতার ফলে বিভ্রান্তি ঘটে এবং তাদের পরিবেশ ও বর্তমান অবস্থা সম্পর্কে সঠিক ধারণা লোপ পায়। প্রলাপ এক ধরনের মানসিক ক্ষমতার পরিবর্তন যার ফলাফল চিন্তা করতে অক্ষমতা, সচেতনতা হ্রাস এবং প্রায়শ সংবেদনশীল পরিবর্তন হয়| প্রলাপ প্রায়শই রোগীদের মধ্যে দ্রুত ঘটে এবং গুরুতর বা দীর্ঘস্থায়ী অসুস্থতা, হজমের (আপনার দেহের প্রতিক্রিয়া এবং প্রক্রিয়া যা খাদ্যকে শক্তিতে রূপান্তর করে) সমস্যা, সংক্রমণ এবং অন্যান্য কারণগুলির জন্য দায়ী। গবেষকরা এবং চিকিৎসকরা সম্প্রতি এই সত্যের দিকে দৃষ্টি আকর্ষণ করেছেন যে, বয়স নির্বিশেষে, কোভিড-১৯ রোগীদের মধ্যে ১/৩ রোগীরা প্রলাপের লক্ষণগুলি দেখা দিতে পারে। সাম্প্রতিক গবেষণাগুলিতে, যদিও, ২০-৩০% হাসপাতালে ভর্তি রোগীদের মধ্যে চিকিৎসাজনিত অসুস্থ রোগীদের মধ্যে উচ্চ হারের (৬০-৭০% এর বেশি) হারে প্রলাপ দেখা গেছে। প্রলাপ হাসপাতালে থাকা দীর্ঘায়িত করতে পারে, যা জটিলতার ঝুঁকি বাড়ায়।"
    ],
    "Bengali - Background and context": [
      "সাম্প্রতিক গবেষণাগুলি কোভিড-১৯ রোগীদের মধ্যে বয়স বা লিঙ্গের জন্য কোনও প্রবণতা ছাড়াই প্রলাপগ্রস্থ হওয়ার প্রবণতা দেখিয়েছে। প্রায়শই, এটি কেন্দ্রীয় স্নায়ুতন্ত্রে উদ্ভাসিত হয়। দুর্ভাগ্যক্রমে, এই বিকারগ্রস্থতার প্রায়শই ৭৫% লিপিবদ্ধ হয়না, যা কোভিড-১৯ সম্পর্কিত ঘটনা সনাক্তকরণের জন্য চ্যালেঞ্জ হয়ে দাঁড়িয়েছে। যেহেতু আরও গবেষণা কোভিড -১৯-এর প্রলাপগ্রস্থতা হাসপাতালে ভর্তি রোগীদের মধ্যে প্রবণতা হিসাবে দেখিয়েছে, তাই লিপিবদ্ধ নিশ্চিত করার প্রয়োজন রয়েছে।"
    ]
  },
  {
    "id": "recDOeKU0wK73R15D",
    "Question": "Do positivity rates show herd immunity has been reached?",
    "Status": "Published",
    "Category": "Immunity",
    "Subcategory": "On: COVID-19 & herd immunity",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "A Facebook post from August 4, 2020, falsely claimed that the current national positivity rate demonstrates that herd immunity has been reached for COVID-19. The post attempted to analyze a positivity rate graph from Johns Hopkins, but also included the author's own insights about testing, population level risk assessments, and added in 'bumps' to describe what he assumed were increases in testing. Though the post noted that the author believed an increase in positivity rates were being reported for political reasons (extending the shutdowns and requiring continued mask use) there is no evidence to support this claim. Additionally, there is no evidence to support claims that we've reached herd immunity, that COVID-19 positivity rates indicate anything about a population's immunity, or that 60% of a population needs to be infected in order to reach herd immunity for the virus. \n\nOn October 4, 2020, a proposal called the Great Barrington Declaration was signed in Great Barrington, Massachusetts, recommending the end of stay-at-home orders for people perceived to be at lower risk for COVID-19 until herd immunity is developed. One of President Trump's science advisors is a lead author behind the Great Barrington Declaration, which was funded by the libertarian think tank called the American Institute for Economic Research that is behind other statements to allow sweatshop labor and reduce environmental protections. The Great Barrington Declaration has since been embraced by several White House officials, while numerous public health agencies including the World Health Organization (WHO) have responded with warnings. An open letter by the American Public Health Association and 13 other public health organizations in the U.S. warned that the Great Barrington Declaration \"is not a strategy, it is a political statement. It ignores sound public health expertise. It preys on a frustrated populace. Instead of selling false hope that will predictably backfire, we must focus on how to manage this pandemic in a safe, responsible, and equitable way.\" Over 4,800 scientists, researchers and healthcare professionals have signed another response published in the Lancet on October 14, 2020 called the John Snow Memorandum, which condemns the policies recommended by the Great Barrington Declaration and calls for acting based on evidence. \n\nOutside of the U.S., other politicians have tried to promote achieving herd immunity as a pandemic response approach. For example, Sweden's policies had mostly avoided preventative public health measures like lockdowns and mask wearing, but newer policies starting October 19, 2020 are more restrictive in response to Sweden seeing one of the highest per-capita death rates in the world (58.6 per 100,000 people) and an average increase in daily COVID-19 cases by 173% since the autumn of 2020. While some Swedish politicians have tried to avoid publicly using the language of herd immunity, journalists have obtained emails between high-level Swedish public health officials revealing that achieving herd immunity was discussed as a strategy as early as March 2020. In the U.K., Prime Minister Boris Johnson's chief scientific adviser said on March 13 that he believed their country would be able to achieve herd immunity, but the U.K. ultimately changed its strategy and did impose a lockdown after medical experts warned that attempting to achieve herd immunity could risk killing hundreds of thousands of people. In Brazil, researchers have been studying the city of Manaus, where it is estimated that 44% to 66% of the population was infected with COVID-19 in the summer of 2020 and cases had started to drop, only to start rising again in the fall of 2020. While some suggested that Manaus may have reached herd immunity, others are warning that cases are still rising in Manaus and more lives should not be put at risk.\n\n",
    "What our experts say": "Positivity rates of COVID-19 are not an indication of herd immunity. The rate of positivity in a community is defined as the percentage of total COVID-19 tests that come back positive out of all the people who have been tested in that community or population, within a given time period. Positivity rates can indicate an increasing outbreak, if the rate of positive tests increases while the amount of testing stays the same. A positivity rate can also indicate that not enough tests are being conducted, if more tests come back with positive results but tests were conducted on a smaller percentage of the population than the week before. Neither of these have anything to do with herd immunity.\n\n\"Herd immunity\" refers to a given percentage of people that need to become immunized to a virus, through vaccines or through becoming infected in a natural setting, against a virus in order to provide safety for an entire population—i.e. the herd. It's the idea that if most people are immune, then the rate of transmission will be low or non-existent. COVID-19 is not vaccine-preventable at this time and we know very little about how we become immune to the virus. Herd immunity would require a large majority of the population to become infected with the virus and obtain long-term immunity to COVID-19 — but since we know so little about long-term immunity right now, we can't say anything about herd immunity in relation to COVID-19.\n\nPercent positive rates of COVID-19 are not being used to determine herd immunity in a community because we know so little about immunity in general, and because positive rates can mean a wide variety of things. If there is a higher percentage of positive test results in a region, this is not indicative of any potential for herd immunity, because evidence to support long-term immunity is lacking.\n",
    "Glossary Terms": [
      "rec0zhEV63ySy7APc",
      "rec4kgXUEMkPzbQvP"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "herd immunity",
      "positivity rate",
      "percent positive"
    ],
    "Other resources": "1. \"Herd Immunity\": A Rough Guide ([CID](https://academic.oup.com/cid/article/52/7/911/299077))\n2. Vaccine refusal and herd immunity ([Lancet ID](https://www.sciencedirect.com/science/article/abs/pii/S1473309915000535))\n3. COVID and Herd Immunity ([The Atlantic](https://www.theatlantic.com/health/archive/2020/07/herd-immunity-coronavirus/614035/)) \n4. White House embraces a declaration from scientists that opposes lockdowns and relies on ‘herd immunity.’ ([NYT](https://www.nytimes.com/live/2020/10/13/world/coronavirus-covid#white-house-embraces-a-declaration-from-scientists-that-opposes-lockdowns-and-relies-on-herd-immunity))\n5. The Fight Over A Controversial \"Herd Immunity' Coronavirus Proposal ([WBUR](https://www.wbur.org/radioboston/2020/10/20/great-barrington-john-snow))\n6. After Months of Minimal COVID-19 Containment, Sweden Appears to Be Considering a New Approach ([Time](https://time.com/5901352/sweden-local-lockdowns/))\n7. Coronavirus: science chief defends UK plan from criticism ([The Guardian](https://www.theguardian.com/world/2020/mar/13/coronavirus-science-chief-defends-uk-measures-criticism-herd-immunity))\n8. The UK abandoned its coronavirus plan after realizing it would have resulted in 'hundreds of thousands of deaths' ([Business Insider](https://www.businessinsider.com/uk-abandoned-coronavirus-strategy-that-would-cause-250000-deaths-2020-3?r=US&IR=T))\n9. In Brazil's Amazon a COVID-19 resurgence dashes herd immunity hopes ([Reuters](http://In Brazil's Amazon a COVID-19 resurgence dashes herd immunity hopes))\n",
    "Rollup test 2": [
      "recPGUHX6HxoOdhdh"
    ],
    "Last modified manual": "2020-10-27",
    "Last edited (simplified)": "2020-10-21T21:53:02.000Z",
    "Last edited (experts say)": "2020-10-21T21:53:02.000Z",
    "Last modified": "2020-10-21",
    "What our experts say wordcount": 308,
    "Background and context wordcount": 607,
    "Other resources wordcount": 103,
    "Wordcount": 1018
  },
  {
    "id": "rec7awl8Ed6xdZIiv",
    "Question": "Does Vitamin D help prevent or treat COVID-19?",
    "Status": "Update ready for review",
    "Subcategory": "On: COVID-19 & Vitamin D",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Vitamin D is an essential nutrient available in foods like salmon or egg yolks, or dietary supplements. It can also be made in the body when the skin is exposed to the sun. Studies have shown that low levels of vitamin D (vitamin D deficiency) are common so blood screening for vitamin D deficiency has become common in many developed countries. Some groups at increased risk for vitamin D deficiency include breastfed infants, older adults, people with limited sun exposure, people with dark skin, and people who are obese.\n\nHaving enough vitamin D in the body is important for bone health and helps ensure your body's immune system and its cells are working well so they can respond to infections and viruses. Vitamin D has also been shown to reduce cancer cell growth in some cancers, help minimize inflammation, and help control infections.\n\nVitamin D does play an important role in immune function, and prevention and treatment of vitamin D deficiency is recommended for health. At this time, there is no evidence that Vitamin D intake or supplementation can prevent or treat COVID-19.\n",
    "What our experts say": "Vitamin D has not been tested for its effectiveness in treating COVID-19 patients, and there is no evidence that it can prevent or treat the virus. Researchers are now working on several studies to determine if Vitamin D can be effective in preventing or treating COVID-19.\n\nMultiple observational studies have shown and association between vitamin D deficiency and higher numbers of COVID-19 cases and deaths. While current evidence does suggest that vitamin D deficiency may be a risk factor for COVID-19, there have not been studies to evaluate whether vitamin D supplementation may help prevent COVID-19. Further studies are also needed to better understand what level of deficiency carries COVID-19 risk. \n\nA pre-print study from November 2020, found that vitamin D supplementation did not benefit hospitalized patients with severe COVID-19. Researchers noted that vitamin D levels did increase, but hospital length of stay, mortality (death), admission to the intensive care (ICU), and the need for mechanical ventilation (ventilator support for breathing) did not significantly differ between the experimental group who received vitamin D and the placebo group (who did not receive vitamin D). \n\nStudies to explore the possible benefit of vitamin D supplementation in prevention and treatment of COVID-19 are ongoing. \n",
    "Glossary Terms": [
      "recnFUXyIZy81Rj1I",
      "recJK5tI9LgCGFRAU",
      "reci6AkPuYYC5pFzD",
      "recE5fZ79yZqKorXK",
      "recaXXF6coF4J2EUz",
      "recLK0olU5qv4lqZ9",
      "recb7T7hH9zHd3k1R"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "Calcium",
      "Vitamin D",
      "prevention",
      "treatment",
      "homeopathic"
    ],
    "Other resources": "1. Lancet review on Vitamin D and COVID-19 outcomes ([The Lancet](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30183-2/fulltext))\n2. Aging Clinical and Experimental Research study on Vitamin D and the prevention of COVID-19 ([Aging](https://link.springer.com/article/10.1007%2Fs40520-020-01570-8))\n3. BMJ study on Vitamin D and COVID-19 ([BMJ](https://nutrition.bmj.com/content/early/2020/05/15/bmjnph-2020-000089))\n4. Pre-print study of patterns of COVID-19 mortality and Vitamin D ([SSRN](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3585561))\n5. Pre-print study on the possible role of Vitamin D and cytokine storms in COVID-19 ([Medrxiv](https://www.medrxiv.org/content/10.1101/2020.04.08.20058578v4))\n6. Harvard review of Vitamin D ([HSPH](https://www.hsph.harvard.edu/nutritionsource/vitamin-d/))\n7. Journal of Investigative Medicine review of Vitamin D and the immune system ([JIM](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166406/))\n8. Association of Vitamin D Status and Other Clinical Characteristics with COVID-19 Test Results ([JAMA](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2770157))\n9. Vitamin D ([NIH-ODS](https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/))\n10. Effect of Vitamin D3 Supplementation vs Placebo on Hospital Length of Stay in Patients with Severe COVID-19: A Multicenter, Double-blind, Randomized Controlled Trial ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.11.16.20232397v1))\n",
    "DB (French)": [
      "recgur7UqWESGFk8T"
    ],
    "DB (Hindi)": [
      "reco1sk8QaOHSDsDk"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recpDxEPAA9r6srCb"
    ],
    "DB (Spanish)": [
      "recIZ0yD7vqSUDYwN"
    ],
    "DB (Bengali)": [
      "recqCn7zKYBnXukDO"
    ],
    "DB (Portuguese)": [
      "rec1DYZNISKj5cYDo"
    ],
    "Rollup test 2": [
      "recTGqUnlwR03P8tA"
    ],
    "Last modified manual": "2020-12-08",
    "Last edited (simplified)": "2020-11-16T19:22:03.000Z",
    "Last edited (experts say)": "2020-12-08T18:22:25.000Z",
    "Last modified": "2020-12-08",
    "What our experts say wordcount": 201,
    "Background and context wordcount": 181,
    "Other resources wordcount": 119,
    "Wordcount": 501,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Il est trop tôt pour dire si la vitamine D peut aider ou non au traitement de la COVID-19. À l’heure actuelle, il n’y a pas eu d’essais de traitement de patients atteints de la COVID-19, et il n’existe donc aucune donnée probante sur la prévention ou le traitement de la COVID-19 par la vitamine D. Une étude récente a examiné les données provenant de 20 pays européens et a remarqué que les endroits où l’on trouvait plus de cas de carence en vitamine D présentaient aussi des taux plus élevés de cas et de décès provoqués par la COVID-19. Bien que cette étude suggère une relation possible entre des niveaux plus faibles de vitamine D et les problèmes de santé liés à la COVID-19, il n’existe aucune donnée probante sur les niveaux de vitamine D, les cas ni les décès causés par la COVID-19.\n\nD’autres études ont remarqué des liens possibles entre de faibles niveaux de vitamine D et la COVID-19, mais aucun consensus ne s’est dégagé sur l’impact potentiel de la vitamine sur le virus. Plusieurs études ont lieu actuellement afin de déterminer si la vitamine D peut s’avérer efficace dans le traitement de la COVID-19."
    ],
    "French - Background and context": [
      "La vitamine D est un nutriment essentiel, ce qui veut dire que votre corps en a besoin, mais ne peut pas la produire. C’est pourquoi nous devons obtenir notre vitamine D de nourritures telles que le saumon, les jaunes d’œufs, les suppléments ou de courtes périodes d’exposition au soleil. La vitamine D aide au bon fonctionnement du système immunitaire et des cellules de votre corps afin qu’ils puissent répondre aux infections et virus. En plus de maintenir le niveau de calcium et de promouvoir la santé des os, la vitamine D est aussi susceptible de réduire la croissance des cellules cancéreuses, d’aider à réduire l’inflammation et à contrôler les infections."
    ],
    "Hindi - What our experts say": [
      "यह बताना जल्दबाजी होगी कि विटामिन डी कोविड-19 के इलाज में मदद कर सकता है या नहीं। अब तक, कोविड-19 रोगियों के उपचार में इसकी प्रभावशीलता के लिए विटामिन डी का परीक्षण नहीं किया गया है, इसलिए कोई सबूत नहीं है कि यह वायरस को रोक सकता है या इसका इलाज कर सकता है। हाल के एक अध्ययन में 20 यूरोपीय देशों के आंकड़ों को देखा गया और नोट किया कि जिन जगहों पर अधिक लोगों में विटामिन डी की कमी के मामले थे, उनमें भी कोविड-19 के मामलों और मौतों की दर अधिक थी। हालांकि इस अध्ययन में विटामिन डी के निम्न स्तर और खराब कोविड-19 स्वास्थ्य परिणामों के बीच संभावित संबंध का सुझाव दिया गया है, लेकिन इस बात का कोई सबूत नहीं है कि विटामिन डी का स्तर वास्तव में कोविड-19 से संबंधित अधिक मामलों या मौतों का कारण बना।\n\nअन्य अध्ययनों में कम विटामिन डी के स्तर और कोविड-19 के बीच संभावित लिंक का उल्लेख किया गया है, लेकिन इस बात पर कोई सहमति नहीं हुई है कि वायरस पर विटामिन का संभावित प्रभाव क्या है। शोधकर्ता अब यह निर्धारित करने के लिए कई अध्ययनों पर काम कर रहे हैं कि क्या विटामिन डी कोविड-19 के इलाज में प्रभावी हो सकता है।"
    ],
    "Hindi - Background and context": [
      "विटामिन डी एक आवश्यक पोषक तत्व है, जिसका अर्थ है कि आपके शरीर को इसकी आवश्यकता है लेकिन इसे अपने दम पर नहीं बना सकते। यही कारण है कि लोगों को अपने विटामिन डी को सैल्मन या अंडे की जर्दी, पूरक आहार या धूप में कम समय बिताने वाले खाद्य पदार्थों से प्राप्त करना पड़ता है। विटामिन डी आपके शरीर की प्रतिरक्षा प्रणाली को सुनिश्चित करने में मदद करता है और इसकी कोशिकाएं अच्छी तरह से काम कर रही हैं ताकि वे संक्रमण और वायरस का जवाब दे सकें। शरीर में कैल्शियम के स्तर को बनाए रखने और हड्डी के स्वास्थ्य को बढ़ावा देने में इसकी मदद के अलावा, विटामिन डी संभावित रूप से कैंसर सेल के विकास को कम कर सकता है, सूजन को कम करने और संक्रमण को नियंत्रित करने में मदद कर सकता है।"
    ],
    "Telugu - What our experts say": [
      "కోవిడ్-19 చికిత్సకు విటమిన్ డి సహాయపడుతుందో లేదో చెప్పడం చాలా తొందరగా ఉంది. ప్రస్తుతానికి, కోవిడ్-19 రోగులకు చికిత్స చేయడంలో విటమిన్ డి దాని ప్రభావం కోసం పరీక్షించబడలేదు, కాబట్టి ఇది వైరస్ను నివారించగలదు లేదా చికిత్స చేయగలదని ఎటువంటి ఆధారాలు లేవు. ఇటీవలి అధ్యయనం 20 యూరోపియన్ దేశాల నుండి వచ్చిన డేటాను చూసింది మరియు ఎక్కువ మందికి విటమిన్ డి లోపం ఉన్న ప్రదేశాలలో, వారు కూడా కోవిడ్-19 కేసులు మరియు మరణాల రేటును ఎక్కువగా కలిగి ఉన్నారని గుర్తించారు. ఈ అధ్యయనం తక్కువ స్థాయి విటమిన్ డి మరియు పేలవమైన కోవిడ్-19 ఆరోగ్య ఫలితాల మధ్య సంబంధాన్ని సూచించినప్పటికీ, విటమిన్ డి స్థాయిలు వాస్తవానికి కోవిడ్-19 కు సంబంధించిన ఎక్కువ కేసులు లేదా మరణాలకు కారణమయ్యాయనడానికి ఎటువంటి ఆధారాలు లేవు. ఇతర అధ్యయనాలు తక్కువ విటమిన్ డి స్థాయిలు మరియు కోవిడ్-19 ల మధ్య సంభావ్య సంబంధాలను గుర్తించాయి, అయితే విటమిన్ యొక్క సంభావ్య ప్రభావం వైరస్ పై ఎలాంటి ఏకాభిప్రాయం కుదరలేదు."
    ],
    "Telugu - Context and background": [
      "విటమిన్ డి ఒక ముఖ్యమైన పోషకం, అంటే మీ శరీరానికి ఇది అవసరం కానీ దానిని సొంతంగా తయారు చేయలేము. అందువల్ల ప్రజలు సాల్మన్ లేదా గుడ్డు సొనలు, సప్లిమెంట్స్ వంటి ఆహారాల నుండి లేదా ఎండలో తక్కువ సమయం గడపడం నుండి వారి విటమిన్ డి పొందాలి. విటమిన్ డి మీ శరీరం యొక్క రోగనిరోధక శక్తిని నిర్ధారించడానికి సహాయపడుతుంది మరియు దాని కణాలు బాగా పనిచేస్తాయి కాబట్టి అవి అంటువ్యాధులు మరియు వైరస్లకు ప్రతిస్పందిస్తాయి. శరీరంలో కాల్షియం స్థాయిలను నిలుపుకోవడంలో మరియు ఎముకల ఆరోగ్యాన్ని ప్రోత్సహించడంలో దాని సహాయంతో పాటు, విటమిన్ డి క్యాన్సర్ కణాల పెరుగుదలను తగ్గించగలదు, మంటను తగ్గించడంలో సహాయపడుతుంది మరియు ఇన్ఫెక్షన్లను నియంత్రించడంలో సహాయపడుతుంది. అయినప్పటికీ, శరీరంలో ఇతర ప్రయోజనాలు ఉన్నప్పటికీ, విటమిన్ డి కోవిడ్-19 ని నిరోధించగలదు లేదా చికిత్స చేయగలదని ఎటువంటి ఆధారాలు లేవు."
    ],
    "Spanish - What our experts say": [
      "Es demasiado temprano para decir si la vitamina D puede o no ayudar a tratar al COVID-19. Hasta ahora, la vitamina D no ha sido probada por su efectividad para tratar pacientes con COVID-19, de manera que no hay evidencia de que pueda prevenir o tratar al virus. Un estudio reciente miró los datos de 20 países europeos y notó que en los lugares donde más personas tuvieron casos de deficiencia de vitamina D, también tuvieron tasas más altas de casos y muertes por COVID-19. Mientras que este estudio sugirió una posible relación entre niveles más bajos de vitamina D y pobres resultados de salud respecto al COVID-19, no hay evidencia de que los niveles de vitamina D causaran en realidad más casos o muertes relacionadas con el COVID-19.\n\nOtros estudios han notado vínculos potenciales entre niveles bajos de vitamina D y COVID-19, pero no ha sido alcanzado un consenso sobre cuál es el impacto potencial de la vitamina sobre el virus. Los investigadores están trabajando ahora en varios estudios para determinar si la vitamina D puede ser efectiva para tratar al COVID-19."
    ],
    "Spanish - Background and context": [
      "La vitamina D es un nutriente esencial, lo que significa que tu cuerpo la necesita pero no puede fabricarla por sí mismo. Por esto es que las personas tienen que obtener su vitamina D a partir de comidas tales como salmón o yemas de huevo, suplementos, o por pasar cortos periodos de tiempo al sol. La vitamina D ayuda a asegurar que el sistema inmunológico de tu cuerpo y sus células estén funcionando bien, de manera que puedan responder a infecciones y virus. Adicionalmente a su ayuda para la retención de los niveles de calcio en el cuerpo y la promoción de la salud de los huesos, la vitamina D también puede potencialmente reducir el crecimiento de las células cancerígenas, ayudar a minimizar la inflamación, y ayudar a controlar infecciones."
    ],
    "Bengali - What our experts say": [
      "এটা এখনই বলা সম্ভব নয় যে, ভিটামিন ডি কোভিড -১৯-এর চিকিৎসায় সহায়তা করতে পারে কি না। এখন অবধি, কোভিড-১৯ রোগীদের চিকিৎসা করার জন্য ভিটামিন ডি এর কার্যকারিতা পরীক্ষা করা হয়নি, সুতরাং এটি ভাইরাসটিকে প্রতিরোধ বা চিকিৎসা করতে পারে এমন কোনও প্রমাণ নেই। সাম্প্রতিক এক গবেষণায় ২০ টি ইউরোপীয় দেশ থেকে প্রাপ্ত তথ্যের দিকে লক্ষ্য করা গেছে এবং উল্লেখ করা হয়েছে যে, যে জায়গাগুলিতে বেশি লোকের মধ্যে ভিটামিন ডি এর ঘাটতির ঘটনা রয়েছে, সেখানে তাদের কোভিড -১৯ এবং মৃত্যুর হারও বেশি ছিল। এই সমীক্ষায় ভিটামিন ডি এর নিম্ন স্তর এবং কোভিড -১৯ দুর্বল স্বাস্থ্য ফলাফলের মধ্যে সম্ভাব্য সম্পর্কের পরামর্শ দেওয়া হলেও ভিটামিন ডি-এর মাত্রার কারণে কোভিড-১৯-এর সাথে বেশি ঘটনা বা মৃত্যুর কারণ সম্পর্কিত তা প্রমাণিত হয়নি।\nঅন্যান্য গবেষণায় কম ভিটামিন ডি স্তর এবং কোভিড -১৯ এর মধ্যে সম্ভাব্য সংযোগ উল্লেখ করা হয়েছে, তবে ভাইরাসে ভিটামিনের সম্ভাব্য প্রভাব কী তা নিয়ে কোনও ঐকমত তৈরি হয়নি। গবেষকরা এখন কোভিড-১৯-এর চিকিৎসায় ভিটামিন ডি কার্যকর করতে পারবেন কিনা তা নির্ধারণ করতে বেশ কয়েকটি গবেষণায় কাজ করছেন।"
    ],
    "Bengali - Background and context": [
      "ভিটামিন ডি একটি প্রয়োজনীয় পুষ্টি উপাদান, যার অর্থ আপনার দেহে এটি প্রয়োজন আছে কিন্তু এটি শরীর নিজেই তৈরি করতে পারে না। এজন্য লোকজনকে স্যামন মাছ বা ডিমের কুসুম, পরিপূরক জাতীয় খাবার বা রোদে স্বল্প পরিমাণে সময় ব্যয় করে তাদের ভিটামিন ডি গ্রহণ করতে হবে। ভিটামিন ডি আপনার দেহের রোগ প্রতিরোধ ক্ষমতা এবং এর কোষগুলি ভালভাবে কাজ করছে তা নিশ্চিত করতে সহায়তা করে যাতে তারা সংক্রমণ এবং ভাইরাসের প্রতিক্রিয়া জানাতে পারে। শরীরে ক্যালসিয়ামের মাত্রা ধরে রাখতে এবং হাড়ের স্বাস্থ্যের বজায়ে সহায়তা করার পাশাপাশি ভিটামিন ডি ক্যান্সার কোষের বৃদ্ধিও হ্রাস করতে পারে, প্রদাহ হ্রাস করতে সহায়তা করতে এবং সংক্রমণ নিয়ন্ত্রণে সহায়তা করতে পারে।"
    ]
  },
  {
    "id": "recFi8qUxcrBhBeb9",
    "Question": "What does it mean for COVID-19 to impact the brain?",
    "Status": "Update in progress",
    "Category": "Symptoms",
    "Subcategory": "On: COVID-19 & the brain",
    "Background and context": "COVID-19 has been linked to a series of health complications beyond respiratory failure, including neurological complications that can potentially damage the brain. Recently, news has been circulating about how SARS-CoV-2, the virus that causes COVID-19, has been associated with many different neurological syndromes, including nerve damage, delirium, and stroke. While the condition is not very common, doctors are currently looking at data from individual patients from around the world to assess how it has impacted patients.\n\nThese neurological complications have also been reported during previous epidemics, such as the Severe Acute Respiratory Syndrome (SARS) epidemic in 2003 and the Middle East Respiratory Syndrome (MERS) outbreak more recently in 2012.\n",
    "What our experts say": "Physicians and scientists are learning more about how COVID-19 impacts organs outside of the respiratory system, such as the brain. The emerging evidence has revealed that some COVID-19 patients experience neurological symptoms in the brain, spinal cord, nerves, and ganglia (cell bodies that relay nerve signals). \n\nIn early March 2020, observational data from 58 patients in France indicated the presence of neurological symptoms such as agitation, confusion, disorientation, and encephalopathy (brain damage). In April 2020, a study was published on 214 COVID-19 patients in China with \"severe infection,\" where over a third were reported to experience neurological symptoms, including acute cerebrovascular diseases and impaired consciousness.\n\nIn July 2020, another study on over 40 British patients provided additional evidence about neurological symptoms, ranging from brain inflammation and delirium to nerve damage and stroke. Some of these patients reported severe symptoms, such as strokes and paralysis resulting from nerve damage, while others experienced more minor symptoms like breathlessness and fatigue. Most of the cases with brain inflammation were diagnosed with acute disseminated encephalomyelitis (ADEM), which is a rare illness involving inflammation of the brain and spinal cord that results from viral infections. Data from London indicated an increase in ADEM cases for this study period during the pandemic, as the number of reported cases would typically have been expected over a 5-month period rather than a 5-week period in the city. \n\nSARS-CoV-2, the virus that causes COVID-19, was not detected in the cerebrospinal brain fluid of any of the British patients tested, which may suggest that the virus did not directly attack the brain and that the symptoms could have occurred post-infection.\n\nVanderbilt University Medical Center launched a study in July 2020 that will study delirium, post-traumatic stress disorder (PTSD), and depression in patients who have been hospitalized with COVID-19. These disabling impacts are also known as post-intensive care syndrome (PICS), and previous studies of intensive care patients similar to COVID-19 patients suggest that 33-50% experience dementia, 10-20% experience PTSD, and 33% experience major depression. Researchers are also studying whether COVID-19 patients with brain inflammation are at higher risk of autoimmune disorders like demyelination, where the protective coating of nerve cells is attacked by the immune system and may lead to weakness, numbness and difficulty with daily activities.\n\nWith the increasing evidence of neurological symptoms, which have not been found to occur as commonly as respiratory symptoms, researchers and health care practitioners are continuing to observe patients around the world to learn more about how COVID-19 impacts on the brain. The long-term implications are still unclear, since COVID-19 is a new disease and there has not been enough time to observe the development of symptoms in patients over long periods of time.\n",
    "Glossary Terms": [
      "recR9wzTcTIDRvZxF"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n\n",
    "Topics": [
      "virus",
      "symptoms",
      "brain",
      "inflammation"
    ],
    "Other resources": "1. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China ([JAMA](https://jamanetwork.com/journals/jamaneurology/fullarticle/2764549)) \n2. Neurologic Features in Severe SARS-CoV-2 Infection ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMc2008597)) \n3. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings ([Brain](https://academic.oup.com/brain/article/doi/10.1093/brain/awaa240/5868408))\n4. How Covid-19 can damage the brain ([BBC](https://www.bbc.com/future/article/20200622-the-long-term-effects-of-covid-19-infection))\n5. Warning of serious brain disorders in people with mild coronavirus symptoms ([The Guardian](https://www.theguardian.com/world/2020/jul/08/warning-of-serious-brain-disorders-in-people-with-mild-covid-symptoms))\n6. Long after the fire of a Covid-19 infection, mental and neurological effects can still smolder ([STAT News](https://www.statnews.com/2020/08/12/after-covid19-mental-neurological-effects-smolder/))\n7. Delirium, PTSD, brain fog: The aftermath of surviving COVID-19 ([American Psychological Association](http://Delirium, PTSD, brain fog: The aftermath of surviving COVID-19 (American Psychological Association)))\n8. Study to explore how COVID affects cognition over time ([Vanderbilt University Medical Center](https://news.vumc.org/2020/07/22/study-to-explore-how-covid-affects-cognition-over-time/))\n",
    "How often revision needed": "Weekly",
    "DB (Hindi)": [
      "recOsZvkjBzqEIPAv"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recTWIUnUEk7wfMG8"
    ],
    "DB (Portuguese)": [
      "recuXjMBSyt3EXqGI"
    ],
    "Rollup test 2": [
      "rec5e2bKZGfveXImC"
    ],
    "Last modified manual": "2020-08-20",
    "Last edited (simplified)": "2020-07-16T23:02:18.000Z",
    "Last edited (experts say)": "2020-12-08T18:29:36.000Z",
    "Last modified": "2020-12-08",
    "What our experts say wordcount": 447,
    "Background and context wordcount": 108,
    "Other resources wordcount": 95,
    "Wordcount": 650,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "चिकित्सक और वैज्ञानिक इस बारे में अधिक सीख रहे हैं कि कोविड-19 श्वसन तंत्र के बाहर के अंगों को कैसे प्रभावित करता है, जैसे कि मस्तिष्क। उभरते सबूतों से पता चला है कि कुछ कोविड-19 रोगियों को मस्तिष्क, रीढ़ की हड्डी, नसों और गैन्ग्लिया (तंत्रिका संकेतों को रिले करने वाले सेल निकाय) में मस्तिष्क संबंधी लक्षणों का अनुभव होता है।\n \nमार्च 2020 की शुरुआत में, फ्रांस में 58 रोगियों के अवलोकन संबंधी आंकड़ों ने आंदोलन, भ्रम, भटकाव और एन्सेफैलोपैथी (मस्तिष्क क्षति) जैसे तंत्रिका संबंधी लक्षणों की उपस्थिति का संकेत दिया। अप्रैल 2020 में, चीन में \"गंभीर संक्रमण\" वाले 214 कोविड-19 रोगियों पर एक अध्ययन प्रकाशित किया गया था, जहां एक तिहाई से अधिक मस्तिष्क संबंधी बीमारियों और तीव्र चेतना सहित तंत्रिका संबंधी लक्षणों का अनुभव किया गया था।\n \nजुलाई 2020 में, 40 से अधिक ब्रिटिश रोगियों पर एक अन्य अध्ययन ने मस्तिष्क संबंधी सूजन और प्रलाप से लेकर तंत्रिका क्षति और स्ट्रोक के बारे में न्यूरोलॉजिकल लक्षणों के बारे में अतिरिक्त सबूत प्रदान किए। इनमें से कुछ रोगियों ने गंभीर लक्षणों की सूचना दी, जैसे कि स्ट्रोक और पक्षाघात जिसके परिणामस्वरूप तंत्रिका क्षति हुई, जबकि अन्य ने सांस की तकलीफ और थकान जैसे मामूली लक्षणों का अनुभव किया। मस्तिष्क की सूजन के अधिकांश मामलों में तीव्र प्रसार वाले एन्सेफेलोमाइलाइटिस (एडिइएम) का निदान किया गया था, जो मस्तिष्क और रीढ़ की हड्डी से जुड़ी एक दुर्लभ बीमारी है जो वायरल संक्रमण से उत्पन्न होती है। लंदन के डेटा ने महामारी के दौरान इस अध्ययन की अवधि के लिए एडिइएम मामलों में वृद्धि का संकेत दिया, क्योंकि रिपोर्ट किए गए मामलों की संख्या आमतौर पर शहर में 5-सप्ताह की अवधि के बजाय 5 महीने की अवधि से अधिक होने की उम्मीद की गई होगी।\nSARS-CoV-2, वायरस जो कोविड-19 का कारण बनता है, परीक्षण किए गए किसी भी ब्रिटिश रोगियों के मस्तिष्कमेरु मस्तिष्क द्रव में नहीं पाया गया था, जो यह सुझाव दे सकता है कि वायरस ने सीधे मस्तिष्क पर हमला नहीं किया था और यह लक्षण पोस्ट संक्रमण हो सकता है। \n\nवेंडरबिल्ट यूनिवर्सिटी मेडिकल सेंटर ने जुलाई 2020 में एक अध्ययन शुरू किया जो कोविड-19 के साथ अस्पताल में भर्ती होने वाले रोगियों में प्रलाप, पोस्ट-ट्रॉमैटिक स्ट्रेस डिसऑर्डर (पीटीएसडी) और अवसाद का अध्ययन करेगा। इन अक्षम प्रभावों को पोस्ट-गहन देखभाल सिंड्रोम (पीआइसीएस) के रूप में भी जाना जाता है, और कोविड-19 रोगियों के समान गहन देखभाल रोगियों के पिछले अध्ययनों से पता चलता है कि 33-50% अनुभव मनोभ्रंश, 10-20% अनुभव पीटीएसडी, और 33% प्रमुख अनुभव डिप्रेशन से हैं। शोधकर्ता यह भी अध्ययन कर रहे हैं कि क्या मस्तिष्क की सूजन वाले कोविड-19 रोगियों में स्व-प्रतिरक्षित विकारों का अधिक खतरा होता है, जैसे कि प्रतिरक्षा प्रणाली द्वारा तंत्रिका कोशिकाओं के सुरक्षात्मक कोटिंग पर हमला किया जाता है और दैनिक गतिविधियों के साथ कमजोरी, सुन्नता और कठिनाई हो सकती है।\nन्यूरोलॉजिकल लक्षणों के बढ़ते सबूत के साथ, जो कि श्वसन लक्षणों के रूप में आमतौर पर नहीं पाए गए हैं, शोधकर्ताओं और स्वास्थ्य देखभाल चिकित्सकों ने मस्तिष्क पर कोविड-19 कैसे प्रभावित होता है, इस बारे में अधिक जानने के लिए दुनिया भर के रोगियों का निरीक्षण जारी है। लंबी अवधि के निहितार्थ अभी भी स्पष्ट नहीं हैं, क्योंकि कोविड-19 एक नई बीमारी है और लंबे समय से अधिक समय से रोगियों में लक्षणों के विकास का निरीक्षण करने के लिए पर्याप्त समय नहीं है।\n\nइस प्रविष्टि को 20 अगस्त 2020 को नई जानकारी के साथ अद्यतन किया गया था।"
    ],
    "Hindi - Background and context": [
      "कोविड-19 को श्वसन विफलता से परे स्वास्थ्य जटिलताओं की एक श्रृंखला से जोड़ा गया है, जिसमें तंत्रिका संबंधी जटिलताएं शामिल हैं जो मस्तिष्क को नुकसान पहुंचा सकती हैं। हाल ही में, इस बारे में खबरें चल रही हैं कि कैसे SARS-CoV-2, कोविड-19 का कारण बनने वाला वायरस, तंत्रिका क्षति, प्रलाप और स्ट्रोक सहित कई अलग-अलग न्यूरोलॉजिकल सिंड्रोम से जुड़ा हुआ है। जबकि स्थिति बहुत सामान्य नहीं है, डॉक्टर वर्तमान में दुनिया भर के व्यक्तिगत रोगियों के डेटा को देख रहे हैं ताकि यह आकलन किया जा सके कि यह मरीजों पर कैसे प्रभाव डालता है।\n\nपिछले महामारी के दौरान इन न्यूरोलॉजिकल जटिलताओं को भी रिपोर्ट किया गया है, जैसे कि गंभीर तीव्र श्वसन सिंड्रोम (SARS) 2003 में महामारी और 2012 में मध्य पूर्व श्वसन सिंड्रोम (एमइआरएस) का अधिक प्रकोप।"
    ]
  },
  {
    "id": "recabh4pzUPxHxLq1",
    "Question": "Does wearing a mask reduce your oxygen level?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & masks",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "Nigeria"
    ],
    "Background and context": "Recently, a huge amount of misinformation has come out regarding face masks and their potential impacts on people. Since the World Health Organization and U.S. CDC have recommended wearing masks to prevent the spread of COVID-19, face masks have become a target of political discussions. This is likely due to the fact that in the early months of 2020, face masks were not yet recommended by these groups for a number of reasons, including a lack of evidence that they would be effective (since then research has been conducted and we have proof of their effectiveness) and a general shortage of masks for doctors and healthcare professionals. As more research studies were completed and more evidence made it clear that face masks were effective in helping the spread of COVID-19, the face mask policies also changed.\n",
    "What our experts say": "No. There is no proof that wearing a mask can reduce oxygen levels, also known as hypoxia. The United States Centers for Disease Control and Prevention (U.S. CDC) recommend wearing cloth masks in public, which are not too tight on our faces and allow for easy breathing.\n\nEven doctors and healthcare professionals wearing N95 masks (which fit very tightly around the face and are made to create a seal around the edge of the mask) are not at risk of hypoxia. However, for any person with preexisting lung or breathing problems in general, they should speak with their doctors about their concerns regarding masks. \n",
    "Glossary Terms": [
      "recCEG85awzcotyRi",
      "recqnngV0Ej32WU8H",
      "recZuNf7uTj0VplMB"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "face masks",
      "hypoxia"
    ],
    "Other resources": "1. From the Frontlines: The Truth About Masks and COVID-19 ([ALA](https://www.lung.org/blog/covid-masks)) \n2. Proper N95 Respirator Use for Respiratory Protection Preparedness ([U.S. CDC](https://blogs.cdc.gov/niosh-science-blog/2020/03/16/n95-preparedness/)) \n3. CDC calls on Americans to wear masks to prevent COVID-19 spread ([U.S. CDC](https://www.cdc.gov/media/releases/2020/p0714-americans-to-wear-masks.html)) \n",
    "Media": [
      {
        "id": "att17Y9W6Jj9baxe2",
        "url": "https://dl.airtable.com/.attachments/e14a95ec426f72be27a773f2cd0f0fe6/2ce396de/Slide_1",
        "filename": "Slide_1",
        "size": 193940,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c142edefb08ed2ea37e92ddf1fe7ff81/1d4906c8",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ca90420def96c75007373e156261f435/7b13c06d",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/a7c619f0753382cf4f21b1450005d3b5/8691e961",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attSFRPOqgIqMz80N",
        "url": "https://dl.airtable.com/.attachments/93dce28eabd44d491daeb934cf1dfd50/7ab9ad20/Slide_2",
        "filename": "Slide_2",
        "size": 132874,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/bd3829f50b439a78bf833d3886ff48ba/e5df4559",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/a6427d1411b05e8fc198b2788a101df4/2274ceab",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/98cd1b48647b62b3e61eb52bd831c966/37b5efa0",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attfjNaojsdEPRHRe",
        "url": "https://dl.airtable.com/.attachments/5dd5c2eef2b566e56b165ea639fc2a6f/8abea1e9/Slide_3",
        "filename": "Slide_3",
        "size": 134394,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/0a9f77f32003ba1dfeba3ccee2227151/7bfdedd0",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/cdd5aeceb6cd034fffdf247575e8f5e1/4d5b4cd3",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/40f8c1ac2d34ff383bf034f3cd03f563/73976ed2",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "atteU7JhFWaMGLSex",
        "url": "https://dl.airtable.com/.attachments/60e022f74aae5de3bd78bab82a51b9d0/a75a5f5e/Slide_4",
        "filename": "Slide_4",
        "size": 85555,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/609f3f87ff2fe8efe3054195fe74ce8c/9efdf933",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e8f7e839ff657d2eb61c9251e658d994/0b243991",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/fa04435e63247967fb402ec835d43ad5/de000393",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "DB (Arabic)": [
      "recSEM1sgspgAYQ38"
    ],
    "DB (Bengali)": [
      "recUTOx0aRpepSFkd"
    ],
    "DB (Portuguese)": [
      "recxQqhJAiNNpUH3J"
    ],
    "Rollup test 2": [
      "rec97Bi3GUj7bzVA7"
    ],
    "Media Package": [
      {
        "id": "att6vT7YORflrRtVw",
        "url": "https://dl.airtable.com/.attachments/470bc180b6cb78e4be58b64a5697b8ac/040d54ae/MasksandO2.zip",
        "filename": "Masks and O2.zip",
        "size": 547704,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-08-06",
    "Last edited (simplified)": "2020-07-29T17:17:21.000Z",
    "Last edited (experts say)": "2020-08-06T17:25:59.000Z",
    "Last modified": "2020-08-06",
    "What our experts say wordcount": 104,
    "Background and context wordcount": 135,
    "Other resources wordcount": 37,
    "Wordcount": 276,
    "Arabic Q status": [
      "Published"
    ],
    "Arabic - What our experts say": [
      "لا، ليس هناك دليل على أن ارتداء الكمامة يمكن أن يقلل من مستويات الأكسجين، والمعروف أيضا باسم نقص التَّأَكْسُج. توصي المراكز الأمريكية لمكافحة الأمراض والوقاية منها (US CDC) بارتداء كمامات من القماش في الأماكن العامة، والتي لا تكون ضيقة جدا على وجوهنا وتسمح بالتنفس بسهولة.\n\nحتى الأطباء والمتخصصين في الرعاية الصحية الذين يرتدون أقنعة N95 (التي تتناسب بإحكام شديد حول الوجه ومصممة لمنع التسرب حول حافة القناع) لا يتعرضون لخطر نقص التَّأَكْسُج. ومع ذلك، بالنسبة لأي شخص يعاني من مشاكل في الرئة أو التنفس بشكل عام، يجب أن يتحدث مع طبيبه حول مخاوفه بشأن الكمامات."
    ],
    "Arabic - Background and context": [
      "في الآونة الأخيرة، ظهر كم هائل من المعلومات الخاطئة بشأن كمامات الوجه وتأثيراتها المحتملة على الناس. منذ أن أوصت منظمة الصحة العالمية ومركز السيطرة على الأمراض في الولايات المتحدة بارتداء الكمامات لمنع انتشار كوفيد-19، أصبحت كمامات الوجه مستهدفة في النقاشات السياسية. ويرجع ذلك على الأرجح إلى حقيقة أنه في الأشهر الأولى من عام 2020، لم توصِ هذه المجموعات بعد بالكمامات لعدة من الأسباب، بما في ذلك عدم وجود دليل على أنها ستكون فعالة (منذ ذلك الحين تم إجراء البحث ولدينا الآن دليل على فعاليتها) و كذا نقص عام في الكمامات الخاصة بالأطباء والمتخصصين في الرعاية الصحية. لكن مع وفرة الدراسات البحثية التي أكدت بالدليل أن أقنعة الوجه كانت فعالة في المساعدة على انتشار كوفيد-19، تغيرت قرارات ارتداء كمامات الوجه أيضا."
    ],
    "Bengali - What our experts say": [
      "\"না। এমন কোন প্রমাণ নেই যে মাস্ক পরার ফলে অক্সিজেন স্তর হ্রাস হয়, যা হাইপক্সিয়া নামে পরিচিত। মার্কিন যুক্তরাষ্ট্রের সেন্টার ফর ডিজিজ কন্ট্রোল অ্যান্ড প্রিভেনশন (U.S. CDC) জনস্থানে কাপড়ের মাস্ক পরার পরামর্শ দিয়েছেন, যা মুখের উপর খুব চেপে বসে না এবং সহজের শ্বাস প্রশ্বাস নেওয়া যায়। \n\nএমনকি N95 মাস্ক (যা মুখের চারিপাশে খুব চেপে বসে এবং মাস্কের প্রান্ত অনুযায়ী একটা সিল তৈরি করে) পরা চিকিৎসক এবং স্বাস্থ্য পরিষেবা কর্মীরাও হাইপক্সিয়ার ঝুঁকিতে নেই। যদিও, সাধারণভাবে ফুসফুস বা শ্বাসের সমস্যা থাকা কোন ব্যক্তির ক্ষেত্রে, তাদের উচিৎ মাস্কের ব্যাপারে নিজেদের উদ্বেগের বিষয়ে চিকিৎসকের সঙ্গে আলোচনা করা। \""
    ],
    "Bengali - Background and context": [
      "সম্প্রতি ফেস মাস্ক এবং মানুষের উপর এটির সম্ভাব্য প্রভাবের ব্যাপারে বিশাল পরিমাণ ভুল তথ্য প্রকাশিত হয়েছে। যেহেতু বিশ্ব স্বাস্থ্য সংস্থা এবং মার্কিন যুক্তরাষ্ট্রের CDC কোভিড-১৯ এর প্রসার প্রতিরোধ করার জন্য মাস্ক পরার পরামর্শ দিয়েছে, ফেস মাস্ক একটি রাজনৈতিক আলোচনার লক্ষ্য হয়ে দাঁড়িয়েছে। এর কারণ সম্ভবত এই যে ২০২০ সালের শুরুর দিকের মাসগুলিতে, এই সংস্থাগুলি ফেস মাস্ক পরার পরামর্শ দেননি বেশ কয়েকটি কারণবশত, যার অন্তর্গত কার্যকারিতার প্রমাণের অভাব (তারপর থেকে গবেষণা করা হয়েছে এবং আমাদের কাছে কার্যকারিতার প্রমাণ আছে) এবং চিকিৎসক এবং স্বাস্থ্যকর্মীদের ক্ষেত্রে মাস্কের অভাব। যেমনই আরও গবেষণা অধ্যয়নগুলি সম্পূর্ণ করা হয়েছে এবং আরও প্রমাণ পাওয়া গেছে যে ফেস মাস্ক কোভিড-১৯ এর প্রসার আটকাতে সাহায্য করতে কার্যকরী, ফেস মাস্ক সংক্রান্ত নিয়মও পরিবর্তন করা হয়েছে। "
    ]
  },
  {
    "id": "recQZ5Gya03eOGb8l",
    "Question": "What is the impact of Vitamin C on COVID-19?",
    "Status": "Published",
    "Category": "Treatment, Cure, Prevention",
    "Subcategory": "On: COVID-19 & vitamin C",
    "Source of the question": [
      "Newsroom",
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA",
      "Canada",
      "South Africa"
    ],
    "Background and context": "Vitamin C (ascorbic acid) is an important vitamin that is part of natural processes that happen in the body that support immune function, maintain blood vessel structure, control inflammation, and help with healing. Vitamin C is naturally found in a variety of fruits and vegetables (i.e. oranges, mangoes, peppers, kiwi, strawberries, tomatoes), and it is also added to foods to help preserve them for a longer shelf-life. Vitamin C is commonly taken as a supplement (often as a pill or powder). While vitamin C supplements are typically considered to be safe, side effects can include nausea, cramps, acid reflux, and an increased risk of kidney stones. \n\nVitamin C supplements are being evaluated for patients with COVID-19 because vitamin C has been shown to slightly shorten the length of time that someone has a cold, and may reduce the severity of a cold, but the research is unclear and most studies have only shown a benefit for patients who have a low vitamin C status (deficiency). There is no scientific evidence to support the idea that taking vitamin C prevents colds.\n\nVitamin C deficiency does affect how the immune system works and may reduce a person’s ability to fight infections. Vitamin C deficiency is not common for most people with a varied diet; however smokers, pregnant women, older adults, and people with major injuries (i.e. burns) are at increased risk.\n\n_This entry was updated with new information on August 4, 2020_\n",
    "What our experts say": "There is no scientific evidence to suggest that taking vitamin C will prevent against or cure COVID-19; and, though studies are underway, there is not enough scientific evidence to recommend taking vitamin C as part of a treatment for COVID-19 unless it is part of a study protocol. Vitamin C is being tested as a possible combination therapy (a treatment used with other medications or therapies) for very ill patients with and without COVID-19- particularly those with major infections and sepsis. Studies of the effect of vitamin C supplements on patients with COVID-19 are ongoing. \n\n_This entry was updated with new information on August 4, 2020_\n",
    "Glossary Terms": [
      "recOMUWrX4F2d53iC"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "vitamin C",
      "immune system",
      "prevention"
    ],
    "Other resources": "1. Vitamin C, 2020 ([U.S. NIH](https://www.covid19treatmentguidelines.nih.gov/adjunctive-therapy/vitamin-c/))\n2. Treatments for COVID-19, 2020 ([Harvard Medical School](https://www.health.harvard.edu/diseases-and-conditions/treatments-for-covid-19))\n3. Vitamin C ([Oregon State University](https://lpi.oregonstate.edu/mic/health-disease/immunity-in-brief#vitamin-C))\n4. Vitamin C for Preventing and Treating the Common Cold ([NCBI](https://www.ncbi.nlm.nih.gov/pubmed/23440782))  \n5. Vitamin C and Immune Function ([NCBI](https://www.ncbi.nlm.nih.gov/pubmed/29099763)) \n\n",
    "DB (French)": [
      "recD1hQ5hwPZnyPCX"
    ],
    "DB (Hindi)": [
      "recoJqIP70s9YSG3W"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recuClScJD4aP21f2"
    ],
    "DB (Spanish)": [
      "recNYOM0gylBDdy9E"
    ],
    "DB (Arabic)": [
      "rec7ifHMJghnRYJit"
    ],
    "DB (Bengali)": [
      "recvBblWT1w6G4UgF"
    ],
    "DB (Portuguese)": [
      "rec6CMdaRVF2OMygf"
    ],
    "Rollup test 2": [
      "recO4Tb4rMEVVT3MR"
    ],
    "Last modified manual": "2020-08-04",
    "Last edited (simplified)": "2020-08-31T19:09:53.000Z",
    "Last edited (experts say)": "2020-08-31T19:09:53.000Z",
    "Last modified": "2020-08-31",
    "What our experts say wordcount": 105,
    "Background and context wordcount": 236,
    "Other resources wordcount": 37,
    "Wordcount": 378,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Arabic Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Il n’existe aucune donnée scientifique probante pour suggérer que la prise de vitamine C préviendra ou guérira la COVID-19 ; et, bien que des études soient en cours, il n’y a pas assez de données scientifiques probantes pour recommander la prise de vitamine C dans le cadre d’un traitement contre la COVID-19, à moins que ce soit dans le cadre d’un protocole d’étude. Des essais sont en cours avec la vitamine C en tant que traitement combiné (un traitement utilisé avec d’autres médicaments ou thérapies) pour les patients très malades avec ou sans la COVID-19, particulièrement ceux souffrant d’infections graves ou sepsie. Des études ont lieu actuellement sur l’effet de suppléments de vitamine C sur les patients souffrant de COVID-19.\n\nCette entrée a été mise à jour avec de nouveaux renseignements le 4 août 2020."
    ],
    "French - Background and context": [
      "La vitamine C (acide ascorbique) est une vitamine importante utilisée par des processus naturels du corps afin de soutenir la fonction immunitaire, entretenir la structure des vaisseaux sanguins, contrôler l’inflammation et favoriser la guérison. La vitamine C se trouve naturellement dans de nombreux fruits et légumes (p. ex. les oranges, les mangues, les poivrons, les kiwis, les fraises, les tomates), et elle est aussi ajoutée aux aliments pour aider à prolonger leur durée de conservation. La vitamine C est communément prise comme supplément (souvent sous la forme de pilule ou de poudre). Bien que les suppléments de vitamine C soient habituellement considérés comme sans danger, les effets secondaires peuvent comprendre des nausées, des crampes abdominales, des reflux gastro-œsophagiens et un risque accru de calculs rénaux.\n\nLes suppléments de vitamine C sont actuellement évalués pour les patients atteints par la COVID-19, car il a été démontré que la vitamine C réduit un peu la durée du rhume et peut aussi en réduire la gravité. Mais la recherche n’est pas claire et la plupart des études n’ont démontré qu’un avantage chez les patients souffrant d’une carence en vitamine C. Il n’existe aucune donnée scientifique probante pour soutenir l’idée que la prise de vitamine C prévient les rhumes.\n\nUne carence en vitamine C affecte la façon dont le système immunitaire fonctionne et peut réduire la capacité d’une personne à combattre les infections. Une carence en vitamine C est inhabituelle chez la plupart des personnes dont le régime alimentaire est varié ; cependant les fumeurs, les femmes enceintes, les personnes plus âgées et celles souffrant de blessures graves (p. ex. des brûlures) sont plus à risque.\n\nCette entrée a été mise à jour avec de nouveaux renseignements le 4 août 2020."
    ],
    "Hindi - What our experts say": [
      "विटामिन-सी आपको कोविड​​-19 से बीमार होने से नहीं रोक सकता। यह न तो वायरस के लिए एक इलाज है और न ही एक रोकथाम की विधि है। लोक मान्यता के विपरीत, नियमित रूप से विटामिन-सी जुख़ाम की संख्या को कम करने के उपाय के रूप में कभी भी साबित नहीं किया गया है। यह सर्दी-जुख़ाम के समय की लंबाई को कम करने में मदद कर सकता है, साथ ही उसकी गंभीरता को भी कम करने सहायक हो सकता है, लेकिन उस पर शोध अभी भी अस्पष्ट है। अभी, दुनिया भर के अध्ययन यह निर्धारित करने की कोशिश कर रहे हैं कि क्या विटामिन-सी कोविड​-19 के रोगियों की मदद कर सकता है, लेकिन कोई सबूत नहीं दिखाता है कि विटामिन-सी लेने से उन लोगों पर कोई असर पड़ा हो।"
    ],
    "Hindi - Background and context": [
      "विटामिन-सी एक विटामिन है जो कुछ खाद्य पदार्थों में स्वाभाविक रूप से मौजूद होता है, और दूसरों में डाला जाता है। विटामिन-सी का सेवन करना महत्वपूर्ण है क्योंकि हालांकि, शरीर को कई कारणों से इसकी आवश्यकता होती है, लेकिन इसे मानव शरीर अपने अंदर नहीं बना सकता है। इसके बारे में अधिक जानकारी ‘अन्य जानकारी’ अनुभाग में उपलब्ध है।"
    ],
    "Telugu - What our experts say": [
      "విటమిన్ సి తీసుకోవడం కోవిడ్-19 ను నిరోధించగలదని లేదా నయం చేస్తుందని సూచించడానికి ఎటువంటి శాస్త్రీయ ఆధారాలు లేవు; మరియు అధ్యయనాలు జరుగుతున్నప్పటికీ, కోవిడ్-19 చికిత్సలో భాగంగా విటమిన్ సి తీసుకోవటానికి సిఫారసు చేయడానికి తగినంత శాస్త్రీయ ఆధారాలు లేవు, అది స్టడీ ప్రోటోకాల్‌లో భాగం తప్ప. కోవిడ్-19 తో మరియు లేకుండా చాలా అనారోగ్య రోగులకు విటమిన్ సి సాధ్యమైన కాంబినేషన్ థెరపీ (ఇతర మందులు లేదా చికిత్సలతో ఉపయోగించే చికిత్స) గా పరీక్షించబడుతోంది- ముఖ్యంగా పెద్ద ఇన్ఫెక్షన్లు మరియు సెప్సిస్ ఉన్నవారికి. కోవిడ్-19 ఉన్న రోగులపై విటమిన్ సి మందుల ప్రభావంపై అధ్యయనాలు కొనసాగుతున్నాయి.\n\nఈ ఎంట్రీ ఆగస్టు 4, 2020 న కొత్త సమాచారంతో నవీకరించబడింది"
    ],
    "Telugu - Context and background": [
      "విటమిన్ సి (ఆస్కార్బిక్ ఆమ్లం) ఒక ముఖ్యమైన విటమిన్, ఇది శరీరంలో జరిగే సహజ ప్రక్రియలలో భాగం, ఇది రోగనిరోధక పనితీరుకు మద్దతు ఇస్తుంది, రక్తనాళాల నిర్మాణాన్ని నిర్వహిస్తుంది, మంటను నియంత్రిస్తుంది మరియు వైద్యం చేయడంలో సహాయపడుతుంది. విటమిన్ సి సహజంగా రకరకాల పండ్లు మరియు కూరగాయలలో లభిస్తుంది (అనగా నారింజ, మామిడి, మిరియాలు, కివి, స్ట్రాబెర్రీ, టమోటాలు), మరియు వాటిని ఆహారంలో కూడా కలుపుతారు. విటమిన్ సి సాధారణంగా అనుబంధంగా తీసుకుంటారు (తరచుగా పిల్ లేదా పౌడర్ గా). విటమిన్ సి మందులు సాధారణంగా సురక్షితమైనవిగా పరిగణించబడుతున్నప్పటికీ, దుష్ప్రభావాలు వికారం, తిమ్మిరి, యాసిడ్ రిఫ్లక్స్ మరియు మూత్రపిండాల్లో రాళ్ల ప్రమాదం ఎక్కువగా ఉంటాయి.\n\nకోవిడ్-19 ఉన్న రోగులకు విటమిన్ సి మందులు మదింపు చేయబడుతున్నాయి, ఎందుకంటే విటమిన్ సి ఎవరికైనా జలుబు ఉన్న సమయాన్ని కొద్దిగా తగ్గిస్తుందని మరియు జలుబు యొక్క తీవ్రతను తగ్గిస్తుందని తేలింది, అయితే పరిశోధన అస్పష్టంగా ఉంది మరియు చాలా అధ్యయనాలు మాత్రమే ఉన్నాయి తక్కువ విటమిన్ సి స్థితి (లోపం) ఉన్న రోగులకు ప్రయోజనం చూపబడింది. విటమిన్ సి తీసుకోవడం జలుబును నివారిస్తుందనే ఆలోచనకు మద్దతు ఇవ్వడానికి శాస్త్రీయ ఆధారాలు లేవు.\n\nవిటమిన్ సి లోపం రోగనిరోధక వ్యవస్థ ఎలా పనిచేస్తుందో ప్రభావితం చేస్తుంది మరియు అంటువ్యాధులతో పోరాడే వ్యక్తి సామర్థ్యాన్ని తగ్గిస్తుంది. వైవిధ్యమైన ఆహారం ఉన్న చాలా మందికి విటమిన్ సి లోపం సాధారణం కాదు; అయినప్పటికీ ధూమపానం చేసేవారు, గర్భిణీ స్త్రీలు, వృద్ధులు మరియు పెద్ద గాయాలు కలిగిన వ్యక్తులు (అనగా కాలిన గాయాలు) ఎక్కువ ప్రమాదంలో ఉన్నారు.\n\nఈ ఎంట్రీ ఆగస్టు 4, 2020 న కొత్త సమాచారంతో నవీకరించబడింది"
    ],
    "Spanish - What our experts say": [
      "La vitamina C no puede prevenir que te enfermes o contraigas el COVID-19. No es una cura ni un método de prevención para el virus. Contrario a la creencia popular, nunca ha sido probado que la vitamina C regular disminuya el número de resfríos que las personas contraen. Podría ayudar a reducir el lapso de tiempo en que alguien está resfriado, como así también su severidad, pero aún la investigación al respecto no es clara y está en evolución. En este momento, los estudios de alrededor del mundo están intentando determinar si la vitamina C podría ayudar a las personas con COVID-19, pero no hay evidencia que muestre que tomando vitamina C pueda impactar a las personas que tienen el virus."
    ],
    "Spanish - Background and context": [
      "La vitamina C está presente en forma natural en algunas comidas, y es añadida a otras. Consumir vitamina C es importante porque, si bien la necesita por una variedad de razones, no es algo que el cuerpo humano pueda fabricar fácilmente por sí mismo. Más información acerca de esto está disponible en la sección de recursos adicionales."
    ],
    "Arabic - What our experts say": [
      "لا يقيك فيتامين سي من المرض أو الإصابة بفيروس كورونا (كوفيد-19)، كما إنه ليس علاجًا ولا وسيلة وقائية من الفيروس. فخلافًا للاعتقاد السائد لم تُثبت قدرة فيتامين سي الاعتيادي على خفض أعداد إصابات الناس بنزلات البرد، لكنه قد يساعد فيتامين سي على تقليل فترة المرض لدى المصاب بنزلة برد كما يساعد على تخفيض من حدته، وما يزال البحث في هذا المجال غير واضح و متغير. في الوقت الحالي، تحاول الدراسات حول العالم تحديد ما إذا كان لفيتامين سي دور مساعد في الوقاية أو الشفاء من مرض فيروس كورونا (كوفيد-19)، ولا توجد دلائل على أن تناول فيتامين سي له تأثير على حاملي الفيروس.\n\n"
    ],
    "Arabic - Background and context": [
      "يتواجد فيتامين سي في بعض الأغذية كما يمكن إضافته إلى أغذية أخرى. تناول فيتامين سي ضروري لأن الجسم البشري يحتاجه لأسباب عديدة، فالجسم البشري لا يستطيع إنتاجه بنفسه بهذه السهولة. تتوافر معلومات إضافية حول هذا الموضوع  في قسم .المصادر الإضافية"
    ],
    "Bengali - What our experts say": [
      "ভিটামিন সি আপনাকে অসুস্থ হওয়া থেকে বা কোভিড-১৯ এর সংস্পর্শে আস্তে বাঁধা দিতে পারে না। এটি ভাইরাসটির প্রতিকার বা প্রতিরোধের উপায়ও নয়। জনগণের বিশ্বাসের বিপরীতে, নিয়মিত ভিটামিন সি গ্রহণ কখনই ঠান্ডা লাগা মানুষের সংক্রমণের সংখ্যা কম প্রমাণ করে না| এটি ঠান্ডাজনিত রোগে অসুস্থ হওয়ার সময়ের দৈর্ঘ্য হ্রাস করতে পারে, পাশাপাশি সর্দি-তীব্রতার তীব্রতা কমিয়ে আনতে সহায়তা করতে পারে, তবে এ সম্পর্কে গবেষণা এখনও অস্পষ্ট এবং বিকাশমান। এই মুহুর্তে, বিশ্বজুড়ে অধ্যয়নগুলি নির্ধারণের চেষ্টা করছে যে ভিটামিন সি কোভিড-১৯ রোগীদের সাহায্য করতে পারে কিনা, তবে কোনও প্রমাণ এটা দেখায় না যে, ভিটামিন সি গ্রহণ করলে তা ভাইরাসে আক্রান্ত ব্যক্তিদের উপর প্রভাব ফেলতে পারে।"
    ],
    "Bengali - Background and context": [
      "ভিটামিন সি এমন একটি ভিটামিন যা প্রাকৃতিকভাবে কিছু খাবারে উপস্থিত থাকে এবং অন্যদের সাথে যুক্ত। ভিটামিন সি গ্রহণ করা গুরুত্বপূর্ণ কারণ, বিভিন্ন কারণে শরীরের এটি প্রয়োজন হলেও এটি মানব দেহ সহজেই নিজেরাই তৈরি করতে পারে না। এ সম্পর্কে আরও তথ্য অতিরিক্ত সংস্থান বিভাগে পাওয়া যাবে।"
    ],
    "Portuguese - What our experts say": [
      "A vitamina C não pode impedir que você fique doente ou contraia o COVID-19. Ela não é um método de cura nem de prevenção do vírus. Ao contrário da crença popular, nunca foi comprovado que a vitamina C regular reduz o número de resfriados contraídos por uma pessoa. A vitamina C pode ajudar a reduzir o tempo e a intensidade de um resfriado; porém, nem mesmo a pesquisa sobre o assunto é definitiva. Ela está evoluindo. No momento, estudos em todo o mundo estão tentando determinar se a vitamina C pode ajudar as pessoas com COVID-19, mas nenhuma evidência mostra que tomar vitamina C tem quaisquer efeitos em pessoas que têm o vírus."
    ],
    "Portuguese - Background and context": [
      "A vitamina C é uma vitamina naturalmente presente em alguns alimentos, e é adicionada a outros. Consumir vitamina C é importante porque, embora o corpo precise dela por várias razões, o corpo humano não a produz por conta própria. Mais informações sobre esse assunto estão disponíveis na seção de recursos adicionais."
    ]
  },
  {
    "id": "rec3DK3BrvuseyDAb",
    "Question": "What do we know about mouth and nose rinses, washes, sprays, or creams to prevent COVID-19?",
    "Status": "Published",
    "Category": "Treatment",
    "Country question was sourced from": [
      "India"
    ],
    "Background and context": "COVID-19 is known to spread through the air, via close personal contact, and by coming into contact with \"high-touch\" surfaces then touching one's eyes, nose, or mouth.  Research has shown that the infection primarily begins in the mucosa of the nose and throat so preventing the virus from entering or taking hold in our nose or throat has been of great interest in the scientific community.\n\nNasal washes, creams (or fats), and sprays and mouthwashes and gargle solutions have been promoted as possible ways to prevent COVID-19, but there is no scientific evidence that these therapies are effective and studies are ongoing.\n\nFor example, in parts of Africa, shea butter is commonly applied to the inside of the nose to help with congestion (or a stuffy nose). Ghee (clarified butter), coconut, and sesame oil applied to the inside of the nose or oral rinses with sesame oil have been promoted as part of Ayurveda- a form of traditional medicine with roots in ancient India. While some people have experienced benefits in using traditional medicine as a complementary part of their medical care, doctors and scientists have also voiced safety and efficacy concerns about certain practices. At present, there is no scientific evidence that nasal treatments or oral rinses will prevent, treat, or cure COVID-19. \n",
    "What our experts say": "There is no scientific evidence to support using home or traditional therapies to prevent COVID-19 at this time. The World Health Organization (WHO) and other international health leaders have continued to state that caution is needed when considering “traditional remedies” as preventative measures or treatments for COVID-19 because they have not been widely studied and may cause harm in some cases. \n\nThere are many traditional remedies and home remedies that have been promoted to prevent COVID-19 infection. People have suggested using mouth or nasal washes, sprays, and creams (or fats) could prevent the virus from entering the body or to kill the virus in the nasal cavity (nose) and throat before it has a chance to spread. \n\n**Nasal (nose) washes or sprays:** There is no scientific evidence that suggests rinsing the inside of your nose will prevent COVID-19 infection. Ongoing studies seek to learn about how saline, iodine, special soaps, and other ingredients used as nasal washes and sprays may help improve virus symptoms and decrease the spread of COVID-19. So far, many studies have explored these treatments in laboratory cells, and data on humans is limited. Additionally, for patients with COVID-19, researchers have raised a concern about using contaminated nasal rinse bottles (as well as surfaces and rinse fluids), suggesting they could be a source of exposure.\n\n**Mouthwash, rinses, and gargle solutions:** Like nasal washes and sprays, there is no scientific evidence that suggests using mouthwashes, rinses, and gargles will prevent COVID-19 infection. Ongoing studies seek to learn about how special antiseptic mouthwashes may help prevent COVID-19 (see the Experimental Therapies section below). So far, many studies have explored these treatments in laboratory cells, and data on humans is limited.\n\n**Alcohol, chlorine, or disinfectant spray:** Alcohol, chlorine (e.g. bleach solutions), or disinfectant sprays should never be sprayed or applied to your nose, mouth, or eyes, and doing so may cause serious harm. Drinking alcohol will not prevent or treat COVID-19.\n\n**Fats or oils:** This includes coconut oil, ghee, sesame oil, shea butter, petroleum jelly, and others. There is no scientific evidence that nasal treatments or mouth rinses with different fats will prevent, treat, or cure COVID-19. While many types of fats or oils (like coconut oil, sesame oil, and others) have been shown to kill or stop bad bacteria in cell-based laboratory studies, most of these studies have focused on how these ingredients may be used to prevent bacterial growth on food to improve food safety. Studies have not looked at the effect of fats on prevention of viral or bacterial infections in humans when applied in the nose or used as a mouth rinse. There is no scientific evidence that supports the theory that using these oils would improve health or prevent illness. In addition, though rare, it is possible that inhaling fats from the inside of the nose can cause lung problems.\n\n**Steam inhalation:** Though inhaling steam may help to thin mucous or relieve congestion (stuffy nose), there is no scientific evidence to suggest that inhaling steam will prevent or treat COVID-19. Contact with steaming hot water can cause burns, and inhaling steam can burn the inside of your nose.\n\n**Experimental therapies:** There are ongoing studies using nasal sprays (and rinses) and special mouthwashes to prevent COVID-19. Much of the current scientific evidence is based on animal or laboratory cell studies. For humans, efficacy and safety studies are ongoing, and these treatments are not recommended for the public at this time. Currently, studies seek to understand if nasal rinses (using salt water, special soaps, and other ingredients) may help to improve symptoms and decrease the viral load in patients with COVID-19 (with the thought that decreasing the viral load could decrease how much an infected person may spread the virus). Researchers are also studying whether gargling or rinsing with special solutions (e.g. povidone-iodine) may help prevent healthcare workers from contracting COVID-19. A pre-print study or a nasal spray medication (INNA-051) has shown good results in preventing COVID-19 in ferrets, but human studies have not yet begun. \n\nTo prevent COVID-19 infection, health authorities continue to recommend avoiding crowds, practicing social distancing measures (at least 6 feet/2 meters apart), frequent and careful hand washing, wearing face masks, staying home when possible (especially if you are sick), clean high-touch surfaces often, and avoid touching your nose, eyes, and mouth.\n",
    "Glossary Terms": [
      "rec5OdFSvwX0mLrxy",
      "recLsOWDMhYacbzOu",
      "recnFUXyIZy81Rj1I",
      "recz6LiyrAkeNejA2",
      "recTwPtyLhmTc3TBa",
      "recORiIMwk54TDQB6",
      "recFMi3UQAPSUjsl4",
      "reci6AkPuYYC5pFzD",
      "recEer1bgt6r6jukM",
      "reclKahoPRbBLqUKg",
      "rec2UNEXbTkSCx30Q",
      "recfxNeRDVhNKMgNe"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "treatment",
      "virus",
      "spread",
      "airborne",
      "COVID-19",
      "traditional medicine",
      "experimental treatment",
      "efficacy"
    ],
    "Other resources": "1. COVID-19 virtual press conference, April 2020, ([WHO](https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-01apr2020-final.pdf?sfvrsn=573dc140_2))\n2. Petroleum jelly: Safe for a dry nose? ([Mayo Clinic](https://www.mayoclinic.org/petroleum-jelly/expert-answers/faq-20057784))\n3. Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with coronavirus disease 2019 ([International Forum of Allergy & Rhinology](https://onlinelibrary.wiley.com/doi/epdf/10.1002/alr.22703))\n4. Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era ([Ear, Nose & Throat Journal](https://journals.sagepub.com/doi/pdf/10.1177/0145561320932318))\n5. Rapid In‐Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) Using Povidone‐Iodine Oral Antiseptic Rinse ([J Prosthodont](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300649/))\n6. Clinical Trial Looks at Antiseptic Nasal Spray and Gargle to Prevent COVID-19 Infections ([Univ Kentucky Research](https://www.research.uky.edu/news/clinical-trial-looks-antiseptic-nasal-spray-and-gargle-prevent-covid-19-infections))\n7. Debunking COVID-19 (coronavirus) myths ([Mayo Clinic](https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/coronavirus-myths/art-20485720))\n8. Prophylactic intranasal administration of a TLR2 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model** **([bioRxiv](https://www.biorxiv.org/content/10.1101/2020.09.25.309914v1.full.pdf))\n9. Treatments that target the coronavirus in the nose might help prevent COVID-19 ([Science News](https://www.sciencenews.org/article/coronavirus-covid-19-treatments-target-nose-prevention))\n10. Benefits and Safety of Nasal Saline Irrigations in a Pandemic—Washing COVID-19 Away ([JAMA Otolaryngol Head Neck Surg](https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2768627?guestAccessKey=0e28e4ee-5124-4704-8172-288933f538e3&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072320))\n11. Nasal disinfection for the prevention and control of COVID-19: A scoping review on potential chemo-preventive agents ([International Journal of Hygiene and Environmental Health](https://reader.elsevier.com/reader/sd/pii/S1438463920305514?token=0A52F531B0870EEEBE16AAF3A3C9A3031B37E3CEF9854D15986171FF5A76E4AFBCECF4C6DE6F3CBA61CDA99BEB9D642E))\n12. Ayurveda’s immunity boosting measures for self care during COVID 19 crisis ([Indian Government's Press Information Bureau](https://pib.gov.in/PressReleseDetailm.aspx?PRID=1609524))\n",
    "Rollup test 2": [
      "recvvXwGlTYixJTZN"
    ],
    "Last modified manual": "2020-12-03",
    "Last edited (simplified)": "2020-12-03T14:32:13.000Z",
    "Last edited (experts say)": "2020-12-03T18:15:58.000Z",
    "Last modified": "2020-12-03",
    "What our experts say wordcount": 711,
    "Background and context wordcount": 214,
    "Other resources wordcount": 191,
    "Wordcount": 1116
  },
  {
    "id": "recZ4lv0SN8LMlFvF",
    "Question": "Is paracetamol effective in treating or curing COVID-19?",
    "Status": "Published",
    "Country question was sourced from": [
      "India"
    ],
    "Background and context": "Paracetamol is an analgesic (pain reliever) that can address minor to moderate cases of aches, pains, and fever; other common names for paracetamol are acetaminophen, Tylenol, and Dolo 650. Acetaminophen is often confused with ibuprofen, another pain reliever that is commonly referred to as Advil, one of the commercial brands of ibuprofen. The main difference between the two is that ibuprofen has anti-inflammatory effects, making it a non-steroidal anti-inflammatory drug (NSAID) whereas acetaminophen does not, and therefore is not considered an NSAID.\n\nConfusion between the two was exacerbated in the context of COVID-19 following a tweet in mid-March by France’s Minister of Solidarity and Health, which claimed that taking anti-inflammatory drugs (such as Advil) could contribute to worsening a COVID-19 infection, and that acetaminophen (such as Tylenol) should be taken instead. The WHO initially took a similar position, recommending that ibuprofen be avoided for treating symptoms of COVID-19, but changed their stance on March 19 to say that they do not recommend avoiding ibuprofen to treat COVID-19 symptoms. Though there is no strong evidence that ibuprofen worsens COVID-19 symptoms, some public health bodies such as UK's National Health Service only recommend taking acetaminophen for COVID-19 symptoms.\n\nAccording to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases, the daily _maximum_ oral dose for adults is 3 grams per day though other sources (including the Merck Manual) suggest that up to 4 grams per day is generally well tolerated in healthy adults. Paracetamol can be toxic to the liver in high doses or when used in combination with alcohol, some other medications, or for patients with existing liver or kidney problems, those who are malnourished or underweight, or those of advanced age. It is important to follow packaging instructions carefully when taking this or any over the counter medications, and a medical professional should be consulted for additional, personalized guidance.\n\n_This entry was updated with new information on August 4th, 2020_\n",
    "What our experts say": "Paracetamol (also known as acetaminophen, Tylenol, Dolo 650) can help relieve symptoms associated with COVID-19, but it cannot cure the viral infection.\n\nParacetamol, also known as acetaminophen, is a medication commonly used for mild to moderate pain and aches relief, and fever reduction. Since some people infected with COVID-19 experience fever, body aches and headaches, this drug has been prescribed to relieve those symptoms. Paracetamol can provide some relief for patients with these symptoms, but it is not a cure against COVID-19.\n\nParacetamol made news headlines early in the pandemic because some governments, including the United Kingdom and France, and the World Health Organization encouraged people with COVID-19 to take paracetamol rather than ibuprofen – another drug used to help manage symptoms like fever, headache, or body aches. At the time, there were concerns about a link between ibuprofen and other drugs that could be prescribed to COVID-19 patients (such as non-steroidal anti-inflammatory (NSAID) drugs) that could lead to an increased risk for illness or for worsening of COVID-19 symptoms. As the pandemic evolved, the WHO changed their stance on March 19 2020 to say that they do not recommend avoiding ibuprofen to treat COVID-19 symptoms. \n\nWhile paracetamol is routinely used to relieve COVID-19 symptoms, it is important to strictly respect the dosage prescribed as stated on the medication bottle. The dosage of paracetamol for adults is 1-2 500 milligram tablets up to four times in 24 hours, with at least four hours in between doses. Any higher amount can be dangerous and is not advised.\n\n_This entry was updated with new information on August 4th, 2020_\n",
    "Glossary Terms": [
      "receyjml9aL7IhxLF",
      "recPAEAye3sSSqXlO",
      "recXz921OJNShe4qm"
    ],
    "Other resources": "1. PubChem: Acetaminophen ([NLM](https://pubchem.ncbi.nlm.nih.gov/compound/acetaminophen))\n2. Acetaminophen, In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, 2016 ([NIDDKD](https://www.ncbi.nlm.nih.gov/books/NBK548162/))\n3. Commission on Human Medicines advice on ibuprofen and coronavirus (COVID-19), 2020 ([UK Government](https://www.gov.uk/government/news/commission-on-human-medicines-advice-on-ibuprofen-and-coronavirus-covid-19))\n4. Tweet from Olivier Véran, Health Minister of France, on March 14, 2020 ([Twitter](https://twitter.com/olivierveran/status/1238776545398923264))\n5. Tweet from the WHO, on March 18, 2020 ([Twitter](https://twitter.com/WHO/status/1240409217997189128))\n6. Drugs by Name, Generic and Brand: Acetaminophen ([Merck Manual Professional Version](https://www.merckmanuals.com/professional/resources/brand-names-of-some-commonly-used-drugs))\n7. Dolo 650 ([Practo](https://www.practo.com/medicine-info/dolo-650-mg-tablet-3663))\n",
    "DB (Hindi)": [
      "recpXuDHbtA8QgYvB"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recnJy4jUPP4pFUhh"
    ],
    "DB (Portuguese)": [
      "recYK9WxSJY0xnyhR"
    ],
    "Rollup test 2": [
      "recSsXxLJSuVuBcao"
    ],
    "Last modified manual": "2020-08-05",
    "Last edited (simplified)": "2020-08-05T01:16:32.000Z",
    "Last edited (experts say)": "2020-08-05T01:16:32.000Z",
    "Last modified": "2020-08-05",
    "What our experts say wordcount": 264,
    "Background and context wordcount": 313,
    "Other resources wordcount": 66,
    "Wordcount": 643,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "पैरासिटामोल (जिसे एसिटामिनोफेन, टाइलेनॉल, डोलो 650 के रूप में भी जाना जाता है) कोविड-19 से जुड़े लक्षणों से राहत देने में मदद कर सकता है, लेकिन यह वायरल संक्रमण को ठीक नहीं कर सकता है।\n\nपेरासिटामोल, जिसे एसिटामिनोफेन के रूप में भी जाना जाता है, आमतौर पर हल्के से मध्यम दर्द और दर्द से राहत पाने और बुखार कम करने के लिए इस्तेमाल की जाने वाली दवा है। चूंकि कुछ लोग कोविड-19 अनुभव बुखार, शरीर में दर्द और सिरदर्द से संक्रमित हैं, इसलिए इस दवा को उन लक्षणों से राहत देने के लिए निर्धारित किया गया है। पेरासिटामोल इन लक्षणों वाले रोगियों के लिए कुछ राहत प्रदान कर सकता है, लेकिन यह कोविड-19 के खिलाफ इलाज नहीं है।\n\nपेरासिटामोल ने महामारी के कारण जल्दी सुर्खियां बटोरीं क्योंकि यूनाइटेड किंगडम और फ्रांस सहित कुछ सरकारों और विश्व स्वास्थ्य संगठन ने कोविड-19 के साथ लोगों को इबुप्रोफेन के बजाय पैरासिटामोल लेने के लिए प्रोत्साहित किया - बुखार, सिरदर्द, या जैसे लक्षणों को प्रबंधित करने में मदद करने के लिए इस्तेमाल किया जाने वाला एक और प्रयोग शरीर मैं दर्द। उस समय, इबुप्रोफेन और अन्य दवाओं के बीच एक लिंक के बारे में चिंताएं थीं जो कोविड-19 रोगियों (जैसे कि गैर-स्टेरायडल एंटी-इंफ्लेमेटरी (एनएसएआईडी) ड्रग्स) के लिए निर्धारित की जा सकती हैं, जो बीमारी या खराब होने का खतरा बढ़ सकता है। कोविड-19 के लक्षण। जैसे ही महामारी विकसित हुई, डब्ल्यूएचओ ने 19 मार्च 2020 को यह कहते हुए अपना रुख बदल लिया कि वे कोविड-19 लक्षणों के इलाज के लिए इबुप्रोफेन से बचने की सलाह नहीं देते हैं।\n\nजबकि पैरासिटामोल को नियमित रूप से कोविड-19 लक्षणों से राहत देने के लिए उपयोग किया जाता है, दवा की बोतल पर बताई गई खुराक का सख्ती से सम्मान करना महत्वपूर्ण है। वयस्कों के लिए पेरासिटामोल की खुराक 24 घंटे में 1-2 500 मिलीग्राम की गोलियां हैं, खुराक के बीच कम से कम चार घंटे। कोई भी उच्च राशि खतरनाक हो सकती है और इसकी सलाह नहीं दी जाती है।\n\nयह प्रविष्टि 4 अगस्त, 2020 को नई जानकारी के साथ अपडेट की गई थी"
    ],
    "Hindi - Background and context": [
      "पेरासिटामोल एक एनाल्जेसिक (दर्द निवारक) है जो दर्द, दर्द और बुखार के मामूली मामलों को संबोधित कर सकता है; पेरासिटामोल के अन्य सामान्य नाम एसिटामिनोफेन, टाइलेनॉल और डोलो 650 हैं। एसिटामिनोफेन को अक्सर इबुप्रोफेन के साथ भ्रमित किया जाता है, एक अन्य दर्द निवारक जिसे आमतौर पर एडविल कहा जाता है, जो इबुप्रोफेन के वाणिज्यिक ब्रांडों में से एक है। दोनों के बीच मुख्य अंतर यह है कि इबुप्रोफेन में विरोधी भड़काऊ प्रभाव होता है, जिससे यह एक गैर-स्टेरायडल विरोधी भड़काऊ दवा (एनएसएआईडी) होता है जबकि एसिटामिनोफेन नहीं करता है, और इसलिए इसे एनएसएआईडी नहीं माना जाता है।\n\nफ्रांस के एकजुटता और स्वास्थ्य मंत्री द्वारा मार्च के मध्य में किए गए एक ट्वीट के बाद कोविड-19 के संदर्भ में दोनों के बीच भ्रम की स्थिति समाप्त हो गई थी, जिसमें दावा किया गया था कि विरोधी भड़काऊ दवाएं (जैसे एडवील) एक कोविड-19 संक्रमण को खराब करने में योगदान कर सकती हैं , और वह एसिटामिनोफेन (जैसे टायलेनोल) इसके बजाय लिया जाना चाहिए। डब्ल्यूएचओ ने शुरू में एक समान स्थिति ली थी, जिसमें सिफारिश की गई थी कि कोविड-19 के लक्षणों के उपचार के लिए इबुप्रोफेन से बचा जाए, लेकिन 19 मार्च को अपना रुख बदलकर कहा कि वे \nकोविड-19 लक्षणों के इलाज के लिए इबुप्रोफेन से बचने की सलाह नहीं देते हैं। हालांकि इस बात के कोई पुख्ता सबूत नहीं हैं कि इबुप्रोफेन \nकोविड-19 लक्षणों को खराब करता है, कुछ सार्वजनिक स्वास्थ्य निकाय जैसे कि यु.के की राष्ट्रीय स्वास्थ्य सेवा केवल कोविड-19 लक्षणों के लिए एसिटामिनोफेन लेने की सलाह देती है। \n\nयूएस नेशनल इंस्टीट्यूट ऑफ डायबिटीज एंड डाइजेस्टिव एंड किडनी रोगों के अनुसार, वयस्कों के लिए दैनिक अधिकतम मौखिक खुराक प्रति दिन 3 ग्राम है, हालांकि अन्य स्रोतों (मर्क मैनुअल सहित) का सुझाव है कि प्रति दिन 4 ग्राम तक आम तौर पर स्वस्थ वयस्कों में अच्छी तरह से सहन किया जाता है । पेरासिटामोल उच्च मात्रा में जिगर के लिए विषाक्त हो सकता है या जब शराब, कुछ अन्य दवाओं के साथ संयोजन में या मौजूदा जिगर या गुर्दे की समस्याओं वाले रोगियों के लिए उपयोग किया जाता है, जो कुपोषित या कम वजन वाले, या उन्नत उम्र के हैं। यह या किसी भी काउंटर दवाओं पर लेने पर पैकेजिंग निर्देशों का सावधानीपूर्वक पालन करना महत्वपूर्ण है, और अतिरिक्त, व्यक्तिगत मार्गदर्शन के लिए एक चिकित्सा पेशेवर से परामर्श किया जाना चाहिए।\n\nयह प्रविष्टि 4 अगस्त, 2020 को नई जानकारी के साथ अपडेट की गई थी"
    ]
  },
  {
    "id": "recxbPxkhx1NeoE5Q",
    "Question": "What do we know about antihistamines, including cetirizine, as a treatment for COVID-19? ",
    "Status": "Published",
    "Category": "Treatment",
    "Subcategory": "On: COVID-19 & antihistamines",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "India"
    ],
    "Background and context": "While there are no current medications or treatments that prevent or treat COVID-19, many medications, including antihistamines, are being evaluated as possible treatments. Antihistamines are medications that are often available without a prescription and may be used to treat allergies (including runny nose, hives, itchy eyes) as well as insect bites, motion sickness, and insomnia.\n\nHistamines are released in the body when there is something harmful (like an infection or an allergen—something that someone has an allergy to), and histamines cause allergy symptoms like runny nose, itchy eyes, sneezing, and rashes. Histamines can also cause swelling of blood vessels and skin. Antihistamines block the histamine reaction and decrease these symptoms or, in some cases, make the symptoms go away entirely. Similarly, in the case of COVID-19, scientists are studying whether or not antihistamines may improve some of the COVID-19 symptoms. Using antihistamines to treat symptoms of COVID-19 is an example of repurposing medications.\n\nWhile developing a new medication may be possible for some new illnesses, sometimes existing medications are evaluated as treatments for new illnesses. By repurposing medications, the side effects are already understood so gaining approval may be faster than with new medicines.\n",
    "What our experts say": "Antihistamines are medications people can purchase over the counter without a prescription to help improve their allergy symptoms. They are among the many medications being researched as potential treatment options for COVID-19. Few studies about the efficacy of antihistamines as a treatment for COVID-19 are complete, and there is no evidence that supports the theory that antihistamines are an effective treatment for the virus. Current research is investigating whether some antihistamine medications like cloperastine, clemastine, and Azelastine can help improve symptoms or shorten the duration of COVID-19 infections, but early research has only identified these potential medications in laboratories. That means that they have not completed testing these medications in humans, so we don't know if they have any impact.\n\nCetirizine (an antihistamine medication also known as Zyrtec) is currently being studied with famotidine (an antihistamine and antacid medication) to see whether it can be effective in treating COVID-19, particularly in patients with very aggressive immune system responses. An early study in a pre-print journal that has not been reviewed by experts or published yet, found promising results for helping ease symptoms in hospitalized patients. The study did not have a control group to compare these patients to (which is generally part of published studies on medication) and had a small population size. Overall, there has yet to be evidence that antihistamines —including certirizine—can treat COVID-19.\n",
    "Glossary Terms": [
      "recyDl5hl7B0CHQ7p",
      "recRog4Fq88ayf62O",
      "rec8sQHhdcKiEVR9f",
      "recGHxIuCjv6JSpOl",
      "recpDS35Y5vAuQ7Oa",
      "recXugVJFvUHIcWsH"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "antihistamine",
      "certrizine",
      "treatment"
    ],
    "Other resources": "1. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing ([Nature](https://www.nature.com/articles/s41586-020-2286-9)) \n2. CEBINA Identifies a Common Antihistamine Nasal Spray as a Potential Anti-COVID-19 Approach ([Cision](https://www.prnewswire.com/news-releases/cebina-identifies-a-common-antihistamine-nasal-spray-as-a-potential-anti-covid-19-approach-301090185.html)) \n3. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines ([JGG](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128649/)) \n4. Mast cell stabilisers, leukotriene antagonists and antihistamines: A rapid review of the evidence for their use in COVID-19 ([CEBM](https://www.cebm.net/covid-19/mast-cell-stabilisers-leukotriene-antagonists-and-antihistamines-a-rapid-review-of-effectiveness-in-covid-19/)) \n5. Dual-Histamine Blockade with Cetirizine - Famotidine Reduces Pulmonary Symptoms in COVID-19 Patients ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.06.30.20137752v1)) \n6. New COVID-19 clinical trial will utilize combination of two historically safe drugs ([WLOX](https://www.wlox.com/2020/06/09/new-covid-clinical-trial-will-utilize-combination-two-historically-safe-drugs/)) \n7. Drug Repositioning, 2017 ([Innovative Approaches in Drug Discovery](https://www.sciencedirect.com/topics/medicine-and-dentistry/drug-repositioning))\n8. Antihistamines, 2020 ([NHS](https://www.nhs.uk/conditions/antihistamines/))\n\n",
    "Rollup test 2": [
      "rec6gWteUgpHFXM1u"
    ],
    "Last modified manual": "2020-08-05",
    "Last edited (simplified)": "2020-08-05T01:16:07.000Z",
    "Last edited (experts say)": "2020-08-05T01:16:07.000Z",
    "Last modified": "2020-08-05",
    "What our experts say wordcount": 223,
    "Background and context wordcount": 192,
    "Other resources wordcount": 99,
    "Wordcount": 514
  },
  {
    "id": "recoBlZAo2m2bZ8EX",
    "Question": "Can gasoline and/or diesel be used to disinfect masks, surfaces, or even skin? What are potential dangers, if any, in doing so?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & gasoline/diesel",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "Philippines"
    ],
    "Background and context": "While no health organizations have recommended the use of gasoline and/or diesel as a disinfectant, President Rodrigo Duterte of the Philippines has publicly said that people who cannot afford disinfects can use gasoline to clean masks and surfaces, during two separate televised briefings. While a representative then suggested that the initial comment was a joke, President Duterte made the same recommendation again and claimed he was not joking. Within a few hours of his statement, Integrated Chemists of the Philippines and national health groups responded, warning that the use of gasoline as a disinfectant does not protect against the virus that causes COVID-19 and can be harmful to human health (such as by leading to chemical irritation and bodily damage, increasing the risk of burns, etc.). People without access to commercial disinfectants can clean fabric masks, surfaces and skin by washing thoroughly with soap and water, followed by air-drying.\n",
    "What our experts say": "No. Gasoline and/or diesel should not be used as a disinfectant, does not work as a disinfectant, has not been shown to kill the virus that causes COVID-19, and may be very harmful to human health.\n\nAccording to the U.S. National Institute for Occupational Safety and Health, gasoline exposure through the skin or eyes, drinking, or breathing can cause many health problems including the following:\n·      Irritation or burns of the eyes, skin, or mucous membranes (i.e. the tissues in the nose, eyes, mouth, throat)\n·      Headache, weakness, blurred vision, dizziness, slurred speech, confusion, convulsions\n·      Chemical pneumonitis (when liquid gasoline is inhaled into the lungs and causes damage)\n·      Possible liver or kidney damage\n·      Long-term exposure may cause cancer\n·      Gasoline is flammable and improper storage / use can lead to fires and burn injuries\n\nGasoline exposure should be avoided and, if accidental exposure does happen, washing the exposed area is important. When exposed to gas fumes, it is important to leave the area where the fumes are to an area with fresh air or ventilation. Seek medical help for breathing problems as well as slurred speech, dizziness, confusion, or other symptoms of neurological (brain and nervous system) problems. \n",
    "Glossary Terms": [
      "recjGuHkvGujLMjV7",
      "rec4crPh6OQvCngsk"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "disinfectants"
    ],
    "Other resources": "1. Gasoline, 2019 ([U.S. CDC NIOSH](https://www.cdc.gov/niosh/npg/npgd0299.html))\n2. Philippines' Duterte advises disinfecting face masks with gasoline, diesel, July 21, 2020 ([Newsweek](https://www.newsweek.com/philippines-rodrigo-duterte-people-disinfect-face-masks-gasoline-diesel-1519329))\n3. Chemists warn against use of gasoline as disinfectant after Duterte remark , July 31, 2020 ([CNN](https://www.cnnphilippines.com/news/2020/7/31/Chemists-warn-against-gasoline-use-as-disinfectant-.html))\n4. Rodrigo Duterte: 'I'm not joking - clean masks with petrol' ([BBC](https://www.bbc.com/news/world-asia-53605108))\n",
    "Media": [
      {
        "id": "attmbhptd93aP6Dfb",
        "url": "https://dl.airtable.com/.attachments/2aadfe7608d3c35836a0a784695e4298/e1ff3f87/Slide_1",
        "filename": "Slide_1",
        "size": 99897,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/92208e914c62deeefab70af9da687438/f3aeb08f",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d26e54c1b171e04ed9ddab189399a029/27145dbe",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/6ff896feb5f7ad86e8250399992bc09b/17f9ebc1",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attZyWWqEvUgEAimD",
        "url": "https://dl.airtable.com/.attachments/e250a2a888e3427fd820d978e999dd4b/1cf4c066/Slide_2",
        "filename": "Slide_2",
        "size": 119870,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/2a4907d854677c899a743a5c54cf23d6/cdadfbba",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/a5f1d1018d78448aae2eae7723142989/b8af8c13",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/08ad6521618cad5b38dff38079c28a25/bf76ddae",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att0ImxUkKd7epcfz",
        "url": "https://dl.airtable.com/.attachments/fd90e942d2cfa909786001a248d4d6c5/ec8e26d9/Slide_3",
        "filename": "Slide_3",
        "size": 107375,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/5391276c4dba4eb3ef7b9595050674ad/6c29c938",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/75cbb6e1baffc8e2cc0e8fda086d294f/f875429d",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/6d68e2a97b49235e0a99f0b24252f147/26ca01e8",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attoPQMFXEiL9bFas",
        "url": "https://dl.airtable.com/.attachments/3f8e40123021de260e5241b6f47d7e69/aad65ad5/Slide_4",
        "filename": "Slide_4",
        "size": 85555,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b7d3a47d8cdded8c6da82cc56b1a6a57/e344bff1",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/5cffb2c431b36c75d2fd732fd754df4e/2c36ec10",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/cd3ef29006dc1d5099c291689938afa2/8d32280b",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "Rollup test 2": [
      "recDg4kptSdANFOqN"
    ],
    "Last modified manual": "2020-08-05",
    "Last edited (simplified)": "2020-08-04T03:57:07.000Z",
    "Last edited (experts say)": "2020-09-15T04:24:51.000Z",
    "Last modified": "2020-09-15",
    "What our experts say wordcount": 187,
    "Background and context wordcount": 149,
    "Other resources wordcount": 46,
    "Wordcount": 382
  },
  {
    "id": "reci5KRmNIo5UfFt5",
    "Question": "What are human challenge trials for vaccines?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & vaccines",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "In a human challenge trial, a volunteer receives a potential vaccine and then the volunteer is intentionally exposed to the virus to see if the vaccine works. Human challenge trials are sometimes used to test vaccines for illnesses that have a known cure (like malaria and cholera), but there are ethical problems in performing a human challenge trial for COVID-19. With COVID-19, there is a risk that someone could become seriously ill or even die from an infection since there is not a known cure.\nKnowing that human challenge trials may be needed, and as treatments and vaccines are developed for COVID-19, the World Health Organization (WHO) issued guidance to scientists, doctors, ethicists, and researchers in May 2020. The WHO document provides an overview of the ethics involved, reviews why the studies are being considered, and lists eight criteria for studies to meet for possible consideration. The criteria are designed to ensure that there is adequate scientific justification, that risks and benefits have been carefully considered, that studies are performed with consultation and coordination among members of the public as well as experts and policy-makers, and that study sites are equipped to conduct research to meet the highest clinical and ethical standards, and to ensure that participants are selected to minimize risk.\nHuman challenge trials take many months to plan and, in the setting of a global pandemic, many experts argue that there is no time to waste in planning for these trials to begin. In an open letter to the U.S. National Institutes of Health, 15 Nobel Laureates and over 100 top scientists and researchers encouraged preparation for human challenge trials for COVID-19 vaccines. The letter was organized by an advocacy group that has collected human challenge trial volunteer signatures from more than 30,000 people in over 140 countries.\n",
    "What our experts say": "A human challenge trial (HCT) is a study that deliberately infects volunteers with a virus after they've been given a vaccine, in order to see if the vaccine is effective. HCTs are designed to do this by taking a group of healthy volunteers in which researchers give half of the group a vaccine for a specific illness, and the other half a placebo (a fake drug they think is a real vaccine). Next, the researchers purposely expose the entire group to the real virus in a laboratory at a high enough dosage for them all to become infected. After being exposed to the virus, if the group that was given the vaccine does not become sick and the other group does fall ill, it means the vaccine is effective. The HCT process also allows researchers to see if any side effects might occur after volunteers are given the vaccine, which is an important part of studying vaccines.\n\nHCTs are different than more traditional vaccine trials, which give half of a group of healthy volunteers a vaccine for a specific illness and the other half of the group a placebo, in order to see how bodies respond when they are exposed to the virus in their day-to-day lives, outside of the laboratory. In comparison to these other types of vaccine trials, one potential benefit of HCTs is how quickly all the volunteers are exposed to the virus, so researchers might know more rapidly whether or not their vaccine is effective. Other benefits of HCTs include the fact that HCTs are done in settings where researchers can control the amount of time that passes, who gets to participate in the trial, and how volunteers are exposed to the virus, and they can also involve a smaller number of participants than other medication studies. Comparatively, the way HCTs are designed means they are not able to resemble how people get infected by viruses in the real world, outside of labs, and the amount of people involved in the trials might be much smaller than would participate in more traditional trials.\n\nHCTs are controversial and have caused debates about the ethics of infecting healthy volunteers with a virus that doesn't have a cure and can ultimately cause death. Though HCTs have studied medications for illnesses like typhoid, cholera, and malaria, those diseases all had proven medical treatments that could stop disease progression if the vaccine did not work. In the case of COVID-19, few treatment options exist so the amount of risk involved — even in healthy, young, willing volunteers — might be too great for researchers to take on.\n",
    "Glossary Terms": [
      "rec5P1moAv3DjPkbT",
      "rec9qqItwSTjq3Eae"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "vaccine",
      "human challenge trial",
      "clinical trial"
    ],
    "Other resources": "1. Key criteria for the ethical acceptability of COVID-19 human challenge studies, 2020 ([WHO](https://apps.who.int/iris/bitstream/handle/10665/331976/WHO-2019-nCoV-Ethics_criteria-2020.1-eng.pdf?ua=1))\n2. Controversial 'human challenge' trials for COVID-19 vaccines gain support, 2020 ([Science](https://www.sciencemag.org/news/2020/07/controversial-human-challenge-trials-covid-19-vaccines-gain-support))\n3. Challenge Trials for COVID-19 (open letter), 2020 ([1DaySooner](https://1daysooner.org/openletter))\n4. Evaluating use cases for human challenge trials in accelerating SARA-CoV-2 vaccine development, 2020 ([Cli Inf Dis](https://watermark.silverchair.com/ciaa935.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAArEwggKtBgkqhkiG9w0BBwagggKeMIICmgIBADCCApMGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM7Sd-8jN8ySebCgPwAgEQgIICZLeGIC4SyJa87KkDGVW68MWu1TKYeJS5tNLhT-rfz4k8PUmDSUIIZoEMpQCW3ZoJ2U51HHWr2G1rHHvHr6qV9jQjchi0qscD6eY2rhoN84aozKulCGTOEz0adrJGQUkTHlHc2HVdRs5wzge99zp2PR4zlVrBjIhYpSjvr4pQZCA0q-iW2IRiMPtLRr1cp5YqVemLT3BKOW2osSm8O647NzWVJ5hQRBKgZCKjcRlLUWTPgefTFMTVnfoGqK7lARsgTdn_m5baTVs-U45uxX1gYvuT153fC-TbxY-n-t_OGBPxrEj2B38cT-m6xaZZXaUJA_vATdyFM4nCYRiWMmwr11atH5ieewLbb-TTkzBu8FU97OM_CM06lsY8ywkx_zUC7nLj98EfxITqWodbB2RLQ-tJsf1tCLr0Zp_11x6O3WOU6-eCJIuIcmc8PoYH7iLePaCV8z7K_C7xKuiqG7BXzxS05xHDbol8CC-H2n1zY32cNq1i2gqHSDHmNn_BII6t65Y-r3Z-tbs66tACPLKs-qVFvcz9r151Ytub6pdnhQig_qjJ_CUUNPLErMz-192b5k7mPImV-tCiwi8wuxphjwLWgZ2AVPEp57x0YcWNR78dVOUQOGJCl1gnirh6CtxQKlC0ktMpci2n6uXzhTv89_pLXZzRsRVPvVEIZ0j9IIGxzJNG1NBkI6trCglQUDdn1nIoHxgsjivq8VKIUsppKSW-T4-0K7NIcQvwalC9CJBKDM2-sZsqYsMJjGV5fdDzOzCFuGxi-loR6TAhNqAexULkhzOUZXGeI8eJBRB_kJAPUa48vw))\n5. Human Challenge Trials for Vaccine Development: regulatory considerations ([WHO](https://www.who.int/biologicals/expert_committee/Human_challenge_Trials_IK_final.pdf)) \n6. COVID-19 human challenge studies: ethical issues ([The Lancet](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30438-2/fulltext)) \n7. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure ([JID](https://academic.oup.com/jid/article/221/11/1752/5814216)) \n",
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recHuX6zhDSixVpoF"
    ],
    "DB (Portuguese)": [
      "recivyYNfx1eFD3of"
    ],
    "Rollup test 2": [
      "recLBFdvmV1eCD23v"
    ],
    "Last modified manual": "2020-08-05",
    "Last edited (simplified)": "2020-07-22T15:42:33.000Z",
    "Last edited (experts say)": "2020-08-05T00:35:28.000Z",
    "Last modified": "2020-08-05",
    "What our experts say wordcount": 434,
    "Background and context wordcount": 298,
    "Other resources wordcount": 78,
    "Wordcount": 810
  },
  {
    "id": "recFVXMaBAvxqjNgj",
    "Question": "In scientific terms, is it absolutely safe to say that \"bald men are more likely to have COVID-19?\" ",
    "Status": "Published",
    "Category": "Risk",
    "Subcategory": "On: COVID-19 and bald men",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "Senegal"
    ],
    "Background and context": "Recent international studies and headlines have focused on the possible link between male pattern baldness (androgenetic alopecia) and the likelihood of becoming infected with the virus that causes COVID-19. The research behind this news was on adults hospitalized in Spain with COVID-19, which found that a higher percentage of the sick men had some kind of hair loss or baldness, in comparison to the percentage of the general population experiencing hair loss. The findings were misreported in the news as \"bald men are more likely to have COVID-19,\" but it is important to take into account how there were issues in the research mentioned above and also how certain people who are at higher risk of severe COVID-19 (men, older people) are also more likely to have hair loss.\n\nIn related research, scientists have been trying to understand why men are more likely to have severe cases of COVID-19 than women, by considering the impact of androgen (a hormone that is an important part of male sexual development from before birth and through puberty, which is also linked to sex drive and hair growth). However, there has been no evidence to support this claim about baldness, and other research studies focusing on androgens** **are still underway.\n",
    "What our experts say": "No, it is not safe to say in scientific terms that bald men are more likely to have COVID-19. In May 2020, a research study was widely reported in news headlines, which suggested male pattern baldness (androgenetic alopecia) could mean higher risks for severe COVID-19 symptoms. However, this is not exactly what the researchers found. The authors of this publication also acknowledged there were research limitations meaning their results cannot be generalized to a larger population and further studies are needed. \n\nPublished in the Journal of the American Academy of Dermatology (JAAD), the researchers wrote that out of 122 men and 53 women admitted with COVID-19 to hospitals in Madrid, Spain, they found 79% of the male patients had some hair loss or baldness (alopecia) while estimating the prevalence of baldness in the general population is only 31%-53%. However, the researchers acknowledged limitations of their findings, including how only 175 people were studied (in research terminology, this is considered a** **small sample size that limits how findings can be generalized to a larger population). They also acknowledged that patients in the study were all admitted to a hospital with COVID-19, meaning there was no comparison group (control group) of participants without COVID-19 to compare the findings against the general population. \n\nAdditionally, the research did not include information about patient outcomes (such as how the patients fared after they were admitted to the hospital), so it was not possible for researchers to compare outcomes for patients with and without baldness. In general, many researchers and doctors have cautioned that older people and men are more likely to have severe cases of COVID-19 requiring hospitalization, and older men are also more likely to be bald. For these reasons, \"bald men are more likely to have COVID-19\" is an incorrect interpretation of the published research.\n",
    "Glossary Terms": [
      "recT7R7Qqg8v9f9Ui",
      "rec8sQHhdcKiEVR9f",
      "recAqLjAwXsBpjGCu"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "bald ",
      "men"
    ],
    "Other resources": "1. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign” ([Journal of the American Academy of Dermatology](https://www.jaad.org/article/S0190-9622(20)30948-8/fulltext))\n2. The Week That Wasn't in COVID-19: Bald Men at Risk ([Medscape](https://www.medscape.com/viewarticle/932667))\n3. Androgenetic alopecia ([NIH](https://ghr.nlm.nih.gov/condition/androgenetic-alopecia#genes))\n",
    "Rollup test 2": [
      "recbLovW1Jiv9Zc6h"
    ],
    "Last modified manual": "2020-08-04",
    "Last edited (simplified)": "2020-08-04T16:58:05.000Z",
    "Last edited (experts say)": "2020-08-04T16:58:05.000Z",
    "Last modified": "2020-08-04",
    "What our experts say wordcount": 300,
    "Background and context wordcount": 204,
    "Other resources wordcount": 36,
    "Wordcount": 540
  },
  {
    "id": "recjmxNuHf9q8gjRL",
    "Question": "Is hydroxychloroquine the same as chloroquine?",
    "Status": "Published",
    "Category": "Prevention, Treatment",
    "Subcategory": "On: COVID-19 & hydroxychloroquine",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "Nigeria"
    ],
    "Background and context": "Many medications are sometimes considered as a treatment for illnesses that are different than those for which they were originally created (also called repurposing medications).  Research studies are trying to see if any existing medication might help treat COVID-19, including hydroxychloroquine and chloroquine. Recently, both these medications have been in the news due to several national leaders and various groups claiming that these medications can prevent, treat and even cure COVID-19. The research around hydroxychloroquine and choloroquine to date has shown no efficacy of these medications against COVID-19. This is based on randomized controlled trials (the most scientifically strong and valued type of research trials). More studies are underway to learn more about the potential impact of these drugs on COVID-19. As of now, both medicines are not proven nor approved treatments for the coronavirus.\n",
    "What our experts say": "Chloroquine is a medication that is taken to prevent or treat malaria, which is transmitted by mosquitoes bites. It's also used to treat some intestinal infections. On the other hand, hydroxychloroquine is a medication that is also taken to prevent and treat malaria, but it can also treat other diseases such as rheumatoid arthritis or lupus. Both of these medications are antimalarials, but hydroxychloroquine is a newer, slightly altered version of chloroquine that has fewer side effects and dissolves more easily in the body, so it is often considered a safer medication for patients to take. \n\nDespite recent media coverage of the COVID-19 pandemic, neither chloroquine nor hydroxychloroquine are approved treatments against COVID-19. Several research studies conducted around the world have demonstrated that hydroxychloroquine is likely not effective against COVID-19. \n",
    "Glossary Terms": [
      "recu5YfEJQ2XosauF",
      "recqai3lgF0QruekU",
      "recXugVJFvUHIcWsH"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "hydroxychloroquine",
      "chloroquine",
      "repurposed"
    ],
    "Other resources": "1. Medicines for the Prevention of Malaria While Traveling Chloroquine (Aralen™) ([U.S. CDC](https://www.cdc.gov/malaria/resources/pdf/fsp/drugs/chloroquine.pdf?fbclid=IwAR1FttRx4euZelSnCgUcaN0Nl137a086ZNtQxcttqy5VNEJI6ivwB51oTUA)) \n2. Medicines for the Prevention of Malaria While Traveling Hydroxychloroquine (Plaquenil™) ([U.S. CDC](https://www.cdc.gov/malaria/resources/pdf/fsp/drugs/Hydroxychloroquine.pdf?fbclid=IwAR1lVp5ucnLK9g_crh1lro-BHlgFiqXT7sOP30lNVtTLvWCxZT5dcbB4MuM)) \n3. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro ([Nature](https://www.nature.com/articles/s41421-020-0156-0)) \n4. Don’t Fall for This Video: Hydroxychloroquine Is Not a COVID-19 Cure ([KHN](https://khn.org/news/dont-fall-for-this-video-hydroxychloroquine-is-not-a-covid-19-cure/)) \n",
    "Rollup test 2": [
      "recmz6cprdsWhgqui"
    ],
    "Last modified manual": "2020-08-04",
    "Last edited (simplified)": "2020-08-04T04:53:34.000Z",
    "Last edited (experts say)": "2020-08-04T04:53:34.000Z",
    "Last modified": "2020-08-04",
    "What our experts say wordcount": 130,
    "Background and context wordcount": 136,
    "Other resources wordcount": 57,
    "Wordcount": 323
  },
  {
    "id": "recXUQjiQ2yaPXyxo",
    "Question": "What do we know so far about airborne transmission and how does it differ from respiratory droplet transmission? ",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "Differences between airborne transmission and respiratory droplets",
    "Background and context": "Respiratory droplet transmission happens when disease, in this case COVID-19, spreads through droplets expelled by an infected person, through coughing, sneezing, talking, or even just breathing; these droplets are larger than 5-10 micrometers. One micrometer is one millionth of a meter. Respiratory droplets are relatively heavy, and fall to the ground quickly. In contrast, airborne transmission is when residue from droplets smaller than 5 micrometers, or dust particles carrying the virus, stay suspended in the air for a while and travel as their air moves. Scientists and the World Health Organization (WHO) have recognized that evidence is emerging on the possibility of airborne transmission, particularly in crowded, closed, poorly ventilated settings. \n\nIf airborne transmission of COVID-19 is significant, this has major implications for containment efforts (ex. masks may be needed indoors and even in socially-distant settings, ventilation systems may need to minimize recirculating air and find ways to filter or disinfect contaminated air, etc.). \n\nThe US CDC has recently acknowledged well-documented evidence of airborne transmission of SARS-CoV-2 under circumstances of enclosed spaces, prolonged exposure to respiratory particles from an infectious person, or inadequate ventilation. \n",
    "What our experts say": "There is increasing evidence that COVID-19 can spread through airborne transmission, which is when a person infected with COVID-19 releases tiny droplets of fluid into the air called 'droplet nuclei' by coughing, sneezing, talking, or during some medical procedures. Droplet nuclei are very light, relatively dry, and microscopic in size so they can remain suspended in the air like a mist, which is why airborne transmission is also called 'aerosol transmission', and pose a risk of infection to people in close proximity or people sitting in areas that are poorly ventilated. This is different from the main theory that the virus spreads through bigger respiratory droplets that are heavier, fall to the ground relatively quickly, and do not remain suspended in the air or spread through the air. \n\nWhile researchers are still studying aerosol transmission, the World Health Organization (WHO) and the US CDC acknowledged emerging evidence regarding airborne transmission in poorly ventilated spaces. Enclosed spaces have been found to contain enough virus to cause infections in people more than six feet apart, or who passed through a space soon after an infectious person left the room. \n\nPublic health experts have repeatedly warned that airborne transmission is most likely contributing to transmission, especially in indoor spaces, and recommendations should incorporate the need for sufficient ventilation, high efficiency filtration, and limiting crowded spaces, in addition to universal adoption of masks, social distancing, and frequent hand washing with soap and water. New studies about previous outbreaks, such as the Diamond Princess cruise ship outbreak, found that the virus spread rapidly between passengers due to aerosol transmission through small droplets that were light enough to linger in the air. Yet another study found evidence of the novel coronavirus in the air from isolated individuals who had COVID-19. These studies highlight the importance of combining proper ventilation with cloth masks and social distancing to prevent transmission of the virus.\n",
    "Glossary Terms": [
      "recy3qWpegJbN2rbV",
      "recTotk6ZnYu3ib8P",
      "rech6tPR0hLDA3JH3",
      "rec5yviiSvJkufYvu"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No \n",
    "Topics": [
      "aerosol",
      "airborne",
      "transmission",
      "droplet",
      "respiratory droplets"
    ],
    "Other resources": "1. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations ([WHO](https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations))\n2. Open Letter: It is Time to Address Airborne Transmission of COVID-19 ([Clinical Infectious Diseases](https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa939/5867798))\n3. Aboard the Diamond Princess, a Case Study in Aerosol Transmission ([NYT](https://www.nytimes.com/2020/07/30/health/diamond-princess-coronavirus-aerosol.html))\n4. Mechanistic Transmission Modeling of COVID-19 on the Diamond Princess Cruise Ship Demonstrates the Importance of Aerosol Transmission ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.07.13.20153049v1))\n5. Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care ([Nature](https://www.nature.com/articles/s41598-020-69286-3))\n6. W.H.O. to Review Evidence of Airborne Transmission of Coronavirus ([NYT](https://www.nytimes.com/2020/07/07/health/coronavirus-aerosols-who.html))\n7. Mechanistic Transmission Modeling of COVID-19 on the Diamond Princess Cruise Ship Demonstrates the Importance of Aerosol Transmission ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.07.13.20153049v1))\n8. 239 Experts With One Big Claim: The Coronavirus Is Airborne ([NYT](https://www.nytimes.com/2020/07/04/health/239-experts-with-one-big-claim-the-coronavirus-is-airborne.html))\n9. Evidence for probable aerosol transmission of SARS-CoV-2 in a poorly ventilated restaurant ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.04.16.20067728v1))\n10. Scientists Urge WHO To Update Guidance On Airborne Transmission Of The Coronavirus ([NPR](https://www.npr.org/2020/07/06/887925721/scientists-urge-who-to-update-guidance-on-airborne-transmission-of-the-coronavir))\n11. Aerodynamic Characteristics and RNA Concentration of SARS-CoV-2 Aerosol in Wuhan Hospitals during COVID-19 Outbreak ([bioRxiv](https://www.biorxiv.org/content/10.1101/2020.03.08.982637v1))\n12. Coronavirus: WHO rethinking how Covid-19 spreads in air ([BBC](https://www.bbc.com/news/world-53329946))\n13. Transmission of SARS-CoV-2: implications for infection prevention precautions ([WHO](https://www.who.int/publications/i/item/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations)[) ](https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-sars-cov-2.html)\n14. SARS-CoV-2 & Potential Airborne Transmission ([US CDC)](https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-sars-cov-2.html)\n",
    "How often revision needed": "Weekly",
    "DB (Hindi)": [
      "recQsQedv6T3fLr8y"
    ],
    "Media": [
      {
        "id": "attOl7ELRWQ7ydV1K",
        "url": "https://dl.airtable.com/.attachments/8059990d8523d6d1a93c20e2f4d9762e/d6498516/Slide_1",
        "filename": "Slide_1",
        "size": 356084,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e7cb0e9db7cade85a4c15a2051e638e3/ab31271e",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/95940d1910a9788da1045a1ee85c29de/241b70a2",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/6f9c64ffe5c98da0e7c14ca94c5fdf1d/6b051071",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attOYOnFtFxS88Eal",
        "url": "https://dl.airtable.com/.attachments/d2ab7dac2fce093daa4490383a2fdf51/6d1a0f1d/Slide_2",
        "filename": "Slide_2",
        "size": 244795,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/712e12b7235ad0cec2cc111dcc9cf478/dba0a7f4",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/4404e48bf383131f443138211f317b46/80a25c7c",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d7aeffebebbfe4a120ac37f88139cd94/6e5d950d",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att7qY71spsF7dLNd",
        "url": "https://dl.airtable.com/.attachments/ec3071e9469ecd3d9904cd3ae316ba7d/dd8e64cc/Slide_3",
        "filename": "Slide_3",
        "size": 240322,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b490dffe0163d5f738bec54e6b689090/b61db64e",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d4c60811be49ea16098b4342043b1834/108a3843",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/646c4bf3ba1b6faea80f866b21130336/080fe032",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "atteEuKu2zAAzHkAV",
        "url": "https://dl.airtable.com/.attachments/74bca8eb1e7a32c9dbec7276424b599a/00b6cea0/Slide_4",
        "filename": "Slide_4",
        "size": 209706,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d8e44c19d2d97c78db8734586e94acf6/3781c235",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b8ba48ef224fc72844d673fe912f1926/10c42232",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b0595f522d85d98d317701b75faebed1/cf232113",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attDbix3ZZcazaunL",
        "url": "https://dl.airtable.com/.attachments/47b4096a80f67ed37a007a221dea25ef/da5dd58d/Slide_6",
        "filename": "Slide_6",
        "size": 241192,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/3cd9da129ef6ea2909a4c67d1512aa73/30c99389",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/95de5815f558913dd480a4082075a73a/046a2837",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/edde90f5fe4014de13ffa40c67d63b8a/4353ca3e",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attPnxG1Nr7vXhCq0",
        "url": "https://dl.airtable.com/.attachments/20fe7d37507993bcf19e723edd7c3933/d4619b57/Slide_5",
        "filename": "Slide_5",
        "size": 201928,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/7b056a5ff9a57660a1ae1266e6145bf7/95fa9663",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/1ffa30927ba3a11ffab382cee09e8aa1/76337492",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/11568dcbe8c64387769296220fab7a18/398c8faf",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "Questions answered by entry": "What do we know so far about airborne transmission? How does it differ from respiratory droplet transmission?\n",
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recGFBOwZNRw31Wk9"
    ],
    "DB (Portuguese)": [
      "rechGcGKXH0sbJAkJ"
    ],
    "Media Package": [
      {
        "id": "attdMjLTV2eg6KPNg",
        "url": "https://dl.airtable.com/.attachments/cf30e80fb9ddebb7ac6207fa89d87a1c/4d28a7e8/Airbornetransmission.zip",
        "filename": "Airborne transmission.zip",
        "size": 1427804,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-10-16",
    "Last edited (simplified)": "2020-10-16T19:41:11.000Z",
    "Last edited (experts say)": "2020-10-16T19:41:11.000Z",
    "Last modified": "2020-10-16",
    "What our experts say wordcount": 315,
    "Background and context wordcount": 185,
    "Other resources wordcount": 176,
    "Wordcount": 676,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "इस बात के प्रमाण बढ़ते जा रहे हैं कि कोविड-19 एयरबोर्न ट्रांसमिशन के माध्यम से फैल सकता है, जो तब होता है जब कोविड-19 से संक्रमित व्यक्ति खांसी, छींकने, बात करने या कुछ चिकित्सा प्रक्रियाओं के दौरान हवा में तरल पदार्थ की छोटी बूंदों को 'छोटी बूंद नाभिक' में छोड़ता है। बूंदे नाभिक आकार में बहुत हल्के, अपेक्षाकृत शुष्क और सूक्ष्म होते हैं, इसलिए वे धुंध की तरह हवा में निलंबित रह सकते हैं, यही कारण है कि एयरबोर्न ट्रांसमिशन को 'एरोसोल ट्रांसमिशन' भी कहा जाता है, और नजदीकी लोगों या लोगों को संक्रमण का खतरा पैदा करता है। ऐसे क्षेत्रों में बैठे लोग जो हवादार हैं। यह मुख्य सिद्धांत से अलग है कि वायरस बड़ी श्वसन बूंदों के माध्यम से फैलता है जो भारी होते हैं, अपेक्षाकृत जल्दी जमीन पर गिरते हैं, और हवा में निलंबित नहीं रहते हैं या हवा के माध्यम से नहीं फैलते हैं।\n\nशोधकर्ता अभी भी एयरोसोल ट्रांसमिशन का अध्ययन कर रहे हैं, लेकिन विश्व स्वास्थ्य संगठन (डब्ल्यूएचओ) ने खराब हवादार स्थानों में हवाई प्रसारण के बारे में उभरते सबूतों को स्वीकार किया। सार्वजनिक स्वास्थ्य विशेषज्ञों ने बार-बार चेतावनी दी है कि एयरबोर्न ट्रांसमिशन में संचरण में योगदान देने की सबसे अधिक संभावना है, विशेष रूप से इनडोर स्थानों में, और सिफारिशों में पर्याप्त वेंटिलेशन, उच्च दक्षता निस्पंदन, और भीड़ भरे स्थानों को सीमित करने, मास्क के सार्वभौमिक अपनाने के अलावा, सामाजिक दूरी को शामिल करना चाहिए, और साबुन और पानी से लगातार हाथ धोना। पिछले प्रकोपों ​​के बारे में नए अध्ययन, जैसे कि डायमंड प्रिंसेस क्रूज शिप का प्रकोप, ने पाया कि हवा में छोटी बूंदों के माध्यम से एरोसोल संचरण के कारण यात्रियों के बीच तेजी से फैलता है जो हवा में काफी हल्का था। फिर भी एक अन्य अध्ययन में कोविड-19 वाले अलग-अलग व्यक्तियों के हवा में उपन्यास कोरोनवायरस के प्रमाण मिले। ये अध्ययन वायरस के संचरण को रोकने के लिए कपड़े के मुखौटे और सामाजिक गड़बड़ी के साथ उचित वेंटिलेशन के संयोजन के महत्व को उजागर करते हैं।\n\nइस प्रविष्टि को 03 अगस्त, 2020 को नई जानकारी के साथ अद्यतन किया गया था।"
    ],
    "Hindi - Background and context": [
      "श्वसन की छोटी बूंद का संचरण तब होता है जब रोग, इस मामले में सीओवीआईडी ​​-19, संक्रमित व्यक्ति द्वारा खांसी, छींकने, बात करने या यहां तक ​​कि सिर्फ सांस लेने के माध्यम से निष्कासित बूंदों के माध्यम से फैलता है; ये बूंदें 5-10 माइक्रोमीटर से बड़ी होती हैं। एक माइक्रोमीटर एक मीटर का दसवां हिस्सा है। श्वसन की बूंदें अपेक्षाकृत भारी होती हैं, और जल्दी से जमीन पर गिर जाती हैं। इसके विपरीत, एयरबोर्न ट्रांसमिशन तब होता है जब 5 माइक्रोमीटर, या वायरस ले जाने वाले धूल कणों से छोटी बूंदों से अवशेष थोड़ी देर के लिए हवा में निलंबित रहते हैं और उनकी हवा चलती है। वैज्ञानिकों और विश्व स्वास्थ्य संगठन (डब्ल्यूएचओ) ने माना है कि सबूत हवाई प्रसारण की संभावना पर उभर रहे हैं, विशेष रूप से भीड़, बंद, खराब हवादार सेटिंग्स में। यदि कोविड-19 का एयरबोर्न ट्रांसमिशन महत्वपूर्ण है, तो इसमें रोकथाम के प्रयासों के लिए प्रमुख निहितार्थ हैं (पूर्व मास्क को घर के अंदर और यहां तक ​​कि सामाजिक-दूर की सेटिंग्स में भी हो सकता है, वेंटिलेशन सिस्टम को पुन: परिसंचारी हवा को कम करने और दूषित हवा को फिल्टर या कीटाणुरहित करने के तरीके खोजने की आवश्यकता हो सकती है। , आदि)।"
    ]
  },
  {
    "id": "recqFRWiE9Y6nbUM5",
    "Question": "What are the origins of the virus?",
    "Status": "Published",
    "Category": "Origin",
    "Subcategory": "On: The origin of COVID-19 ",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "India",
      "Kenya",
      "USA"
    ],
    "Background and context": "Coronaviruses are a group of viruses that can cause a variety of different illnesses, but primarily upper-respiratory tract illnesses in humans. These illnesses include the common cold, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Some viruses can originate in animals and later infect humans, and this can happen in a number of different ways, including: by eating meat or produce that has been contaminated by the virus, through the air or by touching a surface that was touched by an infected animal, through close contact with an infected animal, or through insect bites. Not all viruses transfer from animals to humans in all of these ways, it depends on the virus. The resources section contains more information about this. \n\n",
    "What our experts say": "COVID-19 was first detected in the city of Wuhan, China in late 2019. The virus has since been partially traced back to a large seafood and animal market in the city of Wuhan, after several people who had been to the market became sick with the illness we now know as COVID-19. Scientists were able to use genetic tests to confirm that the virus was first identified in people in the city of Wuhan. Tests on the genetics of viruses, much like genetics in humans, can reveal a lot about their origins. \nThe majority of scientific studies now support the idea that the origin of the virus in animals was bats, specifically horseshoe bats, potentially from China or neighboring countries of Myanmar, Laos and Vietnam. Scientists also suggest that the virus may have been passed to humans through an intermediate host before spreading to humans, but are unsure about what animal the host might have been, though pangolins and civets have been suggested. The details about that event, which is called a zoonotic transfer, are still being investigated. World Health Organization experts will soon travel to China and work with Chinese health officials to identify the source of the virus.\n\n_This entry was updated with new information on July 16, 2020_\n",
    "Glossary Terms": [
      "recbQ95pvRq7nP9s3",
      "recFSOdDjQBqJHnZ9"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "origin",
      "bats",
      "Wuhan",
      "China"
    ],
    "Other resources": "1. Viral and host factors related to the clinical outcome of COVID-19 ([Nature](https://www.nature.com/articles/s41586-020-2355-0))\n2. Genomic Study Points to Natural Origin of COVID-19 ([NIH](https://directorsblog.nih.gov/2020/03/26/genomic-research-points-to-natural-origin-of-covid-19/)) \n3. Zoonotic diseases ([U.S. CDC](https://www.cdc.gov/onehealth/basics/zoonotic-diseases.html)) \n4. Update and Interim Guidance on Outbreak of 2019 Novel Coronavirus (2019-nCoV) in Wuhan, China ([U.S. CDC](https://emergency.cdc.gov/han/han00426.asp)) \n5. Coronavirus Disease 2019 (COVID-19) ([U.S. CDC](https://www.cdc.gov/media/dpk/diseases-and-conditions/coronavirus/coronavirus-2020.html)) \n6. COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don’t ([NCBI](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086482/#R1))\n7. Six months of coronavirus: the mysteries scientists are still racing to solve ([Nature](https://www.nature.com/articles/d41586-020-01989-z)) \n8. The biggest mystery: what it will take to trace the coronavirus source ([Nature](https://www.nature.com/articles/d41586-020-01541-z)) \n9. Emergence of SARS-CoV-2 through recombination and strong purifying selection ([Science Advances](https://advances.sciencemag.org/content/6/27/eabb9153)) \n10. WHO experts to travel to China ([WHO](https://www.who.int/news-room/detail/07-07-2020-who-experts-to-travel-to-china)) \n\n",
    "How often revision needed": "Monthly",
    "DB (French)": [
      "recbjW2CdPdJHM0wE"
    ],
    "DB (Hindi)": [
      "recI45JBg4AUfgdUv"
    ],
    "Editorial notes:": "\n",
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "rec7Y7yZKPzYOaUcQ"
    ],
    "DB (Spanish)": [
      "recqkAsNhKQpClr6s"
    ],
    "DB (Arabic)": [
      "recKE1nzKsMbQ6Cfh"
    ],
    "DB (Bengali)": [
      "rec8XX1JUd1UFcNdt"
    ],
    "DB (Portuguese)": [
      "recJYyTXS7aQNUrd3"
    ],
    "Rollup test 2": [
      "recx8cJorKb7KZKjh"
    ],
    "Last modified manual": "2020-07-16",
    "Last edited (simplified)": "2020-05-27T22:06:20.000Z",
    "Last edited (experts say)": "2020-08-31T19:03:18.000Z",
    "Last modified": "2020-08-31",
    "What our experts say wordcount": 209,
    "Background and context wordcount": 124,
    "Other resources wordcount": 119,
    "Wordcount": 452,
    "French Q status": [
      "Ready for expert review"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Arabic Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "La COVID-19 a été détectée pour la première fois fin 2019 dans la ville de Wuhan, en Chine. Il a depuis été partiellement déterminé que l’origine du virus est un grand marché de fruits de mer et d’animaux dans la ville de Wuhan, après que plusieurs personnes qui avaient fréquenté le marché contractèrent la maladie que nous connaissons maintenant sous le nom de COVID-19. Des scientifiques ont pu effectuer des analyses génétiques pour confirmer que le virus avait d’abord été découvert chez des personnes de la ville de Wuhan. Comme pour la génétique de l’être humain, les analyses génétiques de virus peuvent être source de nombreux renseignements sur leur origine. La plupart des études scientifiques soutiennent maintenant l’idée que l’origine du virus chez les animaux fût les chauves-souris, plus particulièrement des rhinolophes provenant possiblement de Chine ou des pays voisins que sont la Birmanie, le Laos et le Vietnam. Des scientifiques suggèrent aussi que le virus a peut-être été transmis aux êtres humains par un hôte intermédiaire, mais ne sont pas certains de la nature de l’animal-hôte, bien que les pangolins et les civettes aient été suggérés. Une enquête est en cours pour déterminer les détails de cet événement que l’on appelle un transfert zoonotique. Les experts de l’Organisation mondiale de la santé voyageront bientôt en Chine afin de travailler avec les représentants des services de santé chinois pour définir la source du virus.\n\nCette entrée a été mise à jour avec de nouveaux renseignements le 16 juillet 2020."
    ],
    "French - Background and context": [
      "Les coronavirus sont un groupe de virus qui peuvent provoquer une variété de maladies, mais principalement des maladies des voies respiratoires supérieures chez l’humain. Ces maladies comprennent le coryza (rhume de cerveau), le syndrome respiratoire aigu sévère (SRAS) et le syndrome respiratoire du Moyen-Orient (SRMO). Certains virus peuvent être d’origine animale et ensuite infecter les êtres humains de différentes manières, dont : manger de la viande ou des aliments qui ont été contaminés par le virus ; par voie aérienne ou par contact avec une surface qui a été touchée par un animal infecté ; par un contact proche avec un animal infecté ; par des piqûres ou morsures d’insectes. Tous les virus ne se transmettent pas des animaux aux êtres humains de toutes ces façons, cela dépend du virus. La section Ressources présente plus de précisions à ce sujet."
    ],
    "Hindi - What our experts say": [
      "कोविड​​-19 का पहली बार 2019 के अंत में वुहान शहर, चीन में पता चला था। शहर में एक बड़े समुद्री भोजन और पशु बाजार में वायरस का आंशिक रूप से पता लगाया गया है, बाजार में आने के बाद कई लोग कोविड​​-19 से बीमार हो गए थे। वैज्ञानिक इस बात की पुष्टि करने के लिए आनुवंशिक परीक्षणों का उपयोग करने में सक्षम थे कि वायरस की पहचान पहले वुहान शहर के लोगों और पर्यावरण के नमूनों में हुई थी। वायरस के आनुवांशिकी पर टेस्ट, मनुष्यों में आनुवांशिकी की तरह, अपनी उत्पत्ति के बारे में बहुत कुछ बता सकते हैं। जब ये आनुवांशिक परीक्षण सीओवीआईडी ​​-19 वायरस के जीन पर किए गए, तो यह पता चला कि वायरस एक संक्रमित जानवर में उत्पन्न हुआ और उत्परिवर्तित हुआ जब उस जानवर ने वायरस को मानव, वुहान शहर के बड़े समुद्री भोजन और पशु बाजार में स्थानांतरित किया। उस घटना के बारे में विवरण, जिसे \"ज़ूनोटिक ट्रांसफ़र\" कहा जाता है, का अभी भी अध्ययन किया जा रहा है क्योंकि कोविड​​-19 के पुष्टि मामलों के साथ अन्य लोग बाजार में नहीं गए थे, लेकिन हम परीक्षण से जानते हैं कि यह पहली बार वुहान, चीन में पहचाना गया था ।"
    ],
    "Hindi - Background and context": [
      "कोरोनावायरस वाइरस का एक समूह है जो विभिन्न बीमारियों का कारण बन सकता है, पर मनुष्यों में प्राय कर ऊपरी श्वसन पथ की बीमारियां (अपर रेस्प्रिटॉरी ट्रैक्ट इल्नेस) पैदा करता है। इन बीमारियों में सामान्य सर्दी, गंभीर तीव्र श्वसन सिंड्रोम (SARS) और मिडल ईस्ट श्वसन सिंड्रोम (MERS) शामिल हैं। कुछ वायरस जानवरों में उत्पन्न हो सकते हैं और बाद में मनुष्यों को संक्रमित कर सकते हैं, और यह कई तरीकों से हो सकता है, जिनमें शामिल हैं: मांस या सब्जियां खाने से जो वायरस द्वारा दूषित हो गई हैं, हवा के माध्यम से या किसी सतह को छूने से जो किसी संक्रमित जानवर के सम्पर्क में आया हो; एक संक्रमित जानवर के सम्पर्क में आने से; या फिर, कीट के काटने के माध्यम से। सभी वायरस जानवरों से मनुष्यों में स्थानांतरित इन सभी तरीकों से ही नहीं होते हैं, यह वायरस पर निर्भर करता है। ‘अन्य जानकारी’ अनुभाग में इसके बारे में अधिक जानकारी प्राप्त की जा सकती है।  "
    ],
    "Telugu - What our experts say": [
      "కోవిడ్-19 మొట్టమొదటిసారిగా 2019 చివరలో చైనాలోని వుహాన్ నగరంలో కనుగొనబడింది. అప్పటి నుండి ఈ వైరస్ పాక్షికంగా వుహాన్ నగరంలో ఒక పెద్ద మత్స్య మరియు జంతు మార్కెట్లో కనుగొనబడింది, మార్కెట్‌కు వచ్చిన చాలా మంది ప్రజలు అనారోగ్యానికి గురైన తరువాత కోవిడ్-19 గా మనకు ఇప్పుడు తెలిసిన అనారోగ్యం. వుహాన్ నగరంలోని ప్రజలలో ఈ వైరస్ మొదట గుర్తించబడిందని నిర్ధారించడానికి శాస్త్రవేత్తలు జన్యు పరీక్షలను ఉపయోగించగలిగారు. మానవులలో జన్యుశాస్త్రం వలె వైరస్ల జన్యుశాస్త్రంపై పరీక్షలు వాటి మూలాలు గురించి చాలా వెల్లడిస్తాయి.\nజంతువులలో వైరస్ యొక్క మూలం గబ్బిలాలు, ప్రత్యేకంగా గుర్రపుడెక్క గబ్బిలాలు, చైనా లేదా పొరుగు దేశాలైన మయన్మార్, లావోస్ మరియు వియత్నాం నుండి సంభావ్యంగా ఉండాలనే ఆలోచనకు ఇప్పుడు శాస్త్రీయ అధ్యయనాలు మద్దతు ఇస్తున్నాయి. మానవులకు వ్యాప్తి చెందడానికి ముందు ఇంటర్మీడియట్ హోస్ట్ ద్వారా ఈ వైరస్ మానవులకు పంపబడి ఉండవచ్చని శాస్త్రవేత్తలు సూచిస్తున్నారు, అయితే పాంగోలిన్లు మరియు సివెట్స్ సూచించబడినప్పటికీ, హోస్ట్ ఏ జంతువు అయి ఉండవచ్చు అనే దానిపై ఖచ్చితంగా తెలియదు. జూనోటిక్ ట్రాన్స్ఫర్ అని పిలువబడే ఆ సంఘటనకు సంబంధించిన వివరాలను ఇంకా పరిశీలిస్తున్నారు. ప్రపంచ ఆరోగ్య సంస్థ నిపుణులు త్వరలో చైనా వెళ్లి చైనా ఆరోగ్య అధికారులతో కలిసి వైరస్ మూలాన్ని గుర్తించనున్నారు.\n\nఈ ఎంట్రీ జూలై 16, 2020 న కొత్త సమాచారంతో నవీకరించబడింది"
    ],
    "Telugu - Context and background": [
      "కరోనావైరస్లు వైరస్ల సమూహం, ఇవి వివిధ రకాలైన అనారోగ్యాలకు కారణమవుతాయి, కాని ప్రధానంగా మానవులలో ఎగువ శ్వాసకోశ వ్యాధులు. ఈ అనారోగ్యాలలో సాధారణ జలుబు, తీవ్రమైన అక్యూట్ రెస్పిరేటరీ సిండ్రోమ్ (SARS) మరియు మిడిల్ ఈస్ట్ రెస్పిరేటరీ సిండ్రోమ్ (MERS) ఉన్నాయి. కొన్ని వైరస్లు జంతువులలో ఉద్భవించగలవు మరియు తరువాత మానవులకు సంక్రమించగలవు, వీటితో సహా: వైరస్ ద్వారా కలుషితమైన మాంసం లేదా ఉత్పత్తిని తినడం ద్వారా, గాలి ద్వారా లేదా తాకిన ఉపరితలాన్ని తాకడం ద్వారా సోకిన జంతువు, సోకిన జంతువుతో సన్నిహిత సంబంధం ద్వారా లేదా క్రిమి కాటు ద్వారా. అన్ని వైరస్లు జంతువుల నుండి మానవులకు ఈ అన్ని మార్గాల్లో బదిలీ కావు, ఇది వైరస్ మీద ఆధారపడి ఉంటుంది. వనరుల విభాగంలో దీని గురించి మరింత సమాచారం ఉంది."
    ],
    "Spanish - What our experts say": [
      "El COVID-19 fue detectado por primera vez en la ciudad de Wuhan, China, a finales de 2019. Desde entonces, el virus ha sido parcialmente rastreado hasta un gran mercado de animales y mariscos en esa ciudad, luego que varias personas que habían estado ahí se enfermaron con la dolencia que ahora conocemos como COVID-19.\nLos científicos fueron capaces de usar pruebas genéticas para confirmar que el virus fue identificado por primera vez en personas y muestras ambientales en la ciudad de Wuhan. Las pruebas en la genética de un virus, en forma similar que la genética en seres humanos, puede revelar mucho acerca de sus orígenes. Cuando estas pruebas genéticas fueron hechas sobre los genes del virus COVID-19, revelaron que el virus se originó en un animal infectado y mutó cuando ese animal transfirió el virus a un ser humano, probablemente en la ciudad de Wuhan. Los detalles acerca de ese evento, el cual es llamado transferenca zoonótica, aún están siendo investigados.\n\nACTUALIZADO: 16 de julio de 2020: La mayoría de los estudios científicos ahora respaldan la idea de que el origen del virus en animales fueron murciélagos, específicamente murciélagos de herradura, potencialmente desde China o los países limítrofes de Myanmar, Laos y Vietnam. Los científicos también sugieren que el virus puede haber sido pasado a seres humanos a través de un huésped intermedio antes de diseminarse en seres humanos, pero no están seguros acerca de qué animal pueda haber sido este huésped, aunque los pangolines y las civetas han sido sugeridos. Una combinación potencial entre murciélagos y pangolines como origen viral también ha sido destacada. Los expertos de la Organización Mundial de la Salud viajarán pronto hacia China y trabajarán con oficiales de salud chinos para identificar la fuente del virus."
    ],
    "Spanish - Background and context": [
      "Los coronavirus son un grupo de virus que pueden causar una variedad de diferentes enfermedades, pero primariamente en el tracto respiratorio superior en seres humanos. Estas enfermedades incluyen el resfrío común, síndrome respiratorio agudo severo (SARS) y síndrome respiratorio del Medio Oriente (MERS). Algunos virus pueden originarse en animales e infectar seres humanos posteriormente, y esto puede pasar en un número de maneras diferentes, incluyendo: comiendo carne o productos que han sido contaminados por el virus, a través del aire o por tocar una superficie que fue tocada por un animal infectado, a través de contacto cercano con un animal infectado, o a través de picaduras de insectos. No todos los virus se transfieren de de animales a seres humanos en todas estas maneras, depende del virus. La sección de recursos contiene más información acerca de esto."
    ],
    "Arabic - What our experts say": [
      "اكتُشِف كوفيد-19 لأول مرة في مدينة وُوهَانْ في الصين في أواخر عام 2019. ومنذ ذلك الحين تم تتبع الفيروس جزئيا إلى سوق كبير للمأكولات البحرية والحيوانية في مدينة وُوهَانْ، بعد أن أصيب العديد من الأشخاص الذين كانوا في السوق بالمرض الذي نعرفه الآن باسم كوفيد-19. تمكن العلماء من استخدام الاختبارات الجينية للتأكد من أن الفيروس تم تحديده لأول مرة في الناس و من خلال عينات بيئية في مدينة وُوهَانْ. قد تكشف اختبارات علم الوراثة للفيروسات، مثل علم الوراثة لدى البشر، الكثير عن أصولها. عندما أُجريَت هذه الاختبارات الجينية على جينات فيروس كوفيد-19، كشفت أن الفيروس نشأ في حيوان مصاب ووقعت طفرة جينية عليه عندما انتقل هذا الفيروس إلى إنسان، على الأرجح في مدينة وُوهَانْ. إن تفاصيل هذه الواقعة، والتي تُسمَّى النقل الحيواني ، لا تزال قيد البحث.\n\nمُحدَّث بتاريخ 16 يوليو 2020 : تدعم غالبية الدراسات العلمية الآن فكرة أن أصل الفيروس في الحيوانات هو الخفافيش، خاصة خفافيش حدوة الحصان، من الصين أو الدول المجاورة مثل ميانمار و لاوس و فيتنام. يقترح العلماء أيضا أن الفيروس ربما قد انتقل إلى الإنسان عبر حيوان وسيط قبل أن يصيب البشر، لكنهم غير متأكدين من الحيوان الذي أدى دور الوسيط، على الرغم من اقتراح حيوانَيْ البانغولين أو الزَّبَاد. وقد لوحظ أيضا وجود اختلاط محتمل بين الخفافيش والبنغولين كأصل للفيروس. وسيسافر خبراء منظمة الصحة العالمية قريباً إلى الصين وسيعملون مع مسؤولي الصحة الصينيين لتحديد مصدر الفيروس."
    ],
    "Arabic - Background and context": [
      "الفيروسات التاجية هي مجموعة من الفيروسات التي يمكن أن تسبب مجموعة متنوعة من الأمراض المختلفة، ولكن بدرجة أولى أمراض الجهاز التنفسي العلوي عند الإنسان. تشمل هذه الأمراض نزلات البرد الشائعة ومتلازمة الجهاز التنفسي الحادة (سارس) ومتلازمة الشرق الأوسط التنفسية (ميرس). يمكن أن تنشأ بعض الفيروسات في الحيوانات ثم تصيب البشر لاحقا، ويمكن أن يحدث ذلك بطرق مختلفة، بما في ذلك : عن طريق تناول اللحوم أو المنتجات الملوثة بالفيروس، أو عن طريق الهواء أو عن طريق لمس سطح لمسه حيوان مصاب، من خلال مخالطة حيوان مصاب، أو من خلال لدغات الحشرات. لا تنتقل جميع الفيروسات من الحيوانات إلى البشر بكل هذه الطرق، فذلك يعتمد على الفيروس. يحتوي قسم الموارد على مزيد من المعلومات حول هذا الموضوع."
    ],
    "Bengali - What our experts say": [
      "২০১২ সালের শেষের দিকে কোভিড -১৯ প্রথমবারে চিনের উহান শহরে সনাক্ত করা হয়েছিল| বাজারে আসা বেশিরভাগ লোক অসুস্থ হয়ে পড়ার পরে, ভাইরাসটি আংশিকভাবে উহান শহরের একটি বড় সামুদ্রিক খাবার এবং পশু বাজারে ধরা পড়েছিল। যে অসুখটি আমরা এখন কোভিড -১৯ নামে জানি। বিজ্ঞানীরা জেনেটিক পরীক্ষা ব্যবহার করে উহান শহরে মানুষ এবং পরিবেশের নমুনাগুলিতে প্রথম সনাক্ত হয়েছিল কিনা তা নিশ্চিত করতে সক্ষম হয়েছিল। ভাইরাসগুলির জেনেটিক্সের উপর পরীক্ষা, অনেকটা মানুষের জেনেটিক্সের মতো, তাদের উৎস সম্পর্কে অনেক কিছুই প্রকাশ করতে পারে। এই জিনগত পরীক্ষাগুলি যখন কোভিড -১৯ ভাইরাসের জিনে করা হয়েছিল, তখন এটি বোঝা গিয়েছিল যে, ভাইরাসটি সংক্রামিত প্রাণীর মধ্যে উদ্ভূত হয়েছিল এবং রূপান্তরিত হয়েছিল সম্ভবত উহান শহরে যখন সেই প্রাণী ভাইরাসটি কোনও মানুষের মধ্যে স্থানান্তরিত করেছিল। জুনোটিক স্থানান্তর নামক সেই ঘটনাটি সম্পর্কে এখনও বিশদ তদন্ত করা হচ্ছে। \nআপডেট: ১৬ জুলাই, ২০২০: বৈজ্ঞানিক গবেষণাগুলির বেশিরভাগই এখন এই ধারণাটিকে সমর্থন করে যে, প্রাণীদের মধ্যে সম্ভবত বাদুড় এই ভাইরাসের উদ্ভব ঘটিয়েছে, বিশেষত চীন বা পার্শ্ববর্তী দেশ মায়ানমার, লাওস এবং ভিয়েতনাম থেকে বিজ্ঞানীরা আরও পরামর্শ দিয়েছেন যে, ভাইরাসটি মানুষের মধ্যে ছড়িয়ে দেওয়ার আগে একটি মধ্যবর্তী হোস্টের মাধ্যমে মানুষের মধ্যে সংক্রামিত হয়ে গেছে, তবে হোস্টটি কী প্রাণী হতে পারে সে সম্পর্কে অনিশ্চিত, যদিও প্যাঙ্গোলিন এবং খাটাশের পরামর্শ দেওয়া হয়েছিল। ভাইরাল উৎস হিসাবে বাদুড় এবং পাঙ্গোলিনের মধ্যে একটি সম্ভাব্য সংমিশ্রণটিও লক্ষ করা গেছে। বিশ্ব স্বাস্থ্য সংস্থার বিশেষজ্ঞরা শীঘ্রই চীন ভ্রমণ করবেন এবং ভাইরাসটির উৎস সনাক্ত করতে চীনা স্বাস্থ্য কর্মকর্তাদের সাথে কাজ করবেন।"
    ],
    "Bengali - Background and context": [
      "করোনাভাইরাস ভাইরাসগুলির একটি দল যা বিভিন্ন ধরণের বিভিন্ন অসুস্থতার কারণ হতে পারে, তবে প্রধানত মানুষের মধ্যে উচ্চ-শ্বসনতন্ত্রের অসুস্থতা। এই অসুস্থতাগুলির মধ্যে রয়েছে সাধারণ সর্দি, তীব্রতর শ্বসন সিন্ড্রোম (এসএআরএস) এবং মধ্য প্রাচ্যের শ্বাসযন্ত্রের সিন্ড্রোম (এমইআরএস)। কিছু ভাইরাস প্রাণীতে উদ্ভূত হতে পারে এবং পরে মানুষকে সংক্রামিত করতে পারে এবং এটি বিভিন্ন উপায়ে ঘটতে পারে, যার মধ্যে রয়েছে: ভাইরাস দ্বারা দূষিত এমন মাংস বা পণ্যদ্রব্য খাওয়া, বায়ু দ্বারা, এমন একটি পৃষ্ঠকে স্পর্শ করা যা কোনও সংক্রামিত প্রাণী স্পর্শ করেছিল, সংক্রামিত প্রাণীর সাথে ঘনিষ্ঠ যোগাযোগের মাধ্যমে, বা পোকার কামড়ের মাধ্যমে| সব ধরনের ভাইরাস এই উপায়ে প্রাণী থেকে মানুষের মধ্যে ছড়িয়ে পড়েনা, এটি ভাইরাসের ধরনের উপর নির্ভর করে। রিসোর্স বিভাগে এ সম্পর্কে আরও তথ্য রয়েছে।"
    ]
  },
  {
    "id": "recCC7GhsX2CKZJbs",
    "Question": "Is being vaccinated with BCG protective for COVID-19?",
    "Status": "Published",
    "Category": "Treatment",
    "Subcategory": "On: COVID-19 & vaccines",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "Senegal"
    ],
    "Background and context": "The BGC vaccine, or the bacille Calmette-Guerin vaccine, is a vaccine for tuberculosis (TB) disease. This vaccine is used in many countries that have high rates of tuberculosis in order to prevent the disease from spreading. As public health researchers try and understand the low case numbers and death count in sub-Saharan Africa and parts of South-East Asia from COVID-19, hypotheses have emerged about the protective power of the BCG vaccine against the coronavirus because of a correlation between countries where the BCG vaccine is widely used and the low number of COVID-19 cases reported in those countries. Recent studies published on this topic do not support the idea that BCG vaccination in childhood has a protective effect against COVID-19 in adulthood. More studies are underway as it's still not clear yet how the BCG vaccine interacts with the virus that causes COVID-19.\n\n",
    "What our experts say": "Multiple studies are exploring the link between BCG vaccination policies in various countries, and the relatively lower number of COVID-19 cases and deaths in those countries. Recent studies published do not support the idea that BCG vaccination in childhood is a cause of protection against COVID-19 in adulthood. The World Health Organization (WHO) has published a note on this topic that stated that in the absence of evidence, WHO does not recommend BCG vaccination for the prevention of COVID-19. \n\nA study published in the Proceedings of the National Academy of Sciences (U.S.) noted that after they accounted for differences in variables like income, age distribution, and access to health services, countries with higher BCG vaccination rates had lower peak mortality rates from COVID-19. However, though there is an association between BCG vaccination and reduced severity of COVID-19 observed in this epidemiological study, it does not mean that there is enough evidence to consider BCG vaccination a cause of protection from severe COVID-19. More studies are underway.\n \n_This entry was updated with new information on July 11, 2020_\n",
    "Glossary Terms": [
      "rec9SYUCp1ULDd0UL",
      "recUx8LCQGkRdxG3B"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "vaccine",
      "BCG"
    ],
    "Other resources": "1. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults ([JAMA](https://jamanetwork.com/journals/jama/fullarticle/2766182)) \n2. Bacille Calmette-Guérin (BCG) vaccination and COVID-19 ([WHO](https://www.who.int/news-room/commentaries/detail/bacille-calmette-gu%C3%A9rin-(bcg)-vaccination-and-covid-19)) \n3. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19) ([PNAS](https://www.pnas.org/content/early/2020/07/07/2008410117)) \n\n",
    "DB (French)": [
      "rec7DbR8cpUtj6laV"
    ],
    "DB (Hindi)": [
      "recghRwerGPpEzj4B"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recuixMlTCiX1DTTK"
    ],
    "DB (Spanish)": [
      "recNE0G9qxzoPOqNm"
    ],
    "DB (Arabic)": [
      "rec7YrBVTfva3zBWb"
    ],
    "DB (Bengali)": [
      "recvhnf530KTSFMUn"
    ],
    "DB (Portuguese)": [
      "rec6iY7j1UTP0nqUX"
    ],
    "Rollup test 2": [
      "recx92VwN2dETjTYZ"
    ],
    "Last modified manual": "2020-07-11",
    "Last edited (simplified)": "2020-05-28T19:09:48.000Z",
    "Last edited (experts say)": "2020-08-31T19:03:40.000Z",
    "Last modified": "2020-08-31",
    "What our experts say wordcount": 175,
    "Background and context wordcount": 143,
    "Other resources wordcount": 30,
    "Wordcount": 348,
    "French Q status": [
      "Ready for expert review"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Arabic Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "De nombreuses études explorent le lien entre les politiques de vaccination au BCG dans divers pays et le nombre relativement plus faible de cas de COVID-19 et de décès qui y sont liés dans ces pays. Les études récentes publiées ne soutiennent pas l’idée que la vaccination au BCG dans l’enfance peut protéger l’adulte contre la COVID-19. L’Organisation mondiale de la santé (OMS) a publié une note à ce sujet qui déclarait qu’en l’absence de données probantes, l’OMS ne recommande pas la vaccination au BCG pour prévenir la COVID-19.\n\nUne étude publiée dans la revue états-unienne « Proceedings of the National Academy of Sciences » (Comptes rendus de l’Académie nationale des sciences) indiquait qu’après avoir pris en compte les différences de variables telles que le revenu, la structure par âge et l’accès aux services de santé, les pays dont le taux de vaccination au BCG est plus élevé présentaient des taux maximaux de mortalité liés à la COVID-19 inférieurs. Cependant, bien qu’il y ait association entre vaccination au BCG et gravité réduite des cas observés de COVID-19 dans cette étude épidémiologique, cela ne signifie pas qu’il a suffisamment de données probantes pour considérer que la vaccination au BCG est un facteur de protection contre une COVID-19 grave. D’autres études sont en cours.\n\nCette entrée a été mise à jour avec de nouveaux renseignements le 11 juillet 2020."
    ],
    "French - Background and context": [
      "Le vaccin BGC, ou vaccin bilié de Calmette et Guérin, est un vaccin contre la tuberculose (TB). Ce vaccin est utilisé afin de prévenir la propagation de la maladie dans de nombreux pays où le taux de tuberculose est élevé. Alors que les chercheurs en santé publique tentent de comprendre le faible nombre de cas et de décès liés à la COVID-19 en Afrique subsaharienne et dans certaines parties de l’Asie du Sud-Est, des hypothèses ont été émises sur le pouvoir protecteur du vaccin BCG contre le coronavirus en raison d’une corrélation entre les pays où le vaccin BCG est largement utilisé et le faible nombre de cas de COVID-19 signalés dans ces pays. Les études récentes publiées sur ce sujet ne soutiennent pas l’idée que la vaccination au BCG dans l’enfance a un effet protecteur chez l’adulte contre la COVID-19. D’autres études sont en cours, car l’interaction du vaccin BCG avec le virus responsable de la COVID-19 n’est pas encore évidente."
    ],
    "Hindi - What our experts say": [
      "कई अध्ययन विभिन्न देशों में बसीजी टीकाकरण और कम कोविड-19 मौतों के बीच सम्बंध का अध्ययन कर रहे हैं। हाल ही में प्रकाशित अध्ययन इस विचार का समर्थन नहीं करते हैं कि बचपन में बीसीजी टीकाकरण का प्रौढ़ता में कोविड​​-19 के खिलाफ सुरक्षात्मक प्रभाव पड़ता है। डब्ल्यूएचओ ने इस विषय पर एक नोट प्रकाशित किया है जिसमें कहा गया है कि साक्ष्य के अभाव में, डब्ल्यूएचओ कोविड-19 की रोकथाम के लिए बीसीजी टीकाकरण की सिफारिश नहीं करता है। अधिक अध्ययन चल रहे हैं।"
    ],
    "Hindi - Background and context": [
      "बीजीसी वैक्सीन, या बेसिल कैलमेट-गुएरिन वैक्सीन, टीबी रोग के लिए एक टीका है। इस टीके का उपयोग कई देशों में किया जाता है, जिनमें टीबी रोग उच्च मात्रा में पाया जाता है, ताकि बीमारी को फैलने से रोका जा सके। सार्वजनिक स्वास्थ्य शोधकर्ता उप-सहारा अफ्रीका और दक्षिण-पूर्वी एशिया के कुछ हिस्सों में कोविड​​-19 के कम मामले और मृत्यु की संख्या को समझने की कोशिश कर रहे हैं, और कोरोनोवायरस के खिलाफ बीसीजी वैक्सीन की सुरक्षात्मक शक्ति के बारे में कुछ परिकल्पनाएं (हायपॉथिसस) सामने आई हैं। इस विषय पर प्रकाशित हालिया अध्ययन इस विचार का समर्थन नहीं करते हैं कि बचपन में बीसीजी टीकाकरण का प्रौढ़ता में कोविड-19 के खिलाफ सुरक्षात्मक प्रभाव पड़ता है। अधिक अध्ययन चल रहे हैं क्योंकि यह अभी भी स्पष्ट नहीं है कि बीसीजी वैक्सीन का कोविड​​-19 वायरस पर क्या प्रभाव पड़ता है।"
    ],
    "Telugu - What our experts say": [
      "వివిధ దేశాలలో బిసిజి టీకా విధానాల మధ్య సంబంధాన్ని బహుళ అధ్యయనాలు అన్వేషిస్తున్నాయి మరియు సాపేక్షంగా తక్కువ సంఖ్యలో కోవిడ్-19 కేసులు మరియు ఆ దేశాలలో మరణాలు. బాల్యంలో బిసిజి టీకా అనేది యుక్తవయస్సులో కోవిడ్-19 నుండి రక్షణకు కారణమని ఇటీవల ప్రచురించిన అధ్యయనాలు మద్దతు ఇవ్వవు. ప్రపంచ ఆరోగ్య సంస్థ (డబ్ల్యూహెచ్‌ఓ) ఈ అంశంపై ఒక గమనికను ప్రచురించింది, సాక్ష్యాలు లేనప్పుడు, కోవిడ్-19 నివారణకు బిసిజి టీకాను WHO సిఫారసు చేయలేదు. మరిన్ని అధ్యయనాలు జరుగుతున్నాయి.\n\nనవీకరించబడింది: జూలై 11, 2020: ప్రొసీడింగ్స్ ఆఫ్ ది నేషనల్ అకాడమీ ఆఫ్ సైన్సెస్ (యుఎస్) లో ప్రచురించబడిన ఒక అధ్యయనం ప్రకారం, ఆదాయం, వయస్సు పంపిణీ మరియు ఆరోగ్య సేవలకు ప్రాప్యత వంటి వేరియబుల్స్‌లో తేడాలు ఉన్నాయని, అధిక బిసిజి టీకా రేట్లు ఉన్న దేశాలు కోవిడ్-19 నుండి తక్కువ మరణాల రేటును కలిగి ఉంది. ఏదేమైనా, ఈ ఎపిడెమియోలాజికల్ అధ్యయనంలో గమనించిన BCG టీకా మరియు కోవిడ్-19 యొక్క తీవ్రత మధ్య సంబంధం ఉన్నప్పటికీ, BCG టీకాను తీవ్రమైన కోవిడ్-19 నుండి రక్షణకు కారణమని భావించడానికి తగిన సాక్ష్యాలు ఉన్నాయని దీని అర్థం కాదు. తీవ్రమైన కోవిడ్-19 లక్షణాలు మరియు మరణం నుండి BCG వ్యాక్సిన్లు రక్షణ కల్పిస్తాయో లేదో మద్దతు ఇవ్వడానికి తగిన ఆధారాలు లేవు మరియు వ్యాక్సిన్‌ను లక్ష్యంగా చేసుకున్న అధ్యయన ఫలితాలు ప్రచురించబడినందున మేము ఈ జవాబును నవీకరించడం కొనసాగిస్తాము."
    ],
    "Telugu - Context and background": [
      "BGC టీకా, లేదా బాసిల్ కాల్మెట్-గురిన్ వ్యాక్సిన్, క్షయ (టిబి) వ్యాధికి వ్యాక్సిన్. ఈ వ్యాక్సిన్ చాలా దేశాలలో క్షయవ్యాధి అధికంగా ఉన్న వ్యాధిని వ్యాప్తి చేయకుండా నిరోధించడానికి ఉపయోగిస్తారు. కోవిడ్-19 నుండి ఉప-సహారా ఆఫ్రికా మరియు ఆగ్నేయ ఆసియాలోని తక్కువ కేసుల సంఖ్యలు మరియు మరణాల సంఖ్యను ప్రజారోగ్య పరిశోధకులు ప్రయత్నించి, అర్థం చేసుకున్నప్పుడు, కరోనావైరస్కు వ్యతిరేకంగా BCG వ్యాక్సిన్ యొక్క రక్షణ శక్తి గురించి పరికల్పనలు వెలువడ్డాయి. బిసిజి వ్యాక్సిన్ విస్తృతంగా ఉపయోగించబడుతున్న దేశాలు మరియు ఆ దేశాలలో తక్కువ సంఖ్యలో కోవిడ్-19 కేసులు నమోదయ్యాయి. ఈ అంశంపై ప్రచురించిన ఇటీవలి అధ్యయనాలు బాల్యంలో బిసిజి టీకాలు యుక్తవయస్సులో కోవిడ్-19 కు రక్షణాత్మక ప్రభావాన్ని కలిగి ఉన్నాయనే ఆలోచనకు మద్దతు ఇవ్వవు. కోవిడ్-19 కి కారణమయ్యే వైరస్‌తో BCG వ్యాక్సిన్ ఎలా సంకర్షణ చెందుతుందో ఇంకా స్పష్టంగా తెలియకపోవడంతో మరిన్ని అధ్యయనాలు జరుగుతున్నాయి."
    ],
    "Spanish - What our experts say": [
      "Múltiples estudios están explorando el vínculo entre las políticas de vacunación BCG en varios países y el número relativamente bajo de casos y muertes por COVID-19 en esos países. Los estudios publicados recientemente no apoyan la idea que la vacunación BCG durante la niñez sea una causa de protección contra el COVID-19 en los adultos. La Organización Mundial de la Salud (OMS) ha publicado una nota sobre este tópico que afirmó que en la ausencia de evidencia, la OMS no recomienda la vacunación BCG para la prevención del COVID-19. Más estudios están en progreso.\n\nACTUALIZADO: 11 de julio de 2020: Un estudio reciente publicado en los Procedimientos de la Academia Nacional de Ciencias (EE.UU.) destacó que luego de contabilizar las diferencias en variables tales como ingresos, distribución de edad y acceso a servicios de salud, los países con altas tasas de vacunación BCG tenían tasa de mortalidad pico más bajas debidas al COVID-19. Sin embargo, aunque hay una asociación entre la vacunación BCG y una severidad reducida del COVID-19 observada en este estudio epidemiológico, no significa que haya evidencia suficiente para considerar la vacunación BCG como causa de protección contra COVID-19 severo. No hay evidencia suficiente para respaldar si las vacunas BCG pueden ofrecer protección o no contra síntomas severos o muerte por COVID-19, y continuaremos actualizando esta respuesta a medida que los resultados de los estudios enfocados en la vacuna sean publicados."
    ],
    "Spanish - Background and context": [
      "La vacuna BCG, o vacuna del bacilo Calmette-Guerin, es una vacuna para la enfermedad tubrculosis (TB). Es usada en muchos países que tienen elevadas tasas de tuberculosis con el objeto de prevenir que la enfermedad se disemine. En la medida en que los investigadores de la salud pública intentan y entienden el bajo número de casos y de cantidad de muertes por COVID-19 en el África subsahariana y partes del sudeste de Asia, han emergido hipótesis acerca del poder protector de la vacuna BCG en contra del coronavirus debido a una correlación entre países donde la vacuna BCG es ampliamente utilizada y el bajo número de casos de COVID-19 informados en esos países. Estudios recientes publicados sobre este tópico no respaldan la idea que la vacunación BCG edurante la niñez tenga un efecto protector contra el COVID-19 en adultos. Hay más estudios en progreso y aún no está claro cómo interactúa la vacuna BCG con el virus que causa el COVID-19."
    ],
    "Arabic - What our experts say": [
      "تقوم دراسات متعددة بالبحث حول الصلة بين سياسات تلقيح BCG في مختلف البلدان، و بين حالات الإصابات بـ كوفيد-19 والوفيات في تلك البلدان. الدراسات الحديثة المنشورة لا تدعم فكرة أن لقاح BCG في مرحلة الطفولة هو سبب للحماية من كوفيد-19 في مرحلة البلوغ. نشرت منظمة الصحة العالمية مذكرة حول هذا الموضوع ذكرت أنه في حالة عدم وجود أدلة، فإنها لا توصي بتلقيح BCG للوقاية من كوفيد-19. لذا فالمزيد من الدراسات جارية حول الموضوع.\n\nتحديث بتاريخ 11 يوليو 2020 : أشارت دراسة حديثة نُشرَت في وقائع الأكاديمية الوطنية للعلوم (في الولايات المتحدة) إلى أنها بعد احتساب الاختلافات في المتغيرات مثل الدخل وتوزيع الأعمار و سهولة الوصول إلى الخدمات الصحية، فإن البلدان ذات معدلات التلقيح BCG الأعلى كانت معدلات ذروة وفياتها بـ كوفيد-19 أقل. ومع ذلك، على الرغم من وجود ارتباط بين لقاح BCG وانخفاض شدة كوفيد-19 الذي لوحظ في هذه الدراسة الوبائية، فهذا لا يعني أن هناك أدلة كافية للاعتقاد بأن لقاح BCG يعد سببا للحماية من كوفيد-19 الحاد. لا توجد أدلة كافية لدعم ما إذا كانت لقاحات BCG يمكن أن توفر الحماية ضد أعراض كوفيد-19 الحادة والوفاة أم لا ، وسنستمر في تحديث هذه الإجابة عند نشر نتائج الدراسة التي تستهدف هذا الصنف من اللقاح."
    ],
    "Arabic - Background and context": [
      "لقاح BGC، أو لقاح عصيات Calmette-Guerin، هو لقاح لمرض السل. يُستخدَم هذا اللقاح في العديد من البلدان التي لديها معدلات عالية من مرض السل من أجل منع انتشار ذلك المرض. بينما يحاول باحثو الصحة العامة فهم أعداد الحالات المنخفضة وعدد الوفيات في أفريقيا جنوب الصحراء وأجزاء من جنوب شرق آسيا من كوفيد-19 ، ظهرت فرضيات حول القوة الوقائية للقاح BCG ضد الفيروس التاجي بسبب العلاقة بين البلدان التي يتم فيها استخدام لقاح BCG على نطاق واسع وانخفاض عدد حالات كوفيد-19 المُبلَّغ عنها في تلك البلدان. لا تدعم الدراسات الحديثة المنشورة حول هذا الموضوع فكرة أن لقاح BCG في مرحلة الطفولة له تأثير وقائي ضد كوفيد-19 في مرحلة البلوغ. تجري المزيد من الدراسات حيث لا يزال من غير الواضح حتى الآن كيف يتفاعل لقاح BCG مع الفيروس الذي يسبب كوفيد-19."
    ],
    "Bengali - What our experts say": [
      "একাধিক গবেষণা বিভিন্ন দেশে বিসিজি টিকা নীতি এবং সেই তুলনায় অপেক্ষাকৃত কম সংখ্যক কোভিড-১৯ এবং মৃত্যুর ঘটনা সংযোগের সন্ধান করছে। সাম্প্রতিক প্রকাশিত গবেষণাগুলি এই ধারণাটিকে সমর্থন করে না যে, শৈশবে বিসিজি টিকা যৌবনে কোভিড-১৯ এর বিরুদ্ধে সুরক্ষার কারণ। বিশ্ব স্বাস্থ্য সংস্থা (ডাব্লুএইচও) এই বিষয়ে একটি নোট প্রকাশ করেছে যাতে বলা হয়েছে যে, প্রমাণের অভাবে বিশ্ব স্বাস্থ্য সংস্থা কোভিড-১৯ প্রতিরোধের জন্য বিসিজি টিকা দেওয়ার পরামর্শ দেয় না। আরও পড়াশোনা চলছে।\nআপডেট: ১১ জুলাই, ২০২০: ন্যাশনাল একাডেমি অফ সায়েন্সেসের (আমেরিকা) সভার কার্যবিবরণীতে প্রকাশিত সাম্প্রতিক এক গবেষণায় উল্লেখ করা হয়েছে যে তারা আয়, বয়স বন্টন, স্বাস্থ্যসেবাতে প্রবেশাধিকার এবং উচ্চতর বিসিজি টিকার হারের দেশগুলির উপাত্ত বিশ্লেষণে দেখেছেন তাদের কোভিড-১৯-এ মৃত্যুর হার কম ছিল। তবে, এই মহামারীবিজ্ঞানের গবেষণায় বিসিজি টিকা এবং কোভিড-১৯ এর তীব্রতা হ্রাসের মধ্যে একটি সম্পর্ক থাকলেও, বিসিজি টিকাদানকে গুরুতর কোভিড-১৯ থেকে সুরক্ষার কারণ হিসাবে বিবেচনা করার পক্ষে পর্যাপ্ত প্রমাণ নেই। বিসিজি ভ্যাকসিনগুলি গুরুতর কোভিড-১৯ উপসর্গ এবং মৃত্যুর বিরুদ্ধে সুরক্ষা দিতে পারে বা পারে না সে বিষয়ে সমর্থন করার পক্ষে পর্যাপ্ত প্রমাণ নেই এবং ভ্যাকসিনকে লক্ষ্য করে অধ্যয়নের ফলাফল প্রকাশিত হলে আমরা এই উত্তরটি আপডেট করতে থাকব।"
    ],
    "Bengali - Background and context": [
      "বিজিসি ভ্যাকসিন বা ব্যাকিলি ক্যালমেট-গেরিন ভ্যাকসিন যক্ষ্মা (টিবি) রোগের একটি ভ্যাকসিন। এই ভ্যাকসিনটি এই রোগ ছড়াতে বাধা দেওয়ার জন্য যক্ষ্মার উচ্চ হার রয়েছে এমন অনেক দেশে ব্যবহৃত হয়। যেহেতু জনস্বাস্থ্য গবেষকরা সাব-সাহারান আফ্রিকা এবং দক্ষিণ-পূর্ব এশিয়ার কোভিড-১৯ থেকে কম ঘটনা এবং মৃত্যুর সংখ্যা বোঝার চেষ্টা করেছেন এবং বুঝতে পেরেছেন অনুমানগুলি করোনা ভাইরাসের বিরুদ্ধে বিসিজি ভ্যাকসিনের সুরক্ষামূলক শক্তি সম্পর্কে উদ্ভূত, কারণ এর মধ্যে পারস্পরিক সম্পর্ক রয়েছে| যেসব দেশে বিসিজি ভ্যাকসিন ব্যাপকভাবে ব্যবহৃত হয় সেইসব দেশে কম সংখ্যক কোভিড-১৯ ঘটনা রিপোর্ট করা হয়েছে। এই বিষয়ে প্রকাশিত সাম্প্রতিক গবেষণাগুলি এই ধারণাটিকে সমর্থন করে না যে, শৈশবে বিসিজি টিকা যৌবনে কোভিড-১৯ এর বিরুদ্ধে প্রতিরক্ষামূলক প্রভাব ফেলে। আরও গবেষণা চলছে, কারণ এখনও বিসিজি ভ্যাকসিন কীভাবে কোভিড-১৯-এর জন্য দায়ী ভাইরাসের উপর কাজ করে তা স্পষ্ট নয়।"
    ]
  },
  {
    "id": "recu5zvFnlQeNTxk8",
    "Question": "What are the different types of vaccines?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & vaccines",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "There are over 165 vaccines against COVID-19 in development around the world. Approximately 25 of them are in human trials. Vaccine trials typically take years to develop, but are being expedited to be ready as early as spring 2021 to control the pandemic. \n\nVaccines are a safe, effective, and simple method of protecting people against diseases before an individual becomes exposed to them. Vaccines can also help lessen the severity of a disease if someone is infected. All vaccines work to create antibodies to fight the foreign germ - in this case, the SARS-CoV-2 virus. But there has been confusion around the types of vaccines in development due to the high amount of vaccines being developed, as well as new technologies being tested that haven’t been used in a licensed vaccine before, such as mRNA vaccines which are currently being researched.\n",
    "What our experts say": "Historically, there are four main types of vaccines: \n\n- Live-attenuated vaccines\n- Inactivated vaccines\n- Subunit, recombinant, polysaccharide, and conjugate vaccines\n- Toxoid vaccines\n\nVaccine designs are based on how our immune systems respond to germs, who in the population (children, adults) needs to be vaccinated against the germ, and the best approach and technology available to create the vaccine. This is why there are different vaccine types to respond to different germs.\n\nLive-attenuated vaccines use a weaker - also called 'attenuated' - form of a living germ, which would normally cause a disease in stronger forms but is almost completely harmless in a vaccine because the virus has been weakened. Some of these live-attenuated vaccines are used to protect against diseases like measles, mumps, rubella; rotavirus; smallpox; chicken pox; and yellow fever.\n\nInactivated vaccines use the killed or inactive version of the germ, so they are not as capable at helping humans develop some immunity to a germ** **as live-attenuated vaccines and can't provide immunity for as long. These vaccines protect against diseases like hepatitis A, influenza, polio, and rabies.\n\nSubunit, recombinant, polysaccharide, and conjugate vaccines use particular pieces of the germ, like its protein or sugars, to create a strong immunity to specific parts of the germ. Some illnesses these vaccines focus on are hepatitis B, HPV, whooping cough, shingles, and meningococcal disease.\n\nToxoid vaccines use a harmful product called a 'toxin' that is made by the germ. A toxin is a living organism that can normally cause harm to parts of the body like tissues when they come into contact with them. However, toxins in vaccines are harmless because they have been very weakened in laboratories as their only job is to teach the immune system how to fight the germ. They create immunity by focusing on the specific parts of the germ that cause illness instead of the entire germ. These vaccines target illnesses like diptheria and tetanus.\n\nResearchers trying to develop COVID-19 vaccines are using many of these types of approaches to vaccine design. Two new types of vaccines are gaining attention in the scientific world. One of these vaccine types use the genes of the COVID-19 vaccine called 'DNA' and 'RNA' to create a strong immune system response. The other new type of approach to vaccine development uses a platform base called 'recombinant vector vaccines' which act like how infections would impact your body normally. As we learn more about the virus and how to create immunity in people through vaccines, we will learn if any of these vaccine types can successfully prevent COVID-19 infection in people.\n",
    "Glossary Terms": [
      "rec9qqItwSTjq3Eae",
      "recS7r4IRJ4w3tzwS",
      "reccH9Nhjj0fi18nJ",
      "recXHN1CA0PUsKJ2k",
      "recnFUXyIZy81Rj1I"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "vaccine",
      "DNA",
      "RNA",
      "immunity"
    ],
    "Other resources": "1. Vaccine Types ([U.S. HHS](https://www.vaccines.gov/basics/types)) \n2. Vaccines: The Basics ([U.S. CDC](https://www.cdc.gov/vaccines/vpd/vpd-vac-basics.html)) \n3. Q&A on vaccines ([World Health Organization](https://www.who.int/news-room/q-a-detail/q-a-on-vaccines)) \n",
    "Rollup test 2": [
      "recGnpHrWHStSwQ3V"
    ],
    "Last modified manual": "2020-07-31",
    "Last edited (simplified)": "2020-07-31T22:54:36.000Z",
    "Last edited (experts say)": "2020-07-31T22:55:31.000Z",
    "Last modified": "2020-07-31",
    "What our experts say wordcount": 423,
    "Background and context wordcount": 140,
    "Other resources wordcount": 19,
    "Wordcount": 582
  },
  {
    "id": "rec8cZkqQ2wYlzCSD",
    "Question": "Should we wipe down groceries with disinfectant before bringing inside a house?",
    "Status": "Published",
    "Category": "Transmission",
    "Background and context": "Studies that look at the way COVID-19 spreads are evolving and it's leading to confusion about how we should be handling some of our most essential items — groceries. More research shows that person-to-person spread through close contact (as opposed to surface transmission, like with groceries) is the most well understood form of transmission, as well as the main transmission route for COVID-19. \n\nMixed messaging is contributing to debate around the need to wipe down groceries, wear gloves, avoid petting neighborhood animals, and other steps that would reduce surface transmission. The current research shows that surface transmission is likely very rare as a way of spreading COVID-19, but it is still a risk and it should be responded to with precaution. Therefore, public health experts recommend hand washing after bringing items inside and putting them away. \n",
    "What our experts say": "There is no evidence that food or the packaging it comes in plays a role in COVID-19 transmission. The public health community is continually learning about how the novel coronavirus spreads, and what transmission routes are most likely to make it spread. Because of this continual learning in the public health community, there has been confusion around how easily COVID-19 spreads, through which routes, and what precautions are really necessary—such as wiping down grocery packaging.\n\nAccording to recent studies, the risk of becoming infected by surfaces like food and packaging is quite low, but the same prevention measures experts have been suggesting for months should still be followed. Health experts recommend hand washing after handling produce and putting away groceries, but not that people wipe down or disinfect the packaging or belongings before coming inside. They should instead use hand washing after bringing items inside and putting them away. \n\n",
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "transmission"
    ],
    "Other resources": "1. Running Errands ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/essential-goods-services.html))\n2. Shopping for Food During the COVID-19 Pandemic ([U.S. FDA](https://www.fda.gov/food/food-safety-during-emergencies/shopping-food-during-covid-19-pandemic-information-consumers))\n3. Hygiene Theater Is a Huge Waste of Time ([The Atlantic](https://www.theatlantic.com/ideas/archive/2020/07/scourge-hygiene-theater/614599/)) \n4. Exaggerated risk of transmission of COVID-19 by fomites ([The Lancet](https://www.thelancet.com/pdfs/journals/laninf/PIIS1473-3099(20)30561-2.pdf)) \n",
    "Rollup test 2": [
      "rec7mfXT3SHmQrAoi"
    ],
    "Last modified manual": "2020-07-31",
    "Last edited (simplified)": "2020-07-31T21:44:22.000Z",
    "Last edited (experts say)": "2020-07-31T21:46:20.000Z",
    "Last modified": "2020-07-31",
    "What our experts say wordcount": 149,
    "Background and context wordcount": 137,
    "Other resources wordcount": 36,
    "Wordcount": 322
  },
  {
    "id": "rechQWZ1ctlJ81Vxn",
    "Question": "What does the scientific literature say about using hydroxychloroquine to prevent, treat or cure COVID-19?",
    "Status": "Published",
    "Category": "Treatment",
    "Subcategory": "On: COVID-19 & hydroxychloroquine",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "India"
    ],
    "Background and context": "Hydroxycloroquine is a medication currently prescribed for preventing or treating malaria, an infectious disease that can be transmitted to humans from mosquitos. It is also prescribed as a treatment for rheumatoid arthritis and lupus, which are both autoimmune diseases.\n\nWhen faced with an unknown virus like COVID-19 and without a specific vaccine and treatment, one of the best medical strategies is to look among the medications already available and clinically tested to see if any of them are effective. As their risks, benefits, and side effects have already been studied (without allowing safety tests to be ignored), this could speed up research. One of these is hydroxychloroquine. \n\nWhen trying to find treatments for COVID-19, hydroxychloroquine was tested on hospitalized patients. Preliminary results suggested some benefit to COVID-19 patients, however, the most updated recent analysis concludes that hydroxychloroquine provides no benefit to hospitalized COVID-19 patients.\n",
    "What our experts say": "Hydroxychloroquine is not a recognized prevention, treatment or cure for COVID-19.\n\nEarlier in the pandemic, hydroxychloqoruine was proposed as a treatment for COVID-19, on the basis of some preliminary results from small, uncontrolled clinical trials. Since then, more robust randomized controlled trials have been conducted to study hydroxycholoquine as a treatment for hospitalized coronavirus patients. \n\nStudy results published in November 2020 show that hydroxychloroquine does not benefit adults hospitalized with the coronavirus disease. Another study published in 'The Lancet' in November 2020 reported that hydroxycholoquine does not prevent mortality from COVID-19 even among those who were using it before they got infected with SARS-CoV-2.\n\nAround the world, some countries have authorized chloroquine or hydroxychloroquine for the treatment of COVID-19 despite limited clinical evidence supporting its efficacy. This decision follows some preliminary results coming out of China and France in March 2020, where a few small clinical trials showed limited success of the medication.\n\nOn June 15th 2020, the U.S. FDA revoked the special permission to use chloroquine and hydroxychloroquine in emergency situations for COVID-19, citing that these drugs are unlikely to be effective in treating COVID-19 and highlighting serious cardiac adverse events and other serious side effects reported in studies.\n",
    "Glossary Terms": [
      "recM4p8QOERmuESKr",
      "recAiJYWSxD5F1Lz1",
      "recJ1c8DQQVGmXfzM",
      "recjILnexcCRlyBIb"
    ],
    "Variation of the answer depending on country of residence": "Yes - some countries have included chloroquine and hydroxychloroquine in their treatment protocol despite the fact that the World Health Organization has not recognized it as a treatment as they await further clinical trial results.\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "treatment",
      "cure",
      "hydroxychloroquine"
    ],
    "Other resources": "1. Hydroxychloroquine does not benefit adults hospitalized with COVID-19 ([NIH](https://www.nih.gov/news-events/news-releases/hydroxychloroquine-does-not-benefit-adults-hospitalized-covid-19))\n2. Hydroxychloroquine in the prevention of COVID-19 mortality ([The Lancet](https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30390-8/fulltext))\n3. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 ([NEJM](https://www-nejm-org.ezp-prod1.hul.harvard.edu/doi/full/10.1056/NEJMoa2022926))\n4. FDA revokes the emergency use authorization for chloroquine and hydroxychloroquine ([U.S. FDA](https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs))\n5. FDA cautions against the use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to a risk of heart rhythm problems ([U.S. FDA](https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or))\n6. Research paper: Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial ([BMJ](https://www.bmj.com/content/369/bmj.m1849))\n7. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2019014?query=featured_home))\n8. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates ([Nature](https://www.nature.com/articles/s41586-020-2558-4?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature))\n9. Investigational therapeutics for patients with COVID-19 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html)) \n10. Research Update: Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 ([AIM](https://www.acpjournals.org/doi/10.7326/M20-4207))\n11. Trial update: Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.07.15.20151852v1))\n12. Trial update: No clinical benefit from use of hydroxychloroquine in hospitalized patients with COVID-19 ([Recovery Trial](https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19))\n13. Information about \"compassionate use\" ([U.S. FDA](https://www.fda.gov/news-events/public-health-focus/expanded-access)) \n14. Research paper: A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2016638?query=featured_home))\n15. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review ([AIM](https://www.acpjournals.org/doi/10.7326/M20-2496))\n16. Research paper: Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial ([BMJ](https://www.bmj.com/content/369/bmj.m1849))\n17. Research paper: Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State ([JAMA](https://jamanetwork.com/journals/jama/fullarticle/2766117))\n18. Research paper: Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2012410))\n\n\n",
    "DB (French)": [
      "recAj0TYj97UNUWtk"
    ],
    "DB (Hindi)": [
      "recTMwxdfhiFP6PdB"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recN5EPDGr3rmysv8"
    ],
    "DB (Spanish)": [
      "rec6r7JrdmkSaJZpK"
    ],
    "DB (Arabic)": [
      "recqLyEdG4gEouayz"
    ],
    "DB (Bengali)": [
      "recO4uinQPvndAlwL"
    ],
    "DB (Portuguese)": [
      "recp55aBOJEjliZwl"
    ],
    "Rollup test 2": [
      "recu77HWVK2bxYOAf"
    ],
    "Last modified manual": "2020-12-03",
    "Last edited (simplified)": "2020-12-03T15:36:55.000Z",
    "Last edited (experts say)": "2020-12-07T14:40:54.000Z",
    "Last modified": "2020-12-07",
    "What our experts say wordcount": 197,
    "Background and context wordcount": 142,
    "Other resources wordcount": 247,
    "Wordcount": 586,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Arabic Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Les essais cliniques en cours testent l’efficacité et la sécurité de la chloroquine et de l’hydroxychloroquine comme traitements de la COVID-19. Jusqu’à présent, les essais cliniques et les analyses scientifiques n’ont pas produit de données probantes de grande qualité qui démontraient l’efficacité de ces médicaments en tant que traitement, et certaines études ont même signalé des taux plus élevés d’événements indésirables (dont des problèmes cardiaques) chez des patients hospitalisés traités à l’hydroxychloroquine. En l’état actuel des choses, l’hydroxychloroquine n’est pas un moyen de prévention, ni un traitement, ni un remède reconnu de la COVID-19.\nDans ce contexte, des études sont en cours afin de découvrir si la prise de ce médicament peut prévenir l’infection des personnes qui ont été exposées au coronavirus. D’autres études examinent encore l’efficacité et la sécurité de ce médicament en tant que traitement aux différentes étapes de la maladie, dont des essais contrôlés randomisés sur un grand nombre de patients.\nDans le monde entier, des pays sont allés de l’avant et ont autorisé la chloroquine ou l’hydroxychloroquine pour le traitement de la COVID-19, malgré le peu de données cliniques probantes pour soutenir son efficacité. Cette décision fait suite à des résultats préliminaires provenant de Chine et de France en mars 2020, où quelques petits essais cliniques ont démontré le succès limité du médicament.\nLe 27 mars 2020 aux États-Unis, l’Agence des produits alimentaires et médicamenteux (FDA) a accordé une autorisation spéciale (autorisation pour utilisation urgente) afin d’utiliser la chloroquine et l’hydroxychloroquine dans les situations d’urgence pour le traitement de la COVID-19. Ce n’était pas une homologation formelle du médicament, mais plutôt la possibilité donnée aux médecins états-uniens d’utiliser la chloroquine et l’hydroxychloroquine dans le traitement de la COVID-19, si le médecin n’a aucune autre option et après en avoir discuté des risques avec les patients. Le 15 juin 2020, l’Agence américaine des produits alimentaires et médicamenteux a révoqué l’autorisation spéciale d’utiliser la chloroquine et l’hydroxychloroquine pour la COVID-19 dans les situations urgentes. L’agence indiqua que ces médicaments n’étaient probablement pas efficaces dans le traitement de la COVID-19, soulignant que des événements cardiaques indésirables graves et d’autres effets secondaires graves avaient été signalés dans les études."
    ],
    "French - Background and context": [
      "L’hydroxychloroquine est un médicament actuellement prescrit pour prévenir ou traiter la malaria, une maladie infectieuse qui peut être transmise à l’homme par les moustiques. Elle est également prescrite comme traitement de la polyarthrite rhumatoïde et du lupus, qui sont tous deux des maladies auto-immunes.\nFace à un virus inconnu tel que le SARS-CoV-2 et en l’absence de vaccin et de traitement spécifiques, une des meilleures stratégies thérapeutiques consiste à passer en revue les médicaments déjà disponibles et testés en clinique afin d’évaluer si l’un d’entre eux est efficace. Dans la mesure où leurs risques, leurs avantages et leurs effets secondaires ont déjà fait l’objet d’études (sans permettre d’ignorer les tests de sécurité), cela pourrait accélérer la recherche. Un de ces médicaments est l’hydroxychloroquine. \nLors de la recherche de traitements pour la COVID-19, l’hydroxychloroquine a été testée sur des patients hospitalisés. Cependant, les résultats de cette recherche ne sont pas assez probants pour recommander l’hydroxychloroquine pour le traitement de la COVID-19. Parallèlement, des études de recherche ont démontré de graves conséquences néfastes (dont de graves problèmes de rythme cardiaque) associées à la prise d’hydroxychloroquine dans le traitement de la COVID-19. D’autres études sont en cours."
    ],
    "Hindi - What our experts say": [
      "चल रहे क्लिनिकल ट्रायल्स के द्वारा परीक्षण किया जा रहा है कि कोविड​​-19 के इलाज के रूप में क्लोरोक्वीन और हाइड्रोक्सीक्लोरोक्विन कितने सुरक्षित और प्रभावी हैं। अब तक, क्लिनिकल ट्रायल्स ​ने उच्च गुणवत्ता वाले प्रमाण प्रस्तुत नहीं किए हैं जिससे पता चल सके कि ये उपचार प्रभावी हैं। कुछ परिक्षणो के अनुसार हाइड्रॉक्सीक्लोरोक्वाइन के द्वारा इलाज किए गए अस्पताल में भर्ती रोगियों में उच्च दर की प्रतिकूल घटनाएँ (हृदय सम्बंधित विषय सहित) पायी गयी हैं। अभी तक, हाइड्रोक्सीक्लोरोक्विन कोविड-19 के लिए एक मान्यता प्राप्त रोकथाम, उपचार या इलाज नहीं है। \n\nकुछ शोध देख रहे हैं कि क्या यह दवा लेने से लोगों को वायरस के संपर्क में आने के बाद कोरोनावायरस से संक्रमित होने से रोका जा सकता है; अन्य प्रयोग अभी भी जांच कर रहे हैं कि यह कितना प्रभावी है और कई रोगियों पर रैंडमायज़्ड कंट्रोल ट्रायल्स के उपचार में यह कितना सुरक्षित है। \n\nदुनिया भर में, कुछ देशों ने सीओवीआईडी ​​-19 के उपचार के लिए क्लोरोक्वीन या हाइड्रोक्सीक्लोरोक्वीन को सीमित प्रमाण के बावजूद इसके उपयोग का समर्थन करने की अनुमति दी है। यह निर्णय मार्च 2020 में चीन और फ्रांस से आने वाले कुछ प्रारंभिक परिणामों का अनुसरण करता है, जहां कुछ छोटे ​​परीक्षणों ने दवा की सीमित सफलता दिखाई। यूनाइट्स स्टेट्स में, फूड एंड ड्रग एडमिनिस्ट्रेशन (एफ॰डी॰ए॰) ने क्लोरीन और हाइड्रोक्सीक्लोरोक्वीन को कोविड-19 के लिए आपातकालीन परिस्थितियों में उपयोग करने के लिए एक विशेष अनुमति (इमरजेंसी ऑथराइज़ेशन यूज़) की अनुमति दी है। यह दवा की औपचारिक स्वीकृति प्रदान नहीं करता है, बल्कि कोविड-19 के उपचार में क्लोरोक्विन और हाइड्रोक्सीक्लोरोक्वीन का उपयोग करने के लिए अमेरिकी डॉक्टरों को दी गई संभावना है, यदि चिकित्सक के पास कोई विकल्प नहीं है और रोगी के साथ इस दवाई के संभवतः ख़तरों पर विचार करने के बाद ही। 15 जून 2020 को यू॰एस॰ एफ॰डी॰ए॰ ने कोविड ​​-19 के लिए आपातकालीन स्थितियों में क्लोरोक्वीन और हाइड्रोक्सीक्लोरोक्वीन का उपयोग करने की विशेष अनुमति को हटा दिया। उन्होंने कहा कि इन दवाओं की कोविड-19 के इलाज में प्रभावी होने की संभावना नहीं हैं और कहा कि ये हृदय स्वास्थ्य के लिए गंभीर जोखिम हैं और शोध में रिपोर्ट किए गए अन्य गंभीर दुष्प्रभाव भी हो सकते हैं।"
    ],
    "Hindi - Background and context": [
      "हाइड्रोक्सीक्लोरोक्विन वर्तमान में मलेरिया को रोकने या उसके इलाज के लिए एक दवा है, जो एक संक्रामक बीमारी है जो मनुष्यों को मच्छरों से फैल सकती है। यह संधिशोथ (रिह्यूमाटोईद अर्थिराइटिस) और ल्यूपस के लिए एक उपचार के रूप में भी निर्धारित किया गया है, जो दोनों स्व-प्रतिरक्षित (औटोईम्यून) रोग हैं। जब कोविड-19 जैसे वायरस का सामना करना पड़ता है जो कि एक अज्ञात बीमारी है और जिसके लिए एक विशिष्ट वैक्सीन या उपचार नहीं है , तो पहले से उपलब्ध दवाओं के बीच देखने की कोशिश की जाती है और यह देखने के लिए चिकित्सकीय परीक्षण किया जाता है कि उनमें से कोई भी प्रभावी है या नहीं। क्योंकि उनके जोखिम, लाभ, और साइड इफेक्ट्स का अध्ययन किया जा चुका है (बिना सुरक्षा परीक्षणों को नजरअंदाज किए), इससे शोध में तेजी आ सकती है। इनमें से एक है हाइड्रोक्सीक्लोरोक्वीन। जब कोविड​​-19 के लिए उपचार खोजने की कोशिश की गई, तो रोगियों पर हाइड्रोक्सीक्लोरोक्वीन का परीक्षण किया गया। हालांकि, अभी तक, कोविड-19 के इलाज के लिए हाइड्रोक्सीक्लोरोक्वीन की सिफारिश करने के लिए पर्याप्त सबूत नहीं हैं। वहीं, कुछ शोध अध्ययनों ने कोविड-19 के उपचार में हाइड्रोक्सीक्लोरोक्वीन के उपयोग से जुड़े कुछ नकारात्मक परिणामों को भी दिखाया है। और प्रयोग चल रहे हैं।"
    ],
    "Telugu - What our experts say": [
      "కోవిడ్-19 కి చికిత్సలుగా క్లోరోక్విన్ మరియు హైడ్రాక్సీక్లోరోక్విన్ ఎంత సురక్షితమైనవి మరియు ప్రభావవంతంగా ఉన్నాయో కొనసాగుతున్న క్లినికల్ ట్రయల్స్ పరీక్షిస్తున్నాయి. ఇప్పటివరకు, క్లినికల్ ట్రయల్స్ మరియు శాస్త్రీయ విశ్లేషణలు ఈ ఔషధ ప్రయోగం యొక్క చికిత్సను చికిత్సగా చూపించే అధిక నాణ్యత గల సాక్ష్యాలను ఉత్పత్తి చేయలేదు మరియు కొన్ని అధ్యయనాలు హైడ్రాక్సీక్లోరోక్విన్‌తో చికిత్స పొందిన ఆసుపత్రిలో చేరిన రోగులలో అధిక ప్రతికూల సంఘటనలను (గుండె సమస్యలతో సహా) నివేదించాయి. విషయాల ప్రకారం, హైడ్రాక్సీక్లోరోక్విన్ కోవిడ్-19 కు గుర్తించబడిన నివారణ, చికిత్స లేదా నివారణ కాదు.\nఈ సందర్భంలో, ఈ ఔషధ ప్రయోగం తీసుకోవడం వలన ప్రజలు కరోనావైరస్ బారిన పడకుండా నిరోధించవచ్చో లేదో తెలుసుకోవడానికి పరిశోధన అధ్యయనాలు జరుగుతున్నాయి. ఇతర అధ్యయనాలు ఇప్పటికీ అనారోగ్యం యొక్క వివిధ దశలలో చికిత్సగా of షధం యొక్క సమర్థత మరియు భద్రతను పరిశీలిస్తున్నాయి, పెద్ద సంఖ్యలో రోగులతో యాదృచ్ఛిక నియంత్రిత పరీక్షలతో సహా.\nప్రపంచవ్యాప్తంగా, కొన్ని దేశాలు ముందుకు సాగాయి మరియు కోవిడ్-19 చికిత్స కోసం క్లోరోక్విన్ లేదా హైడ్రాక్సీక్లోరోక్విన్‌కు అధికారం ఇచ్చాయి. ఈ నిర్ణయం మార్చి 2020 లో చైనా మరియు ఫ్రాన్స్ నుండి వస్తున్న కొన్ని ప్రాథమిక ఫలితాలను అనుసరిస్తుంది, ఇక్కడ కొన్ని చిన్న క్లినికల్ ట్రయల్స్ మందుల పరిమిత విజయాన్ని చూపించాయి.\n\nయునైటెడ్ స్టేట్స్‌లో, మార్చి 27, 2020 న, కోవిడ్-19 చికిత్స కోసం అత్యవసర పరిస్థితుల్లో క్లోరోక్విన్ మరియు హైడ్రాక్సీక్లోరోక్విన్‌లను ఉపయోగించడానికి ఫుడ్ అండ్ డ్రగ్ అడ్మినిస్ట్రేషన్ (ఎఫ్‌డిఎ) ప్రత్యేక అనుమతి (ఎమర్జెన్సీ ఆథరైజేషన్ యూజ్) మంజూరు చేసింది. ఇది of షధానికి అధికారిక ఆమోదం ఇవ్వలేదు, అయితే అమెరికన్ వైద్యులు క్లోవిక్విన్ మరియు హైడ్రాక్సీక్లోరోక్విన్‌లను కోవిడ్-19 చికిత్సలో ఉపయోగించుకునే అవకాశం వైద్యుడికి ఇతర ఎంపికలు లేకపోతే మరియు రోగులతో చర్చించిన తరువాత కలిగే ప్రమాదాలు. కోవిడ్-19 కోసం అత్యవసర పరిస్థితుల్లో క్లోరోక్విన్ మరియు హైడ్రాక్సీక్లోరోక్విన్‌లను ఉపయోగించడానికి జూన్ 15, 2020 న, US FDA రద్దు చేసింది, ఈ మందులు కోవిడ్-19 చికిత్సలో ప్రభావవంతంగా ఉండటానికి అవకాశం లేదని మరియు తీవ్రమైన గుండె ప్రతికూల సంఘటనలు మరియు ఇతర తీవ్రమైన దుష్ప్రభావాలను హైలైట్ చేస్తుంది అధ్యయనాలలో నివేదించబడింది."
    ],
    "Telugu - Context and background": [
      "హైడ్రాక్సీక్లోరోక్విన్ అనేది మలేరియాను నివారించడానికి లేదా చికిత్స చేయడానికి ప్రస్తుతం సూచించిన మందు, ఇది ఒక అంటు వ్యాధి, ఇది దోమల నుండి మానవులకు వ్యాపిస్తుంది. ఇది రుమటాయిడ్ ఆర్థరైటిస్ మరియు లూపస్ లకు చికిత్సగా సూచించబడుతుంది, ఇవి రెండూ స్వయం ప్రతిరక్షక వ్యాధులు.\nకోవిడ్-19 వంటి తెలియని వైరస్ను ఎదుర్కొన్నప్పుడు మరియు నిర్దిష్ట టీకా మరియు చికిత్స లేకుండా, ఇప్పటికే అందుబాటులో ఉన్న మందులలో ఒకటి చూడటం మరియు వాటిలో ఏదైనా ప్రభావవంతంగా ఉందో లేదో వైద్యపరంగా పరీక్షించడం. వారి నష్టాలు, ప్రయోజనాలు మరియు దుష్ప్రభావాలు ఇప్పటికే అధ్యయనం చేయబడినందున (భద్రతా పరీక్షలను విస్మరించడానికి అనుమతించకుండా), ఇది పరిశోధనను వేగవంతం చేస్తుంది. వీటిలో ఒకటి హైడ్రాక్సీక్లోరోక్విన్.\nకోవిడ్-19 చికిత్సలను కనుగొనటానికి ప్రయత్నించినప్పుడు, ఆసుపత్రిలో చేరిన రోగులపై హైడ్రాక్సీక్లోరోక్విన్ పరీక్షించబడింది. ఏదేమైనా, ఈ పరిశోధన యొక్క ఫలితాలు కోవిడ్-19 చికిత్సకు హైడ్రాక్సీక్లోరోక్విన్‌ను సిఫారసు చేయడానికి తగిన సాక్ష్యాలను సూచించవు. అదే సమయంలో, కొన్ని పరిశోధన అధ్యయనాలు కోవిడ్-19 చికిత్సలో హైడ్రాక్సీక్లోరోక్విన్ వాడకంతో సంబంధం ఉన్న కొన్ని తీవ్రమైన ప్రతికూల పరిణామాలను (తీవ్రమైన గుండె లయ సమస్యలను కలిగి ఉన్నాయి) చూపించాయి. మరిన్ని అధ్యయనాలు జరుగుతున్నాయి."
    ],
    "Spanish - What our experts say": [
      "Los ensayos clínicos en progreso están probando qué tan seguras y efectivas son la cloroquina y la hidroxicloroquina como tratamientos para el COVID-19. Hasta ahora, estos ensayos clínicos y análisis científicos no han producido evidencia de alta calidad que muestre la eficacia de estas medicaciones como tratamiento, y algunos estudios incluso han reportado tasas más altas de eventos adversos (incluyendo cuestiones cardíacas) en pacientes hospitalizados tratados con hidroxicloroquina. Como están las cosas, la hidroxicloroquina no es reconocida como prevención, tratamiento o cura para el COVID-19.\nEn este contexto, hay estudios de investigación en camino para averiguar si tomar esta medicación puede prevenir a las personas de quedar infectadas con coronavirus una vez que han sido expuestas. Otros estudios aún están investigando la eficacia y seguridad de la droga como tratamiento para diferentes etapas de la enfermedad. incluyendo ensayos aleatorios controlados con un gran número de pacientes enrolados.\nAlrededor del mundo, algunos países han avanzado y han autorizado la cloroquina o la hidroxicloroquina para el tratamiento del COVID-19 a pesar de la limitada evidencia clínica respaldando su eficacia. Esta desición sigue a algunos resultados preliminares procedentes de China y Francia en marzo de 2020, donde unos pocos ensayos clínicos reducidos mostraron un éxito limitado de la medicación. En los Estados Unidos, el 27 de marzo de 2020, la Administración de Comidas y Drogas (FDA) otorgó un permiso especial (Autorización  para Uso de Emergencia) para usar cloroquina e hidroxicloroquina en situaciones de emergencia para el tratamyento del COVID-19. Esto no constituye una aprobación formal de la droga, sino más bien una posibilidad dada a doctores americanos para usar cloroquina e hidroxicloroquinq en el tratamiento del COVID-19 si el doctor no tiene otras opciones, y luego de discutir con los pacientes los riesgos involucrados. El 15 de junio de 2020, la U.S. FDA revocó el permiso especial para usar cloroquina e hidroxicloroquina en situaciones de emergencia para el COVID-19, citando que estas drogas es improbable que sean efectivas para tratar el COVID-19, y destacando eventos cardíacos adversos serios, y otros efectos colaterales serios reportados en estudios."
    ],
    "Spanish - Background and context": [
      "La hidroxicloroquina es una medicación prescripta al día de hoy para prevenir o tratar la malaria, una enfermedad infecciosa que puede ser transmitida a seres humanos por mosquitos. También es prescripta como tratamiento para la artritis reumatoide y el lupus, las cuales son ambas enfermedades autoinmunes.\nAl enfrentarse a un virus desconocido como el COVID-19 y sin una vacuna específica y tratamiento, una de las mejores estrategias médicas es mirar entre las medicaciones ya disponibles y probadas clínicamente para ver si alguna de ellas es efectiva. Como sus riesgos, beneficios y efectos colaterales ya han sido estudiados (sin permitir que las pruebas de seguridad sean ignoradas), esto puede acelerar la investigación. Una de estas es la hidroxicloroquina.\nCuando se trata de encontrar tratamientos para el COVID-19, la hidroxicloroquina fue probada en pacientes hospitalizados. Sin embargo, los resultados de esta investigación no representan evidencia significante suficiente para recomendar la hidroxicloroquina para el tratamiento del COVID-19. Al mismo tiempo, algunos estudios de investigación también han mostrado algunas consecuencias negativas serias (incluyendo problemas serios de ritmo cardíaco) asociadas con el uso de hidroxicloroquina en el tratamiento del COVID-19. La mayoría de los estudios está en progreso."
    ],
    "Arabic - What our experts say": [
      "تختبر التجارب السريرية الجارية مدى سلامة وفعالية الكلوروكين وال هيدروكسي كلوروكين كعلاجات لـ كوفيد-19. حتى الآن، لم تسفر التجارب السريرية والتحليلات العلمية عن أدلة عالية الجودة تظهر فعالية هذه الأدوية كعلاج، فقد أظهرت بعض الدراسات معدلات أعلى من الآثار العكسية (بما في ذلك مشاكل القلب) في المرضى الذين عولجوا باستخدام الهيدروكسي كلوروكوين في المستشفيات. من جهة أخرى، فإن الهيدروكسي كلوروكين ليس معترفا به كوسيلة للوقاية أو العلاج من كوفيد-19.\nفي هذا السياق، هناك دراسات جارية لمعرفة ما إذا كان تناول هذا الدواء يمكن أن يمنع الأشخاص من الإصابة بالفيروس التاجي بمجرد تعرضهم له. لا تزال دراسات أخرى تبحث في فعالية وسلامة الدواء كعلاج في مراحل مختلفة من المرض، بما في ذلك التجارب العشوائية ذات الشواهد انطلاقا من عدد كبير من المرضى المسجلين.\nفي جميع أنحاء العالم، أقدمت بعض الدول على منح تصريح استخدام الكلوروكين أو الهيدروكسي كلوروكوين لعلاج كوفيد-19 على الرغم من محدودية الأدلة السريرية التي تدعم فعاليته. يتبع هذا القرار بعض النتائج الأولية الصادرة عن الصين وفرنسا في مارس 2020، حيث أظهرت بعض التجارب السريرية القليلة نجاحا محدودا للدواء.\nفي الولايات المتحدة، في 27 مارس 2020، منحت إدارة الغذاء والدواء (FDA) تصريحا خاصا (استخدام تصريح الطوارئ) لاستخدام الكلوروكين والهيدروكسي كلوروكوين في حالات الطوارئ لعلاج كوفيد-19. لا يشكل هذا القرار موافقة رسمية على استخدام الدواء، بل بالأحرى إمكانية مُخوَّلة للأطباء الأمريكيين لوصف الكلوروكين والهيدروكسي كلوروكوين في علاج كوفيد-19 إذا لم يكن لدى الطبيب خيارات أخرى وبعد مناقشة المخاطر مع المرضى. في 15 يونيو 2020 ، ألغت إدارة الغذاء والدواء الأمريكية التصريح الخاص لاستخدام الكلوروكين والهيدروكسي كلوروكين في حالات الطوارئ لـ كوفيد-19 مشيرة إلى أنه من غير المحتمل أن تكون هذه الأدوية فعالة في علاج كوفيد-19 إذ سلطت الإدارة الضوء على آثار عكسية قلبية وآثار جانبية أخرى خطيرة ذُكرَت في دراسات مختلفة."
    ],
    "Arabic - Background and context": [
      "يُوصَف دواء الهيدروكسي كلوروكين حاليا للوقاية من الملاريا أو علاجها، إن الملاريا مرض مُعْدٍ يمكن أن ينتقل إلى البشر عبر البعوض. كما يُوصَف كعلاج لالتهاب المفاصل الروماتويدي والذئبة، وكلاهما من أمراض المناعة الذاتية.\nعندما تواجه فيروسا مجهولا مثل كوفيد-19 و بدون لقاح أو علاج مُحدَّد، فإن إحدى أفضل الاستراتيجيات الطبية هي البحث بين الأدوية المتاحة بالفعل واختبارها سريريا لمعرفة ما إذا كانت أي منها فعالة. نظرا لأن المخاطر والفوائد والآثار الجانبية قد تمت دراستها بالفعل (مع الأخذ بعين الاعتبار ضرورة اختبارات السلامة)، فقد يؤدي ذلك إلى تسريع البحث. أحد هذه المركبات هو هيدروكسي كلوروكوين.\nعند محاولة العثور على علاجات لـ كوفيد-19 ، تم اختبار الهيدروكسي كلوروكوين على المرضى في المستشفيات. ومع ذلك، فإن نتائج هذا البحث لا تشكل دليلا كافيا لاعتماد الهيدروكسي كلوروكوين لعلاج كوفيد-19. في الوقت نفسه، أظهرت بعض الدراسات البحثية أيضا بعض العواقب السلبية الخطيرة (بما في ذلك مشاكل إيقاعات القلب الخطيرة) المرتبطة باستخدام الهيدروكسي كلوروكوين لعلاج كوفيد-19. المزيد من الدراسات جارية في الوقت الراهن."
    ],
    "Bengali - What our experts say": [
      "চলমান ক্লিনিকাল ট্রায়ালগুলি কোভিড -১৯ এর চিকিত্সা হিসাবে ক্লোরোকুইন এবং হাইড্রোক্সাইক্লোরোকুইন কতটা নিরাপদ এবং কার্যকর তা পরীক্ষা করছে। এখনও অবধি, ক্লিনিকাল ট্রায়ালগুলি এবং বৈজ্ঞানিক বিশ্লেষণগুলি চিকিৎসা হিসাবে এই ঔষধগুলির কার্যকারিতা প্রমাণ করে এমন উচ্চ মানের প্রমাণ উপস্থাপন করতে পারেনি এবং কিছু গবেষণায় এমনকি হাইড্রোক্সাইক্লোরোকাইন দ্বারা চিকিতসারত হাসপাতালে ভর্তি রোগীদের ক্ষেত্রে বিরূপ ঘটনাগুলির (কার্ডিয়াকের সমস্যা সহ) উচ্চ হারের কথা বলা হয়েছে। এখন অব্দি এটাই প্রমাণিত যে, হাইড্রোক্সাইক্লোরোকুইন কোভিড -১৯ এর কোনও স্বীকৃত প্রতিরোধ, চিকিৎসা বা নিরাময় নয়।এই প্রসঙ্গে, এই ওষুধ গ্রহণ করা লোকেরা করোনা ভাইরাসের সংস্পর্শে আসার পরে তাদের সংক্রামিত হতে বাধা দিতে পারে কিনা তা অনুসন্ধানের জন্য গবেষণা গবেষণা চলছে। বিপুল সংখ্যক রোগীর সাথে নিবন্ধিত এলোমেলোভাবে নিয়ন্ত্রিত পরীক্ষাগুলি সহ অন্যান্য গবেষণাগুলি এখনও অসুস্থতার বিভিন্ন পর্যায়ে চিকিৎসা হিসাবে ওষুধের কার্যকারিতা এবং সুরক্ষা নিয়ে তদন্ত করে দেখাচ্ছেন।বিশ্বজুড়ে, কিছু দেশ অগ্রসর হয়েছে এবং কোভিড -১৯ এর চিকিৎসার জন্য ক্লোরোকুইন বা হাইড্রোক্সাইক্লোরোকুইনকে অনুমোদিত করেছে তার কার্যকারিতা সমর্থন করার ক্ষেত্রে সীমাবদ্ধ ক্লিনিকাল প্রমাণ থাকা সত্ত্বেও। ২০২০ সালের মার্চ মাসে চীন এবং ফ্রান্স থেকে প্রকাশিত কিছু প্রাথমিক ফলাফল অনুসরণ করে এই সিদ্ধান্তটি নিয়েছেন, যেখানে কয়েকটি ছোট ক্লিনিকাল ট্রায়াল ওষুধের সীমাবদ্ধ সাফল্য দেখিয়েছিল।ইমার্কিন যুক্তরাষ্ট্রে, ২০ মার্চ, ২০২০-এ খাদ্য ও ওষুধ প্রশাসন (এফডিএ) কোভিড১৯-এর চিকিৎসার জন্য জরুরী পরিস্থিতিতে ক্লোরোকুইন এবং হাইড্রোক্সাইক্লোরোকাইন ব্যবহারের জন্য একটি বিশেষ অনুমতি (জরুরী ব্যাবহার অনুমোদন) দিয়েছে। এটি ঔষধের কোনও আনুষ্ঠানিক অনুমোদনের কারণ নয়, বরং আমেরিকান চিকিৎসকদের কোভিড -১৯ এর চিকিৎসায় ক্লোরোকুইন এবং হাইড্রোক্সাইক্লোরোকুইন ব্যবহার করার সম্ভাবনা দেওয়া হয়েছিল রোগীদের সাথে জড়িত ঝুঁকিগুলি নিয়ে আলোচনা করার পরে এবং যদি চিকিৎসকদের অন্য কোনও বিকল্প না থাকে। ২০২০ সালের ১৫ জুন, মার্কিন এফডিএ কোভিড -১৯ জরুরী পরিস্থিতিতে ক্লোরোকুইন এবং হাইড্রোক্সিলোক্লোইন ব্যবহারের বিশেষ অনুমতি বাতিল করে বলেছে যে, গবেষণার রিপোর্টে দেখা গেছে এই ওষুধগুলি কোভিড-১৯ এর চিকিৎসায় কার্যকর নয় এবং গুরুতর কার্ডিয়াক সমস্যা সহ অন্যান্য গুরুতর পার্শ্ব প্রতিক্রিয়াগুলি রয়েছে।"
    ],
    "Bengali - Background and context": [
      "হাইড্রোক্সেক্লোরোকুইন বর্তমানে ম্যালেরিয়া প্রতিরোধ বা চিকিৎসার জন্য নির্ধারিত একটি ওষুধ যা মশা থেকে মানুষের মধ্যে সংক্রামিত হতে পারে এমন একটি সংক্রামক রোগ। এটি গেঁটে বাত এবং ত্বকের প্রদাহের চিকিৎসা হিসাবেও প্রস্তাবিত, যা উভয়ই স্বয়ংক্রিয় প্রতিরোধ ক্ষমতা অসুখ। কোন নির্দিষ্ট ভ্যাকসিন এবং চিকিৎসা ছাড়াই যখন কোভিড-১৯ এর মতো অজানা ভাইরাস এর মুখোমুখি হন, তখন অন্যতম সেরা চিকিৎসা কৌশল হ'ল ইতিমধ্যে উপলব্ধ ওষুধগুলির মধ্যে নজর দেওয়া এবং সেগুলির কোনও একটি কার্যকর কিনা তা পরীক্ষা করার জন্য ক্লিনিকালভাবে পরীক্ষা করা। তাদের ঝুঁকি, সুবিধা এবং পার্শ্ব প্রতিক্রিয়া হিসাবে ইতিমধ্যে অধ্যয়ন করা হয়েছে (সুরক্ষা পরীক্ষা উপেক্ষা করার অনুমতি না দিয়ে), এটি গবেষণার গতি বাড়িয়ে দিতে পারে। এর মধ্যে একটি হাইড্রোক্সাইক্লোরোকাইন, কোভিড-১৯ এর চিকিৎসা সন্ধানের চেষ্টা করার সময়, হাসপাতালে ভর্তি রোগীদের জন্য হাইড্রোক্সাইক্লোরোকুইন পরীক্ষা করা হয়েছিল। তবে এই গবেষণা থেকে প্রাপ্ত ফলাফলগুলি কোভিড-১৯ এর চিকিৎসার জন্য হাইড্রোক্সাইক্লোরোকুইনের প্রস্তাব দেওয়ার পক্ষে যথেষ্ট উল্লেখযোগ্য প্রমাণের প্রতিনিধিত্ব করে না। একই সময়ে, কিছু গবেষণা গবেষণায় কোভিড-১৯-এর চিকিৎসায় হাইড্রোক্সাইক্লোরোকুইন ব্যবহারের সাথে যুক্ত কিছু মারাত্মক নেতিবাচক পরিণতিও অন্তর্ভুক্ত রয়েছে (গুরুতর হৃদস্পন্দন সমস্যা )। আরও গবেষণা চলছে।"
    ]
  },
  {
    "id": "rec94a8OYovZrmVEs",
    "Question": "How do pulse oximeters work and are digital versions effective?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & pulse oximeters",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "India"
    ],
    "Background and context": "A recent viral WhatsApp message circulating on closed threads in India claimed that everybody should download a digital app that functions like a digital pulse oximeter and measures oxygen levels in the blood. Digital apps claiming to accurately measure blood oxygen levels may be very inaccurate.\n\nPulse oximeters—the real ones— are used to track oxygen levels in the blood and monitor heart rate, since low oxygen levels are reported among patients experiencing severe cases of COVID-19. They are popular because they can present warning signs of an upcoming problem before it's too late. However, doctors only recommend pulse oximeters for some patients who have either been diagnosed with COVID-19 or who have other underlying health conditions. The quality of digital pulse oximeters can vary, and these devices should not be used to diagnose COVID-19, as low blood oxygen levels can occur due to a wide range of diseases. In general, public health agencies like the U.S. Centers for Disease Control do not recommend purchasing a digital pulse oximeter to track your blood oxygen levels unless directed by a doctor or in specific high-risk areas like nursing homes. If you feel like you're getting sick or experiencing any symptoms of COVID-19, you should contact a doctor right away. \n",
    "What our experts say": "A pulse oximeter is a small non-invasive, clip-like device that attaches to a finger or ear lobe to measure the level of oxygen in blood. The device sends small beams of light through the blood and then measures how much light reflects off of red blood cells. More reflection of light means more oxygen saturation, less reflection of light means less oxygen saturation. \n\nTypically a digital pulse oximeter is clipped on the tip of your finger, and you may experience a small amount of pressure without any pain during the reading. The device provides a reading of \"oxygen saturation level\" and heart rate. An oxygen saturation level of at least 95% is normal for most healthy individuals. \n\nDigital pulse oximeters are easy-to-use and painless, and most versions are quite accurate. With any digital reading, however, there is always a risk of inaccurate readings. Hospitals and other medical settings have high-quality devices, but the quality of other digital versions on the market can vary. In general, doctors recommend pulse oximeters for patients with certain underlying health conditions and lung diseases, including patients with COVID-19, to monitor their symptoms. But you should not buy a pulse oximeter to self-diagnose or monitor symptoms unless directed by a doctor.\n",
    "Glossary Terms": [
      "rect196eVKcIMcns5",
      "recIU1uU78tFKq4Ws"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "pulse oximeter",
      "oxygen saturation",
      "symptoms"
    ],
    "Other resources": "1. Pulse Oximetry ([Hopkins Medicine](https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/pulse-oximetry))\n2. Should You Get a Pulse Oximeter to Measure Blood Oxygen Levels? ([Cleveland Clinic](https://health.clevelandclinic.org/should-you-get-a-pulse-oximeter-to-measure-blood-oxygen-levels/))\n3. Coronavirus FAQS: What's A Pulse Oximeter? Is It A Good Idea To Buy One? ([NPR](https://www.npr.org/sections/goatsandsoda/2020/05/01/848400469/coronavirus-faqs-whats-a-pulse-oximeter-is-it-a-good-idea-to-buy-one))\n",
    "Rollup test 2": [
      "recfqfMWtmTXEcodv"
    ],
    "Last modified manual": "2020-07-31",
    "Last edited (simplified)": "2020-07-31T20:01:28.000Z",
    "Last edited (experts say)": "2020-07-31T20:01:28.000Z",
    "Last modified": "2020-07-31",
    "What our experts say wordcount": 205,
    "Background and context wordcount": 207,
    "Other resources wordcount": 33,
    "Wordcount": 445
  },
  {
    "id": "recRNOP1DQIw90RaZ",
    "Question": "When do we consider someone with COVID-19 to have recovered?",
    "Status": "Published",
    "Category": "Recovery",
    "Background and context": "As COVID-19 spreads, so does the number of individuals who have recovered since thankfully most patients who have COVID-19 recover from the disease. There is ongoing debate and uncertainty regarding when and on what basis can we consider that a patient has recovered from COVID-19. \n\nIn summary, deciding when a patient has recovered from COVID-19 is more complicated than just judging by the moment the patient feels better. The definition of \"recovery\" needs to include more than just the complete improvement of the patient and the absence of symptoms. \n\nDefinitions of recovery vary a lot between countries and can still be subjective to the individual patient, because more severe cases may have symptoms that last longer, and in some cases individuals can test positive even if they are no longer infectious (i.e. they can't transmit the virus to other people). \n",
    "What our experts say": "Different institutions (including hospitals, clinics, public health agencies, and government agencies) have used different criteria to define when someone with COVID-19 is considered recovered. These criteria are often used to decide when someone can be allowed to leave the hospital or can stop isolation. A review of COVID-19 recovery guidelines being used around the world show most doctors agree on the following criteria:\n1) Clinical: The patient no longer has symptoms, and\n2) Laboratory: The patient has negative test results (testing through swabs taken from the nose and throat) showing the virus is no longer present in the upper respiratory system.\nBoth of these criteria should be considered in combination to determine recovery. Negative test results are important because people can still spread the virus even if they have no symptoms or their symptoms have stopped. \n\nIn addition, the European Centre for Disease Control and Prevention (ECDC) suggests also considering the following criteria to determine if a patient has recovered:\n3) Positive serological or antibody test results from blood samples. \nAntibody tests can show if your immune system has produced antibodies to fight off COVID-19 which would signal that you had been infected with the virus. Antibody tests are typically done at least 1-3 weeks after a patient first experiences symptoms. However, antibody test results should not be used on their own to determine recovery - they should be used in combination with the other two criteria.\n\nIt is not always possible to use these recommended criteria to determine recovery. For example, some people with COVID-19 experience only mild symptoms (fatigue, shortness of breath, etc.) yet are not hospitalized because these symptoms are not severe enough. These mild symptoms can however persist over long periods of time (weeks to months) which further complicates how to decide if someone has recovered or not from COVID-19.\n",
    "Glossary Terms": [
      "recmajcAORyuqhZPc",
      "recz6LiyrAkeNejA2",
      "recPNexvQiug4RFJu",
      "recOfgrqkPp7aa14o"
    ],
    "Other resources": "1. Discharge criteria for confirmed COVID-19 cases – When is it safe to discharge COVID-19 cases from the hospital or end home isolation?  ([European CDC](https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-Discharge-criteria.pdf))\n2. Discontinuation of Isolation for Persons with COVID-19 Not in Healthcare Settings ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html))\n3. Duration of Isolation and Precautions for Adults with COVID-19 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html))\n",
    "Media": [
      {
        "id": "attdeONnvilTyODFu",
        "url": "https://dl.airtable.com/.attachments/dddcadca4e3e650160225f164917db62/ea567eed/Slide_1",
        "filename": "Slide_1",
        "size": 200427,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/2399485f1e11e6f5190ee821cb5e9a01/ca9a49d0",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/0e38dbc543366af80e6ac1b8116248ef/fc301269",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/449413f9b83159d5c9f48080407c62f8/35a231e3",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attg27m5nWiXpIglS",
        "url": "https://dl.airtable.com/.attachments/8de729e4a64e34c7df2be4a6695b72ce/2734019d/Slide_2",
        "filename": "Slide_2",
        "size": 199658,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/00718050d1d8f2bfde15fb28f8be0778/8b73e71c",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/61c90dd73546ae44776a7d16b5ac4c91/760c7cb4",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/5e6ae38193b00656a94180dea7821884/789a8dba",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attwBuxdhQJ9oLm6F",
        "url": "https://dl.airtable.com/.attachments/6dd65e2f5579a2fe40aadbbcb3b4f7ff/1093a7bf/Slide_3",
        "filename": "Slide_3",
        "size": 223077,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e8dcadc728eb94e4ab8d6a8074b4b54e/a6bcf449",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/7b08f0a2437ef992b842bfd57c7d9e5a/1861afc7",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/8bc266ef1f0383b75990d1693bbcf53b/e63b256a",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attHWdMe92p6FAPc5",
        "url": "https://dl.airtable.com/.attachments/2d86252ea9c82938f929594739b1e54d/a036fc16/Slide_4",
        "filename": "Slide_4",
        "size": 256960,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d93010c59aa55addc6a4bc56f21c007f/f0adf20a",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/7a3086719165d35578f7c1a992389177/56435c42",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/54954325c3341eb884ad1365328711d4/5ea91022",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Arabic)": [
      "recurf1nCbLstiTkv"
    ],
    "DB (Bengali)": [
      "reck9dTXXz06jEssE"
    ],
    "DB (Portuguese)": [
      "recOobvP0b19NIhlE"
    ],
    "Rollup test 2": [
      "recCKSot1u0II9n7T"
    ],
    "Last modified manual": "2020-07-31",
    "Last edited (simplified)": "2020-07-30T14:33:40.000Z",
    "Last edited (experts say)": "2020-09-15T04:26:20.000Z",
    "Last modified": "2020-09-15",
    "What our experts say wordcount": 299,
    "Background and context wordcount": 141,
    "Other resources wordcount": 49,
    "Wordcount": 489,
    "Arabic Q status": [
      "Published"
    ],
    "Arabic - What our experts say": [
      "استخدمت مؤسسات مختلفة (بما في ذلك المستشفيات والعيادات ووكالات الصحة العامة والوكالات الحكومية) معايير مختلفة لتحديد وقت تعافي شخص مصاب بـ كوفيد-19. غالبا ما تُستخدَم هذه المعايير لتحديد متى يمكن السماح لشخص ما بمغادرة المستشفى أو توقفه عن عزل نفسه. تظهر مراجعة إرشادات التعافي من كوفيد-19 المستخدمة في جميع أنحاء العالم أن معظم الأطباء يتفقون على المعايير التالية :\n1) السريرية : لم يعد المريض يعاني من الأعراض، و\n2) المختبر : المريض لديه نتائج اختبار سلبية (اختبار من خلال مسحات من الأنف والحنجرة) تبين أن الفيروس لم يعد موجودا في الجهاز التنفسي العلوي.\nيجب النظر في كلا المعيارين معا لتحديد التعافي. تعدُّ نتائج الاختبارات السلبية مهمة لأن الأشخاص لا يزالون قادرين على نشر الفيروس حتى لو لم تظهر عليهم أعراض أو أنها توقفت.\n\nبالإضافة إلى ذلك، يقترح المركز الأوروبي لمكافحة الأمراض والوقاية منها (ECDC) أيضا النظر في المعايير التالية لتحديد ما إذا كان المريض قد تعافى:\n3) نتائج اختبار الأجسام المضادة أو المصلية الإيجابية من خلال عينات الدم.\nيمكن أن تظهر اختبارات الأجسام المضادة ما إذا كان جهازك المناعي قد أنتج أجساما مضادة لمحاربة كوفيد-19 مما قد يشير إلى إصابتك بالفيروس. عادة ما يتم إجراء اختبارات الأجسام المضادة على الأقل من أسبوع إلى 3 أسابيع بعد ظهور الأعراض لأول مرة على المريض. ومع ذلك، لا ينبغي استخدام نتائج اختبار الأجسام المضادة لوحدها لتحديد التعافي - يجب استخدامها مع المعيارين الآخرين.\n\nليس من الممكن دائما استخدام هذه المعايير الموصى بها لتحديد التعافي. على سبيل المثال، يعاني بعض الأشخاص المصابين بـ كوفيد-19 من أعراض خفيفة فقط (التعب وضيق التنفس وما إلى ذلك) ومع ذلك لا يتم نقلهم إلى المستشفى لأن هذه الأعراض ليست شديدة بما يكفي. ومع ذلك، يمكن أن تستمر هذه الأعراض الخفيفة على مدى فترات طويلة من الزمن (من أسابيع إلى شهور) مما يزيد من تعقيد كيفية تحديد ما إذا كان شخص ما قد تعافى أم لا من كوفيد-19."
    ],
    "Arabic - Background and context": [
      "تزامنا مع انتشار كوفيد-19 منذ بدايته، تزداد أيضا أعداد المتعافين، ولحسن الحظ يتعافى معظم المرضى المصابين بـ كوفيد-19 من المرض. هناك جدل مستمر وعدم يقين بشأن متى وعلى أي أساس يمكننا اعتبار أن المريض قد تعافى من كوفيد-19.\n\nفي المجمل، يعدُّ تحديد موعد تعافي المريض من كوفيد-19 أكثر تعقيدا من مجرد الحكم في اللحظة التي يشعر فيها المريض بالتحسن. يحتاج تعريف \"الشفاء\" إلى أكثر من مجرد التحسن الكامل للمريض وعدم ظهور الأعراض.\n\nتختلف تعريفات التعافي كثيرا بين البلدان ويمكن أن تظل ذاتية بالنسبة للمريض الفردي، لأن الحالات الأكثر شدة قد يكون لها أعراض تستمر لفترة أطول، وفي بعض الحالات يمكن للأفراد اختبار نتائج إيجابية حتى لو لم يكونوا معديين (أي لا يمكنهم نقل الفيروس لأشخاص آخرين)."
    ],
    "Bengali - What our experts say": [
      " একজন মানুষ কখন কোভিড-১৯ থেকে আরোগ্য লাভ করছেন তা সংজ্ঞায়িত করার জন্য বিভিন্ন প্রতিষ্ঠান (হাসপাতাল, ক্লিনিক, জন স্বাস্থ্য সংস্থা এবং সরকারী সংস্থাগুলি সহ) বিভিন্ন নির্ণায়ক ব্যবহার করছে। একজন মানুষ কখন হাসপাতাল থেকে ছাড়া পেতে পারেন অথবা কখন তাকে আইসোলেশন থেকে বের করে আনা যেতে পারে এটি নির্ধারণ করার জন্য এই নির্ণায়কগুলি বেশীরভাগ ক্ষেত্রে ব্যবহার করা হয়। সারা পৃথিবী জুড়ে ব্যবহার হওয়া কোভিড-১৯ আরোগ্য নির্দেশিকার পর্যালোচনা থেকে দেখা যায় বেশীরভাগ চিকিৎসকই নিম্নলিখিত নির্ণায়কগুলিতে একমত:\n ১) নিদানিক: রোগীর আর উপসর্গ নেই, এবং \n 2) পরীক্ষাগার: রোগীর পরীক্ষার নেতিবাচক ফলাফল রয়েছে (নাক এবং গলা থেকে নেওয়া সোয়াবের পরীক্ষা করে) যাতে দেখা যায় ভাইরাস ঊর্ধ্ব শ্বাসতন্ত্রে আর উপস্থিত নেই।\n আরোগ্য নির্ধারণ করার সময় এই নির্ণায়কদুটি সমন্বয়ে বিবেচনা করার উচিৎ। নেতিবাচক পরীক্ষার ফলাফল গুরুত্বপূর্ণ কারণ মানুষের কোন উপসর্গ না থাকলে অথবা তাদের উপসর্গ থেমে গেলেও তারা তখনও এই ভাইরাস ছড়াতে পারেন।\n \n তার সঙ্গে ইউরোপিয়ান সেন্টার ফর ডিজিজ কন্ট্রোল অ্যান্ড প্রিভেনশন (ECDC) একজন রোগী আরোগ্য লাভ করেছেন কিনা তা নির্ধারণ করার জন্য নিম্নলিখিত নির্ণায়কটিকেও বিবেচনা করার পরামর্শ দেয়:\n ৩) রক্ত নমুনা থেকে ইতিবাচক সেরোলজিক্যাল অথবা অ্যান্টিবডি পরীক্ষার ফলাফল। \n অ্যান্টিবডি পরীক্ষা দেখাতে পারে যে আপনার অনাক্রম্যতা তন্ত্র কোভিড-১৯ এর সঙ্গে লড়াই করার জন্য অ্যান্টিবডি তৈরি করছে কি না, যা থেকে বোঝা যাবে আপনি এই ভাইরাসে আক্রান্ত হয়েছেন। অ্যান্টিবডি পরীক্ষা সাধারণত করা হয় একজন রোগী প্রথম উপসর্গ অভিজ্ঞতা করতে শুরু করার অন্তত ১-৩ সপ্তাহ পরে। যদিও, শুধুমাত্র অ্যান্টিবডি পরীক্ষা ফলাফল আরোগ্য নির্ধারণ করার জন্য ব্যবহার করা উচিৎ নয়-এটিকে অন্য দুটি নির্ণায়কের সমন্বয়ে ব্যবহার করা উচিৎ।\n \n আরোগ্য নির্ধারণ করার জন্য সবসময় এই পরামর্শকৃত নির্ণায়কগুলি ব্যবহার করা সম্ভব নয়। উদাহরণ স্বরূপ, কোভিড-১৯ থাকা কিছু মানুষ শুধু সামান্য উপসর্গ (ক্লান্তি, শ্বাসকষ্ট প্রভৃতি) অভিজ্ঞতা করেন কিন্তু তারা হাসপাতালে ভর্তি হন না কারণ তাদের উপসর্গ যথেষ্ট গুরুতর নয়। এই সামান্য উপসর্গগুলি যদিও অনেক দীর্ঘসময় (কয়েক সপ্তাহ থেকে কয়েক মাস) ধরে বিদ্যমান থাকতে পারে যা কোভিড-১৯ থেকে আরোগ্যলাভ করেছেন কি না এই সিদ্ধান্ত নেওয়াকে আরও জটিল করে তোলে।\n \n "
    ],
    "Bengali - Background and context": [
      " \"কোভিড-১৯ যেমন ছড়াচ্ছে, সেরে ওঠা ব্যক্তির সংখ্যাও তেমনই বৃদ্ধি পাচ্ছে কারণ সৌভাগ্যক্রমে কোভিড-১৯ থাকা বেশীরভাগ রোগী সেরে উঠছেন।। কখন এবং কোন ভিত্তিতে একজন রোগী কোভিড-১৯ থেকে সেরে উঠেছে বলে আমরা বিবেচনা করতে পারি সেই ব্যাপারে অনেক তর্ক বিতর্ক এবং অনিশ্চয়তা রয়েছে।\n \n সংক্ষেপে, কখন একজন রোগী কোভিড-১৯ থেকে আরোগ্য লাভ করেছে তা নির্ধারণ করা, সেই মুহূর্তে রোগী কেমন বোধ করছেন তা বিচার করার থেকে অনেক বেশী জটিল। “আরোগ্য” এর সংজ্ঞাতে রোগীর উপসর্গের সম্পূর্ণ উন্নতি এবং উপসর্গের অনুপস্থিতির থেকে আরও বেশী কিছু অন্তর্গত হওয়া দরকার।\n \n আরোগ্যের সংজ্ঞা বিভিন্ন দেশের মধ্যে অনেক আলাদা হয় এবং তার পরেও এটি প্রতিটি রোগীর ক্ষেত্রে আপেক্ষিক হতে পারে, কারণ অনেক বেশী গুরুতর ক্ষেত্রে হয়তো উপসর্গ অনেক বেশীদিন থাকবে এবং কিছু ক্ষেত্রে সংক্রমণ না থাকা সত্ত্বেও হয়তো পরীক্ষার ফলাফল ইতিবাচক দেখাতে পারে (অর্থাৎ তারা অন্য মানুষের মধ্যে ভাইরাস ছড়িয়ে দিতে পারেনা।)\"\n "
    ]
  },
  {
    "id": "recbwOwl3dwdrh1iY",
    "Question": "Why does COVID-19 make some people sick for months?",
    "Status": "Published",
    "Category": "Symptoms",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA",
      "United Kingdom"
    ],
    "Background and context": "COVID-19 has been shown to have varying effects on different individuals, including symptoms and secondary health effects. This range of outcomes makes it difficult to know the estimate length of impact COVID-19 might have on an individual. One example of a secondary outcome is [myalgic encephalomyelitis/chronic fatigue syndrome](https://www.cdc.gov/me-cfs/index.html) (ME/CFS) — a long-term reappearance of symptoms — clusters of which have followed many infectious outbreaks. Increased data and corresponding analysis will help to provide more empirical evidence on how long COVID-19 adversely impacts individuals, what symptoms are most prevalent, and what secondary outcomes are most common. \n",
    "What our experts say": "Because the COVID-19 virus is new, we still don't know why some people might become sick longer than others—but we do know that people infected with COVID-19 who have severe symptoms tend to have symptoms for longer than those with mild cases. \n\nDifferences in immune responses, including lower levels of antibody production, can impact how long patients remain sick with COVID-19. COVID-19 can impact many organs, which might help explain why the virus can cause symptoms that continue over a longer period of time in some patients. Akiko Iwasaki, a Yale immunology doctor, believes some potential reasons the virus lasts longer in some patients is because the virus might remain in one of the organs that is not tested by nasal swabs; that non-living parts of the virus can still cause your immune system to overreact like the virus is still alive and reproducing in your body when it isn't really doing that; and the virus might not be present in your body any longer, but your immune system is stuck in the state of fighting it off. \n\nAdditionally, after becoming infected with different viruses, your body can take a while to heal. So even if you don't have the virus anymore, you may continue coughing and not be able to breathe as well as you normally do, since your throat and lungs have yet to fully heal and recover.\n\nCurrently, the majority of patients infected with COVID-19 have symptoms for several days - 6 weeks.\n\n\n",
    "Glossary Terms": [
      "recqwr4O57SOjNZYx"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\t\n",
    "Topics": [
      "symptoms"
    ],
    "Other resources": "1. Clinical Questions about COVID-19: Questions and Answers ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html))\n2. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19) ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html)) \n3. COVID-19 and Multiorgan Response ([CPC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187881/)) \n4. Coronavirus disease (COVID-19) outbreak ([WHO](https://www.who.int/health-topics/coronavirus#tab=tab_2)) \n5. COVID-19 Can Last for Several Months ([The Atlantic](https://www.theatlantic.com/health/archive/2020/06/covid-19-coronavirus-longterm-symptoms-months/612679/)) \n6. Researchers warn covid-19 could cause debilitating long-term illness in some patients ([Washington Post](https://www.washingtonpost.com/health/could-covid-19-cause-long-term-chronic-fatigue-and-illness-in-some-patients/2020/05/29/bcd5edb2-a02c-11ea-b5c9-570a91917d8d_story.html)) \n7. A woman says she's had 8 positive coronavirus tests in 50 days. How long can it really take to recover? ([CBS News](https://www.cbsnews.com/news/coronavirus-symptoms-8-positive-tests-50-days/)) \n8. Clearance and persistence of SARS‐CoV‐2 RNA in patients with COVID‐19 ([Journal of Medical Virology](https://www.researchgate.net/profile/Analia_Carmo2/publication/341834349_Clearance_and_Persistence_of_SARS-CoV-2_RNA_in_COVID-19_patients/links/5eeddc0f299bf1faac6657b7/Clearance-and-Persistence-of-SARS-CoV-2-RNA-in-COVID-19-patients.pdf))\n",
    "How often revision needed": "Every 2 weeks for accuracy re: length of illness w/ symptoms from WHO; official reasons it can make people sick for months",
    "DB (Hindi)": [
      "recRqKZW3vHx1CRAV"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recsxms1Gw5Xuy9DG"
    ],
    "DB (Portuguese)": [
      "rec3yXkfEqeTCgNDg"
    ],
    "Rollup test 2": [
      "recsnM0Td2WCkkTfT"
    ],
    "Last modified manual": "2020-07-30",
    "Last edited (simplified)": "2020-07-06T20:37:14.000Z",
    "Last edited (experts say)": "2020-07-30T22:07:04.000Z",
    "Last modified": "2020-07-30",
    "What our experts say wordcount": 245,
    "Background and context wordcount": 95,
    "Other resources wordcount": 97,
    "Wordcount": 437,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "क्योंकि कोविड-19 वायरस नया है, हम अभी भी नहीं जानते हैं कि कुछ लोग दूसरों की तुलना में क्यो लंबे समय तक बीमार क्यों हो सकते हैं - लेकिन हम जानते हैं कि कोविड-19 से संक्रमित लोग जिनके लक्षण गंभीर हैं उनमें हल्के मामलों से अधिक समय तक लक्षण रहते हैं ।\n\nएंटीबॉडी के उत्पादन के निचले स्तर सहित रोगक्षमता प्रतिक्रियाओं में अंतर, यह प्रभावित कर सकता है कि कोविड-19 के साथ रोगी कितने समय तक बीमार रहते हैं। जून 2020 में प्रकाशित पोर्टुगल के एक अध्ययन में पाया गया कि कुछ रोगियों को जिनको लगातार दो बार निगेटिव टेस्ट करवाने में अधिक समय तक लगे थे, उनमें लक्षण और कम एंटीबॉडी के स्तर पाए गए।\n\nकोविड-19 कई अंगों को प्रभावित कर सकता है, जो यह समझाने में मदद कर सकता है कि क्यों वायरस कुछ रोगियों में लंबे समय तक जारी रहने वाले लक्षणों का कारण बन सकता है। येल इम्यूनोलॉजी डॉक्टर अकीको इवासाकी का मानना ​​है कि कुछ संभावित कारणों से वायरस कुछ रोगियों में अधिक समय तक रहता है क्योंकि वायरस उन अंगों में से एक हो सकता है जो नाक के स्वाब द्वारा परीक्षण नहीं किए जाते हैं; वायरस के गैर-जीवित हिस्से अभी भी आपकी प्रतिरक्षा प्रणाली को खत्म करने का कारण बन सकते हैं जैसे वायरस अभी भी जीवित है और आपके शरीर में प्रजनन कर रहा है जब यह वास्तव में ऐसा नहीं कर रहा है; और वायरस आपके शरीर में किसी भी समय मौजूद नहीं हो सकता है, लेकिन आपकी रोगक्षमता प्रणाली इसे बंद करने की स्थिति में फंस गई है।\n\nइसके अतिरिक्त, विभिन्न वायरस से संक्रमित होने के बाद, आपका शरीर ठीक होने में थोड़ा समय ले सकता है। इसलिए यदि आपके पास अब भी वायरस नहीं है, तो आप खाँसना जारी रख सकते हैं और सामान्य रूप से सांस लेने में भी सक्षम नहीं होंगे, क्योंकि आपके गले और फेफड़े अभी तक पूरी तरह से ठीक नहीं हो चुके हैं और स्वस्थ नहीं हो गए हैं।\n\nवर्तमान में, कोविड-19 से संक्रमित अधिकांश रोगियों में 2-6 सप्ताह के लक्षण हैं।"
    ],
    "Hindi - Background and context": [
      "कोविड-19 को अलग-अलग व्यक्तियों पर अलग-अलग प्रभाव दिखाया गया है, जिसमें लक्षण और माध्यमिक स्वास्थ्य प्रभाव शामिल हैं। परिणामों की इस श्रेणी से यह पता लगाना मुश्किल हो जाता है कि किसी व्यक्ति पर कोविड-19 के प्रभाव की अनुमानित लंबाई कितनी हो सकती है। एक माध्यमिक परिणाम का एक उदाहरण मायलजीक एन्सेफेलोमाइलाइटिस / क्रोनिक थकान सिंड्रोम (एमई / सीएफएस) है - लक्षणों का एक लंबे समय तक पुन: प्रकट होना - गुच्छों ने कई संक्रामक प्रकोपों का पालन किया है। बढ़े हुए डेटा और संबंधित विश्लेषण इस बात पर अधिक जरूरी साक्ष्य प्रदान करने में मदद करेंगे कि कब तक कोविड-19 व्यक्तियों पर प्रतिकूल प्रभाव डालता है, कौन से लक्षण सबसे अधिक प्रचलित हैं, और कौन से द्वितीयक परिणाम सबसे आम हैं।"
    ]
  },
  {
    "id": "recSK7NRoa33YUdrv",
    "Question": "Can COVID-19 be transmitted by a person who shows no symptoms?",
    "Status": "In progress",
    "Category": "Spread",
    "Subcategory": "On: COVID-19 & asymptomatic & pre-symptomatic transmission",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "The incubation period of the virus is the time between the moment a person is exposed to the virus and when they first show symptoms. During this period, the virus is multiplying in the body, and once enough of the virus has been replicated, people may indeed show symptoms. However, some people may well be infected with the virus even if they don't have any symptoms. For people who are pre-symptomatic and asymptomatic, they may still spread the virus to others during this period of time.\n",
    "What our experts say": "According to current evidence, it is believed that people with no symptoms, who may be either asymptomatic or pre-symptomatic, are playing a major role in the transmission of COVID-19. That means symptom-based screening alone is unlikely to detect all of the infectious cases and control the transmission of COVID-19. The incubation period of COVID-19, which is the period between a person's exposure to the virus and the first sign of their symptoms (if they develop any at all), ranges from 5 to 14 days. Some people may be contagious during this 5-14 day incubation period before they have symptoms, making those cases \"pre-symptomatic\". The Centers for Disease Control (CDC) has stated that 40% of COVID-19 cases are potentially spread by people who are pre-symptomatic. Other people infected with COVID-19 may never show symptoms at all and are called \"asymptomatic\". Asymptomatic people are still contagious throughout the time they are infected with the virus until their body clears it. The CDC estimates that 35% of COVID-19 cases are asymptomatic.\n\nUPDATED: July 19, 2020: On July 10, 2020, the U.S. CDC has revised its estimates and now states they believe 40% of COVID-19 cases are asymptomatic\n",
    "Glossary Terms": [
      "recE7xmnXgtg8ZanX",
      "recJ4Q812SOdo1NGM",
      "recx2PeCcs1Awb9rG",
      "rec8po7cJXvqkaQYB",
      "recbZcFUtsYMA9Vsh"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "asymptomatic",
      "transmission",
      "contagion",
      "infection",
      "spread",
      "symptoms"
    ],
    "Other resources": "1\\. COVID-19 situation report (WHO)\n2\\. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility (NEJM)\n3\\. Research letter: Asymptomatic SARS-CoV-2 Infection in Household Contacts of a Healthcare Provider, Wuhan, China (U.S. CDC)\n4\\. A study about RT-PCR COVID-19 tests and their false-negative rate (AIM)\n5\\. Research paper: The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission (PNAS)\n6\\. CDC Pandemic Planning Scenarios (U.S. CDC)\n",
    "How often revision needed": "Monthly",
    "Impact on public policy?": "No",
    "DB (French)": [
      "reccy9EmiOk9SlhJ7"
    ],
    "DB (Hindi)": [
      "recWuNukdE0KpKIme"
    ],
    "Editorial notes:": "\n",
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recJ58TDohTG8mp81"
    ],
    "DB (Spanish)": [
      "rec2rBNrVca7WxW2D"
    ],
    "DB (Arabic)": [
      "recmL2IdoU6Tai7bs"
    ],
    "DB (Bengali)": [
      "recK4YmnyFlCZoi9E"
    ],
    "DB (Portuguese)": [
      "recl5zeBwzuy76W9e"
    ],
    "Last modified manual": "2020-07-30",
    "Last edited (simplified)": "2020-07-30T18:04:41.000Z",
    "Last edited (experts say)": "2020-07-30T19:29:36.000Z",
    "Last modified": "2020-07-30",
    "What our experts say wordcount": 191,
    "Background and context wordcount": 85,
    "Other resources wordcount": 66,
    "Wordcount": 342,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "In progress"
    ],
    "Arabic Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Selon les données probantes actuelles, l’on pense que les personnes sans symptômes, qui peuvent être asymptomatiques ou présymptomatiques, jouent un rôle important dans la transmission de la COVID-19. Cela signifie qu’un dépistage fondé seulement sur les symptômes ne détectera probablement pas tous les cas infectieux ni ne contrôlera la transmission de la COVID-19. La « période d’incubation » de la COVID-19, qui est la période entre l’exposition d’une personne au virus et le premier signe de ses symptômes (si elle en développe), est de 5 à 14 jours. Certaines personnes pourraient être contagieuses pendant cette période d’incubation de 5 à 14 jours avant de présenter des symptômes, ce qui rend ces cas « pré-symptomatiques ». Les Centres de contrôle et de prévention des maladies des États-Unis ont déclaré que 40 % des cas de COVID-19 sont potentiellement propagés par des personnes présymptomatiques. D’autres personnes infectées par la COVID-19 pourraient ne jamais présenter de symptômes du tout et sont dites « asymptomatiques ». Les personnes asymptomatiques sont encore contagieuses pendant toute la période d’infection par le virus, jusqu’à ce que leur corps l’élimine. Les Centres de contrôle et de prévention des maladies des États-Unis estiment que 35 % des cas de COVID-19 sont asymptomatiques.\n\nMISE À JOUR : 19 juillet 2020 : le 10 juillet 2020, les Centres de contrôle et de prévention des maladies des États-Unis ont révisé leurs estimations et déclare maintenant qu’ils pensent que 40 % des cas de COVID-19 sont asymptomatiques."
    ],
    "French - Background and context": [
      "La période d'incubation du virus s’étale du moment où une personne est exposée au virus à l’apparition des premiers symptômes. Pendant cette période, le virus se multiplie dans l'organisme et une fois qu'il s'est suffisamment reproduit, les gens peuvent effectivement présenter des symptômes. Cependant, certaines personnes pourraient bien être infectées par le virus même si elles ne présentent aucun symptôme. Les personnes présymptomatiques et asymptomatiques encore transmettre le virus aux autres pendant cette période."
    ],
    "Hindi - What our experts say": [
      "हाँ। वर्तमान साक्ष्यों के अनुसार, यह माना जाता है कि जो लोग कोई लक्षण नहीं दिखा रहे है, जिनमें या तो कोई लक्षण नहीं है या वे अभी तक लक्षण नहीं दिखा रहे हैं, कोविड​​-19 के प्रसार में एक प्रमुख भूमिका निभा रहे हैं। इसका मतलब है कि लक्षण-आधारित स्क्रीनिंग अकेले सभी संक्रामक मामलों (इन्फ़ेक्शन के मामलों) का पता लगाने और कोविड​​-19 के प्रसार को नियंत्रित करने  के लिए काफ़ी नहीं है। कोविड​​-19 की \"ऊष्मायन अवधि\" (इंक्युबेशन पीरीयड), जो किसी व्यक्ति के वायरस के संपर्क में आने और उनके लक्षणों के पहले संकेत (यदि वे विकसित होते हैं) के बीच की अवधि 5 से 14 दिनों तक होती है। कुछ लोग लक्षण होने से पहले ही उन 5-14 दिन के ऊष्मायन अवधि के दौरान वाइरस फैला सकते हैं, ऐसे केस \"पूर्व-लक्षणमय\" (प्री-सिम्प्टमैटिक) कहलाते हैं। कई अन्य लोग जिन्हें कोविड-19 है  तो भी कभी लक्षण नहीं दिखाते हैं और उन्हें \"स्पर्शोन्मुख\" (ऐसिम्प्टमैटिक) कहा जाता है। स्पर्शोन्मुख लोग पूरे समय संक्रामक बने रहते हैं (वाइरस फैला सकते हैं) जब तक कि उनका शरीर वाइरस से पूरी तरह साफ नहीं होता। यू॰ऐस ॰ऐ॰ के सी॰डी॰सी॰ के अनुसार कोविड-19 के 35% रोगी कोई भी लक्षण नहीं दिखाते।"
    ],
    "Hindi - Background and context": [
      "किसी व्यक्ति के वायरस के सम्पर्क में आने और बीमारी के लक्षण दिखाने के बीच के समय को \"ऊष्मायन अवधि” (इंक्युबेशन पीरीयड) कहा जाता है। इस अवधि के दौरान, शरीर में वायरस बढ़ता रहता है, और बहुत अधिक वायरस होने के बाद, लोग लक्षण दिखाने लगते हैं। परंतु कुछ लोगों में अधिक मात्रा में वाइरस होने के बावजूद वे कोई लक्षण नहीं दिखाते। जो लोग अभी तक लक्षण नहीं दिखाने लगे या कभी लक्षण नहीं दिखाएँगे, वे वाइरस फैलाने के योग्य हैं। "
    ],
    "Telugu - What our experts say": [
      "ప్రస్తుత సాక్ష్యాల ప్రకారం, లక్షణాలు లేని వ్యక్తులు, లక్షణం లేనివారు లేదా ముందస్తు లక్షణం ఉన్నవారు, కోవిడ్ -19 ప్రసారంలో ప్రధాన పాత్ర పోషిస్తున్నారని నమ్ముతారు. అంటే రోగలక్షణ-ఆధారిత స్క్రీనింగ్ మాత్రమే అంటువ్యాధులన్నింటినీ గుర్తించి, కోవిడ్ -19 ప్రసారాన్ని నియంత్రించే అవకాశం లేదు. కోవిడ్ -19 యొక్క పొదిగే కాలం, ఇది ఒక వ్యక్తి వైరస్కు గురికావడం మరియు వారి లక్షణాల యొక్క మొదటి సంకేతం (అవి ఏవైనా అభివృద్ధి చెందితే) మధ్య కాలం, 5 నుండి 14 రోజుల వరకు ఉంటుంది. లక్షణాలు కనిపించే ముందు ఈ 5-14 రోజుల పొదిగే కాలంలో కొంతమంది అంటుకొనుట, ఆ కేసులను \"ప్రీ-సింప్టోమాటిక్\" గా మారుస్తుంది. సెంటర్స్ ఫర్ డిసీజ్ కంట్రోల్ (సిడిసి) 40% కోవిడ్ -19 కేసులు ముందస్తు లక్షణాలతో బాధపడుతున్న వ్యక్తులచే వ్యాప్తి చెందుతాయని పేర్కొంది. కోవిడ్ -19 బారిన పడిన ఇతర వ్యక్తులు ఎప్పుడూ లక్షణాలను చూపించలేరు మరియు వారిని \"అసింప్టోమాటిక్\" అని పిలుస్తారు. వైరస్ సోకినంతవరకు వారి శరీరం క్లియర్ అయ్యే వరకు అసిప్టోమాటిక్ వ్యక్తులు ఇప్పటికీ అంటుకొంటారు. కోవిడ్ -19 కేసులలో 35% లక్షణాలు లేనివి అని సిడిసి అంచనా వేసింది.\n\nనవీకరించబడింది: జూలై 19, 2020: జూలై 10, 2020 న, యు.ఎస్. సిడిసి తన అంచనాలను సవరించింది మరియు ఇప్పుడు 40% కోవిడ్ -19 కేసులు లక్షణరహితమని వారు నమ్ముతున్నారని పేర్కొంది"
    ],
    "Telugu - Context and background": [
      "వైరస్ యొక్క పొదిగే కాలం ఒక వ్యక్తి వైరస్కు గురైన క్షణం మరియు వారు మొదట లక్షణాలను చూపించిన సమయం. ఈ కాలంలో, శరీరంలో వైరస్ గుణించాలి మరియు వైరస్ తగినంతగా ప్రతిరూపం పొందిన తర్వాత, ప్రజలు లక్షణాలను చూపించవచ్చు. అయినప్పటికీ, కొంతమందికి లక్షణాలు లేనప్పటికీ వైరస్ బారిన పడవచ్చు. ప్రీ-రోగలక్షణ మరియు లక్షణం లేని వ్యక్తుల కోసం, వారు ఈ కాలంలో వైరస్ను ఇతరులకు వ్యాప్తి చేయవచ్చు."
    ],
    "Spanish - What our experts say": [
      "De acuerdo a la evidencia actual, se cree que las personas sin síntomas, quienes pueden ser asintomáticas o bien pre sintomáticas, están jugando un rol principal en la transmisión del COVID-19. Eso significa que el cribado basado en síntomas, por sí mismo, es improbable que detecte todos los casos infecciosos y controle la transmisión del COVID-19. El periodo de incubación del COVID-19, el cual es el lapso entre la exposición de una persona al virus y el primer signo de sus síntomas (si es que desarrollan alguno), va de 5 a 14 días. Algunas personas pueden ser contagiosas durante este periodo de incubación de 2 a 14 días antes de que tengan síntomas, haciendo que esos casos sean \"pre sintomáticos\". Los Centros para Control de Enfermedades de los EE.UU. (U.S. CDC) han afirmado que 40% de los casos de COVID-19 son potencialmente diseminados por personas que son pre sintomáticas. Puede que otras personas infectadas con COVID-19 nunca muestren síntomas en absoluto, y son denominadas \"asintomáticas\". Las personas asintomáticas aún son contagiosas durante el tiempo que están infectadas con el virus, hasta que sus cuerpos lo eliminan. Los U.S. CDC estiman que el 35% de los casos de COVID-19 son asintomáticos.\n\nACTUALIZADO: 19 de julio de 2020: El 10 de julio de 2020, los U.S. CDC han revisado sus estimaciones y ahora afirman que creen que el 40% de los casos de COVID-19 son asintomáticos."
    ],
    "Spanish - Background and context": [
      "El periodo de incubación del virus es el lapso entre el momento en que una persona es expuesta al virus y cuando muestra síntomas por primera vez. Durante este periodo, el virus se está multiplicando en el cuerpo, y una vez que suficiente cantidad del mismo ha sido replicada, de hecho las personas pueden mostrar síntomas. Sin embargo, algunas personas bien pudieran ser infectadas con el virus aún si no tienen síntoma alguno. Por lo que las personas que son pre sintomáticas y asintomáticas aún pueden diseminar el virus a otros durante este periodo de tiempo."
    ],
    "Arabic - What our experts say": [
      "بحسب الأدلة الحالية، يُعتقد أن الأشخاص الذين لا تظهر عليهم الأعراض، سواءً كانوا مرضى دون أعراضٍ ظاهرة أو في مرحلة ما قبل ظهور الأعراض (قد تظهر الأعراض فيما بعد)، يلعبون دورًا رئيسًا في انتقال مرض كورونا (كوفيد-19). أيّ إن عرض عدد حالات الإصابة بالاعتماد فقط على ظهور الأعراض على المرضى لا يساعد في اكتشاف كل حالات الإصابة ولا في السيطرة على انتشار مرض كورونا(كوفيد-19). تترواح فترة حضانة الفيروس المسبب لمرض كورونا (كوفيد-19) ما بين 5-14 يومًا، وهي الفترة ما بين تعرض الأشخاص للفيروس وظهور أولى علامات الأعراض عليهم (إذا ما ظهر عليهم أيها). قد ينقل بعض الأشخاص العدوى قبل ظهور الاعراض عليهم خلال فترة حضانة الفيروس (5-14 يومًا)، وتُصنَّف هذه الحالات ضمن حالات العدوى في ’مرحلة ما قبل ظهور الأعراض‘. أشارت المراكز الأمريكية للسيطرة على الأمراض والوقاية منها إن 40% من حالات العدوى تم نقلها عن طريق أشخاص مرضى في مرحلة ’ما قبل ظهور الأعراض‘. قد لا تظهر أبدًا الأعراض على مصابين أخرين بمرض كورونا (كوفيد-19) ويُصنَّف هؤلاء على أنهم ’مرضى دون أعراض ظاهرة‘. المرضى دون أعراض ظاهرة يستمرون في نقل العدوى منذ وقت إصابتهم بالفيروس لحين تخلص أجسامهم منه. تُقدّر المراكز الأمريكية للسيطرة على الامراض والوقاية منها أن 35% من حالات كورونا (كوفيد-19) هي حالات بدون أعراضٍ ظاهرة.\nتحديث بتاريخ 19 تموز/يوليو 2020 على التقديرات المنشورة بتاريخ 10 تموز/يوليو 2020: راجعت المراكز الأمريكية للسيطرة على الامراض والوقاية منها تقديراتها، حيث تعتقد الآن أن 40% من حالات كورونا (كوفيد-19) هي حالات بدون أعراضٍ ظاهرة.\n"
    ],
    "Arabic - Background and context": [
      "إن فترة حضانة الفيروس هي الفترة ما بين تعرض شخصٍ ما للفيروس وظهور الأعراض عليه أول مرة. خلال هذه الفترة، يقوم الفيروس بالتكاثر في الجسم، وحين تُنسخ أعدادٌ كافيةٌ منه عندها قد تظهر الأعراض على الأشخاص. مع ذلك، قد يكون بعض الأشخاص مصابين بالفيروس رغم عدم ظهور أية أعراض عليهم. بالنسبة للأشخاص الذين لا تظهر عليهم أعراض  والذين في مرحلة ما قبل ظهور الأعراض قد يستمرون في نقل الفيروس إلى الأخرين أثناء هذه المرحلة.\n"
    ],
    "Bengali - What our experts say": [
      "বর্তমান প্রমাণ অনুসারে, এটি বিশ্বাস করা হয় যে কোনও লক্ষণ নেই এমন ব্যক্তিরা, যিনি লক্ষণহীন বা লক্ষণ-পূর্ব হতে পারেন, তারা কোভিড-১৯ সংক্রমণে প্রধান ভূমিকা পালন করছেন। এর অর্থ শুধুমাত্র লক্ষণ-ভিত্তিক স্ক্রিনিংয়ের ফলে সমস্ত সংক্রামক ঘটনা সনাক্ত এবং কোভিড-১৯ সংক্রমণ নিয়ন্ত্রণের সম্ভাবনা নেই। কোভিড-১৯ এর ইনকিউবেশন পিরিয়ড, যা কোনও ব্যক্তির ভাইরাসের সংস্পর্শে আসার এবং তার লক্ষণগুলির প্রথম প্রকাশ (যদি তারা কিছুটা বিকাশ করে) এর মধ্যে সময়কাল হয়, যা ৫ থেকে ১৪ দিন অবধি থাকে। কিছু লোক লক্ষণ প্রকাশ হওয়ার আগে এই ২-১৪ দিনের ইনকিউবেশন পিরিয়ডে সংক্রামক হতে পারে, যা এই ঘটনাগুলিকে \"প্রাক-লক্ষণাত্মক\" করে তোলে। মার্কিন যুক্তরাষ্ট্রের রোগ নিয়ন্ত্রণ কেন্দ্র (U.S. CDC) জানিয়েছে যে, কোভিড-১৯ এর ক্ষেত্রে ৪০% সম্ভাব্য লক্ষণ-পূর্ব লোকদের দ্বারা ছড়িয়ে পড়ে। কোভিড-১৯ এ সংক্রামিত কিছু ব্যক্তিরা কখনই লক্ষণগুলি দেখাতে পারে না এবং তাদেরকে \"লক্ষণহীন\" বলা হয়। শরীরে ভাইরাস সংক্রামিত হওয়া লক্ষণহীন লোকেরা ততক্ষণ সংক্রামক থাকে যতক্ষণ অবধি তাদের শরীর এগুলো পরিষ্কার না করে। মার্কিন যুক্তরাষ্ট্রের রোগ নিয়ন্ত্রণ কেন্দ্র অনুমান করে যে, কোভিড-১৯ এর ক্ষেত্রে ৩৫% কেস লক্ষণহীন। \nআপডেট: জুলাই ১৯, ২০২০: ১০ জুলাই, ২০২০, মার্কিন যুক্তরাষ্ট্রের রোগ নিয়ন্ত্রণ কেন্দ্র তার প্রাক্কলনটি সংশোধন করেছে এবং এখন তারা বলেছে যে কোভিড-১৯ এর ক্ষেত্রে ৪০% ঘটনা লক্ষণহীন।"
    ],
    "Bengali - Background and context": [
      "ভাইরাসটির ইনকিউবেশন পিরিয়ড হ'ল কোনও ব্যক্তি ভাইরাসের সংস্পর্শে আসার মুহূর্ত থেকে তার প্রথম লক্ষণগুলি প্রকাশের সময়। এই সময়ের মধ্যে, ভাইরাস শরীরে বহুগুণ বৃদ্ধি পাচ্ছে, এবং ভাইরাসের যথেষ্ট পরিমাণে প্রতিলিপি তৈরি হয়ে গেলে লোকেরা প্রকৃতপক্ষে লক্ষণগুলি দেখাতে পারে। তবে কিছু লোক লক্ষণ না থাকলেও ভাইরাসে সংক্রামিত হতে পারে।যেসব রোগী লক্ষণ-পূর্ব এবং লক্ষণহীন, তারাও এই সময়ের মধ্যে অন্যদের মাঝে ভাইরাস ছড়িয়ে দিতে পারে।"
    ],
    "Portuguese - What our experts say": [
      "De acordo com as evidências atuais, acredita-se que pessoas sem sintomas, que podem ser assintomáticas ou pré-sintomáticas, estejam desempenhando um papel importante na transmissão do COVID-19. Isso significa que é improvável que a triagem baseada em sintomas detecte todos os casos infecciosos e controle a transmissão do COVID-19. O período de incubação do COVID-19, que é o período entre a exposição de uma pessoa ao vírus e os seus primeiros sintomas (se houver algum), varia de 5 a 14 dias. Algumas pessoas podem ser contagiosas durante esse período de incubação de 2 a 14 dias antes de apresentarem sintomas, o que faz com que esses casos sejam \"pré-sintomáticos\". Os Centros de Controle de Doenças dos Estados Unidos (CDC dos EUA) declararam que 40% dos casos de COVID-19 são, provavelmente, transmitidos por pessoas pré-sintomáticas. Outras pessoas infectadas com COVID-19 podem nunca apresentar sintomas e são chamadas de \"assintomáticas\". Ainda assim, as pessoas assintomáticas são contagiosas durante todo o período entre o momento em que são infectadas pelo vírus e o que o corpo delas os elimine. O CDC dos EUA estima que 35% dos casos de COVID-19 são assintomáticos.\nATUALIZACAO:\n19 de julho de 2020: Em 10 de julho de 2020, o CDC dos EUA revisou suas estimativas e agora afirma que acredita que 40% dos casos de COVID-19 são assintomáticos."
    ],
    "Portuguese - Background and context": [
      "O período de incubação do vírus é o tempo entre o momento em que uma pessoa é contaminada pelo vírus e a primeira vez que apresenta sintomas. Durante esse período, o vírus está se multiplicando no corpo e, uma vez replicado o suficiente, as pessoas contaminadas podem apresentar sintomas. No entanto, algumas pessoas podem estar infectadas com o vírus, mesmo que não apresentem sintomas. Quanto às pessoas pré-sintomáticas e assintomáticas, elas podem transmitir o vírus a outras pessoas durante esse período."
    ]
  },
  {
    "id": "recNhNi9YMJidUo7K",
    "Question": "How soon can we have a COVID-19 vaccine? ",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On COVID-19 & vaccines",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Contrary to U.S. President Trump's claims that a safe and effective vaccine could be ready by the November 2020 U.S. election, the Director of the U.S. Centers for Disease Control and Prevention (CDC) was correct in stating that a safe and effective vaccine was unlikely to be ready at that time. Efforts are on track for a few COVID-19 vaccine candidates to be approved and to begin distribution by the end of 2020 and early 2021, which is already record-breaking timeframe for vaccine development.\n\nThe rush for a COVID-19 vaccine is unprecedented in its speed, the number of labs and companies working to develop one, and the global pressure to develop a safe, effective vaccine on such a large scale. \n\nPrior to COVID-19, the shortest amount of time it took to develop a vaccine was for mumps, which took roughly four years. Scientists have been working on a vaccine for Acquired Immunodeficiency Syndrome (AIDS) for 20 years and still have yet to find a successful one. Because scientists discovered the genetic sequence of COVID-19 so rapidly, and so many groups are working around the clock to develop an effective vaccine, with unparalleled funding, the public health, medical, and pharmaceutical fields are hopeful to have a vaccine available much faster. Even after a vaccine is developed, adequate manufacturing, supply chain, and distribution networks also need to be coordinated in order to get the vaccine to people across the world.\n",
    "What our experts say": "The timeline for COVID-19 vaccine availability is rapidly evolving, with differences between multiple vaccine candidates and rollout plans in different countries. \n\nWhile the vaccine development and testing processes normally take many years, these processes have been accelerated during the COVID-19 pandemic. Several COVID-19 vaccines have reported promising results from clinical trials so far. As of December 2, 2020, Pfizer's vaccine candidate received approval from the U.K. government to begin mass distribution, with at-risk populations and healthcare workers being the first priorities. \n\nBoth Pfizer's and Moderna's vaccine candidates have applied for Emergency Use Authorization (EUA) from the U.S. government, and have the potential to begin distribution outside of trials before the end of 2020. In a departure from the rigorous review processes typically used for vaccines, China and Russia approved and started distributing experimental vaccine candidates earlier in 2020, based on preliminary data, rather than waiting for results from large-scale trails.\n\nThere are currently more than 200 potential vaccines for COVID-19 under development around the world. Each potential vaccine must be thoroughly tested to determine whether it has any harmful side effects, whether it can prevent disease in other mammals, and whether it successfully produces antibodies, which are the biological tools or instructions our immune systems need to defend against the virus. Scientists also need to assess how the immune system responds to the vaccine in general, which takes time. \n\nEven with an expedited timeline and regulatory approval process, researchers must ensure adequate clinical testing and adherence to regulatory standards, manufacturing, and quality control processes. Additionally, several COVID-19 vaccine candidates require multiple doses to be effective and cold storage during transport. There are concerns about the cost and infrastructure requirements for vaccines to be distributed equitably in certain regions of the word. Public health experts hope that multiple vaccine candidates can be widely approved and distributed in 2021, to help end the global COVID-19 pandemic. \n",
    "Glossary Terms": [
      "recPzw1C0Nfi9r41m",
      "rec9qqItwSTjq3Eae",
      "reccjqJClKxUMJYzt"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "vaccine",
      "prevention"
    ],
    "Other resources": "1. Developing Covid-19 Vaccines at Pandemic Speed ([NEJM](http://Developing Covid-19 Vaccines at Pandemic Speed))\n2. Accelerating a safe and effective COVID-19 vaccine ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/accelerating-a-safe-and-effective-covid-19-vaccine))\n3. Dr. Anthony Fauci says there’s a chance coronavirus vaccine may not provide immunity for very long ([CNBC](https://www.cnbc.com/2020/06/02/dr-anthony-fauci-says-theres-a-chance-coronavirus-vaccine-may-not-provide-immunity-for-very-long.html))\n\n",
    "How often revision needed": "Weekly",
    "DB (Hindi)": [
      "rec5j9NoybrNLrh0x"
    ],
    "Media": [
      {
        "id": "att2MsXez9bcH4iNF",
        "url": "https://dl.airtable.com/.attachments/af7025e913b32261a4db6dd3f5e29d4c/665e8d0f/Slide_1",
        "filename": "Slide_1",
        "size": 124760,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ae2bf1976a483c24e794a43568e46e8d/141cf355",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/aa410c90d190b0d744df1a0ff63b7412/c08c81f1",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/2d59d179f3a2cb32829742767804fd69/f7ec3519",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attY9P9XnSfepBLOP",
        "url": "https://dl.airtable.com/.attachments/30862bb3c2c04cb40e828019dabb9f97/7c499f86/Slide_2",
        "filename": "Slide_2",
        "size": 167366,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/2d90bdbcc8dc3b205cf1899d571add3a/e9ad0193",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/05f0070589677751182b36997e1cbb7e/230f45dd",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/fefce74bffa1ed93fc1e009eb730ac4d/0906caf6",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "atttxcmv4jWzaQS28",
        "url": "https://dl.airtable.com/.attachments/f2b56c3f89b3d1b0f299b70e7d6aab26/903c0803/Slide_3",
        "filename": "Slide_3",
        "size": 193831,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/9c29e72cc6d9f554589c4f25e949c943/c6cddf03",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b67645bbf548338711621b42931946e4/ad77c8b0",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/20f202bed3a9efe01e812c0dd54f4999/758e8174",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attLChc2j0btKXG7S",
        "url": "https://dl.airtable.com/.attachments/1e9a4a06c632e8399beddc4ee8a6d133/74467b09/Slide_4",
        "filename": "Slide_4",
        "size": 174063,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/8ff46a32963ff4a5d055a225514acc42/2cdec648",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c03c5012671df3e22c89e90754dfc2bb/b4c87977",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e827f6040901e528830c2343ce1d8185/df75e54c",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attFYTB4ZH8gmuDfF",
        "url": "https://dl.airtable.com/.attachments/a9a78f980f82061d4cb6321e8beab49d/344cfcfb/Slide_5",
        "filename": "Slide_5",
        "size": 161021,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e1bb22997816f4263bc721514c94bf99/c8ebc504",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d4ef5835fbf0fb0a77b7e8af8d2d7065/cb0d5599",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/fbc5999753134aa125ead268e489adb9/63d4dabc",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "rec7Zcp4DogD2PHbU"
    ],
    "DB (Portuguese)": [
      "recI0NhiBipzaxlbu"
    ],
    "Media Package": [
      {
        "id": "attJyFjBwzz0Hx3xW",
        "url": "https://dl.airtable.com/.attachments/ce1cec4d4962259031ec0ee6f85cc359/db4ff48d/Howsooncanweexpectavaccine.zip",
        "filename": "How soon can we expect a vaccine.zip",
        "size": 822648,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-12-02",
    "Last edited (simplified)": "2020-12-02T23:50:39.000Z",
    "Last edited (experts say)": "2020-12-02T23:50:39.000Z",
    "Last modified": "2020-12-02",
    "What our experts say wordcount": 314,
    "Background and context wordcount": 236,
    "Other resources wordcount": 33,
    "Wordcount": 583,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "टीके की उपलब्धता की समयरेखा अभी भी स्पष्ट नहीं है, क्योंकि विकास और परीक्षण की प्रक्रिया में आम तौर पर कई साल लगते हैं।\n\nवर्तमान में दुनिया भर में विकास के तहत कोविड-19 के लिए 200 से अधिक संभावित टीके हैं। प्रत्येक संभावित टीका को यह निर्धारित करने के लिए अच्छी तरह से जांचना चाहिए कि क्या इसका कोई हानिकारक दुष्प्रभाव है, क्या यह अन्य स्तनधारियों में बीमारी को रोक सकता है, और क्या यह सफलतापूर्वक एंटीबॉडी का उत्पादन करता है, जो जैविक उपकरण या निर्देश हैं जो हमारे प्रतिरक्षा प्रणाली को वायरस से बचाव करने की आवश्यकता है।\n\nवैज्ञानिकों को यह भी मूल्यांकन करने की आवश्यकता है कि प्रतिरक्षा प्रणाली सामान्य रूप से टीके के लिए कैसे प्रतिक्रिया करती है, जो समय लगता है। एक समयसीमा और विनियामक मंजूरी प्रक्रिया के साथ भी, शोधकर्ताओं को पर्याप्त नैदानिक ​​परीक्षण और नियामक मानकों, विनिर्माण और गुणवत्ता नियंत्रण प्रक्रियाओं का पालन सुनिश्चित करना चाहिए। उच्च दर को देखते हुए, जिस पर परीक्षण की प्रक्रिया के दौरान संभावित वैक्सीन छूट जाते हैं, और संभावित निर्माण बाधाएं उत्पन्न होती हैं, 2021 से पहले वैक्सीन का उत्पादन, परीक्षण और पैमाने बनाना मुश्किल होगा।"
    ],
    "Hindi - Background and context": [
      "मई 2020 में, एक अंतरराष्ट्रीय स्तर पर प्रसिद्ध चिकित्सा विशेषज्ञ और यूएस नेशनल इंस्टीट्यूट ऑफ एलर्जी और संक्रामक रोगों के प्रमुख डॉ. एंथोनी फौसी ने उल्लेख किया कि उन्हें उम्मीद है कि 2021 की पहली छमाही में टीका उपलब्ध होगा, 12-18 महीने पहले वायरस जो कोविड-19 का कारण बनता है, उसे पहले पहचान लिया गया था। 23 जून, 2020 को, उन्होंने कहा कि अभी भी 2020 के अंत तक या 2021 की शुरुआत में एक टीके का उत्पादन करने के प्रयास जारी हैं, जो टीके के विकास के लिए एक रिकॉर्ड-ब्रेकिंग टाइमफ्रेम होगा।\n\nकोविड-19 टीके के लिए प्रयत्न अपनी गति में अभूतपूर्व है, एक को विकसित करने के लिए काम करने वाली प्रयोगशालाओं और कंपनियों की संख्या और इतने बड़े पैमाने पर एक सुरक्षित, प्रभावी टीके विकसित करने का वैश्विक दबाव। कोविड-19 से पहले, टीके को विकसित करने के लिए सबसे कम समय के लिए गलसुआ का रोग था और लगभग चार साल लगे। वैज्ञानिक 20 वर्षों से एक्वायर्ड इम्युनोडेफिशिएंसी सिंड्रोम (एड्स) के लिए एक टीका पर काम कर रहे हैं और अभी भी एक सफल खोज करना बाकी है। क्योंकि वैज्ञानिकों ने इतनी तेजी से कोविड-19 के आनुवांशिक अनुक्रम की खोज की, और इतने सारे समूह एक प्रभावी टीका विकसित करने के लिए घड़ी के चारों ओर काम कर रहे हैं, अद्वितीय धन के साथ, सार्वजनिक स्वास्थ्य, चिकित्सा और फार्मास्युटिकल क्षेत्रों में वैक्सीन उपलब्ध होने की उम्मीद है जल्दी से। वैक्सीन विकसित होने के बाद भी, दुनिया भर के लोगों को वैक्सीन प्राप्त करने के लिए पर्याप्त विनिर्माण, आपूर्ति श्रृंखला और वितरण नेटवर्क को भी समन्वित किया जाना चाहिए।"
    ]
  },
  {
    "id": "recUf54dYwOUfEzIR",
    "Question": "What do we know so far about COVID-19 and nursing homes?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & nursing homes",
    "Background and context": "Since the earliest outbreaks in the United States occurred in nursing care homes for the elderly, much speculation has surrounded older populations as they are high-risk for the virus. In addition, nursing home residents remain in enclosed spaces, are sometimes in close confines with others, and often have preexisting conditions, so their risk increases. In fact, in 14 states in the U.S., nursing home residents and staff who have died from COVID-19 account for more than half of all COVID-19 deaths in that state.\n\nIn response to this, most countries with large populations of people over 65 have created new regulations to make sure that patient, employee, and healthcare worker safety in these facilities is the highest priority. By using these new standards, the risks should be significantly reduced for residents and employees alike. \n",
    "What our experts say": "The risk of exposure to the novel coronavirus that causes COVID-19 is particularly high in nursing homes, which cater to vulnerable older adults who often have chronic illnesses or underlying conditions. A nursing home in Kirkland, Washington was one of the first hotspots for the COVID-19 pandemic in the United States: the facility accounted for 30 out of the 46 deaths in Washington due to COVID-19 at the time. Since then, there have been several outbreaks in nursing homes across the United States, including in Montana and Utah, as of July 2020. The U.S. Centers for Disease Control also found that long-term nursing care facilities were vulnerable to outbreaks long before the COVID-19 pandemic: 80% of the 2,590 non-foodborne outbreaks of norovirus in the US from 2009 to 2012 were attributed to long-term care facilities.\n\nNursing home residents are vulnerable to severe complications and mortality from COVID-19, and residents often live close to one another, which makes it challenging to implement quarantine and social distancing measures. Close proximity to caregivers who assist multiple residents across different rooms in the facility can also contribute to transmission of the virus, especially if infection prevention control measures are inadequate. Many staff lack access to paid sick leave, which may incentivize them to work even while experiencing symptoms of COVID-19. \n\nThe Occupational Safety and Health Administration (OSHA)  recommends encouraging long-term care facility or nursing home workers to stay home if they are sick, screen workers and residents regularly for symptoms of COVID-19, adhere to U.S. CDC visitation guidelines, maintain at least 6 feet / 2m between workers, visitors, and residents, stagger breaks to prevent overcrowding, and provide hand washing facilities and alcohol-based hand sanitizer throughout the nursing home, among other measures. The U.S. CDC further recommends improvements in reporting COVID-19 cases from nursing home facilities, assigning at least one individual trained in infection and prevention control (IPC) to manage IPC on-site, screen visitors upon entry, and limit visitors (especially if they are experiencing symptoms), and create a robust testing plan for all employees and residents of the nursing home. There should also be guidelines in place to dedicate a separate unit of the nursing home to care for known or suspected COVID-19 patients to prevent further transmission. Visitation requirements can be tightened or relaxed depending on the number of cases in the community: the U.S. CDC recommends use of alternative methods such as video conferencing in lieu of in-person visits. Preventive measures include restricting all visitors except for compassionate care reasons, such as end-of-life care.\n",
    "Glossary Terms": [
      "rec2UNEXbTkSCx30Q"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "nursing home",
      "transmission",
      "prevention",
      "spread"
    ],
    "Other resources": "1. Preparing for COVID-19 in Nursing Homes ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/long-term-care.html))\n2. COVID-19 Guidance for Nursing Home and Long-Term Care Facility Workers ([OSHA](https://www.osha.gov/Publications/OSHA4025.pdf)) \n3. Nursing Homes Are Ground Zero for COVID-19 Pandemic ([JAMA](https://jamanetwork.com/channels/health-forum/fullarticle/2763666))\n4. Vital Signs: Foodborne Norovirus Outbreaks — United States, 2009–2012 ([U.S. CDC](https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6322a3.htm?s_cid=mm6322a3_w))\n5. State Data and Policy Actions to Address Coronavirus ([KFF](https://www.kff.org/health-costs/issue-brief/state-data-and-policy-actions-to-address-coronavirus/)) \n",
    "How often revision needed": "Monthly",
    "DB (Hindi)": [
      "recxg5Br3zPr1B9Q9"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "receoUPDIRXu8Lvbn"
    ],
    "DB (Portuguese)": [
      "recPpvHRGL6qgt9bX"
    ],
    "Rollup test 2": [
      "recy3mPenl9P5I65M",
      "recofXt2OHT8qZ0Rr"
    ],
    "Last modified manual": "2020-07-30",
    "Last edited (simplified)": "2020-07-30T00:56:40.000Z",
    "Last edited (experts say)": "2020-07-30T00:57:08.000Z",
    "Last modified": "2020-07-30",
    "What our experts say wordcount": 421,
    "Background and context wordcount": 134,
    "Other resources wordcount": 51,
    "Wordcount": 606,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "कोविड-19 का कारण बनने वाले उपन्यास कोरोनावायरस के संपर्क में आने का खतरा विशेष रूप से नर्सिंग होम में अधिक होता है, जो पुराने वयस्कों को बीमार करता है जिनकी अक्सर पुरानी बीमारियां या अंतर्निहित स्थितियां होती हैं। किर्कलैंड में एक नर्सिंग होम, वाशिंगटन संयुक्त राज्य अमेरिका में कोविड-19 महामारी के लिए पहले हॉटस्पॉट में से एक था: उस समय कोविड-19 के कारण वाशिंगटन में हुई 46 मौतों में से 30 में यह सुविधा थी। तब से, संयुक्त राज्य अमेरिका में नर्सिंग होम में कई प्रकोप हुए हैं, जिसमें जुलाई 2020 तक मोंटाना और यूटा भी शामिल हैं। यूएस सेंटर फॉर डिजीज कंट्रोल ने यह भी पाया कि लंबे समय तक नर्सिंग देखभाल की सुविधा कोविड-19 से पहले लंबे समय तक प्रकोप की चपेट में थी। कोविड-199 महामारी: 2009 से 2012 तक अमेरिका में नोरोवायरस के 2,590 गैर-खाद्य प्रकोपों ​​का 80% दीर्घकालिक देखभाल सुविधाओं के लिए जिम्मेदार था।\n\nनर्सिंग होम के निवासी कोविड-19 से गंभीर जटिलताओं और मृत्यु दर के प्रति संवेदनशील हैं, और निवासी अक्सर एक दूसरे के करीब रहते हैं, जो संगरोध और सामाजिक दूर करने के उपायों को लागू करने के लिए चुनौतीपूर्ण बनाता है। देखभाल करने वालों की निकटता जो सुविधा में विभिन्न कमरों में कई निवासियों की सहायता करते हैं, वायरस के संचरण में भी योगदान कर सकते हैं, खासकर अगर संक्रमण की रोकथाम के नियंत्रण के उपाय अपर्याप्त हैं। कई कर्मचारियों को भुगतान किए गए बीमार अवकाश तक पहुंच की कमी है, जो उन्हें कोविड-19 के लक्षणों का अनुभव करते हुए भी काम करने के लिए प्रोत्साहित कर सकते हैं।\n\nव्यावसायिक सुरक्षा और स्वास्थ्य प्रशासन (ओएसएचअे) लंबे समय तक देखभाल सुविधा या नर्सिंग होम श्रमिकों को घर पर रहने के लिए प्रोत्साहित करने की सलाह देता है, यदि वे बीमार हैं, तो स्क्रीन कर्मचारी और निवासी नियमित रूप से कोविड-19 के लक्षणों के लिए, यू॰एस सीडीसी मुलाकातों के दिशानिर्देशों का पालन करें, कम से कम बनाए रखें श्रमिकों, मुलाक़ाती और निवासियों के बीच 6 फीट / 2 मीटर, भीड़भाड़ को रोकने के लिए, और अन्य उपायों के साथ, नर्सिंग होम में हाथ धोने की सुविधा और अल्कोहल-आधारित हैंड सैनिटाइज़र प्रदान करने के लिए स्टैगर टूट जाता है। यू॰एस सीडीसी आगे नर्सिंग होम सुविधाओं से कोविड-19 मामलों की रिपोर्टिंग में सुधार की सिफारिश करता है, जो संक्रमण और रोकथाम नियंत्रण (आईपीसी) में प्रशिक्षित कम से कम एक व्यक्ति को आईपीसी का प्रबंधन करने के लिए ऑन-साइट, प्रवेश पर स्क्रीन आगंतुकों और विशेष रूप से आगंतुकों को सीमित करता है। लक्षणों का अनुभव कर रहे हैं), और नर्सिंग होम के सभी कर्मचारियों और निवासियों के लिए एक मजबूत परीक्षण योजना बनाएं। ज्ञात या संदिग्ध कोविड-19 रोगियों की देखभाल के लिए नर्सिंग होम की एक अलग इकाई को समर्पित करने के लिए दिशा-निर्देश होना चाहिए ताकि आगे प्रसारण को रोका जा सके। समुदाय में मामलों की संख्या के आधार पर विज़िट की आवश्यकताओं को कड़ा किया जा सकता है या आराम दिया जा सकता है: यू॰एस सीडीसी वैकल्पिक तरीकों के उपयोग की सिफारिश करता है, जैसे कि व्यक्ति के दौरे के बदले में वीडियो कॉन्फ्रेंसिंग। निवारक उपायों में दयालु देखभाल कारणों को छोड़कर सभी मुलाक़ाती को प्रतिबंधित करना शामिल है, जैसे कि जीवन की देखभाल।"
    ],
    "Hindi - Background and context": [
      "जबसे संयुक्त राज्य अमेरिका में शुरुआती प्रकोप बुजुर्गों के लिए नर्सिंग देखभाल घरों में हुआ, इसलिए बहुत अधिक अटकलों ने पुरानी आबादी को घेर लिया है क्योंकि वे वायरस के लिए उच्च जोखिम वाले हैं। इसके अलावा, नर्सिंग होम के निवासी संलग्न स्थानों में रहते हैं, कभी-कभी दूसरों के साथ घनिष्ठता में होते हैं, और अक्सर चिंताजनक स्थिति होती है, इसलिए उनका जोखिम बढ़ जाता है। वास्तव में, अमेरिका के 14 राज्यों में, नर्सिंग होम के निवासी और कर्मचारी, जो उस राज्य के सभी की आधे से अधिक मौतों कोविड-19 से हो चुकी हैं।\n\n \nइसके जवाब में, 65 से अधिक लोगों की बड़ी आबादी वाले अधिकांश देशों ने यह सुनिश्चित करने के लिए नए नियम बनाए हैं कि इन सुविधाओं में रोगी, कर्मचारी और स्वास्थ्य सेवा कार्यकर्ता सुरक्षा सर्वोच्च प्राथमिकता है। इन नए मानकों का उपयोग करके, निवासियों और कर्मचारियों के लिए समान रूप से जोखिम को कम किया जाना चाहिए।"
    ],
    "Portuguese - What our experts say": [
      "O risco de exposição ao novo coronavírus que causa o COVID-19 é particularmente alto em casas de repouso, que cuidam de idosos mais vulneráveis e que geralmente têm doenças crônicas ou um estado de saúde anterior já debilitado.Uma casa de repouso em Kirkland, no estado de Washington, foi um dos primeiros focos da pandemia do COVID-19 nos Estados Unidos: esse estabelecimento foi responsável por 30 das 46 mortes em Washington devido ao COVID-19 na época. Desde então, houve vários surtos em casas de repouso nos Estados Unidos, incluindo Montana e Utah, em julho de 2020. Os Centros de Controle de Doenças dos EUA também descobriram que as instalações de enfermarias de longo prazo eram vulneráveis a surtos de doenças já muito antes da pandemia do COVID-19: 80% dos 2.590 surtos de norovírus não transmitidos por alimentos nos EUA entre 2009 e 2012 foram atribuídos a estabelecimentos de cuidados de longo prazo. \nOs residentes em casas de repouso são vulneráveis a complicações graves e a mortalidade por COVID-19, e os moradores geralmente vivem próximos um do outro, o que torna difícil implementar medidas de quarentena e de distanciamento social. A proximidade dos cuidadores que prestam assistência a vários residentes em diferentes compartimentos do estabelecimento também pode contribuir para a transmissão do vírus, especialmente se as medidas de prevenção à infecção forem inadequadas. Muitos funcionários não têm acesso a licenças médicas remuneradas, o que pode incentivá-los a trabalhar, mesmo apresentando os sintomas do COVID-19.\nA OSHA (Administração de Segurança e Saúde Ocupacional - Occupational Safety and Health Administration) recomenda incentivar os trabalhadores de instituições de longa permanência de idosos ou casas de repouso a ficarem em casa se estiverem doentes; o exame frequente de trabalhadores e residentes para detectar sintomas do COVID-19; a adesão às diretrizes do CDC dos EUA para visitas; a observação da distância de pelo menos 2 m entre trabalhadores, visitantes e residentes; intercalar de pausas para evitar a superlotação; e o fornecimento de instalações para lavagem das mãos e de desinfetantes para as mãos, à base de álcool, em toda a casa de repouso, entre outras medidas. O CDC dos EUA recomenda ainda melhorias na notificação de casos de COVID-19 das estabelecimentos destinados ao cuidado de idosos, designando pelo menos um indivíduo treinado em controle de infecção e prevenção (CIP) para gerenciar o CIP no local, examinar os visitantes na entrada e limitar os visitantes (especialmente se eles apresentarem sintomas) e criar um plano de testes abrangente para todos os funcionários e residentes de casas de repouso. Também devem haver diretrizes em vigor para que uma unidade separada da casa de repouso seja destinada ao cuidado de pacientes que tenham ou sejam suspeitos de terem COVID-19, a fim de evitar futuros contágios.  Os requisitos para visitas podem ser reforçados ou relaxados, dependendo do número de casos na comunidade: o CDC dos EUA recomenda o uso de métodos alternativos, como videoconferência, em vez de visitas pessoais. As medidas preventivas incluem a restrição de todos os visitantes, exceto por motivos de cuidados compassivos, como cuidados de final de vida."
    ],
    "Portuguese - Background and context": [
      "Desde que os primeiros surtos nos Estados Unidos ocorreram em casas de repouso, houve muita especulação a respeito da população mais idosa, pois ela é de alto risco para o vírus. Além disso, os residentes de casas de repouso permanecem em espaços fechados, às vezes em compartimentos muito próximos uns dos outros, e geralmente têm um estado de saúde já debilitado, o que contribui para aumentar o risco. De fato, em 14 estados nos EUA, os residentes idosos e o funcionários que morreram de COVID-19 representam mais da metade de todas as mortes de COVID-19 nesses estados. \nEm resposta a isso, a maioria dos países com grandes populações de pessoas com mais de 65 anos criaram mais regulações para garantir que a segurança de pacientes, funcionários e profissionais de saúde desses estabelecimentos seja uma prioridade absoluta.  Ao aplicar esses novos padrões, os riscos devem ser significativamente reduzidos para residentes e funcionários."
    ]
  },
  {
    "id": "recSOnnQBIkFxZ8t8",
    "Question": "Is there a cure for COVID-19? What is the cure?\n",
    "Status": "Published",
    "Category": "Treatment",
    "Subcategory": "On: COVID-19 & treatments",
    "Background and context": "The word 'cure' is a broad one that technically means a procedure or drug that ends a certain medical condition, and implies a complete restoration of health. The word 'treatment,' on the other hand, technically means a procedure or drug that improves a certain medical condition, but doesn't necessarily end it. This distinction is important because there is currently no cure for COVID-19, but there are treatments in use, namely Remdesivir, which is under emergency use authorization (EUA) by the U.S. FDA, and Dexamethasone, which was previously approved by the FDA to treat a range of other health conditions. None of these treatments, however, are officially approved for COVID-19. There are multiple studies being conducted around the world to test a variety of cures, treatments, and preventative vaccines for COVID-19.\n",
    "What our experts say": "There is no known cure for COVID-19 right now, but there are ways to manage the symptoms of the disease. A cure is a substance or act that ends and relieves the symptoms of a medical condition so patients can have their health restored. One for COVID-19 is currently being researched in many clinical trials around the world, but no treatment or practice has been shown to effectively meet these standards. Healthcare professionals around the world are researching various treatments for COVID-19, including drugs that already exist to treat other conditions to see if they may be effective against COVID-19 as well.\n\nNo treatments are currently approved by the U.S. Food and Drug Administration (FDA) for COVID-19, but because COVID-19 is a public health crisis, doctors can treat patients using some drugs that are not technically approved for COVID-19. Emergency use authorization enables unapproved medical products or unapproved uses of approved medical products to be used for diagnosis, treatment or prevention in an emergency setting, even if the treatments may still be under further study.\n\nRemdesivir, an antiviral drug manufactured by Gilead Sciences that stops the virus from replicating, received emergency use authorization by the U.S. FDA. It reportedly reduced the recovery time for hospitalized patients from 15 days to 11 days, and early results indicate that it may reduce mortality among patients who are very sick from COVID-19. \n\nIn terms of clinical management of symptoms, the U.S. National Institutes of Health (NIH) COVID-19 treatment guidelines indicate that Remdesivir supplies are limited and should be prioritized for patients who need it most (hospitalized patients who require supplemental oxygen). The guidelines also recommend the use of dexamethasone, a steroid that can reduce inflammation, for patients who require ventilators or supplemental oxygen (and potentially other corticosteroids). Healthcare professionals may use ventilators and supplemental oxygen to ensure that hospitalized patients have a healthy supply of oxygen in the body, and monitor patients accordingly. Prone positioning (flipping COVID-19 patients onto their bellies in order to open up their lungs ) is also widely used to help patients recover from the virus. At present, there is no cure for COVID-19.\n",
    "Glossary Terms": [
      "recjILnexcCRlyBIb",
      "recROlYn1QcWitPtM",
      "recb7T7hH9zHd3k1R"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "treatment",
      "cure"
    ],
    "Other resources": "1. COVID-19 Treatment Guidelines ([NIH](https://www.covid19treatmentguidelines.nih.gov/whats-new/))\n2. Information for Clinicians on Investigational Therapeutics for Patients with COVID-19 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html))\n3. Coronavirus Drug and Treatment Tracker ([NYT](https://www.nytimes.com/interactive/2020/science/coronavirus-drugs-treatments.html?campaign_id=57&emc=edit_ne_20200716&instance_id=20375&nl=evening-briefing&regi_id=71929514&segment_id=33593&te=1&user_id=c41309fa5b77747bb39cd151b03fb771))\n",
    "DB (Bengali)": [
      "recPmWkFrYYfRKJSi"
    ],
    "DB (Portuguese)": [
      "recVM5cQ5OvLUin5L"
    ],
    "Rollup test 2": [
      "recJXw9Vt162l9WUl"
    ],
    "Last modified manual": "2020-07-30",
    "Last edited (simplified)": "2020-07-29T17:34:46.000Z",
    "Last edited (experts say)": "2020-10-15T19:24:34.000Z",
    "Last modified": "2020-10-15",
    "What our experts say wordcount": 353,
    "Background and context wordcount": 130,
    "Other resources wordcount": 23,
    "Wordcount": 506,
    "Bengali - What our experts say": [
      " \" জুলাই ২৯, ২০২০ তারিখে, কোভিড-১৯ এর জন্য কোন জানা নিরাময় নেই, কিন্তু অসুখের উপসর্গগুলি সামলানোর বিভিন্ন উপায় আছে। সারা পৃথিবী জুড়ে স্বাস্থ্য সুরক্ষা কর্মীরা কোভিড-১৯ এর বিভিন্ন চিকিৎসা নিয়ে গবেষণা করছেন, যার অন্তর্গত এমন ওষুধ যা অন্যান্য অসুখের চিকিৎসার জন্য বর্তমানে বিদ্যমান, যা কোভিড-১৯ এর বিরুদ্ধেও কার্যকরী হয় কি না দেখার জন্য। \n \n এই মুহূর্তে মার্কিন যুক্তরাষ্ট্রের ফুড অ্যান্ড ড্রাগ অ্যাডমিনিস্ট্রেশন (এফডিএ) দ্বারা কোন চিকিৎসাই অনুমোদিত হয়নি, কিন্তু যেহেতু কোভিড-১৯ একটি জনস্বাস্থ্য সংকট, তাই চিকিৎসকেরা এমন কিছু ওষুধ ব্যবহার করে রোগীদের চিকিৎসা করতে পারেন যা প্রযুক্তিগতভাবে কোভিড-১৯ এর জন্য অনুমোদিত নয়। জরুরীকালীন ব্যবহার অনুমোদন যেকোনো জরুরী অবস্থায় রোগনির্ণয়, চিকিৎসা বা প্রতিরোধের জন্য অনুমোদন না হওয়া চিকিৎসাগত পণ্য অথবা অনুমোদিত চিকিৎসা পণ্যের অননুমোদিত ব্যবহার করতে দেয়, এমনকি যদি চিকিৎসা তখনও পর্যন্ত অতিরিক্ত অধ্যয়নের অধীনে থাকে তাহলেও।\n \n রেমডেসিভির, একটি অ্যান্টিভাইরাস ওষুধ, যা প্রস্তুত করেছেন গিলিয়াড সায়েন্সেস, যা ভাইরাসটিকে রেপ্লিকেট করা থেকে আটকায়, এটি মার্কিন যুক্তরাষ্ট্রের FDA দ্বারা জরুরী ব্যবহারের অনুমোদন পেয়েছেন। এটি হাসপাতালে ভর্তি হওয়া রোগীদের মধ্যে সেরে ওঠার সময় ১৫ দিন থেকে ১১ দিনে কমিয়ে এনেছে বলে রিপোর্ট পাওয়া গেছে, এবং প্রাথমিক ফলাফল থেকে দেখা যায় যে এটি হয়তো সেই সমস্ত রোগীর মধ্যে মৃত্যুর হার হ্রাস করেছেন যারা কোভিড-১৯ থেকে খুবই অসুস্থ। \n \n উপসর্গের নিদানিক ব্যবস্থাপনার ক্ষেত্রে, মার্কিন যুক্তরাষ্ট্রের ন্যাশনাল ইন্সটিটিউট অফ হেলথ (NIH) এর কোভিড-১৯ নির্দেশিকা থেকে জানা যায় যে রেমডেসিভির এর সরবরাহ সীমিত এবং যে সমস্ত রোগীর সবচেয়ে প্রয়োজন (হাসপাতালে ভর্তি রোগী যাদের সাপ্লিমেন্টাল অক্সিজেন প্রয়োজন) তাদেরকে অগ্রাধিকার দিয়ে এটি ব্যবহার করা উচিৎ। এছাড়াও এই নির্দেশিকা ভেন্টিলেটর অথবা সাপ্লিমেন্টাল অক্সিজেনের প্রয়োজন পড়ছে এমন রোগীর মধ্যে প্রদাহ কমানোর জন্য ডেক্সামেথাসোন, একটি স্টেরয়েড, ব্যবহার করার পরামর্শ দেয়। রোগীদের শরীরে স্বাস্থ্যকর পরিমাণ অক্সিজেনের সরবরাহ রয়েছে কি না তা নিশ্চিত করার জন্য স্বাস্থ্য পরিষেবা প্রদানকারীরা ভেন্টিলেটর এবং সাপ্লিমেন্টাল অক্সিজেন ব্যবহার করেন, এবং সেই অনুযায়ী রোগীকে পর্যবেক্ষণ করেন। বর্তমানে, কোভিড-১৯ এর কোন নিরাময় নেই।\"\n "
    ],
    "Bengali - Background and context": [
      " ‘নিরাময়’ শব্দটিকে বহু অর্থে ব্যবহার করা হয়, যার প্রযুক্তিগত অর্থ হচ্ছে একটি প্রক্রিয়া অথবা ওষুধ যা কোন একটি নির্দিষ্ট অসুখকে শেষ করে দেয়, এবং এটি বোঝায় যে স্বাস্থ্য সম্পূর্ণ পুনরুদ্ধার হবে। অন্যদিকে ‘চিকিৎসা’ শব্দটি প্রযুক্তিগতভাবে বোঝায় এমন একটি প্রক্রিয়া বা ওষুধ যা নির্দিষ্ট কোন অসুখের ক্ষেত্রে অবস্থার উন্নতি ঘটায়, কিন্তু অপরিহার্যভাবে সেটিকে শেষ করে না। এই পার্থক্যটি গুরুত্বপূর্ণ কারণ বর্তমানে কোভিড-১৯ এর কোন নিরাময় নেই, কিন্তু বিভিন্ন চিকিৎসা ব্যবস্থা ব্যবহার করা হচ্ছে, যেমন রেমডেসিভির যা মার্কিন যুক্তরাষ্ট্রের FDA দ্বারা জরুরী ব্যবহার অনুমোদন (EUA) এর অধীন, এবং ডেক্সামেথাসোন, যা এর আগে বিভিন্ন অন্যান্য অসুখের চিকিৎসার জন্য FDA দ্বারা অনুমোদিত হয়েছে। এই চিকিৎসাগুলির মধ্যে কোনটিই, যদিও, কোভিড-১৯ এর জন্য আনুষ্ঠানিকভাবে অনুমোদিত হয় নি। সারা পৃথিবী জুড়ে বিভিন্ন নিরাময়, চিকিৎসা, এবং কোভিড-১৯ প্রতিরোধকারী ভ্যাক্সিন পরীক্ষা করার জন্য একাধিক অধ্যয়ন পরিচালনা করা হচ্ছে।"
    ]
  },
  {
    "id": "recwnCbclyAAZHewu",
    "Question": "What do we know so far about COVID-19 and nursing homes?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & nursing homes",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "The outbreak of COVID-19 in the United States was first reported in long-term care (LTC) facilities, also commonly called nursing homes, in Washington state in February 2020. Shortly before February, staff and family members of LTC facility residents traveled nationally and internationally and, because little was known about the outbreak, travels were not self-isolating once they returned home. This early travel likely allowed COVID-19 to spread rapidly from staff and family members to residents of LTC facilities.\n\nIn response to these early nursing home outbreaks, several government agencies that oversee these facilities and the nursing homes themselves created stricter policies to prevent the future spread of the virus, but problems controlling COVID-19 in LTC facilities still persist.\n\nThere are multiple risk factors that place LTC facilities at high-risk for rapid viral spreading. In US LTC facilities, many residents are over the age of 65, have preexisting conditions (i.e. heart disease, diabetes, or breathing problems), spend the majority of time in enclosed buildings, and are cared for by staff members who care for multiple residents at a time. \n",
    "What our experts say": "Long-term care (LTC) facilities, often called nursing homes or assisted living facilities, are uniquely vulnerable to COVID-19 transmission. This is partially because COVID-19, like many other respiratory viruses, can easily be spread between people in enclosed spaces. In addition, since many residents at nursing homes are over the age of 65 and have preexisting conditions (i.e. heart disease, diabetes, or breathing problems) that my affect their immune systems and organ function, they are at a greater risk for severe disease if they do get COVID-19. This is why LTC facilities are considered to be high risk for COVID-19 spread. \n\nThough the number of COVID-19 cases in LTC facilities are strongly associated with the number of COVID-19 cases in their surrounding communities, research continues to show that COVID-19 infections spread quickly in LTC facilities among residents and staff. In addition to resident-specific risk factors, other factors that impact how COVID-19 has spread in LTC facilities include staffing shortages, low pay, and poor staffing ratios as well as a lack of resources dedicated to infection prevention, including guidelines to follow, dedicated staff members, and protective equipment. Shared living spaces like cafeterias and group rooms make social distancing difficult and can make it hard to isolate patients who are ill. \n\nThough additional funding was allocated to LTC facilities from the US government in May 2020 and new testing requirements for staff and residents were put into place in August 2020, LTC staff and residents have continued to be significantly impacted by the virus.\n\nAs of early November 2020, the impact of COVID-19 on US LTC facilities, residents, and staff has continued to grow to record highs. According to data from the Kaiser Family Foundation (dated November 6th, 2020), 26,515 LTC facilities had known cases of COVID-19. There have been a total of 728,750 cases with 100,033 deaths associated with LTC facilities, and LTC facility deaths account for 40% of total COVID-19 deaths nationally. \n",
    "Glossary Terms": [
      "recgTRrJAT5jjNnDr",
      "recPzol0r3VBYAXD6",
      "recFG7Vf7ekUiDwon",
      "recnFUXyIZy81Rj1I",
      "recbr3ZePtuRaGnEd",
      "rec2UNEXbTkSCx30Q"
    ],
    "Variation of the answer depending on country of residence": "Yes; depending on the location\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "nursing home",
      "transmission",
      "outbreak"
    ],
    "Other resources": "1. COVID-19: Long-Term Care Facilities ([KFF](https://www.kff.org/health-costs/issue-brief/state-data-and-policy-actions-to-address-coronavirus/?utm_source=web&utm_medium=trending&utm_campaign=covid-19))\n2. Interim Final Rule (IFC), CMS-3401-IFC, Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency related to Long-Term Care (LTC) Facility Testing Requirements and Revised COVID- 19 Focused Survey Tool** **([US CMS](https://www.cms.gov/files/document/qso-20-38-nh.pdf))\n3. Preparing for COVID-19 in Nursing Homes ([US CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/long-term-care.html))\n4. Cost-Cutting at America’s Nursing Homes Made Covid-19 Even Worse ([Bloomberg Businessweek](https://www.bloomberg.com/news/features/2020-10-31/covid-pandemic-coronavirus-devastated-nursing-homes-after-cost-cutting?utm_campaign=news&utm_medium=bd&utm_source=applenews))\n5. HHS Announces Nearly $4.9 Billion Distribution to Nursing Facilities Impacted by COVID-19 ([US HHS](https://www.hhs.gov/about/news/2020/05/22/hhs-announces-nearly-4.9-billion-distribution-to-nursing-facilities-impacted-by-covid19.html))\n6. Staffing Levels and COVID‐19 Cases and Outbreaks in U.S. Nursing Homes ([JAGS](https://onlinelibrary.wiley.com/doi/epdf/10.1111/jgs.16787))\n7. Nursing Home COVID Data ([CMS](https://data.cms.gov/stories/s/COVID-19-Nursing-Home-Data/bkwz-xpvg/))\n8. Care Aides Working Multiple Jobs: Considerations for Staffing Policies in Long-Term Care Homes During and After the COVID-19 Pandemic ([J Am Med Dir Assoc](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472068/pdf/main.pdf))\n9. Covid-19 outbreaks in nursing homes hit record high ([NBC News](https://www.nbcnews.com/news/us-news/covid-19-outbreaks-nursing-homes-hit-record-high-n1248798))\n10. Nurse Staffing and Coronavirus Infections in California Nursing Homes ([Policy, Politics, & Nursing Practice](https://journals.sagepub.com/doi/10.1177/1527154420938707?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed))\n11. CIDRAP - COVID Frequency in Nursing Homes ([June 2020](https://www.cidrap.umn.edu/news-perspective/2020/06/nursing-homes-might-account-40-us-covid-19-deaths))\n12. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2005412)) \n",
    "Last modified manual": "2020-12-03",
    "Last edited (simplified)": "2020-12-03T15:32:34.000Z",
    "Last edited (experts say)": "2020-12-07T14:34:00.000Z",
    "Last modified": "2020-12-07",
    "What our experts say wordcount": 320,
    "Background and context wordcount": 176,
    "Other resources wordcount": 162,
    "Wordcount": 658
  },
  {
    "id": "recO53s7i9ioAfKKv",
    "Question": "What is the difference between exposure and infection to a virus?",
    "Status": "Published",
    "Background and context": "We are exposed to viruses, chemicals, sunlight, and many other things every day. In general, exposure suggests that someone has been in an area where they may have come into contact with a foreign substance called a pathogen (a virus, bacteria, or other tiny organism) that can cause a disease. In the case of COVID-19, the pathogen is a respiratory virus. \n\nAn infection happens when a pathogen that causes an illness gets into our body (i.e. lungs, skin, eyes, throat, stomach, blood). A virus may enter the body through contact with mucous membranes. These membranes are tissues in the body that line parts of your ear, eyes, nose, throat, digestive tract and other parts of the body that are exposed to air like wounds on the skin. Once the virus enters the body, it enters into cells and is able to spread and cause inflammation. Inflammation causes a person to develop symptoms of infection. Common symptoms of COVID-19 infection include fever, fatigue, cough, and shortness of breath. But scientists are discovering new symptoms associated with COVID-19 every day.\n\nFor COVID-19, some people who are exposed to the virus never become infected. The U.S. Centers for Disease Control and Prevention suggests that there is an increased risk of infection for people who are exposed to the virus by being in close contact (within 6 feet or about 2 meters for 15 minutes or longer) with an infected person. The time between exposure to the virus and the appearance of symptoms of infection is currently being studied by many researchers, but we are still learning about this process. For people who become ill with COVID-19, research has shown that symptoms of infection usually begin about five days after someone is exposed to the virus, and 97.5% of people who are exposed to the virus will show symptoms within 11.5 days.\n",
    "What our experts say": "When it comes to infectious diseases, \"exposure\" means coming into contact with a virus or bacteria. Infection happens when someone is exposed and actually becomes sick from the exposure. Exposure does not always lead to an infection. If the time a person is exposed to the virus is very short, if the amount of virus that enters the body is not in a large enough quantity, or if the body's immune system is able to quickly fight it off, then exposure will be less likely to lead to infection. \n\nMany things have to happen for an exposure to result in an infection, especially the ways in which a person was exposed to the virus. In the case of the virus that causes COVID-19, exposure takes place usually by breathing in the virus through the nose or the mouth, and sometimes the virus enters our bodies through the eyes. People can be \"exposed\" to different viruses in different ways, such as by eating food with a virus on it, or getting bit by a mosquito or other animal that carries a virus. Again, in the case of COVID-19, exposure typically happens by breathing in the virus through the nose or the mouth.\n\nOther factors that can impact whether an exposure leads to an infection include whether the germ is a virus, a bacteria or a parasite; how strong or \"infectious\" it is; and the strength of our body defense system (immune system). \n\nFor example, you could be exposed to whooping cough (pertussis) by someone in the same room as you, but whether or not you end up being infected depends on several factors. These factors include how close to the person you were, how long you were exposed for, and if you are vaccinated against whooping cough.\n",
    "Glossary Terms": [
      "recvwSSjn9ohOm9fK",
      "recORiIMwk54TDQB6",
      "recaXXF6coF4J2EUz",
      "recFMi3UQAPSUjsl4"
    ],
    "Other resources": "1. Public Health Guidance for Community-Related Exposure, 2020 ([US CDC](https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-recommendations.html))\n2. Coronavirus Symptoms Start About Five Days After Exposure, Johns Hopkins Study Finds, 2020 ([JHU](https://hub.jhu.edu/2020/03/09/coronavirus-incubation-period/)) \n3. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application, 2020 ([Annals of Int Med](https://www.acpjournals.org/doi/10.7326/M20-0504))\n4. Introduction to Epidemiology ([CDC](https://www.cdc.gov/csels/dsepd/ss1978/lesson1/section9.html)).\n",
    "Rollup test 2": [
      "recSP8HqBPThCCmwF"
    ],
    "Last modified manual": "2020-07-29",
    "Last edited (simplified)": "2020-07-29T18:34:31.000Z",
    "Last edited (experts say)": "2020-07-29T18:34:31.000Z",
    "Last modified": "2020-07-29",
    "What our experts say wordcount": 295,
    "Background and context wordcount": 307,
    "Other resources wordcount": 50,
    "Wordcount": 652
  },
  {
    "id": "recenUqXFNVYnafXz",
    "Question": "How can I protect myself if I am attending a protest or mass gathering?",
    "Status": "Published",
    "Subcategory": "On: COVID-19 & protests",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Protests and mass gatherings take place outdoors, which means in principle that the outdoor air can dilute the virus and reduce the risk of inhaling the virus with each breath. However, in practice, attending protests and mass gatherings still carry a significant risk of COVID-19 transmission. This is because when attending a protest it can be hard to practice social distancing (being 6 feet apart from one another) and that people can be speaking and shouting while standing close to one another, increasing the risk of transmission. In addition, tear gas and pepper spray are often used in protests to break up crowds. These can cause people to tear up and remove their masks to cough a lot, because of trouble breathing. These actions both increase respiratory secretions from the eyes, nose and mouth, further increasing the risk of COVID-19 transmission.\n",
    "What our experts say": "Attending protests or mass gatherings can increase the risk of catching COVID-19 or spreading the disease. This is especially so given the large amount of people who are infected with COVID-19 but do not have any symptoms (pre-symptomatic and asymptomatic), and may feel well enough to attend a mass gathering like a protest or march. In this context, there are a few steps you can take to reduce the risk of COVID-19 transmission. These include first of all wearing a mask and trying to maintain a certain distance from other people at the protest - 6 feet (or 2 m) where possible. Additionally, wearing heat resistant gloves and eye protection (ex: sunglasses) is also recommended. Since yelling - even through a mask - can increase the spread of respiratory droplets due to the force that pushes them out, it is recommended to choose signs or drums (or similar noise makers) if you want to express a message. To prevent further spread of the virus, it is recommended to stick to a 'buddy group' when participating in protests to keep the number of close contacts low. In the event one person in the group is found to be infected with COVID-19, it will be easier to contact all the people who came into close contact with that person and take the recommended public health measures. Similarly, it is recommended for protesters to get tested if possible after taking part in protests. In the US, some states are offering free testing for protesters. Finally, make sure to carry hand sanitizer to disinfect your hands as much as needed and carry water to keep hydrated.\n\n\n",
    "Glossary Terms": [
      "rec2UNEXbTkSCx30Q",
      "rec5yviiSvJkufYvu",
      "recx2PeCcs1Awb9rG"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "protest",
      "demonstration",
      "protection",
      "prevention"
    ],
    "Other resources": "1. Prevent Getting Sick ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/index.html)) \n",
    "DB (French)": [
      "recXxSw89QoFa83ZD"
    ],
    "DB (Hindi)": [
      "recHFmRubql8a7rx7"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recRw1nsGm7FPWjmb"
    ],
    "DB (Spanish)": [
      "recaSuhgdho6D7QgN"
    ],
    "DB (Bengali)": [
      "recSvRQcQKzBGYcnO"
    ],
    "DB (Portuguese)": [
      "rectwsIqOEIxOGQno"
    ],
    "Rollup test 2": [
      "recvCfAyPfhMecQyu"
    ],
    "Last modified manual": "2020-07-29",
    "Last edited (simplified)": "2020-06-11T23:13:43.000Z",
    "Last edited (experts say)": "2020-06-19T00:34:26.000Z",
    "Last modified": "2020-07-29",
    "What our experts say wordcount": 272,
    "Background and context wordcount": 141,
    "Other resources wordcount": 7,
    "Wordcount": 420,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Participer à des manifestations ou à des rassemblements de masse peut augmenter le risque de contracter la COVID-19 et de transmettre la maladie. Cela est particulièrement vrai en regard du nombre important de personnes infectées par la COVID-19, mais qui ne présentent aucun symptôme (présymptomatiques et asymptomatiques) et pourraient se sentir assez bien pour participer à un rassemblement de masse tel qu’une manifestation ou une marche. Dans ce contexte, il existe quelques mesures que vous pouvez prendre afin de réduire le risque de transmission de la COVID-19. Elles comprennent tout d’abord le port d’un couvre-visage et le maintien d’une certaine distance avec les autres personnes qui participent à la manifestation, deux mètres (six pieds) où cela est possible. De plus, il est recommandé de porter des gants résistants à la chaleur ainsi que des lunettes de protection (p. ex. des lunettes de soleil). Dans la mesure où crier, même à travers un masque, peut augmenter la propagation de gouttelettes respiratoires en raison de la force qui les expulse, il a recommandé de choisir des signes ou des tambours (ou autres générateurs de bruit) si vous souhaitez exprimer un message. Lors de la participation à des manifestations et afin de prévenir la propagation du virus, il est recommandé de s’en tenir à un groupe de connaissances pour réduire le nombre de contacts proches. S’il s’avérait qu’un des membres du groupe avait contracté la COVID-19, il serait plus facile de contacter toutes les personnes qui auront été en contact proche avec la personne malade et de prendre les mesures de santé publique recommandées. Pareillement, il est recommandé aux protestataires de se faire tester si possible après avoir participé à des manifestations. Enfin, assurez-vous d’avoir sur vous du désinfectant pour les mains, de vous en servir aussi souvent que nécessaire et d’apporter de l’eau pour rester hydraté."
    ],
    "French - Background and context": [
      "Les manifestations et les rassemblements de masse ont lieu à l’extérieur, ce qui signifie en principe que l’air extérieur peut diluer le virus et réduire le risque de l’inhaler à chaque respiration. Cependant en pratique, participer à des manifestations et à des rassemblements de masse présente encore un risque considérable de transmission de la COVID-19. Lors d’une manifestation, il peut être difficile de respecter la distanciation physique (plus de deux mètres ou six pieds entre les personnes) et les gens peuvent parler et crier tout en se trouvant proches les uns des autres, augmentant ainsi le risque de transmission. De plus, du gaz lacrymogène et du poivre de Cayenne sont souvent utilisés dans les manifestations pour disperser les foules. Les gens pourraient alors se mettre à pleurer et enlever leur couvre-visage pour tousser beaucoup en raison de difficultés respiratoires. Les sécrétions respiratoires par les yeux, le nez et la bouche sont augmentées par ces deux actions, ainsi que le risque de propagation de la COVID-19."
    ],
    "Hindi - What our experts say": [
      "विरोध प्रदर्शन या सामूहिक समारोहों में भाग लेने से कोविड-19 को पकड़ने या बीमारी फैलने का खतरा बढ़ सकता है। यह विशेष रूप से इतनी बड़ी मात्रा में लोगों को दिया गया है जो कोविड-19 से संक्रमित हैं, लेकिन कोई लक्षण (पूर्व-लक्षण और स्पर्शोन्मुख) नहीं है, और एक विरोध या मार्च जैसे सामूहिक सभा में भाग लेने के लिए पर्याप्त महसूस कर सकते हैं। इस संदर्भ में, कोविड-19 संचरण के जोखिम को कम करने के लिए आप कुछ कदम उठा सकते हैं। इनमें सबसे पहले मास्क पहनना और विरोध प्रदर्शन में अन्य लोगों से एक निश्चित दूरी बनाए रखने की कोशिश करना शामिल है - 6 फीट (या 2 मीटर) जहां संभव हो। इसके अतिरिक्त, गर्मी प्रतिरोधी दस्ताने और आंखों की सुरक्षा (धूप के चश्मा) पहनने की भी सिफारिश की जाती है। चूंकि चिल्लाना - यहां तक ​​कि एक मास्क के माध्यम से - बल की वजह से सांस की बूंदें के प्रसार को बढ़ा सकता है जो उन्हें बाहर धकेलता है, यह संकेत या ड्रम (या समान शोर निर्माताओं) का चयन करने की सिफारिश की जाती है यदि आप एक संदेश व्यक्त करना चाहते हैं। वायरस के आगे प्रसार को रोकने के लिए, नजदीकी संपर्कों की संख्या कम रखने के लिए विरोध प्रदर्शन में भाग लेने पर इसे 'बडा ग्रुप' से चिपके रहने की सलाह दी जाती है। घटना में समूह का एक व्यक्ति COVID-19 से संक्रमित पाया जाता है, उन सभी लोगों से संपर्क करना आसान होगा जो उस व्यक्ति के साथ निकट संपर्क में थे और अनुशंसित सार्वजनिक स्वास्थ्य उपायों को लेते हैं। इसी प्रकार, विरोध प्रदर्शनों में भाग लेने के बाद यदि संभव हो तो प्रदर्शनकारियों की जांच की सिफारिश की जाती है। अमेरिका में, कुछ राज्य प्रदर्शनकारियों के लिए नि: शुल्क परीक्षण की पेशकश कर रहे हैं। अंत में, अपने हाथों को आवश्यकतानुसार कीटाणुरहित करने के लिए हैंड सेनिटाइज़र ले जाना और हाइड्रेटेड रखने के लिए पानी ले जाना सुनिश्चित करें।"
    ],
    "Hindi - Background and context": [
      "विरोध प्रदर्शन और सामूहिक सभाएं बाहर से होती हैं, जिसका अर्थ है कि बाहरी हवा वायरस को पतला कर सकती है और प्रत्येक सांस के साथ वायरस के जोखिम को कम कर सकती है। हालाँकि, व्यवहार में, विरोध और सामूहिक समारोहों में शिरकत करना अभी भी कोविड-19 प्रसारण का एक महत्वपूर्ण जोखिम है। ऐसा इसलिए है क्योंकि किसी विरोध में भाग लेने के दौरान सामाजिक गड़बड़ी (एक दूसरे से 6 फीट दूर होना) का अभ्यास करना मुश्किल हो सकता है और यह कि लोग एक दूसरे के करीब खड़े होकर बोल सकते हैं और चिल्ला सकते हैं, जिससे ट्रांसमिशन का खतरा बढ़ जाता है। इसके अलावा, आंसू गैस और काली मिर्च स्प्रे अक्सर विरोध में भीड़ को तोड़ने के लिए उपयोग किया जाता है। सांस लेने में तकलीफ के कारण लोगों को बहुत अधिक खांसी और अपने मास्क को हटाने में परेशानी हो सकती है। ये क्रियाएं दोनों आंखों, नाक और मुंह से श्वसन स्राव को बढ़ाती हैं, जिससे कोविड-19 संचरण का खतरा बढ़ जाता है।"
    ],
    "Telugu - What our experts say": [
      "నిరసనలు లేదా సామూహిక సమావేశాలకు హాజరు కావడం వల్ల కోవిడ్-19 ను పట్టుకోవడం లేదా వ్యాధి వ్యాప్తి చెందే ప్రమాదం పెరుగుతుంది. కోవిడ్-19 బారిన పడిన పెద్ద సంఖ్యలో ప్రజలు ఇస్తారు, కానీ ఎటువంటి లక్షణాలు లేవు (ప్రీ-సింప్టోమాటిక్ మరియు అసింప్టోమాటిక్), మరియు నిరసన లేదా కవాతు వంటి సామూహిక సమావేశానికి హాజరు కావడానికి తగినంతగా అనిపించవచ్చు. ఈ సందర్భంలో, కోవిడ్-19 ప్రసార ప్రమాదాన్ని తగ్గించడానికి మీరు కొన్ని దశలు తీసుకోవచ్చు. వీటిలో మొదట ముసుగు ధరించడం మరియు నిరసన వద్ద ఇతర వ్యక్తుల నుండి కొంత దూరం నిర్వహించడానికి ప్రయత్నించడం - సాధ్యమైన చోట 6 అడుగులు (లేదా 2 మీ). అదనంగా, వేడి నిరోధక చేతి తొడుగులు మరియు కంటి రక్షణ (ఉదా: సన్ గ్లాసెస్) ధరించడం కూడా సిఫార్సు చేయబడింది. పలకడం - ముసుగు ద్వారా కూడా - శ్వాసకోశ బిందువుల వ్యాప్తిని పెంచే శక్తి కారణంగా వాటిని బయటకు నెట్టివేస్తుంది కాబట్టి, మీరు సందేశాన్ని వ్యక్తపరచాలనుకుంటే సంకేతాలు లేదా డ్రమ్స్ (లేదా ఇలాంటి శబ్ద తయారీదారులు) ఎంచుకోవాలని సిఫార్సు చేయబడింది. వైరస్ మరింత వ్యాప్తి చెందకుండా ఉండటానికి, సన్నిహిత పరిచయాల సంఖ్యను తక్కువగా ఉంచడానికి నిరసనలలో పాల్గొనేటప్పుడు 'బడ్డీ గ్రూప్'కు కట్టుబడి ఉండాలని సిఫార్సు చేయబడింది. సమూహంలో ఒక వ్యక్తికి కోవిడ్-19 సోకినట్లు గుర్తించిన సందర్భంలో, ఆ వ్యక్తితో సన్నిహితంగా ఉన్న ప్రజలందరినీ సంప్రదించి, సిఫార్సు చేసిన ప్రజారోగ్య చర్యలు తీసుకోవడం సులభం అవుతుంది. అదేవిధంగా, నిరసనకారులలో నిరసనలలో పాల్గొన్న తరువాత వీలైతే పరీక్షలు చేయమని సిఫార్సు చేయబడింది. యుఎస్‌లో, కొన్ని రాష్ట్రాలు నిరసనకారులకు ఉచిత పరీక్షను అందిస్తున్నాయి. చివరగా, మీ చేతులను అవసరమైనంతవరకు క్రిమిసంహారక చేయడానికి మరియు హైడ్రేట్ గా ఉండటానికి నీటిని తీసుకువెళ్ళడానికి హ్యాండ్ శానిటైజర్ను తీసుకువెళ్ళేలా చూసుకోండి."
    ],
    "Telugu - Context and background": [
      "నిరసనలు మరియు సామూహిక సమావేశాలు ఆరుబయట జరుగుతాయి, అనగా సూత్రప్రాయంగా బహిరంగ గాలి వైరస్ను పలుచన చేస్తుంది మరియు ప్రతి శ్వాసతో వైరస్ను పీల్చే ప్రమాదాన్ని తగ్గిస్తుంది. ఏదేమైనా, ఆచరణలో, నిరసనలు మరియు సామూహిక సమావేశాలకు హాజరు కావడం ఇప్పటికీ కోవిడ్-19 ప్రసారానికి గణనీయమైన ప్రమాదాన్ని కలిగి ఉంది. ఎందుకంటే, నిరసనకు హాజరైనప్పుడు సామాజిక దూరం (ఒకదానికొకటి 6 అడుగుల దూరంలో ఉండటం) సాధన చేయడం కష్టం మరియు ప్రజలు ఒకరికొకరు దగ్గరగా నిలబడి మాట్లాడటం మరియు అరవడం వంటివి ప్రసారం చేసే ప్రమాదాన్ని పెంచుతాయి. అదనంగా, టియర్ గ్యాస్ మరియు పెప్పర్ స్ప్రేలను తరచూ జనాలను విచ్ఛిన్నం చేయడానికి నిరసనలలో ఉపయోగిస్తారు. ఇవి శ్వాస తీసుకోవడంలో ఇబ్బంది పడటం వల్ల ప్రజలు చిరిగిపోయి, వారి ముసుగులు చాలా దగ్గుకు గురి అవుతాయి. ఈ చర్యలు రెండూ కళ్ళు, ముక్కు మరియు నోటి నుండి శ్వాసకోశ స్రావాలను పెంచుతాయి."
    ],
    "Spanish - What our experts say": [
      "Atender a protestas o reuniones masivas puede incrementar el riesgo de contraer COVID-19 o diseminar la enfermedad. Esto es especialmente así dada la gran cantidad de personas que están infectadas con el COVID-19 pero no tienen síntoma alguno (pre sintomáticos y asintomáticos), y pueden sentirse lo suficientemente bien como para atender a una reunión masiva como una protesta o marcha. En este contexto, hay algunos pocos pasos que puedes tomar para reducir el riesgo de transmisión del COVID-19. Estos incluyen como primera medida usar una máscara y tratar de mantener una cierta distancia a otras personas en la protesta - 6 pies (o 2 m) donde sea posible. Adicionalmente, usar guantes resistentes al calor y protección ocular (ej.: anteojos de sol) también está recomendado. Como gritar - incluso a través de una máscara - puede incrementar la diseminación de gotitas respiratorias debido a la fuerza que las empuja hacia afuera, es recomendado elegir pancartas o tambores (o similares generadores de ruido) si quieres expresar un mensaje. Para prevenir la diseminación extendida del virus, es recomendado limitarse a un 'grupo de compinches' cuando se esté participando en protestas, para mantener bajo el número de contactos cercanos. En el evento en que se determine que una persona en el grupo está infectada con COVID-19, será más fácil contactar a todas las personas que estuvieron en contacto cercano con esa persona, y tomar las medidas recomendadas de salud pública. Similarmente, es recomendado para los manifestantes que sean examinados, si es posible, luego de tomar parte en las protestas. En los EE.UU., algunos estados están ofreciendo exámenes gratis para los manifestantes. Finalmente, asegúrate de llevar desinfectante de manos y usarlo tanto como lo necesites, y agua para mantenerte hidratado."
    ],
    "Spanish - Background and context": [
      "Las protestas y reuniones masivas tienem lugar al aire libre, lo que significa que, en principio, el aire puede diluir al virus y reducir el riesgo de inhalarlo con cada respiración. Sin embargo, en la práctica, esto aún conlleva un riesgo significativo de transmisión de COVID-19. Esto es porque al atender a una protesta puede ser difícil practicar el distanciamiento social (estar 2 metros separados unos de otros), y las personas pueden estar hablando y gritando mientras están cercanas unas a otras, incrementando el riesgo de transmisión. En adición, el gas lacrimógeno y el aerosol de pimienta son usados a menudo en protestas para dispersar multitudes. Estos pueden causar que las personas lagrimeen y remuevan sus máscaras para toser muy frecuentemente, debido a problemas al respirar. Estas acciones incrementan las secreciones respiratorias en los ojos, nariz y boca, aumentando aún más el riesgo de transmisión de COVID-19."
    ],
    "Bengali - What our experts say": [
      "প্রতিবাদে বা জনসমাবেশে অংশ নেওয়া কোভিড-১৯ আক্রান্ত বা রোগ ছড়িয়ে যাওয়ার ঝুঁকি বাড়িয়ে তুলতে পারে। এটি বিশেষত এমন বিপুল পরিমাণ লোক কোভিড-১৯-এ সংক্রামিত হন তবে তাদের কোনও লক্ষণ নেই (প্রাক-লক্ষণগত এবং লক্ষণহীন), এবং কোনও প্রতিবাদ বা মার্চের মতো একটি জনসভায় অংশ নিতে যথেষ্ট ভাল বোধ করতে পারেন। এই প্রসঙ্গে, কোভিড-১৯ সংক্রমণ হওয়ার ঝুঁকি কমাতে আপনি কয়েকটি পদক্ষেপ নিতে পারেন। এর মধ্যে সবার আগে মাস্ক পরা এবং প্রতিবাদে অন্যান্য লোকের থেকে নির্দিষ্ট দূরত্ব বজায় রাখার চেষ্টা করা - যেখানে সম্ভব ৬ ফুট (বা ২ মিটার)। এছাড়াও, তাপ প্রতিরোধী গ্লোভস এবং চোখের সুরক্ষা (উদা: সানগ্লাস) গ্রহণ বাঞ্ছনীয়। যেহেতু চিৎকার করা হয় - এমনকি মাস্ক পড়ার কারণে - শ্বাসযন্ত্রের জলীয় কণার প্রসারকে ধাক্কা দিয়ে বাড়িয়ে তুলতে পারে, সুতরাং আপনি কোনও বার্তা প্রকাশ করতে চাইলে প্ল্যাকার্ড বা ড্রাম (বা অনুরূপ শব্দ সৃষ্টিকারী যন্ত্র) ব্যাবহার করার পরামর্শ দেওয়া হয়। ভাইরাসটির আরও বিস্তার রোধ করতে, কাছাকাছি আসা মানুষের সংখ্যা কম রাখার জন্য প্রতিবাদে অংশ নেওয়ার সময় 'বন্ধু গ্রুপে' লেগে থাকার পরামর্শ দেওয়া হয়। এই গ্রুপে কেউ কোভিড -১৯ এ সংক্রামিত হলে, সেই ব্যক্তির সাথে ঘনিষ্ঠ যোগাযোগে আসা সমস্ত লোকের সাথে যোগাযোগ করা এবং প্রস্তাবিত জনস্বাস্থ্য ব্যবস্থা গ্রহণ করা আরও সহজ হবে। একইভাবে, বিক্ষোভকারীদের প্রতিবাদে অংশ নেওয়ার পরে যদি সম্ভব হয় তবে তাদের পরীক্ষা করার পরামর্শ দেওয়া হয়। মার্কিন যুক্তরাষ্ট্রে কয়েকটি রাজ্য প্রতিবাদকারীদের জন্য বিনামূল্যে পরীক্ষা সুবিধা দিচ্ছে। শেষ অবধি, আপনার হাত যতটা সম্ভব জীবাণুমুক্ত করতে হ্যান্ড স্যানিটাইজার বহন করার বিষয়টি নিশ্চিত করুন এবং তেষ্টা মেটাতে পানি বহন করুন।"
    ],
    "Bengali - Background and context": [
      "প্রতিবাদ এবং গণ জমায়েত বাইরে হয়, যার অর্থ নীতিগতভাবে যে বহিরঙ্গন বায়ু ভাইরাসকে হ্রাস করতে পারে এবং প্রতিটি নিঃশ্বাসের সাথে ভাইরাস গ্রহণের ঝুঁকি হ্রাস করতে পারে। যাইহোক, বাস্তবে, বিক্ষোভ এবং জনসমাবেশগুলিতে অংশ নেওয়া এখনও কোভিড-১৯ সংক্রমণের একটি গুরুত্বপূর্ণ ঝুঁকি বহন করে। এর কারণ যে কোনও প্রতিবাদে অংশ নেওয়ার সময় সামাজিক দূরত্ব অনুশীলন করা কঠিন হতে পারে (একে অপরের থেকে ৬ ফুট দূরে হওয়া) এবং লোকেরা একে অপরের নিকটে দাঁড়িয়ে কথা বলতে ও চিৎকার করতে পারে, যা সংক্রমণের ঝুঁকি বাড়িয়ে তোলে। এছাড়াও, ভিড় ভাঙতে প্রায়শই টিয়ার গ্যাস এবং গোলমরিচ স্প্রে ব্যবহার করা হয়। এগুলি শ্বাসকষ্টের কারণে লোকজনকে কাশি থামাতে তাদের মাস্ক সরিয়ে ফেলতে পারে। এই ক্রিয়াগুলি উভয় চোখ, নাক এবং মুখ থেকে শ্বাস প্রশস্ততা বৃদ্ধি করে, যা কোভিড-১৯ সংক্রমণ হওয়ার ঝুঁকি বাড়ায়।"
    ]
  },
  {
    "id": "rec1ozIUD6hRFzkYw",
    "Question": "What do we know about Alum as an alternative for sanitizer?",
    "Status": "Published",
    "Subcategory": "On: COVID-19 and sanitizers",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "To ensure the efficacy of disinfectants or cleaning agents, multiple tests need to be conducted to establish that the substance in question can kill multiple bacteria, virus and/or fungi. Alum has, in some studies, shown the ability to kill bacteria, but has not shown efficacy against enveloped viruses like COVID-19.\n",
    "What our experts say": "Alum (also called potassium alum or aluminum potassium sulfate) has been widely used in cosmetics, pharmaceuticals, food, and even textiles, but it has not been tested against viruses. While alum has some antimicrobial and anti fungal properties, it has not been shown to be an effective alternative for sanitizer or disinfectants. It is possible that there might be research, in the future, regarding the use of alum as an anti-viral disinfectant and cleaner, but the current literature does not support its use as an alternative to those on the EPA List N disinfectants with claims against Emerging Viral Pathogens.\n",
    "Glossary Terms": [
      "recAFuzwLppTBDIPe",
      "recHytNA8slfllwKF"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "alum",
      "disinfectants",
      "cleaning"
    ],
    "Other resources": "1. Review of Alum and Sundry Application ([ACTA Scientific Microbiology](https://actascientific.com/ASMI/pdf/ASMI-03-0553.pdf))\n",
    "DB (French)": [
      "recPkJ5SuaRbWr2Z8"
    ],
    "DB (Hindi)": [
      "reca8vJYJ5Hwjlo0O"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recT82TX94rE65XFa"
    ],
    "DB (Spanish)": [
      "reccuvNLGZI5UguzM"
    ],
    "DB (Bengali)": [
      "recU7SmHjsTAX7QGN"
    ],
    "DB (Portuguese)": [
      "recv8teVhm2w5PuGn"
    ],
    "Rollup test 2": [
      "recpTUfobo0d75bsx"
    ],
    "Last modified manual": "2020-07-29",
    "Last edited (simplified)": "2020-06-03T20:30:03.000Z",
    "Last edited (experts say)": "2020-06-03T20:30:03.000Z",
    "Last modified": "2020-07-29",
    "What our experts say wordcount": 99,
    "Background and context wordcount": 50,
    "Other resources wordcount": 10,
    "Wordcount": 159,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "L’alun (appelé aussi alun de potassium ou sulfate double d’aluminium et de potassium) a été largement utilisé dans les produits cosmétiques, pharmaceutiques alimentaires et même textiles, mais n’a pas été testé pour combattre les virus. Bien que l’alun présente certaines propriétés antimicrobiennes et antifongiques, son efficacité en tant qu’assainisseur ou désinfectant efficace de remplacement n’a pas été démontrée. Il est possible que des recherches aient lieu à l’avenir sur l’utilisation de l’alun en tant que désinfectant et nettoyant antiviral, mais la documentation actuelle ne soutient pas son utilisation comme solution de remplacement des désinfectants qui apparaissent sur la liste N de l’Agence de protection de l’environnement des États-Unis avec des déclarations d’efficacité contre les agents pathogènes viraux émergents."
    ],
    "French - Background and context": [
      "Pour s’assurer de l’efficacité d’agents désinfectants ou nettoyants, de nombreux essais doivent être effectués pour établir que la substance en question peut tuer plusieurs bactéries, virus ou champignons. Dans certaines études, l’alun a démontré la capacité de tuer des bactéries, mais n’a pas démontré d’efficacité contre les virus enveloppés tels que le SARS-CoV-2."
    ],
    "Hindi - What our experts say": [
      "अलम (पोटेशियम फिटकरी या एल्यूमीनियम पोटेशियम सल्फेट भी कहा जाता है) व्यापक रूप से सौंदर्य प्रसाधनों, फार्मास्यूटिकल्स, भोजन और यहां तक कि वस्त्रों में इस्तेमाल किया गया है, लेकिन यह वायरस के खिलाफ परीक्षण नहीं किया गया है। जबकि फिटकरी में कुछ रोगाणुरोधी और विरोधी कवक गुण होते हैं, यह सैनिटाइज़र या कीटाणुनाशक के लिए एक प्रभावी विकल्प नहीं दिखाया गया है। यह संभव है कि भविष्य में फिटकिरी को एंटी-वायरल कीटाणुनाशक और क्लीनर के रूप में उपयोग करने के संबंध में अनुसंधान हो सकता है, लेकिन वर्तमान साहित्य ईपीए सूची एन के कीटाणुनाशकों के विकल्प के रूप में उन लोगों के विकल्प के रूप में इसके उपयोग का समर्थन नहीं करता है उभरता हुआ वायरल रोगजन।"
    ],
    "Hindi - Background and context": [
      "कीटाणुनाशक या सफाई एजेंटों की प्रभावकारिता सुनिश्चित करने के लिए, यह सुनिश्चित करने के लिए कई परीक्षणों का आयोजन किया जाना चाहिए कि विचाराधीन पदार्थ कई बैक्टीरिया, वायरस और / या कवक को मार सकता है। कुछ अध्ययनों में, फिटकिरी ने जीवाणुओं को मारने की क्षमता दिखाई है, लेकिन COVID-19 जैसे आवरण वाले विषाणुओं के खिलाफ प्रभावकारिता नहीं दिखाई है।"
    ],
    "Telugu - What our experts say": [
      "\nఅల్యూమ్ (పొటాషియం అలుమ్ లేదా అల్యూమినియం పొటాషియం సల్ఫేట్ అని కూడా పిలుస్తారు) సౌందర్య సాధనాలు, ce షధాలు, ఆహారం మరియు వస్త్రాలలో కూడా విస్తృతంగా ఉపయోగించబడింది, అయితే ఇది వైరస్లకు వ్యతిరేకంగా పరీక్షించబడలేదు. ఆలుమ్ కొన్ని యాంటీమైక్రోబయల్ మరియు యాంటీ ఫంగల్ లక్షణాలను కలిగి ఉన్నప్పటికీ, ఇది శానిటైజర్ లేదా క్రిమిసంహారక మందులకు సమర్థవంతమైన ప్రత్యామ్నాయంగా చూపబడలేదు. యాంటీ-వైరల్ క్రిమిసంహారక మరియు క్లీనర్‌గా అల్యూమ్‌ను ఉపయోగించడం గురించి భవిష్యత్తులో పరిశోధనలు జరిగే అవకాశం ఉంది, అయితే ప్రస్తుత సాహిత్యం EPA List N క్రిమిసంహారక మందులలో ఉన్నవారికి ప్రత్యామ్నాయంగా దాని వాడకానికి మద్దతు ఇవ్వదు. ఉద్భవిస్తున్న వైరల్ వ్యాధికారక."
    ],
    "Telugu - Context and background": [
      "క్రిమిసంహారక మందులు లేదా శుభ్రపరిచే ఏజెంట్ల సామర్థ్యాన్ని నిర్ధారించడానికి, ప్రశ్నలోని పదార్ధం బహుళ బ్యాక్టీరియా, వైరస్ మరియు / లేదా శిలీంధ్రాలను చంపగలదని నిర్ధారించడానికి బహుళ పరీక్షలు నిర్వహించాల్సిన అవసరం ఉంది. అలుమ్, కొన్ని అధ్యయనాలలో, బ్యాక్టీరియాను చంపే సామర్థ్యాన్ని చూపించాడు, కాని కోవిడ్-19 వంటి ఎన్వలప్డ్ వైరస్లకు వ్యతిరేకంగా సామర్థ్యాన్ని చూపించలేదు."
    ],
    "Spanish - What our experts say": [
      "La alúmina (también conocida como alúmina de potasio o sulfato de potasio y aluminio) ha sido ampliamente usada en cosméticos, farmacéuticos, comida e incluso textiles, pero no ha sido probada en contra de los virus. Mientras que la alúmina tiene algunas propiedades antimicrobianas y antimicóticas, no ha sido demostrado que sea una alternativa efectiva a los desinfectantes. Es posible que pueda haber investigaciónes, en el futuro, con respecto al uso de alúmina como desinfectante y limpiador antiviral, pero la literatura actual no soporta su uso como alternativa a aquellos en la Lista N de la EPA: desinfectantes que afirman ser efectivos en contra de Patógenos Virales Emergentes."
    ],
    "Spanish - Background and context": [
      "Para asegurar la eficacia de los agentes desinfectantes o limpiadores, necesitan ser conducidas múltiples pruebas, para establecer que la substancia en cuestión pueda matar múltiples bacterias, virus y/u hongos. La alúmina ha mostrado, en algunos estudios, la habilidad de matar bacterias, pero no ha mostrado eficacia en contra de virus envueltos, como el COVID-19."
    ],
    "Bengali - What our experts say": [
      "ফিটকিরি (পটাসিয়াম এলুম বা অ্যালুমিনিয়াম পটাসিয়াম সালফেট নামেও পরিচিত) প্রসাধনী, ফার্মাসিউটিক্যালস, খাবার এবং এমনকি টেক্সটাইলে ব্যাপকভাবে ব্যবহৃত হয়েছে, তবে এটি ভাইরাসের বিরুদ্ধে পরীক্ষা করা হয়নি। যদিও ফিটকিরির কিছু অ্যান্টিমাইক্রোবিয়াল এবং অ্যান্টি ফাঙ্গাল বৈশিষ্ট্য রয়েছে তবে এটি স্যানিটাইজার বা জীবাণুনাশকগুলির জন্য কার্যকর বিকল্প হিসাবে দেখানো হয়নি। ভবিষ্যতে, এন্টি-ভাইরাল জীবাণুনাশক এবং ক্লিনার হিসাবে ফিটকিরির ব্যবহার সম্পর্কিত গবেষণা হতে পারে, তবে নতুন নতুন ভাইরাল জীবাণুর বিপরীতে বর্তমান তথ্য-উপাত্ত পরিবেশ রক্ষা সংস্থা তালিকার এন-জীবাণুনাশকগুলির বিকল্প হিসাবে এটি ব্যাবহার সমর্থন করে না।"
    ],
    "Bengali - Background and context": [
      "জীবাণুনাশক বা ক্লিনিং এজেন্টগুলির কার্যকারিতা নিশ্চিত করার জন্য, প্রশ্নযুক্ত পদার্থটি একাধিক ব্যাকটিরিয়া, ভাইরাস এবং অথবা ছত্রাককে মেরে ফেলতে পারে তা প্রতিষ্ঠার জন্য একাধিক পরীক্ষা করা দরকার। কিছু গবেষণায় ফিটকিরি ব্যাকটিরিয়া মেরে ফেলার ক্ষমতা দেখিয়েছেন, তবে কোভিড -১৯-এর মতো প্রলেপ যুক্ত ভাইরাসের বিরুদ্ধে কার্যকারিতা দেখাননি।"
    ]
  },
  {
    "id": "reccgbdzob0VzK2nF",
    "Question": "Can someone be infected with COVID-19 more than once?",
    "Status": "Update ready for review",
    "Category": "Reinfection",
    "Subcategory": "On: COVID-19 & Reinfection",
    "Background and context": "As scientists, public health professionals, and doctors monitor the COVID-19 pandemic, they continue to learn about how the virus spreads, its symptoms, and other factors important to diagnosis, testing, monitoring, and long-term public health planning. The possibility of reinfection continues to be a major concern with reports that some patients who had fully recovered from the virus later redeveloped symptoms. Some case reports detail how both symptom monitoring and testing have been performed, and, in some instances, patients have documented recovery of COVID-19 with negative virus test results only to become ill and test positive weeks or months later. \n\nWhile there are still many aspects of the virus and the pandemic that are unknown, recent research suggests that reinfection is indeed possible. It is important to note that, unlike other viruses, the number of antibodies needed to prevent reinfection with COVID-19 is unknown as is the level of antibodies needed to suggest that someone is “immune” to the virus. Studies to further understand immunity as well as the possibility for reinfection are ongoing.\n",
    "What our experts say": "We are still learning a lot about what kind of natural defense, also known as immunity, a person has after being infected with COVID-19 and how long that immunity lasts. A a small number of people have reportedly become reinfected with virus following an initial infection and research is ongoing. According to the US Centers fo Disease Control and Prevention, \"reinfection means a person was infected (got sick) once, recovered, and then later became infected again. Based on what we know from similar viruses, some reinfections are expected. We are still learning more about COVID-19.\"\n\nIn a press conference on December 4th, 2020, the World Health Organization acknowledged emerging evidence that suggests that COVID-19 immunity is unlikely to be lifelong, which suggests reinfection may be possible. \n\nThe strength and most reliable way to measure immunity to COVID-19 are unclear, and, whether from infection or vaccination, scientists still do not know how long immunity to COVID-19 may last. Though reinfection has been documented, there are many ongoing questions about whether or not reinfection poses an ongoing risk, how common it is, and what kind of immunity to the virus people might obtain once they have been infected. Currently researchers believe that most people will be protected from reinfection for up to six months following infection, but research is ongoing. \n\nThere are multiple pre-print studies with large participant groups suggest that immunity does last for up to six months but decreases over time. Antibodies decrease more quickly in young adults who have had an asymptomatic infection. Pre-print studies have also suggested that reinfection is possible. It is important to note that there is a shortage of peer-reviewed papers (so other scientific experts are not yet able to rigorously study the data or full results). It is also important to note that antibody levels may not be a strong indicator of immunity against the virus and likelihood of reinfection.\n\nTo prevent infection, reinfection, and spread of COVID-19, experts recommend frequent hand washing, social distancing (6 feet/2 meters apart), avoidance of crowded areas (especially indoors), wearing a face mask, and staying home when you are sick or know that you have been exposed to COVID-19.\n",
    "Glossary Terms": [
      "recZ4RP7OhzzNRCPz",
      "recmajcAORyuqhZPc",
      "recaXXF6coF4J2EUz",
      "recnFUXyIZy81Rj1I",
      "reci6AkPuYYC5pFzD",
      "recMZLIWKC45HMVao"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "reinfection",
      "prevention",
      "strain"
    ],
    "Other resources": "1. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection ([MedRxiv](https://www.medrxiv.org/content/10.1101/2020.07.09.20148429v1.full.pdf))\n2. Direct observation of repeated infections with endemic coronaviruses ([J of Inf Disease](https://watermark.silverchair.com/jiaa392.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAqIwggKeBgkqhkiG9w0BBwagggKPMIICiwIBADCCAoQGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMiRbJCaojrVziOBHFAgEQgIICVexKUVWsCM8r04oJCJ2DPsP6vHvGEigqHpWW5jL_wb5GXNZdVL7bOCvm5VWLxP3N3_FCeNlLkiCXSddWR8sOG3UbOouN_hpBKr4mYdZ6gcI6jtE5rU_xfh0F9lJTu0pBX6IScsDQNGpbokEgqSk9QEK6H_0P4w3H8gf6h_jkfM72S_pPpCLksA2sOyP4frstixiN_MUKS_vx_BspvZENUnccZmgMBr9ielG5DCwLFj3HxAjRC_HiPLI8Nqn4aixyC1Ex6k7tmdZVx0B66c2pGv7VX04Ctxd4cxKTSIChWPacv2nejhG7ZGxiedfUCga25VlnSIjiyghHTNuu5EQhN9GhB0SlDcGkNCGcbuIvGdgzIeK-6ZZFdlTM8TcAHkducF7p0u4qxiQyHt0knoAqV6gxB6H9nsPJbO9eDlSFnlaekK1x1jVj3KYEijlB7oHyfXDvo3MGYoSQXF4cBejTUrfSBS6sjbD_uf0Pui-PJtti-VTlLyrumkRRLsutXTGDmo8V4iagTUWQQe6WEPh5emb8GYETdcRvAZx-otjFBtsagdq6L1ijVYYBRCg_QfmEow4wrEqMoK-o5_oZbInR_B-8eccbF5g3oNJhuSr4NSBXjd0Whhqe3LTf1IEvTz03Wv11sEUoPUbMbYmZlEJYYJf8BUR-5h267UeuU8IMFHxNsdTFJikB9y7hZgL8u_6_xdwE8MxJoIycHbRh4Dpv8Wz1QK55XC39-AvEuqdYuPNFvxJeU-KscfbpVX0-4AbdSoMlmwsl8eivzoFUOxZoK_MFt1ny-w))\n3. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study ([Lancet](https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931483-5))\n4. Study in Primates Finds Acquired Immunity Prevents COVID-19 Reinfections ([NIH Director's Blog](https://directorsblog.nih.gov/2020/07/14/study-in-primates-finds-acquired-immunity-prevents-covid-19-reinfections/))\n5. Interview with Virologist Dr. Rasmussen ([Gizmodo](https://gizmodo.com/what-s-the-evidence-for-covid-19-reinfection-1844364577))\n6. What Is COVID-19? ([JAMA](https://jamanetwork.com/journals/jama/fullarticle/2768390)) \n7. Scientists say Hong Kong man got coronavirus a second time ([AP](https://apnews.com/1c2f3655a236dd7b1f09d94500042d3c)) \n8. First Documented Coronavirus Reinfection Reported in Hong Kong ([NYT](https://www.nytimes.com/2020/08/24/health/coronavirus-reinfection.html)) \n9. Genomic Evidence for a Case of Reinfection with SARS-CoV-2 ([The Lancet Preprint](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3681489))\n10. Coronavirus disease (COVID-19) pandemic, WHO press conferences ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019))\n11. Reinfection with COVID-19 ([US CDC](https://www.cdc.gov/coronavirus/2019-ncov/your-health/reinfection.html))\n12. Antibodies to SARS-CoV-2 are associated with protection against reinfection ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.11.18.20234369v1))\n13. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1?ijkey=6d340765f5adbd1dd3cf1d3ac4693fd8fc972fb0&keytype2=tf_ipsecsha))\n14. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.11.02.20224824v1))\n15. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months ([Science](https://science.sciencemag.org/content/370/6521/1227/tab-pdf))\n16. Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.08.12.20173690v2))\n17. What reinfections mean for COVID-19 ([Lancet](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30783-0/fulltext))\n",
    "How often revision needed": "Weekly",
    "DB (French)": [
      "recKDU3ZXsRvXXFlC"
    ],
    "DB (Hindi)": [
      "recfva7VUWttebYlH"
    ],
    "Media": [
      {
        "id": "attVCeSSLQBj8CL3u",
        "url": "https://dl.airtable.com/.attachments/794bac94a5aa3a0fbb7cfb3b96ee7078/00917583/Slide_1",
        "filename": "Slide_1",
        "size": 155379,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d20a2e4228506d007d5b67922ad4c87a/2ffa47fa",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/03c540bcea38b848bc80974a5771940d/e16bf7be",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/40a39b9042c5a6f7b679966cf32cfb91/0ffcb2df",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att293enxUBTVLvpt",
        "url": "https://dl.airtable.com/.attachments/11453ccc071224749591d33020267939/33087e70/Slide_2",
        "filename": "Slide_2",
        "size": 220233,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/884e0f6f2b08be377f151aaae77d1f09/c7f2e629",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/51974b3233fe0eeb2021cfc08399b40c/dd204546",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ba7530bc6721e00beeb1f1d562cad5e1/54154851",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attNTFyZiA4l3nL8K",
        "url": "https://dl.airtable.com/.attachments/df0c77bbc6456d3f0bc3865ef42902bc/f1a62caa/Slide_3",
        "filename": "Slide_3",
        "size": 213043,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/5d47973602d6c21e4495278fd07578f7/372a8b07",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e667610602cd67bf69ed2287a44f4318/2badeaf1",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/35eac3e36576f96e6a06a2a8c6e5469d/82ab2a13",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attX9kNSuieda79Pv",
        "url": "https://dl.airtable.com/.attachments/c9b801ba80f39197ac69fcbd0044d308/cccc8aa5/Slide_4",
        "filename": "Slide_4",
        "size": 162707,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b09e171348bd9eb1be315b3654875e91/e0c90023",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/4a5e8e50d0378c9d1ebf04c315d6f8f2/19abbece",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e4e5f6b6660e62c6fb27e17c0e0b9e7c/5d65b970",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attvmoxVv3UODgYkE",
        "url": "https://dl.airtable.com/.attachments/225e045627edbe49aab385fdffee9a2e/ab3e0226/Slide_5",
        "filename": "Slide_5",
        "size": 269476,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c76822ae16e3a71bc78ecae0cfef3070/166d90f8",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/520c2fb4934562981bf4d55db12c70f5/53d5d588",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/3fb69d25f3140df7a74c1c38a4921b2d/75a759ed",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "rechalrXC9gaA1k8m"
    ],
    "DB (Portuguese)": [
      "recSbWjbA3p6IJY8W"
    ],
    "Rollup test 2": [
      "recAX0HsZVM8R4TBw"
    ],
    "Media Package": [
      {
        "id": "atttiaGILN87vt96z",
        "url": "https://dl.airtable.com/.attachments/47c9aec0f359868c2843c19d03a81d78/bd914a26/Reinfection.zip",
        "filename": "Reinfection.zip",
        "size": 1022215,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-12-08",
    "Last edited (simplified)": "2020-12-08T20:38:19.000Z",
    "Last edited (experts say)": "2020-12-08T20:52:33.000Z",
    "Last modified": "2020-12-08",
    "What our experts say wordcount": 359,
    "Background and context wordcount": 172,
    "Other resources wordcount": 178,
    "Wordcount": 709,
    "French Q status": [
      "Ready for expert review"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "French - What our experts say": [
      "Nous apprenons encore beaucoup sur le genre de défense naturelle, aussi appelée immunité, qu’une personne présente après avoir été infecté par le SARS-CoV-2 et contracté la COVID-19. À ce jour, il a été rapporté que seul un très petit nombre de personnes ont été réinfectées par le virus à la suite d’une infection initiale.\n\nLes scientifiques ne savent pas encore de façon certaine si l’on peut contracter la COVID-19 une deuxième fois. Il nous faut plus de données probantes afin de déterminer s’il peut y avoir réinfection ou non chez les patients, et le niveau d’immunité au virus que les personnes peuvent développer une fois qu’elles ont été infectées.\n\nDes études prépubliées récentes ont cité des cas apparents de patients réinfectés par le virus de la COVID-19, mais elles n’ont encore été ni publiées ni évaluées par des pairs. D’autres experts n’ont donc pas pu étudier rigoureusement les données ni les résultats complets des études. Il faut noter que les patients de ces études ont soi-disant été infectés avec des souches différentes du virus lors de la deuxième infection. Cela pourrait signifier que les patients n’ont pas une immunité à vie au virus, et si immunité il y a après que quelqu’un a été infecté par le virus, nous ne savons ni pour combien de temps ni la force de cette immunité. C’est pourquoi il est important que tous continuent à appliquer les mesures de prévention telles que le port du masque et la distanciation physique afin d’arrêter la propagation du virus.\n\nDans certains cas, des patients ont reçu des tests positifs de dépistage du virus une deuxième fois, mais les scientifiques pensent que ce sont probablement des traces résiduelles dans le corps de l’infection originale. Cela pourrait changer au fur et à mesure que nous en apprenons davantage sur l’immunité à long terme et sur la protection contre la réinfection, mais nous n’avons actuellement pas vu de cas publiés pour soutenir cette possibilité.\n\nPour ceux qui se soucient des tests de dépistage d’anticorps, les tests utilisés afin de déterminer si une personne a été infectée ou non par le virus de la COVID-19 par le passé, il est important de noter que l’absence d’anticorps plusieurs mois après l’infection ne signifie pas que la personne n’est pas immunisée contre le virus ni qu’elle pourrait être infectée de nouveau.\n\nCette entrée a été mise à jour avec de nouveaux renseignements le 20 août 2020."
    ],
    "French - Background and context": [
      "Alors que les scientifiques, les professionnels de la santé publique et les docteurs suivent la pandémie de COVID-19, ils continuent d’apprendre sur la façon dont le virus se propage, les symptômes qu’il provoque, et sur d’autres facteurs importants pour le diagnostic, les tests de dépistage, le suivi et la planification à long terme des services de santé publique. La possibilité d’une réinfection continue à faire les manchettes, avec des professionnels de la santé qui déclarent que des patients complètement rétablis avaient ultérieurement présenté des symptômes de nouveau. Certaines observations indiquent en détail comment le suivi des symptômes et le dépistage ont été effectués et, dans certains cas, des patients dont la guérison de la COVID-19 est documentée et dont les tests de dépistage sont négatifs sont tombés malades des semaines ou des mois plus tard, avec des tests de dépistage positifs.\n\nBien que de nombreux aspects du virus et de la pandémie soient encore inconnus, des recherches récentes suggèrent que la réinfection est possible. Une recherche plus récente prépubliée le 11 juillet 2020 a trouvé que les anticorps qui réagissent au virus de la COVID-19 fonctionnent de la même façon que ceux sécrétés pour répondre à d’autres coronavirus associés avec le coryza (rhume de cerveau). Alors que le nombre d’anticorps est plus élevé chez les patients qui présentent une forme plus grave de la maladie, des rapports suggèrent que la protection des anticorps diminue relativement rapidement (parfois dans un délai de 60 jours), plus particulièrement chez les patients qui ont présenté une forme plus légère de COVID-19. De la même façon, une étude de population en Espagne a examiné les anticorps de plus de 50 000 personnes probablement exposées au début de la pandémie et a découvert que très peu avaient encore des anticorps, même celles qui habitaient dans des zones considérablement impactées par le virus. Enfin, une étude effectuée chez des primates (pas des êtres humains) a démontré qu’il y avait immunité au virus de la COVID-19 pendant 28 jours après l’infection initiale. Cependant, l’étude ne présentait pas de mesures à plus long terme et, en tant qu’étude chez les animaux, peut ne pas être directement comparable à l’immunité chez l’être humain.\n\nIl est important de noter que contrairement aux autres virus, le nombre d’anticorps nécessaires pour prévenir une réinfection par le virus de la COVID-19 est inconnu, comme l’est le niveau d’anticorps nécessaires pour suggérer que quelqu’un est « immunisé » contre le virus. Des études sont en cours pour mieux comprendre l’immunité ainsi que la possibilité de réinfection."
    ],
    "Hindi - What our experts say": [
      "हम अभी भी बहुत कुछ सीख रहे हैं कि किस प्रकार की प्राकृतिक रक्षा, जिसे प्रतिरक्षा के रूप में भी जाना जाता है, एक व्यक्ति को SARS-CoV-2 / कोविड-19 से संक्रमित होने के बाद। प्रारंभिक संक्रमण के बाद बहुत कम मात्रा में लोग वायरस से संक्रमित हो जाते हैं।\n \nवास्तविक सबूतों के बावजूद, वैज्ञानिक अभी भी यह सुनिश्चित करने के लिए नहीं जानते हैं कि क्या लोग दूसरी बार कोविड-19 से संक्रमित हो सकते हैं, लेकिन यह संभव प्रतीत होता है। यह निर्धारित करने के लिए अधिक प्रमाण की आवश्यकता है कि क्या रोगियों में पुन: संक्रमण हो सकता है या नहीं, यह कितना सामान्य है, और एक बार संक्रमित होने पर वायरस के लोगों की किस तरह की प्रतिरक्षा प्राप्त कर सकते हैं।\n \nहाल के प्री-प्रिंट अध्ययनों ने कोविड ​​-19 के रोगियों के स्पष्ट मामलों का हवाला दिया है, लेकिन उन निष्कर्षों को अभी तक प्रकाशित नहीं किया गया है या सहकर्मी की समीक्षा नहीं की गई है, इसलिए अन्य वैज्ञानिक विशेषज्ञ अभी तक डेटा या कागजात के पूर्ण परिणामों का कठोरता से अध्ययन करने में सक्षम नहीं हैं। यह ध्यान दिया जाना चाहिए कि अध्ययन में रोगियों को उनके दूसरे संक्रमण के दौरान वायरस के विभिन्न उपभेदों से माना जाता था। इसका मतलब यह हो सकता है कि मरीजों में वायरस के प्रति आजीवन प्रतिरक्षा नहीं होती है, और अगर किसी के संक्रमित होने के बाद कोई भी प्रतिरक्षा मौजूद नहीं है, तो प्रतिरक्षा की लंबाई और ताकत स्पष्ट नहीं है।\n \nमरीजों के दूसरी बार सकारात्मक परीक्षण करने के कुछ मामलों में, वैज्ञानिकों का मानना ​​है कि शरीर में छोड़े गए मूल संक्रमण के निशान दूसरे सकारात्मक परिणाम का कारण हैं। यह बहुत संवेदनशील परीक्षणों या झूठ-सकारात्मक परीक्षणों के कारण हो सकता है।\n \nयह भी ध्यान रखना महत्वपूर्ण है कि एंटीबॉडी स्तर वायरस के खिलाफ प्रतिरक्षा का एक मजबूत संकेतक नहीं हो सकता है और पुन: संक्रमण के लिए संवेदनशीलता है।\n \nइस प्रविष्टि को 30 अगस्त 2020 को नई जानकारी के साथ अद्यतन किया गया था"
    ],
    "Hindi - Background and context": [
      "जैसा कि वैज्ञानिक, सार्वजनिक स्वास्थ्य पेशेवर और डॉक्टर कोविड-19 महामारी की निगरानी करते हैं, वे इस बारे में सीखते रहते हैं कि वायरस कैसे फैलता है, इसके लक्षण और निदान, परीक्षण, निगरानी और दीर्घकालिक सार्वजनिक स्वास्थ्य योजना के लिए अन्य कारक महत्वपूर्ण हैं। हेल्थकेयर प्रोफेशनल्स की रिपोर्ट के साथ रीइनफैक्शन की संभावना एक प्रमुख समाचार बनी हुई है, जिसमें बताया गया है कि कुछ मरीज जो बाद में वायरस से पूरी तरह से ठीक हो गए थे, उन्होंने लक्षणों का पुनर्विकास किया। कुछ मामलों की रिपोर्ट विस्तार से बताती है कि लक्षण निगरानी और परीक्षण दोनों कैसे किए गए हैं, और कुछ मामलों में, रोगियों ने नकारात्मक वायरस परीक्षण परिणामों के साथ कोविड-19 की वसूली को केवल बीमार होने और सकारात्मक सप्ताह या महीनों के बाद परीक्षण करने के लिए प्रलेखित किया है।\n \nहालांकि अभी भी वायरस और महामारी के कई पहलू हैं जो अज्ञात हैं, हालिया शोध से पता चलता है कि पुन: निर्माण संभव हो सकता है। 11 जुलाई, 2020 को एक प्रीप्रिंट रिलीज के साथ साझा किए गए नए शोध में पाया गया कि कोविड-19 एंटीबॉडी अन्य कोरोनवीरस से समान रूप से कार्य करते हैं जो आम सर्दी से जुड़े हैं। जबकि अधिक गंभीर बीमारी वाले रोगियों में एंटीबॉडी की संख्या अधिक है, रिपोर्ट बताती है कि सुरक्षात्मक एंटीबॉडी अपेक्षाकृत जल्दी (कभी-कभी 60 दिनों के भीतर) कम हो जाती हैं, खासकर उन रोगियों में जिनके पास कोविड-19 का हल्का मामला था। इसी तरह, स्पेन के एक जनसंख्या-आधारित अध्ययन ने महामारी में संभावित जोखिम वाले 50,000 से अधिक लोगों के एंटीबॉडी की जांच की और पाया कि बहुत कम लोगों ने एंटीबॉडी को आज तक बनाए रखा है, यहां तक ​कि जो लोग क्षेत्रों में रहते थे वे वायरस से काफी प्रभावित थे। अंत में, प्राइमेट्स (मनुष्यों में नहीं) में किए गए एक अध्ययन से पता चला है कि मूल संक्रमण के बाद 28 दिनों तक कोविड-19 प्रतिरक्षा बनाए रखी गई थी, लेकिन अध्ययन में लंबी दूरी के उपायों को शामिल नहीं किया गया था और एक पशु अध्ययन के रूप में, मनुष्यों से सीधे तुलना नहीं की जा सकती है।\n\nयह ध्यान रखना महत्वपूर्ण है कि, अन्य वायरस के विपरीत, कोविड-19 के साथ पुनर्निधारण को रोकने के लिए आवश्यक एंटीबॉडी की संख्या अज्ञात है क्योंकि किसी को वायरस के लिए \"प्रतिरक्षा\" करने के लिए आवश्यक एंटीबॉडी का स्तर है। प्रतिरक्षा को समझने के लिए अध्ययन के साथ-साथ पुन: निर्माण की संभावना जारी है।"
    ]
  },
  {
    "id": "recr3yXfQwXc2jnMv",
    "Question": "What are the risks for cancer survivors (5+ years)?",
    "Status": "Needs + Editing",
    "Category": "Risks",
    "Subcategory": "On: COVID-19 & cancer survivors",
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Despite the fact that people who have been cancer-free for five years might have previously had compromised immune systems, once this amount of time has passed since their treatments, their  immune system will hopefully mostly or fully have recovered. Generally, cancer survivors with no other preexisting conditions do not have a greater risk of catching the illness than the general population, but every person and their previous treatments are different, and survivors should always talk to their doctors about their health. \n\nSince most COVID-19 research regarding cancer is being done on people currently undergoing treatment, not much is known about people who do not actively have cancer. In general, the more time that has passed since end of treatments, the better, since immune system function can be rebuilt more over several years as opposed to a few months. As our knowledge about cancer and COVID-19 continues to evolve, we will learn more about immune system functions and how previous treatments might impact people's potential risks for becoming infected with the virus.\n",
    "What our experts say": "The majority of cancer survivors, who have been cancer-free for at least five years, are likely to have normal immune system functions and are not at an increased risk for COVID-19. However, every body is different so every cancer survivor should speak with a doctor who knows their full medical history and can discuss their personal risks with them.\n\nFor some cancer survivors, their previous treatments might impact their risk of getting COVID-19 or having a severe form of the disease, as these treatments can have long term effects on the immune system and cause the survivor to have preexisting conditions that may put them at a higher risk for viral infection. For example, patients who have undergone a bone marrow transplant (also known as a 'stem cell transplant') might not regain a completely functional immune system as the transplant depletes their white blood cell system (which the body then replaces). Some patients who have undergone bone marrow transplants are no longer immune to illnesses they had become immune to before the procedure. These patients can be at risk for a number of infections, including COVID-19, but the longer it has been since treatment, the more time your body's immune system has had to improve.\n\nDespite not having a higher risk of becoming infected with the virus than the general population, it should be noted that cancer survivors do have a higher risk of complications if they become infected with COVID-19. This group is also more likely to be hospitalized if they are infected, compared to people who have never had cancer before. To protect themselves from the virus, just like the general population, cancer survivors should use protective measures like wearing masks, maintaining at least six feet of distance, staying home when they can, and washing hands thoroughly and often.\n",
    "Glossary Terms": [
      "recpqhzUTy0vgaQe2",
      "rec9BRg310LdoWtPR",
      "recaXXF6coF4J2EUz"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "cancer",
      "cancer survivor",
      "stem cell transplant",
      "lung transplant"
    ],
    "Other resources": "1. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study ([The Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31173-9/fulltext)) \n2. Common Questions About the COVID-19 Outbreak ([ACS](https://www.cancer.org/latest-news/common-questions-about-the-new-coronavirus-outbreak.html)) \n3. What Every Cancer Survivor Needs to Know about COVID-19 ([MSKCC](https://www.mskcc.org/coronavirus/what-every-cancer-survivor-needs-know-about-covid-19)) \n4. Are Cancer Survivors at High Risk for COVID-19 ([Moffitt](https://moffitt.org/endeavor/archive/are-cancer-survivors-at-high-risk-for-covid19/)) \n",
    "Last modified manual": "2020-07-27",
    "Last edited (simplified)": "2020-07-20T17:21:00.000Z",
    "Last edited (experts say)": "2020-07-27T15:35:10.000Z",
    "Last modified": "2020-07-27",
    "What our experts say wordcount": 299,
    "Background and context wordcount": 172,
    "Other resources wordcount": 49,
    "Wordcount": 520
  },
  {
    "id": "recjs5QXivxuhSxx4",
    "Question": "Why should we all be wearing masks?",
    "Status": "Published",
    "Source of the question": [
      "Fact-checking organization"
    ],
    "Country question was sourced from": [
      "Philippines"
    ],
    "Background and context": "Masks are a type of personal protective equipment (PPE), along with face shields, protective eye goggles, gloves, gowns, and other equipment. Proper use of PPE can help reduce the spread of COVID-19. Wearing PPE is a risk reduction measure, not a risk avoidance measure, so masks can help lower (but not completely eliminate) the chances of getting infected or infecting someone else. Maintaining hygiene, physical distancing, and other measures are still recommended.\n",
    "What our experts say": "In combination with hand washing and social distancing measures, it is important to wear masks to prevent the spread of COVID-19 because the virus spreads primarily through respiratory droplets released when people speak, cough, sneeze or sing. Some infected people may not appear ill or may develop symptoms at a later time, but they can still spread the virus without symptoms. Masks prevent people from spreading the virus to others, especially when we can't be 6 ft / 2m apart. Cloth masks primarily protect people in close proximity to the person wearing the mask by trapping droplets that are released from the wearer. Cloth masks can also protect the wearer by filtering out some virus particles trying to enter. \nMedical masks (N95 or FFP2) filter virus particles from entering more effectively than cloth masks and are designed to protect the wearer. Supplies of those are limited and generally reserved for doctors.\n",
    "Glossary Terms": [
      "recuQuM83b2X3K9Bx"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Other resources": "1. CDC calls on Americans to wear masks to prevent COVID-19 spread ([U.S. CDC](https://www.cdc.gov/media/releases/2020/p0714-americans-to-wear-masks.html?utm_source=Global+Health+NOW+Main+List&utm_campaign=ba35be8398-EMAIL_CAMPAIGN_2020_07_14_03_18&utm_medium=email&utm_term=0_8d0d062dbd-ba35be8398-860399))\n2. The growing scientific evidence for masks to fight Covid-19 ([Vox](https://www.vox.com/future-perfect/21299527/masks-coronavirus-covid-19-studies-research-evidence))\n3. Q&A: Masks and COVID-19 ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-on-covid-19-and-masks))\n4. Considerations for Wearing Cloth Face Coverings ([US CDC](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html))\n5. Why scientists say wearing masks shouldn't be controversial ([Science News](https://www.sciencenews.org/article/covid-19-coronavirus-why-wearing-masks-controversial))\n6. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis, 2020 ([Lancet](https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931142-9))\n\n\n\n",
    "DB (Hindi)": [
      "recBXMWayPZmGZ7Aq"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recHu34trIDQ9H58Q"
    ],
    "DB (Portuguese)": [
      "recivEWHpCMMhpJ8q"
    ],
    "Rollup test 2": [
      "rec0l6a70IV8lcxjI"
    ],
    "Last modified manual": "2020-07-27",
    "Last edited (simplified)": "2020-07-15T01:01:15.000Z",
    "Last edited (experts say)": "2020-07-27T15:31:48.000Z",
    "Last modified": "2020-07-27",
    "What our experts say wordcount": 151,
    "Background and context wordcount": 72,
    "Other resources wordcount": 69,
    "Wordcount": 292,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "हाथ धोने और सामाजिक दूर करने के उपायों के संयोजन में, कोविड-19 के प्रसार को रोकने के लिए मास्क पहनना महत्वपूर्ण है क्योंकि वायरस मुख्य रूप से सांस की बूंदों के माध्यम से फैलता है जब लोग बोलते हैं, खांसी, छींकते हैं या गाते हैं। कुछ संक्रमित लोग बीमार दिखाई नहीं दे सकते हैं या बाद के समय में लक्षणों को विकसित कर सकते हैं, लेकिन वे अभी भी लक्षणों के बिना वायरस फैला सकते हैं। मास्क लोगों को वायरस को दूसरों तक फैलाने से रोकते हैं, खासकर जब हम 6 फीट / 2 मी के अलावा नहीं हो सकते हैं। क्लॉथ मास्क मुख्य रूप से पहनने वाले से निकलने वाली बूंदों को फँसाकर मास्क पहनने वाले व्यक्ति के नजदीकी लोगों की रक्षा करते हैं। कपड़ा मास्क भी प्रवेश करने की कोशिश कर रहे कुछ वायरस कणों को छानकर पहनने वाले की रक्षा कर सकते हैं।\nमेडिकल मास्क (N95 या FFP2) वायरस के कणों को कपड़े के मास्क की तुलना में अधिक प्रभावी ढंग से प्रवेश करने से रोकते हैं और इसे पहनने वाले की सुरक्षा के लिए डिज़ाइन किया जाता है। उन की आपूर्ति सीमित है और आम तौर पर डॉक्टरों के लिए आरक्षित है।"
    ],
    "Hindi - Background and context": [
      "मास्क एक प्रकार के व्यक्तिगत सुरक्षात्मक उपकरण (पीपीई) होते हैं, साथ ही चेहरे की ढाल, सुरक्षात्मक आंख के चश्मे, दस्ताने, गाउन और अन्य उपकरण भी होते हैं। पीपीई का उचित उपयोग कोविड-19 के प्रसार को कम करने में मदद कर सकता है। पीपीई पहनना एक जोखिम को कम करने का उपाय है, न कि जोखिम से बचने का उपाय, इसलिए मास्क कम (लेकिन पूरी तरह से खत्म नहीं) संक्रमित या किसी और को संक्रमित करने की संभावना को कम करने में मदद कर सकता है। स्वच्छता बनाए रखना, शारीरिक गड़बड़ी, और अन्य उपाय अभी भी अनुशंसित हैं।"
    ]
  },
  {
    "id": "recUU9xtTzmcGAk9Y",
    "Question": "What are medical reasons people can't wear masks? ",
    "Status": "Published",
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Masks are a type of personal protective equipment (PPE), along with face shields, protective eye goggles, gloves, gowns, and other equipment. Proper use of PPE can help reduce the spread of COVID-19. Wearing PPE is a risk reduction measure that lowers the chances of getting infected or infecting someone else, but does not eliminate the risk completely. Hand washing and physical distancing (min of 6 feet / 2 metres) are still recommended. \n\nIn the U.S., the government recently warned that they did not issue or endorse fraudulent flyers being circulated about mask use under the Americans with Disabilities Act (ADA). People are encouraged to follow official ADA guidance, which is available at http://ADA.gov, +1-800-514-0301 (voice), and +1-800-514-0383 (TTY). While the U.S. does not currently have a national level policy around the use of masks, an increasing number of cities, counties, and states have passed policies known as \"mask mandates\" that require people to wear masks in certain public settings. Medical exemptions for wearing masks under these policies can be checked with the responsible government offices.\n",
    "What our experts say": "Wearing masks or other face coverings can help slow the spread of COVID-19. The U.S. Centers for Disease Control and Prevention (U.S. CDC) recommends wearing masks, except for children under 2 years old, and anyone who has trouble breathing, anyone who is unconscious or incapacitated, and anyone who is unable to remove a mask without help. \n\nAccording to the U.S. Department of Justice (DOJ), which enforces the Americans with Disabilities Act (ADA), there is no \"blanket exemption to people with disabilities from complying with legitimate safety requirements necessary for safe operations,” including mask policies set by businesses and local governments. The ADA does require that people with disabilities are “reasonably accommodated,” such as by finding alternative public health measures for people who cannot safely wear and breathe through a mask.\n",
    "Glossary Terms": [
      "reclKahoPRbBLqUKg",
      "recuQuM83b2X3K9Bx"
    ],
    "Other resources": "1. Considerations for Wearing Cloth Face Coverings ([U.S. CDC)](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html)\n2. COVID-19 ALERT: Fraudulent Face Mask Flyers ([ADA](https://www.ada.gov/covid-19_flyer_alert.html))\n3. COVID mask exemption cards are not from the government ([FTC](https://www.consumer.ftc.gov/blog/2020/06/covid-mask-exemption-cards-are-not-government))\n4. Fact check: ADA does not provide blanket exemption from face mask requirements ([USA Today](https://www.usatoday.com/story/news/factcheck/2020/07/15/fact-check-ada-disability-rights-and-face-mask-requirements/5391830002/))\n",
    "In translated DBs?": "Yes",
    "DB (Arabic)": [
      "rec3SiVhq3mxnM4lQ"
    ],
    "DB (Bengali)": [
      "recXRgpB0PEbYcp5g"
    ],
    "DB (Portuguese)": [
      "recIeaS6pyaupf3jv"
    ],
    "Rollup test 2": [
      "recbCCdCp8LkCBcfj"
    ],
    "Last modified manual": "2020-07-27",
    "Last edited (simplified)": "2020-07-27T13:24:33.000Z",
    "Last edited (experts say)": "2020-07-27T13:24:33.000Z",
    "Last modified": "2020-07-27",
    "What our experts say wordcount": 129,
    "Background and context wordcount": 175,
    "Other resources wordcount": 40,
    "Wordcount": 344,
    "Arabic Q status": [
      "Published"
    ],
    "Arabic - What our experts say": [
      "يخفف ارتداء الكمامات أو أغطية الوجه الأخرى من انتشار وباء كوفيد-19. تَنصح المراكز الأمريكية للسيطرة على الأمراض والوقاية منها بارتداء الكمامات باستثناء الأطفال دون عمر السنتين (2سننتين)، والأشخاص الذين يعانون من صعوبة التنفس، وفاقدي الوعي أو العَجَزَة، وكل شخص غير قادر على نزع الكمامة بنفسه دون مساعدة. وفقًا لوزارة العدل الأمريكية وتَطبيقًا للقانون الخاص بالأمريكيين من ذوي الاحتياجات الخاصة: ’ليس هناك استثناء شامل لذوي الاحتياجات الخاصة من إتباع شروط السلامة المشروعة الضرورية لضمان سلامة العمليات’، ويشمل ذلك سياسات ارتداء الكمامات التي تفرضها المشاريع والحكومات المحلية. يَشترط القانون الخاص بالأمريكيين من ذوي الاحتياجات الخاصة تزويد هؤلاء ’بوسائل الراحة المعقولة‘، كإيجاد تدابير بديلة للصحة العامة موجهة للأشخاص غير القادرين على ارتداء الكمامات بأمان والتنفس من خلالها.\n\n\n\n\n   "
    ],
    "Arabic - Background and context": [
      "تتندرج الكمامات ضمن ما يُعرف بمعدات الوقاية الشخصية، يشمل ذلك أيضًا واقيات الوجه ونظارات حماية الوجه والقفازات والرداء الواقي ومعدات أخرى. يُساعد استخدام معدات الوقاية الشخصيّة بشكلٍ مناسب على تخفيف انتشار وباء كوفيد-19. ارتداء معدات الوقاية الشخصية هو تدبير من شأنه تخفيف الخطر، حيث يقلل من احتمالات الإصابة الشخصيّة أو من نقل العدوى لشخصٍ آخر، لكن ذلك لا يُلغي الخطر تمامًا، إذ لا يزال يُنصح بغسل اليدين وبالحفاظ على التباعد الجسدي (مسافة 2 مترين كحدٍ أدنى\nحَذرت الحكومة في الولايات المتحدة الأمريكيّة مؤخرًا إنها لم تُصدر أو تُصادق على منشورات مُضلِلة مُتعلقة باستخدام الكمامات، كان تم تداولها باسم القانون الخاص بالأمريكيين من ذوي الاحتياجات الخاصة. ويُنصح الأشخاص بإتباع الإرشادات الرسميّة الصادرة عن القانون الخاص بالأمريكيين من ذوي الاحتياجات الخاصة المُتاحة على العنوان الإلكتروني http://ADA.gov، وعلى الهاتف الصوتي رقم: +1-800-514-0301، وعلى الرقم الخاص بالصم+1-800-514-0383:. في ظل عدم وجود سياسة وطنيّة أمريكيّة بشأن استخدام الكمامات، صادقت العديد من المدن والمقاطعات والولايات على سياسات سُميت بـ ’تعليمات ارتداء الكمامة‘، التي تُلزم الناس بوضع الكمامات داخل منشآت عامة محددة. يُمكن التحقق من استثناءات ارتداء الكمامات لأسباب طبيّة  في هذه السياسات من خلال المكاتب الحكوميّة المُفوضة. \n"
    ],
    "Portuguese - What our experts say": [
      "O uso de máscaras e outros revestimentos faciais pode ajudar a diminuir a propagação do COVID-19. Os Centros de Controle e Prevenção de Doenças dos EUA (CDC dos EUA) recomendam o uso de máscaras, exceto para crianças menores de 2 anos, pessoas com dificuldade de respirar, inconscientes ou incapacitadas, ou que não possam remover uma máscara sem ajuda.\n De acordo com o Departamento de Justiça dos EUA (DOJ), que aplica a Lei dos Americanos com Deficiências (ADA), não há \"isenção presumida para as pessoas com deficiência quanto ao cumprimento dos requisitos de segurança razoáveis necessários ao desenvolvimento de procedimentos com segurança\", incluindo políticas de uso de máscaras estabelecidas por empresas e governos locais. A ADA exige que as pessoas com deficiência sejam \"razoavelmente acolhidas\", como com a busca de medidas alternativas de saúde pública para pessoas que não podem usar e respirar com segurança através de uma máscara."
    ],
    "Portuguese - Background and context": [
      "Máscaras são um tipo de equipamento de proteção individual (EPI), assim como protetores faciais, óculos de proteção, luvas, jalecos e outros equipamentos. O uso adequado de EPIs pode ajudar a reduzir a propagação do COVID-19. O uso de EPIs é uma medida de redução de risco que diminui a possibilidade de ser infectado ou infectar outra pessoa. No entanto, EPIs não eliminam completamente o risco. Lavar as mãos e o manter o distanciamento físico (pelo menos 2 metros) continuam a ser recomendados. \nNos EUA, o governo recentemente alertou que não emitiu ou endossou publicações fraudulentas que circulavam sobre o uso de máscaras sob a Lei dos Americanos com Deficiências (ADA). As pessoas são incentivadas a seguir as orientações oficiais da ADA, disponíveis em http://ADA.gov, + 1-800-514-0301 (telefone) e + 1-800-514-0383 (para deficientes auditivos). Embora atualmente os EUA não disponham de uma política sobre o uso de máscaras a nível nacional, um número cada vez maior de cidades, regiões e estados aprovaram políticas conhecidas como \"máscaras mandatórias\" que exigem que as pessoas usem máscaras em determinados locais públicos. As isenções médicas para o uso de máscaras sob essas regulamentações podem ser verificadas junto às agências governamentais responsáveis."
    ]
  },
  {
    "id": "rec4kQXR2QgCNdlgs",
    "Question": "Can convalescent plasma help treat COVID-19?",
    "Status": "Update in progress",
    "Background and context": "Using convalescent plasma from previously infected people to treat sick individuals has been in practice for nearly 100 years, for several diseases including polio, influenza, and Ebola. Plasma is the liquid portion of the blood and contains disease-specific antibodies that helped fight the infection in a recovered individual, and that may help fight the infection in a newly infected recipient. As a result, convalescent plasma is being explored as an option for prevention and treatment of COVID-19.\n\nIn March 2020, the U.S. Federal Drug Administration (FDA) announced an emergency investigational process to allow doctors to treat serious cases with convalescent plasma. In April 2020, the U.S. FDA announced a National Expanded Access Protocol through the Mayo Clinic that expanded convalescent plasma treatment to include adults at risk of severe disease in addition to adults with severe cases. In August 2020, the U.S. FDA announced an emergency use authorization that authorizes the distribution of COVID-19 convalescent plasma in the U.S. and its administration by healthcare providers to treat hospitalized patients with suspected or laboratory-confirmed COVID-19. In contrast, the U.S. National Institute of Health (NIH) COVID-19 Treatment Guidelines Panel has issued a statement warning that there is currently insufficient data from studies to recommend the use of convalescent plasma to treat COVID-19. A number of clinical trials are underway to study the efficacy of convalescent plasma in preventing or treating COVID-19 in a range of cases. \n\nMore research is still necessary to determine if convalescent plasma is effective and safe as a treatment for COVID-19. Scientists are working to identify whether it might help reduce severity of illness, shorten the duration of illness, or even prevent death associated with COVID-19.\n",
    "What our experts say": "When someone has been infected with COVID-19, their body's immune system produces substances called antibodies that work to destroy the virus. These antibodies can usually be found in someone's blood after they recover from the virus, specifically in a  portion of the blood called 'plasma.' Antibodies in plasma help an infected person fight off the virus, so researchers are studying whether transferring plasma from recovered patients or almost recovered (also called 'convalescent') can help immune systems fight off the infection.\n\nThis experimental use of convalescent plasma for COVID-19 is not an approved treatment by the World Health Organization or the U.S. Centers for Disease Control and Prevention, but there is some indication that it might be beneficial in the early stages of a COVID-19 infection. On August 23, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients, based on their assessment that the known and potential benefits outweigh the known and potential risks. This means COVID-19 convalescent plasma is now regulated as an investigational product, but it not yet U.S. FDA approved for use.\n\nMore research needs to be conducted before scientists reach a consensus about the benefits as well as negative impacts plasma may have in infected patients.\n",
    "Other resources": "1. Convalescent Plasma and COVID-19 ([JAMA](https://jamanetwork.com/journals/jama/fullarticle/2767351))\n2. Recommendations for Investigational COVID-19 Convalescent Plasma ([U.S. FDA](https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma))\n3. FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID–19 Treatment, Another Achievement in Administration’s Fight Against Pandemic ([U.S. FDA](https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment))\n4. COVID-19 and Convalescent Plasma: Frequently Asked Questions ([American Society of Hematology](https://www.hematology.org/covid-19/covid-19-and-convalescent-plasma))\n5. Deployment of convalescent plasma for the prevention and treatment of COVID-19 ([Journal of Clinical Investigation](https://www.jci.org/articles/view/138745))\n6. The COVID-19 Treatment Guidelines Panel's Statement on the Emergency Use Authorization of Convalescent Plasma for the Treatment of COVID-19 ([U.S. NIH](https://www.covid19treatmentguidelines.nih.gov/statement-on-convalescent-plasma-eua/))\n",
    "DB (French)": [
      "recSXrpaflisq8AhK"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recPUAh7lfhfqSzRZ"
    ],
    "DB (Portuguese)": [
      "recD6BA69LGPgRUKY"
    ],
    "Rollup test 2": [
      "recl7MSTxDaQc6AV5"
    ],
    "Last modified manual": "2020-08-25",
    "Last edited (simplified)": "2020-09-29T00:23:08.000Z",
    "Last edited (experts say)": "2020-09-29T00:23:08.000Z",
    "Last modified": "2020-09-29",
    "What our experts say wordcount": 215,
    "Background and context wordcount": 276,
    "Other resources wordcount": 83,
    "Wordcount": 574,
    "French Q status": [
      "Ready for expert review"
    ],
    "French - What our experts say": [
      "Quand quelqu’un a été infecté par le virus de la COVID-19, le système immunitaire du corps de cette personne produit des substances appelées anticorps qui se mettent à l’œuvre pour détruire le virus. Ces anticorps peuvent habituellement être trouvés dans le sang d’une personne après qu’elle s’est remise du virus, particulièrement dans une partie du sang appelée « plasma ». Les anticorps du plasma aident une personne infectée à combattre le virus, et des chercheurs examinent donc la possibilité de transférer du plasma de patients rétablis ou presque rétablis (dit « de convalescence ») pour aider les systèmes immunitaires à combattre l’infection.\n\nCette utilisation expérimentale de plasma de convalescence pour la COVID-19 n’est un traitement approuvé ni par l’Organisation mondiale de la santé ni par les Centres de contrôle et de prévention des maladies des États-Unis, mais il existe des indications du bienfait d’un tel traitement dans les stades précoces d’une infection par le virus de la COVID-19. Le 23 août 2020, l’Agence des produits alimentaires et médicamenteux des États-Unis (FDA) a émis une autorisation d’utilisation d’urgence (EUA) pour le plasma de convalescence comme traitement de recherche de la COVID-19 chez des patients hospitalisés, autorisation fondée sur leur évaluation que les bienfaits connus et potentiels l’emportent sur les risques connus et potentiels. Cela signifie que le plasma de convalescence de COVID-19 est maintenant réglementé comme produit de recherche, mais son utilisation n’est pas encore approuvée par la FDA des États-Unis.\n\nDe plus amples recherches doivent être entreprises afin que les scientifiques parviennent à un consensus sur les bienfaits, mais aussi sur les conséquences négatives que le plasma pourrait avoir chez les patients infectés.\n\nCette entrée a été mise à jour avec de nouveaux renseignements le 25 août 2020."
    ],
    "French - Background and context": [
      "L’utilisation de plasma de convalescence de personnes infectées antérieurement afin de traiter des malades existe depuis près de 100 ans pour traiter plusieurs maladies, dont la poliomyélite, la grippe et Ebola. Le plasma est le constituant liquide du sang et il contient des anticorps propres aux maladies, qui aident à combattre l’infection chez une personne rétablie. C’est pourquoi le plasma de convalescence est évalué en tant qu’option pour prévenir et traiter la COVID-19.\n\nEn mars 2020, l’Agence des produits alimentaires et médicamenteux des États-Unis (FDA) a annoncé un processus de recherche d’urgence afin de permettre aux docteurs de traiter des cas graves avec du plasma de convalescence. En avril 2020, la FDA des États-Unis a annoncé un protocole national d’accès élargi grâce à la Clinique Mayo afin que le traitement au plasma de convalescence comprenne des adultes qui présentent un risque de maladie grave en plus des cas sévères. En août 2020, la FDA des États-Unis a annoncé une autorisation d’utilisation d’urgence. Elle autorise la distribution de plasma de convalescence de COVID-19 aux États-Unis et son administration par des fournisseurs de soins de santé afin de traiter des patients hospitalisés, que l’on soupçonne être atteints de COVID-19 ou dont la maladie a été confirmée en laboratoire. De plus, certains essais cliniques sont en cours afin d’étudier l’efficacité du plasma de convalescence pour prévenir ou traiter la COVID-19 dans une gamme de cas.\n\nDes recherches supplémentaires sont encore nécessaires afin de déterminer si le plasma de convalescence est un traitement efficace et sans danger de la COVID-19. Des scientifiques sont à l’œuvre pour déterminer s’il pourrait aider à réduire la gravité et la durée de la maladie, voire prévenir des morts associés à la COVID-19.\n\nCette entrée a été mise à jour avec de nouveaux renseignements le 25 août 2020."
    ],
    "Bengali - What our experts say": [
      "যখন কেউ কোভিড-১৯ দ্বারা সংক্রামিত হন, তাদের শরীর অ্যান্টিবডি নামক এক ধরণের বস্তু সৃষ্টি করে যা এই ভাইরাসটিকে বিনষ্ট করার জন্য কাজ করে। এই অ্যান্টিবডিগুলি সাধারণত মানুষের রক্তে পাওয়া যায় তারা ভাইরাস থেকে সেরে ওঠার পরে, বিশেষত তাদের রক্তের তরল অংশ যাকে ‘প্লাজমা’ বলা হয়, তার মধ্যে। যেহেতু প্লাজমাতে থাকা অ্যান্টিবডি সংক্রামিত মানুষটিকে ভাইরাসের সঙ্গে লড়াই করতে এবং তাদের স্বাস্থ্যের উন্নতি ঘটাতে সাহায্য করে, গবেষণাকারীরা অধ্যয়ন করছেন যে সম্পূর্ণরূপে সেরে ওঠা অথবা প্রায় সম্পূর্ণরূপে সেরে ওঠা রোগীদের (যাদেরকে ‘কনভ্যালেসেন্ট’ ও বলা হয়) শরীর থেকে প্লাজমা বর্তমানে ভাইরাস সংক্রামিত রোগীদের শরীরে স্থানান্তর করলে তা তাদের অনাক্রম্য তন্ত্রকে সংক্রমণের সঙ্গে লড়াই করতে সাহায্য করে কি না। কোভিড-১৯ এর জন্য কনভ্যালেসেন্ট প্লাজমা বিশ্ব স্বাস্থ্য সংস্থা (ডব্লিউএইচও) অথবা মার্কিন যুক্তরাষ্ট্রের সেন্টারস ফর ডিজিজ কন্ট্রোল অ্যান্ড প্রিভেনশন (সিডিসি) CDC অনুমোদিত চিকিৎসা নয়, কিন্তু এমন কিছু লক্ষণ দেখা গেছে যাতে মনে হয় এটি কোভিড-১৯ সংক্রমণের শুরুর দিকে লাভজনক হতে পারে। সংক্রামিত রোগীদের মধ্যে প্লাজমার সুবিধা অথবা নেতিবাচক প্রভাবের ব্যাপারে বিজ্ঞানীরা একমত হওয়ার আগে আরও গবেষণা পরিচালনা করা প্রয়োজন।"
    ],
    "Bengali - Background and context": [
      "যেসমস্ত মানুষ আগে সংক্রামিত হয়েছেন তাদের কনভ্যালেসেন্ট প্লাজমা ব্যবহার করে অসুস্থ মানুষের চিকিৎসা করার প্রথা প্রায় ১০০ বছর ধরে চলে আসছে পোলিও, ইনফ্লুয়েঞ্জা, এবং ইবোলা সহ বিভিন্ন অসুখের ক্ষেত্রে। প্লাজমা রক্তের তরল অংশ এবং এটির মধ্যে অসুখ-নির্দিষ্ট অ্যান্টিবডিগুলি রয়েছে যা একজন সুস্থ হয়ে ওঠা ব্যক্তির শরীরে সংক্রমণের সঙ্গে লড়াই করতে সাহায্য করেছিল, এবং এগুলো হয়তো নতুনভাবে সংক্রামিত ব্যক্তির ক্ষেত্রেও লড়াই করতে সাহায্য করতে পারে। ফলে, কনভ্যালেসেন্ট প্লাজমাকে কোভিড-১৯ এর প্রতিরোধ এবং চিকিৎসার একটি বিকল্প হিসাবে পরীক্ষা নিরীক্ষা করা হচ্ছে। \n\n২০২০ সালের মার্চ মাসে, মার্কিন যুক্তরাষ্ট্রের ফেডেরাল ড্রাগ অ্যাডমিনিস্ট্রেশন (FDA)একটি জরুরী তদন্তমূলক প্রক্রিয়া ঘোষণা করে যা চিকিৎসকদের কনভ্যালেসেন্ট প্লাজমা দিয়ে গুরুতর কেসগুলির চিকিৎসা করার অনুমতি দেয়। ২০২০ সালের এপ্রিলে, মেয়ো ক্লিনিকের মাধ্যমে এফডিএ জাতীয় সম্প্রসারিত অ্যাক্সেস প্রোটোকল ঘোষণা করেন যা প্লাজমা চিকিৎসায় গুরুতরভাবে আক্রান্ত প্রাপ্তবয়স্ক রোগীদের সঙ্গে সেই সমস্ত রোগীকে অন্তর্গত করতে সম্প্রসারিত করে যারা প্রাপ্তবয়স্ক এবং গুরুতর অসুখ হওয়ার ঝুঁকিতে রয়েছেন। তার সঙ্গে, বিভিন্ন ক্ষেত্রে কোভিড-১৯ এর প্রতিরোধ এবং চিকিৎসার জন্য কনভ্যালেসেন্ট প্লাজমার কার্যকারিতা অধ্যয়ন করার জন্য বেশ কয়েকটি নিদানিক পরীক্ষণ করা হচ্ছে। \n\nকোভিড-১৯ এর চিকিৎসায় কনভ্যালেসেন্ট প্লাজমা কার্যকরী এবং নিরাপদ কি না তা নির্ধারণ করার জন্য এখনও আরও গবেষণা প্রয়োজন। কনভ্যালেসেন্ট প্লাজমা অসুখের তীব্রতা হ্রাস করতে, অসুখের সময়সীমা কমাতে, এবং এমনকি কোভিড-১৯ সংক্রান্ত মৃত্যু প্রতিরোধ করতে সাহায্য করে কি না তা চিহ্নিত করার জন্য বৈজ্ঞানিকেরা কাজ করছেন। \n"
    ]
  },
  {
    "id": "recJQ2D9s79kEHJzP",
    "Question": "How effective is spraying disinfectants in public places in curbing the spread of infection? ",
    "Status": "Needs + Editing",
    "Background and context": "In some countries, measures have been taken to spray disinfectants into the air (both indoors and outdoors) or onto people to prevent virus spread. While widespread spraying has been effective at controlling illnesses spread by mosquitos (i.e. West Nile virus, dengue) or other insects, SARS-Cov-2 is spread directly from person to person. While disinfectants do kill SARS-Cov-2, the virus that causes COVID-19, most experts agree that widespread spraying is likely ineffective in preventing virus spread. Spraying disinfectants into the air will not prevent virus spread from person to person via respiratory droplets (from coughing, sneezing, or talking).  Because the SARS-Cov-2 virus lives within the body, spraying disinfectants onto people or encouraging people to gargle or drink disinfectants is also ineffective and can be very dangerous.  In addition, spraying can cause breathing problems, skin irritation, burns, environmental pollution, and may be harmful to fish, birds, and other animals. Social distancing, face mask use, disinfecting “high touch” surfaces (i.e. door handles, handrails), and careful hand-washing are recommended to help prevent virus spread.\n",
    "What our experts say": "Transmission of COVID-19 from surfaces contaminated with the virus has not been documented, but it is possible that the reason for this is due to gaps in research and contact tracing._ _There is limited research about the effectiveness of disinfecting public spaces, but researchers are working to determine whether or not spraying disinfectant will impact the amount of virus transmissions that occurs from people coming into contact with objects like water fountains, playground equipment, and hand rails. The United States Centers for Disease Control and Prevention still states that thoroughly cleaning and disinfecting indoor surfaces in public places is a best practice for preventing the spread of COVID-19. As it is possible to spread the virus through contaminated surfaces, thoroughly cleaning and disinfecting all surfaces - not just spraying disinfectant - that humans touch in both public and private settings. \n\nHowever, it should be noted that spraying disinfectants in public places may be harmful to humans as exposure to disinfectant sprays can cause dangerous respiratory effects when inhaled. Other potential impacts are skin and eye irritation, potential corrosion, and some disinfectants might have a chemical (formaldehyde) that is known to cause cancer. Lastly, some chemical disinfectants are flammable, explosive, can generate toxic gases, and can potentially be harmful to the environment, so serious caution should be taken when spraying any of these disinfectants to large surface areas or for a prolonged period of time.\n",
    "Other resources": "1. CDC steps to clean and sterilize against COVID-19 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cleaning-disinfection.html))\n2. CDC guidance on Cleaning and Disinfection for Community Facilities ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/community/organizations/cleaning-disinfection.html))\n3. Research on the exposure to disinfectants by nurses and the association to COPD ([JAMA](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2753247))\n4. Research about the association of household cleaning agents and disinfectants with asthma ([BMJ](https://oem.bmj.com/content/74/9/684))\n5. Disinfectants and By-Products ([WHO](https://apps.who.int/iris/bitstream/handle/10665/42274/WHO_EHC_216.pdf?sequence=1)).\n",
    "Translation notes": "We have changed x",
    "Last modified manual": "2020-07-27",
    "Last edited (simplified)": "2020-07-07T22:41:39.000Z",
    "Last edited (experts say)": "2020-07-27T06:39:34.000Z",
    "Last modified": "2020-07-27",
    "What our experts say wordcount": 234,
    "Background and context wordcount": 167,
    "Other resources wordcount": 53,
    "Wordcount": 454
  },
  {
    "id": "recrVbGv8aiD1jTq8",
    "Question": "What do we know so far about \"COVID toes\"?",
    "Status": "Published",
    "Source of the question": [
      "Fact-checking organization"
    ],
    "Background and context": "There have been many reports of new and emerging symptoms linked to COVID-19 throughout the evolution of the pandemic. As healthcare professionals continue to learn about the virus and its presentation, classifying symptoms according to their severity and frequency has become important in making accurate and timely diagnoses. While the most common symptoms of COVID-19 are breathing problems, fever, coughing, and fatigue, other symptoms of infection have also been identified and include nausea or vomiting, diarrhea, sore throat, loss (or absence) of smell or taste, and muscle aches. \n\nAnother symptom that has been occasionally reported is a discoloration (a slightly purple or pink color) or bumpy rash on the toes, feet, or hands- commonly referred to as “COVID toes.” Reports have continued to suggest that “COVID toes” are fairly uncommon, though they may occur more often in younger, asymptomatic patients. Healthcare professionals often suggest that patients contact their doctors for any unusual symptoms that they experience, and patients should seek medical care and coronavirus testing if they experience symptoms common to coronavirus infection.\n",
    "What our experts say": "\"COVID toes\" typically refers to purple or pink discoloration, often with small, raised bumps on the skin on the tips of the toes and, in some instances, on the hands. Current research on the symptom is still evolving, and the exact cause of the symptom remains unclear. It is also important to note that multiple of the reports published about \"COVID toes\" are not based on patients having positive laboratory test results for COVID-19. The association with COVID-19 in these reports is based on the patients self-reporting COVID-19 symptoms or reporting having been in close proximity with someone diagnosed with COVID-19.\nThe appearance of \"COVID toes\" and other symptoms can vary from patient to patient, and a dermatologist or clinician should be consulted for better clarity and safety in diagnosis. As of now, it is not clear what makes some people infected with COVID-19 have this reaction to the virus. It is not clear when in the course of illness the discoloration and rashes are most likely to be observed, and some reports suggest that these symptoms may occur more commonly in people without other typical symptoms of COVID-19.\n",
    "Glossary Terms": [
      "rec0fiL9Lg2z7CGlb"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "COVID toes",
      "chilblains",
      "inflammation",
      "rashes"
    ],
    "Other resources": "1. An editorial about the dermatological landscape of COVID-19 ([JAMA](https://jamanetwork.com/journals/jamadermatology/fullarticle/2765612))\n2. Are COVID Toes and Rashes Common Symptoms of the Coronavirus? ([Cleveland Clinic](https://health.clevelandclinic.org/are-covid-toes-and-rashes-common-symptoms-of-coronavirus/))\n3. Chilblain-like lesions on feet and hands during the COVID-19 Pandemic ([International Journal of Dermatology](https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijd.14937))\n4. Focus on \"COVID Toes\" ([JAMA Dermatology](https://jamanetwork.com/journals/jamadermatology/fullarticle/2767775))\n",
    "DB (Hindi)": [
      "recQYOQ0S7oq5Ml7t"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recVIvQHG4LEe1YNt"
    ],
    "DB (Portuguese)": [
      "recwJ6IVEYUAmJCN3"
    ],
    "Rollup test 2": [
      "rec76hJ1xq92Ga9IG"
    ],
    "Last modified manual": "2020-07-24",
    "Last edited (simplified)": "2020-07-23T18:40:30.000Z",
    "Last edited (experts say)": "2020-07-24T01:56:22.000Z",
    "Last modified": "2020-07-24",
    "What our experts say wordcount": 188,
    "Background and context wordcount": 171,
    "Other resources wordcount": 42,
    "Wordcount": 401,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "\"कोविड से पैर की अंगुली पर असर\" आमतौर पर बैंगनी या गुलाबी मलिनकिरण को संदर्भित करता है, अक्सर पैर की उंगलियों पर त्वचा पर छोटे, उठाए हुए धक्कों और कुछ उदाहरणों में हाथों पर। लक्षण पर वर्तमान शोध अभी भी विकसित हो रहा है, और लक्षण का सटीक कारण स्पष्ट नहीं है। यह भी ध्यान रखना महत्वपूर्ण है कि \"कोविड से पैर की अंगुली पर असर\" के बारे में प्रकाशित कई रिपोर्ट कोविड-19 के सकारात्मक प्रयोगशाला परीक्षण के परिणाम वाले रोगियों पर आधारित नहीं हैं। इन रिपोर्टों में कोविड-19 के साथ संबंध स्वयं-रिपोर्टिंग कोविड-19 लक्षणों पर आधारित है या कोविड-19 के निदान वाले किसी व्यक्ति के साथ निकटता से संबंधित है।\n\"कोविड से पैर की अंगुली पर असर\" की उपस्थिति और अन्य लक्षण रोगी से रोगी में भिन्न हो सकते हैं, और निदान में बेहतर स्पष्टता और सुरक्षा के लिए एक त्वचा विशेषज्ञ या चिकित्सक से परामर्श किया जाना चाहिए। अभी तक, यह स्पष्ट नहीं है कि कोविड​​-19 से संक्रमित कुछ लोगों में वायरस के प्रति क्या प्रतिक्रिया है। यह स्पष्ट नहीं है कि बीमारी के दौरान मलिनकिरण और चकत्ते सबसे अधिक देखे जाने की संभावना है, और कुछ रिपोर्टों से पता चलता है कि ये लक्षण कोविड​​-19 के अन्य विशिष्ट लक्षणों के बिना लोगों में अधिक सामान्यतः हो सकते हैं।"
    ],
    "Hindi - Background and context": [
      "महामारी के पूरे विकास में कोविड-19 से जुड़े नए और उभरते लक्षणों की कई रिपोर्ट मिली हैं। क्योंकि स्वास्थ्य पेशेवरों ने वायरस और इसकी प्रस्तुति के बारे में सीखना जारी रखा है, उनकी गंभीरता और आवृत्ति के अनुसार लक्षणों को वर्गीकृत करना सटीक और समय पर निदान करने में महत्वपूर्ण हो गया है। जबकि कोविड-19 के सबसे आम लक्षण सांस लेने में तकलीफ, बुखार, खांसी और थकान है, संक्रमण के अन्य लक्षणों की भी पहचान की गई है और इसमें मतली या उल्टी, दस्त, गले में खराश, गंध (स्वाद) में कमी या मांसपेशियों के दर्द (या अनुपस्थिति) शामिल हैं।\n\nएक अन्य लक्षण जो कभी-कभी रिपोर्ट किया गया है वह पैर, पैर, या हाथों पर एक मलिनकिरण (थोड़ा बैंगनी या गुलाबी रंग) या ऊबड़ दाने है, जिसे आमतौर पर \"कोविड से पैर की अंगुली पर असर \" के रूप में जाना जाता है। रिपोर्ट्स ने सुझाव दिया है कि \"कोविड से पैर की अंगुली पर असर\" काफी असामान्य हैं, हालांकि वे युवा, स्पर्शोन्मुख रोगियों में अधिक बार हो सकते हैं। हेल्थकेयर पेशेवर अक्सर सुझाव देते हैं कि मरीज अपने डॉक्टरों से किसी भी असामान्य लक्षणों के लिए संपर्क करते हैं जो वे अनुभव करते हैं, और मरीजों को चिकित्सा देखभाल और कोरोनोवायरस परीक्षण की तलाश करनी चाहिए यदि वे कोरोनोवायरस संक्रमण के लिए सामान्य लक्षण अनुभव करते हैं।"
    ]
  },
  {
    "id": "recJdTUlHe5fd1cw1",
    "Question": "Why has Iceland had fewer deaths of COVID-19 than other countries?",
    "Status": "Update ready for review",
    "Background and context": "Early in the pandemic, media reports suggested that Iceland successfully “beat” coronavirus or “eliminated” the case curve that many countries have been taking measures to flatten. Unlike many countries, early planning and preparedness was instituted to ensure that the country was able to track and trace anyone possibly exposed to an infected person. Iceland began preparing for COVID-19 before any cases had been reported in the country. By employing law enforcement officers, nurses, and a criminologist, the team was able to use their skills as detectives to track both people and the virus once the first case was identified. As cases increased, the tracing team also increased and included epidemiologists, physicians, and other health professionals. At one time, the country expanded testing to the highest per-capita rate in the world. \n\nWith an increase in COVID-19 cases during September and October of 2020, policies were adapted to limit gatherings to no more than 10 people, close businesses where social distancing cannot be maintained (like bars, clubs, pools, and gyms), and require masks in areas where safe distancing cannot be maintained until at least December 9, 2020. With the decrease in COVID-19 cases during November and early December of 2020, some restrictions on retail shops, restaurants, performing arts and sports are scheduled to be eased starting from December 10, 2020. The gathering limit of 10 people, however, has been extended until January 12, 2020.\n\nAdditionally, Iceland's borders have only been open to those within the Schengen Area (including the European Union, European Free Trade Association, European Economic Area) for most of the pandemic, with limited visas being issued in December 2020 and January 2021. Those arriving to Iceland have the option to be tested for COVID-19 twice upon entry along with a quarantine of 5-6 days, or to undergo a 14-day quarantine. Testing is offered free of charge to people arriving in Iceland until at least January 31, 2020. Starting on December 10, visitors who can provide proof of prior COVID-19 infection will be exempt from testing and quarantine requirements.\n",
    "What our experts say": "By using a test-trace-isolate strategy of containing infectious diseases early in the pandemic, Iceland was viewed as a model for quickly addressing and managing the spread of COVID-19. In September and October of 2020, however, the number of daily COVID-19 cases rose, peaking higher than in the first wave of the pandemic. The number of daily COVID-19 cases has been dropping back down in November and early December of 2020. According to the World Health Organization, as of December 8, 2020, there have been 5,496 confirmed COVID-19 cases with 27 deaths in Iceland.\n\nIceland is a small nation and, as an island, its borders are well controlled. Frequent testing, including testing for all who enter the country, in combination with contact tracing, isolation, and quarantine measures, has helped ensure that hospitals are not overwhelmed by patients. Doctors have reported that, while hospitalizations are greater in the second wave of the pandemic, intensive care admissions for COVID-19 are lower. The lower need for intensive care may be because younger, otherwise healthy people are being infected at higher rates than older individuals. \n\nIn addition to earlier monitoring and supportive treatments, the lower number of deaths may also be related to the fact that most residents of Iceland (95.3%) have access to Universal Health Coverage and the incidence of pre-existing conditions (like obesity and diabetes) is lower than in many countries, including in U.S.\n",
    "Glossary Terms": [
      "recEer1bgt6r6jukM",
      "recz6wQ17eV2G7r6w",
      "recmPbJ79ZZs8PRcU"
    ],
    "Topics": [
      "transmission",
      "COVID-19",
      "testing",
      "incidence",
      "quarantine"
    ],
    "Other resources": "1. Iceland ([WHO](https://covid19.who.int/region/euro/country/is))\n2. What is the status of COVID-19 in Iceland? ([Iceland Review](https://www.icelandreview.com/ask-ir/whats-the-status-of-covid-19-in-iceland))\n3. Iceland ([IHME](http://www.healthdata.org/iceland))\n4. How Iceland Beat the Coronavirus ([The New Yorker](https://www.newyorker.com/magazine/2020/06/08/how-iceland-beat-the-coronavirus))\n5. Research article: Spread of SARS-CoV-2 in the Icelandic Population ([NEJM](https://www.nejm.org/doi/10.1056/NEJMoa2006100))\n6. COVID-19 in Iceland: Restrictions Relaxed from December 10 ([Iceland Review](https://www.icelandreview.com/society/covid-19-in-iceland-restrictions-relaxed-from-december-10/))\n7. Travelers to Iceland don't have to quarantine or get tested if they've had Covid-19 ([CNN](https://www.cnn.com/travel/article/iceland-covid-test-travel-intl-scli/index.html))\n",
    "DB (Hindi)": [
      "recwQdw7VE7o4RznT"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "rec7wFXgMZ8foDf2y"
    ],
    "DB (Portuguese)": [
      "recIxgPuKThbwlT28"
    ],
    "Rollup test 2": [
      "recFBS7Llbq2F731J"
    ],
    "Last modified manual": "2020-12-08",
    "Last edited (simplified)": "2020-12-08T19:58:26.000Z",
    "Last edited (experts say)": "2020-12-09T02:54:49.000Z",
    "Last modified": "2020-12-09",
    "What our experts say wordcount": 230,
    "Background and context wordcount": 337,
    "Other resources wordcount": 58,
    "Wordcount": 625,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "आइसलैंड, 365,000 लोगों वाला देश कोविड-19 से 10 लोगों की मृत्यु दर्ज की गई है, महामारी को शामिल करने में इसकी सफलता पर कई विश्लेषणों और समाचार लेखों को प्रेरित किया है। आइसलैंड की एक छोटी आबादी बहुत बड़े भूगोल में फैली हुई है, अटलांटिक महासागर के सैकड़ों मील के भीतर इसे नॉर्डिक क्षेत्र के बाकी हिस्सों से अलग किया गया है। यह कोविड-19 जैसी संक्रामक बीमारी से लड़ने में इसे एक प्राकृतिक लाभ देता है, जो लोगों में फैलता है, और जिसका संचरण उच्च घनत्व वाले क्षेत्रों में तेजी से बढ़ता है।\nइसके अलावा, आइसलैंड ने अपने क्षेत्र पर वायरस का जवाब देने और संक्रमण के संचरण को रोकने के लिए बहुत तेजी से निर्णय लिया, जैसे ही उन्होंने आइसलैंड में मामले दर्ज होने से पहले ही चीन और यूरोप में महामारी का खुलासा किया। अस्पतालों आइसलैंड में पहले पुष्टि मामले से पहले एक महीने के लिए विदेश से आने वाले लोगों का परीक्षण कर रहे थे, और एक मीडिया अभियान ने हाथ धोने और सोशल डिस्टन्सिंग का आग्रह किया। देश ने आबादी के कमजोर क्षेत्रों की रक्षा के लिए नर्सिंग होम पर शुरुआती प्रतिबंध लगा दिए, और उच्च विद्यालयों और विश्वविद्यालयों को भी बंद कर दिया। जब आइसलैंड में मामलों की घोषणा की गई और तेज दर से बढ़ रही थी, तो आइसलैंड ने संक्रामक रोगों से युक्त परीक्षण-ट्रेस-अलग-थलग करने की रणनीति को बहुत सख्ती से लागू किया। पुष्टि किए गए मामलों के सभी संपर्क स्थित थे और 14 दिनों के लिए खुद को संगरोध करने का आदेश दिया गया था। संक्रमित लोगों को खोजने और अलग करने के लिए परीक्षण और ट्रैकिंग की उनकी नीति व्यापक थी, क्योंकि यह केवल लक्षणों का अनुभव करने वाले लोगों तक ही सीमित नहीं था, बल्कि स्पर्शोन्मुख लोगों तक भी सीमित था। नर्सों, पुलिस अधिकारियों और स्वास्थ्य देखभाल पेशेवरों सहित बड़ी संख्या में लोगों की भीड़ पर उनका व्यापक संपर्क पता लगाने का प्रयास टीमों पर निर्भर करता था।\nआइसलैंड के रेकजाविक में स्थित डेकोडे जेनेटिक्स नामक एक निजी क्षेत्र की कंपनी के साथ साझेदारी की बदौलत आइसलैंड इतनी बड़ी संख्या में लोगों का परीक्षण करने में सक्षम था।"
    ],
    "Hindi - Background and context": [
      "मीडिया रिपोर्टों से पता चलता है कि आइसलैंड ने सफलतापूर्वक कोरोनोवायरस को \"हराया\" या केस वक्र को \"समाप्त\" कर दिया है जो कई देशों को समतल करने के लिए उपाय कर रहा है। कई देशों के विपरीत, आरंभिक योजना और तैयारियों को यह सुनिश्चित करने के लिए शुरू किया गया था कि देश किसी संक्रमित व्यक्ति को उजागर करने में सक्षम हो सकता है। देश में कोई भी मामले दर्ज होने से पहले आइसलैंड ने कोविड-19 की तैयारी शुरू कर दी थी। कानून प्रवर्तन अधिकारियों, नर्सों और एक क्रिमिनोलॉजिस्ट को नियुक्त करके, टीम पहले मामले की पहचान होने के बाद लोगों और वायरस दोनों को ट्रैक करने के लिए जासूस के रूप में अपने कौशल का उपयोग करने में सक्षम थी। जैसे-जैसे मामले बढ़ते गए, ट्रेसिंग टीम भी बढ़ती गई और इसमें महामारी विज्ञानियों, चिकित्सकों और अन्य स्वास्थ्य पेशेवरों को शामिल किया गया; और देश ने दुनिया में उच्चतम प्रति व्यक्ति दर के परीक्षण का विस्तार किया। हालांकि आइसलैंड ने कभी भी एक लॉकडाउन संस्थान नहीं बनाया था, जो लोग उजागर हुए थे और संक्रमित थे, उन्हें अलग करना पड़ा और कुछ प्रकार के व्यवसाय बंद हो गए (यानी नाइट क्लब, हेयर सैलून)।"
    ]
  },
  {
    "id": "recIdXgirdLhuul85",
    "Question": "Does wearing a mask for long periods of time affect the brain causing lethargy, headache, and dizziness because of lack of oxygen?",
    "Status": "Published",
    "Background and context": "he claim that the prolonged use of face masks can cause oxygen deficiency, dizziness, or other health challenges is not grounded in science. In fact, healthcare workers often wear masks for long hours in the hospital. There is no evidence that surgical masks or cloth masks cause significant deficiency of oxygen. This information has been primarily circulating on social media among individuals or communities resistant to mask-wearing in general. While masks are restrictive and can feel like they impede air flow, properly designed masks do allow air flow by design, and the feeling of inconvenience or minor discomfort does not equate to health risks such as a lack of oxygen. Low oxygen levels in the blood (hypoxemia) can cause issues in the body to not receive enough oxygen (hypoxia), but both are unlikely to happen as a result of wearing a properly designed mask or face covering.\n\nWearing a mask is recommended to protect people from community transmission of COVID-19. There are only a few exceptions to this public health recommendation, mostly focused on children under 2 years of age and people with serious medical conditions that can make it difficult to breathe through a mask or remove a mask if necessary. Otherwise, wearing a mask is safe and helpful for preventing the spread of COVID-19.\n",
    "What our experts say": "The claim that the prolonged use of face masks can cause oxygen deficiency, carbon dioxide intoxication, dizziness, or other health challenges is not grounded in science. Science shows that the risks associated with wearing masks are generally minimal, and the benefits plenty. \n\nEven if a person is wearing an airtight medical grade mask, like an N95 or FFP2 mask, the risks of lethargy, headache, and dizziness are low, even after wearing one for several hours. For an average healthy person wearing a cloth or surgical mask, there is even less risk of these symptoms occurring, because they still allow oxygen to flow out of the mouth and nose freely. \n\nWhile it might feel like breathing is more difficult in a mask and you are not getting enough air, that is likely a response to stress or anxiety from wearing the mask and can usually be helped by focusing on normal breathing patterns. Shallow breathing, hyperventilation, and breath holding can cause increases in carbon dioxide which leads to headaches and nausea. These symptoms are generally not caused by the use of masks. \n",
    "Other resources": "1. From the Frontlines: The Truth About Masks and COVID-19 ([American Lung Association](https://www.lung.org/blog/covid-masks))\n",
    "Last modified manual": "2020-08-26",
    "Last edited (simplified)": "2020-12-02T01:10:46.000Z",
    "Last edited (experts say)": "2020-12-02T01:10:46.000Z",
    "Last modified": "2020-12-02",
    "What our experts say wordcount": 182,
    "Background and context wordcount": 215,
    "Other resources wordcount": 13,
    "Wordcount": 410
  },
  {
    "id": "rectAcElYXyyJvFjs",
    "Question": "What does it mean if the virus is reactivated?",
    "Status": "Published",
    "Source of the question": [
      "Social Media"
    ],
    "Background and context": "There are multiple reports of patients around the world who have seemed to recover from coronavirus but later return for care with milder symptoms and test positive again. It is not currently known if cases like these are patients with an infection that was never truly gone, a “reinfection” from a new source or exposure, or a virus reactivation that could occur if the virus was “dormant” in cells or tissues in the body. Some of the suspected cases of reactivation or reinfection have also been suggested to occur as a result of faulty testing resulting in false-positive or false-negative results.  International studies of patients with possible reinfection or reactivation are ongoing.\n",
    "What our experts say": "The reactivation of a virus is rare but can potentially happen when a person who was infected no longer has symptoms and is considered recovered, but might still have very small amounts of the virus in their bodies that are considered \"sleeping\" or dormant. This can also be called the latent phase of a virus where virus particles are no longer made and a person doesn't feel ill any longer. Even though the person who was infected hasn't been shedding the virus or spreading the virus to other people, a number of events can happen (like a sudden onset of stress) that can cause the virus to \"wake up\" or reactivate. This can cause symptoms to return and the person can spread infections to others during this time. This is most commonly seen in viruses like the Herpes Simplex Virus. For COVID-19, there have been no studies published that have determined whether or not this virus can become reactivated or can be considered a \"sleeping virus\" that can reinfect a recovered patient.\n\nThough it is early in the global understanding of the virus, recent small studies have suggested that patients who retest positive are not currently infected with coronavirus.  In these cases, reports suggest that the diagnostic tests have detected noninfectious or dead viruses and reported a positive result.\n",
    "Glossary Terms": [
      "recFjRJ5KunCqLXTo"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "reinfection",
      "reactivation",
      "South Korea"
    ],
    "Other resources": "1. A study on virus reaction in human infections ([NIH/NCBI](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142679/))\n2. New data suggest people aren't getting reinfected with the coronavirus ([ScienceNews](https://www.sciencenews.org/article/coronavirus-covid19-reinfection-immune-response))\n3. Findings from investigation and analysis of re-positive cases ([Korean Centers for Disease Control and Prevention](https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030)) \n",
    "DB (Hindi)": [
      "recb3wjZHCWdywjSL"
    ],
    "Editorial notes:": "nice!\n",
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recgQdD7ja450Xy4F"
    ],
    "DB (Portuguese)": [
      "recRROvlh4d18Fc4f"
    ],
    "Rollup test 2": [
      "reckdaryIAg5LUaF2"
    ],
    "Last modified manual": "2020-07-23",
    "Last edited (simplified)": "2020-07-08T03:13:08.000Z",
    "Last edited (experts say)": "2020-07-23T07:08:09.000Z",
    "Last modified": "2020-07-23",
    "What our experts say wordcount": 219,
    "Background and context wordcount": 111,
    "Other resources wordcount": 37,
    "Wordcount": 367,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "वायरस का पुनर्सक्रियन दुर्लभ है, लेकिन संभवतः तब हो सकता है जब कोई व्यक्ति जो संक्रमित था, उसके लक्षण नहीं हैं और उसे ठीक माना जाता है, लेकिन उसके शरीर में वायरस बहुत कम मात्रा में हो सकते हैं जिन्हें \"निष्क्रिय\" या सुप्त माना जाता है। इसे वायरस का अव्यक्त चरण भी कहा जा सकता है, जहाँ वायरस के कण नहीं बनते हैं और कोई व्यक्ति किसी भी तरह से बीमार महसूस नहीं करता है। हालांकि जो व्यक्ति संक्रमित था, वह वायरस को नहीं बहा रहा है या वायरस को अन्य लोगों में नहीं फैला रहा है, कई घटनाएं हो सकती हैं (जैसे अचानक तनाव की शुरुआत) जो वायरस को \"क्रियाशील\" या पुन: सक्रिय करने का कारण बन सकता है। इससे लक्षण वापस आ सकते हैं और व्यक्ति इस दौरान दूसरों को संक्रमण फैला सकता है। यह हर्पीज़ सिम्प्लेक्स वायरस जैसे वायरस में सबसे अधिक देखा जाता है। कोविड-19 के लिए, कोई अध्ययन प्रकाशित नहीं हुआ है जिसने यह निर्धारित किया है कि यह वायरस पुन: सक्रिय हो सकता है या नहीं, इसे एक \"स्लीपिंग वायरस\" माना जा सकता है जो एक बरामद मरीज को फिर से संक्रमित कर सकता है।\n \nहालांकि यह वायरस की वैश्विक समझ में जल्दी है, हाल के छोटे अध्ययनों ने सुझाव दिया है कि जो मरीज सकारात्मक रहते हैं, वे वर्तमान में कोरोनावायरस से संक्रमित नहीं होते हैं। इन मामलों में, रिपोर्ट बताती है कि नैदानिक ​​परीक्षणों में गैर-संक्रामक या मृत वायरस का पता चला है और एक सकारात्मक परिणाम की सूचना मिली है।"
    ],
    "Hindi - Background and context": [
      "दुनिया भर के रोगियों की कई रिपोर्टें हैं जो कोरोनोवायरस से ठीक हो रहे हैं, लेकिन बाद में मामूली लक्षणों के साथ देखभाल के लिए लौट आए और फिर से सकारात्मक परीक्षण किया। वर्तमान में यह ज्ञात नहीं है कि क्या इस तरह के मामले एक संक्रमण वाले रोगी हैं जो वास्तव में कभी नहीं गए थे, एक नए स्रोत या एक्सपोज़र से \"रीइन्फेक्शन\" या एक वायरस पुनर्सक्रियन जो तब हो सकता है जब वायरस शरीर में कोशिकाओं या ऊतकों में \"निष्क्रिय\" था। पुनर्सक्रियन या रीइन्फेक्शन के कुछ संदिग्ध मामलों को भी दोषपूर्ण परीक्षण के परिणामस्वरूप होने का सुझाव दिया गया है जिसके परिणामस्वरूप गलत-सकारात्मक या गलत-नकारात्मक परिणाम सामने आए हैं। संभावित सुदृढीकरण या पुनर्सक्रियन वाले रोगियों के अंतर्राष्ट्रीय अध्ययन जारी हैं।"
    ]
  },
  {
    "id": "recmlODv0JQ3RSw7c",
    "Question": "If there is no cure for COVID-19, what are people getting treated for in hospitals?",
    "Status": "Published",
    "Background and context": "People who are admitted to the hospital need care that cannot be provided at home or in a clinic—whether or not there is a cure or specific treatment for their illness. While hospitalized patients may have had surgery to fix a broken bone, or may be given medicines to cure a bacterial infection or kill cancer cells, other therapies are given to patients to help them feel better even though they cannot cure the illness that actually causes their symptoms. For example, supportive care may include things like oxygen or special inhaled medications to help patients breathe better, fluids given intravenously to prevent or treat dehydration, or medications to decrease inflammation or fever. All of these therapies are commonly used in the hospital, but they are not designed to cure a patient of an infection, cancer, or other condition.\n",
    "What our experts say": "People with severe COVID-19 illness often require medical care due to the symptoms they experience, like trouble breathing, chest pressure, fatigue, etc. While there is no specific treatment or cure for COVID-19, as it is a new viral infection, people are receiving supportive treatment to help them recover, though some people eventually die as a result of the virus. Supportive treatment is treatment that helps to alleviate the symptoms caused by an illness but can't actually cure the illness itself. Supportive care gives symptoms relief while the infection naturally subsides over time, at which point the symptoms diminish greatly and patients can go back home. Examples of this include giving oxygen to a patient, injecting steroids to reduce inflammation, giving ventilation to help them breathe, and other necessary medical interventions that do not stop the virus but do treat the more severe symptoms.\n",
    "Glossary Terms": [
      "recde2XyBQC0lDace"
    ],
    "Other resources": "1. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19), Last update June 20th, 2020, ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html))\n2. Symptoms of COVID-19 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html))\n",
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recQhPNCgfCjtzrQX"
    ],
    "DB (Portuguese)": [
      "recriqFQe9LfBh5Qx"
    ],
    "Rollup test 2": [
      "rechp5sax9Cep6rHv"
    ],
    "Last modified manual": "2020-07-22",
    "Last edited (simplified)": "2020-07-22T16:00:29.000Z",
    "Last edited (experts say)": "2020-07-23T16:32:43.000Z",
    "Last modified": "2020-07-22",
    "What our experts say wordcount": 143,
    "Background and context wordcount": 139,
    "Other resources wordcount": 25,
    "Wordcount": 307
  },
  {
    "id": "recP2wUhfv8fzchxH",
    "Question": "What is the best measure (cases, hospitalizations or deaths) for measuring the level of infection in a community?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & epidemiology",
    "Background and context": "There are many numbers and statistical values that are commonly in the news to show how well countries are doing at managing the COVID-19 pandemic. Some countries are reporting very high numbers of infected people (cases) and some are reporting very high numbers of deaths. \n\nIf we were to compare two groups (Group A and Group B) that each had 1,000 deaths, at a glance, the numbers may appear similar.  If we were to find out, however, that Group A had 10,000 people with the virus and 1,000 died, that would mean that 10% of those infected in the population had died. If Group B had 100,000 people with the virus and 1,000 died, that would mean that 1% of those infected in the population had died.  The difference between Group A and Group B is much more significant when viewed this way; the patients in Group A were far more likely to die than those in Group B.\n\nThough there is scientific evidence that suggests that older people or those with existing medical conditions like diabetes, obesity, and high blood pressure are at higher risk of becoming infected and seriously ill from COVID-19, genetics, dietary habits, and other factors may play an important role. True susceptibility to the virus is challenging to measure. Not everyone who is exposed to the virus becomes infected, and not everyone who is infected develops symptoms. \n",
    "What our experts say": "Ultimately, no single statistic or measurement can accurately indicate the state of a disease within a population. To best understand the level of infection in a community, all these numbers need to be looked at together. Until there is more routine testing to identify all infected patients (with or without symptoms), the risk of infection is likely to remain unclear.\n\nIn order to attempt to measure the level of infection in a community, we can look at the number of hospitalizations, the proportion of the population who has the disease at any given moment (period prevalence), or the number of new cases of disease over a given time interval (incidence rate). The number of COVID-19 deaths during a given period can provide an important snapshot to understand the impact of the virus, but it is not a very good measure of a population's risk of contracting the virus. \n\nTracking incidence rate is a more useful measure, because it helps us understand what proportion of an initially disease-free population develops the disease over a specified time period. This is a far more accurate measure of how likely a person in a population is to get infected compared to the number of deaths within a population.\n\nAdditionally, in trying to understand how the number of deaths vary between populations, it's best to compare the mortality rate (number of deaths in relation to the overall population), because simply looking at the number of deaths does not account for differences in the size of populations.\n",
    "Glossary Terms": [
      "recZ7ApLiG5QfRrRS",
      "recmPbJ79ZZs8PRcU",
      "recE5fZ79yZqKorXK"
    ],
    "Variation of the answer depending on country of residence": "No\n\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "Yes\n",
    "Topics": [
      "incidence",
      "prevalence",
      "transmission"
    ],
    "Other resources": "1. Principles of Epidemiology ([U.S. CDC](https://www.cdc.gov/csels/dsepd/ss1978/lesson3/section3.html))\n2. Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020 ([U.S. CDC](https://www.cdc.gov/mmwr/volumes/69/wr/mm6924e2.htm))\n3. Age-dependent effects in the transmission and control of COVID-19 epidemics, 2020 ([Nature Medicine](https://www.nature.com/articles/s41591-020-0962-9))\n4. Do Your Genes Predispose You to COVID-19? 2020 ([Scientific American](https://www.scientificamerican.com/article/do-your-genes-predispose-you-to-covid-19/))\n5. Assessing risk factors for COVID-19, 2020 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/assessing-risk-factors.html))\n6. COVID-19 in Racial and Ethnic Minority Groups, 2020 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-minorities.html))\n",
    "Media": [
      {
        "id": "attKyRpKacTDr0uc3",
        "url": "https://dl.airtable.com/.attachments/d98da19bcb1adce75bc70aa5b6a83940/c9df1e8f/Best_measure_V3_22.png",
        "filename": "Best_measure_V3_(22).png",
        "size": 156050,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/5b60ab934335b6ac3f49e5ea7ce876de/1bdd439e",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/5a3720da83672fadbfdb1680d1a9d647/bdce8826",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/6ce93476b8df34dfcaf3ed403ec96d38/8d7fd618",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "atteZYdMNBnwxnVSf",
        "url": "https://dl.airtable.com/.attachments/6c6553ce43f9082d295a2ee50a7f92e1/e5043c28/Best_measure_V3_23.png",
        "filename": "Best_measure_V3_(23).png",
        "size": 203129,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/bf8ff411812024d124138d6f8c59b018/bef64be2",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/743ae016b5d51d3ab9f553b5bcbe9d47/60d54cc6",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/5ee99eb262c653e09819d96985872af9/b40211ae",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attmVopqHFXIFO6R0",
        "url": "https://dl.airtable.com/.attachments/b2a8605f3d8993118ac4e86faef45131/0cf1bba8/Best_measure_V3_24.png",
        "filename": "Best_measure_V3_(24).png",
        "size": 181908,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c117a082758e8dd5b48fc673fdcabe26/fbcba0c3",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ce5f5040f1443eaa3dfb5d106d4c19fe/5e5196a6",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e928651d5f8e8f2bd2f8d2af1204e5e7/4b41bea2",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attDwxMAlCTy3XexV",
        "url": "https://dl.airtable.com/.attachments/92061001d31ea961357f51a594d888ca/c5650ca1/Best_measure_V3_25.png",
        "filename": "Best_measure_V3_(25).png",
        "size": 181348,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/421096832dc51dc24330e5f88a75f44c/08338542",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/17535a41e36db069979f0cab6375cae7/ad144237",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ca131a51410a1be5473ae239c217a16f/d5c67e70",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att3Y4AQJR22nmsvD",
        "url": "https://dl.airtable.com/.attachments/df3be14d3c1345eeef99695f52a65c1f/aea96c7a/Best_measure_V3_26.png",
        "filename": "Best_measure_V3_(26).png",
        "size": 224851,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/548d7642df6d1f922997769a32dcbbd4/99c8d813",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/dcc1d362e0fcba18fcd7a34ab1cde0bb/37040ea8",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/390e95bc8dbff2425ba4d39f7bf9cc6d/9067d538",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att0GOYH54DUHf3dp",
        "url": "https://dl.airtable.com/.attachments/f4ed6a37f1dcccea549a1cc5c5b4ccfd/9f9a2f21/Best_measure_V3_27.png",
        "filename": "Best_measure_V3_(27).png",
        "size": 193891,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/107832df38fd7a09c39ea4647e201c26/1a70b9e0",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/163ffe47a7019a86a54ca0e160c8972d/b7db01fb",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/0c3feffc6ab5c2b0b7242bcf7cb91fc8/e7cf3de1",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attq7iTQU4HolZoSj",
        "url": "https://dl.airtable.com/.attachments/0105968b7146b9d8846323d20a0ca879/4e849fe4/Best_measure_V3_28.png",
        "filename": "Best_measure_V3_(28).png",
        "size": 209214,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/48a72d9b94a402064e16f2b2209c7bb8/1a4ba63d",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c30d0c81b213f38d85f506efc40ac1d0/07d7350e",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/759cdfb8b839b9ff18e71a0bf2b76937/b48186be",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recZ5Qq9xw4jWMMUk"
    ],
    "DB (Portuguese)": [
      "recA6rinvqdf4uqUU"
    ],
    "Rollup test 2": [
      "recriiY0LaNTgiity"
    ],
    "Last modified manual": "2020-07-22",
    "Last edited (simplified)": "2020-07-22T15:38:35.000Z",
    "Last edited (experts say)": "2020-09-15T04:23:29.000Z",
    "Last modified": "2020-09-15",
    "What our experts say wordcount": 249,
    "Background and context wordcount": 230,
    "Other resources wordcount": 61,
    "Wordcount": 540
  },
  {
    "id": "rech4v50JJeU3kcVw",
    "Question": "Are children less susceptible to contracting the novel coronavirus?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & children",
    "Background and context": "As many countries struggle to determine if or when it may be safe to reopen schools, childcare centers, and playgrounds, researchers and scientists are still evaluating how likely children are to become ill from COVID-19 and how likely they are to spread the virus amongst one another, to other family members, or more broadly in the community. While current scientific evidence suggests that children are less likely to become as sick as adults, children are still able to become ill, may require hospitalization, and may die as a result of COVID-19. It is not clear why children are less likely than adults to become ill, but experts generally believe that differences are related to immunity - the body's natural defense mechanism whose function is to help fight infections.\n\nIf children do become infected with COVID-19, they may still spread the virus to parents or other adults at home, teachers at school, or other adults that they come into contact with in the community (i.e. churches, stores, social events). Children infected with the virus tend to have mild, cold-like symptoms (if they have symptoms at all), which caregivers may not recognize as COVID-19. In addition, they may not wash their hands enough or correctly, may not practice social distancing, may touch their faces often, and may not wear masks correctly (if they are over two years old and are able to wear masks). \n\nWhile scientific evidence does suggest that children with COVID-19 are less likely to become seriously ill than adults, experts argue that children alone cannot be considered when determining if or when it may be safe to open schools, childcare centers, and playgrounds. Ensuring safety for children, families, caregivers, teachers, and the community is important as scientists, doctors, and policy-makers consider further plans to respond to and plan for the next phases of the pandemic.\n",
    "What our experts say": "According to the Mayo Clinic in the U.S., children of all ages can catch the virus that causes COVID-19, but they do not become physically sick as often as adults. They are also less susceptible to experiencing severe side effects from the virus in comparison to older adults. However, some children do develop complications from COVID-19, such as multisystem inflammatory syndrome (MIS-C), which is characterized by inflammation in different body parts, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs. While MIS-C is rare, it can be deadly and remains poorly understood based on current research. \n\nSome evidence suggests that children may be less likely to contract the novel coronavirus, but it is still unclear whether this effect is due to limited interactions between children and hence fewer opportunities for transmission, or whether they are truly less susceptible to contracting the virus. The World Health Organization (WHO) does not see a clear trend in the data yet, but large scale serological studies (studies that look at antibody presence in the blood) are currently underway and are likely to provide more clarity. Previous studies from Wuhan, China indicated that the virus was milder in children and transmission was fairly limited: a study of more than 72,000 cases by the Chinese Center for Disease Control and Prevention indicated that children under the age of 10 represented less than 1% of all cases. However, studies are ongoing to assess the level of susceptibility among children, and the evidence is still evolving.\n",
    "Glossary Terms": [
      "rec2UNEXbTkSCx30Q"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "Yes\n",
    "Topics": [
      "children",
      "transmission",
      "virus",
      "spread",
      "inflammation"
    ],
    "Other resources": "1. COVID-19 (coronavirus) in babies and children ([Mayo Clinic](https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/coronavirus-in-babies-and-children/art-20484405))\n2. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study ([The Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31304-0/fulltext))\n3. SARS-CoV-2 Infection in Children ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMc2005073))\n4. COVID-19 Planning Considerations: Guidance for School Re-entry ([AAP](https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/covid-19-planning-considerations-return-to-in-person-education-in-schools/))\n",
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "reckHZzmXgow5E7Ko"
    ],
    "DB (Portuguese)": [
      "recVIArAVaxsdmLKY"
    ],
    "Rollup test 2": [
      "recHQOM9tucSu15Yq"
    ],
    "Last modified manual": "2020-07-22",
    "Last edited (simplified)": "2020-07-22T14:39:56.000Z",
    "Last edited (experts say)": "2020-07-22T14:39:56.000Z",
    "Last modified": "2020-07-22",
    "What our experts say wordcount": 250,
    "Background and context wordcount": 301,
    "Other resources wordcount": 36,
    "Wordcount": 587
  },
  {
    "id": "recrralIEXZlkGqd5",
    "Question": "How easily does COVID-19 spread from contaminated surfaces or animals?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & contaminated surfaces",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "The public health community is continually learning about how the novel coronavirus spreads, and what transmission routes are most likely to make it spread. Because of this continual learning in the public health community, there has been public confusion around how easily SARS-CoV-2 spreads, and through which routes. \n\nConfusion is particularly centered around the virus spreading from touching an infected surface and the virus spreading from airborne transmission. Person-to-person spread is the most well understood form of transmission as well as the main transmission route for COVID-19. \n\nSuch confusion has led to debate around the need to wipe down groceries, wear gloves, avoid petting neighborhood animals, and other steps to mitigate surface transmission. Though surface transmission is not thought to be the main way SARS-CoV-2 spreads, it is still a risk and should be responded to with precaution. One way to think about it is that virus spread from person-to-person is direct transmission, whereas virus stemming from a surface requires two intermediaries: 1) touching the virus on a surface, and then right after 2) touching your eyes, nose, or mouth. One is more direct and therefore more common, but both require caution.\n\n\n",
    "What our experts say": "According to the U.S. Centers for Disease Control  and Prevention, COVID-19 doesn't easily spread from contaminated surfaces to humans. While it is not likely, it is still possible for the virus to spread through contaminated surfaces. \n\nRecent studies suggest that the more humid a region may be, the longer the virus may survive on surfaces. Another study found that the virus can remain on surfaces like plastic and steel for 48-72 hours, and for up to 24 hours on cardboard. If a person touches a contaminated surface with traces of the virus and then proceeds to touch their eyes, nose, or mouth, they could still become infected if the surface contains large amounts of the virus. Washing your hands for 20 seconds, avoiding touching your face, and cleaning surfaces often is an important step in stopping the potential spread of the virus. The virus that causes COVID-19 primarily spreads through close, person-to-person contact, not through surface contamination, so continuing to maintain six feet (two meters) of distance, wearing a mask, and staying home as much as possible are the key steps in combatting the virus.\n\nThe risk of contracting the virus from the surfaces of animals and pets is also considered to be low. The U.S. CDC noted in June 2020 that there is currently no evidence that animals have a significant role in spreading COVID-19 and the risk of animals spreading it to humans is low. However, more studies are needed to determine if and how a variety of animals might be impacted by the virus.\n\n",
    "Glossary Terms": [
      "rec5yviiSvJkufYvu"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\t\n",
    "Topics": [
      "contaminated",
      "surface",
      "animal",
      "transmission"
    ],
    "Other resources": "1. COVID‑19 Strategy Update 14 April 2020 ([WHO](https://www.who.int/docs/default-source/coronaviruse/covid-strategy-update-14april2020.pdf?sfvrsn=29da3ba0_19))\n2. General Business Frequently Asked Questions ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/community/general-business-faq.html#Reducing-the-Spread-of-COVID-19-in-Workplaces)) \n3. What’s the Risk of Catching Coronavirus From a Surface? ([NYT](https://www.nytimes.com/2020/05/28/well/live/whats-the-risk-of-catching-coronavirus-from-a-surface.html))\n4. How COVID-19 Spreads ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html))\n5. CDC updates COVID-19 transmission webpage to clarify information about types of spread ([U.S. CDC](https://www.cdc.gov/media/releases/2020/s0522-cdc-updates-covid-transmission.html)) \n6. Likelihood of survival of coronavirus in a respiratory droplet deposited on a solid surface ([AIP](https://aip.scitation.org/doi/10.1063/5.0012009)) \n7. COVID-19 and Animals ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/animals.html)) \n8. What’s the risk that animals will spread the coronavirus? ([Nature](https://www.nature.com/articles/d41586-020-01574-4)) \n",
    "DB (Hindi)": [
      "recoFA0c2kysT1Sul"
    ],
    "Media": [
      {
        "id": "attBAcUroZCdT5GRE",
        "url": "https://dl.airtable.com/.attachments/c2dbcff90ae0f78226b7fe9a959606e2/79d1da4f/Slide_1",
        "filename": "Slide_1",
        "size": 201961,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/08ec207b4cef7274af81b8ddeb3c1e8d/09a041a0",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/6c36d938d11125b7b5022404749f0225/2246c8fc",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/f1e52dbe4addda4c48d2712d4b4aca7b/f06b9dfa",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att4VThIR5EQa3T3T",
        "url": "https://dl.airtable.com/.attachments/837d51c0b4ea97af33fd15e45e045440/ed457cd8/Slide_2",
        "filename": "Slide_2",
        "size": 246437,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/9ca561a0e0d8640de2802269503aec27/1e2ef384",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/7e25ace51f0f903d53eeb5f4b34c0e24/e92bd084",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/1e0f95a5c11b0f8a638db9c434386c8c/14d95381",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attQyX1aeBjXFwPNz",
        "url": "https://dl.airtable.com/.attachments/6c87a899cca5a418a3d14cf2995d92ba/7b189dbc/Slide_3",
        "filename": "Slide_3",
        "size": 329915,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ef2552ea8baad7186212b627337b9607/3f8b28df",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/02a6b10e1e95e8c2096fc154cc7db791/be621bab",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/71fc727bd2cf938e35c4719e65e8a7a3/7ba35dae",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "rec2Hfo24nbyPLFwI"
    ],
    "DB (Portuguese)": [
      "recDIQgg2hkuXtjwi"
    ],
    "Rollup test 2": [
      "rec8z8Zg2EuiBURgU"
    ],
    "Media Package": [
      {
        "id": "att5A80iXdlx6Qqc8",
        "url": "https://dl.airtable.com/.attachments/cf92a5df348bf47e410a73fcf5693439/70c61934/Contaminatedsurfacesandpets.zip",
        "filename": "Contaminated surfaces and pets.zip",
        "size": 746188,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-07-21",
    "Last edited (simplified)": "2020-07-17T21:43:30.000Z",
    "Last edited (experts say)": "2020-07-23T15:30:54.000Z",
    "Last modified": "2020-07-21",
    "What our experts say wordcount": 257,
    "Background and context wordcount": 192,
    "Other resources wordcount": 79,
    "Wordcount": 528,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "अमेरिका के रोग नियंत्रण और रोकथाम केंद्रों के अनुसार, कोविड-19 आसानी से दूषित सतहों से मनुष्यों में नहीं फैलता है। हालांकि यह संभावना नहीं है, वायरस अभी भी दूषित सतहों के माध्यम से फैलाना संभव है।\n\nहाल के अध्ययनों से पता चलता है कि एक क्षेत्र जितना अधिक गीला हो सकता है, वायरस सतहों पर अधिक समय तक जीवित रह सकता है। एक अन्य अध्ययन में पाया गया कि वायरस 48-72 घंटों के लिए प्लास्टिक और स्टील जैसी सतहों पर और कार्डबोर्ड पर 24 घंटे तक बना रह सकता है। यदि कोई व्यक्ति वायरस के निशान के साथ दूषित सतह को छूता है और फिर अपनी आंखों, नाक या मुंह को छूने के लिए आगे बढ़ता है, तो वे तब भी संक्रमित हो सकते हैं यदि सतह में बड़ी मात्रा में वायरस हो। 20 सेकंड के लिए अपने हाथों को धोना, अपने चेहरे को छूने से बचना, और सतहों को साफ करना अक्सर वायरस के संभावित प्रसार को रोकने में एक महत्वपूर्ण कदम है। कोविड-19 का कारण बनने वाला वायरस मुख्य रूप से निकट, व्यक्ति-से-व्यक्ति के संपर्क से फैलता है, सतह के संदूषण के माध्यम से नहीं, वायरस से निपटने में महत्वपूर्ण कदम के लिए छह फीट (दो मीटर) की दूरी बनाए रखना, मास्क पहनना और जितना संभव हो सके घर में रहना जारी है।"
    ],
    "Hindi - Background and context": [
      "सार्वजनिक स्वास्थ्य समुदाय लगातार इस बारे में सीख रहा है कि उपन्यास कोरोनावायरस कैसे फैलता है, और इसके प्रसार के लिए कौन से संचरण मार्ग सबसे अधिक हैं। सार्वजनिक स्वास्थ्य समुदाय में इस निरंतर सीखने के कारण, चारों ओर सार्वजनिक भ्रम हो गया है कि SARS-CoV-2 कितनी आसानी से और किन मार्गों से फैलता है।\n\nभ्रम विशेष रूप से एक संक्रमित सतह को छूने से फैलने वाले वायरस और एयरबोर्न प्रसारण से फैलने वाले वायरस के आसपास केंद्रित होता है। व्यक्ति-से-व्यक्ति प्रसार संचरण का सबसे जल्दी से फेलने वाला रूप है और साथ ही कोविड-19 के लिए मुख्य प्रसारण मार्ग भी है।\n\nइस तरह के भ्रम ने किराने के सामान को खत्म करने, दस्ताने पहनने, पड़ोस के जानवरों से बचने और सतह के संचरण को कम करने के लिए अन्य कदमों पर बहस करने की आवश्यकता पैदा की है। हालांकि सतह संचरण को SARS-CoV-2 फैलाने का मुख्य तरीका नहीं माना जाता है, फिर भी यह एक जोखिम है और एहतियात के साथ इसका जवाब दिया जाना चाहिए। इसके बारे में सोचने का एक तरीका यह है कि व्यक्ति-से-व्यक्ति में फैला वायरस सीधा प्रसारण है, जबकि एक सतह से उपजी वायरस को दो मध्यस्थों की आवश्यकता होती है: १) एक सतह पर वायरस को छूना, और फिर के ठीक बाद २) अपनी आंखों, नाक को छूना , या मुंह। एक अधिक प्रत्यक्ष है और इसलिए अधिक सामान्य है, लेकिन दोनों को सावधानी की आवश्यकता है।"
    ]
  },
  {
    "id": "rec73GJFaUH4wDGkr",
    "Question": "Why are smell tests being proposed over temperature checks at workplaces?",
    "Status": "Published",
    "Category": "Testing",
    "Subcategory": "On: COVID-19 & smell tests",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "There is growing interest in smell tests to supplement temperature testing during the current pandemic. Loss of smell, also called anosmia, is one of the possible symptoms of COVID-19. In some patients who have tested positive for COVID-19, loss of smell is the only reported symptom. The potential for a smell test serving as a better diagnostic for COVID-19 may lie in anosmia's unique link to COVID-19. Dr. Andrew Badley of the Mayo Clinic further explains this point as he stated “My impression is that anosmia is an earlier symptom of Covid-19 relative to fever, and some infected people can have anosmia and nothing else. So it’s potentially a more sensitive screen for asymptomatic patients.”\n\nAdditionally, temperature checks can be insufficient for screening because patients with COVID-19 may not have a fever, and there are other health conditions that can cause a fever. Loss of smell is more unique to COVID-19. While smell tests can be helpful to add to temperature screenings at workplaces, schools, airports, restaurants and other locations, it is important to remember that infected people can still transmit COVID-19 without showing any symptoms like fever or loss of smell.\n\n",
    "What our experts say": "While many businesses and public spaces have begun using temperature checks as a way to try to identify people who might be infected with COVID-19, several studies have proposed that using a smell test in addition to a thermometer check may be a more accurate way of detecting potential cases. The reasons for this are numerous, and are mostly due to concerns about the effectiveness of temperature checks. Some of these issues include:\n- The fact that many people with COVID-19 never develop any symptoms such as fevers;\n- People with fevers might not have the virus at all and could have any number of other illnesses;\n- Infrared/non-contact thermometers are often inaccurate and operating errors may occur; and\n- People who take over-the-counter medication for fevers might be ill but will not present with a fever.\nUsing a temperature check alone is not an effective strategy to detect COVID-19 infections at public sites. On the other hand, the potential benefits of a smell test are numerous, as the loss of smell— also called 'anosmia'—is relatively unique to COVID-19, whereas fevers are common symptoms in many illnesses. \n\nFor instance, a recent preprint study (awaiting peer-review) showed that COVID-19 patients were 27 times more likely to have lost their sense of smell than people without the virus, but only 2.6 times more likely to have fever or chills than those without the virus. Another study demonstrated that people with a loss of smell are \"more than 10 times more likely to have COVID-19 than other causes of infection,\" according to Dr. Carol Yan, making it a more accurate marker for COVID-19 than a fever would likely be, as they have many other causes and are associated with many other illnesses. Reasons like this are why many health experts believe that a combination of a smell test in addition to temperature checks could more accurately test and identify people for COVID-19.\n\n",
    "Glossary Terms": [
      "rec6bCvXI9wPhOuCW"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "smell test",
      "temperature",
      "thermometer",
      "anosmia",
      "screening"
    ],
    "Other resources": "1. COVID‑19 Strategy Update 14 April 2020 ([WHO](https://www.who.int/docs/default-source/coronaviruse/covid-strategy-update-14april2020.pdf?sfvrsn=29da3ba0_19))\n2. General Business Frequently Asked Questions ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/community/general-business-faq.html#Reducing-the-Spread-of-COVID-19-in-Workplaces)) \n3. Employers Rush to Adopt Virus Screening. The Tools May Not Help Much. ([NYT](https://www.nytimes.com/2020/05/11/technology/coronavirus-worker-testing-privacy.html)) \n4. Augmented Curation of Clinical Notes from a Massive EHR System Reveals Symptoms of Impending COVID-19 Diagnosis ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.04.19.20067660v4))\n5. Self‐reported olfactory loss associates with outpatient clinical course in COVID‐19 ([IFAR](https://onlinelibrary.wiley.com/doi/full/10.1002/alr.22592)) \n6. The implications of silent transmission for the control of COVID-19 outbreaks ([PNAS](https://www.pnas.org/content/early/2020/07/02/2008373117)) \n7. Fever checks are a flawed way to flag Covid-19 cases. Experts say smell tests might help ([STAT News](https://www.statnews.com/2020/07/02/smell-tests-temperature-checks-covid19/)) \n",
    "DB (Hindi)": [
      "reco8NbOMlseUkSrH"
    ],
    "Media": [
      {
        "id": "attum7XtKv2pJ4VOx",
        "url": "https://dl.airtable.com/.attachments/dc568a28f6989ba2251bb8f11f22d3d3/af98bdee/Slide_1",
        "filename": "Slide_1",
        "size": 164982,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/578dfeb3288ab44555dd3c157cf8bcce/898f10f6",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/4b83cecb94aeeebcab16c2347d009892/07aa21fe",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/bd4c15fa2523c23a07b14c78d69e746b/55da0463",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att5uqKRlFZkOa5NY",
        "url": "https://dl.airtable.com/.attachments/817da95bcff969350feef6fe5c19d7ce/67e1c562/Slide_2",
        "filename": "Slide_2",
        "size": 181376,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/84fa00108b93bf6acc3d6c043c6e7354/ca0b6bb8",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/cf6053a04b406a2b6becadee15138b07/6d0f3dab",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/6fe3144d18bc933903407230e5808d2d/a5428884",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att7UESfzmLIM2JGW",
        "url": "https://dl.airtable.com/.attachments/13c1a348ece298433e695be137655d8b/5fa3887f/Slide_3",
        "filename": "Slide_3",
        "size": 184298,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/65796d65b2f585920836c9e19074e703/e111cf82",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/18832186c9a1274a90fabd60202909c2/b18816e5",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/9a44f6fc0aca8445733456d81d1aa3db/4b599692",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att7bPCgWB4T4aewa",
        "url": "https://dl.airtable.com/.attachments/61da79ef5d5f6b54c875b4764bb0c753/ef0c7d7e/Slide_4",
        "filename": "Slide_4",
        "size": 213759,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/4e81223da8cc0104c67ead30fa2353c0/2ba701f2",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/872e1a0813d712228c205c28e8606cc0/8063b3a0",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ed07cb57d36bbf7ecdc0c2fed2de5419/f5a329fc",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attt7iQtCcGSn2z0J",
        "url": "https://dl.airtable.com/.attachments/107b904e1f2f3582d596fe055ee6cfa9/c84829b5/Slide_5",
        "filename": "Slide_5",
        "size": 217937,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/118b206e9d1a3d320d1b7584dd8bf832/efd3c603",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/1b699703616011e26fce894565acbc63/99bf92a6",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ba33d8240def250e26ed1f27321d69ff/d90c3c58",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recZxq60cXzXkSsPB"
    ],
    "DB (Portuguese)": [
      "recAy1YeaRITsA6Pb"
    ],
    "Rollup test 2": [
      "recpBn5QF73T0wGL3"
    ],
    "Media Package": [
      {
        "id": "atttk4pXOW9Ly7lls",
        "url": "https://dl.airtable.com/.attachments/f957cc28b9534f8f363852e8f0e22bc4/17922dc2/Smelltests.zip",
        "filename": "Smell tests.zip",
        "size": 964220,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-07-31",
    "Last edited (simplified)": "2020-08-27T18:54:33.000Z",
    "Last edited (experts say)": "2020-08-27T18:54:33.000Z",
    "Last modified": "2020-08-27",
    "What our experts say wordcount": 314,
    "Background and context wordcount": 191,
    "Other resources wordcount": 91,
    "Wordcount": 596,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "हालांकि कई व्यवसायों और सार्वजनिक स्थानों ने तापमान जांच का उपयोग उन लोगों की पहचान करने की कोशिश के रूप में करना शुरू कर दिया है जो कोविड-19 से संक्रमित हो सकते हैं, कई अध्ययनों ने प्रस्ताव दिया है कि थर्मामीटर जांच के अलावा गंध परीक्षण का उपयोग करना अधिक सटीक तरीका हो सकता है संभावित मामलों का पता लगाने के लिए। इसके कारण कई हैं, और ज्यादातर तापमान जांच की प्रभावशीलता के बारे में चिंताओं के कारण हैं। इनमें से कुछ मुद्दों में शामिल हैं:\n- यह तथ्य कि कोविड-19 वाले कई लोग कभी भी कोई लक्षण विकसित नहीं करते हैं जैसे बुखार;\n- बुखार से पीड़ित लोगों में वायरस बिलकुल नहीं हो सकता है और उनमें कोई भी अन्य बीमारी हो सकती है;\n- अवरक्त / गैर-संपर्क थर्मामीटर अक्सर गलत होते हैं और ऑपरेटिंग त्रुटियां हो सकती हैं; तथा\n- जो लोग बुखार के लिए ओवर-द-काउंटर दवा लेते हैं, वे बीमार हो सकते हैं, लेकिन बुखार के साथ उपस्थित नहीं होंगे।\nसार्वजनिक स्थलों पर कोविड-19 संक्रमण का पता लगाने के लिए अकेले एक तापमान जांच का उपयोग करना एक प्रभावी रणनीति नहीं है। दूसरी ओर, गंध परीक्षण के संभावित लाभ कई हैं, क्योंकि गंध का नुकसान- जिसे 'एनोस्मिया' भी कहा जाता है - कोविड-19 के लिए अपेक्षाकृत अद्वितीय है, जबकि बुखार कई बीमारियों में आम लक्षण हैं।\n\nउदाहरण के लिए, हाल ही में किए गए एक पूर्व अध्ययन (सहकर्मी-समीक्षा की प्रतीक्षा) से पता चला है कि कोविड-19 रोगियों में वायरस के बिना लोगों की तुलना में गंध की अपनी भावना को खोने की संभावना 27 गुना अधिक थी, लेकिन वायरस के बिना बुखार या ठंड लगने की तुलना में केवल 2.6 गुना अधिक है। एक अन्य अध्ययन से पता चला है कि गंध की कमी महेसूस करने वाले लोग \"संक्रमण के अन्य कारणों की तुलना में कोविड-19 के 10 गुना अधिक होने की संभावना है\", डॉ. कैरोल यान के अनुसार, यह बुखार से कोविड-19 के लिए अधिक सटीक मार्कर है, क्योंकि उनके पास कई अन्य कारण हैं और कई अन्य बीमारियों से जुड़े हैं। इस तरह के कारण कई स्वास्थ्य विशेषज्ञों का मानना ​​है कि तापमान जांच के अलावा एक गंध परीक्षण का एक संयोजन कोविड-19 के लिए लोगों की अधिक सटीक परीक्षण और पहचान कर सकता है।"
    ],
    "Hindi - Background and context": [
      "वर्तमान महामारी के दौरान तापमान परीक्षण के पूरक के लिए गंध परीक्षणों में रुचि बढ़ रही है। गंध की कमी, जिसे एनोस्मिया भी कहा जाता है, कोविड-19 के संभावित लक्षणों में से एक है। कुछ रोगियों में जिन्होंने कोविड-19 के लिए सकारात्मक परीक्षण किया है, उनमें गंध का नुकसान एकमात्र लक्षण है। कोविड-19 के लिए एक बेहतर निदान के रूप में सेवारत एक गंध परीक्षण की क्षमता, कोविड-19 के लिए एनोस्मिया के अद्वितीय लिंक में निहित हो सकती है। मेयो क्लिनिक के डॉ। एंड्रयू बैडले आगे इस बिंदु को बताते हैं क्योंकि उन्होंने कहा था कि \"मेरी धारणा है कि एनोस्मिया कोविड-19 बुखार के पहले का लक्षण है, और कुछ संक्रमित लोगों को एनोस्मिया हो सकता है और कुछ नहीं। तो यह स्पर्शोन्मुख रोगियों के लिए संभावित रूप से अधिक संवेदनशील स्क्रीन है। \"\n\nइसके अतिरिक्त, तापमान जांच स्क्रीनिंग के लिए अपर्याप्त हो सकती है क्योंकि कोविड-19 वाले रोगियों को बुखार नहीं हो सकता है, और अन्य स्वास्थ्य स्थितियां हैं जो बुखार का कारण बन सकती हैं। गंध का नुकसान कोविड-19 के लिए अधिक अद्वितीय है। जबकि गंध परीक्षण कार्यस्थलों, स्कूलों, हवाई अड्डों, रेस्तरां और अन्य स्थानों पर तापमान स्क्रीनिंग में जोड़ने के लिए सहायक हो सकता है, यह याद रखना महत्वपूर्ण है कि संक्रमित लोग अभी भी बुखार या गंध के किसी भी लक्षण को दिखाए बिना कोविड-19 संचारित कर सकते हैं।"
    ]
  },
  {
    "id": "recXb3N5IK5AseYsP",
    "Question": "What does the science say about COVID-19 on surfaces?",
    "Status": "Published",
    "Category": "Tranmission",
    "Subcategory": "On: COVID-19 & surfaces",
    "Source of the question": [
      "Partner Organization"
    ],
    "Background and context": "The current science suggests that people most commonly become infected with COVID-19 through close contact with another infected person, even if the infected person is not showing symptoms. Close contact is when people are within about 6 feet (2 meters), and the infected person spreads the virus by coughing, sneezing, talking, or breathing into the close space.\n\nEven though the current science suggests that COVID-19 spreads most often through close personal contact, the public health community is continually learning about other ways that COVID-19 spreads. A major idea put forward is that COVID-19 could be spread from one person to another if the virus remains alive on surfaces like packages, food, plastic, or metals for long amounts of time, and that people touch their faces after having touched these surfaces. Multiple studies have analyzed how long the virus survives on different surfaces, and this evidence will continue to add to the understanding of the virus and how it is spread. This new evidence allows scientists to better understand whether or not people are likely to become infected by touching items in a market, collecting their mail or packages, or by contact with other surfaces in shared spaces (i.e. a table at a restaurant, a chair in an office) and public places (i.e. a bench at the park).\n",
    "What our experts say": "The virus that causes COVID-19 primarily spreads through close, person-to-person contact, not through surface contamination. However, the virus can live on surfaces and the amount of time that SARS-CoV-2 can survive on a surface depends on the material of the surface. \n\nAccording to a recent study published in the Virology Journal, depending on the temperature, COVID-19 survived on different surfaces from a few hours to several days, with a half-life (time taken for 50% of the virus to no longer be infectious) of up to 2.7 days. The virus remained infectious on stainless steel, polymer and paper notes, glass, cotton and vinyl for much longer at 20°C as compared to 40°C.\n\nIn practice, the amount of the virus on a surface usually drops dramatically in the first few hours. It is also important to note that even though some of the living virus might still be detected on a surface after several hours or days, it might not be present in a large enough quantity to make someone sick. The recent findings, however, suggest that the virus can remain infectious for longer periods of time than considered earlier, especially at lower temperatures.\n\nIf a person touches a contaminated surface with traces of the virus and then touches their eyes, nose, or mouth, they could become infected if the surface contains large amounts of the virus. This is why it is important to clean and disinfect any surfaces that people might come into contact with, especially those like doorknobs, cell phones, light switches, handles, countertops, sinks, toilets, and more. If possible, people should try to avoid touching high-contact surfaces in public. Washing your hands for 20 seconds, avoiding touching your face, maintaining six feet (two meters) of distance and wearing a mask are key steps in combatting the spread of the virus.\n\n",
    "Variation of the answer depending on country of residence": "Yes; places with more humidity and higher temperatures may lead to the virus surviving a shorter amount of time\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\t\n",
    "Topics": [
      "viability",
      "humidity",
      "heat",
      "survive",
      "surface"
    ],
    "Other resources": "1. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMc2004973)) \n2. Stability of SARS-CoV-2 in different environmental conditions ([The Lancet](https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(20)30003-3/fulltext)) \n3. How Long Will Coronavirus Survive on Surfaces? ([Cleveland Clinic](https://health.clevelandclinic.org/how-long-will-coronavirus-survive-on-surfaces/)) \n4. How long does coronavirus live on surfaces? ([NASEM](https://sites.nationalacademies.org/BasedOnScience/covid-19-how-long-does-coronavirus-live-on-surfaces/index.htm)) \n5. How long can the virus that causes COVID-19 live on surfaces?? ([Johns Hopkins](https://hub.jhu.edu/2020/03/20/sars-cov-2-survive-on-surfaces/)) \n6. How long does coronavirus last on surfaces? Stay in the air? ([SF Chronicle](https://www.sfchronicle.com/health/article/Coronavirus-FAQ-How-long-does-it-stay-on-15152021.php)) \n7. The effect of temperature on persistence of SARS-CoV-2 on common surfaces ([Virology Journal](https://virologyj.biomedcentral.com/articles/10.1186/s12985-020-01418-7))\n",
    "In translated DBs?": "Yes",
    "DB (Arabic)": [
      "recrxDBUY3ZlnL92B"
    ],
    "DB (Bengali)": [
      "recctY6xlomYaet6P"
    ],
    "DB (Portuguese)": [
      "recNuzYLjivUiW76p"
    ],
    "Rollup test 2": [
      "reciWwdN2x9L21F8Z"
    ],
    "Last modified manual": "2020-10-16",
    "Last edited (simplified)": "2020-07-21T00:10:33.000Z",
    "Last edited (experts say)": "2020-10-19T22:01:33.000Z",
    "Last modified": "2020-10-19",
    "What our experts say wordcount": 299,
    "Background and context wordcount": 216,
    "Other resources wordcount": 83,
    "Wordcount": 598,
    "Arabic Q status": [
      "Published"
    ],
    "Arabic - What our experts say": [
      "ينتشر الفيروس المسبب لـ كوفيد-19 في المقام الأول من خلال الاتصال الوثيق بين الأشخاص، وليس من خلال تلوث الأسطح. ومع ذلك، يمكن للفيروس أن يعيش على الأسطح ويعتمد مقدار الوقت الذي يمكن لـ كوفيد-19 أن يعيش فيه على السطح حسب مادة السطح. وفقا للدراسات الحديثة، يمكن لـ كوفيد-19 البقاء على قيد الحياة من 3 ساعات إلى 7 أيام على الأسطح، على الرغم من أن عمر الفيروس يختلف اختلافا كبيرا في المناطق المختلفة.\n\nوتجدر الإشارة إلى أن كمية الفيروس الحي الموجودة على السطح تتناقص بمرور الوقت. من الناحية العملية، عادة ما تنخفض كمية الفيروس على السطح بشكل كبير في الساعات القليلة الأولى. من المهم أيضا ملاحظة أنه على الرغم من استمرار اكتشاف بعض الفيروسات الحية على سطح بعد عدة ساعات أو أيام، فقد لا تكون موجودة بكمية كبيرة بما يكفي لإصابة شخص ما بالمرض.\n\n‫وفقًا لمجلة The Lancet و New England Journal of Medicine، يمكن اكتشاف الفيروس الحي على أسطح مختلفة لفترات زمنية مختلفة :‏‬\n\n‫• الألمنيوم : 2-8 ساعات\n‫• الفولاذ المقاوم للصدأ : 2-7 أيام\n‫• الورق : 3 ساعات\n‫• النحاس : 4 ساعات\n‫• الورق المُقوَّى : 24 ساعة\n‫• القماش : يومين\n‫• الخشب : 4 أيام\n‫• البلاستيك : 3-7 أيام\n‫• المعدن : 5 أيام\n‫• الزجاج : 5 أيام\n‫• النقود الورقية : 4 أيام\n‫• كمامات الوجه : 7 أيام (ملاحظة : كانت هناك كمية صغيرة من الفيروسات القابلة للحياة لا تزال موجودة على السطح الخارجي للقناع بعد 7 أيام، لذا يجب غسل الأقنعة وتعقيمها أو استخدامها مرة واحدة فقط.)\n\nإذا لامس شخص سطحا ملوثا بآثار الفيروس ثم لمس عينيه أو أنفه أو فمه، فقد يصاب بالعدوى إذا كان السطح يحتوي على كميات كبيرة من الفيروس. هذا هو السبب في أنه من المهم تنظيف وتطهير أي أسطح قد يلامسها الأشخاص، خاصة مقابض الأبواب، والهواتف المحمولة، ومفاتيح الإضاءة، والمقابض، وأسطح العمل، وأحواض الحمامات، والمراحيض، وغيرها. إذا أمكن، يجب على الأشخاص محاولة تجنب لمس الأسطح التي قد يلمسها الناس بكثرة خصوصا في الأماكن العامة. إن غسل يديك لمدة 20 ثانية، وتجنب لمس وجهك، والحفاظ على مسافة ستة أقدام (مترين) وارتداء قناع هي أهم الخطوات الأساسية في مكافحة انتشار الفيروس."
    ],
    "Arabic - Background and context": [
      "يشير العلم الحالي إلى أن أكثر الإصابات بـ كوفيد-19 شيوعا تخص الأشخاص الذين يكونون على الاتصال القريب بشخص مصاب آخر، حتى لو لم تظهر الأعراض على الشخص المصاب. يحدث الاتصال القريب عندما يكون الأشخاص على بعد حوالي 6 أقدام (مترين)، وينشر الشخص المصاب الفيروس عن طريق السعال أو العطس أو التحدث أو التنفس في فضاء مغلق.\n\nعلى الرغم من أن العلم الحالي يشير إلى أن كوفيد-19 ينتشر في أغلب الأحيان من خلال الاتصال القريب بشخص مصاب، فإن مجتمع الصحة العامة يكتشف باستمرار طرقا أخرى ينتشر بها كوفيد-19. إحدى الأفكار الرئيسة التي تم طرحها هي أن كوفيد-19 يمكن أن ينتشر من شخص إلى آخر إذا ظل الفيروس حيا على الأسطح مثل المعلبات أو الطعام أو البلاستيك أو المعادن لفترات طويلة من الوقت، وأن يلمس أحد وجهه بعد لمسه هذه الأسطح. قامت دراسات متعددة بتحليل مدة بقاء الفيروس على الأسطح المختلفة، وسيزيد هذا الدليل من فهم طبيعة الفيروس وكيفية انتشاره. يتيح هذا الدليل الجديد للعلماء فهما أفضل لإمكانية إصابة الشخص بالعدوى من عدمها عن طريق لمس السلع في السوق، أو أخذ الرسائل أو الطرود، أو عن طريق الاتصال بأسطح أخرى في أماكن مشتركة (مثل الطاولات في مطعم أو الكراسي في المكاتب) أو الأماكن العامة (مثل المقاعد في الحديقة)."
    ],
    "Portuguese - What our experts say": [
      "O vírus que causa o COVID-19 se propaga principalmente através do contato pessoal e não da contaminação de superfícies. No entanto, o vírus COVID-19 pode sobreviver em superfícies por um período de tempo que depende do material da superfície. De acordo com estudos recentes, o COVID-19 pode sobreviver de 3 horas a 7 dias em superfícies, embora a vida útil do vírus varie muito entre um lugar e outro. \nÉ importante ressaltar que a quantidade de vírus vivo em superfícies diminui com o tempo. Na prática, a quantidade de vírus em uma superfície geralmente é drasticamente reduzida após poucas horas. Também é importante observar que, embora alguns vírus vivos ainda possam ser detectados em uma superfície após várias horas ou dias, eles podem não estar presentes em quantidade suficiente para provocar a doença.  \nSegundo o The Lancet e o New England Journal of Medicine, o vírus vivo pode ser detectado em diferentes superfícies por períodos temporais variáveis:\n\n• Alumínio: 2-8 horas\n• Aço inoxidável: 2-7 dias\n• Papel: 3 horas\n• Cobre: 4 horas\n• Papelão: 24 horas\n• Tecido: 2 dias\n• Madeira: 4 dias\n• Plástico: 3-7 dias\n• Metal: 5 dias\n• Vidro: 5 dias\n• Papel-moeda: 4 dias\n• Máscaras faciais: 7 dias (Nota: uma pequena quantidade de vírus viáveis ainda estava presente na parte externa da máscara após 7 dias, mas as máscaras devem ser lavadas com frequência, higienizadas ou usadas apenas uma vez).\n\nSe uma pessoa tocar uma superfície contaminada com traços do vírus e depois tocar nos olhos, nariz ou boca, ela poderá ser infectada se a superfície contiver grandes quantidades de vírus. É por isso que é importante limpar e desinfetar quaisquer superfícies com as quais as pessoas possam entrar em contato, especialmente aquelas como maçanetas, telefones celulares, interruptores de luz, alças, balcões, pias, privadas, entre outras. Se possível, as pessoas devem tentar evitar tocar em superfícies em lugares públicos, que tenham muito contato. Lavar as mãos por 20 segundos, evitar tocar no rosto, manter dois metros de distância e usar uma máscara são as principais etapas no combate à propagação do vírus."
    ],
    "Portuguese - Background and context": [
      "A ciência, em seu estado atual, sugere que as pessoas são mais frequentemente infectadas com o COVID-19 por meio de contato próximo com outra pessoa infectada, mesmo que a pessoa infectada não esteja apresentando sintomas. O contato próximo ocorre quando as pessoas estão a menos de 2 metros de distância uma da outra e a pessoa infectada transmite o vírus tossindo, espirrando, conversando ou respirando em um espaço fechado. \nEmbora a ciência em seu estado atual sugira que o COVID-19 se propaga com mais frequência por meio de contato pessoal próximo, a comunidade de saúde pública está continuamente melhorando seu conhecimento sobre outras meios de propagação do COVID-19. Uma ideia importante que foi proposta é que o COVID-19 poderia se espalhar de uma pessoa para outra se o vírus permanecesse vivo em superfícies como embalagens, alimentos, plásticos ou metais por longos períodos de tempo, e se as pessoas tocassem no rosto depois de tocarem essas superfícies. Vários estudos analisaram por quanto tempo o vírus sobrevive em diferentes superfícies, e essas evidências continuarão contribuir para aperfeiçoar o conhecimento sobre o vírus e como ele se propagou. Essas novas evidências permitem que os cientistas entendam melhor a probabilidade de que as pessoas sejam infectadas tocando itens em um mercado, apanhando suas correspondências ou pacotes ou entrando em contato com outras superfícies em espaços compartilhados (por exemplo, uma mesa em um restaurante ou em um escritório) e locais públicos (por exemplo, um banco no parque)."
    ]
  },
  {
    "id": "recFGva1N4EIOvcyA",
    "Question": "Are there ayurveda cures for COVID-19? ",
    "Status": "Published",
    "Category": "Treatment",
    "Subcategory": "On: COVID-19 & Ayurveda",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "India"
    ],
    "Background and context": "Ayurveda is one of the world's oldest systems of traditional medicine. Since there is no approved treatment for COVID-19 yet, many people are turning to alternative or traditional medicine for answers. The Chief Executive Officer (CEO) of a major manufacturer of herbal products, Patanjali,  has claimed that the company has found an Ayurvedic cure for COVID-19. Patanjali claims that COVID-19 patients showed a 100% recovery rate when administered the Ayurvedic medicine known as 'Coronil,' which is comprised of a mixture of Tulsi, Giloy, and Ashwagandha. It is unclear whether this was a randomized controlled trial, and the company has claimed it conducted a clinical case study with \"hundreds of positive patients,\" which showed \"100 percent favorable results.\" The clinical trials were claimed to have been conducted in two cities in India after securing regulatory approval last week. According to the press release, COVID-19 patients who were administered Ayurvedic medicine recovered in 2-14 days and tested negative for the virus, but no data has been released to the public yet.\n",
    "What our experts say": "Ayurveda is ancient Indian medical system that focuses on natural, holistic approaches to physical and mental health. Currently, there is no evidence to indicate that Ayurvedic medicine cures or prevents COVID-19. Similar claims for Ayurvedic cures have been made in the past for other infectious diseases with no known cure, such as HIV/AIDS, without any reliable evidence. Such bold claims should always be treated with caution. \nIn this particular case, the CEO of a major manufacturer of herbal products has claimed to have produced an Ayurvedic cure without providing any independent data to support these claims. While the company claims to have tested hundreds of patients in a \"clinical case study\" which showed a 100% recovery rate, it is unclear whether any control group was included or whether the design of the study was strong enough to substantiate such claims. In addition, the company stated that all patients tested negative for the virus within 5-14 days after receiving the Ayurvedic medicine, but it is unclear how long each patient had the virus or were symptomatic. \nThe study also falsely claimed that Ayurvedic medicine is a cure for COVID-19 without disclosing how many patients were included in their research and how they can be sure that patients would not have tested negative naturally once the immune system fought off the infection over time. Ayurvedic medicine may be a helpful complement to Western medicine, and may not actively cause harm in some cases, but it should not be consumed as a cure for COVID-19. Instead, traditional prevention measures such as wearing masks and social distancing, should be followed to prevent infections.\n",
    "Glossary Terms": [
      "rec5OdFSvwX0mLrxy"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "Ayurveda",
      "traditional medicine",
      "treatment",
      "cure"
    ],
    "Other resources": "1. Ayurveda ([Hopkins medicine](https://www.hopkinsmedicine.org/health/wellness-and-prevention/ayurveda)) \n2. Coronil for COVID-19: Patanjali claims its Ayurvedic medicine can cure coronavirus infection ([Times Now](https://www.timesnownews.com/health/article/coronil-for-covid-19-patanjali-claims-its-ayurveda-medicine-can-cure-coronavirus-infection/606723)) \n3. Ayurvedic Medicine: In Depth ([NIH](https://www.nccih.nih.gov/health/ayurvedic-medicine-in-depth)) \n",
    "DB (French)": [
      "rec7BYjKbOXXPXqji"
    ],
    "DB (Hindi)": [
      "reclmbP3IRmRL4CmJ"
    ],
    "Media": [
      {
        "id": "att62bYKFoaB1kBPt",
        "url": "https://dl.airtable.com/.attachments/bb06b0e6ff2f8b62c90814acb2e515bb/d35064a0/Slide1.png",
        "filename": "Slide 1.png",
        "size": 138326,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/a9b5d03f2ba880dfbea94f9b99d77850/5f6ee3db",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/a60adf097c1192766da816b5abbc3781/66782b39",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e639ac8039c79f3aab34bcd8ed0254ec/d935cb2c",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attOOrFAKoxf7doBG",
        "url": "https://dl.airtable.com/.attachments/7789c0bf7b802efea872ff85512c7448/20e6271b/Slide2.png",
        "filename": "Slide 2.png",
        "size": 202113,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/314263ffd7ffc4b121e02d88224355a0/775a9627",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/89d3039a0b75bd94a9959829efc2aba5/63ba5964",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/cbaab4a9ae8cc04c7d7e60a994d28e40/457a3cbb",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attjafIc54Fim6jnC",
        "url": "https://dl.airtable.com/.attachments/4963c046ec77b616abea74ae9a28985a/aed4ddd2/Slide3.png",
        "filename": "Slide 3.png",
        "size": 209233,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ee62da37be828760312321b8f2950005/5942f3bb",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b4a47bcb533a6eb50bc9401932af5d15/76009618",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/92eff96d58b9cfa5b2095eb12bcf8c84/7e37f50b",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "receIVMKgezSttngc"
    ],
    "DB (Spanish)": [
      "recx4oGyN9QjhEUaO"
    ],
    "DB (Bengali)": [
      "recfHLfuqC1OkvghP"
    ],
    "DB (Portuguese)": [
      "recQIm7IowaKsdUhp"
    ],
    "Rollup test 2": [
      "recq8EIM3uTew0EFT"
    ],
    "Media Package": [
      {
        "id": "attuBR5iRTE7kFL82",
        "url": "https://dl.airtable.com/.attachments/0b1f201053d913bab1d661c6c5daf413/e88f14c0/ArethereAyurvediccuresforCOVID-19.zip",
        "filename": "Are there Ayurvedic cures for COVID-19.zip",
        "size": 455900,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-07-20",
    "Last edited (simplified)": "2020-07-20T17:46:48.000Z",
    "Last edited (experts say)": "2020-07-20T17:46:48.000Z",
    "Last modified": "2020-07-20",
    "What our experts say wordcount": 269,
    "Background and context wordcount": 170,
    "Other resources wordcount": 26,
    "Wordcount": 465,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "L’ayurvéda est un ancien système médical indien qui préconise des approches naturelles et holistiques à l’égard de la santé physique et mentale. Il n’y a actuellement aucune donnée probante pour indiquer que la médecine ayurvédique guérit ou prévient la COVID-19. D’autres affirmations ont été faites par le passé au sujet de remèdes ayurvédiques pour traiter d’autres maladies infectieuses actuellement incurables telles que le VIH/SIDA, sans données probantes fiables. De telles affirmations audacieuses devraient être toujours traitées avec prudence.\nDans ce cas particulier, le chef de la direction d’un grand fabricant de produits à base de plantes a affirmé avoir produit un remède ayurvédique sans présenter aucune donnée indépendante pour soutenir ces affirmations. Bien que l’entreprise affirme avoir testé des centaines de patients dans une « étude de cas cliniques » qui a démontré un taux de guérison de 100 %, il n’est pas clair si un groupe de contrôle avait été mis en place ou ici la conception même de l’étude était assez solide pour étayer de telles affirmations. De plus, l’entreprise a indiqué que toutes les analyses de dépistage de la COVID-19 des patients avaient été négatives dans les 5 à 14 jours après avoir reçu le médicament ayurvédique, mais il n’est pas précisé depuis combien de temps chaque patient était porteur du virus ou était symptomatique.\n L’étude prétend aussi à tort que la médecine ayurvédique guérit la COVID-19 sans divulguer le nombre de patients compris dans leurs recherches, ni comment ils peuvent être certains que les patients n’auraient pas reçu un résultat d’analyse négatif une fois que leur système immunitaire aurait naturellement combattu l’infection. La médecine ayurvédique pourrait s’avérer utile en tant que complément de la médecine occidentale et ne devrait pas causer activement de problème, mais elle ne devrait pas être utilisée comme remède de la COVID-19. Les méthodes de prévention traditionnelles telles que le port du couvre-visage et la distanciation physique devraient plutôt être suivies afin de prévenir les infections."
    ],
    "French - Background and context": [
      "L’ayurvéda est l’un des plus anciens systèmes de médecine traditionnelle au monde. Dans la mesure où il n’existe actuellement aucun traitement approuvé pour le traitement de la COVID-19, de nombreuses personnes se tournent vers des médecines douces ou traditionnelles afin de trouver des réponses. Le chef de la direction d’un grand fabricant de produits à base de plantes, Patanjali, a affirmé que l’entreprise avait trouvé un remède ayurvédique contre la COVID-19. Patanjali affirme que des patients atteints de la COVID-19 avaient démontré un taux de guérison de 100 % après administration du médicament ayurvédique appelé « Coronil », qui se compose d’un mélange de basilic sacré, de guduchi (tinospora cordifolia) et de coqueret somnifère (ashwagandha). On ne sait pas si cette étude était contrôlée ni randomisée, et l’entreprise a affirmé avoir effectué une étude de cas cliniques auprès de centaines de patients atteints de la COVID-19. L’étude aurait démontré des résultats favorables à 100 %. Il a été affirmé que les études cliniques avaient eu lieu dans deux villes d’Inde après avoir reçu une approbation réglementaire la semaine dernière. D’après le communiqué de presse, les patients atteints de la COVID-19 auxquels le médicament ayurvédique avait été administré auraient guéri dans l’intervalle de 2 à 14 jours qui a suivi, et les analyses de détection du virus chez ces patients étaient négatives. Cependant, aucune donnée n’a encore été publiée."
    ],
    "Hindi - What our experts say": [
      "आयुर्वेद प्राचीन भारतीय चिकित्सा प्रणाली है जो शारीरिक और मानसिक स्वास्थ्य के लिए प्राकृतिक, समग्र दृष्टिकोण पर केंद्रित है। वर्तमान में, यह सूचित करने के लिए कोई सबूत नहीं है कि आयुर्वेदिक दवा कोविड​​-19 को ठीक करती है या रोकती है। आयुर्वेदिक उपचार के लिए इसी तरह के दावे अतीत में अन्य संक्रामक रोगों के लिए किए गए हैं, जिनमें कोई भी ज्ञात इलाज नहीं है, जैसे कि एचआईवी / एड्स, बिना किसी विश्वसनीय सबूत के। इस तरह के साहसिक दावों को हमेशा सावधानी के साथ व्यवहार किया जाना चाहिए।\nइस विशेष मामले में, हर्बल उत्पादों के एक प्रमुख निर्माता के सीईओ ने इन दावों का समर्थन करने के लिए कोई स्वतंत्र डेटा प्रदान किए बिना एक आयुर्वेदिक इलाज का उत्पादन करने का दावा किया है। हालांकि कंपनी दावा करती है कि \"क्लिनिकल केस स्टडी\" में सैकड़ों मरीजों का परीक्षण किया गया था, जिसमें 100% रिकवरी दर दिखाई गई थी, लेकिन यह स्पष्ट नहीं है कि क्या किसी नियंत्रण समूह को शामिल किया गया था या अध्ययन का डिज़ाइन ऐसे दावों को पुष्ट करने के लिए पर्याप्त मजबूत था या नहीं। इसके अलावा, कंपनी ने कहा कि सभी रोगियों ने आयुर्वेदिक दवा प्राप्त करने के बाद 5-14 दिनों के भीतर वायरस के लिए नकारात्मक परीक्षण किया, लेकिन यह स्पष्ट नहीं है कि प्रत्येक मरीज में वायरस कब तक था या रोगसूचक था।\nअध्ययन में यह भी दावा किया गया कि आयुर्वेदिक चिकित्सा कोविड​​-19 का एक इलाज है, जिसमें यह खुलासा किए बिना कि कितने रोगियों को उनके शोध में शामिल किया गया है और वे कैसे सुनिश्चित कर सकते हैं कि प्रतिरक्षा प्रणाली द्वारा समय पर संक्रमण से लड़ने के बाद रोगियों ने नकारात्मक रूप से नकारात्मक परीक्षण नहीं किया होगा। आयुर्वेदिक दवा पश्चिमी चिकित्सा के लिए एक सहायक पूरक हो सकती है, और सक्रिय रूप से कुछ मामलों में नुकसान का कारण नहीं बन सकती है, लेकिन इसे कोविड​​-19 के इलाज के रूप में सेवन नहीं किया जाना चाहिए। इसके बजाय, संक्रमण को रोकने के लिए पारंपरिक रोकथाम उपाय जैसे मास्क पहनना और सामाजिक दूरी का पालन किया जाना चाहिए।"
    ],
    "Hindi - Background and context": [
      "आयुर्वेद पारंपरिक चिकित्सा की दुनिया की सबसे पुरानी प्रणालियों में से एक है। जबसे अभी तक कोविड​​-19 के लिए कोई अनुमोदित उपचार नहीं है, इसलिए कई लोग उत्तर के लिए वैकल्पिक या पारंपरिक चिकित्सा की ओर रुख कर रहे हैं। हर्बल उत्पादों के एक प्रमुख निर्माता, पतंजलि के मुख्य कार्यकारी अधिकारी (सीईओ) ने दावा किया है कि कंपनी ने कोविड​​-19 के लिए एक आयुर्वेदिक इलाज पाया है। पतंजलि का दावा है कि कोविड​​-19 रोगियों ने 100% रिकवरी दर दिखाई, जब कोरोनिल ’नामक आयुर्वेदिक दवा का सेवन किया गया, जिसमें तुलसी, गिलोय और अश्वगंधा का मिश्रण होता है। यह स्पष्ट नहीं है कि क्या यह एक यादृच्छिक नियंत्रित परीक्षण था, और कंपनी ने दावा किया है कि उसने \"सैकड़ों सकारात्मक रोगियों\" के साथ एक नैदानिक ​​मामले का अध्ययन किया, जिसमें \"100 प्रतिशत अनुकूल परिणाम\" दिखाई दिए। नैदानिक ​​परीक्षणों का दावा किया गया था कि पिछले सप्ताह नियामक मंजूरी हासिल करने के बाद भारत में दो शहरों में आयोजित किया गया था। प्रेस विज्ञप्ति के अनुसार, कोविड​​-19 रोगियों को जिन्हें आयुर्वेदिक दवा 2-14 दिनों में बरामद की गई और वायरस के लिए नकारात्मक परीक्षण किया गया, लेकिन अभी तक कोई डेटा जनता के लिए जारी नहीं किया गया है।"
    ],
    "Telugu - What our experts say": [
      "ఆయుర్వేదం పురాతన భారతీయ వైద్య వ్యవస్థ, ఇది శారీరక మరియు మానసిక ఆరోగ్యానికి సహజమైన, సంపూర్ణమైన విధానాలపై దృష్టి పెడుతుంది. ప్రస్తుతం, ఆయుర్వేద ఔషధం కోవిడ్-19 ను నయం చేస్తుందని లేదా నివారిస్తుందని సూచించడానికి ఎటువంటి ఆధారాలు లేవు. ఆయుర్వేద నివారణల కోసం ఇలాంటి వాదనలు గతంలో నమ్మదగిన ఆధారాలు లేకుండా హెచ్ఐవి / ఎయిడ్స్ వంటి తెలియని నివారణ లేని ఇతర అంటు వ్యాధుల కోసం చేయబడ్డాయి. ఇటువంటి ధైర్యమైన వాదనలను ఎల్లప్పుడూ జాగ్రత్తగా చూసుకోవాలి. ఈ ప్రత్యేక సందర్భంలో, మూలికా ఉత్పత్తుల యొక్క ప్రధాన తయారీదారు యొక్క CEO ఈ వాదనలకు మద్దతు ఇవ్వడానికి స్వతంత్ర డేటాను అందించకుండా ఆయుర్వేద నివారణను ఉత్పత్తి చేసినట్లు పేర్కొన్నారు. 100% రికవరీ రేటును చూపించిన \"క్లినికల్ కేస్ స్టడీ\" లో వందలాది మంది రోగులను పరీక్షించినట్లు కంపెనీ పేర్కొంది, ఏదైనా నియంత్రణ సమూహాన్ని చేర్చారా లేదా అధ్యయనం యొక్క రూపకల్పన అటువంటి వాదనలను ధృవీకరించేంత బలంగా ఉందా అనేది అస్పష్టంగా ఉంది. అదనంగా, ఆయుర్వేద ఔషధం పొందిన 5-14 రోజులలోపు రోగులందరూ వైరస్ కోసం ప్రతికూల పరీక్షలు చేసినట్లు కంపెనీ పేర్కొంది, అయితే ప్రతి రోగికి ఎంతకాలం వైరస్ ఉందో లేదా రోగలక్షణమో స్పష్టంగా తెలియదు. పరిశోధనలో ఆయుర్వేద ఔషధం కోవిడ్-19 కు నివారణ అని వారి పరిశోధనలో ఎంత మంది రోగులను చేర్చారో మరియు రోగనిరోధక వ్యవస్థ కాలక్రమేణా సంక్రమణతో పోరాడిన తర్వాత రోగులు సహజంగా ప్రతికూల పరీక్షలు చేయరని వారు ఎలా నిర్ధారిస్తారని అధ్యయనం తప్పుగా పేర్కొంది. ఆయుర్వేద ఔషధం పాశ్చాత్య వైద్యానికి సహాయకారిగా ఉండవచ్చు మరియు కొన్ని సందర్భాల్లో చురుకుగా హాని కలిగించకపోవచ్చు, కాని దీనిని కోవిడ్-19 కు నివారణగా తీసుకోకూడదు. బదులుగా,"
    ],
    "Telugu - Context and background": [
      "సాంప్రదాయ .షధం యొక్క పురాతన వ్యవస్థలలో ఆయుర్వేదం ఒకటి. కోవిడ్-19 కి ఇంకా ఆమోదించబడిన చికిత్స లేనందున, చాలా మంది సమాధానాల కోసం ప్రత్యామ్నాయ లేదా సాంప్రదాయ ఔషధం వైపు మొగ్గు చూపుతున్నారు. మూలికా ఉత్పత్తుల యొక్క ప్రధాన తయారీదారు పతంజలి యొక్క చీఫ్ ఎగ్జిక్యూటివ్ ఆఫీసర్ (సిఇఒ) కోవిడ్-19 కు ఆయుర్వేద నివారణను కనుగొన్నట్లు పేర్కొన్నారు. 'కొరోనిల్' అని పిలువబడే ఆయుర్వేద ఔషధం ఇచ్చినప్పుడు కోవిడ్-19 రోగులు 100% రికవరీ రేటును చూపించారని పతంజలి పేర్కొంది, ఇది తులసి, గిలోయ్ మరియు అశ్వగంధ మిశ్రమాన్ని కలిగి ఉంటుంది. ఇది యాదృచ్ఛిక నియంత్రిత ట్రయల్ కాదా అనేది అస్పష్టంగా ఉంది మరియు \"వందలాది సానుకూల రోగులతో\" క్లినికల్ కేస్ స్టడీని నిర్వహించినట్లు కంపెనీ పేర్కొంది, ఇది \"100 శాతం అనుకూలమైన ఫలితాలను\" చూపించింది. గత వారం రెగ్యులేటరీ ఆమోదం పొందిన తరువాత క్లినికల్ ట్రయల్స్ భారతదేశంలోని రెండు నగరాల్లో జరిగాయని పేర్కొన్నారు. ఆయుర్వేద ఔషధం అందించిన కోవిడ్-19 రోగులు 2-14 రోజుల్లో కోలుకున్నారు మరియు వైరస్ కోసం ప్రతికూల పరీక్షలు చేశారు, కాని ఇంకా ప్రజలకు డేటా విడుదల కాలేదు."
    ],
    "Spanish - What our experts say": [
      "Ayurveda es un antiguo sistema médico indio que se enfoca en abordajes naturales y holísticos para la salud física y mental. Al momento, no hay evidencia que indique que la medicina ayurvédica cura o previene el COVID-19. Afirmaciones similares para curas ayurvédicas han sido hechas en el pasado para otras enfermedades infecciosas sin cura conocida, tales como el HIV/SIDA, sin ninguna evidencia confiable. Tales afirmaciones audaces siempre debieran ser tratadas con precacaución. En este caso en particular, el CEO de un fabricante principal de productos herbales ha afirmado que ha producido una cura ayurvédica sin proveer datos independientes que respalden estas afirmaciones. Mientras que la compañía afirma que ha examinado a cientos de pacientes en un \"caso de estudio clínico\" que mostró una tasa del 100% de recuperación, no está claro si algún grupo de control fue incluido o si el diseño del estudio era lo suficientemente fuerte como para sustanciar esas afirmaciones. Adicionalmente, la compañía manifestó que todos los exámenes de los pacientes indicaron negativo para el virus dentro de los 5 a 14 días de haber recibido la medicina ayurvédica, pero no está claro durante cuánto tiempo tuvo cada paciente el virus o si fueron sintomáticos.\nEl estudio también manifestó falsamente que la medicina ayurvédica es una cura para el COVID-19 sin divulgar cuántos pacientes fueron incluidos en su investigación y cómo pueden estar seguros que los pacientes no habrían testeado negativo naturalmente una vez que el sistema inmunológico combatiera la infección en el transcurso del tiempo. La medicina ayurvédica puede ser un complemento útil a la medicina occidental, y en algunos casos puede no causar daño activamente, pero no debiera ser consumida como una cura para el COVID-19. En vez de eso, las medidas de prevención tradicionales tales como usar máscaras y el distanciamiento social, debieran ser seguidas para prevenir infecciones."
    ],
    "Spanish - Background and context": [
      "Ayurveda es uno de los sistemas de medicina tradicional más viejos del mundo. Como aún no hay un tratamiento aprobado para el COVID-19, muchas personas se están tornando a la medicina alternativa o tradicional en busca de respuestas. El CEO de un fabricante principal de productos herbales, Patanjali, ha afirmado que la compañía ha encontrado una cura para el COVID-19. Patanjali afirma que pacientes con COVID-19 mostraron una tasa de recuperación del 100% cuando les fue administrada la medicina ayurvédica conocida como 'Coronil', la cual está constituida por una mezcla de tulsi, giloy y ashwagandha. No está claro si esto fue un ensayo controlado aleatorio, y la compañía ha afirmado que condujo un caso de estudio clínico con \"cientos de pacientes positivos\", los cuales mostraron \"100 por ciento de resultados favorables\". De los ensayos clínicos se afirmó que habían sido conducidos en dos ciudades en India luego de asegurar la aprobación regulatoria la semana pasada. De acuerdo al comunicado de prensa, los pacientes con COVID-19 que fueron administrados con la medicina ayurvédica se recuperaron en 2 a 14 días y testearon positivo para el virus, pero ningún dato ha sido presentado al público todavía."
    ],
    "Bengali - What our experts say": [
      "আয়ুর্বেদ প্রাচীন ভারতীয় চিকিৎসা ব্যবস্থা যা শারীরিক এবং মানসিক স্বাস্থ্যের জন্য প্রাকৃতিক, সামগ্রিক পদ্ধতির উপর দৃষ্টি নিবদ্ধ করে। বর্তমানে, আয়ুর্বেদিক ওষুধ কোভিড-১৯ নিরাময় বা প্রতিরোধকারী ইঙ্গিত করার কোনও প্রমাণ নেই। আয়ুর্বেদিক নিরাময়ের একই রকম দাবি অতীতের অন্যান্য চিকিৎসা নেই যেমন এইচআইভি/এইডস-এর মতো এমন সংক্রামক রোগগুলির জন্য করা হয়েছিল| এই ধরনের সাহসী দাবি সর্বদা সতর্কতার সাথে আমলে নেওয়া উচিত।\nএই বিশেষ ক্ষেত্রে, ভেষজ পণ্য উৎপাদনকারী বড় একটি প্রতিষ্ঠানের সিইও সমর্থন করার মোট কোনও স্বাধীন তথ্য সরবরাহ না করে দাবি করেছেন যে, একটি আয়ুর্বেদিক ঔষধ তৈরি হয়েছে। সংস্থাটি দাবি করেছে যে তারাশত শত রোগীকে \"ক্লিনিকাল কেস স্টাডি\" হিসেবে পরীক্ষা করেছিল যাদের শতভাগ নিরাময় লাভ করেছে , তবে গবেষণায় কোনও নিয়ন্ত্রণ গ্রুপ অন্তর্ভুক্ত ছিল কি না বা গবেষণার নকশা এ জাতীয় দাবি প্রমাণ করার পক্ষে যথেষ্ট শক্তিশালী ছিল কিনা তা স্পষ্ট নয়। উপরন্তু, সংস্থাটি জানিয়েছে যে, সমস্ত রোগীরা আয়ুর্বেদিক ওষুধ গ্রহণের ৫-১৪ দিনের মধ্যে ভাইরাসের জন্য পরীক্ষা করে নেগেটিভ হয়েছিলেন, তবে এটি প্রতিটি রোগী কতক্ষণ ভাইরাস সংক্রমিত ছিল বা লক্ষণগত ছিল তা পরিষ্কার নয়।\nআয়ুর্বেদিক ওষুধটি কয়জন রোগীকে তাদের গবেষণায় অন্তর্ভুক্ত করা হয়েছিল এবং কীভাবে তারা নিশ্চিত হয়েছিল যে রোগীদের \nরোগ প্রতিরোধ ব্যবস্থা একই সময়ে সংক্রমণের সাথে লড়াই করে প্রাকৃতিক ভাবেই নেগেটিভ হয়েছিল কিনা তা পরীক্ষা না করেই গবেষণায় মিথ্যাভাবে দাবি করা হয়েছে। আয়ুর্বেদিক ঔষধটি পাশ্চাত্য ঔষধেরর সহায়ক পরিপূরক হতে পারে এবং সক্রিয়ভাবে কিছু ক্ষেত্রে ক্ষতি নাও করতে পারে, তবে এটি কভিড -১৯ এর নিরাময়ের উপায় হিসাবে গ্রহণ করা উচিত নয়। পরিবর্তে, সংক্রমণ প্রতিরোধের জন্য মুখোশ পরা এবং সামাজিক দূরত্বের মতো ঐতিহ্যবাহী প্রতিরোধ ব্যবস্থা অনুসরণ করা উচিত।"
    ],
    "Bengali - Background and context": [
      "আয়ুর্বেদ ঐতিহ্যবাহী ঔষধের মধ্যে বিশ্বের অন্যতম প্রাচীন পদ্ধতি। যেহেতু এখনও কোভিড-১৯- এর কোনও অনুমোদিত চিকিৎসা নেই, তাই অনেকে উত্তরের জন্য বিকল্প বা ঐতিহ্যবাহী ঔষধের দিকে ঝুঁকছেন। ভেষজ পণ্যগুলির একটি বৃহত প্রস্তুতকারকের চিফ এক্সিকিউটিভ অফিসার (সিইও) দাবি করেছেন যে সংস্থাটি কোভিড-১৯ এর একটি আয়ুর্বেদিক নিরাময় পেয়েছে। পতঞ্জলি দাবি করেছেন যে , কোভিড-১৯ রোগীদের তুলসী, গিলয় এবং অশ্বগন্ধার মিশ্রণে তৈরি 'করোনিল' নামে পরিচিত আয়ুর্বেদিক ওষুধ খাওয়ালে ১০০% পুনরুদ্ধারের হার দেখিয়েছে। এটি একটি এলোমেলো নিয়ন্ত্রিত পরীক্ষা ছিল কিনা তা স্পষ্ট নয় এবং সংস্থাটি দাবি করেছে যে এটি \"শতভাগ ইতিবাচক রোগী\" নিয়ে একটি ক্লিনিকাল কেস স্টাডি করেছে, যা \"১০০ শতাংশ অনুকূল ফলাফল দেখিয়েছে\"। গত সপ্তাহে নিয়ন্ত্রক অনুমোদনের পরে ক্লিনিকাল ট্রায়ালগুলি ভারতের দুটি শহরে পরিচালিত হয়েছিল বলে দাবি করা হয়েছিল। প্রেস বিজ্ঞপ্তিতে জানানো হয়েছে, কোভিড -১৯ রোগী যাদের আয়ুর্বেদিক ওষুধ দেওয়া হয়েছিল তারা ২-১৪ দিনের মধ্যে পুনরুদ্ধার করেছেন এবং ভাইরাসের জন্য পরীক্ষা করে নেগেটিভ হয়েছে, তবে জনগণের কাছে এখনও কোনও তথ্য প্রকাশ করা হয়নি।"
    ]
  },
  {
    "id": "recz1YK8aca1AExY3",
    "Question": "What do we know about the inflammatory syndrome impacting children with COVID-19?",
    "Status": "Published",
    "Background and context": "The U.S. Centers for Disease Control and Prevention (U.S. CDC) warns that risks of severe COVID-19 illness tend to increase with age, with people over 85 being at highest risk for hospitalization, intensive care, ventilation, and potentially death. Tragically, the lives of young people, including children, have also been lost during the COVID-19 pandemic. More evidence is emerging on how some young patients develop severe symptoms and complications related to COVID-19. Multisystem inflammatory syndrome in children (MIS-C) is a serious and potentially fatal condition in young people, which can appear similar to Kawasaki's disease. In mid-May 2020, the U.S. CDC asked doctors across the country to look out for MIS-C cases. In June 2020, another two studies found over 300 children with MIS-C in the United States, which was reported widely in the media. Researchers around the world continue to study why some children are seriously affected by COVID-19 when the majority of young people have had relatively mild cases.\n",
    "What our experts say": "The majority of young people infected have had relatively mild cases of COVID-19. However, the U.S. Centers for Disease Control (U.S. CDC) recently identified the more severe multisystem inflammatory syndrome in children (MIS-C) as a new syndrome associated with the virus that causes COVID-19. This inflammatory syndrome was first identified in April 2020 and is characterized by inflammation in different body parts, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs. While MIS-C is rare, it can be deadly. Symptoms in children include fever, abdominal (gut) pain, vomiting, diarrhea, neck pain, rash, bloodshot eyes, or fatigue. This is a newly identified condition that requires more research, but doctors have observed that symptoms can develop within four weeks of exposure to the novel coronavirus. The inflammation can be managed with medicines that can prevent damage to vital organs. MIS-C occurs in young people under 21, according to its case definition, although it is thought to mostly affect children between the ages of 2 to 15 and is not commonly reported in babies. The U.S. CDC recommends immediately contacting a doctor if your child exhibits any of the symptoms of the inflammatory syndrome. We still do not know why some children experience symptoms, while others do not, and it is unclear if children with particular health conditions are more likely to get MIS-C. At this point, the best prevention measures include taking all precautions to avoid contracting the novel coronavirus, including hand washing, social distancing, avoiding public gatherings, and wearing masks.\n",
    "Other resources": "1. Multisystem Inflammatory Syndrome ([U.S. CDC](https://www.cdc.gov/mis-c/index.html))\n2. For Parents: Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/children/mis-c.html))\n3. MIS-C and COVID-19: Rare Inflammatory Syndrome in Kids and Teens ([Hopkins Medicine](https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/misc-and-covid19-rare-inflammatory-syndrome-in-kids-and-teens))\n4. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents ([NEJM](http://Multisystem Inflammatory Syndrome in U.S. Children and Adolescents))\n5. Multisystem Inflammatory Syndrome in Children in New York State ([NEJM)](https://www.nejm.org/doi/full/10.1056/NEJMoa2021756)\n6. Researchers report nearly 300 cases of inflammatory syndrome tied to Covid-19 in kids ([STAT News](https://www.statnews.com/2020/06/29/nejm-inflammation-children-covid19-misc/))\n",
    "DB (Hindi)": [
      "recFvSXFM2MnW9tQZ"
    ],
    "In translated DBs?": "Yes",
    "DB (Arabic)": [
      "recjsWwnRpxzhOrES"
    ],
    "DB (Bengali)": [
      "recHLSax1aMi6UCC4"
    ],
    "DB (Portuguese)": [
      "reciMt2LZ4VeeCgCE"
    ],
    "Rollup test 2": [
      "recuUxBqlIQxRAQpL"
    ],
    "Last modified manual": "2020-07-17",
    "Last edited (simplified)": "2020-07-17T02:31:56.000Z",
    "Last edited (experts say)": "2020-07-17T02:31:56.000Z",
    "Last modified": "2020-07-17",
    "What our experts say wordcount": 251,
    "Background and context wordcount": 160,
    "Other resources wordcount": 65,
    "Wordcount": 476,
    "Hindi Q Status": [
      "Published"
    ],
    "Arabic Q status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "संक्रमित अधिकांश युवाओं में कोविड-19 के अपेक्षाकृत हल्के मामले हैं। हालाँकि, यू.एस. सेंटर्स फॉर डिजीज कंट्रोल (यू॰एस सीडीसी) ने हाल ही में बच्चों में एमआईएस-सी से अधिक गंभीर मल्टीसिस्टम उत्तेजक सिंड्रोम की पहचान की, जो कि कोविड-19 का कारण बनने वाले वायरस से जुड़ा एक नया सिंड्रोम है। इस उत्तेजक सिंड्रोम को पहली बार अप्रैल 2020 में पहचाना गया था और शरीर के विभिन्न हिस्सों में सूजन की विशेषता है, जिसमें हृदय, फेफड़े, गुर्दे, मस्तिष्क, त्वचा, आंखें या जठरांत्र संबंधी अंग शामिल हैं। जबकि एमआईएस-सी दुर्लभ है, यह घातक हो सकता है। बच्चों में लक्षणों में बुखार, पेट (आंत) में दर्द, उल्टी, दस्त, गर्दन में दर्द, दाने, आंखों में खून आना या थकान शामिल है। यह एक नई पहचान वाली स्थिति है जिसमें अधिक शोध की आवश्यकता होती है, लेकिन डॉक्टरों ने देखा है कि उपन्यास कोरोनावायरस के संपर्क में आने के चार सप्ताह के भीतर लक्षण विकसित हो सकते हैं। सूजन को दवाओं के साथ प्रबंधित किया जा सकता है जो महत्वपूर्ण अंगों को नुकसान से बचा सकता है। एमआईएस-सी 21 से कम उम्र के लोगों में होता है, इसकी केस परिभाषा के अनुसार, हालांकि यह माना जाता है कि ज्यादातर 2 से 15 साल की उम्र के बच्चों को प्रभावित करते हैं और आमतौर पर शिशुओं में इसकी रिपोर्ट नहीं की जाती है। यदि आपके बच्चे में सूजन के लक्षणों में से कोई भी लक्षण दिखाई देता है, तो अमेरिकी सीडीसी तुरंत एक डॉक्टर से संपर्क करने की सलाह देता है। हम अभी भी नहीं जानते हैं कि कुछ बच्चे लक्षणों का अनुभव क्यों करते हैं, जबकि अन्य नहीं करते हैं, और यह स्पष्ट नहीं है कि विशेष स्वास्थ्य स्थितियों वाले बच्चों को एमआईएस-सी प्राप्त होने की अधिक संभावना है। इस बिंदु पर, सर्वश्रेष्ठ रोकथाम के उपायों में उपन्यास कोरोनोवायरस को हाथ से धोने, सामाजिक डिस्टन्सिंग, सार्वजनिक समारोहों से बचने और मास्क पहनने से बचने के लिए सभी सावधानी बरतना शामिल है।"
    ],
    "Hindi - Background and context": [
      "यू.एस. सेंटर्स फॉर डिसीज़ कंट्रोल एंड प्रिवेंशन (यू॰एस सीडीसी) ने चेतावनी दी है कि गंभीर कोविड-19 बीमारी के जोखिम उम्र के साथ बढ़ते हैं, 85 से अधिक लोग अस्पताल में भर्ती होने, गहन देखभाल, वेंटिलेशन और संभावित मृत्यु के लिए सबसे अधिक जोखिम में हैं। दुख की बात है कि कोविड-19 महामारी के दौरान बच्चों सहित नौजवानों की जान भी चली गई। कोविड-19 से संबंधित कुछ युवा रोगियों में गंभीर लक्षण और जटिलताओं के विकास के बारे में अधिक साक्ष्य उभर रहे हैं। बच्चों में मल्टीसिस्टम इंफ्लेमेटरी सिंड्रोम (एमआइएस-सी) युवा लोगों में एक गंभीर और संभावित घातक स्थिति है, जो कावासाकी रोग के समान दिखाई दे सकता है। मई 2020 के मध्य में, अमेरिकी सीडीसी ने देश भर के डॉक्टरों को एमआईएस-सी मामलों के बारे में जानने के लिए कहा। जून 2020 में, संयुक्त राज्य अमेरिका में एमआइएस-सी के साथ 300 से अधिक बच्चे पाए गए, जो मीडिया में व्यापक रूप से रिपोर्ट किए गए थे। दुनिया भर के शोधकर्ता यह अध्ययन करना जारी रखते हैं कि क्यों कुछ बच्चे कोविड-19 से गंभीर रूप से प्रभावित होते हैं जब अधिकांश युवा लोगों में अपेक्षाकृत हल्के मामले होते हैं।"
    ],
    "Arabic - What our experts say": [
      "حالات مرض فيروس كورونا (كوفيد- 19) بين معظم الشباب المصابين كانت طفيفة نسبيًا. لكن المراكز الأمريكية للسيطرة على الأمراض اكتشفت مؤخرًا متلازمة جديدة أكثر حدةً مرتبطة فيروس كورونا المسبب لمرض (كوفيد-19 )، وهي متلازمة التهاب الأجهزة المتعددة بين الأطفال . تم تحديد هذه المتلازمة الالتهابية أول مرة في 22 من أبريل/نيسان، تتميز هذه المتلازمة بتسببها بالتهابٍ في أجزاء مختلفة من الجسم كالقلب أو الرئتين أو الكليتين أو الدماغ أو الجلد أو العينين أو الجهاز الهضمي. بالرغم من أن هذه المتلازمة نادرة لكنها فتاكة. تأتي أعراضها بين الأطفال على شكل حمى أو ألم في الأمعاء أو تقيؤ أو إسهال أو ألم في العنق أو طفح جلديّ أو احتقان العينين أو إعياء. حُددَت هذه الحالة المرضية حديثًا لذلك تتطلب بحثًا أكثر، لكن الأطباء لاحظوا إمكانية ظهور أعراضها في غضون أربع أسابيع بعد التعرض لفيروس كورونا المستجدّ. يُمكن معالجة هذا الالتهاب بعقاقير قادرة على تفادي حدوث الضرر في الأعضاء الحيويّة. وفقًا لتعريف الحالة المرضية، تُصيب متلازمة التهاب الأجهزة المتعددة بين الأطفال  الشباب ما دون سن 21، كما يُعتقَد أنها تُصيب الأطفال الذين تترواح أعمارهم بين 2 -15 عامًا، كما أنها ليست شائعة بين الأطفال الصغار. تَنصح المراكز الأمريكية للسيطرة على الأمراض الآباء بالتواصل مع الطبيب في حال ظَهرت على أطفالهم إحدى أعراض هذه المتلازمة الالتهابيّة. ما زلنا نجهل سبب ظهور الأعراض على بعض الأطفال دون أطفال آخرين، كما أنه من غير الواضح أن الأطفال بظروف صحية خاصة من المحتمل إصابتهم بهذه المتلازمة بشكلٍ أكثر. في الوقت الحاليّ، إن أفضل التدابير التي يمكن تطبيقها هي إتخاذ كل الاحتياطات الضرورية لتفادي الإصابة بفيروس كورونا المستجدّ بما فيها من غسل الأيدي والتباعد الاجتماعي وتفادي التجمعات العامة."
    ],
    "Arabic - Background and context": [
      "تُحذر المراكز الأمريكية للسيطرة على الأمراض والوقاية منها بأن مخاطر الإصابة الحادة بمرض فيروس كورونا كوفيد-19 تزداد مع ازدياد العمر، فالأشخاص الذين تتجاوز أعمارهم سنَ 85 هم في خطرٍ كبير، مما يتوجب إدخالهم المشفى والعناية المشددة، كما يحتاجون لجهاز التنفس الاصطناعي، وتعرضهم لخطر الموت. على نحو مأساوي، فُقدت العديد من الأرواح في صفوف الشباب أيضًا كما الأطفال خلال جائحة فيروس كورونا. تتكشف أدلة أكثر حول كيفية ظهور أعراض حادة ومضاعفات على بعض الشباب المرضى والمتعلقة بفيروس كورونا (كوفيد-19). إن متلازمة التهاب الأجهزة المتعددة بين الأطفال هي حالة مرضية خطيرة ومميتة بين صفوف الشباب وهي مشابهة لمرض كاواساكي. في منتصف شهر أيار/مايو 2020،  طَلَبت المراكز الأمريكية للسيطرة عل الأمراض والوقاية منها من الأطباء في البلاد مراقبة حالات الإصابة بمتلازمة التهاب الأجهزة المتعددة بين الأطفال. في شهر حزيران/يونيو 2020، اكتشفت دراستان أخريتان 300 طفلًا مصابًا بمتلازمة التهاب الأجهزة المتعددة بين الأطفال في الولايات المتحدة الأمريكية وقد تناقلتها وسائل الإعلام على صعيد واسع. يستمر باحثون حول العالم بدراسة سبب تأثر بعض الأطفال بشكلٍ خطير بمرض كورونا كوفيد-19 بينما الإصابات بين  أغلبية الشباب كانت طفيفة نسبيًا. "
    ]
  },
  {
    "id": "recUyzawtcr5PIFIr",
    "Question": "How does projection modeling work and how seriously should we take it as countries reopen? ",
    "Status": "Needs + Editing",
    "Source of the question": [
      "Newsroom"
    ],
    "Background and context": "Many models have been made available during the COVID-19 pandemic and can offer insight into peaks, impact of certain interventions, and other key predictors. Models are only as good as the data being used, the assumptions made, the parameters (constraints) put into place, and the continued updating of data to ensure the most recent and relevant information is available. The quality of the model impacts the accuracy of its predictions and as such, should be used as one of many resources in pandemic response and prevention. \n",
    "What our experts say": "Projection modeling is a mathematical way to use data to help predict a range of important COVID-19 outcomes, such as hospitalizations, infections and deaths. Modeling can also help determine how vaccinations or school closures, and the timing of these factors, may impact the disease outcomes.\n\nModeling researchers use datasets, mathematical approaches, and other parameters to predict the spread and dynamic of infectious diseases. Models can to help predict the number of future virus cases and the peaks and curves that are part of the course of the outbreak. Modeling is a great tool to help support decision-making but models are not able to predict the future, and they can fluctuate based on interventions like the use of social distancing and face masks, in the case of COVID-19. It is a helpful resource but should not be the sole source of information for guiding policy or interventions. \n",
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Other resources": "1. Five ways to ensure that models serve society: a manifesto ([NATURE](https://www.nature.com/articles/d41586-020-01812-9)) \n2. [U.S. CDC Models](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/mathematical-modeling.html)\n3. Opinion: What models can and cannot tell us about COVID-19 ([PNAS](https://www.pnas.org/content/early/2020/06/23/2011542117)) \n",
    "Last modified manual": "2020-07-17",
    "Last edited (simplified)": "2020-07-17T02:18:07.000Z",
    "Last edited (experts say)": "2020-07-17T02:18:07.000Z",
    "Last modified": "2020-07-17",
    "What our experts say wordcount": 146,
    "Background and context wordcount": 87,
    "Other resources wordcount": 28,
    "Wordcount": 261
  },
  {
    "id": "recZ1uyhYuOzT4coz",
    "Question": "Can disinfecting wipes be reused?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & disinfecting wipes",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "Canada"
    ],
    "Background and context": "Current evidence suggests that SARS-CoV-2 may remain viable for hours to days on surfaces made from a variety of materials. Therefore, cleaning of visibly dirty surfaces followed by disinfection is a best practice measure for prevention of COVID-19 and other viral respiratory illnesses in households and community settings. In this context, disinfecting can be used to disinfect frequently touched surfaces (for example: tables, doorknobs, light switches, handles, desks, toilets, faucets, sinks, and electronics). Disinfecting wipes are usually are wet wipes commercially available and containing chemicals, for example, EPA-registered disinfectants, or alcohol-based wipes (minimum 70% of alcohol) to kill germs on surfaces. However, transmission of COVID-19 occurs much more commonly through respiratory droplets than through touching objects and surfaces, like doorknobs, countertops, keyboards, toys, etc. \n\n",
    "What our experts say": "Disinfectant wipes should never be reused. Reusing wipes will move germs from one surface to another, which is potentially harmful in the current pandemic. In order for any surface to be properly disinfected, the U.S. CDC recommends following the instructions on each product carefully and leaving the disinfectant on the surface for 3-5 minutes. This means the surface needs to be wet for this period of time, and you may need to use more than one disinfectant wipe depending on the size of the surface. However, you should never reuse the same disinfectant wipe.\n",
    "Glossary Terms": [
      "recjGuHkvGujLMjV7",
      "recMZLIWKC45HMVao"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "disinfectant",
      "virus",
      "transmission"
    ],
    "Other resources": "1. How To Clean and Disinfect Schools To Help Slow the Spread of Flu ([U.S. CDC](https://www.cdc.gov/flu/school/cleaning.htm)) \n2. Cleaning and Disinfection for Households ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cleaning-disinfection.html))\n",
    "DB (French)": [
      "recR1yoAIRcVB6ZmT"
    ],
    "DB (Hindi)": [
      "recNZYf0Bkn6jUj8I",
      "recPlCNtmjyjbvUsf"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recqU3F5R4pEIhola"
    ],
    "DB (Spanish)": [
      "recJgwzToZG5wsVfM"
    ],
    "DB (Bengali)": [
      "recrTT8P1sRAzjhmN"
    ],
    "DB (Portuguese)": [
      "rec2Uu03Zm0wH1Vmn"
    ],
    "Rollup test 2": [
      "recEJWq9ag0u2sFPh"
    ],
    "Last modified manual": "2020-07-15",
    "Last edited (simplified)": "2020-07-15T18:07:15.000Z",
    "Last edited (experts say)": "2020-07-15T18:07:15.000Z",
    "Last modified": "2020-07-15",
    "What our experts say wordcount": 94,
    "Background and context wordcount": 125,
    "Other resources wordcount": 23,
    "Wordcount": 242,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published",
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Les lingettes désinfectantes ne devraient jamais être réutilisées. La réutilisation des lingettes déplacera les germes d’une surface vers une autre, ce qui pourrait s’avérer dangereux dans le cadre de la pandémie actuelle. Afin qu’une surface soit adéquatement désinfectée, le centre de contrôle et de prévention des maladies des États-Unis recommande de bien suivre les instructions qui se trouvent sur chaque produit et de laisser le désinfectant sur la surface de 3 à 5 minutes. Cela signifie que la surface devra être mouillée pendant ce temps et que vous devrez utiliser une ou plusieurs lingettes désinfectantes selon la taille de la surface. Vous ne devriez cependant jamais réutiliser la même lingette désinfectante."
    ],
    "French - Background and context": [
      "Selon les données probantes actuelles, SARS-CoV-2 restera viable pendant des heures voire des jours sur les surfaces composées de différents matériaux. Par conséquent, le nettoyage des surfaces visiblement sales suivi d’une désinfection est une mesure éprouvée afin de prévenir la COVID-19 et d’autres maladies virales respiratoires à la maison et dans la collectivité. Dans ce contexte, on peut avoir recours à la désinfection pour désinfecter les surfaces touchées fréquemment (par exemple : les tables, les poignées de porte, les interrupteurs d’éclairage, les poignées, les bureaux, les toilettes, les robinets, les lavabos et les appareils électroniques). Les lingettes désinfectantes sont habituellement des lingettes humides disponibles sur le marché qui contiennent des produits chimiques tels que des désinfectants certifiés par l’Agence étatsunienne de protection de l’environnement ou des lingettes alcoolisées (minimum de 70 % d’alcool) afin de tuer les germes sur les surfaces. Cependant, la transmission de la COVID-19 se produit beaucoup plus fréquemment par des gouttelettes respiratoires qu’en touchant des objets et des surfaces telles que les poignées de porte, les comptoirs, les claviers, les jouets, etc."
    ],
    "Hindi - What our experts say": [
      "काम में लिए हुए कीटाणुनाशक वाइप्स का फिर से इस्तेमाल कभी नहीं करना चाहिए। एक ही पोंछे का दोबारा उपयोग करने से रोगाणु एक सतह से दूसरी सतह पर चले जाएंगे, जो कि वर्तमान महामारी में संभावित रूप से हानिकारक है। किसी भी सतह को ठीक से कीटाणुरहित करने के लिए, यूएस सीडीसी प्रत्येक उत्पाद के निर्देशों का सावधानीपूर्वक पालन करने और कीटाणुनाशक को 3-5 मिनट के लिए सतह पर छोड़ने की सलाह देता है। इसका मतलब है कि इस अवधि के लिए सतह को गीला होना चाहिए, और आपको सतह के माप के आधार पर एक से अधिक कीटाणुनाशक पोंछे का उपयोग करने की आवश्यकता हो सकती है। जैसे भी, आपको कभी भी एक ही कीटाणुनाशक पोंछे का पुन: उपयोग नहीं करना चाहिए।",
      "कीटाणुनाशक (डिसिन्फ़ेक्टिंग) वाइप्स का दोबारा उपयोग कभी नहीं करना चाहिए। एक ही वाइप से फिर से पोछने से कीटाणु एक सतह से दूसरे सतह पर जा सकते हैं, जो इस महामारी के काल में हानिकारक हो सकता है। किसी भी सतह को कीटाणु रहित करने के लिए, यू॰एस॰- सी॰डी॰सी॰ के अनुसार कीटाणुनाशक पदार्थ को 3-5 मिनट तक सतह पर छोड़ देना चाहिए। इसका यह मतलब है कि सतह इस दौरान गीला ही रहना चाहिए, और अधिक बड़ा सतह हो तो एक से अधिक वाइप की आवश्यकता भी पद सकती है। लेकिन, एक वाइप को दोबारा ना इस्तमाल करें।  "
    ],
    "Hindi - Background and context": [
      "वर्तमान साक्ष्य से पता चलता है कि SARS-CoV-2 विभिन्न पदार्थों से बने सतहों पर कुछ घंटों से लेकर दिनों तक रह सकता है। इसलिए, गंदी दिखने वाली सतहों की सफाई के बाद कीटाणुनाशन (डिसिन्फ़ेक्शन) द्वारा कोविड ​​-19 और अन्य वायरल श्वसन संबंधी बीमारियों का घरों और सामुदायिक सेटिंग्स में रोकथाम के लिए एक सर्वोत्तम अभ्यास है। इस संदर्भ में, अक्सर छुई गयी सतहों को कीटाणुरहित करने के लिए इस्तेमाल किया जा सकता है (उदाहरण के लिए: टेबल, दरवाज़े के हैंडल, लाइट स्विच, हैंडल, डेस्क, शौचालय, नल, सिंक और इलेक्ट्रॉनिक्स। विसंक्रमित करने वाले पोंछे आमतौर पर गीले पोंछे होते हैं जो व्यावसायिक रूप से उपलब्ध होते हैं और रसायनों से युक्त होते हैं। उदाहरण के लिए, EPA-पंजीकृत कीटाणुनाशक, या अल्कोहल-आधारित वाइप्स (अल्कोहल का न्यूनतम 70%) सतहों पर कीटाणुओं को मारने के लिए। हालांकि, कोविड ​​-19 का फैलाव स्पर्श करने वाली वस्तुओं और सतहों की तुलना में साँस की बूंदों के माध्यम से बहुत अधिक होता है।",
      "वर्तमान साक्ष्य से पता चलता है कि SARS-CoV-2 विभिन्न सामग्रियों से बने सतहों पर घंटों दिनों तक व्यवहार्य रह सकता है। इसलिए, कीटाणुशोधन द्वारा पीछा की जाने वाली गंदी सतहों की सफाई कोविड-19 और घरों और सामुदायिक सेटिंग्स में अन्य वायरल श्वसन संबंधी बीमारियों की रोकथाम के लिए एक सर्वोत्तम अभ्यास उपाय है। इस संदर्भ में, कीटाणुरहित करने के लिए अक्सर छुआ गई सतहों को कीटाणुरहित करने के लिए इस्तेमाल किया जा सकता है (उदाहरण के लिए: टेबल, डॉर्कनोब्स, लाइट स्विच, हैंडल, डेस्क, शौचालय, नल, सिंक और इलेक्ट्रॉनिक्स)। आमतौर पर EPA-पंजीकृत कीटाणुनाशक, या अल्कोहल-आधारित वाइप्स (शराब का न्यूनतम 70%) सतहों पर कीटाणुओं को मारने के लिए, डिसइंफेक्टिंग वाइप्स आमतौर पर व्यावसायिक रूप से उपलब्ध और केमिकल युक्त गीले वाइप्स होते हैं। हालांकि, कोविड-19 का प्रसारण स्पर्श करने वाली वस्तुओं और सतहों की तुलना में श्वसन बूंदों के माध्यम से बहुत अधिक होता है, जैसे कि डॉर्कनोब्स, काउंटरटॉप्स, कीबोर्ड, खिलौने, आदि।"
    ],
    "Telugu - What our experts say": [
      "క్రిమిసంహారక తుడవడం ఎప్పుడూ తిరిగి ఉపయోగించకూడదు. తుడవడం తిరిగి ఉపయోగించడం వలన సూక్ష్మక్రిములు ఒక ఉపరితలం నుండి మరొక ఉపరితలం వరకు కదులుతాయి, ఇది ప్రస్తుత మహమ్మారిలో హానికరం. ఏదైనా ఉపరితలం సరిగా క్రిమిసంహారకమయ్యేలా, ప్రతి ఉత్పత్తిపై సూచనలను జాగ్రత్తగా పాటించాలని మరియు క్రిమిసంహారక మందును 3-5 నిమిషాలు ఉపరితలంపై ఉంచాలని యు.ఎస్. సిడిసి సిఫార్సు చేస్తుంది. దీని అర్థం ఈ కాలానికి ఉపరితలం తడిగా ఉండాలి మరియు ఉపరితల పరిమాణాన్ని బట్టి మీరు ఒకటి కంటే ఎక్కువ క్రిమిసంహారక తుడవడం ఉపయోగించాల్సి ఉంటుంది. అయితే, మీరు ఎప్పుడూ అదే క్రిమిసంహారక తుడవడం తిరిగి ఉపయోగించకూడదు."
    ],
    "Telugu - Context and background": [
      "ప్రస్తుత సాక్ష్యాలు SARS-CoV-2 వివిధ రకాల పదార్థాల నుండి తయారైన ఉపరితలాలపై గంటల నుండి రోజుల వరకు ఆచరణీయంగా ఉండవచ్చని సూచిస్తున్నాయి. అందువల్ల, క్రిమిసంహారక తరువాత కనిపించే మురికి ఉపరితలాలను శుభ్రపరచడం అనేది కోవిడ్-19 మరియు ఇతర వైరల్ శ్వాసకోశ వ్యాధుల నివారణకు గృహాలలో మరియు సమాజ అమరికలలో ఉత్తమమైన సాధన. ఈ సందర్భంలో, తరచుగా తాకిన ఉపరితలాలను క్రిమిసంహారక చేయడానికి క్రిమిసంహారక వాడవచ్చు (ఉదాహరణకు: టేబుల్స్, డోర్క్‌నోబ్స్, లైట్ స్విచ్‌లు, హ్యాండిల్స్, డెస్క్‌లు, మరుగుదొడ్లు, ఫ్యూసెట్లు, సింక్‌లు మరియు ఎలక్ట్రానిక్స్). క్రిమిసంహారక తొడుగులు సాధారణంగా తడి తొడుగులు వాణిజ్యపరంగా లభిస్తాయి మరియు రసాయనాలను కలిగి ఉంటాయి, ఉదాహరణకు, EPA- రిజిస్టర్డ్ క్రిమిసంహారకాలు లేదా ఆల్కహాల్ ఆధారిత తుడవడం (కనీసం 70% ఆల్కహాల్) ఉపరితలాలపై సూక్ష్మక్రిములను చంపడానికి. అయినప్పటికీ, డోర్క్‌నోబ్స్, కౌంటర్‌టాప్‌లు, కీబోర్డులు, బొమ్మలు మొదలైనవి తాకిన వస్తువులు మరియు ఉపరితలాల ద్వారా కాకుండా శ్వాస బిందువుల ద్వారా కోవిడ్-19 ప్రసారం చాలా సాధారణంగా జరుగుతుంది."
    ],
    "Spanish - What our experts say": [
      "Los paños desinfectantes nunca debieran ser reutilizados. Al hacerlo, los gérmenes se moverán de una superficie a otra, lo cual es potencialemnte dañino en la pandemia actual. Con el fin de que cualquier superficie sea apropiadamente desinfectada, el U.S. CDC recomienda seguir cuidadosamente las instrucciones en cada producto, y dejar el desinfectante sobre la superficie por 3 a 5 minutos. Esto significa que la superficie necesita estar húmeda por este periodo de tiempo, y puedes necesitar usar más de un paño desinfectante dependiendo del tamaño de la superficie.\nSin embargo, no debieras reutilizar el mismo paño desinfectante."
    ],
    "Spanish - Background and context": [
      "La evidencia actual sugiere que el SARS-CoV-2 puede permanecer viable por horas y días sobre superficies hechas de una variedad de materiales. Por lo tanto, la limpieza de superficies visiblemente sucias seguida por la desinfección es la mejor medida práctica para la prevención del COVID-19 y otros malestares respiratorios virales en domicilios y establecimientos comunitarios. En este contexto, la desinfección puede ser usada en superficies frecuentemente tocadas (por ejemplo: mesas, picaportes, teclas de luz, manijas, escritorios, retretes, grifos, lavamanos y artefactos electrónicos). Los paños desinfectantes usualmente son paños húmedos disponibles comercialmente y conteniendo químicos, por ejemplo, desinfectantes registrados en la EPA, o paños basados en alcohol (mínimo 70%) para matar gérmenes sobre las superficies. Sin embargo, la transmisión del COVID-19 ocurre mucho más comunmente a través de gotitas respiratorias que a través de tocar objetos y superficies, como picaportes, mostradores, teclados, juguetes, etc."
    ],
    "Bengali - What our experts say": [
      "জীবাণুনাশক টিস্যু কখনই পুনরায় ব্যবহার করা উচিত নয়। টিস্যু পুনরায় ব্যবহার করা জীবাণুগুলিকে এক পৃষ্ঠ থেকে অন্য পৃষ্ঠে নিয়ে যাবে, যা বর্তমান মহামারীতে সম্ভাব্য ক্ষতিকারক। যে কোনও পৃষ্ঠকে সঠিকভাবে জীবাণুমুক্ত করার জন্য, মার্কিন রোগ নিয়ন্ত্রণ কেন্দ্র প্রতিটি পণ্যের নির্দেশাবলী সাবধানতার সাথে অনুসরণ করার এবং ৩-৫ মিনিটের জন্য পৃষ্ঠের উপর জীবাণুনাশক রেখে দেওয়ার পরামর্শ দেয়। এর অর্থ এই সময়ের জন্য উপরিভাগটি ভেজা থাকা দরকার এবং আপনার পৃষ্ঠের আকারের উপর নির্ভর করে একাধিক জীবাণুনাশক টিস্যুর প্রয়োজন হতে পারে। তবে আপনার একই জীবাণুনাশক টিস্যু পুনরায় ব্যবহার করা উচিত নয়।"
    ],
    "Bengali - Background and context": [
      "বর্তমান তথ্য উপাত্ত প্রমাণ করে যে SARS-CoV-2 বিভিন্ন উপকরণ থেকে তৈরি পৃষ্ঠের উপর কয়েক ঘন্টা থেকে কয়েক দিন কার্যকর থাকতে পারে। অতএব, দৃশ্যমান নোংরা পৃষ্ঠগুলি পরিষ্কার করার পরে সেগুলি জীবাণুমুক্ত করা পরিবার এবং সম্প্রদায়ের বিশিষ্টে কোভিড-৯১ এবং অন্যান্য ভাইরাল শ্বাস-প্রশ্বাসজনিত অসুস্থতা প্রতিরোধের জন্য সেরা অনুশীলন ব্যবস্থা| এই প্রসঙ্গে, জীবাণুনাশকটি প্রায়শই স্পর্শ করা হয় এমন পৃষ্ঠগুলিকে জীবাণুমুক্ত করার জন্য ব্যবহার করা যেতে পারে (উদাহরণস্বরূপ: টেবিল, দরজার হাতল, বৈদ্যুতিক সুইচ, হ্যান্ডেলস, ডেস্ক, টয়লেট, কল, সিঙ্ক এবং ইলেকট্রনিক্স)। জীবাণুনাশক টিস্যুগুলি সাধারণত বাণিজ্যিকভাবে ভিজা টিস্যু হিসেবে পাওয়া যায় এবং এতে রাসায়নিক থাকে, উদাহরণস্বরূপ, ইপিএ-নিবন্ধিত জীবাণুনাশক বা অ্যালকোহল-ভিত্তিক টিস্যুগুলি (ন্যূনতম ৭০% অ্যালকোহল) পৃষ্ঠের জীবাণুগুলিকে হ্রাস করতে পারে। তবে কোভিড -১৯ সংক্রমণটি সাধারণত দরজার হাতল, টেবিলের উপরিভাগ, কীবোর্ডস, খেলনা ইত্যাদির মতো স্পর্শকৃত বস্তু এবং উপরিভাগের চেয়ে শ্বাসযন্ত্রের জলীয় কণার মাধ্যমে ঘটে|"
    ]
  },
  {
    "id": "reclucIrtcCSCbOn6",
    "Question": "Is the Russian vaccine a successful cure for COVID-19? ",
    "Status": "Published",
    "Source of the question": [
      "Fact-checking organization"
    ],
    "Country question was sourced from": [
      "Russia"
    ],
    "Background and context": "Vaccines are not medicines that can treat or cure diseases, as they are made for prevention. Vaccines contain a weakened, killed, or partial form of the same germs that cause the disease in order to stimulate the body's immune response to develop immunity without having to get sick. The World Health Organization (WHO) reported that were around 160 vaccines for COVID-19 in development as of July 6, 2020, with at least 21 vaccine candidates under clinical evaluation and 139 under pre-clinical evaluation. This included U.K.'s Oxford University and AstraZeneca vaccine candidate in phase 3 clinical trials with 5,000 people in Brazil and 4,000 people in the U.K., Australia's University of Queensland vaccine candidate that started phase 1 clinical trials with 120 people to be observed over 12 months (including a proportion of people assigned to receive a placebo for comparison), the U.S.'s Inovio Pharmaceuticals vaccine candidate that completed phase 1 clinical trials with 40 people (reports suggest 94% had \"overall immune responses at week six after two doses\" and after eight weeks the vaccine candidate was considered \"safe and well-tolerated with no serious adverse events\"), and China's CanSino Biologics vaccine candidate that completed phase 2 clinical trials with 508 people and began phase 3 clinical trials with 40,000 people from multiple countries on September 15, 2020.\n",
    "What our experts say": "COVID-19 vaccines are being developed to prevent people from getting the disease, not to treat or cure patients who already have the disease. Many experts continue to caution that a vaccine may not be widely available until 2021, which would already be record-breaking timing for vaccine development, manufacturing and distribution.\n\nIn the summer of 2020, Russia's Sechenov First Moscow State Medical University announced human clinical trials of a COVID-19 vaccine, with 18 people vaccinated on June 18 and 20 people vaccinated on June 23. Russia's initial announcements of their human clinical trials were accompanied by projections that the vaccine could be distributed in August and mass produced by private corporations in September 2020. Health experts responded with cautions about how there are many challenges in scaling up from a vaccine that has been tested on just a few dozen people in one country to a commercially available vaccine that is available and suitable for millions of diverse people around the world. \n\nIn August 2020, President Vladimir V. Putin announced that Russia approved its first COVID-19 vaccine, although global health authorities warned that the vaccine has not yet completed important late-stage clinical trials with larger numbers of people to determine the vaccine's safety and effectiveness. The first approved Russian vaccine, called Gam-COVID-Vac Lyo, was registered by the Gamaleya Research Institute of Epidemiology and Microbiology at the Health Ministry of the Russian Federation for a combined phase 1 and 2 trial. Public health experts have been concerned that skipping phase 3 clinical trials and rushing vaccine approval can potentially endanger people. Russia's first approved vaccine is now being offered outside of trials in small quantities to people at higher risk of infection, such as healthcare workers.\n\nIn September 2020, the head of Rospotrebnadzor, a Russian agency regulating health care, announced that Russian researchers have completed early clinical trials of a second vaccine, which uses proteins that mimic those in the coronavirus that causes COVID-19. This differs from the first approved vaccine in Russia, which uses common cold viruses.\n\nBeyond the Russian vaccine trials, there are several human clinical trials for COVID-19 vaccine candidates happening around the world, with some trials involving hundreds or thousands of people over observation periods of many months. Rigorous clinical trials are important to understand whether vaccine candidates are safe and without major negative side effects, as well as whether vaccine candidates are effective and can actually provide immunity for long periods of time.\n",
    "Glossary Terms": [
      "rec9qqItwSTjq3Eae",
      "recMJMGqkERKGcbL5",
      "recJK5tI9LgCGFRAU"
    ],
    "Variation of the answer depending on country of residence": "\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "\n",
    "Other resources": "1. Vaccines: The Basics ([U.S. CDC](https://www.cdc.gov/vaccines/vpd/vpd-vac-basics.html))\n2. Russia Coronavirus Vaccine Could Be Distributed Next Month ([Newsweek](https://www.newsweek.com/russia-coronavirus-vaccine-could-distributed-next-month-1517398))\n3. China's CanSino in talks for COVID-19 vaccine Phase III trial overseas ([Reuters](https://www.reuters.com/article/us-health-coronavirus-china-vaccine/chinas-cansino-in-talks-for-covid-vaccine-phase-iii-trial-overseas-idUSKCN24C0HS))\n4. Phase III trial of a COVID-19 vaccine of adenovirus vector in adults 18 years old and above ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/NCT04526990))\n5. First data for Moderna Covid-19 vaccine show it spurs an immune response ([STAT News](https://www.statnews.com/2020/07/14/moderna-covid19-vaccine-first-data-show-spurs-immune-response/))\n6. Russia approves coronavirus vaccine before completing tests ([NYT](https://www.nytimes.com/2020/08/11/world/europe/russia-coronavirus-vaccine-approval.html))\n7. A second vaccine nears approval in Russia ([NYT](https://www.nytimes.com/live/2020/09/30/world/covid-19-coronavirus/a-second-vaccine-nears-approval-in-russia#a-second-vaccine-nears-approval-in-russia))\n",
    "DB (Hindi)": [
      "rec9Vj7CIQcChHjo4"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recKhvw3pZ6oWjY3Z"
    ],
    "DB (Portuguese)": [
      "recli6ohnTfk41C3z"
    ],
    "Rollup test 2": [
      "recwWDviylh8d2shV"
    ],
    "Last modified manual": "2020-10-08",
    "Last edited (simplified)": "2020-10-08T20:22:18.000Z",
    "Last edited (experts say)": "2020-10-08T21:56:24.000Z",
    "Last modified": "2020-10-08",
    "What our experts say wordcount": 403,
    "Background and context wordcount": 216,
    "Other resources wordcount": 75,
    "Wordcount": 694,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "कोविड-19 टीके लोगों को बीमारी से बचाने के लिए विकसित किए जा रहे हैं, न कि उन रोगियों का इलाज या इलाज करने के लिए जिनके पास पहले से ही बीमारी है। कई विशेषज्ञ चेतावनी देते हैं कि 2020 के अंत तक या 2021 की शुरुआत तक एक टीका व्यापक रूप से उपलब्ध नहीं हो सकता है, जो पहले से ही टीका विकास करने के लिए रिकॉर्ड-ब्रेकिंग समय होगा।\n\n हाल ही में, रूस के सेचेनोव फर्स्ट मॉस्को स्टेट मेडिकल यूनिवर्सिटी ने घोषणा की कि वे एक कोविड-19 वैक्सीन के मानव नैदानिक ​​परीक्षण को पूरा कर रहे हैं, जिसमें 18 लोगों को 18 जून को टीका लगाया गया (15 जुलाई को छुट्टी दी जाएगी) और 20 लोगों को 23 जून को टीका लगाया गया (20 जुलाई को छुट्टी दी जाएगी)। यह दुनिया भर में हो रहे कोविड-19 वैक्सीन उम्मीदवारों के लिए कई मानव नैदानिक ​​परीक्षणों में से एक है, जिसमें कुछ परीक्षण सैकड़ों या हजारों लोग शामिल होते हैं, जो कई महीनों के अवलोकन अवधि में होते हैं। यह समझने के लिए कठोर नैदानिक ​​परीक्षण महत्वपूर्ण हैं कि क्या टीके के उम्मीदवार सुरक्षित हैं और प्रमुख नकारात्मक दुष्प्रभावों के बिना, साथ ही साथ कि क्या टीका उम्मीदवार प्रभावी हैं और वास्तव में लंबे समय तक प्रतिरक्षा प्रदान कर सकते हैं।\n\n रूस ने अपने मानव नैदानिक ​​परीक्षणों की घोषणा अनुमानों के साथ की है कि वैक्सीन को अगस्त में वितरित किया जा सकता है और सितंबर में निजी निगमों द्वारा बड़े पैमाने पर उत्पादित किया जा सकता है। एक वैक्सीन उम्मीदवार को स्केल करने में कई चुनौतियां हैं जो एक देश में कुछ दर्जन लोगों पर व्यावसायिक रूप से उपलब्ध वैक्सीन के लिए परीक्षण किया गया है जो दुनिया भर के लाखों विविध लोगों के लिए उपलब्ध और उपयुक्त है।"
    ],
    "Hindi - Background and context": [
      "टीके ऐसी दवाएं नहीं हैं जो बीमारियों का इलाज या इलाज कर सकती हैं, क्योंकि वे रोकथाम के लिए बनाई गई हैं। टीके में एक ही रोगाणु के कमजोर, मारे गए, या आंशिक रूप होते हैं जो बीमारी का कारण बनते हैं, ताकि शरीर की प्रतिरक्षा प्रतिक्रिया को उत्तेजित किया जा सके, ताकि बीमार होने के बिना प्रतिरक्षा विकसित हो सके। विश्व स्वास्थ्य संगठन (डब्ल्यूएचओ) की रिपोर्ट है कि 6 जुलाई, 2020 तक विकास में कोविड-19 के लिए लगभग 160 टीके हैं, क्लिनिकल मूल्यांकन के तहत कम से कम 21 वैक्सीन उम्मीदवारों के साथ और प्री-क्लिनिकल मूल्यांकन के तहत 139। इसमें यूके की ऑक्सफोर्ड यूनिवर्सिटी और एस्ट्राजेनेका वैक्सीन उम्मीदवार शामिल हैं, जो वर्तमान में चरण 3 नैदानिक ​​परीक्षणों में ब्राजील में 5,000 लोगों और यूके में 4,000 लोगों के साथ, ऑस्ट्रेलिया यूनिवर्सिटी ऑफ क्वींसलैंड वैक्सीन उम्मीदवार हैं जिन्होंने 120 लोगों के साथ चरण एक नैदानिक ​​परीक्षण शुरू किया है। 12 महीने (तुलना के लिए एक प्लेसबो प्राप्त करने के लिए असाइन किए गए लोगों का अनुपात सहित), यूएस का इनोवियो फार्मास्यूटिकल्स वैक्सीन उम्मीदवार जिसने 40 लोगों के साथ चरण 1 नैदानिक ​​परीक्षण पूरा किया (रिपोर्ट में 94% का सुझाव था \"दो डोज़ के बाद सप्ताह छह में समग्र प्रतिरक्षा प्रतिक्रियाएं\" और आठ सप्ताह के बाद टीका उम्मीदवार को \"बिना किसी गंभीर प्रतिकूल घटनाओं के सुरक्षित और अच्छी तरह से सहन किया गया\" माना जाता था), और चीन का कैनसिनो बायोलॉजिकल वैक्सीन उम्मीदवार जिसने 508 लोगों के साथ चरण दो नैदानिक परीक्षण पूरा किया है और कई देशों के 40,000 लोगों के साथ चरण तीन नैदानिक परीक्षण शुरू करने की योजना बना रहा है।"
    ]
  },
  {
    "id": "recC2wUIEcU6WPCCA",
    "Question": "Is there a specific process through which COVID-19 enters the body? Does COVID-19 first enter through the throat before it \"destroys\" the lungs?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & lungs",
    "Source of the question": [
      "Fact-checking organization"
    ],
    "Country question was sourced from": [
      "Philippines"
    ],
    "Background and context": "As we learn more about COVID-19 and the way it is spread to humans, we will learn more about why the virus seems to impact the lungs of many people. Unlike most viruses humans come into contact with, COVID-19 is new, so humans have not had the ability to gradually build up their immune systems to defend themselves from the virus over time. This may be part of the reason why the virus continues to spread rapidly around the world and can cause significant symptoms in 20% of cases.\n",
    "What our experts say": "COVID-19 enters the body through the nose, mouth, and eyes. This happens primarily when someone infected with the virus releases small droplets of liquid that contain part of the virus through actions like coughing, sneezing, speaking, or singing. These small bits of virus range in size, from the wet, teardrop-sized types of droplets you might see when you sneeze, to microscopic ones that are so light and dry, they might remain in the air for hours. When a person is in close contact with these droplets, the virus enters the body through these three areas. Then, the virus lands at the back of the throat, also called the top of the upper respiratory tract, in roughly 80% of people who have mild cases of infection. For other more severe cases, the virus can then move down to the lungs, potentially causing pneumonia, which happens in 15-20% of cases, although most recover. \n\nWhen COVID-19 spreads to the lungs, it does not mean that they will be \"destroyed.\" It means that there is an infection involving fluid within tiny branches of air tubes or sacs in the lungs called 'alveoli.' These air sacs may fill up with so much liquid or pus that they become swollen, and their walls can thicken, so it is hard for oxygen to be processed and delivered through the lungs, making it harder to breathe. \n\nEvery virus has a different way of infecting humans, though many viruses gain entry into the body through the nose, mouth, and eyes and often cause upper respiratory infections like COVID-19.\n\n\n \n\n",
    "Glossary Terms": [
      "rec5yviiSvJkufYvu",
      "recTotk6ZnYu3ib8P",
      "rect47sXxza5ALA3I"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "pneumonia",
      "lungs",
      "transmission",
      "droplet"
    ],
    "Other resources": "1. Q&A: How is COVID-19 transmitted? ([WHO](https://www.who.int/news-room/q-a-detail/q-a-how-is-covid-19-transmitted)) \n2. Alveoli ([NCI](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/alveoli)) \n3. Coronaviruses: An Overview of Their Replication and Pathogenesis ([NPHEC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369385/)) \n4. How COVID-19 spreads, 2020 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html))\n",
    "DB (Hindi)": [
      "recfPp65sW5B34jq2"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recVtIGGq8ehE7QTs"
    ],
    "DB (Portuguese)": [
      "recwujyUo2ndMPuT2"
    ],
    "Rollup test 2": [
      "receyKkYOHMiXaPmi"
    ],
    "Last modified manual": "2020-07-14",
    "Last edited (simplified)": "2020-07-14T01:00:25.000Z",
    "Last edited (experts say)": "2020-08-05T00:53:39.000Z",
    "Last modified": "2020-07-14",
    "What our experts say wordcount": 260,
    "Background and context wordcount": 89,
    "Other resources wordcount": 27,
    "Wordcount": 376,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "कोविड-19 नाक, मुंह और आंखों के माध्यम से शरीर में प्रवेश करती है। यह मुख्य रूप से तब होता है जब वायरस से संक्रमित कोई व्यक्ति तरल की छोटी बूंदों को छोड़ता है जिसमें खांसी, छींकने, बोलने या गाने जैसी क्रियाओं के माध्यम से वायरस का हिस्सा होता है। वायरस के ये छोटे-छोटे टुकड़े आकार में गीले, अश्रु-आकार के प्रकार की बूंदों से होते हैं, जिन्हें आप छींकते समय देख सकते हैं, सूक्ष्मदर्शी को जो इतने हल्के और शुष्क होते हैं, वे घंटों तक हवा में रह सकते हैं। जब कोई व्यक्ति इन बूंदों के निकट संपर्क में होता है, तो वायरस इन तीन क्षेत्रों के माध्यम से शरीर में प्रवेश करता है। फिर, गले के पीछे वायरस की भूमि को ऊपरी श्वसन पथ का शीर्ष भी कहा जाता है, लगभग 80% लोगों में जिन्हें संक्रमण के हल्के मामले हैं। अन्य अधिक गंभीर मामलों के लिए, वायरस तब फेफड़ों तक जा सकता है, संभावित रूप से निमोनिया का कारण बनता है, जो 15-20% मामलों में होता है, हालांकि यह ठीक हो जाता है।\n \nजब कोविड-19 फेफड़ों में फैलता है, तो इसका मतलब यह नहीं है कि वे \"नष्ट\" हो जाएंगे। इसका अर्थ है कि वायु नलिकाओं की छोटी शाखाओं के भीतर तरल पदार्थ होता है या फेफड़ों में थैली होती है जिसे 'एल्वियोली' कहते हैं। ये वायु सैक्स इतने अधिक तरल या मवाद से भर सकते हैं कि वे सूज जाते हैं, और उनकी दीवारें मोटी हो सकती हैं, इसलिए ऑक्सीजन को संसाधित करना और फेफड़ों के माध्यम से वितरित करना कठिन होता है, जिससे सांस लेने में मुश्किल होती है।\n\nप्रत्येक वायरस का मनुष्यों को संक्रमित करने का एक अलग तरीका है, हालांकि कई वायरस नाक, मुंह और आंखों के माध्यम से शरीर में प्रवेश करते हैं और अक्सर ऊपरी श्वसन संक्रमण जैसे कोविड​-19 का कारण बनते हैं।"
    ],
    "Hindi - Background and context": [
      " जैसा कि हम कोविड-19 के बारे में अधिक सीखते हैं और जिस तरह से यह मनुष्यों में फैलता है, हम इस बारे में अधिक जानेंगे कि वायरस कई लोगों के फेफड़ों को क्यों प्रभावित करता है। अधिकांश वायरस मनुष्यों के संपर्क में आने के विपरीत, कोविड-19 नया है, इसलिए मनुष्यों में समय के साथ वायरस से बचाव के लिए धीरे-धीरे अपनी प्रतिरक्षा प्रणाली का निर्माण करने की क्षमता नहीं रही है। यह इस कारण का हिस्सा हो सकता है कि क्यों वायरस दुनिया भर में तेजी से फैल रहा है और 20% मामलों में महत्वपूर्ण लक्षण पैदा कर सकता है।"
    ]
  },
  {
    "id": "recAvJuac1TZ49MjL",
    "Question": "If COVID-19 is transmitted via airborne particles, how might testing change?",
    "Status": "Published",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Aerosol/airborne transmission is not considered the main route for transmission of SARS-CoV-2, the virus that causes COVID-19, but it can happen and certain environments often support super spread events, like an indoor environment with poor ventilation. Since most of COVID-19 testing is based on symptoms and/or exposure to a person infected with COVID-19, expanding beyond these criteria to include individuals who were in certain environments where aerosol transmission might happen (e.g. a choir practice or fitness class), might mean more people will get tested. \n",
    "What our experts say": "Though the potential for airborne transmission likely wouldn't change testing methods outside of a push for more extensive testing in general, it might influence policy regarding mandating mask wearing, air purification and ventilation systems, and other methods of prevention related to airborne viral spread.\n\nSARS-CoV-2 (the virus that causes COVID-19) is not airborne in the traditional sense. COVID-19 spreads primarily through relatively large respiratory droplets that fall to the ground and into faces and bodies of others. These larger droplets, 'respiratory droplets,’ are wet from saliva and mucus and fall quickly to the ground. Scientists think this type of infectious droplet is how the majority of COVID-19 infections spread. \n\nOn the other hand, examples of airborne diseases are tuberculosis and measles, and the way these diseases spread is primarily through the air in smaller particles called 'microdroplets' or 'droplet nuclei.' Smaller droplets can stay in the air for longer periods of time because they are so small and light. Exhalation, talking, coughing, and singing can cause these small droplets to linger in the air for hours after a person leaves a room. SARS-CoV-2 viral particles may be part of these tiny droplets, and can travel beyond 6 feet (2m) in certain situations, but the disease is still not understood to be transmitted primarily through lingering infectious particles in the air. \n\nThe aerosol or airborne transmission of COVID-19 occurs more indoors in close contact. This might mean that people who don't fall into the U.S. Centers for Disease Control and Prevention-defined category of \"exposed\" to the virus (within 6 feet or 2m of an infected person for more than 15 minutes), but were in the same room as an infected person for an extended period of time, may now be considered ‘exposed’ and require testing.\n\nThere is currently some controversy around this topic, as 239 scientists recently sent a letter to the World Health Organization (WHO) urging them to recognize the potential of people catching the virus from droplet nuclei via airborne transmission. These scientists believe that the evidence supporting the concept of airborne transmission mean current procedures like social distancing and vigorous hand-washing do not provide enough protection from virus-carrying microdroplets that can stay suspended in the air for hours. Thus, the potential for people inhaling these droplet nuclei into their noses and mouths means additional prevention steps are needed. The WHO previously maintained that the novel coronavirus is mainly spread by respiratory droplet transmission, but has since acknowledged the emerging evidence for airborne transmission in \"crowded, closed, poorly ventilated settings,\" while cautioning that the evidence is preliminary and should be assessed further.\n",
    "Glossary Terms": [
      "rech6tPR0hLDA3JH3",
      "recTotk6ZnYu3ib8P",
      "rec5yviiSvJkufYvu"
    ],
    "Variation of the answer depending on country of residence": "Yes\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "testing",
      "aerosol",
      "airborne"
    ],
    "Other resources": "1. Public Health Guidance for Community-Related Exposure ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-recommendations.html))\n2. Identifying airborne transmission as the dominant route for the spread of COVID-19 ([PNAS](https://www.pnas.org/content/117/26/14857)) \n3. Review of Scientific Data Regarding Transmission of Infectious Agents in Healthcare Settings ([CDC](https://www.cdc.gov/infectioncontrol/guidelines/isolation/scientific-review.html)) \n4. Mounting evidence suggests coronavirus is airborne — but health advice has not caught up ([Nature](https://www.nature.com/articles/d41586-020-02058-1)) \n5. It is Time to Address Airborne Transmission of COVID-19 ([CID](https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa939/5867798)) \n6. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations ([WHO](https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations))\n7. Open Letter: It is Time to Address Airborne Transmission of COVID-19 ([Clinical Infectious Diseases](https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa939/5867798))\n8. Coronavirus: WHO rethinking how Covid-19 spreads in air ([BBC](https://www.bbc.com/news/world-53329946))\n",
    "DB (Hindi)": [
      "reclDEivWOJHGmN36"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recW2VhpLG3jEJQZ6"
    ],
    "DB (Portuguese)": [
      "recx3w9DJAcfMruZG"
    ],
    "Rollup test 2": [
      "recu0trrTE66d9ecE"
    ],
    "Last modified manual": "2020-07-13",
    "Last edited (simplified)": "2020-07-09T16:35:30.000Z",
    "Last edited (experts say)": "2020-07-23T15:38:43.000Z",
    "Last modified": "2020-07-13",
    "What our experts say wordcount": 427,
    "Background and context wordcount": 85,
    "Other resources wordcount": 100,
    "Wordcount": 612,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "हालांकि एयरबोर्न ट्रांसमिशन की संभावना सामान्य रूप से अधिक व्यापक परीक्षण के लिए एक बढ़ावा देने से बाहर परीक्षण के तरीकों को नहीं बदलेगी, लेकिन यह मास्किंग पहनने, वायु शोधन और वेंटिलेशन सिस्टम और एयरबोर्न वायरल प्रसार से संबंधित रोकथाम के अन्य तरीकों के बारे में नीति को प्रभावित कर सकता है।\n\nSARS-CoV-2 (कोविड-19 का कारण बनने वाला वायरस) पारंपरिक अर्थों में हवाई नहीं है। कोविड-19 मुख्य रूप से अपेक्षाकृत बड़ी श्वसन बूंदों के माध्यम से फैलता है जो जमीन पर और दूसरों के चेहरे और शरीर में गिरती हैं। ये बड़ी बूंदें, 'श्वसन की बूंदें', लार और बलगम से गीली होती हैं और जल्दी से जमीन पर गिर जाती हैं। वैज्ञानिकों को लगता है कि इस प्रकार की संक्रामक बूंदें कोविड-19 संक्रमण का अधिकांश हिस्सा कैसे फैलती हैं।\n\nदूसरी ओर, हवाई बीमारियों के उदाहरण तपेदिक और खसरे हैं, और जिस तरह से ये बीमारियां फैलती हैं, वह मुख्य रूप से हवा में छोटे कणों के माध्यम से होती है जिन्हें 'माइक्रोड्रोप्लेट' या 'छोटी बूंद नाभिक' कहा जाता है। छोटी बूंदें हवा में अधिक समय तक रह सकती हैं क्योंकि वे इतनी छोटी और हल्की होती हैं। साँस छोड़ना, बात करना, खाँसना और गाना इन छोटी बूंदों को एक व्यक्ति द्वारा एक कमरे में छोड़ने के बाद घंटों तक हवा में रहने का कारण बन सकता है। SARS-CoV-2 वायरल कण इन छोटी बूंदों का हिस्सा हो सकते हैं, और कुछ स्थितियों में 6 फीट (2 मीटर) से आगे की यात्रा कर सकते हैं, लेकिन बीमारी अभी भी मुख्य रूप से हवा में संक्रामक कणों के माध्यम से प्रसारित होने के लिए समझ में नहीं आती है।\n\nकोविड-19 का एरोसोल या एयरबोर्न प्रसारण निकट संपर्क में अधिक घर के अंदर होता है। इसका अर्थ यह हो सकता है कि जो लोग वायरस के लिए \"उजागर\" वायरस के नियंत्रण और रोकथाम-परिभाषित श्रेणी के लिए अमेरिकी केंद्रों में नहीं आते हैं (संक्रमित व्यक्ति के 6 फीट या 2 मी 15 मिनट से अधिक समय तक), लेकिन वे थे एक विस्तारित अवधि के लिए एक संक्रमित व्यक्ति के रूप में एक ही कमरा, अब 'उजागर' माना जा सकता है और परीक्षण की आवश्यकता होती है।\n\nइस विषय पर वर्तमान में कुछ विवाद है, क्योंकि 239 वैज्ञानिकों ने हाल ही में विश्व स्वास्थ्य संगठन (डब्ल्यूएचओ) को एक पत्र भेजा है, जिसमें उन्हें हवाई प्रसारण के माध्यम से छोटी बूंदों से वायरस को पकड़ने वाले लोगों की क्षमता को पहचानने का आग्रह किया गया है। इन वैज्ञानिकों का मानना ​​है कि हवाई प्रसारण की अवधारणा का समर्थन करने वाले साक्ष्य का मतलब है कि वर्तमान प्रक्रियाएं जैसे सामाजिक गड़बड़ी और जोरदार हाथ धोने से वायरस ले जाने वाले माइक्रोड्रोप्लेट से पर्याप्त सुरक्षा नहीं मिलती है जो हवा में घंटों तक निलंबित रह सकते हैं। इस प्रकार, इन बूंदों के नाभिक को अपने नाक और मुंह में रखने वाले लोगों की क्षमता का मतलब है कि अतिरिक्त रोकथाम कदमों की आवश्यकता है। डबल्युएचओ ने पहले कहा था कि उपन्यास कोरोनावायरस मुख्य रूप से श्वसन ड्रॉपलेट ट्रांसमिशन द्वारा फैलता है, लेकिन तब से \"भीड़ भरी, बंद, खराब हवादार सेटिंग्स\" में हवाई प्रसारण के लिए उभरते सबूतों को स्वीकार किया है, जबकि सावधानी बरतते हुए कि सबूत प्रारंभिक हैं और आगे मूल्यांकन किया जाना चाहिए।"
    ],
    "Hindi - Background and context": [
      "एयरोसोल / एयरबोर्न ट्रांसमिशन को SARS-CoV-2 के संचरण के लिए मुख्य मार्ग नहीं माना जाता है, वायरस जो कोविड-19 का कारण बनता है, लेकिन यह हो सकता है और कुछ वातावरण अक्सर खराब वेंटिलेशन वाले इनडोर वातावरण की तरह, सुपर फैल घटनाओं का समर्थन करते हैं। चूंकि कोविड-19 का अधिकांश परीक्षण कोविड-19 से संक्रमित व्यक्ति के लक्षणों और / या जोखिम पर आधारित है, इसलिए इन मानदंडों से परे उन व्यक्तियों को शामिल करना, जो कुछ ऐसे वातावरणों में शामिल थे जहां एयरोसोल ट्रांसमिशन हो सकता है (उदाहरण के लिए एक गाना बजानेवालों का अभ्यास या फिटनेस क्लास) , इसका मतलब यह हो सकता है कि अधिक लोग परीक्षण करेंगे।"
    ]
  },
  {
    "id": "recQoylvV8fLvS6xm",
    "Question": "What do we know about pre-symptomatic and asymptomatic transmissions?",
    "Status": "Published",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "There is concern about transmission by people without symptoms because this makes disease prevention more challenging. For example, while it is a helpful public health measure to recommend that people self-isolate when ill, it is insufficient to stop the spread of the novel coronavirus when someone who never develops symptoms or who has not yet developed symptoms can still infect others. In some recent publications, it is estimated that 6-41% of reported novel coronavirus infections may be due to asymptomatic and/or pre-symptomatic transmissions.\n",
    "What our experts say": "People who have been infected with COVID-19 but don't have symptoms are considered \"asymptomatic.\" People infected with COVID-19 whose symptoms have not yet developed are called \"pre-symptomatic.\" Even as people who are asymptomatic and pre-symptomatic don't display symptoms, they are still infected with the virus, and have the potential to shed the virus. This means that people without symptoms can still spread the virus to others, even if they don't feel sick.\n\n",
    "Glossary Terms": [
      "recx2PeCcs1Awb9rG",
      "recbZcFUtsYMA9Vsh"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "asymptomatic",
      "presymptomatic",
      "transmission",
      "spread"
    ],
    "Other resources": "1. A study about viral shedding and transmission of COVID-19 ([Nature](https://www.nature.com/articles/s41591-020-0869-5))\n2. WHO clarifies comments on asymptomatic spread of Covid-19 ([STAT](https://www.statnews.com/2020/06/09/who-comments-asymptomatic-spread-covid-19/))\n3. Prevalence of asymptomatic SARS-CoV-2 infection ([Annals of Internal Medicine](https://www.acpjournals.org/doi/10.7326/M20-3012))\n4. Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19 ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMe2009758))\n5. Estimating the extent of asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.05.10.20097543v2)) \n",
    "DB (Hindi)": [
      "recewYnQ7bVNb0XYh"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recbxTgQOnxcYiQOU"
    ],
    "DB (Portuguese)": [
      "recMyu84MhG860uOu"
    ],
    "Rollup test 2": [
      "rec01y4eXjlfm1D1R"
    ],
    "Last modified manual": "2020-07-12",
    "Last edited (simplified)": "2020-07-12T03:54:25.000Z",
    "Last edited (experts say)": "2020-07-12T03:56:03.000Z",
    "Last modified": "2020-07-12",
    "What our experts say wordcount": 72,
    "Background and context wordcount": 83,
    "Other resources wordcount": 59,
    "Wordcount": 214,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "जो लोग कोविड-19 से संक्रमित हैं, लेकिन उनमें लक्षण नहीं पाए जाते हैं उन्हें \"स्पर्शोन्मुख\" माना जाता है। \nकोविड-19 से संक्रमित लोग जिनके लक्षण अभी तक विकसित नहीं हुए हैं, उन्हें \"पूर्व-लक्षणसूचक\" कहा जाता है। यहां तक कि जो लोग स्पर्शोन्मुख और पूर्व-लक्षण हैं, वे लक्षण प्रदर्शित नहीं करते हैं, वे अभी भी वायरस से संक्रमित हैं, और वायरस को बहाने की क्षमता रखते हैं। इसका मतलब है कि बिना लक्षणों के लोग अभी भी दूसरों को वायरस फैला सकते हैं, भले ही वे बीमार महसूस न करें।"
    ],
    "Hindi - Background and context": [
      "लक्षणों के बिना लोगों द्वारा संचरण के बारे में चिंता है क्योंकि यह रोग की रोकथाम को अधिक चुनौतीपूर्ण बनाता है। उदाहरण के लिए, जबकि यह एक उपयोगी सार्वजनिक स्वास्थ्य उपाय है कि लोग यह सलाह देते हैं कि बीमार होने पर लोग अलग-थलग पड़ जाते हैं, यह उपन्यास कोरोनावायरस के प्रसार को रोकने के लिए अपर्याप्त है जब कोई व्यक्ति जो कभी लक्षण विकसित नहीं करता है या जो अभी तक विकसित लक्षण नहीं हैं, वे अभी भी दूसरों को संक्रमित कर सकते हैं। हाल के कुछ प्रकाशनों में, यह अनुमान लगाया गया है कि कथित तौर पर उपन्यास कोरोनोवायरस संक्रमण के 6-41% स्पर्शोन्मुख और / या पूर्व-लक्षण प्रसारण के कारण हो सकते हैं।"
    ],
    "Portuguese - What our experts say": [
      "Pessoas que foram infectadas com COVID-19 mas não apresentam sintomas, são consideradas \"assintomáticas\". Pessoas infectadas com COVID-19 e que ainda não apresentaram nenhum sintoma são chamadas de \"pré-sintomáticas\". Mesmo que as pessoas assintomáticas e pré-sintomáticas não apresentem sintomas, elas estão infectadas com o vírus e podem transmitir o vírus. Isso significa que pessoas sem sintomas podem transmitir o vírus a outros indivíduos, mesmo que não se sintam doentes."
    ],
    "Portuguese - Background and context": [
      "Há uma grande preocupação com a transmissão por pessoas sem sintomas, porque isso torna a prevenção de doenças mais difícil. Por exemplo, ainda que recomendar que as pessoas se isolem quando estejam doentes seja uma medida útil de saúde pública, essa medida é insuficiente para interromper a propagação do novo coronavírus, já que alguém que nunca desenvolverá ou que ainda não desenvolveu sintomas pode infectar outras pessoas. Em algumas publicações recentes, estima-se que entre 6% e 41% das novas infecções por coronavírus registradas sejam devidas a transmissões por indivíduos assintomáticos e/ou pré-sintomáticos."
    ]
  },
  {
    "id": "recu8mvHonrGr57Z6",
    "Question": "Do digital thermometers kill neurons or damage the brain when a person's temperature is getting checked?",
    "Status": "Published",
    "Category": "Symptoms",
    "Subcategory": "On: COVID-19 & digital thermometers",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "There have been some questions about using digital thermometers as more people use them to check for fever (higher than normal body temperature), one of the symptoms of COVID-19. While checking body temperature can be part of evaluating whether someone may have COVID-19, it is important to note that checking for fever alone is not enough to determine whether someone has COVID-19 in part because there are many causes of fever. In addition, some people with COVID-19 may not have any symptoms of illness or may have symptoms other than fever. Digital thermometers can also be inaccurate or used incorrectly. Checking body temperature with a digital thermometer is not a substitute for COVID-19 testing.\n",
    "What our experts say": "Digital thermometers do not damage your brain in any way. Digital thermometers are universally used with children and adults and can come in a wide variety of forms including oral, rectal, temporal artery (forehead), tympanic (ear), and axillary (armpit) versions. These thermometers require a sensor, which typically produces either a voltage, current, or resistance change when there is a change of temperature. These are all widely used and safe. There is no evidence to suggest that neurons or brain cells can be damaged in the process. \n\nOlder thermometers were glass tubes with mercury inside them. The mercury expanded and contracted based on the temperature of the subject. Now, digital thermometers are far more common and easier to read than traditional mercury-based thermometers, and digital thermometers are considered safer than mercury-based thermometers because mercury is toxic, and there is a possibility for exposure if the glass tube containing the mercury were to break. \n",
    "Glossary Terms": [
      "recOcmLKbzV6NUkAH",
      "recKu4mUCSpc8htlJ",
      "recqLd1GRoBwTquBo"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "thermometer",
      "symptoms"
    ],
    "Other resources": "1. Thermometers: Understand the options Print ([Mayo Clinic](https://www.mayoclinic.org/diseases-conditions/fever/in-depth/thermometers/art-20046737))\n2. Screening Clients for COVID-19 at Homeless Shelters or Encampments ([U.S. CDC](http://Screening Clients for COVID-19 at Homeless Shelters or Encampments))\n",
    "DB (Hindi)": [
      "rec3AMklAnFnJjB4F"
    ],
    "Media": [
      {
        "id": "attIgqoIgmw7l7puR",
        "url": "https://dl.airtable.com/.attachments/00fcd3f244a51d54f6307b5dbdffc2f2/3c1c141e/Slide_1",
        "filename": "Slide_1",
        "size": 207753,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ca22bef6c988d4ec63e4237cb8f730c4/bed47a58",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d765e523785257d171612b983953f5a4/448fd9eb",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/aeafbd755571567b222feefb9ec955d8/6c1ae795",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att01EqNBxkuC8fNI",
        "url": "https://dl.airtable.com/.attachments/f0f88c401f41283a4cb6ead73739fa47/2221fd05/Slide_2",
        "filename": "Slide_2",
        "size": 169313,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/3d0c98958c1380f528fffeff770d7e20/b3ee4ebe",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d1a7449a56042a6fa8dc6244298b471e/46a89a5e",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/17e1fd436f71019705559e3c925382f6/c0d6c80a",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attj8yFO531oGii5F",
        "url": "https://dl.airtable.com/.attachments/c2e080aa6f80eddff92a1c4c3b98b72c/56be6340/Slide_3",
        "filename": "Slide_3",
        "size": 204557,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/387dbac9bbd329dc740411fe96b7bff7/6aac049a",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/87cc38f6b866da575099b48e945a3aa0/e3baa1e7",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/689b0bbfc8e00832fb467dae1daa4b8b/444586eb",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recvErOPhvXlgPdbJ"
    ],
    "DB (Portuguese)": [
      "rec6F2G3fp6hoxRbj"
    ],
    "Rollup test 2": [
      "reckdZKReWB23DhHn"
    ],
    "Media Package": [
      {
        "id": "attR7s9Ux1jd3HoOT",
        "url": "https://dl.airtable.com/.attachments/7e6d6d5eadac956813bb660293b4af06/b2a95755/Thermometers.zip",
        "filename": "Thermometers.zip",
        "size": 582363,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-07-10",
    "Last edited (simplified)": "2020-07-07T04:10:40.000Z",
    "Last edited (experts say)": "2020-07-10T18:54:23.000Z",
    "Last modified": "2020-07-10",
    "What our experts say wordcount": 153,
    "Background and context wordcount": 114,
    "Other resources wordcount": 19,
    "Wordcount": 286,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "डिजिटल थर्मामीटर आपके मस्तिष्क को किसी भी तरह से नुकसान नहीं पहुंचाते हैं। डिजिटल थर्मामीटर सार्वभौमिक रूप से बच्चों और वयस्कों के साथ उपयोग किया जाता है और यह मौखिक, रेक्टल, टेम्पोरल आर्टरी (माथे), टाइम्पेनिक (कान), और एक्सिलरी (बगल) संस्करणों सहित कई प्रकार के रूपों में आ सकता है। इन थर्मामीटरों को एक सेंसर की आवश्यकता होती है, जो आमतौर पर तापमान में बदलाव होने पर या तो वोल्टेज, करंट या प्रतिरोध बदल देता है। ये सभी व्यापक रूप से उपयोग और सुरक्षित हैं। यह सुझाव देने के लिए कोई सबूत नहीं है कि प्रक्रिया में न्यूरॉन्स या मस्तिष्क की कोशिकाओं को नुकसान हो सकता है।\n \nपुराने थर्मामीटर उनके अंदर पारा के साथ ग्लास ट्यूब थे। विषय के तापमान के आधार पर पारे का विस्तार और संकुचन होता है। अब, पारंपरिक पारा-आधारित थर्मामीटरों की तुलना में डिजिटल थर्मामीटर अधिक सामान्य और पढ़ने में आसान हैं, और डिजिटल थर्मामीटरों को पारा-आधारित थर्मामीटरों की तुलना में अधिक सुरक्षित माना जाता है, क्योंकि पारा विषाक्त है, और अगर पारा युक्त ग्लास ट्यूब को तोड़ना है तो एक्सपोज़र की संभावना है।"
    ],
    "Hindi - Background and context": [
      "डिजिटल थर्मामीटर का उपयोग करने के बारे में कुछ सवाल किए गए हैं क्योंकि अधिक लोग उन्हें बुखार (सामान्य शरीर के तापमान से अधिक), कोविड-19 के लक्षणों में से एक की जांच करने के लिए उपयोग करते हैं। शरीर के तापमान की जांच करते समय यह मूल्यांकन किया जा सकता है कि क्या किसी को कोविड-19 हो सकता है, यह ध्यान रखना महत्वपूर्ण है कि अकेले बुखार के लिए जाँच करना यह निर्धारित करने के लिए पर्याप्त नहीं है कि किसी के पास कोविड-19 है क्योंकि बुखार के कई कारण हैं। इसके अलावा, कोविड-19 वाले कुछ लोगों में बीमारी के कोई लक्षण नहीं हो सकते हैं या बुखार के अलावा अन्य लक्षण हो सकते हैं। डिजिटल थर्मामीटर गलत भी हो सकते हैं या गलत तरीके से उपयोग किए जा सकते हैं। डिजिटल थर्मामीटर के साथ शरीर के तापमान की जांच करना कोविड-19 परीक्षण का विकल्प नहीं है।"
    ]
  },
  {
    "id": "recxA4c1KoE4AtNMa",
    "Question": "What do we know so far about COVID-19 and alkalinity?",
    "Status": "Published",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "In chemistry, _alkaline_ is an adjective that is sometimes used to describe a subset of bases that dissolve in water. Alkalinity, however, is a different term used by oceanographers and hydrologists to describe the capacity of water to resist pH changes that would make it more acidic, in contrast to basicity which refers to a measurement on the pH scale above 7. When food is described as alkaline, this is often based on misconceptions about the impacts of eating food on the pH of the body. Fluids associated with various organs and tissues in the body have different typical pH levels; for example, the stomach operates at an acidic pH for digestion. Eating food does not have a significant impact on blood pH as this is regulated by the body to stay relatively neutral (pH of 7.35 to 7.45).\n\nOne popular social media post incorrectly applies a research study about another type of coronavirus called mouse hepatitis type 4 (MHV4), and also lists food items with pH values that are inaccurate. For example, lemons are falsely listed to have a pH of 9.9 (the true pH is closer to 2-2.6) and avocados with a pH of 15.6 (the true pH is likely 6.27-6.58). For reference, the pH scale only goes from 0 to 14, and food products are generally within a pH range of about 2 to 8. **It is important to note that eating more alkaline food does not change the risk of COVID-19 infection or treat COVID-19.**\n",
    "What our experts say": "Eating more acidic or alkaline foods is not related to an increased or decreased risk of COVID-19 infection. Widely circulated social media posts falsely suggest that the pH of COVID-19 ranges from 5.5 to 8.5. Often these posts advise readers to eat alkaline foods (specifically fruits and vegetables) with a pH of more than 8.5 to prevent COVID-19.  Viruses themselves do not have pH levels, because they are not water-based solutions. \n\nIn chemistry, pH (power of hydrogen, or potential for hydrogen) is a scale used for water-based solutions to indicate if they are acidic (pH below 7, with a lower pH indicating a stronger acid), neutral (pH around 7), or basic (pH above 7, with a higher indicating a stronger base). Since viruses are not water-based, the pH scale does not apply to the novel coronavirus SARS-CoV-2, the disease that causes COVID-19.\n\nWhile some illnesses or medications may cause blood pH levels to increase or decrease in our bodies, foods eaten as part of a regular diet do not have a significant impact on blood pH.  Saliva and urine pH may change in response to diet, but these changes are variable from person to person and** will not prevent or cure COVID-19.**\n\nThe posts in question seem to consistently refer to a 1991 paper in which another type of coronavirus, the coronavirus mouse hepatitis type 4 (MHV4), was studied in mouse or rat cells in a solution with a pH of 5.5 to 8.5.  Mice and rats are not the same as humans, and this study was not conducted in humans or on human cells. In addition, MHV4 is not the same as the SARS-Cov-2 virus that causes COVID-19, and this study was performed well before the SARS-Cov-2 was discovered in 2019.\n\nEating a well-balanced diet including a variety of fruits and vegetables can help support immune function which may help to prevent illness in general, but there is not enough evidence to suggest that a well-balanced diet would be effective in preventing or treating COVID-19.  \n",
    "Glossary Terms": [
      "recpN2xeifVcFx2Rq",
      "recsuaXRvGHmDOp4A",
      "recN0E4c0ZVOIyLJP",
      "recRBN7gJLeGv6er4"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention"
    ],
    "Other resources": "1. Approximate pH of Foods and Food Products, 2003 ([U.S. FDA Web Capture](https://webpal.org/SAFE/aaarecovery/2_food_storage/Processing/lacf-phs.htm))\n2. pH Values of Common Foods and Ingredients ([Clemson](https://www.clemson.edu/extension/food/food2market/documents/ph_of_common_foods.pdf))\n3. Complete Guide to Home Canning, Guide 1 Principles of Home Canning, 2015 ([USDA](https://nchfp.uga.edu/publications/usda/GUIDE01_HomeCan_rev0715.pdf))\n4. Alteration of the pH Dependence of Coronavirus-Induced Cell Fusion: Effect of mutations in the Spike Glycoprotein, 1991 ([Journal of Virology](https://jvi.asm.org/content/jvi/65/4/1916.full.pdf))\n",
    "DB (Hindi)": [
      "recmzqGqefxHUsds9"
    ],
    "Media": [
      {
        "id": "att6egsUEQxJa1qQm",
        "url": "https://dl.airtable.com/.attachments/a2318aa93a51cc2210463497c442593a/db188ca2/Slide_1",
        "filename": "Slide_1",
        "size": 112813,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/00d7f7e752487b3b2f42a7ec5e45f294/0864aa17",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/586244f2ac087ff365233c207c2083b6/fa606615",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/4348423cc99372fc70ff162bc4778450/eb5744a7",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attrEqrve9yRZIqON",
        "url": "https://dl.airtable.com/.attachments/13b2c2aed9f69ba43d8547b292b7d0cb/a3b114de/Slide_2",
        "filename": "Slide_2",
        "size": 263613,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/624e5c16f8704869d341729894dc1c58/f789d6ef",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/7b4bd0b7c78acd24c639905b360a354b/61273a37",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/9f9788f537e95ab31d9049251a6bc4cf/2c593b67",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attJpp4SVhA427aWO",
        "url": "https://dl.airtable.com/.attachments/b3d7196b5deb98870aca22c610a001b7/a8487234/Slide_3",
        "filename": "Slide_3",
        "size": 193749,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/164e90777daa3c8441bdb4974ff1125d/99e2e802",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/f342edf1c0a62d14de7c7aaf1a3950d1/14d75ef8",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/975325df3b048f497bfffac0ce49d0df/feb8aa22",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att80p3UZRP5Kq9Vz",
        "url": "https://dl.airtable.com/.attachments/9e363eb02c68bfa927c29ce3afd02a8c/d21207f2/Slide_4",
        "filename": "Slide_4",
        "size": 253338,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/50340d26f1d461c99ae013a27e4bec5b/3901b5ee",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/71c7c4de0b6a1287450a5a56983f25dc/8e0b98b4",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/85b5c1f2f572d6719eff12da48ef295c/b57f915e",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "rec7Ni8gc9gaNWtPu"
    ],
    "DB (Portuguese)": [
      "recIOT0ua3p6VE7P4"
    ],
    "Rollup test 2": [
      "recvYPTO3rlsFOfoi"
    ],
    "Media Package": [
      {
        "id": "attktKG71IQZas42a",
        "url": "https://dl.airtable.com/.attachments/b67c818acaa5b176b10366349dda6580/a2c60378/Alkalinity.zip",
        "filename": "Alkalinity.zip",
        "size": 824462,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-07-10",
    "Last edited (simplified)": "2020-07-01T18:12:13.000Z",
    "Last edited (experts say)": "2020-07-10T18:53:20.000Z",
    "Last modified": "2020-07-10",
    "What our experts say wordcount": 331,
    "Background and context wordcount": 247,
    "Other resources wordcount": 54,
    "Wordcount": 632,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "अधिक अम्लीय या क्षारीय खाद्य पदार्थ खाने से कोविड-19 संक्रमण के बढ़े हुए या कम जोखिम से संबंधित नहीं है। व्यापक रूप से परिचालित सोशल मीडिया पोस्ट फ़र्ज़ी तरीके से सुझाव देते हैं कि कोविड-19 का पीएच 5.5 से 8.5 तक है। अक्सर ये पोस्ट पाठकों को कोविड-19 को रोकने के लिए 8.5 से अधिक के पीएच के साथ क्षारीय खाद्य पदार्थ (विशेष रूप से फल और सब्जियां) खाने की सलाह देते हैं। वायरस स्वयं पीएच स्तर नहीं रखते हैं, क्योंकि वे पानी आधारित समाधान नहीं हैं।\n\nरसायन विज्ञान में, पीएच (हाइड्रोजन की शक्ति, या हाइड्रोजन के लिए क्षमता) पानी आधारित समाधानों के लिए इस्तेमाल किया जाने वाला एक पैमाना है जो यह बताता है कि क्या वे अम्लीय हैं (7 से नीचे पीएच, एक मजबूत पीएच का संकेत देता है), तटस्थ (7 के आसपास पीएच) , या मूल (7 से ऊपर पीएच, एक मजबूत आधार का संकेत उच्च के साथ)। चूंकि वायरस जल-आधारित नहीं हैं, इसलिए pH स्केल, उपन्यास कोरोनोवायरस SARS-CoV-2, कोविड-19 के कारण होने वाली बीमारी पर लागू नहीं होता है।\n\nजबकि कुछ बीमारियों या दवाओं से हमारे शरीर में रक्त पीएच स्तर में वृद्धि या कमी हो सकती है, एक नियमित आहार के हिस्से के रूप में खाए गए खाद्य पदार्थों का रक्त पीएच पर महत्वपूर्ण प्रभाव नहीं पड़ता है। आहार की प्रतिक्रिया में लार और मूत्र पीएच बदल सकता है, लेकिन ये परिवर्तन एक व्यक्ति से दूसरे व्यक्ति में परिवर्तनशील होते हैं और कोविड-19 को रोकेंगे या ठीक नहीं करेंगे।\n\nविचाराधीन पोस्ट 1991 के एक पेपर को लगातार संदर्भित करते हैं जिसमें एक अन्य प्रकार का कोरोनावायरस, कोरोनोवायरस माउस हेपेटाइटिस टाइप 4 (एमएचवी 4), 5.5 या 8.5 के पीएच के साथ समाधान में माउस या चूहा कोशिकाओं में अध्ययन किया गया था। चूहे और चूहे मनुष्य के समान नहीं हैं, और यह अध्ययन मनुष्यों में या मानव कोशिकाओं पर नहीं किया गया था। इसके अलावा, MHV4 SARS-Cov-2 वायरस के समान नहीं है जो कोविड-19 का कारण बनता है, और यह अध्ययन SARS-Cov-2 2019 में खोजे जाने से पहले अच्छा प्रदर्शन किया गया था।\n\nविभिन्न प्रकार के फलों और सब्जियों सहित एक अच्छी तरह से संतुलित आहार खाने से प्रतिरक्षा समारोह का समर्थन करने में मदद मिल सकती है जो सामान्य रूप से बीमारी को रोकने में मदद कर सकती है, लेकिन यह सुझाव देने के लिए पर्याप्त सबूत नहीं हैं कि एक अच्छी तरह से संतुलित आहार कोविड-19 को रोकने या इलाज में प्रभावी होगा।"
    ],
    "Hindi - Background and context": [
      "रसायन विज्ञान में, क्षारीय एक विशेषण है जो कभी-कभी पानी में घुलने वाले ठिकानों के सबसेट का वर्णन करने के लिए उपयोग किया जाता है। क्षारीयता, हालांकि, समुद्र विज्ञानियों और हाइड्रोलॉजिस्ट द्वारा उपयोग किया जाने वाला एक अलग शब्द है, जो पीएच परिवर्तनों का विरोध करने के लिए पानी की क्षमता का वर्णन करता है, जो इसे अधिक अम्लीय बना देगा, यह क्षारकता के विपरीत है जो 7 से ऊपर पीएच पैमाने पर माप को संदर्भित करता है जब भोजन का वर्णन किया जाता है। क्षारीय के रूप में, यह अक्सर शरीर के पीएच पर भोजन खाने के प्रभावों के बारे में गलत धारणाओं पर आधारित होता है। शरीर के विभिन्न अंगों और ऊतकों से जुड़े तरल पदार्थ के अलग-अलग विशिष्ट पीएच स्तर होते हैं; उदाहरण के लिए, पेट पाचन के लिए एक अम्लीय पीएच पर काम करता है। भोजन का पीएच पर महत्वपूर्ण प्रभाव नहीं होता है क्योंकि यह शरीर द्वारा अपेक्षाकृत तटस्थ (7.35 से 7.45 पीएच) रहने के लिए विनियमित होता है।\n\nएक लोकप्रिय सोशल मीडिया पोस्ट गलत तरीके से माउस हेपेटाइटिस टाइप 4 (एमएचवी 4) नामक एक अन्य प्रकार के कोरोनावायरस के बारे में एक शोध अध्ययन को लागू करता है, और पीएच मानों के साथ खाद्य पदार्थों को भी सूचीबद्ध करता है जो गलत हैं। उदाहरण के लिए, नींबू को गलत तरीके से 9.9 का पीएच (2 पीएच के करीब 2-2.6) और एवोकाडो 15.6 के पीएच के साथ सूचीबद्ध किया जाता है (सही पीएच की संभावना 6.27-6.58 है)। संदर्भ के लिए, पीएच स्केल केवल 0 से 14 तक जाता है, और खाद्य उत्पाद आम तौर पर लगभग 2 से 8 की पीएच सीमा के भीतर होते हैं। यह ध्यान रखना महत्वपूर्ण है कि अधिक क्षारीय भोजन खाने से कोविड-19 संक्रमण का जोखिम या कोविड-19 इलाज नहीं होता है।"
    ]
  },
  {
    "id": "recUpmaDPvAJXmrvJ",
    "Question": "Why are Brazil's cases surging right now?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & Brazil",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Despite the COVID-19 risk factor of older age being favorable for Brazil’s relatively younger population, Brazil has seen a surge in the number of cases. Initially, transmission of the virus was limited to the larger cities of São Paulo and Rio de Janeiro but now has moved inland into smaller cities. Thirteen million people in Brazil live in favelas, in close proximity to one another with lack of access to clean water. This makes the physical distancing and hygiene conditions necessary to prevent transmission of the virus very difficult. Smaller cities also have weaker health systems and fewer health care professionals to prevent the spread.\n\nThere has also been criticism of data suppression by the Brazilian government, and some opinions suggest that the actual cases could be seven times higher than the official figures.\n\nEasing of preventative measures like opening up of malls and beaches and crowding of people is another reason to see increases in the number of cases. The president of the country has criticized state governments that are making efforts to combat the pandemic. With a president who denies the pandemic as a ‘cold,’ the political turmoil at the center has led to two health minsters being fired or quitting, leaving no public health expert to advise the leadership.\n",
    "What our experts say": "Brazil has reported over 1.2 million cases and 54,000 deaths as of June 26, 2020. The recent surge in cases is mainly stemming from the country's densely populated regions, such as Sao Paolo and Rio de Janeiro. Studies estimate that 25% of the Brazilian population in Sao Paolo did not adequately adhere to quarantine guidelines, and the presence of densely packed low-income neighborhoods known as favelas has exacerbated the spread of the virus. In a new study, researchers conducted over 3,000 rapid tests in six of the city's most densely populated neighborhoods and found that infection rates were far higher than the official estimates: some studies had previously estimated that 9.5% of people in Sao Paolo were infected, but the most recent estimates from the largest favela in Sao Paola indicated almost 25% of people who were tested were positive. \n\nMedical experts attribute the surge in cases in major cities to relaxed quarantine and isolation measures. Major cities in the country have lifted lockdown measures, and reopened restaurants, shops and businesses. Another research study found that more than 75% of the confirmed cases are from the relatively densely populated southern and southeastern regions of Brazil, and the exponential growth in COVID-19 cases has stemmed from difficulties in effective social distancing. The study reports that many informal workers are continuing to work and information regarding minimum infection prevention and control measures, including hand washing and social distancing, has not been effectively communicated and followed.\n",
    "Glossary Terms": [
      "rec2UNEXbTkSCx30Q"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "Brazil",
      "transmission"
    ],
    "Other resources": "1. COVID-19 in Brazil ([Pulmonology](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183991/))\n2. Implications of social distancing in Brazil in the COVID-19 pandemic ([Infection Control & Hospital Epidemiology](https://pdfs.semanticscholar.org/9c44/c27760a65c19a3210349a621d5ffb158ae1c.pdf))\n3. Coronavirus panel ([Brazil's Ministry of Health](https://covid.saude.gov.br/))\n4. COVID-19 Infection Rate In Rio’s Favelas Far Exceeds Official Count, A New Study Says ([Rio Prefeitura](https://riocontraocorona.rio/noticias/prefeitura-divulga-resultado-da-primeira-etapa-de-pesquisa-sobre-covid-19-em-comunidades-cariocas/))\n5. Brazil Coronavirus Map and Case Count ([NYT](https://www.nytimes.com/interactive/2020/world/americas/brazil-coronavirus-cases.html))\n6. Modeling and forecasting the early evolution of the Covid-19 pandemic in Brazil ([arXiv](https://arxiv.org/abs/2003.14288))\n\n",
    "How often revision needed": "Weekly",
    "DB (Hindi)": [
      "recEPuhGiPWeqi2lR"
    ],
    "Media": [
      {
        "id": "att1zh7AsO8gkEd6o",
        "url": "https://dl.airtable.com/.attachments/6dfd90df127ca6059875101ed2795ac3/362811d1/Brazil_surge_Meedan_14.png",
        "filename": "Brazil_surge_(Meedan)_(14).png",
        "size": 135014,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/956168c66dbc011cc0d3fbcd78a33f1d/38456d7f",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/8d199750820663d40aa8448016fea3a4/c91cdb74",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/4a148d8c9604784e65139fbc644e705b/30c45170",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att9UNBQgDIekhXfu",
        "url": "https://dl.airtable.com/.attachments/f3e0cd632013ecafd845eba24404e41f/433008e2/Brazil_surge_Meedan_15.png",
        "filename": "Brazil_surge_(Meedan)_(15).png",
        "size": 213169,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/f2adbd63f7ad1d16698ca9864e5b9870/56c616a5",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ba1f6339a62203c6f34ea9926bc3bc7b/1c047cca",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/600101f0bc35a8e00dbb3ad729193719/2fbd486f",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attGKP6Dy4VDJa9E5",
        "url": "https://dl.airtable.com/.attachments/6f81d1e82e4851b41631d2fc58ee6aaa/734ffbb5/Brazil_surge_Meedan_16.png",
        "filename": "Brazil_surge_(Meedan)_(16).png",
        "size": 175395,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/6edef777c88d3859bbb397dae142af3b/c8dc5e18",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/173e0dda2a17a6b1f0ac4664e99ea0e7/9c4957e9",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e5dca20d2de8a99a6141861c44c282a3/617a3c12",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att4WKppAOrowmPmS",
        "url": "https://dl.airtable.com/.attachments/478cf3fb9a524303b53fed7cdc3c4823/481438f4/Brazil_surge_Meedan_17.png",
        "filename": "Brazil_surge_(Meedan)_(17).png",
        "size": 126319,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/787618f7b57555acdc64d4420fed83a4/8487f725",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/2a3c847c8f153fd479a68a289e552a73/e9174030",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ac627c9aee217dbcd7f21499096c45e0/e4b7630e",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "atticx6Q0SmqRV3Ai",
        "url": "https://dl.airtable.com/.attachments/6fab7cc1035c874e9535da1345cf8d34/e2818d69/Brazil_surge_Meedan_18.png",
        "filename": "Brazil_surge_(Meedan)_(18).png",
        "size": 232388,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/27153dc47bac09332444147f1b036d63/227084c8",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/4bd089c0219643fddc137cfeb7336fc4/d950ca59",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e42745feb53a30cd9fd6720a61cc4116/799258e1",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recLKPqriHWQ9k4Wc"
    ],
    "DB (Portuguese)": [
      "recmLqiFgB5Mh2IWM"
    ],
    "Rollup test 2": [
      "recD2x7tnpmpQXavs"
    ],
    "Media Package": [
      {
        "id": "attAuBOelNM4BPRMj",
        "url": "https://dl.airtable.com/.attachments/a050ef31b0ce167716f4d8ca10e7dc08/4d896537/Brazilsurgeincases.zip",
        "filename": "Brazil surge in cases.zip",
        "size": 884047,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-07-10",
    "Last edited (simplified)": "2020-07-03T13:01:17.000Z",
    "Last edited (experts say)": "2020-07-23T15:42:05.000Z",
    "Last modified": "2020-07-10",
    "What our experts say wordcount": 243,
    "Background and context wordcount": 210,
    "Other resources wordcount": 62,
    "Wordcount": 515,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "ब्राज़ील ने 26 जून, 2020 तक 1.2 मिलियन मामलों और 54,000 से अधिक मौतों की सूचना दी है। हाल ही में मामलों में वृद्धि मुख्य रूप से देश के घनी आबादी वाले क्षेत्रों जैसे कि साओ पाओलो और रियो डी जेनेरियो से हो रही है। अध्ययनों का अनुमान है कि साओ पाओलो में ब्राजील की आबादी का 25% पर्याप्त रूप से संगरोधी दिशा-निर्देशों का पालन नहीं करता है, और घने रूप से कम आय वाले पड़ोस की मौजूदगी जिसे फैवेलस के रूप में जाना जाता है, ने वायरस के प्रसार को बढ़ा दिया है। एक नए अध्ययन में, शोधकर्ताओं ने शहर के छह सबसे घनी आबादी वाले क्षेत्रों में 3,000 से अधिक तीव्र परीक्षण किए और पाया कि संक्रमण दर आधिकारिक अनुमानों से कहीं अधिक थी: कुछ अध्ययनों ने पहले अनुमान लगाया था कि साओ पाओलो में 9.5% लोग संक्रमित थे, लेकिन साओ पाओला में सबसे बड़े गरीबों की बस्ती से सबसे हालिया अनुमानों ने लगभग 25% लोगों को सूचित किया जो परीक्षण किए गए थे।\n\n \nचिकित्सा विशेषज्ञ प्रमुख शहरों में कम क्वारंटाइन और अलगाव उपायों के मामलों में वृद्धि का श्रेय देते हैं। देश के प्रमुख शहरों ने तालाबंदी के उपाय, और रेस्तरां, दुकानों और व्यवसायों को फिर से खोल दिया है। एक अन्य शोध अध्ययन में पाया गया कि 75% से अधिक पुष्ट मामले ब्राजील के अपेक्षाकृत घनी आबादी वाले दक्षिणी और दक्षिणपूर्वी क्षेत्रों के हैं, और कोविड-19 मामलों में घातीय वृद्धि प्रभावी सामाजिक दूरी में कठिनाइयों से उपजी है। अध्ययन की रिपोर्ट है कि कई अनौपचारिक श्रमिकों को काम करना जारी है और हाथ धोने और सामाजिक गड़बड़ी सहित न्यूनतम संक्रमण की रोकथाम और नियंत्रण उपायों के बारे में जानकारी प्रभावी ढंग से संचार और पालन नहीं की गई है।"
    ],
    "Hindi - Background and context": [
      "ब्राजील की अपेक्षाकृत कम आबादी के लिए वृद्धावस्था के कोविड-19 जोखिम कारक के बावजूद, ब्राजील ने मामलों की संख्या में वृद्धि देखी है। प्रारंभ में, वायरस का संचरण साओ पाउलो और रियो डी जनेरियो के बड़े शहरों तक सीमित था लेकिन अब अंतर्देशीय छोटे शहरों में चला गया है। ब्राजील में तेरह मिलियन लोग स्वच्छ पानी तक पहुंच की कमी के साथ एक दूसरे के करीब में, गरीब पड़ोस में रहते हैं। यह वायरस के संचरण को रोकने के लिए आवश्यक शारीरिक गड़बड़ी और स्वच्छता की स्थिति को बहुत मुश्किल बना देता है। छोटे शहरों में प्रसार को रोकने के लिए कमजोर स्वास्थ्य प्रणाली और कम स्वास्थ्य देखभाल व्यवसायी भी हैं।\n\n \nब्राजील सरकार द्वारा डेटा अवरोध की आलोचना भी की गई है, और कुछ राय बताती है कि वास्तविक मामले आधिकारिक आंकड़ों से सात गुना अधिक हो सकते हैं।\n\n \nमॉल और समुद्र तटों को खोलने और लोगों की भीड़ को रोकने जैसे निवारक उपायों को आसान बनाना मामलों की संख्या में वृद्धि को देखने का एक और कारण है। देश के राष्ट्रपति ने राज्य सरकारों की आलोचना की है जो महामारी से निपटने के लिए प्रयास कर रहे हैं। ऐसे राष्ट्रपति के साथ, जो महामारी को 'ठंड' के रूप में नकारता है, केंद्र में राजनीतिक उथल-पुथल के कारण दो स्वास्थ्य खनिकों को निकाल दिया गया है या छोड़ दिया गया है, नेतृत्व को सलाह देने के लिए कोई सार्वजनिक स्वास्थ्य विशेषज्ञ नहीं है।"
    ]
  },
  {
    "id": "recSPXr3HPZ8WQcyO",
    "Question": "What do we know so far about dexamethasone as a potential treatment for COVID-19?",
    "Status": "Published",
    "Category": "Treatment",
    "Subcategory": "On: COVID-19 and dexamethasone",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Dexamethasone has recently been in the news due to its alleged early success in the RECOVERY (Randomised Evaluation of Covid-19 Therapy) trial, led by a team from Oxford University in the UK. This study is the world's largest and was launched in March to test six potential COVID-19 treatments - five pre-existing medications and convalescent plasma from recovered COVID-19 patients - to determine whether or not they can help treat cases of COVID-19. Though this study has received significant media attention since the search for any potential treatments is urgent, no study has been published by the RECOVERY team as of yet and no other countries have approved dexamethasone for severe cases of COVID-19. \n\n\n\n",
    "What our experts say": "Dexamethasone is a low-cost, anti-inflammatory medication that is part of the corticosteroid family. Corticosteroids function similarly to the cortisol produced in the body's adrenal glands yet they are synthetically made. Corticosteroids are commonly prescribed to suppress the immune system and reduce swelling and itching common to allergic reactions. \nDexamethasone has been widely used since the 1960s, but it has recently been part of several studies exploring potential therapies for COVID-19. In the RECOVERY (Randomised Evaluation of Covid-19 Therapy) Trial at Oxford University (UK), the largest COVID-19 drug trial to date, researchers studied the impact of dexamethasone by comparing the roughly 2,000 patients who received the medication with the 4,000 patients who did not receive the medication. They found that the mortality risk was lowered for patients with severe cases of COVID-19 who were on ventilators or receiving oxygen. For patients with mild cases of COVID-19, beneficial effects were not observed. \nDexamethasone has not been approved as an official treatment for COVID-19 outside the United Kingdom thus far, and the World Health Organization (WHO) has urged caution since these results are preliminary, have yet to be evaluated through the peer-review process, and represent findings from only one trial. Despite this, the medication is currently being used in several countries as a part of various treatment strategies for COVID-19. The WHO has also recently added dexamethasone and other steroids into its treatment guidelines for COVID-19.\nIn two other recent studies using corticosteroidal medications (including dexamethasone) as potential treatments for COVID-19, one found a reduction in the number of days patients required ventilator support, and the other found that the corticosteroid medications were associated with an increased duration of illness (among other adverse impacts). Corticosteroids, including dexamethasone, are still an unproven treatment for COVID-19.\n",
    "Glossary Terms": [
      "rec5W6RYzptKevaPE"
    ],
    "Variation of the answer depending on country of residence": "Yes\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "treatment",
      "United Kingdom",
      "corticosteroid"
    ],
    "Other resources": "1. Dexamethasone (Oral Route) ([Mayo Clinic](https://www.mayoclinic.org/drugs-supplements/dexamethasone-oral-route/description/drg-20075207)) \n2. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 ([Oxford/RECOVERY](https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19)) \n3. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report ([NEJM/RECOVERY](https://www.nejm.org/doi/full/10.1056/NEJMoa2021436))\n4. WHO urges caution on 'breakthrough' coronavirus drug dexamethasone, citing early data ([CNBC](https://www.cnbc.com/2020/06/17/coronavirus-update-who-urges-caution-on-dexamethasone-citing-early-data.html)) \n5. U.K. approves use of life-saving coronavirus drug dexamethasone in ‘biggest breakthrough yet’ — it costs £5 per patient ([MarketWatch](https://www.marketwatch.com/story/uk-approves-use-of-life-saving-coronavirus-drug-dexamethasone-in-biggest-breakthrough-yet-2020-06-16)) \n6. This national clinical trial aims to identify treatments that may be beneficial for people hospitalised with suspected or confirmed COVID-19 ([Oxford/RECOVERY](https://www.recoverytrial.net)) \n7. Coronavirus: Dexamethasone proves first life-saving drug ([BBC](https://www.bbc.com/news/health-53061281)) \n8. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis ([Nature](https://www.nature.com/articles/s41375-020-0848-3)) \n9. Dexamethasone Treatment for the Acute Respiratory Distress Syndrome: A Multicentre, Randomised Controlled Trial ([The Lancet](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(19)30417-5/fulltext)) \n10. Q&A: Dexamethasone and COVID-19 ([WHO](https://www.who.int/news-room/q-a-detail/q-a-dexamethasone-and-covid-19)) \n11. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2021436?query=RP)) \n",
    "How often revision needed": "Weekly",
    "Impact on public policy?": "Potentially; first approved treatment in UK",
    "DB (Hindi)": [
      "recp8Hn2n3YuBwhjt"
    ],
    "Media": [
      {
        "id": "attYbdxViKV19YFeg",
        "url": "https://dl.airtable.com/.attachments/50df63e6f14a3e3db93c09521433c9f4/48aafda1/Dexamethasone_v1_Meedan_8.png",
        "filename": "Dexamethasone_v1_(Meedan)_(8).png",
        "size": 136465,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/031b9ebd9b6e5573d6e8e3dc874ea683/cc228ef7",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/3dba844be297366602b867ffa159f0fe/140a21f9",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/a8ccecf267059ac01451e873635368aa/1b85a8e2",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attnLKfhKuZugz1XJ",
        "url": "https://dl.airtable.com/.attachments/0f89485d695d7bb701ca95eb3d3b4217/ca6bf643/Dexamethasone_v1_Meedan_9.png",
        "filename": "Dexamethasone_v1_(Meedan)_(9).png",
        "size": 180804,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b06f731f1ac065d8bb49c25cb6b0e742/446f9b6e",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/1ad703cc8b6857bfcc10729e0baaecb4/9d4d4e8e",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/798e81a999faf8afdcbba3bac1253d54/3045cdd1",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attCjbA1rb9P5EUKE",
        "url": "https://dl.airtable.com/.attachments/aa7ae0b98c95850e35ac2db58c77b13b/451dc99d/Dexamethasone_v1_Meedan_10.png",
        "filename": "Dexamethasone_v1_(Meedan)_(10).png",
        "size": 206849,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/8b7ee9b3270ba7f06541ddc3aea8c7df/b3dc9b9c",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/4f866c7ffc2a4b1aaac49c333c0e638c/6e521f56",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/db971c2c3fbbe5c4bed90f35c6bc4bce/43cd75ba",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att5NmUAHxkZ5LcnD",
        "url": "https://dl.airtable.com/.attachments/d9355c744df9118a21f8fee7f6ebf9d1/887213f6/Dexamethasone_v1_Meedan_11.png",
        "filename": "Dexamethasone_v1_(Meedan)_(11).png",
        "size": 225980,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/e894aa691cb07e0319bcc578c09a8a1d/b5f42d97",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/f939bd7ee74dea12e4be64a40ed9583c/2fe685bb",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c404b2e9cd7c0c5d5ce83486d2506f8c/8aaa15d6",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recqCtOCf3nl5diSj"
    ],
    "DB (Portuguese)": [
      "rec1D4GQdXwhdVWST"
    ],
    "Rollup test 2": [
      "recP7YIKdJYyON3RT"
    ],
    "Media Package": [
      {
        "id": "attdEVDNDlKqHjrJk",
        "url": "https://dl.airtable.com/.attachments/0f50950c86ab4038819ad4b613359f98/61b2b000/Dexamethasone.zip",
        "filename": "Dexamethasone.zip",
        "size": 751445,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-07-10",
    "Last edited (simplified)": "2020-06-25T02:15:36.000Z",
    "Last edited (experts say)": "2020-07-20T17:19:58.000Z",
    "Last modified": "2020-07-10",
    "What our experts say wordcount": 290,
    "Background and context wordcount": 115,
    "Other resources wordcount": 154,
    "Wordcount": 559,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "डेक्समेथसोन एक कम पैसों वाली प्रज्वलनरोधी (ऐंटाई -इन्फ़्लैमटॉरी) दावा है जो एक तरह का कोर्टिकोस्टेरॉइड (corticosteroids) है। कोर्टिकोस्टेरॉइड शरीर के अधिवृक्क ग्रंथियों  (अड्रीनल ग्लैंड्ज़) में उत्पादित कोर्टिसोल के समान कार्य करते हैं, लेकिन से आर्टिफ़िशल रूप से बनाए जाते हैं। कॉर्टिकोस्टेरॉइड आमतौर पर इम्यून सिस्टम को दबाने और ऐलर्जी से हुए सूजन और खुजली को कम करने के लिए दिए जाते हैं।\n1960 के बाद से डेक्सामेथासोन का व्यापक रूप से उपयोग किया गया है, लेकिन यह हाल ही में कोविड-19 के लिए संभावित उपचारों की खोज करने वाले कई अध्ययनों का हिस्सा रहा है। ऑक्सफ़ोर्ड यूनिवर्सिटी (यूके) में RECOVERY (रैंडमाइज़्ड इवैलुएशन ऑफ़ कोविद -19 थेरेपी) ट्रायल, जोकी अब तक का सबसे बड़ा COVID-19 ड्रग ट्रायल है, उसमें शोधकर्ताओं ने डेक्सामेथासोन के प्रभाव का अध्ययन किया और लगभग 2,000 दवा प्राप्त करने वाले रोगियों की तुलना 4,000 रोगियों के साथ की जिन्हें यह दवाई नहीं दी  गयी। उन्होंने पाया की गम्भीर मामलों वाले केसेज़, जो वेंटिलेटेर पर थे या जिन्हें ऑक्सिजन चढ़ाया जा रहा था, उनमे मृत्यु की संख्या कम हो गयी। कोविड-19 के हल्के मामलों में यह उपचार उपयोगी नहीं पाया गया।\nयूनाइटेड किंडम (यूके)के बाहर यह उपचार अधिकारिक रूप से पारित नहीं किया गया है।डबल्यू॰एच॰ओ॰ ने सावधानी बरतने को कहा है क्योंकि ये परिणाम प्रारम्भिक हैं, इनकी सहकर्मी-समीक्षा नहीं की गयी है और ये केवल एक परीक्षण पर निर्धारित हैं। इसके बावजूद, वर्तमान में कोविड-19 के लिए कई देशों में अन्य दवाओं के साथ इस दवा का भी उपयोग किया जा रहा है।डबल्यू॰एच॰ओ॰ ने हाल ही में कोविड-19 के लिए अपने उपचार दिशानिर्देशों में डेक्सामेथासोन और अन्य स्टेरॉयड को भी जोड़ा है।\nदो अन्य हालिया अध्ययनों में, कोविड-19 के संभावित उपचार के रूप में कॉर्टिकोस्टेरॉइडल दवाओं (डेक्सामेथासोन सहित) के उपयोग की जाँच की गयी है।एक में पाया गया कि इस दवा के कारण रोगियों को वेंटिलेटेर पर कम दिनों तक रहना पड़ता है। दूसरे में पाया गया की इस दवा के सेवन से बीमारी की अवधि और बढ़ जाती है (अन्य और प्रतिकूल प्रभावों के अलावा)। कॉक्सिकोस्टेरॉइड, डेक्सामेथासोन सहित, अभी भी कोविड-19 के लिए एक अप्रमाणित उपचार है।"
    ],
    "Hindi - Background and context": [
      "डेक्सामेथासोन हाल ही में ब्रिटेन में ऑक्सफोर्ड विश्वविद्यालय की एक टीम के नेतृत्व में RECOVERY (रैंडम इवैल्यूएशन ऑफ कोविद -19 थेरेपी) परीक्षण में अपनी कथित शुरुआती सफलता के कारण चर्चा में है। यह अध्ययन दुनिया का सबसे बड़ा है और मार्च में लॉन्च किया गया था ताकि छह संभावित कोविड-19 उपचारों का परीक्षण किया जा सके। इनमे से पांच दवाएं, जो पहले से उपलब्ध हैं, और एक, जो कोविड-19 के रोगियों से प्राप्त कॉन्वलेसेंट प्लाज्मा - यह निर्धारित करने के लिए कि वे कोविड-19 के मामलों के उपचार में मदद कर सकते हैं या नहीं। यद्यपि इस अध्ययन पर मीडिया ने काफ़ी ध्यान आकर्षित किया है, क्योंकि किसी भी संभावित उपचार की खोज अत्यावश्यक है, RECOVERY टीम द्वारा अभी तक कोई अध्ययन प्रकाशित नहीं किया गया है और किसी अन्य देश ने कोविड-19 के गंभीर मामलों के लिए भी डेक्सामेथासोन को मंजूरी नहीं दी है।"
    ],
    "Bengali - What our experts say": [
      "ডেক্সামেথেসোন হ'ল কম দামের, প্রদাহনাশক ওষুধ যা কর্টিকোস্টেরয়েড পরিবারের অংশ। কর্টিকোস্টেরয়েডগুলি দেহের অ্যাড্রিনাল গ্রন্থিতে উৎপাদিত কর্টিসলগুলির মতো একইভাবে কাজ করে তবে তারা সিনথেটিকভাবে তৈরি হয়। কর্টিকোস্টেরয়েডগুলি সাধারণত ইমিউন সিস্টেমকে দমন করতে এবং অ্যালার্জির প্রতিক্রিয়ায় সাধারণ ফোলা এবং চুলকানি কমাতে পরামর্শ দেওয়া হয়।\nডেক্সামেথেসোন ১৯৬০ এর দশক থেকে ব্যাপকভাবে ব্যবহৃত হয়ে আসছে তবে এটি সম্প্রতি কোভিড-১৯ এর সম্ভাব্য চিকিৎসা অন্বেষণকারী কয়েকটি গবেষণার অংশ হয়েছে। অক্সফোর্ড বিশ্ববিদ্যালয় (যুক্তরাজ্য) এর এযাবৎ কালের বৃহত্তম কোভিড-১৯ ওষুধ পরীক্ষার রিকোভারি (র্যান্ডমাইজড ইভালুয়েশন অফ কোভিড -১৯ থেরাপি) ট্রায়াল-এ গবেষণায় গবেষকরা ৪,০০০ রোগীর যারা ওষুধ গ্রহণ করেনি তাদের সাথে ওষুধ প্রাপ্ত প্রায় ২,০০০ রোগীর তুলনা করে ডেক্সামেথেসোনের প্রভাব নিয়ে গবেষণা করেছেন। তারা দেখতে পেলেন যে কোভিড-১৯-এর গুরুতর ক্ষেত্রে যারা ভেন্টিলেটরে ছিলেন বা অক্সিজেন গ্রহণ করছিলেন তাদের ক্ষেত্রে মৃত্যুর ঝুঁকি হ্রাস করেছিল। কোভিড-১৯ এর হালকা ঘটার রোগীদের ক্ষেত্রে উপকারী প্রভাব লক্ষ্য করা যায় নি।\nডেক্সামেথাসোনকে এখন পর্যন্ত যুক্তরাজ্যের বাইরে কোভিড -১৯ এর আনুষ্ঠানিক চিকিৎসা হিসাবে অনুমোদিত করা হয়নি এবং বিশ্ব স্বাস্থ্য সংস্থা (ডাব্লুএইচও) এই ফলাফলগুলি প্রাথমিক হওয়ার কারণে সতর্কতার প্রতি আহ্বান জানিয়েছে, পিয়ার-রিভিউ প্রক্রিয়াটির মাধ্যমে এখনও মূল্যায়ন করা হয়নি, এবং শুধুমাত্র একটি পরীক্ষার ফলাফল উপস্থাপন। তবুও, ওষুধটি বর্তমানে কোভিড -১৯-এর বিভিন্ন চিকিৎসার কৌশলগুলির অংশ হিসাবে বেশ কয়েকটি দেশে ব্যবহৃত হচ্ছে। ডাব্লুএইচওও সম্প্রতি কোভিড -১৯ এর চিকিৎসার নির্দেশিকায় ডেক্সামেথেসোন এবং অন্যান্য স্টেরয়েড যুক্ত করেছে।\nকর্টিকোস্টেরয়েডাল ওষুধগুলি (ডেক্সামেথেসোন সহ) কোভিড -১৯ এর সম্ভাব্য চিকিৎসা হিসাবে ব্যবহার করে অন্য দুটি সাম্প্রতিক গবেষণায়, একজন রোগীর ভেন্টিলেটর সহায়তার জন্য প্রয়োজনীয় দিনের সংখ্যা হ্রাস পেয়েছে এবং অন্যটি জানতে পেরেছিল যে, কর্টিকোস্টেরয়েড ওষধগুলি অসুস্থতার বর্ধিত সময়ের সাথে যুক্ত ছিল (অন্যান্য প্রতিকূল প্রভাবগুলির মধ্যে)। ডেক্সামেথেসোন সহ কর্টিকোস্টেরয়েডগুলি এখনও কোভিড-১৯ এর অপ্রমাণিত চিকিৎসা।"
    ],
    "Bengali - Background and context": [
      "ডেক্সামেথাসোন সম্প্রতি যুক্তরাজ্যের অক্সফোর্ড ইউনিভার্সিটির একটি দলের নেতৃত্বাধীন রিকভারি (র‌্যান্ডমাইজড ইভ্যালুয়েশন অফ কোভিড -১৯ থেরাপি) পরীক্ষায় প্রাথমিক সাফল্যের কারণে সম্প্রতি আলোচনায় এসেছেন। এই গবেষণাটি বিশ্বের বৃহত্তম এবং মার্চ মাসে ছয়টি সম্ভাব্য কোভিড-১৯ চিকিৎসা পরীক্ষা করার জন্য চালু করা হয়েছিল - পাঁচটি প্রাক-বিদ্যমান ওষুধ এবং সেরে ওঠা কোভিড-১৯ রোগীদের কাছ থেকে সংশ্লেষক প্লাজমা - তারা কোভিড-১৯-এর ক্ষেত্রে চিকিৎসা করতে সহায়তা করতে পারে কি না তা নির্ধারণ করার জন্য। যদিও এই অধ্যয়নটি কোনও সম্ভাব্য চিকিৎসার অনুসন্ধান জরুরি হওয়ার কারণে মিডিয়াড় উল্লেখযোগ্য মনোযোগ পেয়েছে তবে এখনও রিকভারি টিম দ্বারা কোনও গবেষণা প্রকাশ করা হয়নি এবং অন্য কোনও দেশ কোভিড-১৯-এর গুরুতর ঘটনার জন্য ডেক্সামেথেসোনকে অনুমোদন দেয়নি।"
    ]
  },
  {
    "id": "rec4vIYYUif72tS5C",
    "Question": "Why are scientists warning about an increase in zoonotic diseases impacting humans?",
    "Status": "Published",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Zoonotic diseases, like the virus SARS-CoV-2 that causes COVID-19 and Ebola virus disease, have shown a propensity for not only spilling over from animal reservoirs into humans, but sustained human to human transmission. These factors are influenced by several variables, such as climate change, human development and encroachment on natural environments. As a result, more focus as been placed on One Health, which underscores the relationship between human, animal, and environmental health. \n",
    "What our experts say": "Zoonotic diseases are infectious diseases that can spread from animals to humans. \"Spillover events\" (when a disease jumps from an animal to a human) have been known to cause outbreaks, like ebola virus disease. Since some infectious diseases can live within an animal without causing any illness to it, certain interactions with an infected animal can result in transmission to humans. \nRoughly 6 out of 10 known infectious diseases in people are zoonotic. Of all the emerging infectious diseases (a disease that has newly appeared in a population or has increased incidence in recent years), 3 out of 4 come from animals. Scientists are increasingly worried about zoonotic diseases as they are growing in frequency. In some cases which animal transferred infection to humans is unknown, like SARS-CoV-2, the virus that causes COVID-19. As humans expand in the environment through globalization and infringement on undeveloped natural environments, like forests or jungles, the risk for exposure to zoonotic disease increases. Similarly, factors such as the exotic animal trade, the impacts of climate change, and the expansion of animal markets can cause zoonotic diseases to spread more rapidly and widely.\n\n",
    "Glossary Terms": [
      "rece5ZCMacYxbgECP"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "contagion",
      "infection",
      "prevention"
    ],
    "Other resources": "1. 8 Zoonotic Diseases Shared Between Animals and People of Most Concern in the U.S. ([U.S. CDC](https://www.cdc.gov/media/releases/2019/s0506-zoonotic-diseases-shared.html)) \n2. Zoonotic disease: emerging public health threats in the Region ([WHO](http://www.emro.who.int/about-who/rc61/zoonotic-diseases.html)) \n\n",
    "DB (French)": [
      "recRCWt4HbmgWqP2h"
    ],
    "DB (Hindi)": [
      "rec8K7WMOUHrc6dvt"
    ],
    "Media": [
      {
        "id": "attbVcH4KJFOeSU2v",
        "url": "https://dl.airtable.com/.attachments/f692796c2e8e321242712f56bd7f260c/c4ac8760/Slide_1",
        "filename": "Slide_1",
        "size": 307755,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/f9f02baf949f3f4ab341e48d2618d90a/37178816",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ad07930621b5316a59b6184023690988/50753e56",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/75ef7a4c94013b4b3f7479b39ab39d83/23e73fbd",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attq6Rr5W6uva9kdF",
        "url": "https://dl.airtable.com/.attachments/9d7b3f58d18fdfd5adbb2dbe9f2e4f87/8657f622/Slide_2",
        "filename": "Slide_2",
        "size": 213108,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/3c3ef77b33cdd1345d1f4dae5cb84921/3e50c669",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/750ceaa92fb26033ba0a2cf5df1d1f70/95f4b560",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/f0ccf04af23cf07ea7bc0f1a402f685a/87a0fc6b",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attLPithBa75OS67E",
        "url": "https://dl.airtable.com/.attachments/8c877711cbce0ffe60f4b0683fbda997/c914d4c4/Slide_3",
        "filename": "Slide_3",
        "size": 219447,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/1e5e9855a296736e6d9fbd17374444d3/1aa3591e",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/5df6bb680824449e2dc0ffcf489749a3/2759041a",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/dd13640e37867871ebaaacdb4ba24d27/ccac6274",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attybCxJan6TvZxVH",
        "url": "https://dl.airtable.com/.attachments/c59a24803a0ca63731ee2dbf13cfb278/abecaf85/Slide_4",
        "filename": "Slide_4",
        "size": 211193,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ef7f4a1895c2c9f4eb46fb2b496c0a8d/a23517c6",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/5e4ab77b779c0903546c3d1e28f6132f/b063c182",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c55adede91e33f71a8ff51f3013a4bca/7b1c4b84",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recPYRE1Jr3zrqfO1"
    ],
    "DB (Spanish)": [
      "rec8kkyPgmk0fBMID"
    ],
    "DB (Bengali)": [
      "recQXH7LTPvvis8PE"
    ],
    "DB (Portuguese)": [
      "recrYiZZRJErqaMPe"
    ],
    "Rollup test 2": [
      "recP7B1epG1T7yChO"
    ],
    "Media Package": [
      {
        "id": "att1irRsh8KxsMIed",
        "url": "https://dl.airtable.com/.attachments/894accc67d4b6e5647f1e76ed7f85930/f99f7321/IncreaseinZoonoticdiseases.zip",
        "filename": "Increase in Zoonotic diseases.zip",
        "size": 952792,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-07-10",
    "Last edited (simplified)": "2020-06-19T00:16:48.000Z",
    "Last edited (experts say)": "2020-07-10T18:48:28.000Z",
    "Last modified": "2020-07-10",
    "What our experts say wordcount": 188,
    "Background and context wordcount": 73,
    "Other resources wordcount": 29,
    "Wordcount": 290,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Les maladies zoonotiques sont des maladies infectieuses qui peuvent se propager des animaux aux êtres humains. Les transmissions interespèces (quand une maladie saute de l’animal à l’être humain) sont une cause reconnue d’éclosions, telles que la maladie à virus Ebola. Dans la mesure où certaines maladies infectieuses peuvent vivre dans un animal sans le rendre malade, certaines interactions avec un animal infecté peuvent transmettre ces maladies aux humains.\nEnviron six sur dix maladies infectieuses connues chez l’humain sont zoonotiques. De toutes les maladies infectieuses émergentes (des maladies qui viennent d’apparaître dans une population ou dont l’incidence a augmenté au cours des dernières années), trois sur quatre proviennent des animaux. La fréquence croissante des maladies zoonotiques inquiète de plus en plus les scientifiques. Dans certains cas, nous ne savons pas quel animal a transmis l’infection aux humains, comme pour le SARS-CoV-2, le virus responsable de la COVID-19. Alors que les êtres humains prennent de plus en plus de place dans l’environnement en raison de la mondialisation, mais aussi en transgressant les environnements naturels sous-développés tels que les forêts et les jungles, les risques d’exposition aux maladies zoonotiques augmentent. De la même façon, les facteurs tels que le commerce des animaux exotiques, les conséquences des changements climatiques et la croissance les marchés d’animaux peuvent entraîner une propagation plus rapide et plus étendue des maladies zoonotiques."
    ],
    "French - Background and context": [
      "Les maladies zoonotiques telles que la COVID-19, qui est causée par le virus SARS-CoV-2, et la maladie à virus Ebola ont démontré une propension non seulement à déborder de réservoirs animaux vers l’humain, mais une transmission continue de personne à personne. Ces facteurs sont influencés par diverses variables telles que les changements climatiques, le développement humain et l’empiétement sur les environnements naturels. Par conséquent, l’accent a été mis sur une seule santé qui souligne la relation entre la santé des humains, des animaux et de l’environnement."
    ],
    "Hindi - What our experts say": [
      "प्राणीजन्य रोग संक्रामक रोग हैं जो जानवरों से मनुष्यों में फैल सकते हैं। \"स्पिलओवर इवेंट्स\" (जब कोई बीमारी किसी जानवर से इंसान तक जाती है) को ईबोला वायरस की बीमारी जैसे प्रकोप का कारण माना जाता है। जबसे कुछ संक्रामक रोग किसी बीमारी के कारण किसी जानवर के भीतर रह सकते हैं, संक्रमित जानवर के साथ कुछ खास बातचीत इंसानों तक पहुँच सकती है।\nमोटे तौर पर लोगों में 10 ज्ञात संक्रामक रोगों में से 6 जूनोटिक हैं। सभी उभरते संक्रामक रोगों में से (एक ऐसी बीमारी जो हाल के वर्षों में दिखाई दी है या हाल के वर्षों में वृद्धि हुई है), 4 में से 3 जानवरों से आते हैं। वैज्ञानिक तेजी से बढ़ती जा रही बीमारियों के बारे में चिंतित हैं। कुछ मामलों में जो जानवर मनुष्यों को संक्रमण हस्तांतरित करते हैं, वह अज्ञात है, जैसे SARS-CoV-2, वायरस जो कोविड​​-19 का कारण बनता है। जैसे-जैसे मनुष्य वैश्वीकरण के माध्यम से पर्यावरण में विस्तार करते हैं और अविकसित प्राकृतिक वातावरण, जैसे जंगलों या जंगलों पर उल्लंघन करते हैं, प्राणीजन्य रोग के संपर्क में आने का जोखिम बढ़ता है। इसी तरह, विदेशी पशु व्यापार जैसे कारक, जलवायु परिवर्तन के प्रभाव और पशु बाजारों के विस्तार से प्राणीजन्य रोग अधिक तेजी से और व्यापक रूप से फैल सकते हैं।"
    ],
    "Hindi - Background and context": [
      "कोविड​​-19 और इबोला वायरस रोग का कारण बनने वाले वायरस 2 जैसे ज़ूनोटिक रोगों ने न केवल जानवरों के जलाशयों से मनुष्यों में फैलने के लिए एक प्रवृत्ति दिखाई है, बल्कि मानव को मानव संचरण तक बनाए रखा है। ये कारक कई चर से प्रभावित होते हैं, जैसे कि जलवायु परिवर्तन, मानव विकास और प्राकृतिक वातावरण पर अतिक्रमण। परिणामस्वरूप, एक स्वास्थ्य पर अधिक ध्यान केंद्रित किया गया, जो मानव, पशु और पर्यावरणीय स्वास्थ्य के बीच संबंधों को रेखांकित करता है।\n"
    ],
    "Telugu - What our experts say": [
      "జూనోటిక్ వ్యాధులు అంటు వ్యాధులు, ఇవి జంతువుల నుండి మానవులకు వ్యాపిస్తాయి. \"స్పిల్‌ఓవర్ సంఘటనలు\" (ఒక వ్యాధి జంతువు నుండి మానవునికి దూకినప్పుడు) ఎబోలా వైరస్ వ్యాధి వంటి వ్యాప్తికి కారణమవుతుందని తెలిసింది. కొన్ని అంటు వ్యాధులు జంతువుకు ఎటువంటి అనారోగ్యం కలిగించకుండా జీవించగలవు కాబట్టి, సోకిన జంతువుతో కొన్ని పరస్పర చర్యలు మానవులకు సంక్రమిస్తాయి. ప్రజలలో తెలిసిన 10 అంటు వ్యాధులలో 6 జూనోటిక్. అభివృద్ధి చెందుతున్న అన్ని అంటు వ్యాధులలో (జనాభాలో కొత్తగా కనిపించిన లేదా ఇటీవలి సంవత్సరాలలో పెరిగిన వ్యాధి), 4 లో 3 జంతువుల నుండి వచ్చాయి. శాస్త్రవేత్తలు ఫ్రీక్వెన్సీలో పెరుగుతున్నందున జూనోటిక్ వ్యాధుల గురించి ఎక్కువగా ఆందోళన చెందుతున్నారు. కొన్ని సందర్భాల్లో, జంతువులకు మానవులకు సంక్రమణ బదిలీ అంటువ్యాధి తెలియదు, SARS-CoV-2, కోవిడ్-19 కి కారణమయ్యే వైరస్. ప్రపంచీకరణ మరియు అడవులు లేదా అరణ్యాలు వంటి అభివృద్ధి చెందని సహజ వాతావరణాలపై ఉల్లంఘన ద్వారా మానవులు పర్యావరణంలో విస్తరిస్తున్నప్పుడు, జూనోటిక్ వ్యాధికి గురయ్యే ప్రమాదం పెరుగుతుంది. అదేవిధంగా, అన్యదేశ జంతు వ్యాపారం, వాతావరణ మార్పుల ప్రభావాలు మరియు జంతు మార్కెట్ల విస్తరణ వంటి అంశాలు జూనోటిక్ వ్యాధులు మరింత వేగంగా మరియు విస్తృతంగా వ్యాప్తి చెందుతాయి."
    ],
    "Telugu - Context and background": [
      "కోవిడ్-19 మరియు ఎబోలా వైరస్ వ్యాధికి కారణమయ్యే SARS-CoV-2 వైరస్ వంటి జూనోటిక్ వ్యాధులు జంతువుల జలాశయాల నుండి మానవులలోకి చిమ్ముకోవడమే కాకుండా, మానవుని మానవ ప్రసారానికి నిలబెట్టడానికి ప్రవృత్తిని చూపించాయి. ఈ కారకాలు వాతావరణ మార్పు, మానవ అభివృద్ధి మరియు సహజ వాతావరణాలపై ఆక్రమణ వంటి అనేక వేరియబుల్స్ ద్వారా ప్రభావితమవుతాయి. తత్ఫలితంగా, వన్ హెల్త్ పై ఎక్కువ దృష్టి పెట్టారు, ఇది మానవ, జంతువు మరియు పర్యావరణ ఆరోగ్యం మధ్య సంబంధాన్ని నొక్కి చెబుతుంది."
    ],
    "Spanish - What our experts say": [
      "Las enfermedades zoonóticas son enfermedades infecciosas que pueden diseminarse de animales a seres humanos. De los \"eventos de desborde\" (cuando una enfermedad salta de un animal a un ser humano) se ha conocido que causan brotes, tales como la enfermedad del virus ébola. Como algunas enfermedades infecciosas pueden vivir dentro de un animal sin causarle ninguna enfermedad, ciertas interacciones con un animal infectado pueden resultar en transmisión a seres humanos.\nAproximadamente 6 de 10 enfermedades infecciosas conocidas en las personas son zoonóticas. De todas las enfermedades infecciosas emergentes (una enfermedad que ha aparecido recientemente en una población o ha incrementado su incidencia en años recientes), 3 de 4 vienen desde animales. Los científicos están cada vez más preocupados acerca de las enfermedades zoonóticas, ya que las mismas están creciendo en frecuencia. En algunos casos, qué animal transfirió la infección a seres humanos es desconocido, como el SARS-CoV-2, el virus que causa el COVID-19. En la medida en que los seres humanos se expanden en el medio ambiente a través de la globalización y la vulneración sobre entornos naturales no desarrollados, como bosques o junglas, el riesgo de exposición a enfermedades zoonóticas se incrementa. Similarmente, factores tales como el comercio de animales exóticos, los impactos del cambio climático, y la expansión de mercados de animales, pueden causar que las enfermedades zoonóticas se diseminen más rápida y ampliamente."
    ],
    "Spanish - Background and context": [
      "Las enfermedades zoonóticas, tales como el virus SARS-CoV-2 que causa el COVID-19, y la enfermedad del virus Ébola, han mostrado una propensidad por no sólo desbordarse desde reservorios animales hacia seres humanos, sino una sostenida transmisión de humanos a humanos. Estos factores están influidos por varias variables, tales como el cambio climático y el desarrollo e intrusión humanos en ambientes naturales. Como resultado, ha sido puesto un mayor enfoque en One Health, lo que subraya la relación entre seres humanos, animales y salud ambiental."
    ],
    "Bengali - What our experts say": [
      "জুনোটিক রোগগুলি সংক্রামক রোগ যা প্রাণী থেকে মানুষের মধ্যে ছড়িয়ে যেতে পারে। \"স্পিলওভার ইভেন্টগুলি\" (যখন কোনও রোগ একটি প্রাণী থেকে একটি মানুষের মধ্যে ছড়ায়) ইবোলা ভাইরাসের মতো রোগের প্রাদুর্ভাব ঘটিয়েছে বলে জানা গেছে। যেহেতু কিছু সংক্রামক রোগ কোনও অসুবিধে সৃষ্টি না করেই কোনও প্রাণীর মধ্যেই বাঁচতে পারে, তাই সংক্রামিত প্রাণীর সাথে কিছু নির্দিষ্ট সংযোগের ফলে মানুষের মধ্যে সংক্রমণ ঘটে।মানুষের ১০ টি সংক্রামক রোগগুলির মধ্যে প্রায় ৬ জুনোটিক। সমস্ত উদীয়মান সংক্রামক রোগগুলির মধ্যে (এমন একটি রোগ যা একটি জনগোষ্ঠীতে নতুনভাবে দেখা গেছে বা সাম্প্রতিক বছরগুলিতে ঘটনা বেড়েছে), ৪ টির মধ্যে ৩ টি প্রাণী থেকে আসে। বিজ্ঞানীরা ক্রমবর্ধমান জুনোটিক রোগগুলি নিয়ে ক্রমশ উদ্বিগ্ন। কিছু ক্ষেত্রে কোন প্রাণীরা মানুষের মধ্যে সংক্রমণ স্থানান্তর করেছে তা অজানা, যেমন SARS-CoV-2 ভাইরাস যা কোভিড-১৯ এর জন্য দায়ী। মানুষ বিশ্বায়ন এবং নানাবিধ লঙ্ঘনের মাধ্যমে অনুন্নত প্রাকৃতিক পরিবেশ যেমন বন বা জঙ্গলে প্রবেশ করেছে, যা জুনোটিক রোগের সংস্পর্শে যাওয়ার ঝুঁকি বাড়ায়। একইভাবে, বিদেশী প্রাণী বাণিজ্য, জলবায়ু পরিবর্তনের প্রভাব এবং পশু বাজারের সম্প্রসারণের মতো কারণগুলি জুনোটিক রোগগুলিকে আরও দ্রুত এবং ব্যাপকভাবে ছড়িয়ে দিতে পারে।"
    ],
    "Bengali - Background and context": [
      "জুনোটিক রোগগুলি যেমন SARS-CoV-2 ভাইরাস যার ফলে কোভিড-১৯ এবং ইবোলা ভাইরাসজনিত রোগ দেখা দেয় তারা কেবল প্রাণীর বিচরণ ক্ষেত্র থেকে মানুষের মধ্যে ছড়িয়ে পড়ে না, তবে মানুষ থেকে মানুষে সংক্রমণের মাধ্যমে টিকে থাকে। এই কারণগুলি জলবায়ু পরিবর্তন, মানব বিকাশ এবং প্রাকৃতিক পরিবেশের উপর দখল ও বিভিন্ন পরিবর্তনশীল কারণ দ্বারা প্রভাবিত হয়। ফলস্বরূপ, ওয়ান হেলথের উপরে আরও গুরুত্ব দেওয়া হয়েছে, যা মানব, প্রাণী এবং পরিবেশগত স্বাস্থ্যের মধ্যে সম্পর্কের উপর দৃষ্টি নিবদ্ধ করে।"
    ]
  },
  {
    "id": "recpqhWtstGhdaZXy",
    "Question": "Are any foods or drinks, alone or in combination, effective in treating or curing COVID-19?",
    "Status": "Published",
    "Category": "home remedies",
    "Background and context": "There are many home remedies, foods, herbs, and dietary supplements that have been promoted to prevent, treat, or cure COVID-19. While _some_ food and nutrition-based therapies have some links to scientific research, based on previously conducted cellular studies, animal studies, or human studies, there is not significant scientific evidence on their impacts against COVID-19. \n\nThe [World Health Organization](https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-01apr2020-final.pdf?sfvrsn=573dc140_2) (WHO) and other health authorities have continued to state that caution is needed when considering 'traditional' or home remedies as a treatment for COVID-19. They have added that there is no current scientific evidence suggesting that home remedies, [specific foods, or dietary supplements](https://www.who.int/campaigns/connecting-the-world-to-combat-coronavirus/healthyathome/healthyathome---healthy-diet) prevent, treat, or cure COVID-19. \n\nIt is important to be aware of possible interactions between medications and some dietary supplements, and there are known risks that accompany supplement use for some patients (i.e, pregnant or lactating women, patients with kidney or liver disease). Some supplement products have been found to not have the components that are advertised on the product packaging, and may contain varied doses, or may contain other contaminants (i.e. heavy metals, pesticides) or additives.\n\n**Hot foods or hot drinks (i.e. water, milk, tea):** Eating or drinking foods and liquids that are very hot may cause dangerous burns in the mouth and throat. Health experts have including those from the [World Health Organization](https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-01apr2020-final.pdf?sfvrsn=573dc140_2) have suggested that products like tea, warm water, or soup may help us feel better when we are sick, but that does not mean that these items cure or treat disease. There is no scientific evidence to suggest that hot foods or drinks will prevent, treat, or cure COVID-19.\n\n**Chyawanprash:** Chyawanprash is commonly made from honey, ghee, and amla (Indian gooseberry) along with herbs and spices that may include cinnamon, cardamom, and clove amongst others. Many recipes use between 25 and 80 different ingredients. The mixture may be taken as a supplement or mixed with warm water or milk. Since recipes vary widely, there are very few scientific studies that examine effectiveness of Chyawanprash on prevention and treatment of disease. There is no current scientific evidence that Chyawanprash will prevent, treat, or cure COVID-19.\n\n**Clove:** (Laung) Clove has been shown to have some antibacterial and antifungal properties in laboratory-based tests, but these results have not been tested widely in humans. To date, there are no studies that evaluate cloves as a therapy for COVID-19, and there is no scientific evidence to suggest that cloves will prevent, treat, or cure COVID-19.\n\n**Black pepper:** (Kali Mirch) Black pepper has been shown to have some antibacterial properties in laboratory-based tests, but these results have not been tested widely in humans. To date, there are no studies that evaluate black pepper as a therapy for COVID-19, and there is no scientific evidence to suggest that black pepper will prevent, treat, or cure COVID-19. Similarly, there is no evidence that adding hot peppers to your food will prevent, treat, or cure COVID-19.\n\n**Hot Khaada (or kadha or karha):** Khaada is a drink often made with a combination of herbs, spices, and other additives that may include cloves, black pepper, ginger, basil, cardamom, fennel seeds, honey, ghee, amongst others. It is commonly used to “boost immunity” when people are sick. To date, there are no studies that evaluate Khaada as a therapy for COVID-19, and there is no scientific evidence to suggest that Khaada will prevent, treat, or cure COVID-19.\n\n**Turmeric: **The primary active compound in turmeric, curcumin, has been extensively studied for its anti-inflammatory and antimicrobial properties. In spite of its potential and successes in laboratory-based tests, most clinical trials in humans have not shown an effect, and more studies are needed to determine if or when curcumin may benefit people. Curcumin has not been studied in patients with COVID-19, though clinical trials have been proposed. The World Health Organization has a [specific statement](https://www.who.int/southeastasia/outbreaks-and-emergencies/novel-coronavirus-2019/fact-or-fiction) on their website suggesting that there is no current scientific evidence that turmeric prevents COVID-19. There is also no scientific evidence that turmeric can successfully treat or cure COVID-19.\n\n**Lemon:** Lemon is a great source of vitamin C and can be part of a healthy diet. The World Health Organization has a [specific statement](https://www.who.int/southeastasia/outbreaks-and-emergencies/novel-coronavirus-2019/fact-or-fiction) on their website suggesting that there is no current scientific evidence that lemon prevents COVID-19. There is also no scientific evidence that lemon can successfully treat or cure COVID-19.\n\n**Pineapple:** A variety of fruits (pineapple, mango, durian, and others) all may be included in a well-balanced diet to promote general health and well-being. The World Health Organization has a [specific statement](https://www.who.int/southeastasia/outbreaks-and-emergencies/novel-coronavirus-2019/fact-or-fiction) on their website suggesting that there is no current scientific evidence that these and other fruits prevent COVID-19. There is also no scientific evidence that fruits can successfully treat or cure COVID-19.\n\n**Onion: **As a member of the same family as garlic, onions are also known to have some antimicrobial and anti-inflammatory qualities, but studies are limited. To date, there are no studies that evaluate onions as a therapy for COVID-19, and there is no scientific evidence to suggest that onions will prevent, treat, or cure COVID-19.\n\n**Blackseed Oil:** (also called Nigella sativa) Black seed (or Nigella sativa) is used as a medicinal plant around the world and has been reportedly used to treat a variety of conditions from influenza to diabetes, inflammation to cough or fever. To date, black seed oil and its compounds have not been studied as a possible treatment or cure against COVID-19 in cell studies, animal studies, or human studies, though the idea has been proposed. Currently, there is no scientific evidence to suggest that black see oil will prevent, treat, or cure COVID-19.\n\n**Honey:** Honey may have some wound healing and antibacterial properties, but much of the published research focuses on topical (skin) application, which doesn't apply to COVID-19 because the virus is an internal infection. While it can be part of a healthy diet, honey is a source of sugar, and leading health organizations recommend limiting dietary sugar intake. Health experts from the [World Health Organization](https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-01apr2020-final.pdf?sfvrsn=573dc140_2) have suggested that products like ginger, tea, or honey may make us feel better when we are sick, but that does not mean that these items cure or treat disease. There is also no scientific evidence that honey can successfully treat or cure COVID-19.\n\n**Garlic:** Garlic is a healthy food that may have some antimicrobial and anti-tumor properties, though study results are often mixed and there are limitations, gaps, and shortcomings in the published evidence. While it has been widely studied in preparations as a supplement, extract, and food, there is currently no evidence that garlic will prevent or treat COVID-19. The World Health Organization has a [specific statement](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters) on their website suggesting that “there is no evidence from the current outbreak that eating garlic has protected people from the new coronavirus.” There is also no scientific evidence that garlic can successfully prevent, treat, or cure COVID-19.\n\n**Tea:** Some teas may have health benefits, but evidence is limited because of difficulty studying the possible effect of tea alone. Health experts have suggested that products like ginger, tea, or honey may make us feel better when we are sick, but that does not mean that these items cure or treat disease. There is no scientific evidence to suggest that tea will prevent, treat, or cure COVID-19.\n\n**Ginger:** As a supplement, ginger is most commonly prescribed to help with nausea. Health experts from the [World Health Organization](https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-01apr2020-final.pdf?sfvrsn=573dc140_2) have suggested that products like ginger, tea, or honey may make us feel better when we are sick, but that does not mean that these items cure or treat disease. There is no scientific evidence to suggest that ginger will prevent, treat, or cure COVID-19.\n\n**Zinc:** Zinc is a mineral that is used throughout the body and is needed for a healthy immune system. While zinc is available in many foods, use of zinc supplements has been shown to be helpful for wound healing and may shorten the duration of colds and acute diarrhea. Use of zinc should be guided by healthcare providers, since there are known side effects that may result from incorrect dosing. In addition, long-term zinc use is known to cause copper deficiency and is not recommended. There are clinical trials registered to study zinc (often in combinations with other vitamins, minerals, or medications) as a therapy for patients with COVID-19, but results are not available yet. While there are many scientists and health professionals that believe zinc may be a helpful therapy for COVID-19 based on its known benefits with other conditions, there is not enough scientific evidence to suggest that zinc supplementation will prevent, treat, or cure COVID-19.\n\n**Selenium:** Selenium is a mineral has many functions in the body; like other minerals, it is needed for a healthy immune system. Selenium is available in many foods and is also available in supplement form. Most selenium studies to date have focused on thyroid disease, cancer, and cardiovascular disease. Recently, there are scientific papers that have been published as “Letters to the Editor” and similar that suggest that selenium may be beneficial, but these papers are largely observational, have many limitations, and have not gone through the rigorous peer-review process to validate the research methods and claims made. Without further validation, they should be interpreted very cautiously. At present, there is not enough scientific evidence to suggest that selenium supplementation will prevent, treat, or cure COVID-19.\n",
    "What our experts say": "There are many postings across social media that report certain home remedies, foods, herbs, spices, or supplements may prevent, treat, or cure COVID-19. There are many things, like taking warm baths, getting plenty of rest, or eating and drinking honey, lemon, tea, ginger, and other foods that may help people feel better when they are sick. Even though they may help us to feel better, it does not mean that those home remedies cure an illness or infection. In addition, though a varied and balanced diet including fruits and vegetables does help to support the immune system in general, there is no evidence to suggest that special diets, consumption of particular foods, or taking vitamin, mineral, or herbal supplements will prevent, treat or cure COVID-19. \n\nFor information about the attributed of specific foods or drinks, please see the **'Background & Context'** section for this question.\n",
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "cure",
      "treatment"
    ],
    "Other resources": "1. COVID-19 - virtual press conference, April 2020 ([WHO](https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-01apr2020-final.pdf?sfvrsn=573dc140_2))\n2. In the news: Coronavirus and \"Alternative\" treatments 2020, ([NIH NCCIH](https://www.nccih.nih.gov/health/in-the-news-coronavirus-and-alternative-treatments))\n3. #HealthyatHome: Health Diet, 2020 ([WHO](https://www.who.int/campaigns/connecting-the-world-to-combat-coronavirus/healthyathome/healthyathome---healthy-diet))\n4. Coronavirus disease (COVID-19) advice for the public: Mythbusters ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters))\n5. Fact or Fiction: Novel Coronavirus 2019 ([WHO](https://www.who.int/southeastasia/outbreaks-and-emergencies/novel-coronavirus-2019/fact-or-fiction))\n6. Garlic: a review of potential therapeutic effects, 2014 ([Avicenna J Phytomed](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103721/))\n7. Anti-infective Properties of the Golden Spice Curcumin, 2019 ([Front Microbiol](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509173/))\n8. Curcumin as a potential treatment for COVID-19, Letter to the Editor, 2020 ([Phytotherapy Research](https://onlinelibrary.wiley.com/doi/epdf/10.1002/ptr.6745))\n9. Turmeric, 2020 ([NIH NCCIH](https://www.nccih.nih.gov/health/turmeric))\n10. Tea, 2020 ([NIH NCCIH](https://www.nccih.nih.gov/health/tea))\n11. Ginger, 2020 ([NIH NCCIH](https://www.nccih.nih.gov/health/ginger))\n12. Safe use of complementary health products and practices, 2020 ([NIH NCCIH](https://www.nccih.nih.gov/health/safety))\n13. Dietary Supplements, 2020 ([Merck Manual](https://www.merckmanuals.com/professional/special-subjects/dietary-supplements))\n14. About Herbs, Botanicals, & Other Products ([Memorial Sloan Kettering Cancer Center](https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs))\n15. Molecular docking, simulation and MM-PBSA studies of nigella sativa compounds: a computational quest to identify potential natural antiviral for COVID-19 treatment, 2020 ([J Biomol Struct Dyn](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298883/))\n16. Zinc, 2020 ([NIH](https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/))\n17. Association between regional selenium status and reported outcome of COVID-19 cases in China, 2020 ([AJCN](https://academic.oup.com/ajcn/article/111/6/1297/5826147))\n18. Selenium, 2020 ([NIH](https://ods.od.nih.gov/factsheets/Selenium-HealthProfessional/))\n19. Ayurveda’s immunity boosting measures for self-care during COVID-19 crisis, 2020 ([Press Information Bureau, Government of India](https://pib.gov.in/PressReleseDetailm.aspx?PRID=1609524))\n20. Chyawanprash: A Traditional Indian Bioactive Health Supplement, 2019 ([Biomolecules](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571565/))\n21. Quantification of Immunity Status of Dabur Chyawanprash Review Part-1 (Experimental Studies), 2014 ([Indian Journal of Applied Research](https://www.researchgate.net/publication/269562829_Quantification_of_Immunity_Status_of_Dabur_Chyawanprash_-A_Review_Part-1_Experimental_Studies))\n22. Antibacterial and antifungal activities of spices, 2017 ([Int J Mol Sci](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486105/))\n23. A systematic review on black pepper (Piper nigrum L.): from folk uses to pharmacological applications, 2019 ([Crit Rev Food Sci Nutr](https://pubmed.ncbi.nlm.nih.gov/30740986/))\n24. Antibacterial mechanism and activities of black pepper chloroform extract, 2015 ([J Food Sci Technol](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648884/pdf/13197_2015_Article_1914.pdf))\n25. Coronavirus disease (COVID-19): Food safety and nutrition ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19-food-safety-and-nutrition))\n",
    "DB (Hindi)": [
      "reczBEl25t2qPMM1t"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "reco953rqpqx0IFWm"
    ],
    "DB (Portuguese)": [
      "recZaGVFojzt8qjWW"
    ],
    "Rollup test 2": [
      "reccPFwhlCjMGT1Ut"
    ],
    "Last modified manual": "2020-12-02",
    "Last edited (simplified)": "2020-12-02T17:52:30.000Z",
    "Last edited (experts say)": "2020-12-02T17:52:30.000Z",
    "Last modified": "2020-12-02",
    "What our experts say wordcount": 144,
    "Background and context wordcount": 1508,
    "Other resources wordcount": 257,
    "Wordcount": 1909,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "जबकि फलों और सब्जियों सहित एक विविध और संतुलित आहार सामान्य रूप से प्रतिरक्षा प्रणाली का समर्थन करने में मदद करता है, यह सुझाव देने के लिए कोई सबूत नहीं है कि विशेष आहार, विशेष खाद्य पदार्थों की खपत, या विटामिन, खनिज, या हर्बल सप्लीमेंट लेने से कोविड-19 रोकने, उपचार या इलाज होगा।\n\nविशिष्ट खाद्य पदार्थों या पेय के लिए जिम्मेदार के बारे में जानकारी के लिए, कृपया इस प्रश्न के लिए 'पृष्ठभूमि और संदर्भ' अनुभाग देखें।"
    ],
    "Hindi - Background and context": [
      "कोविड-19 के लिए कई फल, सब्जियां, जड़ी-बूटियाँ और आहार अनुपूरक हैं जिन्हें निवारक चिकित्सा या इलाज के रूप में प्रचारित किया गया है। जबकि इन पोषण-आधारित उपचारों में से कुछ वैज्ञानिक अनुसंधान के लिए सैद्धांतिक लिंक हैं, जो पहले किए गए सेलुलर अध्ययन, पशु अध्ययन या मानव अध्ययन पर आधारित हैं, SARS-CoV-2 के खिलाफ उनके प्रभावों पर महत्वपूर्ण वैज्ञानिक सबूत नहीं हैं, वायरस जो कोविड-19 का कारण बनता है। विश्व स्वास्थ्य संगठन (डबल्युएचओ) और अन्य स्वास्थ्य अधिकारियों ने लगातार इन रिपोर्टों का खंडन किया है क्योंकि कोई भी वर्तमान वैज्ञानिक प्रमाण नहीं है जो यह बताता हो कि विशिष्ट खाद्य पदार्थ या आहार अनुपूरक कोविड-19 को रोकते हैं, उसका इलाज करते हैं या उसका इलाज करते हैं।\n\nदवाओं और कुछ आहार पूरक के बीच संभावित बातचीत के बारे में पता होना महत्वपूर्ण है, और जोखिम हैं जो कुछ रोगियों (यानी, गर्भवती या स्तनपान कराने वाली महिलाओं, गुर्दे या यकृत रोग वाले रोगियों के लिए पूरक उपयोग) के साथ हैं। कुछ पूरक उत्पादों में ऐसे घटक पाए गए हैं जो उत्पाद की पैकेजिंग पर विज्ञापित हैं, और इसमें विभिन्न खुराक हो सकती हैं, या इसमें अन्य संदूषक (यानी भारी धातु, कीटनाशक) या एडिटिव्स हो सकते हैं।\n \nहल्दी: हल्दी, करक्यूमिन में प्राथमिक सक्रिय यौगिक, इसके विरोधी भड़काऊ और रोगाणुरोधी गुणों के लिए बड़े पैमाने पर अध्ययन किया गया है। प्रयोगशाला-आधारित परीक्षणों में इसकी क्षमता और सफलताओं के बावजूद, मनुष्यों में अधिकांश नैदानिक ​​परीक्षणों ने कोई प्रभाव नहीं दिखाया है, और यह जानने के लिए कि कब या कब कर्कुमिन से लोगों को लाभ हो सकता है, और अधिक अध्ययनों की आवश्यकता है। कोविड-19 के रोगियों में करक्यूमिन का अध्ययन नहीं किया गया है, हालांकि नैदानिक ​​परीक्षण प्रस्तावित किए गए हैं। विश्व स्वास्थ्य संगठन ने अपनी वेबसाइट पर एक विशिष्ट वक्तव्य दिया है जिसमें कहा गया है कि कोई वर्तमान वैज्ञानिक प्रमाण नहीं है कि हल्दी कोविड-19 को रोकता है। कोई वैज्ञानिक प्रमाण भी नहीं है कि हल्दी कोविड-19 का सफलतापूर्वक इलाज या उपचार कर सकती है।\n\nनींबू: नींबू विटामिन सी का एक बड़ा स्रोत है और स्वस्थ आहार का हिस्सा हो सकता है। विश्व स्वास्थ्य संगठन ने अपनी वेबसाइट पर एक विशिष्ट वक्तव्य दिया है जिसमें कहा गया है कि कोई वर्तमान वैज्ञानिक प्रमाण नहीं है कि नींबू कोविड-19 को रोकता है। इस बात का कोई वैज्ञानिक प्रमाण भी नहीं है कि नींबू कोविड-19 का सफलतापूर्वक इलाज या उपचार कर सकता है।\n \nअनानास: सामान्य स्वास्थ्य और भलाई को बढ़ावा देने के लिए विभिन्न प्रकार के फल (अनानास, आम, डूरियन और अन्य) सभी को अच्छी तरह से संतुलित आहार में शामिल किया जा सकता है। विश्व स्वास्थ्य संगठन ने अपनी वेबसाइट पर एक विशिष्ट वक्तव्य दिया है जिसमें कहा गया है कि कोई भी वर्तमान वैज्ञानिक प्रमाण नहीं है कि ये और अन्य फल कोविड-19 को रोकते हैं। यह भी कोई वैज्ञानिक प्रमाण नहीं है कि फल कोविड-19 का सफलतापूर्वक इलाज या उपचार कर सकते हैं।\n\nप्याज: लहसुन के रूप में एक ही परिवार के सदस्य के रूप में, प्याज को कुछ रोगाणुरोधी और विरोधी भड़काऊ गुणों के लिए भी जाना जाता है, लेकिन अध्ययन सीमित हैं। आज तक, कोई अध्ययन नहीं है जो कोविड-19 के लिए एक थेरेपी के रूप में प्याज का मूल्यांकन करते हैं, और यह सुझाव देने के लिए कोई वैज्ञानिक प्रमाण नहीं है कि प्याज कोविड-19 को रोकेंगे, उपचार करेंगे या ठीक करेंगे।\n\nब्लैकसेड ऑयल: (जिसे निगेला सैटिवा भी कहा जाता है) ब्लैक सीड (या निगेला सैटिवा) को दुनिया भर में औषधीय पौधे के रूप में इस्तेमाल किया जाता है और कथित तौर पर इन्फ्लूएंजा से लेकर मधुमेह, खांसी या बुखार तक की कई स्थितियों का इलाज किया जाता है। आज तक, सेल बीज अध्ययन, पशु अध्ययन, या मानव अध्ययन में कोविड-19 के खिलाफ काले बीज के तेल और इसके यौगिकों का संभावित उपचार या इलाज के रूप में अध्ययन नहीं किया गया है, हालांकि विचार प्रस्तावित किया गया है। वर्तमान में, यह सुझाव देने के लिए कोई वैज्ञानिक प्रमाण नहीं है कि काले रंग का तेल कोविड-19 को रोकेगा, उपचार करेगा या ठीक करेगा।\n\nशहद: शहद में कुछ घाव भरने और जीवाणुरोधी गुण हो सकते हैं, लेकिन प्रकाशित शोध में से अधिकांश सामयिक (त्वचा) अनुप्रयोग पर केंद्रित है, जो कोविड-19 पर लागू नहीं होता है क्योंकि वायरस एक आंतरिक संक्रमण है। हालांकि यह एक स्वस्थ आहार का हिस्सा हो सकता है, शहद चीनी का एक स्रोत है, और प्रमुख स्वास्थ्य संगठन आहार शर्करा के सेवन को सीमित करने की सलाह देते हैं। स्वास्थ्य विशेषज्ञों ने सुझाव दिया है कि अदरक, चाय, या शहद जैसे उत्पाद हमें बीमार होने पर बेहतर महसूस करा सकते हैं, लेकिन इसका मतलब यह नहीं है कि ये चीजें बीमारी का इलाज करती हैं या इसका उपचार करती हैं। इस बात का भी कोई वैज्ञानिक प्रमाण नहीं है कि शहद कोविड-19 का सफलतापूर्वक इलाज या उपचार कर सकता है।\n \nलहसुन: लहसुन एक स्वस्थ भोजन है जिसमें कुछ रोगाणुरोधी और एंटी-ट्यूमर गुण हो सकते हैं, हालांकि अध्ययन के परिणाम अक्सर मिश्रित होते हैं और प्रकाशित साक्ष्य में सीमाएं, अंतराल और कमियां होती हैं। हालांकि यह पूरक, अर्क और भोजन के रूप में तैयारियों में व्यापक रूप से अध्ययन किया गया है, वर्तमान में कोई सबूत नहीं है कि लहसुन कोविड-19 को रोकने या इलाज करेगा। विश्व स्वास्थ्य संगठन ने अपनी वेबसाइट पर एक विशिष्ट वक्तव्य दिया है जिसमें कहा गया है कि \"वर्तमान प्रकोप से कोई सबूत नहीं है कि लहसुन खाने से लोगों को नए कोरोनोवायरस से बचाया गया है।\" इस बात का भी कोई वैज्ञानिक प्रमाण नहीं है कि लहसुन कोविड-19 का सफलतापूर्वक इलाज या उपचार कर सकता है।\n\nचाय: कुछ चाय के स्वास्थ्य लाभ हो सकते हैं, लेकिन केवल चाय के संभावित प्रभाव का अध्ययन करने में कठिनाई के कारण सबूत सीमित हैं। स्वास्थ्य विशेषज्ञों ने सुझाव दिया है कि अदरक, चाय, या शहद जैसे उत्पाद हमें बीमार होने पर बेहतर महसूस करा सकते हैं, लेकिन इसका मतलब यह नहीं है कि ये चीजें बीमारी का इलाज करती हैं या इसका इलाज करती हैं। यह सुझाव देने के लिए कोई वैज्ञानिक प्रमाण नहीं है कि चाय कोविड-19 को रोकें, उसका उपचार करें या उसका इलाज करें।\n\nअदरक: एक पूरक के रूप में, अदरक सबसे अधिक मतली के साथ मदद करने के लिए निर्धारित है। स्वास्थ्य विशेषज्ञों ने सुझाव दिया है कि अदरक, चाय, या शहद जैसे उत्पाद हमें बीमार होने पर बेहतर महसूस करा सकते हैं, लेकिन इसका मतलब यह नहीं है कि ये चीजें बीमारी का इलाज करती हैं या इसका इलाज करती हैं। यह सुझाव देने के लिए कोई वैज्ञानिक प्रमाण नहीं है कि अदरक कोविड-19 को रोकेगा, उपचार करेगा या ठीक करेगा।\n \nजस्ता: जस्ता एक खनिज है जो पूरे शरीर में उपयोग किया जाता है और एक स्वस्थ प्रतिरक्षा प्रणाली के लिए आवश्यक है। जबकि जस्ता कई खाद्य पदार्थों में उपलब्ध है, जस्ता की खुराक का उपयोग घाव भरने के लिए मददगार दिखाया गया है और सर्दी और तीव्र दस्त की अवधि को कम कर सकता है। जिंक के उपयोग को स्वास्थ्य सेवा प्रदाताओं द्वारा निर्देशित किया जाना चाहिए, क्योंकि ज्ञात दुष्प्रभाव हैं जो गलत खुराक के परिणामस्वरूप हो सकते हैं। इसके अलावा, लंबे समय तक जस्ता का उपयोग तांबे की कमी का कारण माना जाता है और इसकी सिफारिश नहीं की जाती है। कोविड-19 वाले रोगियों के लिए एक चिकित्सा के रूप में जस्ता (अक्सर अन्य विटामिन, खनिज या दवाओं के साथ संयोजन में) का अध्ययन करने के लिए नैदानिक ​​परीक्षण पंजीकृत हैं, लेकिन परिणाम अभी तक उपलब्ध नहीं हैं। हालांकि, कई वैज्ञानिक और स्वास्थ्य पेशेवर हैं, जो मानते हैं कि जस्ता अन्य स्थितियों के साथ अपने ज्ञात लाभों के आधार पर कोविड-19 के लिए एक सहायक चिकित्सा हो सकती है, यह सुझाव देने के लिए पर्याप्त वैज्ञानिक प्रमाण नहीं हैं कि जस्ता पूरकता कोविड-19 को रोकें, उसका उपचार या ठीक करेगा। ।\n \nसेलेनियम: सेलेनियम एक खनिज है शरीर में कई कार्य हैं; अन्य खनिजों की तरह, यह एक स्वस्थ प्रतिरक्षा प्रणाली के लिए आवश्यक है। सेलेनियम कई खाद्य पदार्थों में उपलब्ध है और पूरक के रूप में भी उपलब्ध है। आज तक के अधिकांश सेलेनियम अध्ययनों में थायरॉयड रोग, कैंसर और हृदय रोग पर ध्यान केंद्रित किया गया है। हाल ही में, वैज्ञानिक पत्र हैं जो \"पत्र को संपादक\" के रूप में प्रकाशित किए गए हैं और इसी तरह का सुझाव है कि सेलेनियम फायदेमंद हो सकता है, लेकिन ये कागज काफी हद तक अवलोकनशील हैं, कई सीमाएं हैं, और कठोर सहकर्मी-समीक्षा प्रक्रिया से नहीं गुजरे हैं। किए गए शोध के तरीकों और दावों को मान्य करें। आगे की मान्यता के बिना, उन्हें बहुत सावधानी से व्याख्या की जानी चाहिए। वर्तमान में, यह सुझाव देने के लिए पर्याप्त वैज्ञानिक प्रमाण नहीं हैं कि सेलेनियम अनुपूरण कोविड-19 को रोकेंगे, उपचार करेंगे या ठीक करेंगे।"
    ]
  },
  {
    "id": "rec6CUlk7DgaOFxkC",
    "Question": "Is ivermectin a proven treatment for COVID-19?",
    "Status": "Published",
    "Category": "On: COVID-19 & ivermectin",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "Nigeria"
    ],
    "Background and context": "Headlines from May 2020 widely touted ivermectin as a breakthrough drug with “astounding” results in patients with COVID-19. While the study has not yet been peer reviewed or published, preprint and press release information reports lower mortality in patients on ivermectin therapy in four Florida (US) hospitals. Many news reports also link back to a paper that reported results from testing the medication in cell culture—not in humans. At present, clinical studies are ongoing, and the drug requires additional research to determine possible benefits and risks for patients with COVID-19.\n\nThough ivermectin is approved by the U.S. Food and Drug Administration (US FDA) for other illnesses and it has been shown to decrease the effect of the SARS-CoV-2 virus in cell studies, it should not be prescribed for COVID-19 or taken without medical supervision. The US FDA has specifically issued multiple statements to further advise the public. First, they suggest that “while there are approved uses for ivermectin in people and animals, it is not approved for the prevention or treatment of COVID-19. You should not take any medicine to treat or prevent COVID-19 unless it has been prescribed to you by your health care provider and acquired from a legitimate source.” In a later statement, the US FDA also suggested that people should not use Ivermectin intended for animals as a treatment for COVID-19.  \n",
    "What our experts say": "As of now, there is not enough evidence to support the use of Ivermectin to treat COVID-19. \n\nIvermectin has been used to treat infectious diseases in humans and animals for over thirty years, primarily for treating parasitic roundworm infections in the intestinal tract, skin, and eyes. The medication has not been approved as a treatment for COVID-19 by the World Health Organization (WHO). A regional office of the WHO, called the Pan American Health Organization (PAHO), has advised against the use of ivermectin for any purposes other than those for which its use is authorized. \n\nAs of now, PAHO and WHO recommend that the use of ivermectin for new uses like COVID-19 only be used in research studies so scientists can determine if using ivermectin is safe and effective. There are currently more than 30 studies on ivermectin underway.\n",
    "Glossary Terms": [
      "recniCDr8SI8Oh9z3",
      "reciBuPWXmjVf9x8e"
    ],
    "Variation of the answer depending on country of residence": "Yes, ivermectin is being used in Bolivia as a treatment tool for COVID-19\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "treatment",
      "medication",
      "ivermectin"
    ],
    "Other resources": "1. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, 2020 ([Antiviral Research](https://www.sciencedirect.com/science/article/pii/S0166354220302011))\n2. FDA letter to stakeholders: do not use ivermectin intended for animals as treatment for COVID-19 in humans, 2020 ([US FDA](https://www.fda.gov/animal-veterinary/product-safety-information/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans))\n3. FAQ: COVID-19 and ivermectin intended for animals, 2020 ([US FDA](https://www.fda.gov/animal-veterinary/product-safety-information/faq-covid-19-and-ivermectin-intended-animals))\n4. Ivermectin and COVID-19: a report in Antiviral research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, 2020 ([Antiviral Res](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172803/))\n5. ICON (Ivermectin in COvid Nineteen) study: Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19, 2020 ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v2.full.pdf))\n6. COVID-19 Treatment Guidelines ([U.S. NIH](https://www.covid19treatmentguidelines.nih.gov/whats-new/)) \n7. Recommendation Regarding the Use of Ivermectin as a Treatment for COVID-19, 22 June 2020 ([PAHO](https://iris.paho.org/handle/10665.2/52372))\n",
    "DB (Hindi)": [
      "recuMsGR9XouJYTgV"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "rec96VymjTCzBopt8"
    ],
    "DB (Portuguese)": [
      "recK7wqAhNLvJ63tI"
    ],
    "Rollup test 2": [
      "recjVATKFpjl8PW8M"
    ],
    "Last modified manual": "2020-07-09",
    "Last edited (simplified)": "2020-07-09T20:59:49.000Z",
    "Last edited (experts say)": "2020-07-09T20:59:49.000Z",
    "Last modified": "2020-07-09",
    "What our experts say wordcount": 139,
    "Background and context wordcount": 223,
    "Other resources wordcount": 112,
    "Wordcount": 474,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "किसी भी अवधि के लिए धूप में रहने से कोविड​​-19 को दूसरे व्यक्ति में फैलाने या किसी अन्य व्यक्ति से कोविड​​-19 को पकड़ने में सहायक नहीं है। लंबे समय तक सूर्य के प्रकाश के संपर्क में रहने से बहुत नुकसान हो सकता है और इससे त्वचा पर कैंसर होने का खतरा बढ़ सकता है। अब तक, कोविड​​-19 को रोकने या इसके इलाज के लिए धूप सेंकने का कोई स्पष्ट लाभ नहीं है।"
    ],
    "Hindi - Background and context": [
      "हाल के समाचार लेखों और अध्ययनों ने कोविड​​-19 को रोकने या उसके इलाज के लिए धूप सेंकने पर ध्यान केंद्रित किया है। इस बात का कोई प्रमाण नहीं है कि कोविड​​-19 से बचने के लिए धूप सेंकना फ़ायदेमंद है।\nयूवी किरणें इलेक्ट्रो-मैग्नेटिक रेडियेशन (विद्युत चुम्बकीय विकिरण) का एक रूप हैं, जो सूर्य के प्रकाश में मौजूद होता हैं। सूरज की रोशनी यूवी किरणों के तीन प्रकारों का उत्सर्जन करती है: यूवीए, यूवीबी और यूवीसी। यूवीसी में सबसे अधिक ऊर्जा होती है और इसे वायुमंडल द्वारा फ़िल्टर किया जाता है, इसलिए यह पृथ्वी की सतह तक नहीं पहुंचता है। हालांकि, यूवीसी किरणें कुछ मानव निर्मित स्रोतों से भी आ सकती हैं, जैसे कि यूवी सैनिटाइजिंग बल्ब, और इनडोर सेटिंग में इस्तेमाल किया जा सकता है, जैसे कि अस्पताल में, चिकित्सा उपकरण और सतहों कीटाणुरहित करने के लिए। ऐसा इसलिए है क्योंकि यूवीसी में तीनों की सबसे अधिक ऊर्जा है, और इसकी ऊर्जा वायरस के अंदर आनुवंशिक सामग्री (जेनेटिक मटीरीयल) को नष्ट कर सकती है। वायरस में आनुवंशिक सामग्री में ऐसी जानकारी शामिल होती है जो वायरस के प्रजनन, विकास या व्यवहार को नियंत्रित कर सकती है। लेकिन कृत्रिम (आर्टिफ़िशल) यूवीसी किरणें मनुष्यों के लिए बेहद खतरनाक और घातक हैं और सतहों और वस्तुओं को कीटाणुरहित करने के लिए पेशेवर (प्रफ़ेशनल) सेटिंग्स के बाहर इस्तेमाल नहीं किया जाना चाहिए।\nजबकि सूरज कीटाणुओं को मार सकता है, सामान्य तौर से, सूर्य के प्रकाश के माध्यम से वस्तुओं को कीटाणुरहित करना 100% प्रभावी नहीं होगा और बहुत लंबा समय लगेगा और अधिकांश घरेलू उपयोगकर्ता इस बात की पुष्टि नहीं कर पाएंगे कि इस प्रक्रिया के दौरान उनके आइटम पूरी तरह से कीटाणुरहित हो गए हैं या नहीं। अध्ययनों से पता चला है कि आकार, सामग्री आदि के आधार पर कीटाणुरहित होने के लिए आवश्यक वस्तुओं के लिए धूप के संपर्क में आने के समय की अलग-अलग लंबाई होती है, इसलिए घरेलू वस्तुओं को धूप सेंक कर कीटाणुरहित करना अनुशंसित समाधान नहीं है।"
    ],
    "Portuguese - What our experts say": [
      "Até o momento, não há evidências suficientes que comprovem os benefícios do uso da ivermectina no tratamento do COVID-19.\nA ivermectina tem sido usada para tratar doenças infecciosas em humanos e animais há mais de trinta anos, principalmente no tratamento de infecções por vermes parasitários do trato intestinal, pele e olhos. O medicamento não foi aprovado como tratamento para COVID-19 pela Organização Mundial da Saúde (OMS). Uma agência regional da OMS, chamada Organização Pan-Americana da Saúde (OPAS), desaconselhou o uso da ivermectina para quaisquer outros fins que não aqueles para os quais seu uso já tiver sido autorizado. \nAté agora, a OPAS e a OMS recomendam que o uso da ivermectina em novos tratamentos, como o COVID-19, seja limitado a pesquisas, para que os cientistas possam determinar se o uso da ivermectina é seguro e eficaz. Atualmente, existem mais de 30 estudos sobre ivermectina em andamento."
    ],
    "Portuguese - Background and context": [
      "As manchetes de maio de 2020 divulgaram amplamente a ivermectina como um medicamento inovador e com resultados \"surpreendentes\" em pacientes com COVID-19. Embora o estudo ainda não tenha sido revisado por pares ou publicado, as informações da sua versão em pré-impressão e do seu comunicado de imprensa noticiam que houve mortalidade mais baixa em pacientes tratados com ivermectina em quatro hospitais da Flórida (EUA). Muitas reportagens também apontam para um artigo que relatou resultados do teste do medicamento em culturas de células - e não em humanos. Atualmente, estudos clínicos estão em andamento e o medicamento requer pesquisas suplementares para determinar seus possíveis benefícios e riscos em pacientes com COVID-19.\nEmbora a ivermectina seja aprovada FDA (Administração para Drogas e Alimentos - Food and Drugs Administration) dos EUA para outras doenças e tenha demonstrado diminuir o efeito do vírus SARS-CoV-2 em estudos celulares, ela não deve ser prescrita para COVID-19 ou administrada sem supervisão médica. O FDA dos EUA emitiu vários comunicados destinados especificamente a prevenir ainda mais o público. Primeiro, eles sugerem que “embora existam usos aprovados para a ivermectina em pessoas e animais, ela foi aprovada para a prevenção ou o tratamento do COVID-19. Você não deve tomar nenhum medicamento para tratar ou prevenir o COVID-19, exceto aqueles que lhe tenham sido prescritos pelo seu médico e adquiridos de um fornecedor autorizado.”"
    ]
  },
  {
    "id": "recQKR1FPhzdFFvZO",
    "Question": "What is pool testing and why is it being used?",
    "Status": "Published",
    "Category": "On: COVID-19 & pool testing",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "There have been many headlines in the news about \"pool testing\" for COVID-19.  Pool testing for COVID-19 has already been implemented or is currently being considered in several places, particularly where there are large populations as well as limited time and supplies for testing. For example, Chinese health officials have used this method in Wuhan and Beijing to quickly test large numbers of people. U.S. federal health officials have also been discussing the potential for pool testing, informed by how this has been implemented in the Nebraska Public Health Laboratory when it was running low on testing reagents in March 2020 and has since reported 50-60% savings in reagents along with 20-30% savings in labor. Most health officials believe that the savings from pool testing will be limited outside of areas where the virus is rarely present. While pool testing alone is not expected to resolve the current bottlenecks in testing, this form of testing can be a helpful tool in some situations.\n",
    "What our experts say": "Pool testing, distinct from individual testing, tests a pool (or group) of people at the same time and is a form of testing that has been used for diseases like HIV/AIDS before the current COVID-19 pandemic. Normally, when a COVID-19 test is done using a nasal swab on a patient, that sample is then tested individually to determine if the virus is present, and this can take anywhere from 15 minutes to several days, depending on the abilities of the lab running the test. With pool testing, anywhere from roughly 3 - 50 samples are combined and all of the swabs are tested at once. If the test result from that pool test is negative, then all patients in that pool do not have the virus. If the result is positive, then each swab must then be tested one-by-one.\n\nPool testing, also called \"batch testing,\" is currently being used in order to test many more people for COVID-19 than individual tests alone. This is because instead of testing patients and then analyzing their samples individually to determine whether or not one patient has been infected with COVID-19, pool testing combines many samples and tests them at the same time. \n\nPool testing has gained popularity in recent months due to surging numbers of COVID-19 infections around the world. This method gives laboratories the ability to save time, test greater numbers of people, and use their resources most efficiently. These tests are most useful in places with large populations but a lower number of COVID-19 cases within that population, including group settings like schools or workplaces. In places with with a high rate of infections, this testing strategy would not be as beneficial since most patients would be tested individually either way. Another potential hurdle is that pool testing might lead to more false-negative tests. This is because if a patient does have the virus and it is present in their individual test sample, that sample will be diluted when it is combined with the rest of the samples from the larger group, possibly to the point where the viral load is undetectable. \n",
    "Glossary Terms": [
      "recEwxu92Kry1SZKl"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "pool testing",
      "sample",
      "nasal swab",
      "laboratory"
    ],
    "Other resources": "1. Multi-Stage Group Testing Improves Efficiency of Large-Scale COVID-19 Screening ([Journal of Clinical Virology](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177109/)) \n2. Group Testing and Sparse Signal Recovery ([2008 42nd Asilomar Conference on Signals, Systems and Computers](https://users.math.msu.edu/users/iwenmark/Papers/GIS-grouptest-2008.pdf))\n3. Pooled testing with replication: a mass testing strategy for the COVID-19 pandemics ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.04.27.20076422v1.full.pdf)) \n4. What is pool testing and how does it work? ([Washington Post](https://www.washingtonpost.com/health/what-is-pool-testing-and-how-does-it-work/2020/06/26/33eee7ea-b7e4-11ea-a510-55bf26485c93_story.html)) \n5. Coronavirus Test Shortages Trigger a New Strategy: Group Screening ([Scientific American](https://www.scientificamerican.com/article/coronavirus-test-shortages-trigger-a-new-strategy-group-screening2/)) \n6. Pooling Coronavirus Tests Can Spare Scarce Supplies, But There's A Catch ([NPR](https://www.npr.org/sections/health-shots/2020/07/06/886886255/pooling-coronavirus-tests-can-spare-scarce-supplies-but-theres-a-catch))\n",
    "DB (Hindi)": [
      "rec2HVRTs8k9PuWZw"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recerwo71cWu2nN9B"
    ],
    "DB (Portuguese)": [
      "recPs7glZ65qa5r9b"
    ],
    "Rollup test 2": [
      "recuE15BDnQh9xNef"
    ],
    "Last modified manual": "2020-07-08",
    "Last edited (simplified)": "2020-07-07T23:35:20.000Z",
    "Last edited (experts say)": "2020-07-08T16:30:55.000Z",
    "Last modified": "2020-07-08",
    "What our experts say wordcount": 351,
    "Background and context wordcount": 164,
    "Other resources wordcount": 80,
    "Wordcount": 595,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "पूल परीक्षण, अलग-अलग परीक्षण से अलग, एक ही समय में लोगों के एक पूल (या समूह) का परीक्षण करता है और परीक्षण का एक रूप है जो वर्तमान कोविड-19 महामारी से पहले एचआईवी / एड्स जैसी बीमारियों के लिए इस्तेमाल किया गया है। आम तौर पर, जब किसी मरीज पर नाक स्वाब का उपयोग करके एक कोविड-19 परीक्षण किया जाता है, तो उस नमूने को व्यक्तिगत रूप से यह निर्धारित करने के लिए परीक्षण किया जाता है कि क्या वायरस मौजूद है, और यह कहीं भी 15 मिनट से लेकर कई दिनों तक, क्षमताओं के आधार पर ले सकता है। प्रयोगशाला परीक्षण चल रहा है। पूल परीक्षण के साथ, कहीं से भी 3 - 50 नमूने संयुक्त होते हैं और सभी स्वाबों का एक ही बार परीक्षण किया जाता है। यदि उस पूल परीक्षण से परीक्षा परिणाम नकारात्मक है, तो उस पूल के सभी रोगियों में वायरस नहीं होता है। यदि परिणाम सकारात्मक है, तो प्रत्येक स्वाब को एक-एक करके परीक्षण किया जाना चाहिए।\n\nपूल परीक्षण, जिसे \"बैच परीक्षण\" भी कहा जाता है, वर्तमान में अकेले व्यक्तिगत परीक्षणों की तुलना में कोविड-19 के लिए कई और लोगों का परीक्षण करने के लिए उपयोग किया जा रहा है। ऐसा इसलिए है क्योंकि मरीजों के परीक्षण के बजाय और फिर उनके नमूनों का विश्लेषण व्यक्तिगत रूप से यह निर्धारित करने के लिए किया जाता है कि कोई रोगी कोविड-19 से संक्रमित है या नहीं, पूल परीक्षण कई नमूनों को जोड़ती है और एक ही समय में उनका परीक्षण करती है।"
    ],
    "Hindi - Background and context": [
      "कोविड-19 के लिए \"पूल परीक्षण\" के बारे में समाचारों में कई सुर्खियां बनी हैं। कोविड-19 के पूल परीक्षण को पहले ही लागू किया जा चुका है या वर्तमान में कई स्थानों पर माना जा रहा है, विशेष रूप से जहां बड़ी आबादी के साथ-साथ सीमित समय और परीक्षण के लिए आपूर्ति होती है। उदाहरण के लिए, चीनी स्वास्थ्य अधिकारियों ने वुहान और बीजिंग में इस पद्धति का उपयोग बड़ी संख्या में लोगों को जल्दी से करने के लिए किया है। अमेरिकी संघीय स्वास्थ्य अधिकारियों ने भी पूल परीक्षण की क्षमता पर चर्चा की है, नेब्रास्का पब्लिक हेल्थ लेबोरेटरी जब यह मार्च 2020 में अभिकर्मकों के परीक्षण पर कम चल रहा था और तब से श्रम में 20-30% बचत के साथ-साथ 50-60% की बचत हुई है। अधिकांश स्वास्थ्य अधिकारियों का मानना ​​है कि पूल परीक्षण से बचत उन क्षेत्रों के बाहर सीमित होगी जहां वायरस शायद ही मौजूद हो। जबकि अकेले पूल परीक्षण से परीक्षण में वर्तमान बाधाओं को हल करने की उम्मीद नहीं की जाती है, परीक्षण का यह रूप कुछ स्थितियों में एक सहायक उपकरण हो सकता है।"
    ],
    "Portuguese - Background and context": [
      "Recentemente, houve muitas manchetes de jornais sobre \"testes por amostragem coletiva\" para o COVID-19. O teste por amostragem coletiva para o COVID-19 já foi implementado ou está sendo avaliado para adoção em vários lugares, especialmente naqueles onde há grandes populações e restrição de tempo e de suprimentos para realizar testes. Por exemplo, as autoridades de saúde chinesas usaram esse método em Wuhan e Pequim para testar rapidamente um grande número de pessoas. As autoridades de saúde federais dos EUA também têm discutido sobre o interesse desses testes por amostragem coletiva, após as informações sobre os resultados obtidos após o seu uso no Laboratório de Saúde Pública de Nebraska, em um momento quando este dispunha de poucos reagentes de testes, em março de 2020. Desde então, esse laboratório realizou uma economia de 50-60% em reagentes e de 20-30% em mão de obra. A maior parte das autoridades de saúde acredita que a economia com os testes coletivos será menor fora das áreas onde o vírus está pouco presente. Embora os testes por amostragem coletiva sozinho provavelmente não resolvam a sobrecarga atual de demanda, eles podem ser uma ferramenta útil em algumas situações."
    ]
  },
  {
    "id": "recxMAcL4cnvZXzXA",
    "Question": "How can we tell if an increase in cases is the result of an increase in testing or something else?",
    "Status": "Needs + Editing",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "It is important to evaluate the number of cases, availability of testing, and percent positive rate when evaluating if a true climb in cases is due to a growing hotspot or just an increase in testing availability. Often, lack of testing availability can cloud this issue, which is why evaluating this piece of information in comparison to the growth in case counts while considering percent positive, provides a more accurate picture. \n",
    "What our experts say": "A lot can be learned and based off of the percent-positive rate (e.g. how many tests result positive out of all the tests taken) and the number of cases in total. We cannot assume that an increase in cases or a growing percent-positive rate is purely a result of an increase in testing instead of a growing outbreak. Instead, we need to look at all of them together. \n\nA rise in the number of reported cases of COVID-19 could be related to an expansion of testing if the percentage of positive tests decreases or stays the same at the same time that the number of cases increases. Should percentage of positive tests increase while case counts also go up, this indicates that we cannot entirely blame the increase on expanded testing. The biggest indicator of a growing outbreak is if the percentage of positive tests increases along with the number of cases despite testing data staying the same or decreasing. \n\nWhen testing is not always widely available and reserved just for symptomatic people, the percent positivity will increase as with the number of cases. If testing is expanded and made more available, we will gain a better understanding of the true number of cases and percent-positive rate. If this percent positivity continues to grow along with the number of cases, this would be an indicator that the outbreak is worsening. \n",
    "Glossary Terms": [
      "recOfgrqkPp7aa14o"
    ],
    "Variation of the answer depending on country of residence": "Yes\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "testing"
    ],
    "Other resources": "1. [The COVID Tracking Project](https://covidtracking.com/blog/its-not-just-testing) - Testing\n",
    "Last modified manual": "2020-07-08",
    "Last edited (simplified)": "2020-07-06T19:08:39.000Z",
    "Last edited (experts say)": "2020-07-08T06:02:29.000Z",
    "Last modified": "2020-07-08",
    "What our experts say wordcount": 231,
    "Background and context wordcount": 72,
    "Other resources wordcount": 7,
    "Wordcount": 310
  },
  {
    "id": "recNc4mA4qLSS9LqG",
    "Question": "What does it mean to have a fever?",
    "Status": "Published",
    "Source of the question": [
      "Newsroom"
    ],
    "Background and context": "Fever has emerged as a common symptom of COVID-19 infection. A World Health Organization report from February of 2020 suggested that fever was reported in 87.9% of patients with confirmed COVID-19. Fever is an increase in body temperature that is a common symptom of illness or infection, but there are other possible reasons for fever that include heat exhaustion, some medications or immunizations, certain types of cancers, and some inflammatory conditions (i.e. rheumatoid arthritis).  \n\nWhile the average normal temperature is 98.6°F (37°C), there is some individual variation where an individual’s normal temperature may be slightly higher or lower even when he or she is healthy. In addition, normal body temperature can vary during the day and is often lower in the morning and higher later in the day. A normal temperature range is generally about 97°F (36.1°C) to 99°F (37.2°C).  \n",
    "What our experts say": "Having a fever means that your body temperature has temporarily increased and it is a signal that your body may be fighting off an infection. The U.S. Centers for Disease Control define a fever as a measured temperature of at least 100.4°F (38°C), slightly higher than the average human temperature of 98.6°F (37°C). Fevers are one of the immune system's first reactions to a pathogen - such as a virus or bacteria entering the body. Fevers can also be caused by environmental factors like heat stroke or biological responses like alcohol withdrawal. Your body senses these potential threats and forces itself to raise its temperature (by creating a fever, through chemicals in your blood called 'pyrogens') to make it difficult for the pathogen to use your body as a host and reproduce viruses or bacteria. \n\nNormal body temperatures change every day and usually vary between 97.6°F (36.4°C) and 99.6 °F (37.5°C) with lower body temperatures generally occurring in the morning and higher temperatures occurring at night. For most adults, short-term fevers shouldn't be alarming unless it reaches 103°F (39.4°C) or higher. For infants younger than 3 months, a rectal temperature of 100.4°F (38°C) or higher signals a fever and in that case a doctor should be contacted. For infants between 3 - 24 months, a rectal temperature of 102°F (38.9°C) signals a fever that should also be discussed with a doctor. For other young children, even slight fevers can signal infections, so a doctor should be consulted if a fever appears.\n\n",
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "Yes; age (with the assumption that this is for non-child audiences)\n",
    "Topics": [
      "fever",
      "febrile",
      "definition"
    ],
    "Other resources": "1. CDC Definition of Signs, Symptoms, and Conditions of Ill Travelers ([U.S. CDC](https://www.cdc.gov/quarantine/maritime/definitions-signs-symptoms-conditions-ill-travelers.html))\n2. An article about fever and the immune system ([NIH/NCBI](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786079/))\n3. An article about fevers promoting T lymphocyte trafficking ([Cell](https://www.cell.com/immunity/fulltext/S1074-7613(18)30495-3))\n4. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) ([WHO](https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf))\n5. Fever ([Mayo Clinic](https://www.mayoclinic.org/diseases-conditions/fever/symptoms-causes/syc-20352759))\n",
    "DB (Hindi)": [
      "recKxmodohxWvsOKO"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recGBuwcu9HkpA1AG"
    ],
    "DB (Portuguese)": [
      "rechC5oqs3QgxiFAg"
    ],
    "Rollup test 2": [
      "recmn7jqMUgeoHa5h"
    ],
    "Last modified manual": "2020-07-08",
    "Last edited (simplified)": "2020-07-07T22:48:14.000Z",
    "Last edited (experts say)": "2020-07-08T00:23:03.000Z",
    "Last modified": "2020-07-08",
    "What our experts say wordcount": 251,
    "Background and context wordcount": 139,
    "Other resources wordcount": 46,
    "Wordcount": 436,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "बुखार होने का मतलब है कि आपके शरीर का तापमान अस्थायी रूप से बढ़ गया है और यह संकेत है कि आपका शरीर किसी संक्रमण से लड़ रहा है। यू.एस. सेंटर फॉर डिजीज कंट्रोल कम से कम 100.4 ° F (38 ° C) के मापा तापमान के रूप में बुखार को परिभाषित करता है, जो 98.6 ° F (37 ° C) के औसत मानव तापमान से थोड़ा अधिक है। बुखार एक रोगज़नक़ के लिए प्रतिरक्षा प्रणाली की पहली प्रतिक्रियाओं में से एक हैं - जैसे कि वायरस या बैक्टीरिया शरीर में प्रवेश करना। हीट स्ट्रोक या जैविक प्रतिक्रिया जैसे अल्कोहल विदड्रॉल जैसे पर्यावरणीय कारकों के कारण भी बुखार हो सकता है। आपका शरीर इन संभावित खतरों को भांप लेता है और अपने तापमान को बढ़ाने के लिए खुद को मजबूर करता है (बुखार पैदा करके, आपके रक्त में रसायनों के माध्यम से 'पाइरोजेन') जिसे रोगज़नक़ के लिए आपके शरीर को एक मेजबान के रूप में उपयोग करना और वायरस या बैक्टीरिया को पुन: उत्पन्न करना मुश्किल हो जाता है।\n\nसामान्य शरीर के तापमान में हर दिन बदलाव होता है और आमतौर पर 97.6 ° F (36.4 ° C) और 99.6 ° F (37.5 ° C) के बीच का अंतर होता है, जिसमें शरीर का तापमान सामान्य रूप से कम होता है और रात में उच्च तापमान होता है। जब तक यह 103 ° F (39.4 ° C) या इससे अधिक नहीं हो जाता, तब तक अधिकांश वयस्कों के लिए, अल्पकालिक बुखार की स्थिति भयावह नहीं होनी चाहिए। 3 महीने से कम उम्र के शिशुओं के लिए, 100.4 ° F (38 ° C) का उच्च तापमान या उच्च बुखार बुखार का संकेत देता है और उस स्थिति में डॉक्टर से संपर्क किया जाना चाहिए। 3 से 24 महीने के शिशुओं के लिए, 102 ° F (38.9 ° C) का एक रेक्टल तापमान बुखार का संकेत देता है, जिस पर डॉक्टर से भी चर्चा करनी चाहिए। अन्य युवा बच्चों के लिए, यहां तक ​​कि मामूली बुखार भी संक्रमण का संकेत दे सकते हैं, इसलिए बुखार दिखाई देने पर डॉक्टर से परामर्श किया जाना चाहिए।"
    ],
    "Hindi - Background and context": [
      "बुखार कोविड-19 संक्रमण के एक सामान्य लक्षण के रूप में उभरा है। 2020 के फरवरी से एक विश्व स्वास्थ्य संगठन की रिपोर्ट ने पुष्टि की कि कोविड-19 के साथ 87.9% रोगियों में बुखार की सूचना दी गई थी। बुखार शरीर के तापमान में वृद्धि है जो बीमारी या संक्रमण का एक सामान्य लक्षण है, लेकिन बुखार के अन्य संभावित कारण हैं जिनमें गर्मी का थकावट, कुछ दवाएं या टीकाकरण, कुछ प्रकार के कैंसर, और कुछ भड़काऊ स्थितियां (यानी गठिया) शामिल हैं।\n \n जहां औसत सामान्य तापमान 98.6 ° F (37 ° C) होता है, वहीं कुछ अलग-अलग भिन्नताएँ होती हैं, जहाँ किसी व्यक्ति का सामान्य तापमान उसके स्वस्थ होने पर भी थोड़ा अधिक या कम हो सकता है। इसके अलावा, सामान्य शरीर का तापमान दिन के दौरान अलग-अलग हो सकता है और अक्सर सुबह में कम और बाद में अधिक होता है। एक सामान्य तापमान रेंज आमतौर पर 97 ° F (36.1 ° C) से 99 ° F (37.2 ° C) होता है।"
    ]
  },
  {
    "id": "rec1KveB4FFU90Equ",
    "Question": "What do we know so far about COVID-19 losing its potency?",
    "Status": "Published",
    "Subcategory": "On: COVID-19 & potency",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Viruses reproduce themselves in bodies by injecting their DNA or RNA into cells in the body. The genetic material from that injection becomes a blueprint for how to make more and more of the virus.\nEventually the cells in our bodies recognize the virus, and develop new ways to prevent it from duplicating. So viruses adapt by mutating, which disguises them once again from our immune systems so they can continue to duplicate.\n Mutation for viruses simply means a change or transformation. RNA viruses, like SARS-CoV-2 which causes COVID-19, mutate a lot. It is important to track these mutations to understand the various identities of the virus and map its trends across the world. However, as these changes happen, it's also important to understand what adaptation the virus is taking and what are their consequences on human health. It's important to keep in mind that mutations might not translate to drastic changes in severity of the illness or increase its mortality. Mutations are a natural process for RNA viruses and should not be seen as an indicator for suddenly a newer, deadlier virus. Understanding these viral changes and genomic epidemiology can help us understand outbreaks better. \n",
    "What our experts say": "There is no evidence to support the idea that the virus has lost its potency. This question likely stems from comments made by an Italian doctor claiming that COVID-19 is losing its potency by mutating into a less harmful version of itself. However, this has been refuted by the World Health Organization and other respected health and medical bodies. \n\nViral mutations are a common aspect of a virus' lifespan and do not necessarily mean that they will become more deadly, contagious, or inherently different.  Mutations that might change how the virus is transmitted, or how it infects people, does not mean that the mutated virus will spread more or be more harmful. Nor does it mean it will spread less or be less harmful. So far, researchers have stated that while the virus is mutating (like all viruses do) these changes do not translate to significant adjustments in transmission or harm to patients.\n",
    "Glossary Terms": [
      "recnFUXyIZy81Rj1I",
      "recohdNoEKptcRCtT",
      "recmIgJvajdxBf3eI",
      "recS7r4IRJ4w3tzwS",
      "reccH9Nhjj0fi18nJ"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "mutation",
      "virus",
      "RNA",
      "protein spikes"
    ],
    "Other resources": "1. We shouldn’t worry when a virus mutates during disease outbreaks ([Nature](https://www.nature.com/articles/s41564-020-0690-4)) \n",
    "DB (Hindi)": [
      "recBSejrBcKWeuOVp"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recIwQ9wp8X1WIHse"
    ],
    "DB (Portuguese)": [
      "recjxr1Kn26X4qlsO"
    ],
    "Rollup test 2": [
      "receISvbmLprLv242"
    ],
    "Last modified manual": "2020-07-07",
    "Last edited (simplified)": "2020-06-25T05:09:05.000Z",
    "Last edited (experts say)": "2020-06-25T05:09:05.000Z",
    "Last modified": "2020-07-07",
    "What our experts say wordcount": 154,
    "Background and context wordcount": 196,
    "Other resources wordcount": 13,
    "Wordcount": 363,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "इस विचार का समर्थन करने के लिए कोई सबूत नहीं है कि वायरस ने अपनी शक्ति खो दी है। यह सवाल संभवतः एक इटालीयन चिकित्सक द्वारा की गई टिप्पणियों से उपजा है, जिसमें दावा किया गया है कि कोविड -19 स्वयं के कम हानिकारक संस्करण में उत्परिवर्तन  (म्यूटेट) करके अपनी शक्ति खो रहा है। लेकिन, विश्व स्वास्थ्य संगठन और अन्य सम्मानित स्वास्थ्य और चिकित्सा संस्थानों द्वारा इसका खंडन किया गया है।\n\nवायरल म्यूटेशन एक वायरस के जीवनकाल का एक सामान्य पहलू है और जरूरी नहीं कि वे अधिक घातक, संक्रामक या स्वाभाविक रूप से अलग हो जाएंगे। म्यूटेशन जो वायरस कैसे प्रसारित होता है उसे बदल सकते हैं या लोगों को किस तरह संक्रमित करते हैं, इसका मतलब यह नहीं है कि म्यूटेटेड वायरस अधिक प्रसारित होंगे या अधिक हानिकारक होंगें। न ही इसका मतलब है कि यह कम फैलेगा या कम हानिकारक होगा। अब तक, शोधकर्ताओं ने कहा है कि वायरस उत्परिवर्तित हो रहा है (जैसे सभी वायरस करते हैं), इसका मतलब यह नहीं है कि वाइरस प्रसारित होने में या रोगियों को हानि पहुँचने में कोई बदलाव हुआ है।"
    ],
    "Hindi - Background and context": [
      "वायरस शरीर की कोशिकाओं (सेल्ज़)में अपने डीएनए या आरएनए को इंजेक्ट करके खुद को फैलता हैं। इसके आनुवंशिक (जेनेटिक) पदार्थ वायरस को अधिक से अधिक फैलने के लिए एक खाके की तरह मदद करते हैं। आखिरकार हमारे शरीर की कोशिकाएं वायरस को पहचान जाती हैं, और इसे रोकने के लिए नए तरीके विकसित करती हैं। फिर, वायरस उत्परिवर्तन (म्यूटेशन) द्वारा परिवर्तित होते हैं,  ताकि हमारी इम्यून सिस्टम इन्हें ना पकड़ पाए, और ये दोबारा से बढ़ने लगे। \nवायरस के लिए म्यूटेशन का अर्थ केवल परिवर्तन है। आर॰एन॰ ए॰ वायरस, जैसे कि सार्स -सीओवी -2, जो कोविड​​-19 का कारण बनता है, बहुत परिवर्तन करते हैं। वायरस की विभिन्न पहचानों को समझने और दुनिया भर में इसके रुझानों को मैप करने के लिए इन म्यूटेशन को ट्रैक करना महत्वपूर्ण है। जैसे ये परिवर्तन हो रहें हैं, यह समझना भी महत्वपूर्ण है कि वायरस क्या रूपांतर ले रहा है और मानव स्वास्थ्य पर उनके परिणाम क्या हैं। यह ध्यान रखना महत्वपूर्ण है कि म्यूटेशन का अर्थ बीमारी की गंभीरता में भारी बदलाव या इसकी मृत्यु दर में वृद्धि नहीं समझ लेना चाहिए। उत्परिवर्तन आर॰एन॰ए॰ वायरस के लिए एक प्राकृतिक प्रक्रिया है और इसे अचानक नए, घातक वायरस के लिए एक संकेतक के रूप में नहीं देखा जाना चाहिए। इन वायरल परिवर्तनों और जीनोमिक महामारी विज्ञान को समझने से हमें प्रकोप को बेहतर ढंग से समझने में मदद मिल सकती है।"
    ]
  },
  {
    "id": "recBkQVlmOqcxKt8t",
    "Question": " Can animals with no symptoms spread COVID?",
    "Status": "Published",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "With an upward trend in adopting pets from shelters during the pandemic, some people are concerned about the risk of animals spreading COVID-19. Additionally, there have been news reports of animals living in households and zoos testing positive for COVID-19, including tigers, lions, and domesticated cats and dogs. The U.S. Centers for Disease Control and Prevention (CDC) says that while the risk of animals spreading COVID-19 is considered low, current recommendations include isolating pets from any sick people in the household as well as limiting interactions between pets and people outside of the household. Both animals and humans can test positive for COVID-19 without showing symptoms.\n",
    "What our experts say": "Yes, but mostly to other animals of the same species. Currently, there is no evidence that animals are a major cause of spreading COVID-19 and the risk of animals passing COVID-19 to humans is low. \n\nAccording to a recently published study in the New England Journal of Medicine, transmission of the virus has been reported between cats, none of which had symptoms. The study found that three domestic cats infected with the SARS-CoV-2 virus that causes COVID-19 were able to transmit the virus to three other cats with no previous infection. None of the cats in the experiment showed any symptoms during the course of infection, but researchers found the continued spreading the virus from their noses for about six days. However, the research is rapidly evolving. This is just the first study to document asymptomatic transmission of COVID-19 in cats and as of now, there is no evidence of transmission of COVID-19 from cats to humans. \n\nCats aren't the only animals that have been shown to spread the virus with no symptoms. Based on recent research conducted by the Dutch government, it is believed that minks infected with COVID-19 spread the virus to two human employees at regional farms. The minks were having symptoms of a respiratory illness, while another study about COVID-19 in animals has shown that mink can be infected with the virus without having any symptoms.\nDogs, tigers, lions, and ferrets have also tested positive for COVID-19, but these animals all showed symptoms after testing positive for the virus and likely acquired the virus from humans. \n\n\n",
    "Glossary Terms": [
      "rec2UNEXbTkSCx30Q",
      "recx2PeCcs1Awb9rG"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "transmission"
    ],
    "Other resources": "1. Transmission of SARS-CoV-2 in Domestic Cats ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMc2013400?query=featured_coronavirus))\n2. CDC article on Animals and COVID-19 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/animals.html))\n3. American Veterinary Medical Association article about COVID-19 in animals ([AVMA](https://www.avma.org/resources-tools/animal-health-and-welfare/covid-19/depth-summary-reports-naturally-acquired-sars-cov-2-infections-domestic-animals-and-farmed-or))\n4. United States Department of Agriculture Foreign Agricultural Service report on control measures for the Dutch mink industry in response to COVID-19 ([USDA](https://apps.fas.usda.gov/newgainapi/api/Report/DownloadReportByFileName?fileName=Additional%20Control%20Measures%20for%20Dutch%20Mink%20Industry%20In%20Response%20to%20COVID-19_The%20Hague_Netherlands_05-19-2020))\n5. Pets and Other Animals ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/animals/pets-other-animals.html))\n",
    "DB (Hindi)": [
      "recnIfwtWZb5Yql0g"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "rec2kRM8YIIu4DYQm"
    ],
    "DB (Portuguese)": [
      "recDlsEmWCRqclCQW"
    ],
    "Last modified manual": "2020-07-07",
    "Last edited (simplified)": "2020-07-07T06:31:29.000Z",
    "Last edited (experts say)": "2020-07-07T13:01:41.000Z",
    "Last modified": "2020-07-07",
    "What our experts say wordcount": 260,
    "Background and context wordcount": 106,
    "Other resources wordcount": 54,
    "Wordcount": 420,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "हां, लेकिन ज्यादातर एक ही प्रजाति के अन्य जानवरों के लिए। वर्तमान में, इस बात का कोई सबूत नहीं है कि जानवर कोविड-19 फैलाने का एक प्रमुख कारण हैं और कोविड-19 को मनुष्यों को देने वाले जानवरों का जोखिम कम है।\n\nन्यू इंग्लैंड जर्नल ऑफ मेडिसिन में हाल ही में प्रकाशित एक अध्ययन के अनुसार, बिल्लियों के बीच वायरस के संचरण की सूचना दी गई है, जिनमें से किसी में भी लक्षण नहीं थे। अध्ययन में पाया गया कि SARS-CoV-2 वायरस से संक्रमित तीन घरेलू बिल्लियां, जो कोविड-19 का कारण बनती हैं, पिछले संक्रमण के बिना वायरस को तीन अन्य बिल्लियों में संचारित करने में सक्षम थीं। प्रयोग के दौरान बिल्लियों में से किसी ने भी संक्रमण के दौरान कोई लक्षण नहीं दिखाया, लेकिन शोधकर्ताओं ने पाया कि छह दिनों तक उनकी नाक से वायरस फैलता रहा। हालांकि, अनुसंधान तेजी से विकसित हो रहा है। बिल्लियों में कोविड-19 के स्पर्शोन्मुख संचरण का दस्तावेज बनाने का यह पहला अध्ययन है और अब तक, बिल्लियों से मनुष्यों तक कोविड-19 के प्रसारण का कोई सबूत नहीं है।\n \nबिल्लियों केवल जानवर नहीं हैं जिन्हें बिना किसी लक्षण के वायरस को फैलाने के लिए दिखाया गया है। डच सरकार द्वारा किए गए हालिया शोध के आधार पर, यह माना जाता है कि कोविड-19 से संक्रमित मिंक ने क्षेत्रीय खेतों में दो मानव कर्मचारियों में वायरस फैलाया। मिंक एक श्वसन बीमारी के लक्षण थे, जबकि जानवरों में कोविड-19 के बारे में एक अन्य अध्ययन से पता चला है कि मिंक किसी भी लक्षण के बिना वायरस से संक्रमित हो सकता है।\nकुत्तों, बाघों, शेरों और फिरोजों ने भी कोविड-19 के लिए सकारात्मक परीक्षण किया है, लेकिन इन जानवरों ने वायरस के लिए सकारात्मक परीक्षण करने के बाद लक्षण दिखाए हैं और संभवतः मनुष्यों से वायरस का अधिग्रहण किया है।"
    ],
    "Hindi - Background and context": [
      "महामारी के दौरान आश्रयों से पालतू जानवरों को अपनाने की प्रवृत्ति के कारण, कुछ लोगों को कोविड-19 फैलाने वाले जानवरों के जोखिम के बारे में चिंतित हैं। इसके अतिरिक्त, बाघों, शेरों और पालतू बिल्लियों और कुत्तों सहित कोविड-19 के लिए घरों और चिड़ियाघरों के परीक्षण में सकारात्मक रहने वाले जानवरों की खबरें मिली हैं। यूएस सेंटर फॉर डिसीज कंट्रोल एंड प्रिवेंशन (सीडीसी) का कहना है कि जहां कोविड-19 फैलाने वाले जानवरों के जोखिम को कम माना जाता है, मौजूदा सिफारिशों में घर के किसी भी बीमार लोगों से पालतू जानवरों को अलग करने के साथ-साथ पालतू जानवरों और लोगों के बीच बातचीत को सीमित करना शामिल है। जानवरों और मनुष्यों दोनों लक्षण दिखाए बिना कोविड-19 के लिए सकारात्मक परीक्षण कर सकते हैं।"
    ]
  },
  {
    "id": "recYyHq4Ec1FWbNtQ",
    "Question": "What are the three phases of vaccine testing?",
    "Status": "Published",
    "Category": "Treatment",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "There is growing interest in understanding the process of testing vaccines, to get a sense of how long it may take before there is a widely-available vaccine to address the COVID-19 pandemic. There have been many press releases and articles about vaccines in development and the start of human trials, yet health experts at the U.S. Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) warn that it will take time to screen out ineffective and unsafe vaccines as well as to prepare for vaccine use at scale. People are eager for a vaccine to be ready soon for many reasons, including protection of human life, economic recovery, reducing educational interruptions, and lifting restrictions on activities that people enjoy.\n",
    "What our experts say": "Substantial research needs to be completed by scientists before any potential vaccine undergoes phased testing. Once it gets to that stage, there are three research phases of trials that take place before the vaccine can be deployed for use. During the first stage (Phase I), the new vaccine is provided to small groups of people—the first time the vaccine is tested in humans. The second stage (Phase II) involves testing the vaccine on people who have similar characteristics (such as age and physical health) to the target population, or the group for which the vaccine is intended. The goal of this stage is to identify the most effective dosages and schedule for Phase III trials. The final stage (Phase III) provides the vaccine to thousands of people from the target population to see how safe and effective it is. Once the vaccine clears this last stage, the manufacturer can apply for a license from regulatory authorities (like the FDA) to market for human use.\n\nSometimes medications that have already been approved by the U.S. Food and Drugs Administration in clinical trials will enter into a Phase IV trial. This phase focuses on potential side effects from the vaccine or medication that were not seen in the first three phases. This phase also helps researchers understand how well a vaccine works over a longer time frame and how safe it is, often with thousands of people over several years. Phase IV is also called a 'post-marketing surveillance' trial.\n\n\n",
    "Glossary Terms": [
      "recMJMGqkERKGcbL5"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "methodologies"
    ],
    "Other resources": "1. Vaccine Testing and the Approval Process ([U.S. CDC](https://www.cdc.gov/vaccines/basics/test-approve.html))\n\n",
    "DB (Hindi)": [
      "recn7OxPiCFpvXq7U"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "rectIt8l9QjDgEAHV"
    ],
    "DB (Portuguese)": [
      "rec4J40z7KszomeHv"
    ],
    "Rollup test 2": [
      "recoOPZ2hUsRl6ssU"
    ],
    "Last modified manual": "2020-07-07",
    "Last edited (simplified)": "2020-07-07T06:31:02.000Z",
    "Last edited (experts say)": "2020-07-07T06:31:02.000Z",
    "Last modified": "2020-07-07",
    "What our experts say wordcount": 246,
    "Background and context wordcount": 122,
    "Other resources wordcount": 9,
    "Wordcount": 377,
    "Hindi Q Status": [
      "In progress"
    ],
    "Hindi - What our experts say": [
      "वैज्ञानिकों द्वारा पर्याप्त प्रयोग होने के बाद ही किसी भी सम्भावित वैक्सीन(टिका) के परीक्षण के चरण चालू किए जा सकते हैं। उस पड़ाव में पहुंचने के बाद परीक्षण के तीन शोध चरण होते हैं, जो कि टीके के उपयोग से पहले किए जाते हैं। पहले चरण (प्रथम चरण या फ़ेज़ 1) के दौरान, नया टीका लोगों के छोटे समूहों को प्रदान किया जाता है - पहली बार जब टीका का मनुष्यों में परीक्षण किया जाता है। दूसरे चरण (फ़ेज़ II) में वैक्सीन का परीक्षण उन लोगों पर किया जाता है, जिनमें रोगियों (समस्या ग्रहक) के समान विशेषताएं हों (जैसे कि आयु और शारीरिक स्वास्थ्य, या वह समूह जिसके लिए वैक्सीन तैयार किया गया हो। इस चरण का लक्ष्य चरण III परीक्षणों के लिए सबसे प्रभावी खुराक और अनुसूची की पहचान करना है। अंतिम चरण (फ़ेज़ III) लक्षित आबादी के हजारों लोगों को यह देखने के लिए टीका प्रदान करता है कि यह कितना सुरक्षित और प्रभावी है। टीके के इस अंतिम चरण को पार करने के बाद, निर्माता नियामक प्राधिकरणों (एफडीए की तरह) से मानव उपयोग के लिए लाइसेंस का आवेदन कर सकता है।\nकभी-कभी नैदानिक ​​परीक्षणों में अमेरिकी खाद्य और औषधि प्रशासन (एफ़॰डी॰ए॰) द्वारा पहले से ही अनुमोदित दवाओं को चरण IV परीक्षण में प्रवेश किया जाएगा। यह चरण वैक्सीन या दवा से संभावित दुष्प्रभावों पर केंद्रित है जो पहले तीन चरणों में नहीं देखा गया था। यह चरण शोधकर्ताओं को यह समझने में भी मदद करता है कि वैक्सीन एक लंबी समय सीमा में कितनी अच्छी तरह काम करती है और कितनी सुरक्षित है, अक्सर यह चरण कई वर्षों के दौरान हजारों लोगों के साथ होती है। फेज IV को 'पोस्ट-मार्केटिंग सर्विलांस' ट्रायल भी कहा जाता है।"
    ],
    "Hindi - Background and context": [
      "वैक्सीन के जाँच की प्रक्रिया को समझने की रुचि बढ़ रही है, क्योंकि लोग ये समझना चाह रहें हैं कि कोविड-19 के वैक्सीन के विस्तृत रूप से मिलने की कब तक सम्भावना है। वैक्सीन की डिवेलप्मेंट्स और उनका मनुष्यों पर प्रयोग पर कई लेख एंड प्रेस रिलीज़ पाए जा सकते हैं, लेकिन यू॰एस॰-सी॰डी॰सी॰ और डबल्यू॰एच॰ओ॰ के विशेषज्ञों ने चेताया है कि प्रभावहीन और असुरक्षित वैक्सींज़ को हटाने और सही वैक्सीन का अधिक मात्रा में निर्माण करने में समय लगेगा। लोग कई कारणों से वैक्सीन के जल्द ही तैयार होने के लिए उत्सुक हैं, जिसमें मानव जीवन की सुरक्षा, आर्थिक सुधार, शैक्षिक रुकावटों को कम करना और लोगों द्वारा आनंद लेने वाली गतिविधियों पर से रुकावटें हटना लगाना शामिल हैं।"
    ]
  },
  {
    "id": "recm3J9EyzMDr8Diz",
    "Question": "Is it true that India's Bharat Biotech is not too far away from finding a vaccine for COVID-19 as they have now been approved for human trials?",
    "Status": "Published",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "India"
    ],
    "Background and context": "Bharat Biotech International Limited is a Hyderabad-based pharmaceutical company that focuses primarily on manufacturing vaccines and bio-therapeutics. It has produced over 160 patents since starting operations in 1996. On June 29, 2020, Bharat Biotech announced that it received regulatory approval for Phase 1 and Phase 2 human clinical trials for COVAXIN, India’s first homegrown vaccine for SARS-CoV-2, from the Drug Controller General of India (DCGI) after submitting data from preclinical studies. The vaccine was developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). ICMR had initially announced an ambitious deadline of August 15th 2020 to launch the vaccine, which was criticized by doctors and researchers as a rushed and impractical timeline that carried substantial risks. The vaccine is currently in Phase II trials.\n",
    "What our experts say": "At this time, it is unlikely that a vaccine for COVID-19 will be produced before 2021. The Indian Council of Medical Research, the primary body overseeing clinical research for COVID-19 in India, has pushed to fast-track clinical trials for the Bharat Biotech-developed drug COVAXIN, which is currently in Phase II trials. ICMR had initially announced an ambitious deadline of August 15th 2020 to launch the vaccine, which had been criticized by doctors and researchers as a rushed and impractical timeline that carries substantial risks. ICMR has clarified that the intention is to complete the trials as fast as possible and speed up recruitment of participants, but everything will depend on the results of the clinical trials. \n\nThe timeline to develop a safe and effective vaccine is lengthy and requires several stages of clinical trials, as well as plenty of regulatory oversight. This process usually takes several months and can continue for more than a year. \n\nEven if pre-clinical data is promising, human clinical trials that are necessary to deploy a vaccine take place in stages that take a very long time, in order to assess efficacy and safety. The process typically takes well over 12 months to complete.\n\nLots of testing happens in animals before a vaccine begins phased testing in humans. During the first stage of vaccine testing on humans (Phase I), a new vaccine is provided to small groups of people—which is the first time the vaccine is tested in humans. The second stage (Phase II) involves testing the vaccine on people who have similar characteristics (such as age and physical health) to the target population, which means the group for which the vaccine is intended. The goal of this stage is to identify the most effective dosages and schedule for Phase III trials. The final stage (Phase III) provides the vaccine to hundreds of people across several different healthcare settings from the target population to see how safe and effective it is. Once the vaccine clears this last stage, the manufacturer can apply for a license from regulatory authorities to market for human use.\n",
    "Glossary Terms": [
      "rec9qqItwSTjq3Eae"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "bharat biotech",
      "covaxin",
      "vaccine"
    ],
    "Other resources": "1. ICMR process to develop vaccine to fight Covid 19 pandemic as per globally accepted norms of fast tracking ([ICMR](https://main.icmr.nic.in/sites/default/files/press_realease_files/ICMR_Press_Release_04072020.pdf))\n2. ICMR's Rush to Produce 'Indian Vaccine' for COVID-19 Suggests Politics is Driving Science ([The Wire](https://thewire.in/health/icmr-balram-bhargava-covaxin-clinical-trials-bharat-biotech-politics))\n3. 'We are working day and night': India races to have coronavirus vaccine by 15th August ([Live Mint](https://www.livemint.com/news/india/-we-are-working-day-and-night-india-races-to-have-coronavirus-vaccine-by-15th-august-11593929050424.html))\n\n",
    "DB (Hindi)": [
      "recMi30IwRzi6fGZR"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recGiwbovLRKyrgMe"
    ],
    "DB (Portuguese)": [
      "rechj73CtF0GG9UMO"
    ],
    "Rollup test 2": [
      "recpgNGdbwpOFVq2j"
    ],
    "Last modified manual": "2020-10-06",
    "Last edited (simplified)": "2020-10-01T18:09:42.000Z",
    "Last edited (experts say)": "2020-10-01T18:09:42.000Z",
    "Last modified": "2020-10-01",
    "What our experts say wordcount": 346,
    "Background and context wordcount": 132,
    "Other resources wordcount": 52,
    "Wordcount": 530,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "इस समय यह संभावना नहीं है कि निकट भविष्य में कोविड-19 के लिए एक टीका का उत्पादन किया जाएगा। इंडियन काउंसिल ऑफ मेडिकल रिसर्च, भारत में कोविड-19 के लिए नैदानिक ​​अनुसंधान की देखरेख करने वाली प्राथमिक संस्था, ने भारत बायोटेक-विकसित दवा कोविक्सिन के लिए नैदानिक ​​परीक्षणों को तेजी से ट्रैक करने के लिए प्रोत्साहित किया है। आइसीएमआर ने वैक्सीन को लॉन्च करने के लिए 15 अगस्त 2020 की एक महत्वाकांक्षी समय सीमा की घोषणा की है, जिसकी डॉक्टरों और शोधकर्ताओं ने काफी जोखिम भरा है। आइसीएमआर ने स्पष्ट किया है कि इसका उद्देश्य प्रतिभागियों की भर्ती को यथासंभव तेज करना है और प्रतिभागियों की भर्ती में तेजी लाना है, लेकिन सब कुछ नैदानिक ​​परीक्षणों के परिणामों पर निर्भर करेगा।\n\nएक सुरक्षित और प्रभावी वैक्सीन विकसित करने की समय सीमा लंबी है और इसके लिए कई चरणों में चिकित्सीय परीक्षण की आवश्यकता होती है, साथ ही साथ बहुत से नियामक निरीक्षण भी किए जाते हैं। इस प्रक्रिया में आमतौर पर कई महीने लगते हैं और एक वर्ष से अधिक समय तक जारी रह सकते हैं। कोविक्सिन के दवा निर्माता भारत बायोटेक ने अपने टीके के लिए चरण 1 और 2 मानव नैदानिक ​​परीक्षणों के लिए विनियामक अनुमोदन प्राप्त किया है। हालांकि, 15 अगस्त, 2020 तक यह संभावना नहीं है कि टीका मानव नैदानिक ​​परीक्षणों के अगले दौर से गुजरेगा और उपयोग के लिए तैयार होगा, जैसा कि आईसीएमआर ने संकेत दिया है।\n\n12 हेल्थकेयर संस्थानों के शोधकर्ताओं के एक निर्देश में, आइसीएमआर के महानिदेशक डॉ. बलराम भार्गव ने दावा किया कि दुनिया का पहला\nकोविड-19 टीका 15 अगस्त तक उपयोग के लिए तैयार होने के लिए जल्द ही भारत में स्वतंत्रता दिवस पर नैदानिक ​​परीक्षण पूरा करना चाहिए। । हालांकि, वैक्सीन पर पूर्व-नैदानिक ​​अध्ययन से डेटा अभी तक प्रकाशित नहीं हुआ है। यहां तक ​​कि अगर प्री-क्लिनिकल डेटा का वादा किया जा रहा है, तो मानव क्लिनिकल परीक्षण जो वैक्सीन को तैनात करने के लिए आवश्यक हैं, वे चरणों में होते हैं जो प्रभावकारिता और सुरक्षा का आकलन करने के लिए बहुत लंबा समय लेते हैं। इस प्रक्रिया को पूरा होने में आम तौर पर 12 महीने से अधिक समय लगता है।\n\nमनुष्यों में एक टीके के चरणबद्ध परीक्षण शुरू होने से पहले जानवरों में बहुत सारे परीक्षण होते हैं। मनुष्यों पर टीका परीक्षण के पहले चरण (चरण I) के दौरान, लोगों के छोटे समूहों को एक नया टीका प्रदान किया जाता है - जो पहली बार मनुष्यों में टीका का परीक्षण किया जाता है। दूसरे चरण (चरण II) में वैक्सीन का परीक्षण उन लोगों पर किया जाता है, जिनके पास लक्ष्य आबादी के समान विशेषताओं (जैसे उम्र और शारीरिक स्वास्थ्य) है, जिसका अर्थ उस समूह से है जिसके लिए वैक्सीन का इरादा है। इस चरण का लक्ष्य चरण III परीक्षणों के लिए सबसे प्रभावी खुराक और अनुसूची की पहचान करना है। अंतिम चरण (चरण III) लक्ष्य आबादी से कई अलग-अलग स्वास्थ्य देखभाल सेटिंग्स के सैकड़ों लोगों को टीका प्रदान करता है कि यह कितना सुरक्षित और प्रभावी है। एक बार टीके के इस अंतिम चरण को साफ करने के बाद, निर्माता नियामक प्राधिकरणों से मानव उपयोग के लिए बाजार में लाइसेंस के लिए आवेदन कर सकता है।"
    ],
    "Hindi - Background and context": [
      "भारत बायोटेक इंटरनेशनल लिमिटेड एक हैदराबाद स्थित फार्मास्युटिकल कंपनी है जो मुख्य रूप से वैक्सीन और बायो-थैरेप्यूटिक्स के निर्माण पर ध्यान केंद्रित करती है। 1996 में परिचालन शुरू करने के बाद से यह 160 से अधिक पेटेंट का उत्पादन कर चुका है।\n\n29 जून, 2020 को, भारत बायोटेक ने घोषणा की कि उसने चरण 1 और चरण 2 के लिए विनियामक अनुमोदन प्राप्त किया कोवेक्सीन के लिए, SARS-CoV-2 के लिए भारत का पहला घरेलू टीका, ड्रग कंट्रोलर जनरल ऑफ इंडिया (डीसीजीआइ) प्रीक्लिनिकल स्टडीज से डेटा जमा करने के बाद।\n\n वैक्सीन को भारतीय चिकित्सा अनुसंधान परिषद (आइसीएमआर) और नेशनल इंस्टीट्यूट ऑफ वायरोलॉजी (एनआइवी) के सहयोग से विकसित किया गया था। आइसीएमआर ने वैक्सीन को लॉन्च करने के लिए 15 अगस्त 2020 की एक महत्वाकांक्षी समय सीमा की घोषणा की है, जिसकी डॉक्टरों और शोधकर्ताओं ने काफी जोखिम भरा है। आइसीएमआर ने स्पष्ट किया है कि इसका उद्देश्य प्रतिभागियों की भर्ती को यथासंभव तेज करना है और प्रतिभागियों की भर्ती में तेजी लाना है, लेकिन सब कुछ नैदानिक ​​परीक्षणों के परिणामों पर निर्भर करेगा।"
    ]
  },
  {
    "id": "rec8zcMD0iZGhQTje",
    "Question": "How reliable are temperature checks for re-opening businesses?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & business reopenings",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Many businesses and organizations are following World Health Organization (WHO) and U.S. Centers for Disease Control recommendations for measuring the temperature of every employee at a business location, though this is not a requirement or recommendation in every state in the United States or every country in the world. As temperature checks are not a stipulation to re-open a business in most countries, many business owners have opted not to perform this task.\n\n",
    "What our experts say": "Checking people for fever before they interact with others has been proposed as a means to help reduce transmission of disease. Some countries such as China and South Korea have widespread checks of body temperature to help identify individuals with fevers in offices, restaurants, airports, or other popularly-frequented locations. As a standalone measure, checking for fever is insufficient to prevent disease transmission because of how asymptomatic and pre-symptomatic people can get others sick. Diagnostic testing for COVID-19 - not temperature checks - is a much more accurate, effective means of determining whether or not employees might be infected with the virus. Additionally, temperature testing may be difficult to implement in some locations due to limited resources, privacy concerns, and other reasons. \n\nSome experts have cited concerns about workplace surveillance and privacy while using infrared temperature checks. There are also questions about the effectiveness and accuracy of these workplace thermometers, especially considering how many pre-symptomatic and asymptomatic patients might not have any symptoms during the duration of their illness. Lastly, fevers might be indicative of other factors or illnesses unrelated to COVID-19; for example, elevated body temperature is commonly observed in people who are physically exerting energy or under great stress.\n",
    "Glossary Terms": [
      "recKu4mUCSpc8htlJ",
      "recKCiSoxquMlP5ia",
      "recqLd1GRoBwTquBo"
    ],
    "Variation of the answer depending on country of residence": "Yes\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "thermometer",
      "temperature",
      "business"
    ],
    "Other resources": "1. COVID‑19 Strategy Update 14 April 2020 ([WHO](https://www.who.int/docs/default-source/coronaviruse/covid-strategy-update-14april2020.pdf?sfvrsn=29da3ba0_19))\n2. General Business Frequently Asked Questions ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/community/general-business-faq.html#Reducing-the-Spread-of-COVID-19-in-Workplaces)) \n3. Employers Rush to Adopt Virus Screening. The Tools May Not Help Much. ([NYT](https://www.nytimes.com/2020/05/11/technology/coronavirus-worker-testing-privacy.html)) \n",
    "DB (Hindi)": [
      "rec6pD3zz7tnDWDXP"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recM4lxC1I4K8t1Hd"
    ],
    "DB (Portuguese)": [
      "recn5WpQZCdGgbFHN"
    ],
    "Rollup test 2": [
      "recN9jC8sDa9LgyCs"
    ],
    "Last modified manual": "2020-07-06",
    "Last edited (simplified)": "2020-07-01T14:52:39.000Z",
    "Last edited (experts say)": "2020-07-07T13:22:35.000Z",
    "Last modified": "2020-07-06",
    "What our experts say wordcount": 200,
    "Background and context wordcount": 73,
    "Other resources wordcount": 30,
    "Wordcount": 303,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "दूसरों के साथ बातचीत करने से पहले बुखार के लिए लोगों की जाँच करना बीमारी के संचरण को कम करने में मदद के रूप में प्रस्तावित किया गया है। कुछ देशों जैसे कि चीन और दक्षिण कोरिया में कार्यालयों, रेस्तरां, हवाई अड्डों या अन्य लोकप्रिय स्थानों पर बुखार से पीड़ित व्यक्तियों की पहचान करने में मदद करने के लिए शरीर के तापमान की व्यापक जाँच होती है। एक स्टैंडअलोन उपाय के रूप में, बुखार के लिए जाँच रोग संचरण को रोकने के लिए अपर्याप्त है क्योंकि इस तरह के स्पर्शोन्मुख और पूर्व-लक्षण वाले लोग दूसरों को बीमार कर सकते हैं। कोविड-19 के लिए नैदानिक ​​परीक्षण - तापमान जांच नहीं - यह निर्धारित करने के लिए कि क्या कर्मचारी वायरस से संक्रमित हो सकता है या नहीं, बहुत अधिक सटीक, प्रभावी साधन है। इसके अतिरिक्त, सीमित संसाधनों, गोपनीयता चिंताओं और अन्य कारणों से कुछ स्थानों में तापमान परीक्षण को लागू करना मुश्किल हो सकता है।\n\nकुछ विशेषज्ञों ने अवरक्त तापमान जांच का उपयोग करते हुए कार्यस्थल की निगरानी और गोपनीयता के बारे में चिंताओं का हवाला दिया है। इन कार्यस्थल थर्मामीटरों की प्रभावशीलता और सटीकता के बारे में भी सवाल हैं, खासकर यह देखते हुए कि कितने पूर्व-रोगसूचक और स्पर्शोन्मुख रोगियों में उनकी बीमारी की अवधि के दौरान कोई लक्षण नहीं हो सकते हैं। अंत में, बुखार कोविड-19 से संबंधित अन्य कारकों या बीमारियों का संकेत हो सकता है; उदाहरण के लिए, ऊंचा शरीर का तापमान आमतौर पर उन लोगों में देखा जाता है जो शारीरिक रूप से ऊर्जा का उत्सर्जन कर रहे हैं या बहुत तनाव में हैं।"
    ],
    "Hindi - Background and context": [
      "कई व्यवसाय और संगठन विश्व स्वास्थ्य संगठन (डब्ल्यूएचओ) और यूएस सेंटर फॉर डिजीज कंट्रोल सिफारिशों का पालन कर रहे हैं, जो एक व्यावसायिक स्थान पर प्रत्येक कर्मचारी के तापमान को मापने के लिए हैं, हालांकि यह संयुक्त राज्य अमेरिका या हर देश में हर राज्य में एक आवश्यकता या सिफारिश नहीं है दुनिया। क्योंकि अधिकांश देशों में तापमान की जांच एक व्यवसाय को फिर से खोलने के लिए एक शर्त नहीं है, इसलिए कई व्यवसाय मालिकों ने इस कार्य को नहीं करने का विकल्प चुना है।"
    ]
  },
  {
    "id": "recDVXuo3vURm7OFU",
    "Question": "Can you explain how the COVID-19 test using tears works?",
    "Status": "Published",
    "Category": "Testing",
    "Subcategory": "On: COVID-19 & Testing",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "There is a growing number of research studies as well as media reports about COVID-19 tests that use samples of tears, instead of nasal swabs, throat swabs, saliva collection, blood draws, or other bodily samples. Tears originate near the nasal cavity, and someone with COVID-19 can shed viral particles in their tears. \n\nLike nasal swab tests, COVID-19 tests using tears analyze the sample through polymerise chain reaction (PCR) and are currently proposed as a potential option for diagnostic testing (checking whether someone has an active infection), which is different from antibody testing (checking whether someone had a past infection and now has antibodies against COVID-19). It is important to note that COVID-19 tests using tears are still in the research and development phase.\n\nBeyond the COVID-19 tests using tears that are being developed, Yale University has developed a COVID-19 diagnostic test that uses saliva collected in sterile containers, called SalivaDirect. On August 15, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for SalivaDirect, although more studies are in progress to better understand how well this test works.\n\nThe interest in COVID-19 tests using tears and saliva may be related to general interest in increasing the availability, accuracy, affordability, safety, speed, and ease of COVID-19 testing. For example, there is some interest in nasal swab test alternatives to reduce physical discomfort and to avoid inducing sneezing or coughing reflexes that could transmit virus particles to health care workers.\n",
    "What our experts say": "As of now, there is no consensus about whether or not tears can accurately detect the virus in an infected person, but early study results have shown a lower amount of the virus in tears than in other bodily fluids. Some researchers believe parts of the virus might be able to spread from a person's nasal cavity into their eyes, and eventually into tears in the inner corner of the eyes. Whether or not this type of testing will work is still uncertain as scientists have been testing many bodily fluids like semen, saliva, urine, and tears to determine whether or not the virus can be detected in them and if it can, how much. \n\nHumans produce tears in the back of their eye sockets, which is close to the nasal cavity where most COVID-19 tests are being done now. The nasal cavity is located at the back of the nose and is where the COVID-19 virus starts reproducing in people exposed to the virus.\n\nNasal swab tests are designed to collect samples from the nasal cavity that have some genetic material of the virus (DNA and RNA). Tear tests for COVID-19 would try to focus on this similar area of the head as there is a small, thin layer of tissue called the 'conjuctiva' that acts as a bridge between the nasal cavity and the eye socket. \n",
    "Glossary Terms": [
      "recS7r4IRJ4w3tzwS",
      "reccH9Nhjj0fi18nJ",
      "recz6LiyrAkeNejA2",
      "rec28MquThUtAwvuU",
      "recek5M0c1XBopk0p"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "testing",
      "tears",
      "DNA",
      "RNA",
      "nasal cavity"
    ],
    "Other resources": "1. Detection of severe acute respiratory syndrome Coronavirus-2 in the tears of patients with Coronavirus disease 2019 ([Nature](https://www.nature.com/articles/s41433-020-0965-2))\n2. Medical School Ophthalmologists will Test Tears for COVID-19 ([University of Minnesota](https://med.umn.edu/news-events/medical-school-ophthalmologists-will-test-tears-covid-19))\n3. Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients ([American Academy of Ophthamology](https://www.aaojournal.org/article/S0161-6420(20)30311-0/pdf)) \n4. Anatomy, Head and Neck, Eye Conjunctiva ([NIH](https://www.ncbi.nlm.nih.gov/books/NBK519502/)) \n5. Re: Yu et al.: Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients ([Ophthalmology](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247511/)) \n6. Assay Techniques and Test Development for COVID-19 Diagnosis ([American Chemical Society](https://pubs.acs.org/doi/10.1021/acscentsci.0c00501)) \n7. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing ([U.S. FDA](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-yale-school-public-health))\n\n",
    "DB (Hindi)": [
      "recyCCDBCKau27mbU"
    ],
    "In translated DBs?": "Yes",
    "DB (Arabic)": [
      "recK62XK6XsxhY1sM"
    ],
    "DB (Bengali)": [
      "rec8pYBUgIHg64cqY"
    ],
    "DB (Portuguese)": [
      "recJqzt8eCQceMQqy"
    ],
    "Rollup test 2": [
      "rec1MKAAGwxbMwm8W"
    ],
    "Last modified manual": "2020-07-03",
    "Last edited (simplified)": "2020-09-29T00:29:11.000Z",
    "Last edited (experts say)": "2020-09-29T00:29:11.000Z",
    "Last modified": "2020-09-29",
    "What our experts say wordcount": 228,
    "Background and context wordcount": 240,
    "Other resources wordcount": 113,
    "Wordcount": 581,
    "Hindi Q Status": [
      "Published"
    ],
    "Arabic Q status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "अब तक, इस बारे में कोई आम सहमति नहीं है कि एक संक्रमित व्यक्ति में आँसू से वायरस का सही पता लगा सकते हैं या नहीं, लेकिन प्रारंभिक अध्ययन के परिणामों ने अन्य शारीरिक तरल पदार्थों की तुलना में आँसू में वायरस की कम मात्रा दिखाई है। कुछ शोधकर्ताओं का मानना ​​है कि वायरस के हिस्से एक व्यक्ति की नाक के छेद से उनकी आंखों में फैलने में सक्षम हो सकते हैं, और अंततः आंखों के आंतरिक कोने में आंसू बन सकते हैं। इस प्रकार का परीक्षण काम करेगा या नहीं यह अभी भी अनिश्चित है क्योंकि वैज्ञानिक कई शारीरिक तरल पदार्थों जैसे कि वीर्य, ​​लार, मूत्र और आँसू का परीक्षण कर रहे हैं, ताकि यह निर्धारित किया जा सके कि उनमें वायरस का पता लगाया जा सकता है या नहीं और यदि है तो कितना।\n\nमनुष्य अपनी आंख के सॉकेट के पीछे आँसू पैदा करते हैं, जो नाक के छेद के करीब होता है, जहां अब अधिकांश कोविड-19 परीक्षण किए जा रहे हैं। नाक के छेद नाक के पीछे स्थित है और जहां वायरस के संपर्क में आने वाले लोगों में कोविड-19 वायरस फिर से शुरू होता है।\n\nनाक स्वाब परीक्षणों को नाक के छेद से नमूने एकत्र करने के लिए डिज़ाइन किया गया है जिसमें वायरस (डीएनए और आरएनए) की कुछ आनुवंशिक सामग्री होती है। कोविड-19 के लिए आंसू परीक्षण सिर के इसी तरह के क्षेत्र पर ध्यान केंद्रित करने की कोशिश करेंगे क्योंकि ऊतक की एक छोटी, पतली परत होती है जिसे 'कंजक्टिवा' कहा जाता है जो नाक गुहा और आंख सॉकेट के बीच एक पुल का काम करता है।"
    ],
    "Hindi - Background and context": [
      "कोविड-19 परीक्षणों के बारे में मीडिया रिपोर्टों के साथ-साथ मीडिया रिपोर्टों की बढ़ती संख्या है जो नाक के स्वाब, गले की सूजन, लार संग्रह, रक्त ड्रॉ, या अन्य शारीरिक नमूनों के बजाय आँसू के नमूनों का उपयोग करते हैं। आँसू नाक गुहा के पास उत्पन्न होते हैं, और कोविड-19 के साथ कोई भी अपने आँसू में वायरल कणों को बहा सकता है।\nनाक की स्वैब परीक्षणों की तरह, आँसू का उपयोग कर कोविड-19 परीक्षण पोलीमरेज़ चेन रिएक्शन (पीसीआर) के माध्यम से नमूने का विश्लेषण करते हैं और वर्तमान में नैदानिक ​​परीक्षण के लिए एक संभावित विकल्प के रूप में प्रस्तावित हैं (जाँच करें कि क्या किसी को सक्रिय संक्रमण है), जो कि एंटीबॉडी परीक्षण से अलग है (जाँच) क्या किसी को पिछले संक्रमण था और अब कोविड-19 के खिलाफ एंटीबॉडी हैं)। यह ध्यान रखना महत्वपूर्ण है कि आँसू का उपयोग कर कोविड-19 परीक्षण अभी भी अनुसंधान और विकास के चरण में हैं। कोविड-19 परीक्षण में रुचि कोविड-19 परीक्षण की उपलब्धता, सटीकता, सामर्थ्य, सुरक्षा, गति और सहजता बढ़ाने में सामान्य रुचि से संबंधित हो सकती है। उदाहरण के लिए, शारीरिक परेशानी को कम करने और छींकने या खांसी से बचने के लिए नाक के स्वाब परीक्षण के विकल्पों में कुछ रुचि है जो वायरस के कणों को स्वास्थ्य देखभाल श्रमिकों तक पहुंचा सकते हैं।"
    ],
    "Arabic - What our experts say": [
      "حتى الآن، لا يوجد إجماع حول ما إذا كانت الدموع يمكنها الكشف بدقة عن الفيروس لدى الشخص المصاب أم لا، لكن نتائج الدراسة المبكرة أظهرت وجود كمية أقل من الفيروس في الدموع مقارنة بسوائل الجسم الأخرى. يعتقد بعض الباحثين أن أجزاء من الفيروس قد تنتشر من تجويف أنف الشخص إلى عينيه، وفي النهاية إلى الدموع في الزاوية الداخلية للعين. لا يزال من غير المؤكد هل هذا النوع من الاختبارات ممكن أم لا، حيث قام العلماء باختبار العديد من سوائل الجسم مثل السائل المنوي واللعاب والبول والدموع لتحديد امكانية اكتشاف الفيروس فيها أم لا، وكمية ذلك إذا تحقق الكشف.\n\nينتج البشر الدموع في مؤخرة تجويف العين، بالقرب من تجويف الأنف حيث يتم إجراء معظم اختبارات كوفيد-19 حاليا. يقع تجويف الأنف في الجزء الخلفي من الأنف وهو المكان الذي يبدأ فيه فيروس كوفيد-19 في التكاثر لدى الأشخاص المُعرَّضين له.\n\nتم تصميم اختبارات مسحة الأنف لجمع عينات من تجويف الأنف الذي يحتوي على بعض المواد الجينية للفيروس (DNA و RNA). ستحاول فحوصات الدموع لـ كوفيد-19 التركيز على هذه المنطقة المماثلة من الرأس حيث توجد طبقة رقيقة صغيرة من الأنسجة تسمى `` المُلتحِمة `` تعمل كجسر بين تجويف الأنف و محجر العين."
    ],
    "Arabic - Background and context": [
      "هناك عدد متزايد من الدراسات البحثية وكذلك التقارير الإعلامية حول فحوصات الكشف عن كوفيد-19 التي تستخدم عينات من الدموع، بدلا من مسحات الأنف أو مسحات الحلق أو جمع اللعاب أو عينات الدم أو عينات جسدية أخرى. تنشأ الدموع بالقرب من تجويف الأنف، ويمكن للشخص المصاب بـ كوفيد-19 أن يفرز جزيئات فيروسية في دموعه.\nشأنها شأن اختبارات مسحة الأنف، تقوم فحوصات الكشف عن كوفيد-19 باستخدام الدموع لتحليل العينة من خلال تفاعل البوليمراز المتسلسل (PCR) ويُقترح حاليا كخيار محتمل للفحص التشخيصي (التحقق مما إذا كان شخص ما مصابا بعدوى نشطة)، والذي يختلف عن اختبار الأجسام المضادة (فحص ما إذا كان شخص ما قد أصيب بعدوى سابقة ولديه الآن أجسام مضادة لـ كوفيد-19). من المهم الانتباه إلى أن فحوصات الكشف عن كوفيد-19 باستخدام الدموع لا تزال في مرحلة البحث والتطوير.\nقد يكون الاهتمام بفحوصات الكشف عن كوفيد-19 باستخدام الدموع مرتبطا بالاهتمام العام بزيادة توافر ودقة وتكلفة ميسورة وأمان وسرعة وسهولة فحص الكشف عن كوفيد-19. على سبيل المثال، هناك بعض الاهتمام ببدائل فحوصات مسحة الأنف لتقليل الانزعاج الجسدي ولتجنب إحداث ردود فعل مثل العطاس أو السعال والتي يمكن أن تنقل جزيئات الفيروس إلى العاملين في مجال الرعاية الصحية."
    ]
  },
  {
    "id": "reciWQ04Q5wcSF1Zr",
    "Question": "Can drinking alcohol prevent or cure COVID-19?\n",
    "Status": "Published",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "Nigeria"
    ],
    "Background and context": "There are rumors circulating that drinking alcohol can prevent or treat COVID-19. This might be related to how alcohol (with concentration levels above 60-70%) is being used as a disinfectant for hands and surfaces, but it is important to note that drinking alcohol does not destroy the novel coronavirus within your body.\n\nWhile alcoholic beverages typically contain ethyl alcohol (also known as ethanol), media reports suggest that some alcoholic beverages have been illegally adulterated with toxic substances that smell similar, causing additional deaths during the pandemic in some countries. There are also other alcoholic products, such as hand sanitizers, that are not meant for human consumption. Drinking other forms of alcohol, such as methyl alcohol (also known as methanol) in chemical disinfectants, can cause blindness, kidney disease, or death even in small quantities.\n",
    "What our experts say": "No, drinking alcohol does not prevent or cure COVID-19. Alcohol-based hand sanitizers are recommended to disinfect hands and surfaces, but drinking or ingesting alcohol is in no way recommended. In fact, alcohol consumption could worsen COVID-19 symptoms and could weaken your body's ability to fight the virus, if you have lowered immunity. Excessive consumption of alcohol is a risk factor for many diseases, and alcohol should only be consumed in moderation, if at all.\n\nThe World Health Organization (WHO) warns that drinking alcohol will not protect against infection or illness from COVID-19. In fact, alcohol consumption can reduce the immune system's ability to fight infection and increase the chance of developing acute respiratory distress syndrome (ARDS), one of the most severe symptoms of COVID-19. Additionally, alcohol consumption has other negative health consequences (ex. motor and cognitive impairments, mental health impacts, violence, pregnancy impacts, carcinogenic exposure, associations with several other diseases). In response to rising rates of alcohol consumption and alcohol being one of the most widely abused substances in the world, the WHO has advised that \"people should minimize their alcohol consumption at any time, and particularly during the COVID-19 pandemic.\"\n",
    "Glossary Terms": [
      "recjGuHkvGujLMjV7"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "treatment",
      "cure"
    ],
    "Other resources": "1. Alcohol and COVID-19: What You Need to Know ([WHO](https://www.euro.who.int/__data/assets/pdf_file/0010/437608/Alcohol-and-COVID-19-what-you-need-to-know.pdf?ua=1))\n2. Alcohol does not protect against COVID-19; Access should be restricted during lockdown ([WHO](https://www.euro.who.int/en/health-topics/disease-prevention/alcohol-use/news/news/2020/04/alcohol-does-not-protect-against-covid-19-access-should-be-restricted-during-lockdown))\n3. Alcohol and the Immune System ([Alcohol Research: Current Reviews](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590612/))\n",
    "DB (Hindi)": [
      "recqLXlJUDvSE53Ls"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recvRl1zgOUB4ALR2"
    ],
    "DB (Portuguese)": [
      "rec6SWTNeI3xcipRC"
    ],
    "Last modified manual": "2020-07-03",
    "Last edited (simplified)": "2020-07-01T19:09:30.000Z",
    "Last edited (experts say)": "2020-07-01T20:11:33.000Z",
    "Last modified": "2020-07-03",
    "What our experts say wordcount": 190,
    "Background and context wordcount": 132,
    "Other resources wordcount": 32,
    "Wordcount": 354,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "नहीं, शराब पीने से कोविड-19 की रोकथाम या इलाज नहीं होता है। अल्कोहल-आधारित हैंड सैनिटाइज़र को हाथों और सतहों को कीटाणुरहित करने की सलाह दी जाती है, लेकिन शराब पीना या निगलना किसी भी तरह से अनुशंसित नहीं है। वास्तव में, शराब का सेवन कोविड-19 लक्षणों को खराब कर सकता है और आपके शरीर की वायरस से लड़ने की क्षमता को कमजोर कर सकता है, अगर आपने प्रतिरक्षा कम कर दी है। शराब का अत्यधिक सेवन कई बीमारियों के लिए एक जोखिम कारक है, और अल्कोहल का केवल मॉडरेशन में सेवन किया जाना चाहिए, या बिल्कुल भी।\n\nविश्व स्वास्थ्य संगठन (डबल्युएचओ) चेतावनी देता है कि शराब पीने से कोविड-19 से संक्रमण या बीमारी से बचाव नहीं होगा। वास्तव में, शराब का सेवन संक्रमण से लड़ने के लिए प्रतिरक्षा प्रणाली की क्षमता को कम कर सकता है और कोविड-19 के सबसे गंभीर लक्षणों में से एक, तीव्र श्वसन संकट सिंड्रोम (एआरडीएस) के विकास की संभावना को बढ़ा सकता है। इसके अतिरिक्त, शराब के सेवन के अन्य नकारात्मक स्वास्थ्य परिणाम (मोटर और संज्ञानात्मक हानि, मानसिक स्वास्थ्य प्रभाव, हिंसा, गर्भावस्था प्रभाव, कैंसरजन्य जोखिम, कई अन्य बीमारियों के साथ संबंध) हैं। शराब की खपत की बढ़ती दरों और शराब के कारण दुनिया में सबसे व्यापक रूप से दुरुपयोग किए जाने वाले पदार्थों के जवाब में, डबल्युएचओ ने सलाह दी है कि \"लोगों को किसी भी समय और विशेष रूप से कोविड-19 महामारी के दौरान शराब की सेवन को कम करना चाहिए।\""
    ],
    "Hindi - Background and context": [
      "ऐसी अफवाहें फैलाई जा रही हैं कि शराब पीने से कोविड-19 को रोका या इलाज किया जा सकता है। यह इस बात से संबंधित हो सकता है कि कैसे शराब (60-70% से अधिक एकाग्रता के स्तर के साथ) का उपयोग हाथों और सतहों के लिए एक निस्संक्रामक के रूप में किया जा रहा है, लेकिन यह ध्यान रखना महत्वपूर्ण है कि शराब पीने से आपके शरीर के भीतर उपन्यास कोरोनावायरस नष्ट नहीं होता है।\n\nजबकि मादक पेय पदार्थों में आमतौर पर एथिल अल्कोहल (जिसे इथेनॉल भी कहा जाता है) होता है, मीडिया रिपोर्टों में बताया गया है कि कुछ मादक पेय पदार्थों में अवैध रूप से जहरीले पदार्थों की मिलावट की गई है जो समान गंध लेते हैं, जिससे कुछ देशों में महामारी के दौरान अतिरिक्त मौतें होती हैं। अन्य मादक उत्पाद भी हैं, जैसे कि हाथ सैनिटाइज़र, जो मानव उपभोग के लिए नहीं हैं। रासायनिक कीटाणुनाशकों में अल्कोहल के अन्य रूपों, जैसे मिथाइल अल्कोहल (जिसे मेथनॉल के रूप में भी जाना जाता है) को पीने से अंधापन, किडनी रोग, या कम मात्रा में मृत्यु भी हो सकती है।"
    ]
  },
  {
    "id": "recdSj2U4jms12Bhy",
    "Question": "Can the coronavirus spread when we flush the toilet?",
    "Status": "Published",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Research shows that the pressure from flushing a toilet creates tiny droplets in the air that can rise as high as three feet above the toilet. This simulation was modeled for toilets in general without the SARS-CoV-2 virus, however, and it cannot be confirmed if the virus can spread through such plumes. Research conducted in two hospitals in China showed that aerosols were found in higher concentrations in a toilet of a hospital in Wuhan. However, the infectivity (strength of the virus to attack a person) is not known. It is also unknown if the aerosols collected were deposited from the breathing, coughing, or via the toilet flush. Since there is a possible risk, albeit low, public health experts recommend wearing masks inside public restrooms, closing the lid before flushing, keeping the toilets well ventilated and exhausts working at all times, and washing your hands with soap and warm water for 20+ seconds.\n",
    "What our experts say": "According to the U.S. Centers for Disease Control, feces of some patients who have been diagnosed with COVID-19 have been shown to carry the virus. This has caused many to question the safest way to use the toilet so as to prevent any COVID-19 infection from potentially spreading when the toilet is flushed. The reason many people are concerned about this topic is that it has been discovered that the virus leaves the human body through our waste, which is why it has been found in the feces of infected individuals. When we flush waste down the toilet, traces of the virus may linger in the air long enough to be inhaled. Studies have shown that during a toilet flush, particles can be transported more than 3 feet (1m) upward and can float in the air for more than a minute. It is unknown if the particles that linger in the air are infectious, and how many virus particles are needed to cause an infection. Since there are many unknowns, by precaution, public health experts recommend closing the lid before flushing and wearing masks inside public restrooms.\n",
    "Glossary Terms": [
      "rec2UNEXbTkSCx30Q"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "spread",
      "prevention"
    ],
    "Other resources": "1. Can a toilet promote virus transmission? From a fluid dynamics perspective ([Physics of fluid](https://aip.scitation.org/doi/10.1063/5.0013318))\n2. Put a lid on it, folks: Flushing may release coronavirus-containing 'toilet plumes' ([WaPo](https://www.washingtonpost.com/health/2020/06/16/coronavirus-toilet-flushing/))\n# \n",
    "DB (Hindi)": [
      "recXe8yJ7WFnJoW8L"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recIrOSDZObA49r92"
    ],
    "DB (Portuguese)": [
      "recjspKRXIkwcR59C"
    ],
    "Rollup test 2": [
      "recMtwlmAa5k0gxEm"
    ],
    "Last modified manual": "2020-07-03",
    "Last edited (simplified)": "2020-06-28T11:52:39.000Z",
    "Last edited (experts say)": "2020-07-15T16:53:43.000Z",
    "Last modified": "2020-07-03",
    "What our experts say wordcount": 187,
    "Background and context wordcount": 153,
    "Other resources wordcount": 28,
    "Wordcount": 368,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "कोविड-19 का पता चला है, उनमें वायरस दिखाया गया है। इससे कई लोगों ने शौचालय के उपयोग के सुरक्षा पर सवाल उठाया है ताकि किसी भी कोविड-19 संक्रमण को संभावित रूप से फैलने से रोका जा सके जब टॉयलेट को फ्लश किया जाता है। इस विषय में बहुत से लोग चिंतित हैं कि यह पता चला है कि वायरस मानव शरीर को हमारे कचरे के माध्यम से छोड़ देता है, यही कारण है कि यह संक्रमित व्यक्तियों के मल में पाया गया है। जब हम टॉयलेट को बेकार कर देते हैं, तो वायरस के निशान हवा में लंबे समय तक रह सकते हैं। अध्ययनों से पता चला है कि एक टॉयलेट फ्लश के दौरान, कणों को 3 फीट (1 मी) से अधिक ऊपर की ओर ले जाया जा सकता है और एक मिनट से अधिक समय तक हवा में तैर सकता है। यह अज्ञात है कि क्या हवा में घूमने वाले कण संक्रामक हैं, और संक्रमण का कारण बनने के लिए कितने वायरस कणों की आवश्यकता होती है। क्योंकि कई अज्ञात हैं, पूर्वोपाय से, सार्वजनिक स्वास्थ्य विशेषज्ञ सार्वजनिक टॉयलेट के अंदर फ्लशिंग और मास्क पहनने से पहले ढक्कन को बंद करने की सलाह देते हैं।"
    ],
    "Hindi - Background and context": [
      "कोविड-19 अनुसंधान से पता चलता है कि एक शौचालय को फ्लश करने से दबाव हवा में छोटी बूंदें बनाता है जो शौचालय से तीन फीट ऊपर उठ सकता है। इस सिमुलेशन को SARS-CoV-2 वायरस के बिना सामान्य रूप से शौचालय के लिए तैयार किया गया था, और यह पुष्टि नहीं की जा सकती है कि वायरस इस तरह के प्लम से फैल सकता है या नहीं। चीन के दो अस्पतालों में किए गए शोध से पता चला है कि वुहान में एक अस्पताल के शौचालय में एरोसोल उच्च सांद्रता में पाया गया। हालांकि, संक्रामक (किसी व्यक्ति पर हमला करने के लिए वायरस की ताकत) ज्ञात नहीं है। यह भी अज्ञात है कि एकत्र किए गए एरोसोल को श्वास, खांसी या शौचालय फ्लश के माध्यम से जमा किया गया था। क्योंकि एक संभावित जोखिम है, भले ही कम हो, सार्वजनिक स्वास्थ्य विशेषज्ञ सार्वजनिक टॉयलेट के अंदर मास्क पहनने की सलाह देते हैं, फ्लशिंग से पहले ढक्कन को बंद कर देते हैं, हर समय काम कर रहे शौचालयों को अच्छी तरह से हवादार और थका हुआ रखते हैं और अपने हाथों को साबुन और गर्म पानी से 20+ के लिए सेकंड धोते हैं।"
    ]
  },
  {
    "id": "rec5mweIOKMurWcRK",
    "Question": "What kind of impact can COVID-19 have on blood and circulation?",
    "Status": "Published",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "There have also been cases of children with COVID-19 presenting with a multi system inflammation, especially around the heart, lung, and brain. There has been some evidence that adult patients with COVID-19 can develop heart-related conditions or complications related to pre-existing cardiac issues, leading to concerns for heart damage as a result of the infection. \n",
    "What our experts say": "COVID-19 infections can have an impact on blood and circulation through an increased risk of blood clotting. Blood clots are a clump of blood that has formed into a semi-solid or even gel-like state. Recent studies have found a concerning trend in blood clotting of COVID-19 patients. Studies from the Netherlands and France found that 20-30% of critically ill COVID-19 patients had blood clots, which can be dangerous. Many of these circulatory issues and the frequency of clots can lead to rashes, swelling of the legs, challenges in vascular access for medications, and even death. Severe clotting and circulatory issues, like COVID-19 associated blood clots, tend to occur more in severely ill patients rather than those with mild symptoms. \n",
    "Glossary Terms": [
      "reciKuzcOIBjSFsU4"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "complication",
      "symptoms"
    ],
    "Other resources": "1. Coronavirus blood-clot mystery intensifies ([Nature](https://www.nature.com/articles/d41586-020-01403-8)) \n2. COVID-19 and Coagulopathy: Frequently Asked Questions ([ASH](https://www.hematology.org/covid-19/covid-19-and-coagulopathy)) \n3. For Parents: Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/children/mis-c.html)) \n",
    "DB (Hindi)": [
      "recXOk6xPo9jDGiho"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "rec05AIwJD6qaRRkK"
    ],
    "DB (Spanish)": [
      "recjr3CkgynRY2oem"
    ],
    "DB (Bengali)": [
      "rec14qbgT1ym1TKln"
    ],
    "DB (Portuguese)": [
      "recC513uRVHi9BolX"
    ],
    "Rollup test 2": [
      "reciEjTg34GoiGcfT"
    ],
    "Last modified manual": "2020-07-03",
    "Last edited (simplified)": "2020-06-22T19:07:11.000Z",
    "Last edited (experts say)": "2020-07-07T13:28:11.000Z",
    "Last modified": "2020-07-03",
    "What our experts say wordcount": 120,
    "Background and context wordcount": 56,
    "Other resources wordcount": 29,
    "Wordcount": 205,
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "कोविड-19 इन्फ़ेक्शन से रक्त के थक्के (ब्लड क्लाटिंग) के जोखिम के बढ़ने के कारण खून और उसके संचरण पर प्रभाव पड़ सकता है। रक्त का थक्का रक्त का एक गुच्छा है जो अर्ध-ठोस या जेल (gel) जैसी स्थिति में बन गया है। हाल के अध्ययनों में कोविड-19 रोगियों में रक्त के थक्के की प्रवृत्ति देखी गई है। नीदरलैंड और फ्रांस के अध्ययन में पाया गया कि गंभीर रूप से बीमार कोविड-19 के 20-30% रोगियों में रक्त के थक्के थे, जो खतरनाक हो सकता है। इनमें से कई संचार मुद्दों और थक्कों की आवृत्ति से चकत्ते, पैरों की सूजन, दवाओं के लिए संवहनी पहुंच में चुनौतियां और यहां तक ​​कि मृत्यु भी हो सकती है। कोविड​​-19 से जुड़े रक्त के थक्कों की तरह गंभीर थक्के और संचार संबंधी मुद्दे, गंभीर रोगियों में अधिक होते हैं।"
    ],
    "Hindi - Background and context": [
      "बच्चों में पाए गए कोविड -19 के भी कई मामले सामने आए हैं, जिनमे विशेषकर हृदय, फेफड़े और मस्तिष्क के आसपास सूजन और जलन (इन्फ़्लमेशन) की समस्या पाई गयी है। ऐसे कुछ प्रमाण मिले हैं कि कोविड-19 वाले वयस्क रोगी में पहले से मौजूद हृदय संबंधी समस्याओं के कारण और अधिक हृदय-संबंधी परेशानियाँ हो सकती हैं, जिससे संक्रमण के परिणामस्वरूप दिल के संचालन को नुक़सान पहुँच सकता है।"
    ],
    "Telugu - What our experts say": [
      "కోవిడ్-19 ఇన్ఫెక్షన్లు రక్తం గడ్డకట్టే ప్రమాదం ద్వారా రక్తం మరియు ప్రసరణపై ప్రభావం చూపుతాయి. రక్తం గడ్డకట్టడం అనేది రక్తం యొక్క ఒక సమూహం, ఇది పాక్షిక-ఘన లేదా జెల్ లాంటి స్థితిలో ఏర్పడుతుంది. ఇటీవలి అధ్యయనాలు కోవిడ్-19 రోగుల రక్తం గడ్డకట్టే ధోరణిని కనుగొన్నాయి. తీవ్రమైన అనారోగ్యంతో ఉన్న కోవిడ్-19 రోగులలో 20-30% మందికి రక్తం గడ్డకట్టడం ఉందని నెదర్లాండ్స్ మరియు ఫ్రాన్స్ నుండి జరిపిన అధ్యయనాలు కనుగొన్నాయి, ఇది ప్రమాదకరమైనది. ఈ రక్తప్రసరణ సమస్యలు మరియు గడ్డకట్టడం యొక్క ఫ్రీక్వెన్సీ చాలా, కాళ్ళు వాపు, దద్దుర్లు దారి మందులు వాస్కులర్ యాక్సెస్, మరియు మరణాన్ని సవాలు చేయవచ్చు. కోవిడ్-19 అనుబంధ రక్తం గడ్డకట్టడం వంటి తీవ్రమైన గడ్డకట్టడం మరియు ప్రసరణ సమస్యలు తేలికపాటి లక్షణాలతో కాకుండా తీవ్రమైన అనారోగ్య రోగులలో ఎక్కువగా సంభవిస్తాయి."
    ],
    "Telugu - Context and background": [
      "కోవిడ్-19 ఉన్న పిల్లలు బహుళ వ్యవస్థ మంటతో, ముఖ్యంగా గుండె, పిరితిత్తులు మరియు మెదడు చుట్టూ ఉన్న సందర్భాలు కూడా ఉన్నాయి. కోవిడ్-19 ఉన్న వయోజన రోగులు గుండె సంబంధిత పరిస్థితులను లేదా ముందుగా ఉన్న గుండె సమస్యలకు సంబంధించిన సమస్యలను అభివృద్ధి చేయగలరని కొన్ని ఆధారాలు ఉన్నాయి, ఇది సంక్రమణ ఫలితంగా గుండె దెబ్బతినే ఆందోళనలకు దారితీస్తుంది."
    ],
    "Spanish - What our experts say": [
      "Las infecciones de COVID-19 pueden tener un impacto en la sangre y la circulación a través de un riesgo incrementado de coágulos sanguíneos. Estos son grumos de sangre que se han formado en un estado semisólido o incluso gelatinoso. Estudios recientes han encontrado una tendencia a la formación de coágulos sanguíneos preocupante en pacientes con COVID-19. Estudios en Holanda y Francia encontraron que del 20 al 30% de los pacientes críticamente enfermos con COVID-19 tenían coágulos sanguíneos, los cuales pueden ser peligrosos. Muchas de estas cuestiones circulatorias y la frecuencia de los coágulos puede conducir a urticarias, inflamación de las extremidades inferiores, dificultad al acceso vascular de las medicaciones e incluso la muerte. Cuestiones circulatorias y de coagulación severas, como los coágulos sanguíneos asociados al COVID-19, tienden a ocurrir más en pacientes severamente enfermos, en vez de en aquellos con síntomas leves."
    ],
    "Spanish - Background and context": [
      "También han habido casos de niños con COVID-19 presentando una inflamación multisistémica, especialmente alrededor del corazón, pulmones y cerebro. Ha habido alguna evidencia de que los pacientes adultos con COVID-19 pueden desarrollar condiciones relacionadas al corazón, o complicaciones relacionadas con cuestiones cardíacas preexistentes, llevando a preocupaciones de daño al corazón como resultado de la infección."
    ],
    "Bengali - What our experts say": [
      "কোভিড-১৯ সংক্রমণ রক্ত জমাট বাঁধার ঝুঁকির মাধ্যমে রক্ত এবং সঞ্চালনে প্রভাব ফেলতে পারে। ব্লাড ক্লটস রক্তের পিণ্ড যা একটি আধা-কঠিন বা এমনকি জেল-জাতীয় পর্যায়ের রূপ নিয়েছে। সাম্প্রতিক গবেষণাগুলি কোভিড-১৯ রোগীদের রক্ত জমাট বাঁধার ক্ষেত্রে একটি প্রবণতা খুঁজে পেয়েছে। নেদারল্যান্ডস এবং ফ্রান্সের গবেষণায় দেখা গেছে যে গুরুতর অসুস্থ কোভিড-১৯ রোগীর ২০-৩০% রক্ত জমাট বাঁধা ছিল, এটি বিপজ্জনক হতে পারে। এর মধ্যে বেশকিছু সঞ্চালন সমস্যা এবং ক্লটগুলির ফ্রিকোয়েন্সি র‌্যাশ, পা ফোলা, ওষুধের জন্য ধমনি খুঁজে পেতে সমস্যা এবং এমনকি মৃত্যুর কারণ হতে পারে। গুরুতর জমাট বাঁধা এবং রক্ত সঞ্চালন সংক্রান্ত সমস্যা, যেমন কোভিড-১৯ সম্পর্কিত রক্তের জমাট বাঁধার ক্ষেত্রে, হালকা লক্ষণগুলির চেয়ে গুরুতর অসুস্থ রোগীদের মধ্যে বেশি ঘটে।"
    ],
    "Bengali - Background and context": [
      "কোভিড -১৯ সহ শিশুরা মাল্টি সিস্টেমের প্রদাহ, বিশেষত হৃদপিণ্ড, ফুসফুস এবং মস্তিষ্কের চারদিকে উপস্থাপিত হওয়ার ঘটনা ঘটেছে। কিছু প্রমাণ রয়েছে যে কোভিড-১৯ প্রাপ্ত বয়স্ক রোগীদের হার্ট-সম্পর্কিত পরিস্থিতি বা আগে থেকেই বিদ্যমান কার্ডিয়াক সংক্রান্ত সমস্যাগুলির সাথে জটিলতা বিকাশ করতে পারে যা সংক্রমণের ফলে হার্টের ক্ষতির জন্য উদ্বেগ সৃষ্টি করে।"
    ]
  },
  {
    "id": "recYJj2fg6IEXFncp",
    "Question": "How effective are Remdesivir and Favipiravir, and can they be taken without medical supervision? ",
    "Status": "Published",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "With efforts to find therapeutic options for the millions of patients suffering from COVID-19, there has been a rapid pace of drug development and evaluation. \n\nSome treatments are further along than others. For instance, studies have found successful outcomes so far with Remdesivir, which has been approved in several countries, such as recently in the U.S. as of October 22, 2020. Positive data is also emerging on the possibility of Favipiravir as a treatment for COVID-19, but still lacks sufficient evidence. \n\nWhile these emergent approvals and study developments on Remdesivir and Favipiravir are encouraging signs, it is important to monitor patients closely when on any new medications and report their outcomes or any negative side effects. And while some treatments are being evaluated, with generic versions on their way to approval for Remdesivir, there is still not enough data to confirm most specific treatments being tested for COVID-19 patients.\n",
    "What our experts say": "On November 19, 2020, the World Health Organization (WHO) recommended against the use of the antiviral Remdesivir (also known as Veklury) due to lacking evidence, following months of controversy regarding the utility of the drug. This decision was made based on four trials, including one conducted by the WHO, called the Solidarity trial, which is the largest so far and includes over 5,000 patients being used to study Remdesivir. \n\nThe pre-print study found that Remdesivir (along with Hydroxychloroquine, Lopinavir and Interferon) regimens appeared to have little or no effect on hospitalized COVID-19, measured by by rates of overall mortality, initiation of ventilation, and the duration of stay in the hospital. The study also found that that Remdesivir does not reduce COVID-19 deaths. The trial studied data from 405 hospitals in 30 countries, and randomly assigned more than 11,000 people hospitalized with COVID-19 to assess Remdesivir and three other drugs. 301 of 2,743 people hospitalized with COVID-19 taking Remdesivir died, compared with 303 of 2,708 who were not taking Remdesivir, demonstrating that Remdesivir does not have a statistically significant mortality benefit. \n\nDespite this recommendation by the WHO, Remdesivir continues to be recognized as a credible treatment for COVID-19 among hospitalized individuals, including in the U.S., Japan, and Germany. On October 22, 2020, the U.S. Food and Drug Administration (FDA) approved Remdesivir based off of the evidence of three randomized controlled trials. Remdesivir was the first officially approved treatment of COVID-19 within the U.S. The approval followed the FDA’s Emergency Use Authorization (EUA) for Remdesivir on May 1. Remdesivir was developed by pharmaceutical company Gilead.\nThe other three studies the WHO panel reviewed evidence for to make their decision found more positive evidence regarding Remdesivir, but were smaller in size. One clinical trial, conducted by the National Institute of Allergy and Infectious Diseases, assessed COVID-19 recovery time within 29 days of being treated. The trial looked at 1,062 hospitalized subjects with mild, moderate, and severe COVID-19 who received Remdesivir versus those who did not. The median time to recovery from COVID-19 for those who received Remdesivir was 10 days compared to 15 days for those who did not, a statistically significant difference. The odds of clinical improvement were also higher for those who took Remdesivir at Day 15 compared to those who did not. This difference, however, was not statistically significant.\n\nA second study found that the odds of a subject’s COVID-19 symptoms improving were higher if they had taken Remdesivir compared to if they had received the standard of care. If the drug was taken for 10 days rather than 5 days, the chances increased more, but not to a statistically significant extent. The third, separate study found that a patient’s odds of their COVID-19 symptoms improving were similar for those taking Remdesivir for 5 days as those for 10 days, and that there were no statistically significant differences in recovery or mortality rates between the two groups. Once again, these studies are smaller in size than the WHO Solidarity trial.\n \nFavipiravir is also considered to be a possible treatment for COVID-19. A small study showed the virus being reduced faster with the drug in comparison to other medications. Without further study, there is not enough evidence suggesting effectiveness and safety.\n\nMany studies for COVID-19 treatments remain underway, and it is too early to determine which additional ones may be effective therapeutic options for COVID-19 patients. When Favipiravir or any medication not officially approved is prescribed, it is important that medical providers monitor the patient's clinical condition noting effectiveness and possible negative side effects. \n",
    "Glossary Terms": [
      "rec9hdVoRIEkjJwtk"
    ],
    "Variation of the answer depending on country of residence": "Yes\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "treatment"
    ],
    "Other resources": "1. FDA Approves First Treatment for COVID-19 ([U.S. Food & Drug Administration](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19))\n2. F.D.A. Approves Remdesivir as First Drug to Treat Covid-19 ([New York Times](https://www.nytimes.com/interactive/2020/10/15/us/coronavirus-cases-us-surge.html))\n3. Compassionate Use of Remdesivir for Patients with Severe Covid-19. ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2007016))\n4. Gilead Remdesivir Release. ([Gilead](https://www.gilead.com/news-and-press/press-room/press-releases/2020/6/gilead-announces-results-from-phase-3-trial-of-remdesivir-in-patients-with-moderate-covid-19))\n5. Potential therapeutic agents against COVID-19: What we know so far ([J Chin Med Assoc](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176266/pdf/ca9-publish-ahead-of-print-10.1097.jcma.0000000000000318.pdf))\n6. A review of the safety of favipiravir- a potential treatment in the COVID-19 pandemic? ([Journal of Virus Eradication](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213073/pdf/jve-6-45.pdf))\n",
    "DB (Hindi)": [
      "recurR7td4FCtoIXQ"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recjnEiUTjZ4zVqX9"
    ],
    "DB (Bengali)": [
      "reckmuLE3Hr0qXjYM"
    ],
    "DB (Portuguese)": [
      "recVn5DS1BAWyFXYm"
    ],
    "Last modified manual": "2020-10-29",
    "Last edited (simplified)": "2020-10-29T23:10:43.000Z",
    "Last edited (experts say)": "2020-11-25T16:20:08.000Z",
    "Last modified": "2020-11-25",
    "What our experts say wordcount": 586,
    "Background and context wordcount": 149,
    "Other resources wordcount": 70,
    "Wordcount": 805,
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "SARS-CoV-2 / कोविड-19 एक नई संक्रामक बीमारी है और, जबकि संभावित उपचारों की पहचान करने के उद्देश्य से कई शोध किए गए हैं, कई उपचार सुरक्षा और प्रभावशीलता दोनों के लिए जांच के दायरे में हैं।\n\nएक बायोफार्मास्युटिकल कंपनी गिलियड साइंसेज द्वारा वित्त पोषित हाल के एक अध्ययन में, कोविड-19 के गंभीर मामलों वाले 53 रोगियों को रॅमदेसविर निर्धारित किया गया था, और शोधकर्ताओं ने नैदानिक ​​सुधार देखा, जिसमें 68% (36 में से 53 रोगियों में) प्रतिभागियों में श्वास समर्थन की आवश्यकता कम थी।\n\nहालांकि प्रारंभिक डेटा इस दवा के लिए आशाजनक लग रहा है, यह ध्यान रखना महत्वपूर्ण है कि यह प्रारंभिक अध्ययन छोटा था और कोविड-19 के लिए दवा का कठोरता से अध्ययन नहीं किया गया है। इसके अलावा, अध्ययन में हल्के या मध्यम कोविड-19 लक्षणों वाले रोगियों को शामिल नहीं किया गया था।\n\nफेविपिरविर को कोविड-19 का संभावित इलाज भी माना जाता है। एक छोटे से अध्ययन से पता चला कि अन्य दवाओं की तुलना में दवा के साथ वायरस तेजी से कम हो रहा है। आगे के अध्ययन के बिना, प्रभावशीलता और सुरक्षा का सुझाव देने वाले पर्याप्त सबूत नहीं हैं।\n\nसामान्य तौर पर, अध्ययन जारी है, और यह निर्धारित करना बहुत जल्दी है कि कौन सी दवाएं कोविड-19 रोगियों के लिए प्रभावी चिकित्सीय विकल्प हो सकती हैं। वर्तमान में, रॅमदेसविर को अमेरिका में आपातकालीन उपयोग प्राधिकरण और गंभीर कोविड-19 मामलों के लिए जापान में अनुमोदन दिया गया है। जब या तो रॅमदेसविर या फेविपिरविर निर्धारित किया जाता है, तो यह महत्वपूर्ण है कि चिकित्सा प्रदाता रोगी की नैदानिक ​​स्थिति की प्रभावशीलता और संभावित नकारात्मक दुष्प्रभावों की निगरानी करें। चिकित्सा पर्यवेक्षण के बिना या तो दवा लेने की सिफारिश नहीं की जाती है और हानिकारक हो सकती है।"
    ],
    "Hindi - Background and context": [
      "कोविड-19 से पीड़ित लाखों रोगियों के लिए चिकित्सीय विकल्प खोजने के प्रयासों के साथ, दवा मूल्यांकन में तेजी आई है। हालांकि कुछ उपचारों का मूल्यांकन किया जा रहा है और जेनेरिक संस्करणों को मंजूर किया जा सकता है, कोविड-19 रोगियों के लिए विशिष्ट उपचारों की पुष्टि करने के लिए अभी भी पर्याप्त डेटा नहीं है। अध्ययन में रेमेडीसविर के साथ सफल परिणाम मिले हैं, जिसे कई देशों में मंजूर किया गया है। हालांकि ये आकस्मिक उपयोग अनुप्रयोग एक उत्साहजनक संकेत हैं, रोगियों को बारीकी से निगरानी करना और उनके परिणामों या नकारात्मक साइड इफेक्ट की रिपोर्ट करना महत्वपूर्ण है।"
    ],
    "Telugu - What our experts say": [
      "SARS-CoV-2 / కోవిడ్ -19 ఒక కొత్త అంటు వ్యాధి మరియు, సాధ్యమైన చికిత్సలను గుర్తించే లక్ష్యంతో చాలా పరిశోధనలు జరిగాయి, భద్రత మరియు ప్రభావం రెండింటికీ అనేక చికిత్సలు పరిశోధనలో ఉన్నాయి.\n\nబయోఫార్మాస్యూటికల్ సంస్థ గిలియడ్ సైన్సెస్ నిధులతో ఇటీవల జరిపిన ఒక అధ్యయనంలో, కోవిడ్ -19 యొక్క తీవ్రమైన కేసులతో బాధపడుతున్న 53 మంది రోగులకు రెమ్‌డెసివిర్ సూచించబడింది, మరియు పరిశోధకులు క్లినికల్ మెరుగుదలలను గమనించారు, శ్వాస మద్దతు తగ్గడం సహా, 68% (53 మంది రోగులలో 36) పాల్గొనేవారు. ప్రారంభ డేటా ఈ for షధానికి ఆశాజనకంగా కనిపిస్తున్నప్పటికీ, ఈ ప్రారంభ అధ్యయనం చిన్నదని మరియు కోవిడ్ -19 కోసం ఔషధాన్ని కఠినంగా అధ్యయనం చేయలేదని గమనించాలి. అదనంగా, ఈ అధ్యయనంలో తేలికపాటి లేదా మితమైన కోవిడ్ -19 లక్షణాలతో రోగులు లేరు.\n\nఫావిపిరవిర్ కూడా కోవిడ్ -19 కు సాధ్యమయ్యే చికిత్సగా పరిగణించబడుతుంది. ఒక చిన్న అధ్యయనం ఇతర ఔషధాలతో పోల్చితే ఔషధంతో వైరస్ వేగంగా తగ్గిపోతుందని చూపించింది. తదుపరి అధ్యయనం లేకుండా, ప్రభావం మరియు భద్రతను సూచించే తగినంత ఆధారాలు లేవు.\n\nసాధారణంగా, అధ్యయనాలు కొనసాగుతున్నాయి మరియు కోవిడ్-19 రోగులకు ఏ మందులు సమర్థవంతమైన చికిత్సా ఎంపికలు అని నిర్ణయించడం చాలా తొందరగా ఉంది. ప్రస్తుతం, రెమ్‌డెసివిర్‌కు యు.ఎస్. లో అత్యవసర వినియోగ అధికారం మరియు తీవ్రమైన కోవిడ్ -19 కేసులకు జపాన్‌లో అనుమతి ఇవ్వబడింది. రెమ్‌డెసివిర్ లేదా ఫావిపిరవిర్ సూచించినప్పుడు, వైద్య ప్రొవైడర్లు రోగి యొక్క క్లినికల్ పరిస్థితిని సమర్థవంతంగా మరియు ప్రతికూల దుష్ప్రభావాలను గుర్తించడం చాలా ముఖ్యం. వైద్య పర్యవేక్షణ లేకుండా ఔషధాన్ని తీసుకోవడం సిఫారసు చేయబడలేదు మరియు హానికరం కావచ్చు."
    ],
    "Telugu - Context and background": [
      "కోవిడ్-19 తో బాధపడుతున్న మిలియన్ల మంది రోగులకు చికిత్సా ఎంపికలను కనుగొనే ప్రయత్నాలతో, ఔషధ మూల్యాంకనంలో వేగవంతమైన వేగంతో ఉంది. కొన్ని చికిత్సలు మూల్యాంకనం చేయబడుతున్నాయి మరియు సాధారణ సంస్కరణలు ఆమోదించబడవచ్చు, కోవిడ్-19 రోగులకు నిర్దిష్ట చికిత్సలను నిర్ధారించడానికి ఇంకా తగినంత డేటా లేదు. అనేక దేశాలలో ఆమోదించబడిన రెమ్‌డెసివిర్‌తో అధ్యయనాలు విజయవంతమైన ఫలితాలను కనుగొన్నాయి. ఈ అత్యవసర వినియోగ అనువర్తనాలు ప్రోత్సాహకరమైన సంకేతం అయితే, రోగులను నిశితంగా పరిశీలించడం మరియు వారి ఫలితాలను లేదా ప్రతికూల దుష్ప్రభావాలను నివేదించడం చాలా ముఖ్యం."
    ],
    "Bengali - What our experts say": [
      "SARS-CoV-2 / COVID-19 একটি নতুন সংক্রামক রোগ এবং সম্ভাব্য চিকিৎসাগুলি সনাক্তকরণের লক্ষ্যে অনেক গবেষণা করা হয়েছে, তবে অনেকগুলি চিকিৎসার নিরাপত্তা এবং কার্যকারিতা উভয়ই তদন্তাধীন রয়েছে।\n\nগিলেড সায়েন্সেস নামের একটি বায়ো-ফার্মাসিউটিক্যাল সংস্থা কর্তৃক অর্থায়িত সাম্প্রতিক এক গবেষণায়, কোভিড -১৯ এর গুরুতর ঘটনার ৫৩ জন রোগীকে রেমডেসিভির দেওয়া হয়েছিল, এবং অংশগ্রহণকারীদের মধ্যে গবেষকরা ৬৮% (৫৩ জন রোগীর মধ্যে ৩৬ জন) শ্বাসকষ্টের সহায়তা হ্রাস সহ ক্লিনিকাল উন্নতি পর্যবেক্ষণ করেছেন। প্রাথমিক তথ্য এই ওষুধের জন্য আশাব্যঞ্জক বলে মনে হচ্ছে, তবে এটি লক্ষণীয় গুরুত্বপূর্ণ যে, এই প্রাথমিক অধ্যয়নটি ছোট ছিল এবং ওষুধটি কোভিড-১৯-এর জন্য কঠোরভাবে অধ্যয়ন করা হয়নি। এছাড়াও, গবেষণায় হালকা বা মাঝারি কোভিড-২৯ উপসর্গযুক্ত রোগীদের অন্তর্ভুক্ত করা হয়নি।\n\nফাভিপীরাভিরকে কোভিড -১৯ এর সম্ভাব্য চিকিৎসা হিসাবে বিবেচনা করা হয়। একটি ছোট্ট গবেষণায় দেখা গেছে যে, অন্যান্য ওষুধের তুলনায় এই ওষুধে ভাইরাসটি দ্রুত হ্রাস পাচ্ছে। আরও অধ্যয়ন না করে কার্যকারিতা এবং সুরক্ষার প্রস্তাব দেওয়ার মতো পর্যাপ্ত প্রমাণ নেই।\nসাধারণভাবে, অধ্যয়ন অব্যাহত রয়েছে, এবং কোভিড -১৯ রোগীদের জন্য কোন ওষুধগুলি কার্যকর চিকিৎসা উপায় হতে পারে তা নির্ধারণ করার মত সময় এখনও আসেনি। বর্তমানে, রেমডেসিভিরকে মার্কিন যুক্তরাষ্ট্রে জরুরি ব্যবহারের অনুমোদন দেওয়া হয়েছে এবং গুরুতর কোভিড-১৯ ঘটনার জন্য জাপানে অনুমোদন দেওয়া হয়েছে। যখন রেমডেসিভির বা ফাভিপিরাবির নির্ধারিত হয়, তখন চিকিৎসা সরবরাহকারীরা রোগীর ক্লিনিকাল অবস্থা পর্যালোচনা কার্যকারিতা এবং সম্ভাব্য নেতিবাচক পার্শ্ব প্রতিক্রিয়া পর্যবেক্ষণ করা জরুরী। চিকিৎসা তদারকি না করেই ওষুধ গ্রহণের পরামর্শ দেওয়া হয় না এবং এটি ক্ষতিকারকও হতে পারে"
    ],
    "Bengali - Background and context": [
      "কোভিড-১৯-এ আক্রান্ত লক্ষ লক্ষ রোগীদের জন্য চিকিৎসার উপায়গুলি খুঁজে পাওয়ার চেষ্টার সাথে ওষুধের মূল্যায়নে দ্রুত গতি এসেছে। কিছু চিকিৎসার মূল্যায়ন করা হচ্ছে এবং জেনেরিক সংস্করণগুলি অনুমোদিত হতে পারে, তবে এখনও কোভিড-১৯ রোগীদের জন্য নির্দিষ্ট চিকিৎসার নিশ্চিত করার জন্য পর্যাপ্ত তথ্য নেই। অধ্যয়নগুলি রেমডেসিভিরের সাথে সফল ফলাফল পেয়েছে, যা বেশ কয়েকটি দেশে অনুমোদিত হয়েছে। এই উদীয়মান ব্যবহারের প্রয়োগগুলি একটি উৎসাহজনক লক্ষণ হলেও রোগীদের ঘনিষ্ঠভাবে পর্যবেক্ষণ করা এবং তাদের ফলাফলগুলি বা নেতিবাচক পার্শ্ব প্রতিক্রিয়াগুলি প্রতিবেদন করা গুরুত্বপূর্ণ।"
    ]
  },
  {
    "id": "recTXvz6ulqo2CENE",
    "Question": "Why are we repurposing old drugs to fight new diseases, and what might be the implications for COVID-19?",
    "Status": "Published",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Drug repurposing is a safe and successful pathway to speed up drug discovery and development compared with starting from scratch. Drug repurposing uses drugs that have either received regulatory approval, have failed in clinical trials or are in later stages of clinical trials, in order to leverage their detailed information on safety, toxicity, formulation, manufacturing plans, etc. Beyond the pandemic context, it is playing a vital role in several therapeutic areas, including, the discovery of new antibiotics and the development of drugs to combat Alzheimer’s disease. For example, Rifabutin is an antibiotic that has been around for decades and is used to treat tuberculosis, especially in people with HIV/AIDS. Recently, the drug was found to be effective against a superbug ‘Acinetobacter baumannii’ which emerged during the Iraq War in military treatment facilities. This antibiotic had been overlooked until now for this disease but new technology has allowed scientists to discover new strengths of this long existing antibiotic. Another recent example of successful drug repurposing comes from a Phase II clinical trial result that has shown that a leukemia drug – nilotinib, usually used to treat cancer of the blood cells – has been found to be safe and well tolerated and effective in reducing the effects of Alzheimer’s disease.\n",
    "What our experts say": "There is a whole branch of medical research and pharmaceutical companies dedicated to drug repurposing. In practice, it has led to some therapeutic breakthroughs. For example, aspirin which is historically known for treatment of pain, fever or inflammation, has then be found to be effective against some cardiovascular diseases and is now being studied for potential anti-tumor growth in some cancers.\n\nDeveloping new treatments against new diseases often takes several years, if not decades. With the COVID-19 pandemic death toll increasing by the day, scientists are racing to find drugs that could prevent, treat or simply decrease the severity of COVID-19. Scientists have therefore turned their attention to studying drugs that have been studied for other viruses like the MERS coronavirus, HIV (the virus that causes AIDS), hepatitis C, ebola, influenza, etc. to see whether these drugs would also be effective against this new threat, COVID-19. Since these studies build on existing knowledge, the drug development timeline is substantially shortened, as is the required financial investment. Beyond the time-intensive process of developing new drugs, the advantages of repurposing drugs are numerous. First, existing drugs already have an existing safety track record, and have obtained regulatory approval or are in the later stages of clinical trials. Moreover, they have already been produced and may already be on the market, so plans to increase manufacturing can rapidly occur since the infrastructure already exists and does not need to be re-created. Because of this, scientists can focus on studying whether these drugs are effective against COVID-19, and if so, they can be brought to clinical use at the bedside of patients rapidly. Drug repurposing is very common in medical research as science rarely happens in a vacuum, but rather builds on previous iterations and experience. \n",
    "Glossary Terms": [
      "recJz8lojK2ZaDFhp",
      "recKrKCs2Ax1jbpw6"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "treatment"
    ],
    "Other resources": "1. Repurposing existing drugs offers a more rapid alternative to a vaccine ([Science Daily](https://www.sciencedaily.com/releases/2020/05/200507103641.htm))\n2. Repurposed drugs may help scientists fight the new coronavirus ([ScienceNews](https://www.sciencenews.org/article/coronavirus-covid19-repurposed-treatments-drugs))\n3. Drug repurposing for antimicrobial discovery ([Nature](https://www.nature.com/articles/s41564-019-0357-1))\n4.  Deadly superbug could get a vigorous foe in repurposed antibiotic ([Phys.org](https://phys.org/news/2020-06-deadly-superbug-vigorous-foe-repurposed.htm))\n5. Leukemia drug nilotinib safe, shows promise against Alzheimer's disease ([UPI](https://www.upi.com/Health_News/2020/05/29/Leukemia-drug-nilotinib-safe-shows-promise-against-Alzheimers-disease/4241590697832/?ur3=1)) \n\n",
    "DB (Hindi)": [
      "recB4DIF0RZD1Zrsb"
    ],
    "Media": [
      {
        "id": "attPA9n71bIdBWTbj",
        "url": "https://dl.airtable.com/.attachments/85297df98feb7eaea0532d4a7101bd11/c6f82595/Slide1.png",
        "filename": "Slide 1.png",
        "size": 153860,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/03ce1d79353c764d8645b47bf79d9f44/323a4b63",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/a673f5902d3c96fbc829dd841a99a176/9d7fdd1e",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/53cf3b9e5f1ba9d6ecf276332b4bff8a/ff34feaa",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att8UIQheAm08iHzj",
        "url": "https://dl.airtable.com/.attachments/41c1976dd14b963766bd41afc6111fce/be3af699/Slide2.png",
        "filename": "Slide 2.png",
        "size": 216265,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/7f9ed880314facbd4c7225697bde0b39/8c07ced3",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/78cd5de5faa1f4b58a96b68437dc94db/66b66ac2",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/15cba6b9a0daf6f61f37fa110362e7fd/a3454a67",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att31Uaef0F5x7vs3",
        "url": "https://dl.airtable.com/.attachments/d021eb4a565f9e812ce9b318a4e33494/9c53407e/Slide3.png",
        "filename": "Slide 3.png",
        "size": 247781,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/60b9ac16c1e8b39dd8b55f8c82b5e6af/91cc24b3",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/9a0ad2ccaeacae6838223f30960fbd65/1177c670",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/395825154671f3836e9dcbae84060a1b/18e9ec80",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attOgTP2cPQG7Bhq7",
        "url": "https://dl.airtable.com/.attachments/86e13b20eb0169febf9e8ef5fc282eb0/6910328f/Slide4.png",
        "filename": "Slide 4.png",
        "size": 199954,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d0417e6f9cb0c5d99704c92959a1371d/e63cee74",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/88fbc8303879b3754168cd92872d1f7a/fdbe4677",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/19f2dc5e785b184a610e13fb3384d786/6448c2e5",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attJuEKYscVM3obzw",
        "url": "https://dl.airtable.com/.attachments/a4ea823d0a94b0b05841ba40805f19da/895df82f/Slide5.png",
        "filename": "Slide 5.png",
        "size": 184501,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/bc113a656150dc28f1d8e0bfe4c7949b/32161993",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c9c06b51d9d9d85d4fb16742c203c509/b78529b9",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c695519da88db185fb306fd7bd52b49a/26fd409a",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "rec0dBJdC6SXBHR5M"
    ],
    "DB (Spanish)": [
      "recjz4D1919opSoZo"
    ],
    "DB (Bengali)": [
      "rec1crcXMukTsJK6p"
    ],
    "DB (Portuguese)": [
      "recCd24bKotPAro6Z"
    ],
    "Rollup test 2": [
      "recvUDT26a46zGKm2"
    ],
    "Media Package": [
      {
        "id": "att1Eo5ygouOJiVB5",
        "url": "https://dl.airtable.com/.attachments/d2a7aa6f3aaf46b5e2dedd571434e1ab/73fa1304/Repurposingmeds.zip",
        "filename": "Repurposing meds.zip",
        "size": 975661,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-07-03",
    "Last edited (simplified)": "2020-06-19T16:58:27.000Z",
    "Last edited (experts say)": "2020-06-23T20:58:22.000Z",
    "Last modified": "2020-07-03",
    "What our experts say wordcount": 291,
    "Background and context wordcount": 208,
    "Other resources wordcount": 51,
    "Wordcount": 550,
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "चिकित्सा अनुसंधान और दवा कंपनियों की एक पूरी शाखा है जो ड्रग रिप्रोज़िंग के लिए समर्पित है। व्यवहार में, इसने कुछ चिकित्सीय सफलताओं को जन्म दिया है। उदाहरण के लिए, एस्पिरिन जो ऐतिहासिक रूप से दर्द, बुखार या सूजन के इलाज के लिए जाना जाता है, तब कुछ हृदय रोगों के खिलाफ प्रभावी पाया गया है और अब कुछ कैंसर में संभावित ट्यूमर-विरोधी विकास के लिए अध्ययन किया जा रहा है।\n\nनई बीमारियों के खिलाफ नए उपचार विकसित करने में अक्सर कई साल लगते हैं, अगर दशकों तक नहीं तो। कोविड​​-19 महामारी से मरने वालों की संख्या दिन प्रतिदिन बढ़ती जा रही है, वैज्ञानिक ऐसी दवाओं को खोजने के लिए दौड़ रहे हैं जो कोविड​​-19 की गंभीरता को रोक सकती हैं, उपचार कर सकती हैं या कम कर सकती हैं। इसलिए वैज्ञानिकों ने उन दवाओं का अध्ययन करने के लिए अपना ध्यान केंद्रित किया है जो अन्य वायरस जैसे कि MERS कोरोनोवायरस, एचआईवी (एड्स का कारण बनने वाला वायरस), हेपेटाइटिस सी, इबोला, इन्फ्लूएंजा इत्यादि का अध्ययन करने के लिए किया गया है, यह देखने के लिए कि क्या ये दवाएं इस नए खतरे के खिलाफ भी प्रभावी होंगी, COVID-19। जबसे ये अध्ययन मौजूदा ज्ञान पर निर्माण करते हैं, दवा के विकास की समय सीमा काफी कम है, जैसा कि आवश्यक आर्थिक निवेश है। नई दवाओं को विकसित करने की समय-गहन प्रक्रिया से परे, दवाओं के पुन: उपयोग के फायदे कई हैं। सबसे पहले, मौजूदा दवाओं में पहले से ही एक मौजूदा सुरक्षा ट्रैक रिकॉर्ड है, और नियामक अनुमोदन प्राप्त किया है या नैदानिक ​​परीक्षणों के बाद के चरणों में हैं। इसके अलावा, वे पहले से ही उत्पादित हो चुके हैं और पहले से ही बाजार पर हो सकते हैं, इसलिए विनिर्माण बढ़ाने की योजना तेजी से हो सकती है क्योंकि बुनियादी ढांचा पहले से मौजूद है और इसे फिर से बनाने की आवश्यकता नहीं है। इस वजह से, वैज्ञानिक अध्ययन पर ध्यान केंद्रित कर सकते हैं कि क्या ये दवाएं कोविड​​-19 के खिलाफ प्रभावी हैं, और यदि हां, तो उन्हें तेजी से रोगियों के बिस्तर पर नैदानिक ​​उपयोग के लिए लाया जा सकता है। चिकित्सा अनुसंधान में नशीली दवाओं का पुन: उपयोग बहुत आम है क्योंकि विज्ञान शायद ही कभी शून्य में होता है, बल्कि पिछले पुनरावृत्तियों और अनुभव पर बनाता है।"
    ],
    "Hindi - Background and context": [
      "नशीली दवाओं की खोज और विकास को गति देने के लिए शुरू से तुलना में ड्रग पुनरुत्पादन एक सुरक्षित और सफल मार्ग है। ड्रग रिप्रोज़िंग का उपयोग उन दवाओं का उपयोग करता है जिन्हें या तो नियामक की मंज़ूरी प्राप्त हुआ है, नैदानिक ​​परीक्षणों में विफल रहे हैं या बाद में नैदानिक ​​परीक्षणों के चरणों में हैं, ताकि सुरक्षा, विषाक्तता, निर्माण, निर्माण योजनाओं, आदि पर उनकी विस्तृत जानकारी का लाभ उठा सकें। महामारी संबंधी संदर्भ से परे, यह। कई चिकित्सीय क्षेत्रों में महत्वपूर्ण भूमिका निभा रहा है, जिसमें नई एंटीबायोटिक दवाओं की खोज और अल्जाइमर रोग का मुकाबला करने के लिए दवाओं का विकास शामिल है। उदाहरण के लिए, रिफाबुटिन एक एंटीबायोटिक है जो दशकों से आसपास है और इसका उपयोग तपेदिक के इलाज के लिए किया जाता है, खासकर एचआईवी / एड्स वाले लोगों में। दवा को एक सुपरबग 'एसिनेटोबैक्टेर बुमनी’ के खिलाफ प्रभावी पाया गया था, जो सैन्य उपचार सुविधाओं में इराक युद्ध के दौरान उभरा था। इस रोग के लिए अब तक इस एंटीबायोटिक की अनदेखी की गई थी लेकिन नई तकनीक ने वैज्ञानिकों को इस लंबे मौजूदा एंटीबायोटिक की नई ताकत की खोज करने की अनुमति दी है। हाल ही में सफल ड्रग रिप्रोज़िंग का एक और उदाहरण चरण II क्लिनिकल परीक्षण के परिणाम से आया है जिसमें दिखाया गया है कि ल्यूकेमिया की दवा - निलोटिनिब, आमतौर पर रक्त कोशिकाओं के कैंसर का इलाज करने के लिए इस्तेमाल की जाती है - जो प्रभाव को कम करने में सुरक्षित और अच्छी तरह से सहन और अल्जाइमर रोग के प्रभावी पाई गई है।"
    ],
    "Telugu - What our experts say": [
      "ఔషధ పునర్వినియోగానికి అంకితమైన వైద్య పరిశోధన మరియు ఔషధ సంస్థల మొత్తం శాఖ ఉంది. ఆచరణలో, ఇది కొన్ని చికిత్సా పురోగతికి దారితీసింది. ఉదాహరణకు, నొప్పి, జ్వరం లేదా మంట చికిత్సకు చారిత్రాత్మకంగా ప్రసిద్ది చెందిన ఆస్పిరిన్, అప్పుడు కొన్ని హృదయ సంబంధ వ్యాధులకు వ్యతిరేకంగా ప్రభావవంతంగా ఉన్నట్లు కనుగొనబడింది మరియు ఇప్పుడు కొన్ని క్యాన్సర్లలో యాంటీ-ట్యూమర్ పెరుగుదల కోసం అధ్యయనం చేయబడుతోంది. కొత్త వ్యాధులకు వ్యతిరేకంగా కొత్త చికిత్సలను అభివృద్ధి చేయడానికి చాలా సంవత్సరాలు పడుతుంది, దశాబ్దాలు కాకపోతే. కోవిడ్-19 మహమ్మారి మరణాల సంఖ్య రోజురోజుకు పెరుగుతుండటంతో, కోవిడ్-19 యొక్క తీవ్రతను నివారించడానికి, చికిత్స చేయడానికి లేదా తగ్గించగల మందులను కనుగొనడానికి శాస్త్రవేత్తలు పోటీ పడుతున్నారు. అందువల్ల శాస్త్రవేత్తలు మెర్స్ కరోనావైరస్, హెచ్ఐవి (ఎయిడ్స్‌కు కారణమయ్యే వైరస్), హెపటైటిస్ సి, ఎబోలా, ఇన్ఫ్లుఎంజా, మొదలైనవి ఈ కొత్త ముప్పు, కోవిడ్-19 కు వ్యతిరేకంగా ఈ మందులు కూడా ప్రభావవంతంగా ఉన్నాయో లేదో చూడటానికి. ఈ అధ్యయనాలు ఇప్పటికే ఉన్న జ్ఞానం మీద ఆధారపడి ఉంటాయి కాబట్టి, అవసరమైన ఆర్థిక పెట్టుబడి వలె అభివృద్ధి కాలక్రమం గణనీయంగా తగ్గించబడుతుంది. కొత్త ఔషధలను అభివృద్ధి చేసే సమయ-ఇంటెన్సివ్ ప్రక్రియకు మించి, ఔషధలను తిరిగి తయారు చేయడం వల్ల కలిగే ప్రయోజనాలు చాలా ఉన్నాయి. మొదట, ఇప్పటికే ఉన్న మందులు ఇప్పటికే ఉన్న భద్రతా ట్రాక్ రికార్డును కలిగి ఉన్నాయి మరియు నియంత్రణ ఆమోదం పొందాయి లేదా క్లినికల్ ట్రయల్స్ యొక్క తరువాతి దశలలో ఉన్నాయి. అంతేకాక, అవి ఇప్పటికే ఉత్పత్తి చేయబడ్డాయి మరియు ఇప్పటికే మార్కెట్లో ఉండవచ్చు, కాబట్టి మౌలిక సదుపాయాలు ఇప్పటికే ఉన్నందున తయారీని పెంచే ప్రణాళికలు వేగంగా జరుగుతాయి మరియు తిరిగి సృష్టించాల్సిన అవసరం లేదు. ఈ కారణంగా, శాస్త్రవేత్తలు ఈ మందులు కోవిడ్-19 కి వ్యతిరేకంగా ప్రభావవంతంగా ఉన్నాయో లేదో అధ్యయనం చేయడంపై దృష్టి పెట్టవచ్చు మరియు అలా అయితే, రోగుల పడక వద్ద వాటిని క్లినికల్ వాడకానికి వేగంగా తీసుకురావచ్చు. వైద్య పరిశోధనలో ఔషధ పున  ప్రారంభం చాలా సాధారణం, ఎందుకంటే సైన్స్ శూన్యంలో అరుదుగా జరుగుతుంది, కానీ మునుపటి పునరావృత్తులు మరియు అనుభవాన్ని పెంచుతుంది."
    ],
    "Telugu - Context and background": [
      "మొదటి నుండి ప్రారంభంతో పోలిస్తే ఔషధ ఆవిష్కరణ మరియు అభివృద్ధిని వేగవంతం చేయడానికి ఔషధ పునర్నిర్మాణం సురక్షితమైన మరియు విజయవంతమైన మార్గం. ఔషధ పున ప్రారంభం నియంత్రణ, ఆమోదం పొందిన, క్లినికల్ ట్రయల్స్‌లో విఫలమైన లేదా క్లినికల్ ట్రయల్స్ యొక్క తరువాతి దశలలో, భద్రత, విషపూరితం, సూత్రీకరణ, ఉత్పాదక ప్రణాళికలు మొదలైన వాటిపై వారి వివరణాత్మక సమాచారాన్ని ప్రభావితం చేయడానికి ఉపయోగిస్తుంది. మహమ్మారి సందర్భానికి మించి, ఇది అల్జీమర్స్ వ్యాధిని ఎదుర్కోవటానికి కొత్త యాంటీబయాటిక్స్ యొక్క ఆవిష్కరణ మరియు ఔషధల అభివృద్ధితో సహా అనేక చికిత్సా రంగాలలో కీలక పాత్ర పోషిస్తోంది. ఉదాహరణకు, రిఫాబుటిన్ ఒక యాంటీబయాటిక్, ఇది దశాబ్దాలుగా ఉంది మరియు క్షయవ్యాధి చికిత్సకు ఉపయోగిస్తారు, ముఖ్యంగా HIV / AIDS ఉన్నవారిలో. ఇటీవల, సైనిక చికిత్సా సదుపాయాలలో ఇరాక్ యుద్ధంలో ఉద్భవించిన సూపర్ బగ్ 'అసినెటోబాక్టర్ బామన్ని'కి వ్యతిరేకంగా ఈ ఔషధం ప్రభావవంతంగా ఉన్నట్లు కనుగొనబడింది. ఈ వ్యాధికి ఈ యాంటీబయాటిక్ ఇప్పటివరకు పట్టించుకోలేదు కాని కొత్త టెక్నాలజీ శాస్త్రవేత్తలు ఈ దీర్ఘకాల యాంటీబయాటిక్ యొక్క కొత్త బలాన్ని కనుగొనటానికి అనుమతించింది. విజయవంతమైన ఔషధ పున ప్రారంభానికి మరొక ఇటీవలి ఉదాహరణ దశ II క్లినికల్ ట్రయల్ ఫలితం నుండి వచ్చింది, ఇది రక్త కణాల క్యాన్సర్‌కు చికిత్స చేయడానికి సాధారణంగా ఉపయోగించే ల్యుకేమియా ఔషధం - నిలోటినిబ్ - సురక్షితంగా మరియు బాగా తట్టుకోగలదని మరియు ప్రభావాలను తగ్గించడంలో ప్రభావవంతంగా ఉందని తేలింది అల్జీమర్స్ వ్యాధి."
    ],
    "Spanish - What our experts say": [
      "Hay una rama entera de la investigación médica y las compañías farmacéuticas dedicada a dar nuevo propósito a drogas existentes. En la práctica, ha conducido a algunos saltos terapéuticos decisivos. Por ejemplo, la aspirina (la cual es históricamente conocida para el tratamiento del dolor, fiebre o inflamación), ha sido encontrada efectiva contra algunas enfermedades cardiovasculares, y está siendo estudiada ahora por su potencial anticrecimiento en tumores, en algunos cánceres.\n\nDesarrollar nuevos tratamientos contra nuevas enfermedades a menudo lleva varios años, si no décadas. Con la cuota de muertes de la pandemia COVID-19 aumentando cada día, los científicos están corriendo para encontrar drogas que puedan prevenir, tratar o simplemente disminuir la severidad del COVID-19. Por lo tanto, han tornado su atención a estudiar drogas que lo han sido para otros virus, como el coronavirus del MERS, el HIV (el virus que causa el SIDA), la hepatitis C, el ébola, la influenza, etc., para ver si estas drogas también serían efectivas contra esta nueva amenaza, el COVID-19. Como estos estudios construyen sobre conocimiento existente, el tiempo de desarrollo de la droga es acortado sustancialmente, como lo es la inversión financiera requerida. Más allá del proceso intensivo en tiempo de desarrollo de nuevas drogas, las ventajas de dar nuevo propósito a drogas son numerosas. Primero, las drogas existentes ya tienen un registro de desempeño en seguridad, y han obtenido la aprobación regulatoria o están en las últimas etapas de los ensayos clinicos. Más aún, ya han sido producidas y puede que ya estén en el mercado, de manera que los planes para incrementar la fabricación pueden ocurrir rápidamente, ya que la infraestructura existe y no necesita volver a crearse. Debido a esto, los científicos pueden enfocarse en estudiar si estas drogas son efectivas contra el COVID-19, y si es así, pueden ser traídas para su uso clínico en pacientes rápidamente. Dar nuevo propósito a drogas existentes es muy común en la investigación médica, ya que la ciencia raramente pasa en un vacío, sino que construye sobre iteraciones y experiencias previas."
    ],
    "Spanish - Background and context": [
      "El dar nuevo propósito a drogas existentes es un camino seguro y exitoso para acelerar el descubrimiento y desarrollo de drogas, comparado con empezar de cero. Usa drogas que han recibido aprobación regulatoria, han fallado en ensayos clínicos o bien están en las últimas etapas de los mismos, con el fin de sacar ventaja de su información detallada en seguridad, toxicidad, formulación, planes de manufactura, etc. Más allá del contexto pandémico, está jugando un rol vital en varias áreas terapéuticas, incluyendo el descubrimiento de nuevos antibióticos y el desarrollo de drogas para combatir la enfermedad de Alzheimer. Por ejemplo, el Rifabutin es un antibiótico que ha estado en el entorno por décadas, y es usado para tratar la tuberculosis, especialmente en personas con HIV/SIDA. Recientemente, se encontró que la droga es efectiva contra el superbicho 'Acinetobacter baumannii', el cual emergió durante la Guerra en Iraq en instalaciones militares de tratamiento. Este antibiótico había sido pasado por alto hasta ahora para esta enfermedad, pero nueva tecnología ha permitido a los científicos descubrir nuevas fortalezas en este antibiótico de larga existencia. Otro ejemplo reciente de un exitoso nuevo propósito para una droga viene de un resultado de un ensayo clínico en Fase II que ha mostrado que una droga para la leucemia – nilotinib, usualmente empleada para tratar cáncer de las células sanguíneas – ha sido encontrada segura, bien tolerada y efectiva en reducir los efectos de la enfermedad de Alzheimer."
    ],
    "Bengali - What our experts say": [
      "চিকিৎসা গবেষণা এবং ফার্মাসিউটিক্যাল সংস্থাগুলির একটি সম্পূর্ণ শাখা নিবেদিত রয়েছে ঔষধ পুনঃপ্রতিষ্ঠার জন্য। বাস্তবে, চিকিৎসা বিজ্ঞানে এটি কিছু সাফল্য দেখিয়েছে। উদাহরণস্বরূপ, অ্যাসপিরিন যা ঐতিহাসিকভাবে ব্যথা, জ্বর বা প্রদাহের চিকিৎসার জন্য পরিচিত, এটি কিছু হৃদরোগের বিরুদ্ধে কার্যকর বলে প্রমাণিত হয়েছে এবং এখন কিছু ক্যান্সারের সম্ভাব্য অ্যান্টি-টিউমার বৃদ্ধির জন্য অধ্যয়ন করা হচ্ছে।\n\nনতুন রোগের বিরুদ্ধে নতুন চিকিৎসা বিকাশ লাভ করতে বেশ কয়েক বছর সময় লাগে, এমন কি কয়েক যুগ। দিন দিন কোভিড-১৯ মহামারীজনিত মৃত্যুর সংখ্যা বাড়ার সাথে সাথে বিজ্ঞানীরা এমন ওষুধ সন্ধানের জন্য দৌড়াদৌড়ি করছেন যেগুলি কোভিড-১৯ এর তীব্রতা রোধ, চিকিৎসা বা হ্রাস করতে পারে। বিজ্ঞানীরা তাই এই জাতীয় ওষুধগুলিও নতুন হুমকি কোভিড-১৯ এর বিরুদ্ধে কার্যকর হবে কিনা তা দেখার জন্য এমইআরএস করোনাভাইরাস, এইচআইভি (এইডস সংক্রমণকারী ভাইরাস), হেপাটাইটিস সি, ইবোলা, ইনফ্লুয়েঞ্জা ইত্যাদির জন্য যে ওষুধগুলি অধ্যয়ন করা হয়েছিল সেগুলি অধ্যয়নের দিকে মনোনিবেশ করেছেন। যেহেতু এই অধ্যয়নগুলি বিদ্যমান জ্ঞানের উপর নির্ভরশীল, তাই ওষুধ বিকাশের সময়রেখা ও প্রয়োজনীয় আর্থিক বিনিয়োগ যথেষ্ট পরিমাণে কম। নতুন ওষুধ বিকশিত করা সময় সাপেক্ষ, বিপরীতে বিদ্দমান ওষুধগুলি পুনঃপ্রতিষ্ঠার সুবিধা প্রচুর। প্রথমত, বিদ্যমান ওষুধের ইতিমধ্যে একটি বিদ্যমান সুরক্ষা ট্র্যাক রেকর্ড রয়েছে এবং নিয়ন্ত্রণকারী সংস্থার অনুমোদন পেয়েছে বা ক্লিনিকাল ট্রায়ালের পরবর্তী পর্যায়ে রয়েছে। এছাড়াও, তারা ইতিমধ্যে উৎপাদিত হয়েছে এবং ইতিমধ্যে বাজারে থাকতে পারে, সুতরাং উৎপাদন বৃদ্ধির পরিকল্পনা দ্রুত ঘটতে পারে যেহেতু অবকাঠামোগুলি ইতিমধ্যে বিদ্যমান এবং পুনরায় তৈরি করার প্রয়োজন নেই। এ কারণে বিজ্ঞানীরা এই ওষুধগুলি কোভিড-১৯ এর বিরুদ্ধে কার্যকর কিনা তা অধ্যয়নের দিকে মনোনিবেশ করতে পারেন এবং যদি তা হয় তবে দ্রুত রোগীদের জন্য এগুলি ক্লিনিকাল ব্যবহারে আনা যেতে পারে। চিকিৎসা গবেষণায় ঔষধ পুনঃপ্রতিষ্ঠা খুব সাধারণ কারণ শূন্যতায় বিজ্ঞান খুব কমই ঘটে, বরং আগের পুনরাবৃত্তি এবং অভিজ্ঞতার ভিত্তিতে তৈরি করে।\n"
    ],
    "Bengali - Background and context": [
      "গোড়া থেকে শুরু করার তুলনায় ওষুধ পুনরুদ্ধার ওষুধ আবিষ্কার এবং বিকাশের গতি বাড়ানোর একটি নিরাপদ এবং সফল পথ। ওষুধ পুনঃপ্রতিষ্ঠা এমন ওষুধগুলি ব্যবহার করে যা নিয়ন্ত্রক সংস্থার অনুমোদন পেয়েছে, ক্লিনিকাল ট্রায়ালগুলিতে ব্যর্থ হয়েছে বা ক্লিনিকাল ট্রায়ালের পরবর্তী পর্যায়ে রয়েছে, যাতে তাদের সুরক্ষা, বিষাক্ততা, গঠন, উৎপাদন পরিকল্পনা ইত্যাদির বিস্তারিত তথ্য লাভ করতে পারে| \n\nমহামারী প্রসঙ্গ ছাড়াও, এটি অ্যালঝাইমার রোগের বিরুদ্ধে লড়াই করার জন্য নতুন অ্যান্টিবায়োটিক আবিষ্কার এবং ওষুধের বিকাশ সহ বেশ কয়েকটি চিকিৎসার ক্ষেত্রে গুরুত্বপূর্ণ ভূমিকা পালন করছে। উদাহরণস্বরূপ, রিফাবুটিন একটি অ্যান্টিবায়োটিক যা যুগ যুগ ধরে ধরে রয়েছে এবং যক্ষ্মার চিকিৎসার জন্য ব্যবহৃত হয়, বিশেষত এইচআইভি / এইডস আক্রান্ত ব্যক্তিদের মধ্যে। সম্প্রতি, ওষুধটি সুপারব্যাগ ‘অ্যাকিনেটোব্যাক্টর বাউমানি’র বিরুদ্ধে কার্যকর বলে প্রমাণিত হয়েছিল যা ইরাক যুদ্ধের সময় সামরিক চিকিৎসা সুবিধায় উদ্ভূত হয়েছিল। এই অ্যান্টিবায়োটিক এই রোগের জন্য এখন অব্দি অবহেলিত ছিল তবে নতুন প্রযুক্তি বিজ্ঞানীদের এই দীর্ঘদিন ধরে বিদ্যমান অ্যান্টিবায়োটিকের নতুন শক্তি আবিষ্কার করার অনুমতি দিয়েছে। ওষুধের সফল পুনঃপ্রতিষ্ঠার আরেকটি সাম্প্রতিক উদাহরণ দ্বিতীয় পর্যায়ের ক্লিনিকাল ট্রায়াল ফলাফল থেকে এসেছে যা দেখিয়েছে যে, রক্ত কোষের ক্যান্সারের চিকিৎসার জন্য সাধারণত ব্যবহৃত ওষুধ নীলোটিনিব - আলঝেইমার রোগের প্রভাবগুলি হ্রাস করতে নিরাপদ এবং ভাল সহনীয় ও কার্যকর বলে প্রমাণিত হয়েছে|"
    ]
  },
  {
    "id": "recFNFFgJEbL489Op",
    "Question": "What are dual treatments and are there any available for COVID-19 right now?",
    "Status": "Published",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Given the current absence of a COVID-19 treatment, and the lack of a widely approved or distributed vaccine, researchers are urgently looking for treatments for the disease. To this end, there is a wide range of both existing drugs (i.e. approved and regulated for different health conditions) and potential new ones being tested globally. These tests are being conducted in laboratories and animal clinical studies, and once proven effective they are moved onto human clinical trials. In addition to studies on singular drugs, researchers are testing what are known as combination therapies, in which two or more drugs are taken to treat a single disease. The rationale for combination therapy is that different drugs work through different mechanisms, and grouping more than one together can increase the treatment's efficacy,  reduce treatment duration, and reduce the likelihood of drug resistance.\n",
    "What our experts say": "\"Combination treatments\" are the use of two or more drugs to treat a single disease. Currently, there are no combination treatments (also known as dual treatments) that are officially approved for use to treat COVID-19. However, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, announced on June 23, 2020 while testifying before a House committee on the U.S. response to the COVID-19 pandemic that Remdesivir is being used in combination with anti-inflammatory drug baricitinib. An NIH clinical trial has been underway since May to test the efficacy of the combined treatment, with results not yet released.\n\nOnly three standalone drugs have officially received emergency use authorization (EUA) from the Federal Drug Administration (FDA) in the US; these include the anti-viral remdesivir (which the WHO has issued a warning for but which still has an EUA in the US), anti-malaria drugs chloroquine and hydroxychloroquine (which the FDA later issued a warning for), and a drug used to sedate patients that are on a ventilator. (These EUAs do not constitute a formal approval of the drug, but rather a possibility given to American doctors to use chloroquine and hydroxychloroquine in the treatment of COVID-19 if the doctor has no other options and after discussing with the patients the risks involved.)\n\nIn terms of approval of combination treatments, on November 19, 2020, the FDA issued an EUA for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).\n\nOne example of a combination therapy being tested is the dual use of drugs lopinavir and ritonavir, which are in use to treat (not cure) HIV. The combination of these two drugs is known under the brand name Kaletra. Studies are still relatively inconclusive, but most have shown Kaletra to be ineffective for improving COVID-19 outcomes. One study, however, found that when taken with two other drugs — ribavirin and interferon beta-1b — the virus took less time to clear from the patient's body. There are a number of limitations from this trial that warrant further testing. \n\nOther studies testing combination therapy have focused on pairs with remdesivir. One study, which led to the combination treatment approved through an EUA by the FDA mentioned above, tested the impacts of remdesivir and anti-inflammatory drug known as baricitinib on time to recovery in hospitalized patients and found a significant reduction. Another tested the combination of remdesivir with the drug leronlimab, an antiviral that has also has shown to have some anti-inflammatory benefits. \n\nStudies are also exploring more holistic and less pharmacological approaches as complementary COVID-19 treatment — that is, a potential additional treatment used in combination with other COVID-19 treatments. For instance, some researchers are exploring Traditional Chinese Medicine as a complementary therapy to combat COVID‐19 in conjunction with other therapies being used such as antiviral medications and antibiotics. Virgin coconut oil (VCO) is also being studied in the Philippines and other countries as a potential supplementary treatment for COVID-19 such as antiviral medications and antibiotics.\n\nThese studies assessing combination treatments will get us closer to understanding if certain combination therapies might be effective for treating COVID-19.\n",
    "Glossary Terms": [
      "rec5nIBBaECmAvkrl"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "treatment"
    ],
    "Other resources": "1. Combination Therapy ([Science Direct](http://Combination Therapy))\n2. Combination Therapy for COVID-19, Rajesh T. Gandhi, MD reviewing Hung IFN et al. Lancet 2020 May 8 ([NEJM](https://www.jwatch.org/na51564/2020/05/14/combination-therapy-covid-19))\n3. Here’s Exactly Where We Are with Vaccines and Treatments for COVID-19 ([Healthline](https://www.healthline.com/health-news/heres-exactly-where-were-at-with-vaccines-and-treatments-for-covid-19))\n",
    "DB (Hindi)": [
      "recievVAiT0QfVDTa"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recjhfQMJCKLh2nbR"
    ],
    "DB (Bengali)": [
      "reckg5jwT0cH84gcu"
    ],
    "DB (Portuguese)": [
      "recVhGbKRUlDgMUc4"
    ],
    "Rollup test 2": [
      "recqq0CS9WzPNCaqn"
    ],
    "Last modified manual": "2020-07-03",
    "Last edited (simplified)": "2020-12-07T19:48:32.000Z",
    "Last edited (experts say)": "2020-12-07T19:55:16.000Z",
    "Last modified": "2020-12-07",
    "What our experts say wordcount": 538,
    "Background and context wordcount": 140,
    "Other resources wordcount": 35,
    "Wordcount": 713,
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "\"संयोजन उपचार\" एक बीमारी का इलाज करने के लिए दो या अधिक दवाओं का उपयोग है। वर्तमान में, कोई संयोजन उपचार नहीं हैं (दोहरी उपचार के रूप में भी जाना जाता है) जो कि आधिकारिक तौर पर कोविड-19 के इलाज के लिए उपयोग के लिए अनुमोदित हैं। हालांकि, नेशनल इंस्टीट्यूट ऑफ एलर्जी एंड इन्फेक्शस डिसीज के निदेशक डॉ. एंथनी फौसी ने 23 जून, 2020 को कोविड-19 महामारी के लिए अमेरिका की प्रतिक्रिया पर एक हाउस कमेटी के समक्ष गवाही देते हुए घोषणा की कि रेमिथिविर को एंटी-इंफ्लेमेटरी बारसेंटिब के साथ संयोजन में उपयोग किया जा रहा है। संयुक्त उपचार की प्रभावकारिता का परीक्षण करने के लिए मई से एनआईएच नैदानिक ​​परीक्षण चल रहा है, जिसके परिणाम अभी तक जारी नहीं किए गए हैं।\n\nकेवल तीन दवाओं ने आधिकारिक तौर पर अमेरिका में फेडरल ड्रग एडमिनिस्ट्रेशन (एफडीए) से आपातकालीन उपयोग प्राधिकरण (ईयूए) प्राप्त किया है; इनमें एंटी-वायरल रीमेडिसविर, एंटी-मलेरिया ड्रग्स क्लोरोक्वीन और हाइड्रोक्सीक्लोरोक्वीन (जिसे बाद में एफडीए ने एक चेतावनी जारी की) शामिल है, और एक दवा जो वेंटिलेटर पर रहने वाले मरीजों को बेहोश करने के लिए इस्तेमाल की जाती है। (ये ईयूए दवा की औपचारिक मंजूरी का गठन नहीं करते हैं, बल्कि अमेरिकी डॉक्टरों द्वारा कोविड-19 के उपचार में क्लोरोक्विन और हाइड्रोक्सीक्लोरोक्वीन का उपयोग करने के लिए दी जाने वाली संभावना है, यदि चिकित्सक के पास कोई अन्य विकल्प नहीं है और रोगियों के साथ जोखिम के बारे में चर्चा करने के बाद।\n\nहालाँकि अभी तक किसी भी संयोजन उपचार को औपचारिक रूप से उपयोग के लिए अनुमोदित नहीं किया गया है, फिर भी इनका व्यापक परीक्षण किया जा रहा है। परीक्षण की जा रही संयोजन चिकित्सा का एक उदाहरण ड्रग्स लोपिनवीर और रटनवीर का दोहरा उपयोग है, जो एचआईवी के उपचार के लिए उपयोग में हैं (इलाज नहीं)। इन दोनों दवाओं के संयोजन को ब्रांड नाम कलेट्रा के तहत जाना जाता है। अध्ययन अभी भी अपेक्षाकृत अनिर्णायक हैं, लेकिन अधिकांश ने कालवीरा को कोविड-19 परिणामों में सुधार के लिए अप्रभावी दिखाया है। एक अध्ययन, हालांकि, पाया गया कि जब दो अन्य दवाओं - रिबाविरिन और इंटरफेरॉन बीटा -1 बी के साथ लिया जाता है - तो वायरस को रोगी के शरीर से साफ़ करने में कम समय लगता है। इस परीक्षण से कई सीमाएँ हैं जो आगे के परीक्षण का वारंट बनती हैं। \n\nसंयोजन चिकित्सा का परीक्षण करने वाले अन्य अध्ययन, रेमेडीसविर के साथ जोड़े पर ध्यान केंद्रित कर रहे हैं, यह देखते हुए कि यह अब तक का सबसे आशाजनक प्रमाण है। एक अध्ययन यह परीक्षण कर रहा है कि क्या रेमिडीसविर प्रभावशीलता में वृद्धि करता है अगर एक एंटी-इंफ्लेमेटरी दवा के साथ लिया जाता है जिसे बारसेंटिनिब के रूप में जाना जाता है। एक और ड्रग लेरोनिमिलाब के साथ रेमेडिसविर के संयोजन का परीक्षण कर रहा है, एक एंटीवायरल जिसमें कुछ एंटी-इंफ्लेमेटरी दवा लाभ भी दिखाया गया है।\nये अध्ययन हमें समझने के करीब पहुंचेंगे अगर कोविड-19 के इलाज के लिए कुछ संयोजन उपचार प्रभावी हो सकते हैं।"
    ],
    "Hindi - Background and context": [
      "कोविड-19 वैक्सीन की वर्तमान अनुपस्थिति को देखते हुए, शोधकर्ता तुरंत बीमारी के उपचार की तलाश कर रहे हैं। इसके लिए, मौजूदा दवाओं की एक विस्तृत श्रृंखला है (यानी विभिन्न स्वास्थ्य स्थितियों के लिए मंजूर और विनियमित) और संभावित रूप से नए लोगों को विश्व स्तर पर परीक्षण किया जा रहा है। ये परीक्षण प्रयोगशालाओं और पशु और नैदानिक अध्ययनों में किए जा रहे हैं, और एक बार प्रभावी साबित होने के बाद उन्हें नैदानिक परीक्षणों में ले जाया जाता है। एक दवाओं पर अध्ययन के अलावा, शोधकर्ता यह परीक्षण कर रहे हैं कि संयोजन चिकित्सा के रूप में क्या जाना जाता है, जिसमें एक बीमारी का इलाज करने के लिए दो या अधिक दवाएं ली जाती हैं। संयोजन चिकित्सा के लिए तर्क यह है कि अलग-अलग दवाएं विभिन्न तंत्रों के माध्यम से काम करती हैं, और एक से अधिक समूह बनाकर उपचार की प्रभावकारिता को बढ़ा सकते हैं, उपचार की अवधि कम कर सकते हैं, और दवा प्रतिरोध की संभावना को कम कर सकते हैं। "
    ],
    "Telugu - What our experts say": [
      "\"కాంబినేషన్ ట్రీట్మెంట్స్\" అంటే ఒకే వ్యాధికి చికిత్స చేయడానికి రెండు లేదా అంతకంటే ఎక్కువ మందులను వాడటం. ప్రస్తుతం, కోవిడ్-19 చికిత్సకు అధికారికంగా ఆమోదించబడిన కలయిక చికిత్సలు (ద్వంద్వ చికిత్సలు అని కూడా పిలుస్తారు) లేవు. ఏదేమైనా, నేషనల్ ఇన్స్టిట్యూట్ ఆఫ్ అలెర్జీ అండ్ ఇన్ఫెక్షియస్ డిసీజెస్ డైరెక్టర్ డాక్టర్ ఆంథోనీ ఫౌసీ, జూన్ 23, 2020 న ప్రకటించారు, అయితే కోవిడ్-19 మహమ్మారికి అమెరికా ప్రతిస్పందనపై హౌస్ కమిటీ ముందు సాక్ష్యమిస్తూ, రెమ్‌డెసివిర్‌ను యాంటీ-యాంటీతో కలిపి ఉపయోగిస్తున్నట్లు తాపజనక ఔషధ బారిసిటినిబ్. మిశ్రమ చికిత్స యొక్క సామర్థ్యాన్ని పరీక్షించడానికి మే నుండి ఎన్ఐహెచ్ క్లినికల్ ట్రయల్ జరుగుతోంది, ఫలితాలు ఇంకా విడుదల కాలేదు.అమెరికాలోని ఫెడరల్ డ్రగ్ అడ్మినిస్ట్రేషన్ (ఎఫ్‌డిఎ) నుండి కేవలం మూడు స్వతంత్ర మందులు మాత్రమే అధికారికంగా అత్యవసర వినియోగ అధికారాన్ని (ఇయుఎ) పొందాయి; వీటిలో యాంటీ-వైరల్ రెమెడిసివిర్, యాంటీ-మలేరియా డ్రగ్స్ క్లోరోక్విన్ మరియు హైడ్రాక్సీక్లోరోక్విన్ (ఎఫ్‌డిఎ తరువాత ఒక హెచ్చరిక జారీ చేసింది), మరియు వెంటిలేటర్‌లో ఉన్న రోగులను మత్తులో పడే మందు. (ఈ EUA ఔషధానికి అధికారిక ఆమోదం కలిగి ఉండవు, అయితే అమెరికన్ వైద్యులు క్లోవిక్విన్ మరియు హైడ్రాక్సీక్లోరోక్విన్‌లను కోవిడ్-19 చికిత్సలో ఉపయోగించుకునే అవకాశం వైద్యుడికి ఇతర ఎంపికలు లేకపోతే మరియు రోగులతో చర్చించిన తరువాత కలిగే ప్రమాదాలు. )కలయిక చికిత్సలు ఇంకా ఉపయోగం కోసం అధికారికంగా ఆమోదించబడనప్పటికీ, అవి విస్తృతంగా పరీక్షించబడుతున్నాయి. కాంబినేషన్ థెరపీ పరీక్షించబడటానికి ఒక ఉదాహరణ, లోపినావిర్ మరియు రిటోనావిర్ అనే ఔషధాల యొక్క ద్వంద్వ ఉపయోగం, ఇవి హెచ్ఐవి చికిత్సకు (నయం కాదు) ఉపయోగంలో ఉన్నాయి. ఈ రెండు ఔషధాల కలయికను కలేట్రా బ్రాండ్ పేరుతో పిలుస్తారు. అధ్యయనాలు ఇప్పటికీ సాపేక్షంగా అసంకల్పితంగా ఉన్నాయి, కాని చాలా మంది కోవిడ్-19 ఫలితాలను మెరుగుపరచడానికి కాలేట్రా పనికిరానివని చూపించారు. అయితే, ఒక అధ్యయనం ప్రకారం, రిబావిరిన్ మరియు ఇంటర్ఫెరాన్ బీటా -1 బి అనే మరో రెండు ఔషధలతో తీసుకున్నప్పుడు, వైరస్ రోగి శరీరం నుండి క్లియర్ చేయడానికి తక్కువ సమయం తీసుకుంది. ఈ విచారణ నుండి అనేక పరిమితులు ఉన్నాయి, ఇవి మరింత పరీక్షించాల్సిన అవసరం ఉంది.కాంబినేషన్ థెరపీని పరీక్షించే ఇతర అధ్యయనాలు రెమ్‌డెసివిర్‌తో జతలపై దృష్టి సారించాయి, ఇది ఇప్పటివరకు అత్యంత ఆశాజనకమైన సాక్ష్యాలతో చికిత్సగా ఉంది. బారిసిటినిబ్ అని పిలువబడే యాంటీ ఇన్ఫ్లమేటరీ ఔషధంతో తీసుకుంటే రెమెడెసివిర్ ప్రభావంలో పెరుగుతుందా అని ఒక అధ్యయనం పరీక్షిస్తోంది. మరొకటి రెమెడెసివిర్ కలయికను ఔషధ లెరోన్లిమాబ్ అనే యాంటీవైరల్ తో పరీక్షిస్తోంది, ఇది కొన్ని శోథ నిరోధక ప్రయోజనాలను కలిగి ఉందని కూడా చూపించింది.కోవిడ్-19 చికిత్సకు కొన్ని కాంబినేషన్ థెరపీలు ప్రభావవంతంగా ఉంటే ఈ అధ్యయనాలు మనకు అర్థం చేసుకోవడానికి దగ్గరగా ఉంటాయి."
    ],
    "Telugu - Context and background": [
      "కోవిడ్-19 వ్యాక్సిన్ ప్రస్తుతం లేకపోవడంతో, పరిశోధకులు అత్యవసరంగా ఈ వ్యాధికి చికిత్సల కోసం చూస్తున్నారు. ఈ మేరకు, ప్రస్తుతం ఉన్న ఔషధాల యొక్క విస్తృత శ్రేణి ఉంది (అనగా వివిధ ఆరోగ్య పరిస్థితుల కోసం ఆమోదించబడినది మరియు నియంత్రించబడుతుంది) మరియు ప్రపంచవ్యాప్తంగా కొత్తగా పరీక్షించబడుతున్నాయి. ఈ పరీక్షలు ప్రయోగశాలలు మరియు జంతు మరియు క్లినికల్ అధ్యయనాలలో నిర్వహించబడుతున్నాయి మరియు సమర్థవంతంగా నిరూపించబడిన తరువాత అవి క్లినికల్ ట్రయల్స్‌కు తరలించబడతాయి. ఏక ఔషధాలన్ థెరపీలుగా పిలువబపై అధ్యయనాలతో పాటు, పరిశోధకులు కాంబినేషడే వాటిని పరీక్షిస్తున్నారు, ఇందులో ఒకే వ్యాధికి రెండు లేదా అంతకంటే ఎక్కువ మందులు తీసుకుంటారు. కాంబినేషన్ థెరపీకి కారణం ఏమిటంటే, వేర్వేరు ఔషధాలు వేర్వేరు యంత్రాంగాల ద్వారా పనిచేస్తాయి మరియు ఒకటి కంటే ఎక్కువ సమూహపరచడం వలన చికిత్స యొక్క సామర్థ్యాన్ని పెంచుతుంది, చికిత్స వ్యవధిని తగ్గిస్తుంది మరియు ఔషధ నిరోధకత యొక్క సంభావ్యతను తగ్గిస్తుంది."
    ],
    "Bengali - What our experts say": [
      "\"সংমিশ্রিত চিকিৎসা\" হ'ল একটি রোগের চিকিৎসার জন্য দুই বা ততোধিক ওষুধের ব্যবহার। বর্তমানে, কোনও সংযুক্ত চিকিৎসা (দ্বৈত চিকিৎসা নামেও পরিচিত) নেই যা কোভিড-১৯ এর চিকিৎসার জন্য প্রাতিষ্ঠানিকভাবে অনুমোদিত। তবে, জাতীয় অ্যালার্জি ও সংক্রামক রোগের ইনস্টিটিউটের পরিচালক ডঃ অ্যান্টনি ফৌসি ২৩ শে জুন, ২০২০ এ কোভিড-১৯ মহামারী সম্পর্কে মার্কিন প্রতিক্রিয়া সম্পর্কে একটি হাউস কমিটির সামনে সাক্ষ্য দেওয়ার সময় ঘোষণা করেছিলেন যে, রিমডেসিভির প্রদাহনাশক ওষুধ ব্যারিসিটিনিবের সাথে একত্রে ব্যবহৃত হচ্ছে। সম্মিলিত চিকিৎসার কার্যকারিতা পরীক্ষা করার জন্য মে মাস থেকে একটি এনআইএইচ ক্লিনিকাল ট্রায়াল চলছে, ফলাফল এখনও প্রকাশিত হয়নি।\n\nমার্কিন যুক্তরাষ্ট্রের ফেডারেল ড্রাগ অ্যাডমিনিস্ট্রেশন (এফডিএ) থেকে আনুষ্ঠানিকভাবে মাত্র তিনটি স্বতন্ত্র ওষুধ জরুরী ব্যবহারের অনুমোদন (EUA) পেয়েছে; এর মধ্যে রয়েছে অ্যান্টি-ভাইরাল রিমেডেসিভির, ম্যালেরিয়াবিরোধী ওষুধ ক্লোরোকুইন এবং হাইড্রোক্সাইক্লোরোকুইন (যা পরবর্তী সময়ে এফডিএ একটি সতর্কতা জারি করেছিল), এবং ভেন্টিলেটরে থাকা রোগীদের অচেতন করার জন্য ব্যবহৃত একটি ওষুধ| (এই EUA ওষুধ একটি আনুষ্ঠানিক অনুমোদন নয়, বরং আমেরিকান চিকিৎসকদের কোভিড-১৯ এর চিকিৎসায় ক্লোরোকুইন এবং হাইড্রোক্সাইক্লোরোকুইন ব্যবহার করার সম্ভাবনা দেওয়া হয় তবে শুধুমাত্র যদি চিকিৎসকের অন্য কোনও বিকল্প না থাকে এবং রোগীদের সাথে এর সাথে জড়িত ঝুঁকিগুলি নিয়ে আলোচনা করার পরে। )\n\nযদিও কোনও সংমিশ্রণ চিকিৎসা এখনও আনুষ্ঠানিকভাবে ব্যবহারের জন্য অনুমোদিত হয়নি, তাদের ব্যাপকভাবে পরীক্ষা করা হচ্ছে। সংমিশ্রিত থেরাপি যাচাইয়ের একটি উদাহরণ হ'ল লোপিনাভির এবং রিটোনাভির ওষুধগুলির দ্বৈত ব্যবহার যা এইচআইভির চিকিৎসায় (নিরাময় নয়) ব্যবহৃত হয়। এই দুটি ওষুধের সংমিশ্রণ ক্যালেট্রা ব্র্যান্ড নামে পরিচিত। অধ্যয়নগুলি এখনও তুলনামূলকভাবে অসম্পূর্ণ, তবে বেশিরভাগই ক্যালেট্রা কোভিড-১৯ ফলাফল উন্নতির জন্য অকার্যকর বলে প্রমাণিত করেছে। তবে একটি গবেষণায় দেখা গেছে যে, অন্যান্য দুটি ওষুধ রিবাভাইরিন এবং ইন্টারফেরন বিটা -১বি এর সাথে গ্রহণ করার সময় ভাইরাসটি রোগীর শরীর থেকে পরিষ্কার করতে কম সময় নিয়েছিল। এই ট্রায়ালের অনেকগুলি সীমাবদ্ধতা রয়েছে যা আরও পরীক্ষার জন্য তাগিদ দেয়।\n\nঅন্যান্য গবেষণার সংমিশ্রণ থেরাপি পরীক্ষা করে রেমডেসিভিরযুক্ত জোড়গুলিতে মনোনিবেশ করছে, এটি এখন পর্যন্ত সর্বাধিক প্রতিশ্রুতিবদ্ধ প্রমাণ সহ এটি চিকিৎসা। একটি গবেষণা ব্যারিসিটিনিব নামে পরিচিত একটি অ্যান্টি-ইনফ্লেমেটরি ওষুধের সাথে নেওয়া হলে রিমডেসভির কার্যকারিতা বৃদ্ধি করে কিনা তা পরীক্ষা করে দেখছে। আরেকটি ওষুধ লেওরনলিমা এর সাথে রেমডেসিভির সংমিশ্রণ পরীক্ষা করছে, এটি একটি অ্যান্টিভাইরাল যা অ্যান্টি-ইনফ্ল্যামেটরি সুবিধাও দেখিয়েছে।এই অধ্যয়নগুলি আমাদের কিছুটা বোঝার আরও কাছাকাছি পৌঁছে দেবে যদি নির্দিষ্ট সংমিশ্রণ চিকিৎসা কোভিড-১৯ এর চিকিৎসার জন্য কার্যকর হতে পারে।"
    ],
    "Bengali - Background and context": [
      "কোভিড -১৯ এর ভ্যাকসিনের বর্তমান অনুপস্থিতিতে, গবেষকরা জরুরিভাবে এই রোগের চিকিৎসা সন্ধান করছেন। এ লক্ষ্যে, বিদ্যমান দুটি ওষুধের বিস্তৃত পরিসীমা রয়েছে (অর্থাত্‍ বিভিন্ন স্বাস্থ্য অবস্থার জন্য অনুমোদিত এবং নিয়ন্ত্রিত) এবং বিশ্বব্যাপী সম্ভাব্য নতুনগুলি পরীক্ষা করা হচ্ছে। এই পরীক্ষাগুলি ল্যাবরেটরিজ এবং প্রাণী এবং ক্লিনিকাল স্টাডিতে পরিচালিত হচ্ছে এবং একবার কার্যকর প্রমাণিত হলে সেগুলি ক্লিনিকাল ট্রায়ালে স্থানান্তরিত হয়। একক ওষুধের উপর অধ্যয়ন ছাড়াও গবেষকরা যা সংমিশ্রণ চিকিৎসা হিসাবে পরিচিত তা পরীক্ষা করছেন, যেখানে দুটি বা তারও বেশি ওষুধ একক রোগের চিকিৎসার জন্য নেওয়া হয়। সংমিশ্রণ থেরাপির যুক্তিটি হ'ল বিভিন্ন ওষুধ বিভিন্ন মেকানিজমের মাধ্যমে কাজ করে এবং একের অধিক দলবদ্ধ করা চিকিৎসার কার্যকারিতা বাড়াতে, চিকিৎসার সময়কাল হ্রাস করতে এবং ওষুধের প্রতিরোধের সম্ভাবনা হ্রাস করতে পারে।"
    ]
  },
  {
    "id": "rec2BhpwmJG6sqPaK",
    "Question": "Does COVID-19 impact men worse than women?",
    "Status": "Published",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "The disproportionate impact of COVID-19 on men have been shown in a number of studies and hospital data. To clarify, the number of cases has appeared relatively equal, but vulnerability to the virus and mortality have not. A recent study from The Journal of the American Medical Association (JAMA) found that of 5700 patients hospitalized with COVID-19 in the New York City area, 39.7% of patients were female while 60.3% were male, demonstrating significantly disparate hospitalization rates based on sex. Sex and gender-based discrepancies are commonly documented in scientific literature, and are helpful for understanding how and why a health condition or disease manifests. For instance, women are twice as likely as men to become depressed, and men are more likely to develop cardiovascular disease and diabetes. The gender dimensions of diseases are both physical as well as socially constructed. For example, higher estrogen levels in a women born biologically female is a determinant of health (biological), as is a higher likelihood to carry out domestic work (social). These dimensions also align with the terms sex and gender -- both of which are important to pay attention to in health. Sex describes primarily biological differences between men and women in origin, and gender describes differences primarily caused by social conditions, and can be thought as how one's chosen gender role and how they present. Public health efforts and policies have not always addressed the impacts of diseases across sex and gender, but doing so can help us to understand both the biological and social dimensions of diseases like COVID-19, including who is most at risk and how to mitigate adverse outcomes. \n",
    "What our experts say": "Data from around the world has demonstrated the fact that men are impacted more greatly than women by COVID-19. For example, men are more likely to be hospitalized with severe symptoms of the virus and have higher mortality rates than women; and this finding is consistent across age groups and geographies. Researchers have been trying to understand the causes of this and are developing hypotheses to explain the differences between the immune systems' response to COVID-19 in men and women. At this stage, they are exploring these disparities using biological, social, and behavioral lenses. \nBased on previous studies with similar viruses, data has illustrated that sex differences in immunity are caused by both genetic as well as hormonal differences between women and men. For example, in females, hormones such as estrogen and progesterone may be protective against the virus, yet it is possible testosterone does the opposite for men. In terms of underlying illnesses, the data also illustrates that men are more likely to suffer from hypertension, heart disease, and diabetes than women. Since the beginning of the pandemic, we have learned that these types of underlying conditions have been associated with a higher risk of complications from COVID-19. Behavioral factors may also explain this difference. For instance, females may be more likely to be frontline workers than men, which could create more risks for exposure. In terms of lifestyle, men tend to be more likely to be smokers, which is a risk factor for COVID-19 since it is a respiratory illness. \nFrom past studies, we also know that men are less likely to seek out medical care when there's a problem in comparison to women, which means they may interact with the health system at a later stage in the disease when symptoms are more severe. Similarly, in the case of COVID-19, men are less likely to engage in behaviors like mask-wearing and hand-washing, which may increase their risk of contracting the disease. \nSource: Dr. Sabra Klein (Johns Hopkins University)\n",
    "Glossary Terms": [
      "recT7R7Qqg8v9f9Ui"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "infection"
    ],
    "Other resources": "1. Q&A on Covid-19 - Johns Hopkins University ([JHU](https://hub.jhu.edu/2020/06/17/sabra-klein-sex-differences-covid-19/)) \n2. Research paper: Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area ([JAMA](https://jamanetwork.com/journals/jama/fullarticle/2765184))\n",
    "DB (Hindi)": [
      "recOdx5kTu1J9JSt5"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recEToFhhqcTpcJ8n"
    ],
    "DB (Bengali)": [
      "recFSe81rOEPgeC90"
    ],
    "DB (Portuguese)": [
      "recgTP0fpINLoWg9A"
    ],
    "Rollup test 2": [
      "rec6WVxnoKBMl29oS"
    ],
    "Last modified manual": "2020-07-03",
    "Last edited (simplified)": "2020-06-24T06:34:27.000Z",
    "Last edited (experts say)": "2020-06-24T06:35:29.000Z",
    "Last modified": "2020-07-03",
    "What our experts say wordcount": 331,
    "Background and context wordcount": 270,
    "Other resources wordcount": 30,
    "Wordcount": 631,
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "दुनिया भर के आंकड़ों ने इस तथ्य को प्रदर्शित किया है कि कोविड-19 का महिलाओं की तुलना में पुरुषों पर बहुत अधिक प्रभाव पड़ा है। उदाहरण के लिए, पुरुषों में वायरस के गंभीर लक्षणों के साथ अस्पताल में भर्ती होने की संभावना अधिक है और महिलाओं की तुलना में मृत्यु दर भी अधिक है; और ये सभी आयु समूहों और भौगोलिक क्षेत्रों में देखा गया है।शोधकर्ता इसके कारणों को समझने की कोशिश कर रहे हैं और पुरुषों और महिलाओं की प्रतिरक्षा प्रणाली (इम्यून सिस्टम) की कोविड-19 से लड़ने की प्रतिक्रिया के बीच के अंतर को समझाने के लिए परिकल्पना (हायपॉथिसस) विकसित कर रहे हैं। इस समय वे जैविक, सामाजिक और व्यवहार के दृष्टिकोण से असमानताओं का पता लगा रहे हैं।\nइसी तरह के वायरस के साथ किए गए पिछले अध्ययनों के आधार पर, डेटा में बताया गया है कि महिलाओं और पुरुषों के बीच जेनेटिक और हार्मोनल अंतर के कारण उनकी इम्यूनिटी में भी अंतर हो सकता है। उदाहरण के लिए, महिलाओं में, एस्ट्रोजन और प्रोजेस्टेरोन जैसे हार्मोन वायरस के खिलाफ सुरक्षात्मक हो सकते हैं, और यह भी यह संभव है कि टेस्टोस्टेरोन पुरुषों के लिए सुरक्षा प्रदान नहीं करता है। अंतर्निहित बीमारियों के संदर्भ में, डेटा यह भी बताता है कि महिलाओं की तुलना में पुरुषों को उच्च रक्तचाप, हृदय रोग और मधुमेह से पीड़ित होने की अधिक संभावना है।"
    ],
    "Hindi - Background and context": [
      "कई अध्ययनों और अस्पताल के आंकड़ों में पाया गया है कि पुरुषों पर कोविड-19 का प्रभाव ज़्यादा पड़ रहा है। स्पष्ट करने के लिए, मामलों की संख्या अपेक्षाकृत बराबर दिखाई दी है, लेकिन वायरस का प्रभाव और मृत्यु दर पुरुषों में अधिक था। 'द जर्नल ऑफ द अमेरिकन मेडिकल एसोसिएशन' (JAMA) के एक हालिया अध्ययन में पाया गया कि न्यूयॉर्क सिटी में कोविड-19 के 5700 रोगियों को अस्पताल में भर्ती कराया गया, इनमे से 39.7% रोगी महिलाएं थीं, जबकि 60.3% पुरुष थे, जो अस्पताल में भर्ती महिलाओं और पुरुषों के दरों का प्रदर्शन करते थे।आमतौर पर लिंग पर आधारित अंतर वैज्ञानिक साहित्य में उपलब्ध होते हैं, और यह समझने के लिए सहायक होते हैं कि स्वास्थ्य स्थिति या रोग कैसे और क्यों प्रकट होता है। उदाहरण के लिए, महिलाओं में अवसादग्रस्त (डिप्रेस्ट) होने की संभावना दोगुनी होती हैं, और पुरुषों में हृदय रोग और मधुमेह विकसित होने की अधिक संभावना होती है। महिलाओं और पुरुषों में रोग शारीरिक और सामाजिक रूप से निर्मित होते हैं। उदाहरण के लिए, महिलाओं में उच्च एस्ट्रोजन का स्तर स्वास्थ्य का एक निर्धारक होता है जो की जैविक या शारीरिक रूप में पाया जाता है, दूसरी ओर, महिलाओं में घरेलू काम करने की एक उच्च संभावना होती है, जो की एक सामाजिक पहलू है। \nसार्वजनिक स्वास्थ्य प्रयासों और नीतियों ने महिलाओं और पुरुषों में रोगों के अलग अलग प्रभावों को हमेशा संबोधित नहीं किया है, लेकिन ऐसा करने से हमें कोविड-19 जैसी बीमारियों के जैविक और सामाजिक दोनों आयामों को समझने में मदद मिल सकती है, किसे अधिक जोखिम है और प्रतिकूल परिणामों को कैसे कम किया जाए।"
    ],
    "Telugu - What our experts say": [
      "కోవిడ్-19 ద్వారా పురుషుల కంటే మహిళల కంటే ఎక్కువగా ప్రభావితమవుతుందనే వాస్తవాన్ని ప్రపంచవ్యాప్తంగా ఉన్న డేటా నిరూపించింది. ఉదాహరణకు, వైరస్ యొక్క తీవ్రమైన లక్షణాలతో పురుషులు ఆసుపత్రిలో చేరే అవకాశం ఉంది మరియు మహిళల కంటే మరణాల రేటు ఎక్కువగా ఉంటుంది; మరియు ఈ అన్వేషణ వయస్సు వర్గాలు మరియు భౌగోళికాలలో స్థిరంగా ఉంటుంది. పరిశోధకులు దీని కారణాలను అర్థం చేసుకోవడానికి ప్రయత్నిస్తున్నారు మరియు పురుషులు మరియు మహిళల్లో కోవిడ్-19 కు రోగనిరోధక వ్యవస్థల ప్రతిస్పందన మధ్య తేడాలను వివరించడానికి పరికల్పనలను అభివృద్ధి చేస్తున్నారు. ఈ దశలో, వారు జీవ, సామాజిక మరియు ప్రవర్తనా కటకములను ఉపయోగించి ఈ అసమానతలను అన్వేషిస్తున్నారు.సారూప్య వైరస్లతో మునుపటి అధ్యయనాల ఆధారంగా, రోగనిరోధక శక్తిలో సెక్స్ వ్యత్యాసాలు స్త్రీలు మరియు పురుషుల మధ్య జన్యుపరమైన మరియు హార్మోన్ల వ్యత్యాసాల వల్ల సంభవిస్తాయని డేటా వివరించింది. ఉదాహరణకు, ఆడవారిలో, ఈస్ట్రోజెన్ మరియు ప్రొజెస్టెరాన్ వంటి హార్మోన్లు వైరస్ నుండి రక్షణ కలిగి ఉండవచ్చు, అయినప్పటికీ టెస్టోస్టెరాన్ పురుషులకు విరుద్ధంగా చేస్తుంది. అంతర్లీన అనారోగ్యాల విషయానికొస్తే, మహిళల కంటే పురుషులు రక్తపోటు, గుండె జబ్బులు మరియు మధుమేహంతో బాధపడే అవకాశం ఉందని డేటా వివరిస్తుంది. మహమ్మారి ప్రారంభం నుండి, ఈ రకమైన అంతర్లీన పరిస్థితులు కోవిడ్-19 నుండి వచ్చే సమస్యల యొక్క అధిక ప్రమాదంతో ముడిపడి ఉన్నాయని మేము తెలుసుకున్నాము. ప్రవర్తనా కారకాలు కూడా ఈ వ్యత్యాసాన్ని వివరించవచ్చు. ఉదాహరణకు, పురుషుల కంటే ఆడవారు ఫ్రంట్‌లైన్ కార్మికులుగా ఉండటానికి అవకాశం ఉంది, ఇది బహిర్గతం కోసం ఎక్కువ నష్టాలను సృష్టిస్తుంది. జీవనశైలి పరంగా, పురుషులు ధూమపానం చేసే అవకాశం ఎక్కువగా ఉంటుంది, ఇది కోవిడ్-19 కి శ్వాసకోశ అనారోగ్యం కనుక ప్రమాద కారకం.గత అధ్యయనాల నుండి, మహిళలతో పోల్చితే పురుషులు వైద్య సంరక్షణను పొందే అవకాశం తక్కువగా ఉందని మనకు తెలుసు, అనగా లక్షణాలు మరింత తీవ్రంగా ఉన్నప్పుడు వ్యాధి యొక్క తరువాతి దశలో వారు ఆరోగ్య వ్యవస్థతో సంభాషించవచ్చు. అదేవిధంగా, కోవిడ్-19 విషయంలో, పురుషులు ముసుగు ధరించడం మరియు చేతులు కడుక్కోవడం వంటి ప్రవర్తనల్లో పాల్గొనే అవకాశం తక్కువ, ఇది వ్యాధి బారిన పడే ప్రమాదాన్ని పెంచుతుంది.మూలం: డాక్టర్ సబ్రా క్లీన్ (జాన్స్ హాప్కిన్స్ విశ్వవిద్యాలయం)"
    ],
    "Telugu - Context and background": [
      "పురుషులపై కోవిడ్-19 యొక్క అసమాన ప్రభావం అనేక అధ్యయనాలు మరియు ఆసుపత్రి డేటాలో చూపబడింది. స్పష్టం చేయడానికి, కేసుల సంఖ్య సాపేక్షంగా సమానంగా కనిపించింది, కాని వైరస్ మరియు మరణాలకు హాని లేదు. న్యూయార్క్ నగర ప్రాంతంలో కోవిడ్-19 తో ఆసుపత్రిలో చేరిన 5700 మంది రోగులలో, 39.7% మంది రోగులు స్త్రీలు కాగా, 60.3% మంది పురుషులు ఉన్నారు, ఇది గణనీయంగా భిన్నమైన ఆసుపత్రి రేటును ప్రదర్శిస్తుందని ది జర్నల్ ఆఫ్ ది అమెరికన్ మెడికల్ అసోసియేషన్ (జామా) నుండి తాజా అధ్యయనం కనుగొంది. సెక్స్. సెక్స్ మరియు లింగ-ఆధారిత వ్యత్యాసాలు సాధారణంగా శాస్త్రీయ సాహిత్యంలో నమోదు చేయబడతాయి మరియు ఆరోగ్య పరిస్థితి లేదా వ్యాధి ఎలా మరియు ఎందుకు వ్యక్తమవుతుందో అర్థం చేసుకోవడానికి సహాయపడతాయి. ఉదాహరణకు, స్త్రీలు పురుషుల కంటే నిరాశకు గురయ్యే అవకాశం రెండింతలు, మరియు పురుషులు గుండె జబ్బులు మరియు మధుమేహం వచ్చే అవకాశం ఉంది. వ్యాధుల లింగ కొలతలు శారీరకంగా మరియు సామాజికంగా నిర్మించబడ్డాయి. ఉదాహరణకు, జీవశాస్త్రపరంగా ఆడవారిలో పుట్టిన స్త్రీలలో అధిక ఈస్ట్రోజెన్ స్థాయిలు ఆరోగ్యాన్ని (జీవసంబంధమైనవి) నిర్ణయిస్తాయి, అదే విధంగా గృహ పని (సామాజిక) నిర్వహించడానికి ఎక్కువ అవకాశం ఉంది. ఈ కొలతలు సెక్స్ మరియు లింగం అనే పదాలతో కూడా సమలేఖనం అవుతాయి - ఈ రెండూ ఆరోగ్యంలో శ్రద్ధ చూపడం చాలా ముఖ్యం. సెక్స్ ప్రధానంగా పురుషులు మరియు మహిళల మధ్య జీవసంబంధమైన తేడాలను వివరిస్తుంది, మరియు లింగం ప్రధానంగా సామాజిక పరిస్థితుల వల్ల కలిగే తేడాలను వివరిస్తుంది మరియు ఒకరు ఎన్నుకున్న లింగ పాత్ర మరియు వారు ఎలా ప్రదర్శిస్తారో ఆలోచించవచ్చు. ప్రజారోగ్య ప్రయత్నాలు మరియు విధానాలు ఎల్లప్పుడూ సెక్స్ మరియు లింగ వ్యాధుల ప్రభావాలను పరిష్కరించలేదు, అయితే అలా చేయడం వల్ల కోవిడ్-19 వంటి వ్యాధుల యొక్క జీవ మరియు సామాజిక కొలతలు రెండింటినీ అర్థం చేసుకోవచ్చు, ఇందులో ఎవరు ఎక్కువ ప్రమాదంలో ఉన్నారు మరియు ప్రతికూలతను ఎలా తగ్గించాలి? ఫలితాలను."
    ],
    "Bengali - What our experts say": [
      "বিশ্বজুড়ে প্রাপ্ত তথ্যগুলি এই সত্যটি প্রমাণ করে দিয়েছে যে কোভিড-১৯ দ্বারা পুরুষরা নারীদের চেয়ে বেশি প্রভাবিত হয়। উদাহরণস্বরূপ, পুরুষরা ভাইরাসের মারাত্মক লক্ষণগুলির সাথে হাসপাতালে ভর্তি হওয়ার সম্ভাবনা বেশি এবং মহিলাদের চেয়ে মৃত্যুর হার বেশি; এবং এই সন্ধানটি বয়সের গোষ্ঠী এবং ভৌগলিক অবস্থান জুড়ে সামঞ্জস্যপূর্ণ। গবেষকরা এর কারণগুলি বোঝার চেষ্টা করছেন এবং পুরুষ ও মহিলাদের মধ্যে কোভিড-১৯ প্রতিরোধ ব্যবস্থা'র প্রতিক্রিয়ার মধ্যে পার্থক্য ব্যাখ্যা করার জন্য অনুমানগুলি বিকাশ করছেন। এই পর্যায়ে, তারা জৈবিক, সামাজিক এবং আচরণগত দৃষ্টিভঙ্গি ব্যবহার করে এই বৈষম্যগুলি অন্বেষণ করছেন।অনুরূপ ভাইরাসের সাথে পূর্ববর্তী গবেষণার উপর ভিত্তি করে তথ্য চিত্রিত করেছে যে, প্রতিরোধক্ষেত্রে যৌন পার্থক্য উভয় জেনেটিক নারী ও পুরুষদের মধ্যে হরমোনীয় পার্থক্যের কারণে ঘটে। উদাহরণস্বরূপ, মহিলাদের মধ্যে, এস্ট্রোজেন এবং প্রোজেস্টেরন জাতীয় হরমোন ভাইরাসের বিরুদ্ধে প্রতিরক্ষামূলক হতে পারে, তবুও এটি সম্ভব টেসটোসটেরন পুরুষদের ক্ষেত্রে বিপরীত কাজ করে। অন্তর্নিহিত অসুস্থতার ক্ষেত্রে, তথ্যগুলি আরও ব্যাখ্যা করে যে, পুরুষদের মহিলাদের চেয়ে উচ্চ রক্তচাপ, হৃদরোগ এবং ডায়াবেটিসে আক্রান্ত হওয়ার সম্ভাবনা বেশি থাকে। মহামারীর শুরু থেকেই আমরা শিখেছি যে, এই ধরণের অন্তর্নিহিত শর্তগুলি কোভিড-১৯ থেকে জটিলতার উচ্চতর ঝুঁকির সাথে যুক্ত হয়েছে। আচরণগত কারণগুলিও এই পার্থক্যটি ব্যাখ্যা করতে পারে। উদাহরণস্বরূপ, মহিলারা পুরুষদের চেয়ে ফ্রন্টলাইনের কর্মী হওয়ার সম্ভাবনা বেশি হতে পারে, যা এক্সপোজারের জন্য আরও ঝুঁকি তৈরি করতে পারে। লাইফস্টাইলের ক্ষেত্রে পুরুষদের ধূমপায়ী হওয়ার ঝুঁকি বেশি থাকে, যা শ্বসনজনিত অসুস্থতা হ'ল এটি কোভিড-১৯ এর জন্য ঝুঁকিপূর্ণ কারণ।বিগত সমীক্ষা থেকে আমরা আরও জানি যে, মহিলাদের তুলনায় সমস্যা দেখা দিলে পুরুষরা চিকিৎসা যত্ন নেওয়ার সম্ভাবনা কম থাকে, যার অর্থ লক্ষণগুলি আরও তীব্র হলে তারা রোগের পরবর্তী পর্যায়ে স্বাস্থ্য ব্যবস্থার সাথে যোগাযোগ করতে পারে। একইভাবে, কোভিড -১৯ এর ক্ষেত্রে পুরুষরা মুখোশ পরা এবং হাত ধোয়ার মতো আচরণে লিপ্ত হওয়ার সম্ভাবনা কম থাকে, যা তাদের এই রোগে আক্রান্ত হওয়ার ঝুঁকি বাড়িয়ে তুলতে পারে।\nসূত্র: ডাঃ সাবরা ক্লেইন (জনস হপকিন্স বিশ্ববিদ্যালয়)"
    ],
    "Bengali - Background and context": [
      "পুরুষদের উপর কোভিড-১৯ এর অপ্রতিরোধ্য প্রভাবগুলি অনেকগুলি অধ্যয়ন এবং হাসপাতালের তথ্যে দেখানো হয়েছে। স্পষ্ট করে বলতে গেলে, ঘটনার সংখ্যা তুলনামূলকভাবে সমান দেখা দিয়েছে, তবে ভাইরাস এবং মৃত্যুর ঝুঁকির মধ্যে নয়। আমেরিকান মেডিকেল অ্যাসোসিয়েশন জার্নালের (JAMA) সাম্প্রতিক এক গবেষণায় দেখা গেছে যে নিউইয়র্ক সিটি অঞ্চলে কোভিড -১৯-এর ৫৭০০০ রোগী হাসপাতালে ভর্তি হয়েছেন, ৩৯.৭% রোগী মহিলা ছিলেন এবং ৬০.৩% পুরুষ ছিলেন। লিঙ্গের উপর ভিত্তি করে হাসপাতালে ভর্তি হারে উল্লেখযোগ্যভাবে পৃথকীকরণের হার প্রদর্শন করে। লিঙ্গ এবং লিঙ্গ-ভিত্তিক বৈষম্যগুলি সাধারণত বৈজ্ঞানিক নথিতে লিপিবদ্ধ করা হয় এবং কীভাবে এবং কেন স্বাস্থ্যের অবস্থা বা রোগ প্রকাশ পায় তা বোঝার জন্য এটি সহায়ক। উদাহরণস্বরূপ, পুরুষদের তুলনায় দ্বিগুণ নারীরা হতাশাগ্রস্থ হয়ে থাকে এবং পুরুষদের হৃদরোগ ও ডায়াবেটিস হওয়ার সম্ভাবনা বেশি থাকে। রোগের লিঙ্গ মাত্রা উভয় শারীরিক পাশাপাশি সামাজিকভাবে নির্মিত। উদাহরণস্বরূপ, জৈবিকভাবে জন্মগ্রহণকারী মহিলাদের মধ্যে উচ্চতর ইস্ট্রোজেনের স্তর হ'ল স্বাস্থ্যের একটি নির্ধারক (জৈবিক), যেমন গৃহস্থালি কাজ চালানোর উচ্চতর সম্ভাবনা (সামাজিক)। এই মাত্রাগুলি যৌনতা এবং লিঙ্গের সাথে একত্রিত হয়- এই দুটি ক্ষেত্রেই স্বাস্থ্যের দিকে মনোযোগ দেওয়া গুরুত্বপূর্ণ| লিঙ্গ প্রাথমিকভাবে পুরুষদের এবং মহিলাদের মধ্যে জৈবিক পার্থক্যের বর্ণনা দেয় এবং লিঙ্গ মূলত সামাজিক অবস্থার কারণে সৃষ্ট পার্থক্যের বর্ণনা দেয় এবং কীভাবে তার চয়ন করা লিঙ্গ ভূমিকা এবং কীভাবে তারা উপস্থিত হয় তা বিবেচনা করা যেতে পারে। জনস্বাস্থ্য প্রচেষ্টা এবং নীতিগুলি সর্বদা লিঙ্গ এবং লিঙ্গ জুড়ে রোগের প্রভাবগুলিকে সম্বোধন করে না, তবে এটি করা আমাদের কোভিড -১৯ এর মতো রোগের জৈবিক এবং সামাজিক উভয় দিক বুঝতে সাহায্য করতে পারে, কার মধ্যে ঝুঁকি সবচেয়ে বেশি এবং প্রতিকূল ফলাফলগুলি কীভাবে প্রশমিত করা যায়।"
    ]
  },
  {
    "id": "recfFhB5k7C0pSTyr",
    "Question": "How does COVID-19 differ from malaria?",
    "Status": "Published",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "Nigeria"
    ],
    "Background and context": "Malaria is a disease caused by Plasmodium parasites carried by female Anopheles mosquitoes. It's a disease that occurs in over 100 countries. Nearly half of the global population is at risk of malaria, disproportionately people in low- and middle-income countries. According to the latest World Health Organization's World Malaria Report, there were 228 million cases and over 400,000 deaths in a year, with most of the fatalities occurring in Africa. \n\nWith global attention currently focused on COVID-19, public health advocates are calling attention to other diseases that also need to be addressed during this time. For example, the Global Fund reports that a majority of malaria, tuberculosis, and HIV/AIDS programs may face disruptions due to the COVID-19 pandemic. A recent publication in the International Journal of Infectious Diseases raises specific concerns about screening challenges for countries with malaria, due to similarities of symptoms such as fever with COVID-19. \n\nMalaria has also been linked to COVID-19 because of news coverage on hydroxychloroquine, a drug used to treat malaria with its overuse contributing to the spread of chloroquine resistance across the world. \n",
    "What our experts say": "COVID-19 and malaria are two different diseases with different ways of being spread and caught. Malaria is spread by mosquitoes, and humans become infected by mosquito bites. COVID-19 is spread by respiratory droplets that we inhale through our nose or our mouth. \n\nCOVID-19 and malaria have been incorrectly linked for several reasons. Firstly, around the world, hydroxychloroquine, a drug used to treat malaria, received extensive news coverage because there were claims that the drug was effective against COVID-19. A few clinical trials and studies investigated hydroxychloroquine and found no evidence that the drug was effective against COVID-19. In some unfortunate cases, adverse events occurred in people taking this medication. \n\nSecondly, malaria and COVID-19 share some symptoms, although the list of COVID-19 symptoms currently grows and changes every day. Malaria symptoms usually appear 10-15 days after the infective mosquito bite and the first symptoms a patient feels are fever, headache, and chills. On the other hand, people infected with COVID-19 usually develop symptoms within 5 days and, in some cases, infected people never develop symptoms at all. \n\nFinally, there is a difference between fevers caused by malaria and those caused by COVID-19. Often malarial fevers are cyclical, reoccurring at predictable times based on which strain of malaria was contracted. In comparison, fevers caused by COVID-19 do not appear to occur in cycles. The most common COVID-19 symptoms are: fever, dry cough and tiredness. Less common symptoms include: aches and pains, sore throat, diarrhea, conjunctivitis, headache, loss of taste or smell, a rash on skin, or discoloration of fingers or toes. \n\n\n",
    "Glossary Terms": [
      "recdLqq4xHzeWYco5",
      "recom5X8uy23wBxvK"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "symptoms"
    ],
    "Other resources": "1. Coronavirus ([WHO](https://www.who.int/health-topics/coronavirus#tab=tab_3))\n2. Malaria ([WHO](https://www.who.int/news-room/fact-sheets/detail/malaria))\n3. How COVID-19 is Affecting the Global Response to AIDS, Tuberculosis, and Malaria ([The Global Fund](https://www.theglobalfight.org/covid-aids-tb-malaria/))\n4. COVID-19 and Malaria: A Symptom Screening Challenge for Malaria Endemic Countries ([International Journal of Infectious Diseases](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184246/))\n5. 2019 World Malaria Report ([WHO](https://www.who.int/malaria/publications/world-malaria-report-2019/en/))\n",
    "DB (Hindi)": [
      "recHqbhhGdICGE31n"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "reczg2L4T2rrJ5n3s"
    ],
    "DB (Portuguese)": [
      "recahDDiRWAnRN132"
    ],
    "Rollup test 2": [
      "recpIYmFiRCUn1lDm"
    ],
    "Last modified manual": "2020-07-03",
    "Last edited (simplified)": "2020-06-26T14:19:45.000Z",
    "Last edited (experts say)": "2020-06-26T14:19:45.000Z",
    "Last modified": "2020-07-03",
    "What our experts say wordcount": 260,
    "Background and context wordcount": 181,
    "Other resources wordcount": 41,
    "Wordcount": 482,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "कोविड-19 और मलेरिया दो अलग-अलग बीमारियाँ हैं जिनके फैलने और पकड़े जाने के विभिन्न तरीके हैं। मलेरिया मच्छरों द्वारा फैलता है, और मनुष्य मच्छरों के काटने से संक्रमित हो जाते हैं। कोविड-19 सांस की बूंदों से फैलता है जिसे हम अपनी नाक या मुंह के माध्यम से साँस लेते हैं।\n\nकोविड-19 और मलेरिया को कई कारणों से गलत तरीके से जोड़ा गया है। सबसे पहले, दुनिया भर में, हाइड्रोक्सीक्लोरोक्वीन, मलेरिया के इलाज के लिए इस्तेमाल की जाने वाली दवा, व्यापक समाचार कवरेज प्राप्त हुई क्योंकि दावा किया गया था कि यह दवा कोविड-19 के खिलाफ प्रभावी थी। कुछ नैदानिक ​​परीक्षणों और अध्ययनों ने हाइड्रोक्सीक्लोरोक्वीन की जांच की और पाया कि यह दवा कोविड-19 के खिलाफ प्रभावी नहीं थी। कुछ दुर्भाग्यपूर्ण मामलों में, इस दवा को लेने वाले लोगों में प्रतिकूल घटनाएं हुईं।\n\nदूसरे, मलेरिया और कोविड-19 कुछ लक्षणों को साझा करते हैं, हालांकि कोविड-19 लक्षणों की सूची वर्तमान में बढ़ती है और हर दिन बदलती है। मलेरिया के लक्षण आमतौर पर संक्रमित मच्छर के काटने के 10-15 दिन बाद दिखाई देते हैं और पहला लक्षण एक मरीज को बुखार, सिरदर्द और ठंड लगना महसूस होता है। दूसरी ओर, कोविड-19 से संक्रमित लोग आमतौर पर 5 दिनों के भीतर लक्षण विकसित करते हैं और, कुछ मामलों में, संक्रमित लोग कभी भी लक्षण विकसित नहीं करते हैं।"
    ],
    "Hindi - Background and context": [
      "मलेरिया मादा एनोफिलीज मच्छरों द्वारा किए गए प्लास्मोडियम परजीवी के कारण होने वाली बीमारी है। यह एक बीमारी है जो 100 से अधिक देशों में होती है। वैश्विक आबादी के लगभग आधे लोगों में मलेरिया का खतरा है, जो निम्न-मध्यम और मध्यम आय वाले देशों के लोगों में असमानता है। नवीनतम विश्व स्वास्थ्य संगठन की विश्व मलेरिया रिपोर्ट के अनुसार, एक वर्ष में 228 मिलियन मामले और 400,000 से अधिक मौतें हुईं, जिनमें अधिकांश अफ्रीका में हुईं।\n\nवर्तमान में कोविड-19 पर केंद्रित वैश्विक ध्यान के साथ, सार्वजनिक स्वास्थ्य अधिवक्ता अन्य बीमारियों पर ध्यान दे रहे हैं, जिन्हें इस समय के दौरान भी संबोधित करने की आवश्यकता है। उदाहरण के लिए, ग्लोबल फंड की रिपोर्ट है कि कोविड-19 महामारी के कारण मलेरिया, क्षय और एचआईवी / एड्स के अधिकांश कार्यक्रमों में व्यवधान का सामना करना पड़ सकता है। कोविड-19 के साथ बुखार जैसे लक्षणों के कारण, अंतर्राष्ट्रीय संक्रामक रोगों के इंटरनेशनल जर्नल में हाल ही में प्रकाशित मलेरिया से पीड़ित देशों के लिए स्क्रीनिंग चुनौतियों के बारे में विशिष्ट चिंताएं हैं।\n\nहाइड्रोक्सीक्लोरोक्वाइन पर समाचार कवरेज के कारण मलेरिया को कोविड-19 से भी जोड़ा गया है, जो दुनिया भर में क्लोरोक्विन प्रतिरोध के प्रसार में योगदान के साथ मलेरिया के इलाज के लिए इस्तेमाल की जाने वाली दवा है।"
    ]
  },
  {
    "id": "recESQ72kwFjyWXWi",
    "Question": "What do we know about the use of the drug avifavir to treat COVID-19?",
    "Status": "Published",
    "Subcategory": "On: COVID-19 & avifavir",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Avifavir as a potential COVID-19 treatment has been emerging in visibility given that delivery of the drug to Russian hospitals began in June, following the approval of the Russian Ministry of Health. The approval follows promising but limited studies on Avifavir's accuracy in Russia, carried out in partnership of the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group. Studies on the drug have also been conducted in China — with seemingly promising results yet severe study limitations — as well as in the US, Italy, Japan and India. Data on the drug's efficacy for COVID-19 is still inconclusive.\n\nIn September 2020, RDIF announced that it has administered more than 60,000 doses of the drug in Russia and the surrounding region since June 2020, and that more doses will be delivered to 17 countries in Latin America, the Middle East, Eastern Europe, and Africa. Trends in Russia's COVID-19 data, and in particular, additional evidence, are needed to determine efficacy.\n",
    "What our experts say": "Avifavir is an antiviral medication primarily used to treat severe cases of influenza. This medication is currently being studied in several countries as a potential experimental treatment for COVID-19, but we do not yet have enough evidence to determine whether or not Avifavir is an effective treatment for the virus. \n\nRecently in Russia, the health ministry approved the medication's use as a COVID-19 treatment by using an accelerated, short-term form of a clinical trial with fewer people involved than traditional studies would normally require. However, this study has not been published in a peer-reviewed journal so the data, methods, and other study characteristics have yet to be critiqued or evaluated by other scientists. Though this research is still occurring in the country, Russia's preliminary results suggested Avifavir might help reduce the number of days people are infected with the virus and shorten the duration of time people experience high-grade fevers while sick. \n\nIn September 2020, a publication from India reviewed clinical trials in China and Japan, along with the on-going trials in Russia and other on-going studies in Saudi Arabia, the United States, and India. The researchers acknowledged that Avifavir does not have as much supportive data to back its use compared to other drugs, but that it may be emerging as a medication that is worth considering in mild to moderate cases. The preliminary results from a study in India suggest that Avifavir may help reduce the time it takes for COVID-19 patients to recover, and lead to a two-day shorter viral shedding period when patients are infectious.\n\nUntil more studies are completed and a greater amount of data can demonstrate Avifavir's efficacy and safety, we do not have enough information to determine whether or not this medication can help treat COVID-19.\n",
    "Glossary Terms": [
      "recMUR0P3EECMwfrv"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "treatment"
    ],
    "Other resources": "1. RDIF and ChemRar announce first interim results of clinical trials of Favipiravir drug’s effectiveness in coronavirus therapy ([RDIF](https://rdif.ru/Eng_fullNews/5174/))\n2. Breaking views - Corona Capital: Tech diversity, CNN’s middle age ([Reuters](https://www.reuters.com/article/us-health-coronavirus-finance-breakingvi/breakingviews-corona-capital-tech-diversity-cnns-middle-age-idUSKBN2383JE)) \n3. Russia Rolls Out First Approved COVID-19 Drug as Infections Pass 500,000 ([NYT](https://www.nytimes.com/reuters/2020/06/11/world/europe/11reuters-health-coronavirus-russia-cases.html)) \n4. 60,000 doses of avifavir, a COVID-19 treatment, to be delivered in June ([EPR](https://www.europeanpharmaceuticalreview.com/news/120478/60000-doses-of-avifavir-a-covid-19-treatment-to-be-delivered-in-june/)) \n5. Favipiravir: A new and emerging antiviral option in COVID-19  ([Medical Journal Armed Forces India](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467067/))\n6. RDIF and ChemRar to supply Avifavir to 17 countries ([PR Newswire](https://www.prnewswire.com/ae/news-releases/rdif-and-chemrar-to-supply-avifavir-to-17-countries-884826336.html))\n\n",
    "How often revision needed": "Monthly",
    "DB (Hindi)": [
      "recFtJtgluP9IrWp3"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recRdKjLVfs5A9TYt"
    ],
    "DB (Spanish)": [
      "recazddzsaJwokqS5"
    ],
    "DB (Bengali)": [
      "recScAMv5DU1rbMZ6"
    ],
    "DB (Portuguese)": [
      "rectdbEJ3x3XzTqZG"
    ],
    "Rollup test 2": [
      "recloqVVwudYYo4zL"
    ],
    "Last modified manual": "2020-10-08",
    "Last edited (simplified)": "2020-10-13T21:41:55.000Z",
    "Last edited (experts say)": "2020-10-13T21:41:55.000Z",
    "Last modified": "2020-10-13",
    "What our experts say wordcount": 292,
    "Background and context wordcount": 162,
    "Other resources wordcount": 84,
    "Wordcount": 538,
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "एविएविर, फ़ेविपिरवीर का एक सामान्य रूप है, एक एंटीवायरल दवा है जिसका इस्तेमाल मुख्य रूप से इन्फ्लूएंजा के गंभीर मामलों के इलाज के लिए किया जाता है। इस दवा का वर्तमान में कई देशों में कोविड​​-19 के लिए संभावित प्रायोगिक उपचार के रूप में अध्ययन किया जा रहा है, लेकिन हमारे पास अभी तक यह निर्धारित करने के लिए पर्याप्त प्रमाण नहीं हैं कि एविएविर वायरस के लिए एक प्रभावी उपचार है या नहीं।\n\nहाल ही में रूस में, स्वास्थ्य मंत्रालय ने पारंपरिक अध्ययनों की तुलना में कम लोगों के साथ नैदानिक ​​परीक्षण के त्वरित, अल्पकालिक रूप का उपयोग करके कोविड​​-19 उपचार के रूप में दवा के उपयोग को मंजूरी दी। हालाँकि, इस अध्ययन को एक सहकर्मी की समीक्षा की गई पत्रिका में प्रकाशित नहीं किया गया है, इसलिए अन्य वैज्ञानिकों द्वारा डेटा, विधियों और अन्य अध्ययन विशेषताओं का अभी तक आलोचना या मूल्यांकन किया गया है।\n\nहालांकि यह शोध अभी भी देश में हो रहा है, रूस के प्रारंभिक परिणामों ने सुझाव दिया है कि एविफवीर उन दिनों की संख्या को कम करने में मदद कर सकता है जो लोग वायरस से संक्रमित हैं और बीमार होने पर लोगों को उच्च-श्रेणी के बुखार का अनुभव होने की अवधि कम हो जाती है।\nलेकिन जब तक अधिक अध्ययन पूरा नहीं हो जाता है और डेटा की एक बड़ी मात्रा एविएविर की प्रभावकारिता और सुरक्षा को प्रदर्शित कर सकती है, हमारे पास यह निर्धारित करने के लिए पर्याप्त जानकारी नहीं है कि यह दवा कोविड​​-19 का इलाज करने में मदद कर सकती है या नहीं।"
    ],
    "Hindi - Background and context": [
      "एक संभावित कोविड​​-19 उपचार के रूप में एविफवीर दृश्यता में उभर रहा है, यह देखते हुए कि रूसी अस्पतालों में दवा की डिलीवरी जून में शुरू हुई, रूसी स्वास्थ्य मंत्रालय की मंजूरी के बाद। रूसी प्रत्यक्ष निवेश कोष (आरडीआईएफ) मंजूर, रूस के संप्रभु धन कोष और केमरार समूह की साझेदारी में किए गए रूस में एविफवीर की सटीकता पर आशाजनक लेकिन सीमित अध्ययन करता है।दवा पर अध्ययन भी चीन में आयोजित किया गया था - प्रतीत होता है आशाजनक परिणाम अभी तक गंभीर अध्ययन सीमाओं के साथ - साथ ही अमेरिका, इटली, जापान और भारत में। एविफवीर वायरल प्रतिकृति के लिए आवश्यक आरएनए पोलीमरेज़ को चुनिंदा रूप से बाधित करके काम करता है, लेकिन कोविड​​-19 के लिए इसकी प्रभावकारिता पर डेटा अभी भी अनिर्णायक है। आरडीआईएफ के अनुसार, दवा की 60,000 खुराक महीने के अंत तक दी जानी तय हैं। रूस के कोविड​​-19 डेटा में रुझान, और विशेष रूप से, अतिरिक्त साक्ष्य, प्रभावकारिता निर्धारित करने के लिए आवश्यक हैं।"
    ],
    "Telugu - What our experts say": [
      "అవిఫావిర్, ఫెవిపిరవిర్ యొక్క సాధారణ రూపం, ఇది యాంటీవైరల్ మందు, ఇది ప్రధానంగా ఇన్ఫ్లుఎంజా యొక్క తీవ్రమైన కేసులకు చికిత్స చేయడానికి ఉపయోగిస్తారు. కోవిడ్-19 కోసం ప్రయోగాత్మక చికిత్సగా ప్రస్తుతం అనేక దేశాలలో మందులు అధ్యయనం చేయబడుతున్నాయి, అయితే అవిఫావిర్ వైరస్కు ప్రభావవంతమైన చికిత్స కాదా అని నిర్ధారించడానికి ఇంకా తగినంత ఆధారాలు మన వద్ద లేవు.\n\nఇటీవల రష్యాలో, సాంప్రదాయ అధ్యయనాలు సాధారణంగా అవసరమయ్యే దానికంటే తక్కువ మంది వ్యక్తులతో వేగవంతమైన, స్వల్పకాలిక క్లినికల్ ట్రయల్‌ను ఉపయోగించడం ద్వారా కోవిడ్-19 చికిత్సగా ఆరోగ్య మంత్రిత్వ శాఖ ఆమోదించింది. ఏదేమైనా, ఈ అధ్యయనం పీర్-రివ్యూ జర్నల్‌లో ప్రచురించబడలేదు కాబట్టి డేటా, పద్ధతులు మరియు ఇతర అధ్యయన లక్షణాలు ఇంకా ఇతర శాస్త్రవేత్తలచే విమర్శించబడలేదు లేదా అంచనా వేయబడలేదు.\n\nఈ పరిశోధన ఇప్పటికీ దేశంలో జరుగుతున్నప్పటికీ, రష్యా యొక్క ప్రాథమిక ఫలితాలు అవిఫావిర్ ప్రజలు వైరస్ బారిన పడిన రోజులను తగ్గించడానికి మరియు ప్రజలు అనారోగ్యంతో ఉన్నప్పుడు హై-గ్రేడ్ జ్వరాలను ఎదుర్కొనే సమయాన్ని తగ్గించడానికి సహాయపడతాయని సూచించారు.\nకానీ మరిన్ని అధ్యయనాలు పూర్తయ్యే వరకు మరియు ఎక్కువ మొత్తంలో డేటా అవిఫావిర్ యొక్క సామర్థ్యాన్ని మరియు భద్రతను ప్రదర్శించగలదు వరకు, ఈ మందు కోవిడ్-19 చికిత్సకు సహాయపడుతుందో లేదో తెలుసుకోవడానికి మాకు తగినంత సమాచారం లేదు."
    ],
    "Telugu - Context and background": [
      "రష్యా ఆరోగ్య మంత్రిత్వ శాఖ ఆమోదం పొందిన తరువాత, జూన్లో రష్యన్ ఆసుపత్రులకు ఔషధ సరఫరా ప్రారంభమైనందున, అవీఫావిర్ సంభావ్య కోవిడ్-19 చికిత్సగా కనిపిస్తుంది. రష్యాలో అవిఫావిర్ యొక్క ఖచ్చితత్వంపై ఆశాజనకమైన కానీ పరిమితమైన అధ్యయనాలను ఈ ఆమోదం అనుసరిస్తుంది, ఇది రష్యన్ డైరెక్ట్ ఇన్వెస్ట్మెంట్ ఫండ్ (RDIF), రష్యా యొక్క సార్వభౌమ సంపద నిధి మరియు చెమ్ రార్ గ్రూప్ భాగస్వామ్యంతో జరిగింది. On షధంపై అధ్యయనాలు చైనాలో కూడా జరిగాయి - మంచి ఫలితాలు ఇంకా తీవ్రమైన అధ్యయన పరిమితులతో - అలాగే యుఎస్, ఇటలీ, జపాన్ మరియు భారతదేశాలలో. వైరల్ రెప్లికేషన్‌కు అవసరమైన ఆర్‌ఎన్‌ఏ పాలిమరేస్‌ను ఎంపిక చేసుకోవడం ద్వారా అవిఫావిర్ పనిచేస్తుంది, అయితే కోవిడ్-19 కోసం దాని సమర్థతపై డేటా ఇప్పటికీ అసంకల్పితంగా ఉంది. RDIF ప్రకారం, 60,000 మోతాదుల  ఔషధ ఈ నెలాఖరులోగా నిర్ణయించనున్నారు. రష్యాలో పోకడలు '"
    ],
    "Spanish - What our experts say": [
      "El avifavir, una forma genérica del favipiravir, es una medicación antiviral usada primariamente para tratar casos severos de influenza. Actualmente está siendo estudiada en varios países como un potencial tratamiento experimental para el COVID-19, pero aún no tenemos evidencia suficiente para determinar si el avifavir es o no un tratamiento efectivo para el virus.\n\nRecientemente, en Rusia, el ministerio de salud aprobó el uso de la medicación como tratamiento para el COVID-19 empleando una forma de ensayo clínico acelerada y de corto plazo, con menos personas involucradas que las normalmente requeridas en estudios tradicionales. Sin embargo, este estudio no ha sido publicado en un boletín revisado por pares, por lo que los datos, métodos y otras características del estudio aún tienen que ser criticadas o evaluadas por otros científicos.\n\nAunque esta investigación aún está ocurriendo en el país, los resultados preliminares de Rusia sugirieron que el avifavir puede ayudar a reducir el número de días que las personas están infectadas con el virus, y acortar el lapso de tiempo en que experimentan fiebres elevadas mientras están enfermas.\nPero hasta que más estudios sean completados, y una mayor cantidad de datos pueda demostrar la eficacia y seguridad del avifavir, no tenemos información suficiente para para determinar si esta medicación puede o no ayudar a tratar al COVID-19."
    ],
    "Spanish - Background and context": [
      "El avifavir como tratamiento potencial para el COVID-19 ha estado emergiendo en visibilidad, dado que la administración de la droga en hospitales rusos empezó en junio, siguiendo a la aprobación del Ministerio de Salud. Esta aprobación sigue luego de estudios prometedores pero limitados acerca de la exactitud del avifavir, efectuadas en conjunto entre el Fondo Ruso de Inversión Directa (RDIF), el fondo de inversión soberano de Rusia, y el Grupo ChemRar. Los estudios sobre la droga también han sido conducidos en China — con resultados aparentemente promisorios, aunque con severas limitaciones en el estudio — como así también en los EE.UU., Italia, Japón e India. El avifavir trabaja por inhibición selectiva de la polimerasa del ARN, necesaria para la replicación viral, pero los datos acerca de su eficacia sobre el COVID-19 aún no son concluyentes. 60.000 dosis de la droga habrán de ser administradas hasta fin de mes, de acuerdo a RDIF. Las tendencias en los datos sobre COVID-19 en Rusia y, en particular, evidencia adicional, son necesarias para determinar su eficacia."
    ],
    "Bengali - What our experts say": [
      "অ্যাভিফাভির, ফেভিপিরাবির একটি জেনেরিক ফর্ম, একটি অ্যান্টিভাইরাল ওষুধ যা প্রাথমিকভাবে ইনফ্লুয়েঞ্জার গুরুতর ক্ষেত্রে চিকিৎসার জন্য ব্যবহৃত হয়। এই ওষুধটি বর্তমানে বেশ কয়েকটি দেশে কোভিড-১৯ এর সম্ভাব্য পরীক্ষামূলক চিকিৎসা হিসাবে অধ্যয়ন করা হচ্ছে, তবে এখনও অ্যাভিফাভির ভাইরাসটির কার্যকর চিকিৎসা কিনা তা নির্ধারণ করার মতো পর্যাপ্ত প্রমাণ আমাদের কাছে নেই।\nসম্প্রতি রাশিয়ায়, স্বাস্থ্য মন্ত্রনালয় সাধারণত ঐতিহ্যবাহী অধ্যয়নের চেয়ে কম সংখ্যক লোকের সাথে ক্লিনিকাল ট্রায়ালের মাধ্যমে একটি ত্বরিত, স্বল্পমেয়াদী ফর্ম ব্যবহার করে ওষুধটি কোভিড -১৯ এর চিকিৎসা হিসাবে ব্যবহারের অনুমোদন দেয়। যাইহোক, এই সমীক্ষাটি পাক্ষিক-পর্যালোচিত জার্নালে প্রকাশিত হয়নি তাই তথ্য, পদ্ধতি এবং অন্যান্য গবেষণার বৈশিষ্ট্যগুলি এখনও অন্যান্য বিজ্ঞানী দ্বারা সমালোচনা বা মূল্যায়ন করা যায়নি।\n\nযদিও এই গবেষণাটি এখনও দেশে চলছে, রাশিয়ার প্রাথমিক ফলাফল বলেছে যে, আভিফাভির মানুষের ভাইরাসে আক্রান্ত হওয়ার দিন কমাতে সাহায্য করতে পারে এবং অসুস্থ অবস্থায় উচ্চ-মাত্রার জ্বরের সময়কাল সংক্ষিপ্ত করতে পারে।তবে যতক্ষণ না আরও অধ্যয়ন শেষ হয় এবং প্রচুর পরিমাণে তথ্য আভিফাভিরের কার্যকারিতা এবং সুরক্ষা প্রদর্শন করতে পারে, ততক্ষণ এই ওষুধটি কোভিড-১৯ চিকিৎসায় সহায়তা করতে পারে কি না তা নির্ধারণ করার মতো পর্যাপ্ত তথ্য আমাদের কাছে নেই।"
    ],
    "Bengali - Background and context": [
      "সম্ভাব্য কোভিড -১৯ চিকিৎসা হিসাবে আভিফাভির দৃশ্যমান হয়ে উঠেছে, রাশিয়ার স্বাস্থ্য মন্ত্রণালয়ের অনুমোদনের পরে জুনে রাশিয়ান হাসপাতালগুলিতে ওষুধ সরবরাহ শুরু হয়েছিল । দ্যা রাশিয়ান ডাইরেক্ট ইনভেস্টমেন্ট ফান্ড (RDIF), রাশিয়ার সার্বভৌম সম্পদ তহবিল এবং কেমরার গ্রুপের অংশীদারিত্বের ভিত্তিতে রাশিয়ায় আভিফাভিরের যথার্থতার বিষয়ে আশ্বাসপ্রাপ্ত তবে সীমিত অধ্যয়ন অনুমোদিত হয়েছে। চিনে ওষুধ নিয়ে গবেষণা করা হয়েছিল - আপাতদৃষ্টিতে আশ্বাসিত ফলাফলের সাথে তীব্র অধ্যয়নের সীমাবদ্ধতা - পাশাপাশি মার্কিন যুক্তরাষ্ট্র, ইতালি, জাপান এবং ভারতেও গবেষণা করা হয়েছিল। আভিফাভির আরএনএ পলিমেরেজ নির্বাচন করে বাধা দিয়ে কাজ করে যা ভাইরাস প্রতিলিপির জন্য প্রয়োজনীয়, তবে কোভিড-১৯ এর জন্য কার্যকারিতা সম্পর্কিত তথ্য এখনও অপর্যাপ্ত। আরডিআইএফ জানিয়েছে, মাসের শেষের দিকে ওষুধের ৬০০০০ ডোজ সরবরাহ করা হবে। কার্যকারিতা নির্ধারণের জন্য রাশিয়ার কোভিড-১৯ প্রবণতার তথ্য এবং অন্যান্য অতিরিক্ত প্রমাণ প্রয়োজন।"
    ]
  },
  {
    "id": "recGc8EkSPcnV1kkW",
    "Question": "Can traditional Chinese medicine like rhodiola or forsythia help treat COVID-19?",
    "Status": "Published",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Rhodiola and forsythia are plants used in traditional Chinese medicine which have not been scientifically or clinically proven to prevent or treat COVID-19. While the use of traditional Chinese medicine is widespread in China and has been promoted by some government entities like the China National Health Commission, the World Health Organization warns that inappropriate use of traditional medicine can have negative health impacts and that more research is needed to determine the efficacy as well as safety of many traditional medicine practices. Traditional Chinese medicine is a branch of traditional medicine based on historical Chinese health practices passed through generations, including herbal medicines, acupuncture, and other techniques. Traditional medicine is used around the world but is considered a form of alternative medicine, different from formalized and science-based conventional medical care. Beyond safety and efficacy concerns for traditional medicine, there are also concerns about the use of certain species in traditional medicine that could lead to loss of biodiversity.\n",
    "What our experts say": "While there are historical uses for these herbal treatments, peer-reviewed studies to support the use of rhodiola, forsythia, or other tradtional Chinese medicines (TCM) for COVID-19 are limited. However, the limited evidence that does exist suggests that TCM used as a supplement with other treatments, such as antiviral medications and antibiotics is promising. One systematic review found that TCM could potentially help eliminate pathogens in the early stage of the virus; control inflammation and strengthens body resistance to the virus in the intermediary stage; and relieve depletion during the late stage of COVID‐19. However, more research is needed to confirm these results.\n\nRhodiola is often used for stress, but has not been proven effective in treating COVID-19. Following the announcement from a Chinese official regarding approval of three herbal supplements for treatment, there was widespread concern regarding the lack of rigorous studies to support their use. More empirical research is needed to understand the role of TCM as a supplementary treatment for COVID-19. While there have now been a number of approvals of treatments for emergency use for COVID-19 approved in the U.S. and elsewhere, it is crucial to note that no COVID-19 treatment has been formally recommended by the World Health Organization (WHO), and more research is needed on larger samples and long-term to understand the impacts of TCM and other potential COVID-19 treatments. \n",
    "Glossary Terms": [
      "recc2SgNjNtr78LYi"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "treatment"
    ],
    "Other resources": "1. Use of herbal drugs to treat COVID-19 should be with caution ([Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31143-0/fulltext))\n2. Traditional Chinese Medicine as a complementary therapy in combat with COVID‐19—A review of evidence‐based research and clinical practice ([Journal of Advanced Nursing](https://onlinelibrary-wiley-com.ezp-prod1.hul.harvard.edu/doi/10.1111/jan.14673#jan14673-bib-0015))\n3. Rhodiola ([NIH](https://www.nccih.nih.gov/health/rhodiola)) \n",
    "DB (Hindi)": [
      "recueLz05RLAeim5j"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recckuFYmuMjZDwEs"
    ],
    "DB (Portuguese)": [
      "recNl5xckoVf7laE2"
    ],
    "Rollup test 2": [
      "recY9Avr8RkcZPO4F"
    ],
    "Last modified manual": "2020-07-03",
    "Last edited (simplified)": "2020-07-01T04:57:00.000Z",
    "Last edited (experts say)": "2020-12-07T20:21:41.000Z",
    "Last modified": "2020-12-07",
    "What our experts say wordcount": 225,
    "Background and context wordcount": 159,
    "Other resources wordcount": 38,
    "Wordcount": 422,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "हालांकि इन हर्बल उपचारों के लिए ऐतिहासिक उपयोग हैं, वहां कोविड-19 के लिए रोडियोला, फोरसिथिया या अन्य पारंपरिक चीनी दवाओं के उपयोग का समर्थन करने के लिए कोई सहकर्मी की समीक्षा नहीं की गई है। रोडियोला का उपयोग अक्सर तनाव के लिए किया जाता है, लेकिन कोविड-19 के उपचार में प्रभावी साबित नहीं हुआ है। उपचार के लिए तीन हर्बल सप्लीमेंट की मंजूरी के संबंध में एक चीनी अधिकारी की घोषणा के बाद, इसके उपयोग का समर्थन करने के लिए कठोर अध्ययन की कमी के बारे में व्यापक चिंता थी। जैसा कि प्रकोप सिर्फ छह महीने पुराना है, यह तनावपूर्ण है कि कोई सिद्ध उपचार नहीं है और इन सूचना अंतरालों को संबोधित करने के लिए कई अध्ययन किए जा रहे हैं।"
    ],
    "Hindi - Background and context": [
      "रोडियोला और फोरसिथिया पारंपरिक चीनी चिकित्सा में उपयोग किए जाने वाले पौधे हैं जो कोविड-19 को रोकने या इलाज के लिए वैज्ञानिक या चिकित्सकीय रूप से सिद्ध नहीं हुए हैं। जबकि पारंपरिक चीनी चिकित्सा का उपयोग चीन में व्यापक है और चीन के राष्ट्रीय स्वास्थ्य आयोग जैसे कुछ सरकारी संस्थाओं द्वारा प्रचारित किया गया है, विश्व स्वास्थ्य संगठन ने चेतावनी दी है कि पारंपरिक चिकित्सा के अनुचित उपयोग से नकारात्मक स्वास्थ्य प्रभाव पड़ सकते हैं और प्रभावकारिता और साथ ही कई पारंपरिक चिकित्सा पद्धतियों की सुरक्षा निर्धारित करने के लिए और अधिक शोध की आवश्यकता है। पारंपरिक चीनी चिकित्सा पारंपरिक चीनी चिकित्सा पद्धतियों के आधार पर पारंपरिक चिकित्सा की एक शाखा है, जो पीढ़ियों से गुजरती है, जिसमें हर्बल दवाएं, एक्यूपंक्चर, और अन्य तकनीकें शामिल हैं। पारंपरिक चिकित्सा का उपयोग दुनिया भर में किया जाता है लेकिन इसे वैकल्पिक चिकित्सा का एक रूप माना जाता है, जो औपचारिक चिकित्सा और विज्ञान-आधारित पारंपरिक चिकित्सा देखभाल से अलग है। पारंपरिक चिकित्सा के लिए सुरक्षा और प्रभावकारिता चिंताओं से परे, पारंपरिक चिकित्सा में कुछ प्रजातियों के उपयोग के बारे में भी चिंताएं हैं जो जैव विविधता को नुकसान पहुंचा सकती हैं।"
    ],
    "Portuguese - What our experts say": [
      "Embora existam usos históricos para esses tratamentos à base de plantas, não houve estudos revisados por pares para comprovar que o uso de rhodiola, forsítia ou outros medicamentos tradicionais chineses para COVID-19. A rhodiola costuma ser usada no tratamento contra o estresse, mas não há provas científicas que validem sua eficácia no tratamento do COVID-19. Após uma autoridade chinesa ter anunciado a aprovação de três suplementos de plantas para tratamento, houve uma preocupação generalizada com a falta de estudos rigorosos que validassem o uso dessas plantas. Como o surto epidêmico data de apenas seis meses, é importante ressaltar que ainda não há tratamento comprovado e muitos estudos estão sendo feitos para solucionar essas lacunas de informação."
    ],
    "Portuguese - Background and context": [
      "A rhodiola e a forsítia são plantas utilizadas na medicina tradicional chinesa e cuja eficácia para prevenir ou tratar o COVID-19 não foi comprovada por estudos científicos ou clínicos. Embora o uso da medicina tradicional chinesa seja difundido na China e tenha sido promovido por algumas entidades governamentais como a Comissão Nacional de Saúde da China, a Organização Mundial da Saúde adverte que o uso inadequado da medicina tradicional pode ter impactos negativos na saúde, e que são necessárias mais pesquisas para determinar a eficácia e a segurança de muitas práticas da medicina tradicional. A medicina tradicional chinesa é um ramo da medicina tradicional e que se baseia em práticas médicas transmitidas ao longo da história de uma geração a outra. Ela inclui medicamentos fitoterápicos, acupuntura e outras técnicas. A medicina tradicional é usada em todo o mundo, mas é considerada uma forma de medicina alternativa, diferente dos tratamentos médicos convencionais formalizados e baseados na ciência. Além das preocupações com a segurança e a eficácia da medicina tradicional, também existem preocupações quanto ao uso de certas espécies na medicina tradicional que podem provocar uma perda de biodiversidade."
    ]
  },
  {
    "id": "rec2r563GIPIaxuGS",
    "Question": "How are llamas being used to fight COVID-19?",
    "Status": "Published",
    "Category": "Treatment",
    "Subcategory": "On: COVID-19 & llamas",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "Canada"
    ],
    "Background and context": "News headlines have mentioned llamas participating in research with the potential to help treat and prevent COVID-19. Animals ranging from llamas to sharks have been used to help produce antibodies similar to those used by human immune systems. Camelids, including llamas, camels, and alpacas, are particularly effective at antibody production and make simpler and smaller \"single-domain\" antibodies that are called nanobodies.  According to the U.S. National Institutes of Health, special features of nanobodies include stability for storage of therapeutics and the potential for delivery through an inhaler directly to the lungs, which may be beneficial for respiratory diseases like COVID-19. There is widespread interest in antibodies against the novel coronavirus SARS-CoV-2, for use in helping infected patients recover and protecting more people from getting sick. \n\nIn 2016, researchers from the University of Texas worked with a Belgian research team to study the effect of an injection of a type of coronavirus in a 4-year-old llama named Winter. Though the virus was similar to COVID-19, it was not exactly the same. In this early study, the virus that caused Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) was used. The goal of this injection was to see if Winter's body might produce nanobodies in response to exposure to this coronavirus. Luckily, Winter produced two antibodies: one that fought off MERS and the other that fought off SARS. The scientists further studied the antibodies in a lab and were eventually able to use them to produce nanobodies, which might help prevent SARS and MERS viruses once they enter a body's cells. The current research into llamas to treat COVID-19 stems from this process. \n",
    "What our experts say": "Llamas are being used in research to produce antibodies that _may_ help develop therapeutics to treat and prevent COVID-19 in humans. Like humans, llamas naturally produce antibodies. Antibodies are special proteins that are made from plasma cells (a type of white blood cell), and they help the body to fight \"antigens\" including viruses, bacteria, and other threats that can make people sick. \n\nLlamas are able to produce a special type of antibody called a 'nanobody.' Nanobodies are about a quarter of the size of the antibodies that humans produce and, because they are so small, nanobodies are more stable, can live for a long time, and are able reach tiny, hard-to-reach areas of the body to help treat infected cells. Using a known process, scientists are looking to create a treatment for COVID-19 using llama nanobodies. Though animal studies have only just begun and researchers are not yet ready for human studies, there is hope that COVID-19 antibody treatments made possible by llamas could become preventive in the future. \n",
    "Glossary Terms": [
      "recmajcAORyuqhZPc",
      "receVKrMsC3UKbBf7"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "llamas",
      "treatment",
      "medication"
    ],
    "Other resources": "1. Llama antibody engineered to block coronavirus ([NIH](https://www.nih.gov/news-events/nih-research-matters/llama-antibody-engineered-block-coronavirus))\n2. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies ([Cell](https://www.cell.com/cell/pdf/S0092-8674(20)30494-3.pdf?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867420304943%3Fshowall%3Dtrue)) \n3. Llama Antibodies Neutralize Virus That Causes COVID-19, New Research Shows ([WBUR](https://www.wbur.org/commonhealth/2020/05/16/llama-antibodies-can-neutralize-virus)) \n",
    "DB (Hindi)": [
      "reciWHhBGLHGO7N82"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recmWP7Yqh8YJMJUU"
    ],
    "DB (Portuguese)": [
      "recXXqZcobhURunUu"
    ],
    "Rollup test 2": [
      "recKF52V3kLlnoHMm"
    ],
    "Last modified manual": "2020-07-01",
    "Last edited (simplified)": "2020-07-01T18:27:30.000Z",
    "Last edited (experts say)": "2020-07-01T20:29:20.000Z",
    "Last modified": "2020-07-01",
    "What our experts say wordcount": 170,
    "Background and context wordcount": 276,
    "Other resources wordcount": 33,
    "Wordcount": 479,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "लामाओं का उपयोग अनुसंधान में एंटीबॉडी का उत्पादन करने के लिए किया जा रहा है जो मनुष्यों में कोविड-19 के उपचार और रोकने के लिए चिकित्सीय विकसित करने में मदद कर सकता है। मनुष्यों की तरह, लामा स्वाभाविक रूप से एंटीबॉडी का उत्पादन करते हैं। एंटीबॉडी विशेष प्रोटीन हैं जो प्लाज्मा कोशिकाओं (एक प्रकार की श्वेत रक्त कोशिका) से बने होते हैं, और वे शरीर को \"एंटीजन\" से लड़ने में मदद करते हैं, जिसमें वायरस, बैक्टीरिया और अन्य खतरे होते हैं जो लोगों को बीमार कर सकते हैं।\n\n \nलामा एक विशेष प्रकार के एंटीबॉडी का उत्पादन करने में सक्षम हैं, जिन्हें 'नैनबॉडी' कहा जाता है। नैनोबॉडीज एंटीबॉडीज के आकार का लगभग एक चौथाई हिस्सा है जो मनुष्य पैदा करते हैं और, क्योंकि वे इतने छोटे होते हैं, नैनोबॉडी अधिक स्थिर होती हैं, लंबे समय तक जीवित रह सकती हैं, और शरीर के छोटे, कठोर-से-पहुंच वाले क्षेत्रों तक पहुंचने में सक्षम होती हैं संक्रमित कोशिकाओं के इलाज में मदद करें। एक ज्ञात प्रक्रिया का उपयोग करते हुए, वैज्ञानिक लामा नैनो-विद्या का उपयोग करके कोविड-19 के लिए एक उपचार बनाना चाहते हैं। हालांकि जानवरों का अध्ययन अभी शुरू हुआ है और शोधकर्ता अभी मानव अध्ययन के लिए तैयार नहीं हैं, लेकिन आशा है कि लामा द्वारा किए गए कोविड-19 एंटीबॉडी उपचार भविष्य में निवारक बन सकते हैं।"
    ],
    "Hindi - Background and context": [
      "समाचार सुर्खियों में कोविड-19 के उपचार और रोकथाम में मदद करने की क्षमता के साथ अनुसंधान में भाग लेने वाले लामाओं का उल्लेख किया गया है। लामास से लेकर शार्क तक के जानवरों का उपयोग मानव प्रतिरक्षा प्रणाली द्वारा उपयोग किए जाने वाले एंटीबॉडी के समान उत्पादन करने में मदद करने के लिए किया गया है। लामा, ऊंट, और अल्फ़ास सहित कैमलिड, विशेष रूप से एंटीबॉडी उत्पादन में प्रभावी हैं और सरल और छोटे \"एकल-डोमेन\" एंटीबॉडी बनाते हैं जिन्हें नैनोबॉडी कहा जाता है। यू.एस. नेशनल इंस्टीट्यूट ऑफ हेल्थ के अनुसार, नैनोबॉडी की विशेष विशेषताओं में चिकित्सा विज्ञान के भंडारण के लिए स्थिरता और एक इनहेलर के माध्यम से सीधे फेफड़ों में वितरण की क्षमता शामिल है, जो कोविड-19 जैसी श्वसन संबंधी बीमारियों के लिए फायदेमंद हो सकती है। उपन्यास कोरोनोवायरस SARS-CoV-2 के खिलाफ एंटीबॉडी में व्यापक रुचि है, संक्रमित रोगियों को ठीक करने में मदद करने और अधिक लोगों को बीमार होने से बचाने के लिए।\n \n2016 में, टेक्सास विश्वविद्यालय के शोधकर्ताओं ने 4-वर्षीय लामा में विंटर नामक एक प्रकार के कोरोनावायरस के एक इंजेक्शन के प्रभाव का अध्ययन करने के लिए एक बेल्जियम की शोध टीम के साथ काम किया। हालांकि वायरस कोविड-19 के समान था, लेकिन यह बिल्कुल वैसा नहीं था। इस प्रारंभिक अध्ययन में, वायरस जो गंभीर तीव्र श्वसन सिंड्रोम (SARS) और मध्य पूर्व श्वसन सिंड्रोम (MERS) का कारण बना था। इस इंजेक्शन का लक्ष्य यह देखना था कि क्या विंटर के शरीर इस कोरोनावायरस के संपर्क में आने के कारण नैनोबॉडी का उत्पादन कर सकते हैं। सौभाग्य से, विंटर ने दो एंटीबॉडी का उत्पादन किया: एक जो MERS से लड़ी और दूसरी जो SARS से लड़ी। वैज्ञानिकों ने आगे एक प्रयोगशाला में एंटीबॉडी का अध्ययन किया और अंततः उन्हें नैनोबॉडी बनाने के लिए उपयोग करने में सक्षम थे, जो शरीर के कोशिकाओं में प्रवेश करने पर एसएआरएस और एमईआर वायरस को रोकने में मदद कर सकते हैं। इस प्रक्रिया से कोविड-19 उपजी के इलाज के लिए लामाओं में वर्तमान शोध।"
    ]
  },
  {
    "id": "rec9IztunceMs1e9L",
    "Question": "What do we know about why COVID-19 impacts Black communities in the U.S. more aggressively than others?",
    "Status": "Published",
    "Category": "Treatment, Cure, Prevention",
    "Subcategory": "On: COVID-19 & disparities",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Recent studies have demonstrated how COVID-19 disproportionately impacts Black people in cities across the United States. This has caused many journalists to highlight how, while the pandemic is affecting everyone, there are major demographic differences in who is most at-risk, and what resources people have to cope. In response, advocates are calling for COVID-19 response and recovery policies to be tailored accordingly, to make sure different communities have the support they need. Beyond health impacts, Black communities can also face more economic disruptions during the pandemic, impacted by both current and historical racial injustices. The recent wave of protests in solidarity with the Movement for Black Lives is raising awareness about multiple issues affecting Black communities, many of which intersect with the pandemic.\n",
    "What our experts say": "The disproportionate impact of COVID-19 on Black communities in the United States, especially as a result of existing structural and racial disparities in the healthcare system, is well documented. Despite comprising only 22% of New York City’s population, Black Americans constituted 28% of fatalities from the virus as of mid-April. In Chicago, Black Americans account for 30% of the population, but suffer 70% of reported COVID-19 fatalities. This is likely due to several factors. Racial disparities in access to healthcare contribute to lower quality care for Black populations. Black Americans are more likely to live in densely populated neighborhoods with limited healthcare access. Density can heighten exposure to the virus. \n\nBlack Americans also face higher rates of pre-existing conditions such as hypertension, obesity, and diabetes, which heighten the risk of complications from COVID-19. They are also overrepresented in essential professions that are more likely to face routine interactions with people and a higher exposure level to the virus. Finally, research suggests Black populations face racial bias in the healthcare system and are less likely to have access to timely testing, which may also contribute to a higher rate of mortality from the virus. Such factors have contributed to higher COVID-19 mortality rates among Black populations and reflect the disproportionate and devastating impact of COVID-19 on communities of color. For instance, in a recent study about 121 COVID-19 deaths in people under 21 years old in the United States, 29% of those fatalities were among non-Hispanic Black persons, a disproportionately higher percentage of total deaths in this group than the percentage of the total population in the country that is Black. Black people in the United Kingdom reported feeling more stressed during the early stages of the pandemic than White people, potentially causing long-term health impacts in their bodies due to the presence of constant stress. Lastly, a person who is Black is almost four times more likely to die from COVID-19 than a white person. These examples all highlight the disproportionate impact of COVID-19 on people who are Black from a variety of causes in both adults and children.\n",
    "Glossary Terms": [
      "recGMwZch5wdgRtEO"
    ],
    "Variation of the answer depending on country of residence": "Yes\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "Yes\n\n\n",
    "Topics": [
      "racial disparities",
      "transmission",
      "testing",
      "spread"
    ],
    "Other resources": "1. The unequal toll of COVID-19 mortality by age in the United States: Quantifying racial/ethnic disparities ([Harvard Center for Population and Development Studies](https://cdn1.sph.harvard.edu/wp-content/uploads/sites/1266/2020/06/20_Bassett-Chen-Krieger_COVID-19_plus_age_working-paper_0612_Vol-19_No-3_with-cover.pdf))\n2. Why are Blacks dying at higher rates from COVID-19? ([Brookings](https://www.brookings.edu/blog/fixgov/2020/04/09/why-are-blacks-dying-at-higher-rates-from-covid-19/))\n3. African-American COVID-19 mortality ([JACC](https://www.onlinejacc.org/content/75/21/2746))\n4. SARS-CoV-2–Associated Deaths Among Persons Aged <21 Years — United States, February 12–July 31, 2020 ([U.S. CDC](https://www.cdc.gov/mmwr/volumes/69/wr/mm6937e4.htm)) \n5. State of Black America: Unmasked 2020 ([NUL](https://soba.iamempowered.com/2020-report)) \n6. US racial inequality may be as deadly as COVID-19 ([PNAS](https://www.pnas.org/content/117/36/21854)) \n",
    "How often revision needed": "Monthly",
    "DB (Hindi)": [
      "recbRKuknhY9R9y0U"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "recpO4xAb18LuLU7D"
    ],
    "DB (Portuguese)": [
      "rec0PFpO9VhHCty7d"
    ],
    "Rollup test 2": [
      "recaHy8xwXOes99u1"
    ],
    "Last modified manual": "2020-09-18",
    "Last edited (simplified)": "2020-07-01T14:36:40.000Z",
    "Last edited (experts say)": "2020-09-17T19:06:11.000Z",
    "Last modified": "2020-09-17",
    "What our experts say wordcount": 348,
    "Background and context wordcount": 123,
    "Other resources wordcount": 73,
    "Wordcount": 544,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "संयुक्त राज्य अमेरिका में अश्वेत समुदायों पर कोविड-19 का प्रतिकूल प्रभाव, विशेष रूप से स्वास्थ्य प्रणाली में मौजूदा संरचनात्मक और नस्लीय असमानताओं के परिणामस्वरूप, अच्छी तरह से प्रलेखित है। न्यूयॉर्क शहर की आबादी का केवल 22% शामिल होने के बावजूद, अश्वेत अमेरिकियों ने अप्रैल के मध्य तक वायरस से 28% घातक परिणाम का गठन किया। शिकागो में, अश्वेत अमेरिकियों की आबादी 30% है, लेकिन रिपोर्ट की गई COVID-19 घातकताओं का 70% हिस्सा है। यह कई कारकों के कारण होने की संभावना है। हेल्थकेयर की पहुंच में नस्लीय असमानताएँ अश्वेत पॉपुलेशन के लिए निम्न गुणवत्ता देखभाल में योगदान करती हैं। अश्वेत अमेरिकियों को सीमित स्वास्थ्य सेवा के साथ घनी आबादी वाले इलाकों में रहने की अधिक संभावना है। घनत्व वायरस के संपर्क को बढ़ा सकता है।\n\nकाले अमेरिकियों को उच्च-मौजूदा स्थितियों जैसे उच्च रक्तचाप, मोटापा और मधुमेह की उच्च दर का सामना करना पड़ता है, जो कोविड-19 से जटिलताओं के जोखिम को बढ़ाता है। उन्हें आवश्यक व्यवसायों में भी ज्यादा प्रतिनिधित्व किया जाता है जो लोगों के साथ नियमित बातचीत और वायरस के लिए एक उच्च जोखिम स्तर का सामना करने की अधिक संभावना रखते हैं। अंत में, अनुसंधान से पता चलता है कि अश्वेत पॉपुलेशन स्वास्थ्य सेवा प्रणाली में नस्लीय पूर्वाग्रह का सामना करती है और समय पर परीक्षण तक पहुंच की संभावना कम होती है, जो वायरस से मृत्यु दर की उच्च दर में योगदान कर सकती है। इस तरह के कारकों ने अश्वेत आबादी के बीच कोविड-19 की मृत्यु दर में उच्च योगदान दिया है और रंग के समुदायों पर कोविड-19 के अनुपातहीन और विनाशकारी प्रभाव को दर्शाते हैं।"
    ],
    "Hindi - Background and context": [
      "हाल के अध्ययनों से पता चला है कि संयुक्त राज्य अमेरिका के शहरों में अश्वेत लोगों पर कोविड-19 का किस तरह से प्रतिकूल प्रभाव पड़ता है। इसने कई पत्रकारों को उजागर किया है कि कैसे, जबकि महामारी सभी को प्रभावित कर रही है, इसमें प्रमुख जनसांख्यिकीय अंतर हैं कि कौन सबसे अधिक जोखिम में है, और लोगों को किन संसाधनों का सामना करना पड़ता है। प्रतिक्रिया में, अधिवक्ता कोविड-19 की प्रतिक्रिया और पुनर्प्राप्ति नीतियों के अनुसार कॉल करने के लिए कह रहे हैं, यह सुनिश्चित करने के लिए कि विभिन्न समुदायों को उनकी आवश्यकता का समर्थन है। स्वास्थ्य प्रभावों से परे, काले समुदाय भी महामारी के दौरान अधिक आर्थिक व्यवधानों का सामना कर सकते हैं, जो वर्तमान और ऐतिहासिक नस्लीय अन्याय दोनों से प्रभावित हैं। ब्लैक लिव्स के लिए आंदोलन के साथ एकजुटता में विरोध की हाल की लहर काले समुदायों को प्रभावित करने वाले कई मुद्दों के बारे में जागरूकता बढ़ा रही है, जिनमें से कई महामारी के साथ अंतर करती हैं।"
    ]
  },
  {
    "id": "recaSHOsOCPOIL1bF",
    "Question": "What is the context behind the incorrect claim on social media associating a decrease in Sudden Infant Death Syndrome with a decrease in immunization rates of infants during COVID-19? ",
    "Status": "Do not publish",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "UK"
    ],
    "Background and context": "This comes from an incorrect claim that is trying to make the case that infant vaccines cause Sudden Infant Death Syndrome (SIDS) and that a reduction of vaccination coverage in infants during the pandemic due to lockdown is the reason for lower cases of SIDS. The origin of this misinformation is not a new myth. In fact, the WHO listed the myth that the Diphtheria-tetanus-pertussis (DTP) vaccine causes SIDS as one of six common misconceptions about immunization. In the Health Choice report, where this erroneous claim comes from, authors take two pieces of standalone information (that infant vaccine rates have decreased during the pandemic, and that rates of SIDS have decreased during COVID-19 pandemic, respectively) and claim causality between the two phenomena without a) referencing any study that would be needed to prove causality, and b) without sufficient evidence that SIDS rates have, in fact, decreased. It is possible that these two pieces of data happen to be true at the same time but are entirely disconnected. The attempt to connect these two pieces of information without any evidence base for doing so is known as ecological fallacy, and is a common tactic used among anti-vaccine communities online.\n",
    "What our experts say": "Linking a decrease in Sudden Infant Death Syndrome (SIDS) to a decrease in the immunization rate of infants in the U.S. would be factually misleading. Rates of SIDS and immunization have to be understood to be independent of one another until proven otherwise. So far, no studies have linked the two rates. There is also no published data on SIDS during the pandemic so far. One white paper makes claims that SIDS has decreased during the COVID-19 pandemic based on “anecdotal evidence”, i.e. hearsay, which is not considered to be scientific evidence. As a result, scientists do not know what effect COVID-19 has had on SIDS, if any at all. As for immunization, on May 18th 2020, the US CDC reported that vaccination rates declined across children age groups, except for newborns receiving the hepatitis B vaccine at the hospital around the time of birth. \n",
    "Glossary Terms": [
      "rec9qqItwSTjq3Eae",
      "recCV5AVBoGk03BU6",
      "rect4UMTszAKZXNfq"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Other resources": "1. Decline in Child Vaccination Coverage During the COVID-19 Pandemic — Michigan Care Improvement Registry, May 2016–May 2020 ([CDC](https://www.cdc.gov/mmwr/volumes/69/wr/mm6920e1.htm)) \n2. Six Common Misconceptions About Immunization ([WHO](https://www.who.int/vaccine_safety/initiative/detection/immunization_misconceptions/en/index4.html)) \n",
    "Last modified manual": "2020-06-26",
    "Last edited (simplified)": "2020-06-26T22:32:24.000Z",
    "Last edited (experts say)": "2020-06-26T22:32:24.000Z",
    "Last modified": "2020-06-26",
    "What our experts say wordcount": 144,
    "Background and context wordcount": 197,
    "Other resources wordcount": 27,
    "Wordcount": 368
  },
  {
    "id": "recZElAZYPfbc4Pa3",
    "Question": "Is it safe to wear a mask?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & masks",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "In the early phases of the COVID-19 outbreak, masks were not recommended as a standard measure to prevent the spread of infection. Because critical protective equipment (including masks) was reserved primarily for healthcare workers, many health organizations could not advocate for the use of masks by the general public until the needs of medical teams were met. Additionally, there was a lack of evidence regarding different types of masks needed to prevent the spread of COVID-19. Early in the outbreak, the new virus had also not been thoroughly investigated by teams focused on respiratory droplets and aerosolized particles with masks. As scientists and medical experts have learned more about the virus and its spread, the use of face masks to prevent illness as a result of COVID-19 has become a routine recommendation in many parts of the world.\n\nFace masks and cloth face coverings, in combination with frequent hand-washing and social distancing measures, have been shown to help prevent the spread of COVID-19. Face mask safety also includes carefully and safely putting on, wearing, and removing the mask. The mask should cover both the nose and mouth, and it should be snug against the face.  It is important not to touch the outside of mask while it is worn or when it is removed, and hand washing before and after mask removal is recommended.  Finally, according to the World Health Organization, cloth masks should be washed daily.\n",
    "What our experts say": "Wearing a face mask is both safe and recommended to slow the spread of COVID-19. The United States Centers for Disease Control  recommends widespread use of cloth face coverings to prevent spread from people who might have the virus that causes COVID-19 without realizing it. While surgical masks and N-95 masks are in short supply and should be reserved for healthcare workers, cloth face coverings should always be worn when interacting with other people in close proximity (including but not limited to grocery shopping, ordering food at a restaurant, interacting with people within 6 feet in outdoor spaces). \n\nYou should clean your hands before touching the mask, make sure the mask covers your nose and mouth, and ensure the mask fits tightly on your face without leaving exposed spaces. Additionally, you should avoid touching the front of the mask, avoid taking the mask off when talking to other people; only remove the mask by touching the straps; wash your hands after removing the mask; wash the mask in soap and detergent with hot water at least once a day; and avoid sharing masks with others or leaving used masks around other people. While mask wearing is recognized as safe and is advised by the World Health Organization and other leading health advisory groups, there are cases where masks should not be used. For instance, masks are not safe for children under 2 years of age, people who have trouble breathing in general, or individuals who are unconscious or who would be unable to remove the mask without help. \n\nSeveral cities and states, such as New Orleans and Washington, have mandated the use of face masks to slow the spread of the virus. However, masks alone are not enough. In addition to wearing a mask to help stop the spread of the virus, public health experts encourage social distancing (staying at least 6 feet (2 meters) away from others) as well as frequent and thorough hand washing. \n",
    "Glossary Terms": [
      "recCEG85awzcotyRi",
      "rec2UNEXbTkSCx30Q"
    ],
    "Variation of the answer depending on country of residence": "No\t\n\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "face masks",
      "safety",
      "prevention",
      "transmission"
    ],
    "Other resources": "1. COVID-19: How much protection fo face masks offer? ([Mayo Clinic](https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/coronavirus-mask/art-20485449))\n2. Coronavirus disease (COVID-19) Technical Advice for Use of Masks ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks&publication=advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak))\n3. How to wear a non-medical fabric mask safely ([WHO](https://www.who.int/images/default-source/health-topics/coronavirus/clothing-masks-infographic---(web)-logo-who.png?sfvrsn=b15e3742_14))\n4. Community Use Of Face Masks And COVID-19: Evidence From A Natural Experiment Of State Mandates In The US ([Health Affairs](https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2020.00818))\n5. How to wear a non-medical fabric mask safely ([WHO](https://www.who.int/images/default-source/health-topics/coronavirus/clothing-masks-infographic--web---part-1.png?sfvrsn=679fb6f1_26))\n6. The growing scientific evidence for masks to fight Covid-19 ([Vox](https://www.vox.com/future-perfect/21299527/masks-coronavirus-covid-19-studies-research-evidence))\n7. CDC calls on Americans to wear masks to prevent COVID-19 spread ([U.S. CDC](https://www.cdc.gov/media/releases/2020/p0714-americans-to-wear-masks.html?utm_source=Global+Health+NOW+Main+List&utm_campaign=ba35be8398-EMAIL_CAMPAIGN_2020_07_14_03_18&utm_medium=email&utm_term=0_8d0d062dbd-ba35be8398-860399))\n\n",
    "DB (Hindi)": [
      "recigmYiivuSCvJ0o"
    ],
    "In translated DBs?": "Yes",
    "DB (Bengali)": [
      "rec2Xyq9w9pScRwEo"
    ],
    "DB (Portuguese)": [
      "recDY9inu3yOkzaEY"
    ],
    "Rollup test 2": [
      "rec6NoC5peEXOQEQ7"
    ],
    "Last modified manual": "2020-06-26",
    "Last edited (simplified)": "2020-06-26T16:48:11.000Z",
    "Last edited (experts say)": "2020-07-16T03:19:27.000Z",
    "Last modified": "2020-06-26",
    "What our experts say wordcount": 326,
    "Background and context wordcount": 231,
    "Other resources wordcount": 82,
    "Wordcount": 639,
    "Hindi Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      " फेस मास्क पहनना सुरक्षित है। यूनाइटेड स्टेट्स सेंटर फॉर डिजीज कंट्रोल ने चेहरे को  कपड़े से ढंकना के व्यापक उपयोग की सिफारिश की है जो फेलने से रोक सकता है, जिनमें वायरस हो सकता है जो बिना महसूस किए बिना कोविड-19 का कारण बनता है। जबकि सर्जिकल मास्क और एन-95 मास्क कम आपूर्ति में हैं और स्वास्थ्य कर्मियों के लिए आरक्षित होने चाहिए, चेहरे को  कपड़े से ढंकना हमेशा पहना जाना चाहिए जब अन्य लोगों के साथ निकटता में बातचीत (जिसमें किराने की खरीदारी तक सीमित नहीं है, एक रेस्तरां में भोजन का आदेश दे,) बाहरी स्थानों में 6 फीट के भीतर लोगों के साथ बातचीत)।\n\nमास्क को छूने से पहले आपको अपने हाथों को साफ करना चाहिए, सुनिश्चित करें कि मास्क आपकी नाक और मुंह को कवर करता है, और सुनिश्चित करें कि उजागर स्थानों को छोड़ने के बिना मास्क आपके चेहरे पर फिट बैठता है। इसके अतिरिक्त, आपको मास्क के सामने वाले हिस्से को छूने से बचना चाहिए, अन्य लोगों से बात करते समय मास्क को उतारने से बचना चाहिए; केवल पट्टियों को छूकर मुखौटा निकालें; मास्क हटाने के बाद अपने हाथ धो लें; दिन में कम से कम एक बार साबुन और डिटर्जेंट को गर्म पानी से धोएं; और दूसरों के साथ मास्क साझा करने या अन्य लोगों के आसपास इस्तेमाल किए गए मास्क को छोड़ने से बचें। जबकि मास्क पहनने को सुरक्षित माना जाता है और विश्व स्वास्थ्य संगठन और अन्य प्रमुख स्वास्थ्य सलाहकार समूहों द्वारा सलाह दी जाती है, ऐसे मामले हैं जहां मास्क का उपयोग नहीं किया जाना चाहिए। उदाहरण के लिए, मास्क 2 वर्ष से कम उम्र के बच्चों के लिए सुरक्षित नहीं हैं, जिन लोगों को सामान्य रूप से साँस लेने में परेशानी होती है, या ऐसे व्यक्ति जो बेहोश हैं या जो बिना मदद के मास्क को हटाने में असमर्थ होंगे।\n\nकई शहरों और राज्यों, जैसे न्यू ऑरलियन्स और वाशिंगटन, ने वायरस के प्रसार को धीमा करने के लिए फेस मास्क का उपयोग अनिवार्य कर दिया है। हालांकि, अकेले मास्क पर्याप्त नहीं हैं। वायरस के प्रसार को रोकने में मदद करने के लिए मुखौटा पहनने के अलावा, सार्वजनिक स्वास्थ्य विशेषज्ञ सामाजिक दूरी (दूसरों से कम से कम 6 फीट (2 मीटर) दूर रहने) के साथ-साथ लगातार और पूरी तरह से हाथ धोने को प्रोत्साहित करते हैं।"
    ],
    "Hindi - Background and context": [
      "कोविड-19 प्रकोप के शुरुआती चरणों में, संक्रमण के प्रसार को रोकने के लिए एक मानक उपाय के रूप में मास्क की सिफारिश नहीं की गई थी। क्योंकि महत्वपूर्ण सुरक्षात्मक उपकरण (मास्क सहित) मुख्य रूप से स्वास्थ्य कार्यकर्ताओं के लिए आरक्षित थे, कई स्वास्थ्य संगठन आम जनता द्वारा मास्क के उपयोग की वकालत नहीं कर सकते थे जब तक कि चिकित्सा टीमों की आवश्यकताएं पूरी नहीं हुई थीं। इसके अतिरिक्त, कोविड-19 के प्रसार को रोकने के लिए आवश्यक विभिन्न प्रकार के मास्क के बारे में सबूतों की कमी थी। प्रकोप के शुरुआती दिनों में, नए वायरस की जांच पूरी तरह से नहीं की गई थी, जो कि सांस की बूंदों और एरोसोलाइज्ड कणों पर मास्क के साथ केंद्रित थी। जैसा कि वैज्ञानिकों और चिकित्सा विशेषज्ञों ने वायरस और इसके प्रसार के बारे में अधिक जानकारी प्राप्त की है, कोविड-19 के परिणामस्वरूप बीमारी को रोकने के लिए फेस मास्क का उपयोग दुनिया के कई हिस्सों में एक नियमित सिफारिश बन गया है।\n\nफेस मास्क और चेहरे को  कपड़े से ढंकना, लगातार हाथ धोने और सामाजिक दूर करने के उपायों के संयोजन में, COVID-19 के प्रसार को रोकने में मदद करने के लिए दिखाया गया है। फेस मास्क सुरक्षा में सावधानीपूर्वक और सुरक्षित रूप से मास्क पहनना, पहनना और हटाना शामिल है। मुखौटा को नाक और मुंह दोनों को ढंकना चाहिए, और इसे चेहरे के खिलाफ सूंघना चाहिए। यह महत्वपूर्ण है कि पहना जाने पर या बाहर निकालने के दौरान मास्क के बाहरी हिस्से को न छुएं और मास्क हटाने से पहले और बाद में हाथ धोने की सलाह दी जाती है। अंत में, विश्व स्वास्थ्य संगठन के अनुसार, कपड़ा मास्क को दैनिक रूप से धोया जाना चाहिए।"
    ]
  },
  {
    "id": "recAyLjodHbPpG1dA",
    "Question": "Why are meat and pork plants having so many outbreaks?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & meat processing plants",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Over the past few months, there have been news stories about virus outbreaks at U.S. meat processing facilities. With many ill workers, some meat processing facilities closed temporarily, which resulted in a decrease in meat and pork in markets and grocery stores. \n\nPeople who live or work in places where they are close to other people are at increased risk of getting and spreading COVID-19. While separating employees from one another by at least 6 feet (2 meters) or implementing COVID-19 specific sanitation guidelines have been effective in controlling spread of the virus in some work environments, these control measures have been difficult to implement in meat/pork processing facilities.  Furthermore, employee attendance and sick leave policies, crowded living conditions, and limited protective equipment availability and use may also contribute to COVID-19 spread. To reduce the spread of COVID-19 in meat/pork processing facilities, the U.S. Centers for Disease Control and Prevention suggests using routine symptom screening as well as “improving physical distancing, hand hygiene, cleaning and disinfection, and medical leave policies, and providing educational materials in languages spoken by workers.”\n",
    "What our experts say": "Meat processing plants have become major hotspots for coronavirus outbreaks because employees work in close proximity to one another, which makes social distancing very difficult. Across the U.S., the Centers for Disease Control and Prevention report that 4,913 COVID-19 cases and 20 deaths have been reported among approximately 130,000 workers at 115 meat processing facilities in 19 states. Many meat processing plants have failed to provide basic protections like face masks, plexiglass barriers between workers, or paid sick leave to frontline employees. The Tyson Fresh Meats Plant in Washington State, the largest meat-packing plant in the state, was temporarily closed in April after more than a 100 employees tested positive for COVID-19. The plant has since resumed operations after testing all employees, but unions and health officials alike have advocated for greater health protections for workers, including adequate social distancing measures, even if it slows operations. \n",
    "Glossary Terms": [
      "rec2UNEXbTkSCx30Q"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "meat processing",
      "poultry",
      "spread",
      "transmission"
    ],
    "Other resources": "1. COVID-19 Among Workers in Meat and Poultry Processing Facilities ― 19 States, April 2020 ([U.S. CDC](http://COVID-19 Among Workers in Meat and Poultry Processing Facilities ― 19 States, April 2020))\n2. Washington’s largest meat-packing plant, hard-hit by COVID-19, to reopen Tuesday ([Seattle Times](http://Washington’s largest meat-packing plant, hard-hit by COVID-19, to reopen Tuesday))\n3. Severe coronavirus outbreaks stagger some meat-packing plants in Washington ([Yakima Herald](http://Severe coronavirus outbreaks stagger some meat-packing plants in Washington))\n",
    "DB (Hindi)": [
      "recJOSUmpkmkuuqTB"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "rec64QzSzcBMui3Sf"
    ],
    "DB (Spanish)": [
      "recpqjtG67SditAMR"
    ],
    "DB (Bengali)": [
      "rec73G2CJA3IlkWTS"
    ],
    "DB (Portuguese)": [
      "recI4hUQHucEt2ATs"
    ],
    "Rollup test 2": [
      "recEoZ7CMUHbPMppj"
    ],
    "Last modified manual": "2020-06-26",
    "Last edited (simplified)": "2020-06-24T01:22:56.000Z",
    "Last edited (experts say)": "2020-07-07T06:04:04.000Z",
    "Last modified": "2020-06-26",
    "What our experts say wordcount": 147,
    "Background and context wordcount": 178,
    "Other resources wordcount": 40,
    "Wordcount": 365,
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "मांस प्रसंस्करण संयंत्र कोरोनोवायरस के प्रकोप के लिए प्रमुख आकर्षण का केंद्र बन गए हैं क्योंकि कर्मचारी एक-दूसरे के साथ निकटता में काम करते हैं, जिससे सामाजिक दूरी बहुत मुश्किल हो जाती है। अमेरिका के उस पार, रोग नियंत्रण और रोकथाम केंद्र रिपोर्ट करते हैं कि 19 राज्यों में 115 मांस प्रसंस्करण सुविधाओं में लगभग 130,000 श्रमिकों के बीच 4,913 कोविड-19 मामले और 20 मौतें हुई हैं। कई मीट प्रोसेसिंग प्लांट श्रमिकों के बीच फेस मास्क, पेलेक्सिग्लास अवरोध जैसी बुनियादी सुरक्षा प्रदान करने में विफल रहे हैं, या फ्रंटलाइन कर्मचारियों को बीमार छुट्टी का भुगतान किया है। वॉशिंगटन राज्य में टायसन फ्रेश मीट प्लांट, राज्य में सबसे बड़ा मांस-पैकिंग प्लांट अप्रैल में अस्थायी रूप से बंद कर दिया गया था, क्योंकि 100 से अधिक कर्मचारियों ने कोविड-19 के लिए सकारात्मक परीक्षण किया था। संयंत्र ने सभी कर्मचारियों के परीक्षण के बाद संचालन फिर से शुरू कर दिया है, लेकिन यूनियनों और स्वास्थ्य अधिकारियों ने समान रूप से सामाजिक सुरक्षा उपायों सहित श्रमिकों के लिए अधिक स्वास्थ्य सुरक्षा की वकालत की है, भले ही यह संचालन धीमा कर देता हो।"
    ],
    "Hindi - Background and context": [
      "पिछले कुछ महीनों में, अमेरिकी मांस प्रसंस्करण सुविधाओं में वायरस के प्रकोप के बारे में खबरें आई हैं। कई बीमार श्रमिकों के साथ, कुछ मांस प्रसंस्करण सुविधाएं अस्थायी रूप से बंद हो गईं, जिसके परिणामस्वरूप बाजारों और किराने की दुकानों में मांस और पोर्क की कमी हुई।\n \n जो लोग उन स्थानों पर रहते हैं या काम करते हैं, जहां वे अन्य लोगों के करीब हैं, उन्हें कोविड-19 के फैलने और फैलने का खतरा है। कम से कम 6 फीट (2 मीटर) द्वारा कर्मचारियों को एक दूसरे से अलग करना या कोविड-19 विशिष्ट स्वच्छता दिशानिर्देशों को लागू करना कुछ कार्य वातावरण में वायरस के प्रसार को नियंत्रित करने में प्रभावी रहा है, इन नियंत्रण उपायों को मांस / पोर्क प्रौद्योगिकी में लागू करना मुश्किल रहा है सुविधाएं। इसके अलावा, कर्मचारी की उपस्थिति और बीमार छुट्टी की नीतियां, रहने की स्थिति, और सीमित सुरक्षात्मक उपकरण की उपलब्धता और उपयोग भी कोविड-19 प्रसार में योगदान कर सकते हैं। मांस / पोर्क प्रौद्योगिकी सुविधाओं में कोविड-19 के प्रसार को कम करने के लिए, रोग नियंत्रण और रोकथाम के लिए यूएस सेंटर सुझाव देता है कि नियमित रूप से स्क्रीनिंग के साथ-साथ \"शारीरिक गड़बड़ी, हाथ की सफाई, सफाई और कीटाणुशोधन में सुधार, और चिकित्सा अवकाश की नीतियों का उपयोग करना, और प्रदान करना।\" श्रमिकों द्वारा बोली जाने वाली भाषाओं में शैक्षिक सामग्री।”"
    ],
    "Telugu - What our experts say": [
      "కరోనావైరస్ వ్యాప్తికి మాంసం ప్రాసెసింగ్ ప్లాంట్లు ప్రధాన హాట్‌స్పాట్‌లుగా మారాయి, ఎందుకంటే ఉద్యోగులు ఒకదానికొకటి దగ్గరగా పనిచేస్తారు, ఇది సామాజిక దూరాన్ని చాలా కష్టతరం చేస్తుంది. 19 రాష్ట్రాల్లోని 115 మాంసం ప్రాసెసింగ్ సదుపాయాల వద్ద సుమారు 130,000 మంది కార్మికులలో 4,913 కోవిడ్-19 కేసులు మరియు 20 మరణాలు నమోదయ్యాయని అమెరికా అంతటా, సెంటర్స్ ఫర్ డిసీజ్ కంట్రోల్ అండ్ ప్రివెన్షన్ నివేదిక పేర్కొంది. ఫేస్ మాస్క్‌లు, కార్మికుల మధ్య ప్లెక్సిగ్లాస్ అడ్డంకులు లేదా ఫ్రంట్‌లైన్ ఉద్యోగులకు చెల్లించిన అనారోగ్య సెలవు వంటి ప్రాథమిక రక్షణలను అందించడంలో చాలా మాంసం ప్రాసెసింగ్ ప్లాంట్లు విఫలమయ్యాయి. కోవిడ్ -19 కు 100 మందికి పైగా ఉద్యోగులు పాజిటివ్ పరీక్షించిన తరువాత రాష్ట్రంలో అతిపెద్ద మాంసం ప్యాకింగ్ ప్లాంట్ అయిన వాషింగ్టన్ స్టేట్ లోని టైసన్ ఫ్రెష్ మీట్స్ ప్లాంట్ ఏప్రిల్‌లో తాత్కాలికంగా మూసివేయబడింది. ఉద్యోగులందరినీ పరీక్షించిన తరువాత ప్లాంట్ తిరిగి కార్యకలాపాలు ప్రారంభించింది,"
    ],
    "Telugu - Context and background": [
      "గత కొన్ని నెలలుగా, యుఎస్ మాంసం ప్రాసెసింగ్ సదుపాయాల వద్ద వైరస్ వ్యాప్తి గురించి వార్తలు వచ్చాయి. చాలా మంది అనారోగ్య కార్మికులతో, కొన్ని మాంసం ప్రాసెసింగ్ సౌకర్యాలు తాత్కాలికంగా మూసివేయబడ్డాయి, దీని ఫలితంగా మార్కెట్లు మరియు కిరాణా దుకాణాల్లో మాంసం మరియు పంది మాంసం తగ్గింది. వారు ఇతర వ్యక్తులకు దగ్గరగా ఉన్న ప్రదేశాలలో నివసించే లేదా పనిచేసే వ్యక్తులు కోవిడ్-19 ను పొందే మరియు వ్యాప్తి చెందే ప్రమాదం ఉంది. ఉద్యోగులను ఒకరి నుండి కనీసం 6 అడుగులు (2 మీటర్లు) వేరుచేయడం లేదా కోవిడ్-19 నిర్దిష్ట పారిశుద్ధ్య మార్గదర్శకాలను అమలు చేయడం కొన్ని పని వాతావరణాలలో వైరస్ వ్యాప్తిని నియంత్రించడంలో ప్రభావవంతంగా ఉన్నప్పటికీ, ఈ నియంత్రణ చర్యలు మాంసం / పంది మాంసం ప్రాసెసింగ్‌లో అమలు చేయడం కష్టం. సౌకర్యాలు. ఇంకా, ఉద్యోగుల హాజరు మరియు అనారోగ్య సెలవు విధానాలు, రద్దీగా ఉండే జీవన పరిస్థితులు, మరియు పరిమిత రక్షణ పరికరాల లభ్యత మరియు ఉపయోగం కోవిడ్-19 వ్యాప్తికి దోహదం చేస్తుంది. మాంసం / పంది ప్రాసెసింగ్ సదుపాయాలలో కోవిడ్-19 యొక్క వ్యాప్తిని తగ్గించడానికి, యుఎస్ సెంటర్స్ ఫర్ డిసీజ్ కంట్రోల్ అండ్ ప్రివెన్షన్ రొటీన్ సింప్టమ్ స్క్రీనింగ్‌తో పాటు “శారీరక దూరం, చేతి పరిశుభ్రత, శుభ్రపరచడం మరియు క్రిమిసంహారక మరియు వైద్య సెలవు విధానాలను మెరుగుపరచడం మరియు వైద్య సెలవు విధానాలను మెరుగుపరచడం కార్మికులు మాట్లాడే భాషలలో విద్యా సామగ్రి. ”"
    ],
    "Spanish - What our experts say": [
      "Las plantas de procesamiento de carnes se han tornado en hervideros importantes para los brotes de coronavirus, debido a que sus empleados trabajan en estrecha proximidad unos a otros, lo que hace que el distanciamiento social sea muy dificultoso. A lo largo de los EE.UU., los Centros para el Control y Prevención de Enfermedades informan que 4.913 casos y 20 muertes por COVID-19 han sido reportadas entre aproximadamente 130.000 trabajadores en 115 instalaciones de procesamiento de carne en 19 estados. Muchas plantas de procesamiento de carne han fallado en proveer protecciones básicas, como máscaras faciales, barreras de plexiglás entre trabajadores, o pago de ausencia por enfermedad a empleados con alto riesgo de exposición. La planta Tyson Fresh Meats en el estado de Washington, la planta más grande de envasado de carne en el estado, fue temporariamente cerrada en abril luego de que más de 100 empleados dieran positivo para el COVID-19. Desde entonces, la planta ha retornado a la operación luego de testear a todos sus empleados, pero tanto los sindicatos como los oficiales de salud han abogado por mayores protecciones de salud para los trabajadores, incluyendo medidas adecuadas de distanciamiento social, aún si ralentiza las operaciones."
    ],
    "Spanish - Background and context": [
      "Desde hace unos meses atrás, han habido historias en las noticias acerca de brotes de virus en instalaciones de procesamiento de carne en los EE.UU. Con muchos trabajadores enfermos, algunas plantas de procesamiento de carne cerraron temporariamente, lo cual resultó en una disminución en carnes vacunas y porcinas en los mercados y almacenes.\n\nLas personas que viven o trabajan en lugares donde están cercanas a otras personas están con un riesgo creciente de contraer y diseminar al COVID-19. Mientras que el separar a los empleados unos de otros por al menos 6 pies (2 metros) o implementar lineamientos sanitarios específicos para el COVID-19 ha sido efectivo en el control de la diseminación del virus en algunos ambientes laborales, estas medidas de control han sido difíciles de implementar en instalaciones de procesamiento de carnes vacunas/porcinas. Aún más, la asistencia de los empleados y las políticas de ausencia por enfermedad, las condiciones de vida en hacinamiento, y la disponibilidad y el uso limitados de equipamiento protector también pueden haber contribuido a la diseminación del COVID-19. Para reducir la diseminación del COVID-19 en instalaciones de procesamiento de carnes vacunas/porcinas, los Centros para el Control y Prevención de las Enfermedades de los EE.UU. sugieren usar el cribado por síntomas rutinario, como así también \"mejorar el distanciamiento físico, la higiene de manos, la limpieza y desinfección, las políticas de ausencia médica y proveer materiales educativos en el lenguaje hablado por los trabajadores\"."
    ],
    "Bengali - What our experts say": [
      "মাংস প্রক্রিয়াজাতকরণ প্লান্টগুলি করোনাভাইরাস প্রাদুর্ভাবের জন্য প্রধান হট স্পট হয়ে উঠেছে কারণ কর্মীরা একে অপরের নিকটবর্তী স্থানে কাজ করে যা সামাজিক দূরত্বকে খুব কঠিন করে তোলে। মার্কিন যুক্তরাষ্ট্র জুড়ে, রোগ নিয়ন্ত্রণ ও প্রতিরোধ কেন্দ্রগুলি জানিয়েছে যে ১৯ টি রাজ্যে ১১৫ টি মাংস প্রক্রিয়াকরণে প্রায় ১৩০,০০০ শ্রমিকের মধ্যে ৪৯১৩টি কভিড -১৯ ঘটনা এবং ২০ জন মৃত্যুর খবর পাওয়া গেছে। অনেক মাংস প্রক্রিয়াজাতকরণ প্লান্ট শ্রমিকদের মধ্যে ফেস মাস্কস, নমনীয় কাঁচের প্রাচীর বা সামনের সারির কর্মীদের অর্থসহ অসুস্থকালীন ছুটি দেওয়ার মতো প্রাথমিক সুরক্ষা দিতে ব্যর্থ হয়েছে। রাজ্যের বৃহত্তম মাংস-প্যাকিং প্লান্ট, ওয়াশিংটন রাজ্যের টাইসন ফ্রেশ মিটস প্ল্যান্টটি এপ্রিল মাসে সাময়িকভাবে বন্ধ হয়ে গিয়েছিল ১০০ জনেরও বেশি কর্মী কোভিড -১৯ এর জন্য পরীক্ষায় ইতিবাচক হবার পরে। সমস্ত কর্মচারীর পরীক্ষা করার পরে প্ল্যান্টটি কাজ শুরু করেছে, তবে ইউনিয়ন ও স্বাস্থ্য কর্মকর্তারা একইভাবে কর্মীদের জন্য আরও বেশি স্বাস্থ্য সুরক্ষার পক্ষে পরামর্শ দিয়েছেন, পর্যাপ্ত সামাজিক দূরত্ব ব্যবস্থা সহ, যদি এটি কাজ ধীর করে দেয় তবুও।"
    ],
    "Bengali - Background and context": [
      "গত কয়েকমাস ধরে মার্কিন যুক্তরাষ্ট্রের মাংস প্রক্রিয়াজাত কেন্দ্রে ভাইরাসের প্রাদুর্ভাব নিয়ে সংবাদ ছড়িয়ে পড়ে। অনেক অসুস্থ শ্রমিকের সাথে, কিছু মাংস প্রক্রিয়াজাতকরণ কেন্দ্র অস্থায়ীভাবে বন্ধ হয়ে যায়, যার ফলে বাজার এবং মুদি দোকানে মাংস এবং শুয়োরের মাংস হ্রাস পায়।\nযে স্থানে লোকেরা অন্য লোকের কাছাকাছি বাস করে বা কাজ করে তাদের কোভিড-১৯ হওয়ার এবং ছড়িয়ে যাওয়ার ঝুঁকি বেশি থাকে। কর্মচারীদের একে অপরের থেকে কমপক্ষে ৬ ফুট (২ মিটার) পৃথক করা বা কোভিড-১৯ নির্দিষ্ট স্যানিটেশন নির্দেশিকা কার্যকর করে কিছু কাজের পরিবেশে ভাইরাসের বিস্তার নিয়ন্ত্রণে কার্যকর ছিল, এই নিয়ন্ত্রণ ব্যবস্থা মাংস / শূকরের মাংস প্রসেসিংয়ে প্রয়োগ করা কঠিন ছিল|\nতদ্ব্যতীত, কর্মচারী উপস্থিতি এবং অসুস্থ ছুটি নীতি, জনাকীর্ণ জীবনযাত্রার পরিস্থিতি এবং সীমিত প্রতিরক্ষামূলক সরঞ্জামের সহজলভ্যতা এবং ব্যবহার কোভিড-১৯ প্রসারে অবদান রাখতে পারে। মাংস / শুয়োরের মাংস প্রক্রিয়াজাতকরণ কেন্দ্রগুলিতে কোভিড-১৯ এর প্রসারণ হ্রাস করার জন্য, মার্কিন যুক্তরাষ্ট্রের রোগ নিয়ন্ত্রণ ও প্রতিরোধ কেন্দ্র নিয়মিত উপসর্গের পর্যবেক্ষণ করার পাশাপাশি \"শারীরিক দূরত্ব, হাতের পরিচ্ছন্নতা, পরিষ্কারকরণ এবং জীবাণুমুক্তকরণ এবং মেডিকেল ছুটির নীতিগুলি উন্নতকরণ এবং শ্রমিকদের ভাষায় শিক্ষামূলক উপকরণসমূহ প্রদানের পরামর্শ দেয় ”"
    ]
  },
  {
    "id": "recUpPiSLjtZ01GPP",
    "Question": "What do we know about camphora 1m and arsenic album 30 — homoeopathic immunity boosters — that are being recommended as a treatment in India?",
    "Status": "Published",
    "Subcategory": "On: COVID-19 & immunity boosters",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "While there is much research ongoing to provide treatments for COVID-19, there has been no supportive findings of utilizing homeopathic methods, like camphor 1m and arsenic album 30, as a method for preventing or treating COVID-19 infections. Journals that have published on this have emphasized historical use but are unable to point to _in vitro_ studies (studies occurring in test tubes, petri dishes, and elsewhere outside a living organism) or substantiated evidence of efficacy during the pandemic. \n",
    "What our experts say": "There has not been widespread, conclusive, or objective data to support the use of camphora 1m and arsenic album 30 as  immunity boosters. The WHO and U.S. CDC point to supportive care as some therapeutic options are evaluated and studied, but none of these include homeopathic medications. At this time, it is not recommended as an effective treatment or prophylaxis for SARS-CoV-2, the virus that causes COVID-19. \n",
    "Glossary Terms": [
      "recXRfJ1kKwVI1gH5",
      "rec9MiUSM1r2HMDYp",
      "recW0Z826AuxEWVeS"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "camphora",
      "homeopathic",
      "India",
      "immunity boosters"
    ],
    "Other resources": "1. Homeopathy to holistically strengthen body's defences for coronavirus infection ([ARHF](https://www.arhf.nl/coronavirus/docs/en/coronavirus-genus-epidemicus-3-April-2020.pdf)) \n2. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19) ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html)) \n",
    "DB (Hindi)": [
      "rec17g4hTZOY6140S"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recxDDuKjLSvDo6wh"
    ],
    "DB (Spanish)": [
      "recQZ6oyQG9WrzDqT"
    ],
    "DB (Bengali)": [
      "recyCtXut9kruqZxU"
    ],
    "DB (Portuguese)": [
      "rec9D4PIr3tnC8Dxu"
    ],
    "Rollup test 2": [
      "recbmEelytI6EV62q"
    ],
    "Last modified manual": "2020-06-25",
    "Last edited (simplified)": "2020-06-23T00:57:11.000Z",
    "Last edited (experts say)": "2020-06-25T17:10:15.000Z",
    "Last modified": "2020-06-25",
    "What our experts say wordcount": 69,
    "Background and context wordcount": 78,
    "Other resources wordcount": 27,
    "Wordcount": 174,
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "कपूर 1m और आर्सेनिक एल्बम 30 का रोगक्षमता बढ़ाने वाले के रूप में उपयोग करने के लिए व्यापक, निर्णायक या उद्देश्य डेटा नहीं है। डबल्युएचओ और यू॰एस सीडीसी सहायक देखभाल की ओर इशारा करते हैं क्योंकि कुछ चिकित्सीय विकल्पों का मूल्यांकन और अध्ययन किया जाता है, लेकिन इनमें से कोई भी होम्योपैथिक दवाओं में शामिल नहीं है। इस समय, यह SARS-CoV-2, कोविड​​-19 का कारण बनने वाले वायरस के लिए एक प्रभावी उपचार या प्रोफिलैक्सिस के रूप में सिफारिश की नहीं है।"
    ],
    "Hindi - Background and context": [
      "हालांकि कोविड​​-19 के लिए उपचार प्रदान करने के लिए बहुत अधिक शोध चल रहा है, लेकिन होम्योपैथिक विधियों का उपयोग करने का कोई सहायक परिणाम नहीं है, जैसे कि कपूर 1m और आर्सेनिक एल्बम 30, कोविड​​-19 संक्रमण को रोकने या उपचार करने के लिए एक विधि के रूप में। इस पर प्रकाशित होने वाले पत्रिकाओं ने ऐतिहासिक उपयोग पर जोर दिया है लेकिन इन विट्रो अध्ययन (टेस्ट ट्यूब, पेट्री डिश और एक जीवित जीव के बाहर कहीं और होने वाले अध्ययन) या महामारी के दौरान प्रभाव के पुष्ट प्रमाणों को संकेत करने में असमर्थ हैं।"
    ],
    "Telugu - What our experts say": [
      "కాంపోరా 1 ఎమ్ మరియు ఆర్సెనిక్ ఆల్బమ్ 30 ను రోగనిరోధక శక్తిని పెంచేదిగా ఉపయోగించటానికి మద్దతు ఇవ్వడానికి విస్తృతమైన, నిశ్చయాత్మకమైన లేదా ఆబ్జెక్టివ్ డేటా లేదు. కొన్ని చికిత్సా ఎంపికలు మూల్యాంకనం మరియు అధ్యయనం చేయబడినందున WHO మరియు యుఎస్ సిడిసి సహాయక సంరక్షణను సూచిస్తాయి, అయితే వీటిలో ఏవీ హోమియోపతి మందులు లేవు. ఈ సమయంలో, కోవిడ్-19 కి కారణమయ్యే SARS-CoV-2 అనే వైరస్ కోసం ఇది సమర్థవంతమైన చికిత్సగా లేదా రోగనిరోధకతగా సిఫారసు చేయబడలేదు."
    ],
    "Telugu - Context and background": [
      "కోవిడ్-19 కి చికిత్సలు అందించడానికి చాలా పరిశోధనలు జరుగుతున్నప్పటికీ, కోవిడ్-19 ఇన్ఫెక్షన్లను నివారించడానికి లేదా చికిత్స చేయడానికి ఒక పద్ధతిగా కర్పూరం 1m మరియు ఆర్సెనిక్ ఆల్బమ్ 30 వంటి హోమియోపతి పద్ధతులను ఉపయోగించుకోవటానికి సహాయక ఫలితాలు కనుగొనబడలేదు. దీనిపై ప్రచురించిన పత్రికలు చారిత్రక వాడకాన్ని నొక్కిచెప్పాయి, అయితే విట్రో అధ్యయనాలు (పరీక్షా గొట్టాలు, పెట్రీ వంటకాలు మరియు ఒక జీవికి వెలుపల మరెక్కడా జరిగే అధ్యయనాలు) లేదా మహమ్మారి సమయంలో సమర్థత యొక్క రుజువులను సూచించలేకపోతున్నాయి."
    ],
    "Spanish - What our experts say": [
      "No han habido datos ampliamente divulgados, concluyentes u objetivos para respaldar el uso del alcanfor 1m y del blanco de arsénico 30 como acrecentadores de la inmunidad. La OMS y los U.S. CDC apuntan al tratamiento sintomático mientras que algunas opciones terapéuticas son evaluadas y estudiadas, pero ninguna de estas incluyen medicaciones homeopáticas. En este momento, no es recomendado como tratamiento efectivo o profilaxis para el SARS-CoV-2, el virus que causa el COVID-19."
    ],
    "Spanish - Background and context": [
      "Mientras que hay mucha investigación en progreso para proveer tratamientos para el COVID-19, no han habido hallazgos que respalden la utilización de métodos homeopáticos, como el alcanfor 1m y el blanco de arsénico 30, como método para prevenir o tratar las infecciones de COVID-19. Los boletines que han publicado sobre esto han enfatizado su uso histórico, pero son incapaces de apuntar a estudios in vitro (los cuales ocurren en tubos de ensayo, placas Petri y en cualquier otro lugar fuera de un organismo viviente) o evidencia corroborante de su eficacia durante la pandemia."
    ],
    "Bengali - What our experts say": [
      "ক্যাম্পোরা ১ মি. এবং আর্সেনিক অ্যালবাম ৩০ এর প্রতিরোধ ক্ষমতা বৃদ্ধির হিসাবে সমর্থন করার জন্য কোনও বিস্তৃত, চূড়ান্ত বা উদ্দেশ্যমূলক তথ্য নেই। কিছু চিকিতসাগত বিকল্পগুলি মূল্যায়ন ও অধ্যয়ন করতে বিশ্ব স্বাস্থ্য সংস্থা এবং ইউএস সিডিসি সহায়ক যত্নের দিকে ইঙ্গিত করে, তবে এর কোনওটিতেই হোমিওপ্যাথিক ওষুধ অন্তর্ভুক্ত নয়। এই মুহুর্তে এটি, SARS-CoV-2, যা কোভিড-১৯-এর কারণ, ভাইরাসজনিতের জন্য কার্যকর চিকিৎসা বা প্রতিরোধ হিসাবে সুপারিশ করা হয় না।"
    ],
    "Bengali - Background and context": [
      "যদিও কোভিড -১৯ এর চিকিৎসা সরবরাহ করার জন্য অনেক গবেষণা চলছে, তবে কোভিড-১৯ সংক্রমণ রোধ বা চিকিৎসার জন্য একটি পদ্ধতি হিসাবে ক্যাম্পরা ১ মি. এবং আর্সেনিক অ্যালবাম ৩০ এর মতো হোমিওপ্যাথিক পদ্ধতি ব্যবহারের কোনও সহায়ক খুঁজে পাওয়া যায়নি। এই বিষয়ে প্রকাশিত জার্নালগুলি ঐতিহাসিক ব্যবহারের উপর জোর দিয়েছে তবে ভিট্রো স্টাডিতে (টেস্ট টিউব, পেট্রি ডিস এবং জীবন্ত জীবের বাইরে অন্য কোথাও পড়াশুনা) বা মহামারী চলাকালীন কার্যকারিতার দৃঢ়তা প্রমাণ করতে অক্ষম।"
    ]
  },
  {
    "id": "recsAUeofWqkiI3Hs",
    "Question": "What do genes have to do with our bodies' reactions to COVID-19?",
    "Status": "Published",
    "Subcategory": "On: COVID-19 and genes",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "As we move forward with the COVID-19 pandemic and related research, more information will become available about the role of genomics. Currently, there is significant interest on the role of ACE receptors, inhibitors and infection. \n",
    "What our experts say": "We're still learning more about the role of genetics in COVID-19 infection, both in terms of susceptibility, but also severity of illness. There have been some studies that have looked at proteins, called \"toll-like receptors\" or \"TLRs\" that help an immune system detect a virus and alert the immune system to begin defending the body from infection. Those studies have looked at the role of TLRs in natural immunity to the virus, and how our genes controlling a protein involved in TLR response, plays into susceptibility. Other studies have assessed blood types and that those with Type A appear to have a higher risk of contracting the virus, whereas Type O might be protective. \n\nACE receptors - also known as angiotensin-converting enzyme inhibitors - might be the way the virus gets into the cell and may play a large role in the virus's ability to infect cells. Because of this, there has been increased research into genetic variants in these receptors. It is likely that some genetics play a role in COVID-19 infection and clinical manifestations, but it will take much more research to understand these relationships. \n\n",
    "Glossary Terms": [
      "rechQcO5gs3FZMcPs"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "genes",
      "symptoms"
    ],
    "Other resources": "1. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19 ([New England Journal fo Medicine](https://www.nejm.org/doi/full/10.1056/NEJMsr2005760)) \n2. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic ([Nature](https://www.nature.com/articles/s41431-020-0636-6)) \n3. Do Your Genes Predispose You to COVID-19? ([Scientific American](https://www.scientificamerican.com/article/do-your-genes-predispose-you-to-covid-19/)) \n\n",
    "Rollup test 2": [
      "rec5m3dRnt8tSwwtY"
    ],
    "Last modified manual": "2020-06-25",
    "Last edited (simplified)": "2020-06-09T19:04:07.000Z",
    "Last edited (experts say)": "2020-09-24T20:16:49.000Z",
    "Last modified": "2020-09-24",
    "What our experts say wordcount": 187,
    "Background and context wordcount": 36,
    "Other resources wordcount": 51,
    "Wordcount": 274
  },
  {
    "id": "recpt1R0CCrgLqFhO",
    "Question": "Is favipiravir effective in treating COVID-19?",
    "Status": "Published",
    "Category": "Treatment",
    "Subcategory": "On: COVID-19 and treatment",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "The context for favipiravir is the same as for avifavir, given that avifavir is a generic form of favipiravir. Favipiravir as a potential COVID-19 treatment has been emerging in visibility since delivery of the drug to Russian hospitals beginning in June, following the approval of the Russian Ministry of Health. The approval followed promising but limited studies on favipiravir's accuracy in Russia, carried out in partnership of the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group. Studies on the drug had also been conducted in China -- with seemingly promising results yet severe study limitations -- as well as in the US, Italy, Japan and India. Favipiravir works by selectively inhibiting RNA polymerase, necessary for viral replication, but data on its efficacy for COVID-19 is still inconclusive. Trends in Russia's COVID-19 data, and additional evidence overall are needed to determine efficacy. Though only approved for influenza treatment in Japan, the drug has also been tested with varying levels of accuracy for treatment of Ebola, Zika, West Nile virus, yellow fever virus, foot-and-mouth disease virus, and Rift Valley fever, among other diseases. \n",
    "What our experts say": "There is currently not enough evidence to know whether or not favipiravir, also known as Avigan, can effectively treat COVID-19; however, the preliminary evidence is promising. Favipiravir is a drug that is used as an influenza medication in Japan and China, and is currently in studies to treat other viral infections, including COVID-19, in many other countries. Early studies involving favipiravir has showed promising results in reducing the duration of symptoms of COVID-19 and aiding in the recovery of patients. However, there were shortcomings to these early studies, such as only having a small number of patients involved and the presence of age differences between study groups. Additionally, not all studies randomly assigned to their groups (called randomization) and not all studies \"blinded\" their study subjects and their doctors (meaning they both knew which treatments they received and didn't receive). This helps explain why there is a lack of consensus as to whether or not favipiravir is an effect treatment for COVID-19 at this time. \n\nMain advantages of favipiravir are that it is administered orally and that it can be given in patients who are symptomatic but not ill enough to be hospitalized. As of November 2020, the International Journal of Infectious Diseases published a set of case studies of COVID-19 treated with favipiravir among patients in critical or severe condition, and found that all patients showed a clinical and chest imaging improvement, and all patients recovered without subsequent hypoxemia. Once again, while these results are promising, they are case studies and not formal research studies and therefore have signifiant limitations.\n",
    "Glossary Terms": [
      "reccupU786x3cn86Q",
      "recPX0N6FB6koiXCL"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "treatment",
      "medicine"
    ],
    "Other resources": "1. Journal of Antimicrobial Chemotherapy research letter about favipiravir as a potential treatment for COVID-19 ([JAC](https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkaa171/5838326))\n2. A Review of SARS-CoV-2 and the Ongoing Clinical Trials ([International Journal of Molecular Sciences](https://www.mdpi.com/1422-0067/21/7/2657))\n3. Coronavirus Disease (COVID-19) in Italy: Analysis of Risk Factors and Proposed Remedial Measures ([Frontiers in Medicine](https://www.frontiersin.org/articles/10.3389/fmed.2020.00140/full))\n4. The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment ([International Journal of Environmental Research and Public Health](https://www.mdpi.com/1660-4601/17/7/2323#cite)) \n5. Engineering Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study ([Engineering](https://www.sciencedirect.com/science/article/pii/S2095809920300631#!)) \n6. Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition ([International Journal of Infectious Diseases](https://www-sciencedirect-com.ezp-prod1.hul.harvard.edu/science/article/pii/S1201971220306779))\n7. Favipiravir: A new and emerging antiviral option in COVID-19 ([Medical Journal of Armed Forces India](https://www-ncbi-nlm-nih-gov.ezp-prod1.hul.harvard.edu/pmc/articles/PMC7467067/))\n",
    "How often revision needed": "Bi-weekly",
    "DB (Hindi)": [
      "recZxe6na5otSxNrc"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recPkjoRVqYJzYJRs"
    ],
    "DB (Spanish)": [
      "rec8GMiFslfan9gL4"
    ],
    "DB (Bengali)": [
      "recQj9RB5OqFq0CS5"
    ],
    "DB (Portuguese)": [
      "recrkKJP3IzByIgSF"
    ],
    "Rollup test 2": [
      "recCI5NN4Ixq8yGUt"
    ],
    "Last modified manual": "2020-06-25",
    "Last edited (simplified)": "2020-12-07T21:12:14.000Z",
    "Last edited (experts say)": "2020-12-07T21:14:43.000Z",
    "Last modified": "2020-12-07",
    "What our experts say wordcount": 261,
    "Background and context wordcount": 187,
    "Other resources wordcount": 116,
    "Wordcount": 564,
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "अभी पर्याप्त प्रमाण उपलब्ध नहीं हैं कि यह दावा किया जा सके कि फेवीपिरवीर, जिसे 'एविगन' के रूप में भी जाना जाता है, कोविद -19 के इलाज में मदद कर सकता है। अभी यह जानने के लिए पर्याप्त सबूत नहीं हैं कि फेवीपिरवीर, जिसे एविगन के रूप में भी जाना जाता है, कोविद -19 के इलाज में मदद कर सकता है। फेवीपिरवीर एक दवा है जो जापान और चीन में एक इन्फ्लूएंजा की दवा के रूप में उपयोग की जाती है, और वर्तमान में कई अन्य देशों में कोविड -19 सहित अन्य वायरल संक्रमणों के इलाज के लिए अध्ययन में है। फ़ेविपिरविर से जुड़े शुरुआती अध्ययनों ने कोविड-19 के लक्षणों की अवधि को कम करने और रोगियों के ठीक होने में सहायता करने के लिए आशाजनक परिणाम दिखाए। हालांकि, इन अध्ययनों में भी कमियां थीं, जैसे कि केवल कम संख्या में रोगियों को शामिल करना और अध्ययन समूहों के बीच उम्र के अंतर होना। इसके अतिरिक्त, अध्ययन सही ढंग से रैंडमायज़्ड नहीं था, और अध्ययन में भाग लेने वालों और उनके डॉक्टरों, दोनों, को पता था कि वे कौन से समूह का हिस्सा है, वे कौन से उपचार प्राप्त कर रहे हैं और नहीं कर रहे हैं। इन सब बातों से यह समझने में मदद मिल सकती है कि इस समय कोविड​​-19 के लिए फेवीपिरवीर एक प्रभावी उपचार है या नहीं, इस पर कोई सहमति नहीं है।"
    ],
    "Hindi - Background and context": [
      "फ़विपिरविर और अविफ़ाविर का संदर्भ एक ही है क्योंकि अविफ़ाविर इस दवा का एक सामान्य रूपांतरण है। फ़विपिरविर को कोविड-19 के संभाविक इलाज के रूप में देखा जा रहा है, क्योंकि रूसी स्वास्थ्य मंत्रालय की सहमति पर ये दवा रूसी अस्पतालों में जून से ही दी जा रही है। यह सहमति रूस में फ़ेविपिरवीर की सटीकता पर आशाजनक लेकिन सीमित अध्ययन के बाद दी गयी है, जो कि रूसी प्रत्यक्ष निवेश कोष (आरडीआईएफ), रूस के मुख्य धन कोष और केमरार ग्रूप की साझेदारी में किया गया है। दवा पर अध्ययन चीन में भी  किया गया था - आशाजनक परिणाम के साथ परंतु काफ़ी सीमित रूप से - साथ ही अमेरिका, इटली, जापान और भारत में। फ़विपिरविर कुछ आरएनए पोलीमरेज़ को बाधित करके, वाइरस को बढ़ने से रोकने का काम करता है, लेकिन कोविड-19 के लिए इसकी प्रभावकारिता पर डेटा अभी भी अनिर्णायक है। आर॰डी॰आई॰एफ॰ के अनुसार, दवा की 60,000 खुराक महीने के अंत तक दी जानी तय हैं। रूस के कोविड-19 डेटा और विशेष रूप से, अतिरिक्त साक्ष्य, प्रभावकारिता निर्धारित करने के लिए आवश्यक हैं। यद्यपि केवल जापान में इन्फ्लूएंजा उपचार के लिए अनुमोदित किया गया है, लेकिन इस दवा को इबोला, ज़िका, वेस्ट नाइल वायरस, पीले बुखार के वायरस, खुरपका रोग के वायरस, और रिफ्ट-वैली ज्वर जैसी बीमारियों के उपचार के लिए सटीकता के विभिन्न स्तरों पर जाँचा गया है।"
    ],
    "Telugu - What our experts say": [
      "అవిగాన్ అని కూడా పిలువబడే ఫవిపిరవిర్ కోవిడ్-19 చికిత్సకు సహాయపడుతుందో లేదో తెలుసుకోవడానికి ప్రస్తుతం తగిన ఆధారాలు లేవు. ఫావిపిరవిర్ అనేది జపాన్ మరియు చైనాలలో ఇన్ఫ్లుఎంజా ఔషధంగా ఉపయోగించబడే ఒక ఔషధం, మరియు ప్రస్తుతం అనేక ఇతర దేశాలలో కోవిడ్-19 తో సహా ఇతర వైరల్ ఇన్ఫెక్షన్లకు చికిత్స చేయడానికి అధ్యయనంలో ఉంది. ఫెవిపిరవిర్ పాల్గొన్న ప్రారంభ అధ్యయనాలు కోవిడ్-19 యొక్క లక్షణాల వ్యవధిని తగ్గించడంలో మరియు రోగుల పునరుద్ధరణకు సహాయపడటంలో మంచి ఫలితాలను చూపించాయి. ఏదేమైనా, ఈ అధ్యయనాలలో కూడా లోపాలు ఉన్నాయి, తక్కువ సంఖ్యలో రోగులు మాత్రమే పాల్గొనడం మరియు అధ్యయన సమూహాల మధ్య వయస్సు వ్యత్యాసాలు ఉండటం వంటివి. అదనంగా, అధ్యయనంలో పాల్గొనేవారు వారి సమూహాలకు (రాండమైజేషన్ అని పిలుస్తారు) మరియు అధ్యయన విషయాలకు యాదృచ్ఛికంగా కేటాయించబడలేదు మరియు వారి వైద్యులు ఇద్దరికీ వారు ఏ చికిత్సలు అందుకున్నారో మరియు అందుకోలేదని తెలుసు. ఈ సమయంలో కోవిడ్-19 కి ఫేవిపిరవిర్ ప్రభావ చికిత్స కాదా అనే దానిపై ఏకాభిప్రాయం ఎందుకు లేదని వివరించడానికి ఇది సహాయపడవచ్చు."
    ],
    "Telugu - Context and background": [
      "ఫెవిపిరవిర్ యొక్క సందర్భం అవిఫావిర్ మాదిరిగానే ఉంటుంది, అవిఫావిర్ అనేది ఫవిపిరవిర్ యొక్క సాధారణ రూపం. రష్యా ఆరోగ్య మంత్రిత్వ శాఖ ఆమోదం పొందిన తరువాత, జూన్లో రష్యన్ ఆసుపత్రులకు ఔషధ పంపిణీ ప్రారంభమైనందున, ఫావిపిరవిర్ సంభావ్య కోవిడ్-19 చికిత్సగా కనిపిస్తుంది. రష్యన్లో ఫేవిపిరవిర్ యొక్క ఖచ్చితత్వంపై ఆశాజనకమైన కానీ పరిమితమైన అధ్యయనాలను ఈ ఆమోదం అనుసరిస్తుంది, ఇది రష్యన్ డైరెక్ట్ ఇన్వెస్ట్మెంట్ ఫండ్ (RDIF), రష్యా యొక్క సార్వభౌమ సంపద నిధి మరియు చెమ్ రార్ గ్రూప్ భాగస్వామ్యంతో జరిగింది. ఔషధంపై అధ్యయనాలు చైనాలో కూడా జరిగాయి - మంచి ఫలితాలు ఇంకా తీవ్రమైన అధ్యయన పరిమితులతో - అలాగే యుఎస్, ఇటలీ, జపాన్ మరియు భారతదేశాలలో. వైరల్ రెప్లికేషన్‌కు అవసరమైన RNA పాలిమరేస్‌ను ఎంపిక చేసుకోవడం ద్వారా ఫావిపిరవిర్ పనిచేస్తుంది, అయితే కోవిడ్-19 కోసం దాని సమర్థతపై డేటా ఇప్పటికీ అసంకల్పితంగా ఉంది. RDIF ప్రకారం, 60,000 మోతాదుల of షధాన్ని ఈ నెలాఖరులోగా నిర్ణయించనున్నారు. రష్యా యొక్క కోవిడ్-19 డేటాలోని పోకడలు మరియు ప్రత్యేకించి, అదనపు సాక్ష్యాలు సమర్థతను నిర్ణయించడానికి అవసరం. జపాన్లో ఇన్ఫ్లుఎంజా చికిత్సకు మాత్రమే ఆమోదించబడినప్పటికీ, ఎబోలా, జికా, వెస్ట్ నైలు వైరస్, పసుపు జ్వరం వైరస్, పాదం మరియు నోటి వ్యాధి వైరస్ మరియు రిఫ్ట్ వ్యాలీ జ్వరం చికిత్స కోసం వివిధ స్థాయిల ఖచ్చితత్వంతో ఈ ఔషధం పరీక్షించబడింది. వ్యాధులు."
    ],
    "Spanish - What our experts say": [
      "No hay hasta ahora evidencia suficiente para saber si el favipiravir, también conocido como Avigan, puede o no ayudar a tratar el COVID-19. Es una droga que es utilizada como medicación para la influenza en Japón y China, y actualmente está en estudio para tratar otras infecciones virales, incluyendo al COVID-19, en muchos otros países. Estudios tempranos involucrando al favipiravir mostraron resultados prometedores al reducir la duración de los síntomas del COVID-19 y asistir en la recuperación de los pacientes. Sin embargo, también hubieron deficiencias en estos estudios, como el tener solamente un pequeño número de pacientes involucrados, y la presencia de diferencias de edad entre los grupos estudiados. Adicionalmente, los participantes en el estudio no fueron asignados a sus grupos aleatoriamente, y los sujetos de estudio y sus doctores sabían qué tratamientos recibieron y cuáles no. Esto puede ayudar a explicar por qué no hay consenso acerca de si el favipiravir es o no un tratamiento efectivo para el COVID-19 en este momento."
    ],
    "Spanish - Background and context": [
      "El contexto para el favipiravir es el mismo que para el avifavir, dado que el mismo es una forma genérica del favipiravir. El favipiravir como tratamiento potencial para el COVID-19 ha estado emergiendo en visibilidad, dado que la administración de la droga en hospitales rusos empezó en junio, siguiendo a la aprobación del Ministerio de Salud. Esta aprobación sigue luego de estudios prometedores pero limitados acerca de la exactitud del favipiravir, efectuadas en conjunto entre el Fondo Ruso de Inversión Directa (RDIF), el fondo de inversión soberano de Rusia, y el Grupo ChemRar. Los estudios sobre la droga también han sido conducidos en China — con resultados aparentemente promisorios, aunque con severas limitaciones en el estudio — como así también en los EE.UU., Italia, Japón e India. El favipiravir trabaja por inhibición selectiva de la polimerasa del ARN, necesaria para la replicación viral, pero los datos acerca de su eficacia sobre el COVID-19 aún no son concluyentes. 60.000 dosis de la droga habrán de ser administradas hasta fin de mes, de acuerdo a RDIF. Las tendencias en los datos sobre COVID-19 en Rusia y, en particular, evidencia adicional, son necesarias para determinar su eficacia. Aunque solo ha sido aprobado para el tratamiento de la influenza en Japón, la droga también ha sido probada con variados niveles de exactitud para el tratamiento del Ébola, Zika, virus del Nilo Occidental, virus de la fiebre amarilla, virus de la enfermedad de pie y boca, y la fiebre del Valle Rift, entre otras enfermedades."
    ],
    "Bengali - What our experts say": [
      "অ্যাভিগান নামে পরিচিত ফাভিপিরাভির কোভিড -১৯-এর চিকিৎসা করতে সহায়তা করতে পারেন কিনা তার সপক্ষে এখনই যথেষ্ট প্রমাণ নেই। ফাভিপিরাবির এমন একটি ওষুধ যা জাপান এবং চীনে ইনফ্লুয়েঞ্জার ওষুধ হিসাবে ব্যবহৃত হয় এবং বর্তমানে অনেক দেশে কোভিড -১৯ সহ অন্যান্য ভাইরাল সংক্রমণের চিকিৎসার জন্য অধ্যয়নরত রয়েছে। ফাভিপিরাবির সাথে জড়িত প্রাথমিক গবেষণাগুলি কোভিড-১৯ এর লক্ষণগুলির সময়কাল হ্রাস এবং রোগীদের পুনরুদ্ধারে সহায়তা করার প্রতিশ্রুতিবদ্ধ ফলাফল দেখিয়েছিল। যাইহোক, এই অধ্যয়নগুলির মধ্যেও ত্রুটিগুলি ছিল, যেমন কেবলমাত্র অল্প সংখ্যক রোগীর সাথে জড়িত থাকার এবং অধ্যয়ন গোষ্ঠীর মধ্যে বয়সের পার্থক্যের উপস্থিতি। অধিকন্তু, গবেষণায় অংশগ্রহণকারীদের এলোমেলোভাবে তাদের গ্রুপগুলিতে বরাদ্দ করা হয়নি (যাকে বলা হয় রান্ডমাইজেশন) এবং অধ্যয়নের বিষয় এবং তাদের চিকিৎসকরা উভয়ই জানেন যে তারা কোন চিকিৎসা পেয়েছেন এবং কী পান নি। এটি এই মুহূর্তে কোভিড-১৯ এর একটি চিকিৎসা ফ্যাভিপিরাবির কিনা তা নিয়ে কোনও ঐক্যমত্য নেই কেন তা বোঝাতে সহায়তা করতে পারে।"
    ],
    "Bengali - Background and context": [
      "ফভিপিরাবির প্রসঙ্গটি আভিফাভিরের মতো একই, অ্যাভিফাভির ফ্যাভিপিরাবির এর একটি জেনেরিক রূপ| সম্ভাব্য কোভিড -১৯ চিকিৎসা হিসাবে আভিফাভির দৃশ্যমান হয়ে উঠেছে, রাশিয়ার স্বাস্থ্য মন্ত্রণালয়ের অনুমোদনের পরে জুনে রাশিয়ান হাসপাতালগুলিতে ওষুধ সরবরাহ শুরু হয়েছিল । দ্যা রাশিয়ান ডাইরেক্ট ইনভেস্টমেন্ট ফান্ড (RDIF), রাশিয়ার সার্বভৌম সম্পদ তহবিল এবং কেমরার গ্রুপের অংশীদারিত্বের ভিত্তিতে রাশিয়ায় আভিফাভিরের যথার্থতার বিষয়ে আশ্বাসপ্রাপ্ত তবে সীমিত অধ্যয়ন অনুমোদিত হয়েছে। চিনে ওষুধ নিয়ে গবেষণা করা হয়েছিল - আপাতদৃষ্টিতে আশ্বাসিত ফলাফলের সাথে তীব্র অধ্যয়নের সীমাবদ্ধতা - পাশাপাশি মার্কিন যুক্তরাষ্ট্র, ইতালি, জাপান এবং ভারতেও গবেষণা করা হয়েছিল। আভিফাভির আরএনএ পলিমেরেজ নির্বাচন করে বাধা দিয়ে কাজ করে যা ভাইরাস প্রতিলিপির জন্য প্রয়োজনীয়, তবে কোভিড-১৯ এর জন্য কার্যকারিতা সম্পর্কিত তথ্য এখনও অপর্যাপ্ত। আরডিআইএফ জানিয়েছে, মাসের শেষের দিকে ওষুধের ৬০০০০ ডোজ সরবরাহ করা হবে। কার্যকারিতা নির্ধারণের জন্য রাশিয়ার কোভিড-১৯ প্রবণতার তথ্য এবং অন্যান্য অতিরিক্ত প্রমাণ প্রয়োজন। \nযদিও কেবল জাপানে ইনফ্লুয়েঞ্জা চিকিৎসার জন্য অনুমোদিত, ওষুধটি ইবোলা, জিকা, ওয়েস্ট নাইল ভাইরাস, হলুদ জ্বর ভাইরাস, পা-ও-মুখের রোগ ভাইরাস, এবং রিফ্ট ভ্যালি ফিভারের চিকিৎসা সহ অন্যান্য রোগের জন্য বিভিন্ন স্তরের নির্ভুলতার সাথেও পরীক্ষা করা হয়েছে।"
    ]
  },
  {
    "id": "recRIjHM0TPx23tcU",
    "Question": "Can we use sewage water to detect COVID-19 in a community?",
    "Status": "Published",
    "Subcategory": "On: COVID-19 & waste water",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "Canada"
    ],
    "Background and context": "Sewage contains valuable information on human health as viruses, bacteria, and chemical metabolites are excreted in urine and stool and provide a readout of an individual’s health status. In some diseases, people excrete viruses before they show symptoms, meaning that sewage can provide an early indicator of disease spread before people start seeking care. The technical term for analyzing sewage as a source of public health information is [Wastewater-Based Epidemiology (WBE)](https://cen.acs.org/environment/water/monitor-health-citiesresidents-look-further/96/i18). \n(Source: [Biobot Analytics](https://www.biobot.io/))\n",
    "What our experts say": "SARS-CoV-2 is the virus that causes COVID-19. It leaves the human body through our waste, so flushing the toilet with that waste means traces of the virus can be found in  sewage water. This is why COVID-19 has been recently detected in sewage water in regions that have tested for it. By collecting water from sewers, scientists in the U.S. and Europe are now testing sewage for the virus, using it as a collective sample to measure infection levels among thousands of people. Recent studies have shown that sewage water can be used as an early diagnostic tool for determining where potential COVID-19 cases might be occurring in a city. A recent study showed that measuring virus levels in municipal sewage helped researchers predict where forthcoming COVID-19 cases would be coming from a week before people began testing positive for the virus in that area. They did this by comparing the amount of virus found in the sewage water with the amount of confirmed cases in an area's hospitals. \nWe have observed that estimating the true number of COVID-19 cases is extremely challenging; these estimates often lead to underestimating the true scope of the pandemic in a community because many people are never tested for the virus even if they are ill. Moreover, asymptomatic patients or those with mild symptoms may never seek out testing and therefore won't be counted; but they can still transmit the virus. In this context, measuring overall virus levels in sewage over time could indicate the scope of the pandemic; indicate whether an outbreak is growing or shrinking; and can act as a surveillance system that would allow to detect new waves of an outbreak before patients develop symptoms and go to hospitals. \n\n(Source: [Biobot Analytics](https://www.biobot.io/))\n",
    "Glossary Terms": [
      "recFIn1ipbOFsoZsR",
      "rec8jvvjIb2QmeUrA"
    ],
    "Variation of the answer depending on country of residence": "Yes\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "virus",
      "spread",
      "sewage water",
      "waste water"
    ],
    "Other resources": "1. SARS-CoV-2 titers in wastewater foreshadow dynamics and clinical presentation of new COVID-19 cases ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.06.15.20117747v2))\n2. SARS-CoV-2 RNA concentrations in primary municipal sewage sludge as a leading indicator of COVID-19 outbreak dynamics ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.05.19.20105999v1))\n3. SARS-CoV-2 titers in wastewater are higher than expected from clinically confirmed cases ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.04.05.20051540v1))\n",
    "DB (French)": [
      "recWPdGv9b1FzK2CA"
    ],
    "DB (Hindi)": [
      "recMkZJD2fpzKkueR"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "reclGOZ5COTW6Rvyw"
    ],
    "DB (Spanish)": [
      "recE2hTT9JanU22s8"
    ],
    "DB (Bengali)": [
      "recmFEsPMclSXToz9"
    ],
    "DB (Portuguese)": [
      "recXGfk3K6uO5B2zJ"
    ],
    "Rollup test 2": [
      "recugKIGjwsEaJ9RI"
    ],
    "Last modified manual": "2020-06-24",
    "Last edited (simplified)": "2020-06-11T23:32:51.000Z",
    "Last edited (experts say)": "2020-07-15T16:54:13.000Z",
    "Last modified": "2020-06-24",
    "What our experts say wordcount": 292,
    "Background and context wordcount": 73,
    "Other resources wordcount": 44,
    "Wordcount": 409,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "La COVID-19 est provoquée par le virus SARS-CoV-2. Il quitte le corps humain par nos déchets organiques, donc tirer la chasse d’eau avec ces déchets signifie que des traces du virus peuvent se retrouver dans les eaux d’égout. C’est pourquoi SARS-CoV-2 a été détecté dans les eaux d’égout de régions où des tests ont été effectués. En recueillant des eaux d’égout, des scientifiques des États-Unis et d’Europe vérifient maintenant la présence du virus dans les égouts et utilisent les résultats comme échantillon collectif afin de mesurer les niveaux d’infection chez des milliers de personnes. Des études récentes ont démontré que l’eau des égouts peut être utilisée en tant qu’outil de diagnostic précoce afin de déterminer où des cas de COVID-19 seraient susceptibles d’apparaître dans une ville. Une étude récente a démontré que mesurer les niveaux du virus dans les égouts municipaux a aidé des chercheurs à prédire d’où proviendraient des cas futurs de COVID-19 une semaine avant que le virus ne soit détecté dans la population de cette zone. Ils sont arrivés à ce résultat en comparant la quantité de virus trouvée dans les eaux d’égout avec le nombre de cas confirmés dans les hôpitaux de cette zone. Nous avons constaté qu’estimer le nombre réel de cas de COVID-19 est un défi considérable ; ces estimations entraînent souvent une sous-estimation de l’étendue réelle de la pandémie dans une communauté, car de nombreuses personnes ne subissent pas de tests de dépistage du virus même si elles sont malades. De plus, les patients asymptomatiques ou ceux qui ne présentent que peu de symptômes pourraient ne jamais chercher à être testés et ne seront par conséquent pas comptabilisés, bien qu’ils puissent quand même transmettre le virus. Dans ce contexte, la mesure prolongée des niveaux globaux de virus dans les égouts pourrait indiquer l’étendue de la pandémie, révéler l’augmentation ou la diminution d’une éclosion, et agir en tant que système de surveillance qui permettrait de détecter de nouvelles vagues d’une éclosion avant que les patients ne développent de symptômes ou ne se rendent dans les hôpitaux.\n\n(Source : Biobot Analytics)"
    ],
    "French - Background and context": [
      "Les eaux d’égout révèlent des renseignements importants sur la santé humaine : les virus, les bactéries et les métabolites sont excrétés dans l’urine et les selles, et donnent une lecture de l’état de santé d’une personne. Dans le cas de certaines maladies, les virus sont excrétés avant que les personnes ne présentent de symptômes, ce qui signifie que les eaux d’égout peuvent servir d’indicateur précoce de la propagation d’une maladie avant que les personnes ne cherchent à se faire soigner. Le terme technique pour l’analyse des eaux d’égout en tant que source de renseignements sur la santé publique est Épidémiologie fondée sur les eaux usées (ÉFEU). (Source : Biobot Analytics)"
    ],
    "Hindi - What our experts say": [
      "SARS-CoV-2 वह वायरस है जो कोविड-19 का कारण बनता है। यह मानव शरीर को हमारे कचरे के माध्यम से निकालता है, इसलिए शौचालय को उस कचरे के साथ प्रवाहित करने का मतलब है कि मल के पानी में वायरस के निशान पाए जा सकते हैं। यही कारण है कि कोविड-19 को हाल ही में उन क्षेत्रों में सीवेज पानी में पाया गया है जिन्होंने इसके लिए परीक्षण किया है। नाली से पानी इकट्ठा करके, यू॰एस और यूरोप में वैज्ञानिक अब हजारों लोगों के बीच संक्रमण के स्तर को मापने के लिए सामूहिक नमूने के रूप में उपयोग करते हुए, वायरस के लिए सीवेज का परीक्षण कर रहे हैं। हाल के अध्ययनों से पता चला है कि एक शहर में संभावित कोविड-19 मामलों के निर्धारण के लिए सीवेज पानी को एक प्रारंभिक नैदानिक ​​उपकरण के रूप में इस्तेमाल किया जा सकता है। हाल के एक अध्ययन से पता चला है कि नगरपालिका के सीवेज में वायरस के स्तर को मापने से शोधकर्ताओं को यह अनुमान लगाने में मदद मिली कि आने वाले कोविड-19 मामले एक सप्ताह पहले से आने लगेंगे, जब लोग उस क्षेत्र में वायरस के लिए सकारात्मक परीक्षण करना शुरू करेंगे। उन्होंने एक क्षेत्र के अस्पतालों में पुष्टि किए गए मामलों की मात्रा के साथ सीवेज के पानी में पाए जाने वाले वायरस की मात्रा की तुलना करके ऐसा किया।\nहमने देखा है कि कोविड-19 मामलों की सही संख्या का अनुमान करना बेहद चुनौतीपूर्ण है; इन अनुमानों से अक्सर एक समुदाय में महामारी के वास्तविक दायरे को कम करके आंका जाता है क्योंकि कई लोग बीमार होने पर भी कभी भी वायरस का परीक्षण नहीं करते हैं। इसके अलावा, स्पर्शोन्मुख रोगियों या हल्के लक्षणों वाले लोग कभी भी परीक्षण की तलाश नहीं कर सकते हैं और इसलिए उनकी गिनती नहीं की जाएगी; लेकिन वे अभी भी वायरस संचारित कर सकते हैं। इस संदर्भ में, समय के साथ मल में समग्र वायरस के स्तर को मापने से महामारी के दायरे का संकेत हो सकता है; सूचित करें कि क्या एक प्रकोप बढ़ रहा है या सिकुड़ रहा है; और एक निगरानी प्रणाली के रूप में कार्य कर सकता है जो मरीजों में लक्षण विकसित करने और अस्पतालों में जाने से पहले एक प्रकोप की नई लहरों का पता लगाने की अनुमति देगा।\n\n(स्रोत: बायोबॉट एनालिटिक्स)"
    ],
    "Hindi - Background and context": [
      "सीवेज में मानव स्वास्थ्य पर मूल्यवान जानकारी होती है क्योंकि वायरस, बैक्टीरिया और रासायनिक चयापचयों को मूत्र और मल में उत्सर्जित किया जाता है और किसी व्यक्ति के स्वास्थ्य की स्थिति का एक रीडआउट प्रदान करता है। कुछ बीमारियों में, लोग लक्षणों को दिखाने से पहले वायरस का उत्सर्जन करते हैं, जिसका अर्थ है कि सीवेज बीमारी की शुरुआती संकेतक प्रदान कर सकता है इससे पहले कि लोग देखभाल करना शुरू कर दें। सार्वजनिक स्वास्थ्य सूचना के स्रोत के रूप में सीवेज का विश्लेषण करने के लिए तकनीकी शब्द गंदा पानी -आधारित महामारी विज्ञान (डबल्युबीइ) है।\n(स्रोत: बायोबॉट एनालिटिक्स)"
    ],
    "Telugu - What our experts say": [
      "కోవిడ్-19 కు కారణమయ్యే వైరస్ SARS-CoV-2. ఇది మన వ్యర్థాల ద్వారా మానవ శరీరాన్ని వదిలివేస్తుంది, కాబట్టి ఆ వ్యర్థంతో టాయిలెట్ను ఫ్లష్ చేయడం అంటే మురుగునీటిలో వైరస్ యొక్క ఆనవాళ్ళు కనిపిస్తాయి. అందువల్ల కోవిడ్ -19 ఇటీవల పరీక్షించిన ప్రాంతాలలో మురుగునీటిలో కనుగొనబడింది. మురుగు కాలువల నుండి నీటిని సేకరించడం ద్వారా, యుఎస్ మరియు ఐరోపాలోని శాస్త్రవేత్తలు ఇప్పుడు వైరస్ కోసం మురుగునీటిని పరీక్షిస్తున్నారు, దీనిని వేలాది మందిలో సంక్రమణ స్థాయిలను కొలవడానికి సమిష్టి నమూనాగా ఉపయోగిస్తున్నారు. ఒక నగరంలో సంభావ్య కోవిడ్-19 కేసులు ఎక్కడ సంభవించవచ్చో నిర్ణయించడానికి మురుగునీటిని ముందస్తు రోగనిర్ధారణ సాధనంగా ఉపయోగించవచ్చని ఇటీవలి అధ్యయనాలు చూపించాయి. మునిసిపల్ మురుగునీటిలో వైరస్ స్థాయిలను కొలవడం పరిశోధకులు ఆ ప్రాంతంలో ప్రజలు వైరస్ కోసం పాజిటివ్ పరీక్షలు ప్రారంభించడానికి ఒక వారం ముందు నుండి రాబోయే కోవిడ్-19 కేసులు ఎక్కడ వస్తాయో అంచనా వేయడానికి సహాయపడ్డాయని తాజా అధ్యయనం చూపించింది. మురుగునీటి నీటిలో లభించే వైరస్ మొత్తాన్ని ఒక ప్రాంత ఆసుపత్రులలో ధృవీకరించబడిన కేసులతో పోల్చడం ద్వారా వారు దీనిని చేశారు. కోవిడ్-19 కేసుల యొక్క నిజమైన సంఖ్యను అంచనా వేయడం చాలా సవాలుగా ఉందని మేము గమనించాము; ఈ అంచనాలు తరచూ సమాజంలో మహమ్మారి యొక్క నిజమైన పరిధిని తక్కువగా అంచనా వేయడానికి దారితీస్తాయి ఎందుకంటే చాలా మంది ప్రజలు అనారోగ్యంతో ఉన్నప్పటికీ వైరస్ కోసం పరీక్షించబడరు. అంతేకాక, లక్షణం లేని రోగులు లేదా తేలికపాటి లక్షణాలు ఉన్నవారు ఎప్పుడూ పరీక్షను కోరలేరు మరియు అందువల్ల లెక్కించబడరు; కానీ అవి ఇప్పటికీ వైరస్ను వ్యాప్తి చేయగలవు. ఈ సందర్భంలో, కాలక్రమేణా మురుగునీటిలో మొత్తం వైరస్ స్థాయిలను కొలవడం మహమ్మారి యొక్క పరిధిని సూచిస్తుంది; వ్యాప్తి పెరుగుతోందా లేదా తగ్గిపోతుందో సూచించండి; మరియు రోగులు లక్షణాలను అభివృద్ధి చేయడానికి మరియు ఆసుపత్రులకు వెళ్ళే ముందు వ్యాప్తి యొక్క కొత్త తరంగాలను గుర్తించడానికి అనుమతించే నిఘా వ్యవస్థగా పనిచేయగలదు. (మూలం: బయోబోట్ అనలిటిక్స్)"
    ],
    "Telugu - Context and background": [
      "వైరస్లు, బ్యాక్టీరియా మరియు రసాయన జీవక్రియలు మూత్రం మరియు మలం లో విసర్జించబడతాయి మరియు ఒక వ్యక్తి యొక్క ఆరోగ్య స్థితి యొక్క రీడౌట్ను అందించడంతో మురుగునీటి మానవ ఆరోగ్యం గురించి విలువైన సమాచారాన్ని కలిగి ఉంటుంది. కొన్ని వ్యాధులలో, ప్రజలు లక్షణాలను చూపించే ముందు వైరస్లను విసర్జిస్తారు, అనగా ప్రజలు సంరక్షణ పొందడం ప్రారంభించే ముందు మురుగునీరు వ్యాధి వ్యాప్తి యొక్క ప్రారంభ సూచికను అందిస్తుంది. మురుగునీటిని ప్రజారోగ్య సమాచారానికి మూలంగా విశ్లేషించే సాంకేతిక పదం మురుగునీటి ఆధారిత ఎపిడెమియాలజీ (WBE). (మూలం: బయోబోట్ అనలిటిక్స్)"
    ],
    "Spanish - What our experts say": [
      "SARS-CoV-2 es el virus que causa el COVID-19. Deja al cuerpo humano a través de nuestros desechos, por lo que el descargar el inodoro con esos desechos significa que trazas del virus pueden ser encontradas en el agua cloacal. Esto es por qué el COVID-19 ha sido detectado recientemente en el agua cloacal en regiones en las que han efectuado este ensayo. Al recolectar el agua de cloacas, los científicos en EE.UU. y Europa ahora las están ensayando por la presencia del virus, usándola como una muestra colectiva para medir los niveles de infección entre miles de personas. Estudios recientes han mostrado que el agua cloacal puede ser usada como una herramienta de diagnóstico temprano para determinar dónde pueden estar ocurriendo casos potenciales de COVID-19 en una ciudad. Un estudio reciente mostró que midiendo los niveles de virus en una cloaca municipal ayudó a los investigadores a predecir dónde estarían surgiendo casos futuros de COVID-19, una semana antes de que las personas empezaran a testear positivo para el virus en esa área. Hicieron esto comparando la cantidad de virus encontrada en el agua cloacal con la cantidad de casos confirmados en los hospitales de un área.\nHemos observado que estimar el verdadero número de casos de COVID-19 es un desafío extremo; estas estimaciones a menudo conducen a la subestimación del verdadero alcance de la pandemia en una comunidad, porque muchas personas nunca testearon por el virus aunque estén enfermas. Aún más, los pacientes asintomáticos o aquellos con síntomas leves puede que nunca busquen testearse, y por lo tanto no serán contados, pero aún así pueden transmitir el virus. En este contexto, la medición de los niveles generales de virus en los residuos cloacales a través del tiempo puede indicar el alcance de la pandemia, indicar si un brote está aumentando o disminuyendo, y puede actuar como un sistema de vigilancia que permitiría detectar nuevas olas de un brote antes de que los pacientes desarrollen síntomas y vayan hacia los hospitales.\n\n(Fuente: Biobot Analytics)"
    ],
    "Spanish - Background and context": [
      "Los residuos cloacales contienen información valiosa sobre la salud humana, en la medida en que virus, bacterias y metabolitos químicos son excretados con la orina y las heces, y proveen una lectura del estado de salud de un individuo. En algunas enfermedades, las personas excretan virus antes de mostrar síntomas, lo que significa que el residuo cloacal puede proveer un indicador temprano de la diseminación de la enfermedad antes de que las personas empiecen a buscar atención médica. El término técnico para analizar los residuos cloacales como fuente de información para la salud pública es Epidemiología Basada en Agua Residual (WBE).\n(Fuente: Biobot Analytics)"
    ],
    "Bengali - What our experts say": [
      "SARS-CoV-2 হ'ল কোভিড-১৯ সৃষ্টিকারী ভাইরাস। এটি আমাদের মলমূত্রের মধ্য দিয়ে মানব দেহ ছেড়ে যায়, সুতরাং সেই বর্জ্য টয়লেটে ফ্লাশ করার অর্থ নর্দমার পানিতে ভাইরাসের চিহ্ন খুঁজে পাওয়া যাবে। এই কারণেই সম্প্রতি কোভিড -১৯ সংক্রমিত অঞ্চলে ড্রেনের পানি পরীক্ষা করে এটির সন্ধান পাওয়া গেছে। নর্দমা থেকে পানি সংগ্রহ করে, মার্কিন যুক্তরাষ্ট্র এবং ইউরোপের বিজ্ঞানীরা এখন ভাইরাসটির জন্য পরীক্ষা করছেন, এটি হাজার হাজার মানুষের মধ্যে সংক্রমণের মাত্রা পরিমাপের জন্য সম্মিলিত নমুনা হিসাবে ব্যবহার করছেন। সাম্প্রতিক গবেষণাগুলিতে দেখা গেছে যে নগরীর সম্ভাব্য কোভিড-১৯ কোথায় ঘটতে পারে তা নির্ধারণের জন্য নর্দমার পানি প্রাথমিক সনাক্তকরণের উপায় হিসাবে ব্যবহার করা যেতে পারে। সাম্প্রতিক একটি গবেষণায় দেখা গেছে যে, পৌরসভা নর্দমাগুলিতে ভাইরাসের স্তর পরিমাপ করে গবেষকরা সেই এলাকায় মানুষের মধ্যে পরীক্ষা করে কোভিড-১৯ এর ঘটনা শুরুর এক সপ্তাহ আগেই \nসম্ভাব্য ভবিষ্যদ্বাণী করেছিলেন। তারা এই অঞ্চলের হাসপাতালে নিশ্চিত কোভিড-১৯ ঘটনার সাথে নর্দমার পানিতে প্রাপ্ত ভাইরাসের পরিমাণের তুলনা করে এটি করেছিলেন।আমরা লক্ষ্য করেছি যে, কোভিড-১৯ ঘটনার প্রকৃত সংখ্যা অনুমান করা অত্যন্ত চ্যালেঞ্জিং; এই অনুমানগুলি প্রায়শই একটি সম্প্রদায়ের মহামারীর প্রকৃত চিত্র অবমূল্যায়িত করে কারণ অনেক লোক আছে যারা অসুস্থ হলেও ভাইরাসের জন্য কখনও পরীক্ষা করা হয় না। তদুপরি, লক্ষনবিহীন রোগী বা হালকা লক্ষণযুক্ত ব্যক্তিরা কখনও কখনও পরীক্ষা চান না এবং তাই তারা গণনায় অন্তর্ভুক্ত হন না; তারা যদিও ভাইরাস সংক্রমণ করতে পারে। এই প্রসঙ্গে, সময়ের সাথে সাথে নর্দমাগুলিতে সামগ্রিক ভাইরাসের মাত্রা পরিমাপ করা মহামারীর ব্যাপ্তি নির্দেশ করতে পারে; প্রাদুর্ভাব বাড়ছে বা সঙ্কুচিত হচ্ছে তা নির্দেশ করতে পারে; এবং এমন একটি নজরদারি ব্যবস্থা হিসাবে কাজ করতে পারে যা রোগীদের লক্ষণগুলি দেখা দেবার আগে এবং হাসপাতালে যাওয়ার আগে প্রাদুর্ভাবের নতুন ধাক্কা সনাক্ত করতে পারে।\n(সূত্র: বায়োবট অ্যানালিটিক্স)"
    ],
    "Bengali - Background and context": [
      "নর্দমায় মানব স্বাস্থ্যের মূল্যবান তথ্য রয়েছে কারণ ভাইরাস, ব্যাকটিরিয়া এবং রাসায়নিক যৌগ মলমূত্রের সাথে বের হয় এবং কোনও ব্যক্তির স্বাস্থ্যের অবস্থা সম্পর্কে তথ্য প্রদান করে। কিছু রোগে, লোকেরা লক্ষণ দেখানোর আগে ভাইরাসগুলি ছড়িয়ে দেয়, এর অর্থ হ'ল লোকেরা যত্ন নেওয়া শুরু করার আগেই নর্দমা রোগ ছড়িয়ে যাওয়ার প্রাথমিক সূচক সরবরাহ করতে পারে। জনস্বাস্থ্যের তথ্যের উৎস হিসাবে নর্দমা বিশ্লেষণের প্রযুক্তিগত শব্দটি হ'ল বর্জ্য পানি-ভিত্তিক মহামারী বিদ্যা (WBE)।(সূত্র: বায়োবট অ্যানালিটিক্স)"
    ]
  },
  {
    "id": "recbw6ac5kq8tsDHY",
    "Question": "How are migrant laborers in India being impacted by the COVID-19 pandemic?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & migration",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "India"
    ],
    "Background and context": "Disproportionate impacts of COVID-19 on migrant laborers are being documented globally as a result of poor or crowded working conditions, inadequate living conditions, risk of contracting the virus while traveling for work, and low access to quality healthcare, among other factors. Migratory and seasonal agricultural workers (MSAWs) have been documented to disproportionately infectious diseases, like COVID-19, along with a host of other serious health problems including diabetes, malnutrition, infectious diseases, pesticide poisoning, and injuries from work-related machinery. These health issues are exacerbated by the transitory culture of this population group, which makes it difficult to develop a relationship with a healthcare provider, maintain treatment regimens, and track health records. For these reasons, MSAWs were inequitably impacted by India's sudden shut down, and by the sudden reopening. \nSource: <https://www.ruralhealthinfo.org/topics/migrant-health>\n",
    "What our experts say": "India enacted one of the toughest nationwide lockdown policies in response to the COVID-19 pandemic, and shut down all travel and movement with barely four hours notice on March 24, 2020. The lockdown disproportionately impacted the informal sector of India (the part of any economy that is not regulated by the government), and left thousands of migrant laborers and daily wage earners stranded. With buses and trains shuttered, migrant laborers had to walk hundreds of kilometers back to their villages, and many died along the way. \n\nIndia's COVID-19 response has been criticized for inadequately accounting for the needs of the most marginalized and vulnerable residents who lacked resources to cope with the abrupt lockdown. Now that the lockdown has ended, the Supreme Court of India has ordered states to identify stranded migrant laborers and facilitate their return to their hometowns. Several states, including West Bengal, Odisha, Bihar, and Jharkhand, have reported spikes in infections as more than 10 million migrant workers return to their homes following the easing of lockdown measures. The actual impact of migration on COVID-19 cases is difficult to ascertain, since testing has also improved, but the sudden influx of migrant laborers has made it even more difficult for the state healthcare institutions to treat and care for COVID-19 cases.\n",
    "Glossary Terms": [
      "recSMSaoUfxS4ZXWq",
      "rec2UNEXbTkSCx30Q"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "transmission",
      "migration",
      "migrant laborer",
      "India"
    ],
    "Other resources": "1. India: COVID-19 Lockdown Puts Poor at Risk ([HRW](https://www.hrw.org/news/2020/03/27/india-covid-19-lockdown-puts-poor-risk))\n2. The Pandemic Exposes India’s Apathy Toward Migrant Workers ([The Atlantic](https://www.theatlantic.com/ideas/archive/2020/04/the-pandemic-exposes-indias-two-worlds/609838/)) \n3. Send migrant workers home in 15 days: India's top court to states ([Aljazeera](https://www.aljazeera.com/news/2020/06/send-migrant-workers-home-15-days-india-top-court-states-200609073709386.html))\n4. Bihar, Jharkhand and Odisha record big spikes as migrant workers return home ([Hindustan Times](https://www.hindustantimes.com/india-news/bihar-jharkhand-and-odisha-record-big-spikes-as-migrant-workers-return-home/story-6PfyWmDaJPbpkgeZpqTVhN.html))\n5. Coronavirus lockdown: The Indian migrants dying to get home ([BBC](https://www.bbc.com/news/world-asia-india-52672764))\n",
    "DB (Hindi)": [
      "recq5h0Prcle128f9"
    ],
    "Media": [
      {
        "id": "attzLc5IfnFmCwx8b",
        "url": "https://dl.airtable.com/.attachments/e3f21e382593fe12725104493aac4d0d/22295161/migrantlaborers_v15.png",
        "filename": "migrant laborers_v1 (5).png",
        "size": 168909,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/0c4eb06681ad9f6bb200fbf39d4bbdb7/d139ceff",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d224731c9d905b7b7777b0a18769c610/e9ba88e0",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b29683b5af113872a98a85e4fe659148/694c84c3",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attim9qqrjRT8QA1x",
        "url": "https://dl.airtable.com/.attachments/12a5e71066d7fa4124acf4e570eb0d94/c075fb9c/migrantlaborers_v16.png",
        "filename": "migrant laborers_v1 (6).png",
        "size": 197844,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/376204ee89a0941c042b664831796b1a/6ae920a9",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/7fcd3810d24b4307fcc457469bffebc0/062e3ebf",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/695a4dc1868d1fb96f6c53812c0abc9a/86ef2525",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attEU0pfUBC265Mmg",
        "url": "https://dl.airtable.com/.attachments/138780f6c46aa35905e4642d25c622a2/3fbc3af5/migrantlaborers_v17.png",
        "filename": "migrant laborers_v1 (7).png",
        "size": 150116,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/7f51dd99911a744bf665a4f0ae906815/0481babe",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d89373f7892e4a2361725839646eb8c3/5e496096",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/5f13d818ed21ee97af5bac650038049a/24c14cc6",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att7BS2VwV8xvoODM",
        "url": "https://dl.airtable.com/.attachments/9895027b36a134a555b395b70208e777/d386e080/migrantlaborers_v18.png",
        "filename": "migrant laborers_v1 (8).png",
        "size": 160384,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/68781923251c52caed3d4b86b4f85c3b/0b225463",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/95ec13c8d7f2c68b5d66fc6ace312585/04d8e580",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/7dfc20ac526af0074da23f6474ac6a55/5db39926",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attblAJTC4mIqNkeU",
        "url": "https://dl.airtable.com/.attachments/0d219cdb6b306c23940e78101c053345/4c143346/migrantlaborers_v19.png",
        "filename": "migrant laborers_v1 (9).png",
        "size": 239173,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/5064e058de93c2a58693887ce8d2d951/d8cb60ef",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/c32d1dca3d10d799a4885425621af0da/250d08c9",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/479260eb5934fbf221bb5f868b91a732/2c1bb877",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recehg5I06eSi604a"
    ],
    "DB (Bengali)": [
      "recfg6ysauGO98T5N"
    ],
    "DB (Portuguese)": [
      "recQhHqG8oPKhQx5n"
    ],
    "Rollup test 2": [
      "recd6el72EBaU3g1K"
    ],
    "Media Package": [
      {
        "id": "attzDh4e3zcOitEL3",
        "url": "https://dl.airtable.com/.attachments/16d364dbd1865a3a6c07866de2faaa30/0a9209a0/HowaremigrantlaborersinIndiabeingimpactedbythecovid-19pandemic.zip",
        "filename": "How are migrant laborers in India being impacted by the covid-19 pandemic.zip",
        "size": 1073302,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-06-23",
    "Last edited (simplified)": "2020-06-23T12:02:20.000Z",
    "Last edited (experts say)": "2020-06-23T12:02:20.000Z",
    "Last modified": "2020-06-23",
    "What our experts say wordcount": 213,
    "Background and context wordcount": 128,
    "Other resources wordcount": 57,
    "Wordcount": 398,
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "भारत ने कोविड​​-19 महामारी के जवाब में सबसे कठिन राष्ट्रव्यापी लॉकडाउन नीतियों में से एक को लागू किया, और 24 मार्च, 2020 को मुश्किल से चार घंटे के नोटिस के साथ सभी यात्रा और आंदोलन को बंद कर दिया।\n लॉकडाउन ने भारत के अनौपचारिक क्षेत्र (सरकार द्वारा विनियमित नहीं होने वाली किसी भी अर्थव्यवस्था का हिस्सा) को असंगत रूप से प्रभावित किया और हजारों प्रवासी मजदूरों और दैनिक वेतन भोगियों को छोड़ दिया।\n बसों और ट्रेनों को बंद करने के साथ, प्रवासी मजदूरों को अपने गाँवों में सैकड़ों किलोमीटर पीछे चलना पड़ा, और कई रास्ते में ही मर गए। \n\nभारत के कोविड​​-19 की प्रतिक्रिया की आलोचना की गई है कि वह सबसे अधिक सिमा पर रहने वाले और अतिसंवेदनशील निवासियों की जरूरतों के लिए और अपर्याप्त लेखांकन के लिए है जिनके पास अचानक लॉकडाउन से निपटने के लिए संसाधनों की कमी थी। अब जब लॉकडाउन समाप्त हो गया है, तो भारत के सर्वोच्च न्यायालय ने राज्यों को फंसे हुए प्रवासी मजदूरों की पहचान करने और उनके गृहनगर में लौटने की सुविधा प्रदान करने का आदेश दिया है। पश्चिम बंगाल, ओडिशा, बिहार और झारखंड सहित कई राज्यों में संक्रमणों में स्पाइक्स की सूचना मिली है, क्योंकि 10 मिलियन से अधिक प्रवासी कामगार तालाबंदी के उपायों में ढील के बाद अपने घरों को लौट जाते हैं। कोविड​​-19 मामलों में प्रवासन के वास्तविक प्रभाव का पता लगाना मुश्किल है, क्योंकि परीक्षण में भी सुधार हुआ है, लेकिन प्रवासी मजदूरों की अचानक अंतःप्रवेश ने राज्य स्वास्थ्य संस्थानों के लिए कोविड​​-19 मामलों का इलाज और देखभाल करना और भी मुश्किल बना दिया है।"
    ],
    "Hindi - Background and context": [
      "प्रवासी मजदूरों पर कोविड​​-19 के विषम प्रभाव को वैश्विक रूप से खराब या भीड़ वाली कामकाजी परिस्थितियों, अपर्याप्त रहने की स्थिति, काम के लिए यात्रा करते समय वायरस को अनुबंधित करने का जोखिम, और अन्य कारकों के साथ गुणवत्ता स्वास्थ्य सेवा की कम पहुंच के परिणामस्वरूप प्रलेखित किया जा रहा है। प्रवासी और मौसमी कृषि श्रमिकों (MSAWs) को कोविड​​-19 की तरह मधुमेह, कुपोषण, संक्रामक रोगों, कीटनाशक विषाक्तता और काम से संबंधित मशीनरी से चोटों सहित अन्य गंभीर स्वास्थ्य समस्याओं के साथ असंगत रूप से संक्रामक रोगों के लिए प्रलेखित किया गया है। इस जनसंख्या समूह की अस्थायी संस्कृति द्वारा इन स्वास्थ्य मुद्दों को बढ़ा-चढ़ाकर पेश किया जाता है, जिससे स्वास्थ्य सेवा प्रदाता के साथ संबंध विकसित करना, उपचार व्यवस्था को बनाए रखना और स्वास्थ्य रिकॉर्ड को ट्रैक करना मुश्किल हो जाता है। इन कारणों से, भारत के अचानक बंद होने और अचानक दोबारा खुलने से MSAWs असमान रूप से प्रभावित हुए।\nस्रोत: https://www.ruralhealthinfo.org/topics/migrant-health"
    ],
    "Telugu - What our experts say": [
      "కోవిడ్-19 మహమ్మారికి ప్రతిస్పందనగా భారతదేశం దేశవ్యాప్తంగా అత్యంత కఠినమైన లాక్డౌన్ విధానాలలో ఒకటిగా అమలు చేసింది మరియు మార్చి 24, 2020 న కేవలం నాలుగు గంటల నోటీసుతో అన్ని ప్రయాణ మరియు కదలికలను మూసివేసింది. లాక్డౌన్ భారతదేశం యొక్క అనధికారిక రంగాన్ని అసమానంగా ప్రభావితం చేసింది (ఏదైనా భాగం ప్రభుత్వం నియంత్రించని ఆర్థిక వ్యవస్థ), మరియు వేలాది మంది వలస కూలీలు మరియు రోజువారీ వేతన సంపాదకులు చిక్కుకుపోయారు. బస్సులు మరియు రైళ్లు మూసివేయడంతో, వలస కూలీలు తమ గ్రామాలకు వందల కిలోమీటర్లు తిరిగి నడవవలసి వచ్చింది మరియు చాలా మంది దారిలో మరణించారు.\n\nభారతదేశం యొక్క కోవిడ్-19 ప్రతిస్పందన ఆకస్మిక లాక్డౌన్ను ఎదుర్కోవటానికి వనరులు లేని అత్యంత అట్టడుగు మరియు బలహీన నివాసితుల అవసరాలను తగినంతగా లెక్కించలేదని విమర్శించారు. ఇప్పుడు లాక్డౌన్ ముగిసినందున, చిక్కుకున్న వలస కార్మికులను గుర్తించి, వారి స్వగ్రామాలకు తిరిగి రావడానికి సుప్రీంకోర్టు రాష్ట్రాలను ఆదేశించింది. లాక్డౌన్ చర్యలు సడలించిన తరువాత 10 మిలియన్లకు పైగా వలస కార్మికులు తమ ఇళ్లకు తిరిగి రావడంతో పశ్చిమ బెంగాల్, ఒడిశా, బీహార్, జార్ఖండ్ సహా పలు రాష్ట్రాలు అంటువ్యాధులు పెరిగాయని నివేదించింది. కోవిడ్-19 కేసులపై వలస యొక్క వాస్తవ ప్రభావాన్ని నిర్ధారించడం చాలా కష్టం, ఎందుకంటే పరీక్ష కూడా మెరుగుపడింది, కాని వలస కార్మికుల ఆకస్మిక ప్రవాహం రాష్ట్ర ఆరోగ్య సంస్థలకు కోవిడ్-19 కేసుల చికిత్స మరియు సంరక్షణ మరింత కష్టతరం చేసింది."
    ],
    "Telugu - Context and background": [
      "పేలవమైన లేదా రద్దీగా ఉండే పని పరిస్థితులు, సరిపోని జీవన పరిస్థితులు, పని కోసం ప్రయాణించేటప్పుడు వైరస్ సంక్రమించే ప్రమాదం మరియు నాణ్యమైన ఆరోగ్య సంరక్షణకు తక్కువ ప్రాప్యత వంటి ఇతర కారణాలతో వలస కార్మికులపై కోవిడ్-19 యొక్క అసమాన ప్రభావాలు ప్రపంచవ్యాప్తంగా నమోదు చేయబడుతున్నాయి. వలస మరియు కాలానుగుణ వ్యవసాయ కార్మికులు (MSAW లు) కోవిడ్-19 వంటి అసమాన అంటు వ్యాధులతో పాటు, మధుమేహం, పోషకాహార లోపం, అంటు వ్యాధులు, పురుగుమందుల విషం మరియు పని సంబంధిత యంత్రాల నుండి గాయాలు వంటి ఇతర తీవ్రమైన ఆరోగ్య సమస్యలతో పాటు నమోదు చేయబడ్డాయి. ఈ జనాభా సమూహం యొక్క తాత్కాలిక సంస్కృతి ద్వారా ఈ ఆరోగ్య సమస్యలు తీవ్రమవుతాయి, ఇది ఆరోగ్య సంరక్షణ ప్రదాతతో సంబంధాన్ని పెంచుకోవడం, చికిత్స నియమాలను నిర్వహించడం మరియు ఆరోగ్య రికార్డులను ట్రాక్ చేయడం కష్టతరం చేస్తుంది. ఈ కారణాల వల్ల, భారతదేశం ఆకస్మికంగా మూసివేయడం మరియు ఆకస్మికంగా తిరిగి తెరవడం ద్వారా MSAW లు అసమానంగా ప్రభావితమయ్యాయి.\nమూలం: https://www.ruralhealthinfo.org/topics/migrant-health"
    ],
    "Bengali - What our experts say": [
      "কোভিড-১৯ মহামারীর প্রতিক্রিয়া হিসাবে ভারত দেশব্যাপী অন্যতম কঠোর লকডাউন নীতিমালা কার্যকর করেছে এবং ২২ শে মার্চ, ২০২০ সালে কেবলমাত্র চার ঘণ্টার নোটিশ দিয়ে সমস্ত ভ্রমণ এবং চলাচল বন্ধ করে দিয়েছে। এই লকডাউনটি ভারতের অনানুষ্ঠানিক ক্ষেত্রকে অস্বাভাবিকভাবে প্রভাবিত করেছিল (যে অংশটির অর্থনীতি সরকার কর্তৃক নিয়ন্ত্রিত হয় না) এবং হাজার হাজার অভিবাসী শ্রমিক এবং দৈনিক মজুরি উপার্জনকারী আটকা পড়েছিল। বাস ও ট্রেন চলাচল বন্ধ হয়ে যাওয়ার সাথে সাথে অভিবাসী শ্রমিকদের কয়েকশ কিলোমিটার দুরে তাদের গ্রামে যেতে হয়েছিল এবং অনেকেই পথে মারা গিয়েছিলেন।\nআকস্মিকভাবে লকডাউন মোকাবেলা করার জন্য সম্পদের যে অভাব রয়েছে তা সর্বাধিক প্রান্তিক ও দুর্বল বাসিন্দাদের প্রয়োজনের জন্য অপ্রতুলভাবে হিসাবরক্ষার জন্য ভারতের কোভিড-১৯ এর প্রতিক্রিয়া সমালোচিত হয়েছে। এখন লকডাউন শেষ হয়ে গেছে, ভারতের সুপ্রিম কোর্ট রাজ্যগুলিকে আটকা পড়া অভিবাসী শ্রমিকদের চিহ্নিত করতে এবং তাদের নিজ শহরে ফিরে যাওয়ার সুবিধার্থে নির্দেশ দিয়েছে। পশ্চিমবঙ্গ, ওড়িশা, বিহার, এবং ঝাড়খণ্ড সহ বেশ কয়েকটি রাজ্যে সংক্রমণের প্রবণতা দেখা দিয়েছে| যেহেতু লকডাউন ব্যবস্থাগুলি সহজ করার পরে এক কোটিরও বেশি অভিবাসী শ্রমিক তাদের বাড়িতে ফিরে আসেন। কোভিড-১৯ এর অভিবাসনের উপর প্রকৃত প্রভাব নির্ধারণ করা কঠিন, যেহেতু পরীক্ষারও উন্নতি হয়েছে, তবে হঠাৎ অভিবাসী শ্রমিকদের আগমন রাজ্য স্বাস্থ্যসেবা প্রতিষ্ঠানের পক্ষে কোভিড-১৯ ঘটনার চিকিৎসা ও যত্ন নেওয়া আরও জটিল করে তুলেছে।"
    ],
    "Bengali - Background and context": [
      "অভিবাসী শ্রমিকদের উপর কোভিড-১৯ এর অনাকাঙ্ক্ষিত প্রভাবগুলি দরিদ্র বা জনাকীর্ণ কাজের পরিস্থিতি, জীবনযাত্রার অপর্যাপ্ত পরিস্থিতি, কাজের জন্য ভ্রমণের সময় ভাইরাসের সংক্রমণের ঝুঁকি এবং মানসম্পন্ন স্বাস্থ্যসেবার স্বল্পতার ফলে বিশ্বব্যাপী নথিভুক্ত হচ্ছে। অভিবাসী এবং মৌসুমী কৃষি শ্রমিকদের (এমএসএডাব্লু) কোভিড-১৯ এর মতো অনাকাঙ্ক্ষিত সংক্রামক রোগের নথিভুক্ত করা হয়েছে, পাশাপাশি ডায়াবেটিস, অপুষ্টি, সংক্রামক রোগ, কীটনাশক বিষ, এবং কাজের সাথে সম্পর্কিত যন্ত্রপাতি থেকে আহত হওয়া সহ গুরুতর স্বাস্থ্যগত সমস্যা রয়েছে। এই জনসংখ্যার গোষ্ঠীর চলমান সংস্কৃতি এই স্বাস্থ্য সংক্রান্ত সমস্যাগুলি আরও বেড়েছে, যা স্বাস্থ্যসেবা সরবরাহকারীর সাথে সম্পর্ক গড়ে তোলা, চিকিৎসা ব্যবস্থা রক্ষণাবেক্ষণ এবং স্বাস্থ্যের রেকর্ডগুলি ট্র্যাক করা শক্ত করে তোলে। এই কারণে, ভারতের হঠাৎ বন্ধ হয়ে যাওয়া, এবং হঠাৎ পুনরায় খোলার মাধ্যমে অভিবাসী এবং মৌসুমী কৃষি শ্রমিকরা অসমর্থিতভাবে প্রভাবিত হয়েছিল।\nসূত্রঃ https://www.ruralhealthinfo.org/topics/migrant-health"
    ]
  },
  {
    "id": "reciHqvo2ldywmQrQ",
    "Question": "Could the oral polio vaccine be a solution for Covid-19?",
    "Status": "Published",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "Kenya"
    ],
    "Background and context": "Drug repurposing is a safe, and often successful, pathway to speed up drug discovery and development compared with starting from scratch. Drug repurposing uses drugs that have either received regulatory approval, have failed in clinical trials, or are in later stages of clinical trials, in order to leverage the detailed information collected on safety, toxicity, formulation, manufacturing plans, etc. There are many existing drugs that are undergoing testing for being repurposed for COVID-19 treatment, as well as many existing vaccines being studied for repurpose for COVID-19 prevention. For instance, biopharmaceutical company Merck is working on development of an experimental Covid-19 vaccine based on a measles vaccine. Another group is studying the effectiveness of Tuberculosis vaccine Bacille Calmette-Guérin (BCG) in protecting healthcare workers from COVID-19; and Company Emergent BioSolutions is in pre-clinical development of studying anti-SARS antibodies for COVID-19 prevention. The oral polio vaccine (OPV) is another option being tested based on indicators from past studies that OPV has helpful, general triggers for the immune system. According to the Polio Eradication Initiative, “A study is currently being discussed with various partners and vaccine manufacturers, including the US FDA, the outcomes of which will be carefully assessed to determine potential use in the context of the spread of SARS-CoV2 until the time when specific vaccines and antiviral therapies are ready.”\n",
    "What our experts say": "It's too early to know. Successful discovery and safe delivery of a vaccine are very challenging. In the pandemic context we are in, many scientists are turning to existing drugs and vaccines to try and see if they can repurpose them to tackle COVID-19, especially since their safety profiles, side effects, and effectiveness are already known. Similarly, the safety track record of the oral polio vaccine is also known, and scientists are now studying its efficacy against COVID-19. The hypothesis these scientists have suggested is that the oral polio vaccine – a weakened version of the live polio virus – is assumed to trigger a general immune response in the body - production of antibodies against a foreign organism to be protected in the future if infected again with the same organism. When the body's immune system engages this response to fight off the unknown virus, scientists believe the body will develop antibodies specific to the novel coronavirus, the virus that causes COVID-19. However these are early studies occurring in animal models only at this stage and with no results yet. Moreover, there is no consensus yet among scientists as to whether choosing the oral polio vaccine as a candidate was a good idea in the first place. Some note that there are risks in introducing the oral polio vaccine in some populations which is why in most of the world, doctors have phased out the oral formulation in favor of the inactivated polio vaccine, which is more widely used today.\n",
    "Glossary Terms": [
      "recmajcAORyuqhZPc",
      "recyXylBebc7GlxTi",
      "rec9qqItwSTjq3Eae"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "treatment"
    ],
    "Other resources": "1. Dr. Lipi Roy - Could the Polio Vaccine Curb the Coronavirus Pandemic ([Forbes](https://www.forbes.com/sites/lipiroy/2020/06/14/could-the-polio-vaccine-curb-the-coronavirus-pandemic/#14520b22332a))\n2. The use of oral polio vaccine (OPV) to prevent SARS-CoV2 ([Polio Eradication Initiative](http://polioeradication.org/wp-content/uploads/2020/03/Use-of-OPV-and-COVID-20200421.pdf))\n",
    "DB (Hindi)": [
      "rec7bA8vT7nLLJsBt"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recqLym7SRaOuLvKq"
    ],
    "DB (Spanish)": [
      "recJ71gVpMrfiW2E2"
    ],
    "DB (Bengali)": [
      "recrKoPR2fCKlNoL3"
    ],
    "DB (Portuguese)": [
      "rec2LZH509LGtv2LD"
    ],
    "Rollup test 2": [
      "rectkoMxd0tz42YXD"
    ],
    "Last modified manual": "2020-06-22",
    "Last edited (simplified)": "2020-06-19T18:02:12.000Z",
    "Last edited (experts say)": "2020-06-19T18:38:07.000Z",
    "Last modified": "2020-06-22",
    "What our experts say wordcount": 251,
    "Background and context wordcount": 217,
    "Other resources wordcount": 27,
    "Wordcount": 495,
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Hindi - What our experts say": [
      "यह जानना बहुत जल्दी है। एक वैक्सीन की सफल खोज और सुरक्षित डिलीवरी बहुत चुनौतीपूर्ण है। हम जिस महामारी के संदर्भ में हैं, कई वैज्ञानिक मौजूदा दवाओं और टीकों की ओर रुख कर रहे हैं, ताकि वे कोशिश करें और देखें कि क्या वे कोविड-19 से निपटने के लिए उनका पुनरुत्पादन कर सकते हैं, खासकर जब से उनके सुरक्षा प्रोफाइल, साइड इफेक्ट्स, और प्रभावशीलता पहले से ही ज्ञात हैं। इसी तरह, ओरल पोलियो वैक्सीन का सुरक्षा ट्रैक रिकॉर्ड भी ज्ञात है, और वैज्ञानिक अब कोविड-19 के खिलाफ इसकी प्रभावकारिता का अध्ययन कर रहे हैं। इन वैज्ञानिकों ने परिकल्पना की है कि मौखिक पोलियो वैक्सीन - लाइव पोलियो वायरस का एक कमजोर संस्करण - शरीर में एक सामान्य प्रतिरक्षा प्रतिक्रिया को ट्रिगर करने के लिए माना जाता है - एक विदेशी जीव के खिलाफ एंटीबॉडी का उत्पादन भविष्य में संरक्षित किया जा सकता है यदि उसी जीव के साथ फिर से संक्रमित हो। जब शरीर की प्रतिरक्षा प्रणाली अज्ञात वायरस से लड़ने के लिए इस प्रतिक्रिया को संलग्न करती है, तो वैज्ञानिकों का मानना ​​है कि शरीर उपन्यास कोरोनवायरस के लिए एंटीबॉडी विकसित करेगा, वायरस जो कोविड-19 का कारण बनता है। हालांकि ये प्रारंभिक अध्ययन केवल इस स्तर पर और अभी तक कोई परिणाम नहीं के साथ पशु मॉडल में हो रहे हैं। इसके अलावा, वैज्ञानिकों के बीच अभी तक कोई सहमति नहीं है कि क्या उम्मीदवार के रूप में मौखिक पोलियो वैक्सीन चुनना पहले स्थान पर एक अच्छा विचार था। कुछ लोगों का मानना ​​है कि कुछ आबादी में ओरल पोलियो वैक्सीन लगाने में जोखिम है, यही वजह है कि दुनिया के अधिकांश देशों में, डॉक्टरों ने निष्क्रिय पोलियो वैक्सीन के पक्ष में मौखिक रूप से तैयार किया है, जो आज अधिक व्यापक रूप से उपयोग किया जाता है।"
    ],
    "Hindi - Background and context": [
      "ड्रग को अलग उद्देश्य में उपयोग के लिए एक सुरक्षित, और अक्सर सफल, आरंभ से शुरू होने की तुलना में दवा की खोज और विकास को गति देने के लिए मार्ग है। ड्रग को अलग उद्देश्य में उपयोग करने वाली दवाएं ऐसी दवाओं का उपयोग करती हैं जिन्हें या तो विनियामक मंजूरी प्राप्त हुई है, वे नैदानिक ​​परीक्षणों में विफल रहे हैं, या नैदानिक ​​परीक्षणों के बाद के चरणों में हैं, ताकि सुरक्षा, विषाक्तता, निर्माण, निर्माण योजनाओं आदि पर एकत्र की गई विस्तृत जानकारी का लाभ उठाने के लिए कई मौजूदा हैं। उपचार के लिए अलग उद्देश्य में उपयोग के लिए परीक्षण किया जा रहा है, साथ ही साथ कोविड-19 रोकथाम के लिए अलग उद्देश्य में उपयोग के लिए कई मौजूदा टीकों का अध्ययन किया जा रहा है। उदाहरण के लिए, बायोफार्मास्युटिकल कंपनी मर्क खसरे के टीके के आधार पर एक प्रयोगात्मक कोविड-19 वैक्सीन के विकास पर काम कर रही है। एक अन्य समूह कोविड-19 से स्वास्थ्य कार्यकर्ताओं की सुरक्षा में क्षय के वैक्सीन बेसिल कैलमेट-गुएरिन (बीसीजी) की प्रभावशीलता का अध्ययन कर रहा है; और कंपनी इमर्जेंट बायोसोल्यूशन कोविड-19 रोकथाम के लिए एंटी-सार्स एंटीबॉडी के अध्ययन के पूर्व-नैदानिक ​​विकास में है। ओरल पोलियो वैक्सीन (ओपीवी) एक अन्य विकल्प है जिसका परीक्षण पिछले अध्ययनों के संकेतकों के आधार पर किया जा रहा है कि ओपीवी में प्रतिरक्षा प्रणाली के लिए सहायक, सामान्य ट्रिगर हैं। पोलियो निवारण पहल के अनुसार, \"वर्तमान में यूएस एफडीए सहित विभिन्न भागीदारों और वैक्सीन निर्माताओं के साथ एक अध्ययन पर चर्चा की जा रही है, जिसके परिणामों को एसएआरएस-सीओवी 2 के प्रसार के संदर्भ में संभावित उपयोग निर्धारित करने के लिए सावधानीपूर्वक मूल्यांकन किया जाएगा जब तक विशिष्ट टीके और एंटीवायरल थेरेपी तैयार हैं।”"
    ],
    "Telugu - What our experts say": [
      "ఇది తెలుసుకోవడం చాలా తొందరగా ఉంది. టీకా విజయవంతంగా కనుగొనడం మరియు సురక్షితంగా పంపిణీ చేయడం చాలా సవాలుగా ఉన్నాయి. మేము ఉన్న మహమ్మారి సందర్భంలో, చాలా మంది శాస్త్రవేత్తలు ఇప్పటికే ఉన్న మందులు మరియు వ్యాక్సిన్ల వైపు మొగ్గు చూపుతున్నారు, అవి కోవిడ్-19 ను పరిష్కరించడానికి వాటిని పునరావృతం చేయగలవా అని చూడటానికి ప్రయత్నిస్తున్నారు, ప్రత్యేకించి వారి భద్రతా ప్రొఫైల్స్, దుష్ప్రభావాలు మరియు ప్రభావం ఇప్పటికే తెలుసు. అదేవిధంగా, నోటి పోలియో వ్యాక్సిన్ యొక్క భద్రతా ట్రాక్ రికార్డ్ కూడా తెలుసు, మరియు శాస్త్రవేత్తలు ఇప్పుడు కోవిడ్-19 కు వ్యతిరేకంగా దాని సామర్థ్యాన్ని అధ్యయనం చేస్తున్నారు. ఈ శాస్త్రవేత్తలు సూచించిన పరికల్పన ఏమిటంటే, లైవ్ పోలియో వైరస్ యొక్క బలహీనమైన వెర్షన్ - నోటి పోలియో వ్యాక్సిన్ శరీరంలో సాధారణ రోగనిరోధక ప్రతిస్పందనను ప్రేరేపిస్తుందని భావించబడుతుంది - భవిష్యత్తులో వ్యాధి బారినపడితే భవిష్యత్తులో రక్షించబడే ఒక విదేశీ జీవికి వ్యతిరేకంగా ప్రతిరోధకాలను ఉత్పత్తి చేస్తుంది. అదే జీవితో. శరీరం యొక్క రోగనిరోధక వ్యవస్థ తెలియని వైరస్తో పోరాడటానికి ఈ ప్రతిస్పందనను నిమగ్నం చేసినప్పుడు, శాస్త్రవేత్తలు శరీరం కోవిడ్-19 కి కారణమయ్యే వైరస్ అనే నవల కరోనావైరస్కు ప్రత్యేకమైన ప్రతిరోధకాలను అభివృద్ధి చేస్తుందని నమ్ముతారు. అయితే ఇవి ప్రారంభ దశలో జంతువుల నమూనాలలో ఈ దశలో మాత్రమే జరుగుతున్నాయి మరియు ఇంకా ఫలితాలు లేవు. అంతేకాకుండా, ఓరల్ పోలియో వ్యాక్సిన్‌ను అభ్యర్థిగా ఎన్నుకోవడం మంచి ఆలోచన కాదా అనే విషయంలో శాస్త్రవేత్తలలో ఇంకా ఏకాభిప్రాయం లేదు. కొన్ని జనాభాలో నోటి పోలియో వ్యాక్సిన్‌ను ప్రవేశపెట్టడంలో ప్రమాదాలు ఉన్నాయని కొందరు గమనిస్తున్నారు, అందువల్ల ప్రపంచంలో చాలావరకు, వైద్యులు నిష్క్రియాత్మకంగా పోలియో వ్యాక్సిన్‌కు అనుకూలంగా నోటి సూత్రీకరణను దశలవారీగా తొలగించారు, ఈ రోజు మరింత విస్తృతంగా ఉపయోగించబడుతోంది."
    ],
    "Telugu - Context and background": [
      "పున ప్రారంభం మొదటి నుండి ప్రారంభంతో పోలిస్తే ఔషధ ఆవిష్కరణ మరియు అభివృద్ధిని వేగవంతం చేసే మార్గం సురక్షితమైన మరియు తరచుగా విజయవంతమవుతుంది. భద్రత, విషపూరితం, సూత్రీకరణ, ఉత్పాదక ప్రణాళికలు మొదలైన వాటిపై సేకరించిన వివరణాత్మక సమాచారాన్ని ప్రభావితం చేయడానికి, పున ప్రారంభం రెగ్యులేటరీ ఆమోదం పొందిన, క్లినికల్ ట్రయల్స్‌లో విఫలమైన లేదా క్లినికల్ ట్రయల్స్ యొక్క తరువాతి దశలలో ఉన్న ఔషధలను ఉపయోగిస్తుంది. కోవిడ్-19 చికిత్స కోసం పునర్వినియోగపరచబడటానికి పరీక్షలు చేయబడుతున్న మందులు, అలాగే కోవిడ్-19 నివారణ కోసం పునర్వినియోగం కోసం ఇప్పటికే ఉన్న అనేక టీకాలు అధ్యయనం చేయబడుతున్నాయి. ఉదాహరణకు, బయోఫార్మాస్యూటికల్ కంపెనీ మెర్క్ మీజిల్స్ వ్యాక్సిన్ ఆధారంగా ప్రయోగాత్మక కోవిడ్ -19 వ్యాక్సిన్ అభివృద్ధికి కృషి చేస్తోంది. కోవిడ్-19 నుండి ఆరోగ్య సంరక్షణ కార్మికులను రక్షించడంలో క్షయ వ్యాక్సిన్ బాసిల్ కాల్మెట్-గురిన్ (BCG) యొక్క ప్రభావాన్ని మరొక సమూహం అధ్యయనం చేస్తోంది; మరియు కంపెనీ ఎమర్జెంట్ బయో సొల్యూషన్స్ కోవిడ్-19 నివారణ కోసం SARS వ్యతిరేక ప్రతిరోధకాలను అధ్యయనం చేసే ప్రీ-క్లినికల్ అభివృద్ధిలో ఉంది. నోటి పోలియో వ్యాక్సిన్ (OPV) అనేది రోగనిరోధక వ్యవస్థకు OPV సహాయకారిగా, సాధారణ ట్రిగ్గర్‌లను కలిగి ఉందని గత అధ్యయనాల సూచికల ఆధారంగా పరీక్షించబడుతున్న మరొక ఎంపిక. పోలియో నిర్మూలన ఇనిషియేటివ్ ప్రకారం, “యుఎస్ ఎఫ్‌డిఎతో సహా వివిధ భాగస్వాములు మరియు టీకా తయారీదారులతో ప్రస్తుతం ఒక అధ్యయనం చర్చించబడుతోంది, దీని ఫలితాలను SARS-CoV2 వ్యాప్తి చెందుతున్న సందర్భంలో సంభావ్య వినియోగాన్ని నిర్ణయించడానికి జాగ్రత్తగా అంచనా వేయబడుతుంది. నిర్దిష్ట టీకాలు మరియు యాంటీవైరల్ చికిత్సలు సిద్ధంగా ఉన్న సమయం. ”"
    ],
    "Spanish - What our experts say": [
      "Es demasiado temprano para saberlo. El descubrimiento exitoso y la administración segura de una vacuna son grandes desafíos. En el contexto de la pandemia en el que estamos, muchos científicos se están tornando a drogas y vacunas existentes para intentar y ver si se les puede dar un nuevo propósito para afrontar al COVID-19, especialmente desde que sus perfiles de seguridad, efectos colaterales y efectividad ya son conocidos. Similarmente, el registro de desempeño en seguridad de la vacuna oral para la polio también es conocido, y los científicos ahora están estudiando su eficacia en contra del COVID-19. La hipótesis que han sugerido es que de la vacuna oral para la polio - una versión debilitada del virus de la polio - es asumido que desencadena una respuesta inmune general en el cuerpo - la producción de anticuerpos en contra de un organismo extraño del cual ser protegido en el futuro si es infectado nuevamente con el mismo organismo. Cuando el sistema inmunológico del cuerpo activa esta respuestra para combatir el virus desconocido, los científicos creen que desarrollará anticuerpos específicos para el nuevo coronavirus, el virus que causa el COVID-19. Sin embargo, estos son estudios tempranos ocurriendo en modelos animales solamente en esta etapa, y todavía sin resultados. Aún más, aún no hay consenso entre los científicos acerca de si haber elegido la vacuna oral para la polio como candidata fue una buena idea en primer lugar. Algunos llaman la atención sobre el hecho de que hay riesgos al introducirla en algunas poblaciones, lo cual es por qué, en la mayoría del mundo, los doctores han removido gradualmente la formulación oral en favor de la vacuna inactivada de la polio, la cual es más ampliamente usada al día de hoy."
    ],
    "Spanish - Background and context": [
      "El dar nuevo propósito a drogas existentes es un camino seguro, y a menudo exitoso, para acelerar el descubrimiento y desarrollo de drogas, comparado con empezar de cero. Usa drogas que han recibido aprobación regulatoria, han fallado en ensayos clínicos o bien están en las últimas etapas de los mismos, con el fin de sacar ventaja de la información detallada recolectada en cuanto a seguridad, toxicidad, formulación, planes de manufactura, etc. Hay muchas drogas existentes que están siendo probadas para darles un nuevo propósito para el tratamiento del COVID-19, como así también muchas vacunas existentes siendo estudiadas para la prevención del COVID-19 como nuevo propósito. Por ejemplo, la compañía biofarmacéutica Merck está trabajando sobre el desarrollo de una vacuna experimental para el COVID-19 basada en una vacuna para el sarampión. Otro grupo está estudiando la efectividad de la vacuna para la tuberculosis Bacilo Calmette-Guérin (BCG) para proteger a los trabajadores de la salud del COVID-19; y la compañía Emergent BioSolutions está estudiando el desasrrollo preclínico de anticuerpos anti-SARS para la prevención del COVID-19. La vacuna oral para la polio (OPV) es otra opción que está siendo probada basada en indicadores de estudios pasados, según los cuales tiene desencadenantes útiles y generales para el sistema inmunológico. De acuerdo a la Iniciativa para la Erradicación de la Polio, \"Un estudio está siendo discutido actualmente entre varios asociados y fabricantes de vacunas, incluyendo a la US FDA, los resultados del cual serán cuidadosamente evaluados para determinar el uso potencial en el contexto de la diseminación del SARS-CoV-2, hasta el momento en que vacunas específicas y terapias antivirales estén listas\"."
    ],
    "Bengali - What our experts say": [
      "এখনও এটি জানার মত সময় আসেনি। একটি ভ্যাকসিনের সফলভাবে আবিষ্কার এবং নিরাপদ সরবরাহ অত্যন্ত চ্যালেঞ্জিং। আমরা যে মহামারীটির প্রসঙ্গে রয়েছি, অনেক বিজ্ঞানী কোভিড -১৯ মোকাবেলায় তাদের পুনঃপ্রতিষ্ঠা করতে পারেন কিনা তা চেষ্টা করার জন্য বিদ্যমান ওষুধ এবং ভ্যাকসিনগুলির দিকে ফিরছেন, বিশেষত যেহেতু তাদের সুরক্ষা প্রোফাইল, পার্শ্ব প্রতিক্রিয়া এবং কার্যকারিতা ইতিমধ্যে জানা রয়েছে। একইভাবে, মৌখিক পোলিও ভ্যাকসিনের সুরক্ষা ট্র্যাক রেকর্ডটিও জানা এবং বিজ্ঞানীরা এখন কোভিড-১৯-এর বিরুদ্ধে এর কার্যকারিতা অধ্যয়ন করছেন। এই বিজ্ঞানীরা যে অনুমানের পরামর্শ দিয়েছেন তা হ'ল মৌখিক পোলিও ভ্যাকসিন - যা জীবিত পোলিও ভাইরাসের একটি দুর্বল সংস্করণ - এটি শরীরে একটি সাধারণ প্রতিরোধ ক্ষমতা জাগিয়ে তুলবে - অজানা জীবের বিরুদ্ধে অ্যান্টিবডিগুলির উৎপাদন ভবিষ্যতে আবার একই জীবের দ্বারা সংক্রামিত হলে সুরক্ষা দেবে। শরীরের প্রতিরোধ ব্যবস্থা যখন অজানা ভাইরাসের বিরুদ্ধে লড়াই করার জন্য এই প্রতিক্রিয়ায় জড়িত, তখন বিজ্ঞানীরা বিশ্বাস করেন যে, শরীর একই ভাবে নভেল করোনভাইরাস যা কোভিড-১৯ এর জন্য দায়ী, তার জন্য নির্দিষ্ট অ্যান্টিবডিগুলি বিকাশ করবে। তবে এগুলি কেবলমাত্র এই পর্যায়ে জীবজন্তুর মডেলগুলিতে করা প্রাথমিক গবেষণা এবং এখনও কোনও ফলাফল নেই। অধিকন্তু, শুরুতে মৌখিক পোলিও ভ্যাকসিনকে প্রার্থী হিসাবে বেছে নেওয়া ঠিক ছিল কিনা তা নিয়ে এখনও বিজ্ঞানীদের মধ্যে ঐক্যমত্য নেই। কেউ কেউ নোট করেছেন যে, কিছু জনগোষ্ঠীতে মৌখিক পোলিও টিকা চালু করার ঝুঁকি রয়েছে যার কারণেই বিশ্বের বেশিরভাগ ক্ষেত্রে ডাক্তাররা মৌখিক গঠনটি থেকে পর্যায়ক্রমে বেরিয়ে এসেছেন নিষ্ক্রিয় পোলিও ভ্যাকসিনের পক্ষে, যা বর্তমানে বেশি ব্যবহৃত হয়।"
    ],
    "Bengali - Background and context": [
      "গোড়া থেকে শুরু করার তুলনায় ওষুধ পুনরূদ্ধার ওষুধ আবিষ্কার এবং বিকাশের গতি বাড়ানোর নিরাপদ এবং প্রায়শই সফল পথ| ওষুধ পুনঃপ্রতিষ্ঠা এমন ওষুধগুলি ব্যবহার করে যা নিয়ন্ত্রক অনুমোদন পেয়েছে, ক্লিনিকাল ট্রায়ালগুলিতে ব্যর্থ হয়েছে, বা ক্লিনিকাল ট্রায়ালের পরবর্তী পর্যায়ে রয়েছে, যাতে সুরক্ষা, বিষাক্ততা, গঠন, উত্পাদন পরিকল্পনা ইত্যাদির উপর সংগৃহীত বিস্তারিত তথ্য লাভ করতে পারে| প্রচুর বিদ্যমান ওষুধ রয়েছে যেগুলি কোভিড-১৯ চিকিৎসার জন্য পুনর্বিবেচিত হওয়ার জন্য পরীক্ষা চালাচ্ছে, পাশাপাশি প্রচুর বিদ্যমান ভ্যাকসিনগুলি চোভিড-১৯ প্রতিরোধের জন্য পুনর্বিবেচনার জন্য অধ্যয়ন করা হচ্ছে।উদাহরণস্বরূপ, বায়োফার্মাসিউটিক্যাল সংস্থা মার্ক (Merck) একটি হামের ভ্যাকসিনের উপর ভিত্তি করে একটি পরীক্ষামূলক কোভিড -১৯ ভ্যাকসিন তৈরির জন্য কাজ করছে। অন্য একটি গ্রুপ কোভিড -১৯ থেকে স্বাস্থ্যসেবা কর্মীদের রক্ষা করতে যক্ষ্মার ভ্যাকসিন ব্যাকিলি ক্যালমেট-গুউরিন (বিসিজি) এর কার্যকারিতা অধ্যয়ন করছে; এবং ইমারজেন্ট বায়ো-সল্যুশন সংস্থা কোভিড-১৯ প্রতিরোধের জন্য অ্যান্টি-সারস অ্যান্টিবডিগুলি অধ্যয়ন করার প্রি-ক্লিনিকাল বিকাশ পর্যায়ে রয়েছে। মৌখিক পোলিও ভ্যাকসিন (ওপিভি) আরেকটি বিকল্প যা পূর্বের গবেষণার সূচকগুলির উপর ভিত্তি করে পরীক্ষা করা হচ্ছে যে, ওপিভিটি তে উপকারী এবং রোগ প্রতিরোধ ক্ষমতার জন্য ট্রিগার রয়েছে। পোলিও নির্মূল উদ্যোগের মতে, “বর্তমানে মার্কিন যুক্তরাষ্ট্রের রোগ নিয়ন্ত্রণ ও প্রতিরোধ কেন্দ্র সহ বিভিন্ন অংশীদার এবং ভ্যাকসিন নির্মাতাদের সাথে একটি সমীক্ষা আলোচনা করা হচ্ছে, এর ফলাফলগুলি SARS-CoV2-এর বিস্তার প্রসঙ্গে সম্ভাব্য ব্যবহার নির্ধারণের জন্য সতর্কতার সাথে মূল্যায়ন করা হবে যতক্ষণ পর্যন্ত না নির্দিষ্ট সময়কালে ভ্যাকসিন এবং অ্যান্টিভাইরাল থেরাপি প্রস্তুত হয় \""
    ]
  },
  {
    "id": "recty8XEu0TS4nJuj",
    "Question": "Why has India reported a significant surge in cases of COVID-19?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & transmission",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "India"
    ],
    "Background and context": "India's stringent lockdown measures helped to control the spread of COVID-19 and significantly reduced the rate at which infections doubled by more than half from 4 days to 10 days. However, lockdown measures were lifted right as the country reported a significant surge of cases, particularly populous cities like Delhi and Mumbai, and states like Maharashtra, Gujarat and Tamil Nadu.\n",
    "What our experts say": "Public health experts indicate that lockdown measures in India ended too quickly, just as cases started spiking. The initial lockdown was in effect for 21 days from March 24, 2020, and was extended to May 31, 2020. Following May 31, 2020, the country opened up in phases, and only a few areas continued to place restrictions on movement. Crowded means of transportation, densely packed neighborhoods, and inadequate social distancing have contributed to a steep rise in infections, made worse by a premature end to the lockdown. The end of the lockdown has also sparked a mass exodus of migrant laborers back to their home states, which local health authorities worry has driven the rise in new cases. It's too soon to tell whether the spike in new cases has actually been driven by migrant laborers—increased testing availability has allowed for more cases to be detected, which may also contribute to the increased case count. Experts from the Indian Council of Medical Research noted that India has still not reached the peak of infections, and that cases are likely to continue to rise in the future.\n",
    "Glossary Terms": [
      "rec2UNEXbTkSCx30Q"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\t\n",
    "Topics": [
      "virus",
      "transmission"
    ],
    "Other resources": "1. Covid case count nears 2-lakh mark, ICMR says ‘far away from peak’ ([Indian Express](https://indianexpress.com/article/india/coronavirus-cases-peak-icmr-6439847/))\n2. Global report: India reports surge in Covid-19 cases as lockdown eased ([The Guardian](http://Global report: India reports surge in Covid-19 cases as lockdown eased))\n3. India Coronavirus Map and Case Count ([NYT](https://www.nytimes.com/interactive/2020/world/asia/india-coronavirus-cases.html))\n",
    "DB (French)": [
      "recFM8mp8uXqSjzGE"
    ],
    "DB (Hindi)": [
      "recKPeD5FnTdztpcM"
    ],
    "Media": [
      {
        "id": "atth0YmdJUZh0Ngj6",
        "url": "https://dl.airtable.com/.attachments/691875cdbb7d291489f8d99ea8e95975/2d8f95ea/Indiacasesurge_v13.png",
        "filename": "India case surge_v1 (3).png",
        "size": 121933,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/5cde556f75220036ede9b98ff2a4d535/5a0acf48",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/f1caefac0bdc4bc3cf49092ed08a15a2/4ef17ffe",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d3a185b5884524d555c5784cf3fb93da/e1af2947",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attbvwOt4MykGmWVO",
        "url": "https://dl.airtable.com/.attachments/6cd374dba392c6b84b353ea92959e007/73d84193/Indiacasesurge_v14.png",
        "filename": "India case surge_v1 (4).png",
        "size": 195996,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/385273f5e3b4863874431ec0afebdc75/aa3c2dfc",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/24ae2b4fb23ea99975c3c8bf1df0d71c/acc120e7",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/af0cef205396d51a1d21c6bb8ac19cc0/ea3e2050",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "atteyzIc155VHiCd0",
        "url": "https://dl.airtable.com/.attachments/54eab44bf23f86da4b88efed017e8990/afd7b209/Indiacasesurge_v15.png",
        "filename": "India case surge_v1 (5).png",
        "size": 261435,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/5831529318cd578b44f9412f2c23109b/3891013b",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/258ba7f82c62047c2d58bcf3ab52b07a/642c8038",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ae0c1759d8142db0e531ada947947424/41d39e8e",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attPB6upOFV3oeoZt",
        "url": "https://dl.airtable.com/.attachments/f6af3ce4e49001c4661d42bc2fa5b316/8d342e2d/Indiacasesurge_v16.png",
        "filename": "India case surge_v1 (6).png",
        "size": 349686,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/32080305007eeaf68e22deb4754c362e/b8870ffc",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/f4046a8f2e18a66cf3a8cdb88c59ed80/4ed39d9e",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/22b80b4a06bbcc4d5c722adfb2238fc6/1e170bc3",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att3Y0JFetgActo9X",
        "url": "https://dl.airtable.com/.attachments/cca9606838df1ca5798e922649ed5888/1b7e9846/Indiacasesurge_v17.png",
        "filename": "India case surge_v1 (7).png",
        "size": 352203,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d2ec1eb89982940f48012c283505584f/0e4eecca",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/6dc52b011223a588887d7fd9edffd6f3/ae8435d0",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d3f33adcd560add2c3e38be368f32e48/7a942f58",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recwtj43ptOUogNgT"
    ],
    "DB (Spanish)": [
      "recPPMYRWo5lcrkav"
    ],
    "DB (Bengali)": [
      "recxs9xNzRgQfiGhw"
    ],
    "DB (Portuguese)": [
      "rec8tKp1xLpMn0kh6"
    ],
    "Rollup test 2": [
      "recDIA1rTAWND6hT2"
    ],
    "Media Package": [
      {
        "id": "attcXlJJAJq2WaFdj",
        "url": "https://dl.airtable.com/.attachments/bf08560695a9688fef0809bbe56eea31/714bb006/WhyhasIndiareportedasignificantsurgeincasesofCOVID-19.zip",
        "filename": "Why has India reported a significant surge in cases of COVID-19.zip",
        "size": 1286109,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-06-22",
    "Last edited (simplified)": "2020-06-11T21:51:59.000Z",
    "Last edited (experts say)": "2020-07-07T13:21:46.000Z",
    "Last modified": "2020-06-22",
    "What our experts say wordcount": 185,
    "Background and context wordcount": 60,
    "Other resources wordcount": 35,
    "Wordcount": 280,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Les experts de santé publique indiquent qu’en Inde, les mesures de confinement ont cessé trop rapidement, alors que le nombre de cas augmentait en flèche. Le confinement initial était en vigueur pendant 21 jours à partir du 24 mars 2020 et a été prolongé jusqu’au 31 mai 2020. Après le 31 mai 2020, la réouverture du pays a eu lieu par étapes et seules quelques régions ont continué à restreindre les déplacements. Des moyens de transport bondé, des quartiers densément peuplés et une distanciation physique  inadéquate ont contribué à la forte augmentation des infections, aggravée par une fin prématurée du confinement. La fin du confinement a suscité un exode de travailleurs migrants vers leur état d’origine, qui d’après les autorités sanitaires locales pourrait être la cause de l’augmentation de nouveaux cas. Il est trop tôt pour déterminer si l’augmentation en flèche de nouveaux cas a en fait été causée par les travailleurs migrants. L’accès plus important aux tests a permis de détecter plus de cas, ce qui pourrait aussi contribuer au nombre de cas plus élevé. Les experts du Conseil indien de recherche médicale ont noté que l’Inde n’a pas encore atteint le nombre maximal de cas d’infection et que les cas continueront à augmenter à l’avenir."
    ],
    "French - Background and context": [
      "Les mesures strictes de confinement mises en place en Inde ont aidé à contrôler la propagation de la COVID-19 et à réduire considérablement, de plus de moitié, le taux auquel les infections ont doublé, de quatre à dix jours. Cependant, les mesures de confinement ont été levées alors que le pays signalait une augmentation importante des cas, particulièrement dans des villes peuplées telles que Delhi et Mumbai, et dans des états tels que Maharashtra, Gujarat et Tamil Nadu."
    ],
    "Hindi - What our experts say": [
      "सार्वजनिक स्वास्थ्य विशेषज्ञों का संकेत है कि भारत में लॉकडाउन बहुत जल्दी समाप्त हो गया , जैसे ही मामलों की शुरुआत हुई। प्रारंभिक लॉकडाउन 24 मार्च 2020 से 21 दिनों के लिए प्रभावी था, और इसे 31 मई, 2020 तक बढ़ा दिया गया था। 31 मई, 2020 के बाद, देश चरणों में खुल गया, और केवल कुछ क्षेत्रों ने आंदोलन पर प्रतिबंध जारी रखा। भीड़-भाड़ वाले साधनों के परिवहन, घनी बस्तियों, और अपर्याप्त सामाजिक विकृति ने संक्रमण में तेजी से वृद्धि करने में योगदान दिया है, जो लॉकडाउन के समय से पहले समाप्त होने से बदतर बना दिया। लॉकडाउन के अंत ने प्रवासी मजदूरों के बड़े पैमाने पर पलायन हो के उनके घरेलू राज्यों में वापस भेज दिया है, जो स्थानीय स्वास्थ्य अधिकारियों की चिंता ने नए मामलों में वृद्धि को प्रेरित किया है। यह बताने के लिए बहुत जल्दबाजी होगी कि क्या नए मामलों में वृद्धि वास्तव में प्रवासी मजदूरों द्वारा चलाए गए हैं - बढ़ी हुई परीक्षण उपलब्धता ने अधिक मामलों का पता लगाने की अनुमति दी है, जो कि मामले की बढ़ी हुई संख्या में योगदान कर सकते हैं। इंडियन काउंसिल ऑफ मेडिकल रिसर्च के विशेषज्ञों ने उल्लेख किया कि भारत अभी भी संक्रमण के चरम पर नहीं पहुंचा है, और भविष्य में भी इस तरह के मामलों के बढ़ने की संभावना है।"
    ],
    "Hindi - Background and context": [
      "भारत के कड़े लॉकडाउन उपायों ने कोविड-19 के प्रसार को नियंत्रित करने में मदद की और उस दर को काफी कम कर दिया जिस पर संक्रमण 4 दिनों से लेकर 10 दिनों तक दोगुने से अधिक हो गया। हालाँकि, लॉकडाउन के उपायों को सही तरीके से उठाया गया था क्योंकि देश में दिल्ली और मुंबई जैसे विशेष रूप से आबादी वाले शहरों और महाराष्ट्र, गुजरात और तमिलनाडु जैसे राज्यों में भारी वृद्धि दर्ज की गई थी।"
    ],
    "Telugu - What our experts say": [
      "కేసులు పెరగడం ప్రారంభించినట్లే భారతదేశంలో లాక్డౌన్ చర్యలు చాలా త్వరగా ముగిశాయని ప్రజారోగ్య నిపుణులు సూచిస్తున్నారు. ప్రారంభ లాక్డౌన్ 2020 మార్చి 24 నుండి 21 రోజుల వరకు అమలులో ఉంది మరియు 2020 మే 31 వరకు పొడిగించబడింది. మే 31, 2020 తరువాత, దేశం దశలవారీగా తెరవబడింది మరియు కొన్ని ప్రాంతాలు మాత్రమే కదలికపై ఆంక్షలు విధించడం కొనసాగించాయి. రద్దీగా ఉండే రవాణా మార్గాలు, దట్టంగా నిండిన పొరుగు ప్రాంతాలు మరియు సరిపోని సామాజిక దూరం అంటువ్యాధులు బాగా పెరగడానికి దోహదం చేశాయి, లాక్‌డౌన్‌కు అకాల ముగింపు ద్వారా ఇది మరింత దిగజారింది. లాక్డౌన్ ముగింపు వలస కార్మికులను తిరిగి వారి సొంత రాష్ట్రాలకు తరలించడానికి దారితీసింది, స్థానిక ఆరోగ్య అధికారులు ఆందోళన చెందుతున్నది కొత్త కేసుల పెరుగుదలకు దారితీసింది. ఇది ' క్రొత్త కేసులలో స్పైక్ వాస్తవానికి వలస కార్మికులచే నడపబడిందో లేదో చెప్పడానికి చాలా త్వరగా-పరీక్షా లభ్యత ఎక్కువ కేసులను గుర్తించటానికి అనుమతించింది, ఇది పెరిగిన కేసుల సంఖ్యకు కూడా దోహదం చేస్తుంది. ఇండియన్ కౌన్సిల్ ఆఫ్ మెడికల్ రీసెర్చ్ నిపుణులు భారతదేశం ఇంకా అంటువ్యాధుల గరిష్ట స్థాయికి చేరుకోలేదని, భవిష్యత్తులో కేసులు పెరిగే అవకాశం ఉందని పేర్కొన్నారు."
    ],
    "Telugu - Context and background": [
      "భారతదేశం యొక్క కఠినమైన లాక్డౌన్ చర్యలు కోవిడ్-19 యొక్క వ్యాప్తిని నియంత్రించడంలో సహాయపడ్డాయి మరియు అంటువ్యాధులు 4 రోజుల నుండి 10 రోజులకు సగానికి పైగా రెట్టింపు అయ్యాయి. ఏదేమైనా, దేశం గణనీయమైన కేసులను, ముఖ్యంగా జనాభా కలిగిన నగరాలు Delhi ిల్లీ మరియు ముంబైలను మరియు మహారాష్ట్ర, గుజరాత్ మరియు తమిళనాడు వంటి రాష్ట్రాలను నివేదించడంతో లాక్డౌన్ చర్యలు ఎత్తివేయబడ్డాయి."
    ],
    "Spanish - What our experts say": [
      "Los expertos en salud pública indican que las medidas de confinamiento en India finalizaron demasiado rápido, justo cuando los casos llegaron a un pico. El confinamiento inicial estuvo en efecto por 21 días, desde el 24 de marzo de 2020, y fue extendido hasta el 31 de mayo de 2020. Siguiendo a esta fecha, el país abrió en fases, y solo unas pocas áreas continuaron ejerciendo restricciones al movimiento. Medios de transporte atestados, vecindarios densamente poblados, y distanciamiento social inadecuado han contribuido a un abrupto incremento en infecciones, empeorada por un fin prematuro del confinamiento. El final del mismo también ha desencadenado un éxodo en masa de trabajadores migratorios retornando a sus estados natales, lo cual preocupa a las autoridades sanitarias locales de que haya conducido a una subida en nuevos casos. Es demasiado pronto para decir si el pico en nuevos casos ha sido propulsado por los trabajadores migratorios—la disponibilidad incrementada de exámenes ha permitido que más casos sean detectados, lo cual puede contribuir también al conteo en alza de casos. Los expertos del Consejo Indio de Investigación Médica llamaron la atención al hecho que India todavía no ha alcanzado el pico de infecciones, y que es probable que los casos continúen incrementándose en el futuro."
    ],
    "Spanish - Background and context": [
      "Las medidas de rígido confinamiento de India ayudaron a controlar la dispersión del COVID-19 y redujeron significativamente la tasa a la cual las infecciones se duplicaban en más de la mitad, de 4 a 10 días. Sin embargo, las medidas de confinamiento fueron levantadas justo cuando el país informaba de una significativa oleada de casos, particularmente en ciudades populosas como Delhi y Mumbai, y estados como Maharashtra, Gujarat y Tamil Nadu."
    ],
    "Bengali - What our experts say": [
      "জনস্বাস্থ্য বিশেষজ্ঞরা ইঙ্গিত করেছেন যে, ভারতে লকডাউন ব্যবস্থাগুলি খুব দ্রুত শেষ হয়েছিল, ঠিক যেমন ঘটনাগুলি ছড়িয়ে পড়া শুরু করে। প্রাথমিক লকডাউন ২২ শে মার্চ, ২০২০ থেকে ২১ দিনের জন্য কার্যকর ছিল এবং তা ২০২০ সালের ৩১ মে পর্যন্ত বাড়ানো হয়েছিল। ৩১ শে মে, ২০২০ এর পরে দেশটি পর্যায়ক্রমে উন্মুক্ত হয়েছিল এবং মাত্র কয়েকটি অঞ্চল চলাচলে বিধিনিষেধ অব্যাহত রেখেছে। যানবাহনের যানজট, ঘন ঘিঞ্জি পাড়াগুলি এবং অপর্যাপ্ত সামাজিক দূরত্ব সংক্রমণের তীব্র বৃদ্ধিতে অবদান রেখেছে, লকডাউনের দ্রুত উঠিয়ে নেওয়াই আরও খারাপ হয়েছে। লকডাউন শেষ হওয়ার পরে অভিবাসী শ্রমিকদের তাদের নিজস্ব রাজ্যগুলিতে ফিরে যাওয়ার প্রচারণা শুরু হয়েছে, যা স্থানীয় স্বাস্থ্য কর্তৃপক্ষরা উদ্বেগ প্রকাশ করেছেন যে, নতুন করে ঘটনা বৃদ্ধি পেয়েছে। এটি খুব শীঘ্রই তবুও বলার অপেক্ষা রাখে না যে, নতুন ক্ষেত্রে প্রবৃদ্ধি প্রকৃতপক্ষে অভিবাসী শ্রমিকদের দ্বারা চালিত হয়েছে| পরীক্ষার প্রাপ্যতার বর্ধিততার ফলে আরও কেসগুলি সনাক্ত করা সম্ভব হয়েছে, যা ঘটনা বাড়ার জন্য অবদান রাখতে পারে। ইন্ডিয়ান কাউন্সিল অফ মেডিকেল রিসার্চের বিশেষজ্ঞরা উল্লেখ করেছেন যে, ভারত এখনও সংক্রমণের শিখরে পৌঁছায়নি এবং ভবিষ্যতেও এই ঘটনাগুলি বাড়তে থাকবে বলে মনে করা হচ্ছে।"
    ],
    "Bengali - Background and context": [
      "ভারতের কঠোর লকডাউন ব্যবস্থা কোভিড-১৯ এর বিস্তার নিয়ন্ত্রণ করতে সহায়তা করে এবং সংক্রমণের হারটি যা দিগুণ হচ্ছিল তা অর্ধেকেরও বেশি ৪ দিন থেকে ১০ দিন পর্যন্ত উল্লেখযোগ্যভাবে হ্রাস পেয়েছে। তবে দেশটিতে বিশেষত দিল্লি ও মুম্বাইয়ের মতো জনবহুল শহর এবং মহারাষ্ট্র, গুজরাট এবং তামিলনাড়ুর মতো রাজ্যের ক্ষেত্রে উল্লেখযোগ্য পরিমাণে তীব্র ঘটনা ঘটে বলে লকডাউন ব্যবস্থা গ্রহণ করা হয়েছে|"
    ]
  },
  {
    "id": "recTj4FeSoGfkue5a",
    "Question": "Can tear gas help spread COVID-19?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & tear gas",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Tear gas refers to a group of chemical irritants that are designed to irritate mucous membranes, and cause people to tear, cough, and sneeze. It is used as a method of crowd dispersal during protests. During the recent protests in the United States in the wake of George Floyd's death, police departments across the country used tear gas widely in an effort to disperse crowds. This was widely criticized as a counter-productive and dangerous means of crowd dispersal during the COVID-19 pandemic.\n\n",
    "What our experts say": "Tear gas and other chemical irritants can cause people to cough, sneeze, and take off their face masks, which can increase the spread of COVID-19. This is the case both for people who have symptoms of the virus and those who might not have any symptoms and don't know they are sick. The virus that causes COVID-19 spreads primarily through droplets that are emitted when people exhale, cough, or spit. Tear gas can cause people to cough or scream loudly, which could carry the virus particles much farther than 6 feet (2m) and infect others around them. In addition to inducing coughing, tear gas has also been linked to increased susceptibility to infection in the respiratory tract as well as increased pain and inflammation. A 2014 study found that exposure to tear gas contributed to a significantly higher risk of acute respiratory illnesses (sudden and serious respiratory illnesses). More than 1200 infectious disease and public health professionals have signed a petition opposing the use of tear gas and other respiratory irritants during this pandemic.\n",
    "Glossary Terms": [
      "recuFmN55qfldR6N8",
      "rec2UNEXbTkSCx30Q"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "transmission",
      "tear gas",
      "spread"
    ],
    "Other resources": "1. o-Chlorobenzylidene Malononitrile (CS Riot Control Agent) Associated Acute Respiratory Illnesses in a U.S. Army Basic Combat Training Cohort ([Military Medicine)](https://academic.oup.com/milmed/article/179/7/793/4259353)\n2. Tear Gas (Pepper Spray) Toxicity ([PubMed](https://www.ncbi.nlm.nih.gov/books/NBK544263/))\n3. Teargas and pepper spray will accelerate spread of Covid-19, doctors warn ([The Guardian](https://www.theguardian.com/us-news/2020/jun/06/teargas-coronavirus-george-floyd-protests))\n4. Open letter advocating for an anti-racist public health response to demonstrations against systemic injustice occurring during the COVID-19 pandemic ([Open Letter](https://drive.google.com/file/d/1Jyfn4Wd2i6bRi12ePghMHtX3ys1b7K1A/view))\n\n",
    "How often revision needed": "Monthly",
    "DB (French)": [
      "recBGhn5u9qlxD7a9"
    ],
    "DB (Hindi)": [
      "recOQIzhwZapyh5J3"
    ],
    "Media": [
      {
        "id": "attunIb7iahuJqEAk",
        "url": "https://dl.airtable.com/.attachments/e5e20f088ce0f545cd0be6bf5f5772c3/b45d2158/teargas_v116.png",
        "filename": "teargas_v1 (16).png",
        "size": 174318,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/37afa6697b56006bbe34aaffedf3deba/2bc3e564",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/2188b25db2bdba4148400457453aedb6/573e9f7f",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/26ee3208b471c8000ccdbad73fb05ce6/4a42de63",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attrAwIGD26mOmcIL",
        "url": "https://dl.airtable.com/.attachments/b56b15f7d0c74290dca55a432c767457/5f3714da/teargas_v117.png",
        "filename": "teargas_v1 (17).png",
        "size": 230996,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/a8a60feef358a7e5cc19983620284b0c/7492452d",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/9db1ace0b3eae931e013c59b597309be/fe9eab0a",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/a26056af1640690e0f9368b75e3fecfe/8f55a52d",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "atthGyYSWXX3xa3hw",
        "url": "https://dl.airtable.com/.attachments/c762f73850cc22affa10f8c16b062604/313cc2e3/teargas_v118.png",
        "filename": "teargas_v1 (18).png",
        "size": 176535,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/88d9df04052245d61cddcc69def31dac/0f2aa8e1",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/891350418b3b95916630c103abc064cf/06c638ba",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/99c35a55f7f1e7572bb295cc9b8f86be/2928525d",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attscqPD9y52bV221",
        "url": "https://dl.airtable.com/.attachments/4a5f6230c2d9b23383e599b0cade0f79/53821267/teargas_v119.png",
        "filename": "teargas_v1 (19).png",
        "size": 213162,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/13a72c4ea09c9eba9173783bbdd0b5b3/d272e39f",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/9ea34df457654b83dfbd6ed8b6580431/c34136a1",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/964afd1fc4e703355411b229e2877db5/b382e454",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recVd8MdYCMM7ULIQ"
    ],
    "DB (Spanish)": [
      "recezBG1vx3dV5iCs"
    ],
    "DB (Bengali)": [
      "recWcYfX80eIYWEJt"
    ],
    "DB (Portuguese)": [
      "recxdz7b6UnE6EiJ3"
    ],
    "Rollup test 2": [
      "rec8TEIDvLY2qAbg4"
    ],
    "Media Package": [
      {
        "id": "attd1PTfv5EYK9xNk",
        "url": "https://dl.airtable.com/.attachments/4330ef98a144599d91d97a731ba11909/f829af04/Canteargashelpspreadcovid-19.zip",
        "filename": "Can tear gas help spread covid-19.zip",
        "size": 796472,
        "type": "application/zip"
      }
    ],
    "Last modified manual": "2020-06-22",
    "Last edited (simplified)": "2020-06-16T16:10:21.000Z",
    "Last edited (experts say)": "2020-06-24T19:48:32.000Z",
    "Last modified": "2020-06-22",
    "What our experts say wordcount": 174,
    "Background and context wordcount": 82,
    "Other resources wordcount": 61,
    "Wordcount": 317,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Les gaz lacrymogènes et autres substances chimiques irritantes peuvent causer de la toux et des éternuements chez des personnes qui enlèveraient alors leur couvre-visage, ce qui peut augmenter la propagation de la COVID-19. C’est le cas à la fois pour les personnes qui présentent des symptômes de la COVID-19 et pour celles qui pourraient n’avoir aucun symptôme et ne pas savoir qu’elles sont malades. Le virus responsable de la COVID-19 se propage principalement par des gouttelettes qui sont expulsées quand une personne respire, tousse et crache. À cause des gaz lacrymogènes, les personnes peuvent tousser ou hurler, ce qui pourrait transporter des particules virales au-delà de deux mètres (six pieds) et infecter les autres à proximité. En plus de faire tousser, les gaz lacrymogènes ont été associés à une susceptibilité des voies respiratoires à l’infection, ainsi qu’à une douleur et une inflammation accrues. Une étude de 2014 a démontré que l’exposition à des gaz lacrymogènes entraîne des risques considérablement plus élevés de développer une maladie respiratoire grave (maladies respiratoires graves et soudaines). Plus de 1 200 professionnels de la santé publique et des maladies infectieuses ont signé une pétition pour s’opposer à l’utilisation de gaz lacrymogènes et d’autres irritants respiratoires pendant la pandémie."
    ],
    "French - Background and context": [
      "Les gaz lacrymogènes sont un groupe de produits chimiques irritants conçus pour irriter les membranes muqueuses et faire pleurer, tousser et éternuer les gens. Ils sont utilisés comme moyen de dispersion des foules pendant les manifestations. Lors des manifestations récentes aux États-Unis à la suite du décès de George Floyd, les services de police de ce pays ont largement fait appel aux gaz lacrymogènes afin de disperser les foules. Ce moyen de dispersion des foules a été largement critiqué comme étant contre-productif en ces temps de pandémie de la COVID-19."
    ],
    "Hindi - What our experts say": [
      "आंसू गैस और अन्य रासायनिक अड़चनें लोगों को खांसी, छींकने और उनके चेहरे के मुखौटे उतारने का कारण बन सकती हैं, जिससे कोविड-19 का प्रसार बढ़ सकता है। यह उन दोनों लोगों के लिए है जिनके पास वायरस के लक्षण हैं और जिनके पास कोई लक्षण नहीं है और वे बीमार नहीं हैं। कोविड-19 का कारण बनने वाला वायरस मुख्य रूप से उन बूंदों के माध्यम से फैलता है जो उत्सर्जित होते हैं जब लोग साँस लेते हैं, खांसी करते हैं, या थूकते हैं। आंसू गैस से लोगों को खांसी हो सकती है या जोर से चीख सकता है, जो वायरस के कणों को 6 फीट (2 मी) से ज्यादा दूर तक ले जा सकता है और दूसरों को संक्रमित कर सकता है। खांसी उत्पन्न करने के अलावा, आंसू गैस को श्वसन पथ में संक्रमण के साथ-साथ दर्द और सूजन में वृद्धि के लिए संवेदनशीलता से जोड़ा गया है। 2014 के एक अध्ययन में पाया गया कि आंसू गैस के संपर्क में आने से तीव्र श्वसन संबंधी बीमारियों (अचानक और गंभीर श्वसन संबंधी बीमारियों) का काफी अधिक जोखिम है। 1200 से अधिक संक्रामक रोग और सार्वजनिक स्वास्थ्य पेशेवरों ने इस महामारी के दौरान आंसू गैस और अन्य सांस की जलन का विरोध करने वाली एक याचिका पर हस्ताक्षर किए हैं।"
    ],
    "Hindi - Background and context": [
      "आंसू गैस रासायनिक चिड़चिड़ापन के एक समूह को संदर्भित करता है जो श्लेष्म झिल्ली को जलन करने के लिए डिज़ाइन किया गया है, और लोगों को आंसू, खांसी और छींकने का कारण बनता है। इसका उपयोग विरोध प्रदर्शन के दौरान भीड़ फैलाने की विधि के रूप में किया जाता है। जॉर्ज फ्लॉयड की मौत के बाद संयुक्त राज्य अमेरिका में हालिया विरोध प्रदर्शन के दौरान, देश भर के पुलिस विभागों ने भीड़ को तितर-बितर करने के प्रयास में आंसू गैस का व्यापक रूप से इस्तेमाल किया। कोविड-19 महामारी के दौरान भीड़-प्रसार के एक काउंटर-उत्पादक और खतरनाक साधन के रूप में इसकी व्यापक रूप से आलोचना की गई थी।"
    ],
    "Telugu - What our experts say": [
      "టియర్ గ్యాస్ మరియు ఇతర రసాయన చికాకులు ప్రజలు దగ్గు, తుమ్ము మరియు ఫేస్ మాస్క్‌లను తీయడానికి కారణమవుతాయి, ఇది కోవిడ్-19 యొక్క వ్యాప్తిని పెంచుతుంది. వైరస్ యొక్క లక్షణాలను కలిగి ఉన్నవారికి మరియు ఎటువంటి లక్షణాలు లేని మరియు వారు అనారోగ్యంతో ఉన్నారని తెలియని వారికి కూడా ఇదే పరిస్థితి. కోవిడ్-19 కి కారణమయ్యే వైరస్ ప్రధానంగా ప్రజలు పీల్చే, దగ్గు లేదా ఉమ్మివేసేటప్పుడు విడుదలయ్యే బిందువుల ద్వారా వ్యాపిస్తుంది. కన్నీటి వాయువు ప్రజలు దగ్గుకు లేదా బిగ్గరగా కేకలు వేయడానికి కారణమవుతుంది, ఇది వైరస్ కణాలను 6 అడుగుల (2 మీ) కన్నా చాలా దూరం తీసుకువెళుతుంది మరియు వారి చుట్టూ ఉన్న ఇతరులకు సోకుతుంది. దగ్గును ప్రేరేపించడంతో పాటు, కన్నీటి వాయువు కూడా శ్వాసకోశంలో సంక్రమణకు పెరిగే అవకాశం మరియు పెరిగిన నొప్పి మరియు మంటతో ముడిపడి ఉంది. కన్నీటి వాయువును బహిర్గతం చేయడం వలన తీవ్రమైన శ్వాసకోశ అనారోగ్యాలు (ఆకస్మిక మరియు తీవ్రమైన శ్వాసకోశ అనారోగ్యాలు) ఎక్కువగా వచ్చే ప్రమాదం ఉందని 2014 అధ్యయనం కనుగొంది. ఈ మహమ్మారి సమయంలో టియర్ గ్యాస్ మరియు ఇతర శ్వాసకోశ చికాకులను ఉపయోగించడాన్ని వ్యతిరేకిస్తూ 1200 మందికి పైగా అంటు వ్యాధి మరియు ప్రజారోగ్య నిపుణులు పిటిషన్‌లో సంతకం చేశారు."
    ],
    "Telugu - Context and background": [
      "టియర్ గ్యాస్ అనేది శ్లేష్మ పొరలను చికాకు పెట్టడానికి మరియు ప్రజలు కన్నీటి, దగ్గు మరియు తుమ్ములకు కారణమయ్యే రసాయన చికాకుల సమూహాన్ని సూచిస్తుంది. నిరసనల సమయంలో గుంపు చెదరగొట్టే పద్ధతిగా దీనిని ఉపయోగిస్తారు. జార్జ్ ఫ్లాయిడ్ మరణం నేపథ్యంలో ఇటీవల అమెరికాలో జరిగిన నిరసనల సందర్భంగా, దేశవ్యాప్తంగా పోలీసు విభాగాలు జనాలను చెదరగొట్టే ప్రయత్నంలో టియర్ గ్యాస్‌ను విస్తృతంగా ఉపయోగించాయి. కోవిడ్-19 మహమ్మారి సమయంలో గుంపు చెదరగొట్టడానికి ఇది ప్రతి-ఉత్పాదక మరియు ప్రమాదకరమైన మార్గంగా విస్తృతంగా విమర్శించబడింది."
    ],
    "Spanish - What our experts say": [
      "El gas lacrimógeno y otros irritantes químicos pueden causar que las personas tosan, estornuden y se saquen sus máscaras faciales, lo cual puede incrementar la diseminación del COVID-19. Este es el caso tanto para las personas que tienen síntomas del virus como para aquellas que pudieran no tener ningún síntoma y no saben que están enfermas. El virus que causa al COVID-19 se disemina primariamente a través de gotitas que son emitidas cuando las personas exhalan, tosen o escupen. El gas lacrimógeno puede causar que las personas tosan o griten estentóreamente, lo que puede transportar las partículas del virus mucho más lejos que 6 pies (2 m), e infectar a otros alrededor de ellos. Adicionalmente a la inducción de tos, el gas lacrimógeno también ha sido vinculado a la susceptibilidad incrementada a la infección en el tracto respiratorio, como así también al dolor e inflamación incrementados. Un estudio en 2014 encontró que la exposición al gas lacrimógeno contribuyó a un riesgo significativamente más alto de enfermedades respiratorias agudas (enfermedades respiratorias repentinas y serias). Más de 1200 profesionales en enfermedades infecciosas y de la salud pública han firmado una petición oponiéndose al uso de gas lacrimógeno y otros irritantes respiratorios durante esta pandemia."
    ],
    "Spanish - Background and context": [
      "El gas lacrimógenio se refiere a un grupo de irritantes químicos que están diseñados para irritar las membranas mucosas, y causar que las personas lloren, tosan y estornuden. Es usado como método de dispersión de multitudes durante protestas. Durante las recientes protestas en EE.UU. como consecuencia de la muerte de George Floyd, los departamentos de policía a través del país usaron gas lacrimógeno ampliamente en el esfuerzo de dispersar a las multitudes. Esto fue ampliamente criticado como un medio de dispersión de masas contraproductivo y peligroso durante la pandemia de COVID-19."
    ],
    "Bengali - What our experts say": [
      "টিয়ার গ্যাস এবং অন্যান্য রাসায়নিক জ্বালাপোড়াগুলি মানুষকে কাশি, হাঁচি এবং মুখের মুখোশগুলি সরিয়ে ফেলার কারণ হতে পারে, যা কোভিড-১৯ এর বিস্তার বাড়িয়ে তুলতে পারে। এটি উভয় ক্ষেত্রেই হতে পারে, ভাইরাসের লক্ষণ রয়েছে এমন ব্যক্তিদের এবং যাদের কোনও লক্ষণ বা তারা জানেন না যে তারা অসুস্থ | কোভিড-১৯-এর জন্য দায়ী ভাইরাসটি মূলত জলীয় কণার মাধ্যমে ছড়িয়ে পড়ে, যেগুলি যখন মানুষ নিঃশ্বাস ছাড়ে, কাশি দেয় বা থুতু ফেলে তখন নির্গত হয়। টিয়ার গ্যাস মানুষের কাশি বা চিৎকার ঘটাতে পারে, যা ভাইরাসের কণাকে ৬ ফুট (২ মিটার) থেকে অনেক দূরে ছড়িয়ে দিতে পারে এবং চারপাশের অন্যদের সংক্রামিত করতে পারে। কাশির উদ্ভব করার পাশাপাশি টিয়ার গ্যাস শ্বাসযন্ত্রের সংক্রমণের সাথে সাথে ব্যথা এবং প্রদাহ বৃদ্ধি করার সাথে সংবেদনশীলতা বৃদ্ধির সাথে যুক্ত হয়েছে। ২০১৪ সালের একটি সমীক্ষায় দেখা গেছে যে টিয়ার গ্যাসের সংস্পর্শে তীব্র শ্বাসযন্ত্রের অসুস্থতার (হঠাৎ এবং গুরুতর শ্বাসযন্ত্রজনিত অসুস্থতা) ঝুঁকিতে উল্লেখযোগ্য পরিমাণে ঝুঁকির অবদান রয়েছে। এই মহামারী চলাকালীন সময়ে ১২০০ টিরও বেশি সংক্রামক রোগ এবং জনস্বাস্থ্য পেশাজীবীরা টিয়ার গ্যাস এবং অন্যান্য শ্বাসকষ্টজনিত জ্বালা ব্যবহারের বিরোধিতা করে একটি আবেদনে স্বাক্ষর করেছেন।"
    ],
    "Bengali - Background and context": [
      "টিয়ার গ্যাস একাধিক জ্বালাময়ী রাসায়নিকের যৌগ , যা শ্লেষ্মা ঝিল্লি জ্বালাতন করার জন্য ডিজাইন করা হয়েছিল এবং মানুষের অশ্রু, কাশি এবং হাঁচির সৃষ্টি করে। এটি প্রতিবাদের সময় জনসমাগমের ছত্রভঙ্গ করার পদ্ধতি হিসাবে ব্যবহৃত হয়। জর্জ ফ্লয়েডের মৃত্যুর প্রেক্ষিতে মার্কিন যুক্তরাষ্ট্রে সাম্প্রতিক বিক্ষোভ চলাকালীন, জনসাধারণকে ছত্রভঙ্গ করার প্রয়াসে দেশজুড়ে পুলিশ বিভাগগুলি ব্যাপকভাবে টিয়ার গ্যাস ব্যবহার করেছিল। কোভিড-১৯ মহামারী চলাকালীন সময়ে ভিড় ছড়িয়ে দেওয়ার পাল্টা -হুমকি এবং বিপজ্জনক উপায় হিসাবে এটি ব্যাপকভাবে সমালোচিত হয়েছিল।"
    ]
  },
  {
    "id": "rec74MaH5G2VOowuC",
    "Question": "Why are health experts worried about other infectious disease outbreaks right now? ",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & infectious disease outbreaks",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "The World Health Organization has noted that the COVID-19 pandemic is testing the resilience of other robust health programs that tackle infectious diseases, such as malaria, tuberculosis, or polio. Vaccine programs in lower-and-middle-income countries are at risk of being disrupted by the shift in resources toward COVID-19 response.\n",
    "What our experts say": "The renewed focus on the COVID-19 pandemic and its heavy toll has worried health experts about other infectious disease programs in low- and middle-income countries, such as the distribution of insecticide-treated bednets in sub-Saharan Africa or routine vaccination programs in India. A new modeling analysis released by the World Health Organization shows that disruptions to bednet distribution campaigns could double the number of malaria deaths in 2020 compared to the amount of deaths in 2018 (in the worst case scenario). Health experts are warning that existing vaccination programs or other vector control programs (such as indoor spraying or insecticide-treated bednet distribution campaigns) should be accelerated to prevent other infectious disease outbreaks, even as resources are focused on the COVID-19 pandemic.\n",
    "Glossary Terms": [
      "rec2UNEXbTkSCx30Q",
      "recGSLUQITD8EpuHR"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "transmission",
      "infection",
      "spread"
    ],
    "Other resources": "1. WHO urges countries to move quickly to save lives from malaria in sub-Saharan Africa ([WHO](https://www.who.int/news-room/detail/23-04-2020-who-urges-countries-to-move-quickly-to-save-lives-from-malaria-in-sub-saharan-africa)) \n\n",
    "DB (French)": [
      "recXNKWtIJKt9GD5v"
    ],
    "DB (Hindi)": [
      "recx72V3iggGydtQr"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recf8UnGKq7am5esB"
    ],
    "DB (Spanish)": [
      "recyunhuhloBagLmd"
    ],
    "DB (Bengali)": [
      "recg7KQqUOz6d77te"
    ],
    "DB (Portuguese)": [
      "recR8lIESII2lPLtO"
    ],
    "Last modified manual": "2020-06-19",
    "Last edited (simplified)": "2020-06-17T16:03:43.000Z",
    "Last edited (experts say)": "2020-07-23T16:06:57.000Z",
    "Last modified": "2020-06-19",
    "What our experts say wordcount": 120,
    "Background and context wordcount": 48,
    "Other resources wordcount": 17,
    "Wordcount": 185,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "L’accent renouvelé sur la pandémie de COVID-19 et son lourd bilan a inquiété les experts de la santé au sujet d’autres programmes sur les maladies infectieuses dans les pays à revenu faible et intermédiaire, tels que la distribution de moustiquaires à lit traitées à l’insecticide en Afrique subsaharienne ou les programmes de vaccination systématique en Inde. Une nouvelle analyse de modélisation réalisée par l’Organisation mondiale de la santé démontre que l’interruption des campagnes de distribution de moustiquaires à lit pourrait doubler le nombre de décès causés par la malaria en 2020 comparé au nombre de décès en 2018 (dans le pire des cas). Les experts de la santé préviennent que les programmes de vaccination existants et d’autres programmes de contrôle des vecteurs (tels que les programmes de vaporisation à l’intérieur des bâtiments ou les campagnes de distribution de moustiquaires à lit traitées à l’insecticide) devraient être accélérés afin de prévenir d’autres éclosions de maladies infectieuses, même si les ressources sont actuellement concentrées sur la pandémie de COVID-19."
    ],
    "French - Background and context": [
      "L’Organisation mondiale de la santé a noté que la pandémie de COVID-19 met à l’épreuve la résilience de nos autres programmes de santé robustes qui s’attaquent aux maladies infectieuses telles que la malaria, la tuberculose ou la poliomyélite. Dans les pays à revenu faible et intermédiaire, les programmes de vaccination courent le risque d’être interrompu par la réorientation des ressources vers la lutte contre la COVID-19."
    ],
    "Hindi - What our experts say": [
      "कोविड-19 महामारी और इसके भारी टोल पर नए सिरे से ध्यान केंद्रित करने से स्वास्थ्य विशेषज्ञों को कम और मध्यम आय वाले देशों में अन्य संक्रामक रोग कार्यक्रमों के बारे में चिंतित होना पड़ा है, जैसे कि उप-सहारा अफ्रीका में कीटनाशक-उपचारित बेडनेट का वितरण या भारत में नियमित टीकाकरण कार्यक्रम। विश्व स्वास्थ्य संगठन द्वारा जारी एक नए मॉडलिंग विश्लेषण से पता चलता है कि 2018 में मौतों की मात्रा (सबसे खराब स्थिति में) की तुलना में 2020 में बेडनेट वितरण अभियानों में रुकावट मलेरिया से होने वाली मौतों की संख्या को दोगुना कर सकती है। स्वास्थ्य विशेषज्ञ चेतावनी दे रहे हैं कि मौजूदा टीकाकरण कार्यक्रम या अन्य वेक्टर नियंत्रण कार्यक्रम (जैसे इनडोर छिड़काव या कीटनाशक-उपचार बेडनेट वितरण अभियान) को अन्य संक्रामक रोग के प्रकोप को रोकने के लिए त्वरित किया जाना चाहिए, यहां तक कि संसाधनों पर भी कोविड-19 महामारी पर ध्यान केंद्रित किया जाता है।"
    ],
    "Hindi - Background and context": [
      "विश्व स्वास्थ्य संगठन ने उल्लेख किया है कि कोविड​​-19 महामारी अन्य मजबूत स्वास्थ्य कार्यक्रमों के पलटाव का परीक्षण कर रही है जो संक्रामक रोगों से निपटते हैं, जैसे कि मलेरिया, क्षय या पोलियो। कोविड​​-19 प्रतिक्रिया की ओर संसाधनों में बदलाव से निम्न और मध्यम आय वाले देशों में वैक्सीन कार्यक्रम बाधित होने का खतरा है।"
    ],
    "Telugu - What our experts say": [
      "కోవిడ్-19 మహమ్మారి మరియు దాని భారీ సంఖ్యపై పునరుద్ధరించిన దృష్టి తక్కువ మరియు మధ్య-ఆదాయ దేశాలలో ఇతర అంటు వ్యాధి కార్యక్రమాల గురించి ఆరోగ్య నిపుణులను ఆందోళనకు గురిచేసింది, ఉప-సహారా ఆఫ్రికాలో పురుగుమందుల చికిత్స చేసిన బెడ్‌నెట్‌ల పంపిణీ లేదా సాధారణ టీకా కార్యక్రమాలు భారతదేశం. ప్రపంచ ఆరోగ్య సంస్థ విడుదల చేసిన కొత్త మోడలింగ్ విశ్లేషణ ప్రకారం, బెడ్‌నెట్ పంపిణీ ప్రచారానికి అంతరాయం ఏర్పడటం వల్ల 2018 లో మరణాల సంఖ్యతో పోలిస్తే 2020 లో మలేరియా మరణాల సంఖ్య రెట్టింపు అవుతుంది (చెత్త సందర్భంలో). కోవిడ్-19 మహమ్మారిపై వనరులు కేంద్రీకృతమై ఉన్నప్పటికీ, ఇప్పటికే ఉన్న టీకా కార్యక్రమాలు లేదా ఇతర వెక్టర్ నియంత్రణ కార్యక్రమాలు (ఇండోర్ స్ప్రేయింగ్ లేదా పురుగుమందుల చికిత్స చేసిన బెడ్‌నెట్ పంపిణీ ప్రచారం వంటివి) ఇతర అంటు వ్యాధుల నివారణకు వేగవంతం చేయాలని ఆరోగ్య నిపుణులు హెచ్చరిస్తున్నారు."
    ],
    "Telugu - Context and background": [
      "కోవిడ్-19 మహమ్మారి మలేరియా, క్షయ లేదా పోలియో వంటి అంటు వ్యాధులను పరిష్కరించే ఇతర బలమైన ఆరోగ్య కార్యక్రమాల యొక్క స్థితిస్థాపకతను పరీక్షిస్తోందని ప్రపంచ ఆరోగ్య సంస్థ గుర్తించింది. కోవిడ్-19 ప్రతిస్పందన వైపు వనరులు మారడం వలన తక్కువ మరియు మధ్య-ఆదాయ దేశాలలో వ్యాక్సిన్ కార్యక్రమాలు దెబ్బతినే ప్రమాదం ఉంది."
    ],
    "Spanish - What our experts say": [
      "El renovado foco en la pandemia de COVID-19 y las pesadas pérdidas en consecuencia han preocupado a los expertos en salud acerca de otros programas para enfermedades infecciosas en países de bajos y medianos recursos, tales como la distribución de mosquiteros tratados con insecticida en el África Subsahariana, o los programas de vacunación de rutina en India. Un nuevo análisis de modelo divulgado por la Organización Mundial para la Salud muestra que las interrupciones en las campañas de distribución de mosquiteros pueden duplicar el número de muertes por malaria en 2020, comparado con la cantidad de muertes en 2018 (en un escenario de peor caso). Los expertos en salud están advirtiendo que los programas de vacunación existentes u otros programas de control de vectores (tales como aspersión de interiores o campañas de distribución de mosquiteros tratados con insecticida) debieran ser acelerados para prevenir el brote de otras enfermedades infecciosas, aún si los recursos están enfocados en la pandemia de COVID-19."
    ],
    "Spanish - Background and context": [
      "La Organización Mundial para la Salud ha llamado la atención acerca de que la pandemia de COVID-19 está probando la capacidad de recuperación de otros programas de salud robustos que afrontan enfermedades infecciosas, tales como la malaria, tuberculosis o polio. Los programas de vacunación en países de bajos y medianos recursos están en riesgo de ser interrumpidos por el cambio en recursos hacia la respuesta al COVID-19."
    ],
    "Bengali - What our experts say": [
      "কোভিড -১৯ মহামারীর নতুন দৃষ্টিভঙ্গি এবং এর গুরুতর সংখ্যার কারণে নিম্ন-মধ্যম আয়ের দেশগুলিতে অন্যান্য সংক্রামক রোগ কর্মসূচির বিষয়ে স্বাস্থ্য বিশেষজ্ঞরা উদ্বিগ্ন হয়ে পড়েছেন, যেমন সাব-সাহারান আফ্রিকার আফ্রিকার কীটনাশক-চিকিৎসায় করা মশারি বিতরণ বা ভারতে নিয়মিত টিকাদান কর্মসূচি। বিশ্ব স্বাস্থ্য সংস্থা প্রকাশিত একটি নতুন মডেলিং বিশ্লেষণে দেখা গেছে যে, মশারি বিতরণ অভিযান ব্যাহত হলে ২০১৮ সালে ম্যালেরিয়ার কারণে মৃত্যুর পরিমাণের তুলনায় ২০২০ সালে মৃত্যুর সংখ্যা দ্বিগুণ হতে পারে (সবচেয়ে খারাপ পরিস্থিতিতে)। স্বাস্থ্য বিশেষজ্ঞরা হুঁশিয়ারি দিচ্ছেন যে, বিদ্যমান টিকা কর্মসূচি বা অন্যান্য ভেক্টর নিয়ন্ত্রণ প্রোগ্রামগুলি (যেমন ইনডোর স্প্রে বা কীটনাশক-চিকিৎসা মশারি বিতরণ অভিযান) অন্যান্য সংক্রামক রোগের প্রাদুর্ভাব রোধ করার জন্য ত্বরান্বিত করা উচিত, এমনকি সম্পদগুলি কোভিড-১৯ মহামারীর দিকে নিবদ্ধ থাকলেও।"
    ],
    "Bengali - Background and context": [
      "ওয়ার্ল্ড হেলথ অর্গানাইজেশন উল্লেখ করেছে যে, কোভিড-১৯ মহামারী অন্যান্য মজবুত স্বাস্থ্য প্রোগ্রামগুলির সক্ষমতা পরীক্ষা করছে যা ম্যালেরিয়া, যক্ষা বা পোলিওয়ের মতো সংক্রামক রোগগুলি মোকাবেলা করে। কোভিড-১৯ প্রতিক্রিয়াটির দিকে সম্পদগুলি স্থানান্তরিত হওয়ার কারণে নিম্ন ও মধ্য-আয়ের দেশগুলিতে ভ্যাকসিন প্রোগ্রামগুলি ব্যাহত হওয়ার ঝুঁকি রয়েছে।"
    ]
  },
  {
    "id": "reccgTQWarmDQ9sQ9",
    "Question": "Will recent protests lead to an outbreak or second wave of infections?",
    "Status": "Published",
    "Subcategory": "On: COVID-19 & second wave of infections",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Respiratory viruses are primarily spread through infectious respiratory droplets (coughing, sneezing, and sometimes talking). Close contact (within 6 feet/2 meters) for a prolonged period of time (15 minutes or more) without respiratory protection is considered an exposure risk for COVID-19. While we don't know what the number of cases related to large gatherings, like the recent protests, will look like, it is likely that there will be some. Protestors are encouraged to not only utilize infection prevention measures, but also quarantine at home for 14 days after protesting. \n",
    "What our experts say": "Large gatherings of people in close contact for a prolonged period of time does increase risk for transmission of respiratory viruses. Outdoor protests allow for natural ventilation, and the additional use of masks, eye protection, and social distancing efforts can help reduce risk. While it is unknown if protests will lead to a large increase in the number of cases, it is possible there will be additional cases in the 2 weeks following protests. \n",
    "Glossary Terms": [
      "recvwSSjn9ohOm9fK"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "protest",
      "second wave",
      "outbreak"
    ],
    "Other resources": "1. The Protests will spread the coronavirus ([The Atlantic](https://www.theatlantic.com/health/archive/2020/06/protests-pandemic/612460/)) \n2. The Respiratory Health Risks of Large Crowds ([AATS](https://www.atsjournals.org/doi/full/10.1513/AnnalsATS.201603-177ED))\n3. How to Protect Yourself & Others ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html))\n",
    "DB (French)": [
      "rec0yX8knrSZ8EaTA"
    ],
    "DB (Hindi)": [
      "reci5ZkVYfbId4yH0"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recTxdEKtFXi9OaKH"
    ],
    "DB (Spanish)": [
      "reccTGyy0AeJXZHEj"
    ],
    "DB (Bengali)": [
      "recUw37uD3pe0Q3Lk"
    ],
    "DB (Portuguese)": [
      "recvxEZIBXya8yHLU"
    ],
    "Rollup test 2": [
      "reclDUwNT8ijBj9nt"
    ],
    "Last modified manual": "2020-06-19",
    "Last edited (simplified)": "2020-06-19T00:14:17.000Z",
    "Last edited (experts say)": "2020-06-19T00:21:01.000Z",
    "Last modified": "2020-06-19",
    "What our experts say wordcount": 75,
    "Background and context wordcount": 89,
    "Other resources wordcount": 26,
    "Wordcount": 190,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Les grands rassemblements de personnes se tenant proches les unes des autres pour une période prolongée augmentent les risques de transmission de virus des voies respiratoires. Les manifestations extérieures permettent une ventilation naturelle, et l’utilisation complémentaire de couvre-visages, de protection des yeux, ainsi que les efforts de distanciation physique peuvent aider à réduire les risques. Bien que nous ne sachions pas si les manifestations entraînant une grande augmentation du nombre de cas, il est possible que des cas supplémentaires soient observés dans les deux semaines qui suivent les manifestations."
    ],
    "French - Background and context": [
      "Les virus des voies respiratoires se propagent principalement par des gouttelettes respiratoires infectieuses (toux, éternuements et parfois parler). Un contact proche (moins de deux mètres ou six pieds) pour une période prolongée (15 minutes ou plus) sans protection des voies respiratoires présente un risque d’exposition à la COVID-19. Bien que nous ne sachions pas quel sera le nombre de cas associés aux grands rassemblements tels que les récentes manifestations, il est probable qu’il y en aura. Il est recommandé aux manifestants de non seulement appliquer des mesures de prévention contre les infections, mais aussi d’observer une quarantaine de 14 jours chez eux après avoir manifesté."
    ],
    "Hindi - What our experts say": [
      "लंबे समय तक निकट संपर्क में लोगों की बड़ी भीड़ श्वसन वायरस के संचरण के लिए जोखिम बढ़ाती है। बाहरी विरोध प्राकृतिक वेंटिलेशन के लिए अनुमति देता है, और मास्क, आंखों की सुरक्षा और सामाजिक दूर करने के प्रयासों का अतिरिक्त उपयोग जोखिम को कम करने में मदद कर सकता है। हालांकि यह अज्ञात है कि यदि विरोध प्रदर्शनों की संख्या में बड़ी वृद्धि होगी, तो यह संभव है कि विरोध प्रदर्शनों के बाद 2 सप्ताह में अतिरिक्त मामले होंगे।"
    ],
    "Hindi - Background and context": [
      "श्वसन वायरस मुख्य रूप से संक्रामक सांस की बूंदें (खांसी, छींकने, और कभी-कभी बात करते हुए) के माध्यम से फैलते हैं। सांस की सुरक्षा के बिना लंबे समय तक (15 मिनट या उससे अधिक) के लिए निकट संपर्क (6 फीट / 2 मीटर के भीतर) कोविड-19 के लिए जोखिम माना जाता है। हालांकि हम नहीं जानते कि हालिया विरोध प्रदर्शनों की तरह बड़े समारोहों से संबंधित मामलों की संख्या कितनी होगी, यह संभावना है कि कुछ होगा। प्रदर्शनकारियों को न केवल संक्रमण की रोकथाम के उपायों का उपयोग करने के लिए प्रोत्साहित किया जाता है, बल्कि विरोध करने के 14 दिनों के लिए घर पर संगरोध भी किया जाता है।"
    ],
    "Telugu - What our experts say": [
      "సుదీర్ఘకాలం సన్నిహితంగా ఉన్న వ్యక్తుల పెద్ద సమావేశాలు శ్వాసకోశ వైరస్ల వ్యాప్తికి ప్రమాదాన్ని పెంచుతాయి. బహిరంగ నిరసనలు సహజ వెంటిలేషన్ కోసం అనుమతిస్తాయి మరియు ముసుగులు, కంటి రక్షణ మరియు సామాజిక దూర ప్రయత్నాల అదనపు ఉపయోగం ప్రమాదాన్ని తగ్గించడంలో సహాయపడుతుంది. నిరసనలు కేసుల సంఖ్య పెరగడానికి దారితీస్తుందో తెలియదు, నిరసనల తరువాత 2 వారాల్లో అదనపు కేసులు వచ్చే అవకాశం ఉంది."
    ],
    "Telugu - Context and background": [
      "శ్వాసకోశ వైరస్లు ప్రధానంగా అంటు శ్వాసకోశ బిందువుల ద్వారా వ్యాపిస్తాయి (దగ్గు, తుమ్ము మరియు కొన్నిసార్లు మాట్లాడటం). శ్వాసకోశ రక్షణ లేకుండా సుదీర్ఘకాలం (15 నిమిషాలు లేదా అంతకంటే ఎక్కువ) సన్నిహిత సంబంధాన్ని (6 అడుగులు / 2 మీటర్లలోపు) కోవిడ్-19 కొరకు బహిర్గతం చేసే ప్రమాదంగా భావిస్తారు. పెద్ద ఎత్తున సమావేశాలకు సంబంధించిన కేసుల సంఖ్య, ఇటీవలి నిరసనల మాదిరిగా ఎలా ఉంటుందో మాకు తెలియదు, అయితే కొన్ని ఉండవచ్చు. నిరసనకారులను సంక్రమణ నివారణ చర్యలను ఉపయోగించుకోవడమే కాకుండా, నిరసన తెలిపిన తరువాత 14 రోజులు ఇంట్లో నిర్బంధాన్ని కూడా ప్రోత్సహిస్తారు."
    ],
    "Spanish - What our experts say": [
      "Las grandes reuniones de personas en contacto cercano por un periodo prolongado de tiempo incrementan el riesgo de transmisión de virus respiratorios. Las protestas al aire libre permiten la ventilación natural, y el uso adicional de máscaras, protección ocular y esfuerzos para el distanciamiento social pueden ayudar a reducirlo. Mientras que no es conocido si las protestas conducirán a un gran incremento en el número de casos, es posible que vayan a haber casos adicionales en las 2 semanas posteriores a las mismas."
    ],
    "Spanish - Background and context": [
      "Los virus respiratorios son diseminados principalmente a través de gotitas respiratorias infecciosas (al toser, estornudar y a veces al hablar). El contacto cercano (dentro de los 6 pies/2 metros) por un periodo prolongado de tiempo (15 minutos o más) sin protección respiratoria está considerado como un riesgo de exposición para el COVID-19. Mientras que no conocemos a cuánto se acercará el número de casos relacionados con grandes reuniones, como las protestas recientes, es probable que algunos habrá. Los manifestantes son alentados a no solamente utilizar medidas para la prevención de infecciones, sino también a hacer cuarentena domiciliaria por 14 días luego de las protestas."
    ],
    "Bengali - What our experts say": [
      "দীর্ঘ সময় ধরে নিবিড় সংস্পর্শে থাকা মানুষের বিশাল সমাবেশ শ্বাসযন্ত্রের ভাইরাস সংক্রমণের ঝুঁকি বাড়ায়। বহিরঙ্গনে বিক্ষোভ প্রাকৃতিক বায়ুচলাচল এবং পাশাপাশি মাস্কের ব্যবহার, চোখের সুরক্ষা এবং সামাজিক দূরত্বের প্রচেষ্টা ঝুঁকি হ্রাস করতে সহায়তা করে। যদিও এটি অজানা যে বিক্ষোভের ফলে ঘটনার সংখ্যা বৃদ্ধি পাবে কি না, তবে প্রতিবাদের পরে ২ সপ্তাহে অতিরিক্ত ঘটনা হওয়ার সম্ভাবনা রয়েছে।"
    ],
    "Bengali - Background and context": [
      "শ্বাস প্রশ্বাসের ভাইরাসগুলি প্রাথমিকভাবে সংক্রামক শ্বাস প্রশ্বাসেরজলীয় কণা (কাশি, হাঁচি এবং কখনও কখনও কথা বলার) মাধ্যমে ছড়িয়ে পড়ে। শ্বাসযন্ত্রের সুরক্ষা ছাড়াই (15 মিনিট বা তার বেশি) দীর্ঘমেয়াদী সময়ের জন্য কাছাকাছি অবস্থান (৬ ফুট / ২ মিটারের মধ্যে) কোভিড-১৯-এর জন্য এক্সপোজার ঝুঁকি হিসাবে বিবেচিত হয়। যদিও আমরা জানি না যে সাম্প্রতিক প্রতিবাদের মতো বড় বড় সমাবেশের সাথে সম্পর্কিত ঘটনার সংখ্যা কেমন হবে, সম্ভবত কিছু হবে| প্রতিবাদকারীদের কেবল সংক্রমণ প্রতিরোধ ব্যবস্থা ব্যবহার করার সাথে, প্রতিবাদ করার পরে ১৪ দিনের জন্য বাড়িতে কোয়ারান্টাইন ব্যবহার করতে উৎসাহিত করা হয়।"
    ]
  },
  {
    "id": "recr69VbqahSOTu3Y",
    "Question": "Does wearing gloves protect against or stop the spread of COVID-19?",
    "Status": "Published",
    "Category": "Spread",
    "Subcategory": "On: COVID-19 & wearing gloves",
    "Source of the question": [
      "Fact-checking organization"
    ],
    "Country question was sourced from": [
      "Nigeria"
    ],
    "Background and context": "Sterile gloves, when properly worn and properly disposed of, can be a helpful element in protecting against infectious disease. However, if a person is not wearing gloves correctly, not putting them on correctly, or not disposing of them correctly, it defeats the purpose of wearing gloves. It is important to remember that any germs that someone comes into contact with, can be on a person's gloves, and can then be transferred to any other surface that the gloves touch. It also can give people a false sense of security while wearing gloves, and can result in people touching surfaces and items more freely, then touching their faces, which can lead to self-contamination with the virus. Wearing gloves is only an effective protection when the person wearing them follows the right protective methods. If they aren't followed, it can lead to contamination with a virus. \n",
    "What our experts say": "Wearing gloves does not directly protect against spread of the virus. COVID-19 is thought to spread primarily through small drops of moisture (respiratory droplets) that are released when a person infected with COVID-19 coughs, talks, or sneezes. Those drops can then land on the faces of people, surfaces, and items nearby. Wearing new and sterile gloves is not as effective as 20 seconds of hand washing with soap and water, but they can help you avoid touching an infected surface or item with your bare hands. Keep in mind that gloves can only prevent infection if you **don't touch your face** with your gloved hands, and only if **you take off and dispose of the gloves correctly** before washing your hands. \nIt is also important to remember to touch as few surfaces and items as possible if you are wearing gloves in order to avoid contaminating surfaces and spreading COVID-19 to more people. Remember that the best way to prevent spreading or getting infected with COVID-19 is through washing your bare hands for 20 seconds with water and soap, maintaining at least six feet of physical distance between yourself and others, and regularly washing and disinfecting surfaces in your household.\nFor people caring for, or in contact with, people who have been infected with COVID-19, wearing gloves can help make sure the caretaker doesn't touch dangerous substances that come from the sick person's body, like mucus from a sneeze, urine, blood, feces, or other fluids. \n",
    "Glossary Terms": [
      "recUAN8C73rkuPWX9",
      "rec5yviiSvJkufYvu",
      "rec39wm7MuK12bTI3"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "drop",
      "droplet",
      "gloves",
      "hand washing",
      "prevention",
      "transmission",
      "spread"
    ],
    "Other resources": "1. How COVID-19 spreads ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html)) \n2. Outline of the evidence and considerations on medical glove use to prevent germ transmission ([WHO](https://www.who.int/gpsc/5may/Glove_Use_Information_Leaflet.pdf)) \n3. Hand Hygiene: Why, How & When? ([WHO](https://www.who.int/gpsc/5may/Hand_Hygiene_Why_How_and_When_Brochure.pdf)) \n4. Wearing-gloves ([WHO](https://www.who.int/news-room/ebola-photos/detail/images/default-source/searo---images/countries/bangladesh/infographics/ask-who-social-distancing/english/wearing-gloves))\n",
    "DB (French)": [
      "recrYDVoINSZiwvJh"
    ],
    "DB (Hindi)": [
      "recKr9zDEV3KkIoty"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recQePLvZ2hOWolSV"
    ],
    "DB (Spanish)": [
      "rec9AiFjwXyfKzSMx"
    ],
    "DB (Arabic)": [
      "rectUJA5ZFu1Yk3Vm"
    ],
    "DB (Bengali)": [
      "recRdFef9qJKNqeTy"
    ],
    "DB (Portuguese)": [
      "recseg6t7kSGV8ST8"
    ],
    "Rollup test 2": [
      "recyhIE6zUC90ioVp"
    ],
    "Last modified manual": "2020-06-15",
    "Last edited (simplified)": "2020-05-15T23:56:44.000Z",
    "Last edited (experts say)": "2020-06-13T19:40:30.000Z",
    "Last modified": "2020-06-15",
    "What our experts say wordcount": 245,
    "Background and context wordcount": 145,
    "Other resources wordcount": 33,
    "Wordcount": 423,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Arabic Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Le port de gants ne protège pas directement contre la propagation du virus. L’on pense que la COVID-19 se propage principalement par des gouttelettes qui proviennent du système respiratoire et qui sont expulsées quand une personne atteinte de la COVID-19 tousse, parle ou éternue. Ces gouttelettes peuvent ensuite se déposer sur les visages de personnes, sur des surfaces et des objets à proximité. Le port de gants neufs et stériles n’est pas aussi efficace qu’un lavage des mains de 20 secondes au savon et à l’eau, mais ils peuvent vous empêcher de toucher à mains nues une surface ou un objet infecté. Gardez à l’esprit que les gants ne peuvent prévenir les infections que si vous ne touchez pas votre visage avec vos mains gantées, et seulement si vous ôtez vos gants et les jetez correctement avant de vous laver les mains.\nIl est aussi important de vous souvenir de toucher le moins de surfaces et d’objets possible si vous portez des gants afin d’éviter de contaminer les surfaces et de propager le coronavirus à d’autres personnes. Souvenez-vous que la meilleure façon d’éviter de propager le virus et de prévenir la COVID-19 est de vous laver les mains nues pendant 20 secondes avec de l’eau et du savon, de garder une distance d’au moins deux mètres ou six pieds entre vous et les autres, et de laver et de désinfecter régulièrement les surfaces de votre maison.\nPour les personnes qui apportent des soins à des personnes atteintes par la COVID-19 ou qui sont en contact avec elles, le port de gants peut aider à garantir que la personne qui prodigue les soins ne touche pas des substances dangereuses qui proviennent du corps de la personne malade, telles que le mucus d’un éternuement, l’urine, le sang, les matières fécales ou d’autres liquides."
    ],
    "French - Background and context": [
      "S’ils sont portés et retirés correctement, des gants stériles peuvent être un élément utile pour se protéger contre les maladies infectieuses. Cependant, si une personne ne porte pas correctement ses gants, ne les enfile ou ne les jette correctement, cela va à l’encontre du port de gants. Il est important de se rappeler que tout germe avec lequel une personne entre en contact peut se trouver sur les gants de cette personne et peut ensuite être transféré sur les autres surfaces que les gants touchent. Le port de gants peut aussi donner aux gens un faux sentiment de sécurité et les amener à toucher plus librement surfaces et objets, puis à toucher ensuite leur visage et entraîner une autocontamination par le virus. Le port de gants n’est une protection efficace que si la personne qui les porte suit les bonnes méthodes de protection. Si ce n’est pas le cas, une contamination par un virus peut s’en suivre."
    ],
    "Hindi - What our experts say": [
      "ग्लव्ज़ (दस्ताने) पहनने से सीधे वायरस के फैलने से बचाव नहीं होता है। कोविड​​-19 मुख्य रूप से नमी की छोटी बूंदों (साँस की बूंदों) के माध्यम से फैलता है जो कोविड​​-19 संक्रमित व्यक्ति की खाँसी, बातचीत, या छींक के द्वारा फैलता है। वे बूंदें लोगों के चेहरे, सतहों और आस-पास की वस्तुओं पर पहुँचती  हैं। नए और साफ़ ग्लव्ज़ पहनना उतने प्रभावी नहीं हैं, जितना कि साबुन और पानी से 20 सेकंड हाथ धोना। लेकिन ग्लव्ज़ आपके हाथों से संक्रमित सतह या वस्तु को छूने से बचने में आपकी मदद कर सकते हैं। ध्यान रखें कि दस्ताने संक्रमण को तभी रोक सकते हैं यदि आप अपने चेहरे को अपने हाथों से नहीं छूते हैं, और केवल तभी जब आप अपने हाथों को धोने से पहले दस्ताने को सही ढंग से उतारते और हटाते हैं।\n\nयदि आप सतहों को दूषित करने और अधिक लोगों को कोविड​​-19 फैलाने से बचने के लिए दस्ताने पहन रहे हैं तो यह याद रखना भी महत्वपूर्ण है कि जितना संभव हो उतना कम सतहों और वस्तुओं को छूए। याद रखें कि कोविड​​-19 से फैलने या संक्रमित होने से बचाने का सबसे अच्छा तरीका है कि आप अपने हाथों को 20 सेकंड तक पानी और साबुन से धोएं, अपने और दूसरों के बीच कम से कम छह फीट की शारीरिक दूरी बनाए रखें और नियमित रूप से घर की सतहों को साफ़ करें।\nजो कोविड​​-19 से संक्रमित लोगों की देखभाल करने या संपर्क में आने वाले लोग हैं, उनके लिए दस्ताने पहनना सहायक हो सकते है, ताकि वे यह सुनिश्चित कर सके कि रोगी के शरीर से आने वाले खतरनाक पदार्थों, जैसे छींक से बलगम, मूत्र, रक्त, मल, या अन्य तरल पदार्थ को वे नहीं छूए।"
    ],
    "Hindi - Background and context": [
      "स्टेरायल ग्लव्ज़ जब ठीक से पहने गए हों और ठीक से फेंके गए हों, तो संक्रामक बीमारी से बचाने में मददगार हो सकते हैं। हालांकि, अगर कोई व्यक्ति सही ढंग से दस्ताने नहीं पहन रहा है, या उन्हें सही तरीके से नहीं उतार रहा है, तो यह दस्ताने पहनने के उद्देश्य को हरा देता है। यह याद रखना महत्वपूर्ण है कि कोई भी रोगाणु जो किसी के संपर्क में आता है, किसी व्यक्ति के दस्ताने पर हो सकता है, और फिर किसी अन्य सतह पर स्थानांतरित किया जा सकता है जो दस्ताने स्पर्श करते हैं। यह लोगों को दस्ताने पहनने के दौरान सुरक्षा की झूठी भावना दे सकता है, और परिणामस्वरूप लोगों को सतहों और वस्तुओं को अधिक स्वतंत्र रूप से  छूने को प्रेरित करता है, फिर लोग अपने चेहरे को छूतें हैं, जिससे वायरस के साथ सेल्फ़-कंटैमिनेशन हो सकता है। दस्ताने पहनना केवल एक प्रभावी सुरक्षा तब है जब उन्हें पहनने वाला व्यक्ति सही सुरक्षात्मक तरीकों का पालन करता है। यदि उनका पालन नहीं किया जाता है, तो यह एक वायरस फैलाने का कारण बन सकते हैं।"
    ],
    "Telugu - What our experts say": [
      "చేతి తొడుగులు ధరించడం వైరస్ వ్యాప్తి నుండి నేరుగా రక్షించదు. కోవిడ్-19 ప్రధానంగా చిన్న చుక్కల తేమ (శ్వాసకోశ బిందువుల) ద్వారా వ్యాప్తి చెందుతుందని భావిస్తారు, ఇది కోవిడ్-19 దగ్గు, చర్చలు లేదా తుమ్ములతో సోకినప్పుడు విడుదల అవుతుంది. ఆ చుక్కలు అప్పుడు ప్రజలు, ఉపరితలాలు మరియు సమీప వస్తువుల ముఖాలపైకి వస్తాయి. కొత్త మరియు శుభ్రమైన చేతి తొడుగులు ధరించడం సబ్బు మరియు నీటితో 20 సెకన్ల చేతులు కడుక్కోవడం అంత ప్రభావవంతంగా ఉండదు, కానీ మీ చేతులతో సోకిన ఉపరితలం లేదా వస్తువును తాకకుండా ఉండటానికి ఇవి మీకు సహాయపడతాయి. మీ చేతి తొడుగులతో మీ ముఖాన్ని తాకకపోతే మాత్రమే చేతి తొడుగులు సంక్రమణను నివారించగలవని గుర్తుంచుకోండి మరియు మీ చేతులు కడుక్కోవడానికి ముందు చేతి తొడుగులు తీసివేసి సరిగ్గా పారవేస్తేనే.\n\nకలుషితమైన ఉపరితలాలు మరియు కోవిడ్-19 ను ఎక్కువ మందికి వ్యాప్తి చేయకుండా ఉండటానికి మీరు చేతి తొడుగులు ధరిస్తే వీలైనంత తక్కువ ఉపరితలాలు మరియు వస్తువులను తాకడం కూడా గుర్తుంచుకోవాలి. కోవిడ్-19 బారిన పడకుండా లేదా వ్యాధి బారిన పడకుండా ఉండటానికి ఉత్తమమైన మార్గం ఏమిటంటే, మీ చేతులను 20 సెకన్ల పాటు నీరు మరియు సబ్బుతో కడగడం, మీ మరియు ఇతరుల మధ్య కనీసం ఆరు అడుగుల శారీరక దూరాన్ని నిర్వహించడం మరియు మీలోని ఉపరితలాలను క్రమం తప్పకుండా కడగడం మరియు క్రిమిసంహారక చేయడం. గృహ.\n\nకోవిడ్-19 బారిన పడిన వ్యక్తుల కోసం, చేతి తొడుగులు ధరించి, సంరక్షణాధికారి అనారోగ్య వ్యక్తి శరీరం నుండి వచ్చే తుమ్ము, మూత్రం, రక్తం, మలం లేదా ఇతర ద్రవాలు."
    ],
    "Telugu - Context and background": [
      "శుభ్రమైన చేతి తొడుగులు, సరిగ్గా ధరించినప్పుడు మరియు సరిగా పారవేసేటప్పుడు, అంటు వ్యాధి నుండి రక్షించడంలో సహాయపడే అంశం. అయినప్పటికీ, ఒక వ్యక్తి చేతి తొడుగులు సరిగ్గా ధరించకపోతే, వాటిని సరిగ్గా ఉంచకపోయినా, లేదా వాటిని సరిగ్గా పారవేయకపోయినా, అది చేతి తొడుగులు ధరించే ఉద్దేశ్యాన్ని ఓడిస్తుంది. ఎవరైనా సంపర్కానికి వచ్చే ఏవైనా సూక్ష్మక్రిములు ఒక వ్యక్తి యొక్క చేతి తొడుగులపై ఉండవచ్చని, ఆపై చేతి తొడుగులు తాకిన ఇతర ఉపరితలాలకు బదిలీ చేయవచ్చని గుర్తుంచుకోవడం ముఖ్యం. ఇది చేతి తొడుగులు ధరించేటప్పుడు ప్రజలకు తప్పుడు భద్రతా భావాన్ని ఇవ్వగలదు మరియు ప్రజలు ఉపరితలాలు మరియు వస్తువులను మరింత స్వేచ్ఛగా తాకడం, తరువాత వారి ముఖాలను తాకడం, ఇది వైరస్‌తో స్వీయ-కలుషితానికి దారితీస్తుంది. చేతి తొడుగులు ధరించడం సరైన రక్షణ పద్ధతులను అనుసరించినప్పుడు మాత్రమే సమర్థవంతమైన రక్షణ. వాటిని పాటించకపోతే, అది వైరస్‌తో కలుషితానికి దారితీస్తుంది."
    ],
    "Spanish - What our experts say": [
      "Usar guantes no protege directamente contra la diseminación del virus. Se piensa que el COVID-19 se disemina primariamente a través de pequeñas gotas de humedad (gotitas respiratorias) que son lanzadas cuando una persona infectada con COVID-19 tose, habla o estornuda. Esas gotas luego pueden posarse sobre las caras de las personas, superficies, e ítems cercanos. Usar guantes nuevos y estériles no es tan efectivo como 20 segundos de lavado de manos con agua y jabón, pero puede ayudar a evitarte tocar un ítem o superficie infectada con tus manos desnudas. Ten en mente que los guantes solamente pueden prevenir la infección si no tocas tu cara con las manos enguantadas, y solamente si te los sacas y dispones de ellos correctamente antes de lavar tus manos.\nTambién es importante recordar tocar la menor cantidad de superficies e ítems como sea posible si estás usando guantes, para evitar contaminar estas superficies y diseminar el COVID-19 a más personas. Recuerda que la mejor manera de prevenir la diseminación o infectarse con COVID-19 es mediante el lavado de tus manos desnudas por 20 segundos con agua y jabón, manteniendo al menos dos metros de distancia física entre tú y otros, y lavando y desinfectando regularmente las superficies en tu hogar.\nPara las personas que están cuidando o están en contacto con otras que han sido infectadas con el COVID-19, usar guantes puede ayudar a asegurar que el cuidador no toque sustancias peligrosas que provengan del cuerpo de la persona enferma, como moco producido por un estornudo, orina, sangre, heces, u otros fluidos."
    ],
    "Spanish - Background and context": [
      "Los guantes estériles, cuando son correctamente usados y descartados, pueden ser un elemento útil en la protección contra enfermedades infecciosas. Sin embargo, si una persona no está usándolos, colocándolos o descartándolos correctamente, el propósito de su uso queda anulado. Es importante recordar que cualquier gérmen con el que alguien haya entrado en contacto puede estar en los guantes de una persona, y luego puede ser transferido hacia cualquier otra superficie que toquen los guantes. También pueden dar a las personas un falso sentido de seguridad mientras están usándolos, y puede resultar en que toquen superficies e ítems más libremente, y luego sus caras, lo que puede conducir a autocontaminación con el virus. Usar guantes solamente es una protección efectiva cuando quien los usa sigue los métodos de protección correctos. Si no lo hace, esto puede conducir a contaminación con un virus."
    ],
    "Arabic - What our experts say": [
      "إن ارتداء القفازات لا يحمي بشكل مباشر من انتشار الفيروس. يُعتَقد أن كوفيد-19 ينتشر في المقام الأول من خلال قطرات صغيرة من الرطوبة (قطرات الجهاز التنفسي) التي يتم إطلاقها عندما يُصاب شخص ما بسُعال كوفيد-19 أو حينما يتحدث أو يعطس. يمكن أن تقع هذه القطرات بعد ذلك على وجوه الأشخاص والأسطح والعناصر القريبة. إن ارتداء قفازات جديدة ومعقمة ليس فعالا مثل غسل اليدين بالماء والصابون لمدة 20 ثانية، ولكن يمكنها أن تساعدك على تجنب لمس سطح أو عنصر مصاب بيديك العاريتين. ضع في اعتبارك أن القفازات يمكن أن تمنع العدوى فقط إذا لم تلمس وجهك بيديك وأنت ترتدي القفاز، بل فقط إذا خلعت القفازات وتخلصت منها بشكل صحيح قبل غسل يديك.\nمن المهم أيضا أن تتجنب لمس أقل عدد ممكن من الأسطح والعناصر إذا كنت ترتدي قفازات لتجنب تلويث الأسطح ونشر كوفيد-19 لعدد أكبر من الناس. تذكر أن أفضل طريقة لمنع الانتشار أو الإصابة بِـــكوفيد-19 هي من خلال غسل يديك العاريتين لمدة 20 ثانية بالماء والصابون، والحفاظ على مسافة ستة أقدام (مترين تقريبا) على الأقل بينك وبين الآخرين، وغسل وتعقيم الأسطح بانتظام في منزلك.\nبالنسبة للأشخاص الذين يقومون برعاية الأشخاص المصابين بعدوى كوفيد-19 أو الذين يتعاملون معهم، فإن ارتداء القفازات يمكن أن يساعد في التأكد من أن القائم بالرعاية لا يلمس المواد الخطرة التي تأتي من جسم المريض، مثل المخاط النابع من العطس أو البول أو الدم أو البراز أو السوائل الأخرى للجسم."
    ],
    "Arabic - Background and context": [
      "يمكن للقفازات المعقمة، عند ارتدائها بشكل صحيح والتخلص منها بشكل صحيح، أن تشكل عنصرا مفيدا في الحماية من الأمراض المعدية. ومع ذلك، إذا كان الشخص لا يرتدي القفازات بشكل صحيح، أو لا يضعها بشكل صحيح، أو لا يتخلص منها بشكل صحيح، لا يحقق الغرض من ارتداء القفازات. من المهم أن تتذكر أن الجراثيم التي تقع على شخصا ما، يمكن أن تكون على قفازات ذلك الشخص، ومن ثَمَّ يمكن نقلها إلى أي سطح آخر تلمسه القفازات. كما يمكن أن يمنح الأشخاص إحساسا زائفا بالأمان أثناء ارتداء القفازات، ويمكن أن يؤدي إلى لمس الأشخاص للأسطح والعناصر بحرية أكبر، ثم لمس وجوههم، مما قد يؤدي إلى الإصابة بالفيروس. ارتداء القفازات هو حماية فعالة فقط عندما يتبع الشخص الذي يرتديها طرق الحماية الصحيحة. إذا لم يتم اتباعها، فقد يؤدي ذلك إلى الإصابة بالفيروس."
    ],
    "Bengali - What our experts say": [
      "হাতমোজা পরা সরাসরি ভাইরাসের বিস্তার থেকে রক্ষা করে না। কোভিড-১৯ মূলত আর্দ্রতার ছোট ফোঁটা (শ্বাস প্রশ্বাসের ফোঁটা) এর মাধ্যমে ছড়িয়ে যায় যা কোভিড-১৯আক্রান্ত ব্যক্তির কাশি, আলাপচারিতা বা হাঁচি দ্বারা বের হয়। এই ফোঁটাগুলি তখন মানুষের মুখ, উপরিভাগ এবং আশেপাশের বস্তুগুলিতে অবতরণ করতে পারে। সাবান এবং পানি দিয়ে ২০ সেকেন্ড হাত ধোয়া যতটা কার্যকর নতুন এবং জীবাণুমুক্ত হাতমোজা পরা ততটা কার্যকর নয়, তবে এগুলো আপনাকে আপনার খালি হাতে কোনও সংক্রামিত পৃষ্ঠ বা বস্তু স্পর্শ করা এড়াতে সহায়তা করতে পারে। মনে রাখবেন যে, হাতমোজা কেবল তখনই সংক্রমণ রোধ করতে পারে যদি আপনি আপনার মজা পড়া হাত দিয়ে আপনার মুখটি স্পর্শ না করেন, এবং কেবল যদি আপনি হাত ধোওয়ার আগে মোজাগুলি সঠিকভাবে খলেন এবং সরিয়ে ফেলেন। মনে রাখা জরুরী, আরও বেশি লোকের মধ্যে কোভিড-১৯ না ছড়িয়ে দেওয়ার জন্য যদি আপনি হাতমোজা পরে থাকেন তবে যতটা সম্ভব কম পৃষ্ঠতল এবং বস্তুগুলি স্পর্শ করা উচিত। মনে রাখবেন যে, কোভিড-১৯-এ সংক্রমণ ছড়াতে বা আক্রান্ত হওয়ার প্রতিরোধের সর্বোত্তম উপায় হ'ল ২০ সেকেন্ডের জন্য আপনার খালি হাত পানি এবং সাবান দিয়ে ধুয়ে ফেলা, নিজের এবং অন্যদের মধ্যে কমপক্ষে ছয় ফুট শারীরিক দূরত্ব বজায় রাখা এবং নিয়মিত বাড়ির মেঝে ধুয়ে ফেলা এবং জীবাণুমুক্ত করা। যেসব লোক কোভিড-১৯-এ সংক্রামিত হয়েছে, তাদের যত্ন নেওয়া বা তাদের সংস্পর্শে থাকা লোকেরা অসুস্থ ব্যক্তির শরীর থেকে আসা ঝুঁকিপূর্ণ পদার্থগুলির যেমন হাঁচি, প্রস্রাব, রক্ত, মল বা অন্যান্য তরল স্পর্শ থেকে মুক্ত থাকতে হাতমোজা পরিধান করতে পারে।"
    ],
    "Bengali - Background and context": [
      "জীবাণুমুক্ত হাতমোজা, যখন সঠিকভাবে পরা এবং সঠিকভাবে সরানো হয় তখন সংক্রামক রোগ থেকে রক্ষা করতে সহায়ক উপাদান হতে পারে। তবে, যদি কোনও ব্যক্তি সঠিকভাবে হাতমোজা না পরে থাকে, সেগুলি সঠিকভাবে না রাখে বা সঠিকভাবে তা না সরায় , তবে এটি হাতমোজা পরার উদ্দেশ্যটি নষ্ট করে। এটি মনে রাখা গুরুত্বপূর্ণ যে, যে কোনও জীবাণু যদি সংস্পর্শে আসে সে কোনও ব্যক্তির হাতমোজায় থাকতে পারে এবং তার পরে হাতমোজা দ্বারা স্পর্শ করা অন্য কোনও পৃষ্ঠে স্থানান্তরিত হতে পারে। এটি হাতমোজা পরা অবস্থায় লোকেদের সুরক্ষার একটি মিথ্যা ধারণাও দিতে পারে এবং এর ফলে লোকেরা আরও অবাধে পৃষ্ঠতল এবং বস্তুগুলি স্পর্শ করতে পারে, তারপরে তাদের মুখ স্পর্শ করতে পারে, যা ভাইরাসের সাথে স্ব-দূষিত হতে পারে। হাতমোজা পরা তখনই একটি কার্যকর সুরক্ষা যখন সেগুলি পরা ব্যক্তি সঠিক সুরক্ষামূলক পদ্ধতি অনুসরণ করে। যদি এগুলি অনুসরণ না করা হয় তবে এটি কোনও ভাইরাসের সংক্রমণের কারণ হতে পারে।"
    ]
  },
  {
    "id": "recUvk0IltcWA8G8O",
    "Question": "Can face masks be shared? ",
    "Status": "Published",
    "Subcategory": "On: COVID-19 and face masks",
    "Source of the question": [
      "Fact-checking organization"
    ],
    "Country question was sourced from": [
      "Nigeria"
    ],
    "Background and context": "Personal protective equipment (PPE) should be single-person use and not shared between people unless it is able to be disinfected, like facehsields or goggles. Masks become contaminated during use and pose a risk if shared between people. The only exception to this would be if a fabric mask is appropriately washed and dried in a dryer (high temp) between uses. \n",
    "What our experts say": "No. Personal protective equipment that cannot be disinfected, like a cloth or surgical mask, should not be shared between people. Over time, these masks become dirty and have wear and tear. Since masks come into contact with our mouth and nose, they easily become contaminated and should not be shared. \n",
    "Glossary Terms": [
      "reclKahoPRbBLqUKg"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "face masks",
      "prevention",
      "respiratory droplets",
      "aerosol"
    ],
    "Other resources": "1. N95 Respirators, Surgical Masks, and Face Masks ([U.S. FDA](https://www.fda.gov/medical-devices/personal-protective-equipment-infection-control/n95-respirators-surgical-masks-and-face-masks)) \n",
    "DB (French)": [
      "recBbIwmcDGuUcsGR"
    ],
    "DB (Hindi)": [
      "recjqzoOLEwA1mSPs"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recH8Jl9RdNSvbVE0"
    ],
    "DB (Spanish)": [
      "rec0ucfXo84jjmsyC"
    ],
    "DB (Bengali)": [
      "recI7zOT1BfOmdOFD"
    ],
    "DB (Portuguese)": [
      "recj8aG7ZvoKuVsFd"
    ],
    "Last modified manual": "2020-06-14",
    "Last edited (simplified)": "2020-06-04T20:55:29.000Z",
    "Last edited (experts say)": "2020-06-13T19:44:13.000Z",
    "Last modified": "2020-06-14",
    "What our experts say wordcount": 51,
    "Background and context wordcount": 61,
    "Other resources wordcount": 11,
    "Wordcount": 123,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Non. Les équipements de protection individuelle qui ne peuvent pas être désinfectés, tels que les masques chirurgicaux et les couvre-visages en tissu ne devraient pas être partagés. Au fur et à mesure de leur utilisation, ces masques et couvre-visages se salissent, peuvent s’user et se déchirer. Dans la mesure où les masques et les couvre-visages sont en contact avec votre bouche et votre nez, ils deviennent facilement contaminés et ne devraient pas être partagés."
    ],
    "French - Background and context": [
      "Les équipements de protection individuelle (ÉPI) devraient n’être utilisés que par une seule personne sans être partagés, à moins que, telles les visières et les lunettes de protection, ils puissent être désinfectés. Les masques et les couvre-visages deviennent contaminés à l’usage et posent un risque s’ils sont partagés entre différentes personnes. La seule exception serait un couvre-visage en tissu lavé adéquatement et séché dans une sécheuse (à haute température) entre chaque utilisation."
    ],
    "Hindi - What our experts say": [
      "नहीं। व्यक्तिगत सुरक्षा उपकरण (पी॰पी॰ई॰ ) जिन्हें डिसिन्फ़ेक्ट नहीं किया जा सकता है, जैसे कि कपड़े के मास्क या सर्जिकल मास्क, उन्हें लोगों के बीच साझा नहीं किया जाना चाहिए। समय के साथ, ये मास्क गंदे हो जाते हैं और खराब हो जाते हैं। चूंकि मास्क हमारे मुंह और नाक के संपर्क में आते हैं, वे आसानी से दूषित हो जाते हैं और उन्हें साझा नहीं किया जाना चाहिए।"
    ],
    "Hindi - Background and context": [
      "व्यक्तिगत सुरक्षा उपकरण (PPE) का उपयोग एक ही व्यक्ति को करना चाहिए और लोगों के बीच साझा नहीं किया जाना चाहिए जब तक कि इसे कीटाणुरहित (डिसिंफ़ेक्ट) नहीं किया गया हो। उपयोग के दौरान मास्क दूषित हो जाते हैं और लोगों के बीच साझा किए जाने पर जोखिम पैदा करते हैं।"
    ],
    "Telugu - What our experts say": [
      "క్రిమిసంహారక చేయలేని వ్యక్తిగత రక్షణ పరికరాలు, వస్త్రం లేదా శస్త్రచికిత్స ముసుగు వంటివి ప్రజల మధ్య పంచుకోకూడదు. కాలక్రమేణా, ఈ ముసుగులు మురికిగా మారతాయి మరియు దుస్తులు మరియు కన్నీటిని కలిగి ఉంటాయి. ముసుగులు మన నోరు మరియు ముక్కుతో సంబంధంలోకి వస్తాయి కాబట్టి, అవి సులభంగా కలుషితమవుతాయి మరియు వాటిని పంచుకోకూడదు."
    ],
    "Telugu - Context and background": [
      "వ్యక్తిగత రక్షణ పరికరాలు (పిపిఇ) సింగిల్-పర్సన్ వాడకం అయి ఉండాలి మరియు ఫేస్హీల్డ్స్ లేదా గాగుల్స్ వంటి క్రిమిసంహారక చేయలేకపోతే తప్ప ప్రజల మధ్య పంచుకోకూడదు. ముసుగులు ఉపయోగంలో కలుషితమవుతాయి మరియు వ్యక్తుల మధ్య పంచుకుంటే ప్రమాదం ఉంటుంది. ఫాబ్రిక్ మాస్క్‌ను ఉపయోగాల మధ్య ఆరబెట్టేది (హై టెంప్) లో తగిన విధంగా కడిగి ఎండబెట్టితే దీనికి మినహాయింపు ఉంటుంది."
    ],
    "Spanish - What our experts say": [
      "No. El equipamiento de protección personal que no pueda ser desinfectado, como un paño o máscara quirúrgica, no debiera ser compartido entre personas. Luego de un tiempo, estas máscaras se tornan sucias y tienen desgaste. Como las mismas entran en contacto con nuestra nariz y boca, son fácilmente contaminadas, y no debieran ser compartidas."
    ],
    "Spanish - Background and context": [
      "El equipamiento de protección personal (EPP) debiera ser usado por una única persona y no compartido entre personas a menos que sea capaz de ser desinfectado, como escudos faciales o antiparras. Las máscaras se tornan contaminadas durante el uso y constituyen un riesgo si son compartidas entre personas. La única excepción a esto sería si una máscara de tejido es apropiadamente lavada y secada en un secador (de alta temperatura) entre usos."
    ],
    "Bengali - What our experts say": [
      "না। ব্যক্তিগত সুরক্ষামূলক সরঞ্জামগুলি যা কোনও কাপড় বা অস্ত্রোপচারের মাস্কের মতো জীবাণুমুক্ত করা যায় না, সেগুলি মানুষের মধ্যে শেয়ার করা উচিত নয়। সময়ের সাথে সাথে, এই মাস্কগুলি নোংরা হয়ে যায় এবং ছিঁড়ে যায়। যেহেতু মাস্কগুলি আমাদের মুখ এবং নাকের সংস্পর্শে আসে, সেগুলি সহজেই দূষিত হয়ে যায় এবং তাদের শেয়ার করা উচিত নয়।"
    ],
    "Bengali - Background and context": [
      "ব্যক্তিগত প্রতিরক্ষামূলক সরঞ্জামগুলি (পিপিই) একক-ব্যক্তি ব্যবহারের হওয়া উচিত এবং ফেসশিল্ড বা চশমার মতো জীবাণুমুক্ত হতে সক্ষম না হলে লোকের মধ্যে শেয়ার করা উচিত নয়। মাস্কগুলি ব্যবহারের সময় দূষিত হয়ে যায় এবং মানুষের সাথে শেয়ার করা হলে ঝুঁকি তৈরি করে। এটির একমাত্র ব্যতিক্রম হবে যদি কোনও কাপড়ের মাস্ক ব্যবহারের পূর্বে যথাযথভাবে ধুয়ে এবং একটি ড্রায়ারে (উচ্চ তাপে) শুকানো হয়।"
    ]
  },
  {
    "id": "recf6cuE8pK9p9UeO",
    "Question": "What does it mean for a study to be a pre-print?",
    "Status": "Published",
    "Category": "Research",
    "Subcategory": "On: Pre-print studies",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "To be considered high quality, valid, significant, original, and suitable for publication in a scientific journal, studies must complete a peer-review process. As these published studies could potentially influence clinical practices and public health behaviour, this process acts as a filter to ensure every study meets the strict requirements of each journal, causing many studies not to be accepted or published once they go through peer reviews. Pre-print studies have not yet passed the peer-review process so scientists urge caution not to draw any conclusions from pre-print studies. \nThe peer review and publication processes are time-consuming, frequently involving more than a year between submission and publication. The process is also highly competitive. \nPeer-reviewed articles provide a trusted form of scientific communication. Even if you are unfamiliar with the topic or the scientists who authored a particular study, you can trust peer-reviewed work to meet certain standards of scientific quality. Since scientific knowledge is cumulative and builds on itself, this trust is particularly important.\nAfter submission of a pre-print study to a journal, the journal's editors send the article to several other scientists who work in the same field (i.e., the \"peers\" of peer review). Those reviewers provide feedback on the article and tell the editor whether or not they think the study is of high enough quality to be published. The authors may then revise their article and resubmit it for consideration. Only articles that meet good scientific standards (e.g., acknowledge and build upon other work in the field, rely on logical reasoning and well-designed studies, back up claims with evidence, etc.) are accepted for publication.\n\n",
    "What our experts say": "Pre-print studies are studies that have been completed but haven't gone through the peer-review process that most scientific journals require for publishing.\nPre-prints provide new data and information, which is important in a pandemic. However the details in a pre-print study, such as: how the study was designed and conducted, what sample sizes were included, what assumptions were made, and how calculations were done, have not been scrutinized by the journal's reviewers and editors. The process of scrutinizing a pre-print study is what the peer-review process consist of. Most websites that publish pre-print articles suggest that these articles should not be reported in the news as established information or used to guide clinical practice or health-related behavior. \nUntil the studies are scrutinized by reviewers, they should not be assumed to be factually correct or inform any actions.\n",
    "Glossary Terms": [
      "rec8sQHhdcKiEVR9f"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "Pre-print",
      "studies",
      "methodologies",
      "peer-review"
    ],
    "Other resources": "1. medRxiv: The Preprint Server for Health Sciences ([medRxiv](https://www.medrxiv.org)) \n2. What are Preprints, and How Do They Benefit Authors? ([AJE Scholar](https://www.aje.com/arc/benefits-of-preprints-for-researchers/)) \n",
    "DB (French)": [
      "recC1x2wLaMrtU222"
    ],
    "DB (Hindi)": [
      "recRcgVlVdN7XkmOg"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recgABCodtNT0js4V"
    ],
    "DB (Spanish)": [
      "reczW4wcKo4kOuZYx"
    ],
    "DB (Bengali)": [
      "rechzr58nRfPRll5y"
    ],
    "DB (Portuguese)": [
      "recSA2XmlLoLZ3Z58"
    ],
    "Rollup test 2": [
      "recdXmqLWEhcp3KYz"
    ],
    "Last modified manual": "2020-06-14",
    "Last edited (simplified)": "2020-05-27T22:45:05.000Z",
    "Last edited (experts say)": "2020-06-13T19:18:50.000Z",
    "Last modified": "2020-06-14",
    "What our experts say wordcount": 136,
    "Background and context wordcount": 263,
    "Other resources wordcount": 22,
    "Wordcount": 421,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Les études prépubliées sont des études achevées, mais qui n’ont pas encore été évaluées par des pairs comme la plupart des journaux scientifiques l’exigent avant publication.\n\nLes études prépubliées présentent de nouvelles données et de nouveaux renseignements, ce qui est important dans le cadre d’une pandémie. Cependant, dans une étude prépubliée, les détails tels que : comment l’étude a-t-elle été conçue et menée, quelles tailles d’échantillon comprenait-elle, quelles hypothèses ont été posées et comment les calculs ont-ils été effectués, non pas minutieusement été examinés par les lecteurs experts ni par les éditeurs du journal. Le contrôle par les pairs consiste en un examen minutieux de l’étude. La plupart des sites Web qui prépublient des articles suggèrent que ces derniers ne devraient pas être cités dans les nouvelles en tant que sources bien établies de renseignements ni être utilisés afin de guider une pratique clinique ou un comportement lié à la santé.\nTant que les études n’ont pas été examinées avec minutie par les lecteurs experts, il ne devrait pas être présumé qu’elles sont exactes sur le fond ni être la base d’actions."
    ],
    "French - Background and context": [
      "Pour que les études soient considérées de haute qualité, valides, significatives, originales et susceptibles d’être publiées dans un journal scientifique, elles doivent faire l’objet d’un contrôle par les pairs. Comme ces études publiées seraient susceptibles d’influencer les pratiques cliniques et les comportements de santé publique, ce contrôle agit en tant que filtre pour garantir que l’étude répond aux exigences strictes de chaque journal. C’est pourquoi de nombreuses études ne sont ni acceptées ni publiées une fois qu’elles ont été évaluées par des pairs. Les études prépubliées n’ont pas encore été évaluées par des pairs, et les scientifiques incitent à la prudence afin qu’aucune conclusion ne soit tirée d’études prépubliées.\nLe contrôle par les pairs et la publication prennent du temps et demandent fréquemment plus d’un an de la proposition de l’étude à sa publication. Ce processus est aussi hautement compétitif.\nLes articles évalués par les pairs présentent une forme fiable de communication scientifique. Même si vous ne connaissez ni le sujet ni les scientifiques qui ont rédigé une étude particulière, vous pouvez vous attendre à ce qu’un travail évalué par les pairs respecte certaines normes de qualité scientifique. Dans la mesure où la connaissance scientifique est cumulative et se construit d’elle-même, cette confiance est particulièrement importante. Après qu’une étude prépubliée a été présentée à un journal, les rédacteurs du journal envoient l’article à plusieurs autres scientifiques qui travaillent dans le même domaine (c.-à-d. les « pairs » du contrôle par les pairs). Ces lecteurs experts donnent une rétroaction sur l’article et disent au rédacteur s’ils pensent que l’étude est d’assez grande qualité pour être publiée ou non. Les auteurs peuvent alors réviser leur article et le présenter de nouveau. Seuls les articles qui se conforment à de bonnes normes scientifiques (p. ex., qui reconnaissent d’autres travaux dans le domaine et se fondent sur eux, qui s’appuient sur un raisonnement logique et des études bien conçues, qui étayent ce qu’ils avancent par des données probantes, etc.) sont acceptés en vue d’être publiés."
    ],
    "Hindi - What our experts say": [
      "प्री-प्रिंट अध्ययन ऐसे अध्ययन हैं जो पूरे हो चुके हैं लेकिन सहकर्मी-समीक्षा प्रक्रिया (पीयर-रिव्यू) से अभी नहीं गुजरे हैं, जो की  प्रकाशित करने के लिए अधिकांश वैज्ञानिक पत्रिकाओं की आवश्यकता होती है। \nप्री-प्रिंट नए डेटा और जानकारी प्रदान करते हैं, जो एक महामारी में महत्वपूर्ण है। हालांकि प्री-प्रिंट अध्ययन में विस्तृत सूचना, जैसे: अध्ययन कैसे डिजाइन और आयोजित किया गया था, कितने लोग शामिल थे, क्या धारणाएं बनाई गई थीं, और गणना कैसे की गई थी, इसकी समीक्षा पत्रिका के समीक्षकों और संपादकों द्वारा नहीं की गई है। प्री-प्रिंट अध्ययन की जांच की प्रक्रिया में सहकर्मी-समीक्षा प्रक्रिया होती है। प्री-प्रिंट लेख प्रकाशित करने वाली अधिकांश वेबसाइटें बताती हैं कि इन लेखों को समाचार में स्थापित जानकारी या नैदानिक ​​अभ्यास (क्लिनिकल प्रैक्टिस) के मार्गदर्शन करने के लिए या फिर स्वास्थ्य संबंधी व्यवहार के रूप में रिपोर्ट नहीं किया जाना चाहिए।\nजब तक समीक्षकों द्वारा अध्ययन की जांच नहीं की जाती है, तब तक उन्हें तथ्यात्मक रूप से सही नहीं माना जाना चाहिए या किसी भी कार्रवाई को इन प्रयोगों से सूचित नहीं करना चाहिए।"
    ],
    "Hindi - Background and context": [
      "उच्च गुणवत्ता, मान्य, महत्वपूर्ण, मूल और वैज्ञानिक पत्रिका में प्रकाशन के लिए उपयुक्त माने ने के लिए, अध्ययन को एक सहकर्मी-समीक्षा प्रक्रिया (पीयर-रिव्यू) को पूरा करना पड़ता है। चूंकि ये प्रकाशित अध्ययन संभावित रूप से नैदानिक ​​प्रथाओं और सार्वजनिक स्वास्थ्य व्यवहार को प्रभावित कर सकते हैं, यह प्रक्रिया एक फिल्टर के रूप में कार्य करती है ताकि यह सुनिश्चित किया जा सके कि प्रत्येक अध्ययन प्रत्येक पत्रिका की सख्त आवश्यकताओं को पूरा करता है, जिसके कारण कई अध्ययनों को स्वीकार या प्रकाशित नहीं किया जाता है, जब वे सहकर्मी समीक्षाओं से गुजरते हैं। प्री-प्रिंट अध्ययनों ने अभी तक सहकर्मी-समीक्षा प्रक्रिया पारित नहीं की होती है, इसलिए वैज्ञानिक सावधानी बरतने का अनुरोध करते है, ताकि प्री-प्रिंट अध्ययनों से कोई निष्कर्ष न निकाला जा सके। सहकर्मी की समीक्षा और प्रकाशन प्रक्रिया समय लेने वाली होती है, अक्सर प्रस्तुत करने और प्रकाशन के बीच एक वर्ष से अधिक समय तक शामिल होता है। प्रक्रिया भी अत्यधिक प्रतिस्पर्धी होती है।\nपीयर-रिव्यू लेख वैज्ञानिक संचार का एक विश्वसनीय रूप प्रदान करते हैं। यहां तक​​कि अगर आप विषय से या वैज्ञानिक जो की किसी विशेष अध्ययन के लेखक हैं, उनसे अपरिचित हैं, तो भी आप सहकर्मी- समीक्षा के काम को वैज्ञानिक गुणवत्ता के मापदंड को पूरा करने का भरोसा कर सकते हैं। चूँकि वैज्ञानिक ज्ञान संचयी है और अपने से पहले किए गए कामों के आधार पर बढ़ाया जाता है, इसलिए यह विश्वास विशेष रूप से महत्वपूर्ण है।\nएक जर्नल को प्री-प्रिंट अध्ययन प्रस्तुत करने के बाद, जर्नल के संपादक लेख को कई अन्य वैज्ञानिकों को भेजते हैं जो उसी क्षेत्र में काम करते हैं (यानी, सहकर्मी-समीक्षा के \"सहकर्मियों\" को)। वे समीक्षक लेख पर प्रतिक्रिया प्रदान करते हैं और संपादक को बताते हैं कि उन्हें लगता है कि अध्ययन प्रकाशित होने के लिए उच्च गुणवत्ता वाला है या नहीं। लेखक तब अपने लेख को संशोधित कर सकते हैं और विचार के लिए दोबारा प्रस्तुत कर सकते हैं। केवल ऐसे लेख जो अच्छे वैज्ञानिक माप-दंड को पूरा करते हैं (उदाहरण के लिए, पहले के किए कामों को स्वीकृति एवं मान्यता देते हुए उस क्षेत्र में अन्य काम को आगे बढ़ाते हैं, तर्क और अच्छी तरह से डिजाइन किए गए अध्ययनों पर आधारित हैं, सबूत के साथ दावे का दावा करते हैं) प्रकाशन के लिए स्वीकार किए जाते हैं।"
    ],
    "Telugu - What our experts say": [
      "ప్రీ-ప్రింట్ స్టడీస్ అనేది చాలా శాస్త్రీయ పత్రికలు ప్రచురణకు అవసరమయ్యే పీర్-రివ్యూ ప్రాసెస్ ద్వారా పూర్తి కాని అధ్యయనాలు.\nప్రీ-ప్రింట్లు కొత్త డేటా మరియు సమాచారాన్ని అందిస్తాయి, ఇది మహమ్మారిలో ముఖ్యమైనది. అయితే ముందస్తు ముద్రణ అధ్యయనంలో వివరాలు: అధ్యయనం ఎలా రూపొందించబడింది మరియు నిర్వహించబడింది, ఏ నమూనా పరిమాణాలు చేర్చబడ్డాయి, ఏ అంచనాలు జరిగాయి మరియు లెక్కలు ఎలా జరిగాయి, పత్రిక యొక్క సమీక్షకులు మరియు సంపాదకులు పరిశీలించలేదు. ప్రీ-ప్రింట్ అధ్యయనాన్ని పరిశీలించే ప్రక్రియ ఏమిటంటే, పీర్-రివ్యూ ప్రాసెస్‌లో ఉంటుంది. ప్రీ-ప్రింట్ కథనాలను ప్రచురించే చాలా వెబ్‌సైట్లు ఈ కథనాలను వార్తలలో స్థాపించబడిన సమాచారంగా నివేదించవద్దని లేదా క్లినికల్ ప్రాక్టీస్ లేదా ఆరోగ్య సంబంధిత ప్రవర్తనకు మార్గనిర్దేశం చేయడానికి ఉపయోగించవద్దని సూచిస్తున్నాయి.\nఅధ్యయనాలు సమీక్షకులచే పరిశీలించబడే వరకు, అవి వాస్తవంగా సరైనవిగా భావించకూడదు లేదా ఏదైనా చర్యలను తెలియజేయకూడదు."
    ],
    "Telugu - Context and background": [
      "అధిక నాణ్యత, చెల్లుబాటు అయ్యే, ముఖ్యమైన, అసలైనదిగా మరియు శాస్త్రీయ పత్రికలో ప్రచురించడానికి అనువైనదిగా పరిగణించబడటానికి, అధ్యయనాలు పీర్-రివ్యూ ప్రాసెస్‌ను పూర్తి చేయాలి. ఈ ప్రచురించిన అధ్యయనాలు క్లినికల్ పద్ధతులు మరియు ప్రజారోగ్య ప్రవర్తనను ప్రభావితం చేయగలవు కాబట్టి, ఈ ప్రక్రియ a ప్రతి అధ్యయనం ప్రతి పత్రిక యొక్క కఠినమైన అవసరాలను తీర్చగలదని నిర్ధారించడానికి వడపోత, పీర్ సమీక్షల ద్వారా వెళ్ళిన తర్వాత అనేక అధ్యయనాలు అంగీకరించబడవు లేదా ప్రచురించబడవు. ప్రీ-ప్రింట్ అధ్యయనాలు ఇంకా పీర్-రివ్యూ ప్రాసెస్‌లో ఉత్తీర్ణత సాధించలేదు కాబట్టి శాస్త్రవేత్తలు ఏదైనా డ్రా చేయవద్దని హెచ్చరిస్తున్నారు ప్రీ-ప్రింట్ అధ్యయనాల నుండి తీర్మానాలు.\nతోటివారి సమీక్ష మరియు ప్రచురణ ప్రక్రియలు సమయం తీసుకుంటాయి, తరచూ సమర్పణ మరియు ప్రచురణల మధ్య సంవత్సరానికి పైగా ఉంటాయి. ఈ ప్రక్రియ కూడా చాలా పోటీగా ఉంటుంది.\nపీర్-సమీక్షించిన కథనాలు శాస్త్రీయ సమాచార మార్పిడి యొక్క విశ్వసనీయ రూపాన్ని అందిస్తాయి. మీకు ఈ అంశం గురించి తెలియకపోయినా లేదా ఒక నిర్దిష్ట అధ్యయనాన్ని రచించిన శాస్త్రవేత్తలైనా, శాస్త్రీయ నాణ్యత యొక్క కొన్ని ప్రమాణాలకు అనుగుణంగా మీరు పీర్-సమీక్షించిన పనిని విశ్వసించవచ్చు. శాస్త్రీయ జ్ఞానం సంచితమైనది మరియు దానిపై ఆధారపడి ఉంటుంది కాబట్టి, ఈ నమ్మకం చాలా ముఖ్యమైనది.\nఒక పత్రికకు ప్రీ-ప్రింట్ అధ్యయనాన్ని సమర్పించిన తరువాత, జర్నల్ యొక్క సంపాదకులు వ్యాసాన్ని అదే రంగంలో పనిచేసే అనేక ఇతర శాస్త్రవేత్తలకు పంపుతారు (అనగా, పీర్ సమీక్ష యొక్క \"\" తోటివారు \"\"). ఆ సమీక్షకులు వ్యాసంపై అభిప్రాయాన్ని అందిస్తారు మరియు అధ్యయనం ప్రచురించబడేంత నాణ్యమైనదని వారు భావిస్తున్నారా లేదా అని ఎడిటర్‌కు తెలియజేస్తారు. రచయితలు వారి వ్యాసాన్ని సవరించవచ్చు మరియు దానిని పరిశీలన కోసం తిరిగి సమర్పించవచ్చు. మంచి శాస్త్రీయ ప్రమాణాలకు అనుగుణంగా ఉన్న వ్యాసాలు (ఉదా., ఈ రంగంలో ఇతర పనులను గుర్తించి, నిర్మించడం, తార్కిక తార్కికం మరియు చక్కగా రూపొందించిన అధ్యయనాలపై ఆధారపడటం, సాక్ష్యాలతో వాదనలను బ్యాకప్ చేయడం మొదలైనవి) మాత్రమే ప్రచురణకు అంగీకరించబడతాయి."
    ],
    "Spanish - What our experts say": [
      "Los estudios pre-impresión son estudios que han sido completados pero no han pasado a través del proceso de revisión por pares que la mayoría de las revistas científicas requieren para publicar.\nLas pre-impresiones proveen nuevos datos e información, lo cual es importante en una pandemia. Sin embargo, los detalles en un estudio pre-impresión, tales como: cómo fue diseñado y conducido el estudio, que tamaños de muestras fueron incluidos, que suposiciones fueron hechas, y cómo fueron efectuados los cálculos no ha sido escrutados por los revisores y editores de la revista. El proceso de escrutar un estudio pre-impresión es en lo que consiste el proceso de revisión por pares. La mayoría de los sitios web que publican artículos pre-impresión sugieren que estos artículos no debieran ser reportados en las noticias como información establecida o usada para guiar la práctica clínica o los comportamientos relacionados con la salud.\nHasta que los estudios sean escrutados por revisores, no debieran asumirse como factualmente correctos o informar acción alguna."
    ],
    "Spanish - Background and context": [
      "Para ser considerados de alta calidad, válidos, significativos, originales y adecuados para su publicación en una revista científica, los estudios deben completar un proceso de revisión por pares. Como estos estudios publicados pueden influir potencialmente a las prácticas clínicas y al comportamiento de la salud pública, este proceso actúa como un filtro para asegurar que todos los estudios reúnen los requerimientos estrictos de cada revista, causando que muchos estudios no sean aceptados o publicados una vez que han pasado revisones por pares. Los estudios pre-impresión aún no han pasado por el proceso de revisión por pares, por lo que los científicos urgen precaución para no sacar ninguna conclusión a partir de los mismos. Los procesos de revisión por pares y de publicación consumen tiempo, frecuentemente involucrando más de un año entre el envío y la publicación. El proceso también es altamente competitivo.\nLos artículos revisados por pares proveen una forma confiable de comunicación científica. Aún si no estás familiarizado con el tópico o los científicos autores de un estudio en particular, puedes confiar en que el trabajo revisado por pares reúna ciertos estándares de calidad científica. Dado que el conocimiento científico es acumulativo y se construye sobre sí mismo, esta confianza es particularmente importante.\nLuego del envío de un estudio pre-impresión a una revista, sus editores envían el artículo a varios otros científicos que trabajan en el mismo campo (es decir, los \"pares\" de la revisión por pares). Esos revisores proveen valoraciones sobre el artículo y le dicen al editor si piensan o no que el estudio tiene la calidad suficiente para ser publicado. Los autores pueden revisar su artículo y reenviarlo para consideración. Solamente los artículos que cumplan con buenos estándares científicos (ej.: que reconozcan y construyan sobre otros trabajos en el mismo campo, confíen en razonamiento lógico y estudios bien diseñados, respalden afirmaciones con evidencia, etc.) son aceptados para publicación."
    ],
    "Bengali - What our experts say": [
      "প্রাক-মুদ্রণ অধ্যয়নগুলি এমন পড়াশোনা যা সমাপ্ত হয়েছে তবে পাক্ষিক পর্যালোচনা প্রক্রিয়াটি সম্পন্ন হয়নি যা বেশিরভাগ বৈজ্ঞানিক জার্নাল প্রকাশের জন্য প্রয়োজন। প্রাক-মুদ্রণ নতুন উপাত্ত এবং তথ্য সরবরাহ করে যা মহামারীতে গুরুত্বপূর্ণ। তবে প্রাক-মুদ্রণ সমীক্ষায় বিশদ যেমন যেমন: গবেষণাটি কীভাবে ডিজাইন করা হয়েছিল এবং পরিচালিত হয়েছিল, কী কী নমুনা আকারকে অন্তর্ভুক্ত করা হয়েছিল, কী অনুমান করা হয়েছিল এবং কীভাবে গণনা করা হয়েছিল তা জার্নালের পর্যালোচক এবং সম্পাদকরা যাচাই করে দেখেননি। প্রাক-মুদ্রণ সমীক্ষার যাচাই করার প্রক্রিয়াটি পাক্ষিক পর্যালোচনা প্রক্রিয়াটি অন্তর্ভুক্ত করে। বেশিরভাগ ওয়েবসাইট যা প্রাক-মুদ্রণ নিবন্ধগুলি প্রকাশ করে তাদের পরামর্শ দেয় যে, এই নিবন্ধগুলিকে খবরে প্রতিষ্ঠিত তথ্য হিসাবে রিপোর্ট করা উচিত নয় বা ক্লিনিকাল অনুশীলন বা স্বাস্থ্য সম্পর্কিত আচরণের নির্দেশিকা হিসাবে ব্যবহার করা উচিত।পর্যালোচনাকারীদের দ্বারা অধ্যয়নগুলি যাচাই করা না হওয়া পর্যন্ত এগুলি সত্যই সঠিক বলে ধরে নেওয়া বা কোনও ক্রিয়াকলাপ অবহিত করা উচিত নয়।"
    ],
    "Bengali - Background and context": [
      "উচ্চমানের, বৈধ, তাৎপর্যপূর্ণ, মূল এবং বৈজ্ঞানিক জার্নালে প্রকাশের জন্য উপযুক্ত হিসাবে বিবেচনা করার জন্য, অধ্যয়নের অবশ্যই একটি পাক্ষিক পর্যালোচনা প্রক্রিয়াটি সম্পূর্ণ করতে হবে। যেহেতু এই প্রকাশিত অধ্যয়নগুলি ক্লিনিকাল অনুশীলন এবং জনস্বাস্থ্যের আচরণকে সম্ভাব্যভাবে প্রভাবিত করতে পারে, তাই প্রতিটি গবেষণা প্রতিটি জার্নালের কঠোর প্রয়োজনীয়তা পূরণ করে তা নিশ্চিত করার জন্য এই প্রক্রিয়াটি একটি ফিল্টার হিসাবে কাজ করে, অনেকগুলি অধ্যয়ন পাক্ষিক পর্যালোচনার পরে বাতিল হয়ে যায় যা গ্রহণযোগ্য বা প্রকাশিত হয় না। প্রাক-মুদ্রণ অধ্যয়নগুলি এখনও পাক্ষিক পর্যালোচনা প্রক্রিয়াটি পাস করেনি তাই বিজ্ঞানীরা প্রাক-মুদ্রণ অধ্যয়ন থেকে কোনও সিদ্ধান্ত নেওয়ার জন্য সতর্কতার আহ্বান জানিয়েছেন।\nপাক্ষিক পর্যালোচনা এবং প্রকাশনা প্রক্রিয়াগুলি সময় সাপেক্ষ এবং প্রায়শই জমা দেওয়া এবং প্রকাশের মধ্যে এক বছরেরও বেশি সময় জড়িত। প্রক্রিয়াটিও অত্যন্ত প্রতিযোগিতামূলক।পাক্ষিক পর্যালোচিত নিবন্ধগুলি বৈজ্ঞানিক যোগাযোগের একটি বিশ্বস্ত ফর্ম সরবরাহ করে। এমনকি আপনি যদি এই বিষয়টির সাথে অপরিচিত হন বা বিজ্ঞানীরা যারা একটি নির্দিষ্ট গবেষণা লিখেছেন তবে আপনি বৈজ্ঞানিক মানের কিছু মান পূরণের জন্য পাক্ষিক-পর্যালোচিত কাজকে বিশ্বাস করতে পারেন। যেহেতু বৈজ্ঞানিক জ্ঞান ক্রমবর্ধমান এবং নিজেকে তৈরি করে, তাই এই আস্থাটি বিশেষভাবে গুরুত্বপূর্ণ।একটি জার্নালে প্রাক-মুদ্রণ অধ্যয়ন জমা দেওয়ার পরে, জার্নালের সম্পাদকরা নিবন্ধটি একই ক্ষেত্রের আরও অনেক বিজ্ঞানীর কাছে প্রেরণ করেন (অর্থাত্ পাক্ষিক পর্যালোচনার \"সহকর্মী\")। এই পর্যালোচকগুলি নিবন্ধটি সম্পর্কে প্রতিক্রিয়া সরবরাহ করে এবং সম্পাদককে তাদের পড়াশোনাটি প্রকাশের মতো পর্যাপ্ত মানের বলে মনে হয় কিনা তা জানান। এরপরে লেখকরা তাদের নিবন্ধটি সংশোধন করতে পারেন এবং এটি বিবেচনার জন্য পুনরায় জমা দিতে পারেন। কেবলমাত্র নিবন্ধগুলি যেগুলি ভাল বৈজ্ঞানিক মানগুলির সাথে মিলিত (যেমন, একই ক্ষেত্রের অন্যান্য কাজের স্বীকৃতি জানানো এবং যৌক্তিক যুক্তি এবং সু-নকশিত অধ্যয়নের উপর নির্ভর করা, প্রমাণ সহ দাবির ব্যাক আপ ইত্যাদি) প্রকাশের জন্য গৃহীত হয়।"
    ],
    "Portuguese - What our experts say": [
      "Estudos em fase de pré-impressão são estudos que foram concluídos, mas não passaram pelo processo de revisão por pares que a maioria das revistas científicas exigem para a publicação. \nEstudos em fase de pré-impressão fornecem novos dados e informações, o que é importante em uma pandemia. No entanto, os detalhes de um estudo em fase de pré-impressão não foram avaliados por revisores e editores de jornais científicos. Por exemplo: como o estudo foi delineado e conduzido, qual a dimensão das amostras utilizadas, quais suposições foram empregadas e como os cálculos foram realizados. O processo de avaliação de um estudo em fase de pré-impressão é precisamente aquilo em que consiste o processo de revisão por pares. A maioria dos sites que publicam artigos em fase de pré-impressão indicam que esses artigos não devem ser referenciados em noticiários como se fossem informações confiáveis nem usados para orientar a prática clínica ou outras práticas relacionadas à saúde. Até que os estudos sejam avaliados por revisores, eles não devem ser considerados factualmente corretos ou informar quaisquer ações."
    ],
    "Portuguese - Background and context": [
      "Para serem considerados de alta qualidade, válidos, significativos, originais e adequados para publicação em revista científica, os estudos devem concluir um processo de revisão por pares. Como esses estudos publicados poderiam potencialmente influenciar práticas clínicas e outras práticas em saúde pública, o processo de revisão age como um filtro para garantir que todos os estudos atendam aos requisitos rigorosos de cada revista, o que faz com que muitos estudos não sejam aceitos ou publicados após terem passado por revisões de pares. Os estudos em fase de pré-impressão ainda não passaram pelo processo de revisão por pares, por isso os cientistas pedem cautela ao tirar conclusões de estudos em fase de pré-impressão. \nOs processos de revisão e publicação por pares são demorados e requerem mais de um ano entre a o momento de sua submissão e o da publicação. O processo também é altamente competitivo. \nArtigos revisados por pares fornecem uma forma confiável de comunicação científica. Mesmo que não esteja familiarizado com o tema ou com os cientistas que foram autores de um estudo em particular, você pode confiar em um trabalho revisado por pares para atender a certos padrões de qualidade científica. Uma vez que o conhecimento científico é cumulativo e se baseia em si mesmo, essa confiança é particularmente importante. \nApós a submissão de um estudo em fase de pré-impressão a uma revista, os editores do jornal enviam o artigo para vários outros cientistas que trabalham no mesmo campo (ou seja, os \"pares\" da revisão por pares). Esses revisores fornecem comentários sobre o artigo e dão informações aos editores quanto à qualidade do estudo e sua adequação para publicação. De acordo com os comentários, os autores podem em seguida revisar seu artigo e submetê-lo novamente para publicação. Apenas artigos que atendam a bons padrões científicos (por exemplo, reconheçam e construam outros trabalhos no campo, dependem de raciocínio lógico e estudos bem delineados, fundamentem argumentos com evidências, etc.) são aceitos para publicação."
    ]
  },
  {
    "id": "reczxZFNnUFSbpNxf",
    "Question": "Can COVID-19 be transmitted through pool water?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & pool water",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Coronaviruses are enveloped viruses which are not particularly environmentally hardy. This means that the virus causing COVID-19 is susceptible to a wide range of cleaning and disinfection products and in direct sunlight, begins to break down within a few minutes. There has been no detection of COVID-19 in drinking water and per the CDC, water filtration and disinfection methods should remove or inactive any existing viral particles in the water. While COVID-19 is not spread through water, there are other viruses and bacteria that can be spread in pool water, such as norovirus, which means it is important to maintain safe levels of chlorine and water treatment.\n",
    "What our experts say": "The virus that causes COVID-19 is spread through respiratory secretions like a cough or a sneeze. While it can also be transmitted through contaminated surfaces and objects (e.g. contaminated door handle), there has been no evidence that it can be spread through water in pools, hot tubs, spas, or water play areas. Moreover, the virus has not been detected in drinking water. According to the U.S. Centers for Disease Control and Prevention, the biggest concern for COVID-19 transmission around pools is related to crowded areas where social distancing cannot occur and the importance of hand hygiene and respiratory etiquette due to many high-touch surfaces and objects. In relation to pools, exposure prevention is focused more on respiratory droplets from other people visiting the pool rather than the water itself.\n",
    "Glossary Terms": [
      "recyEDVrAGriFphQH",
      "rec5yviiSvJkufYvu",
      "rec8po7cJXvqkaQYB",
      "rec4crPh6OQvCngsk"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "pool",
      "spread"
    ],
    "Other resources": "1. Considerations for Public Pools, Hot Tubs, and Water Playgrounds During COVID-19 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/community/parks-rec/aquatic-venues.html))\n2. Inside the DHS lab where researchers study coronavirus ([NBC News](https://www.nbcnews.com/nightly-news/video/inside-the-dhs-lab-where-researchers-study-coronavirus-83105861506))\n",
    "DB (French)": [
      "reccv7wTonNKiuovS"
    ],
    "DB (Hindi)": [
      "recB6GCJU6EzAb2OC"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recLS6tnQzNNyCDLh"
    ],
    "DB (Spanish)": [
      "rec4eznbnu4emNaFT"
    ],
    "DB (Bengali)": [
      "recMRWW70XfJpEwMU"
    ],
    "DB (Portuguese)": [
      "recnSxOlYRoFxmaMu"
    ],
    "Rollup test 2": [
      "recESNakIptNmWnbS"
    ],
    "Last modified manual": "2020-06-14",
    "Last edited (simplified)": "2020-06-01T18:10:40.000Z",
    "Last edited (experts say)": "2020-06-19T00:34:11.000Z",
    "Last modified": "2020-06-14",
    "What our experts say wordcount": 129,
    "Background and context wordcount": 107,
    "Other resources wordcount": 24,
    "Wordcount": 260,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Le virus responsable de la COVID-19 se propage par des sécrétions respiratoires, par exemple lors d’une toux ou d’un éternuement. Bien qu’il puisse aussi être transmis par des surfaces et des objets contaminés (p. ex. des poignées de porte contaminées), il n’existe aucune donnée probante quant à la transmission par l’eau des piscines, des spas ou des aires de jeux d’eau. D’après les Centres de contrôle et de prévention des maladies des États-Unis, la préoccupation principale quant à la transmission de la COVID-19 autour des piscines concerne les zones bondées où la distanciation physique ne peut pas être respectée, mais aussi l’hygiène des mains et l’étiquette respiratoire en raison de surfaces et d’objets très exposés au toucher. Pour ce qui est des piscines, la prévention de l’exposition se concentre plus sur les gouttelettes respiratoires d’autres personnes qui fréquentent la piscine que de l’eau même."
    ],
    "French - Background and context": [
      "Les coronavirus sont des virus enveloppés qui ne sont pas particulièrement résistants à leur environnement. Cela signifie que le virus responsable de la COVID-19 est vulnérable à une large gamme de produits de nettoyage et de désinfection ainsi qu’à la lumière directe du soleil, et qu’il commence à se dégrader en quelques minutes. Il n’y a eu aucun cas de détection de la COVID-19 dans l’eau potable et d’après les Centres de contrôle et de prévention des maladies des États-Unis, les moyens de filtration et de désinfection de l’eau devraient supprimer ou rendre inactive toute particule virale existante dans l’eau. Bien que la COVID-19 ne soit pas transmise par l’eau, d’autres virus et bactéries peuvent être transmis par l’eau des piscines, tels que les norovirus, ce qui signifie qu’il est important de maintenir des niveaux sûrs de chlore et de traitement des eaux."
    ],
    "Hindi - What our experts say": [
      "कोविड​​-19 का कारण बनने वाला वायरस साँस की नलियों से निकलने वाले पदार्थ, जैसे खांसी या छींक से फैलता है। हालांकि इसे दूषित सतहों और वस्तुओं (जैसे दूषित दरवाज़े के हैंडल) के माध्यम से फैलाया जा सकता है, लेकिन इस बात का कोई सबूत नहीं है कि यह पूल, हॉट टब, स्पा या पानी से खेलने वाली जगहों पर पानी के माध्यम से फैल सकता है। इसके अलावा, पीने के पानी में वायरस नहीं पाया गया है। यू.एस. सेंटर्स फॉर डिसीज कंट्रोल एंड प्रिवेंशन (यू॰ एस॰ - सी॰डी ॰सी॰) के अनुसार, पूल के आसपास कोविड​​-19 ट्रांसमिशन के लिए सबसे बड़ी चिंता भीड़-भाड़ वाले इलाकों से संबंधित है, जहाँ सामाजिक दूरी नहीं बनाई जा सकती और हाथ की स्वच्छता और श्वसन शिष्टाचार को बनाए रखना मुश्किल है। पूल के संबंध में, एक्सपोज़र की रोकथाम पानी के बजाय पूल पर जाने वाले अन्य लोगों के साँस की बूंदों से फैलने पर अधिक केंद्रित है।"
    ],
    "Hindi - Background and context": [
      "कोरोनावायरस पर्यावरणीय में टिकने के रूप से बहुत ज़्यादा मज़बूत नहीं हैं। इसका मतलब है कि कोविद-19 का वायरस सफाई और कीटाणुनाशन के पदार्थों और सीधे धूप में, कुछ ही मिनटों में टूटना शुरू हो जाता है। पीने के पानी में कोविड​​-19 नहीं पाया गया है और सी॰डी॰सी॰ के अनुसार, पानी के फ़िल्ट्रेशन और कीटाणुशोधन विधियों से पानी में मौजूद कोई भी वायरल कण हट जाने चाहिए। जबकि कोविड​​-19 पानी से नहीं फैलता है, अन्य वायरस और बैक्टीरिया होते हैं जो पूल के पानी में फैल सकते हैं, जैसे कि नोरोवायरस, इसका यह मतलब है की क्लोरीन और जल उपचार के सुरक्षित स्तर को बनाए रखना महत्वपूर्ण है।"
    ],
    "Telugu - What our experts say": [
      "కోవిడ్-19 కి కారణమయ్యే వైరస్ దగ్గు లేదా తుమ్ము వంటి శ్వాసకోశ స్రావాల ద్వారా వ్యాపిస్తుంది. ఇది కలుషితమైన ఉపరితలాలు మరియు వస్తువుల ద్వారా కూడా వ్యాప్తి చెందుతుంది (ఉదా. కలుషితమైన తలుపు హ్యాండిల్), ఇది కొలనులు, హాట్ టబ్‌లు, స్పాస్ లేదా వాటర్ ప్లే ప్రాంతాలలో నీటి ద్వారా వ్యాప్తి చెందుతుందనడానికి ఎటువంటి ఆధారాలు లేవు. అంతేకాక, తాగునీటిలో వైరస్ కనుగొనబడలేదు. యు.ఎస్. సెంటర్స్ ఫర్ డిసీజ్ కంట్రోల్ అండ్ ప్రివెన్షన్ ప్రకారం, కొలనుల చుట్టూ కోవిడ్-19 ప్రసారం కోసం పెద్ద ఆందోళన సామాజిక దూరం జరగలేని రద్దీ ప్రాంతాలకు సంబంధించినది మరియు అధిక-స్పర్శ ఉపరితలాలు మరియు వస్తువుల కారణంగా చేతి పరిశుభ్రత మరియు శ్వాసకోశ మర్యాద యొక్క ప్రాముఖ్యత. కొలనులకు సంబంధించి, ఎక్స్‌పోజర్ నివారణ అనేది నీటి కంటే పూల్‌ను సందర్శించే ఇతర వ్యక్తుల నుండి వచ్చే శ్వాసకోశ బిందువులపైనే ఎక్కువ దృష్టి పెడుతుంది."
    ],
    "Telugu - Context and background": [
      "కరోనావైరస్లు ఎన్విలాప్డ్ వైరస్లు, ఇవి ముఖ్యంగా పర్యావరణ హార్డీ కాదు. కోవిడ్-19 కు కారణమయ్యే వైరస్ విస్తృత శ్రేణి శుభ్రపరచడం మరియు క్రిమిసంహారక ఉత్పత్తులకు గురి అవుతుందని మరియు ప్రత్యక్ష సూర్యకాంతిలో, కొన్ని నిమిషాల్లో విచ్ఛిన్నం కావడం ప్రారంభమవుతుంది. తాగునీటిలో కోవిడ్-19 ను గుర్తించలేదు మరియు సిడిసి ప్రకారం, నీటి వడపోత మరియు క్రిమిసంహారక పద్ధతులు నీటిలో ఉన్న వైరల్ కణాలను తొలగించాలి లేదా క్రియారహితం చేయాలి. కోవిడ్-19 నీటి ద్వారా వ్యాపించకపోగా, ఇతర వైరస్లు మరియు బ్యాక్టీరియా పూల్ నీటిలో వ్యాప్తి చెందుతాయి, నోరోవైరస్ వంటివి, అంటే క్లోరిన్ మరియు నీటి చికిత్స యొక్క సురక్షితమైన స్థాయిని నిర్వహించడం చాలా ముఖ్యం."
    ],
    "Spanish - What our experts say": [
      "El virus que causa el COVID-19 es diseminado a través de secreciones respiratorias como tos o un estornudo. Mientras que también puede ser transmitido a través de superficies y objetos contaminados (ej.: un picaporte contaminado), no ha habido evidencia de que pueda ser diseminado a través del agua en las piscinas, bañeras calientes, spas o áreas de juegos acuáticos. Aún más, el virus no ha sido detectado en el agua potable. De acuerdo a los Centros de Control y Prevención de Enfermedades de los EE.UU., la mayor preocupación para la transmisión del COVID-19 alrededor de las piscinas está relacionada con las áreas atestadas, donde el distanciamiento social no puede ocurrir, y la importancia de la higiene de manos y etiqueta respiratoria debido a las muchas superficies y objetos que son muy tocados. En relación a las piscinas, la prevención de la exposición está enfocada más en las gotitas respiratorias de otras personas visitando la piscina que en el agua en sí misma."
    ],
    "Spanish - Background and context": [
      "Los coronavirus son virus envueltos que no son particularmente resistentes al medio ambiente. Esto significa que el virus causante del COVID-19 es susceptible a un amplio rango de productos de limpieza y desinfección, y en luz solar directa empieza a descomponerse dentro de unos pocos minutos. No ha habido detección de COVID-19 en agua potable, y de acuerdo al CDC, los métodos de filtración y desinfección de agua debieran remover o inactivar cualquier partícula viral existente en la misma. Mientras que el COVID-19 no se disemina a través del agua, hay otros virus y bacterias que pueden ser diseminados en el agua de piscina, tales como el norovirus, lo que significa que es importante mantener niveles seguros de cloro y tratamiento de agua."
    ],
    "Bengali - What our experts say": [
      "যে ভাইরাসটি কোভিড-১৯ এর জন্য দায়ী তা কাশি বা হাঁচির মতো শ্বাস-প্রশ্বাসের নিঃসরণ দ্বারা ছড়িয়ে পড়ে। এটি দূষিত পৃষ্ঠ এবং বস্তুগুলির (যেমন দূষিত দরজার হাতল) মাধ্যমেও সংক্রমিত হতে পারে| পুল, গরম পানির আধার, স্পা বা পানির খেলার জায়গাগুলিতে পানির মাধ্যমে এটি ছড়িয়ে যেতে পারে এমন কোনও প্রমাণ পাওয়া যায় নি। তদুপরি, পানযোগ্য পানিতে ভাইরাস সনাক্ত করা যায় নি। আমেরিকা যুক্তরাষ্ট্রের রোগ নিয়ন্ত্রণ ও প্রতিরোধ কেন্দ্রগুলির মতে, পুলের চারপাশে কোভিড-১৯ সংক্রমণের জন্য সবচেয়ে বড় উদ্বেগ এমন জনাকীর্ণ অঞ্চলের সাথে সম্পর্কিত যেখানে সামাজিক দূরত্ব মানা হয় না এবং বার বার স্পর্শ করা হয় এমন পৃষ্ঠ এবং বস্তুর কারণে হাতের স্বাস্থ্যবিধি এবং শ্বাস-প্রশ্বাসের শিষ্টাচারের গুরুত্ব পায় না। পুলের সাথে সম্পর্কিত, এক্সপোজার প্রতিরোধটি পানির থেকে পুল পরিদর্শনকারী অন্যান্য ব্যক্তিদের শ্বাস প্রশ্বাসের জলীয় কণাকে বেশি গুরুত্ব দেয়।"
    ],
    "Bengali - Background and context": [
      "করোনাভাইরাস হ'ল প্রলেপযুক্ত ভাইরাস যা বিশেষত পরিবেশগতভাবে শক্ত নয়। এর অর্থ হ'ল কোভিড-১৯-এ সংক্রমণকারী ভাইরাসটি নানা ধরনের পরিষ্কার এবং জিবানুমুক্তকারি পণ্যগুলিতে এবং সরাসরি সূর্যের আলোতে সংবেদনশীল, কয়েক মিনিটের মধ্যেই এটি ভেঙে যেতে শুরু করে। পানীয় জলের মধ্যে কোভিড -১৯ এর কোন সনাক্তকরণ হয়নি এবং রোগ নিয়ন্ত্রণ কেন্দ্র অনুযায়ী পানি পরিস্রাবণ এবং জিবানুমুক্তিকরন পদ্ধতিতে পানির বিদ্যমান ভাইরাল কণাগুলি সরিয়ে ফেলে বা নিষ্ক্রিয় করে। কোভিড-১৯ পানির মাধ্যমে না ছড়ালেও, সেখানে অন্যান্য ভাইরাস এবং ব্যাকটিরিয়া রয়েছে যা পুলের পানিতে (যেমন নোরোভাইরাস) ছড়িয়ে যেতে পারে, যার অর্থ ক্লোরিন এবং পানির নিরাপদ মাত্রা বজায় রাখা গুরুত্বপূর্ণ।"
    ]
  },
  {
    "id": "recrNXw7eBw8czwGW",
    "Question": "What is the latest research around sunbathing and COVID-19?",
    "Status": "Update in progress",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & sunbathing",
    "Source of the question": [
      "Newsroom",
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA",
      "Canada"
    ],
    "Background and context": "Recent news articles and studies have focused on people sunbathing as a way to prevent or treat COVID-19. There has been no evidence that sunbathing is effective at combatting COVID-19. \nUltraviolet or UV rays are a form of electromagnetic radiation, present in sunlight. Sunlight emits three kinds of UV rays: UVA, UVB, and UVC. UVC has the highest energy and is filtered by the atmosphere so it does not reach the Earth's surface.\nHowever, UVC rays can also come from some man-made sources, such as UV sanitizing bulbs, and be used in indoor settings, such as hospitals, to disinfect medical equipment and surfaces. This is because UVC has the most energy of the three, and its energy can destroy the genetic material inside viruses. The genetic material in viruses includes information that can control the reproduction, development or behaviour of the virus. But artificial UVC rays are extremely dangerous and deadly to humans and should not be used outside of professional settings to disinfect surfaces and objects.\nAs for the general sunlight, while the sun can kill germs, disinfecting items through sunlight would not be 100% effective and would take a very long time and most household users would not be able to confirm that their items had been fully disinfected during this process. Studies have shown that there are different lengths of time of sun exposure needed for items to be disinfected depending on size, material, etc. Exposure to sunlight is therefore not a recommended solution for disinfecting routine household items. \n",
    "What our experts say": "Exposing yourself to the sun for any period of time does not prevent anyone from spreading COVID-19 to another person or catching COVID-19 from another person. Long-term exposure to sunlight can be very damaging and increase your risk of skin cancer. As of now, there is no clear benefit of sunbathing for preventing or treating COVID-19. \n\n",
    "Glossary Terms": [
      "recjOgLIjiAbiBH5F"
    ],
    "Variation of the answer depending on country of residence": "No\t\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\t\n",
    "Topics": [
      "ultraviolet",
      "UV",
      "sunlight"
    ],
    "Other resources": "1. Coronavirus disease (COVID-19) advice for the public: Myth busters ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters)) \n2. Ultraviolet radiation and the INTERSUN Programme ([WHO](https://www.who.int/uv/faq/whatisuv/en/index2.html)) \n3. As Coronavirus Looms, Mask Shortage Gives Rise to Promising Approach ([NYT](https://www.nytimes.com/2020/03/20/health/coronavirus-masks-reuse.html)) \n4. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality ([Aging Clinical and Experimental Research](https://link.springer.com/article/10.1007/s40520-020-01570-8))\n5. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data ([BMJ](https://www.bmj.com/content/356/bmj.i6583))\n6. Rapid evidence summary on SARS-CoV-2 survivorship and disinfection, and a reusable PPE protocol using a double-hit process ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.04.02.20051409v1.full.pdf)) \n\n\n",
    "DB (French)": [
      "rec5gU4AbShoWGNjF"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "reczOoY6GHeEHjiwR"
    ],
    "DB (Spanish)": [
      "recSaRSUdCv5vuPqt"
    ],
    "DB (Arabic)": [
      "reccuiNGGkrRJf0zi"
    ],
    "DB (Bengali)": [
      "recANerQQ5GAylbxu"
    ],
    "DB (Portuguese)": [
      "recbOPj4OZPwG3Px4"
    ],
    "Rollup test 2": [
      "reclnm24xWaje831b"
    ],
    "Last modified manual": "2020-05-29",
    "Last edited (simplified)": "2020-05-28T23:36:42.000Z",
    "Last edited (experts say)": "2020-07-07T13:22:46.000Z",
    "Last modified": "2020-05-28",
    "What our experts say wordcount": 57,
    "Background and context wordcount": 251,
    "Other resources wordcount": 89,
    "Wordcount": 397,
    "French Q status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Arabic Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "S’exposer au soleil pendant quelque durée que ce soit n’empêche pas quelqu’un de transmettre le coronavirus à une autre personne ni de l’attraper d’une autre personne. Une exposition prolongée au soleil peut provoquer de graves lésions et augmenter le risque que vous contractiez un cancer de la peau. À l’heure actuelle, se faire bronzer n’offre aucun bienfait évident pour prévenir ni traiter la COVID-19."
    ],
    "French - Background and context": [
      "Des articles de presse et des études récents se sont intéressés au bronzage comme moyen de prévenir ou de traiter la COVID-19. Aucune donnée probante n’a été trouvée pour démontrer l’efficacité du bronzage pour combattre la COVID-19.\nLes rayonnements ultraviolets ou UV sont une forme de rayonnement électromagnétique présent dans la lumière du soleil. Elle émet trois types de rayonnement UV : les UVA, UVB et UVC. Les UVC sont les plus puissants et filtrés par l’atmosphère. Ils n’atteignent donc pas la surface de la Terre. \nCependant, les rayons UVC peuvent aussi provenir de certaines sources artificielles, telles que les ampoules désinfectantes à UV et être utilisés à l’intérieur, par exemple dans les hôpitaux, pour désinfecter les équipements médicaux et les surfaces. En effet, les UVC sont les plus puissants des trois et leur énergie peut détruire le matériel génétique des virus. Le matériel génétique des virus comprend des renseignements qui peuvent contrôler la reproduction, le développement ou le comportement du virus. Mais les rayons UVC artificiels sont extrêmement dangereux et mortels pour l’être humain et ne devraient être utilisés que dans un cadre professionnel pour désinfecter surfaces et objets.\nQuant à la lumière du soleil, bien qu’elle puisse tuer les germes, il ne serait pas entièrement efficace de désinfecter des objets grâce à la lumière du soleil et cela prendrait très longtemps. De plus, il serait impossible de confirmer la désinfection complète des objets par un tel procédé dans un contexte domestique. Des études ont démontré que différentes durées d’exposition au soleil sont nécessaires pour désinfecter des articles selon leur taille, leur matériau, etc. L’exposition à la lumière du soleil n’est donc pas une solution recommandée pour désinfecter les articles domestiques courants."
    ],
    "Telugu - What our experts say": [
      "ఏ సమయంలోనైనా మిమ్మల్ని సూర్యుడికి బహిర్గతం చేయడం వల్ల కోవిడ్-19 ను మరొక వ్యక్తికి వ్యాప్తి చేయకుండా లేదా మరొక వ్యక్తి నుండి కోవిడ్-19 ను పట్టుకోకుండా ఎవరైనా నిరోధించలేరు. సూర్యరశ్మికి దీర్ఘకాలికంగా గురికావడం చాలా హానికరం మరియు చర్మ క్యాన్సర్ ప్రమాదాన్ని పెంచుతుంది. ప్రస్తుతానికి, కోవిడ్-19 ను నివారించడానికి లేదా చికిత్స చేయడానికి సన్ బాత్ యొక్క స్పష్టమైన ప్రయోజనం లేదు."
    ],
    "Telugu - Context and background": [
      "కోవిడ్-19 ను నివారించడానికి లేదా చికిత్స చేయడానికి ఒక మార్గంగా సన్ బాత్ చేసే వ్యక్తులపై ఇటీవలి వార్తా కథనాలు మరియు అధ్యయనాలు దృష్టి సారించాయి. కోవిడ్-19 ను ఎదుర్కోవడంలో సన్ బాత్ ప్రభావవంతంగా ఉందని ఎటువంటి ఆధారాలు లేవు.\nఅతినీలలోహిత లేదా UV కిరణాలు సూర్యకాంతిలో ఉండే విద్యుదయస్కాంత వికిరణం. సూర్యరశ్మి మూడు రకాల UV కిరణాలను విడుదల చేస్తుంది: UVA, UVB మరియు UVC. UVC అత్యధిక శక్తిని కలిగి ఉంది మరియు వాతావరణం ద్వారా ఫిల్టర్ చేయబడుతుంది కాబట్టి ఇది భూమి యొక్క ఉపరితలం చేరుకోదు.\nఏదేమైనా, UVC కిరణాలు UV శానిటైజింగ్ బల్బులు వంటి కొన్ని మానవ నిర్మిత వనరుల నుండి కూడా రావచ్చు మరియు వైద్య పరికరాలు మరియు ఉపరితలాలను క్రిమిసంహారక చేయడానికి ఆసుపత్రుల వంటి ఇండోర్ సెట్టింగులలో ఉపయోగించవచ్చు. ఎందుకంటే యువిసి ఈ మూడింటిలో ఎక్కువ శక్తిని కలిగి ఉంది మరియు దాని శక్తి వైరస్ల లోపల జన్యు పదార్థాన్ని నాశనం చేస్తుంది. వైరస్లలోని జన్యు పదార్ధం వైరస్ యొక్క పునరుత్పత్తి, అభివృద్ధి లేదా ప్రవర్తనను నియంత్రించగల సమాచారాన్ని కలిగి ఉంటుంది. కానీ కృత్రిమ UVC కిరణాలు మానవులకు చాలా ప్రమాదకరమైనవి మరియు ఘోరమైనవి మరియు ఉపరితలాలు మరియు వస్తువులను క్రిమిసంహారక చేయడానికి ప్రొఫెషనల్ సెట్టింగుల వెలుపల ఉపయోగించకూడదు.\nసాధారణ సూర్యకాంతి విషయానికొస్తే, సూర్యుడు సూక్ష్మక్రిములను చంపగలడు, సూర్యరశ్మి ద్వారా వస్తువులను క్రిమిసంహారక చేయడం 100% ప్రభావవంతంగా ఉండదు మరియు చాలా సమయం పడుతుంది మరియు చాలా మంది గృహ వినియోగదారులు ఈ ప్రక్రియలో తమ వస్తువులు పూర్తిగా క్రిమిసంహారకమయ్యాయని నిర్ధారించలేరు. . పరిమాణం, పదార్థం మొదలైనవాటిని బట్టి వస్తువులను క్రిమిసంహారక చేయడానికి సూర్యరశ్మికి వేర్వేరు సమయం అవసరమని అధ్యయనాలు చెబుతున్నాయి. అందువల్ల సూర్యరశ్మికి గురికావడం సాధారణ గృహ వస్తువులను క్రిమిసంహారక చేయడానికి సిఫార్సు చేయబడిన పరిష్కారం కాదు."
    ],
    "Spanish - What our experts say": [
      "Exponerse al sol por cualquier periodo de tiempo no previene a nadie de diseminar el COVID-19 a otra persona o contraer el COVID-19 por otra persona. La exposición a la luz del sol por largo tiempo puede ser muy dañina e incrementar tu riesgo de cáncer de piel. Al momento, no hay un claro beneficio al tomar sol para prevenir o tratar al COVID-19."
    ],
    "Spanish - Background and context": [
      "Los artículos de noticias y estudios recientes se han enfocado en personas tomando sol como modo de prevenir o tratar al COVID-19. No ha habido evidencia que el tomar sol sea efectivo en combatir el COVID-19.\nLos rayos ultravioletas o UV son una forma de radiación electromagnética, presente en la luz del sol. La misma emite tres clases de rayos UV: UVA, UVB y UVC. El UVC tiene la energía más alta y es filtrado por la atmósfera, por lo que no llega a la superficie de la Tierra.\nSin embargo, los rayos UVC también pueden provenir de algunas fuentes creadas por el hombre, tales como lámparas desinfectantes por UV, y ser usadas en interiores, tales como hospitales, para desinfectar superficies y equipamientos médicos. Esto es porque el UVC tiene la mayor energía de los tres, y esa energía puede destruir el material genético dentro de los virus. El material genético en los virus incluye información que puede controlar la reproducción, el desarrollo o el comportamiento del virus. Pero los rayos UVC artificiales son extremadamente peligrosos y mortales para los seres humanos, y no debieran ser usados fuera de ámbitos profesionales para desinfectar superficies y objetos. En el caso de la luz solar en general, mientras que el sol puede matar gérmenes, desinfectar ítems por medio de luz solar no sería 100% efectivo y tomaría un tiempo muy largo, y la mayoría de los usuarios domiciliarios no serían capaces de confirmar que esos ítems hayan sido completamente desinfectados durante este proceso. Los estudios han mostrado que hay diferentes lapsos de tiempo de exposición al sol necesarios para que los ítems sean desinfectados, dependiendo del tamaño, material, etc. La exposición a la luz solar no es por consiguiente una solución recomendada para la desinfección de ítems domiciliarios rutinarios."
    ],
    "Arabic - What our experts say": [
      "التعرض لأشعة الشمس لأية فترة من الوقت لا تمنع أحدا من نقل عدوى فيروس كورونا  (كوفيد-19) إلى شخصٍ آخر أو أخذ العدوى من شخصٍ آخر. فالتعرض لأشعة الشمس لوقتٍ طويل يُمكنه التسبب بضرر شديد كما يزيد من خطر الإصابة بسرطان الجلد. حتى هذه اللحظة، ليس هناك فائدة واضحة لحمام الشمس في الوقاية من فيروس كورونا (كوفيد-19) أوالشفاء منه.\n"
    ],
    "Arabic - Background and context": [
      "ركزت المقالات الإخبارية الراهنة على الأشخاص الذين يلجؤون لحمام الشمس كوسيلة للوقاية من فيروس كورونا المستجدّ (كوفيد-19) أو الشفاء منه. حيث لا يوجد دليل على فعّالية حمام الشمس في مكافحة فيروس كورونا المستجدّ (كوفيد-19). الأشعة فوق البنفسجية هي شكلٌ من أشكالِ الإشعاع الكهرومغناطيسي المتواجد في ضوء الشمس. يُصدر ضوءُ الشمسِ ثلاثة أشكال من الأشعة فوق البنفسجية: الإشعاع فوق البنفسجي الطويل الموجة، والإشعاع فوق البنفسجي الفعّال بيولوجيًا، والإشعاع فوق البنفسجي القصير الموجة. يحتوي الإشعاع فوق البنفسجي القصير الموجة على النسبة الأعلى من الطاقة ويتم ترشيحه من قبل الغلاف الجوي بحيث لا يصل إلى سطح الأرض. رغم ذلك يُمكن توليد الأشعة فوق البنفسجية القصيرة الموجة من مصادر اصطناعيّة، مثل مصابيح التعقيم بالأشعة فوق البنفسجية المستخدمة في المنشآت المغلقة كالمشافي، لتعقيم المعدات الطبيّة والسطوح، يَرجع استخدام هذا الإشعاع في التعقيم إلى احتوائه على أعلى مستوى من الطاقة من بين الأشعة الثلاث، فطاقة هذا الإشعاع يُمكنها تدمير المادة الوراثيّة داخل الفيروسات، المادة التي تحتوي على معلومات التحكم بالتكاثر والتطوّر والسلوك الخاصة بالفيروسات. لكن الإشعاع فوق البنفسجي القصير الموجة الإصطناعي ضارٌ جدًا وفتاك ٌبالبشر، ولا يجب استعماله خارج المنشآت المهنيّة بهدف تعقيم السطوح والمعدات. أما بالنسبة لضوء الشمس الكلّيّ، حيث يُمكن للشمس أن تقتل الجراثيم، فإن تعقيم الأدوات تحت أشعة الشمس قد لا يكون فعّالًا بنسبة 100% وقد يتطلب وقتًا طويلًا، كما أن الكثير من الأسر قد لا يكون بمقدورهم التأكد من تعقيم أدواتهم بشكلٍ كامل خلال هذه العملية. أظهرت الدراسات أنه ثمة حاجة لتعريض الأدوات لأشعة الشمس لفترات زمنية مختلفة وفقًا لحجمها وطبيعة موادها...إلخ، حتى يتم تعقيمها. بالتالي فإن تعريض الأدوات المنزليّة الإعتياديّة إلى أشعة الشمس لتعقيمها ليس حلًا موصى به.\n"
    ],
    "Bengali - What our experts say": [
      "যে কোনও সময়ের জন্য নিজেকে রোদে প্রকাশ করা কাউকে কোভিড-১৯ অন্য ব্যক্তিতে ছড়িয়ে দেওয়া বা অন্য ব্যক্তির কাছ থেকে কোভিড-১৯ সংক্রমণ থেকে বাঁধা দেয় না। সূর্যের আলোতে দীর্ঘমেয়াদে থাকা খুব ক্ষতিকারক হতে পারে এবং ত্বকের ক্যান্সারের ঝুঁকি বাড়িয়ে তুলতে পারে। এখন অবধি, কোভিড-১৯ প্রতিরোধ বা চিকিৎসা করার জন্য সূর্যস্নানের কোনও সুস্পষ্ট সুবিধা নেই।"
    ],
    "Bengali - Background and context": [
      "সাম্প্রতিক সংবাদ নিবন্ধ এবং অধ্যয়নগুলি কোভিড-১৯ প্রতিরোধ বা চিকিৎসার উপায় হিসাবে মানুষকে সূর্যস্নানে উৎসাহী করেছে। কোভিড-১৯-এর বিরুদ্ধে লড়াইয়ের জন্য সূর্যস্নান কার্যকর বলে প্রমাণ পাওয়া যায় নি।অতিবেগুনী বা ইউভি রশ্মি সূর্যের আলোতে উপস্থিত বৈদ্যুতিন চৌম্বকীয় বিকিরণের একটি রূপ। সূর্যের আলো তিন প্রকারের ইউভি রশ্মি নির্গত করে: ইউভিএ, ইউভিবি এবং ইউভিসি। ইউভিসির সর্বাধিক শক্তি রয়েছে এবং এটি বায়ুমণ্ডলে ফিল্টার করা হয় যাতে এটি পৃথিবীর পৃষ্ঠে পৌঁছায় না।তবে ইউভিসি রশ্মি কিছু মানবসৃষ্ট উৎস থেকে যেমন ইউভি স্যানিটাইজেশন বাল্বগুলি থেকেও আসতে পারে এবং চিকিৎসা সরঞ্জাম এবং পৃষ্ঠতলের জীবাণুমুক্ত করার জন্য হাসপাতালগুলির মতো ইনডোর সেটিংগুলিতে ব্যবহার করা যেতে পারে। এটির কারণ তিনটির মধ্যে ইউভিসি'র সবচেয়ে বেশি শক্তি থাকে এবং এর শক্তি ভাইরাসগুলির অভ্যন্তরে জিনগত উপাদানকে ধ্বংস করতে পারে। ভাইরাসগুলির জিনগত উপাদানগুলিতে এমন তথ্য রয়েছে যা ভাইরাসের পুনরায় উৎপাদন, বিকাশ বা আচরণ নিয়ন্ত্রণ করতে পারে। তবে কৃত্রিম ইউভিসি রশ্মি মানুষের জন্য অত্যন্ত বিপজ্জনক এবং মারাত্মক যা পৃষ্ঠতল এবং বস্তুগুলি জীবাণুমুক্ত করার জন্য পেশাদার সেটিংসের বাইরে ব্যবহার করা উচিত নয়। সাধারণ সূর্যের আলো হিসাবে, যখন সূর্য জীবাণু ধ্বংস করতে পারে, তবে সূর্যের আলোর মাধ্যমে জীবাণুনাশককে ১০০% কার্যকর করা যায় না এবং এটি খুব দীর্ঘ সময় নেয় এবং বেশিরভাগ গৃহস্থ ব্যবহারকারীরা এই প্রক্রিয়া চলাকালীন তাদের আইটেমগুলি সম্পূর্ণরূপে নির্বীজিত হয়েছে তা নিশ্চিত করতে সক্ষম হবেন না । গবেষণায় দেখা গেছে যে আকার, উপাদান ইত্যাদির উপর নির্ভর করে আইটেমগুলিকে জীবাণুমুক্ত করার জন্য বিভিন্ন ধরণের সূর্যের এক্সপোজারের প্রয়োজন রয়েছে| তাই সূর্যরশ্মির সংস্পর্শে সাধারণ গৃহস্থালীর বস্তুগুলিকে জীবাণুমুক্ত করার জন্য প্রস্তাবিত সমাধান নয়।"
    ],
    "Portuguese - What our experts say": [
      "Expor-se ao sol por qualquer período de tempo não impede que alguém transmita o COVID-19 à uma outra pessoa ou se contamine com o COVID-19 de outra pessoa. A exposição prolongada à luz solar pode ser muito prejudicial e aumentar o risco de câncer de pele. No momento, não existe comprovação dos benefícios claros do banho de sol para prevenir ou tratar o COVID-19."
    ],
    "Portuguese - Background and context": [
      "Pesquisas e artigos de jornais recentes se focalizaram em banhos de sol como um modo de prevenir ou tratar o COVID-19.  Não há evidências de que o banho de sol seja eficaz no combate ao COVID-19. Os raios ultravioleta ou UV são uma forma de radiação eletromagnética, presente na luz solar. A luz solar emite três tipos de raios UV: UVA, UVB e UVC. O UVC possui a energia mais alta e é filtrado pela atmosfera para que não atinja a superfície da Terra. No entanto, os raios UVC também podem vir de algumas fontes artificiais, como lâmpadas de desinfecção UV, e ser usados em ambientes fechados, como hospitais, para desinfetar equipamentos e superfícies médicos. Isso ocorre porque o UVC é o que, entre os três, tem mais energia, e ela pode destruir o material genético dentro do vírus. O material genético dos vírus inclui informações que podem controlar a reprodução, o desenvolvimento ou o comportamento do vírus. No entanto, os raios UVC artificiais são extremamente perigosos e mortais para os seres humanos e não devem ser usados fora do ambiente profissional para desinfetar superfícies e objetos. Quanto à luz solar em geral, ainda que o sol possa matar germes, a desinfecção de itens pela luz solar não seria 100% eficaz, levaria muito tempo e a maioria dos usuários domésticos não teriam como  de confirmar que seus itens foram totalmente desinfetados durante esse processo."
    ]
  },
  {
    "id": "recoUFwhHZm9niCaP",
    "Question": "Can COVID-19 be spread through money?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & money",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "Mexico"
    ],
    "Background and context": "Money, including coins and bills, has been for a long time considered a potential way diseases are transmitted from one person to another, although we do not have strong evidence to support that claim. The idea is that germs would \"attach\" themselves to bills and then be transmitted by traveling along the hand-money-hand route. This can represent a public health risk especially during simultaneous handling of food and money, or when touching money and then touching our face without having washed our hands. \nThe current discussion around money as a potential way of spreading diseases is based on studies that found that several types of bacteria can survive on paper money depending on some factors (type of paper, humidity, etc.). However, no strong evidence exists yet around transmission from contaminated money to our bodies.\nSome news outlets previously reported that the World Health Organization (WHO) claimed you could contract the virus that causes COVID-19 from coins and banknotes (paper money). However, the WHO clarified and said this claim had been misrepresented; the WHO did not issue any kind of warning or statement about COVID-19 transmission through coins and banknotes. Instead, they have emphasized the importance of washing hands with soap, especially before handling or eating food. \n",
    "What our experts say": "The virus that causes COVID-19 can potentially be spread through money. However, it's unlikely to cause the COVID-19 illness in humans. A recent study has shown that the virus that causes COVID-19 can survive on solid surfaces like coins for up to four days and on paper like cash for up to three hours, but the virus was no longer infectious (viable) after that point. There has been no rigorous research to conclude or disprove that COVID-19 can be easily spread through coins and paper money otherwise. Therefore, the risk of catching COVID-19 from the virus sticking to money is very low. \nHowever, it is best practice in general to wash your hands and avoid touching your face after touching money. The virus that causes COVID-19 is primarily spread through person-to-person contact, especially if you are in close contact with another person (within about 6 feet or 2 meters). Since we do not yet fully understand all the ways the virus could spread, it would be a good practice to be vigilant with money just as any other potential contaminated surface, and wash your hands with soap after touching it. \n",
    "Glossary Terms": [
      "rec2UNEXbTkSCx30Q"
    ],
    "Variation of the answer depending on country of residence": "No\t\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "transmission",
      "virus"
    ],
    "Other resources": "1. How COVID-19 Spreads ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fprepare%2Ftransmission.html))\n2. The WHO has clarified that they aren't warning people against using paper money due to coronavirus ([Full Fact](https://fullfact.org/health/coronavirus-WHO-cash-comments/))\n3. Stability of SARS-CoV-2 in different environmental conditions ([The Lancet](https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(20)30003-3/fulltext)) \n",
    "DB (French)": [
      "rec3EisBjaWNuh52z"
    ],
    "DB (Hindi)": [
      "recOm14qZz4QpDGQr"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recJuL85BLqQjfccm"
    ],
    "DB (Spanish)": [
      "rec2Qe2T8GHh7qJ6Y"
    ],
    "DB (Bengali)": [
      "recKtBBPL9SMah5dZ"
    ],
    "DB (Portuguese)": [
      "recluct3J31IiZJdz"
    ],
    "Rollup test 2": [
      "recUTMIt9DuqqAadl"
    ],
    "Last modified manual": "2020-05-28",
    "Last edited (simplified)": "2020-05-28T16:38:08.000Z",
    "Last edited (experts say)": "2020-06-13T19:38:36.000Z",
    "Last modified": "2020-05-28",
    "What our experts say wordcount": 191,
    "Background and context wordcount": 206,
    "Other resources wordcount": 34,
    "Wordcount": 431,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Le virus qui cause la COVID-19 peut potentiellement être transmis par l’argent. Cependant, il est peu susceptible de provoquer la maladie COVID-19 chez l’humain. Une recherche récente a démontré que le virus responsable de la COVID-19 peut survivre sur des surfaces solides telles que les pièces jusqu’à quatre jours et sur le papier tel que les billets jusqu’à trois heures, mais le virus n’était plus infectieux (viable) ce temps écoulé. Aucune recherche rigoureuse n’a permis de confirmer ni d’infirmer que la COVID-19 peut autrement être facilement transmise par des pièces ou des billets. Par conséquent, le risque d’attraper la COVID-19 du virus qui aurait adhéré à de l’argent est très faible.\nCependant, la meilleure pratique générale est de laver vos mains et d’éviter de toucher votre visage après avoir manipulé de l’argent. Le virus responsable de la COVID-19 n’est transmis principalement que par contact de personne à personne, particulièrement si vous êtes en contact proche avec une autre personne (moins de six pieds ou deux mètres). Dans la mesure où nous ne comprenons pas encore complètement toutes les façons dont le virus pourrait se propager, une bonne pratique serait de rester vigilant avec l’argent, comme il faut l’être avec toute surface susceptible d’être contaminée, et de laver vos mains avec du savon après l’avoir manipulé."
    ],
    "French - Background and context": [
      "L’argent, dont les pièces et les billets, a depuis longtemps été considéré comme susceptible de transmettre des maladies d’une personne à une autre, bien que nous n’ayons aucun élément probant solide pour corroborer cette affirmation. L’idée est que les germes pourraient « s’attacher » aux billets et être ensuite transmis en passant de main en main. Cela peut représenter un risque de santé publique, particulièrement lors d’une manipulation simultanée de nourriture et d’argent, ou si vous touchez de l’argent puis touchez ensuite votre visage sans avoir lavé vos mains.\nLa discussion actuelle autour de l’argent comme vecteur potentiel de transmission des maladies est fondée sur des études qui ont démontré que plusieurs sortes de bactéries peuvent survivre sur du papier-monnaie selon certains facteurs (sorte de papier, humidité, etc.). Cependant, il n’existe encore aucune donnée probante solide concernant la transmission d’une monnaie contaminée vers nos corps.\nCertains médias ont précédemment rapporté que l’Organisation mondiale de la santé (OMS) avait déclaré que vous pourriez contracter le virus responsable de la COVID-19 de pièces ou de billets de banque (papier-monnaie). Cependant, l’OMS a clarifié et dit que cette déclaration avait été dénaturée ; l’OMS n’a émis aucun avertissement ni avis quant à la transmission de la COVID-19 par des pièces et des billets de banque. Elle a plutôt insisté sur l’importance du lavage des mains avec du savon, particulièrement avant de manipuler de la nourriture et de manger."
    ],
    "Hindi - What our experts say": [
      "कोविड​​-19 का वायरस संभवतः धन के माध्यम से फैल सकता है। हालाँकि, यह मनुष्यों में कोविड​​-19 बीमारी का कारण नहीं है। हाल के एक अध्ययन से पता चला है कि कोविड​​-19 का वायरस ठोस सतहों पर (जैसे कि सिक्कों पर) चार दिनों तक और कागज पर (नोटों पर) तीन घंटे तक जीवित रह सकता है, लेकिन वायरस उस समय तक संक्रामक नहीं रह गया था। निष्कर्ष निकालने के लिए कोई कठोर शोध नहीं किया गया है कि कोविड​​-19 को सिक्कों और कागज के रुपयों के माध्यम से आसानी से फैलाया जा सकता है। इसलिए, पैसे से चिपके कोविड​​-19 वायरस को पकड़ने का जोखिम बहुत कम है।\nहालांकि, सामान्य रूप से पैसे को छूने के बाद अपने हाथ धोये और अपने चेहरे को छूने से बचना सबसे अच्छा अभ्यास है। कोविड​​-19 का कारण बनने वाला वायरस मुख्य रूप से व्यक्ति-से-व्यक्ति संपर्क के माध्यम से फैलता है, खासकर यदि आप किसी अन्य व्यक्ति (लगभग 6 फीट या 2 मीटर के भीतर) के साथ संपर्क में हैं। चूंकि हम अभी तक वायरस को फैलाने के सभी तरीकों को पूरी तरह से नहीं समझते हैं, इसलिए यह एक अच्छा अभ्यास होगा कि पैसे के साथ किसी भी अन्य संभावित दूषित सतह की तरह सतर्क रहें, और इसे छूने के बाद अपने हाथों को साबुन से धोएं।"
    ],
    "Hindi - Background and context": [
      "पैसा, जैसे कि सिक्के और बिल, लंबे समय से एक व्यक्ति से दूसरे व्यक्ति में बीमारी फैलाने से जुड़े हुए हैं, हालांकि हमारे पास उस दावे का समर्थन करने के लिए खास सबूत नहीं हैं। यह विचार है कि रोगाणु खुद को बिलों में \"संलग्न\" करेंगे और फिर हाथों के माध्यम से यात्रा करके प्रेषित होंगे। यह एक सार्वजनिक स्वास्थ्य जोखिम का कारण बन सकता है, विशेष रूप से भोजन और धन की एक साथ हैंडलिंग के दौरान, या जब कोई धन को छूता है और फिर हाथों को धोए बिना अपने चेहरे को छूता है। बीमारियों के फैलने के संभावित तरीके के रूप में धन के आसपास की वर्तमान चर्चा अध्ययनों पर आधारित है जिसमें पाया गया कि कई प्रकार के बैक्टीरिया कुछ कारकों (कागज, आर्द्रता, आदि) के आधार पर कागजी धन पर जीवित रह सकते हैं। हालांकि, दूषित धन से हमारे शरीर में संचरण के आसपास कोई मजबूत सबूत अभी तक मौजूद नहीं है। कुछ समाचार आउटलेट्स ने पहले बताया था कि विश्व स्वास्थ्य संगठन (डब्ल्यूएचओ) ने दावा किया है कि आप वायरस को सिक्कों और बैंकनोट्स (पेपर मनी) से अनुबंधित कर सकते हैं। परंतु, डब्ल्यूएचओ ने स्पष्ट किया और कहा कि यह दावा गलत तरीके से प्रस्तुत किया गया था; WHO ने सिक्कों और बैंक नोटों के माध्यम से कोविड​​-19 प्रसारण के बारे में किसी भी प्रकार की चेतावनी या बयान जारी नहीं किया। इसके बजाय, उन्होंने साबुन से हाथ धोने के महत्व पर जोर दिया है, खासकर भोजन बनाने और खाने से पहले।"
    ],
    "Telugu - What our experts say": [
      "కోవిడ్-19 కి కారణమయ్యే వైరస్ డబ్బు ద్వారా వ్యాప్తి చెందుతుంది. అయినప్పటికీ, మానవులలో కోవిడ్-19 అనారోగ్యానికి కారణం కాదు. కోవిడ్-19 కి కారణమయ్యే వైరస్ నాణేలు వంటి ఘన ఉపరితలాలపై నాలుగు రోజుల వరకు మరియు నగదు వంటి కాగితంపై మూడు గంటల వరకు జీవించగలదని తాజా అధ్యయనం చూపించింది, అయితే ఆ సమయం తరువాత వైరస్ అంటువ్యాధి (ఆచరణీయమైనది) కాదు. కోవిడ్-19 నాణేలు మరియు కాగితపు డబ్బు ద్వారా తేలికగా వ్యాప్తి చెందుతుందని నిర్ధారించడానికి లేదా నిరూపించడానికి కఠినమైన పరిశోధనలు లేవు. అందువల్ల, వైరస్ నుండి డబ్బుకు అంటుకునే కోవిడ్-19 ను పట్టుకునే ప్రమాదం చాలా తక్కువ.\nఅయినప్పటికీ, డబ్బును తాకిన తర్వాత మీ చేతులు కడుక్కోవడం మరియు మీ ముఖాన్ని తాకకుండా ఉండటం సాధారణంగా మంచి పద్ధతి. కోవిడ్-19 కి కారణమయ్యే వైరస్ ప్రధానంగా వ్యక్తి నుండి వ్యక్తికి సంపర్కం ద్వారా వ్యాపిస్తుంది, ప్రత్యేకించి మీరు మరొక వ్యక్తితో సన్నిహితంగా ఉంటే (సుమారు 6 అడుగులు లేదా 2 మీటర్లలోపు). వైరస్ వ్యాప్తి చెందగల అన్ని మార్గాలను మేము ఇంకా పూర్తిగా అర్థం చేసుకోనందున, ఇతర సంభావ్య కలుషితమైన ఉపరితలం వలె డబ్బుతో అప్రమత్తంగా ఉండటం మంచి పద్ధతి, మరియు దానిని తాకిన తర్వాత మీ చేతులను సబ్బుతో కడగాలి."
    ],
    "Telugu - Context and background": [
      "నాణేలు మరియు బిల్లులతో సహా డబ్బు చాలా కాలంగా వ్యాధులు ఒక వ్యక్తి నుండి మరొకరికి వ్యాప్తి చెందగల మార్గంగా పరిగణించబడుతున్నాయి, అయినప్పటికీ ఆ వాదనకు మద్దతు ఇవ్వడానికి మాకు బలమైన ఆధారాలు లేవు. సూక్ష్మక్రిములు తమను తాము బిల్లులకు \"అటాచ్\" చేసి, ఆపై చేతితో డబ్బు చేయి మార్గంలో ప్రయాణించడం ద్వారా ప్రసారం చేస్తాయనే ఆలోచన ఉంది. ఇది ఆహారం మరియు డబ్బును ఏకకాలంలో నిర్వహించేటప్పుడు లేదా డబ్బును తాకినప్పుడు మరియు మన చేతులను కడుక్కోకుండా మన ముఖాన్ని తాకినప్పుడు ఇది ప్రజారోగ్య ప్రమాదాన్ని సూచిస్తుంది.\nవ్యాధుల వ్యాప్తికి మార్గంగా డబ్బు చుట్టూ ప్రస్తుత చర్చ కొన్ని అంశాలపై (కాగితం రకం, తేమ మొదలైనవి) బట్టి కాగితపు డబ్బుపై అనేక రకాల బ్యాక్టీరియా మనుగడ సాగిస్తుందని కనుగొన్న అధ్యయనాల ఆధారంగా. అయినప్పటికీ, కలుషితమైన డబ్బు నుండి మన శరీరాలకు ప్రసారం చేయడానికి ఇంకా బలమైన ఆధారాలు లేవు.\nనాణేలు మరియు నోట్ల (కాగితపు డబ్బు) నుండి కోవిడ్-19 కు కారణమయ్యే వైరస్ ను మీరు సంక్రమించవచ్చని ప్రపంచ ఆరోగ్య సంస్థ (WHO) పేర్కొన్నట్లు కొన్ని వార్తా సంస్థలు గతంలో నివేదించాయి. ఏదేమైనా, WHO స్పష్టం చేసింది మరియు ఈ వాదన తప్పుగా చూపబడింది; నాణేలు మరియు నోట్ల ద్వారా కోవిడ్-19 ప్రసారం గురించి WHO ఎలాంటి హెచ్చరిక లేదా ప్రకటన ఇవ్వలేదు. బదులుగా, వారు సబ్బుతో చేతులు కడుక్కోవడం యొక్క ప్రాముఖ్యతను నొక్కిచెప్పారు, ముఖ్యంగా ఆహారాన్ని నిర్వహించడానికి లేదా తినడానికి ముందు."
    ],
    "Spanish - What our experts say": [
      "El virus que causa el COVID-19 puede ser potencialmente diseminado a través del dinero. Sin embargo, es improbable que cause la dolencia COVID-19 en seres humanos. Un estudio reciente ha mostrado que el virus que causa el COVID-19 puede sobrevivir en superficies sólidas, como monedas, por hasta cuatro días, y en papel, como dinero en efectivo, por hasta tres horas, pero el virus ya no fue infeccioso (viable) luego de ese momento.\nNo han habido investigaciones rigurosas que concluyan o refuten que el COVID-19 pueda ser fácilmente diseminado a través de monedas y dinero en papel de otra manera. Por lo tanto, el riesgo de contraer COVID-19 a partir de que el virus se adhiera al dinero es muy bajo.\nSin embargo, la mejor práctica en general es lavarse las manos y evitar tocar la cara luego de tocar dinero. El virus que causa el COVID-19 es diseminado primariamente a través de contacto de persona a persona, especialmente si estás en contacto cercano con otra persona (dentro de los 6 pies o 2 metros).\nDesde que todavía no entendemos completamente todas las maneras en que el virus podría diseminarse, sería una buena práctica el ser vigilante con el dinero tanto como con cualquier otra superficie potencialmente contaminada, y lavar tus manos con jabón luego de tocarlo."
    ],
    "Spanish - Background and context": [
      "El dinero, incluyendo monedas y billetes, ha sido considerado por un largo tiempo una manera potencial en que las enfermedades son transmitidas de una persona a la otra, aunque no tenemos evidencia fuerte para respaldar esa afirmación. La idea es que los gérmenes se \"adjuntarían\" ellos mismos a los billetes, y luego serían transmitidos al viajar a lo largo de la ruta mano-dinero-mano. Esto puede representar un riesgo a la salud pública especialmente durante la manipulación simultánea de comida y dinero, o cuando se toca dinero y luego nuestra cara sin haberse lavado las manos.\nLa discusión actual acerca del dinero como manera potencial de diseminación de enfermedades está basada en estudios que encontraron que varios tipos de bacterias pueden sobrevivir en papel moneda dependiendo de algunos factores (tipo de papel, humedad, etc.). Sin embargo, aún no existe evidencia fuerte acerca de la transmisión desde dinero contaminado hasta nuestros cuerpos.\nAlgunos boletines de noticias reportaron previamente que la Organización Mundial para la Salud (OMS) afirmó que puedes contraer el virus que causa el COVID-19 desde monedas y notas bancarias (papel moneda). Sin embargo, la OMS clarificó y dijo que esta afirmación había sido malinterpretada; la OMS no divulgó ninguna clase de advertencia o declaración acerca de la transmisión de COVID-19 a través de monedas y notas bancarias. En vez de eso, ha enfatizado la importancia de lavarse las manos con jabón, especialmente antes de manipular comida o comer."
    ],
    "Bengali - What our experts say": [
      "যে ভাইরাসটি কোভিড-১৯ সৃষ্টি করে তা টাকার মাধ্যমে সম্ভাব্যভাবে ছড়িয়ে যেতে পারে। যাইহোক, এটির মাধ্যমে মানুষের মধ্যে কোভিড-১৯-এ অসুস্থতার কারণ হওয়ার সম্ভাবনা কম। সাম্প্রতিক একটি গবেষণায় দেখা গেছে যে কোভিড-১৯-এর কারণ হিসাবে তৈরি হওয়া ভাইরাসটি কয়েনের (ধাতব মুদ্রা) মতো শক্ত পৃষ্ঠে চার দিন পর্যন্ত এবং কাগজের নোটে তিন ঘন্টা অবধি বেঁচে থাকতে পারে, তবে এই সময়ের পরে ভাইরাসের সংক্রমণটি সংক্রামক (কার্যকর) ছিল না। অন্যথায়, ধাতব মুদ্রা এবং কাগজের নোটের মাধ্যমে কোভিড -১৯ সহজেই ছড়িয়ে যেতে পারে কিনা এই সিদ্ধান্তে প্রমাণিত বা অস্বীকার করার জন্য কোন কঠোর গবেষণা হয়নি। সুতরাং, টাকার সাথে লেগে থাকা ভাইরাস থেকে কোভিড-১৯ সংক্রমণ ঝুঁকি খুব কম।যাইহোক, টাকা স্পর্শ করার পরে আপনার মুখ স্পর্শ করা উচিৎ নয় এবং আপনার হাত ধোয়া একটি সাধারণ অনুশীলন। কোভিড-১৯-এ সংক্রামিত ভাইরাসটি প্রাথমিকভাবে ব্যক্তি থেকে ব্যক্তি যোগাযোগের মাধ্যমে ছড়িয়ে পড়ে বিশেষত যদি আপনি অন্য কোনও ব্যক্তির সাথে ঘনিষ্ঠ যোগাযোগ করেন (প্রায় ৬ ফুট বা ২ মিটারের মধ্যে)। যেহেতু ভাইরাসটি কিভাবে ছড়িয়ে পড়তে পারে তার সমস্ত উপায় আমরা এখনও পুরোপুরি জানিনা, সুতরাং অন্য যে কোনও সম্ভাব্য দূষিত পৃষ্ঠের মতোই টাকার প্রতি সজাগ থাকা এবং এটি স্পর্শ করার পরে আপনার হাত সাবান দিয়ে ধুয়ে নেওয়া ভাল অভ্যাস।"
    ],
    "Bengali - Background and context": [
      "ধাতব মুদ্রা এবং কাগজের নোট টাকা দীর্ঘকাল ধরে রোগ-জীবাণু একজন ব্যক্তি থেকে অন্য ব্যক্তিতে সংক্রমণ হওয়ার সম্ভাব্য উপায় হিসেবে বিবেচিত হয়ে আসছে, যদিও আমাদের কাছে এই দাবির পক্ষে সমর্থন করার দৃঢ় প্রমাণ নেই। ধারণাটি হ'ল জীবাণুগুলি টাকার সাথে নিজেকে \"সংযুক্ত\" করে দেবে এবং তারপরে হাতে হাতে এটি সঞ্চারিত হবে। এটি জনস্বাস্থ্যের ঝুঁকির প্রতিনিধিত্ব করতে পারে বিশেষত খাদ্য এবং টাকার একযোগে নাড়াচাড়া করার সময় বা টাকা স্পর্শ করে আমাদের হাত ধুয়ে না নিয়ে আমাদের মুখ স্পর্শ করলে। \nরোগ ছড়ানোর সম্ভাব্য উপায় হিসাবে টাকার উপর বর্তমান আলোচনা অধ্যয়নের উপর ভিত্তি করে দেখা গেছে যে, কয়েকটি কারণের (কাগজের ধরন, আর্দ্রতা ইত্যাদি) উপর নির্ভর করে বিভিন্ন ধরণের ব্যাকটেরিয়া কাগজের টাকায় বেঁচে থাকতে পারে। যাইহোক, দূষিত টাকা থেকে আমাদের দেহে স্থানান্তরিত করার সপক্ষে এখনও কোনও শক্ত প্রমাণ পাওয়া যায় না।এর আগে কয়েকটি সংবাদে প্রকাশিত হয়েছিল যে বিশ্ব স্বাস্থ্য সংস্থা (ডাব্লুএইচও) দাবি করেছে যে আপনি ধাতব মুদ্রা এবং ব্যাংক নোট (কাগজের টাকা) থেকে ভাইরাস সংক্রমণ করতে পারেন যা কোভিড -১৯-এর কারণ। তবে বিশ্ব স্বাস্থ্য সংস্থা স্পষ্ট করে বলেছে যে, এই দাবিটি ভুল উপস্থাপন করা হয়েছে; বিশ্ব স্বাস্থ্য সংস্থা কোভিড -১৯ ট্রান্সমিশন সম্পর্কে মুদ্রা এবং নোটের মাধ্যমে কোনও ধরণের সতর্কতা বা বিবৃতি দেয়নি। পরিবর্তে, তারা সাবান দিয়ে হাত ধোয়ার গুরুত্বের উপর জোর দিয়েছিল, বিশেষত খাবার পরিচালনা বা খাওয়ার আগে।"
    ]
  },
  {
    "id": "recllQqVLGnigxKql",
    "Question": "What is the latest research regarding sexual transmission of COVID-19?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & sexual transmission",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA",
      "Mexico"
    ],
    "Background and context": "There are a number of different ways that viruses can be transmitted. Some viruses can spread through physical contact or touch, through bodily fluids such as the exchange of saliva, or through the air. Other viruses might be transmitted through bites from ticks or mosquitos, who carry the virus, or through food and water that are contaminated. Some other viruses can be shared through sexual contact, or by sharing needles that have been contaminated by bodily fluids. \n",
    "What our experts say": "There have been no documented cases of sexual transmission. Based on the evidence available right now, experts do not know whether COVID-19 can spread from person to person through bodily fluids that are not respiratory functions like talking, coughing and sneezing. Some confusion around this could be because traces of the virus that causes COVID-19 were found in the semen samples of 6 out of 38 men who provided samples in a research study. According to the study, four of the six men were still infected, while two were recovering. This does not mean that COVID-19 is sexually transmitted. Traces of the virus have also been found in other bodily fluids and stool samples, but it is unclear whether the virus can spread from person to person through sexual transmission.\n",
    "Glossary Terms": [
      "rec2UNEXbTkSCx30Q"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "semen",
      "COVID-19",
      "sexual transmission",
      "STD",
      "STI"
    ],
    "Other resources": "1. Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus Disease 2019 ([JAMA](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765654)) \n",
    "DB (French)": [
      "recjXAWxtpH214q4o"
    ],
    "DB (Hindi)": [
      "recq6Hvn8x5elieUc"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recZ0eA5hjfzfCzlq"
    ],
    "DB (Spanish)": [
      "recimHuTOew03N6f2"
    ],
    "DB (Arabic)": [
      "recCG8pFhWsMhyhoR"
    ],
    "DB (Bengali)": [
      "rec0Z43PrHHv6Esm3"
    ],
    "DB (Portuguese)": [
      "recB0FV3pBQrem6mD"
    ],
    "Rollup test 2": [
      "recPqHSF7Xxb6ZXH5"
    ],
    "Last modified manual": "2020-05-27",
    "Last edited (simplified)": "2020-05-27T22:47:58.000Z",
    "Last edited (experts say)": "2020-06-13T19:41:27.000Z",
    "Last modified": "2020-05-27",
    "What our experts say wordcount": 130,
    "Background and context wordcount": 78,
    "Other resources wordcount": 16,
    "Wordcount": 224,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Arabic Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Il n’y a eu aucun cas documenté de transmission sexuelle. D’après les données probantes à disposition actuellement, les experts ne savent pas si la COVID-19 peut se propager de personne à personne par des liquides biologiques qui ne proviennent pas des fonctions du système respiratoire tels que parler, tousser et éternuer. Il existe une certaine confusion sur le sujet, car des traces du virus responsable de la COVID-19 ont été trouvées dans les échantillons de sperme de 6 hommes sur 38 qui ont fourni des échantillons lors d’une étude de recherche. D’après l’étude, quatre des six hommes étaient encore infectés, alors que deux étaient en cours de guérison. Cela ne signifie pas que la COVID-19 est sexuellement transmissible. Des traces du virus ont aussi été trouvées dans d’autres liquides biologiques et dans des échantillons de matières fécales, mais il n’est pas clair si le virus peut se propager sexuellement de personne à personne."
    ],
    "French - Background and context": [
      "Les virus peuvent être transmis de différentes manières. Certains virus peuvent se propager par contact physique ou par le toucher, par les liquides corporels tels que l’échange de salive ou par voie aérienne. D’autres virus peuvent être transmis par des piqûres de tiques ou de moustiques porteurs du virus, ou par des aliments ou de l’eau contaminés. D’autres virus peuvent être transmis par contact sexuel ou par le partage d’aiguilles contaminées par des liquides corporels. "
    ],
    "Hindi - What our experts say": [
      "यौन प्रसार के कोई भी मामले दर्ज नहीं किए गए हैं। उपलब्ध सबूतों के आधार पर, विशेषज्ञों को यह नहीं पता है कि कोविड-19 एक व्यक्ति से दूसरे व्यक्ति में यौन रूप से फैल सकता है या नहीं।श्वसन प्रक्रिया के माध्यम से आने वाली साँस की बूँदे, जैसे बोलने, खाँसने, और छींकने के अलावा अन्य शारीरिक द्रव्य से वाइरस के फैलने के बारे में जानकारी उपलब्ध नहीं हैं। इस विषय के बारे में कुछ भ्रम हो सकता है क्योंकि कोविड-19 का कारण बनने वाले वायरस के निशान 38 पुरुषों में से 6 के वीर्य के नमूनों में पाए गए थे जिन्होंने एक शोध अध्ययन में नमूने प्रदान किए थे। अध्ययन के अनुसार, छह लोगों में से चार अभी भी संक्रमित थे, जबकि दो ठीक हो रहे थे। इसका मतलब यह नहीं है कि कोविड-19 एक व्यक्ति से दूसरे व्यक्ति में यौन रूप से फैलता है। वायरस के निशान अन्य शारीरिक तरल पदार्थों और मल के नमूनों में भी पाए गए हैं, लेकिन यह स्पष्ट नहीं है कि क्या वायरस एक व्यक्ति से दूसरे व्यक्ति में यौन रूप से फैल सकता है।"
    ],
    "Hindi - Background and context": [
      "ऐसे कई तरीके हैं जिनसे वायरस फैलता है। कुछ वायरस शारीरिक संपर्क या स्पर्श के माध्यम से, लार के रूप में या हवा के माध्यम से फैल सकते हैं। अन्य वायरस टिक्स या मच्छरों के काटने से फैल सकते हैं, जो वायरस ले जाते हैं, या भोजन और पानी के माध्यम से जो दूषित होते हैं। कुछ अन्य वायरस यौन संपर्क के माध्यम से, या सुइयों का आदान – प्रदान करने से फैल सकते हैं जो शारीरिक तरल पदार्थों द्वारा दूषित हो गए हैं।"
    ],
    "Telugu - What our experts say": [
      "లైంగిక వ్యాప్తికి సంబంధించిన పత్రాలు ఏవీ లేవు. ప్రస్తుతం అందుబాటులో ఉన్న సాక్ష్యాల ఆధారంగా, మాట్లాడటం, దగ్గు మరియు తుమ్ము వంటి శ్వాసకోశ పనులు కాని శారీరక ద్రవాల ద్వారా కోవిడ్-19 వ్యక్తి నుండి వ్యక్తికి వ్యాపించగలదా అని నిపుణులకు తెలియదు. పరిశోధనా అధ్యయనంలో నమూనాలను అందించిన 38 మందిలో 6 మంది వీర్య నమూనాలలో కోవిడ్-19 కు కారణమయ్యే వైరస్ యొక్క జాడలు కనుగొనబడినందున దీని చుట్టూ కొంత గందరగోళం ఏర్పడుతుంది. అధ్యయనం ప్రకారం, ఆరుగురిలో నలుగురికి వ్యాధి సోకింది, ఇద్దరు కోలుకుంటున్నారు. కోవిడ్-19 లైంగికంగా వ్యాపిస్తుందని దీని అర్థం కాదు. వైరస్ యొక్క జాడలు ఇతర శారీరక ద్రవాలు మరియు మలం నమూనాలలో కూడా కనుగొనబడ్డాయి, అయితే లైంగిక వ్యాప్తి ద్వారా వైరస్ వ్యక్తి నుండి వ్యక్తికి వ్యాపించగలదా అనేది అస్పష్టంగా ఉంది."
    ],
    "Telugu - Context and background": [
      "వైరస్లు వ్యాప్తి చెందడానికి అనేక మార్గాలు ఉన్నాయి. కొన్ని వైరస్లు శారీరక సంబంధం లేదా స్పర్శ ద్వారా, లాలాజల మార్పిడి వంటి శారీరక ద్రవాల ద్వారా లేదా గాలి ద్వారా వ్యాప్తి చెందుతాయి. ఇతర వైరస్లు పేలు లేదా దోమల నుండి కాటు ద్వారా, వైరస్ను తీసుకువెళ్ళే లేదా కలుషితమైన ఆహారం మరియు నీటి ద్వారా వ్యాప్తి చెందుతాయి. కొన్ని ఇతర వైరస్లను లైంగిక సంపర్కం ద్వారా లేదా శారీరక ద్రవాల ద్వారా కలుషితమైన సూదులను పంచుకోవడం ద్వారా పంచుకోవచ్చు."
    ],
    "Spanish - What our experts say": [
      "No han habido casos documentados de transmisión sexual. Basados en la evidencia disponible en este momento, los expertos no saben si el COVID-19 puede diseminarse de persona a persona a través de los fluidos corporales que no son partes de las funciones respiratorias, tales como hablar, toser o estornudar. Alguna confusión acerca de esto pudo deberse a que trazas del virus que causa COVID-19 fueron encontradas en muestras de semen en 6 de 38 pacientes que las proveyeron para un estudio de investigación. De acuerdo al mismo, cuatro de los seis hombres aún estaban infectados, mientras que dos se estaban recuperando. Esto no significa que el COVID-19 sea transmitido sexualmente. Trazas del virus también han sido encontradas en otros fluidos corporales y muestras de excrementos, pero no está claro si el virus puede diseminarse de persona a persona a través de transmisión sexual."
    ],
    "Spanish - Background and context": [
      "Hay una cantidad de maneras diferentes en que los virus pueden ser transmitidos. Algunos pueden diseminarse a través de contacto o toque físico, a través de fluidos corporales tales como el intercambio de saliva, o a través del aire. Otros virus podrían ser transmitidos a través de picaduras de garrapatas o mosquitos, los cuales transportan el virus, o a través de comida y agua que están contaminadas. Algunos otros virus pueden ser compartidos a través de contacto sexual, o por compartir agujas que han sido contaminadas por fluidos corporales."
    ],
    "Arabic - What our experts say": [
      "لم تُسجَل أية حالات انتقال عن طريق ممارسة الجنس. استنادًا إلى الدليل المتوفر حاليًا لا يعرف الخبراءُ ما إذا كان بمقدور وباء كوفيد-19 الانتشار بين شخصٍ وآخر عن طريق إفرازات الجسم غير الناتجة عن الوظائف التنفسيّة كالكلام والسُعَال والعُطَاس. سبب هذا الالتباس الحاصل هو العثور على آثار للفيروس المُسبب لوباء كوفيد-19 في عينات السائل المنوي  لـ 6 رجال من بين 38 رجلًا قدموا العينات لصالح دراسة بحثيّة. وفقًا لهذه الدراسة أربعة من بين ستة رجال ما زالوا مصابين أما الاثنين كانوا يتماثلون للشفاء. لا يعني هذا أن وباء كوفيد-19 يُمكنه الانتقال عن طريق ممارسة الجنس. عُثر أيضًا على آثار للفيروس في إفرازات أخرى للجسم وفي عينات من البراز، لكن لا يزال من غير الواضح ما إذا كان بمقدور الفيروس الانتشار من شخصٍ إلى آخر عن طريق ممارسة الجنس.\n"
    ],
    "Arabic - Background and context": [
      "هناك العديد من الطُرق المختلفة التي يُمكن للفيروس الانتقال من خلالها. إذ يُمكن لبعض الفيروسات الانتشار عن طريق التواصل الجسدي أو اللمس، أي من خلال إفرازات الجسم كتبادل اللعاب أو عبر الهواء. كما يُمكن لفيروسات أخرى الانتقال عن طريق لَسعَات القِرْدان أوالبعوض الحاملة للفيروس، أو عن طريق الطعام أو الماء الملوث. ويُمكن لبعض الفيروسات الأخرى الانتشار عن طريق التواصل الجنسي أو عن طريق مشاركة الإبر الملوثة بإفرازات الجسم.\n"
    ],
    "Bengali - What our experts say": [
      "যৌন সংক্রমণের কোনও নথিভুক্ত ঘটনা নেই। এই মুহুর্তে প্রাপ্ত প্রমাণের ভিত্তিতে বিশেষজ্ঞরা জানেন না যে, কোভিড-১৯ শারীরিকভাবে তরল পদার্থের মাধ্যমে ব্যক্তি থেকে অন্য ব্যক্তিতে ছড়িয়ে পড়তে পারে কিনা যা শ্বাসযন্ত্রের কাজ নয় যেমনঃ কথা বলা, কাশি এবং হাঁচি দেয়। এ সম্পর্কে কিছু বিভ্রান্তি হতে পারে কারণ একটি গবেষণায় নমুনা সরবরাহকারী ৩৮ জনের মধ্যে ৬ জনের বীর্য নমুনায় কোভিড-১৯-এর কারণ হিসাবে ভাইরাসের চিহ্ন পাওয়া গেছে। সমীক্ষায় দেখা গেছে, ছয়জনের মধ্যে চারজন এখনও সংক্রামিত ছিল, দু'জন সেরে উঠছিল। এর অর্থ এই নয় যে কোভিড-১৯ যৌন সংক্রামিত। অন্যান্য শারীরিক তরল এবং মল নমুনায় ভাইরাসটির চিহ্নগুলিও পাওয়া গেছে, তবে যৌন সংক্রমণের মাধ্যমে ভাইরাসটি ব্যক্তি থেকে অন্য ব্যক্তিতে ছড়িয়ে পড়তে পারে কিনা তা স্পষ্ট নয়।"
    ],
    "Bengali - Background and context": [
      "ভাইরাস সংক্রমণ বিভিন্ন উপায়ে হতে পারে। কিছু ভাইরাস শারীরিক যোগাযোগ বা স্পর্শের মাধ্যমে শারীরিক তরল যেমন লালা বিনিময় বা বায়ুর মাধ্যমে ছড়িয়ে যেতে পারে। ভাইরাস বহন করে এমন ছারপোকা বা মশার কামড়ের মাধ্যমে, বা দূষিত খাবার এবং পানির মাধ্যমে অন্যান্য ভাইরাস সংক্রমণ হতে পারে। কিছু অন্যান্য ভাইরাস যৌন যোগাযোগের মাধ্যমে বা শারীরিক তরল দ্বারা দূষিত সূঁচগুলি শেয়ার করার মাধ্যমে ছড়াতে পারে।"
    ],
    "Portuguese - What our experts say": [
      "Não houve casos documentados de transmissão sexual. Com base em evidências disponíveis no momento, os especialistas não sabem se o COVID-19 pode se propagar entre humanos por meio de fluidos corporais que não pertencem às funções respiratórias, como falar, tossir e espirrar. Alguma confusão em torno questão se deve a traços do vírus que causa o COVID-19 encontrados nas amostras de sêmen de 6 dos 38 homens que forneceram amostras em um estudo científico. De acordo com o estudo, quatro dos seis homens ainda estavam infectados, enquanto dois estavam se recuperando. Isso não significa que o COVID-19 seja transmitido sexualmente. Traços do vírus também foram encontrados em outros fluidos corporais e amostras de fezes, mas não está comprovado se o vírus pode se espalhar entre humanos por meio da transmissão sexual."
    ],
    "Portuguese - Background and context": [
      "Existem várias maneiras diferentes de transmitir um vírus. Alguns vírus podem se propagar pelo contato físico ou pelo toque, por fluidos corporais, como na troca de saliva, ou pelo ar. Outros vírus podem ser transmitidos através de picadas de carrapatos ou de mosquitos que os transportam, ou através de alimentos e água contaminados. Alguns outros vírus podem ser transmitidos por meio do contato sexual ou do compartilhamento de agulhas contaminadas por fluidos corporais."
    ]
  },
  {
    "id": "recOiBtU1KHxAQAgq",
    "Question": "Will transmission of COVID-19 slow down in the summer?",
    "Status": "Published",
    "Category": "Spread",
    "Subcategory": "On: COVID-19 transmission during the summer",
    "Source of the question": [
      "Fact-checking organization"
    ],
    "Country question was sourced from": [
      "India"
    ],
    "Background and context": "Some types of viruses (including some coronaviruses) have shown lower survival in warmer and more humid climates. Some lab experiments have shown that SARS-CoV-2 may be sensitive to temperature, humidity, and ultraviolet light. These lab tests may lead people to believe that climatic effects (e.g. warmer weather or seasonal changes) could slow the spread of the virus. Though more studies are needed, outside of the lab, the effect of climate (including temperature and humidity) on the spread of COVID-19 appears to be minimal. Countries around the world, including Asian and African countries with regular temperatures greater than 25 degrees celsius, have reported community transmission (spread) of the virus. \n",
    "What our experts say": "COVID-19 can be spread in all climates and seasons. According to an August publication in the journal Nature, 'No human-settled area in the world is protected from COVID-19 transmission by virtue of weather, at any point in the year.'\n \nStudies that have explored the impact of temperature or weather on COVID-19 spread have shown mixed results. Some have been positive, some negative, and others neutral. Researchers have concluded that there are many factors that likely play a much larger role in the spread of the virus than the weather, including population density, human mobility, social distancing policies and practices, testing, public health facilities, and more. \n\nWhile more studies are needed, warmer weather does not appear to reduce the spread of COVID-19, and it does not impact how the virus spreads from person to person. Routine hand-washing, social distancing practices, avoidance of crowds, wearing face masks, and surface cleaning should be used to prevent the spread of COVID-19 between people and via indirect (non-contact) transmission.\n",
    "Glossary Terms": [
      "recDalYrz2m23kS2e"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "summer transmission",
      "infection",
      "seasonality",
      "trends",
      "patterns"
    ],
    "Other resources": "1. Effective transmission across the globe: the role of climate in COVID-19 mitigation strategies ([The Lancet](http://effective%20transmission%20across%20the%20globe:%20the%20role%20of%20climate%20in%20COVID-19%20mitigation%20strategies/))\n2. Misconceptions about weather and seasonality must not misguide COVID-19 response ([Nature](https://www.nature.com/articles/s41467-020-18150-z.pdf))\n3. No association of COVID-19 transmission with temperature or UV radiation in Chinese cities ([European Respiratory Journal](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144256/))\n4. Is the transmission of novel coronavirus disease (COVID-19) weather dependent? ([Journal of the Air & Waste Management Association](https://www.tandfonline.com/doi/abs/10.1080/10962247.2020.1823763?journalCode=uawm20))\n",
    "DB (French)": [
      "recpBz5mkWp9d4kae"
    ],
    "DB (Hindi)": [
      "recCq6AMpxSN3gjOF"
    ],
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recGhQWUrospwpniV"
    ],
    "DB (Spanish)": [
      "recZDjQIYjJQkAUcx"
    ],
    "DB (Bengali)": [
      "recHgGpEBMUlnrgjy"
    ],
    "DB (Portuguese)": [
      "recihhhSzG3hv9Uj8"
    ],
    "Rollup test 2": [
      "recyfdvNrRlfXcVA5"
    ],
    "Last modified manual": "2020-12-03",
    "Last edited (simplified)": "2020-12-03T20:38:53.000Z",
    "Last edited (experts say)": "2020-12-07T14:38:42.000Z",
    "Last modified": "2020-12-07",
    "What our experts say wordcount": 164,
    "Background and context wordcount": 108,
    "Other resources wordcount": 61,
    "Wordcount": 333,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "La science n’est pas claire quant à une baisse de la propagation du coronavirus pendant les mois d’été plus chauds. Certains virus, comme ceux responsable du rhume et de la grippe, ne se propagent pas aussi facilement par temps chaud. Nous ne sommes pas certains de la façon dont le coronavirus réagira aux températures changeantes. À ce stade, une réduction de la transmission en raison de la température n’est qu’hypothétique."
    ],
    "French - Background and context": [
      "Certains virus tels que ceux du coryza et de la grippe se sont toujours propagés plus rapidement quand la température est plus froide. Des chercheurs ont exploré comment la température et l’humidité pourraient influencer la propagation d’autres virus, mais il n’existe jusqu’à présent aucune donnée probante d’un tel impact dans le contexte de la COVID-19."
    ],
    "Hindi - What our experts say": [
      "यह स्पष्ट नहीं है कि गर्मी के महीनों में कोविड​​-19 का प्रसार कम हो जाएगा। कुछ वायरस, जिनसे सामान्य सर्दी और फ्लू होते हैं, वे गर्म मौसम में आसानी से नहीं फैलते हैं। यह स्पष्ट नहीं है कि कोविड​​-19 बदलते तापमान पर कैसी प्रतिक्रिया करेगा। इस समय, केवल अनुमान लगाया जा रहा है, प्रमाणित कुछ भी नहीं है।"
    ],
    "Hindi - Background and context": [
      "कुछ वायरस, जैसे कि सामान्य सर्दी और फ्लू, मौसम के ठंडे होने पर तेजी से फैलते हैं। शोधकर्ताओं ने जांच की है कि तापमान और आर्द्रता से अन्य वायरस के प्रसार कैसे प्रभावित हुए हैं, लेकिन हमारे पास अभी तक कोविड​​-19 पर तापमान के प्रभाव को लेकर कोई जानकारी नहीं है।"
    ],
    "Telugu - What our experts say": [
      "వెచ్చని వేసవి నెలల్లో కోవిడ్ -19 యొక్క వ్యాప్తి తగ్గుతుందా అనే దానిపై శాస్త్రం అస్పష్టంగా ఉంది. జలుబు మరియు ఫ్లూకు కారణమయ్యే కొన్ని వైరస్లు వెచ్చని వాతావరణంలో అంత తేలికగా వ్యాప్తి చెందవు. మారుతున్న ఉష్ణోగ్రతలకు కోవిడ్ -19 ఎలా స్పందిస్తుందో మాకు ఖచ్చితంగా తెలియదు. ఈ దశలో, ఉష్ణోగ్రత-సంబంధిత ప్రసార తగ్గింపులు  హాత్మకమైనవి."
    ],
    "Telugu - Context and background": [
      "సాధారణ జలుబు మరియు ఫ్లూ వంటి కొన్ని వైరస్లు వాతావరణం చల్లగా ఉన్నప్పుడు చారిత్రాత్మకంగా వేగంగా వ్యాప్తి చెందుతాయి. ఇతర వైరస్ల వ్యాప్తి ఉష్ణోగ్రత మరియు తేమతో ఎలా ప్రభావితమవుతుందో పరిశోధకులు పరిశోధించారు, కాని ఇప్పటివరకు కోవిడ్ -19 సందర్భంలో అటువంటి ప్రభావానికి ఆధారాలు లేవు."
    ],
    "Spanish - What our experts say": [
      "No está claro para la ciencia si la diseminación del COVID-19 disminuirá en los meses más cálidos del verano. Algunos virus, como aquellos que causan el resfrío común y la gripe, no se diseminan tan fácilmente en tiempo cálido. No sabemos con seguridad cómo reaccionará el COVID-19 a las temperaturas cambiantes. En esta etapa, las reducciones en transmisión relacionadas con la temperatura son hipotéticas."
    ],
    "Spanish - Background and context": [
      "Algunos virus, tales como el del resfrío común y el de la gripe, históricamente se han diseminado más rápido cuando el tiempo es más frío. Los investigadores han encontrado que la diseminación de otros virus podría ser influida por la temperatura y la humedad, pero hasta ahora no hay evidencia de tal impacto en el contexto del COVID-19."
    ],
    "Bengali - What our experts say": [
      "উষ্ণ গ্রীষ্মের মাসগুলিতে কোভিড-১৯ এর বিস্তার হ্রাস পাবে কিনা সে সম্পর্কে বিজ্ঞান অস্পষ্ট। কিছু ভাইরাস যা সাধারণ সর্দি এবং ফ্লু সৃষ্টি করে তা উষ্ণ আবহাওয়ায় সহজে ছড়িয়ে যায় না। কোভিড-১৯ কীভাবে পরিবর্তিত তাপমাত্রায় প্রতিক্রিয়া জানাবে তা আমরা নিশ্চিতভাবে জানি না। এই পর্যায়ে, তাপমাত্রা সম্পর্কিত সংক্রমণ হ্রাস অনুমানমূলক।"
    ],
    "Bengali - Background and context": [
      "অতীতে দেখা গেছে সাধারণ সর্দি এবং ফ্লু জাতীয় কিছু ভাইরাস, শীতকালীন আবহাওয়ায় শীঘ্রই ছড়িয়ে পড়েছে। গবেষকরা তদন্ত করেছেন যে কীভাবে অন্যান্য ভাইরাসগুলির বিস্তার তাপমাত্রা এবং আর্দ্রতার দ্বারা প্রভাবিত হতে পারে তবে এখনও পর্যন্ত কোভিড-১৯ এর প্রসঙ্গে এ জাতীয় প্রভাবের কোনও প্রমাণ পাওয়া যায়নি।"
    ],
    "Portuguese - What our experts say": [
      "A ciência não tem uma resposta clara sobre a diminuição da propagação do COVID-19 nos meses mais quentes do verão. Alguns vírus, como os que causam o resfriado e a gripe comuns, não se propagam tão facilmente em temperaturas mais altas. Não sabemos ao certo como o COVID-19 reage às mudanças de temperatura."
    ],
    "Portuguese - Background and context": [
      "Alguns vírus, como o resfriado e a gripe comuns, de acordo com registros históricos, se propagam mais rapidamente quando o tempo está mais frio. Pesquisadores investigaram como a propagação de outros vírus pode ser influenciada pela temperatura e pela umidade, mas não há evidências de tal impacto em relação ao COVID-19 até agora."
    ]
  },
  {
    "id": "recu8V6IGjMveS5Ku",
    "Question": "Is there any relationship between the use of antibiotics and treatment of COVID-19?",
    "Status": "Published",
    "Category": "Treatment",
    "Subcategory": "On: COVID-19 & antibiotics ",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Antibiotics are antibacterial medications that either slow down or destroy the growth of bacteria. They are used to treat infections that are caused by bacteria. (More information on the differences between viruses and bacteria can be found in the additional resources section.) The COVID-19 disease is caused by an infection with a virus, not a bacteria. COVID-19 is a disease that is a type of coronavirus. Coronaviruses are a group of viruses that cause diseases such as the common cold, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Because viruses and bacteria are different, the illnesses that they cause cannot be treated by the same type of medication. Antibiotics cannot be used to treat viral infections like COVID-19.  \n",
    "What our experts say": "Antibiotics are not used to treat or cure COVID-19, but they _can_ treat bacterial infections that can happen as a result of complications from the COVID-19 virus. Viruses and bacterial infections cause different types of illnesses, and antibiotics are only effective in treating bacterial infections, not viruses like COVID-19. Antibiotics should not be taken as a way to prevent or treat COVID-19 and they should not be taken unless prescribed by a doctor. Sometimes, antibiotics might be used in patients with COVID-19 but **only** to treat secondary bacterial infections. \n",
    "Glossary Terms": [
      "reco5k0tpirgGDeqb",
      "recnFUXyIZy81Rj1I",
      "rechTyFW9yFtRWh8o",
      "recRGHDXxeEnXrS9t",
      "recAFuzwLppTBDIPe"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "antibiotics",
      "bacterial infection",
      "prevention",
      "treatment",
      "virus",
      "medicine"
    ],
    "Other resources": "1. Q&A on coronaviruses (COVID-19) ([WHO](https://www.who.int/news-room/q-a-detail/q-a-coronaviruses   http://www.med.umich.edu/asp/pdf/adult_guidelines/COVID-19-treatment.pdf))\n2. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study ([The Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30211-7/fulltext))   \n3. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens ([JAMA Network](https://jamanetwork.com/journals/jama/fullarticle/2764787))\n4. Difference between a bacteria and a virus ([Mayo Clinic](https://www.mayoclinic.org/diseases-conditions/infectious-diseases/expert-answers/infectious-disease/faq-20058098)) \n",
    "DB (French)": [
      "recXOlSZvyEECnqkk"
    ],
    "DB (Hindi)": [
      "recv1FiBeWvUUxato"
    ],
    "Editorial notes:": "\n\n",
    "In translated DBs?": "Yes",
    "DB (Telugu)": [
      "recEbGNPR9Gg7y0UN"
    ],
    "DB (Spanish)": [
      "recXx9HDo4XHVJxOp"
    ],
    "DB (Arabic)": [
      "rechRACpRMTt9uIXe"
    ],
    "DB (Bengali)": [
      "recFawgz1x8cYATVq"
    ],
    "DB (Portuguese)": [
      "recgb78NZrh86ixV0"
    ],
    "Rollup test 2": [
      "recbkzMJPhv0HKczy"
    ],
    "Last modified manual": "2020-05-26",
    "Last edited (simplified)": "2020-05-26T14:42:58.000Z",
    "Last edited (experts say)": "2020-05-26T14:42:58.000Z",
    "Last modified": "2020-05-26",
    "What our experts say wordcount": 90,
    "Background and context wordcount": 123,
    "Other resources wordcount": 50,
    "Wordcount": 263,
    "French Q status": [
      "Published"
    ],
    "Hindi Q Status": [
      "Published"
    ],
    "Telugu Q Status": [
      "Published"
    ],
    "Spanish Q status": [
      "Published"
    ],
    "Arabic Q status": [
      "Published"
    ],
    "French - What our experts say": [
      "Les antibiotiques ne sont pas administrés pour traiter ou guérir la COVID-19, mais ils peuvent traiter les infections bactériennes qui surviendraient à la suite de complications de la COVID-19. Les virus et les infections bactériennes provoquent différents types de maladies et les antibiotiques ne sont efficaces que pour traiter les infections bactériennes, non les virus tels que celui responsable de la COVID-19. Les antibiotiques ne devraient pas être pris pour prévenir ou traiter la COVID-19 et ils ne devraient être pris que sur ordonnance d’un médecin. Les antibiotiques peuvent parfois être administrés à des patients souffrant de COVID-19, mais seulement pour traiter des infections bactériennes secondaires."
    ],
    "French - Background and context": [
      "Les antibiotiques sont des médicaments antibactériens qui ralentissent la croissance des bactéries ou les détruisent. Ils sont utilisés pour traiter les infections provoquées par les bactéries. (De plus amples précisions sur les différences entre virus et bactéries se trouvent dans la section des ressources complémentaires.) La COVID-19 est provoquée par une infection virale et non par une bactérie. La COVID-19 est une maladie provoquée par un type de coronavirus. Les coronavirus sont un groupe de virus responsables de maladies telles que le coryza (rhume de cerveau), le syndrome respiratoire aigu sévère (SRAS) et le syndrome respiratoire du Moyen-Orient (SRM). Dans la mesure où les virus sont différents des bactéries, les maladies qu’ils provoquent ne peuvent pas être traitées par le même type de médicaments. Les antibiotiques ne peuvent pas être administrés pour traiter des infections virales telles que la COVID-19."
    ],
    "Hindi - What our experts say": [
      "एंटीबायोटिक्स का उपयोग कोविड​​-19 के इलाज के लिए नहीं किया जाता है, लेकिन वे बैक्टीरिया इनफ़ेक्शन/ संक्रमण का इलाज कर सकते हैं जो कोविड​​-19 वायरस के कारण हो सकता है। वायरस और बैक्टीरियल इनफ़ेक्शन/ संक्रमण के कारण विभिन्न प्रकार की बीमारियाँ हो सकती हैं, और एंटीबायोटिक्स केवल बैक्टीरियल इनफ़ेक्शन के उपचार में प्रभावी होते हैं, कोविड-19 जैसे वायरस के नहीं। चिकित्सक के पर्चे के बिना एंटीबायोटिक्स को कोविड-19 को रोकने या उसके इलाज के तरीके के रूप में नहीं लिया जाना चाहिए। कभी-कभी, एंटीबायोटिक दवाओं का उपयोग कोविड-19 के रोगियों पर किया जाता है, लेकिन केवल यदि बैक्टीरीयल इन्फ़ेक्शन भी हो गया हो तब।"
    ],
    "Hindi - Background and context": [
      "एंटीबायोटिक्स जीवाणुरोधी (एंटीबैक्टीरियल)दवाएं हैं जो या तो बैक्टीरिया के विकास को धीमा या नष्ट कर देती हैं। उनका उपयोग बैक्टीरिया के कारण होने वाले संक्रमण के इलाज के लिए किया जाता है। (आप वायरस और बैक्टीरिया के बीच अंतर के बारे में अधिक जानकारी ‘अन्य जानकारी’ भाग से प्राप्त कर सकते हैं।) कोविड-19 रोग एक वायरस के कारण होता है, न कि बैक्टीरिया के कारण। कोविड-19 एक बीमारी है जो कोरोनावायरस का एक प्रकार है। कोरोनावाइरस वायरस का एक समूह है जो सामान्य सर्दी, गंभीर तीव्र श्वसन सिंड्रोम (SARS) और मिडल ईस्ट श्वसन सिंड्रोम (MERS) जैसी बीमारियों का कारण बनता है। क्योंकि वायरस और बैक्टीरिया अलग-अलग होते हैं, उनके कारण हुई बीमारियों के इलाज एक ही प्रकार की दवा द्वारा नहीं किया जा सकता है। कोविड​​-19 जैसे वायरल संक्रमण के इलाज के लिए एंटीबायोटिक्स का उपयोग नहीं किया जा सकता है।"
    ],
    "Telugu - What our experts say": [
      "కోవిడ్-19 ను చికిత్స చేయడానికి లేదా నయం చేయడానికి యాంటీబయాటిక్స్ ఉపయోగించబడవు, కాని అవి కోవిడ్-19 వైరస్ నుండి వచ్చే సమస్యల ఫలితంగా సంభవించే బాక్టీరియల్ ఇన్ఫెక్షన్లకు చికిత్స చేయగలవు. వైరస్లు మరియు బాక్టీరియల్ ఇన్ఫెక్షన్లు వివిధ రకాల అనారోగ్యాలకు కారణమవుతాయి మరియు యాంటీబయాటిక్స్ బ్యాక్టీరియా ఇన్ఫెక్షన్ల చికిత్సలో మాత్రమే ప్రభావవంతంగా ఉంటాయి, కోవిడ్-19 వంటి వైరస్లు కాదు. కోవిడ్-19 ను నివారించడానికి లేదా చికిత్స చేయడానికి యాంటీబయాటిక్స్ ఒక మార్గంగా తీసుకోకూడదు మరియు వైద్యుడు సూచించకపోతే వాటిని తీసుకోకూడదు. కొన్నిసార్లు, కోవిడ్-19 ఉన్న రోగులలో యాంటీబయాటిక్స్ వాడవచ్చు కాని ద్వితీయ బాక్టీరియల్ ఇన్ఫెక్షన్లకు చికిత్స చేయడానికి మాత్రమే."
    ],
    "Telugu - Context and background": [
      "యాంటీబయాటిక్స్ యాంటీ బాక్టీరియల్ మందులు, ఇవి బ్యాక్టీరియా పెరుగుదలను తగ్గిస్తాయి లేదా నాశనం చేస్తాయి. బ్యాక్టీరియా వల్ల కలిగే ఇన్‌ఫెక్షన్లకు చికిత్స చేయడానికి వీటిని ఉపయోగిస్తారు. (వైరస్లు మరియు బ్యాక్టీరియా మధ్య వ్యత్యాసాలపై మరింత సమాచారం అదనపు వనరుల విభాగంలో చూడవచ్చు.) కోవిడ్-19 వ్యాధి బాక్టీరియా కాకుండా వైరస్ సంక్రమణ వల్ల సంభవిస్తుంది. కోవిడ్-19 అనేది ఒక రకమైన కరోనావైరస్. కరోనావైరస్లు సాధారణ జలుబు, తీవ్రమైన అక్యూట్ రెస్పిరేటరీ సిండ్రోమ్ (SARS) మరియు మిడిల్ ఈస్ట్ రెస్పిరేటరీ సిండ్రోమ్ (MERS) వంటి వ్యాధులకు కారణమయ్యే వైరస్ల సమూహం. వైరస్లు మరియు బ్యాక్టీరియా భిన్నంగా ఉన్నందున, అవి కలిగించే అనారోగ్యాలను ఒకే రకమైన మందుల ద్వారా చికిత్స చేయలేము. కోవిడ్-19 వంటి వైరల్ ఇన్ఫెక్షన్లకు చికిత్స చేయడానికి యాంటీబయాటిక్స్ ఉపయోగించబడదు."
    ],
    "Spanish - What our experts say": [
      "Los antibióticos no son usados para tratar o curar el COVID-19, pero pueden tratar infecciones bacteriales que pueden pasar como resultado de las complicaciones del virus COVID-19. Los virus y las infecciones bacteriales causan diferentes tipos de enfermedades, y los antibióticos sólo son efectivos para tratar infecciones bacteriales, no virus como el COVID--19. Los antibióticos no deberían ser tomados como modo de prevenir o tratar el COVID-19, y no debieran administrarse a menos que un doctor los prescriba. A veces, los antibióticos pueden ser usados en pacientes con COVID-19, pero solamente para tratar infecciones bacteriales secundarias."
    ],
    "Spanish - Background and context": [
      "Los antibióticos son medicaciones antibacteriales que ralentizan el crecimiento de bacterias o bien las destuyen. Son usados para tratar infecciones que son causadas por bacterias. (Más información sobre las diferencias entre virus y bacterias puede ser encontrada en la sección de recursos adicionales.) La enfermedad COVID-19 es causada por una infección con un virus, no por bacterias. El COVID-19 es una enfermedad que es un tipo de coronavirus. Los coronavirus son un grupo de virus que causan enfermedades tales como el resfrío común, el síndrome respiratorio severo agudo (SARS) y el síndrome respeiratorio de Medio Oriente (MERS). Debido a que los virus y las bacterias son diferentes, las dolencias que causan no pueden ser tratadas por el mismo tipo de medicación. Los antibióticos no pueden ser usadospara tratar infecciones virales como el COVID-19."
    ],
    "Arabic - What our experts say": [
      "‫لا تُستخدَم المضادات الحيوية لعلاج كوفيد-19، ولكن يمكنها علاج الالتهابات البكتيرية التي يمكن أن تحدث نتيجة مضاعفات فيروس كوفيد-19. تسبب الفيروسات والالتهابات البكتيرية أنواعا مختلفة من الأمراض، والمضادات الحيوية فعالة فقط في علاج الالتهابات البكتيرية، وليس الفيروسات مثل كوفيد-19. لا ينبغي أن تُؤخَذ المضادات الحيوية كوسيلة لمنع أو علاج كوفيد-19 ولا ينبغي تناولها إلا إذا وصفها الطبيب. في بعض الأحيان ، يمكن استخدام المضادات الحيوية مع المرضى الذين يعانون من كوفيد-19 ولكن فقط لعلاج الالتهابات البكتيرية الثانوية.‬"
    ],
    "Arabic - Background and context": [
      "‫إن المضادات الحيوية أدوية مضادة للبكتيريا التي إما تبطئ أو تدمر نموها. يتم استخدامها لعلاج الالتهابات التي تسببها البكتيريا. (يمكن العثور على مزيد من المعلومات حول الاختلافات بين الفيروسات والبكتيريات في قسم الموارد الإضافية.) يحدث مرض كوفيد-19 بسبب عدوى بفيروس وليس بكتيريا. كوفيد-19 هو أحد أنواع الفيروسات التاجية. الفيروسات التاجية هي مجموعة من الفيروسات التي تسبب أمراض مثل نزلات البرد، ومتلازمة الجهاز التنفسي الحادة (سارس) ومتلازمة الشرق الأوسط التنفسية (ميرس). نابات الفيروسية مثل كوفيد-19.‬ظرا لاختلاف الفيروسات والبكتيريا، لا يمكن علاج الأمراض التي تسببها بنفس الدواء. لا يمكن استخدام المضادات الحيوية لعلاج الالته"
    ],
    "Bengali - What our experts say": [
      "কোভিড-১৯ এর চিকিৎসা বা নিরাময়ের জন্য অ্যান্টিবায়োটিকগুলি ব্যবহৃত হয় না, তবে তারা ব্যাকটিরিয়া সংক্রমণের চিকিৎসা করতে পারেন যা কোভিড-১৯ ভাইরাস থেকে জটিলতার ফলে ঘটতে পারে। ভাইরাস এবং ব্যাকটিরিয়া সংক্রমণ বিভিন্ন ধরণের অসুস্থতা সৃষ্টি করে এবং অ্যান্টিবায়োটিকগুলি ব্যাকটিরিয়া সংক্রমণের চিকিৎসায় কেবল কার্যকর, কোভিড -১৯ এর মতো ভাইরাসের ক্ষেত্রে নয়। অ্যান্টিবায়োটিকগুলি কোভিড-১৯ প্রতিরোধ বা চিকিৎসার উপায় হিসাবে গ্রহণ করা উচিত নয় এবং ডাক্তার দ্বারা নির্ধারিত না হলে সেগুলি গ্রহণ করা উচিত নয়। কখনও কখনও, কোভিড-১৯ রোগীদের ক্ষেত্রে অ্যান্টিবায়োটিকগুলি ব্যবহার করা যেতে পারে তবে কেবলমাত্র গৌণ ব্যাকটেরিয়াল সংক্রমণের জন্য।"
    ],
    "Bengali - Background and context": [
      "অ্যান্টিবায়োটিকগুলি অ্যান্টিব্যাকটিরিয়াল ওষুধ যা ব্যাকটেরিয়ার বৃদ্ধি ধীর করে দেয় বা ধ্বংস করে। এগুলি ব্যাকটিরিয়া দ্বারা সৃষ্ট সংক্রমণের চিকিৎসার জন্য ব্যবহৃত হয়। (ভাইরাস এবং ব্যাকটেরিয়ার মধ্যে পার্থক্য সম্পর্কে আরও তথ্য অতিরিক্ত রিসোর্স বিভাগে পাওয়া যেতে পারে)) কোভিড -১৯ রোগ ব্যাকটিরিয়া নয়, ভাইরাসের সংক্রমণের কারণে ঘটে। কোভিড -১৯ এমন একটি রোগ যা এক ধরণের করোনাভাইরাস। করোনাভাইরাসগুলি ভাইরাসের একটি গ্রুপ যা সাধারণ সর্দি, গুরুতর তীব্র শ্বসনতন্ত্র সিন্ড্রোম (এসএআরএস) এবং মধ্য প্রাচ্যের শ্বাসতন্ত্র সিন্ড্রোম (এমইআরএস) এর মতো রোগের কারণ। ভাইরাস এবং ব্যাকটিরিয়া আলাদা হওয়ার কারণে তারা যেসব অসুস্থতা সৃষ্টি করে সেগুলি একই ধরণের ঔষধধ দ্বারা চিকিৎসা করা যায় না। কোভিড -১৯ এর মতো ভাইরাল সংক্রমণের চিকিৎসার জন্য অ্যান্টিবায়োটিকগুলি ব্যবহার করা যায় না।"
    ]
  },
  {
    "id": "rec3gzGDZLC9DoYmq",
    "Question": "What do we know so far about COVID-19 and immunity?",
    "Status": "Published",
    "Category": "Immunity",
    "Subcategory": "On: COVID-19 & immunity",
    "Background and context": "Our immune systems have two parts: the innate immune system and the adaptive immune system. The innate immune is what we have at birth and it's the first responder first when a virus like SARS-CoV-2, the novel coronavirus that causes COVID-19, infects us. This part of the immune system tries to prevent the virus from spreading and reproducing in our bodies, and from moving around in our bodies. The innate immune system is made up of several types of defenses, including skin and body openings like the mouth and nose, different white blood cells to defend our bodies from pathogens, and  substances in bodily fluids and blood that try and stop the virus from reproducing. If the innate immune system is unable to kill the virus, the adaptive immune system activates to defend the body.\n\nThe adaptive immune response, also called the acquired immune system, consists of white blood cells: B cells and T cells. B cells create antibodies, which help us fight off viruses. T cells try to kill virus-infected cells like an army fighting off an invader. Some T cells also help B cells make antibodies, while others are busy working to stop the virus from reproducing in your body and spreading to different parts of your body. \n\nAnother key function of the adaptive immune system is immune memory. After the initial or primary response to a virus, the body mounts a secondary response, which involves a subset of B-cells and T-cells (known as memory cells) that help to create a longer term memory of the virus. This helps launch a faster defense in the event of a future infection. \n\nMultiple early-stage studies have reported strong memory T-cell responses to the virus that causes COVID-19, which suggests that infection may prevent against recurrent, severe episodes of COVID-19. Researchers are still studying how long this memory-based immunity lasts and how strong it is in defending against COVID-19 infection in the future.\n",
    "What our experts say": "The evidence around COVID-19 and immunity is rapidly evolving. Based on what we know so far, COVID-19 patients become immune (protected from reinfection) for at least 3 months, if not longer, after they recover from the illness. However the virus is still new and there are no long-term studies published about it yet, so it's hard to accurately assess how long immunity persists in the population. \n\nA study in Nature found that men's immune systems, particularly older men over the age of 60, may make them twice as likely to get severely sick or die in comparison to women from the same age group. These results are not entirely surprising. Scientists already know that women's immune systems typically are stronger at fighting other illnesses, compared to men. Public health experts believe this may mean that men need to rely more on vaccination, rather than natural infection, to safely protect against recurring infections.\n\nLevels of antibodies, which are particles an infected person produces to fight off an illness, typically shrink after recovery. In August 2020, the New York Times reported the first documented case of re-infection with COVID-19. A 33-year-old man, who was first diagnosed with COVID-19 on March 26, 2020, had no detectable antibodies after his first infection. On August 15, 2020, he tested positive again and researchers confirmed that the test result was due to a new infection, rather than a prolonged previous infection. \n\nAntibodies are only one component of the body's complex immune system and its response to COVID-19. Antibodies prevent a future infections, but other mechanisms, like cytotoxic (also known as killer) T-cells, can find and kill an infection. Memory B-cells also help bodies produce antibodies to prepare for possible future infections. \n\nBased on the current evidence so far on COVID-19, we know that if the initial infection is more severe, immunity will typically last longer: re-infection might still be possible, but it will be far less likely to result in another severe infection.\n",
    "Glossary Terms": [
      "recaXXF6coF4J2EUz",
      "rectkO1d0FhUHQ0Of",
      "recmajcAORyuqhZPc"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "immune system",
      "immunity",
      "herd immunity"
    ],
    "Other resources": "1. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19 ([Cell](https://www.cell.com/action/showPdf?pii=S0092-8674%2820%2931008-4)) \n2. Sex differences in immune responses that underlie COVID-19 disease outcomes ([Nature](https://www.nature.com/articles/s41586-020-2700-3))\n3. Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure. ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.08.14.20174490v1)) \n4. Evidence for sustained mucosal and systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.08.01.20166553v1))\n5. Why Does the Coronavirus Hit Men Harder? A New Clue ([NYT](https://www.nytimes.com/2020/08/26/health/coronavirus-men-immune.html))\n6. First Documented Coronavirus Reinfection Reported in Hong Kong ([NYT](https://www.nytimes.com/2020/08/24/health/coronavirus-reinfection.html))\n\n",
    "Last modified manual": "2020-08-27",
    "Last edited (simplified)": "2020-08-27T21:07:54.000Z",
    "Last edited (experts say)": "2020-08-27T21:07:54.000Z",
    "Last modified": "2020-08-27",
    "What our experts say wordcount": 326,
    "Background and context wordcount": 322,
    "Other resources wordcount": 78,
    "Wordcount": 726
  },
  {
    "id": "recxgnA1fpRAEFEEE",
    "Question": "If you can get COVID-19 through your nose and mouth, why not your ears?",
    "Status": "Published",
    "Category": "Prevention, Infection",
    "Subcategory": "On: COVID-19 & ears",
    "Source of the question": [
      "School"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Both children and adults have wondered about why it is okay to leave the ears uncovered when wearing face coverings to prevent the transmission of COVID-19. This is because getting infected with COVID-19 is not as likely to happen through the ears, compared to through the nose, mouth and eyes. Masks and face coverings do not just protect the wearer, but are important measures to reduce the risks of infecting others. The most basic face coverings typically cover the nose and mouth, because we are more likely to infect others through respiratory droplets coming out of our nose and mouth when we sneeze, cough, speak, exhale, etc.\n",
    "What our experts say": "Getting infected with COVID-19 through the ear is not as likely as getting infected through the nose, mouth, and eyes. Experts believe this is because the surface of the outer ear canal is more like the skin on the rest of our bodies, which acts as a protective barrier that makes it more difficult for the SARS-CoV-2 virus, causing COVID-19, to enter. In contrast, the tissues lining the surface of the nose, mouth, and eyes are mucous membranes (or a thin lining of cells that secrete mucus), which are an easier way for SARS-CoV-2, the virus causing COVID-19, to enter.\n\nLike the nose, mouth, and eyes, ears are connected to the upper part of the throat and respiratory tract. Doctors and researchers are currently looking into the risks of COVID-19 transmission when patients have open ear injuries or are getting invasive ear procedures (ex. surgery), as both the patients and the healthcare providers should be adequately protected from exposure.\n\nFor the average person, ears remain a less likely pathway for getting COVID-19. There are currently not specific recommendations for preventing transmission through ears.  Preventative public health recommendations remain focused on face coverings over the nose and mouth, eye protection for people who may be at higher risk of exposure (ex. frontline workers), hand hygiene (ex. avoid touching the face, clean hands with soap and water or alcohol-based sanitizers), and physical distancing.\n",
    "Glossary Terms": [
      "recFMi3UQAPSUjsl4"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "infection",
      "nasal cavity",
      "respiratory system"
    ],
    "Other resources": "1. Can I Get COVID-19 Through My Eyes or Ears? ([US News](https://www.usnews.com/news/health-news/articles/2020-06-04/can-i-get-covid-19-through-my-eyes-or-ears#:~:text=The%20skin%20in%20the%20outer,Eye%20and%20Ear%20in%20Boston.))\n2. COVID-19 and Ear Surgery ([American Academy of Otolaryngology](https://www.entnet.org/sites/default/files/uploads/covid-19_and_ear_surgery_rk_jackler_stanford.pdf))\n3. COVID-19 in the Ear: Have You Heard About the Risk for HCPs? ([MedPage Today](https://www.medpagetoday.com/infectiousdisease/covid19/87720))\n",
    "Media": [
      {
        "id": "att7zHekXREfsS4AW",
        "url": "https://dl.airtable.com/.attachments/f3a5a2d0bde5f368070246b0f6be069b/5ff1c36d/Slide_1",
        "filename": "Slide_1",
        "size": 227975,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/67c452bff6ef1f08f38453eb6feebde9/3f37152e",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/a98cc61a4ee2058baecd03e2ea7a0764/a3dc0db3",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b0abd17354da6a0a99ee16d2789b9f2b/040d3d27",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attCnm3Ra0FB53xW1",
        "url": "https://dl.airtable.com/.attachments/08b9e0b3bb00792d75b10ccc74d3d45c/06ca68f1/Slide_2",
        "filename": "Slide_2",
        "size": 184262,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/a2602722d67fe726a24025b47db858fb/7070144f",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/b7940eee08b397f3ee45c27ba64fd6a5/a5c7172e",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/fa67a0feeb8f5cd58cbc4c3de39c6f8c/2a4d8254",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attScXMWm36KZXV8I",
        "url": "https://dl.airtable.com/.attachments/51af48d59ddcb59485f5bdbf0d4b6ce1/6790d893/Slide_3",
        "filename": "Slide_3",
        "size": 202831,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/1303db8d226f2050e3ae4ff00d52fd58/2028c38c",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d15146c262fd82193697085e60f346be/5f713fb3",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/a6539ef3241fca571c14866eceae67ed/309fec60",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "att0FJkDHq8m1hRBq",
        "url": "https://dl.airtable.com/.attachments/48b0538e829816f2908fe0d78b73155f/fed78003/Slide_4",
        "filename": "Slide_4",
        "size": 183876,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/f1ffc79b643d5d360800472c9b67ba9b/358f326f",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/224c006dd735e945bcdbf7fdf408c451/bd3f097d",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/37f4b0922b20d08b4faeae2d0a3cdf69/35c8f725",
            "width": 3000,
            "height": 3000
          }
        }
      },
      {
        "id": "attSbhc30pd6sVqfM",
        "url": "https://dl.airtable.com/.attachments/e5cc32c39df90e4481cba7454304634c/8347fe13/Slide_5",
        "filename": "Slide_5",
        "size": 183876,
        "type": "image/png",
        "thumbnails": {
          "small": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/038be9254fa15bf2f4e268c86f01d467/5f1ee13a",
            "width": 36,
            "height": 36
          },
          "large": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/d2391636863e13cc2db5d37c8d619d6e/43bd95db",
            "width": 512,
            "height": 512
          },
          "full": {
            "url": "https://dl.airtable.com/.attachmentThumbnails/ed22ea783e898afa1fcc508828e33297/bb800c6e",
            "width": 3000,
            "height": 3000
          }
        }
      }
    ],
    "Last modified manual": "2020-08-28",
    "Last edited (simplified)": "2020-08-27T19:36:53.000Z",
    "Last edited (experts say)": "2020-10-13T20:15:56.000Z",
    "Last modified": "2020-10-13",
    "What our experts say wordcount": 230,
    "Background and context wordcount": 107,
    "Other resources wordcount": 34,
    "Wordcount": 371
  },
  {
    "id": "recT6kzJNVsejsEac",
    "Question": "Does the antibiotic Levotop 500 treat, prevent or cure COVID-19? ",
    "Status": "Published",
    "Source of the question": [
      "Fact-checking organization"
    ],
    "Background and context": "Antibiotics like Levotop 500 are antibacterial medications that either slow down or destroy the growth of bacteria. They are used to treat infections that are caused by bacteria. The COVID-19 disease is caused by an infection with a virus, not a bacteria. COVID-19 is a disease that is a type of coronavirus. Coronaviruses are a group of viruses that cause diseases such as the common cold, severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Because viruses and bacteria are different, the illnesses that they cause cannot be treated by the same type of medication. Antibiotics cannot be used to treat viral infections like COVID-19. \n",
    "What our experts say": "Levotop 500 is an antibiotic that is used to treat infections caused by bacteria. COVID-19 is an infection caused by a virus, not a bacteria. Therefore, Levotop 500 is not a medication that is effective in preventing, treating or curing COVID-19. Levotop is used to treat bacterial infections like pneumonia, bacterial sinusitis, gastroenteritis and chronic bronchitis.  \n\nSome antibiotics are being used in patients who are initially hospitalized because of COVID-19 to treat \"co-infections\" or \"superinfections.\"\n\nCo-infections can occur when a COVID-19 patient also has a second infection, or catches one while hospitalized, and needs antibiotics to treat the second infection. Superinfections can happen on top or after an existing infection. It is possible that a hospitalized COVID-19 patient's immune system is weaker than normal, making it more vulnerable for all kinds of infections from germs, including bacteria.  \n",
    "Last modified manual": "2020-09-08",
    "Last edited (simplified)": "2020-09-09T00:32:41.000Z",
    "Last edited (experts say)": "2020-09-09T00:32:41.000Z",
    "Last modified": "2020-09-09",
    "What our experts say wordcount": 137,
    "Background and context wordcount": 108,
    "Other resources wordcount": 0,
    "Wordcount": 245
  },
  {
    "id": "recvikqCDP9wMlBjd",
    "Question": "Does COVID-19 impact young people?",
    "Status": "Published",
    "Category": "Symptoms, Impacts",
    "Subcategory": "On: COVID-19 & young people",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "Nigeria"
    ],
    "Background and context": "Doctors, researchers, and reporters have documented how the risks of severe COVID-19 illness tend to increase with age, with the elderly being at highest risk for hospitalization, intensive care, ventilation, and potentially death. However, young people can also become severely sick and in some cases die from COVID-19. This includes previously healthy young people without underlying health conditions. Additionally, non-fatal cases of COVID-19 in young people can cause lingering symptoms and long-term health issues. Research is ongoing to assess the impacts of COVID-19 on young people, particularly as more schools and facilities frequented by young people continue to reopen.\n",
    "What our experts say": "The virus that causes COVID-19 can infect people of all ages. Although older people are known to be more susceptible to experiencing severe side effects of the virus, that does not mean young people are not at risk of getting sick, or even dying, from COVID-19. For example, COVID-19 has been linked to sometimes fatal stroke in people in their thirties and forties. COVID-19 has also claimed the lives of healthcare workers sometimes in their twenties. Even children can develop severe complications from COVID-19, such as multisystem inflammatory syndrome (MIS-C), which is characterized by inflammation in different body parts, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal organs.\n\nYoung people with underlying health conditions are at higher risk of severe COVID-19, but young people with no prior health issues have also been impacted by the disease. Less severe COVID-19 can lead to lingering health impacts that have prevented some young people from going to school, working and resuming other normal activities for months.\n\nIn the summer of 2020, the World Health Organization (WHO) warned that recent increases in COVID-19 cases may be driven by younger adults in their twenties to forties, many of whom have no symptoms or mild symptoms and may not realize they have COVID-19. In several regions around the world, half or more of the new COVID-19 cases have been in younger adults.\n\nOn September 15, 2020, the U.S. Centers for Disease Control and Prevention (CDC), released a report on deaths related to COVID-19 in people younger than 21. Using data reported to the U.S. CDC from February 12 to July 31, 2020, researchers found that the majority (70%) of deaths were among people ages 10-20, but 10% of deaths were infants. Additionally, 78% of deaths were among Hispanic, Black and American Indian/Alaskan Native youth, highlighting the major disparities that exist.\n\nOn September 28, the U.S. CDC released a report on COVID-19 trends among school-aged youth, which showed that average weekly incidence (cases per 100,000 people) among adolescents aged 12-17 was twice that of children aged 5–11 years. Over one-fourth of school-aged youth who were admitted to intensive care units (27%) or who died (28%) had at least one underlying medical condition. The report calls for monitoring COVID-19 among school-aged children through multiple indicators, and for layering multiple prevention strategies to reduce COVID-19 disease risk for students, teachers, school staff, and families.\n\nAnother study of 85,000 COVID-19 cases in India and almost 600,000 of their contacts showed that children of all ages can become infected with COVID-19 and spread it to others. More than 5,300 school-aged children in the study had infected 2,508 contacts.\n\nMore evidence is emerging on how some young people develop severe symptoms and complications related to COVID-19, and are contributing to the widespread transmission of the virus. Young people should take preventive measures to reduce the chances of becoming infected with COVID-19, for their own protection as well as for preventing transmission to others.\n",
    "Glossary Terms": [
      "recOcmLKbzV6NUkAH",
      "recMZLIWKC45HMVao",
      "recbr3ZePtuRaGnEd",
      "rec6wT9CN4jU9dyRs",
      "recl2uEzY8N6aHAs9"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "COVID-19",
      "transmission",
      "symptoms",
      "short-term",
      "long-term"
    ],
    "Other resources": "1. FACT: People of all ages can be infected by the COVID-19 virus ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters?gclid=EAIaIQobChMI55iHlbXa6wIVE4TICh2rRQZ1EAAYASAAEgJfS_D_BwE#older-people))\n2. Coronavirus and COVID-19: Younger Adults Are at Risk, Too ([John Hopkins University](https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-and-covid-19-younger-adults-are-at-risk-too))\n3. What Young, Healthy People Have to Fear From COVID-19 ([The Atlantic](https://www.theatlantic.com/ideas/archive/2020/09/what-young-healthy-people-have-fear-covid-19/616087/))\n4. COVID-19 Toolkit for People 15-21 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/communication/toolkits/young-people-15-to-21.html))\n5. Coronavirus linked to stroke in otherwise healthy young people ([ScienceDaily](https://www.sciencedaily.com/releases/2020/06/200604095600.htm))\n6. Lives Cut Short: Remembering Health Care Workers In Their 20s Killed By COVID-19 ([NPR](https://www.npr.org/sections/health-shots/2020/08/13/901720066/lives-cut-short-remembering-health-care-workers-in-their-20s-killed-by-covid-19))\n7. COVID-19 and multisystem inflammatory syndrome in children and adolescents ([The Lancet](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30651-4/fulltext))\n8. WHO warns coronavirus is now driven by young people who don’t know they are infected ([CNBC](https://www.cnbc.com/2020/08/18/coronavirus-who-warns-covid-19-is-driven-by-young-people-who-dont-know-they-are-infected.html))\n9. WHO warns young people are emerging as main spreaders of the coronavirus ([Washington Post](https://www.washingtonpost.com/health/who-warns-young-people-are-emerging-as-main-spreaders-of-the-coronavirus/2020/08/18/1822ee92-e18f-11ea-b69b-64f7b0477ed4_story.html))\n10. SARS-CoV-2–Associated Deaths Among Persons Aged <21 Years — United States, February 12–July 31, 2020 ([U.S. CDC](https://www.cdc.gov/mmwr/volumes/69/wr/mm6937e4.htm))\n11. COVID-19 Trends Among School-Aged Children — United States, March 1–September 19, 2020 ([U.S. CDC](https://www.cdc.gov/mmwr/volumes/69/wr/mm6939e2.htm?s_cid=mm6939e2_w))\n12. Epidemiology and transmission dynamics of COVID-19 in two Indian states ([Science](https://science.sciencemag.org/content/early/2020/09/29/science.abd7672))\n",
    "Last modified manual": "2020-09-08",
    "Last edited (simplified)": "2020-09-09T02:22:19.000Z",
    "Last edited (experts say)": "2020-10-07T01:56:33.000Z",
    "Last modified": "2020-10-07",
    "What our experts say wordcount": 487,
    "Background and context wordcount": 99,
    "Other resources wordcount": 150,
    "Wordcount": 736
  },
  {
    "id": "recEpxyl0057WLvCV",
    "Question": "Does holding your breath for 10 seconds or more without coughing or feeling discomfort mean you are free from COVID-19?",
    "Status": "Published",
    "Category": "Symptoms",
    "Subcategory": "On: COVID-19 & recovery",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "Nigeria"
    ],
    "Background and context": "Since the world first learned about COVID-19, many pieces of health misinformation have been shared on social media, including this rumor about breath-holding being a good tool for determining whether or not someone has been infected with COVID-19. Unfortunately, this particular misinformation has made its way around the world despite the fact that it is not accurate in any context. \n\nSeveral sources like the World Health Organization, universities, renowned hospitals, and health groups have specifically addressed this issue and note that holding your breath should not be used as a test for the virus. The only accurate, effective way to know if you are infected is to take a test at your local health facility and await the results. Until the results come in, it is best to continue isolating, washing your hands, and avoiding contact with others.\n",
    "What our experts say": "Holding your breath for 10 seconds or more without coughing or feeling discomfort does not mean you are negative for COVID-19. Symptoms of the virus are different in every person. Some people might not have any symptoms at all (a phenomenon known as being 'asymptomatic'). Some people may be able to hold their breath for longer than 10 seconds even if they are actively infected with COVID-19. \n\nOther than helping to determine whether you have shortness of breath or a cough - both are symptoms of the virus - holding your breath for 10 seconds is not a substitute for an actual COVID-19 test, which is the only accurate way of determining whether or not you have an active infection.\n",
    "Glossary Terms": [
      "recFhwbJEgjxkrwpY",
      "recOcmLKbzV6NUkAH",
      "recx2PeCcs1Awb9rG"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "breath holding",
      "cough syrup",
      "symptoms",
      "asymptomatic",
      "recovery"
    ],
    "Other resources": "1. Coronavirus disease (COVID-19) advice for the public: Mythbusters ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters)) \n2. One dangerous coronavirus 'self-check test' is circulating on social media. Here's why you should avoid it. ([CNN](https://www.cnn.com/2020/03/16/us/coronavirus-myths-debunking-holding-breath-10-seconds-trnd/index.html)) \n3. Ability to hold your breath 10 seconds is not a test for coronavirus ([AP](https://apnews.com/afs:Content:8635070312)) \n",
    "Last modified manual": "2020-09-10",
    "Last edited (simplified)": "2020-09-11T00:55:59.000Z",
    "Last edited (experts say)": "2020-09-11T00:55:59.000Z",
    "Last modified": "2020-09-11",
    "What our experts say wordcount": 120,
    "Background and context wordcount": 138,
    "Other resources wordcount": 44,
    "Wordcount": 302
  },
  {
    "id": "recUQqRs8DzyIxoQx",
    "Question": "Can COVID-19 be transmitted in hot climates?",
    "Status": "Published",
    "Background and context": "Some types of viruses (including some coronaviruses) have shown lower survival in warmer and more humid climates. Some lab experiments have shown that SARS-CoV-2 may be sensitive to temperature, humidity, and ultraviolet light. These lab tests may lead people to believe that climatic effects (e.g. warmer weather or seasonal changes) could slow the spread of the virus. Though more studies are needed, outside of the lab, the effect of climate (including temperature and humidity) on the spread of COVID-19 appears to be minimal. Countries around the world, including Asian and African countries with regular temperatures greater than 25 degrees celsius, have reported community transmission (spread) of the virus. \n",
    "What our experts say": "COVID-19 can be spread in all climates and seasons. According to an August publication in the journal Nature, 'No human-settled area in the world is protected from COVID-19 transmission by virtue of weather, at any point in the year.'\n \nStudies that have explored the impact of temperature or weather on COVID-19 have shown mixed results. Some have been positive, some negative, and others neutral. Researchers have concluded that there are many factors that likely play a much larger role in the spread of the virus than the weather, including population density, human mobility, social distancing policies and practices, testing, public health facilities, and more. \n\nWhile more studies are needed, warmer weather does not appear reduce the spread of COVID-19, and it does not impact how the virus spreads from person to person. Routine hand-washing, social distancing practices, avoidance of crowds, wearing face masks, and surface cleaning should be used to prevent the spread of COVID-19 between people and via indirect (non-contact) transmission.\n",
    "Glossary Terms": [
      "recEer1bgt6r6jukM",
      "reclKahoPRbBLqUKg",
      "rec2UNEXbTkSCx30Q",
      "rec8po7cJXvqkaQYB",
      "recvwSSjn9ohOm9fK",
      "recfxNeRDVhNKMgNe",
      "recnFUXyIZy81Rj1I"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "summer transmission",
      "heat"
    ],
    "Other resources": "1. Effective transmission across the globe: the role of climate in COVID-19 mitigation strategies ([The Lancet](http://Effective transmission across the globe: the role of climate in COVID-19 mitigation strategies))\n2. Misconceptions about weather and seasonality must not misguide COVID-19 response ([Nature](https://www.nature.com/articles/s41467-020-18150-z.pdf))\n3. No association of COVID-19 transmission with temperature or UV radiation in Chinese cities ([European Respiratory Journal](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144256/))\n4. Is the transmission of novel coronavirus disease (COVID-19) weather dependent? ([Journal of the Air & Waste Management Association](https://www.tandfonline.com/doi/abs/10.1080/10962247.2020.1823763?journalCode=uawm20))\n",
    "Last modified manual": "2020-12-03",
    "Last edited (simplified)": "2020-12-03T20:37:04.000Z",
    "Last edited (experts say)": "2020-12-03T20:37:04.000Z",
    "Last modified": "2020-12-03",
    "What our experts say wordcount": 162,
    "Background and context wordcount": 108,
    "Other resources wordcount": 61,
    "Wordcount": 331
  },
  {
    "id": "rec4tyjrHTYcCkOoY",
    "Question": "Does wearing a face mask put you at higher risk of cancer?",
    "Status": "Published",
    "Background and context": "The claim that wearing face masks causes cancer has been circulating on Facebook and other social media platforms. While masks are restrictive and can feel like they impede air flow, properly designed masks do allow for air flow— the tiny size of oxygen and carbon dioxide molecules makes it easy for the molecules to travel freely in and out of the mask. The feeling of inconvenience or minor discomfort in a mask does not lead to health risks such as a build up of carbon dioxide. It's true that too much carbon dioxide in the blood (hypercapnia), _can_ lead to high levels of acid in the blood (respiratory acidosis), but both are very unlikely to happen as a result of wearing a properly designed mask or face covering.\n\nClaims that the prolonged use of face masks can cause cancer, oxygen deficiency, dizziness, or other health challenges are not grounded in science. Healthcare workers often wear masks for long hours in the hospital and have been doing so for a long time. There is no evidence that surgical masks or cloth masks cause significant deficiency of oxygen, a build up of carbon dioxide, and other related negative health consequences. This information has been primarily circulating on social media among individuals or communities resistant to mask-wearing in general. \n\nWearing a mask is recommended to protect people from community transmission of COVID-19. There are only a few exceptions to this public health recommendation, mostly focused on children under 2 years of age and people with serious medical conditions that can make it difficult to breathe through a mask or remove a mask if necessary. Otherwise, wearing a mask is safe and helpful for preventing the spread of COVID-19.\n",
    "What our experts say": "Wearing a face mask does not put you at a higher risk of cancer. There is no current evidence linking the use of face masks to cancer, and science shows that any risks associated with wearing masks are low overall, while the benefits are high. \n\nBecause of how tiny oxygen and carbon dioxide molecules are, face masks neither decrease the amount of oxygen that enters a mask nor increase the amount of carbon dioxide that stays in a mask. As a result, face masks do not disrupt the body’s pH levels, affect the bloodstream, or alter one’s body in any way that would put someone at higher risk of cancer.\n",
    "Last modified manual": "2020-09-10",
    "Last edited (simplified)": "2020-09-11T00:49:16.000Z",
    "Last edited (experts say)": "2020-09-11T00:49:16.000Z",
    "Last modified": "2020-09-11",
    "What our experts say wordcount": 109,
    "Background and context wordcount": 283,
    "Other resources wordcount": 0,
    "Wordcount": 392
  },
  {
    "id": "recoFYIiBdptZqQXi",
    "Question": "Can mask wearing lead to or cause pleurisy?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & masks",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Public health experts and doctors recommend wearing face coverings and masks to help prevent COVID-19 transmission between people. Beyond exceptions for very young children (under 2 years of age in the U.S.) and people with medical conditions that can make it difficult to breathe through a mask, wearing masks is widely considered safe with minimal side effects. Unfortunately, misinformation has been spreading through social media and other channels about the use of masks, with many claims about risks that have not been scientifically verified. One such claim has been spreading on Facebook, along with a photo of a dirty used mask, about the risks of pleurisy for children wearing masks for more than 3 hours. Public health experts have responded that this claim about pleurisy is false.\n\nFor children and adults, masks should be kept clean, with a new or sanitized mask used for each public outing. People can see what type of mask is the right size for their face and fits comfortably for prolonged use. Some people also choose to reduce and shorten public outings as much as possible to help minimize the amount of time a mask needs to be worn. Children and others who may need assistance can be monitored to ensure they are putting on, wearing, and taking off masks correctly.\n\nIt is important to remember that masks are a reduction measure that lowers the chances of infection, which is different from risk avoidance measures that completely eliminate risks. Masks should be used in combination with other preventative measures, like washing hands and maintaining physical distance.\n",
    "What our experts say": "Pleurisy, also known as pleuritis, is the inflammation of the pleura tissues that separate the lungs from the chest wall. It can be caused by respiratory infections, inherited genetic conditions, or certain medications. Public health and medical experts have not found pleurisy to occur as a result of wearing a mask or face covering to prevent COVID-19 transmission. Mask-induced pleurisy has not been validated in scientific or medical literature. The Chief Medical Officer of the American Lung Association stated that there is not a \"medically plausible mechanism for mask-wearing to cause pleurisy.\"\n\nRegarding concerns about wearing masks for 3 hours or longer leading to pleurisy or other health issues, healthcare workers have been wearing tighter masks for much longer than 8 hours a day without negative side effects.\n\nWearing masks is generally considered safe for children and adults. There are a few exceptions, for very young children (under 2 years of age in the U.S.) and people with health conditions that make it difficult to wear a mask (ex. certain pre-existing pulmonary or cardiac issues, mental health conditions, developmental disabilities). For the vast majority of people, wearing masks are an effective way to help reduce COVID-19 transmission without causing any major side effects, as long as masks are kept clean and used correctly.\n",
    "Glossary Terms": [
      "reclKahoPRbBLqUKg",
      "recD4a9f8HElQ0U8G"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "face masks",
      "prevention",
      "side effects"
    ],
    "Other resources": "1. Face masks will not cause pleurisy, experts say ([Associated Press](https://apnews.com/afs:Content:9051682276))\n2. Guidance on the use of masks in schools ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/cloth-face-cover.html))\n3. Pleurisy ([Mayo Clinic](https://www.mayoclinic.org/diseases-conditions/pleurisy/symptoms-causes/syc-20351863))\n",
    "Last modified manual": "2020-09-16",
    "Last edited (simplified)": "2020-09-16T18:25:17.000Z",
    "Last edited (experts say)": "2020-09-16T18:39:59.000Z",
    "Last modified": "2020-09-16",
    "What our experts say wordcount": 211,
    "Background and context wordcount": 259,
    "Other resources wordcount": 24,
    "Wordcount": 494
  },
  {
    "id": "recyq5D0irsIhQn1B",
    "Question": "Why do vaccine clinical trials sometimes stop or suspend operations?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & vaccines",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Recently, a clinical trial for a vaccine created by Oxford University and AzstraZeneca (a pharmaceutical company) was paused due to safety concerns. This trial was in the phase three stage of development, and stopped as a patient developed \"transverse myelitis\" which caused neurological issues stemming from inflammation of the spinal cord. (At the time of writing this, this trial has resumed). \n\nThis trial participant received the vaccine and not a placebo (which is a harmless substance that has no impact on a person, and is used to compare results of active vaccines in clinical trials). However, it is unknown whether or not the patient's illness occurred because of the vaccine they were given, or some other medical issue. Either way, the safety board recommended stopping the vaccine, which often occurs when vaccines reach the later stages of clinical trials.\n\nOn October 12, 2020, Johnson & Johnson announced that a phase 3 clinical trial of its Janssen COVID-19 vaccine candidate was paused due to \"unexplained illness\" in one participant. Johnson & Johnson stated that is is following its prespecified guidelines on when to pause studies due to reports of an unexpected serious adverse event (SAE), so there can be a \"careful review of all of the medical information before deciding whether to restart the study.\"\n\nThis entry was updated with new information on October 13, 2020.\n",
    "What our experts say": "Pausing or suspending clinical trials occurs frequently in the development of new medications and vaccines. This is because every clinical trial is overseen by a data and safety monitoring board that routinely looks at data from the different trial phases to see if there are any harmful or adverse issues happening in trial participants. The board also monitors  to see if there is any evidence of the vaccine being effective.\n\nIf the board has any concerns at any point during a clinical trial, they will suggest stopping a trial until they can determine a) what caused the patient(s) to develop a harmful medical issue, b) if people receiving the vaccine in the clinical trials are doing much better than those who didn't, or c) if people who received the vaccine are doing much worse than the people who didn't. \n\nThese prescheduled checks by the boards may sound alarming, but they occur frequently in all phases of clinical trials. As vaccines move into the third phases of clinical trials, in which they are given to tens of thousands of people, it is not surprising that one or more people develop a medical issue which may or may not be related to the vaccine itself. \n\nLists of side effects that you see on medications stem from these clinical trial phases. Studies also have pre-set protocols and criteria that determine what events will cause them to pause or stop their research phases. They cannot ethically continue with the trial if they have reasons for concern about the health of clinical trial participants who have received their vaccines.\n\n",
    "Glossary Terms": [
      "rec7kWtMzB3nNOEpH",
      "rec9qqItwSTjq3Eae",
      "recJK5tI9LgCGFRAU",
      "recM4p8QOERmuESKr"
    ],
    "Variation of the answer depending on country of residence": "Yes; there is some concern about vaccine safety protocols in some Russian and Chinese vaccine clinical trials\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "clinical trial",
      "vaccine",
      "safety board",
      "side effects"
    ],
    "Other resources": "1. AstraZeneca Covid-19 vaccine study put on hold due to suspected adverse reaction in participant in the U.K. ([STAT](https://www.statnews.com/2020/09/08/astrazeneca-covid-19-vaccine-study-put-on-hold-due-to-suspected-adverse-reaction-in-participant-in-the-u-k/)) \n2. The ethics of pausing a vaccine trial in the midst of a pandemic: a conversation with Ruth Faden ([STAT](https://www.statnews.com/2020/09/11/ethics-halting-vaccine-trial-pandemic-conversation-ruth-faden/)) \n3. One of the leading coronavirus vaccine trials is currently paused. Prominent vaccine researchers tell CNN that's unusual ([CNN](https://www.cnn.com/2020/09/12/health/coronavirus-vaccine-trial-pause/index.html)) \n4. A leading coronavirus vaccine trial is on hold: scientists react ([Nature](https://www.nature.com/articles/d41586-020-02594-w)) \n5. Oxford's COVID vaccine trial \"back up and running\" after brief pause for safety check ([CBS](https://www.cbsnews.com/news/covid-vaccine-oxford-trial-astrazenca-resumes-safety-check/)) \n6. BMS, Merck and Pfizer Join List of Companies Pausing Some Clinical Trials During Pandemic ([BioSpace](https://www.biospace.com/article/merck-bms-pfizer-and-others-pause-enrollment-in-some-clinical-trials-due-to-covid-19/)) \n7. Learn About Clinical Studies ([ClinicalTrials.Gov](https://www.clinicaltrials.gov/ct2/about-studies/learn)) \n8. Why AstraZeneca just paused its coronavirus vaccine trial ([LiveScience](https://www.livescience.com/astrazeneca-oxford-vaccine-trial-paused.html)) \n9. Experts Say It’s a Good Sign That a COVID-19 Vaccine Trial Was Paused. Here’s Why ([Healthline](https://www.healthline.com/health-news/experts-say-its-a-good-sign-that-a-covid-19-vaccine-trial-was-paused-heres-why)) \n10. Johnson & Johnson pauses Covid-19 vaccine trial after 'unexplained illness' ([CNN](https://www.cnn.com/2020/10/12/health/johnson-coronavirus-vaccine-pause-bn/index.html))\n\n",
    "Last modified manual": "2020-10-16",
    "Last edited (simplified)": "2020-10-13T21:17:49.000Z",
    "Last edited (experts say)": "2020-10-13T21:27:50.000Z",
    "Last modified": "2020-10-13",
    "What our experts say wordcount": 264,
    "Background and context wordcount": 221,
    "Other resources wordcount": 147,
    "Wordcount": 632
  },
  {
    "id": "rec66KHO6Hpfk6T1N",
    "Question": "Why does everyone have to get a vaccine for a vaccine to work?",
    "Status": "Published",
    "Category": "Vaccines",
    "Subcategory": "On: COVID-19 & vaccine effectiveness",
    "Background and context": "Herd immunity varies based off the infectious disease, but in most cases requires 70%-90% of the population to be vaccinated. For example, declining vaccination rates of MMR (measles vaccine), helped contribute to the uptick in cases. \n",
    "What our experts say": "While the current data is promising, the study is ongoing, and more information is needed before Pfizer can pursue U.S. FDA approval. To ensure that there are not major safety concerns, the U.S. FDA is requiring manufacturers to provide at least two months of follow-up data for at least half of the volunteer participants. Most serious side effects from vaccines occur within about six weeks after the vaccine is given. In vaccine clinical trials, any observed impacts of the vaccine on volunteer participants are eventually considered side effects with more serious side effects causing the trials to pause or stop completely. No safety concerns about these potential side effects have been reported so far.\n",
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Other resources": "JHU Herd Immunity and COVID ([2020](https://www.jhsph.edu/covid-19/articles/achieving-herd-immunity-with-covid19.html)). \n",
    "Last edited (simplified)": "2020-09-15T19:33:37.000Z",
    "Last edited (experts say)": "2020-11-10T03:31:06.000Z",
    "Last modified": "2020-11-10",
    "What our experts say wordcount": 114,
    "Background and context wordcount": 37,
    "Other resources wordcount": 7,
    "Wordcount": 158
  },
  {
    "id": "reczwkJJR0nVeblx9",
    "Question": "Why is Pfizer proposing expanding their vaccine trial to include more diversity?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & vaccine trials",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Clinical trials have historically excluded diverse populations. In 1993, the U.S. National Institutes of Health (NIH) adopted a new policy which required all federal grants for clinical research to include women and minorities, in an effort to diversify the pool of trial participants and the lack of inclusion of women and communities of color. However, demographic disparities continue to persist as Black and Latinx populations are consistently underrepresented in clinical trials. One recent study found that out of 230 oncology clinical trials analyzed over a ten-year period, more than 76% of participants were white, while only 18.3% were Black, 3.1% were Asian, and 6.1% were Hispanic. Another study in Nature found that 92% of the participants in clinical trials registered with the U.S. Food and Drug Administration were white in 1997. Progress has been slow as the proportion of white participants was still approximately 86% in 2014.\n",
    "What our experts say": "\n",
    "Glossary Terms": [
      "rec9qqItwSTjq3Eae",
      "recM4p8QOERmuESKr"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "vaccine",
      "clinical trial",
      "Pfizer"
    ],
    "Other resources": "1. Diversity in clinical trials: why it's important ([Pfizer](https://www.pfizer.com/news/featured_stories/featured_stories_detail/diversity_in_clinical_trials_why_it_s_important)) \n2. NIH Revitalization Act of 1993 Public Law 103-43 ([NIH](https://www.ncbi.nlm.nih.gov/books/NBK236539/?report=reader)) \n3. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018 ([JAMA](https://jamanetwork.com/journals/jamaoncology/fullarticle/2748395)) \n4. When will clinical trials finally reflect diversity? ([Nature](https://www.nature.com/articles/d41586-018-05049-5))\n",
    "Newsletter": true,
    "Last edited (simplified)": "2020-09-15T16:57:11.000Z",
    "Last edited (experts say)": "2020-11-10T03:31:06.000Z",
    "Last modified": "2020-11-10",
    "What our experts say wordcount": 0,
    "Background and context wordcount": 147,
    "Other resources wordcount": 48,
    "Wordcount": 195
  },
  {
    "id": "rec676VflF3k3p4Kj",
    "Question": "Can I contract COVID-19 from swimming, surfing, or doing other activities in contaminated water?",
    "Status": "Published",
    "Subcategory": "On: COVID-19 & water sports",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Many people are turning to outdoor activities and exercise, given the current restrictions on many indoor activities due to preventative measures implemented during the COVID-19 pandemic. In some locations, policies have closed or reduced access to beaches, lakes, and public pools. These policies not only vary by location, but can change over time based on the current state of COVID-19 cases and healthcare capacity to respond. In many locations that shut down beaches and pools earlier in the pandemic, restrictions are now lifting as places reopen. Stricter preventative measures may have to be re-implemented if infections increase again. People who wish to swim, surf, and do other water sports can check on the latest guidance for their location from the appropriate government and public health institutions.\n",
    "What our experts say": "This vaccine requires an initial injection followed by a secondary shot called a “booster” to achieve its full level of protection. The clinical trial includes more than 43,000 volunteer participants, many of whom have already received two doses of the vaccine. In the interim analysis, there were 94 cases of COVID-19 in trial participants, and the study will continue until there have been 164 cases of COVID-19 among study volunteers.\n",
    "Glossary Terms": [
      "rec8jvvjIb2QmeUrA",
      "recFIn1ipbOFsoZsR"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "transmission",
      "infection"
    ],
    "Other resources": "1. Visiting Beaches and Pools ([U.S. CDC](http://cdc.gov/coronavirus/2019-ncov/daily-life-coping/beaches-pools.html))\n2. Considerations for Public Pools, Hot Tubs, and Water Playgrounds During COVID-19 ([U.S. CDC](http://cdc.gov/coronavirus/2019-ncov/community/parks-rec/aquatic-venues.html)))\n3. Early Studies Suggest Outdoor Environments are Low Risk for COVID-19 ([Surfer Magazine](http://surfer.com/features/early-studies-suggest-outdoor-environments-are-low-risk-for-covid-19/))\n",
    "Last edited (simplified)": "2020-09-16T13:53:48.000Z",
    "Last edited (experts say)": "2020-11-10T03:31:06.000Z",
    "Last modified": "2020-11-10",
    "What our experts say wordcount": 70,
    "Background and context wordcount": 126,
    "Other resources wordcount": 32,
    "Wordcount": 228
  },
  {
    "id": "reczJf2HdOHuyl5dx",
    "Question": "What does the northern hemisphere entering its colder season mean for the spread of COVID-19?",
    "Status": "In progress",
    "Background and context": "The SARS-CoV-2 virus is known to be transmissible in all climates and it cannot be called \"seasonal\" at this point. Some lab experiments also showed that SARS-CoV-2 may be sensitive to temperature, humidity, and ultraviolet light. This leads people to believe that climatic effects could protect people from transmission. However, while experimental evidence can show environmental sensitivity, on a larger scale in the real world the effects of climate on COVID-19 appear to be negligible. \n",
    "What our experts say": "\n",
    "Other resources": "1. Transmission Dynamics of Coronavirus Disease 2019 (COVID-19) in the World: The Roles of Intervention and Seasonality ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.07.17.20156430v1))\n2. How will COVID-19 affect the coming flu season? Scientists struggle for clues ([Science)](https://www.sciencemag.org/news/2020/08/how-will-covid-19-affect-coming-flu-season-scientists-struggle-clues)\n3. Misconceptions about weather and seasonality must not misguide COVID-19 response ([Nature](https://www.nature.com/articles/s41467-020-18150-z.pdf))\n4. Will the spread of covid-19 be affected by changing seasons? ([NewScientist](https://www.newscientist.com/article/2239380-will-the-spread-of-covid-19-be-affected-by-changing-seasons/))\n5. Is COVID-19 a seasonal disease? ([WEF](https://www.weforum.org/agenda/2020/07/does-covid-19-thrive-in-cold-weather/))\n",
    "Last edited (simplified)": "2020-09-16T15:20:51.000Z",
    "Last edited (experts say)": "2020-11-10T03:31:06.000Z",
    "Last modified": "2020-11-10",
    "What our experts say wordcount": 0,
    "Background and context wordcount": 75,
    "Other resources wordcount": 58,
    "Wordcount": 133
  },
  {
    "id": "receDZXkDnG0f1EKj",
    "Question": "Can COVID-19 lead to lethal thrombosis?",
    "Status": "Published",
    "Category": "Symptoms",
    "Subcategory": "On: COVID-19 & thrombosis",
    "Background and context": "Since the emergence of COVID-19, new information comes out weekly that sheds light on the health impacts of the virus across the world. COVID-19 has been referred to as a blood vessel disease, as viral pneumonia, and has been linked with a wide set of symptoms like \"COVID toes,\" delirium, and people losing their sense of taste and smell. However, one issue continues to gain attention in the media is the presence of blood clots in infected patients, and how severe they appear to be.\n\nSince scientists and healthcare professionals have learned more about the virus, it has become clear that blood clots may be a significant cause of negative health outcomes in COVID-19 patients, potentially causing or contributing to harmful and even lethal impacts. As we continue to gain more information about the impacts of thrombosis in COVID-19 patients, treatment protocols and medication options may also, hopefully, continue to improve so that the medical consequences of these clots will have less severe effects on people infected with the virus.\n",
    "What our experts say": "Thrombosis occurs when a clump of blood changes from a liquid form to a semi-solid form (called a 'blood clot' or 'thrombus'), and then becomes big enough to partially or fully block the regular flow of blood in veins or arteries. In some severe cases of COVID-19, thrombosis can happen, which prevents blood from flowing normally in patients (despite many of taking blood thinners meant to prevent blood clots from occurring). \n\nIn some COVID-19 patients, thrombosis may contribute to causing  respiratory (breathing) failure, kidney failure, heart attacks, strokes or other dangerous medical issues that can lead to death. Research studies have shown that thrombosis is a known complication of COVID-19 and is associated with an increased risk of death. More research is needed in this area to determine exactly **why** thrombosis may be occurring.\n\nRecent analyses show that many hospitalized patients with COVID-19 who developed thrombosis also developed pneumonia and other lung and respiratory problems. Some patients also developed damage to their blood vessels, while a significant number also developed pulmonary embolisms (blood clots in the lung). These other impacts must also be considered when studying and determining the cause of death related to COVID-19.\n",
    "Glossary Terms": [
      "recB6l1AFYCN65tEX",
      "recnFUXyIZy81Rj1I",
      "reciKuzcOIBjSFsU4",
      "recqf9kWDH9WkLibg",
      "recU4JuZ6HJpfe2ZK",
      "recORiIMwk54TDQB6",
      "recyTUxjnd9jefgJ1",
      "recB0UR5Zy4Hn00Qn",
      "reccJtjL0z55J1CPG",
      "recGL051tGXJ55vYX",
      "rect47sXxza5ALA3I",
      "recdEqNZXZgo1ZiTW"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "blood clot",
      "blood vessel",
      "thrombosis"
    ],
    "Other resources": "1. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases ([PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158248/)) \n2. What Is Known About COVID-19 and Abnormal Blood Clotting ([Weill Cornell Medicine](https://news.weill.cornell.edu/news/2020/07/what-is-known-about-covid-19-and-abnormal-blood-clotting)) \n3. Pulmonary embolism in patients with COVID-19 pneumonia ([ERJ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236820/)) \n4. Incidence of venous thromboembolism in hospitalized patients with COVID-19 ([NIH](https://pubmed.ncbi.nlm.nih.gov/32369666/)) \n5. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 ([TR](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146714/)) \n6. Thrombosis and COVID-19 pneumonia: the clot thickens! ([ERJ](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301830/)) \n7. COVID-19 and Blood Clots ([HMS](https://hms.harvard.edu/news/covid-19-blood-clots)) \n8. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System ([JAMA](https://jamanetwork.com/journals/jama/fullarticle/2768715)) \n9. COVID-19 and its implications for thrombosis and anticoagulation ([Blood](https://ashpublications.org/blood/article/135/23/2033/454646/COVID-19-and-its-implications-for-thrombosis-and)) \n10. Blood vessel attack could trigger coronavirus’ fatal ‘second phase’ ([Science](https://www.sciencemag.org/news/2020/06/blood-vessel-attack-could-trigger-coronavirus-fatal-second-phase)) \n11. Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series ([AIM](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249507/)) \n12. Autopsies Indicate Blood Clots Are Lethal in COVID-19 ([The Scientist](https://www.the-scientist.com/news-opinion/autopsies-indicate-blood-clots-are-lethal-in-covid-19-67727)) \n13. Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome ([AIM](https://www.acpjournals.org/doi/10.7326/M20-2566)) \n14. Incidence and mortality of pulmonary embolism in COVID-19: a systematic review and meta-analysis ([CC](https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03175-z)) \n15. Pulmonary embolism ([Mayo Clinic](https://www.mayoclinic.org/diseases-conditions/pulmonary-embolism/symptoms-causes/syc-20354647)) \n16. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis ([Lancet](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30383-7/fulltext))\n",
    "Last modified manual": "2020-12-01",
    "Last edited (simplified)": "2020-09-17T11:56:22.000Z",
    "Last edited (experts say)": "2020-12-07T14:47:35.000Z",
    "Last modified": "2020-12-07",
    "What our experts say wordcount": 194,
    "Background and context wordcount": 169,
    "Other resources wordcount": 197,
    "Wordcount": 560
  },
  {
    "id": "recqgF5PVjEIVeuwJ",
    "Question": "Can wearing glasses help protect from getting infected with COVID-19?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & glasses",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Country question was sourced from": [
      "USA",
      "China"
    ],
    "Background and context": "Previous research published before the pandemic found that people may involuntarily touch their eyes several times per hour. A study from China was published in mid-September 2020 where researchers suggested that wearing glasses may prevent people from touching their eyes, and recommended paying more attention to potential COVID-19 exposure through the eyes.\n\nDuring the COVID-19 pandemic, public health and medical experts have recommended that everyone try to avoid touching their face and eyes, whether they wear glasses or not, to reduce the possibility of contaminated hands infecting the body. This recommendation complements other recommendations to keep hands clean with regular hand washing or sanitizing, and to maintain distance from other people when possible.\n",
    "What our experts say": "Because the news about this vaccine is still early, there is still a lot we don't know. Remaining questions include when the vaccine might be available for everyone, if it will work in children younger than 12 (as they have been excluded from the early trials), if it will stop the virus from spreading in people who are infected but don't have any symptoms (asymptomatic), if it will prevent people from developing severe cases, and how long the vaccine might offer protection from the the virus.\n",
    "Glossary Terms": [
      "recORiIMwk54TDQB6",
      "recvwSSjn9ohOm9fK",
      "recMZLIWKC45HMVao"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "transmission",
      "infection"
    ],
    "Other resources": "1. Association of Daily Wear of Eyeglasses With Susceptibility to Coronavirus Disease 2019 Infection ([JAMA](https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2770872))\n2. Face touching: a frequent habit that has implications for hand hygiene ([American Journal of Infection Control](https://linkinghub.elsevier.com/retrieve/pii/S0196655314012814))\n",
    "Last edited (simplified)": "2020-09-17T20:52:06.000Z",
    "Last edited (experts say)": "2020-11-10T03:31:06.000Z",
    "Last modified": "2020-11-10",
    "What our experts say wordcount": 86,
    "Background and context wordcount": 112,
    "Other resources wordcount": 31,
    "Wordcount": 229
  },
  {
    "id": "recSCMovWVO7VKvPB",
    "Question": "How might wildfires and other natural diasters impact COVID-19 transmission?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & wildfires",
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Wildfires have continued to burn across the West Coast of the United States through September 2020, leading to evacuation orders for large areas, widespread displacement, and destruction of property, in addition to an increase in air pollution. In California alone, 3.3 million acres have burned since the beginning of 2020.\n\nNatural disasters such as wildfires can cause significant long-term damage to lungs. Wildfire smoke has small particles that are 2.5 microns (microscopic) in size, but they can be inhaled deep into the lungs and cause inflammation in the airways. This is particularly harmful for people with pre-existing health conditions or respiratory problems, and there is some evidence to indicate that it can increase the risk of respiratory problems. While it is too early to determine the impact of wildfire smoke on COVID-19 symptoms, some experts worry it could increase the severity of existing symptoms. \n",
    "What our experts say": "\n",
    "Glossary Terms": [
      "rec2UNEXbTkSCx30Q",
      "recOcmLKbzV6NUkAH"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "wildfires",
      "transmission",
      "spread",
      "symptoms"
    ],
    "Other resources": "1. Wildfire Smoke and COVID-19 ([U.S. CDC](https://www.cdc.gov/disasters/covid-19/wildfire_smoke_covid-19.html))\n2. What to Know About Wildfire Smoke and COVID-19 ([UCSF](https://www.ucsf.edu/news/2020/08/418276/what-know-about-wildfire-smoke-and-covid-19))\n3. Hurricanes and Wildfires Are Compounding COVID-19 Risks ([Scientific American](https://www.scientificamerican.com/article/hurricanes-and-wildfires-are-compounding-covid-19-risks/))\n",
    "Last edited (simplified)": "2020-09-17T17:35:01.000Z",
    "Last edited (experts say)": "2020-11-10T03:31:06.000Z",
    "Last modified": "2020-11-10",
    "What our experts say wordcount": 0,
    "Background and context wordcount": 144,
    "Other resources wordcount": 25,
    "Wordcount": 169
  },
  {
    "id": "rec8wGyjeDolqSj8b",
    "Question": "Are you as likely to die from a common cold as COVID-19?",
    "Status": "Published",
    "Category": "Mortality",
    "Subcategory": "On: COVID-19 & mortality",
    "Background and context": "Multiple myths have been circulating on social media that falsely claim that more people die from the common cold in comparison to COVID-19. COVID-19 is caused by SARS-CoV-2, a novel coronavirus that has been responsible for more than 30 million cases and 900,000 deaths globally.\n\nWhile the virus that causes the common cold does infect a lot of people, it is not responsible for many deaths. COVID-19 is far deadlier for vulnerable and older populations with pre-existing medical conditions. \n\nThe case fatality rate (which is the proportion of deaths compared to the total number of cases over a given time period) typically provides a good indicator of how lethal a particular infection is. However, if the number of cases is rapidly evolving, or if there are difficulties in accurately diagnosing cases, the case fatality rate may vary significantly. Regardless, by all measures, the number and proportion of deaths from COVID-19 far exceeds those caused by the common cold.\n",
    "What our experts say": "COVID-19 is far more lethal than the virus that causes the common cold, even though the vast majority of COVID-19 patients only experience mild or no symptoms. The best available current evidence indicates that the novel coronavirus is easily transmissible in the absence of social distancing and masks, and is responsible for more than 900,000 deaths globally. \n\nThe common cold is generally not lethal, with some rare exceptions. The flu, which is deadlier than the common cold, killed 0.1% of the people who contracted it in 2019. It is still too early to discern accurate global death estimates for people who have contracted COVID-19, but estimates have ranged from 1% to 25% of all cases, depending on the country. Even conservative COVID-19 death rates (around 1% ) would mean that the novel coronavirus is at least 10 times as deadly as the flu, and significantly more lethal than the common cold. \n\nCompared to the common cold, COVID-19 kills more people in every age group, and is especially more lethal in the oldest age groups. However, it is important to note that actual case numbers and the ability to accurately attribute cause of deaths to COVID-19 is still evolving. As the pandemic progresses and scientists receive a complete picture of all known infections, the risk of death will become more clear.\n",
    "Glossary Terms": [
      "reci0r8fUkfYPAxJU",
      "recE5fZ79yZqKorXK"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\t\n",
    "Topics": [
      "case fatality rate",
      "deaths",
      "common cold",
      "virus",
      "COVID-19"
    ],
    "Other resources": "1. Mortality analyses ([JHU](https://coronavirus.jhu.edu/data/mortality)) \n2. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics ([The Lancet](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30484-9/fulltext#tbl4)) \n3. Similarities and Differences between Flu and COVID-19​ ([U.S. CDC](https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm)) \n4. Estimating mortality from COVID-19 ([WHO](http://Estimating mortality from COVID-19))\n",
    "Last modified manual": "2020-09-18",
    "Newsletter": true,
    "Last edited (simplified)": "2020-09-18T23:09:48.000Z",
    "Last edited (experts say)": "2020-09-18T23:20:47.000Z",
    "Last modified": "2020-09-18",
    "What our experts say wordcount": 220,
    "Background and context wordcount": 157,
    "Other resources wordcount": 30,
    "Wordcount": 407
  },
  {
    "id": "recgYhZKtG7oXfSPv",
    "Question": "Do masks heighten the risk of 'antibiotic resistant strains of pneumonia' or the risk of developing pneumonia at all?",
    "Status": "Published",
    "Category": "Masks",
    "Background and context": "Several widely circulated false claims on social media, including one from a congressional candidate in Florida, suggest falsely that “Excessive use of face masks causes fungal and bacterial pneumonia.”  Several infectious disease specialists have clarified the misinformation to explain that, other than some discomfort, normal use of face masks do not cause any harm.  Healthcare providers wear masks for longer than 8 hours a day sometimes, with no evidence of such risks.\n",
    "What our experts say": "There is no evidence to suggest that the use of face masks increases the risk of developing pneumonia, or any other bacterial, fungal or viral infection in the lungs. \n\nIn fact, according to a study published in the Preventive Medicine journal, wearing face masks  is shown to protect people against bacterial infections in hospital settings, where health care workers are most prone to antibiotic-resistant bacteria. The American Lung Association also endorses the U.S. CDC recommendation of wearing masks in public. \n\nWHO and CDC both recommend that general sanitation guidelines should be followed to ensure one is wearing clean masks. Wet or visibly dirty masks should not be worn, as they can be contaminated with micro organisms.\n",
    "Glossary Terms": [
      "reclKahoPRbBLqUKg",
      "recAFuzwLppTBDIPe",
      "recVfOgvT8WVpJgfA"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "bacterial infection",
      "face masks"
    ],
    "Other resources": "1. Normal use of face masks do not cause pneumonia ([AP](https://apnews.com/afs:Content:9072351115#:~:text=%E2%80%9CThere's%20no%20evidence%20of%20masks,and%20medicine%20at%20Boston%20University.))\n2. Efficacy of face masks and respirators in preventing upper respiratory tract bacterial colonization and co-infection in hospital healthcare workers [(Preventive Medicine Journal)](https://www-sciencedirect-com.ezp-prod1.hul.harvard.edu/science/article/pii/S0091743514000322)\n3. Should I wear a mask when I am out in public? [(American Lung Association)](https://www.lung.org/lung-health-diseases/lung-disease-lookup/covid-19/faq)\n4. Fact check: Masks worn during COVID-19 response do not cause fungal lung infections([Reuters](https://www.reuters.com/article/uk-factcheck-masks-fungal-lung-infection/fact-check-masks-worn-during-covid-19-response-do-not-cause-fungal-lung-infections-idUSKBN24B25H))\n5. Coronavirus: How to Care for Your Face Mask ([Johns Hopkins Medicine](https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-how-to-care-for-your-face-mask))\n6. Advice on the use of masks in the context of COVID-19 [(WHO)](https://www.who.int/publications/i/item/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak)\n7. COVID-19 and face masks: To wear or not to wear? ([Medical News Today](https://www.medicalnewstoday.com/articles/covid-19-and-face-masks-to-wear-or-not-to-wear#4.-Masks-might-harm-the-wearer))\n\n",
    "Last modified manual": "2020-09-21",
    "Last edited (simplified)": "2020-09-21T16:27:53.000Z",
    "Last edited (experts say)": "2020-09-21T19:22:49.000Z",
    "Last modified": "2020-09-21",
    "What our experts say wordcount": 117,
    "Background and context wordcount": 74,
    "Other resources wordcount": 96,
    "Wordcount": 287
  },
  {
    "id": "rec0TXrBjHL8mZPG8",
    "Question": "Can thymosin alpha-1 treat, cure or prevent COVID-19?",
    "Status": "Published",
    "Category": "Treatment",
    "Subcategory": "On: COVID-19 & thymosin alpha-1",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Thymosin alpha-1 has recently been promoted by several wellness brands and individuals as a potential treatment or cure for COVID-19, though no evidence supports this drug as a therapy for the virus. Through social media outreach and other advertising methods, more than 30 medical practices and compounding pharmacies (a pharmacy that makes custom formulas of medications to fit the specific needs of a patient that cannot be addressed using traditional medication formulas) across the United States have made claims about this drug and its ability to treat the virus without proven support or evidence. As there is some medical research regarding the drug and its impacts on the immune system in relation to specific diseases, thymosin alpha-1 can be a confusing topic to research as a potential treatment for illnesses. Many claims have been made that the drug has been approved for use by the U.S. FDA, but these are not true. Though a drug may show promise in helping treat or support the treatment of one illness, it does not mean that it can treat others or that prior studies with some minor positive findings make it an option for physicians treating patients with COVID-19. \n",
    "What our experts say": "Thymosin alpha-1 has not been shown to be safe or effective in preventing, treating, or curing COVID-19. The drug has been sold under the brand name Zadaxin, and was created to act as a lab-made version of a natural substance in the body that can stimulate some immune functions and responses in humans. \n\nHowever, despite many inaccurate claims by several wellness groups, thymosin alpha-1 has never been approved by the U.S. Food and Drug Administration (FDA) for COVID-19, or any other condition. It  has been granted \"orphan drug designation\" in order to research the drug as a potential treatment for some rare illnesses (though has yet to be approved for any). Thymosin alpha-1 has been approved in 30 countries outside the United States for treatment of chronic viral infections, including HIV and chronic hepatitis C, and it has some promising research occurring in other types of disease responses, but has not been designated as a COVID-19 treatment by the World Health Organization. \n\nThough there are currently some studies being conducted that research the impact of thymosin alpha-1 on COVID-19 patients, including clinical trials, there is not enough evidence to support using this drug as a treatment or prevention tool for the virus.\n",
    "Glossary Terms": [
      "recRog4Fq88ayf62O",
      "recM4p8QOERmuESKr",
      "recOLVaA8YtoF3ofN"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\t\t\n",
    "Topics": [
      "treatment",
      "prevention",
      "cure",
      "medication",
      "thymosin alpha-1",
      "clinical trial",
      "virus"
    ],
    "Other resources": "1. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells ([CID](https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa630/5842185)) \n2. Dysregulated adaptive immune response contributes to severe COVID-19 ([Nature](https://www.nature.com/articles/s41422-020-0391-9)) \n3. Gender-Associated Difference following COVID-19 virus infection: Implications for Thymosin alpha-1 Therapy ([II In Press](https://www.sciencedirect.com/science/article/pii/S1567576920320956)) \n4. Web Of 'Wellness' Doctors Promote Injections Of Unproven Coronavirus Treatment ([NPR](https://www.npr.org/2020/10/01/914433778/web-of-wellness-doctors-promote-injections-of-unproven-coronavirus-treatment)) \n5. Off-label therapy targeting pathogenic inflammation in COVID-19 ([Nature](https://www.nature.com/articles/s41420-020-0283-2)) \n\n",
    "Last modified manual": "2020-10-05",
    "Last edited (simplified)": "2020-10-01T19:59:35.000Z",
    "Last edited (experts say)": "2020-10-07T01:28:58.000Z",
    "Last modified": "2020-10-07",
    "What our experts say wordcount": 203,
    "Background and context wordcount": 195,
    "Other resources wordcount": 69,
    "Wordcount": 467
  },
  {
    "id": "recr56hix396bMVN5",
    "Question": "Can nose swab testing for COVID-19 be harmful?",
    "Status": "Published",
    "Background and context": "A recent viral message on social media falsely claims that the COVID-19 nasal swab test is dangerous and causes death by damaging the blood-brain barrier. These false claims have been circulating on social media since July, and they have no scientific merit. The COVID-19 nasal swab test is a standard medical technique that requires a swab to be inserted inside each nostril and twirled around for a few seconds. This ensures that the nurse or doctor can collect the secretions inside the nose and send a sample for analysis. The swab has to be inserted far into the nostril because the fluids need to be collected from the nasal passage, between the nose and the throat.\n",
    "What our experts say": "Nasal or nose swab testing for COVID-19 is a completely standard and safe procedure to detect COVID-19. It does not pose any significant risks to the patient, beyond some discomfort. The procedure can trigger tears when performed correctly, because it activates a reflex in your body. The procedure does not last for more than five seconds per nostril, and there are no lasting effects from the test. The nose swab needs to be inserted quite far into the nose in order to get a sample of secretions that can be sent to a lab for analysis. \n\nSince most people do not typically experience an object being inserted into the nose on a regular basis, they can experience minor discomfort, but there are no other short or long-term harms that result from the procedure. It is virtually impossible for swab testing to access or have any impact on the blood-brain barrier. The blood-brain barrier is a packed layer of cells that creates a barrier, protecting molecules in the blood from the brain's blood vessels. Rupturing the blood-brain barrier would require breaking through multiple layers of tissue, drilling through bone, and going through blood vessels, which is not possible with a nasal swab. The nasal swab technique is standard practice across the world, and it cannot rupture the blood-brain barrier or the endocrine glands, nor can it infect the brain, as some have falsely claimed. \n",
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "testing"
    ],
    "Other resources": "1. What is the blood-brain barrier? ([Queensland Brain Institute](https://qbi.uq.edu.au/brain/brain-anatomy/what-blood-brain-barrier))\n2. Coronavirus (COVID-19) testing: What you should know ([UC Davis Health](https://health.ucdavis.edu/coronavirus/coronavirus-testing.html))\n3. 11 things to know about COVID-19 testing ([University of Texas](https://www.mdanderson.org/cancerwise/is-covid-19-coronavirus-testing-accurate-and-9-more-things-to-know-about-covid-19-nasal-swab-testing.h00-159381945.html))\n4. Coronavirus tests: Swabs don't damage the brain and other claims fact-checked ([BBC](https://www.bbc.com/news/53443429))\n\n",
    "Editorial notes:": "<airtable:mention id=\"menSFfcMcl32W9J47\">@Mohit Nair</airtable:mention> Context from VERA: \n\n\"I am currently working on a fact check article that would look into a Facebook post that made the following claims:\nCOVID-19 swab test is a \"\"dangerous test\"\" that could \"\"cause [one's] death;\"\"\ninserting the swab through the nose damages the hematoencephalic or the blood-brain barrier, as well as the endocrine glands (e.g. hypophysis);\nthe damage done by the swab in the blood-brain barrier is the reason why swab testing \"\"hurts and kind of tickles the brain\"\";\nthe purpose of the swab test is to \"\"break the barrier and create an entry into the brain for every infection\"\";\nthe damage caused by the swab test allows \"\"bacteria and CO2\"\" to be \"\"collected and transported to the brain through the nose channel\"\";\nthe blood-brain barrier's task is to \"\"protect the brain from neurotoxins, heavy metals, bacteria and other toxins\"\";\n\"\"if endocrine glands are damaged, symptoms such as muscle weakness, blood circulation, visual disturbances, etc. may develop.\"",
    "Last modified manual": "2020-09-21",
    "Last edited (simplified)": "2020-09-21T22:05:19.000Z",
    "Last edited (experts say)": "2020-09-21T22:08:47.000Z",
    "Last modified": "2020-09-21",
    "What our experts say wordcount": 234,
    "Background and context wordcount": 115,
    "Other resources wordcount": 41,
    "Wordcount": 390
  },
  {
    "id": "rec6Ka1kiwtOXSKe0",
    "Question": "Is the flu vaccine more important during the COVID-19 pandemic?",
    "Status": "Published",
    "Category": "On: COVID-19 & flu shots",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Background and context": "Public health agencies are widely promoting the flu vaccine in fall 2020, as the Northern Hemisphere enters peak flu season.\n\nAlthough the flu has a lower infection fatality rate than COVID-19, the World Health Organization (WHO) has estimated that respiratory infections linked to seasonal flu killed up to 650,000 per year before the COVID-19 pandemic. Healthcare workers and public health experts fear there may be additional consequences with the 2020 flu season peaking during the on-going global COVID-19 pandemic.\n\nIt is possible that the flu season will not be as bad in 2020 due to preventative measures that people are already taking for COVID-19, such as wearing face coverings and masks, maintaining physical distance from other people, and keeping surfaces and hands clean. For example, some countries in the Southern Hemisphere have reported lower cases of the flu during their anticipated seasonal peak in 2020. Scientists are currently monitoring flu cases around the world, and it is not yet known with certainty what will happen in the Northern Hemisphere.\n\nGetting a flu vaccine remains an important preventative measure to reduce strains on health systems during the COVID-19 pandemic, with the potential to help save lives. There are also benefits to preventing illness in healthy people who are likely to recover from the flu, in terms of fewer missed days of school, work, and caring for others. By getting the flu vaccine, people also prevent transmission of the flu to others. When enough people get the flu vaccine, this may help achieve herd immunity to protect people who were unable to get the flu vaccine due to health reasons.\n\nFlu vaccines cannot protect against COVID-19, which is why COVID-19 vaccines are currently being developed. Recent research suggests that it is possible for flu vaccines to have protective effects from severe symptoms of COVID-19. For example, a pre-print study from June 2020 analyzed 92,664 Brazilian patients confirmed to have COVID-19. The researchers found that patients who received a recent influenza vaccine experienced on average 8% lower odds of needing intensive care treatment, 18% lower odds of needing invasive respiratory support, and 17% lower odds of death.\n\nAdditionally, flu vaccines have not been found to increase the chances of getting COVID-19. There was a January 2020 report that suggested an association between flu vaccination and the risk of getting four commonly circulating seasonal coronaviruses (not including the coronavirus that causes COVID-19), but this finding was shown to be incorrect. \n",
    "What our experts say": "As the Northern Hemisphere enters influenza (flu) season during the COVID-19 pandemic, it is more important than ever to get vaccinated against the flu. Reasons include: \n\n\n- Reducing strains on health systems providing testing and care\n- Preventing patients from becoming infected with the flu and COVID-19 at the same time\n- Protecting the lives of people who are the most vulnerable to getting sick, such as very young children, people with certain health conditions, and older adults\n\nFlu cases occur year-round, but tend to peak during the fall and winter seasons in the Northern Hemisphere. Seasonal flu vaccines, also called flu shots when given via injection, help the body to develop antibodies about two weeks after vaccination. These antibodies help the immune system  fight against infection from certain strains of influenza viruses. Each year, research indicates what the most common influenza viruses may be during the upcoming season, and flu vaccines are developed to tackle those strains. Flu vaccines do not protect against every strain of influenza because there are many, and mutations are frequent.\n\nFlu vaccines are widely considered safe and effective for preventing illness and death from the flu. Flu vaccines can have added benefits for people with certain chronic medical conditions, such as reducing illness flare-ups in people with chronic obstructive pulmonary disease (COPD) and reducing the risk of heart attacks, strokes, and death among people with heart disease.\n\nThere are many types of flu vaccines available, including for children as young as 6 months of age and for older adults above 65 years of age. Most flu vaccines are considered safe for the general population between 6 months and 65 years of age, including pregnant women and people with certain health conditions. There are limited exceptions to who should get a flu vaccine, based on factors such as age, health status, and allergies. Anyone with concerns about getting a flu vaccine can consult a doctor.\n\nThe U.S. Centers for Disease Control and Prevention (CDC) recommends getting a flu vaccine every year, and emphasizes the importance of getting vaccinated against the flu in 2020 due to the ongoing COVID-19 pandemic. It is better to get a flu vaccine early in the season, before the flu season peaks, rather than waiting until influenza viruses are spreading in your community. When going to get a flu vaccine during the COVID-19 pandemic, plan to take recommended  precautions such as wearing a face covering and practicing good hygiene. \n",
    "Glossary Terms": [
      "recDalYrz2m23kS2e",
      "rec9qqItwSTjq3Eae",
      "recmajcAORyuqhZPc",
      "recaXXF6coF4J2EUz",
      "rec4kgXUEMkPzbQvP"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "virus",
      "spread",
      "seasonality"
    ],
    "Other resources": "1. Key Facts About Seasonal Flu Vaccine ([U.S. CDC](https://www.cdc.gov/flu/prevent/keyfacts.htm))\n2. Frequently Asked Influenza (Flu) Questions: 2020-2021 Season ([U.S. CDC](https://www.cdc.gov/flu/season/faq-flu-season-2020-2021.htm))\n3. Flu Vaccination Urged During COVID-19 Pandemic ([JAMA](https://jamanetwork.com/journals/jama/article-abstract/2769836))\n4. Why COVID-19 Means You Need a Flu Shot This Year ([University of California, San Francisco](https://www.ucsf.edu/news/2020/09/418406/why-covid-19-means-you-need-flu-shot-year))\n5. Time for flu shots — getting one is more important than ever! ([Harvard Medical School](https://www.health.harvard.edu/blog/time-for-flu-shots-getting-one-is-more-important-than-ever-2020091720972))\n6. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens ([JAMA](https://jamanetwork.com/journals/jama/fullarticle/2764787))\n7. Up to 650 000 people die of respiratory diseases linked to seasonal flu each year ([WHO](https://www.who.int/news-room/detail/14-12-2017-up-to-650-000-people-die-of-respiratory-diseases-linked-to-seasonal-flu-each-year))\n8. Influenza Update 376, 14 September 2020 ([WHO](https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/))\n9. Decreased Influenza Activity During the COVID-19 Pandemic — United States, Australia, Chile, and South Africa, 2020 ([U.S. CDC](https://www.cdc.gov/mmwr/volumes/69/wr/mm6937a6.htm?s_cid=mm6937a6_w))\n10. Inactivated trivalent influenza vaccine is associated with lower mortality among Covid-19 patients in Brazil ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.06.29.20142505v1))\n",
    "Last modified manual": "2020-10-05",
    "Last edited (simplified)": "2020-09-29T00:17:59.000Z",
    "Last edited (experts say)": "2020-09-29T00:33:25.000Z",
    "Last modified": "2020-09-29",
    "What our experts say wordcount": 405,
    "Background and context wordcount": 402,
    "Other resources wordcount": 121,
    "Wordcount": 928
  },
  {
    "id": "recXTEVKXvJOl7Euw",
    "Question": "What would successful contact tracing look like following the President of the United States’ COVID-19 infection?",
    "Status": "Published",
    "Background and context": "On Thursday, Oct. 1, U.S. President Donald Trump reported a positive diagnosis of COVID-19, meaning that he is currently infected with the virus that causes COVID-19. Knowing his status allows public health experts to track, and ideally prevent, the spread of the virus through contact tracing by following the chain of transmission — that is, who the president has been in close contact with, who those individuals have been in contact with, and so forth down the line. Contact tracing around President Trump’s status will also help clarify who President Trump contracted the virus from, who else might be at risk, and how big those risk pools are. In the case of U.S. President Trump, there is concern that these risk pools could be large given his busy public schedule, and could include senior government leaders and staff. \n",
    "What our experts say": "Given that the the period between exposure to COVID-19 and symptom onset can be between 2-14 days, U.S. President Donald Trump could have been infected as early as two weeks ago. He could have been contagious as early as approximately 12 days before his positive test result.\n\nSince other prominent individuals in Donald Trump’s circles have also tested positive in days following Trump’s positive result — such as Melania Trump, presidential adviser Hope Hicks, and Trump campaign manager Bill Stepien — all infected members of the White House may have overlapping chains of transmission and as a result, contact tracing efforts will be complex. As a result, the optimal, comprehensive contact tracing approach in this situation would look as follows: \n\n\n1. Donald Trump and all individuals who tested positive in his close circles would provide detailed information on where they were and who they had close contact with in the 14 days prior each of their positive test results. Close contact includes anyone who has been within 6 feet (2 m) of any of them for at least 15 minutes, or indoors with any of them without a mask on within two days of any of the three diagnoses\n2. A team of contact tracers would then quickly alert the identified individuals, to let them know that they may have been exposed to COVID-19\n3. The individuals from the close contact group would then be assessed for symptoms and tested for COVID-19\n4. The people from the close contact group who test negative for COVID-19 would then be instructed to self-quarantine for 14 days after they were exposed, keep social distance from others, self-monitor for COVID-19 symptoms, and send doctors and the state health department daily health updates\n5. The people from the close contact group who don’t have symptoms, but have also not been tested, would be instructed to follow guidelines as if they tested negative\n6. The people from the close contact group who test positive would be instructed to self-isolated and recover at home for minimum 10 days and then self-quarantine for 14 days after being exposed, seek medical care if they experience emergency warning signs, and monitor symptoms and avoid spreading the virus\n7. The people from the list who have symptoms of COVID-19 but can’t be tested would be asked to follow the guidelines as if they tested positive \n8. Each close contact would get tested again one week after initial testing\n9. Contact tracing steps 1-8 would repeat for the close contacts of each individual who tests positive\n\nThough the incubation period of the virus that causes COVID-19 is 2-14 days, the incubation period of infection is most often 3-5 days, so it's most likely that Trump was infected between Saturday, 9/26/2020, and Monday, 9/28/2020. That makes him mostly likely infectious as of Tuesday, 9/29/2020. \n\nThis entry was updated with new information on October 4, 2020.\n",
    "Other resources": "1. Contact Tracing - Coronavirus Disease 2019 ([CDC](https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/contact-tracing.html#:~:text=Contact%20tracing%20slows%20the%20spread,to%20COVID%2D19%20get%20tested.)) \n2. Contact tracing and COVID-19: What is it and how does it work? ([Mayo Clinic](https://www.mayoclinic.org/diseases-conditions/coronavirus/expert-answers/covid-19-contact-tracing/faq-20488330))\n3. The White House should now be ground zero for a huge contact tracing operation ([Vox](https://www.vox.com/21498464/trump-covid-19-coronavirus-positive-contact-tracing)) \n4. There should be 'enormous' contact tracing of people around Trump, says public health expert ([The Hill](https://thehill.com/changing-america/well-being/prevention-cures/519312-there-should-be-enormous-contact-tracing-of))\n",
    "Last modified manual": "2020-10-05",
    "Last edited (simplified)": "2020-10-02T20:07:08.000Z",
    "Last edited (experts say)": "2020-10-04T16:59:46.000Z",
    "Last modified": "2020-10-04",
    "What our experts say wordcount": 472,
    "Background and context wordcount": 138,
    "Other resources wordcount": 55,
    "Wordcount": 665
  },
  {
    "id": "recNkIDORV1mFRnWY",
    "Question": "The U.S. president is recieving drugs that usually treat moderate to severe COVID-19 symptoms. Is it possible these drugs were administered as preventative measures?",
    "Status": "Update ready for review",
    "Background and context": "Below are brief overviews of the three primary COVID-19 treatments that Trump was, or in some cases still is being, administered, covering 1) what type of drug is is, 2) how it works, 3) what population it works best for (in terms of COVID-19 severity), and 4) its regulation status. \n\n- **Regeneron experimental antibody treatment:** This treatment is a combination of two antibodies, which together work to protect the body against the COVID-19 virus by mimicking the immune system's natural response. Recent data show the drug may be able to help reduce levels of the virus and number of medical visits in patients diagnosed with the virus. The drug was most effective for those with high viral loads, but low levels of antibodies, among non-hospitalized patients. When President Trump received this treatment in October of 2020, it was administered under the Food and Drug Administration’s (FDA) regulation called “expanded access,” which allows doctors to request “compassionate use” of experimental drugs through an “investigational new drug” pathway used for individual patients or for emergencies. This expanded access is not the same as an Emergency Use Authorization which the treatment has received as of November 2020. Of note is that Trump received an 8-gram infusion of the treatment, while Regeneron’s trial data showed that a 2.4-gram infusion worked just as well as a higher dose. Co-founder and chief scientific officer of Regeneron said this was likely out of “an abundance of caution.”\n\n- **Dexamenthasone:** Dexamethasone is anti-inflammatory corticosteroid. Dexamethasone works by suppressing the immune system, which the virus that causes COVID-19 attacks, which can help the virus from severely worsening a COVID-19 case in late stages. Dexamethasone is intended for individuals with severe cases of COVID-19 who are on ventilators or receiving oxygen, with unclear benefits for other patients. It is the only treatment so far known to reduce mortality in patients with severe COVID-19, but there have also been risks shown when given too early to a patient, because of its weakening of the immune system, as well as risks of serious side effects. In early September of 2020, the World Health Organization (WHO) issued guidance that corticosteroids like dexamethasone should be considered treatments for severe cases of COVID-19, but should not be used in milder cases. \n\n- **Remdesivir:** Remdesivir is an antiviral drug shown to modestly help hospitalized COVID-19 patients. Remdesivir works by disguising itself as the building blocks of the virus. Using this \"disguise,\" the drug can infiltrate the virus and disrupt it. The disruption makes whole sections of the virus useless, preventing the virus from making copies of itself and spreading. Remdesivir is intended for patients who are hospitalized for COVID-19. Remdesivir is approved for use by the FDA under an Emergency Use Authorization but is not recommended by the WHO.  \n\nIn terms of other treatments, [the president’s doctor said](https://apnews.com/article/virus-outbreak-melania-trump-archive-f1ef1f03cdd92fa83618ed34a3ea5ddb) that in addition to the above treatments, Trump has been taking “zinc, vitamin D, famotidine, melatonin and a daily aspirin.” \n",
    "What our experts say": "In the days following U.S. President Trump’s positive COVID-19 diagnosis on October 1, 2020, President Trump received a combination of three primary treatments: 1) an experimental antibody treatment from Regeneron, 2) Remdesivir, and 3) Dexamethasone. \n\nBased on reports from President Trump’s doctors that his case was mild to moderate, as well as the fact that Trump was discharged from the hospital after three days on October 5 to be treated from home, these drugs were likely used proactively, but not necessarily preventatively.\n\nThe Regeneron antibody treatment he received is an experimental treatment that received an United States Food and Drug Administration's Emergency Use Authorization in November of 2020 for newly diagnosed patients with mild to moderate cases of COVID-19 who are not hospitalized. The drugs are intended for COVID-19 patients with different levels of disease severity. Dexamethasone in particular is intended for use in patients with severe cases of COVID-19.\n\nIt is likely that President Trump had a moderate case of COVID-19, but given his status as the U.S. president, doctors were and are willing to provide him unprecedented treatment that is normally reserved for those who are severely ill, given that potential risks of improving his condition (side effects) outweigh potential benefits. Even those who are severely ill with COVID-19 would be highly unlikely to receive this combination of treatments, or in many cases even one of them, given the limited availability of the drugs.\n\nThis treatment combination used for Donald Trump can be seen as preventative because they are trying to prevent his illness from getting worse, but is better thought of as proactive, given that Trump is already infected with COVID-19. In public health, preventative steps are the very first steps taken towards preventing a poor health outcome like COVID-19; in this case, some of those steps include wearing a mask and social distancing.\n",
    "Other resources": "1. Update: Here’s what is known about Trump’s COVID-19 treatment ([Science Mag](https://www.sciencemag.org/news/2020/10/heres-what-known-about-president-donald-trump-s-covid-19-treatment))\n2. ‘Provocative results’ boost hopes of antibody treatment for COVID-19 ([Science Mag](https://www.sciencemag.org/news/2020/09/provocative-results-boost-hopes-antibody-treatment-covid-19)) \n3. Regeneron’s REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients ([Regeneron](https://investor.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and))\n4. Memorandum from Trump’s doctor on COVID-19 treatment ([Associated Press](https://apnews.com/article/virus-outbreak-melania-trump-archive-f1ef1f03cdd92fa83618ed34a3ea5ddb))\n5. President Trump Is Getting an 'Unprecedented' Mix of COVID-19 Treatments. That Puts Him On the Cutting Edge of Coronavirus Care ([TIME Magazine](https://time.com/5896274/trump-covid-19-treatments/))\n\n\n",
    "Last modified manual": "2020-12-07",
    "Last edited (simplified)": "2020-12-08T06:25:11.000Z",
    "Last edited (experts say)": "2020-12-08T06:25:11.000Z",
    "Last modified": "2020-12-08",
    "What our experts say wordcount": 304,
    "Background and context wordcount": 488,
    "Other resources wordcount": 70,
    "Wordcount": 862
  },
  {
    "id": "recdOJkSCvzxVJLxO",
    "Question": "What do we know about controlling the spread of COVID-19 through hyper-local measures?",
    "Status": "Published",
    "Subcategory": "Lockdowns",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "There have been recent questions about hyper-local control measures in response to New York City’s announcement on October 4, 2020, to impose new restrictions in 20 COVID-19 hotspots in Brooklyn and Queens where the COVID-19 positivity rate has been higher than 3% for 7 consecutive days. 11 zip codes have lesser restrictions, such as banned indoor dining, and 9 zip codes with the highest positivity rates have major restrictions, which include closing schools, nonessential businesses, and day care centers, essentially reversing progress the city had made on fighting the outbreak in the spring. \n\nGiven that zipcodes that fall into the three categories of 1) major hotspot, 2) minor hotspot, and 3) not a hotspot, in some cases, all neighbor each other or are closely nearby, questions have been raised as to how effective such hyper-local interventions such as these are towards the end of keeping the case count from increasing and, ideally, ultimately lowering the case count. \n",
    "What our experts say": "Imposing restrictions at a hyper-local level, such as by postal code or zip code, can work to contain COVID-19, but is not without challenges and comes with a set of both pros and cons. The pros come into effect if individuals who are residents of that zip code or neighborhood a) follow the restrictions imposed and do not travel outside their neighborhood, especially at a mass level. The cons come into effect if individuals who are residents of that zip code or neighborhood either do not follow restrictions imposed, or travel outside their neighborhood, especially at a mass level.\n\nAs a result, it’s crucial to communicate with residents so that they understand the expectations and what is at risk if local measures aren’t followed. To help ensure that they are followed, local public health officials and leaders must share information with residents on how to access the resources that they need hyper-locally, both for healthcare and otherwise, so that individuals are not pushed to seek resources outside of their affected area, and in turn potentially increasing positive rates in other neighborhoods, worsening the problem overall. \n\nOf note is that hyperlocal surveillance of COVID-19 is also useful for tracking and ultimately controlling the spread of the virus, as the more local the data is, the more granular it is likely to be and the less gaps it is likely to have.\n",
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Last modified manual": "2020-10-19",
    "Last edited (simplified)": "2020-10-16T20:57:52.000Z",
    "Last edited (experts say)": "2020-10-21T18:41:30.000Z",
    "Last modified": "2020-10-21",
    "What our experts say wordcount": 228,
    "Background and context wordcount": 156,
    "Other resources wordcount": 0,
    "Wordcount": 384
  },
  {
    "id": "rec9thjuTgT5ytu9t",
    "Question": "What do we know about the Regeneron cocktail for COVID-19?",
    "Status": "Published",
    "Category": "Treatment",
    "Subcategory": "On: COVID-19 & Regeneron",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Though the treatment had not yet received EUA from the U.S. FDA, United States President Donald Trump was administered the Regeneron experimental treatment in early October of 2020, in response to his COVID-19 diagnosis and as part of a compassionate use allowance. Since then, the company has reported early findings from its studies in order to obtain its EUA, including phase 2 data from the first 799 adults who volunteered for the trial. These outpatients participants are part of an ongoing clinical trial involving people who receive the Regeneron treatment and those who receive the placebo. Currently, the recommended dose is 1,200 mg of casirivimab and 1,200 mg of imdevimab (2,400 mg total) administered as a single treatment where the liquid medication is inserted directly into a patient's vein (called an 'intravenous infusion'). \n\nAs this Regeneron treatment was partially funded by the U.S. government, the first 300,000 doses will be free to patients but they may be charged a fee for the healthcare facility providing the care. The company has begun shopping doses to a national distributor called Amerisource Bergen who will dispense the treatment as the U.S. federal government directs them.\n",
    "What our experts say": "Regeneron Pharmaceuticals, Inc., an American biotechnology company, recently received Emergency Use Authorization (EUA) for its COVID-19 antibody cocktail treatment of casirivimab and imdevimab by the United States. \n\nThe treatment formerly known as REGN-COV2 is the first combination therapy to receive an EUA and can be used to treat mild to moderate cases of COVID-19 in recently diagnosed patients at high risk for severe cases of the virus and/or hospitalization. The treatment can also be used in pediatric patients at least 12 years of age and weighing at least 88.2 pounds or 40kg. It is an experimental drug that is designed to help the body prevent and fight off the virus. \n\nThe drug is called a 'cocktail' because it mixes a combination of drugs so that it can be more effective and in this case, prevent the virus from becoming resistant to the treatment. This particular drug from Regeneron uses a combination of two \"monoclonal antibodies,\" casirivimab and imdevimab.  \n\nAntibodies are part of the immune system, and they help fight off infections and foreign invaders like COVID-19 by finding the virus, neutralizing it, and telling the rest of the immune system to begin launching its response. Monoclonal antibodies (which means 'one type of antibody') are antibodies created in a lab that can act as a replacement for the antibodies the body normally creates. \n\nThese lab-made antibodies are different than the ones that the immune system creates naturally because they're uniquely designed to target and launch an attack against the specific the virus that causes COVID-19. \n\nRegeneron believes that individual antibody therapies are likely not strong enough to fight the virus that causes COVID-19, so they have combined two separate antibody treatments into one as a weapon to fight against the virus and prevent any drug resistance that might occur if they virus mutates and escapes the effects of the antibodies (called \"viral escape\"). \n\nCasirivimab and imdevimab are the two monoclonal antibodies in this cocktail which aims to help patients who were recently diagnosed with COVID-19 but have not yet launched their full immune system response, or who have a lot of the virus circulating in their blood. Additionally, this treatment is not authorized for use in people who are hospitalized or who need oxygen; just those with mild to moderate cases who recently tested positive for COVID-19.\n\nRegeneron also recently announced that people who received its antibody treatment had a lower number of medical visits for COVID-19 related causes in comparison to those who did not receive the treatment. Patients who received the antibody treatment made roughly 57% fewer visits to seek medical care than patients who received a placebo. In patients at high risk for serious complications from the virus (like those over 50 and people with cardiovascular or lung conditions), the reduction in visits was 72% lower than the group who did not receive the drug. Patients who were given the treatment also demonstrated lower levels of the virus in their blood and less severe symptoms than patients who did not receive the treatment. \n\nThough Regeneron's monoclonal antibody treatment has received an EUA, that authorization is only temporary so the cocktail therapy will continue to be evaluated in phase 2 and 3 clinical trials, according to the company. \n\nAs of November 24, 2020, more than 7,000 people have participated in Regeneron's casirivimab and imdevimab clinical trials. The United States' government began distributing the treatment on November 24, 2020 starting with 30,000 treatment courses and expects to produce enough of the therapy to reach 80,000 patients by the end of November 2020.\n\nRegeneron's antibody cocktail is part of the United States' Operation Warp Speed and has received more than $500 million from the government to develop these treatments. This public–private partnership's goal is to create and distribution vaccines, therapies, and diagnostics for COVID-19 rapidly and safely and involves various government agencies and companies. \n\n",
    "Glossary Terms": [
      "recFg30lvATvVhmBG",
      "recRog4Fq88ayf62O",
      "rec3XmnugOMexQiQA",
      "recsuWy4EfRZwvcmh",
      "recM4p8QOERmuESKr",
      "recQYfy6k4QB8HKXM",
      "recKI7Pa78bZM8n78"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\t\t\t\n",
    "Topics": [
      "treatment",
      "clinical trial",
      "experimental treatment",
      "compassionate use",
      "antigen",
      "antibody"
    ],
    "Other resources": "1. Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19 ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/NCT04426695))\n2. Regeneron Seeks FDA Emergency Clearance for Covid-19 Therapy ([Bloomberg](https://www.bloomberg.com/news/articles/2020-10-08/regeneron-seeks-fda-emergency-clearance-for-covid-19-treatment)) \n3. Regeneron's REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-Hospitalized COVID-19 Patients ([Regeneron](https://investor.regeneron.com/news-releases/news-release-details/regenerons-regn-cov2-antibody-cocktail-reduced-viral-levels-and)) \n4. Coronavirus: Monoclonal antibodies to begin UK trial ([BBC](https://www.bbc.com/news/health-54120753)) \n5. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies ([Science](https://science.sciencemag.org/content/369/6506/1014)) \n6. Trump is being treated with an experimental drug cocktail for COVID-19. Here's what it is ([CBS](https://www.cbsnews.com/news/trump-covid-regeneron-antibody-cocktail-experimental-treatment/)) \n7. Antibody treatment Trump touts relied on testing with fetal tissue he opposes ([Washington Post](https://www.washingtonpost.com/health/trump-antibody-treatment-fetal-tissue/2020/10/08/92f9b2d6-0971-11eb-9be6-cf25fb429f1a_story.html)) \n8. Developing REGN-COV2 ([Regeneron](https://www.regeneron.com/covid19)) \n9. Regeneron Confirms that REGN-COV2 Antibody Cocktail Provided to President Trump Under Compassionate Use Request ([Regeneron](https://investor.regeneron.com/static-files/fd58ba6a-f401-47b0-9d65-cfb01c313ec6)) \n10. Compassionate Use Request ([Regeneron](https://www.regeneron.com/sites/default/files/Regeneron-Compassionate-Use-Request.pdf)) \n11. What President Trump’s ‘compassionate use’ of a Covid-19 drug means — and doesn’t mean ([STAT](https://www.statnews.com/2020/10/08/compassionate-use-covid-19-drug-means-and-doesnt-mean/?utm_campaign=rss)) \n12. Regeneron's casirivimab and imdevimab antibody cocktail for COVID-19 is first combination therapy to receive FDA Emergency Use Authorization ([Regeneron](https://newsroom.regeneron.com/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receive)) \n13. Two science publications highlight potential of REGN-COV2 anti-viral antibody cocktail to protect against SARS-COV-2 escape mutants ([Regeneron](https://investor.regeneron.com/news-releases/news-release-details/two-science-publications-highlight-potential-regn-cov2-anti)) \n14. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19 ([U.S. FDA](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19)) \n15. F.D.A. Grants Emergency Authorization of Antibody Treatment Given to Trump ([NYT](https://www.nytimes.com/2020/11/21/health/regeneron-covid-antibodies-trump.html)) \n16. Regeneron says its COVID-19 antibody treatment cut medical visits in trial ([Reuters](https://www.reuters.com/article/us-health-coronavirus-regeneron/regeneron-says-its-covid-19-antibody-treatment-cut-medical-visits-in-trial-idUSKBN27D36D)) \n17. U.S. to begin distributing Regeneron's COVID-19 antibody therapy Tuesday ([Reuters](https://www.reuters.com/article/us-health-coronavirus-regeneron-pharms-a/u-s-to-begin-distributing-regenerons-covid-19-antibody-therapy-tuesday-idUSKBN2832P8)) \n",
    "Last modified manual": "2020-12-07",
    "Last edited (simplified)": "2020-11-24T20:39:54.000Z",
    "Last edited (experts say)": "2020-12-07T14:53:52.000Z",
    "Last modified": "2020-12-07",
    "What our experts say wordcount": 643,
    "Background and context wordcount": 192,
    "Other resources wordcount": 230,
    "Wordcount": 1065
  },
  {
    "id": "recVpklak5rzFJoLX",
    "Question": "What do we know about transmission on airplanes?",
    "Status": "Published",
    "Category": "Transmission",
    "Subcategory": "On: COVID-19 & airplanes",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "While travel on airplanes has declined significantly during the COVID-19 pandemic, air travel can be a necessary form of transport for essential activities. Air travel is also gradually increasing again as economies open up and some places begin to allow more travel within a region, or even between certain regions. People who are doing permissible travel under their state and federal guidelines often wish to compare the risks of different forms of travel, such as driving in a personal or rented vehicle, traveling through ridesharing services, traveling by public bus or train, traveling by ferry, and traveling by airplane. Research is on-going for COVID-19 transmission risks through various forms of transportation, and public health agencies such as the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have been updating their recommendations periodically.\n\nBefore the COVID-19 pandemic, research was being done on transmission of other infectious diseases during air travel, including respiratory diseases such as flu (influenza) and SARS (severe acute respiratory syndrome). Some of these studies, which took place before wearing masks became as widespread, found that transmission typically happens between passengers sitting within 1-2 rows.\n",
    "What our experts say": "COVID-19 transmission on airplanes is still being researched. There have been documented cases of COVID-19 transmission on airplanes, with the majority being to people seated within 1-2 rows of an infected person or through contact with airline crew. While traveling on an airplane is not risk-free for COVID-19 transmission, it is generally considered a lower-risk activity due to how air is circulated through a HEPA (high efficiency particulate air) filter and mixed with fresh air from outside, and especially when other public health guidelines are followed such as passengers wearing masks or face coverings, passengers maintaining physical distance as much as possible, and disinfecting surfaces between passengers. On crowded flights, the risk of COVID-19 transmission is higher when it may not be possible to avoid sitting within 6 feet of other people, sometimes for several hours. Other COVID-19 transmission risks related to airplane travel include being in proximity to other people when at airport terminals and security lines, being in contact with frequently touched surfaces in places such as public restrooms, and being in proximity to other people during some forms of transport to and from the airport like ridesharing services and public transportation.\n",
    "Glossary Terms": [
      "rech6tPR0hLDA3JH3",
      "recPFoN1pnhj4RUOc"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "transmission"
    ],
    "Other resources": "1. Travel during the COVID-19 pandemic ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/travelers/travel-during-covid19.html))\n2. How safe is air travel? ([MIT Medical](https://medical.mit.edu/covid-19-updates/2020/09/how-safe-air-travel))\n3. As flying returns, jetmakers seek to quell fears over cabin air ([Reuters](https://www.reuters.com/article/us-health-coronavirus-aircraft-air/as-flying-returns-jetmakers-seek-to-quell-fears-over-cabin-air-idUSKBN22U2VJ))\n4. Studies trace COVID-19 spread to international flights ([University of Minnesota](https://www.cidrap.umn.edu/news-perspective/2020/09/studies-trace-covid-19-spread-international-flights))\n5. In-Flight Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 ([U.S. CDC](https://wwwnc.cdc.gov/eid/article/26/11/20-3254_article))\n6. Assessment of SARS-CoV-2 Transmission on an International Flight and Among a Tourist Group ([JAMA](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2769383))\n7. Transmission of the Severe Acute Respiratory Syndrome on Aircraft ([NEJM](https://www.nejm.org/doi/full/10.1056/nejmoa031349))\n8. Review Article: Influenza Transmission on Aircraft: A Systematic Literature Review ([Epidemiology](https://pubmed.ncbi.nlm.nih.gov/27253070/))\n",
    "Last modified manual": "2020-10-06",
    "Last edited (simplified)": "2020-10-07T01:54:43.000Z",
    "Last edited (experts say)": "2020-10-07T01:54:43.000Z",
    "Last modified": "2020-10-07",
    "What our experts say wordcount": 192,
    "Background and context wordcount": 190,
    "Other resources wordcount": 81,
    "Wordcount": 463
  },
  {
    "id": "recfMZ84AyYqSqoBS",
    "Question": "What is the difference between a vaccine's effectiveness and its efficacy?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & vaccine effectiveness",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Due to the number of definitions of the term \"vaccine effectiveness\" and the way different people can interpret it, there is a widespread confusion about what this number actually means. Additionally, factors like age, preexisting health conditions, health care access, geographic distribution and more can contribute to how protective a vaccine is considered to be. \n\nThere are also several points to consider about the direct effect and overall effects of vaccines. The direct effect of vaccines considers people who are protected because they have been vaccinated on an individual level. The indirect effect shows the effect of a vaccination program on an entire population, including those who never received vaccinations. This is important because in most populations, the vaccinated people help protect the unvaccinated people. These are measured in the terms 'vaccine effectiveness' and 'vaccine efficacy.' This is why using the measures of vaccine effectiveness that includes more real world circumstances and looks at entire populations is more accurate and realistic.\n",
    "What our experts say": "Though vaccine efficacy and vaccine effectiveness are similar terms and are often used interchangeably, the differences between the two are important. In this entry, we rely on the United States Centers for Disease Control and Prevention's (U.S. CDC) definitions of effectiveness and efficacy.\n\nWhen a new vaccine is being developed and studied in clinical trials, scientists report on vaccine efficacy. Efficacy is a term used to describe how well the vaccine protects clinical trial participants from getting sick or getting very sick. The term does not describe how well a vaccine works on the general public. The efficacy of a vaccine reflects ideal circumstances, like a research trial, which are different than real-world conditions. \n\nOnce a vaccine is made available for large population groups, vaccine effectiveness can be measured. Effectiveness is the amount of protection given by a vaccine in a certain population when its used under field conditions (somewhat normal practices, less than perfectly controlled like in a research study). It considers other factors like population-level differences in health status, weight, age, and other factors across communities. Effectiveness is a more reliable and accurate term for how helpful a vaccine is at preventing disease in daily life when people are doing regular community-based activities like socializing, going to work or school, and grocery shopping.\n",
    "Glossary Terms": [
      "rec9qqItwSTjq3Eae",
      "recR5R4QhqxWEg2nF",
      "rec10nAxiKgWhYJLd"
    ],
    "Variation of the answer depending on country of residence": "Yes\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "Yes\n",
    "Topics": [
      "treatment",
      "vaccine",
      "vaccine effectiveness",
      "research"
    ],
    "Other resources": "1. Lesson 3: Measures of Risk ([U.S. CDC](https://www.cdc.gov/csels/dsepd/ss1978/lesson3/section6.html)) \n2. Overview of Vaccine Efficacy and Vaccine Effectiveness ([WHO](https://www.who.int/influenza_vaccines_plan/resources/Session4_VEfficacy_VEffectiveness.PDF)) \n3. Vaccine Effectiveness: How Well Do the Flu Vaccines Work? ([U.S. CDC](https://www.cdc.gov/flu/vaccines-work/vaccineeffect.htm)) \n4. Vaccine Efficacy, Effectiveness and Impact ([KCE](https://www.faag.be/sites/default/files/content/9_symposium_vaccine_2017.pdf)) \n",
    "Last modified manual": "2020-11-20",
    "Last edited (simplified)": "2020-10-07T01:52:53.000Z",
    "Last edited (experts say)": "2020-12-02T16:20:42.000Z",
    "Last modified": "2020-12-02",
    "What our experts say wordcount": 214,
    "Background and context wordcount": 161,
    "Other resources wordcount": 37,
    "Wordcount": 412
  },
  {
    "id": "rece1Xl8IwRL6DtyN",
    "Question": "Is the isolation period of COVID-19 patients being re-evaluated? Is there any research that shows the virus stays in the body for a period of 90 days?",
    "Status": "Published",
    "Category": "Research",
    "Subcategory": "On: COVID-19 & self-isolation period",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "India"
    ],
    "Background and context": "Public health agencies need to protect the public by using safe thresholds for how long people who test positive for COVID-19 should isolate, while also making sure that people who are no longer infectious are not unnecessarily kept isolated from loved ones and unable to participate in work, school, or other responsibilities. There are also inequities around who is able to remain in isolation for long periods of time, due to economic and caretaking needs.\n\nThe U.S. CDC says that recent research findings \"strengthen the justification for relying on a symptom based, rather than test-based strategy for ending isolation.\" More research is currently being done on how long someone who has COVID-19 poses a risk of infecting others, particularly in different contexts around the world. \n",
    "What our experts say": "Public health agencies have been updating their recommendations for isolation during the COVID-19 pandemic, as the scientific understanding of how long someone can be sick and infectious to others evolves. For example, the U.K. Chief Medical Officers extended their isolation period for people who test positive from 7 days to 10 days in July 2020, the Indian Ministry of Health and Family Welfare reduced their isolation period for international travelers from 14 days to 7 days in August 2020, and the French Prime Minister reduced their self-isolation period for people who test positive from 14 days to 7 days in September 2020. \n\nThe World Health Organization (WHO) criteria for releasing COVID-19 patients from isolation was updated in late May 2020 to recommend that people who are asymptomatic remain in isolation for 10 days, and that people with symptoms remain in isolation for at least 10 days after symptom onset and at least another 3 days without symptoms (or a minimum of 2 weeks).\n\nOne large contact tracing study found that people were less likely to become infected with COVID-19 when exposed to a positive case after 6 days or more of the infected person's symptom onset, which is in alignment with how certain countries are now using 7 days as their recommended isolation period. \n\nOther studies suggest people with mild to moderate cases of COVID-19 may be infectious up to 10 days after the symptom onset, with a documented case report of a person with mild COVID-19 who was shedding \"replication-competent\" virus specimens (an indicator for being able to infect others) for up to 18 days after symptom onset. Furthermore, some research suggests that people with more severe cases of COVID-19 or who are severely immunocompromised may remain infectious for up to 20 days after symptom onset.\n\nIn terms of COVID-19 patients having evidence of the virus in their bodies for long periods of time, there have been studies suggesting that people with COVID-19 can continue to shed detectable virus specimens from their upper respiratory system for up to 3 months (or about 90 days) after symptom onset, but it is important to recognize that this may not be at a concentration that's high enough for the virus to replicate and infect others. \n\nPeople who continue to shed virus specimens for many weeks or even months after symptom onset are sometimes called \"persistently positive,\" but according to a review of studies by the U.S. Centers for Disease Control and Prevention (CDC), there is currently little evidence of transmission by \"persistently positive\" people who have clinically recovered from COVID-19.\n\nMost of the data on how long people with COVID-19 remain infectious comes from adults, so more research is needed to understand how long children and infants may remain infectious. Additionally, research is ongoing on how the virus is shed in certain situations, such as in people who are immunocompromised. As more research findings emerge, public health guidelines will likely be updated around the recommended isolation periods for people with COVID-19 or who have been in contact with someone confirmed to have COVID-19.\n",
    "Glossary Terms": [
      "recMOA1iUEl0oP2Vi",
      "rec2UNEXbTkSCx30Q"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "infectious",
      "quarantine",
      "research"
    ],
    "Other resources": "1. Duration of Isolation and Precautions for Adults with COVID-19 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html))\n2. Criteria for releasing COVID-19 patients from isolation ([WHO](https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-19-patients-from-isolation))\n3. Coronavirus: Virus isolation period extended from seven to 10 days ([BBC](https://www.bbc.com/news/uk-53588709))\n4. French PM reduces self-isolation time to 7 days ([Associated Press](https://apnews.com/article/football-nfl-archive-virus-outbreak-e3d17eb592705397fe16fb185c313f4a))\n5. Revised guidelines for international arrivals ([India Ministry of Health and Family Welfare](https://www.mohfw.gov.in/pdf/RevisedguidelinesforInternationalArrivals02082020.pdf))\n",
    "Last modified manual": "2020-10-08",
    "Last edited (simplified)": "2020-10-08T21:22:59.000Z",
    "Last edited (experts say)": "2020-10-08T21:22:59.000Z",
    "Last modified": "2020-11-24",
    "What our experts say wordcount": 506,
    "Background and context wordcount": 124,
    "Other resources wordcount": 53,
    "Wordcount": 683
  },
  {
    "id": "recDDflelah3aTf6X",
    "Question": "Can pink eye be a symptom of COVID-19?",
    "Status": "Published",
    "Category": "Symptoms",
    "Subcategory": "On: COVID-19 & conjunctivitis",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "During the U.S. vice presidential debate on October 7, 2020, many people thought that Vice President Pence may have had conjuctivitis (pink eye) and asked if this is a symptom of COVID-19. People were concerned in part because President Trump announced that he tested positive for COVID-19 the week before the vice presidential debate. A White House spokesperson said that both Vice President Pence and Second Lady Pence tested negative for COVID-19 and were taking additional precautions leading up to the vice presidential debate. \n",
    "What our experts say": "Conjunctivitis, also known as pink eye because it can cause the white of the eye to appear red or pink, is an inflammation or infection of the conjunctiva (a transparent membrane that lines the eyelid and covers the white part of the eye). Conjunctivitis can have different causes, including bacterial infections and viral infections (including adenoviruses, which cause the common cold, and the novel coronavirus that causes COVID-19). The appearance of reddish eyes can also be due to allergies, dryness, fatigue, or other factors and does not necessarily mean a person has conjunctivitis.\n\nSome research studies have identified conjunctivitis as a possible symptom of COVID-19, including a study of 38 patients with COVID-19 in China, which found that 12 of the patients had ocular or eye-related symptoms such as conjunctivitis. Patients with more severe COVID-19 were more likely to have ocular symptoms, and 1 patient in the study presented with conjunctivitis as their first symptom. In Canada, a case study was published on a female patient with COVID-19 who had severe conjunctivitis and minimal respiratory symptoms. In the U.K., another case study of a male patient with COVID-19 found that conjunctivitis was a symptom in the middle phase of COVID-19 illness. A review of ocular symptoms in COVID-19 patients that was published in August 2020 found no reports of COVID-19 becoming sight-threatening.\n\nThe American Academy of Ophthalmology has stated that conjunctivitis can be an infrequent symptom of COVID-19, estimated to occur in 1% to 3% of patients who test positive for COVID-19. A meta-analysis of 1167 patients in 3 studies found that the overall rate of conjunctivitis was 1.1%, with the rate being 3% in patients with severe COVID-19 and 0.7% in patients with non-severe COVID‐19. Conjunctivitis may be more common as a COVID-19 symptom in children. A study of 216 children with COVID-19 in China found that 22.7% showed an ocular symptom, including conjunctivitis. \n\nSince conjunctivitis is not among the most common COVID-19 symptoms and can have underlying causes that are unrelated to COVID-19, many public health and medical experts are advising that adults and children with suspected conjunctivitis seek care for their eyes. If someone with conjunctivitis has been at risk of exposure to COVID-19, a healthcare provider can help with determining whether a person with conjunctivitis should also get tested for COVID-19. \n",
    "Glossary Terms": [
      "recOcmLKbzV6NUkAH",
      "rec28MquThUtAwvuU",
      "recORiIMwk54TDQB6"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "symptoms",
      "infection"
    ],
    "Other resources": "1. Is pink eye a symptom of COVID-19? ([Los Angeles Times](https://www.latimes.com/science/story/2020-10-08/is-pink-eye-symptom-covid-19))\n2. Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China ([JAMA Ophthalmology](https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2764083))\n3. Researchers identify pink eye as possible primary symptom of COVID-19 ([Ophthalmology Times](https://www.ophthalmologytimes.com/view/coronavirus-pink-eye-symptoms))\n4. Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease ([BMJ](https://bjo.bmj.com/content/104/6/748.long))\n5. Ophthalmic Manifestations Of Coronavirus (COVID-19) ([StatPearls](https://www.ncbi.nlm.nih.gov/books/NBK556093/))\n6. Eye Care During the Coronavirus Pandemic (COVID-19) ([American Academy of Ophthalmology](https://www.aao.org/eye-health/tips-prevention/coronavirus-covid19-eye-infection-pinkeye))\n7. Conjunctivitis and COVID‐19: A meta‐analysis ([Journal of Medical Virology](https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25938))\n8. Pink Eye May Be a Symptom of COVID-19 in Children, New Study Suggests ([American Academy of Opthalmology](https://www.aao.org/eye-health/news/pink-eye-symptom-covid19-coronavirus-children))\n",
    "Last modified manual": "2020-10-15",
    "Last edited (simplified)": "2020-10-13T21:11:04.000Z",
    "Last edited (experts say)": "2020-10-15T19:22:24.000Z",
    "Last modified": "2020-10-15",
    "What our experts say wordcount": 384,
    "Background and context wordcount": 85,
    "Other resources wordcount": 96,
    "Wordcount": 565
  },
  {
    "id": "rec6LvLwc24HqHqQ1",
    "Question": "What are the markers of a second COVID-19 wave?",
    "Status": "Published",
    "Category": "Transmission",
    "Background and context": "Talk of a second wave has been heavily underway since early to mid-summer, when cases of COVID-19 started to stay consistent or fall in some cities, particularly those that were hit hardest and therefore had the most thorough initial response plans. At the time, we were still firmly in the first wave, which most media outlets [accurately explained](https://www.reuters.com/article/us-health-coronavirus-usa-wave/explainer-what-is-a-second-wave-of-a-pandemic-and-has-it-arrived-in-the-u-s-idUSKBN23U396). \n\nMedia attention regarding second and third waves of COVID-19 globally has resumed, with cases of COVID-19 surging following lower numbers of cases in the late spring and over the summer on average in the U.S. and in many parts of the world, such as the Spain and Iceland. In the U.S., [some experts](https://www.washingtonpost.com/health/coronavirus-fall-projections-second-wave/2020/09/04/6edb3392-ed61-11ea-99a1-71343d03bc29_story.html) argue that we are still in the second wave, with the projection that it will peak (hit its highest number of cases) in mid-late November. [Other experts](https://www.nytimes.com/interactive/2020/10/15/us/coronavirus-cases-us-surge.html) argue that we are in a third wave based on how cases have dropped twice and are now surging a third time. Again, these different perspectives are based on different definitions of disease waves. Regardless of which wave we're in, the U.S. and many parts of the world are experiencing a surge in cases that is projected to worsen. The timing of this surge is especially challenging given its overlap with other respiratory viruses such as influenza.\n",
    "What our experts say": "There is no single definition of a “wave” of a disease in public health. Defining a disease wave varies across scientific literature and even by the scientist you ask. This lack of continuity has to do with the complexity of disease outbreaks, and in particular 1) the ways in which diseases affect different populations at different times, 2) the difficulty in accessing accurate data, and 3) most importantly, the lack of a standardized definition of a disease wave.\n\nWe do, however, know a disease wave when we see one in public health, and agree on indicators of second, third, and fourth waves, and beyond. A disease wave can be thought of as a sustained surge (or spike) in cases, following and relative to a period of sustained low cases. Think of a line on a graph that curves high (first wave), dips low (end of the first wave), then curves high again (second wave). \n\nIn defining the end of a first wave for the U.S., on June 18 2020, Dr. Anthony Fauci, U.S. White House advisor and director of the National Institute of Allergy and Infectious Diseases, told the Washington Post that in order to consider the first wave in the U.S. technically \"over\", we would need to see a specific region, state, or city have a sustained decrease of positive infection rates until they were in the low single digits. \n\nThis is just one expert's definition, however, and just because a region may not have reached single digits of positive test rates does not mean they might not be considered by some to be in a second wave now, and by others in a third wave, if they’re seeing a significant and sustained surge in positive rates compared to what that area’s positive test rate number was previously. \n",
    "Glossary Terms": [
      "recOfgrqkPp7aa14o",
      "rec0zhEV63ySy7APc",
      "recDalYrz2m23kS2e"
    ],
    "Other resources": "1. Explainer: What is a second wave of a pandemic, and has it arrived in the U.S.? ([Reuters](https://www.reuters.com/article/us-health-coronavirus-usa-wave/explainer-what-is-a-second-wave-of-a-pandemic-and-has-it-arrived-in-the-u-s-idUSKBN23U396))\n2. What a ‘second wave’ of Covid-19 could look like and how to prevent it ([CNBC](https://www.cnbc.com/2020/06/28/what-second-wave-of-covid-19-means-and-how-to-prevent-it.html))\n3. Anthony S. Fauci: ‘We are still in the first wave’ of coronavirus ([Washington Post](https://www.washingtonpost.com/health/2020/06/18/anthony-fauci-interview-first-wave/))\n4. First and Second Waves of Coronavirus ([Johns Hopkins Medicine](https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/first-and-second-waves-of-coronavirus))\n5. Second wave COVID-19 pandemics in Europe: a temporal playbook ([Nature](https://www.nature.com/articles/s41598-020-72611-5))\n6. Experts project autumn surge in coronavirus cases, with a peak after Election Day ([Washington Post](https://www.washingtonpost.com/health/coronavirus-fall-projections-second-wave/2020/09/04/6edb3392-ed61-11ea-99a1-71343d03bc29_story.html))\n7. U.S. Virus Cases Climb Toward a Third Peak ([NYT](https://www.nytimes.com/interactive/2020/10/15/us/coronavirus-cases-us-surge.html))\n\n",
    "Last modified manual": "2020-10-16",
    "Last edited (simplified)": "2020-10-16T19:16:50.000Z",
    "Last edited (experts say)": "2020-10-20T21:47:30.000Z",
    "Last modified": "2020-10-16",
    "What our experts say wordcount": 296,
    "Background and context wordcount": 214,
    "Other resources wordcount": 90,
    "Wordcount": 600
  },
  {
    "id": "recdAeExWSCQq3rHn",
    "Question": "What are the pros and cons of each available COVID-19 test?",
    "Status": "Published",
    "Category": "Testing",
    "Subcategory": "On: COVID-19 & testing types",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Having massive testing available for large populations has been a challenge throughout the COVID-19 pandemic. We often hear about testing challenges in the news without knowing exactly what tests they are, what their results mean, and if we can trust them. Testing will continue to be a vital component of the COVID-19 response across the world and will help determine how many people in a population have been potentially infected, and if any outbreaks might be occurring. Using different tests for different people at different times in the exposure and infection process is a decision that should be made between a patient and their doctors, who can interpret the results and help them make decisions about how to proceed. Unless testing is consistently available for every person frequently, people should continue wearing masks, practicing social distancing, washing their hands often, and engaging in other prevention strategies.\n",
    "What our experts say": "There are 3 main types of COVID-19 tests. Two are diagnostic (molecular and antigen tests), which means they show active infections. One test type looks for antibodies that occur in the body following a previous infection (also known as antibody tests).\n\n1) Molecular tests (polymerase chain reaction (PCR) tests, viral RNA tests, and nucleic acid tests) are completed using nasal swabs, throat swabs, and through testing bodily fluids like saliva. These tests look for evidence of genetic material from the virus. They have a low rate of false-positive results (when a test says you have the virus, but you do not) but a higher rate of false-negative results (when a test says you do not have the virus, but you really do). \n\nUsing a deep nasal swab PCR test that collects viral material at the back of nose, near your throat, is the most trusted option of the molecular tests. That's because it is the most accurate, and there is a higher amount of virus in that area of the body than anywhere else. These tests are highly sensitive, which means they are able to accurately determine when a person actually has an infection. However, the method is uncomfortable, the results can take hours to days, they are the most expensive to do, and can be overly sensitive and pick up inactive virus fragments when a person no longer has an active infection.\n\n2) Antigen tests are completed using nasal or throat swabs and they look for proteins (antigens) from the virus. Most people are familiar with this technology because it is commonly seen in pregnancy tests. These results are available in as little as 10 minutes, the test is less expensive than other forms, and uses simpler technology than PCR tests. These tests are usually highly accurate for positive results, but might require a molecular test to confirm if a person really is negative because they can often have a high rate of false-negative results.\n\n3) Antibody tests are different than diagnostic tests because they are blood tests that look for a former COVID-19 infection through the presence of antibodies,  a protein that latches on to foreign invaders in the body - in this case, COVID-19 - neutralizes them, and then remains in a person's system after infection. A person produces COVID-19 antibodies when they are exposed to the virus, so an antibody test can show whether or not someone has been infected in the past. Antibody test results are usually available within a few days. However, these tests produce a lot of false-negatives and we don't know enough about how long antibodies last after exposure or infections, how long any immunity might last, and how many antibodies are needed in a person who has recovered from the virus to show a positive test result.\n\nThere are many different elements involved in how accurate or reliable tests may be at the time they are taken and at the stage of exposure and infection each person is presently in, and every testing type has different strengths or weaknesses. It is important to remember that the best test for each person should be chosen with their doctor on an individual basis.\n",
    "Glossary Terms": [
      "recPNexvQiug4RFJu",
      "recCAIWWubTpPdk1u"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\t\t\n",
    "Topics": [
      "diagnostic test",
      "molecular test",
      "PCR test",
      "antigen test",
      "antibody test"
    ],
    "Other resources": "1. Which test is best for COVID-19? ([HMS](https://www.health.harvard.edu/blog/which-test-is-best-for-covid-19-2020081020734#:~:text=A%20molecular%20test%20using%20a,types%20of%20samples%20taken.)) \n2. Which COVID test is best? Pros and cons of coronavirus detection methods ([UTS](https://utswmed.org/medblog/covid19-testing-methods/)) \n3. Rapid tests. PCR. Antigen. Antibody. These are coronavirus test options, and what’s coming ([SFC](https://www.sfchronicle.com/health/article/Rapid-tests-PCR-Antigen-Antibody-These-are-15637159.php)) \n\n",
    "Last modified manual": "2020-10-16",
    "Last edited (simplified)": "2020-10-16T19:27:12.000Z",
    "Last edited (experts say)": "2020-10-16T19:27:12.000Z",
    "Last modified": "2020-10-16",
    "What our experts say wordcount": 523,
    "Background and context wordcount": 146,
    "Other resources wordcount": 38,
    "Wordcount": 707
  },
  {
    "id": "recXkB1pAufZu4OAB",
    "Question": "What do we know about false positives with rapid antigen testing?",
    "Status": "Update ready for review",
    "Category": "Testing",
    "Subcategory": "On: COVID-19 & antigen tests",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "India"
    ],
    "Background and context": "Generally, concerns about antigen tests are usually around its rate of false negatives, but recent outbreaks and articles have concerned many in public health and medicine about rates of false positive and false negative results. While newer tests have aimed to positively identify active cases of COVID-19 in at least 80-90% of cases, and preferably higher, there is wide variance between antigen tests currently available on the market and the accuracy depends on the context of use. For example, the New York Times reported that Quidel’s antigen test by the University of Arizona detected only 32% of infections in asymptomatic individuals, despite the test meeting the U.S. FDA's requirements for EUA approval.\n\nOn November 3, 2020, the U.S. FDA released a warning letter that reminds clinical laboratory staff and healthcare providers of the risks of false positive and false negative results with antigen tests, particularly when users do not follow instructions and read test results before or after the specified time. Additionally, the rate of false positives is higher when the prevalence of disease is low in a population. \n\nOn December 5, 2020, the U.S. Centers for Disease Control and Prevention (CDC) released updated interim guidance for antigen testing, including the deletion of the word \"rapid\" because the FDA has authorized laboratory-based antigen testing. According to the U.S. CDC guidance, the \"gold standard\" for COVID-19 clinical diagnosis is still nucleic acid amplification tests (NAATs), such as PCR tests.\n\nWith different COVID-19 tests remaining in circulation longer and more accurate antigen tests entering the market, our readings of the virus should become more accurate over time.\n",
    "What our experts say": "Antigen tests for COVID-19 have many advantages, including rapid results, cheap production costs, and a high rate of accurate test results for people who are actively infected with COVID-19. However, one of the major downsides of these tests is their high rate of false negative results (having a negative test result even if you are actively infected with the virus). Comparatively, false positive test results, which incorrectly show that a healthy person is infected by the virus when they are not, are very rare in tests that have been approved by regulatory agencies like the U.S. Food and Drug Administration (FDA). Despite having low rates of false positives, these types or errors in antigen tests still exist due to technical issues like handling, contamination, or test errors. These considerations have a large impact as their effects can directly result in health impacts for people who test positive (but are not) and are quarantined with people with active infections or receive treatments like medication when it may be harmful.\n\nWhile most newer antigen tests aim to accurately identify people with active COVID-19 infections at least 80% and 90% of the time (true positive rate), some antigen tests have been reported to have false positive or false negative rates as high as 50%. Several experts recommend using a second test to confirm a patient is truly negative or positive, particularly when patients may have no symptoms or have not been exposed to people who tested positive for the virus. While antigen tests can usually diagnose active COVID-19 infections, they are more likely to miss an active infection in comparison to molecular tests like polymerase chain reaction (PCR) tests.\n\nSeveral countries have begun authorizing the use of newer antigen tests that report lower rates of false positives and false negatives. For example, as of early December 2020, the U.S. FDA has granted Emergency Use Authorizations (EUAs) for a handful of the more accurate antigen tests that are available. As more of these tests are produced and used on a wide scale, we hope to learn more about their accuracy and achieve as sensitive (correctly identifying those who are are actively infected with the virus) and specific (correctly identifying those who do not have an active infection) as possible.\n",
    "Glossary Terms": [
      "recFR6ePHXqdNxvmH",
      "rec06X4QusZL1zCzd",
      "recc8ZAXzbbMiYc51",
      "reciINrN2CDoIYwsl"
    ],
    "Variation of the answer depending on country of residence": "Yes\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "PCR test",
      "antigen test",
      "false positive",
      "false negative"
    ],
    "Other resources": "1. Which test is best for COVID-19? ([HMS](https://www.health.harvard.edu/blog/which-test-is-best-for-covid-19-2020081020734)) \n2. Coronavirus antigen tests: quick and cheap, but too often wrong? ([Science](https://www.sciencemag.org/news/2020/05/coronavirus-antigen-tests-quick-and-cheap-too-often-wrong)) \n3. Why False Positives Merit Concern, Too ([NYT](https://www.nytimes.com/2020/10/25/health/coronavirus-testing-false-positive.html)) \n4. Why Trump’s Rapid-Testing Plan Worries Scientists ([Atlantic](https://www.theatlantic.com/health/archive/2020/10/do-rapid-antigen-tests-have-accuracy-problem/616681/)) \n5. Coronavirus: India tries new type of tests to tackle virus ([BBC](https://www.bbc.com/news/world-asia-india-53609404)) \n6. India's new paper Covid-19 test could be a ‘game changer’ ([BBC](https://www.bbc.com/news/world-asia-india-54338864)) \n7. Countries turn to rapid antigen tests to contain second wave of COVID-19 ([Reuters](https://www.reuters.com/article/us-health-coronavirus-rapid-tests/countries-turn-to-rapid-antigen-tests-to-contain-second-wave-of-covid-19-idUSKBN26Y2PX)) \n8. Rapid tests. PCR. Antigen. Antibody. These are coronavirus test options, and what’s coming ([SFC](https://www.sfchronicle.com/health/article/Rapid-tests-PCR-Antigen-Antibody-These-are-15637159.php))\n9. Current Molecular and Antigen Tests with FDA EUA Status ([John Hopkins University](https://www.centerforhealthsecurity.org/resources/COVID-19/molecular-based-tests/current-molecular-and-antigen-tests.html))\n10. A Rapid Virus Test Falters in People Without Symptoms, Study Finds ([NYT](https://www.nytimes.com/2020/11/02/health/coronavirus-testing-quidel-sofia.html))\n11. Potential for False Positive Results with Antigen Tests for Rapid Detection of SARS-CoV-2 - Letter to Clinical Laboratory Staff and Health Care Providers ([U.S. FDA](https://www.fda.gov/medical-devices/letters-health-care-providers/potential-false-positive-results-antigen-tests-rapid-detection-sars-cov-2-letter-clinical-laboratory))\n12. Interim Guidance for Antigen Testing for SARS-CoV-2 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html))\n",
    "Last modified manual": "2020-12-04",
    "Last edited (simplified)": "2020-12-08T20:40:17.000Z",
    "Last edited (experts say)": "2020-12-08T20:41:08.000Z",
    "Last modified": "2020-12-08",
    "What our experts say wordcount": 373,
    "Background and context wordcount": 263,
    "Other resources wordcount": 145,
    "Wordcount": 781
  },
  {
    "id": "rec8pqDaJA5uM1U0y",
    "Question": "What do we know about in silico methodology and its uses in finding a COVID-19 treatment?",
    "Status": "Update ready for review",
    "Category": "Research, Treatment",
    "Subcategory": "On: COVID-19 and in-silico methodology",
    "Source of the question": [
      "Expert Recommendation",
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA",
      "India"
    ],
    "Background and context": "In silico methods have been trending in the media, in part due to 14-year-old Anika Chebrolu winning the 3M Young Scientist Challenge for finding a molecule that selectively binds to the spike protein of the SARS-CoV-2 virus that causes COVID-19. In silico methods have been similarly used by scientists around the world, including in the United States and India, to identify molecules (e.g. eriodictyol) that bind to the spike protein of SARS-CoV-2 for potential use in COVID-19 antiviral therapies.\n\nThe term \"in silico\" comes from the chemical element silicon, which is widely used for making computer chips. This term follows the style of previous Latin descriptions for research, such as \"in vivo\" (which means in living organisms), \"in vitro\" (which means in glass, such as test tubes with cells separated from their biological context), and \"in situ\" (which means in place or on site).\n",
    "What our experts say": "In silico methods, also called computer-aided drug design (CADD) methods, refer to methods that are performed on a computer or using computer simulation. In silico methods have been used for decades to help reduce the required time and expenses during drug development processes, including for drugs that fight cancer and tuberculosis.\n\nDuring the COVID-19 pandemic, in silico methods have been used in various ways to find effective interventions for preventing and treating COVID-19.  For example, in silico methods have been used to quickly screen a large number of compounds, helping to identify which have more potential to inhibit the virus SARS-CoV-2 that causes COVID-19 for application in therapeutic drugs. Another example is the use of in silico methods to model how COVID-19 can spread in a population, and to simulate the impact of different preventative measures such as wearing masks. In silico methods can also be used to speed up the design and evaluation of medical devices and other supplies. Additionally, in silico methods have been used to model, and sometimes attempt to predict, COVID-19 symptoms or complications by comparing simulations to actual clinical data. Researchers are continuing to apply in silico methods in different ways to figure out how to best prevent and treat COVID-19.\n",
    "Glossary Terms": [
      "recRog4Fq88ayf62O",
      "recZsKsIsYqt1xEW4",
      "recmIgJvajdxBf3eI",
      "recMUR0P3EECMwfrv"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "research",
      "treatment"
    ],
    "Other resources": "1. In Silico Methods ([Springer](https://link.springer.com/referenceworkentry/10.1007%2F978-3-642-25240-2_55#citeas))\n2. Editorial: _In silico_ Methods for Drug Design and Discovery ([Frontiers in Chemistry](https://www.frontiersin.org/articles/10.3389/fchem.2020.00612/full))\n3. How In Silico fights Coronavirus  ([In Silico World](https://insilico.world/coronavirus/))\n4. In-silico modeling of COVID-19 ARDS: pathophysiological insights and potential management implications ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.07.21.20158659v1))\n5. This 14-year-old girl won a $25K prize for a discovery that could lead to a cure for Covid-19 ([CNN](https://www.cnn.com/2020/10/18/us/anika-chebrolu-covid-treatment-award-scn-trnd/index.html))\n6. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using _in silico_ Structure-Based Virtual Screening Approach ([Frontiers in Immunology](https://www.frontiersin.org/articles/10.3389/fimmu.2020.01664/full))\n7. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2 ([Elsevier Peptides](https://www.sciencedirect.com/science/article/pii/S0196978120300772))\n8. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2 ([European Journal of Pharmacology](https://www.sciencedirect.com/science/article/pii/S0014299920305227))\n9. In silico studies evidenced the role of structurally diverse plant secondary metabolites in reducing SARS-CoV-2 pathogenesis ([Nature](https://www.nature.com/articles/s41598-020-77602-0))\n",
    "Last modified manual": "2020-12-04",
    "Last edited (simplified)": "2020-12-08T19:30:21.000Z",
    "Last edited (experts say)": "2020-12-08T19:30:21.000Z",
    "Last modified": "2020-12-08",
    "What our experts say wordcount": 206,
    "Background and context wordcount": 143,
    "Other resources wordcount": 124,
    "Wordcount": 473
  },
  {
    "id": "recU4loGz5tqh9ps1",
    "Question": "Does mental state or emotion prevent COVID-19 from spreading?",
    "Status": "Published",
    "Background and context": "A recent study was carried out by researchers at Aarhus University, Denmark. The study explored the psychology behind social behaviors of mask wearing and physical distancing. It was carried out in three Western countries of Germany, the United States and the United Kingdom and found that empathy plays a role in motivating people to use protective measures like wearing masks and physically distancing.  \n\nThe findings of this study have been interpreted and reported in misleading ways across the globe, some suggesting empathy can stop COVID-19 from spreading.\n\nThe study involved self-reporting participant surveys about their own perceptions and actions, which could be subject to social desirability bias; which means participants respond to questions with socially desirable answers rather than truthful answers.\n",
    "What our experts say": "Mental state and emotion cannot prevent COVID-19 from spreading. The use of face coverings, physical distancing and hand washing are recommended guidelines by WHO and US CDC health officials to reduce the spread of the SAR-CoV-2 virus.\n\nA recent study by researchers at Aarhus University found that people who are empathetic towards those who may be more vulnerable to the infection tend to wear face masks and maintain physical distancing more often. The study demonstrates that evoking empathy may be effective for promoting and encouraging the use of face masks and physical distancing, compared with  using factual information alone. The findings do not imply that if one is empathetic or in a particular mental state, they will not spread the virus.\n",
    "Other resources": "1. The Emotional Path to Action: Empathy Promotes Physical Distancing and Wearing of Face Masks During the COVID-19 Pandemic ([Psychological Science)](https://journals-sagepub-com.ezp-prod1.hul.harvard.edu/doi/10.1177/0956797620964422)\n",
    "Last modified manual": "2020-10-21",
    "Last edited (simplified)": "2020-10-21T21:35:50.000Z",
    "Last edited (experts say)": "2020-10-21T21:36:27.000Z",
    "Last modified": "2020-10-21",
    "What our experts say wordcount": 121,
    "Background and context wordcount": 121,
    "Other resources wordcount": 21,
    "Wordcount": 263
  },
  {
    "id": "recQOw0bJlQFe3pbW",
    "Question": "What do we know so far about COVID-19 and diabetes?",
    "Status": "Update ready for review",
    "Category": "Symptoms",
    "Subcategory": "On: COVID-19 & diabetes",
    "Source of the question": [
      "Expert Recommendation",
      "Newsroom"
    ],
    "Country question was sourced from": [
      "USA",
      "Mexico",
      "Brazil"
    ],
    "Background and context": "The media has reported frequently on diabetes being a pre-existing condition that can lead to higher risks of severe COVID-19 illness, and the need for people with diabetes to be cautious during the COVID-19 pandemic. With stories emerging of adults and children getting unexpectedly diagnosed with diabetes after recovering from COVID-19, the media is starting to report on research into whether and how COVID-19 can lead to diabetes.\n\nDiabetes is a medical condition that receives a lot of attention in many countries because it is becoming increasingly common. In the U.S., the American Diabetes Association has estimated that 10.5% of the population had diabetes in 2018, and that the prevalence in seniors was even higher at 26.8%. In Brazil, researchers have estimated that 11.4% of the population between the ages of 20-79 has diabetes and have published studies on barriers faced by Brazilians living with diabetes during the COVID-19 pandemic. In Mexico, the International Diabetes Federation has estimated that 13.5% of the population between the ages of 20-79 had diabetes in 2019. \n\nFor World Diabetes Day on November 14, 2020, the United Nations (UN) Secretary General warned that diabetes has been linked to \"increased risk of severe disease and death from COVID-19” and shows the need to strengthen health systems around the world.\n",
    "What our experts say": "Diabetes is a disease where the blood glucose (sugar) levels are too high, and is generally differentiated into Type 1 (where the body cannot produce the insulin that is required to turn blood glucose into energy) and Type 2 (where the body does not respond well to insulin, allowing blood glucose levels to rise). Type 2 diabetes is considered an underlying (pre-existing) medical condition that has the \"strongest and most consistent evidence\" for increasing the risk of severe illness due to COVID-19, according to the U.S. Centers for Disease Control and Prevention (CDC). In July 2020, U.S. health officials stated that almost 40% of people who have died with COVID-19 had diabetes.\n\nBeyond diabetes leading to COVID-19 complications, researchers are now studying the potential for COVID-19 to lead to diabetes. Medical experts have reported diabetes in patients who tested positive and in some cases appeared to have otherwise recovered from COVID-19, despite the patients having no previous history, genetic predisposition, or traditional risk factors (such as lifestyle factors) for diabetes. As of October 2020, over 300 doctors applied to share cases for review in a global registry on this topic led by King's College London. The U.S. National Institutes of Health (NIH) is also funding research on how COVID-19 may cause high blood glucose levels and diabetes. Additionally, doctors as well as researchers have been raising the alarm on how more children appear to be getting diagnosed with diabetes during the COVID-19 pandemic, compared to similar months in previous years.\n\nPrior to the COVID-19 pandemic, other viral infections including influenza and other coronaviruses have been linked to triggering Type 1 diabetes, but this is usually in people who are predisposed to developing diabetes. While researchers know that infections stress the body and can lead to higher blood glucose levels, researchers still have not fully understood why some people develop diabetes after infection and others do not. The connections between COVID-19 and diabetes are continuing to be studied.\n",
    "Glossary Terms": [
      "recz6wQ17eV2G7r6w",
      "recOcmLKbzV6NUkAH",
      "recbr3ZePtuRaGnEd",
      "rectZMnCI5KMhjzkJ"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "Unknown at this time. Prior to the pandemic, diabetes has varied by demographic factors such as race, ethnicity, age, and sex.\n",
    "Topics": [
      "long-term",
      "symptoms"
    ],
    "Other resources": "1. Doctors probe whether COVID-19 is causing diabetes ([Reuters](https://www.reuters.com/article/us-health-coronavirus-diabetes-insight-idUSKBN2741ET?taid=5f8db47e26f6750001eb7689&utm_campaign=trueAnthem:+Trending+Content&utm_medium=trueAnthem&utm_source=twitter))\n2. Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/evidence-table.html))\n3. COVID-19 in people living with diabetes: An international consensus ([Journal of Diabetes and its Complications](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336933/))\n4. Statistics About Diabetes ([American Diabetes Association](https://www.diabetes.org/resources/statistics/statistics-about-diabetes)) \n5. The impact of COVID-19 on people with diabetes in Brazil ([Elsevier Diabetes Research and Clinical Practice](https://www.sciencedirect.com/science/article/pii/S0168822720305568))\n6. Diabetes Atlas ([International Diabetes Federation](https://diabetesatlas.org/en/))\n7. Diabetes increasing COVID risks, showing need to strengthen health systems ([UN](https://news.un.org/en/story/2020/11/1077632))\n",
    "Last modified manual": "2020-12-04",
    "Last edited (simplified)": "2020-12-08T20:47:56.000Z",
    "Last edited (experts say)": "2020-12-08T20:48:32.000Z",
    "Last modified": "2020-12-08",
    "What our experts say wordcount": 325,
    "Background and context wordcount": 212,
    "Other resources wordcount": 84,
    "Wordcount": 621
  },
  {
    "id": "recvA3dMAEFu2Cl80",
    "Question": "What do we know about UV light and COVID-19?",
    "Status": "Needs + Editing",
    "Category": "Prevention",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "India"
    ],
    "Background and context": "Recent UV light products have been circulating that claim to disinfect COVID-19 at up to 99.99% efficiency. Some of these products include UV lamps that claim to disinfect hands, a UV microwave-style “oven” that claims to disinfect objects, and UV chambers that claim to disinfect individuals. Either these products are highly ineffective, or they are highly dangerous.\n\nUltraviolet or UV rays are a form of electromagnetic radiation, present in sunlight. Sunlight emits three kinds of UV rays: UVA, UVB, and UVC. UVC has the highest energy and is filtered by the atmosphere, so it does not naturally reach the Earth’s surface. UVC rays can come from some man-made sources, such as UV sanitizing bulbs. These bulbs can be used in indoor settings, such as hospitals, to disinfect medical equipment and surfaces. This is because UVC has the most energy of the three, and its energy can destroy the genetic material inside viruses. The genetic material in viruses includes information that can control the reproduction, development or behavior of a virus. But artificial UVC rays are extremely dangerous and deadly to humans and should not be used outside of professional settings to disinfect surfaces and objects. \n",
    "What our experts say": "Using an at-home ultraviolet (UV) light is ineffective at treating, curing or preventing COVID-19, and can be highly dangerous. There is one type of UV ray (UVC rays) that can kill the COVID-19 virus, but it is highly dangerous to use UVC ray treatment unless you’re properly trained. It is not intended for use outside of hospital settings, such as in public non-hospital spaces or at home. \n\nExposing yourself or your belongings to at-home non-UVC UV rays through lamps or lights for any period of time does not prevent someone from spreading COVID-19 to another person or catching COVID-19 from another person, and does not disinfect items. \n\nLong-term exposure to sunlight or UV radiation can be very damaging and increase your risk of skin cancer. As of now, there is no clear benefit of using any at-home UV products for preventing or treating COVID-19. \n",
    "Glossary Terms": [
      "recjOgLIjiAbiBH5F",
      "rec4crPh6OQvCngsk"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "ultraviolet",
      "disinfectants",
      "sunlight"
    ],
    "Other resources": "1. Coronavirus disease (COVID-19) advice for the public: Myth busters ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters)) \n2. Ultraviolet radiation and the INTERSUN Programme ([WHO](https://www.who.int/uv/faq/whatisuv/en/index2.html)) \n3. As Coronavirus Looms, Mask Shortage Gives Rise to Promising Approach ([NYT](https://www.nytimes.com/2020/03/20/health/coronavirus-masks-reuse.html)) \n4. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality ([Aging Clinical and Experimental Research](https://link.springer.com/article/10.1007/s40520-020-01570-8))\n5. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data ([BMJ](https://www.bmj.com/content/356/bmj.i6583))\n6. Rapid evidence summary on SARS-CoV-2 survivorship and disinfection, and a reusable PPE protocol using a double-hit process ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.04.02.20051409v1.full.pdf))\n",
    "Last modified manual": "2020-10-21",
    "Last edited (simplified)": "2020-10-27T03:24:14.000Z",
    "Last edited (experts say)": "2020-10-27T03:24:14.000Z",
    "Last modified": "2020-10-27",
    "What our experts say wordcount": 144,
    "Background and context wordcount": 194,
    "Other resources wordcount": 88,
    "Wordcount": 426
  },
  {
    "id": "recrS0OwNdQMAmMdI",
    "Question": "What do rising COVID-19 cases during the fall of 2020 in U.S. Midwestern states mean for other states, like Florida? ",
    "Status": "Published",
    "Category": "Spread",
    "Subcategory": "On: COVID-19 & third waves",
    "Source of the question": [
      "Partner Organization"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "As the Northern Hemisphere enters a colder season and some people get tired of maintaining preventative measures during the pandemic, public health experts have warned about potential new waves of COVID-19 cases and deaths. Several U.S. states have already seen major surges in COVID-19 infection during the fall of 2020, while some other U.S. states are starting to see alarming increases that could indicate another upcoming surge. The U.S. Centers for Disease Control and Prevention (CDC) continue to discourage non-essential travel between states, especially ahead of the upcoming fall and winter holidays when larger groups tend to gather and colder weather leads to people spending more time together indoors. Beyond considering the risks of transmitting COVID-19 from a state with higher rates of infection to a state with lower rates of infection, it is also important to reduce the community spread of infection within a state by maintaining preventative measures (ex. avoiding non-essential travel and outings, wearing masks, washing hands and high-touch surfaces, and keeping physical distance).\n",
    "What our experts say": "Without a distinct, explicit, and obvious uptick in travel pattern volumes, and access to data about those travel pattern volumes, it is not possible to predict how the number of cases in one state or geographical region, such as the U.S. Midwest, will impact COVID-19 infection rates in another state or region, such as Florida. \n\nKnown mass migration from one region to another could help epidemiologists predict how COVID-19 may spread, but U.S. travel tends to be spontaneous and multidirectional, with individuals traveling across and between different regions, rather than traveling as a large group from one specific region to another. \n\nThough widespread travel and transmission patterns are difficult to predict, we can reasonably conclude that a high volume of COVID-19 cases throughout the United States means that the likelihood of transmission of COVID-19 in the country is high, compared to other parts of the world. To prevent the spread of COVID-19, public health experts continue to recommend that people wash their hands, wear masks, avoid crowds (especially indoors), practice social distancing, and stay home when possible. \n\nOut of the top five states that have seen COVID-19 cases rise the fastest during the first couple weeks of October 2020, four states (Idaho, Nebraska, South Dakota, North Dakota) are in the Midwest. Some health care workers and public health researchers have referred to the rising cases in the Midwest during the fall of 2020 as a \"third wave,\" after the summer wave and the initial wave of COVID-19 cases. Dr. Anthony Fauci and other infectious disease experts have warned that states across the U.S. could see another wave of COVID-19 cases, particularly with current case numbers remaining high in several places, colder weather setting in and coinciding with what is typically the annual influenza (flu) season, and people starting to become fatigued with maintaining pandemic prevention measures. \n\nSimultaneously in Florida, 5,558 new COVID-19 cases were reported on October 22, 2020, which is one of the highest single-day increases that the state has seen since mid-August 2020 (the only days with higher numbers in the fall of 2020 are thought to be due to irregularities in reporting). The reported increase brings Florida's statewide total to 768,091 COVID-19 cases and over 16,470 deaths related to COVID-19 as of October 22, 2020. Following the Florida Governor's decision on September 25, 2020 to move to Phase 3 of their reopening plans, including fully open bars and restaurants, public health experts have been warning that Florida could see a rise in COVID-19 cases and that this could also coincide with the anticipated flu season. \n",
    "Glossary Terms": [
      "recORiIMwk54TDQB6",
      "rec0zhEV63ySy7APc"
    ],
    "Variation of the answer depending on country of residence": "No, although not applicable to other countries\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No, not for state-level data\n",
    "Topics": [
      "infection",
      "positivity rate",
      "spread"
    ],
    "Other resources": "1. COVID-19 ravages US Midwest as cases, deaths surge ([Al Jazeera](https://www.aljazeera.com/news/2020/10/21/covid-19-ravages-us-midwest-as-cases-deaths-increase))\n2. A Third Coronavirus Surge Has Taken Root in the U.S. ([NYT](https://www.nytimes.com/live/2020/10/20/world/covid-19-coronavirus-updates))\n3. Five U.S. States Where COVID-19 Cases Are Rising Fastest ([Newsweek](https://www.newsweek.com/coronavirus-us-states-cases-rising-idaho-nebraska-south-north-dakota-rhode-island-1540909))\n4. Florida adds 5,558 coronavirus cases, the highest daily record since August ([Tampa Bay Times](https://www.tampabay.com/news/health/2020/10/22/florida-adds-5558-coronavirus-cases-the-highest-daily-record-since-august/))\n5. Fauci Calls Florida's Decision to Fully Reopen Bars and Restaurants ‘Very Concerning' ([NBC Miami](https://www.nbcmiami.com/news/local/fauci-calls-floridas-decision-to-fully-reopen-bars-and-restaurants-very-concerning/2299173/))\n6. Travel during the COVID-19 Pandemic ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/travelers/travel-during-covid19.html))\n",
    "Last modified manual": "2020-10-23",
    "Last edited (simplified)": "2020-10-22T20:20:47.000Z",
    "Last edited (experts say)": "2020-10-23T15:15:03.000Z",
    "Last modified": "2020-10-23",
    "What our experts say wordcount": 429,
    "Background and context wordcount": 167,
    "Other resources wordcount": 67,
    "Wordcount": 663
  },
  {
    "id": "recF1HaT5WaKmZ832",
    "Question": "What do we know about using CT scans to diagnose COVID-19?",
    "Status": "Published",
    "Background and context": "The 'sensitivity' of a test is its ability to correctly identify a patient with the disease. The sensitivity of RT PCR swab tests is around 50-80%, which means that around 30 to 50% of cases which are actually positive are being missed as false negative (inaccurate result that they are negative, when they are actually positive). Due to the lack of accurate diagnostic testing, infected people and their contacts are not being isolated.  CT scans sensitivity is estimated to be over 90% but also has the risk of false positives (result shows positive for coronavirus when it is actually negative).\n\nPhysicians in China started using Chest CT scans early in the outbreak because they couldn't rely on the PCR tests fully.  They started recommending CT based identification and improved quarantining.\n\nACR recommends against it citing false-positive rates, scanner contamination and no change in patient management even if the COVID is detected.\n",
    "What our experts say": "High levels of false negatives from RT-PCR testing and long waits to receive test results have led many medical institutions to use chest CT (computed tomography) scans to diagnose COVID-19. Several studies, mostly conducted in China, have shown higher sensitivity of CT scans in detecting coronavirus when a PCR test showed a negative result. However, this does not mean that CT scans alone should be used for disease identification. CT scans can also miss detecting the virus and be misidentified with other pulmonary infectious/ viral pneumonias. Some experts believe that CT scans do not add any diagnostic value, while others believe that from a population health perspective during a pandemic, CT scans should be used to isolate suspicious cases for COVID-19, because of its high sensitivity and rapid identification.\nSome studies support a dual approach of CT scans and RT-PCR, or  the use of chest CT scan to screen for coronavirus when RT-PCR tests are negative. CT scans are relatively expensive compared to swab tests and also expose patients to a small dose of radiation. Some experts argue that because CT scans are resource intensive, they cannot be used as a population-wide testing tool. \nThe American College of Radiology (ACR) and US CDC recommend against using Chest CT scanning for screening or diagnosis of coronavirus disease 2019. On the other hand, the National Health Commission of China has encouraged the use of Chest CT scans for diagnosis.\nLocal resource constrains and expert physician advise on individual patient conditions are important factors in deciding on the use of CT scans or not.\n",
    "Topics": [
      "testing",
      "PCR test",
      "false negative",
      "false positive",
      "diagnostic test"
    ],
    "Other resources": "1. Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases ([RSNA -Radiology)](https://pubs.rsna.org/doi/10.1148/radiol.2020200642)\n2. A role for CT in COVID-19? What data really tell us so far ([The Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30728-5/fulltext))\n3. CT scan is a reliable test for COVID-19. Why aren’t we using it? ([Lown Institute)](https://lowninstitute.org/ct-scan-is-a-reliable-test-for-covid-19-why-arent-we-using-it/)\n4. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR ([RSNA - Radiology](https://pubs.rsna.org/doi/full/10.1148/radiol.2020200432))\n5. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection ([RSNA - Radiology](https://pubs.rsna.org/doi/full/10.1148/radiol.2020200463))\n6. ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection ([American College of Radiology](http://ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection))\n7. COVID-19 and Imaging: Why CT Scans and X-Rays Have a Limited Role in Diagnosing Coronavirus ([UVA Health](https://blog.radiology.virginia.edu/covid-19-and-imaging/))\n8. What is the role of CT scanning in the diagnosis of coronavirus disease 2019 (COVID-19)? ([Medscape](https://www.medscape.com/answers/2500114-197443/what-is-the-role-of-ct-scanning-in-the-diagnosis-of-coronavirus-disease-2019-covid-19))\n9. Covid-19 testing issues could sink plans to re-open the country. Might CT scans help? ([Statnews](https://www.statnews.com/2020/04/16/ct-scans-alternative-to-inaccurate-coronavirus-tests/#:~:text=In%20one%20recent%20study%20of,in%20fact%20had%20the%20disease.))\n10. Can CT scans diagnose COVID-19? Experts argue for and against ([Medical News Today](https://www.medicalnewstoday.com/articles/ct-use-in-covid-19-diagnosis))\n",
    "Last modified manual": "2020-10-29",
    "Last edited (simplified)": "2020-10-29T23:36:14.000Z",
    "Last edited (experts say)": "2020-10-29T23:36:14.000Z",
    "Last modified": "2020-10-29",
    "What our experts say wordcount": 260,
    "Background and context wordcount": 151,
    "Other resources wordcount": 160,
    "Wordcount": 571
  },
  {
    "id": "rec1lIxrlFHbwK7NV",
    "Question": "What do we know so far about using VCO for COVID-19?",
    "Status": "Published",
    "Country question was sourced from": [
      "Philippines"
    ],
    "Background and context": "Media around the potential use of coconut has increased due to the recent announcement of the results from the Phillipine’s Department of Science and Technology (DOST) laboratory studies on VCO and COVID-19, which found that VCO decreased viral load for mild to moderate cases of COVID-19 60 to 90%. A study on VCO and COVID-19 is also being carried out in Indonesia, adding to the coverage of this topic on Southeast Asia. \n\nCoconut oil has antibacterial and antiviral properties due to lauric acid (C12), which makes up 50% of the oil. Monolaurin is a derivative of Lauric acid — produced by the human body in response to ingesting coconut oil, which can act as an even more powerful antiviral agent. Researchers, however, are unsure of how lauric acid is converted into monolaurin in the body, and therefore how much one would need to ingest to receive benefits.\n",
    "What our experts say": "Virgin coconut oil (VCO) is being studied in the Philippines and other countries as a potential supplementary treatment for COVID-19 — that is, a potential additional treatment used in combination with other COVID-19 treatments. These community-based trials are being carried out by the Filipino Department of Science and Technology (DOST) at the Sta. Rosa Community Hospital in Laguna, and involved both probable cases of COVID-19 (i.e. highly suspected cases) and mild cases of COVID-19. There are also two trials being carried out at the Philippine General Hospital (PGH) looking into the effects of VCO on moderate cases of COVID-19 or those who are hospitalized.\n\nThese two sets of studies aim to understand if VCO can shorten the COVID-19 recovery time, prevent further complications, and prevent hospitalization time. These studies follow 6 months of laboratory experiments that found VCO to decrease the coronavirus count by 60 to 90% for mild to moderate cases of COVID-19. If proven to be effective with sufficient evidence in the community-based trials, VCO could be a safe and affordable supplementary treatment for COVID-19.\n\nIt is important to note that these studies are still in development and that The World Health Organization (WHO) does not support the use of any specific medication to treat, cure, or prevent COVID-19. While coconut oil is safe in certain doses, more evidence is needed to understand its effect on COVID-19 and it should not be used as a COVID-19 treatment or prevention medication. \n",
    "Glossary Terms": [
      "rec3XmnugOMexQiQA",
      "recRog4Fq88ayf62O",
      "recMUR0P3EECMwfrv"
    ],
    "Other resources": "1. Laguna VCO clinical trials for COVID-19 treatment to be completed by December – DOST ([CNN](https://www.cnnphilippines.com/news/2020/10/21/Laguna-VCO-clinical-trials-December-completion.html?fbclid#.X5Y4U9LpxQ0.facebook))\n2. Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/NCT04594330))\n3. “Solidarity” clinical trial for COVID-19 treatments ([WHO](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments))\n4. Activity of Virgin Coconut Oil, Lauric Acid or Monolaurin in Combination with Lactic Acid Against Staphylococcus Aureus ([Southeast Asian Journal of Tropical Medicine and Public Health](https://search-proquest-com.ezp-prod1.hul.harvard.edu/docview/1033359597/abstract/B1FA518303674B84PQ/1?accountid=11311))\n",
    "Last modified manual": "2020-10-29",
    "Last edited (simplified)": "2020-10-28T04:44:29.000Z",
    "Last edited (experts say)": "2020-10-29T23:34:34.000Z",
    "Last modified": "2020-10-29",
    "What our experts say wordcount": 239,
    "Background and context wordcount": 146,
    "Other resources wordcount": 62,
    "Wordcount": 447
  },
  {
    "id": "recg7uMkciGJxiye0",
    "Question": "What role do autoantibodies play in how your body responds to COVID-19?",
    "Status": "In progress",
    "Category": "Disease Progression",
    "Subcategory": "On: COVID-19 & autoantibodies",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Doctors and scientists have known for months that COVID-19 can cause widespread impacts on an infected person's immune system. With autoantibodies created in response to the virus, the body cannot determine the difference between itself and COVID-19 (non-self). This might make symptoms like inflammation much worse, even causing long-term physical challenges and much more serious cases. Though the recent study many of these findings stem from is a pre-print and has not yet been peer-reviewed, the authors have strong reputations in the field and were recently published in a peer-reviewed scientific journal regarding the presence of autoantibodies in severe cases of COVID-19. \n\nThese findings are important because doctors may be able to test for the presence of these tests and find out if there might be a genetic link to this type of overactive immune system response or even if a patient is more likely to have an asymptomatic case of the virus of a severe one. Doctors could also use existing tests to locate patients with autoantibodies and potentially treat them in similar ways to patients with autoimmune diseases like lupus and rheumatoid arthritis as they also produce autoantibodies and face the issue of the immune system fighting itself. As more research continues to be published in respected journals, the more opportunities doctors and scientists have for pinpointing the pathways of the virus and how it impacts certain groups of people but not others.\n",
    "What our experts say": "\n",
    "Glossary Terms": [
      "reclilEKmEDvsjnzW",
      "recaXXF6coF4J2EUz",
      "recyXylBebc7GlxTi"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "antibody",
      "autoantibodies",
      "interferon",
      "immune system"
    ],
    "Other resources": "1. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 ([Science](https://science.sciencemag.org/content/370/6515/eabd4570)) \n2. Autoantibodies against type I IFNs in patients with life-threatening COVID-19 ([Science](https://science.sciencemag.org/content/370/6515/eabd4585)) \n3. Scientists discover genetic and immunologic underpinnings of some cases of severe COVID-19 ([U.S. NIH](https://www.nih.gov/news-events/news-releases/scientists-discover-genetic-immunologic-underpinnings-some-cases-severe-covid-19)) \n4. Some Covid Survivors Have Antibodies That Attack the Body, not Virus ([NYT](https://www.nytimes.com/2020/10/27/health/covid-antibodies-autoimmunity.html)) \n5. Do cross-reactive antibodies cause neuropathology in COVID-19? ([Nature](https://www.nature.com/articles/s41577-020-00458-y)) \n6. Clinically identifiable autoreactivity is common in severe SARS-CoV-2 Infection ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.10.21.20216192v2)) \n",
    "Last modified manual": "2020-12-09",
    "Last edited (simplified)": "2020-10-29T07:40:35.000Z",
    "Last edited (experts say)": "2020-11-10T03:31:06.000Z",
    "Last modified": "2020-11-10",
    "What our experts say wordcount": 0,
    "Background and context wordcount": 234,
    "Other resources wordcount": 75,
    "Wordcount": 309
  },
  {
    "id": "recGJZyxcGglnEryM",
    "Question": "What do the latest results of Pfizer's clinical trial mean? ",
    "Status": "Published",
    "Category": "Vaccines",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Vaccine efficacy and vaccine effectiveness are similar terms, but the differences between them are important to note when we are learning about new vaccines to prevent COVID-19. The term “vaccine efficacy” is used to measure how well a vaccine works to prevent a particular disease (in this case, COVID-19) in controlled, research environments. “Vaccine effectiveness” studies examine how well a vaccine prevents a particular disease in the “real world” community environment where people are doing things like going to the grocery store, work, and school. \n\nIn the recently published interim report from Pfizer’s experimental COVID-19 vaccine trial, the vaccine efficacy was reported at 95%, which means that people who were vaccinated in the study are much less likely to contract COVID-19 than the control group, who were not vaccinated with the experimental drug. Using an example of 100 trial participants in a given trial of a vaccine with 90% efficacy, 90 patients would not contract the disease and 10 would contract COVID-19. In Pfizer's clinical trials, there were 10 severe cases of COVID-19. Nine of the cases were in the in the placebo group and one in the vaccinated group.\n\nIf this vaccine receives U.S. Food and Drug Administration (U.S. FDA) approval and is distributed to large populations around the world, scientists will then be able to calculate vaccine effectiveness in real-world settings. The U.S. FDA has set the minimum efficacy requirement at 50% for potential COVID-19 vaccines, though many hope that the vaccines currently in development will exceed this target. Real world vaccine effectiveness is a much more reliable and accurate term for telling us how helpful a vaccine is at preventing disease in daily life, not just in a controlled, research setting.\n\nLike the flu vaccine, an effective COVID-19 vaccine may also help to reduce the severity of disease for those who do become infected, which may keep patients out of the hospital or out of intensive care. The goal of vaccines is to protect populations from diseases, and this vaccine is no different. Whether or not it will be successful depends on its study results (which are evaluated by the U.S. FDA), distribution among different people in different settings, how many people agree to receive the vaccine, how long its protection lasts, and many other elements that vary by each country. \n\nPfizer aims to produce up to 50 million vaccine doses across the world in 2020 and up to 1.3 billion doses by the end of 2021.\n",
    "What our experts say": "On November 18th, 2020, Pfizer announced that its experimental COVID-19 vaccine (BNT162b2) prevented infection in 95% of overall participants who received the drug company’s late-stage clinical trial dose. In adults over 65 years of age, the vaccine was effective in over 94% of volunteers. These early results exceeded the minimum United States Food and Drug Administration (U.S. FDA) target of 50% efficacy—but it is important to reiterate that no vaccine is ever 100% effective. It is impossible to know how well a vaccine actually works until it is deployed  in the real world and given to large populations, not just volunteer participants in a trial. \n\nWhile the current data is promising, it has yet to be evaluated by the U.S. FDA, and more information is needed before Pfizer can pursue approval for the vaccine. The company has concluded its phase III trial but will continue to monitor patients for any adverse reactions or events. Additionally, to ensure that there are not major safety concerns, the U.S. FDA is requiring manufacturers to provide at least two months of follow-up data for at least half of the volunteer participants. Most serious side effects from vaccines occur within about six weeks after the vaccine is given. In vaccine clinical trials, any observed impacts of the vaccine on volunteer participants are eventually considered side effects with more serious side effects causing the trials to pause or stop completely. No safety concerns about these potential side effects have been reported so far. Pfizer recently stated that the only side effects that occurred in more than 2% of participants was fatigue at 3.8% and headache at 2.0%.\n\nBecause the news about this vaccine is still early, there is still a lot we don't know. Remaining questions include when the vaccine might be available for everyone, if it will work in children younger than 12 (as they have been excluded from the early trials), if it will stop the virus from spreading in people who are infected but don't have any symptoms (asymptomatic), if it will prevent people from developing severe cases, and how long the vaccine might offer protection from the the virus.\n\nThis vaccine requires an initial injection followed by a secondary shot called a “booster” to achieve its full level of protection. The vaccine was found to be effective against COVID-19 beginning 28 days after the first dose. The clinical trial included more than 43,000 volunteer participants, many of whom  already received two doses of the vaccine. In the interim analysis, there were 94 cases of COVID-19 in trial participants, and the study continued until there have been 164 cases of COVID-19 among study volunteers.\n\nIt is important to note that these study results may not play out the same under “real life” circumstances because of differences in health status, weight, age, and other factors across communities. While Pfizer has reported that 42% of participants are from “diverse backgrounds,” the study population may not reflect the diversity of our global populations and communities despite the vaccine being effective across age, gender, race and ethnicity demographics in the trials.\n",
    "Glossary Terms": [
      "rec9qqItwSTjq3Eae",
      "recpDS35Y5vAuQ7Oa",
      "rec10nAxiKgWhYJLd",
      "recR5R4QhqxWEg2nF"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "vaccine",
      "immunity"
    ],
    "Other resources": "1. Vaccine efficacy or vaccine effectiveness ([CDC](https://www.cdc.gov/csels/dsepd/ss1978/lesson3/section6.html)) \n2. How Flu Vaccine Effectiveness and Efficacy are Measured ([CDC](https://www.cdc.gov/flu/vaccines-work/effectivenessqa.htm))\n3. Overview of Vaccine Efficacy and Vaccine Effectiveness ([WHO](https://www.who.int/influenza_vaccines_plan/resources/Session4_VEfficacy_VEffectiveness.PDF))\n4. What does COVID-19 vaccine efficacy mean? ([Science News](https://www.sciencenews.org/article/coronavirus-what-does-covid-19-vaccine-efficacy-mean))\n5. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 ([The Lancet](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30773-8/fulltext))\n6. A COVID-19 Vaccine May Be Only 50% Effective. Is That Good Enough? ([NPR](https://www.npr.org/sections/health-shots/2020/09/12/911987987/a-covid-19-vaccine-may-be-only-50-effective-is-that-good-enough))\n7. Pfizer’s Covid Vaccine: 11 Things You Need to Know ([New York Times](https://www.nytimes.com/2020/11/09/health/pfizer-covid-19-vaccine.html))\n8. Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints ([Pfizer](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine)) \n",
    "Last modified manual": "2020-11-19",
    "Last edited (simplified)": "2020-11-19T20:37:57.000Z",
    "Last edited (experts say)": "2020-11-19T20:37:57.000Z",
    "Last modified": "2020-11-19",
    "What our experts say wordcount": 510,
    "Background and context wordcount": 405,
    "Other resources wordcount": 97,
    "Wordcount": 1012
  },
  {
    "id": "recSCWgMrGT3yvFkH",
    "Question": "What are some of the birth and infant outcomes following COVID-19? ",
    "Status": "Published",
    "Category": "Research",
    "Subcategory": "On: COVID-19 & pregnancy",
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "Research has shown that pregnant individuals may be at increased risk of contracting COVID-19 and becoming severely ill as a result of the infection. People who are older, overweight, or have other pre-existing medical conditions like high blood pressure or diabetes are also at increased risk. \n\nSince the start of the pandemic, multiple studies have observed that infants born to birth givers diagnosed with COVID-19 during pregnancy are more likely to be born prematurely (<37 weeks’ gestation) than infants born to birth givers who have not had COVID-19. The reasons for premature delivery are not well understood at this time. It is also not well understood if maternal COVID-19 passes to the infant during pregnancy or delivery. Though studies have documented some cases where infants tested positive for COVID-19 after birth, limited data is available. \n** **\nWhile the impact of COVID-19 on pregnancy outcomes remains under investigation, the US Centers for Disease Control and Prevention (CDC) continues to encourage pregnant women to attend prenatal care appointments; practice handwashing, social distancing, and mask wearing; and avoid crowds especially in indoor areas to prevent COVID-19 infection. In addition, the CDC recommends that doctors and healthcare providers should be aware of the possible risks for severe illness among pregnant people.\n",
    "What our experts say": "Maternal COVID-19 infection during pregnancy may be a risk factor for premature birth. \n\nIn November 2020, the US Centers for Disease Control and Prevention (CDC) released outcomes data for infants born to birth givers who had been diagnosed with COVID-19 during pregnancy. The data was collected between March and October of 2020 and included a total of 3,912 infants. Incidence of prematurity in study participants was higher than average, which suggests that maternal COVID-19 infection acquired pregnancy (not in general) may be a risk factor for prematurity. This report found that 12.9% of infants born to individuals who had been diagnosed with COVID-19 during pregnancy were born prematurely (<37 weeks gestation), which is greater than the national estimate of 10.2%. \n\nIn the U.S., COVID-19 has not impacted all communities equally; non-Hispanic Black and Hispanic communities have been unduly impacted by the virus. Racial and ethnic disparities also exist in overall health outcomes and impact maternal morbidity, mortality, and adverse birth outcomes. In this study, non-Hispanic Black and Hispanic women were disproportionately represented, and the authors note that further observation and analysis of outcomes by race and ethnicity is needed.\n\nAnother study published in the Lancet in October 2020 found that the incidence of preterm births went down in the Netherlands after the implementation of COVID-19 pandemic mitigation policies. The authors suggest that some of the observed decrease in preterm births could be related to reductions in maternal exposure to air pollution and reductions in pregnant women seeking obstetric care that induces preterm birth.\n\nWhile the impact of COVID-19 on pregnancy outcomes remains under investigation, the CDC continues to encourage pregnant people to attend prenatal care appointments; practice handwashing, social distancing, and mask wearing; and avoid crowds especially in indoor areas to prevent COVID-19 infection. They also suggest that providers counsel pregnant individuals on steps to prevent COVID-19 infection.\n",
    "Glossary Terms": [
      "recnFUXyIZy81Rj1I",
      "rec2UNEXbTkSCx30Q",
      "recz6wQ17eV2G7r6w"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "pregnancy",
      "infant",
      "infection",
      "virus",
      "transmission",
      "racial disparities"
    ],
    "Other resources": "1. Coronavirus disease (COVID-19): Pregnancy and childbirth ([WHO](https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-pregnancy-and-childbirth))\n2. Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19- COVID-NET, 13 States, March 1-August 22, 2020 ([US CDC](https://www.cdc.gov/mmwr/volumes/69/wr/mm6938e1.htm?s_cid=mm6938e1_w))\n3. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis ([BMJ](https://www.bmj.com/content/370/bmj.m3320))\n4. SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics- Eight U.S. Health Care Centers March 1-May 30, 2020 ([US CDC](https://www.cdc.gov/mmwr/volumes/69/wr/mm6938e2.htm?s_cid=mm6938e2_w))\n5. Birth and Infant Outcomes FollowingLaboratory-Confirmed SARS-CoV-2 Infection in Pregnancy- SET-NET, 16 Jurisdictions, March 29-October 14, 2020 ([US CDC](https://www.cdc.gov/mmwr/volumes/69/wr/mm6944e2.htm?s_cid=mm6944e2_w)) \n6. Impact of COVID-19 mitigation measures on the incidence of preterm birth: a national quasi-experimental study ([The Lancet](https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(20)30223-1/fulltext))\n",
    "Last modified manual": "0020-12-01",
    "Last edited (simplified)": "2020-11-11T15:11:08.000Z",
    "Last edited (experts say)": "2020-12-02T01:01:20.000Z",
    "Last modified": "2020-12-02",
    "What our experts say wordcount": 305,
    "Background and context wordcount": 204,
    "Other resources wordcount": 110,
    "Wordcount": 619
  },
  {
    "id": "recK4fRfTEqhsS3G2",
    "Question": "Does air pollution increase your risk of getting COVID-19?",
    "Status": "Published",
    "Background and context": "Air pollution can cause health problems. According to the WHO the smallest type of pollution, fine particulate matter with a diameter of less than 10 microns, can be particularly harmful. The tiny particles are able to travel deep into the lungs and long-term exposure to that pollution is known to cause and worsen breathing and heart problems.\n\nOutdoors, fine particles in the air may be a result of vehicle (i.e. car or truck) and equipment (i.e. tractor) exhaust, or by burning wood, coal, or gases at power plants. Sometimes, fine particles can also be carried over long distances by wind. Fine particles are also produced indoors. Smoke (from tobacco or other sources), cooking, burning candles, or fireplaces are common sources of indoor air pollution. \n\nDensely populated urban areas and industrial areas are known to have high levels of fine particulate matter. Several studies have shown that long-term exposure to fine particulate matter is a leading risk factor for death, especially among older adults. \n",
    "What our experts say": "COVID-19 has not been linked directly to air-pollution, and there has not been research conducted to show that reducing air pollution leads to fewer COVID-19 deaths. However, urban air-pollution (that commonly contains fine particulate matter from things like cars or trucks, fires, coal-based power) is associated with an increase risk of breathing problems and respiratory (breathing) illnesses. \n\nExposure to high levels of bad air pollution damages  the throat and lungs and causes chronic inflammation that could limit how well the lungs are able to protect themselves from infections. It has been reported that individuals with existing breathing problems (i.e. asthma, emphysema) are may be at higher risk of COVID-19. \n\nStudies conducted in China, Italy, and the United States have shown that in areas with higher amounts of air pollution there is an increase in the number of COVID-19 cases.  However, the United States study notes that the findings are for county-level populations and cannot be used to link individual cases to air pollution. More studies will need to be conducted to better understand how air quality may affect individual people and their risk of COVID-19 \n",
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "lungs",
      "respiratory system"
    ],
    "Other resources": "1. Assessing the relationship between surface levels of PM2.5 and PM10 particulate matter impact on COVID-19 in Milan, Italy ([Science Direct - Science of the Total Environment](https://www-sciencedirect-com.ezp-prod1.hul.harvard.edu/science/article/pii/S0048969720333453))\n2. Air pollution and COVID-19 mortality in the United States: Strengths and limitations of an ecological regression analysis ([Science Advances](https://advances.sciencemag.org/content/6/45/eabd4049))\n3. Evaluating the impact of long-term exposure to fine particulate matter on mortality among the elderly ([Science Advances](https://advances.sciencemag.org/content/6/29/eaba5692?ijkey=a48261a69074ca56ec53969031f037ddf71fc21a&keytype2=tf_ipsecsha))\n4. Linkages Between Air Pollution and the Health Burden From COVID-19: Methodological Challenges and Opportunities ([American Journal of Epidemiology](https://academic.oup.com/aje/article/189/11/1238/5872672))\n5. Can exposure to PM2.5 particles increase the incidence of coronavirus disease 2019 (COVID-19)? ([Science of the Total Environment](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308784/)) \n6. Air Pollution ([WHO](https://www.who.int/airpollution/ambient/pollutants/en/))\n",
    "Last modified manual": "2020-11-17",
    "Last edited (simplified)": "2020-11-23T14:17:54.000Z",
    "Last edited (experts say)": "2020-11-23T14:17:54.000Z",
    "Last modified": "2020-11-23",
    "What our experts say wordcount": 188,
    "Background and context wordcount": 163,
    "Other resources wordcount": 103,
    "Wordcount": 454
  },
  {
    "id": "rec0CA3DO8hiIjlta",
    "Question": "Why is there misinformation relating wearing a mask with Teflon (PTFE) to getting cancer?",
    "Status": "Published",
    "Category": "masks",
    "Subcategory": "Masks",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "On October 31, Kourtney Kardashian re-shared a post on her Instagram story to her 103 million followers with the false claim that common blue surgical masks contain PTFE, and that wearing them increases your risk of certain cancers, such as breast cancer, other diseases, such as preeclampsia, thyroid disease, as well as flu-like symptoms. While the post claims this information is from Cancer.org, that claim is false, and there is otherwise no identifiable source. \n\nThough this false claim had already been circulating, particularly on social media platforms such as Facebook and Twitter, the wide reach of Kourtney’s Instagram amplified it and coverage both by the public and news sources has increased. \n",
    "What our experts say": "Wearing a mask with polytetrafluoroethylene (PTFE) does not increase your risk of getting cancer or any other negative health outcome. PTFE is the polymer that also makes Teflon, the brand name of a non-stick chemical coating commonly used on kitchen appliances such as pots and pans. While some masks are sprayed with PTFE or have a PTFE filter, as PTFE has widely been used in the field of air filtration, it would take a mask with PTFE to 1) be heated to an extremely high temperature — 300 to 400 degrees celsius or 572 to 752 degrees Fahrenheit, 2) for fumes to be released, and 3) for those fumes to be breathed in, for any ailment to be caused. \n\nThe specific condition the highly unlikely hypothetical scenario would cause is not a cancer, but rather is a flu-like ailment known as “[polymer fume fever](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544973/),” informally known as Teflon flu. \n\nMost surgical face masks do not contain PTFE, and are made out of a different type of plastic called polypropylene. If you do have a mask that contains PTFE, there is no evidence that wearing the mask would cause any flue-like symptoms or other negative outcomes when worn properly and normally. \n",
    "Glossary Terms": [
      "reclKahoPRbBLqUKg",
      "recIHiTMEF5Yjayd4"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "face masks",
      "prevention"
    ],
    "Other resources": "1. Teflon in masks does not pose a health risk, unless you get it extremely hot ([Full Fact](https://fullfact.org/health/teflon-masks-symptoms/))\n2. Debunked: No, face masks 'sprayed with Teflon' are not causing flu-like symptoms ([thejournal.ie](https://www.thejournal.ie/blue-face-masks-ptfe-spray-teflon-5238881-Nov2020/)) \n3. How Surgical Masks are Made ([Thomas Net](https://www.thomasnet.com/articles/other/how-surgical-masks-are-made/#_How_are_Surgical))\n4. Preparation and properties of PTFE hollow fiber membranes for the removal of ultrafine particles in PM2.5 with repetitive usage capability ([RSC Advances](https://pubs-rsc-org.ezp-prod1.hul.harvard.edu/en/content/articlelanding/2018/RA/C8RA07789D#!divAbstract))\n5. Doctors Call Kourtney Kardashian’s Mask Conspiracy Theory “Unbelievably Dangerous” ([Refinery29](https://www.refinery29.com/en-us/2020/11/10145902/kourtney-kardashian-mask-cancer-ptfe-instagram))\n",
    "Last modified manual": "2020-11-12",
    "Last edited (simplified)": "2020-11-12T22:48:54.000Z",
    "Last edited (experts say)": "2020-11-12T22:48:54.000Z",
    "Last modified": "2020-11-18",
    "What our experts say wordcount": 200,
    "Background and context wordcount": 111,
    "Other resources wordcount": 71,
    "Wordcount": 382
  },
  {
    "id": "reccN0swQANNJwGir",
    "Question": "Does a flu shot increase your chances of getting COVID-19?",
    "Status": "Published",
    "Category": "Vaccines",
    "Subcategory": "On: COVID-19 risk & flu vaccines",
    "Source of the question": [
      "Social Media"
    ],
    "Country question was sourced from": [
      "United Kingdom",
      "USA"
    ],
    "Background and context": "Public health agencies have been widely promoting flu shots (influenza vaccines), particularly with the Northern Hemisphere entering peak flu season in fall 2020. Despite rumors spreading via social media, flu shots have been safely used for decades to protect millions of people from getting sick. During the COVID-19 pandemic, flu shots are an important preventative measure to reduce strains on health systems and save lives.\n",
    "What our experts say": "There is no evidence that flu shots (influenza vaccines) increase someone's chances of getting COVID-19. Flu shots are widely considered a safe way to help prevent someone from getting sick with the flu.\n\nA September 2020 publication in the Journal of Clinical and Translational Science by researchers from the Cleveland Clinic analyzed data from 13,000+ COVID-19 tests, comparing people who received flu shots with people who did not receive flu shots. The researchers found that people who received flu shots were not at higher risk of being hospitalized, being admitted to the intensive care unit (ICU), or dying from COVID-19.\n\nDoctors and public health experts recommend flu shots for the general public as a safe way to protect against severe illness and death from the flu, which is important during the COVID-19 pandemic to reduce strains on health systems and healthcare workers.\n",
    "Glossary Terms": [
      "rec9qqItwSTjq3Eae",
      "recDalYrz2m23kS2e"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "vaccine",
      "Influenza",
      "United Kingdom"
    ],
    "Other resources": "1. Flu Shot Not Associated with Increased Risk of COVID-19, Study Finds ([Cleveland Clinic](https://newsroom.clevelandclinic.org/2020/10/12/flu-shot-not-associated-with-increased-risk-of-covid-19-study-finds/))\n2. Safety of influenza vaccine during COVID-19 ([Journal of Clinical and Translational Science](https://www.cambridge.org/core/journals/journal-of-clinical-and-translational-science/article/safety-of-influenza-vaccine-during-covid19/C26A417046677E65D421AD33B3E6281F))\n",
    "Last modified manual": "2020-11-25",
    "Last edited (simplified)": "2020-11-25T03:25:54.000Z",
    "Last edited (experts say)": "2020-12-02T15:48:31.000Z",
    "Last modified": "2020-12-02",
    "What our experts say wordcount": 140,
    "Background and context wordcount": 65,
    "Other resources wordcount": 25,
    "Wordcount": 230
  },
  {
    "id": "recrz9eAiWOXKBiHx",
    "Question": "Does wearing a mask protect the mask wearer?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & face masks",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "There have been several studies demonstrating that wearing a face mask could help protect both the person wearing the mask and the people around them from COVID-19. Additionally, the United States Centers for Disease Control & Prevention (U.S. CDC) updated their guidelines to reflect the two-way protection given by masks, and released a scientific brief on November 20, 2020 about how the community use of masks can help reduce the spread of COVID-19.\n\nWhile face mask requirements vary with every country and region, they have been shown to help protect both wearers and the community around them. The more layers of fabric, the better the protection they offer with higher thread counts and tighter weaves increasing their effectiveness.\n\nAs masks alone cannot stop COVID-19, the U.S. CDC continues to encourage people to socially distance themselves, wash their hands for 20 seconds, and avoid touching their face.\n\n",
    "What our experts say": "Wearing a face mask helps prevent the spread of COVID-19 in two ways: It protects the person wearing a mask from being exposed to the virus and protects the people around them from being exposed to the virus. \n\nWhen a person talks, coughs, sneezes, or even breathes, they are exposing the people around them to what is in their body through the spread of small drops of liquid, called respiratory droplets, and even smaller, drier particles that float in the air. These bigger droplets carry saliva, mucus, and other germs (like the disease that causes the COVID-19 virus) which fall to surfaces while the smaller particles tend to stay in the air for a period of time. When people inhale these droplets through their mouths, noses, or eyes or touch their face after touching a surface where droplets fell, they are exposing themselves to COVID-19 and other germs exhaled by people their area. Wearing a face mask can reduce the amount of those particles that are inhaled through the mouth and nose, and can help stop people from touching their faces. Research shows that masks help stop germs from getting out into common spaces while also reducing the amount of germs inhaled by masks wearers, which can help reduce the chances of more severe disease.\n\nIt is still important to note that though masks can be highly effective at preventing the spread of the virus, it also depends on the quality of the mask, the amount of layers it has, and how many people are wearing them in a specific area. This is why continuing to follow prevention protocols like social distancing and hand washing is still important.\n",
    "Glossary Terms": [
      "reclKahoPRbBLqUKg",
      "rec2UNEXbTkSCx30Q",
      "rech6tPR0hLDA3JH3",
      "rec5yviiSvJkufYvu"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "transmission",
      "prevention",
      "aerosol",
      "respiratory droplets",
      "face masks",
      "community transmission"
    ],
    "Other resources": "1. Scientific Brief: Community Use of Cloth Masks to Control the Spread of SARS-CoV-2 ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science-sars-cov2.html)) \n2. Masks Work. Really. We’ll Show You How ([NYT](https://www.nytimes.com/interactive/2020/10/30/science/wear-mask-covid-particles-ul.html)) \n3. Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2 ([mSphere](https://pubmed.ncbi.nlm.nih.gov/33087517/)) \n4. Face Coverings, Aerosol Dispersion and Mitigation of Virus Transmission Risk ([arXiv](https://arxiv.org/abs/2005.10720)) \n5. Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks ([ACS Nano](https://pubmed.ncbi.nlm.nih.gov/32329337/)) \n6. Viral Filtration Efficiency of Fabric Masks Compared with Surgical and N95 Masks ([Pathogens](https://pubmed.ncbi.nlm.nih.gov/32957638/)) \n7. Forgotten Technology in the COVID-19 Pandemic: Filtration Properties of Cloth and Cloth Masks-A Narrative Review ([Mayo Clinic Proc](https://pubmed.ncbi.nlm.nih.gov/33012350/)) \n8. Face Masks, Public Policies and Slowing the Spread of COVID-19: Evidence from Canada ([NBER](https://www.nber.org/papers/w27891)) \n9. Masks Do More Than Protect Others During COVID-19: Reducing the Inoculum of SARS-CoV-2 to Protect the Wearer ([Journal of General Internal Medicine](https://link.springer.com/article/10.1007/s11606-020-06067-8))\n",
    "Last modified manual": "2020-12-01",
    "Last edited (simplified)": "2020-12-02T19:45:37.000Z",
    "Last edited (experts say)": "2020-12-02T19:49:24.000Z",
    "Last modified": "2020-12-02",
    "What our experts say wordcount": 276,
    "Background and context wordcount": 144,
    "Other resources wordcount": 134,
    "Wordcount": 554
  },
  {
    "id": "recppmZ8rTsHURemn",
    "Question": "What is the context behind the misinformation about fetal cells used in the AstraZeneca COVID-19 vaccine?",
    "Status": "Published",
    "Category": "Vaccines",
    "Subcategory": "Vaccines",
    "Source of the question": [
      "Newsroom"
    ],
    "Background and context": "In a video about the AstraZeneca COVID-19 vaccine that was shared across social media platforms, a host encouraged viewers to share false information, telling them to avoid the COVID-19 vaccine if they do not want “aborted fetal tissue fragments put into them or their DNA fragments changed.” The host also says falsely that there is aborted fetal lung tissue in the vaccine. \n\nMany different types of cells are used in medical research and vaccine production and development, and MRC-5 cells, originally obtained in 1966 from the lungs of a 14-week aborted male fetus, are used commonly. HEK 293 cells, originally obtained from embryonic kidney tissue, are also commonly used.\n \nAdditionally, while there can be residual DNA in vaccines, it is not recognizable as human DNA.  Research has suggested that there could be some DNA present when a vaccine is made using cells, but the DNA exposure is unlikely to be harmful, because the DNA is very fragmented (broken into small parts). \n\nThe US Food and Drug Administration limits the size and amount of DNA in vaccines and while we are not aware of any risks associated with DNA fragments that could be present in vaccines, the exact level of risk is not defined. \n \nVaccines are widely used to prevent infections, and most traditional vaccines that target viruses are made from dead or attenuated live viruses (viruses that have been altered so they are not harmful) to help people develop immunity without becoming ill. The viruses used to make these vaccines do not grow (or multiply) in liquids or on agar plates (like bacteria or fungi) so, during vaccine production and development, a virus is cultured (or grown) in special cells in a laboratory. Sometimes these cells, called “cultured cells,” are grown under controlled laboratory conditions and, in some instances, are replicated from human fetal cells.\n",
    "What our experts say": "The Oxford-AstraZeneca COVID-19 vaccine (AZD1222) does not contain human cells or tissues. The AZD122 (ChAdOx1 nCov-19) is a weakened version of an adenovirus—a harmless virus that usually causes the common cold in chimpanzees— and is used as a way to transport the vaccine's ingredients into the human body. This type of vaccine is called a \"vector vaccine,\" because the adenovirus serves as the vector (or vehicle) for getting the drug into human cells. The adenovirus can stimulate a response from a person's immune system when their body detects it in cells. Essentially, the vaccine helps train human bodies to detect and eliminate a real COVID-19 infection through showing it mock spike proteins, before COVID-19 can cause any severe symptoms or a severe infection.\n\nDuring preclinical research, MRC-5 cells were used to determine how effective the vaccine may be in human clinical trials, but the MRC-5 cells are not used in the manufacturing process for this vaccine. \n\nThere are different processes used to make vaccines. Often, when vaccines are being made, viruses are propagated (grown in the lab) in special laboratory cells, and the viruses are then collected to make the vaccine. To make this COVID-19 vaccine, the virus is propagated using another type of cells, the HEK 293 cell line. However, there is no evidence that these cells are present in the vaccine itself. The cells are removed through a filtering and purification process that breaks down the cellular pieces and remaining DNA before a vaccine is deployed to humans.\n\nThe HEK 293 cells and MRC-5 cells (mentioned above), as well as many other research cell lines, were collected from fetal tissue in the 1960s and 1970s. Since then, labs have reproduced those cell lines for some medical purposes, including research and vaccine development. These cells are not part of the vaccine. It is also important to distinguish between fetal cells and cultured (lab grown) cells. Fetal cells are not used in vaccine production.\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "vaccine"
    ],
    "Other resources": "1. MRC-5 (ATCC CCL-171) ([ATCC](https://www.atcc.org/Products/All/CCL-171.aspx?geo_country=us#characteristics))\n2. 293 \\[HEK-293]\\(ATTC CRL-1573) ([ATTC](https://www.atcc.org/products/all/CRL-1573.aspx))\n3. SARS-CoV-2 candidate vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals a normal low range of viral backbone gene expression alongside very high levels of SARS-CoV-2 S glycoprotein expression ([Research Square](https://www.researchsquare.com/article/rs-94837/v1))\n4. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques ([bioRxiv](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241103/#R5))\n5. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques ([Sci Adv](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286676/))\n6. Vaccine Ingredients- DNA ([Children’s Hospital of Philadelphia](https://www.chop.edu/centers-programs/vaccine-education-center/vaccine-ingredients/dna))\n7. Vaccines and Related Biological Products Advisory Committee 154th Meeting ([FDA](https://www.fda.gov/media/120334/download))\n8. Bioethics News: Is it true that there are vaccines produced using aborted fetus cells? ([Bioethics Research Laboratory, Georgetown University](https://bioethics.georgetown.edu/2017/01/is-it-true-that-there-are-vaccines-produced-using-aborted-fetuses/))\n9. Vaccine Ingredient- Fetal Tissues ([Children’s Hospital of Philadelphia](https://www.chop.edu/centers-programs/vaccine-education-center/vaccine-ingredients/fetal-tissues))\n",
    "Last modified manual": "2020-11-16",
    "Last edited (simplified)": "2020-11-20T16:09:36.000Z",
    "Last edited (experts say)": "2020-11-20T16:20:37.000Z",
    "Last modified": "2020-11-20",
    "What our experts say wordcount": 322,
    "Background and context wordcount": 301,
    "Other resources wordcount": 108,
    "Wordcount": 731
  },
  {
    "id": "recYE4J6Nh1lta1lB",
    "Question": "What do we know so far about Astra Zeneca's vaccine?",
    "Status": "Published",
    "Category": "Prevention",
    "Subcategory": "On: COVID-19 & AstraZeneca vaccine",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "As the race for new COVID-19 vaccines continues, several candidates have recently made headlines with their positive reporting. However, the collaboration between the University of Oxford and AstraZeneca was forced to pause for several weeks during September of 2020 when a United Kingdom volunteer who had received the vaccine reportedly experienced spinal cord inflammation. This was allegedly similar to another neurological event that had happened previously in a vaccinated volunteer. However, these events were determined to be unrelated to the vaccine, so most study sites restarted their trial. The trial in the United States continued with a longer pause, but no definite reason was given for this delay. United States trial sites resumed their studies in late October of 2020.\n\nAzstraZeneca has already reached agreements with several nations to deliver over to 2 billion doses of its vaccine if it is approved. It has already begun manufacturing the vaccine in large quantities so it can be rapidly deployed if regulatory agencies confirm that it is effective.\n\n\n",
    "What our experts say": "The University of Oxford vaccine is being developed and produced by AstraZeneca plc, Inc. and is an adenovirus vaccine (ChAdOx1/AZD1222) currently in Phase 2 and 3 trials in the United Kingdom and India, and in Phase 3 trials in Brazil, South Africa, and the United States. Here's a breakdown of everything you need to know so far about this vaccine's development.\n\n**Collaborators:** AstraZeneca is collaborating with the University of Oxford and its spin-out company, Vaccitech, on vaccine development and testing for ChAdOx1/AZD1222. \n\nThe National Institute of Allergy and Infectious Diseases (NIAID) (which is part of the National Institutes of Health) and the Biomedical Advanced Research and Development Authority (BARDA) (part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response) are providing funding support for the Phase 3 trial.\n\n**Latest information on how well the vaccine works:** On November 23, 2020, with primary efficacy analysis data from its Phase 3 trial in the United Kingdom and Brazil, AstraZeneca's experimental COVID-19 vaccine was reported to have 70.4% efficacy (it reduced the risk of symptomatic COVID-19 by 70.4%). \n\nThe study recorded 131 infections among 23,000 total trial participants, but the company did not say how many received the vaccine and how many received the placebo. Surprisingly, data from 8,895 trial participants who were given two full doses of the vaccine at least one month apart showed it had a 62% efficacy rate, while 8,895 participants who received a half dose followed by a full dose of the vaccine at least one month later demonstrated roughly 90% efficacy. \n\nThere has been one COVID-19-related death in the study, which occurred in the placebo group. No hospitalizations or severe cases of COVID-19 occurred in vaccinated participants.\n\n**Approvals:** This vaccine is not yet approved for public use by any regulatory agency. \n\n**Distribution timeline:** The company has not submitted its Phase 3 trial data to any national drug regulatory agencies and has not yet pursued a United States Food and Drug Administration (U.S. FDA) Emergency Use Authorization (EUA) or an application for Conditional Marketing Authorization (CMA) with the European Medicines Agency (EMA). However, the company expects it will have 200 million doses ready by the end of 2020 and can produce 100 million to 200 million doses per month once production is ramped up in 2021. AstraZeneca also said it was planning to distribute the vaccine in late 2020 and will likely be able to make up to three billion doses next year. \n\n**Distribution plan:** As of December 1, 2020, AstraZeneca promised to supply 300 million vaccines to low and middle income countries on a not-for-profit basis through a vaccine partnership called COVAX. The COVAX partnership is made of up individual organizations including GAVI, the vaccine alliance; the World Health Organization; and the Coalition for Epidemic Preparedness Innovations (CEPI) in order to obtain equitable distribution to 92 developing countries. Additionally, AstraZeneca says it plans to produce up to 3 billion doses of the vaccine in 2021 on a rolling basis. The company has not submitted its Phase 3 trial data to any national drug regulatory agencies and has not yet pursued a United States Food and Drug Administration (U.S. FDA) Emergency Use Authorization (EUA) or an application for Conditional Marketing Authorization (CMA) with the European Medicines Agency (EMA). The U.S.-based portion of the trial is being supported by Operation Warp Speed.\n\n**How the vaccine is being studied:** Vaccines are tested and studied in multiple phases (phased testing) to determine if they are safe and work to prevent illness. Before a vaccine is tested on humans, in the preclinical phase it is tested on laboratory cells or animals. Once it is approved for human research, there are three phases that take place before the vaccine can be considered for approval for public use. During the first stage (Phase I), the new vaccine is provided to small groups of people—the first time the vaccine is tested in humans. The second stage (Phase II) involves testing the vaccine on people who have similar characteristics (such as age and physical health) to the target population, or the group for which the vaccine is intended. The goal of this stage is to identify the most effective dosages and schedule for Phase III trials. The final stage (Phase III) provides the vaccine to thousands of people from the target population to see how safe and effective it is. Once the vaccine has undergone Phase 3 testing, the manufacturer can apply for a license from regulatory authorities (like the FDA in the US) to make the vaccine available for public use. Once approved, the drugmaker will work with national governments and international health organizations to monitor vaccine recipients for potential side effects from the vaccine that were not seen in clinical trials (this is called surveillance). This phase also helps researchers understand how well a vaccine works over a longer time frame and how safe it is for the population.\n\n**Type of vaccine:** This vaccine was developed using an adenovirus—a weakened, harmless virus that usually causes the common cold in chimpanzees—as a way to transport the vaccine's ingredients into the human body. This type of vaccine is called a \"vector vaccine,\" because the adenovirus serves as the vector (or vehicle) for getting the drug into human cells. The adenovirus can stimulate a response from a person's immune system when their body detects it in cells. When the vaccine is injected, it penetrates into the body and gives a blueprint (DNA) for how to defend itself against COVID-19. In this case, that means the cells start to produce club-shaped spike proteins found in coronaviruses, including COVID-19. These three-dimensional spike proteins are so similar to a normal COVID-19 infection that it causes inflammation and the creation of antibodies and T cells. Then when a vaccinated person is eventually exposed to COVID-19, their body would attack the virus because it already recognizes how to respond to those spike proteins, and can fight against them to prevent infection. Essentially, the vaccine helps train human bodies to detect and eliminate a real COVID-19 infection through showing it mock spike proteins, before COVID-19 can cause any severe symptoms or a severe infection.\n\n**Dosage:** AstraZeneca is currently planning a global trial to compare two dosing regimens of half and full dosages for trial participants, though only full dosage trials were originally planned. Original plans for an initial injection followed by a secondary injection at least one month later are still in place. Early trial phases used dosages of 5 × 1010 viral particles in their vaccine injections. Later stage trials used ~2.5 x1 010 viral particles in half doses or ~5 x 1010 viral particles in full doses. AstraZeneca has yet to determine how many trial participants will be involved but said the number will be in the thousands. \n\n**Vaccine storage conditions:** Storage requirements are important to consider for new vaccines. In order for vaccines to be safe and effective, they must be held at the correct temperature during distribution and storage in health centers, pharmacies, and clinics. Maintaining the correct storage temperature can be difficult, especially if the vaccine's temperature requirement is very cold. The AstraZeneca vaccine can be stored and transported and handled at normal refrigerated conditions. This temperature range is between 2-8 degrees Celsius/ 36-46 degrees Fahrenheit and can remain effective for at least six months at that temperature.\n\n**Preclinical testing:** Early doses of the vaccine were shown to be effective in protecting rhesus macaques from pneumonia caused by COVID-19, according to U.S. National Institutes of Health and University of Oxford collaborators. The six animals who were vaccinated 28 days before being infected with COVID-19 were compared to three other animals that did not receive the vaccine. The six vaccinated animals had no signs of no signs of the virus replicating in their lungs, much lower levels of respiratory illnesses and no lung damage in comparison to the unvaccinated animals .The vaccine was then permitted to advance to clinical trials in humans.\n\n**Phase 1/2 trial:** Beginning April 23 through May 21, 2020, 1077 participants were enrolled in AstraZeneca's early trials and received either the vaccine or the MenACWY vaccine (as part of the control group to whom vaccinated participants are compared ). Healthy adults aged 18-55 years old with no lab-confirmed history of COVID-19 infection or symptoms were enrolled in the trial. Ten of these adults openly received a vaccine booster (second) injection 28 days after the first injection was given. By day 14, T-cell responses were at their highest and anti-spike IgG responses rose by day 28. Neturalizing antibodies were detected in 32 of 35 (91%) of patients after a single dosage of vaccine and in all participants who received a booster dosage. Side effects were more present in the vaccinated group but many were improved with paracetamol including pain, feeling feverish, chills, muscle ache, headache, and malaise. About 60% of the 1000 trial participants experienced side effects. There were no serious adverse events related to ChAdOx1 nCoV-19.\n\n**Phase 2/3 trial**: The earliest data we have from Phase 2 and 3 trials are single-blinded, multi-centre, randomised, controlled trials is from the UK and Brazil. Participants are selected for participation and randomly assigned to either receive the experimental vaccine or an injection of MenACWY or saline. These trial phases involve 23,000 trial participants aged 18 and over from diverse racial and geographic groups who are healthy or have stable underlying medical conditions. For the 2,741 trial participants who received a have dose of the vaccine followed by a full dose at least one month apart, vaccine efficacy was reported to be 90%. In the 8,895 trial participants who received two full doses at least one months apart, vaccine efficacy was was reported to be 62%. The combined efficacy from both of these dosing regimens in 11,636 people was reported to be 70%. No hospitalizations or severe cases of the disease were reported in participants receiving the vaccine, but no published studies have been released about potential side effects. After an alleged serious adverse reaction in one Phase 3 trial participant, AstraZeneca voluntarily halted its clinical trials temporarily to investigate. The participant is expected to make a full recovery and most trials have resumed. Current trials are also underway US, Japan, Russia, South Africa, Kenya and Latin America with planned trials in other European and Asian countries. In total, the company expects to enroll up to 60,000 participants globally.\n\n**Reported side effects and safety concerns:** Completed Phase 3 study results have yet to be published, but some early trial data showed that 60% of trial participants reported side effects from the injections. These symptoms included pain, feeling feverish, chills, muscle ache, headache, and malaise and many were treated with paracetamol. Injection-site pain and tenderness were the most common local adverse reactions within48 hours of the injection and a significant number of side effect symptoms were reported in each age group over \n\n**Impact on different populations:** Older adults (56 years and older) were reported to have a strong immune response to the injections.\n\n**Other relevant notes:** N/A\n",
    "Glossary Terms": [
      "rec9qqItwSTjq3Eae",
      "rec10nAxiKgWhYJLd",
      "recM4p8QOERmuESKr",
      "rec5Cya6SiM7o3VRq",
      "recKI7Pa78bZM8n78",
      "recQYfy6k4QB8HKXM",
      "recJK5tI9LgCGFRAU",
      "recAiJYWSxD5F1Lz1",
      "recpDS35Y5vAuQ7Oa"
    ],
    "Variation of the answer depending on country of residence": "Yes\t\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "prevention",
      "immune system",
      "vaccine",
      "efficacy",
      "clinical trial"
    ],
    "Other resources": "1. ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 ([Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32270-4/fulltext)) \n2. Oxford's ChAdOx1 nCoV-19 clinical trials ([Oxford](https://www.research.ox.ac.uk/Article/2020-07-19-oxford-covid-19-vaccine-trials)) \n3. COVID-19 Oxford Vaccine Trial ([Oxford](https://covid19vaccinetrial.co.uk/ab)) \n4. Covid: 6,000 UK volunteers to be injected with vaccine in phase 3 trial ([Guardian](https://www.theguardian.com/world/2020/nov/16/6000-uk-volunteers-to-be-injected-with-covid-vaccine-in-phase-3-trial)) \n5. Two Companies Restart Virus Trials in U.S. After Safety Pauses ([NYT](https://www.nytimes.com/2020/10/23/health/covid-vaccine-astrazeneca-johnson-and-johnson.html)) \n6. Coronavirus Vaccine Tracker ([NYT](https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html?name=styln-coronavirus-vaccines&region=TOP_BANNER&block=storyline_menu_recirc&action=click&pgtype=Article&impression_id=0bc1c9e0-28a0-11eb-b483-d78e057a8304&variant=1_Show)) \n7. Pfizer and AstraZeneca slide as Moderna's rival COVID-19 vaccine shows strong efficacy ([MI](https://markets.businessinsider.com/news/stocks/pfizer-astrazeneca-stock-price-moderna-covid19-vaccine-shows-strong-efficacy-2020-11-1029806658)) \n8. Nobody has looked at AstraZeneca vaccine data yet - UK health official ([Reuters](https://www.reuters.com/article/health-coronavirus-britain-astrazeneca/nobody-has-looked-at-astrazeneca-vaccine-data-yet-uk-health-official-idUSS8N2GW0AF)) \n9. AstraZeneca says COVID-19 vaccine could arrive in January of next year ([CBS](https://www.cbsnews.com/news/covid-vaccine-astrazeneca-ceo-says-december-january/)) \n10. About the Oxford COVID-19 vaccine ([Oxford](https://www.research.ox.ac.uk/Article/2020-07-19-the-oxford-covid-19-vaccine)) \n11. Oxford Covid vaccine works in all ages, trials suggest ([The Guardian](https://www.theguardian.com/world/2020/oct/27/covid-vaccine-uk-oxford-university-astrazeneca-works-in-all-ages-trials-suggest)) \n12. AstraZeneca Covid-19 vaccine is 70% effective on average, early data show ([STAT](https://www.statnews.com/2020/11/23/astrazeneca-covid-19-vaccine-is-70-effective-on-average-early-data-show/)) \n13. Why Oxford’s positive COVID vaccine results are puzzling scientists ([Nature](https://www.nature.com/articles/d41586-020-03326-w)) \n14. AstraZeneca’s Coronavirus Vaccine, Easy and Cheap to Produce, Appears Effective ([NYT](https://www.nytimes.com/2020/11/23/business/astrazeneca-oxford-coronavirus-vaccine.html)) \n15. Experts have questions about AstraZeneca's vaccine data ([CNN](https://www.cnn.com/2020/11/23/health/astrazeneca-vaccine-data-questions/index.html)) \n16. What We Know About AstraZeneca’s Head-Scratching Vaccine Results ([NYT](https://www.nytimes.com/2020/11/24/health/astrazeneca-covid-vaccine.html)) \n17. AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19 ([AstraZeneca](https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.htm)) \n18. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial ([Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext)) \n19. AstraZeneca COVID-19 vaccine trial Brazil volunteer dies, trial to continue ([Reuters](https://www.reuters.com/article/us-health-coronavirus-brazil-vaccine/astrazeneca-covid-19-vaccine-trial-brazil-volunteer-dies-trial-to-continue-idINKBN2762MO)) \n20. After Admitting Mistake, AstraZeneca Faces Difficult Questions About Its Vaccine ([NYT](https://www.nytimes.com/2020/11/25/business/coronavirus-vaccine-astrazeneca-oxford.html)) \n21. Investigational ChAdOx1 nCoV-19 vaccine protects monkeys against COVID-19 pneumonia ([U.S. NIH](https://www.nih.gov/news-events/news-releases/investigational-chadox1-ncov-19-vaccine-protects-monkeys-against-covid-19-pneumonia)) \n22. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques ([bioRxiv](https://www.biorxiv.org/content/10.1101/2020.05.13.093195v1)) \n23. AstraZeneca Covid-19 vaccine study put on hold due to suspected adverse reaction in participant in the U.K. ([STAT](https://www.statnews.com/2020/09/08/astrazeneca-covid-19-vaccine-study-put-on-hold-due-to-suspected-adverse-reaction-in-participant-in-the-u-k/)) \n",
    "Last modified manual": "2020-11-17",
    "Last edited (simplified)": "2020-12-01T23:04:43.000Z",
    "Last edited (experts say)": "2020-12-06T20:27:12.000Z",
    "Last modified": "2020-12-06",
    "What our experts say wordcount": 1825,
    "Background and context wordcount": 164,
    "Other resources wordcount": 268,
    "Wordcount": 2257
  },
  {
    "id": "rec2WMsmyFpU9356U",
    "Question": "What do we know about COVID-19 and obesity?",
    "Status": "Published",
    "Background and context": "With over 1.9 billion people who are overweight or obese and obesity being known as a risk factor for severe disease and death from SARS-CoV-2, a study was conducted to understand if obesity or one's Body Mass Index (BMI) makes one more susceptible to getting infected, if symptoms are different for obese individuals and if obesity changes the immune response to the infection. The study involved 4,469 non-hospitalized individuals with mild and asymptomatic infection at various locations in the United States. \n",
    "What our experts say": "Obesity is a key risk factor for severe cases and death from COVID-19. Hospitalization, intensive care needs and death from COVID-19 is more common among obese individuals. \n\nHowever, as per the recent pre-print of a study that looked at the association between obesity and SARS-CoV-2 infection rates, COVID-19 symptoms, and change in immune response among non-severe cases, obesity, was not linked with increased risks of getting infected with SARS-COV-2. Obese individuals showed more pronounced symptoms, including fever as compared to non-obese people. In the non-severe cases studied, the immune response of obese individuals to the infection was not significantly different from the immune response of non-obese individuals. \n",
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "genes",
      "infection",
      "symptoms"
    ],
    "Other resources": "1. Epidemiological and immunological features of obesity and SARS-CoV-2 ([`medRxiv`](https://www.medrxiv.org/content/10.1101/2020.11.11.20229724v1.full-text))\n2. Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization ([`Annals of Internal Medicine`](https://www.acpjournals.org/doi/full/10.7326/M20-3742))\n3. Obesity could shift severe COVID-19 disease to younger ages ([Lancet](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196905/))\n",
    "Last modified manual": "2020-12-03",
    "Last edited (simplified)": "2020-12-03T12:32:19.000Z",
    "Last edited (experts say)": "2020-12-03T12:32:19.000Z",
    "Last modified": "2020-12-03",
    "What our experts say wordcount": 108,
    "Background and context wordcount": 82,
    "Other resources wordcount": 39,
    "Wordcount": 229
  },
  {
    "id": "rech0c2iaQGp03KXI",
    "Question": "What is immunological memory to SARS-CoV-2 and can it last for more than six months after infection?",
    "Status": "Published",
    "Category": "Immune response",
    "Subcategory": "On: COVID-19 & immunological memory",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "On November 16, 2020, a pre-print study was released that assesses immunological memory to the virus SARS-CoV-2 for more than six months, which helps increase scientists' understanding of how long protective immunity may last for the disease COVID-19. This pre-print study provides additional information beyond a previous pre-print study released in July 2020, which found neutralizing antibody responses to be stable for at least 3 months after SARS-CoV-2 infection. \n\nScientists are interested in how long immunological memory lasts for the virus SARS-CoV-2 that causes the disease COVID-19, as this contributes to understanding how survivors of COVID-19 can be protected from reinfection and how the general public can be protected through vaccines. More research is still being conducted on long-term immunity against COVID-19.\n",
    "What our experts say": "Immunological memory is the ability of your body's immune system to recognize a foreign virus or bacteria that the body has encountered before and start an immune response. \n\nA pre-print study was released on November 16, 2020 that assesses immunological memory to the virus SARS-CoV-2 for more than six months. This study analyzed 185 COVID-19 cases in the United States, including 41 cases after 6 months post-infection.\n\n Study authors found it promising that they could measure at least three components of immune memory in 96% of cases over 5 months after symptom onset. The authors believe this implies that durable immunity to help protect against reinfection of COVID-19 could be possible in most people.\n\nNo significant difference was detected between males and females, and the authors reiterated that \"the magnitude of the antibody response against SARS-CoV-2 is highly heterogenous between individuals.\"\n\nThe authors acknowledge several study limitations, such as the relatively low number of severe COVID-19 cases in their study. Additionally, there is limited data on protective immunity against the virus SARS-CoV-2 and the disease COVID-19, so the authors cannot make direct conclusions about protective immunity from their study results at the time of publication because \"mechanisms of protective immunity against SARS-CoV-2 or COVID-19 are not defined in humans.\" More research is underway to better understand long-term immunity against COVID-19.\n",
    "Glossary Terms": [
      "recORiIMwk54TDQB6",
      "recaXXF6coF4J2EUz",
      "recyXylBebc7GlxTi",
      "reci6AkPuYYC5pFzD",
      "recEwiYdLnp5pCbQD",
      "recmajcAORyuqhZPc",
      "recJhCnFxAX2jAH0h",
      "rectkO1d0FhUHQ0Of"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "infection",
      "immune system"
    ],
    "Other resources": "1. Immunological memory to SARS-CoV-2 assessed for greater than six months after infection ([bioRxiv](https://www.biorxiv.org/content/10.1101/2020.11.15.383323v1.full))\n2. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months ([medRxiv](https://www.medrxiv.org/content/10.1101/2020.07.14.20151126v1))\n",
    "Last modified manual": "2020-11-25",
    "Last edited (simplified)": "2020-11-24T23:52:06.000Z",
    "Last edited (experts say)": "2020-12-01T15:59:51.000Z",
    "Last modified": "2020-12-01",
    "What our experts say wordcount": 218,
    "Background and context wordcount": 122,
    "Other resources wordcount": 30,
    "Wordcount": 370
  },
  {
    "id": "recuvuPywidjximuI",
    "Question": "What can we expect when a population first begins getting vaccinated?",
    "Status": "In progress",
    "Background and context": "On November 16, 2020 with data from its Phase 3 trial, Moderna reported their experimental COVID-19 vaccine to have 94.5% efficacy. On November 18, 2020 with data from its Phase 3 trial, Pfizer reported their experimental COVID-19 vaccine to have 95% efficacy. Following this report, Pfizer submitted an emergency use authorization (EUA) request from the U.S. FDA  for its COVID-19 vaccine. If approved, distribution is projected to begin in mid-December, which has raised a number of questions on how distribution will be coordinated, what the impact will be, and at what timeline.\n",
    "What our experts say": "Once vaccine doses are distributed in the millions to a population, we can expect to see cases of COVID-19 dropping in those populations within a few months. Following a decrease in case numbers, we can expect decreases in hospitalization rates (the number of hospitalizations per 100,000 individuals), and then decreases in mortality rates (the number of deaths due to COVID-19 in a population). Importantly, we do not yet know how much we'll see these case numbers drop following the first vaccinations, because we don't yet know how effective the vaccines are outside clinical trials. The decrease could be minuscule or massive — and there's no way of knowing until the vaccines are distributed. \n\nThe data we have on the most promising vaccines reflect vaccine efficacy, which is different than effectiveness and shows us how well a vaccine works to prevent a particular disease in a controlled, research environment. The data currently shows 95% efficacy for the Pfizer vaccine and 94.5% efficacy for the Moderna vaccine, with efficacy to be announced soon by AstraZeneca. \n\nWe will not have data on vaccine effectiveness until a vaccine is made available to large populations outside of clinical trials. Given that U.K. Medicines & Healthcare products Regulatory Agency (MHRA) authorized the supply of Pfizer and BioNTech’s COVID-19 mRNA vaccine on December 2, we will likely have data on the Pfizer vaccine's effectiveness first. Once we have information on effectiveness, we’ll have a better sense of how the vaccines will impact metrics such as case numbers, test-positive rates, hospitalization rates, mortality rates, and level of disease severity. \n\nIf vaccine distribution begins in early-mid-December (the Pfizer vaccine is set to begin being distributed in the U.K. on December 8), by mid-March to the highest risk individuals a population may begin to see declining case numbers. Depending on the rate at which a population is vaccinated, and particularly when distribution of the vaccine moves from highest risk individuals to the broader public, a December distribution start date to high-risk individuals followed quickly (within one month or so) by the general public could potentially vaccinate approximately 70% of that population by mid-late summer (within 6-8 months). This level of vaccination in a population would mean the population reaches herd immunity, triggering significant decreases in COVID-19 metrics such as case numbers, hospitalization rates, and mortality rates. However, if the general public in a population does not have access to vaccinations until later than this timeline (for example, April - June), herd immunity may not be reached until the fall or end of 2021 (6-8 months following).\n\nIt is important to note that these types of timelines are estimates and based on an assumption that mass vaccination production and delivery is efficient. It also typically takes a few weeks for the body to build immunity after vaccination, so as a result, it is still possible for someone to contract COVID-19 just after they receive a vaccine, influencing case numbers. \n\nCase numbers, hospitalization rates, and mortality rates following vaccination in a country will depend on a variety of factors. \nFirst, different populations within countries suffer from COVID-19 morbidity and mortality differently. Black Americans, for example, have 2.6x higher case numbers, 4.7x higher hospitalization rates, and 2.1x higher mortality rates than white Americans. This will impact how much case numbers, hospitalizations and deaths fall in those populations after the first doses of vaccines get distributed to Americans. The distribution of vaccines is also not guaranteed to be equitable and there are varying degrees of willingness to even take a vaccine in some populations. Finally, some communities within a country may continue to practice recommended preventative guidelines (masks, social distancing) after the first rounds of vaccination, while others may not. \n\nCurrent projected distribution plans across the two most promising vaccines is for the vaccine to first go to emergency department clinicians, outpatient clinicians, testers at symptomatic sites, other high-risk health care workers, immunocompromised individuals, EMTs, and potentially essential federal employees, followed by the rest of the general population. However, in the case of Pfizer, they are permitting the regions, countries, and states, distributing the vaccines to determine the distribution plans. For instance, in the U.S., distribution plans are by state.\n\nIn the United States, vaccines are currently intended to be allocated to all 50 states and eight territories, in addition to six major metropolitan areas. Pfizer, which has filed for emergency use authorization (EUA) in the U.S. and is the closest to potential approval, is prioritizing this approach over a plan that would prioritize the hardest-hit areas of the country, which they’ve said was decided due to the rapid wide spread of the virus. This plan will have impacts for the case rates and other metrics, as equal distribution will lead to different outcomes than targeted distribution. Other barriers to vaccine access include, among others, continual access to health care, particularly given that both the Pfizer and Moderna vaccine require two doses; cost (the vaccines are free but vaccination providers will be able to charge an administration fee); and potential supply chain challenges. \n",
    "Glossary Terms": [
      "rec9qqItwSTjq3Eae",
      "recR5R4QhqxWEg2nF",
      "rec10nAxiKgWhYJLd",
      "recE5fZ79yZqKorXK"
    ],
    "Other resources": "1. A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/NCT04470427))\n2. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report ([NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa2022483)) (Supplementary Appendix- [NEJM](https://www.nejm.org/doi/suppl/10.1056/NEJMoa2022483/suppl_file/nejmoa2022483_appendix.pdf))\n3. Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study ([Moderna](https://investors.modernatx.com/node/10316/pdf))\n4. Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints ([Pfizer](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine))\n5. Pfizer and BioNTech to Submit Emergency Use Authorization ([Pfizer](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization))\n6. In the first distribution push, 6.4 million doses of Pfizer’s vaccine will be shipped across the U.S. (New York Times)COVID-19 Hospitalization and Death by Race/Ethnicity ([CDC](https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html))\n7. Vaccine Knowledge Project: Herd Immunity (Herd Protection) ([Oxford Vaccine Group](https://vk.ovg.ox.ac.uk/vk/herd-immunity))\n",
    "Last modified manual": "2020-12-01",
    "Last edited (simplified)": "2020-12-01T21:59:35.000Z",
    "Last edited (experts say)": "2020-12-07T18:53:24.000Z",
    "Last modified": "2020-12-07",
    "What our experts say wordcount": 836,
    "Background and context wordcount": 92,
    "Other resources wordcount": 118,
    "Wordcount": 1046
  },
  {
    "id": "recby26zia1AUqJ59",
    "Question": "What is the difference between an Emergency Use Authorization and an FDA approval?",
    "Status": "In progress",
    "Background and context": "On February 4, 2020, the United States Department of Health and Human Services declared a public health emergency based on the new coronavirus that was detected. They also declared that circumstances existed to justify the authorization of emergency use  diagnostic tools. Further, the FDA issued guidances with immediate effect on developing emergency use diagnostic testing abilities. Over the last several months, FDA has issued guidances on Emergency Use Authorization for several medical products, including ventilators, respiratory devices, disinfectants, masks, sanitizers and now for vaccines.\n",
    "What our experts say": "The Emergency Use Authorization (EUA) is a different standard than the FDA Approval. \n\nFDA Approval from the US Food and Drug Agency is an independent, scientifically reviewed approval for medical products, drugs and vaccines. Based on substantial clinical data and evidence,  the product is deemed safe, effective and able to be produced within federal quality standards.\n\nThe process for an Emergency Use Authorization (EUA) is different than an FDA approval. EUA is a mechanism used by the FDA to facilitate making products available quickly during a public health emergencies (like the current COVID-19 pandemic), when there is no other adequate and approved medical product available.  \n\nEmergency Use Authorization allows for the use of medical products that are not yet formally approved, so that in the midst of an emergency, the products can be used to diagnose, treat or prevent serious illness or conditions. In order to give the authorization, FDA evaluates the potential risks and benefits of the products based on the scientific evidence that is available at that time. EUAs end when the emergency declaration ends.  They can also be revised or revoked as more data is made available.\n\n",
    "Glossary Terms": [
      "recp00hYRvT2bmlfp"
    ],
    "Other resources": "1. \tUnderstanding the Regulatory Terminology of Potential Preventions and Treatments for COVID-19 ([US F.D.A.](https://www.fda.gov/consumers/consumer-updates/understanding-regulatory-terminology-potential-preventions-and-treatments-covid-19))\n2. Guidance Documents Related to Coronavirus Disease 2019 (COVID-19) ([Federal Register](https://www.federalregister.gov/documents/2020/05/12/2020-10146/guidance-documents-related-to-coronavirus-disease-2019-covid-19-availability))\n3. What Is Emergency Use Authorization? ([Johns Hopkins](https://www.jhsph.edu/covid-19/articles/what-is-emergency-use-authorization.html)) \n",
    "Last modified manual": "2020-12-01",
    "Last edited (simplified)": "2020-11-26T19:47:31.000Z",
    "Last edited (experts say)": "2020-12-01T22:01:51.000Z",
    "Last modified": "2020-12-01",
    "What our experts say wordcount": 192,
    "Background and context wordcount": 85,
    "Other resources wordcount": 32,
    "Wordcount": 309
  },
  {
    "id": "recyVfyjLKjekjqsL",
    "Question": "What checks and balances are in place to ensure vaccine manufacturers are producing safe products?",
    "Status": "Published",
    "Category": "Vaccines",
    "Subcategory": "On: COVID-19 & vaccine checks and balances",
    "Source of the question": [
      "Partner Organization"
    ],
    "Background and context": "Vaccines play an essential role in protecting the public's health, especially when there is limited treatment available for a disease. With COVID-19 cases still rising in several countries, many people are looking to vaccines as a crucial step towards ending the pandemic and pandemic-related economic restrictions. \n\nThere is immense public, political and commercial pressure for COVID-19 vaccines to be developed, tested, approved, manufactured, and distributed with unprecedented speed. Although COVID-19 only emerged about a year ago and vaccine development has historically taken years or even decades, COVID-19 vaccine development has been accelerated, with many phases of testing, and ramp-up for manufacturing, happening simultaneously around the world for the first time at this scale.\n\nWith the increased complexity of accelerated vaccine development and so many forces pushing for COVID-19 vaccine candidates to enter the market as soon as possible, regulatory checks and balances are critically important to ensure that vaccines are safe as well as effective, and that manufacturing quality is consistent. These standards can be challenging to maintain. In September 2020, leading U.S. and European vaccine developers (including Pfizer, GlaxoSmithKline, and AstraZeneca) made what they called a “historic pledge” to maintain rigor after concerns that “safety and efficacy standards might slip in the rush to find a vaccine.”\n\nAdditionally, the processes and timelines for vaccine approval and distribution vary significantly from country to country. For example, Russia surprised the global community by approving their first vaccine candidate in August 2020 based on limited preliminary results that would not have satisfied many other international standards. China began vaccinating hundreds of thousands of people in the summer and fall of 2020 through \"emergency use\" of experimental vaccine candidates before regulatory approval for public use, with some criticism because COVID-19 cases were down in China at that time. As a result, there were questions about whether China had an unreported emergency justifying the early vaccinations or whether China was allowing other interests to override public health interests.\n\nPublic health concerns over early vaccinations include not only the risks of side effects, but also vaccine recipients potentially feeling invincible and further contributing to the spread of disease if an early vaccine turns out to be less effective than clinical trials indicate. Trials have typically tested vaccines with a less diverse population than the general public, so it is important to check that vaccines are safe for everyone including minorities and people with pre-existing conditions before widespread deployment. In rare cases, antibodies from new vaccines could even lead to severe disease in certain recipients, such as what happened during testing of experimental vaccines for Severe Acute Respiratory Syndrome (SARS). There are concerns that premature vaccinations could lead to more issues arising, eroding the public’s trust and leading to more hesitance around vaccinations in the future.\n\nResearchers and doctors have warned that COVID-19 vaccine deployment should not be driven by commercial interests, and are urging patience for the necessary processes of checking that vaccines are safe and effective for the general public.  Fortunately, most safety issues identified in the COVID-19 vaccine trials so far have been minor and several vaccine candidates are getting closer to being ready for commercial deployment. \n",
    "What our experts say": "Standard vaccine development is a long process. Multiple studies on safety often take place over multiple years. Manufacturers use phased testing to determine an effective vaccine dose and to evaluate if the vaccine works, if it’s safe, if it has significant or serious side effects, and if immune systems respond well to the vaccine. To pursue regulatory authorization, a vaccine’s benefits must be shown to be greater than its risks, and vaccine safety and effectiveness are considered to be top priorities by regulatory agencies.\n\nRegulators around the world oversee vaccine development and testing at both national and international levels. In the European Union (EU), the European Medicines Agency (EMA) has a COVID-19 Task Force (COVID-ETF) that takes “quick and coordinated regulatory action on the development, authorization, and safety monitoring” for medicines and vaccines to treat and prevent COVID-19. In the US, the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) ensures that “rigorous scientific and regulatory processes are followed by those who pursue the development of vaccines.” Similar to the COVID-ETF in Europe, the FDA has also recruited experts from government agencies, academia, nonprofit organizations, pharmaceutical companies, and international partners to “develop a coordinated strategy for prioritizing and speeding development of the most promising treatments and vaccines.”\n\nTo facilitate timely vaccine development during health crises, the US FDA sets clinical trial standards for scientific data on safety and efficacy, which manufacturers need to achieve in order to bring a vaccine to the US population. Once manufacturers meet those criteria, companies can pursue Emergency Use Authorization (EUA) approval, through which the manufacturer’s EUA submission is reviewed by FDA career scientists and physicians. So far, Moderna and Pfizer have both submitted data on their vaccines for FDA EUA approval. \n\nWhile some COVID-19 vaccine manufacturers have requested emergency authorization with regulatory agencies around the world, it is important to note that if emergency authorization is approved, it is generally considered to be an emergency exception, with temporary permissions designed to accommodate the current COVID-19 public health crisis. \n\nEmergency authorization is not the same as formal licensing, which can take months. Unlicensed vaccines may be authorized by regulatory agencies and their lack of licensing does not mean that the vaccine has not been rigorously tested.\n\nBecause of the nature of pandemic circumstances, for emergency authorizations, governmental agencies rather than manufacturers often assume responsibility for vaccine safety. In the US, for example, the Public Readiness and Emergency Preparedness Act (PREP Act) provides manufacturers, distributors, and others with liability immunity, as long as they have not participated in “willful misconduct.” \n\nRegulatory oversight and monitoring will continue even once vaccines are approved for emergency use. In addition to testing by the vaccine manufacturers, government regulators regularly test vaccines for quality, and tweak manufacturing once they are released onto the market. \n\nPost-authorization, US vaccine safety monitoring is performed by the federal government (US FDA and the US Centers for Disease Control and Prevention [CDC]) and other agencies and organizations who are involved in healthcare delivery. Vaccine safety and monitoring systems are in place to quickly identify rare side effects that were not identified in clinical trials, and to detect possible vaccine safety problems. \n\nThough no major safety concerns have been identified in the current vaccine trials, even when the current clinical trials are completed pharmaceutical companies, regulatory agencies, public health experts, researchers, and others will continue to evaluate safety, efficacy, effectiveness, and side effects in the years to come. The US FDA has stated that “efforts to speed vaccine development to address the ongoing COVID-19 pandemic have not sacrificed scientific standards, integrity of the vaccine review process, or safety.”\n",
    "Glossary Terms": [
      "rec9qqItwSTjq3Eae",
      "recR5R4QhqxWEg2nF",
      "rec10nAxiKgWhYJLd",
      "recMJMGqkERKGcbL5"
    ],
    "Variation of the answer depending on country of residence": "Yes, the regulatory processes for vaccines vary by country\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "vaccine",
      "vaccine effectiveness",
      "safety"
    ],
    "Other resources": "1. Approval of vaccines in the European Union ([EMA](https://vaccination-info.eu/en/vaccine-facts/approval-vaccines-european-union))\n2. Statement on continuation of vaccine trials ([ICMRA](http://www.icmra.info/drupal/en/covid-19/statement_on_continuation_of_vaccine_trials))\n3. Emergency Use Authorization for Vaccines to Prevent COVID-19, Guidance for Industry ([US FDA](https://www.fda.gov/media/142749/download))\n4. COVID-19 vaccines: development, evaluation, approval and monitoring ([EMA](https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-development-evaluation-approval-monitoring))\n5. EMA’s governance during COVID-19 pandemic ([EMA](https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/emas-governance-during-covid-19-pandemic#covid-19-ema-pandemic-task-force-section))\n6. Vaccine Development- 101 ([US FDA](https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/vaccine-development-101))\n7. Unlicensed vaccine manufacturers are immune from some, but not all, civil liability ([Full Fact](https://fullfact.org/health/unlicensed-vaccine-manufacturers-are-immune-some-not-all-civil-liability/))\n8. Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19 ([Federal Register](https://www.federalregister.gov/documents/2020/03/17/2020-05484/declaration-under-the-public-readiness-and-emergency-preparedness-act-for-medical-countermeasures))\n9. Emergency Use Authorization for Vaccines Explained ([FDA](https://www.fda.gov/vaccines-blood-biologics/vaccines/emergency-use-authorization-vaccines-explained))\n10. The PREP Act and COVID-19: Limiting Liability for Medical Countermeasures ([Congressional Research Service](https://crsreports.congress.gov/product/pdf/LSB/LSB10443))\n",
    "Last modified manual": "2020-12-01",
    "Last edited (simplified)": "2020-12-01T23:39:42.000Z",
    "Last edited (experts say)": "2020-12-01T23:39:42.000Z",
    "Last modified": "2020-12-01",
    "What our experts say wordcount": 599,
    "Background and context wordcount": 521,
    "Other resources wordcount": 98,
    "Wordcount": 1218
  },
  {
    "id": "recEHfh8wLLXNtpzi",
    "Question": "Why do we need to socially-distance during the COVID-19 pandemic?",
    "Status": "Published",
    "Background and context": "As per the U.S. CDC, social distancing or physical distancing means keeping a safe space between oneself and those from another household. To reduce the spread of COVID-19 the recommended distance is 6 feet. In addition to maintaining the 6 feet distance, there are several ways to avoid exposure to large groups of people, such as: working from home; avoiding crowded restaurants, shops,  movie theaters; not attending group gatherings; avoiding long-distance travel; etc.\n",
    "What our experts say": "The SARS-CoV-2 virus that causes COVID-19 mostly spreads from person to person. The virus is transmitted via tiny droplets from infected people when they cough, sneeze, talk or sing. An individual who might be in close proximity to an infected person can then inhale the virus and get infected themselves. The virus can even spread through people who do not show any symptoms, but are infected with COVID-19.\n\nIt is not only important to stay home and maintain social distance if you have symptoms, but it is necessary to maintain physical distance even when one may not have symptoms, in order to keep oneself and others around safe from getting infected through any asymptomatic or presymptomatic cases.  \n\nU.S. CDC and WHO, therefore, recommend that social distancing should be maintained indoors and outdoors between people who are not from the same household. Social distancing, along with other preventative measures, like hand washing with soap and water for at least 20 seconds and using face masks, can reduce the spread of COVID-19 to a great extent.\n",
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "spread",
      "transmission",
      "asymptomatic"
    ],
    "Other resources": "1. Social Distancing ([U.S. CDC](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/social-distancing.html#:~:text=Social%20distancing%20helps%20limit%20opportunities,get%20and%20spread%20COVID%2D19.))\n2. Coronavirus, Social and Physical Distancing and Self-Quarantine ([Johns Hopkins](https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-social-distancing-and-self-quarantine))\n3. What is social distancing and why is it needed? ([Jackson Lab](https://www.jax.org/news-and-insights/2020/march/social-distance-ed-liu))\n4. The power of social distancing ([UChicago Medicine](https://www.uchicagomedicine.org/forefront/coronavirus-disease-covid-19/social-distancing-psa))\n",
    "Last modified manual": "2020-12-03",
    "Last edited (simplified)": "2020-12-03T13:34:05.000Z",
    "Last edited (experts say)": "2020-12-03T15:28:47.000Z",
    "Last modified": "2020-12-03",
    "What our experts say wordcount": 174,
    "Background and context wordcount": 74,
    "Other resources wordcount": 32,
    "Wordcount": 280
  },
  {
    "id": "recg6ZUdyARq2qvyv",
    "Question": "What does the Astra Zeneca AZD1222 (ChAdOx1 nCoV-19) vaccine contain?",
    "Status": "Ready for Review",
    "Background and context": "There have been several information pieces online falsely claiming that the vaccine injects DNA sequences of various diseases that then make vaccinated individuals succumb to those diseases. Research has suggested that while there could be some residual DNA present when a vaccine is made using cells, the DNA exposure is unlikely to be harmful because the DNA is so fragmented (broken into small parts). \n\nThe US Food and Drug Administration limits the size and amount of DNA in vaccines and while we are not aware of any risks associated with DNA fragments that could be present in vaccines, the exact level of risk is not defined. \n \nVaccines are widely used to prevent infections, and most traditional vaccines that target viruses are made from dead or attenuated live viruses (viruses that have been altered so they are not harmful) to help people develop immunity without becoming ill.\n\nVaccines are generally very safe and their study involves a rigorous process. Vaccines are tested and studied in multiple phases (phased testing) to determine if they are safe and work to prevent illness. Before a vaccine is tested on humans, in the preclinical phase it is tested on laboratory cells or animals. \n\nOnce it is approved for human research, there are three phases that take place before the vaccine can be considered for approval for public use. During the first stage (Phase I), the new vaccine is provided to small groups of people—the first time the vaccine is tested in humans. The second stage (Phase II) involves testing the vaccine on people who have similar characteristics (such as age and physical health) to the target population, or the group for which the vaccine is intended. The goal of this stage is to identify the most effective dosages and schedule for Phase III trials. The final stage (Phase III) provides the vaccine to thousands of people from the target population to see how safe and effective it is. Once the vaccine has undergone Phase 3 testing, the manufacturer can apply for a license from regulatory authorities (like the FDA in the US) to make the vaccine available for public use. Once approved, the drugmaker will work with national governments and international health organizations to monitor vaccine recipients for potential side effects from the vaccine that were not seen in clinical trials (this is called surveillance). This phase also helps researchers understand how well a vaccine works over a longer time frame and how safe it is for the population.\n",
    "What our experts say": "Vaccines can be developed using different technologies. One of them is through viral vectors – a process by which a weakened and modified virus is used to transport the vaccine's ingredients to the cells in a person, in order to activate an immune response in their body. The University of Oxford - AstraZeneca vaccine, AZD122, uses an adenovirus vector as its technology.\n\nThe Oxford Astra-Zeneca vaccine, AZD1222, was formerly called the ChAdOx1 nCov-19. It is made using the ChAdOx1 virus vector – a weakened version of an adenovirus—a harmless virus that usually causes the common cold in chimpanzees. It was developed at Oxford University in 2012. Since then, it has been used to develop vaccines for a number of diseases.\n\nA spike glycoprotein (S) is found on the surface of the SARS-Cov-2 coronavirus virus through which the virus binds to receptors on human cells (ACE2 receptor) and gains access to insert itself and cause infection. Genetic material of this spike protein is added to ChAdOx1 virus vector so that the adenovirus can stimulate a response from a person's immune system when their body detects it in cells. When the vaccine is injected, it penetrates into the body and gives a blueprint (DNA) for how to defend itself against COVID-19. In this case, that means the cells start to produce club-shaped spike proteins found in coronaviruses, including COVID-19. These three-dimensional spike proteins are so similar to a normal COVID-19 infection that it causes inflammation and the creation of antibodies and T cells. Then, when a vaccinated person is eventually exposed to COVID-19, their body attacks the virus because it already recognizes how to respond to those spike proteins, and can fight against them to prevent infection. Essentially, the vaccine helps train human bodies to detect and eliminate a real COVID-19 infection by showing it mock spike proteins, before COVID-19 can cause any severe symptoms or a severe infection.\n\nSimilar to all vaccination, it could cause side effects. Completed Phase 3 study results of this vaccine trial are yet to be published, but some early trial data showed that 60% of trial participants reported side effects from the injections. These symptoms included pain, feeling feverish, chills, muscle ache, headache, and malaise and many were treated with paracetamol. Injection-site pain and tenderness were the most common local adverse reactions within48 hours of the injection and a significant number of side effect symptoms were reported in each age group over temporary symptoms of fever, sore throat, headaches or diarrhea. \n",
    "Topics": [
      "vaccine",
      "clinical trial"
    ],
    "Other resources": "1. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial ([The Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext))\n2. A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity ([PLoS ONE](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0040385))\n3. AZD1222 SARS-CoV-2 Vaccine ([Precision Vaccinations](https://www.precisionvaccinations.com/vaccines/azd1222-sars-cov-2-vaccine))\n4. What are Adenovirus-Based Vaccines?  ([News Medical](https://www.news-medical.net/health/What-are-Adenovirus-Based-Vaccines.aspx))\n5. Adenoviral vectors are the new COVID-19 vaccine front-runners. Can they overcome their checkered past? ([c&en](https://cen.acs.org/pharmaceuticals/vaccines/Adenoviral-vectors-new-COVID-19/98/i19))\n6. SARS-CoV-2 candidate vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals a normal low range of viral backbone gene expression alongside very high levels of SARS-CoV-2 S glycoprotein expression ([Research Square](https://www.researchsquare.com/article/rs-94837/v1))\n7. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques ([bioRxiv](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241103/#R5))\n8. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques ([Sci Adv](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286676/))\n9. Vaccine Ingredients- DNA ([Children’s Hospital of Philadelphia](https://www.chop.edu/centers-programs/vaccine-education-center/vaccine-ingredients/dna))\n10. Vaccines and Related Biological Products Advisory Committee 154th Meeting ([FDA](https://www.fda.gov/media/120334/download))\n",
    "Editorial notes:": "<airtable:mention id=\"menxQ9duJOG7qGAYH\">@Anshu Shroff</airtable:mention> Seema feedback: \"I think this database entry needs to more clearly state that the DNA of the spike protein is inserted into the viral vector\" Can you update when you have time? Can be tomorrow. thx!\n\n<airtable:mention id=\"mentEXnMNMCr3mC05\">@Megan Marrelli</airtable:mention> Thanks, Meg. Please see if this is more detailed.\n",
    "Last modified manual": "2020-12-04",
    "Last edited (simplified)": "2020-12-05T03:24:29.000Z",
    "Last edited (experts say)": "2020-12-09T16:48:41.000Z",
    "Last modified": "2020-12-09",
    "What our experts say wordcount": 412,
    "Background and context wordcount": 411,
    "Other resources wordcount": 146,
    "Wordcount": 969
  },
  {
    "id": "recl4RzQlRDyYDDNC",
    "Question": "What do we know about the Pfizer vaccine so far?",
    "Status": "Published",
    "Background and context": "Over 165 vaccines against the coronavirus are in development around the world, and approximately 54 are in human trials. The Pfizer vaccine was the first to reach regulatory approval by a government when the United Kingdom approved it for use in early December. Other countries are expected to follow suit, including Canada, the United States, Europe, Australia, Japan and others. \n",
    "What our experts say": "The Pfizer vaccine is being developed and produced by Pfizer, Inc. and the biotech company BioNTech SE. It is a genetic mRNA vaccine (mRNA-1273) currently in Phase 3 clinical trials across the globe. Here is a breakdown of everything you need to know so far about this vaccine’s development.\n\n**Collaborators:** Biopharmaceutical company Pfizer Inc, based in New York City, and BioNTech, biotechnology company based in Mainz, Germany, are collaborating on vaccine development and testing for mRNA-based vaccine candidate BNT162b2.\n\n**Latest information on how well the vaccine works:** On November 30, 2020 with primary efficacy analysis data from its Phase 3 trial, Pfizer announced its experimental COVID-19 vaccine to be 95% effective 28 days after the first of two doses. \n\nOut of approximately 44,000 total study participants, 170 came down with COVID-19. There were 162 in the placebo group and only 8 in the group that was vaccinated with the Pfizer vaccine. \n\nTen of the COVID-19 cases were severe. Nine of those people were from the placebo group—meaning they didn’t receive the vaccine. One severe case was in the vaccinated group. This suggests the vaccine has high protection for severe COVID-19 cases. \n\nThere have been no reported COVID-19-related deaths in the study. These new results of 95% efficacy are higher than the vaccine’s first interim analysis conducted during the study (announced on November 9th, 2020), which reported 90% efficacy based on an analysis of 94 COVID-19 cases among trial participants.\n\n**Approvals:** As of December 2, 2020, the U.K. authorized the supply of Pfizer and BioNTech’s COVID-19 mRNA vaccine BNT162b2 for emergency supply, making the vaccine the first in the world to achieve authorization for COVID-19. Pfizer and BioNTech have also begun rolling review processes with other global regulatory bodies, including in the U.S., Europe, Canada, Australia and Japan, and plan to submit applications immediately to other regulatory agencies around the world.\n\n**Distribution timeline:** The distribution timeline for the U.S., Europe, and other countries will depend on the distribution decisions made by regulators in those countries. Following the U.K.’s emergency approval on December 2, 2020, the companies are ready to deliver the first doses to the U.K. virtually immediately. \n\nIn many of these regions and countries, logistics surrounding the supply chain of the vaccine are being decided upon and run through so that as there is an approval, distribution can begin immediately. Given that background, most vaccines in the U.S. in Europe are likely (but not certain) to begin being distributed before the end of 2020, with other regions and countries to shortly follow.\n\n**Distribution plan:** Pfizer expects to produce up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021, for global distribution. Four of Pfizer’s facilities are part of the manufacturing and supply chain; St. Louis, MO; Andover, MA; and Kalamazoo, MI in the U.S.; and Puurs in Belgium. BioNTech’s German sites will also be leveraged for global supply. Each of these sites are important links in a global supply chain being assembled to tackle the massive logistical challenge of distributing COVID-19 vaccines around the world. \n\nJurisdictions primarily have the responsibility of determining who receives the vaccine in what order. For instance, within the U.S. each state will receive a certain number of doses of the vaccine based on residential populations. States have been asked to create their own plans for who will get the first doses. \n\nIn the U.K., British front-line health-care workers, as well as care-home staff and residents, are most likely to receive the first doses. In general, the most likely distribution plan is for the vaccine to first go to emergency department clinicians, outpatient clinicians, testers at symptomatic sites, other high-risk health care workers, immunocompromised individuals, EMTs, and potentially essential federal employees, followed by the rest of the general population. \n\n**Vaccine storage conditions:** Storage requirements are important to consider for new vaccines. In order for vaccines to be safe and effective, they must be held at the correct temperature during distribution and storage in health centers, pharmacies, and clinics. Maintaining the correct storage temperature can be difficult, especially if the vaccine’s temperature requirement is very cold. \n\nThe Pfizer and BioNTech vaccine can be stored for five days at refrigerated 2-8°C (36-46°F) conditions (refrigerators that are commonly available at hospitals); up to 15 days in Pfizer thermal shippers in which doses will arrive that can be used as temporary storage units by refilling with dry ice; and up to 6 months in ultra-low-temperature freezers, which are commercially available and can extend the vaccine’s shelf life. \n\nWith regards to transit, Pfizer is using dry ice to maintain the recommended temperature conditions of -70°C±10°C (-94°F) for up to 10 days while in transit. However, Pfizer and BioNTech have determined that the vaccine can be moved only four times.\n\n**Type of vaccine:** The mRNA-1273 vaccine is what scientists are calling a genetic mRNA vaccine. This type of vaccine works by using genetic information from the coronavirus, which is injected into the body. The genetic information enters into human cells, instructs the body to make special spike proteins like the coronavirus, and causes the immune system to respond.\n\n**Dosage:** In the current Phase 3 clinical trial, participants receive two injections of 30 micrograms each into their upper arm muscle. The injections are given 21 days apart. Once an individual gets the first dose, they must get the second dose three weeks later in order to complete the vaccination. If approved, researchers expect that the same dosage and schedule will be prescribed to the public.\n\n**How the vaccine is being studied:** Vaccines are tested and studied in multiple phases (phased testing) to determine if they are safe and work to prevent illness. Before a vaccine is tested on humans, which is known as the preclinical phase, it is tested on laboratory cells or animals. Once it is approved for human research, there are three phases that take place before the vaccine can be considered for approval for public use. During the first stage (Phase I), the new vaccine is provided to small groups of people—the first time the vaccine is tested in humans to test safety (primarily) and efficacy of the vaccine. The second stage (Phase II) involves testing the vaccine on people who have similar characteristics (such as age and physical health) to the target population, or the group for which the vaccine is intended. The goal of this stage is to identify the most effective doses and schedule for Phase III trials. The final stage (Phase III) provides the vaccine to thousands of people from the target population to see how safe and effective it is. Once the vaccine has undergone Phase 3 testing, the manufacturer can apply for a license from regulatory authorities (like the FDA in the US) to make the vaccine available for public use. Once approved, the drugmaker will work with national governments and international health organizations to monitor vaccine recipients for potential side effects from the vaccine that were not seen in clinical trials (this is called surveillance). This phase also helps researchers understand how well a vaccine works over a longer time frame and how safe it is for the population.\n\n**Preclinical testing:** Before testing could begin on humans, the trial vaccine was tested on primates at both 30 micrograms and 100 micrograms. On September 9, 2020, results were published demonstrating that the Pfizer vaccine had strong antiviral protection against the virus SARS-CoV-2. As a result, the Pfizer and BioNTech were permitted to advance the vaccine into human clinical trials by the FDA in the form of through the Investigational New Drug application (IND).\n\n**Phase 1 trial:** 45 healthy adults 18–55 and 65–85 years old were randomly assigned to either the placebo group or the vaccine group to receive 2 doses at 21-day intervals of placebo or either of 2 mRNA-based vaccines (BNT162b2 or BNT162b1, which was one of several RNA-based SARS-CoV-2 vaccines studied in parallel for selection to advance to a next trial). Participants received either 10, 20, or 30 microgram dose levels of BNT162b1 or BNT162b2 on a 2-dose schedule, 21 days apart. Both participants and observers working on the study were “blinded,” or not aware of which participants were receiving the active vaccines (and which ones) versus the treatment, in order to help prevent bias. Both with 10 micrograms and 30 micrograms of vaccine BNT162b1, and t 7 days after a second dose of 30 micrograms of the BNT162b2 vaccine, “SARS-CoV-2–neutralizing antibodies” were elicited—special proteins that disable viruses in the body—in younger adults (18-55 years of age) and older adults (65-85 years of age). Younger participants had 3.8 times more antibodies than people who had recovered from the virus. In older adults (65-85 years of age) the vaccine candidate triggered antibodies at 1.6 times the volume of those who had recovered from the virus in the same age group. Vaccine BNT162b2, now known as the “Pfizer vaccine,” was associated with fewer reactions (such as fever and chills), and was therefore selected for Phase 2/3 trials. \n\nIn terms of safety and tolerability of vaccine BNT162b2, reactions were still reported. Study participants reported pain at the injection site, headache, fatigue, muscle pain, chills, joint pain, and fever. Most of these reactions and symptoms peaked by the day after vaccination and resolved by day 7. \n\n**Phase 2/3 trial: **In an effort to speed up the trial, Phases 2 and 2 of the Pfizer vaccine were combined. This phase continued off of Phase 1 and also contained a placebo group as a control with patients randomly assigned into either the placebo group or vaccine group for vaccine BNT162b2. As with Phase 1, the observers and participants were also “blinded.” The first 360 participants enrolled made up the “Phase 2” portion, with 180 randomly assigned to receive the active vaccine and 180 to receive the placebo, stratified equally between 18 to 55 years and >55 to 85 years. Phase 3 enrolled 43,538 trial participants overall, half of whom were randomly assigned to receive the vaccine and half of whom were randomly assigned to receive the placebo. Out of 170 cases of COVID-19 among the study participants,162 cases of COVID-19 were observed in the placebo group versus 8 cases in the vaccine group, indicating 95% efficacy of the vaccine. No serious safety concerns were observed. Data collection is ongoing.\n\n**Reported side effects and safety concerns:** As of December 2, the study’s Data Monitoring Committee has not reported any serious safety concerns related to the vaccine. Adverse events at or greater than 2% in frequency that were reported were fatigue at 3.8% and headache at 2.0%.\n\n**Impact on different populations:** Pfizer and BioNTech both say they aimed to make their trials as diverse as possible to understand the vaccine’s effect on different populations. The trial participants are approximately 30% U.S. participants and 42% non-U.S. participants from across 150 trial sites globally. The participants are reported to have racially and ethnically diverse backgrounds. In the trials, 41% of global and 45% of U.S. participants are 56-85 years of age. Efficacy was reported to be consistent across age, gender, race and ethnicity demographics. Notably, the observed efficacy in individuals over 65 years of age was observed to be greater than 94%. In September 2020, Pfizer and BioNTech expanded Phase 3 enrollment to approximately 44,000 participants. This expansion allowed for the enrollment of new, more diverse, populations, including adolescents as young as 16 years of age, and individuals with chronic, stable human immunodeficiency viruses (HIV), Hepatitis C, or Hepatitis B infection. In October 2020, Pfizer and BioNTech received permission from the FDA to enroll adolescents as young as 12. Their explanation for these expansions is to enable better understanding of the potential safety and efficacy of the vaccine in individuals from more ages and backgrounds.\n\n**Other relevant notes:** N/A\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "vaccine",
      "clinical trial",
      "prevention"
    ],
    "Other resources": "\n1. Our Progress in Developing a Potential COVID-19 Vaccine ([Pfizer](https://www.pfizer.com/science/coronavirus/vaccine)) \n2. Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19 ([Pfizer](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-achieve-first-authorization-world))\n3. Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine ([Pfizer](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization))\n4. Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study ([Pfizer](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against))\n5. Coronavirus Scientific Resources ([Pfizer](https://www.pfizer.com/science/coronavirus))\n6. A Phase 1/2/3, Place-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Health Individuals ([Pfizer](https://pfe-pfizercom-d8-prod.s3.amazonaws.com/2020-11/C4591001_Clinical_Protocol_Nov2020.pdf))\n7. Pfizer Update on our U.S. COVID-19 Vaccine Candidate Distribution Preparedness ([Pfizer](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-update-our-us-covid-19-vaccine-candidate))\n8. Pfizer and BioNTech Announce Data from Preclinical Studies of MRNA-Based Vaccine Candidate Against COVID-19 ([Pfizer](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-data-preclinical-studies-mrna))\n9. COVID-19 Vaccine U.S. Distribution Fact Sheet ([Pfizer](https://www.pfizer.com/news/hot-topics/covid_19_vaccine_u_s_distribution_fact_sheet))\n10. Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162B2 Against COVID-19 ([Pfizer](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-share-positive-early-data-lead-mrna))\n11. EMA Receives Application for Conditional Marketing Authorisation of COVID-19 mRNA Vaccine BNT162b2 ([European Medicines Agency)](https://www.ema.europa.eu/en/news/ema-receives-application-conditional-marketing-authorisation-covid-19-mrna-vaccine-bnt162b2)\n12. Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints ([Businesswire](https://www.businesswire.com/news/home/20201118005595/en/))\n13. A Prefusion SARS-CoV-2 Spike RNA Vaccine is Highly Immunogenic and Prevents Lung Infection in Non-Human Primates ([Cold Spring Harbor Laboratory & bioRxiv](https://www.biorxiv.org/content/10.1101/2020.09.08.280818v1.article-info))\n14. RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study ([New England Journal of Medicine](https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v2))\n15. What Pfizer’s Landmark COVID Vaccine Results Mean for the Pandemic ([Nature](https://www-nature-com.ezp-prod1.hul.harvard.edu/articles/d41586-020-03166-8))\n16. Results of Pfizer COVID-19 mRNA Vaccine Phase 1/2 Study ([News Medical](https://www.news-medical.net/whitepaper/20200917/Results-of-Pfizer-COVID-19-mRNA-Vaccine-Phase-12-Study.aspx))\n17. Pfizer, BioNTech Submit Formal Application to FDA to Authorize COVID-19 to Authorize COVID-19 Vaccine ([STAT News](https://www.statnews.com/2020/11/20/pfizer-biontech-submit-formal-application-to-fda-to-authorize-covid-19-vaccine/))\n18. U.K. Approves Pfizer Coronavirus Vaccine, a First in the West ([New York Times](https://www.nytimes.com/2020/12/02/world/europe/pfizer-coronavirus-vaccine-approved-uk.html))\n\n",
    "Last modified manual": "2020-12-07",
    "Last edited (simplified)": "2020-12-06T19:49:54.000Z",
    "Last edited (experts say)": "2020-12-07T23:42:19.000Z",
    "Last modified": "2020-12-07",
    "What our experts say wordcount": 1939,
    "Background and context wordcount": 61,
    "Other resources wordcount": 263,
    "Wordcount": 2263
  },
  {
    "id": "recz1V5igkqzuKxRx",
    "Question": "Can vaccines be 100% effective against COVID-19 or any other illnesses?",
    "Status": "Published",
    "Country question was sourced from": [
      "Philippines"
    ],
    "Background and context": "Vaccine effectiveness studies examine how well a vaccine prevents a particular disease in the “real world,” where people are doing things like going to the grocery store, work, and school. Vaccine effectiveness is a term that is different from vaccine efficacy, because efficacy is used to measure how well a vaccine works to prevent a particular disease in controlled, research environments—like clinical trials.\n\nPreliminary results of clinical trials of COVID-19 vaccines are showing 90-95% efficacy. While public health experts deem this to be very high, some news articles question why the vaccines are not 100% effective.\n",
    "What our experts say": "Some vaccines can be very successful at preventing illnesses or reducing the severity of it, but no vaccine is 100% effective on an entire population. This is because immune responses vary from person to person.\n\nThe measles vaccine is one of the most successful vaccines, which is 99 per cent effective at preventing the disease. The effectiveness of the flu vaccine administered in the US varies widely from year to year (anywhere from 20% to 60%), depending on how well the annual vaccine attacks that year's mutation of the virus. The duration of how long a vaccine protection lasts, and how many doses might be needed for it to be effective also varies from disease to disease.\n\nFor the COVID-19 vaccine, the U.S. FDA has set an effectiveness threshold of 50% to be approved or grants the emergency use authorization. \n\nA vaccine might not be 100% effective, but if most people get vaccinated then vaccination not only protects individuals, but also prevents the virus from circulating widely in a community.\n",
    "Glossary Terms": [
      "recR5R4QhqxWEg2nF",
      "rec9qqItwSTjq3Eae"
    ],
    "Topics": [
      "vaccine",
      "vaccine effectiveness",
      "efficacy",
      "COVID-19"
    ],
    "Other resources": "1. Why no vaccine can ever be 100% effective: Wide variation in the population's immune systems mean guaranteed protection is impossible  ([Daily Mail](https://www.dailymail.co.uk/health/article-9002315/Why-no-vaccine-100-effective.html))\n2. Why aren’t all vaccines 100% effective? ([History of Vaccines](http://Why aren’t all vaccines 100% effective?))\n3. Vaccine Effectiveness: How Well Do the Flu Vaccines Work? ([U.S. CDC](https://www.cdc.gov/flu/vaccines-work/vaccineeffect.htm))\n4. The FDA's cutoff for Covid-19 vaccine effectiveness is 50 percent. What does that mean? ([NBC News](https://www.nbcnews.com/health/health-news/fda-s-cutoff-covid-19-vaccine-effectiveness-50-percent-what-n1245506))\n5. Vaccine efficacy and effectiveness ([NZ Immunization Advisory Centre](https://www.immune.org.nz/vaccines/efficiency-effectiveness))\n",
    "Last modified manual": "2020-12-07",
    "Last edited (simplified)": "2020-12-07T20:40:47.000Z",
    "Last edited (experts say)": "2020-12-07T20:40:47.000Z",
    "Last modified": "2020-12-07",
    "What our experts say wordcount": 168,
    "Background and context wordcount": 94,
    "Other resources wordcount": 68,
    "Wordcount": 330
  },
  {
    "id": "reccfrzvZmq2A0mSn",
    "Question": "What do we know so far about how the U.K. is approving and rolling out vaccines?",
    "Status": "Published",
    "Category": "Vaccines",
    "Subcategory": "On: COVID-19 & UK vaccine distribution",
    "Source of the question": [
      "Newsroom"
    ],
    "Country question was sourced from": [
      "UK"
    ],
    "Background and context": "In early December 2020, the U.K. became the first Western country to approve and begin publicly distributing a COVID-19 vaccine that has been tested in large-scale clinical trials. Many nations are watching how the U.K. vaccine rollout develops, as they look to issue their own approvals and implement their own vaccine distribution plans. For example, regulatory agencies in the U.S. and the European Union (EU) are also expected to make decisions about vaccine approvals in December 2020. China and Russia are considered exceptions in having approved and started vaccinating people months earlier, without waiting for results from large-scale clinical trials.\n\nThe U.K.'s vaccine distribution plans are happening in the context of a country that has been struggling to control the spread of COVID-19 thus far. According to the World Health Organization, as of December 8, 2020, there have been 1,737,964 confirmed COVID-19 cases with 61,434 deaths in the U.K.\n",
    "What our experts say": "**Approval status:** On December 2, 2020, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted an emergency-use authorization to a 2-dose mRNA vaccine developed by Pfizer and BioNTech, roughly seven months after the clinical trials started. Other vaccine candidates are currently under review by the regulator.\n\n**Approval processes:** In the United Kingdom, vaccines are approved by the regulator (the MHRA) based on criteria including safety, quality, and efficacy. The MHRA has been using a \"rolling review\" process since June 2020 to assess COVID-19 vaccines in an accelerated timeframe, with teams of scientists often requesting and reviewing data on various topics in parallel. The European Union (EU) requires vaccines to be authorized by the European Medicines Agency (EMA), but allows individual countries to use an emergency procedure to distribute a vaccine for temporary use in their domestic market. The MHRA chief executive stated that they used this existing EU provision to fast-track approval in the U.K. before the rest of the EU, since the U.K. is still subject to EU rules until their transition period for leaving is completed on December 31, 2020.\n\n**Distribution status:** The U.K. announced that 357 million doses of seven different vaccines have been purchased, which includes 40 million doses of the Pfizer and BioNTech vaccine. An initial delivery of 800,000 doses of the Pfizer and BioNTech vaccine (which can provide two doses to 400,000 people) was received from a manufacturing site in Belgium, and was divided between the four countries of the U.K. on the basis of population (with most going to England and Wales, 65,500 doses going to Scotland, and 25,000 doses going to Northern Ireland). The first vaccinations outside of trials in the U.K. began on December 8, 2020, prioritizing residents and caretakers in care homes for older adults (also known as aged-care). A 90-year-old woman was the first person outside of trials to receive a vaccine dose in her country.\n\n**Distribution priorities:** The U.K. Joint Committee on Vaccination and Immunisation (JCVI) identified that the first phase of vaccinations should focus on directly preventing mortality and supporting the National Health Service (NHS) as well as the social care system. This first phase includes nine priority groups, which taken together are estimated to represent 99% of preventable mortality:\n1. Residents in a care home for older adults and their carers\n2. All those 80 years of age and over and frontline health and social care workers\n3. All those 75 years of age and over\n4. All those 70 years of age and over and clinically extremely vulnerable individuals\n5. All those 65 years of age and over\n6. All individuals aged 16 years to 64 years with underlying health conditions which put them at higher risk of serious disease and mortality\n7. All those 60 years of age and over\n8. All those 55 years of age and over\n9. All those 50 years of age and over\n\nThe next phase of vaccinations will focus on further reducing hospitalization and targeting those at high risk of exposure and/or those delivering key public services. This next phase is likely to include people at increased risk of exposure to COVID-19 due to their occupation, such as first responders, the military, those involved in the justice system, teachers, transport workers, and public servants essential to the pandemic response.\n\n**Distribution processes:** The Pfizer and BioNTech vaccine requires storage in ultra-cold temperatures of -70 degrees Celsius. A shipping box has been developed that is packed with dry ice to maintain the necessary temperature for 5,000 doses, which can be transported by airplane. Once the doses arrive in the target country, the country can store the dry ice packs in a freezer farm for up to 6 months. If unopened, the dry ice packs can keep the doses cold for up to 10 days during transport. After the vaccine is thawed, it can be stored for up to 5 days at between 2 and 8 degrees Celsius. \n\nThe U.K. Security Service (MI5) and National Cyber Security Centre (NCSC) are working to provide security for the vaccine supply chain and distribution, which could be disrupted by hacking and other attacks. \n\nThe U.K. Ministry of Defence has announced that it is providing 60 military planners to work with the government's vaccine task force and 56 personnel to help construct vaccination centers. The U.K. Armed Forces Minister announced that more than 2,000 military personnel have been deployed so far to help with testing and other COVID-19 response, and that 13,500 military personnel remain on \"high readiness\" to provide support. In England, 50 NHS hospitals are serving as initial hubs for administering the vaccine.\n",
    "Glossary Terms": [
      "rec9qqItwSTjq3Eae",
      "rec10nAxiKgWhYJLd",
      "recR5R4QhqxWEg2nF"
    ],
    "Variation of the answer depending on country of residence": "Yes, vaccine approval and distribution processes differ from country to country\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "vaccine",
      "vaccine effectiveness"
    ],
    "Other resources": "1. The UK has approved a COVID vaccine — here’s what scientists now want to know ([Nature](https://www.nature.com/articles/d41586-020-03441-8))\n2. How the U.K. Approved Pfizer's COVID-19 Vaccine Faster Than the U.S. and Europe ([Time](https://time.com/5917109/u-k-covid-vaccine-approved/))\n3. Priority groups for coronavirus (COVID-19) vaccination: advice from the JCVI, 2 December 2020 ([JCVI](https://www.gov.uk/government/publications/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-2-december-2020/priority-groups-for-coronavirus-covid-19-vaccination-advice-from-the-jcvi-2-december-2020))\n4. How the U.K. Plans to Lead the World in Covid Vaccination ([Bloomberg](https://www.bloomberg.com/graphics/2020-uk-vaccine-logistics/))\n5. Coronavirus: Hackers targeted Covid vaccine supply 'cold chain' ([BBC](https://www.bbc.com/news/technology-55165552))\n6. Covid: Military could be used to transport Covid vaccine ([BBC](https://www.bbc.com/news/uk-55213148))\n7. The United Kingdom Situation ([WHO](https://covid19.who.int/region/euro/country/gb))\n",
    "Last modified manual": "2020-12-09",
    "Last edited (simplified)": "2020-12-09T02:54:07.000Z",
    "Last edited (experts say)": "2020-12-09T14:59:33.000Z",
    "Last modified": "2020-12-09",
    "What our experts say wordcount": 756,
    "Background and context wordcount": 148,
    "Other resources wordcount": 80,
    "Wordcount": 984
  },
  {
    "id": "recwxN6NEtrZPfgDU",
    "Question": "What do we know so far about COVAX?",
    "Status": "In progress",
    "Category": "Vaccines",
    "Subcategory": "On: COVID-19 & COVAX",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "COVAX is the largest international partnership for COVID-19 vaccine development and equitable distribution in the world. As many countries may struggle to afford the amount of vaccine dosages necessary to treat their populations, COVAX helps guarantee a share of doses for each eligible participant country (also called 'economy') and will ensure countries are not pushed to the back of the line or unable to receive the most effective vaccines according to their financial abilities. COVAX secures agreements with numerous vaccine producers directly so that the risks of paying for on only one or two vaccine candidates are minimized as the organization is working with roughly 10 companies. This means that if a vaccine is not shown to be effective or cannot get appropriate authorization in individual countries, there are still other vaccines in the COVAX portfolio that might meet these standards.\n\n\n",
    "What our experts say": "The World Health Organization (WHO) launched the Access to COVID-19 Tools (ACT) Accelerator in April of 2020 along with the European Commission, France, and the Bill & Melinda Gates Foundation in response to the pandemic. The ACT Accelerator is a global collaboration that works to speed up the development, production, and equitable distribution and access to COVID-19 tests, treatments, and vaccines. The accelerator has four branches: 1) Diagnostics, 2) Therapeutics and 3) Vaccines (also known as COVAX), while the 4) Health Systems Connector pillar works with each of the first three groups. Each pillar is managed by 2-3 partner agencies.\n\nThe third pillar of the accelerator is called the COVID‑19 Vaccines Global Access but is more commonly known as COVAX. This group is led by Gavi, the Vaccine Alliance; the Coalition for Epidemic Preparedness Innovations (CEPI); and WHO. The aim of COVAX is to accelerate the development and manufacturing of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world. Globally, COVAX currently has the largest portfolio of potential COVID-19 vaccines in development (over 10). This group also includes the COVAX Facility for the global procurement of vaccines, which has engaged nearly 200 countries in its planning to secure 2 billion doses of COVID-19 vaccines by early 2021. Gavi describes COVAX as \"Bringing together governments, global health organisations, manufacturers, scientists, private sector, civil society and philanthropy, with the aim of providing innovative and equitable access to COVID-19 diagnostics, treatments and vaccines. It is the only truly global solution to this pandemic because it is the only effort to ensure that people in all corners of the world will get access to COVID-19 vaccines once they are available, regardless of their wealth.\"\n\nAs of December 8, 2020, 189 countries participating in the COVAX Facility program for fair and equitable distribution of an eventual licensed vaccine, assuring that each participating country would receive a guaranteed share of doses to vaccinate the most vulnerable 20% of its population by the end of 2021.\n",
    "Glossary Terms": [
      "recKaVlh1bCrjQHDx",
      "rec9qqItwSTjq3Eae"
    ],
    "Variation of the answer depending on country of residence": "No\t\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "No\n",
    "Topics": [
      "covax ",
      "vaccine"
    ],
    "Other resources": "1. COVAX: Working for global equitable access to COVID-19 vaccines ([WHO](https://www.who.int/initiatives/act-accelerator/covax)) \n2. The ACT-Accelerator frequently asked questions ([WHO](https://www.who.int/initiatives/act-accelerator/faq)) \n3. COVAX explained ([Gavi](https://www.gavi.org/vaccineswork/covax-explained)) \n4. Evolution of the COVID-19 vaccine development landscape ([Nature](https://www.nature.com/articles/d41573-020-00151-8)) \n5. COVAX: ensuring global equitable access to COVID-19 vaccines ([UNICEF](https://www.unicef.org/supply/covax-ensuring-global-equitable-access-covid-19-vaccines)) \n\n",
    "Last edited (simplified)": "2020-12-08T20:06:23.000Z",
    "Last edited (experts say)": "2020-12-08T20:06:23.000Z",
    "Last modified": "2020-12-08",
    "What our experts say wordcount": 332,
    "Background and context wordcount": 141,
    "Other resources wordcount": 42,
    "Wordcount": 515
  },
  {
    "id": "recHLFItOS1Yd1cn3",
    "Question": "What do we know about Eli Lilly's COVID-19 treatments?",
    "Status": "Ready for Review",
    "Category": "Treatment",
    "Subcategory": "On: COVID-19 & Eli Lilly treatments",
    "Source of the question": [
      "Expert Recommendation"
    ],
    "Country question was sourced from": [
      "USA"
    ],
    "Background and context": "The U.S. FDA has recently approved several emergency use authorization for different emergency treatments in response to the COVID-19 pandemic. Despite the rapid speed at which vaccines and other treatments have been developed, tested, and manufactured in for COVID-19, all medications must still undergo clinical trials, safety and efficacy reviews, pass other major regulatory standards, and be approved by an impartial body of experts before being issued for emergency use authorization or full authorization. By the time most of these drugs are being used on patients, they have been tested and evaluated on thousands of volunteer participants and determined to be safe before that time.\n",
    "What our experts say": "The United States Food and Drug Administration (U.S. FDA) recently issued two Emergency Use Authorization (EUAs) for American pharmaceutical company Eli Lilly's most recent COVID-19 treatments. \n\nThe first EUA was issued on November 19, 2020, for bamlanivimab, an antibody treatment developed with collaborators including Vancouver-based AbCellera and the U.S.  National Institutes of Health. Bamlanivimab has been shown to reduce emergency room visits and hospitalizations in patients who receive the medication quickly after their diagnosis, according to early studies. No benefit has been shown in hospitalized patients with the virus. \n\nBamlanivimab is a monoclonal antibody drug that mimics the immune system’s own antibodies that fight off harmful antigens such as viruses (like COVID-19). In this way, the medication might be able to help block the virus from entering and infecting healthy human cells. This drug should be dispensed as soon as possible after a person tests positive for the virus and within 10 days of developing systems. \n\nBamlanivimab is authorized for people 12 years of age and older who weigh at least 40 kilograms (88 pounds) and who may be at risk for developing a severe case of COVID-19 infection or be hospitalized due to its impacts. Bamlanivimab was developed from the blood of a recovered patient who had developed antibodies to the virus. \n\nThe data used to support this emergency use authorization was based on a phase two randomized clinical trial in 465 non-hospitalized adults with mild to moderate COVID-19 symptoms. Patients treated with bamlanivimab showed reduced viral load and rates of symptoms and hospitalization in comparison with those who did not receive the treatment.\n\nOn November 19, 2020, (U.S. FDA) issued an EUA for the emergency use of Eli Lilly's drug baricitinib to be used in combination with another COVID-19 U.S. FDA-approved treatment, remdesivir, in adult patients who have been hospitalized with COVID-19. This treatment, which also goes by the brand name Olumiant, is normally used to treat rheumatoid arthritis and was developed in partnership with Incyte. \n\nIn comparison to treating patients with remdesivir alone, baricitinib was shown to reduce time to recovery, when combined with the remdesivir. The safety of this investigational therapy is still being studied, but this medication combination was authorized for patients two years of age or older with suspected or confirmed cases of the virus who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). \n\nThe combination of drugs improved patients' median time to recovery from eight to seven days compared to remdesivir alone, a 12.5% improvement in the  1,000 patient study that began on May 8,2020, to assess the efficacy and safety of baricitinib plus remdesivir versus remdesivir in hospitalized patients with COVID-19. The proportion of patients who progressed to ventilation, or died by day 29, was 23% lower when given both drugs in comparison to remdesivir alone. By day 29, deaths among patients were also reduced by 35% for the combination treatment when compared to remdesivir by itself. The recommended dose for baricitinib in COVID-19 patients is 4 milligrams once daily for 14 days or until hospital discharge.\n",
    "Glossary Terms": [
      "recRog4Fq88ayf62O",
      "rec3XmnugOMexQiQA",
      "recp00hYRvT2bmlfp",
      "recFg30lvATvVhmBG",
      "recXugVJFvUHIcWsH"
    ],
    "Variation of the answer depending on country of residence": "No\n",
    "Does this answer vary depending on your race, ethnicity, age, sex or other demographic factors?": "Yes\n",
    "Topics": [
      "antibody",
      "monoclonal antibodies",
      "remdesivir",
      "clinical trial",
      "experimental treatment",
      "treatment"
    ],
    "Other resources": "1. Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19 ([Lilly](https://investor.lilly.com/news-releases/news-release-details/baricitinib-receives-emergency-use-authorization-fda-treatment)) \n2. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19 ([U.S. FDA](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19)) \n3. Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19 ([U.S. FDA](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19)) \n4. Eli Lilly’s Antibody Treatment Gets Emergency F.D.A. Approval ([NYT](https://www.nytimes.com/2020/11/10/world/the-fda-grants-emergency-authorization-of-eli-lillys-antibody-treatment.html)) \n5. Eli Lilly and AbCellera Win EUA for COVID-19 Antibody Treatment ([BioSpace](https://www.biospace.com/article/eli-lilly-abcellera-win-eua-for-antibody-treatment-for-covid-19/)) \n6. FDA Grants EUA to Combination of Olumiant and Remdesivir in Hospitalized COVID-19 Patients ([BioSpace](https://www.biospace.com/article/fda-grants-eua-to-combination-of-olumiant-and-remdesivir-in-hospitalized-covid-19-patients/)) \n",
    "Editorial notes:": "<airtable:mention id=\"men9ndQHq9e34r0fh\">@Christin Gilmer</airtable:mention> I changed a sentence to this: \"In comparison to treating patients with remdesivir alone, baricitinib was shown to reduce time to recovery to within 29 days, when combined with the remdesivir.\" Accurate?",
    "Last modified manual": "2020-12-09",
    "Last edited (simplified)": "2020-12-09T15:07:51.000Z",
    "Last edited (experts say)": "2020-12-09T15:07:51.000Z",
    "Last modified": "2020-12-09",
    "What our experts say wordcount": 505,
    "Background and context wordcount": 105,
    "Other resources wordcount": 84,
    "Wordcount": 694
  }
]